activity_id,cmpd_id,protein_id,ref_id,std_type,activity_relation,std_value,std_unit,action_type,published_type,published_value,published_unit,published_sd,published_label,comments,assay_type,assay_description,cell_system,sub_prod,cmpd_conc,cmpd_conc_unit,action_strength,species,datasource_id,datasource_version,last_update
mbbd000000001,mbcd0000508,mbtp000001,mbrf0000995,,=,,,inhibitor,3,100.0,%,,KRN5500,,,"membrane fraction from MDR1-expressing LLC-GA5-COL150 cells; inhibition of Azidopine photoaffinity labelling (Azidopine: 0.4 microM, KRN5500: 400 microM)",LLC-GA5-COL150,,400,microM,,human,mbds0003,v2007,2013-10-15 01:42:00
mbbd000000002,mbcd0027062,mbtp000001,mbrf0000996,,,,,substrate,,,,,verapamil,,,MDR1-expressing LLC-PK1 cell; transepithelial transport (basal to apical),LLC-PK1,,,,,human,mbds0003,v2007,2013-12-09 19:55:24
mbbd000000003,mbcd0002207,mbtp000001,mbrf0000996,,=,,,inhibitor,25,0.3,microM,,Norverapamil,,,Caco-2 cell; inhibition of Digoxin transepithelial transport (basal to apical) (Digoxin: 5 microM),Caco-2,mbcd0001050,,,,human,mbds0003,v2007,2013-12-09 19:55:25
mbbd000000004,mbcd0002207,mbtp000001,mbrf0000996,,,,,substrate,,,,,norverapamil,,,MDR1-expressing LLC-PK1 cell; transepithelial transport (basal to apical),LLC-PK1,,,,,human,mbds0003,v2007,2013-12-09 19:55:23
mbbd000000008,mbcd0027062,mbtp000001,mbrf0000997,,=,,,inhibitor,25,2.1,microM,,Verapamil,,,Caco-2 cell; inhibition of Digoxin transepithelial transport (basal to apical) (Digoxin: 5 microM),Caco-2,mbcd0001050,,,,human,mbds0003,v2007,2013-12-09 20:14:38
mbbd000000009,mbcd0001533,mbtp000001,mbrf0000997,,=,,,inhibitor,25,6.5,microM,,saquinavir,,,Caco-2 cell; inhibition of Digoxin transepithelial transport (basal to apical) (Digoxin: 5 microM),Caco-2,mbcd0001050,,,,human,mbds0003,v2007,2013-12-09 19:55:27
mbbd000000010,mbcd0001938,mbtp000001,mbrf0000997,,=,,,inhibitor,25,3.8,microM,,ritonavir,,,Caco-2 cell; inhibition of Digoxin transepithelial transport (basal to apical) (Digoxin: 5 microM),Caco-2,mbcd0001050,,,,human,mbds0003,v2007,2013-12-09 20:51:10
mbbd000000011,mbcd0027018,mbtp000001,mbrf0000997,,=,,,inhibitor,25,2.2,microM,,Quinidine,,,Caco-2 cell; inhibition of Digoxin transepithelial transport (basal to apical) (Digoxin: 5 microM),Caco-2,mbcd0001050,,,,human,mbds0003,v2007,2013-12-09 20:08:53
mbbd000000012,mbcd0000721,mbtp000001,mbrf0000997,,=,,,inhibitor,25,0.11,microM,,Valspodar,,,Caco-2 cell; inhibition of Digoxin transepithelial transport (basal to apical) (Digoxin: 5 microM),Caco-2,mbcd0001050,,,,human,mbds0003,v2007,2013-12-09 20:51:09
mbbd000000013,mbcd0026632,mbtp000001,mbrf0000997,,=,,,inhibitor,25,1.4,microM,,Nelfinavir,,,Caco-2 cell; inhibition of Daunorubicin transepithelial transport (basal to apical) (Daunorubicin: 5 microM),Caco-2,mbcd0005183,,,,human,mbds0003,v2007,2013-12-09 20:51:09
mbbd000000014,mbcd0000547,mbtp000001,mbrf0000997,,=,,,inhibitor,25,0.08,microM,,LY-335979,,,Caco-2 cell; inhibition of Indinavir transepithelial transport (basal to apical) (Indinavir: 0.05 microM),Caco-2,mbcd0002323,,,,human,mbds0003,v2007,2013-12-09 20:51:10
mbbd000000015,mbcd0000547,mbtp000001,mbrf0000997,,=,,,inhibitor,25,0.05,microM,,LY-335979,,,Caco-2 cell; inhibition of Indinavir transepithelial transport (basal to apical) (Indinavir: 0.05 microM),Caco-2,mbcd0002323,,,,human,mbds0003,v2007,2013-12-09 20:51:10
mbbd000000016,mbcd0000547,mbtp000001,mbrf0000997,,=,,,inhibitor,25,0.02,microM,,LY-335979,,,Caco-2 cell; inhibition of Nelfinavir transepithelial transport (basal to apical) (Nelfinavir: 0.02 microM),Caco-2,mbcd0026632,,,,human,mbds0003,v2007,2013-12-09 20:51:10
mbbd000000017,mbcd0000547,mbtp000001,mbrf0000997,,=,,,inhibitor,25,0.024,microM,,LY-335979,,,Caco-2 cell; inhibition of Digoxin transepithelial transport (basal to apical) (Digoxin: 5 microM),Caco-2,mbcd0001050,,,,human,mbds0003,v2007,2013-12-09 20:51:10
mbbd000000018,mbcd0017104,mbtp000001,mbrf0000997,,=,,,inhibitor,25,1.2,microM,,Ketoconazole,,,Caco-2 cell; inhibition of Digoxin transepithelial transport (basal to apical) (Digoxin: 5 microM),Caco-2,mbcd0001050,,,,human,mbds0003,v2007,2013-12-09 20:51:09
mbbd000000019,mbcd0002323,mbtp000001,mbrf0000997,,=,,,inhibitor,25,44.0,microM,,Indinavir,,,Caco-2 cell; inhibition of Digoxin transepithelial transport (basal to apical) (Digoxin: 5 microM),Caco-2,mbcd0001050,,,,human,mbds0003,v2007,2013-12-09 20:51:09
mbbd000000020,mbcd0000311,mbtp000001,mbrf0000997,,=,,,inhibitor,25,1.3,microM,,cyclosporin A,,,Caco-2 cell; inhibition of Digoxin transepithelial transport (basal to apical) (Digoxin: 5 microM),Caco-2,mbcd0001050,,,,human,mbds0003,v2007,2013-12-09 19:54:17
mbbd000000021,mbcd0000805,mbtp000001,mbrf0000998,,,,,inhibitor,,,,,Tamolarizine,,,"K562/DXR cell, FACScan; increase in Rhodamine 123 intracellular accumulation (R123: 10 microM, Tamolarizine: 10 microM)",K562/DXR,mbcd0000746,10,microM,,human,mbds0003,v2007,2013-12-09 19:54:17
mbbd000000024,mbcd0027062,mbtp000001,mbrf0001000,,=,,,inducer,111,2.5,fold,0.41,verapamil,,,LS-180V; Western,LS180V,,10,microM,,human,mbds0003,v2007,2013-12-09 19:54:16
mbbd000000025,mbcd0001533,mbtp000001,mbrf0001000,,=,,,inducer,111,2.4,fold,,saquinavir,,,LS-180V; Western,LS180V,,10,microM,,human,mbds0003,v2007,2013-12-09 19:54:16
mbbd000000026,mbcd0026632,mbtp000001,mbrf0001000,,=,,,inducer,111,2.0,fold,,nelfinavir,,,LS-180V; Western,LS180V,,3,microM,,human,mbds0003,v2007,2013-12-09 19:54:15
mbbd000000027,mbcd0002323,mbtp000001,mbrf0001000,,=,,,inducer,111,1.6,fold,0.1,indinavir,,,LS-180V; Western,LS180V,,10,microM,,human,mbds0003,v2007,2013-12-09 19:54:16
mbbd000000028,mbcd0002383,mbtp000001,mbrf0001000,,=,,,inducer,111,2.0,fold,,amprenavir,,,LS-180V; Western,LS180V,,3,microM,,human,mbds0003,v2007,2013-12-09 19:54:13
mbbd000000029,mbcd0002820,mbtp000001,mbrf0001001,,=,,,inhibitor,25,1.6,microM,,Mibefradil,,,Caco-2 cell; inhibition of Digoxin transepithelial transport (basal to apical) (Digoxin: 5 microM),Caco-2,mbcd0001050,,,,human,mbds0003,v2007,2013-12-09 19:54:14
mbbd000000031,mbcd0028592,mbtp000001,mbrf0001002,,=,,,inhibitor,74,0.3,microM,,Bergaptol,,,Caco-2 cell; increase uptake (Vinblastine: 0.01 microM),Caco-2,mbcd0001151,,,,human,mbds0003,v2007,2013-12-09 20:50:55
mbbd000000032,mbcd0022796,mbtp000001,mbrf0001002,,=,,,inhibitor,74,0.05,microM,,Bergapten,,,Caco-2 cell; increase uptake (Vinblastine: 0.01 microM),Caco-2,mbcd0001151,,,,human,mbds0003,v2007,2013-12-09 20:50:55
mbbd000000033,mbcd0022804,mbtp000001,mbrf0001002,,=,,,inhibitor,74,0.035,microM,,Bergamottin,,,Caco-2 cell; increase uptake (Vinblastine: 0.01 microM),Caco-2,mbcd0001151,,,,human,mbds0003,v2007,2013-12-09 20:50:55
mbbd000000035,mbcd0000889,mbtp000001,mbrf0001003,,~,,,inhibitor,3,90.0,%,,V-104,,,"MDR1-expressing MDCKII cell; inhibition of Daunorubicin transepithelial transport (basal to apical)(Daunorubicin: 2 microM, V-104: 15 microM)",MDCKII,mbcd0005183,15,microM,,human,mbds0003,v2007,2013-12-09 20:50:54
mbbd000000036,mbcd0000695,mbtp000001,mbrf0001003,,~,,,inhibitor,1,87.0,%,,Pluronic L61,,,"MDR1-expressing LLC-PK1 cell; inhibition of Vinblastine transepithelial transport (basal to apical) (Vinblastine: 2 microM, Pluronic L61: 0.04%)",LLC-PK1,mbcd0001151,0.04,%,,human,mbds0003,v2007,2013-12-09 20:50:55
mbbd000000037,mbcd0001470,mbtp000001,mbrf0001004,28,=,5600.0,microM,substrate,28,5.6,mM,,Levofloxacin,,,Caco-2 cell; transepithelial transport (basal to apical),Caco-2,,5; 1000,microM,,human,mbds0003,v2007,2013-12-09 20:50:55
mbbd000000038,mbcd0001038,mbtp000001,mbrf0001004,28,=,580.0,microM,substrate,28,0.58,mM,,Grepafloxacin,,,Caco-2 cell; transepithelial transport (basal to apical),Caco-2,,5,microM,,human,mbds0003,v2007,2013-12-09 20:50:54
mbbd000000039,mbcd0027062,mbtp000001,mbrf0001005,,=,,,inhibitor,25,224.0,microM,,Verapamil,,,MDR1-expressing LLC-PK1 cell; inhibition of Digoxin transepithelial transport (basal to apical) (Digoxin: 0.1 microM),LLC-PK1,mbcd0001050,,,,human,mbds0003,v2007,2013-12-09 20:50:54
mbbd000000040,mbcd0000721,mbtp000001,mbrf0001005,,=,,,inhibitor,25,0.0222,microM,,Valspodar,,,MDR1-expressing LLC-PK1 cell; inhibition of Digoxin transepithelial transport (basal to apical) (Digoxin: 0.1 microM),LLC-PK1,mbcd0001050,,,,human,mbds0003,v2007,2013-12-09 20:57:59
mbbd000000041,mbcd0001668,mbtp000001,mbrf0001006,,=,,,inhibitor,25,8.2,microM,0.5,cholesterol,,,NIH-3T3-G185 cell line (expressing hMDR1); increase in Daunorubicn intracellular accumulation,NIH-3T3-G185,mbcd0005183,,,,human,mbds0003,v2007,2013-12-09 08:30:07
mbbd000000042,mbcd0027062,mbtp000001,mbrf0001007,,,,,inhibitor,,,,,verapamil,,,"membrane from K562/DOX cells; inhibition of Azidopine photoaffinity labelling (Azidopine: 0.1 microM, Verapamil: 100 microM)",K562/DOX,,100,microM,,human,mbds0003,v2007,2013-12-10 22:19:00
mbbd000000043,mbcd0000746,mbtp000001,mbrf0001007,,,,,substrate,,,,,rhodamine 123,,,K562/DXR cells; intracellular accumulation,K562/DXR,,,,,human,mbds0003,v2007,2013-12-10 22:19:00
mbbd000000044,mbcd0027835,mbtp000001,mbrf0001007,,,,,inhibitor,,,,,mefloquine,,,"membrane from K562/DOX cells; inhibition of Azidopine photoaffinity labelling (Azidopine: 0.1 microM, Mefloquine: 10 microM)",K562/DOX,,10,microM,,human,mbds0003,v2007,2013-12-10 22:19:00
mbbd000000045,mbcd0027835,mbtp000001,mbrf0001007,,,,,inhibitor,,,,,mefloquine,,,"K562/DOX cells; increase in Rhodamine 123 intracellular accumulation (R123: 10 microM, Mefloquine: 10 microM)",K562/DOX,mbcd0000746,10,microM,,human,mbds0003,v2007,2013-12-10 22:19:00
mbbd000000046,mbcd0002576,mbtp000001,mbrf0001008,,=,,,inhibitor,25,17.5,microM,,Nicardipine,,,MDR1-expressing LLC-PK1 cell; inhibition of Daunorubicin transepithelial transport (basal to apical) (Daunorubicin: 0.035 microM),LLC-PK1,mbcd0005183,,,,human,mbds0003,v2007,2013-12-09 20:57:59
mbbd000000047,mbcd0000553,mbtp000001,mbrf0001008,,=,,,inhibitor,25,4.6,microM,,Manidipine,,,MDR1-expressing LLC-PK1 cell; inhibition of Daunorubicin transepithelial transport (basal to apical) (Daunorubicin: 0.035 microM),LLC-PK1,mbcd0005183,,,,human,mbds0003,v2007,2013-12-09 20:57:59
mbbd000000048,mbcd0000370,mbtp000001,mbrf0001008,,=,,,inhibitor,25,20.6,microM,,Efonidipine,,,"MDR1-expressing LLC-PK1 cell; inhibition of Daunorubicin transepithelial transport (basal to apical), (+)-efonidipine (Daunorubicin: 0.035 microM)",LLC-PK1,mbcd0005183,,,,human,mbds0003,v2007,2013-12-09 19:59:18
mbbd000000049,mbcd0000370,mbtp000001,mbrf0001008,,=,,,inhibitor,25,17.3,microM,,Efonidipine,,,"MDR1-expressing LLC-PK1 cell; inhibition of Daunorubicin transepithelial transport (basal to apical), (-)-efonidipine (Daunorubicin: 0.035 microM)",LLC-PK1,mbcd0005183,,,,human,mbds0003,v2007,2013-12-09 20:57:58
mbbd000000050,mbcd0000167,mbtp000001,mbrf0001008,,=,,,inhibitor,25,9.5,microM,,Benidipine,,,MDR1-expressing LLC-PK1 cell; inhibition of Daunorubicin transepithelial transport (basal to apical) (Daunorubicin: 0.035 microM),LLC-PK1,mbcd0005183,,,,human,mbds0003,v2007,2013-12-09 20:52:22
mbbd000000051,mbcd0000166,mbtp000001,mbrf0001008,,=,,,inhibitor,25,8.6,microM,,Barnidipine,,,MDR1-expressing LLC-PK1 cell; inhibition of Daunorubicin transepithelial transport (basal to apical) (Daunorubicin: 0.035 microM),LLC-PK1,mbcd0005183,,,,human,mbds0003,v2007,2013-12-09 20:54:51
mbbd000000052,mbcd0028580,mbtp000001,mbrf0001008,,=,,,inhibitor,25,22.0,microM,,Amlodipine,,,MDR1-expressing LLC-PK1 cell; inhibition of Daunorubicin transepithelial transport (basal to apical) (Daunorubicin: 0.035 microM),LLC-PK1,mbcd0005183,,,,human,mbds0003,v2007,2013-12-09 20:54:51
mbbd000000053,mbcd0001151,mbtp000001,mbrf0001009,,=,,,substrate,81,46.3,,12.0,vinblastine,,,KB-3-1 and KB-V1 cell; cell accumulation,KB-V1,,1,microM,,human,mbds0003,v2007,2013-12-09 20:54:51
mbbd000000054,mbcd0001938,mbtp000001,mbrf0001009,,=,,,substrate,81,5.3,,1.4,Ritonavir,,,KB-3-1 and KB-V1 cell; cell accumulation,KB-V1,,1,microM,,human,mbds0003,v2007,2013-12-09 20:54:51
mbbd000000055,mbcd0001892,mbtp000001,mbrf0001009,,=,,,non-substrate,81,1.1,,0.1,progesterone,,,KB-3-1 and KB-V1 cell; cell accumulation,KB-V1,,1,microM,,human,mbds0003,v2007,2013-12-09 20:54:50
mbbd000000056,mbcd0001892,mbtp000001,mbrf0001009,,=,,,substrate,82,0.9,,0.1,progesterone,,,MDR1-expressing LLC-PK1 cell; transepithelial transport (basal to apical),LLC-PK1,,1,microM,,human,mbds0003,v2007,2013-12-09 20:54:50
mbbd000000057,mbcd0000598,mbtp000001,mbrf0001009,,=,,,substrate,81,12.4,,2.9,compound C,,,"KB-3-1 and KB-V1 cell; cell accumulation; cellular accumulation ratio (KB-3-1)/(KB-V1): KB-V1, a human MDR1 P-gp-overexpressing multidrug-resistant human epidermoid carcinoma cell line, and its parental cell line KB-3-1",KB-V1,,1,microM,,human,mbds0003,v2007,2013-12-09 20:54:48
mbbd000000058,mbcd0000598,mbtp000001,mbrf0001009,,=,,,substrate,82,10.3,,0.3,compound C,,,MDR1-expressing LLC-PK1 cell; transepithelial transport (basal to apical),LLC-PK1,,1,microM,,human,mbds0003,v2007,2013-12-09 20:54:48
mbbd000000061,mbcd0000582,mbtp000001,mbrf0001009,,=,,,non-substrate,81,0.8,,0.2,MK-0991,,,KB-3-1 and KB-V1 cell; cell accumulation,KB-V1,,10,microM,,human,mbds0003,v2007,2013-12-09 19:57:21
mbbd000000062,mbcd0000582,mbtp000001,mbrf0001009,,=,,,non-substrate,82,1.1,,0.1,MK-0991,,,MDR1-expressing LLC-PK1 cell; transepithelial transport (basal to apical),LLC-PK1,,10,microM,,human,mbds0003,v2007,2013-12-09 19:56:49
mbbd000000063,mbcd0000581,mbtp000001,mbrf0001009,,=,,,non-substrate,81,0.9,,0.1,MK-0826,,,KB-3-1 and KB-V1 cell; cell accumulation,KB-V1,,10,microM,,human,mbds0003,v2007,2013-12-09 19:56:49
mbbd000000064,mbcd0000581,mbtp000001,mbrf0001009,,=,,,non-substrate,82,1.1,,0.1,MK-0826,,,MDR1-expressing LLC-PK1 cell; transepithelial transport (basal to apical),LLC-PK1,,10,microM,,human,mbds0003,v2007,2013-12-09 19:57:23
mbbd000000065,mbcd0002323,mbtp000001,mbrf0001009,,=,,,substrate,81,11.4,,1.5,Indinavir,,,KB-3-1 and KB-V1 cell; cell accumulation,KB-V1,,1,microM,,human,mbds0003,v2007,2013-12-09 19:57:25
mbbd000000066,mbcd0001050,mbtp000001,mbrf0001009,,=,,,substrate,81,4.2,,0.9,digoxin,,,KB-3-1 and KB-V1 cell; cell accumulation,KB-V1,,1,microM,,human,mbds0003,v2007,2013-12-09 19:57:21
mbbd000000067,mbcd0003903,mbtp000001,mbrf0001009,,=,,,non-substrate,81,1.2,,0.1,Diazepam,,,KB-3-1 and KB-V1 cell; cell accumulation,KB-V1,,1,microM,,human,mbds0003,v2007,2013-12-09 19:57:22
mbbd000000068,mbcd0003903,mbtp000001,mbrf0001009,,=,,,non-substrate,82,1.0,,0.1,Diazepam,,,MDR1-expressing LLC-PK1 cell; transepithelial transport (basal to apical),LLC-PK1,,1,microM,,human,mbds0003,v2007,2013-12-09 19:57:25
mbbd000000069,mbcd0000066,mbtp000001,mbrf0001009,,=,,,substrate,81,6.2,,1.4,compound B,,,"KB-3-1 and KB-V1 cell; cell accumulation; cellular accumulation ratio (KB-3-1)/(KB-V1): KB-V1, a human MDR1 P-gp-overexpressing multidrug-resistant human epidermoid carcinoma cell line, and its parental cell line KB-3-1",KB-V1,,1,microM,,human,mbds0003,v2007,2013-12-09 19:57:25
mbbd000000070,mbcd0000066,mbtp000001,mbrf0001009,,=,,,substrate,82,17.6,,1.9,compound B,,,MDR1-expressing LLC-PK1 cell; transepithelial transport (basal to apical),LLC-PK1,,1,microM,,human,mbds0003,v2007,2013-12-09 20:51:18
mbbd000000076,mbcd0003001,mbtp000001,mbrf0001010,,~,,,non-inhibitor,1,104.0,%,4,testosterone,,,"MDR1-expressing LLC-PK1 cell; inhibition of Digoxin transepithelial transport (basal to apical)(Digoxin: 0.025 microM, Testosterone: 50 microM)",LLC-PK1,mbcd0001050,,,,human,mbds0003,v2007,2013-12-09 20:51:18
mbbd000000077,mbcd0003001,mbtp000001,mbrf0001010,,~,,,non-inhibitor,1,106.0,%,3,testosterone,,,"MDR1-expressing LLC-PK1 cell; inhibition of Daunorubicin transepithelial transport (basal to apical)(Daunorubicin: 0.035 microM, Testosterone: 50 microM)",LLC-PK1,mbcd0005183,,,,human,mbds0003,v2007,2013-12-09 20:51:18
mbbd000000080,mbcd0007511,mbtp000001,mbrf0001010,,~,,,non-inhibitor,1,107.0,%,4,Nifedipine,,,"MDR1-expressing LLC-PK1 cell; inhibition of Daunorubicin transepithelial transport (basal to apical) (Daunorubicin: 0.035 microM, Nifedipine: 50 microM)",LLC-PK1,mbcd0005183,,,,human,mbds0003,v2007,2013-12-09 20:07:59
mbbd000000081,mbcd0001735,mbtp000001,mbrf0001010,,~,,,non-inhibitor,1,104.0,%,3,Midazolam,,,"MDR1-expressing LLC-PK1 cell; inhibition of Digoxin transepithelial transport (basal to apical)(Digoxin: 0.025 microM, Midazolam: 50 microM)",LLC-PK1,mbcd0001050,,,,human,mbds0003,v2007,2013-12-09 20:08:00
mbbd000000082,mbcd0001735,mbtp000001,mbrf0001010,,~,,,non-inhibitor,1,96.0,%,7,Midazolam,,,"MDR1-expressing LLC-PK1 cell; inhibition of Daunorubicin transepithelial transport (basal to apical)(Daunorubicin: 0.035 microM, Midazolam: 50 microM)",LLC-PK1,mbcd0005183,,,,human,mbds0003,v2007,2013-12-09 20:08:00
mbbd000000083,mbcd0000332,mbtp000001,mbrf0001010,,=,,,inhibitor,25,41.8,microM,,Desmethylazelastine,,,MDR1-expressing LLC-PK1 cell; inhibition of Digoxin transepithelial transport (basal to apical) (Digoxin: 0.025 microM),LLC-PK1,mbcd0001050,,,,human,mbds0003,v2007,2013-12-09 20:08:00
mbbd000000084,mbcd0000332,mbtp000001,mbrf0001010,,=,,,inhibitor,25,11.8,microM,,Desmethylazelastine,,,MDR1-expressing LLC-PK1 cell; inhibition of Daunorubicin transepithelial transport (basal to apical) (Daunorubicin: 0.035 microM),LLC-PK1,mbcd0005183,,,,human,mbds0003,v2007,2013-12-09 20:03:11
mbbd000000085,mbcd0000329,mbtp000001,mbrf0001010,,=,,,inhibitor,25,25.2,microM,,Desethylamiodarone,,,MDR1-expressing LLC-PK1 cell; inhibition of Digoxin transepithelial transport (basal to apical) (Digoxin: 0.025 microM),LLC-PK1,mbcd0001050,,,,human,mbds0003,v2007,2013-12-09 20:07:59
mbbd000000086,mbcd0000329,mbtp000001,mbrf0001010,,=,,,inhibitor,25,15.4,microM,,Desethylamiodarone,,,MDR1-expressing LLC-PK1 cell; inhibition of Daunorubicin transepithelial transport (basal to apical) (Daunorubicin: 0.035 microM),LLC-PK1,mbcd0005183,,,,human,mbds0003,v2007,2013-12-09 20:07:59
mbbd000000087,mbcd0024687,mbtp000001,mbrf0001010,,=,,,inhibitor,25,30.0,microM,,Azelastine,,,MDR1-expressing LLC-PK1 cell; inhibition of Digoxin transepithelial transport (basal to apical) (Digoxin: 0.025 microM),LLC-PK1,mbcd0001050,,,,human,mbds0003,v2007,2013-12-09 20:03:12
mbbd000000088,mbcd0024687,mbtp000001,mbrf0001010,,=,,,inhibitor,25,16.0,microM,,Azelastine,,,MDR1-expressing LLC-PK1 cell; inhibition of Daunorubicin transepithelial transport (basal to apical) (Daunorubicin: 0.035 microM),LLC-PK1,mbcd0005183,,,,human,mbds0003,v2007,2013-12-09 20:03:09
mbbd000000089,mbcd0002192,mbtp000001,mbrf0001010,,=,,,inhibitor,25,45.6,microM,,Amiodarone,,,MDR1-expressing LLC-PK1 cell; inhibition of Digoxin transepithelial transport (basal to apical) (Digoxin: 0.025 microM),LLC-PK1,mbcd0001050,,,,human,mbds0003,v2007,2013-12-09 20:03:10
mbbd000000090,mbcd0002192,mbtp000001,mbrf0001010,,=,,,inhibitor,25,22.5,microM,,Amiodarone,,,MDR1-expressing LLC-PK1 cell; inhibition of Daunorubicin transepithelial transport (basal to apical) (Daunorubicin: 0.035 microM),LLC-PK1,mbcd0005183,,,,human,mbds0003,v2007,2013-12-09 20:53:10
mbbd000000093,mbcd0000089,mbtp000001,mbrf0001010,,~,,,non-inhibitor,1,100.0,%,3,6beta-hydroxytestosterone,,,"MDR1-expressing LLC-PK1 cell; inhibition of Digoxin transepithelial transport (basal to apical)(Digoxin: 0.025 microM, 6_-hydroxytestosterone: 50 microM)",LLC-PK1,mbcd0001050,,,,human,mbds0003,v2007,2013-12-09 20:53:09
mbbd000000094,mbcd0000089,mbtp000001,mbrf0001010,,~,,,non-inhibitor,1,101.0,%,2,6beta-hydroxytestosterone,,,"MDR1-expressing LLC-PK1 cell; inhibition of Daunorubicin transepithelial transport (basal to apical)(Daunorubicin: 0.035 microM, 6_-hydroxytestosterone: 50 microM)",LLC-PK1,mbcd0005183,,,,human,mbds0003,v2007,2013-12-09 20:01:08
mbbd000000095,mbcd0000068,mbtp000001,mbrf0001010,,~,,,non-inhibitor,1,107.0,%,2,4-Hydroxymidazolam,,,"MDR1-expressing LLC-PK1 cell; inhibition of Daunorubicin transepithelial transport (basal to apical)(Daunorubicin: 0.035 microM, 4-hydroxymidazolam: 50 microM)",LLC-PK1,mbcd0005183,,,,human,mbds0003,v2007,2013-12-09 20:01:07
mbbd000000098,mbcd0001533,mbtp000001,mbrf0001011,,,,,substrate,,,,,saquinavir,,,MDR1-expressing LLC-PK1 cell; transepithelial transport (basal to apical),LLC-PK1,,,,,human,mbds0003,v2007,2013-12-09 20:53:12
mbbd000000099,mbcd0001938,mbtp000001,mbrf0001011,,,,,substrate,,,,,ritonavir,,,MDR1-expressing LLC-PK1 cell; transepithelial transport (basal to apical),LLC-PK1,,,,,human,mbds0003,v2007,2013-12-09 20:53:11
mbbd000000100,mbcd0001581,mbtp000001,mbrf0001012,,=,,,substrate,87,30.0,,7.3,digitoxin,,,MDR1-expressing LLC-PK1 cell; transepithelial transport (basal to apical),LLC-PK1,,,,,human,mbds0003,v2007,2013-12-09 20:52:35
mbbd000000101,mbcd0000179,mbtp000001,mbrf0001012,,=,,,substrate,87,14.7,,0.7,beta-acetyldigoxin,,,MDR1-expressing LLC-PK1 cell; transepithelial transport (basal to apical),LLC-PK1,,,,,human,mbds0003,v2007,2013-12-09 19:55:16
mbbd000000103,mbcd0001416,mbtp000001,mbrf0001013,,,,,inducer,,,,,Rifampin,,,LS174T cell; Northern,LS174T,,,,,human,mbds0003,v2007,2013-12-09 19:55:17
mbbd000000104,mbcd0001941,mbtp000001,mbrf0001013,,,,,inducer,,,,,Reserpine,,,LS174T cell; Northern,LS174T,,,,,human,mbds0003,v2007,2013-12-09 19:55:14
mbbd000000105,mbcd0000702,mbtp000001,mbrf0001013,,,,,inducer,,,,,pregnenolone 16alpha-carbonitrile,,,LS174T cell; Northern,LS174T,,,,,human,mbds0003,v2007,2013-12-09 19:55:12
mbbd000000106,mbcd0007511,mbtp000001,mbrf0001013,,,,,inducer,,,,,Nifedipine,,,LS174T cell; Northern,LS174T,,,,,human,mbds0003,v2007,2013-12-09 19:55:16
mbbd000000107,mbcd0001299,mbtp000001,mbrf0001013,,,,,inducer,,,,,RU486,,,LS174T cell; Northern,LS174T,,,,,human,mbds0003,v2007,2013-12-09 19:55:15
mbbd000000109,mbcd0002959,mbtp000001,mbrf0001013,,,,,inducer,,,,,Dexamethasone,,,LS174T cell; Northern,LS174T,,,,,human,mbds0003,v2007,2013-12-09 20:57:46
mbbd000000110,mbcd0003905,mbtp000001,mbrf0001013,,,,,inducer,,,,,Corticosterone,,,LS174T cell; Northern,LS174T,,,,,human,mbds0003,v2007,2013-12-09 20:09:40
mbbd000000111,mbcd0002493,mbtp000001,mbrf0001013,,,,,inducer,,,,,Clotrimazole,,,LS174T cell; Northern,LS174T,,,,,human,mbds0003,v2007,2013-12-09 20:09:41
mbbd000000112,mbcd0002985,mbtp000001,mbrf0001013,,,,,inducer,,,,,carbamazepine,,,LS174T cell; Northern,LS174T,,,,,human,mbds0003,v2007,2013-12-09 20:00:34
mbbd000000113,mbcd0000078,mbtp000001,mbrf0001013,,,,,inducer,,,,,"5beta-pregnane-3,20-dione",,,LS174T cell; Northern,LS174T,,,,,human,mbds0003,v2007,2013-12-09 20:09:39
mbbd000000114,mbcd0002666,mbtp000001,mbrf0001014,,=,,,inhibitor,1,73.1,%,,Ranitidine,,,"Caco-2 cell; inhibition of Vinblastine transepithelial transport (basal to apical) (Vinblastine: 0.004 microM, Ranitidipine: 3000 microM)",Caco-2,mbcd0001151,,,,human,mbds0003,v2007,2013-12-09 20:00:33
mbbd000000115,mbcd0002576,mbtp000001,mbrf0001014,,=,,,inhibitor,1,46.59,%,,Nicardipine,,,"Caco-2 cell; inhibition of Vinblastine transepithelial transport (basal to apical)(Vinblastine: 0.004 microM, Nicardipine: 60 microM)",Caco-2,mbcd0001151,,,,human,mbds0003,v2007,2013-12-09 20:09:39
mbbd000000116,mbcd0001808,mbtp000001,mbrf0001014,,=,,,inhibitor,1,28.75,%,,GF120918,,,"MDR1-expressing MDCK cell; inhibition of Cimetidine transepithelial transport (basal to apical) (Cimetidine: 10 microM, GF120918: 0.5 microM)",MDCK,mbcd0001111,,,,human,mbds0003,v2007,2013-12-09 20:09:38
mbbd000000117,mbcd0001808,mbtp000001,mbrf0001014,,=,,,non-inhibitor,1,105.6,%,,GF120918,,,"Caco-2 cell; inhibition of Cimetidine transepithelial transport (basal to apical) (Cimetidine: 0.004 microM, GF120918: 0.5 microM)",Caco-2,mbcd0001111,,,,human,mbds0003,v2007,2013-12-09 20:09:38
mbbd000000118,mbcd0001808,mbtp000001,mbrf0001014,,=,,,inhibitor,1,45.81,%,,GF120918,,,"Caco-2 cell; inhibition of Vinblastine transepithelial transport (basal to apical) (Vinblastine: 0.004 microM, GF120918: 0.5 microM)",Caco-2,mbcd0001151,,,,human,mbds0003,v2007,2013-12-09 20:09:36
mbbd000000119,mbcd0001111,mbtp000001,mbrf0001014,,=,,,inhibitor,1,77.52,%,,Cimetidine,,,"Caco-2 cell; inhibition of Vinblastine transepithelial transport (basal to apical)(Vinblastine: 0.004 microM, Cimetidine: 3000 microM)",Caco-2,mbcd0001151,,,,human,mbds0003,v2007,2013-12-09 20:09:37
mbbd000000120,mbcd0001111,mbtp000001,mbrf0001014,,,,,substrate,,,,,cimetidine,,,MDR1-expressing MDCK cell; transepithelial transport (basal to apical),MDCK,,,,,human,mbds0003,v2007,2013-12-09 20:58:08
mbbd000000121,mbcd0001111,mbtp000001,mbrf0001014,,,,,substrate,,,,,cimetidine,,,Caco-2 cell; transepithelial transport (basal to apical),Caco-2,,,,,human,mbds0003,v2007,2013-12-09 20:58:06
mbbd000000122,mbcd0002985,mbtp000001,mbrf0001015,,~,,,non-inhibitor,8,1.0,,0.5,CBZ,ratio FL1,,"human lymphocyte; inhibition of Rhodamine 123 efflux (R123: 1.5 microg/mL, Carbamazepine: 100 microM)",human lymphocyte,mbcd0000746,100,microM,,human,mbds0003,v2007,2013-12-09 20:58:06
mbbd000000123,mbcd0002985,mbtp000001,mbrf0001015,,,,,non-substrate,,,,,CBZ,,,Caco-2 cell; transepithelial transport (basal to apical),Caco-2,,,,,human,mbds0003,v2007,2013-12-09 20:58:05
mbbd000000124,mbcd0002989,mbtp000001,mbrf0001016,,,,,substrate,,,,,sparfloxacin,,,MDR1-expressing LLC-PK1 cell; transepithelial transport (basal to apical),LLC-PK1,,,,,human,mbds0003,v2007,2013-12-09 20:58:10
mbbd000000125,mbcd0001038,mbtp000001,mbrf0001016,,,,,substrate,,,,,grepafloxacin,,,MDR1-expressing LLC-PK1 cell; transepithelial transport (basal to apical),LLC-PK1,,,,,human,mbds0003,v2007,2013-12-09 20:58:10
mbbd000000126,mbcd0001316,mbtp000001,mbrf0001017,,,,,substrate,,,,,tacrolimus,,,"in vivo, recipients of living-donor liver transplantation ; mRNA expression level of MDR1 was inversely related to the concentration/dose ratio",human mucosal cells of the upper jejunum,,,,,human,mbds0003,v2007,2013-12-09 20:58:10
mbbd000000127,mbcd0000535,mbtp000001,mbrf0001018,,,,,inhibitor,,,,,Lomerizine,,,"K562/DOX cell; increase in Calcein intracellular accumulation (Calcein: 1 microM, Lomerizine: 10 microM)",K562/DOX,mbcd0029351,,,,human,mbds0003,v2007,2013-12-09 20:58:09
mbbd000000128,mbcd0001151,mbtp000001,mbrf0001019,,=,,,inhibitor,29,36.5,microM,,Vinblastine,,,Caco-2 cell; inhibition of Taxol transepithelial transport (basal to apical),Caco-2,mbcd0001532,,,,human,mbds0003,v2007,2013-12-09 20:58:05
mbbd000000129,mbcd0027062,mbtp000001,mbrf0001019,,=,,,inhibitor,29,3.0,microM,,Verapamil,,,Caco-2 cell; inhibition of Taxol transepithelial transport (basal to apical),Caco-2,mbcd0001532,,,,human,mbds0003,v2007,2013-12-09 20:58:05
mbbd000000130,mbcd0027018,mbtp000001,mbrf0001019,,=,,,inhibitor,29,1.5,microM,,Quinidine,,,Caco-2 cell; inhibition of Taxol transepithelial transport (basal to apical),Caco-2,mbcd0001532,,,,human,mbds0003,v2007,2013-12-09 20:11:07
mbbd000000131,mbcd0003154,mbtp000001,mbrf0001019,,=,,,non-inhibitor,1,111.0,%,,Probenecid,,,"Caco-2 cell; inhibition of Taxol transepithelial transport (basal to apical) (Taxol: 0.8 microM, Probenecid: 1000 micro)",Caco-2,mbcd0001532,,,,human,mbds0003,v2007,2013-12-09 20:11:08
mbbd000000132,mbcd0002466,mbtp000001,mbrf0001019,,=,,,inhibitor,29,276.0,microM,,Etoposide,,,Caco-2 cell; inhibition of Taxol transepithelial transport (basal to apical),Caco-2,mbcd0001532,,,,human,mbds0003,v2007,2013-12-09 20:11:08
mbbd000000133,mbcd0025844,mbtp000001,mbrf0001019,,=,,,inhibitor,29,8.5,microM,,doxorubicin,,,Caco-2 cell; inhibition of Taxol transepithelial transport (basal to apical),Caco-2,mbcd0001532,,,,human,mbds0003,v2007,2013-12-09 20:11:09
mbbd000000134,mbcd0005183,mbtp000001,mbrf0001019,,=,,,inhibitor,29,2.5,microM,,daunorubicin,,,Caco-2 cell; inhibition of Taxol transepithelial transport (basal to apical),Caco-2,mbcd0001532,,,,human,mbds0003,v2007,2013-12-09 20:11:06
mbbd000000135,mbcd0000311,mbtp000001,mbrf0001019,,=,,,stimulator,1,137.0,%,,CsA,,,Caco-2 cell; inhibition of Taxol transepithelial transport (basal to apical),Caco-2,mbcd0001532,,,,human,mbds0003,v2007,2013-12-09 20:11:06
mbbd000000136,mbcd0000242,mbtp000001,mbrf0001019,,=,,,inhibitor,29,313.0,microM,,Celiprolol,,,Caco-2 cell; inhibition of Taxol transepithelial transport (basal to apical),Caco-2,mbcd0001532,,,,human,mbds0003,v2007,2013-12-09 20:11:06
mbbd000000137,mbcd0024448,mbtp000001,mbrf0001020,,=,,,inhibitor,25,7.5,microM,,MET,,,Caco-2 cell; inhibition of Rhodamine 123 transepithelial transport (basal to apical) (Rhodamine 123: 5 microM),Caco-2,mbcd0000746,,,,human,mbds0003,v2007,2013-12-09 20:11:07
mbbd000000138,mbcd0024448,mbtp000001,mbrf0001020,,,,,non-substrate,,,,,MET,,,Caco-2 cell; transepithelial transport (basal to apical),Caco-2,,,,,human,mbds0003,v2007,2013-12-09 20:11:09
mbbd000000139,mbcd0014354,mbtp000001,mbrf0001021,,=,,,inducer,111,2.2,fold increase,,TZD,increase in protein level,,LS180V cell; Western,LS180V,,10,microM,,human,mbds0003,v2007,2013-12-09 20:11:10
mbbd000000140,mbcd0025582,mbtp000001,mbrf0001021,,=,,,inhibitor,25,4.7,microM,,NFZ,,,Caco-2 cell; inhibition of Rhodamine 123 transepithelial transport (basal to apical) (R123: 5 microM),Caco-2,mbcd0000746,,,,human,mbds0003,v2007,2013-12-09 20:58:34
mbbd000000141,mbcd0025582,mbtp000001,mbrf0001021,,,,,non-substrate,,,,,NFZ,,,Caco-2 cell; transepithelial transport (basal to apical),Caco-2,,,,,human,mbds0003,v2007,2013-12-09 20:58:34
mbbd000000142,mbcd0025582,mbtp000001,mbrf0001021,,=,,,inducer,111,2.2,fold increase,,NFZ,increase in protein level,,LS-180V; Western,LS180V,,10,microM,,human,mbds0003,v2007,2013-12-09 20:58:35
mbbd000000143,mbcd0000409,mbtp000001,mbrf0001022,,,,,substrate,,,,,flesinoxan,,,MDR1-expressing LLC-PK1 cell; transepithelial transport (basal to apical),LLC-PK1,,,,,human,mbds0003,v2007,2013-12-09 20:58:35
mbbd000000145,mbcd0001194,mbtp000001,mbrf0001024,,=,,,inhibitor,25,46.0,microM,,Simvastatin,,,3T3-G185; inhibition of Rhodamine 123 transport,NIH-3T3-G185,mbcd0000746,,,,human,mbds0003,v2007,2013-12-09 20:58:35
mbbd000000146,mbcd0001194,mbtp000001,mbrf0001024,,=,,,inhibitor,25,9.0,microM,,Simvastatin,,,3T3-G185; inhibition of Daunorubucin transport,NIH-3T3-G185,mbcd0005183,,,,human,mbds0003,v2007,2013-12-09 20:58:36
mbbd000000147,mbcd0025591,mbtp000001,mbrf0001024,,=,,,inhibitor,25,67.0,microM,,lovastatin,,,3T3-G185; inhibition of Rhodamine 123 transport,NIH-3T3-G185,mbcd0000746,,,,human,mbds0003,v2007,2013-12-09 20:58:35
mbbd000000148,mbcd0025591,mbtp000001,mbrf0001024,,=,,,inhibitor,25,26.0,microM,,lovastatin,,,3T3-G185; inhibition of Daunorubucin transport,NIH-3T3-G185,mbcd0005183,,,,human,mbds0003,v2007,2013-12-09 20:58:36
mbbd000000149,mbcd0026093,mbtp000001,mbrf0001024,,=,,,inhibitor,25,307.0,microM,,Atorvastatin,,,3T3-G185; inhibition of Rhodamine 123 transport,NIH-3T3-G185,mbcd0000746,,,,human,mbds0003,v2007,2013-12-09 20:58:36
mbbd000000150,mbcd0026093,mbtp000001,mbrf0001024,,=,,,inhibitor,25,271.0,microM,,Atorvastatin,,,3T3-G185; inhibition of Daunorubucin transport,NIH-3T3-G185,mbcd0005183,,,,human,mbds0003,v2007,2013-12-09 20:14:02
mbbd000000151,mbcd0001532,mbtp000001,mbrf0001025,28,=,0.014,microM,substrate,28,14.0,nM,,Paclitaxel,,,human breast BC19 carcinoma cells (MDR1-transfected variant of MCF7 cells); uptake,BC19,,1-1500,nM,,human,mbds0003,v2007,2013-11-27 07:12:55
mbbd000000152,mbcd0027018,mbtp000001,mbrf0001026,,=,,,substrate,28,18.2,microM,4.8,Quinidine,,,membrane from P-gp expressing insect cell; ATP hydrolysis,insect cells,,0-200,microM,,human,mbds0003,v2007,2013-12-09 20:14:01
mbbd000000154,mbcd0024865,mbtp000001,mbrf0001026,,=,,,substrate,28,34.4,microM,4.8,CP-122721,,,membrane from P-gp expressing insect cell; ATP hydrolysis,insect cells,,0-200,microM,,human,mbds0003,v2007,2013-12-09 20:14:04
mbbd000000155,mbcd0025827,mbtp000001,mbrf0001027,,=,,,non-inhibitor,151,6.24,%,,vinorelbine,,,MDR1-expressing MDCKII cell; inhibition of Calcein-AM efflux,MDCKII,mbcd0000212,,,,human,mbds0003,v2007,2013-12-09 20:14:04
mbbd000000156,mbcd0025827,mbtp000001,mbrf0001027,,,,,substrate,,,,,vinorelbine,,,MDR1-expressing MDCKII cell; transepithelial transport (basal to apical),MDCKII,,,,,human,mbds0003,v2007,2013-12-09 20:14:04
mbbd000000157,mbcd0025827,mbtp000001,mbrf0001027,,,,,substrate,,,,,vinorelbine,"found not to be an ATPase activator, but found to be effluxed in MDCKII-MDR1 cells",,MDR1-expressing Sf9 cell; ATP hydrolysis,Sf9,,,,,human,mbds0003,v2007,2014-03-01 04:42:09
mbbd000000158,mbcd0001135,mbtp000001,mbrf0001027,,=,,,non-inhibitor,151,8.4,%,,vincristine,,,MDR1-expressing MDCKII cell; inhibition of Calcein-AM efflux,MDCKII,mbcd0000212,,,,human,mbds0003,v2007,2013-12-09 20:14:05
mbbd000000159,mbcd0001135,mbtp000001,mbrf0001027,,,,,substrate,,,,,vincristine,"found not to be an ATPase activator, but found to be effluxed in MDCKII-MDR1 cells",,MDR1-expressing Sf9 cell; ATP hydrolysis,Sf9,,,,,human,mbds0003,v2007,2014-03-01 04:42:09
mbbd000000160,mbcd0027062,mbtp000001,mbrf0001027,,,,,non-substrate,,,,,verapamil,,,MDR1-expressing MDCKII cell; transepithelial transport (basal to apical),MDCKII,,,,,human,mbds0003,v2007,2013-12-09 20:53:13
mbbd000000161,mbcd0003115,mbtp000001,mbrf0001027,,=,,,non-inhibitor,151,1.35,%,,Trimethoprim,,,MDR1-expressing MDCKII cell; inhibition of Calcein-AM efflux,MDCKII,mbcd0000212,,,,human,mbds0003,v2007,2013-12-09 20:53:13
mbbd000000162,mbcd0003115,mbtp000001,mbrf0001027,,,,,substrate,,,,,trimethoprim,,,MDR1-expressing MDCKII cell; transepithelial transport (basal to apical),MDCKII,,,,,human,mbds0003,v2007,2013-12-09 20:53:12
mbbd000000163,mbcd0003115,mbtp000001,mbrf0001027,,,,,substrate,,,,,trimethoprim,found to be an ATPase activator and to be effluxed in MDCKII-MDR1 cells,,MDR1-expressing Sf9 cell; ATP hydrolysis,Sf9,,,,,human,mbds0003,v2007,2014-03-01 05:28:05
mbbd000000164,mbcd0003001,mbtp000001,mbrf0001027,,=,,,inhibitor,151,69.0,%,,testosterone,,,MDR1-expressing MDCKII cell; inhibition of Calcein-AM efflux,MDCKII,mbcd0000212,,,,human,mbds0003,v2007,2013-12-09 21:00:44
mbbd000000165,mbcd0003001,mbtp000001,mbrf0001027,,,,,non-substrate,,,,,testosterone,found not to be an ATPase activator in Sf9-MDR1 cells and not to be effluxed,,MDR1-expressing MDCKII cell; transepithelial transport (basal to apical),MDCKII,,,,,human,mbds0003,v2007,2014-03-01 05:01:09
mbbd000000166,mbcd0001532,mbtp000001,mbrf0001027,,=,,,non-inhibitor,151,0.98,%,,Taxol,,,MDR1-expressing MDCKII cell; inhibition of Calcein-AM efflux,MDCKII,mbcd0000212,,,,human,mbds0003,v2007,2013-12-09 21:00:42
mbbd000000167,mbcd0001532,mbtp000001,mbrf0001027,,,,,substrate,,,,,paclitaxel; taxol,found to be an ATPase activator and to be effluxed in MDCKII-MDR1 cells,,MDR1-expressing Sf9 cell; ATP hydrolysis,Sf9,,,,,human,mbds0003,v2007,2014-03-01 05:28:04
mbbd000000168,mbcd0001941,mbtp000001,mbrf0001027,,,,,substrate,,,,,reserpine,found to be an ATPase activator in Sf9-MDR1 cells and to be effluxed,,MDR1-expressing MDCKII cell; transepithelial transport (basal to apical),MDCKII,,,,,human,mbds0003,v2007,2014-03-01 05:28:04
mbbd000000169,mbcd0000723,mbtp000001,mbrf0001027,,=,,,non-inhibitor,151,1.91,%,,Puromycin,,,MDR1-expressing MDCKII cell; inhibition of Calcein-AM efflux,MDCKII,mbcd0000212,,,,human,mbds0003,v2007,2013-12-09 20:53:09
mbbd000000170,mbcd0000723,mbtp000001,mbrf0001027,,,,,substrate,,,,,puromycin,,,MDR1-expressing MDCKII cell; transepithelial transport (basal to apical),MDCKII,,,,,human,mbds0003,v2007,2013-12-09 20:55:11
mbbd000000171,mbcd0000723,mbtp000001,mbrf0001027,,,,,substrate,,,,,puromycin,"found not to be an ATPase activator, but found to be effluxed in MDCKII-MDR1 cells",,MDR1-expressing Sf9 cell; ATP hydrolysis,Sf9,,,,,human,mbds0003,v2007,2014-03-01 04:42:09
mbbd000000172,mbcd0003024,mbtp000001,mbrf0001027,,=,,,inhibitor,151,26.6,%,,Prazosin,,,MDR1-expressing MDCKII cell; inhibition of Calcein-AM efflux,MDCKII,mbcd0000212,,,,human,mbds0003,v2007,2013-12-09 20:15:26
mbbd000000173,mbcd0003024,mbtp000001,mbrf0001027,,,,,substrate,,,,,prazosin,found to be an ATPase activator in Sf9-MDR1 cells and to be effluxed,,MDR1-expressing MDCKII cell; transepithelial transport (basal to apical),MDCKII,,,,,human,mbds0003,v2007,2014-03-01 05:28:04
mbbd000000174,mbcd0003135,mbtp000001,mbrf0001027,,=,,,inhibitor,151,48.3,%,,Nitrendipine,,,MDR1-expressing MDCKII cell; inhibition of Calcein-AM efflux,MDCKII,mbcd0000212,,,,human,mbds0003,v2007,2013-12-09 20:15:29
mbbd000000175,mbcd0003135,mbtp000001,mbrf0001027,,,,,non-substrate,,,,,nitrendipine,,,MDR1-expressing MDCKII cell; transepithelial transport (basal to apical),MDCKII,,,,,human,mbds0003,v2007,2013-12-09 20:15:31
mbbd000000176,mbcd0003135,mbtp000001,mbrf0001027,,,,,non-substrate,,,,,nitrendipine,"found to be an ATPase activator, but found not to be effluxed in MDCKII-MDR1 cells",,MDR1-expressing Sf9 cell; ATP hydrolysis,Sf9,,,,,human,mbds0003,v2007,2014-03-01 04:42:09
mbbd000000177,mbcd0007511,mbtp000001,mbrf0001027,,,,,non-substrate,,,,,nifedipine,"found to be an ATPase activator, but found not to be effluxed in MDCKII-MDR1 cells",,MDR1-expressing Sf9 cell; ATP hydrolysis,Sf9,,,,,human,mbds0003,v2007,2014-03-01 04:42:09
mbbd000000178,mbcd0002576,mbtp000001,mbrf0001027,,,,,non-substrate,,,,,nicardipine,,,MDR1-expressing MDCKII cell; transepithelial transport (basal to apical),MDCKII,,,,,human,mbds0003,v2007,2013-12-09 20:15:25
mbbd000000179,mbcd0002576,mbtp000001,mbrf0001027,,,,,non-substrate,,,,,nicardipine,"found to be an ATPase activator, but found not to be effluxed in MDCKII-MDR1 cells",,MDR1-expressing Sf9 cell; ATP hydrolysis,Sf9,,,,,human,mbds0003,v2007,2014-03-01 04:42:02
mbbd000000180,mbcd0003928,mbtp000001,mbrf0001027,,=,,,non-inhibitor,151,0.31,%,,Neostigmine,,,MDR1-expressing MDCKII cell; inhibition of Calcein-AM efflux,MDCKII,mbcd0000212,,,,human,mbds0003,v2007,2013-12-09 21:01:07
mbbd000000181,mbcd0003928,mbtp000001,mbrf0001027,,,,,substrate,,,,,neostigmine,,,MDR1-expressing MDCKII cell; transepithelial transport (basal to apical),MDCKII,,,,,human,mbds0003,v2007,2013-12-09 21:01:07
mbbd000000182,mbcd0003928,mbtp000001,mbrf0001027,,,,,substrate,,,,,neostigmine,"found not to be an ATPase activator, but found to be effluxed in MDCKII-MDR1 cells",,MDR1-expressing Sf9 cell; ATP hydrolysis,Sf9,,,,,human,mbds0003,v2007,2014-03-01 04:17:57
mbbd000000183,mbcd0000584,mbtp000001,mbrf0001027,,=,,,inhibitor,151,52.2,%,,Monensin,,,MDR1-expressing MDCKII cell; inhibition of Calcein-AM efflux,MDCKII,mbcd0000212,,,,human,mbds0003,v2007,2013-12-09 21:01:07
mbbd000000184,mbcd0000584,mbtp000001,mbrf0001027,,,,,substrate,,,,,monensin,found to be an ATPase activator in Sf9-MDR1 cells and to be effluxed,,MDR1-expressing MDCKII cell; transepithelial transport (basal to apical),MDCKII,,,,,human,mbds0003,v2007,2014-03-01 05:28:04
mbbd000000185,mbcd0002981,mbtp000001,mbrf0001027,,=,,,non-inhibitor,151,2.89,%,,mitoxantrone,,,MDR1-expressing MDCKII cell; inhibition of Calcein-AM efflux,MDCKII,mbcd0000212,,,,human,mbds0003,v2007,2013-12-09 21:01:06
mbbd000000186,mbcd0002981,mbtp000001,mbrf0001027,,,,,substrate,,,,,mitoxantrone,,,MDR1-expressing MDCKII cell; transepithelial transport (basal to apical),MDCKII,,,,,human,mbds0003,v2007,2013-12-09 21:01:07
mbbd000000187,mbcd0002981,mbtp000001,mbrf0001027,,,,,substrate,,,,,mitoxantrone,"found not to be an ATPase activator, but found to be effluxed in MDCKII-MDR1 cells",,MDR1-expressing Sf9 cell; ATP hydrolysis,Sf9,,,,,human,mbds0003,v2007,2014-03-01 04:42:02
mbbd000000188,mbcd0001735,mbtp000001,mbrf0001027,,,,,non-substrate,,,,,midazolam,"found to be an ATPase activator, but found not to be effluxed in MDCKII-MDR1 cells",,MDR1-expressing Sf9 cell; ATP hydrolysis,Sf9,,,,,human,mbds0003,v2007,2014-03-01 04:42:02
mbbd000000189,mbcd0012513,mbtp000001,mbrf0001027,,=,,,inhibitor,151,38.6,%,,Mebendazole,,,MDR1-expressing MDCKII cell; inhibition of Calcein-AM efflux,MDCKII,mbcd0000212,,,,human,mbds0003,v2007,2013-12-09 21:01:08
mbbd000000190,mbcd0012513,mbtp000001,mbrf0001027,,,,,non-substrate,,,,,mebendazole,,,MDR1-expressing MDCKII cell; transepithelial transport (basal to apical),MDCKII,,,,,human,mbds0003,v2007,2013-12-09 20:17:00
mbbd000000191,mbcd0012513,mbtp000001,mbrf0001027,,,,,non-substrate,,,,,mebendazole,"found to be an ATPase activator, but found not to be effluxed in MDCKII-MDR1 cells",,MDR1-expressing Sf9 cell; ATP hydrolysis,Sf9,,,,,human,mbds0003,v2007,2014-03-01 04:42:02
mbbd000000192,mbcd0002323,mbtp000001,mbrf0001027,,=,,,non-inhibitor,151,0.14,%,,Indinavir,,,MDR1-expressing MDCKII cell; inhibition of Calcein-AM efflux,MDCKII,mbcd0000212,,,,human,mbds0003,v2007,2013-12-09 20:17:00
mbbd000000193,mbcd0002323,mbtp000001,mbrf0001027,,,,,substrate,,,,,indinavir,found to be an ATPase activator and to be effluxed in MDCKII-MDR1 cells,,MDR1-expressing Sf9 cell; ATP hydrolysis,Sf9,,,,,human,mbds0003,v2007,2014-03-01 05:28:04
mbbd000000194,mbcd0000474,mbtp000001,mbrf0001027,,=,,,non-inhibitor,151,3.49,%,,Hoechst 33342,,,MDR1-expressing MDCKII cell; inhibition of Calcein-AM efflux,MDCKII,mbcd0000212,,,,human,mbds0003,v2007,2013-12-09 20:16:57
mbbd000000195,mbcd0000474,mbtp000001,mbrf0001027,,,,,substrate,,,,,Hoechst 33342,,,MDR1-expressing MDCKII cell; transepithelial transport (basal to apical),MDCKII,,,,,human,mbds0003,v2007,2013-12-09 20:16:59
mbbd000000196,mbcd0001808,mbtp000001,mbrf0001027,,,,,non-substrate,,,,,GF120918,,,MDR1-expressing MDCKII cell; transepithelial transport (basal to apical),MDCKII,,,,,human,mbds0003,v2007,2013-12-09 20:16:55
mbbd000000197,mbcd0002466,mbtp000001,mbrf0001027,,=,,,non-inhibitor,151,1.34,%,,Etoposide,,,MDR1-expressing MDCKII cell; inhibition of Calcein-AM efflux,MDCKII,mbcd0000212,,,,human,mbds0003,v2007,2013-12-09 20:16:56
mbbd000000198,mbcd0002466,mbtp000001,mbrf0001027,,,,,substrate,,,,,etoposide,"found not to be an ATPase activator, but found to be effluxed in MDCKII-MDR1 cells",,MDR1-expressing Sf9 cell; ATP hydrolysis,Sf9,,,,,human,mbds0003,v2007,2014-03-01 04:42:02
mbbd000000199,mbcd0000937,mbtp000001,mbrf0001027,,=,,,non-inhibitor,151,4.35,%,,Erythromycin,,,MDR1-expressing MDCKII cell; inhibition of Calcein-AM efflux,MDCKII,mbcd0000212,,,,human,mbds0003,v2007,2013-12-09 20:17:01
mbbd000000200,mbcd0000937,mbtp000001,mbrf0001027,,,,,substrate,,,,,erythromycin,,,MDR1-expressing MDCKII cell; transepithelial transport (basal to apical),MDCKII,,,,,human,mbds0003,v2007,2013-12-09 20:51:03
mbbd000000201,mbcd0000937,mbtp000001,mbrf0001027,,,,,substrate,,,,,erythromycin,found to be an ATPase activator and to be effluxed in MDCKII-MDR1 cells,,MDR1-expressing Sf9 cell; ATP hydrolysis,Sf9,,,,,human,mbds0003,v2007,2014-03-01 05:27:59
mbbd000000202,mbcd0000373,mbtp000001,mbrf0001027,,=,,,non-inhibitor,151,3.39,%,,Emetine,,,MDR1-expressing MDCKII cell; inhibition of Calcein-AM efflux,MDCKII,mbcd0000212,,,,human,mbds0003,v2007,2013-12-09 20:51:01
mbbd000000203,mbcd0000373,mbtp000001,mbrf0001027,,,,,substrate,,,,,emetine,found to be an ATPase activator in Sf9-MDR1 cells and to be effluxed,,MDR1-expressing MDCKII cell; transepithelial transport (basal to apical),MDCKII,,,,,human,mbds0003,v2007,2014-03-01 05:27:59
mbbd000000204,mbcd0028144,mbtp000001,mbrf0001027,,=,,,non-inhibitor,151,2.6,%,,eletriptan,,,MDR1-expressing MDCKII cell; inhibition of Calcein-AM efflux,MDCKII,mbcd0000212,,,,human,mbds0003,v2007,2013-12-09 20:51:01
mbbd000000205,mbcd0028144,mbtp000001,mbrf0001027,,,,,substrate,,,,,eletriptan,,,MDR1-expressing MDCKII cell; transepithelial transport (basal to apical),MDCKII,,,,,human,mbds0003,v2007,2013-12-09 20:51:01
mbbd000000206,mbcd0028144,mbtp000001,mbrf0001027,,,,,substrate,,,,,eletriptan,found to be an ATPase activator and to be effluxed in MDCKII-MDR1 cells,,MDR1-expressing Sf9 cell; ATP hydrolysis,Sf9,,,,,human,mbds0003,v2007,2014-03-01 05:27:59
mbbd000000207,mbcd0003100,mbtp000001,mbrf0001027,,=,,,inhibitor,151,98.2,%,,Dipyridamole,,,MDR1-expressing MDCKII cell; inhibition of Calcein-AM efflux,MDCKII,mbcd0000212,,,,human,mbds0003,v2007,2013-12-09 20:51:00
mbbd000000208,mbcd0003100,mbtp000001,mbrf0001027,,,,,substrate,,,,,dipyridamole,found to be an ATPase activator in Sf9-MDR1 cells and to be effluxed,,MDR1-expressing MDCKII cell; transepithelial transport (basal to apical),MDCKII,,,,,human,mbds0003,v2007,2014-03-01 05:27:59
mbbd000000209,mbcd0002338,mbtp000001,mbrf0001027,,=,,,inhibitor,151,37.3,%,,Diltiazem,,,MDR1-expressing MDCKII cell; inhibition of Calcein-AM efflux,MDCKII,mbcd0000212,,,,human,mbds0003,v2007,2013-12-09 20:51:04
mbbd000000210,mbcd0002959,mbtp000001,mbrf0001027,,=,,,non-inhibitor,151,1.72,%,,Dexamethasone,,,MDR1-expressing MDCKII cell; inhibition of Calcein-AM efflux,MDCKII,mbcd0000212,,,,human,mbds0003,v2007,2013-12-09 19:53:37
mbbd000000211,mbcd0005183,mbtp000001,mbrf0001027,,=,,,non-inhibitor,151,-0.69,%,,daunorubicin,,,MDR1-expressing MDCKII cell; inhibition of Calcein-AM efflux,MDCKII,mbcd0000212,,,,human,mbds0003,v2007,2013-12-09 19:53:36
mbbd000000212,mbcd0005183,mbtp000001,mbrf0001027,,,,,substrate,,,,,daunorubicin,"found not to be an ATPase activator, but found to be effluxed in MDCKII-MDR1 cells",,MDR1-expressing Sf9 cell; ATP hydrolysis,Sf9,,,,,human,mbds0003,v2007,2014-03-01 04:42:02
mbbd000000213,mbcd0000311,mbtp000001,mbrf0001027,,,,,substrate,,,,,cyclosporin A,"found not to be an ATPase activator, but found to be effluxed in MDCKII-MDR1 cells",,MDR1-expressing Sf9 cell; ATP hydrolysis,Sf9,,,,,human,mbds0003,v2007,2014-03-01 04:41:52
mbbd000000214,mbcd0002667,mbtp000001,mbrf0001027,,=,,,non-inhibitor,151,-0.74,%,,Colchicine,,,MDR1-expressing MDCKII cell; inhibition of Calcein-AM efflux,MDCKII,mbcd0000212,,,,human,mbds0003,v2007,2013-12-09 19:53:31
mbbd000000215,mbcd0002667,mbtp000001,mbrf0001027,,,,,substrate,,,,,colchicine,,,MDR1-expressing MDCKII cell; transepithelial transport (basal to apical),MDCKII,,,,,human,mbds0003,v2007,2013-12-09 19:53:29
mbbd000000216,mbcd0002667,mbtp000001,mbrf0001027,,,,,substrate,,,,,colchicine,"found not to be an ATPase activator, but found to be effluxed in MDCKII-MDR1 cells",,MDR1-expressing Sf9 cell; ATP hydrolysis,Sf9,,,,,human,mbds0003,v2007,2014-03-01 04:41:52
mbbd000000217,mbcd0001517,mbtp000001,mbrf0001027,,=,,,non-inhibitor,151,2.71,%,,Clarythromycin,,,MDR1-expressing MDCKII cell; inhibition of Calcein-AM efflux,MDCKII,mbcd0000212,,,,human,mbds0003,v2007,2013-12-09 19:53:33
mbbd000000218,mbcd0001517,mbtp000001,mbrf0001027,,,,,substrate,,,,,clarythromycin,,,MDR1-expressing MDCKII cell; transepithelial transport (basal to apical),MDCKII,,,,,human,mbds0003,v2007,2013-12-09 19:53:41
mbbd000000219,mbcd0001517,mbtp000001,mbrf0001027,,,,,substrate,,,,,clarythromycin,found to be an ATPase activator and to be effluxed in MDCKII-MDR1 cells,,MDR1-expressing Sf9 cell; ATP hydrolysis,Sf9,,,,,human,mbds0003,v2007,2014-03-01 05:27:59
mbbd000000220,mbcd0002340,mbtp000001,mbrf0001027,,=,,,inhibitor,151,30.4,%,,Chlorpromazine,,,MDR1-expressing MDCKII cell; inhibition of Calcein-AM efflux,MDCKII,mbcd0000212,,,,human,mbds0003,v2007,2013-12-09 20:51:13
mbbd000000221,mbcd0002340,mbtp000001,mbrf0001027,,,,,non-substrate,,,,,chlorpromazine,,,MDR1-expressing MDCKII cell; transepithelial transport (basal to apical),MDCKII,,,,,human,mbds0003,v2007,2013-12-09 20:51:13
mbbd000000222,mbcd0003088,mbtp000001,mbrf0001027,,=,,,non-inhibitor,151,2.49,%,,Chloroquine,,,MDR1-expressing MDCKII cell; inhibition of Calcein-AM efflux,MDCKII,mbcd0000212,,,,human,mbds0003,v2007,2013-12-09 20:51:13
mbbd000000223,mbcd0003088,mbtp000001,mbrf0001027,,,,,substrate,,,,,chloroquine,,,MDR1-expressing MDCKII cell; transepithelial transport (basal to apical),MDCKII,,,,,human,mbds0003,v2007,2013-12-09 20:51:13
mbbd000000224,mbcd0003088,mbtp000001,mbrf0001027,,,,,substrate,,,,,chloroquine,"found not to be an ATPase activator, but found to be effluxed in MDCKII-MDR1 cells",,MDR1-expressing Sf9 cell; ATP hydrolysis,Sf9,,,,,human,mbds0003,v2007,2014-03-01 04:41:52
mbbd000000225,mbcd0002383,mbtp000001,mbrf0001027,,=,,,inhibitor,151,17.6,%,,Amprenavir,,,MDR1-expressing MDCKII cell; inhibition of Calcein-AM efflux,MDCKII,mbcd0000212,,,,human,mbds0003,v2007,2013-12-09 20:51:13
mbbd000000226,mbcd0002383,mbtp000001,mbrf0001027,,,,,substrate,,,,,amprenavir,found to be an ATPase activator in Sf9-MDR1 cells and to be effluxed,,MDR1-expressing MDCKII cell; transepithelial transport (basal to apical),MDCKII,,,,,human,mbds0003,v2007,2014-03-01 05:27:59
mbbd000000227,mbcd0001372,mbtp000001,mbrf0001027,,=,,,non-inhibitor,151,1.39,%,,Actinomycin,,,MDR1-expressing MDCKII cell; inhibition of Calcein-AM efflux,MDCKII,mbcd0000212,,,,human,mbds0003,v2007,2013-12-09 20:51:13
mbbd000000228,mbcd0001372,mbtp000001,mbrf0001027,,,,,substrate,,,,,actinomycin,,,MDR1-expressing MDCKII cell; transepithelial transport (basal to apical),MDCKII,,,,,human,mbds0003,v2007,2013-12-09 20:51:12
mbbd000000229,mbcd0001372,mbtp000001,mbrf0001027,,,,,substrate,,,,,actinomycin,"found not to be an ATPase activator, but found to be effluxed in MDCKII-MDR1 cells",,MDR1-expressing Sf9 cell; ATP hydrolysis,Sf9,,,,,human,mbds0003,v2007,2014-03-01 04:41:52
mbbd000000230,mbcd0027733,mbtp000001,mbrf0001028,,=,,,inhibitor,25,2.7,microM,,SCH66336,,,MDR1-expressing NIH3T3 cell; inhibition of DNR efflux (DNR: ? microM),NIH-3T3,mbcd0005183,,,,human,mbds0003,v2007,2013-12-09 19:54:40
mbbd000000231,mbcd0001151,mbtp000001,mbrf0001029,,=,,,inhibitor,25,29.5,microM,0.6,Vinblastine,,,NIH-3T3-G185 cell; inhibition of Rhodamine 123 efflux,NIH-3T3-G185,mbcd0000746,,,,human,mbds0003,v2007,2013-12-09 19:54:39
mbbd000000232,mbcd0001151,mbtp000001,mbrf0001029,,=,,,inhibitor,25,19.9,microM,0.2,Vinblastine,,,NIH-3T3-G185 cell; inhibition of LDS-751 efflux,NIH-3T3-G185,mbcd0030453,,,,human,mbds0003,v2007,2013-12-09 19:54:38
mbbd000000233,mbcd0001151,mbtp000001,mbrf0001029,,=,,,inhibitor,25,17.7,microM,0.3,Vinblastine,,,NIH-3T3-G185 cell; inhibition of Daunorubicin efflux,NIH-3T3-G185,mbcd0005183,,,,human,mbds0003,v2007,2013-12-09 19:54:38
mbbd000000234,mbcd0027062,mbtp000001,mbrf0001029,,=,,,inhibitor,25,446.5,microM,313.3,Verapamil,,,NIH-3T3-G185 cell; inhibition of Fluo-3-AM efflux,NIH-3T3-G185,mbcd0031383,,,,human,mbds0003,v2007,2013-12-09 19:54:44
mbbd000000235,mbcd0027062,mbtp000001,mbrf0001029,,=,,,inhibitor,25,28.9,microM,6.0,Verapamil,,,NIH-3T3-G185 cell; inhibition of Calcein-AM efflux,NIH-3T3-G185,mbcd0000212,,,,human,mbds0003,v2007,2013-12-09 19:54:43
mbbd000000236,mbcd0027062,mbtp000001,mbrf0001029,,=,,,inhibitor,25,42.0,microM,2.5,Verapamil,,,NIH-3T3-G185 cell; inhibition of JC-1 efflux,NIH-3T3-G185,mbcd0000497,,,,human,mbds0003,v2007,2013-12-09 19:54:42
mbbd000000237,mbcd0027062,mbtp000001,mbrf0001029,,=,,,inhibitor,25,38.2,microM,3.1,Verapamil,,,NIH-3T3-G185 cell; inhibition of Tetramethylrosamine efflux,NIH-3T3-G185,mbcd0000841,,,,human,mbds0003,v2007,2013-12-09 19:54:41
mbbd000000238,mbcd0027062,mbtp000001,mbrf0001029,,=,,,inhibitor,25,6.5,microM,0.7,Verapamil,,,NIH-3T3-G185 cell; inhibition of Rhodamine 123 efflux,NIH-3T3-G185,mbcd0000746,,,,human,mbds0003,v2007,2013-12-09 19:54:45
mbbd000000239,mbcd0027062,mbtp000001,mbrf0001029,,=,,,inhibitor,25,4.7,microM,1.3,Verapamil,,,NIH-3T3-G185 cell; inhibition of LDS-751 efflux,NIH-3T3-G185,mbcd0030453,,,,human,mbds0003,v2007,2013-12-09 19:54:44
mbbd000000240,mbcd0027062,mbtp000001,mbrf0001029,,=,,,inhibitor,25,4.2,microM,1.0,Verapamil,,,NIH-3T3-G185 cell; inhibition of Daunorubicin efflux,NIH-3T3-G185,mbcd0005183,,,,human,mbds0003,v2007,2013-12-09 20:51:26
mbbd000000241,mbcd0028263,mbtp000001,mbrf0001029,,=,,,inhibitor,25,86.3,microM,3.4,Troleandomycin,,,NIH-3T3-G185 cell; inhibition of Rhodamine 123 efflux,NIH-3T3-G185,mbcd0000746,,,,human,mbds0003,v2007,2013-12-09 20:51:26
mbbd000000242,mbcd0028263,mbtp000001,mbrf0001029,,=,,,inhibitor,25,78.2,microM,2.7,Troleandomycin,,,NIH-3T3-G185 cell; inhibition of LDS-751 efflux,NIH-3T3-G185,mbcd0030453,,,,human,mbds0003,v2007,2013-12-09 20:51:26
mbbd000000243,mbcd0028263,mbtp000001,mbrf0001029,,=,,,inhibitor,25,68.3,microM,3.0,Troleandomycin,,,NIH-3T3-G185 cell; inhibition of Daunorubicin efflux,NIH-3T3-G185,mbcd0005183,,,,human,mbds0003,v2007,2013-12-09 20:51:26
mbbd000000244,mbcd0002885,mbtp000001,mbrf0001029,,=,,,inhibitor,25,10.9,microM,7.6,Trifluoperazine,,,NIH-3T3-G185 cell; inhibition of Rhodamine 123 efflux,NIH-3T3-G185,mbcd0000746,,,,human,mbds0003,v2007,2013-12-09 20:51:26
mbbd000000245,mbcd0002885,mbtp000001,mbrf0001029,,=,,,inhibitor,25,6.3,microM,0.2,Trifluoperazine,,,NIH-3T3-G185 cell; inhibition of LDS-751 efflux,NIH-3T3-G185,mbcd0030453,,,,human,mbds0003,v2007,2013-12-09 20:51:27
mbbd000000246,mbcd0002885,mbtp000001,mbrf0001029,,=,,,inhibitor,25,7.2,microM,0.2,Trifluoperazine,,,NIH-3T3-G185 cell; inhibition of Daunorubicin efflux,NIH-3T3-G185,mbcd0005183,,,,human,mbds0003,v2007,2013-12-09 20:51:26
mbbd000000247,mbcd0001644,mbtp000001,mbrf0001029,,>,,,non-inhibitor,25,500.0,microM,,TPP+,,,NIH-3T3-G185 cell; inhibition of Rhodamine 123 efflux,NIH-3T3-G185,mbcd0000746,,,,human,mbds0003,v2007,2013-12-09 20:51:26
mbbd000000248,mbcd0001644,mbtp000001,mbrf0001029,,=,,,inhibitor,25,426.6,microM,15.3,TPP,,,NIH-3T3-G185 cell; inhibition of LDS-751 efflux,NIH-3T3-G185,mbcd0030453,,,,human,mbds0003,v2007,2013-12-09 20:51:25
mbbd000000249,mbcd0001644,mbtp000001,mbrf0001029,,=,,,inhibitor,25,490.0,microM,27.6,TPP,,,NIH-3T3-G185 cell; inhibition of Daunorubicin efflux,NIH-3T3-G185,mbcd0005183,,,,human,mbds0003,v2007,2013-12-09 20:51:26
mbbd000000250,mbcd0002337,mbtp000001,mbrf0001029,,=,,,inhibitor,25,2.7,microM,0.1,Terfenadine,,,NIH-3T3-G185 cell; inhibition of Rhodamine 123 efflux,NIH-3T3-G185,mbcd0000746,,,,human,mbds0003,v2007,2013-12-09 19:56:09
mbbd000000251,mbcd0002337,mbtp000001,mbrf0001029,,=,,,inhibitor,25,2.5,microM,0.2,Terfenadine,,,NIH-3T3-G185 cell; inhibition of LDS-751 efflux,NIH-3T3-G185,mbcd0030453,,,,human,mbds0003,v2007,2013-12-09 19:56:09
mbbd000000252,mbcd0002337,mbtp000001,mbrf0001029,,=,,,inhibitor,25,1.8,microM,0.3,Terfenadine,,,NIH-3T3-G185 cell; inhibition of Daunorubicin efflux,NIH-3T3-G185,mbcd0005183,,,,human,mbds0003,v2007,2013-12-09 19:56:13
mbbd000000253,mbcd0001532,mbtp000001,mbrf0001029,,=,,,inhibitor,25,70.2,microM,2.7,Paclitaxel,,,NIH-3T3-G185 cell; inhibition of Rhodamine 123 efflux,NIH-3T3-G185,mbcd0000746,,,,human,mbds0003,v2007,2013-12-09 19:56:11
mbbd000000254,mbcd0001532,mbtp000001,mbrf0001029,,=,,,inhibitor,25,53.9,microM,4.1,Paclitaxel,,,NIH-3T3-G185 cell; inhibition of LDS-751 efflux,NIH-3T3-G185,mbcd0030453,,,,human,mbds0003,v2007,2013-12-09 19:56:15
mbbd000000255,mbcd0001532,mbtp000001,mbrf0001029,,=,,,inhibitor,25,54.0,microM,1.3,Paclitaxel,,,NIH-3T3-G185 cell; inhibition of Daunorubicin efflux,NIH-3T3-G185,mbcd0005183,,,,human,mbds0003,v2007,2013-12-09 19:56:14
mbbd000000256,mbcd0002889,mbtp000001,mbrf0001029,,=,,,inhibitor,25,31.4,microM,1.5,Tamoxifen,,,NIH-3T3-G185 cell; inhibition of Rhodamine 123 efflux,NIH-3T3-G185,mbcd0000746,,,,human,mbds0003,v2007,2013-12-09 19:56:16
mbbd000000257,mbcd0002889,mbtp000001,mbrf0001029,,=,,,inhibitor,25,12.1,microM,0.2,Tamoxifen,,,NIH-3T3-G185 cell; inhibition of LDS-751 efflux,NIH-3T3-G185,mbcd0030453,,,,human,mbds0003,v2007,2013-12-09 19:56:16
mbbd000000258,mbcd0002889,mbtp000001,mbrf0001029,,=,,,inhibitor,25,6.4,microM,0.3,Tamoxifen,,,NIH-3T3-G185 cell; inhibition of Daunorubicin efflux,NIH-3T3-G185,mbcd0005183,,,,human,mbds0003,v2007,2013-12-09 19:56:08
mbbd000000259,mbcd0001194,mbtp000001,mbrf0001029,,=,,,inhibitor,25,26.1,microM,0.7,Simvastatin,,,NIH-3T3-G185 cell; inhibition of LDS-751 efflux,NIH-3T3-G185,mbcd0030453,,,,human,mbds0003,v2007,2013-12-09 19:56:06
mbbd000000260,mbcd0001194,mbtp000001,mbrf0001029,,=,,,inhibitor,25,56.8,microM,5.7,Simvastatin,,,NIH-3T3-G185 cell; inhibition of Rhodamine 123 efflux,NIH-3T3-G185,mbcd0000746,,,,human,mbds0003,v2007,2013-12-09 20:57:55
mbbd000000261,mbcd0001941,mbtp000001,mbrf0001029,,=,,,inhibitor,25,2.1,microM,0.5,Reserpine,,,NIH-3T3-G185 cell; inhibition of Fluo-3-AM efflux,NIH-3T3-G185,mbcd0031383,,,,human,mbds0003,v2007,2013-12-09 20:57:56
mbbd000000262,mbcd0001941,mbtp000001,mbrf0001029,,=,,,inhibitor,25,2.6,microM,0.3,Reserpine,,,NIH-3T3-G185 cell; inhibition of Calcein-AM efflux,NIH-3T3-G185,mbcd0000212,,,,human,mbds0003,v2007,2013-12-09 20:57:56
mbbd000000263,mbcd0001941,mbtp000001,mbrf0001029,,=,,,inhibitor,25,6.1,microM,0.7,Reserpine,,,NIH-3T3-G185 cell; inhibition of JC-1 efflux,NIH-3T3-G185,mbcd0000497,,,,human,mbds0003,v2007,2013-12-09 20:57:56
mbbd000000264,mbcd0001941,mbtp000001,mbrf0001029,,=,,,inhibitor,25,5.3,microM,0.1,Reserpine,,,NIH-3T3-G185 cell; inhibition of Tetramethylrosamine efflux,NIH-3T3-G185,mbcd0000841,,,,human,mbds0003,v2007,2013-12-09 20:57:56
mbbd000000265,mbcd0001941,mbtp000001,mbrf0001029,,=,,,inhibitor,25,3.9,microM,0.5,Reserpine,,,NIH-3T3-G185 cell; inhibition of Rhodamine 123 efflux,NIH-3T3-G185,mbcd0000746,,,,human,mbds0003,v2007,2013-12-09 20:57:56
mbbd000000266,mbcd0001941,mbtp000001,mbrf0001029,,=,,,inhibitor,25,2.1,microM,0.1,Reserpine,,,NIH-3T3-G185 cell; inhibition of LDS-751 efflux,NIH-3T3-G185,mbcd0030453,,,,human,mbds0003,v2007,2013-12-09 20:52:34
mbbd000000267,mbcd0001941,mbtp000001,mbrf0001029,,=,,,inhibitor,25,0.5,microM,0.1,Reserpine,,,NIH-3T3-G185 cell; inhibition of Daunorubicin efflux,NIH-3T3-G185,mbcd0005183,,,,human,mbds0003,v2007,2013-12-09 20:57:56
mbbd000000268,mbcd0001092,mbtp000001,mbrf0001029,,=,,,inhibitor,25,112.4,microM,7.7,Quinine,,,NIH-3T3-G185 cell; inhibition of Fluo-3-AM efflux,NIH-3T3-G185,mbcd0031383,,,,human,mbds0003,v2007,2013-12-09 20:52:35
mbbd000000269,mbcd0001092,mbtp000001,mbrf0001029,,=,,,inhibitor,25,167.8,microM,36.4,Quinine,,,NIH-3T3-G185 cell; inhibition of Calcein-AM efflux,NIH-3T3-G185,mbcd0000212,,,,human,mbds0003,v2007,2013-12-09 20:52:35
mbbd000000270,mbcd0001092,mbtp000001,mbrf0001029,,=,,,inhibitor,25,159.3,microM,4.5,Quinine,,,NIH-3T3-G185 cell; inhibition of JC-1 efflux,NIH-3T3-G185,mbcd0000497,,,,human,mbds0003,v2007,2013-12-09 21:01:22
mbbd000000271,mbcd0001092,mbtp000001,mbrf0001029,,=,,,inhibitor,25,184.9,microM,20.0,Quinine,,,NIH-3T3-G185 cell; inhibition of Tetramethylrosamine efflux,NIH-3T3-G185,mbcd0000841,,,,human,mbds0003,v2007,2013-12-09 20:54:45
mbbd000000272,mbcd0001092,mbtp000001,mbrf0001029,,=,,,inhibitor,25,87.6,microM,10.6,Quinine,,,NIH-3T3-G185 cell; inhibition of Rhodamine 123 efflux,NIH-3T3-G185,mbcd0000746,,,,human,mbds0003,v2007,2013-12-09 20:54:43
mbbd000000273,mbcd0001092,mbtp000001,mbrf0001029,,=,,,inhibitor,25,74.4,microM,5.9,Quinine,,,NIH-3T3-G185 cell; inhibition of LDS-751 efflux,NIH-3T3-G185,mbcd0030453,,,,human,mbds0003,v2007,2013-12-09 20:54:42
mbbd000000274,mbcd0001092,mbtp000001,mbrf0001029,,=,,,inhibitor,25,22.6,microM,1.5,Quinine,,,NIH-3T3-G185 cell; inhibition of Daunorubicin efflux,NIH-3T3-G185,mbcd0005183,,,,human,mbds0003,v2007,2013-12-09 20:54:42
mbbd000000275,mbcd0027018,mbtp000001,mbrf0001029,,=,,,inhibitor,25,33.9,microM,1.7,Quinidine,,,NIH-3T3-G185 cell; inhibition of Rhodamine 123 efflux,NIH-3T3-G185,mbcd0000746,,,,human,mbds0003,v2007,2013-12-09 20:54:42
mbbd000000276,mbcd0027018,mbtp000001,mbrf0001029,,=,,,inhibitor,25,1.0,microM,0.1,Quinidine,,,NIH-3T3-G185 cell; inhibition of LDS-751 efflux,NIH-3T3-G185,mbcd0030453,,,,human,mbds0003,v2007,2013-12-09 20:54:42
mbbd000000277,mbcd0027018,mbtp000001,mbrf0001029,,=,,,inhibitor,25,18.8,microM,8.7,Quinidine,,,NIH-3T3-G185 cell; inhibition of Daunorubicin efflux,NIH-3T3-G185,mbcd0005183,,,,human,mbds0003,v2007,2013-12-09 19:58:31
mbbd000000278,mbcd0001892,mbtp000001,mbrf0001029,,=,,,inhibitor,25,192.2,microM,2.1,Progesterone,,,NIH-3T3-G185 cell; inhibition of Rhodamine 123 efflux,NIH-3T3-G185,mbcd0000746,,,,human,mbds0003,v2007,2013-12-09 19:58:42
mbbd000000279,mbcd0001892,mbtp000001,mbrf0001029,,=,,,inhibitor,25,88.1,microM,6.4,Progesterone,,,NIH-3T3-G185 cell; inhibition of LDS-751 efflux,NIH-3T3-G185,mbcd0030453,,,,human,mbds0003,v2007,2013-12-09 19:58:39
mbbd000000280,mbcd0001892,mbtp000001,mbrf0001029,,=,,,inhibitor,25,96.2,microM,4.5,Progesterone,,,NIH-3T3-G185 cell; inhibition of Daunorubicin efflux,NIH-3T3-G185,mbcd0005183,,,,human,mbds0003,v2007,2013-12-09 20:11:05
mbbd000000281,mbcd0000606,mbtp000001,mbrf0001029,,=,,,inhibitor,25,8.6,microM,0.2,N-norgallopamil,,,NIH-3T3-G185 cell; inhibition of Rhodamine 123 efflux,NIH-3T3-G185,mbcd0000746,,,,human,mbds0003,v2007,2013-12-09 20:11:05
mbbd000000282,mbcd0000606,mbtp000001,mbrf0001029,,=,,,inhibitor,25,4.9,microM,0.1,N-norgallopamil,,,NIH-3T3-G185 cell; inhibition of LDS-751 efflux,NIH-3T3-G185,mbcd0030453,,,,human,mbds0003,v2007,2013-12-09 20:11:04
mbbd000000283,mbcd0000606,mbtp000001,mbrf0001029,,=,,,inhibitor,25,3.6,microM,0.1,N-norgallopamil,,,NIH-3T3-G185 cell; inhibition of Daunorubicin efflux,NIH-3T3-G185,mbcd0005183,,,,human,mbds0003,v2007,2013-12-09 20:11:05
mbbd000000284,mbcd0002576,mbtp000001,mbrf0001029,,=,,,inhibitor,25,14.6,microM,1.8,Nicardipine,,,NIH-3T3-G185 cell; inhibition of Fluo-3-AM efflux,NIH-3T3-G185,mbcd0031383,,,,human,mbds0003,v2007,2013-12-09 20:11:02
mbbd000000285,mbcd0002576,mbtp000001,mbrf0001029,,=,,,inhibitor,25,6.6,microM,0.4,Nicardipine,,,NIH-3T3-G185 cell; inhibition of Calcein-AM efflux,NIH-3T3-G185,mbcd0000212,,,,human,mbds0003,v2007,2013-12-09 20:11:04
mbbd000000286,mbcd0002576,mbtp000001,mbrf0001029,,=,,,inhibitor,25,7.1,microM,0.7,Nicardipine,,,NIH-3T3-G185 cell; inhibition of JC-1 efflux,NIH-3T3-G185,mbcd0000497,,,,human,mbds0003,v2007,2013-12-09 20:11:00
mbbd000000287,mbcd0002576,mbtp000001,mbrf0001029,,=,,,inhibitor,25,11.7,microM,0.6,Nicardipine,,,NIH-3T3-G185 cell; inhibition of Tetramethylrosamine efflux,NIH-3T3-G185,mbcd0000841,,,,human,mbds0003,v2007,2013-12-09 20:11:01
mbbd000000288,mbcd0002576,mbtp000001,mbrf0001029,,>,,,inhibitor,25,25.8,microM,,Nicardipine,,,NIH-3T3-G185 cell; inhibition of Rhodamine 123 efflux,NIH-3T3-G185,mbcd0000746,,,,human,mbds0003,v2007,2013-12-09 20:10:58
mbbd000000289,mbcd0002576,mbtp000001,mbrf0001029,,=,,,inhibitor,25,5.6,microM,0.5,Nicardipine,,,NIH-3T3-G185 cell; inhibition of LDS-751 efflux,NIH-3T3-G185,mbcd0030453,,,,human,mbds0003,v2007,2013-12-09 20:10:59
mbbd000000290,mbcd0002576,mbtp000001,mbrf0001029,,=,,,inhibitor,25,3.2,microM,0.1,Nicardipine,,,NIH-3T3-G185 cell; inhibition of Daunorubicin efflux,NIH-3T3-G185,mbcd0005183,,,,human,mbds0003,v2007,2013-12-09 20:58:04
mbbd000000291,mbcd0025591,mbtp000001,mbrf0001029,,=,,,inhibitor,25,32.7,microM,2.2,lovastatin,,,NIH-3T3-G185 cell; inhibition of LDS-751 efflux,NIH-3T3-G185,mbcd0030453,,,,human,mbds0003,v2007,2013-12-09 20:58:04
mbbd000000292,mbcd0025591,mbtp000001,mbrf0001029,,=,,,inhibitor,25,114.4,microM,7.3,lovastatin,,,NIH-3T3-G185 cell; inhibition of Rhodamine 123 efflux,NIH-3T3-G185,mbcd0000746,,,,human,mbds0003,v2007,2013-12-09 20:58:05
mbbd000000293,mbcd0017104,mbtp000001,mbrf0001029,,=,,,inhibitor,25,53.4,microM,3.4,Ketoconazole,,,NIH-3T3-G185 cell; inhibition of Rhodamine 123 efflux,NIH-3T3-G185,mbcd0000746,,,,human,mbds0003,v2007,2013-12-09 20:58:05
mbbd000000294,mbcd0017104,mbtp000001,mbrf0001029,,=,,,inhibitor,25,23.4,microM,1.0,Ketoconazole,,,NIH-3T3-G185 cell; inhibition of LDS-751 efflux,NIH-3T3-G185,mbcd0030453,,,,human,mbds0003,v2007,2013-12-09 20:58:04
mbbd000000295,mbcd0017104,mbtp000001,mbrf0001029,,=,,,inhibitor,25,5.6,microM,0.4,Ketoconazole,,,NIH-3T3-G185 cell; inhibition of Daunorubicin efflux,NIH-3T3-G185,mbcd0005183,,,,human,mbds0003,v2007,2013-12-09 20:58:04
mbbd000000296,mbcd0002191,mbtp000001,mbrf0001029,,>,,,non-inhibitor,25,500.0,microM,,itraconazole,,,NIH-3T3-G185 cell; inhibition of Rhodamine 123 efflux,NIH-3T3-G185,mbcd0000746,,,,human,mbds0003,v2007,2013-12-09 20:58:04
mbbd000000297,mbcd0002191,mbtp000001,mbrf0001029,,=,,,inhibitor,25,2.4,microM,0.4,itraconazole,,,NIH-3T3-G185 cell; inhibition of LDS-751 efflux,NIH-3T3-G185,mbcd0030453,,,,human,mbds0003,v2007,2013-12-09 20:58:04
mbbd000000298,mbcd0003025,mbtp000001,mbrf0001029,,>,,,non-inhibitor,25,500.0,microM,,indomethacin,,,"NIH-3T3-G185 cell; inhibition of Daunorubicin, LDS-751 and Rhodamine 123 efflux",NIH-3T3-G185,mbcd0005183,,,,human,mbds0003,v2007,2013-12-09 20:58:04
mbbd000000299,mbcd0003975,mbtp000001,mbrf0001029,,>,,,non-inhibitor,25,500.0,microM,,Forskolin,,,NIH-3T3-G185 cell; inhibition of Rhodamine 123 efflux,NIH-3T3-G185,mbcd0000746,,,,human,mbds0003,v2007,2013-12-09 20:58:03
mbbd000000300,mbcd0003975,mbtp000001,mbrf0001029,,=,,,inhibitor,25,188.2,microM,24.0,Forskolin,,,NIH-3T3-G185 cell; inhibition of LDS-751 efflux,NIH-3T3-G185,mbcd0030453,,,,human,mbds0003,v2007,2013-12-09 20:57:33
mbbd000000301,mbcd0003975,mbtp000001,mbrf0001029,,=,,,inhibitor,25,80.2,microM,36.1,Forskolin,,,NIH-3T3-G185 cell; inhibition of Daunorubicin efflux,NIH-3T3-G185,mbcd0005183,,,,human,mbds0003,v2007,2013-12-09 20:57:33
mbbd000000302,mbcd0003897,mbtp000001,mbrf0001029,,=,,,inhibitor,25,10.4,microM,0.6,Fluphenazine,,,NIH-3T3-G185 cell; inhibition of Rhodamine 123 efflux,NIH-3T3-G185,mbcd0000746,,,,human,mbds0003,v2007,2013-12-09 20:57:32
mbbd000000303,mbcd0003897,mbtp000001,mbrf0001029,,=,,,inhibitor,25,5.7,microM,0.5,Fluphenazine,,,NIH-3T3-G185 cell; inhibition of LDS-751 efflux,NIH-3T3-G185,mbcd0030453,,,,human,mbds0003,v2007,2013-12-09 20:57:32
mbbd000000304,mbcd0003897,mbtp000001,mbrf0001029,,=,,,inhibitor,25,6.5,microM,0.4,Fluphenazine,,,NIH-3T3-G185 cell; inhibition of Daunorubicin efflux,NIH-3T3-G185,mbcd0005183,,,,human,mbds0003,v2007,2013-12-09 20:57:32
mbbd000000305,mbcd0003011,mbtp000001,mbrf0001029,,>,,,inhibitor,25,60.0,microM,,felodipine,,,NIH-3T3-G185 cell; inhibition of Rhodamine 123 efflux,NIH-3T3-G185,mbcd0000746,,,,human,mbds0003,v2007,2013-12-09 20:57:32
mbbd000000306,mbcd0003011,mbtp000001,mbrf0001029,,=,,,inhibitor,25,32.3,microM,0.4,felodipine,,,NIH-3T3-G185 cell; inhibition of LDS-751 efflux,NIH-3T3-G185,mbcd0030453,,,,human,mbds0003,v2007,2013-12-09 20:57:32
mbbd000000307,mbcd0003011,mbtp000001,mbrf0001029,,=,,,inhibitor,25,26.3,microM,1.2,felodipine,,,NIH-3T3-G185 cell; inhibition of Daunorubicin efflux,NIH-3T3-G185,mbcd0005183,,,,human,mbds0003,v2007,2013-12-09 20:07:43
mbbd000000308,mbcd0000373,mbtp000001,mbrf0001029,,=,,,inhibitor,25,130.3,microM,24.9,Emetine,,,NIH-3T3-G185 cell; inhibition of Fluo-3-AM efflux,NIH-3T3-G185,mbcd0031383,,,,human,mbds0003,v2007,2013-12-09 20:07:43
mbbd000000309,mbcd0000373,mbtp000001,mbrf0001029,,=,,,inhibitor,25,35.1,microM,5.5,Emetine,,,NIH-3T3-G185 cell; inhibition of Calcein-AM efflux,NIH-3T3-G185,mbcd0000212,,,,human,mbds0003,v2007,2013-12-09 20:07:43
mbbd000000310,mbcd0000373,mbtp000001,mbrf0001029,,=,,,inhibitor,25,115.6,microM,8.3,Emetine,,,NIH-3T3-G185 cell; inhibition of JC-1 efflux,NIH-3T3-G185,mbcd0000497,,,,human,mbds0003,v2007,2013-12-09 20:57:27
mbbd000000311,mbcd0000373,mbtp000001,mbrf0001029,,=,,,inhibitor,25,207.1,microM,123.3,Emetine,,,NIH-3T3-G185 cell; inhibition of Tetramethylrosamine efflux,NIH-3T3-G185,mbcd0000841,,,,human,mbds0003,v2007,2013-12-09 20:57:27
mbbd000000312,mbcd0000373,mbtp000001,mbrf0001029,,=,,,inhibitor,25,9.6,microM,0.9,Emetine,,,NIH-3T3-G185 cell; inhibition of Rhodamine 123 efflux,NIH-3T3-G185,mbcd0000746,,,,human,mbds0003,v2007,2013-12-09 20:57:27
mbbd000000313,mbcd0000373,mbtp000001,mbrf0001029,,=,,,inhibitor,25,2.4,microM,0.1,Emetine,,,NIH-3T3-G185 cell; inhibition of LDS-751 efflux,NIH-3T3-G185,mbcd0030453,,,,human,mbds0003,v2007,2013-12-09 19:53:24
mbbd000000314,mbcd0000373,mbtp000001,mbrf0001029,,=,,,inhibitor,25,9.2,microM,0.3,Emetine,,,NIH-3T3-G185 cell; inhibition of Daunorubicin efflux,NIH-3T3-G185,mbcd0005183,,,,human,mbds0003,v2007,2013-12-09 20:57:27
mbbd000000315,mbcd0003100,mbtp000001,mbrf0001029,,=,,,inhibitor,25,34.3,microM,2.3,Dipyridamole,,,NIH-3T3-G185 cell; inhibition of Rhodamine 123 efflux,NIH-3T3-G185,mbcd0000746,,,,human,mbds0003,v2007,2013-12-09 20:57:27
mbbd000000316,mbcd0003100,mbtp000001,mbrf0001029,,=,,,inhibitor,25,23.7,microM,1.6,Dipyridamole,,,NIH-3T3-G185 cell; inhibition of LDS-751 efflux,NIH-3T3-G185,mbcd0030453,,,,human,mbds0003,v2007,2013-12-09 20:57:27
mbbd000000317,mbcd0003100,mbtp000001,mbrf0001029,,=,,,inhibitor,25,22.7,microM,0.3,Dipyridamole,,,NIH-3T3-G185 cell; inhibition of Daunorubicin efflux,NIH-3T3-G185,mbcd0005183,,,,human,mbds0003,v2007,2013-12-09 20:57:27
mbbd000000318,mbcd0000311,mbtp000001,mbrf0001029,,=,,,inhibitor,25,2.4,microM,0.1,cyclosporin A,,,NIH-3T3-G185 cell; inhibition of Fluo-3-AM efflux,NIH-3T3-G185,mbcd0031383,,,,human,mbds0003,v2007,2013-12-09 20:57:26
mbbd000000319,mbcd0000311,mbtp000001,mbrf0001029,,=,,,inhibitor,25,1.7,microM,0.2,cyclosporin A,,,NIH-3T3-G185 cell; inhibition of Calcein-AM efflux,NIH-3T3-G185,mbcd0000212,,,,human,mbds0003,v2007,2013-12-09 20:57:27
mbbd000000320,mbcd0000311,mbtp000001,mbrf0001029,,=,,,inhibitor,25,4.3,microM,0.2,cyclosporin A,,,NIH-3T3-G185 cell; inhibition of JC-1 efflux,NIH-3T3-G185,mbcd0000497,,,,human,mbds0003,v2007,2013-12-09 20:05:17
mbbd000000321,mbcd0000311,mbtp000001,mbrf0001029,,=,,,inhibitor,25,2.1,microM,0.1,cyclosporin A,,,NIH-3T3-G185 cell; inhibition of Tetramethylrosamine efflux,NIH-3T3-G185,mbcd0000841,,,,human,mbds0003,v2007,2013-12-09 20:05:16
mbbd000000322,mbcd0000311,mbtp000001,mbrf0001029,,=,,,inhibitor,25,1.7,microM,0.1,cyclosporin A,,,NIH-3T3-G185 cell; inhibition of Rhodamine 123 efflux,NIH-3T3-G185,mbcd0000746,,,,human,mbds0003,v2007,2013-12-09 20:05:19
mbbd000000323,mbcd0000311,mbtp000001,mbrf0001029,,=,,,inhibitor,25,1.8,microM,0.1,cyclosporin A,,,NIH-3T3-G185 cell; inhibition of LDS-751 efflux,NIH-3T3-G185,mbcd0030453,,,,human,mbds0003,v2007,2013-12-09 20:05:18
mbbd000000324,mbcd0000311,mbtp000001,mbrf0001029,,=,,,inhibitor,25,1.4,microM,0.1,cyclosporin A,,,NIH-3T3-G185 cell; inhibition of Daunorubicin efflux,NIH-3T3-G185,mbcd0005183,,,,human,mbds0003,v2007,2013-12-09 20:05:20
mbbd000000325,mbcd0005776,mbtp000001,mbrf0001029,,=,,,inhibitor,25,1.0,microM,8.6,Clofazimine,,,NIH-3T3-G185 cell; inhibition of Rhodamine 123 efflux,NIH-3T3-G185,mbcd0000746,,,,human,mbds0003,v2007,2013-12-09 20:05:19
mbbd000000326,mbcd0005776,mbtp000001,mbrf0001029,,=,,,inhibitor,25,1.1,microM,0.03,Clofazimine,,,NIH-3T3-G185 cell; inhibition of LDS-751 efflux,NIH-3T3-G185,mbcd0030453,,,,human,mbds0003,v2007,2013-12-09 20:05:20
mbbd000000327,mbcd0005776,mbtp000001,mbrf0001029,,=,,,inhibitor,25,0.6,microM,0.2,Clofazimine,,,NIH-3T3-G185 cell; inhibition of Daunorubicin efflux,NIH-3T3-G185,mbcd0005183,,,,human,mbds0003,v2007,2013-12-09 20:05:20
mbbd000000328,mbcd0001517,mbtp000001,mbrf0001029,,=,,,inhibitor,25,86.7,microM,3.6,Clarithromycin,,,NIH-3T3-G185 cell; inhibition of Fluo-3-AM efflux,NIH-3T3-G185,mbcd0031383,,,,human,mbds0003,v2007,2013-12-09 20:05:21
mbbd000000329,mbcd0001517,mbtp000001,mbrf0001029,,=,,,inhibitor,25,56.1,microM,13.3,Clarithromycin,,,NIH-3T3-G185 cell; inhibition of Calcein-AM efflux,NIH-3T3-G185,mbcd0000212,,,,human,mbds0003,v2007,2013-12-09 20:05:20
mbbd000000330,mbcd0001517,mbtp000001,mbrf0001029,,=,,,inhibitor,25,50.2,microM,1.2,Clarithromycin,,,NIH-3T3-G185 cell; inhibition of JC-1 efflux,NIH-3T3-G185,mbcd0000497,,,,human,mbds0003,v2007,2013-12-09 20:55:00
mbbd000000331,mbcd0001517,mbtp000001,mbrf0001029,,=,,,inhibitor,25,23.8,microM,6.7,Clarithromycin,,,NIH-3T3-G185 cell; inhibition of Tetramethylrosamine efflux,NIH-3T3-G185,mbcd0000841,,,,human,mbds0003,v2007,2013-12-09 20:55:00
mbbd000000332,mbcd0001517,mbtp000001,mbrf0001029,,=,,,inhibitor,25,15.1,microM,3.6,Clarithromycin,,,NIH-3T3-G185 cell; inhibition of Rhodamine 123 efflux,NIH-3T3-G185,mbcd0000746,,,,human,mbds0003,v2007,2013-12-09 20:55:00
mbbd000000333,mbcd0001517,mbtp000001,mbrf0001029,,=,,,inhibitor,25,7.2,microM,0.4,Clarithromycin,,,NIH-3T3-G185 cell; inhibition of LDS-751 efflux,NIH-3T3-G185,mbcd0030453,,,,human,mbds0003,v2007,2013-12-09 20:55:00
mbbd000000334,mbcd0001517,mbtp000001,mbrf0001029,,=,,,inhibitor,25,3.8,microM,0.1,Clarithromycin,,,NIH-3T3-G185 cell; inhibition of Daunorubicin efflux,NIH-3T3-G185,mbcd0005183,,,,human,mbds0003,v2007,2013-12-09 20:55:00
mbbd000000335,mbcd0026732,mbtp000001,mbrf0001029,,=,,,inhibitor,25,6.6,microM,0.5,carvedilol,,,NIH-3T3-G185 cell; inhibition of Rhodamine 123 efflux,NIH-3T3-G185,mbcd0000746,,,,human,mbds0003,v2007,2013-12-09 20:55:01
mbbd000000336,mbcd0026732,mbtp000001,mbrf0001029,,=,,,inhibitor,25,6.0,microM,0.3,carvedilol,,,NIH-3T3-G185 cell; inhibition of LDS-751 efflux,NIH-3T3-G185,mbcd0030453,,,,human,mbds0003,v2007,2013-12-09 20:55:00
mbbd000000337,mbcd0026732,mbtp000001,mbrf0001029,,=,,,inhibitor,25,4.6,microM,0.2,carvedilol,,,NIH-3T3-G185 cell; inhibition of Daunorubicin efflux,NIH-3T3-G185,mbcd0005183,,,,human,mbds0003,v2007,2013-12-09 20:55:00
mbbd000000338,mbcd0026585,mbtp000001,mbrf0001030,,=,,,inhibitor,25,3.2,microM,,Valinomycin,,,NIH-3T3-G185 cell; inhibition of Daunorubicin efflux,NIH-3T3-G185,mbcd0005183,,,,human,mbds0003,v2007,2013-12-09 20:55:01
mbbd000000339,mbcd0003094,mbtp000001,mbrf0001030,,=,,,inhibitor,25,23.6,microM,,Spironolactone,,,NIH-3T3-G185 cell; inhibition of Daunorubicin efflux,NIH-3T3-G185,mbcd0005183,,,,human,mbds0003,v2007,2013-12-09 20:55:01
mbbd000000340,mbcd0025573,mbtp000001,mbrf0001030,,>,,,non-inhibitor,25,250.0,microM,,P-Nitrophenol,,,NIH-3T3-G185 cell; inhibition of Daunorubicin efflux,NIH-3T3-G185,mbcd0005183,,,,human,mbds0003,v2007,2013-12-09 20:52:21
mbbd000000341,mbcd0002207,mbtp000001,mbrf0001030,,=,,,inhibitor,25,0.9,microM,,Norverapamil,,,NIH-3T3-G185 cell; inhibition of Daunorubicin efflux,NIH-3T3-G185,mbcd0005183,,,,human,mbds0003,v2007,2013-12-09 20:52:19
mbbd000000342,mbcd0003243,mbtp000001,mbrf0001030,,=,,,inhibitor,25,11.5,microM,,Nobiletin,,,NIH-3T3-G185 cell; inhibition of Daunorubicin efflux,NIH-3T3-G185,mbcd0005183,,,,human,mbds0003,v2007,2013-12-09 20:52:19
mbbd000000343,mbcd0007511,mbtp000001,mbrf0001030,,=,,,inhibitor,25,113.0,microM,,Nifedipine,,,NIH-3T3-G185 cell; inhibition of Daunorubicin efflux,NIH-3T3-G185,mbcd0005183,,,,human,mbds0003,v2007,2013-12-09 20:52:19
mbbd000000344,mbcd0003884,mbtp000001,mbrf0001030,,>,,,non-inhibitor,25,250.0,microM,,Lidocaine,,,NIH-3T3-G185 cell; inhibition of Daunorubicin efflux,NIH-3T3-G185,mbcd0005183,,,,human,mbds0003,v2007,2013-12-09 20:52:22
mbbd000000345,mbcd0026044,mbtp000001,mbrf0001030,,=,,,inhibitor,25,3.2,microM,,Gallopamil,,,NIH-3T3-G185 cell; inhibition of Daunorubicin efflux,NIH-3T3-G185,mbcd0005183,,,,human,mbds0003,v2007,2013-12-09 20:57:47
mbbd000000346,mbcd0003113,mbtp000001,mbrf0001030,,>,,,non-inhibitor,25,250.0,microM,,Diclofenac,,,NIH-3T3-G185 cell; inhibition of Daunorubicin efflux,NIH-3T3-G185,mbcd0005183,,,,human,mbds0003,v2007,2013-12-09 20:52:22
mbbd000000347,mbcd0003089,mbtp000001,mbrf0001030,,>,,,non-inhibitor,25,250.0,microM,,Dextromethorphan,,,NIH-3T3-G185 cell; inhibition of Daunorubicin efflux,NIH-3T3-G185,mbcd0005183,,,,human,mbds0003,v2007,2013-12-09 20:52:21
mbbd000000348,mbcd0003906,mbtp000001,mbrf0001030,,>,,,non-inhibitor,25,250.0,microM,,cyclophosphamide,,,NIH-3T3-G185 cell; inhibition of Daunorubicin efflux,NIH-3T3-G185,mbcd0005183,,,,human,mbds0003,v2007,2013-12-09 20:03:59
mbbd000000349,mbcd0017980,mbtp000001,mbrf0001030,,>,,,non-inhibitor,25,250.0,microM,,ciprofloxacin,,,NIH-3T3-G185 cell; inhibition of Daunorubicin efflux,NIH-3T3-G185,mbcd0005183,,,,human,mbds0003,v2007,2013-12-09 20:03:58
mbbd000000350,mbcd0028157,mbtp000001,mbrf0001030,,>,,,non-inhibitor,25,250.0,microM,,Azithromycin,,,NIH-3T3-G185 cell; inhibition of Daunorubicin efflux,NIH-3T3-G185,mbcd0005183,,,,human,mbds0003,v2007,2013-12-09 20:54:34
mbbd000000351,mbcd0003872,mbtp000001,mbrf0001030,,>,,,non-inhibitor,25,250.0,microM,,Acetaminophen,,,NIH-3T3-G185 cell; inhibition of Daunorubicin efflux,NIH-3T3-G185,mbcd0005183,,,,human,mbds0003,v2007,2013-12-09 20:54:35
mbbd000000352,mbcd0001938,mbtp000001,mbrf0001031,,~,,,stimulator,100,59.0,%,,ritonavir,,,"LS-180V; Western, efflux of Rhodamine 123",LS180V,mbcd0000746,3,microM,,human,mbds0003,v2007,2013-12-09 20:54:35
mbbd000000353,mbcd0017104,mbtp000001,mbrf0001032,,=,,,inhibitor,25,5.6,microM,,Ketoconazole,,,G185 cell; inhibition of Daunorubucin transport,G185,mbcd0005183,,,,human,mbds0003,v2007,2013-12-09 20:54:35
mbbd000000354,mbcd0002191,mbtp000001,mbrf0001032,,=,,,inhibitor,25,1.7,microM,,itraconazole,,,G185 cell; inhibition of Daunorubucin transport,G185,mbcd0005183,,,,human,mbds0003,v2007,2013-12-09 20:54:34
mbbd000000355,mbcd0023577,mbtp000001,mbrf0001032,,,,,non-inhibitor,,,,,Fluconazole,,,G185 cell; inhibition of Daunorubucin transport,G185,mbcd0005183,,,,human,mbds0003,v2007,2013-12-09 20:54:34
mbbd000000356,mbcd0022900,mbtp000001,mbrf0001033,,=,,,inhibitor,25,17.9,microM,,Pantoprazole,,,Caco-2 cell; inhibition of Digoxin transepithelial transport (basal to apical) (Digoxin: 5 microM),Caco-2,mbcd0001050,,,,human,mbds0003,v2007,2013-12-09 20:54:34
mbbd000000357,mbcd0022900,mbtp000001,mbrf0001033,,,,,substrate,,,,,pantoprazole,,,MDR1-expressing LLC-PK1 cell; transepithelial transport (basal to apical),LLC-PK1,,,,,human,mbds0003,v2007,2013-12-09 20:54:34
mbbd000000358,mbcd0001021,mbtp000001,mbrf0001033,,=,,,inhibitor,25,17.7,microM,,omeprazole,,,Caco-2 cell; inhibition of Digoxin transepithelial transport (basal to apical) (Digoxin: 5 microM),Caco-2,mbcd0001050,,,,human,mbds0003,v2007,2013-12-09 20:54:35
mbbd000000359,mbcd0001021,mbtp000001,mbrf0001033,,,,,substrate,,,,,omeprazole,,,MDR1-expressing LLC-PK1 cell; transepithelial transport (basal to apical),LLC-PK1,,,,,human,mbds0003,v2007,2013-12-09 20:54:35
mbbd000000360,mbcd0003121,mbtp000001,mbrf0001033,,=,,,inhibitor,25,62.8,microM,,lansoprazole,,,Caco-2 cell; inhibition of Digoxin transepithelial transport (basal to apical) (Digoxin: 5 microM),Caco-2,mbcd0001050,,,,human,mbds0003,v2007,2013-12-09 20:02:27
mbbd000000361,mbcd0003121,mbtp000001,mbrf0001033,,,,,substrate,,,,,lansoprazole,,,MDR1-expressing LLC-PK1 cell; transepithelial transport (basal to apical),LLC-PK1,,,,,human,mbds0003,v2007,2013-12-09 20:02:26
mbbd000000362,mbcd0027062,mbtp000001,mbrf0001034,,=,,,inhibitor,17,3.1,microM,,Verapamil,,,MDA435/LCC6 MDR1 cell; reversal of Vinblastine accumulation (Vinblastine: 0.005 microM),MDA435/LCC6,mbcd0001151,,,,human,mbds0003,v2007,2013-12-09 20:02:28
mbbd000000364,mbcd0001892,mbtp000001,mbrf0001034,,=,,,inhibitor,17,21.2,microM,,Progesterone,,,MDA435/LCC6 MDR1 cell; reversal of Vinblastine accumulation (Vinblastine: 0.005 microM),MDA435/LCC6,mbcd0001151,,,,human,mbds0003,v2007,2013-12-09 20:01:52
mbbd000000365,mbcd0000311,mbtp000001,mbrf0001034,,=,,,inhibitor,17,0.6,microM,,cyclosporin A,,,MDA435/LCC6 MDR1 cell; reversal of Vinblastine accumulation (Vinblastine: 0.005 microM),MDA435/LCC6,mbcd0001151,,,,human,mbds0003,v2007,2013-12-09 20:01:51
mbbd000000366,mbcd0001151,mbtp000001,mbrf0001035,,=,,,substrate,28,5.71,microM,3.20,Vinblastine,,,membrane fraction from High Five (BTI-TN5B1-4) cell; ATP hydrolysis,High Five (BTI-TN5B1-4),,22.5,nM,,human,mbds0003,v2007,2014-03-04 00:45:10
mbbd000000367,mbcd0027062,mbtp000001,mbrf0001035,,=,,,substrate,28,4.06,microM,1.38,Verapamil,,,membrane fraction from High Five (BTI-TN5B1-4) cell; ATP hydrolysis,High Five (BTI-TN5B1-4),,11.8,nM,,human,mbds0003,v2007,2014-03-04 00:45:10
mbbd000000368,mbcd0027018,mbtp000001,mbrf0001035,,=,,,substrate,28,5.42,microM,0.95,Quinidine,,,membrane fraction from High Five (BTI-TN5B1-4) cell; ATP hydrolysis,High Five (BTI-TN5B1-4),,50,nM,,human,mbds0003,v2007,2014-03-04 00:45:10
mbbd000000369,mbcd0001892,mbtp000001,mbrf0001035,,=,,,substrate,28,53.6,microM,30.7,Progesterone,,,membrane fraction from High Five (BTI-TN5B1-4) cell; ATP hydrolysis,High Five (BTI-TN5B1-4),,7,nM,weak substrate,human,mbds0003,v2007,2014-03-04 00:45:10
mbbd000000370,mbcd0002539,mbtp000001,mbrf0001035,,=,,,substrate,28,13.8,microM,4.4,Loperamide,,,membrane fraction from High Five (BTI-TN5B1-4) cell; ATP hydrolysis,High Five (BTI-TN5B1-4),,1,microM,,human,mbds0003,v2007,2014-03-04 00:45:10
mbbd000000371,mbcd0000387,mbtp000001,mbrf0001035,,=,,,substrate,82,0.95,,0.306,E217betaG,corrected flux ratio for transport in LLC-MDR1 cells,,membrane fraction from High Five (BTI-TN5B1-4) cell; ATP hydrolysis,High Five (BTI-TN5B1-4),,22.7,nM,weak substrate,human,mbds0003,v2007,2014-02-27 20:45:01
mbbd000000372,mbcd0001050,mbtp000001,mbrf0001035,,=,,,substrate,28,25.9,microM,18.1,Digoxin,,,membrane fraction from High Five (BTI-TN5B1-4) cell; ATP hydrolysis,High Five (BTI-TN5B1-4),,52.6,nM,,human,mbds0003,v2007,2014-03-04 00:45:10
mbbd000000373,mbcd0003903,mbtp000001,mbrf0001035,,=,,,substrate,28,72.4,microM,16.5,Diazepam,,,membrane fraction from High Five (BTI-TN5B1-4) cell; ATP hydrolysis,High Five (BTI-TN5B1-4),,12.1,nM,weak substrate,human,mbds0003,v2007,2014-03-04 00:45:10
mbbd000000374,mbcd0002959,mbtp000001,mbrf0001035,,=,,,substrate,82,2.08,,0.28,dexamethasone,corrected flux ratio for transport in LLC-MDR1 cells,,membrane fraction from High Five (BTI-TN5B1-4) cell; ATP hydrolysis,High Five (BTI-TN5B1-4),,24.7,nM,,human,mbds0003,v2007,2014-02-27 20:45:01
mbbd000000375,mbcd0005183,mbtp000001,mbrf0001035,,=,,,substrate,28,1.74,microM,1.08,Daunomycin,,,membrane fraction from High Five (BTI-TN5B1-4) cell; ATP hydrolysis,High Five (BTI-TN5B1-4),,200,nM,,human,mbds0003,v2007,2014-03-04 00:45:10
mbbd000000376,mbcd0000311,mbtp000001,mbrf0001035,,=,,,substrate,28,0.17,microM,0.02,Cyclosporin A,,,membrane fraction from High Five (BTI-TN5B1-4) cell; ATP hydrolysis,High Five (BTI-TN5B1-4),,35.7,nM,,human,mbds0003,v2007,2014-03-04 00:45:10
mbbd000000377,mbcd0001111,mbtp000001,mbrf0001035,,=,,,non-substrate,82,0.81,,0.237,cimetidine,corrected flux ratio for transport in LLC-MDR1 cells,,membrane fraction from High Five (BTI-TN5B1-4) cell; ATP hydrolysis,High Five (BTI-TN5B1-4),,64.5,nM,,human,mbds0003,v2007,2014-02-27 20:45:00
mbbd000000380,mbcd0025580,mbtp000001,mbrf0001037,,~,,,inhibitor,72,890.0,%,,pentamethoxyquercetin,,,K562/ADM cell; increase in Vincristine intracellular accumulation (0.025 microM),K562/ADM,mbcd0001135,,,,human,mbds0003,v2007,2013-12-09 20:14:34
mbbd000000388,mbcd0001050,mbtp000001,mbrf0001038,,~,,,inducer,97,430.0,%,75,Digoxin,,,Caco-2 cell; RT-PCR,Caco-2,,1,microM,,human,mbds0003,v2007,2013-12-09 20:53:07
mbbd000000389,mbcd0000824,mbtp000001,mbrf0001039,,=,,,inhibitor,1,79.0,%,,Temocaprilat,,,"MDR1-expressing LLC-PK1 cell; inhibition of Digoxin transepithelial transport (basal to apical)(Digoxin: 0.1 microM, Temocaprilat: 50 microM)",LLC-PK1,mbcd0001050,,,,human,mbds0003,v2007,2013-12-09 20:53:06
mbbd000000390,mbcd0000823,mbtp000001,mbrf0001039,,=,,,inhibitor,1,87.21,%,,Temocapril,,,"MDR1-expressing LLC-PK1 cell; inhibition of Digoxin transepithelial transport (basal to apical)(Digoxin: 0.1 microM, Temocapril: 50 microM)",LLC-PK1,mbcd0001050,,,,human,mbds0003,v2007,2013-12-09 21:00:52
mbbd000000391,mbcd0000673,mbtp000001,mbrf0001039,,=,,,inhibitor,1,68.95,%,,Perindoprilat,,,"MDR1-expressing LLC-PK1 cell; inhibition of Digoxin transepithelial transport (basal to apical) (Digoxin: 0.1 microM, Perindoprilat: 50 microM)",LLC-PK1,mbcd0001050,,,,human,mbds0003,v2007,2013-12-09 21:00:52
mbbd000000392,mbcd0001277,mbtp000001,mbrf0001039,,=,,,inhibitor,1,67.12,%,,Perindopril,,,"MDR1-expressing LLC-PK1 cell; inhibition of Digoxin transepithelial transport (basal to apical) (Digoxin: 0.1 microM, Perindopril: 50 microM)",LLC-PK1,mbcd0001050,,,,human,mbds0003,v2007,2013-12-09 20:55:11
mbbd000000393,mbcd0002822,mbtp000001,mbrf0001039,,=,,,inhibitor,1,86.3,%,,Metoprolol,,,"MDR1-expressing LLC-PK1 cell; inhibition of Digoxin transepithelial transport (basal to apical)(Digoxin: 0.1 microM, Metprolol: 50 microM)",LLC-PK1,mbcd0001050,,,,human,mbds0003,v2007,2013-12-09 21:00:50
mbbd000000394,mbcd0027333,mbtp000001,mbrf0001039,,=,,,non-inhibitor,1,94.06,%,,Losartan,,,"MDR1-expressing LLC-PK1 cell; inhibition of Digoxin transepithelial transport (basal to apical) (Digoxin: 0.1 microM, Losartan: 50 microM)",LLC-PK1,mbcd0001050,,,,human,mbds0003,v2007,2013-12-09 21:00:52
mbbd000000395,mbcd0003061,mbtp000001,mbrf0001039,,=,,,non-inhibitor,1,94.06,%,,Lisinopril,,,"MDR1-expressing LLC-PK1 cell; inhibition of Digoxin transepithelial transport (basal to apical) (Digoxin: 0.1 microM, Lisinopril: 50 microM)",LLC-PK1,mbcd0001050,,,,human,mbds0003,v2007,2013-12-09 21:00:52
mbbd000000396,mbcd0003498,mbtp000001,mbrf0001039,,=,,,inhibitor,1,83.11,%,,Enalapril,,,"MDR1-expressing LLC-PK1 cell; inhibition of Digoxin transepithelial transport (basal to apical)(Digoxin: 0.1 microM, Enalapril: 50 microM)",LLC-PK1,mbcd0001050,,,,human,mbds0003,v2007,2013-12-09 21:00:52
mbbd000000397,mbcd0003930,mbtp000001,mbrf0001039,,=,,,inhibitor,1,33.33,%,,Doxazosin,,,"MDR1-expressing LLC-PK1 cell; inhibition of Digoxin transepithelial transport (basal to apical)(Digoxin: 0.1 microM, Doxazosin: 50 microM)",LLC-PK1,mbcd0001050,,,,human,mbds0003,v2007,2013-12-09 21:00:53
mbbd000000398,mbcd0000323,mbtp000001,mbrf0001039,,=,,,non-inhibitor,1,102.3,%,,Delapril,,,"MDR1-expressing LLC-PK1 cell; inhibition of Digoxin transepithelial transport (basal to apical)(Digoxin: 0.1 microM, Delapril: 50 microM)",LLC-PK1,mbcd0001050,,,,human,mbds0003,v2007,2013-12-09 20:55:11
mbbd000000399,mbcd0000269,mbtp000001,mbrf0001039,,=,,,inhibitor,1,71.69,%,,Cilazaprilat,,,"MDR1-expressing LLC-PK1 cell; inhibition of Digoxin transepithelial transport (basal to apical)(Digoxin: 0.1 microM, Cilazaprilat: 50 microM)",LLC-PK1,mbcd0001050,,,,human,mbds0003,v2007,2013-12-09 20:55:11
mbbd000000400,mbcd0001568,mbtp000001,mbrf0001039,,=,,,non-inhibitor,1,92.24,%,,Cilazapril,,,"MDR1-expressing LLC-PK1 cell; inhibition of Digoxin transepithelial transport (basal to apical)(Digoxin: 0.1 microM, Cilazapril: 50 microM)",LLC-PK1,mbcd0001050,,,,human,mbds0003,v2007,2013-12-09 21:01:30
mbbd000000401,mbcd0026732,mbtp000001,mbrf0001039,,=,,,inhibitor,1,36.53,%,,carvedilol,,,"MDR1-expressing LLC-PK1 cell; inhibition of Digoxin transepithelial transport (basal to apical)(Digoxin: 0.1 microM, Carvedilol: 50 microM)",LLC-PK1,mbcd0001050,,,,human,mbds0003,v2007,2013-12-09 21:01:30
mbbd000000402,mbcd0003142,mbtp000001,mbrf0001039,,=,,,inhibitor,1,83.11,%,,Captopril,,,"MDR1-expressing LLC-PK1 cell; inhibition of Digoxin transepithelial transport (basal to apical)(Digoxin: 0.1 microM, Captopril: 50 microM)",LLC-PK1,mbcd0001050,,,,human,mbds0003,v2007,2013-12-09 21:01:31
mbbd000000403,mbcd0027729,mbtp000001,mbrf0001039,,=,,,non-inhibitor,1,95.43,%,,Candesartan cilexetil,,,"MDR1-expressing LLC-PK1 cell; inhibition of Digoxin transepithelial transport (basal to apical)(Digoxin: 0.1 microM, Candesartan cilexetil: 50 microM)",LLC-PK1,mbcd0001050,,,,human,mbds0003,v2007,2013-12-09 21:01:32
mbbd000000404,mbcd0003962,mbtp000001,mbrf0001039,,=,,,non-inhibitor,1,92.69,%,,Candesartan,,,"MDR1-expressing LLC-PK1 cell; inhibition of Digoxin transepithelial transport (basal to apical)(Digoxin: 0.1 microM, Candesartan: 50 microM)",LLC-PK1,mbcd0001050,,,,human,mbds0003,v2007,2013-12-09 21:01:32
mbbd000000405,mbcd0003875,mbtp000001,mbrf0001039,,=,,,inhibitor,1,89.5,%,,Atenolol,,,"MDR1-expressing LLC-PK1 cell; inhibition of Digoxin transepithelial transport (basal to apical)(Digoxin: 0.1 microM, Atenolol: 50 microM)",LLC-PK1,mbcd0001050,,,,human,mbds0003,v2007,2013-12-09 21:01:29
mbbd000000406,mbcd0000984,mbtp000009,mbrf0001040,,=,,,repressor,111,70.0,%,,T3,protein level % of control,,Caco-2 cell; competitive PCR and Western,Caco-2,,,,,human,mbds0003,v2007,2013-12-09 21:01:32
mbbd000000407,mbcd0014953,mbtp000001,mbrf0001041,,>,,,non-inhibitor,25,100.0,microM,,ABZ,,,"MDR1-expressing LLC-PK1 cell; inhibition of Digoxin transepithelial transport (basal to apical) (Digoxin: 5 microM, Albendazole: 100 microM)",LLC-PK1,mbcd0001050,,,,human,mbds0003,v2007,2013-12-09 21:01:32
mbbd000000408,mbcd0014953,mbtp000001,mbrf0001041,,,,,non-substrate,,,,,ABZ,,,MDR1-expressing LLC-PK1 cell; transepithelial transport (basal to apical),LLC-PK1,,,,,human,mbds0003,v2007,2013-12-09 21:01:29
mbbd000000409,mbcd0002466,mbtp000001,mbrf0001042,,=,,,substrate,28,254.96,microM,94.39,Etoposide,,,MDR1-expressing MDCKII cell; transepithelial transport (basal to apical),MDCKII,,1-500,microM,,human,mbds0003,v2007,2013-12-09 21:01:30
mbbd000000410,mbcd0027669,mbtp000001,mbrf0001043,,,,,substrate,,,,,methylprednisolone,,,"Caco-2 cell; transepithelial transport (basal to apical), inhibited by Verapamil",Caco-2,,,,,human,mbds0003,v2007,2013-12-09 20:16:12
mbbd000000411,mbcd0000594,mbtp000001,mbrf0001044,,=,,,inhibitor,29,0.4,microM,,MS-209,,,Caco-2 cell; inhibition of Taxol transepithelial transport (basal to apical),Caco-2,mbcd0001532,,,,human,mbds0003,v2007,2013-12-09 20:16:12
mbbd000000412,mbcd0000042,mbtp000001,mbrf0001045,,=,,,inducer,111,2.1,fold,,2-AAF,,,embryonic HEK-293 cells; RNase protection assay,HEK293,,100,microM,,human,mbds0003,v2007,2013-11-20 20:30:43
mbbd000000413,mbcd0028263,mbtp000001,mbrf0001046,,=,,,inhibitor,29,483.3,microM,,Troleandomycin,,,MDR1-expressing LLC-PK1 cell; increase in Calcein-AM intracellular accumulation,LLC-PK1,mbcd0000212,,,,human,mbds0003,v2007,2013-12-09 20:16:12
mbbd000000414,mbcd0028263,mbtp000001,mbrf0001046,,=,,,inhibitor,29,87.64,microM,,Troleandomycin,,,MDR1-expressing LLC-PK1 cell; increase in Vinblastine intracellular accumulation,LLC-PK1,mbcd0001151,,,,human,mbds0003,v2007,2013-12-09 20:16:11
mbbd000000415,mbcd0001941,mbtp000001,mbrf0001046,,=,,,inhibitor,29,12.2,microM,,Reserpine,,,MDR1-expressing LLC-PK1 cell; increase in Calcein-AM intracellular accumulation,LLC-PK1,mbcd0000212,,,,human,mbds0003,v2007,2013-12-09 20:16:10
mbbd000000416,mbcd0001941,mbtp000001,mbrf0001046,,=,,,inhibitor,29,0.97,microM,,Reserpine,,,MDR1-expressing LLC-PK1 cell; increase in Vinblastine intracellular accumulation,LLC-PK1,mbcd0001151,,,,human,mbds0003,v2007,2013-12-09 20:16:08
mbbd000000417,mbcd0002825,mbtp000001,mbrf0001046,,=,,,inhibitor,29,55.5,microM,,miconazole,,,MDR1-expressing LLC-PK1 cell; increase in Calcein-AM intracellular accumulation,LLC-PK1,mbcd0000212,,,,human,mbds0003,v2007,2013-12-09 20:16:06
mbbd000000418,mbcd0002825,mbtp000001,mbrf0001046,,=,,,inhibitor,29,26.36,microM,,miconazole,,,MDR1-expressing LLC-PK1 cell; increase in Vinblastine intracellular accumulation,LLC-PK1,mbcd0001151,,,,human,mbds0003,v2007,2013-12-09 20:16:13
mbbd000000419,mbcd0002820,mbtp000001,mbrf0001046,,=,,,inhibitor,25,1.2,microM,,Mibefradil,,,Caco-2 cell; inhibition of Digoxin transepithelial transport (basal to apical) (Digoxin: 5 microM),Caco-2,mbcd0001050,,,,human,mbds0003,v2007,2013-12-09 20:16:13
mbbd000000420,mbcd0017104,mbtp000001,mbrf0001046,,=,,,inhibitor,29,24.9,microM,,Ketoconazole,,,MDR1-expressing LLC-PK1 cell; increase in Calcein-AM intracellular accumulation,LLC-PK1,mbcd0000212,,,,human,mbds0003,v2007,2013-12-09 21:00:51
mbbd000000421,mbcd0017104,mbtp000001,mbrf0001046,,=,,,inhibitor,29,5.27,microM,,Ketoconazole,,,MDR1-expressing LLC-PK1 cell; increase in Vinblastine intracellular accumulation,LLC-PK1,mbcd0001151,,,,human,mbds0003,v2007,2013-12-09 21:00:51
mbbd000000422,mbcd0023577,mbtp000001,mbrf0001046,,>,,,inhibitor,29,1000.0,microM,,Fluconazole,,,MDR1-expressing LLC-PK1 cell; increase in Calcein-AM intracellular accumulation,LLC-PK1,mbcd0000212,,,,human,mbds0003,v2007,2013-12-09 21:00:51
mbbd000000423,mbcd0023577,mbtp000001,mbrf0001046,,>,,,inhibitor,29,400.0,microM,,Fluconazole,,,MDR1-expressing LLC-PK1 cell; increase in Vinblastine intracellular accumulation,LLC-PK1,mbcd0001151,,,,human,mbds0003,v2007,2013-12-09 21:00:51
mbbd000000424,mbcd0000937,mbtp000001,mbrf0001046,,>,,,inhibitor,29,1000.0,microM,,Erythromycin,,,MDR1-expressing LLC-PK1 cell; increase in Calcein-AM intracellular accumulation,LLC-PK1,mbcd0000212,,,,human,mbds0003,v2007,2013-12-09 21:00:52
mbbd000000425,mbcd0000937,mbtp000001,mbrf0001046,,=,,,inhibitor,29,37.79,microM,,Erythromycin,,,MDR1-expressing LLC-PK1 cell; increase in Vinblastine intracellular accumulation,LLC-PK1,mbcd0001151,,,,human,mbds0003,v2007,2013-12-09 21:00:52
mbbd000000426,mbcd0003937,mbtp000001,mbrf0001046,,=,,,inhibitor,29,98.9,microM,,Ergotamine,,,MDR1-expressing LLC-PK1 cell; increase in Calcein-AM intracellular accumulation,LLC-PK1,mbcd0000212,,,,human,mbds0003,v2007,2013-12-09 21:00:51
mbbd000000427,mbcd0003937,mbtp000001,mbrf0001046,,=,,,inhibitor,29,14.25,microM,,Ergotamine,,,MDR1-expressing LLC-PK1 cell; increase in Vinblastine intracellular accumulation,LLC-PK1,mbcd0001151,,,,human,mbds0003,v2007,2013-12-09 21:00:51
mbbd000000428,mbcd0025599,mbtp000001,mbrf0001046,,=,,,inhibitor,29,115.5,microM,,Ergometrine,,,MDR1-expressing LLC-PK1 cell; increase in Calcein-AM intracellular accumulation,LLC-PK1,mbcd0000212,,,,human,mbds0003,v2007,2013-12-09 21:00:51
mbbd000000429,mbcd0025599,mbtp000001,mbrf0001046,,>,,,inhibitor,29,100.0,microM,,Ergometrine,,,MDR1-expressing LLC-PK1 cell; increase in Vinblastine intracellular accumulation,LLC-PK1,mbcd0001151,,,,human,mbds0003,v2007,2013-12-09 21:00:51
mbbd000000430,mbcd0028790,mbtp000001,mbrf0001046,,=,,,inhibitor,29,12.2,microM,,Ergocryptine,,,MDR1-expressing LLC-PK1 cell; increase in Calcein-AM intracellular accumulation,LLC-PK1,mbcd0000212,,,,human,mbds0003,v2007,2013-12-09 20:14:28
mbbd000000431,mbcd0028790,mbtp000001,mbrf0001046,,=,,,inhibitor,29,6.43,microM,,Ergocryptine,,,MDR1-expressing LLC-PK1 cell; increase in Vinblastine intracellular accumulation,LLC-PK1,mbcd0001151,,,,human,mbds0003,v2007,2013-12-09 20:14:26
mbbd000000432,mbcd0002994,mbtp000001,mbrf0001046,,=,,,inhibitor,29,42.8,microM,,Ergocristine,,,MDR1-expressing LLC-PK1 cell; increase in Calcein-AM intracellular accumulation,LLC-PK1,mbcd0000212,,,,human,mbds0003,v2007,2013-12-09 20:14:30
mbbd000000433,mbcd0002994,mbtp000001,mbrf0001046,,=,,,inhibitor,29,13.33,microM,,Ergocristine,,,MDR1-expressing LLC-PK1 cell; increase in Vinblastine intracellular accumulation,LLC-PK1,mbcd0001151,,,,human,mbds0003,v2007,2013-12-09 20:14:29
mbbd000000434,mbcd0000380,mbtp000001,mbrf0001046,,=,,,inhibitor,29,105.2,microM,,Ergocornine,,,MDR1-expressing LLC-PK1 cell; increase in Calcein-AM intracellular accumulation,LLC-PK1,mbcd0000212,,,,human,mbds0003,v2007,2013-12-09 20:14:32
mbbd000000435,mbcd0000380,mbtp000001,mbrf0001046,,=,,,inhibitor,29,24.5,microM,,Ergocornine,,,MDR1-expressing LLC-PK1 cell; increase in Vinblastine intracellular accumulation,LLC-PK1,mbcd0001151,,,,human,mbds0003,v2007,2013-12-09 20:14:31
mbbd000000436,mbcd0026179,mbtp000001,mbrf0001046,,>,,,inhibitor,29,1000.0,microM,,Dihydroergotamine,,,MDR1-expressing LLC-PK1 cell; increase in Calcein-AM intracellular accumulation,LLC-PK1,mbcd0000212,,,,human,mbds0003,v2007,2013-12-09 20:14:33
mbbd000000437,mbcd0026179,mbtp000001,mbrf0001046,,=,,,inhibitor,29,119.94,microM,,Dihydroergotamine,,,MDR1-expressing LLC-PK1 cell; increase in Vinblastine intracellular accumulation,LLC-PK1,mbcd0001151,,,,human,mbds0003,v2007,2013-12-09 20:14:33
mbbd000000438,mbcd0028961,mbtp000001,mbrf0001046,,=,,,inhibitor,29,360.5,microM,,Dihydroergocryptine,,,MDR1-expressing LLC-PK1 cell; increase in Calcein-AM intracellular accumulation,LLC-PK1,mbcd0000212,,,,human,mbds0003,v2007,2013-12-09 20:14:25
mbbd000000439,mbcd0028961,mbtp000001,mbrf0001046,,=,,,inhibitor,29,19.82,microM,,Dihydroergocryptine,,,MDR1-expressing LLC-PK1 cell; increase in Vinblastine intracellular accumulation,LLC-PK1,mbcd0001151,,,,human,mbds0003,v2007,2013-12-09 20:14:23
mbbd000000440,mbcd0000349,mbtp000001,mbrf0001046,,=,,,inhibitor,29,511.0,microM,,Dihydroergocristine,,,MDR1-expressing LLC-PK1 cell; increase in Calcein-AM intracellular accumulation,LLC-PK1,mbcd0000212,,,,human,mbds0003,v2007,2013-12-09 21:00:33
mbbd000000441,mbcd0000349,mbtp000001,mbrf0001046,,=,,,inhibitor,29,16.0,microM,,Dihydroergocristine,,,MDR1-expressing LLC-PK1 cell; increase in Vinblastine intracellular accumulation,LLC-PK1,mbcd0001151,,,,human,mbds0003,v2007,2013-12-09 21:00:33
mbbd000000442,mbcd0000311,mbtp000001,mbrf0001046,,=,,,inhibitor,29,4.66,microM,,cyclosporin,,,MDR1-expressing LLC-PK1 cell; increase in Calcein-AM intracelullar accumulation,LLC-PK1,mbcd0000212,,,,human,mbds0003,v2007,2013-12-09 21:00:33
mbbd000000443,mbcd0000311,mbtp000001,mbrf0001046,,=,,,inhibitor,29,1.3,microM,,cyclosporin,,,MDR1-expressing LLC-PK1 cell; increase in Vinblastine intracellular accumulation,LLC-PK1,mbcd0001151,,,,human,mbds0003,v2007,2013-12-09 21:00:33
mbbd000000445,mbcd0002493,mbtp000001,mbrf0001046,,=,,,inhibitor,29,44.0,microM,,Clotrimazole,,,MDR1-expressing LLC-PK1 cell; increase in Calcein-AM intracellular accumulation,LLC-PK1,mbcd0000212,,,,human,mbds0003,v2007,2013-12-09 21:00:32
mbbd000000446,mbcd0002493,mbtp000001,mbrf0001046,,=,,,inhibitor,29,29.92,microM,,Clotrimazole,,,MDR1-expressing LLC-PK1 cell; increase in Vinblastine intracellular accumulation,LLC-PK1,mbcd0001151,,,,human,mbds0003,v2007,2013-12-09 21:00:32
mbbd000000447,mbcd0026046,mbtp000001,mbrf0001046,,=,,,inhibitor,29,2.81,microM,,bromocriptine,,,MDR1-expressing LLC-PK1 cell; increase in Calcein-AM intracellular accumulation,LLC-PK1,mbcd0000212,,,,human,mbds0003,v2007,2013-12-09 21:00:33
mbbd000000448,mbcd0026046,mbtp000001,mbrf0001046,,=,,,inhibitor,29,3.96,microM,,bromocriptine,,,MDR1-expressing LLC-PK1 cell; increase in Vinblastine intracellular accumulation,LLC-PK1,mbcd0001151,,,,human,mbds0003,v2007,2013-12-09 21:00:32
mbbd000000449,mbcd0001229,mbtp000001,mbrf0001047,,=,,,inhibitor,25,4.5,microM,,sufentanil,,,Caco-2 cell; inhibition of Digoxin transepithelial transport (basal to apical) (Digoxin: 5 microM),Caco-2,mbcd0001050,,,,human,mbds0003,v2007,2013-12-09 21:00:32
mbbd000000450,mbcd0001229,mbtp000001,mbrf0001047,,,,,non-substrate,,,,,sufentanil,,,MDR1-expressing LLC-PK1 cell; transepithelial transport (basal to apical),LLC-PK1,,,,,human,mbds0003,v2007,2013-12-09 20:13:03
mbbd000000451,mbcd0002539,mbtp000001,mbrf0001047,,=,,,inhibitor,25,2.5,microM,,Loperamide,,,Caco-2 cell; inhibition of Digoxin transepithelial transport (basal to apical) (Digoxin: 5 microM),Caco-2,mbcd0001050,,,,human,mbds0003,v2007,2013-12-09 20:13:02
mbbd000000452,mbcd0003948,mbtp000001,mbrf0001047,,=,,,inhibitor,25,6.5,microM,,fentanyl,,,Caco-2 cell; inhibition of Digoxin transepithelial transport (basal to apical) (Digoxin: 5 microM),Caco-2,mbcd0001050,,,,human,mbds0003,v2007,2013-12-09 20:13:02
mbbd000000453,mbcd0026101,mbtp000001,mbrf0001047,,=,,,inhibitor,25,112.0,microM,,Alfentanil,,,Caco-2 cell; inhibition of Digoxin transepithelial transport (basal to apical) (Digoxin: 5 microM),Caco-2,mbcd0001050,,,,human,mbds0003,v2007,2013-12-09 20:13:01
mbbd000000454,mbcd0026101,mbtp000001,mbrf0001047,,,,,non-substrate,,,,,alfentanil,,,MDR1-expressing LLC-PK1 cell; transepithelial transport (basal to apical),LLC-PK1,,,,,human,mbds0003,v2007,2013-12-09 20:13:03
mbbd000000455,mbcd0003893,mbtp000001,mbrf0001048,,=,,,substrate,28,12.4,microM,6.3,risperidone,,,membrane from MDR1-expressing insect cells; human P-gp membranes from baculovirus-infected insect cells from Gentest Inc.; ATP hydrolysis,insect cells,,,,,human,mbds0003,v2007,2013-11-26 01:55:29
mbbd000000456,mbcd0027670,mbtp000001,mbrf0001048,,=,,,substrate,28,12.3,microM,5.1,Quetiapine,,,"membrane from MDR1-expressing insect cells; human P-gp membranes from baculovirus-infected insect cells from Gentest Inc.; ATP hydrolysis; P-gp ATPase activity, a putative measure of P-gp affinity",insect cells,,,,,human,mbds0003,v2007,2013-11-26 01:55:29
mbbd000000457,mbcd0001018,mbtp000001,mbrf0001048,,=,,,substrate,28,8.3,microM,3.7,Olanzapine,,,"membrane from MDR1-expressing insect cells; human P-gp membranes from baculovirus-infected insect cells from Gentest Inc.; ATP hydrolysis; P-gp ATPase activity, a putative measure of P-gp affinity",insect cells,,,,,human,mbds0003,v2007,2013-11-26 01:55:29
mbbd000000458,mbcd0001777,mbtp000001,mbrf0001048,,=,,,substrate,28,33.0,microM,14.2,Haloperidol,,,membrane from MDR1-expressing insect cell; ATP hydrolysis,insect cells,,1-1000,microM,weak substrate,human,mbds0003,v2007,2014-02-27 02:31:31
mbbd000000459,mbcd0003888,mbtp000001,mbrf0001048,,=,,,substrate,28,58.0,microM,31,Clozapine,,,membrane from MDR1-expressing insect cell; ATP hydrolysis,insect cells,,1-1000,microM,,human,mbds0003,v2007,2013-12-09 20:14:42
mbbd000000460,mbcd0002340,mbtp000001,mbrf0001048,,=,,,substrate,28,27.4,microM,12.8,chlorpromazine,,,membrane from MDR1-expressing insect cells; human P-gp membranes from baculovirus-infected insect cells from Gentest Inc.; ATP hydrolysis,insect cells,,,,,human,mbds0003,v2007,2013-11-26 01:55:29
mbbd000000461,mbcd0028571,mbtp000001,mbrf0001049,,,,,substrate,,,,,apafant,,,Caco-2 cell; transepithelial transport (basal to apical),Caco-2,,,,,human,mbds0003,v2007,2013-12-09 20:58:14
mbbd000000462,mbcd0003135,mbtp000001,mbrf0001050,,=,,,inhibitor,25,68.2,microM,,Nitrendipine,,,MDR1-expressing LLC-PK1 cell; inhibition of Digoxin transepithelial transport (basal to apical) (Digoxin: 0.1 microM),LLC-PK1,mbcd0001050,,,,human,mbds0003,v2007,2013-12-09 20:58:13
mbbd000000463,mbcd0001058,mbtp000001,mbrf0001050,,=,,,inhibitor,25,44.1,microM,,Nisoldipine,,,MDR1-expressing LLC-PK1 cell; inhibition of Digoxin transepithelial transport (basal to apical) (Digoxin: 0.1 microM),LLC-PK1,mbcd0001050,,,,human,mbds0003,v2007,2013-12-09 20:58:14
mbbd000000464,mbcd0001716,mbtp000001,mbrf0001050,,=,,,inhibitor,25,18.0,microM,,Nilvadipine,,,MDR1-expressing LLC-PK1 cell; inhibition of Digoxin transepithelial transport (basal to apical) (Digoxin: 0.1 microM),LLC-PK1,mbcd0001050,,,,human,mbds0003,v2007,2013-12-09 20:58:13
mbbd000000465,mbcd0007511,mbtp000001,mbrf0001050,,=,,,inhibitor,25,472.0,microM,,Nifedipine,,,MDR1-expressing LLC-PK1 cell; inhibition of Digoxin transepithelial transport (basal to apical) (Digoxin: 0.1 microM),LLC-PK1,mbcd0001050,,,,human,mbds0003,v2007,2013-12-09 20:58:13
mbbd000000466,mbcd0002576,mbtp000001,mbrf0001050,,=,,,inhibitor,25,4.54,microM,,Nicardipine,,,MDR1-expressing LLC-PK1 cell; inhibition of Digoxin transepithelial transport (basal to apical) (Digoxin: 0.1 microM),LLC-PK1,mbcd0001050,,,,human,mbds0003,v2007,2013-12-09 20:58:13
mbbd000000467,mbcd0000553,mbtp000001,mbrf0001050,,=,,,inhibitor,25,4.65,microM,,Manidipine,,,MDR1-expressing LLC-PK1 cell; inhibition of Digoxin transepithelial transport (basal to apical) (Digoxin: 0.1 microM),LLC-PK1,mbcd0001050,,,,human,mbds0003,v2007,2013-12-09 20:58:13
mbbd000000468,mbcd0000370,mbtp000001,mbrf0001050,,=,,,inhibitor,25,13.0,microM,,Efonidipine,,,MDR1-expressing LLC-PK1 cell; inhibition of Digoxin transepithelial transport (basal to apical) (Digoxin: 0.1 microM),LLC-PK1,mbcd0001050,,,,human,mbds0003,v2007,2013-12-09 20:58:14
mbbd000000469,mbcd0002338,mbtp000001,mbrf0001050,,=,,,inhibitor,25,77.7,microM,,Diltiazem,,,MDR1-expressing LLC-PK1 cell; inhibition of Digoxin transepithelial transport (basal to apical) (Digoxin: 0.1 microM),LLC-PK1,mbcd0001050,,,,human,mbds0003,v2007,2013-12-09 20:58:14
mbbd000000470,mbcd0000167,mbtp000001,mbrf0001050,,=,,,inhibitor,25,4.96,microM,,Benidipine,,,MDR1-expressing LLC-PK1 cell; inhibition of Digoxin transepithelial transport (basal to apical) (Digoxin: 0.1 microM),LLC-PK1,mbcd0001050,,,,human,mbds0003,v2007,2013-12-09 20:09:51
mbbd000000471,mbcd0000166,mbtp000001,mbrf0001050,,=,,,inhibitor,25,12.6,microM,,Barnidipine,,,MDR1-expressing LLC-PK1 cell; inhibition of Digoxin transepithelial transport (basal to apical) (Digoxin: 0.1 microM),LLC-PK1,mbcd0001050,,,,human,mbds0003,v2007,2013-12-09 20:09:51
mbbd000000472,mbcd0001135,mbtp000001,mbrf0001051,,=,,,inhibitor,29,213.0,microM,,vincristine,,,MDR1-expressing MDCK cell; inhibition of Digoxin transepithelial transport (basal to apical),MDCK,mbcd0001050,,,,human,mbds0003,v2007,2013-12-09 20:09:52
mbbd000000473,mbcd0001151,mbtp000001,mbrf0001051,,=,,,inhibitor,29,140.0,microM,,Vinblastine,,,MDR1-expressing MDCK cell; inhibition of Digoxin transepithelial transport (basal to apical),MDCK,mbcd0001050,,,,human,mbds0003,v2007,2013-12-09 20:09:52
mbbd000000474,mbcd0001151,mbtp000001,mbrf0001051,,=,,,substrate,28,252.8,microM,134.7,Vinblastine,,,MDR1-expressing MDCK cell; transepithelial transport (basal to apical),MDCK,,0-160,microM,,human,mbds0003,v2007,2013-12-09 20:09:48
mbbd000000475,mbcd0027062,mbtp000001,mbrf0001051,,=,,,inhibitor,29,15.1,microM,,Verapamil,,,MDR1-expressing MDCK cell; inhibition of Digoxin transepithelial transport (basal to apical),MDCK,mbcd0001050,,,,human,mbds0003,v2007,2013-12-09 20:09:47
mbbd000000476,mbcd0001941,mbtp000001,mbrf0001051,,=,,,inhibitor,29,11.5,microM,,Reserpine,,,MDR1-expressing MDCK cell; inhibition of Digoxin transepithelial transport (basal to apical),MDCK,mbcd0001050,,,,human,mbds0003,v2007,2013-12-09 20:09:50
mbbd000000477,mbcd0027018,mbtp000001,mbrf0001051,,=,,,inhibitor,29,8.59,microM,,Quinidine,,,MDR1-expressing MDCK cell; inhibition of Digoxin transepithelial transport (basal to apical),MDCK,mbcd0001050,,,,human,mbds0003,v2007,2013-12-09 20:09:49
mbbd000000478,mbcd0001808,mbtp000001,mbrf0001051,,=,,,inhibitor,29,0.44,microM,,GF120918,,,MDR1-expressing MDCK cell; inhibition of Digoxin transepithelial transport (basal to apical),MDCK,mbcd0001050,,,,human,mbds0003,v2007,2013-12-09 20:09:53
mbbd000000479,mbcd0002466,mbtp000001,mbrf0001051,,=,,,inhibitor,29,768.0,microM,,Etoposide,,,MDR1-expressing MDCK cell; inhibition of Digoxin transepithelial transport (basal to apical),MDCK,mbcd0001050,,,,human,mbds0003,v2007,2013-12-09 20:09:53
mbbd000000480,mbcd0005183,mbtp000001,mbrf0001051,,=,,,inhibitor,29,111.0,microM,,daunorubicin,,,MDR1-expressing MDCK cell; inhibition of Digoxin transepithelial transport (basal to apical),MDCK,mbcd0001050,,,,human,mbds0003,v2007,2013-12-09 20:57:51
mbbd000000481,mbcd0000311,mbtp000001,mbrf0001051,,=,,,inhibitor,29,2.18,microM,,CsA,,,MDR1-expressing MDCK cell; inhibition of Digoxin transepithelial transport (basal to apical),MDCK,mbcd0001050,,,,human,mbds0003,v2007,2013-12-09 20:57:52
mbbd000000482,mbcd0000739,mbtp000001,mbrf0001052,,,,,substrate,,,,,ramosetron,,,LLC-PK1 cell and LLC-GA5-COL300 cell; uptake,LLC-PK1; LLC-GA5-COL300,,,,,human,mbds0003,v2007,2013-12-09 20:57:52
mbbd000000483,mbcd0000879,mbtp000001,mbrf0001053,,=,,,non-inhibitor,1,101.3,%,,Tween 80,,,"MDR1-expressing MDCK cell; inhibition of Taxol transepithelial transport (basal to apical)(Taxol: 0.04-0.06 microM, Tween 80: 0.05 %)",MDCK,mbcd0001532,,,,human,mbds0003,v2007,2013-12-09 20:57:52
mbbd000000484,mbcd0000879,mbtp000001,mbrf0001053,,=,,,inhibitor,1,59.48,%,,Tween 80,,,"Caco-2 cell; inhibition of Taxol transepithelial transport (basal to apical)(Taxol: 0.04-0.06 microM,Tween 80: 0.05 %)",Caco-2,mbcd0001532,,,,human,mbds0003,v2007,2013-12-09 20:57:52
mbbd000000489,mbcd0001324,mbtp000001,mbrf0001054,,=,,,inhibitor,25,1.25,microM,,Sirolimus,,,HCT-8 cell; inhibition of Rhodamine 123 transport (basal to apical) (R123: 15 microM),HCT8,mbcd0000746,,,,human,mbds0003,v2007,2013-12-09 20:57:50
mbbd000000490,mbcd0001324,mbtp000001,mbrf0001054,,,,,non-substrate,,,,,sirolimus,,,HCT-8 cell; transepithelial transport (basal to apical),HCT8,,,,,human,mbds0003,v2007,2013-12-09 20:08:50
mbbd000000491,mbcd0023577,mbtp000001,mbrf0001055,,,,,non-substrate,,,,,FCZ,,,MDR1-expressing LLC-PK1 cell; transepithelial transport (basal to apical),LLC-PK1,,,,,human,mbds0003,v2007,2013-12-09 20:08:49
mbbd000000492,mbcd0000349,mbtp000001,mbrf0001055,,,,,substrate,,,,,dihydroergocristine,,,MDR1-expressing LLC-PK1 cell; transepithelial transport (basal to apical),LLC-PK1,,,,,human,mbds0003,v2007,2013-12-09 20:08:49
mbbd000000493,mbcd0002192,mbtp000001,mbrf0001055,,=,,,inhibitor,29,5.78,microM,,Amiodarone,,,MDR1-expressing LLC-PK1 cell; increase in Calcein-AM intracellular accumulation,LLC-PK1,mbcd0000212,,,,human,mbds0003,v2007,2013-12-09 20:08:48
mbbd000000494,mbcd0003957,mbtp000001,mbrf0001056,,,,,inducer,,,,,Levothyroxine,,,"in vivo, duodenal; RT-PCR and immunohistochemistry",human duodenum,,,,,human,mbds0003,v2007,2013-12-13 18:37:40
mbbd000000495,mbcd0000498,mbtp000001,mbrf0001057,,,,,inhibitor,,,,,JTV-519,,,"K562/MDR cell; inhibition of Adriamycin efflux (Adriamycin: 10 microM, JTV-519: 10 microM)",K562/ADM,mbcd0025844,,,,human,mbds0003,v2007,2013-12-09 20:08:47
mbbd000000496,mbcd0026894,mbtp000001,mbrf0001058,,,,,non-substrate,,,,,cortexolone,,,MDR1-expressing LLC-PK1 cell; transepithelial transport (basal to apical),LLC-PK1,,,,,human,mbds0003,v2007,2013-12-09 20:08:46
mbbd000000497,mbcd0027062,mbtp000001,mbrf0001059,,,,,non-inducer,,,,,Vp,,,HK-2 cell; RT-PCR and Western,HK-2,,,,,human,mbds0003,v2007,2013-12-09 20:08:45
mbbd000000498,mbcd0003115,mbtp000001,mbrf0001059,,,,,non-inducer,,,,,Trimethoprim,,,HK-2 cell; RT-PCR and Western,HK-2,,,,,human,mbds0003,v2007,2013-12-09 20:08:45
mbbd000000499,mbcd0001892,mbtp000001,mbrf0001059,,,,,non-inducer,,,,,Progesterone,,,HK-2 cell; RT-PCR and Western,HK-2,,,,,human,mbds0003,v2007,2013-12-09 20:08:45
mbbd000000500,mbcd0001636,mbtp000001,mbrf0001059,,,,,inducer,,,,,PAF,,,HK-2 cell; RT-PCR and Western,HK-2,,,,,human,mbds0003,v2007,2013-12-09 20:54:52
mbbd000000501,mbcd0002959,mbtp000001,mbrf0001059,,,,,inducer,,,,,Dex,,,HK-2 cell; RT-PCR and Western,HK-2,,,,,human,mbds0003,v2007,2013-12-09 20:54:52
mbbd000000502,mbcd0000311,mbtp000001,mbrf0001059,,,,,inducer,,,,,CsA,,,HK-2 cell; RT-PCR and Western,HK-2,,,,,human,mbds0003,v2007,2013-12-09 20:54:52
mbbd000000503,mbcd0001111,mbtp000001,mbrf0001059,,,,,non-inducer,,,,,Cimetidine,,,HK-2 cell; RT-PCR and Western,HK-2,,,,,human,mbds0003,v2007,2013-12-09 20:54:52
mbbd000000504,mbcd0001675,mbtp000001,mbrf0001059,,,,,inducer,,,,,Aldosterone,,,HK-2 cell; Western,HK-2,,,,,human,mbds0003,v2007,2013-12-09 20:54:53
mbbd000000505,mbcd0013555,mbtp000001,mbrf0001059,,,,,repressor,,,,,3-MC,,,HK-2 cell; Western,HK-2,,,,,human,mbds0003,v2007,2013-12-09 20:54:53
mbbd000000506,mbcd0000042,mbtp000001,mbrf0001059,,,,,repressor,,,,,2-AAF,,,HK-2 cell; RT-PCR and Western,HK-2,,,,,human,mbds0003,v2007,2013-12-09 20:54:53
mbbd000000507,mbcd0000685,mbtp000001,mbrf0001060,,=,,,inhibitor,100,10.0,fold increase,,Phenylhexyl ITC,,,"MCF-7/ADR cell; increase in Vinblastine intracellular accumulation (Daunomycin: 0.05 microM, Phenylhexyl isothiocyanate: 100 microM)",MCF7/ADR,mbcd0001151,,,,human,mbds0003,v2007,2013-12-09 20:54:53
mbbd000000508,mbcd0026443,mbtp000001,mbrf0001060,,~,,,inhibitor,100,2.5,fold increase,,BITC,,,"MCF-7/ADR cell; increase in Daunomycin intracellular accumulation (Daunomycin: 0.05 microM, Benzylisothiocyanate: 100 microM)",MCF7/ADR,mbcd0005183,,,,human,mbds0003,v2007,2013-12-09 20:54:52
mbbd000000509,mbcd0028378,mbtp000001,mbrf0001060,,=,,,inhibitor,100,4.0,fold increase,,NITC,,,"MCF-7 ADR cell; increase in Daunomycin intracellular accumulation (Daunomycin: 0.05 microM, NITC: 100 microM)",MCF7/ADR,mbcd0005183,,,,human,mbds0003,v2007,2013-12-09 20:54:52
mbbd000000510,mbcd0001682,mbtp000001,mbrf0001061,,=,,,non-inhibitor,151,7.4,%,,Zimeldine,,,"MDR1-expressing MDCKII cell; increase in Calcein-AM intracellular accumulation (Calcein-AM: ? microM, Zimeldine: 100 microM)",MDCKII,mbcd0000212,100,microM,,human,mbds0003,v2007,2013-12-09 20:05:42
mbbd000000511,mbcd0001682,mbtp000001,mbrf0001061,,,,,non-substrate,,,,,zimeldine,,,MDR1-expressing MDCKII cell; transepithelial transport (basal to apical),MDCKII,,,,,human,mbds0003,v2007,2013-12-09 20:05:43
mbbd000000512,mbcd0009726,mbtp000001,mbrf0001061,,=,,,non-inhibitor,151,4.76,%,,Tacrine,,,"MDR1-expressing MDCKII cell; increase in Calcein-AM intracellular accumulation (Calcein-AM: ? microM, Tacrine: 100 microM)",MDCKII,mbcd0000212,100,microM,,human,mbds0003,v2007,2013-12-09 20:05:41
mbbd000000513,mbcd0009726,mbtp000001,mbrf0001061,,,,,non-substrate,,,,,tacrine,,,MDR1-expressing MDCKII cell; transepithelial transport (basal to apical),MDCKII,,,,,human,mbds0003,v2007,2013-12-09 20:05:41
mbbd000000514,mbcd0001204,mbtp000001,mbrf0001061,,=,,,non-inhibitor,151,0.76,%,,sumatriptan,,,"MDR1-expressing MDCKII cell; increase in Calcein-AM intracellular accumulation (Calcein-AM: ? microM, Sumatriptan: 100 microM)",MDCKII,mbcd0000212,100,microM,,human,mbds0003,v2007,2013-12-09 20:05:48
mbbd000000515,mbcd0001204,mbtp000001,mbrf0001061,,,,,non-substrate,,,,,sumatriptan,,,MDR1-expressing MDCKII cell; transepithelial transport (basal to apical),MDCKII,,,,,human,mbds0003,v2007,2013-12-09 20:05:49
mbbd000000516,mbcd0014496,mbtp000001,mbrf0001061,,=,,,non-inhibitor,151,3.02,%,,selegiline,,,"MDR1-expressing MDCKII cell; increase in Calcein-AM intracellular accumulation (Calcein-AM: ? microM, Selegiline: 100 microM)",MDCKII,mbcd0000212,100,microM,,human,mbds0003,v2007,2013-12-09 20:05:44
mbbd000000517,mbcd0014496,mbtp000001,mbrf0001061,,,,,non-substrate,,,,,selegiline,,,MDR1-expressing MDCKII cell; transepithelial transport (basal to apical),MDCKII,,,,,human,mbds0003,v2007,2013-12-09 20:05:46
mbbd000000518,mbcd0001251,mbtp000001,mbrf0001061,,=,,,non-inhibitor,151,0.54,%,,Scopolamine,,,"MDR1-expressing MDCKII cell; increase in Calcein-AM intracellular accumulation (Calcein-AM: ? microM, Scopolamine: 100 microM)",MDCKII,mbcd0000212,100,microM,,human,mbds0003,v2007,2013-12-09 20:05:40
mbbd000000519,mbcd0001251,mbtp000001,mbrf0001061,,,,,non-substrate,,,,,scopolamine,,,MDR1-expressing MDCKII cell; transepithelial transport (basal to apical),MDCKII,,,,,human,mbds0003,v2007,2013-12-09 20:05:41
mbbd000000520,mbcd0000631,mbtp000001,mbrf0001061,,=,,,non-inhibitor,151,5.17,%,,Nordazepam,,,"MDR1-expressing MDCKII cell; increase in Calcein-AM intracellular accumulation (Calcein-AM: ? microM, Nordazepam: 100 microM)",MDCKII,mbcd0000212,100,microM,,human,mbds0003,v2007,2013-12-09 20:57:30
mbbd000000521,mbcd0000631,mbtp000001,mbrf0001061,,,,,non-substrate,,,,,nordazepam,,,MDR1-expressing MDCKII cell; transepithelial transport (basal to apical),MDCKII,,,,,human,mbds0003,v2007,2013-12-09 20:57:30
mbbd000000522,mbcd0001618,mbtp000001,mbrf0001061,,=,,,non-inhibitor,151,3.66,%,,Nitrazepam,,,"MDR1-expressing MDCKII cell; increase in Calcein-AM intracellular accumulation (Calcein-AM: ? microM, Nitrazepam: 100 microM)",MDCKII,mbcd0000212,100,microM,,human,mbds0003,v2007,2013-12-09 20:57:29
mbbd000000523,mbcd0001618,mbtp000001,mbrf0001061,,,,,non-substrate,,,,,nitrazepam,,,MDR1-expressing MDCKII cell; transepithelial transport (basal to apical),MDCKII,,,,,human,mbds0003,v2007,2013-12-09 20:55:16
mbbd000000524,mbcd0001226,mbtp000001,mbrf0001061,,=,,,non-inhibitor,151,2.03,%,,naltrexone,,,"MDR1-expressing MDCKII cell; increase in Calcein-AM intracellular accumulation (Calcein-AM: ? microM, Naltrexone: 100 microM)",MDCKII,mbcd0000212,100,microM,,human,mbds0003,v2007,2013-12-09 20:57:29
mbbd000000525,mbcd0001226,mbtp000001,mbrf0001061,,,,,non-substrate,,,,,naltrexone,,,MDR1-expressing MDCKII cell; transepithelial transport (basal to apical),MDCKII,,,,,human,mbds0003,v2007,2013-12-09 20:57:29
mbbd000000526,mbcd0001496,mbtp000001,mbrf0001061,,,,,non-substrate,,,,,naloxone,,,MDR1-expressing MDCKII cell; transepithelial transport (basal to apical),MDCKII,,,,,human,mbds0003,v2007,2013-12-09 20:57:28
mbbd000000528,mbcd0001735,mbtp000001,mbrf0001061,,,,,non-substrate,,,,,midazolam,,,MDR1-expressing MDCKII cell; transepithelial transport (basal to apical),MDCKII,,,,,human,mbds0003,v2007,2013-12-09 20:55:18
mbbd000000529,mbcd0026438,mbtp000001,mbrf0001061,,=,,,inhibitor,100,84.4,% increase,,Metergoline,,,"MDR1-expressing MDCKII cell; increase in Calcein-AM intracellular accumulation (Calcein-AM: ? microM, Metergoline: 100 microM)",MDCKII,mbcd0000212,100,microM,,human,mbds0003,v2007,2013-12-09 20:55:18
mbbd000000530,mbcd0026438,mbtp000001,mbrf0001061,,,,,non-substrate,,,,,metergoline,,,MDR1-expressing MDCKII cell; transepithelial transport (basal to apical),MDCKII,,,,,human,mbds0003,v2007,2013-12-09 20:08:14
mbbd000000531,mbcd0001042,mbtp000001,mbrf0001061,,=,,,non-inhibitor,151,2.24,%,,Meprobamate,,,"MDR1-expressing MDCKII cell; increase in Calcein-AM intracellular accumulation (Calcein-AM: ? microM, Meprobamate: 100 microM)",MDCKII,mbcd0000212,100,microM,,human,mbds0003,v2007,2013-12-09 21:00:33
mbbd000000532,mbcd0001042,mbtp000001,mbrf0001061,,,,,non-substrate,,,,,meprobamate,,,MDR1-expressing MDCKII cell; transepithelial transport (basal to apical),MDCKII,,,,,human,mbds0003,v2007,2013-12-09 20:08:14
mbbd000000533,mbcd0020385,mbtp000001,mbrf0001061,,=,,,inhibitor,100,36.7,% increase,,Maprotiline,,,"MDR1-expressing MDCKII cell; increase in Calcein-AM intracellular accumulation (Calcein-AM: ? microM, Maprotiline: 100 microM)",MDCKII,mbcd0000212,100,microM,,human,mbds0003,v2007,2013-12-09 21:00:34
mbbd000000534,mbcd0020385,mbtp000001,mbrf0001061,,,,,non-substrate,,,,,maprotiline,,,MDR1-expressing MDCKII cell; transepithelial transport (basal to apical),MDCKII,,,,,human,mbds0003,v2007,2013-12-09 20:08:15
mbbd000000535,mbcd0027314,mbtp000001,mbrf0001061,,=,,,non-inhibitor,151,1.23,%,,Ketamine,,,"MDR1-expressing MDCKII cell; increase in Calcein-AM intracellular accumulation (Calcein-AM: ? microM, Ketamine: 100 microM)",MDCKII,mbcd0000212,100,microM,,human,mbds0003,v2007,2013-12-09 20:08:15
mbbd000000536,mbcd0027314,mbtp000001,mbrf0001061,,,,,non-substrate,,,,,ketamine,,,MDR1-expressing MDCKII cell; transepithelial transport (basal to apical),MDCKII,,,,,human,mbds0003,v2007,2013-12-09 21:00:37
mbbd000000537,mbcd0003898,mbtp000001,mbrf0001061,,=,,,non-inhibitor,151,5.37,%,,Imipramine,,,"MDR1-expressing MDCKII cell; increase in Calcein-AM intracellular accumulation (Calcein-AM: ? microM, Imipramine: 100 microM)",MDCKII,mbcd0000212,100,microM,,human,mbds0003,v2007,2013-12-09 20:08:15
mbbd000000538,mbcd0003898,mbtp000001,mbrf0001061,,,,,non-substrate,,,,,imipramine,,,MDR1-expressing MDCKII cell; transepithelial transport (basal to apical),MDCKII,,,,,human,mbds0003,v2007,2013-12-09 20:08:16
mbbd000000539,mbcd0001777,mbtp000001,mbrf0001061,,=,,,inhibitor,100,37.2,% increase,,Haloperidol,,,"MDR1-expressing MDCKII cell; increase in Calcein-AM intracellular accumulation (Calcein-AM: ? microM, Haloperidol: 100 microM)",MDCKII,mbcd0000212,100,microM,,human,mbds0003,v2007,2013-12-09 20:08:16
mbbd000000540,mbcd0001777,mbtp000001,mbrf0001061,,,,,non-substrate,,,,,haloperidol,,,MDR1-expressing MDCKII cell; transepithelial transport (basal to apical),MDCKII,,,,,human,mbds0003,v2007,2013-12-09 20:53:07
mbbd000000541,mbcd0000923,mbtp000001,mbrf0001061,,=,,,inhibitor,100,20.8,% increase,,fluvoxamine,,,"MDR1-expressing MDCKII cell; increase in Calcein-AM intracellular accumulation (Calcein-AM: ? microM, Fluvoxamine: 100 microM)",MDCKII,mbcd0000212,100,microM,,human,mbds0003,v2007,2013-12-09 20:53:07
mbbd000000542,mbcd0000923,mbtp000001,mbrf0001061,,,,,non-substrate,,,,,fluvoxamine,,,MDR1-expressing MDCKII cell; transepithelial transport (basal to apical),MDCKII,,,,,human,mbds0003,v2007,2013-12-09 20:53:08
mbbd000000543,mbcd0001214,mbtp000001,mbrf0001061,,=,,,inhibitor,100,22.6,% increase,,Flurazepam,,,"MDR1-expressing MDCKII cell; increase in Calcein-AM intracellular accumulation (Calcein-AM: ? microM, Fluramazepam: 100 microM)",MDCKII,mbcd0000212,100,microM,,human,mbds0003,v2007,2013-12-09 20:53:07
mbbd000000544,mbcd0001214,mbtp000001,mbrf0001061,,,,,non-substrate,,,,,flurazepam,,,MDR1-expressing MDCKII cell; transepithelial transport (basal to apical),MDCKII,,,,,human,mbds0003,v2007,2013-12-09 20:53:07
mbbd000000545,mbcd0022530,mbtp000001,mbrf0001061,,=,,,inhibitor,100,23.5,% increase,,Fluoxetine,,,"MDR1-expressing MDCKII cell; increase in Calcein-AM intracellular accumulation (Calcein-AM: ? microM, Fluoxetine: 100 microM)",MDCKII,mbcd0000212,100,microM,,human,mbds0003,v2007,2013-12-09 20:53:07
mbbd000000546,mbcd0022530,mbtp000001,mbrf0001061,,,,,non-substrate,,,,,fluoxetine,,,MDR1-expressing MDCKII cell; transepithelial transport (basal to apical),MDCKII,,,,,human,mbds0003,v2007,2013-12-09 20:17:47
mbbd000000547,mbcd0017921,mbtp000001,mbrf0001061,,=,,,non-inhibitor,151,3.89,%,,Flumazenil,,,"MDR1-expressing MDCKII cell; increase in Calcein-AM intracellular accumulation (Calcein-AM: ? microM, Flumazenil: 100 microM)",MDCKII,mbcd0000212,100,microM,,human,mbds0003,v2007,2013-12-09 20:00:24
mbbd000000548,mbcd0017921,mbtp000001,mbrf0001061,,,,,non-substrate,,,,,flumazenil,,,MDR1-expressing MDCKII cell; transepithelial transport (basal to apical),MDCKII,,,,,human,mbds0003,v2007,2013-12-09 20:00:37
mbbd000000549,mbcd0009851,mbtp000001,mbrf0001061,,=,,,inhibitor,100,15.3,% increase,,Doxepin,,,"MDR1-expressing MDCKII cell; increase in Calcein-AM intracellular accumulation (Calcein-AM: ? microM, Doxepin: 100 microM)",MDCKII,mbcd0000212,100,microM,,human,mbds0003,v2007,2013-12-09 20:00:35
mbbd000000550,mbcd0009851,mbtp000001,mbrf0001061,,,,,non-substrate,,,,,doxepin,,,MDR1-expressing MDCKII cell; transepithelial transport (basal to apical),MDCKII,,,,,human,mbds0003,v2007,2013-12-09 20:02:59
mbbd000000551,mbcd0002995,mbtp000001,mbrf0001061,,=,,,inhibitor,100,12.8,% increase,,Desipramine,,,"MDR1-expressing MDCKII cell; increase in Calcein-AM intracellular accumulation (Calcein-AM: ? microM, Desipramine: 100 microM)",MDCKII,mbcd0000212,100,microM,,human,mbds0003,v2007,2013-12-09 20:03:00
mbbd000000552,mbcd0002995,mbtp000001,mbrf0001061,,,,,non-substrate,,,,,desipramine,,,MDR1-expressing MDCKII cell; transepithelial transport (basal to apical),MDCKII,,,,,human,mbds0003,v2007,2013-12-09 20:05:33
mbbd000000553,mbcd0003925,mbtp000001,mbrf0001061,,=,,,inhibitor,100,48.2,% increase,,Clomipramine,,,"MDR1-expressing MDCKII cell; increase in Calcein-AM intracellular accumulation (Calcein-AM: ? microM, Clomipramine: 100 microM)",MDCKII,mbcd0000212,100,microM,,human,mbds0003,v2007,2013-12-09 20:02:59
mbbd000000554,mbcd0003925,mbtp000001,mbrf0001061,,,,,non-substrate,,,,,clomipramine,,,MDR1-expressing MDCKII cell; transepithelial transport (basal to apical),MDCKII,,,,,human,mbds0003,v2007,2013-12-09 20:05:31
mbbd000000555,mbcd0001539,mbtp000001,mbrf0001061,,=,,,inhibitor,100,57.5,% increase,,Chlorprothixene,,,"MDR1-expressing MDCKII cell; increase in Calcein-AM intracellular accumulation (Calcein-AM: ? microM, Chlorprothixene: 100 microM)",MDCKII,mbcd0000212,100,microM,,human,mbds0003,v2007,2013-12-09 21:01:18
mbbd000000556,mbcd0001539,mbtp000001,mbrf0001061,,,,,non-substrate,,,,,chlorprothixene,,,MDR1-expressing MDCKII cell; transepithelial transport (basal to apical),MDCKII,,,,,human,mbds0003,v2007,2013-12-09 20:02:57
mbbd000000557,mbcd0002985,mbtp000001,mbrf0001061,,=,,,non-inhibitor,151,1.22,%,,carbamazepine,,,"MDR1-expressing MDCKII cell; increase in Calcein-AM intracellular accumulation (Calcein-AM: ? microM, Carbamazepine: 100 microM)",MDCKII,mbcd0000212,100,microM,,human,mbds0003,v2007,2013-12-09 21:01:16
mbbd000000558,mbcd0002985,mbtp000001,mbrf0001061,,,,,non-substrate,,,,,carbamazepine,,,MDR1-expressing MDCKII cell; transepithelial transport (basal to apical),MDCKII,,,,,human,mbds0003,v2007,2013-12-09 20:05:34
mbbd000000559,mbcd0003932,mbtp000001,mbrf0001061,,=,,,inhibitor,100,24.1,% increase,,Buspirone,,,"MDR1-expressing MDCKII cell; increase in Calcein-AM intracellular accumulation (Calcein-AM: ? microM, Buspirone: 100 microM)",MDCKII,mbcd0000212,100,microM,,human,mbds0003,v2007,2013-12-09 20:03:01
mbbd000000560,mbcd0003932,mbtp000001,mbrf0001061,,,,,non-substrate,,,,,buspirone,,,MDR1-expressing MDCKII cell; transepithelial transport (basal to apical),MDCKII,,,,,human,mbds0003,v2007,2013-12-09 20:54:12
mbbd000000561,mbcd0026046,mbtp000001,mbrf0001061,,,,,non-substrate,,,,,bromocriptine,,,MDR1-expressing MDCKII cell; transepithelial transport (basal to apical),MDCKII,,,,,human,mbds0003,v2007,2013-12-09 20:54:12
mbbd000000562,mbcd0001287,mbtp000001,mbrf0001061,,=,,,non-inhibitor,151,4.97,%,,Biperiden,,,"MDR1-expressing MDCKII cell; increase in Calcein-AM intracellular accumulation (Calcein-AM: ? microM, Biperiden: 100 microM)",MDCKII,mbcd0000212,100,microM,,human,mbds0003,v2007,2013-12-09 20:10:17
mbbd000000563,mbcd0001287,mbtp000001,mbrf0001061,,,,,non-substrate,,,,,biperiden,,,MDR1-expressing MDCKII cell; transepithelial transport (basal to apical),MDCKII,,,,,human,mbds0003,v2007,2013-12-09 20:54:11
mbbd000000564,mbcd0003081,mbtp000001,mbrf0001061,,=,,,inhibitor,100,25.5,% increase,,Amitriptylline,,,"MDR1-expressing MDCKII cell; increase in Calcein-AM intracellular accumulation (Calcein-AM: ? microM, Amitriptyline: 100 microM)",MDCKII,mbcd0000212,100,microM,,human,mbds0003,v2007,2013-12-09 20:10:18
mbbd000000565,mbcd0003081,mbtp000001,mbrf0001061,,,,,non-substrate,,,,,amitriptylline,,,MDR1-expressing MDCKII cell; transepithelial transport (basal to apical),MDCKII,,,,,human,mbds0003,v2007,2013-12-09 20:54:12
mbbd000000566,mbcd0003083,mbtp000001,mbrf0001061,,=,,,non-inhibitor,151,2.1,%,,Amantadine,,,"MDR1-expressing MDCKII cell; increase in Calcein-AM intracellular accumulation (Calcein-AM: ? microM, Amantadine: 100 microM)",MDCKII,mbcd0000212,100,microM,,human,mbds0003,v2007,2013-12-09 20:54:12
mbbd000000567,mbcd0003083,mbtp000001,mbrf0001061,,,,,non-substrate,,,,,amantadine,,,MDR1-expressing MDCKII cell; transepithelial transport (basal to apical),MDCKII,,,,,human,mbds0003,v2007,2013-12-09 20:54:12
mbbd000000568,mbcd0000547,mbtp000001,mbrf0001062,,,,,inhibitor,,,,,LY335979,Growth inhibition,,MDR1-expressing HL60/Vinc; drug resistance (vinorelbine),HL60/VINC,mbcd0025827,,,,human,mbds0003,v2007,2013-12-09 20:54:13
mbbd000000569,mbcd0000547,mbtp000001,mbrf0001062,,,,,inhibitor,,,,,LY335979,Growth inhibition,,MDR1-expressing HL60/Vinc; drug resistance (mitozantrone),HL60/VINC,mbcd0002981,,,,human,mbds0003,v2007,2013-12-09 20:54:13
mbbd000000570,mbcd0000182,mbtp000001,mbrf0001063,,,,,non-substrate,,,,,sitosterol,,,MDR1-expressing NIH3T3 cell; Flow cytometry,NIH-3T3,,,,,human,mbds0003,v2007,2013-12-09 20:04:29
mbbd000000571,mbcd0001151,mbtp000001,mbrf0001064,,,,,substrate,,,,,vinblastine,,,MDR1-expressing LLC-PK1 cell,LLC-PK1,,,,,human,mbds0003,v2007,2013-12-09 20:04:30
mbbd000000572,mbcd0001938,mbtp000001,mbrf0001064,,=,,,inhibitor,25,15.7,microM,,ritonavir,,,MDR1-expressing LLC-PK1 cell; inhibition of cyclosporin A uptake (cyclosporin A: 10 microM),LLC-PK1,mbcd0000311,,,,human,mbds0003,v2007,2013-12-09 20:04:31
mbbd000000573,mbcd0000592,mbtp000001,mbrf0001064,,,,,substrate,,,,,MRK-1,,,MDR1-expressing LLC-PK1 cell,LLC-PK1,,,,,human,mbds0003,v2007,2013-12-09 20:04:32
mbbd000000574,mbcd0000311,mbtp000001,mbrf0001064,,=,,,inhibitor,72,50.0,%,,cyclosporin A,,,"MDR1-expressing LLC-PK1 cell; inhibition of MRK-1 uptake (vinblastine: 10 microM, CsA: 10 microM)",LLC-PK1,mbcd0000592,,,,human,mbds0003,v2007,2013-12-09 20:04:24
mbbd000000575,mbcd0000311,mbtp000001,mbrf0001064,,=,,,inhibitor,72,30.0,%,,cyclosporin A,,,"MDR1-expressing LLC-PK1 cell; inhibition of MRK-1 uptake (MRK-1: 10 microM, CsA: 10 microM)",LLC-PK1,mbcd0000592,,,,human,mbds0003,v2007,2013-12-09 20:04:25
mbbd000000576,mbcd0027062,mbtp000001,mbrf0001065,,~,,,inhibitor,100,580.0,%,200,Verapamil,,,MDA435/LCC6MDR1 cell; cell accumulation of daunomycin,MDA435/LCC6,mbcd0005183,50,microM,,human,mbds0003,v2007,2013-12-09 20:04:25
mbbd000000577,mbcd0022617,mbtp000001,mbrf0001065,,~,,,inhibitor,100,420.0,%,300,Silymarin,,,MDA435/LCC6MDR1 cell; cell accumulation of daunomycin,MDA435/LCC6,mbcd0005183,50,microM,,human,mbds0003,v2007,2013-12-09 20:04:27
mbbd000000578,mbcd0004171,mbtp000001,mbrf0001065,,~,,,inhibitor,100,280.0,%,100,Phloretin,,,MDA435/LCC6MDR1 cell; cell accumulation of daunomycin,MDA435/LCC6,mbcd0005183,50,microM,,human,mbds0003,v2007,2013-12-09 20:04:23
mbbd000000579,mbcd0003059,mbtp000001,mbrf0001065,,~,,,inhibitor,100,580.0,%,300,Morin,,,MDA435/LCC6MDR1 cell; cell accumulation of daunomycin,MDA435/LCC6,mbcd0005183,50,microM,,human,mbds0003,v2007,2013-12-09 20:04:24
mbbd000000580,mbcd0003026,mbtp000001,mbrf0001065,,~,,,inhibitor,100,640.0,%,180,Biochanin A,,,MDA435/LCC6MDR1 cell; cell accumulation of daunomycin,MDA435/LCC6,mbcd0005183,50,microM,,human,mbds0003,v2007,2013-12-09 20:52:20
mbbd000000581,mbcd0027062,mbtp000001,mbrf0001065,,~,,,inhibitor,72,605.0,%,,Verapamil,,,"MDA435/LCC6 MDR1 cell; inhibition of Daunorubicin intracellular accumulation (DMN: 0.05 microM, Verapamil: 100 microM)",MDA435/LCC6,mbcd0005183,,,,human,mbds0003,v2007,2013-12-09 20:52:19
mbbd000000582,mbcd0022617,mbtp000001,mbrf0001065,,~,,,inhibitor,72,420.0,%,,Silymarin,,,"MDA435/LCC6 MDR1 cell; increase in Daunomycin intracellular accumulation (Daunomycin: 0.05 microM, Silymarin: 50 microM)",MDA435/LCC6,mbcd0005183,,,,human,mbds0003,v2007,2013-12-09 20:52:20
mbbd000000583,mbcd0003059,mbtp000001,mbrf0001065,,~,,,inhibitor,72,585.0,%,,Morin,,,"MDA435/LLC6MDR1 cell; increase in Daunomycin intracellular accumulation (Daunomycin: 0.05 microM, Morin: 50 microM)",MDA435/LCC6,mbcd0005183,,,,human,mbds0003,v2007,2013-12-09 20:52:20
mbbd000000584,mbcd0003026,mbtp000001,mbrf0001065,,~,,,inhibitor,72,645.0,%,,Biochanin A,,,"MDA435/LLC6MDR1 cell; increase in Daunomycin intracellular accumulation (Daunomycin: 0.05 microM, BiochaninA: 50 microM)",MDA435/LCC6,mbcd0005183,,,,human,mbds0003,v2007,2013-12-09 20:52:20
mbbd000000585,mbcd0001117,mbtp000001,mbrf0001066,,,,,non-substrate,,,,,cisplatin,,,MDR1-expressing MCF7 cell; drug resistance,MCF7,,,,,human,mbds0003,v2007,2013-12-09 20:52:20
mbbd000000587,mbcd0020601,mbtp000001,mbrf0001066,,,,,non-substrate,,,,,camptothecin,,,MDR1-expressing MCF7 cell; drug resistance,MCF7,,,,,human,mbds0003,v2007,2013-12-09 20:52:21
mbbd000000588,mbcd0001135,mbtp000001,mbrf0001066,,,,,substrate,,,,,vincristine,,,MDR1-expressing MCF7 cell; drug resistance,MCF7,,,,,human,mbds0003,v2007,2013-12-09 20:52:21
mbbd000000589,mbcd0025844,mbtp000001,mbrf0001066,,,,,substrate,,,,,doxorubicin,,,MDR1-expressing MCF7 cell; drug resistance,MCF7,,,,,human,mbds0003,v2007,2013-12-09 20:52:21
mbbd000000590,mbcd0001532,mbtp000001,mbrf0001066,,,,,substrate,,,,,paclitaxel,,,MDR1-expressing MCF7 cell; drug resistance,MCF7,,,,,human,mbds0003,v2007,2013-12-09 19:59:12
mbbd000000591,mbcd0027062,mbtp000001,mbrf0001067,,=,,,inhibitor,29,0.88,microM,,Verapamil,,,Caco-2 cell; transepithelial transport of digoxin (basal to apical),Caco-2,mbcd0001050,,,,human,mbds0003,v2007,2013-12-09 19:59:13
mbbd000000592,mbcd0027018,mbtp000001,mbrf0001067,,=,,,inhibitor,29,0.43,microM,,Quinidine,,,Caco-2 cell; transepithelial transport of digoxin (basal to apical),Caco-2,mbcd0001050,,,,human,mbds0003,v2007,2013-12-09 19:59:10
mbbd000000593,mbcd0001151,mbtp000001,mbrf0001067,,=,,,inhibitor,29,15.0,microM,,Vinblastine,,,Caco-2 cell; transepithelial transport of digoxin (basal to apical),Caco-2,mbcd0001050,,,,human,mbds0003,v2007,2013-12-09 19:59:11
mbbd000000594,mbcd0001941,mbtp000001,mbrf0001067,,=,,,inhibitor,29,2.31,microM,,Reserpine,,,Caco-2 cell; transepithelial transport of digoxin (basal to apical),Caco-2,mbcd0001050,,,,human,mbds0003,v2007,2013-12-09 19:59:16
mbbd000000595,mbcd0000311,mbtp000001,mbrf0001067,,=,,,inhibitor,29,0.35,microM,,CsA,,,Caco-2 cell; transepithelial transport of digoxin (basal to apical),Caco-2,mbcd0001050,,,,human,mbds0003,v2007,2013-12-09 19:59:17
mbbd000000596,mbcd0001808,mbtp000001,mbrf0001067,,=,,,inhibitor,29,0.04,microM,,GF120918,,,Caco-2 cell; transepithelial transport of digoxin (basal to apical),Caco-2,mbcd0001050,,,,human,mbds0003,v2007,2013-12-09 19:59:14
mbbd000000599,mbcd0001151,mbtp000001,mbrf0001068,,=,,,inhibitor,25,50.0,microM,,Vinblastine,,,MDR1-expressing LLC-PK1 cell; inhibition of Calcein-AM efflux,LLC-PK1,mbcd0000212,,,,human,mbds0003,v2007,2013-12-09 19:59:18
mbbd000000600,mbcd0027062,mbtp000001,mbrf0001068,,=,,,inhibitor,25,6.3,microM,,Verapamil,,,MDR1-expressing LLC-PK1 cell; inhibition of Calcein-AM efflux,LLC-PK1,mbcd0000212,,,,human,mbds0003,v2007,2013-12-09 20:58:14
mbbd000000601,mbcd0002337,mbtp000001,mbrf0001068,,=,,,inhibitor,25,1.4,microM,,Terfenadine,,,MDR1-expressing LLC-PK1 cell; inhibition of Calcein-AM efflux,LLC-PK1,mbcd0000212,,,,human,mbds0003,v2007,2013-12-09 20:58:15
mbbd000000602,mbcd0001533,mbtp000001,mbrf0001068,,=,,,inhibitor,25,12.0,microM,,saquinavir,,,MDR1-expressing LLC-PK1 cell; inhibition of Calcein-AM efflux,LLC-PK1,mbcd0000212,,,,human,mbds0003,v2007,2013-12-09 20:58:14
mbbd000000603,mbcd0001938,mbtp000001,mbrf0001068,,=,,,inhibitor,25,12.0,microM,,ritonavir,,,MDR1-expressing LLC-PK1 cell; inhibition of Calcein-AM efflux,LLC-PK1,mbcd0000212,,,,human,mbds0003,v2007,2013-12-09 20:58:14
mbbd000000604,mbcd0002666,mbtp000001,mbrf0001068,,=,,,inhibitor,25,50.0,microM,,Ranitidine,,,MDR1-expressing LLC-PK1 cell; inhibition of Calcein-AM efflux,LLC-PK1,mbcd0000212,,,,human,mbds0003,v2007,2013-12-09 20:58:15
mbbd000000605,mbcd0027018,mbtp000001,mbrf0001068,,=,,,inhibitor,25,5.6,microM,,Quinidine,,,MDR1-expressing LLC-PK1 cell; inhibition of Calcein-AM efflux,LLC-PK1,mbcd0000212,,,,human,mbds0003,v2007,2013-12-09 20:58:16
mbbd000000606,mbcd0001918,mbtp000001,mbrf0001068,,=,,,inhibitor,25,2.9,microM,,Pimozide,,,MDR1-expressing LLC-PK1 cell; inhibition of Calcein-AM efflux,LLC-PK1,mbcd0000212,,,,human,mbds0003,v2007,2013-12-09 20:58:15
mbbd000000607,mbcd0002576,mbtp000001,mbrf0001068,,=,,,inhibitor,25,2.3,microM,,Nicardipine,,,MDR1-expressing LLC-PK1 cell; inhibition of Calcein-AM efflux,LLC-PK1,mbcd0000212,,,,human,mbds0003,v2007,2013-12-09 20:58:15
mbbd000000608,mbcd0026632,mbtp000001,mbrf0001068,,=,,,inhibitor,25,3.4,microM,,Nelfinavir,,,MDR1-expressing LLC-PK1 cell; inhibition of Calcein-AM efflux,LLC-PK1,mbcd0000212,,,,human,mbds0003,v2007,2013-12-09 20:09:32
mbbd000000609,mbcd0002723,mbtp000001,mbrf0001068,,=,,,inhibitor,25,50.0,microM,,morphine,,,MDR1-expressing LLC-PK1 cell; inhibition of Calcein-AM efflux,LLC-PK1,mbcd0000212,,,,human,mbds0003,v2007,2013-12-09 20:58:16
mbbd000000610,mbcd0001735,mbtp000001,mbrf0001068,,=,,,inhibitor,25,50.0,microM,,Midazolam,,,MDR1-expressing LLC-PK1 cell; inhibition of Calcein-AM efflux,LLC-PK1,mbcd0000212,,,,human,mbds0003,v2007,2013-12-09 20:09:55
mbbd000000611,mbcd0002825,mbtp000001,mbrf0001068,,=,,,inhibitor,25,3.5,microM,,miconazole,,,MDR1-expressing LLC-PK1 cell; inhibition of Calcein-AM efflux,LLC-PK1,mbcd0000212,,,,human,mbds0003,v2007,2013-12-09 20:09:54
mbbd000000612,mbcd0002820,mbtp000001,mbrf0001068,,=,,,inhibitor,25,1.8,microM,,Mibefradil,,,MDR1-expressing LLC-PK1 cell; inhibition of Calcein-AM efflux,LLC-PK1,mbcd0000212,,,,human,mbds0003,v2007,2013-12-09 20:09:55
mbbd000000613,mbcd0017104,mbtp000001,mbrf0001068,,=,,,inhibitor,25,4.8,microM,,Ketoconazole,,,MDR1-expressing LLC-PK1 cell; inhibition of Calcein-AM efflux,LLC-PK1,mbcd0000212,,,,human,mbds0003,v2007,2013-12-09 20:09:55
mbbd000000614,mbcd0001172,mbtp000001,mbrf0001068,,=,,,inhibitor,25,0.1,microM,,Ivermectin,,,MDR1-expressing LLC-PK1 cell; inhibition of Calcein-AM efflux,LLC-PK1,mbcd0000212,,,,human,mbds0003,v2007,2013-12-09 20:09:56
mbbd000000615,mbcd0002191,mbtp000001,mbrf0001068,,=,,,inhibitor,25,2.1,microM,,itraconazole,,,MDR1-expressing LLC-PK1 cell; inhibition of Calcein-AM efflux,LLC-PK1,mbcd0000212,,,,human,mbds0003,v2007,2013-12-09 20:09:55
mbbd000000616,mbcd0002635,mbtp000001,mbrf0001068,,=,,,inhibitor,25,50.0,microM,,Hydrocortisone,,,MDR1-expressing LLC-PK1 cell; inhibition of Calcein-AM efflux,LLC-PK1,mbcd0000212,,,,human,mbds0003,v2007,2013-12-09 20:09:58
mbbd000000617,mbcd0002466,mbtp000001,mbrf0001068,,=,,,inhibitor,25,50.0,microM,,Etoposide,,,MDR1-expressing LLC-PK1 cell; inhibition of Calcein-AM efflux,LLC-PK1,mbcd0000212,,,,human,mbds0003,v2007,2013-12-09 20:09:57
mbbd000000618,mbcd0000937,mbtp000001,mbrf0001068,,=,,,inhibitor,25,50.0,microM,,Erythromycin,,,MDR1-expressing LLC-PK1 cell; inhibition of Calcein-AM efflux,LLC-PK1,mbcd0000212,,,,human,mbds0003,v2007,2013-12-09 20:09:58
mbbd000000620,mbcd0001050,mbtp000001,mbrf0001068,,=,,,inhibitor,25,50.0,microM,,Digoxin,,,MDR1-expressing LLC-PK1 cell; inhibition of Calcein-AM efflux,LLC-PK1,mbcd0000212,,,,human,mbds0003,v2007,2013-12-09 21:00:34
mbbd000000621,mbcd0002959,mbtp000001,mbrf0001068,,=,,,inhibitor,25,50.0,microM,,Dexamethasone,,,MDR1-expressing LLC-PK1 cell; inhibition of Calcein-AM efflux,LLC-PK1,mbcd0000212,,,,human,mbds0003,v2007,2013-12-09 21:00:34
mbbd000000622,mbcd0000311,mbtp000001,mbrf0001068,,=,,,inhibitor,25,0.8,microM,,cyclosporin A,,,MDR1-expressing LLC-PK1 cell; inhibition of Calcein-AM efflux,LLC-PK1,mbcd0000212,,,,human,mbds0003,v2007,2013-12-09 21:00:34
mbbd000000623,mbcd0002667,mbtp000001,mbrf0001068,,=,,,inhibitor,25,50.0,microM,,Colchicine,,,MDR1-expressing LLC-PK1 cell; inhibition of Calcein-AM efflux,LLC-PK1,mbcd0000212,,,,human,mbds0003,v2007,2013-12-09 21:00:34
mbbd000000624,mbcd0002493,mbtp000001,mbrf0001068,,=,,,inhibitor,25,6.7,microM,,Clotrimazole,,,MDR1-expressing LLC-PK1 cell; inhibition of Calcein-AM efflux,LLC-PK1,mbcd0000212,,,,human,mbds0003,v2007,2013-12-09 21:00:35
mbbd000000625,mbcd0001111,mbtp000001,mbrf0001068,,=,,,inhibitor,25,50.0,microM,,Cimetidine,,,MDR1-expressing LLC-PK1 cell; inhibition of Calcein-AM efflux,LLC-PK1,mbcd0000212,,,,human,mbds0003,v2007,2013-12-09 21:00:35
mbbd000000626,mbcd0002109,mbtp000001,mbrf0001068,,=,,,inhibitor,25,1.3,microM,,Astemizole,,,MDR1-expressing LLC-PK1 cell; inhibition of Calcein-AM efflux,LLC-PK1,mbcd0000212,,,,human,mbds0003,v2007,2013-12-09 21:00:36
mbbd000000627,mbcd0001151,mbtp000001,mbrf0001068,,=,,,inhibitor,72,75.0,%,,Vinblastine,,,Caco-2 cell; inhibition of Rhodamine 123 efflux,Caco-2,mbcd0000746,,,,human,mbds0003,v2007,2013-12-09 21:00:36
mbbd000000628,mbcd0027062,mbtp000001,mbrf0001068,,=,,,inhibitor,72,28.0,%,,Verapamil,,,Caco-2 cell; inhibition of Rhodamine 123 efflux,Caco-2,mbcd0000746,,,,human,mbds0003,v2007,2013-12-09 21:00:34
mbbd000000629,mbcd0002337,mbtp000001,mbrf0001068,,=,,,inhibitor,72,6.0,%,,Terfenadine,,,Caco-2 cell; inhibition of Rhodamine 123 efflux,Caco-2,mbcd0000746,,,,human,mbds0003,v2007,2013-12-09 21:00:34
mbbd000000630,mbcd0001533,mbtp000001,mbrf0001068,,=,,,inhibitor,72,43.0,%,,saquinavir,,,Caco-2 cell; inhibition of Rhodamine 123 efflux,Caco-2,mbcd0000746,,,,human,mbds0003,v2007,2013-12-09 20:13:16
mbbd000000631,mbcd0001938,mbtp000001,mbrf0001068,,=,,,inhibitor,72,116.0,%,,ritonavir,,,Caco-2 cell; inhibition of Rhodamine 123 efflux,Caco-2,mbcd0000746,,,,human,mbds0003,v2007,2013-12-09 20:13:15
mbbd000000632,mbcd0002666,mbtp000001,mbrf0001068,,=,,,non-inhibitor,72,0.0,%,,ranitidine,,,Caco-2 cell; inhibition of Rhodamine 123 efflux,,,,,,human,mbds0003,v2007,2013-12-09 20:13:15
mbbd000000633,mbcd0027018,mbtp000001,mbrf0001068,,=,,,inhibitor,72,36.0,%,,Quinidine,,,Caco-2 cell; inhibition of Rhodamine 123 efflux,Caco-2,mbcd0000746,,,,human,mbds0003,v2007,2013-12-09 20:13:15
mbbd000000634,mbcd0001918,mbtp000001,mbrf0001068,,=,,,inhibitor,72,37.0,%,,Pimozide,,,Caco-2 cell; inhibition of Rhodamine 123 efflux,Caco-2,mbcd0000746,,,,human,mbds0003,v2007,2013-12-09 20:13:15
mbbd000000635,mbcd0002576,mbtp000001,mbrf0001068,,=,,,inhibitor,72,100.0,%,,Nicardipine,,,Caco-2 cell; inhibition of Rhodamine 123 efflux,Caco-2,mbcd0000746,,,,human,mbds0003,v2007,2013-12-09 20:13:14
mbbd000000636,mbcd0026632,mbtp000001,mbrf0001068,,=,,,inhibitor,72,30.0,%,,Nelfinavir,,,Caco-2 cell; inhibition of Rhodamine 123 efflux,Caco-2,mbcd0000746,,,,human,mbds0003,v2007,2013-12-09 20:13:14
mbbd000000637,mbcd0002723,mbtp000001,mbrf0001068,,=,,,inhibitor,72,2.0,%,,morphine,,,Caco-2 cell; inhibition of Rhodamine 123 efflux,Caco-2,mbcd0000746,,,,human,mbds0003,v2007,2013-12-09 20:13:13
mbbd000000638,mbcd0001735,mbtp000001,mbrf0001068,,=,,,inhibitor,72,12.0,%,,Midazolam,,,Caco-2 cell; inhibition of Rhodamine 123 efflux,Caco-2,mbcd0000746,,,,human,mbds0003,v2007,2013-12-09 20:13:13
mbbd000000639,mbcd0002825,mbtp000001,mbrf0001068,,=,,,inhibitor,72,22.0,%,,miconazole,,,Caco-2 cell; inhibition of Rhodamine 123 efflux,Caco-2,mbcd0000746,,,,human,mbds0003,v2007,2013-12-09 20:13:13
mbbd000000640,mbcd0002820,mbtp000001,mbrf0001068,,=,,,inhibitor,72,60.0,%,,Mibefradil,,,Caco-2 cell; inhibition of Rhodamine 123 efflux,Caco-2,mbcd0000746,,,,human,mbds0003,v2007,2013-12-09 21:00:31
mbbd000000641,mbcd0017104,mbtp000001,mbrf0001068,,=,,,inhibitor,72,35.0,%,,Ketoconazole,,,Caco-2 cell; inhibition of Rhodamine 123 efflux,Caco-2,mbcd0000746,,,,human,mbds0003,v2007,2013-12-09 21:00:31
mbbd000000642,mbcd0001172,mbtp000001,mbrf0001068,,=,,,inhibitor,72,34.0,%,,Ivermectin,,,Caco-2 cell; inhibition of Rhodamine 123 efflux,Caco-2,mbcd0000746,,,,human,mbds0003,v2007,2013-12-09 21:00:37
mbbd000000643,mbcd0002191,mbtp000001,mbrf0001068,,=,,,inhibitor,72,2.0,%,,itraconazole,,,Caco-2 cell; inhibition of Rhodamine 123 efflux,Caco-2,mbcd0000746,,,,human,mbds0003,v2007,2013-12-09 21:00:31
mbbd000000644,mbcd0002635,mbtp000001,mbrf0001068,,=,,,non-inhibitor,72,0.0,%,,hydrocortisone,,,Caco-2 cell; inhibition of Rhodamine 123 efflux,,,,,,human,mbds0003,v2007,2013-12-09 21:00:31
mbbd000000645,mbcd0002466,mbtp000001,mbrf0001068,,=,,,inhibitor,72,1.0,%,,Etoposide,,,Caco-2 cell; inhibition of Rhodamine 123 efflux,Caco-2,mbcd0000746,,,,human,mbds0003,v2007,2013-12-09 20:57:27
mbbd000000646,mbcd0000937,mbtp000001,mbrf0001068,,=,,,inhibitor,72,1.0,%,,Erythromycin,,,Caco-2 cell; inhibition of Rhodamine 123 efflux,Caco-2,mbcd0000746,,,,human,mbds0003,v2007,2013-12-09 21:00:29
mbbd000000648,mbcd0001050,mbtp000001,mbrf0001068,,=,,,inhibitor,72,1.0,%,,Digoxin,,,Caco-2 cell; inhibition of Rhodamine 123 efflux,Caco-2,mbcd0000746,,,,human,mbds0003,v2007,2013-12-09 20:57:27
mbbd000000649,mbcd0002959,mbtp000001,mbrf0001068,,=,,,non-inhibitor,72,0.0,%,,dexamethasone,,,Caco-2 cell; inhibition of Rhodamine 123 efflux,,,,,,human,mbds0003,v2007,2013-12-09 20:57:27
mbbd000000650,mbcd0000311,mbtp000001,mbrf0001068,,=,,,inhibitor,72,43.0,%,,cyclosporin A,,,Caco-2 cell; inhibition of Rhodamine 123 efflux,Caco-2,mbcd0000746,,,,human,mbds0003,v2007,2013-12-09 20:07:46
mbbd000000651,mbcd0002667,mbtp000001,mbrf0001068,,=,,,inhibitor,72,8.0,%,,Colchicine,,,Caco-2 cell; inhibition of Rhodamine 123 efflux,Caco-2,mbcd0000746,,,,human,mbds0003,v2007,2013-12-09 20:07:46
mbbd000000652,mbcd0002493,mbtp000001,mbrf0001068,,=,,,inhibitor,72,29.0,%,,Clotrimazole,,,Caco-2 cell; inhibition of Rhodamine 123 efflux,Caco-2,mbcd0000746,,,,human,mbds0003,v2007,2013-12-09 20:07:48
mbbd000000653,mbcd0001111,mbtp000001,mbrf0001068,,=,,,inhibitor,72,4.0,%,,Cimetidine,,,Caco-2 cell; inhibition of Rhodamine 123 efflux,Caco-2,mbcd0000746,,,,human,mbds0003,v2007,2013-12-09 20:07:47
mbbd000000654,mbcd0002109,mbtp000001,mbrf0001068,,=,,,inhibitor,72,39.0,%,,Astemizole,,,Caco-2 cell; inhibition of Rhodamine 123 efflux,Caco-2,mbcd0000746,,,,human,mbds0003,v2007,2013-12-09 20:07:44
mbbd000000656,mbcd0001151,mbtp000001,mbrf0001069,,,,,substrate,,,,,vinblastine,,,MDR1-expressing BeWo cell; efflux,BeWo,,,,,human,mbds0003,v2007,2013-12-09 20:07:46
mbbd000000657,mbcd0000311,mbtp000001,mbrf0001069,,~,,,inhibitor,100,210.0,%,,cyclosporin A,,,MDR1-expressing BeWo cell; inhibition of Vinblastine efflux,BeWo,mbcd0001151,20,microM,,human,mbds0003,v2007,2013-12-09 20:07:45
mbbd000000659,mbcd0000855,mbtp000001,mbrf0001071,,~,,,inhibitor,145,10.0,%,,TPGS,permeability B-A % of control,,Caco-2 cell; transepithelial transport of cyclosporin A,Caco-2,mbcd0000311,2.0,%,,human,mbds0003,v2007,2013-12-09 20:07:43
mbbd000000664,mbcd0000311,mbtp000001,mbrf0001072,,,,,substrate,,,,,CsA; cyclosporin A,,,Caco-2 cell; transepithelial transport,Caco-2,,,,,human,mbds0003,v2007,2013-12-09 20:58:01
mbbd000000666,mbcd0001808,mbtp000001,mbrf0001073,,~,,,inhibitor,103,37.0,%,2,GF120918,,,MDR1-expressing EPG85-257 cell; inhibition of C6-NBD-PS efflux,EPG85-257,mbcd0031470,10,microM,,human,mbds0003,v2007,2013-12-09 20:57:52
mbbd000000668,mbcd0001050,mbtp000001,mbrf0001074,,,,,substrate,,,,,digoxin,,,Caco-2 cell; transepithelial transport,Caco-2,,,,,human,mbds0003,v2007,2013-12-09 19:59:28
mbbd000000669,mbcd0027018,mbtp000001,mbrf0001074,,,,,substrate,,,,,quinidine,,,Caco-2 cell; transepithelial transport,Caco-2,,,,,human,mbds0003,v2007,2013-12-09 20:57:52
mbbd000000670,mbcd0000804,mbtp000001,mbrf0001074,,,,,substrate,,,,,talinolol,,,Caco-2 cell; transepithelial transport,Caco-2,,,,,human,mbds0003,v2007,2013-12-09 19:54:21
mbbd000000671,mbcd0002822,mbtp000001,mbrf0001074,,,,,non-substrate,,,,,metoprolol,,,Caco-2 cell; transepithelial transport,Caco-2,,,,,human,mbds0003,v2007,2013-12-09 20:08:50
mbbd000000672,mbcd0003875,mbtp000001,mbrf0001074,,,,,non-substrate,,,,,atenolol,,,Caco-2 cell; transepithelial transport,Caco-2,,,,,human,mbds0003,v2007,2013-12-09 19:54:21
mbbd000000673,mbcd0022617,mbtp000001,mbrf0001075,,=,,,inhibitor,29,457.0,microM,,Silymarin,,,"Caco-2 cell; increase in digoxin intracellular accumulation (VBL: 27nM, silymarin: 100 microM)",Caco-2,mbcd0001050,,,,human,mbds0003,v2007,2013-12-09 20:11:12
mbbd000000674,mbcd0003026,mbtp000001,mbrf0001075,,=,,,inhibitor,29,33.2,microM,,Biochanin A,,,"Caco-2 cell; increase in digoxin intracellular accumulation (VBL: 27nM, biochanin A: 150 microM)",Caco-2,,,,,human,mbds0003,v2007,2013-12-09 20:13:00
mbbd000000675,mbcd0022617,mbtp000001,mbrf0001075,,=,,,inhibitor,29,30.7,microM,,Silymarin,,,"Caco-2 cell; increase in digoxin intracellular accumulation (digoxin: 11nM, silymarin: 100 microM)",Caco-2,,,,,human,mbds0003,v2007,2013-12-09 19:54:22
mbbd000000676,mbcd0003026,mbtp000001,mbrf0001075,,=,,,inhibitor,29,32.7,microM,,Biochanin A,,,"Caco-2 cell; increase in digoxin intracellular accumulation (digoxin: 11nM, biochanin A: 150 microM)",Caco-2,,,,,human,mbds0003,v2007,2013-12-09 19:54:21
mbbd000000677,mbcd0001151,mbtp000001,mbrf0001076,,,,,substrate,,,,,vinblastine,+(0.1 microM),,MDR1-expressing MDCK cell; transepithelial transport,MDCKII,,,,,human,mbds0003,v2007,2013-12-09 19:54:21
mbbd000000678,mbcd0027062,mbtp000001,mbrf0001076,,,,,substrate,,,,,verapamil,+(0.1 microM),,MDR1-expressing MDCK cell; transepithelial transport,MDCKII,,,,,human,mbds0003,v2007,2013-12-09 19:54:13
mbbd000000679,mbcd0001532,mbtp000001,mbrf0001076,,,,,substrate,,,,,taxol,+(10 microM),,MDR1-expressing MDCK cell; transepithelial transport,MDCKII,,,,,human,mbds0003,v2007,2013-12-09 19:54:11
mbbd000000680,mbcd0000804,mbtp000001,mbrf0001076,,,,,substrate,,,,,talinolol,+(20 microM),,MDR1-expressing MDCK cell; transepithelial transport,MDCKII,,,,,human,mbds0003,v2007,2013-12-09 19:54:07
mbbd000000681,mbcd0001533,mbtp000001,mbrf0001076,,,,,substrate,,,,,saquinavir,+(20 microM),,MDR1-expressing MDCK cell; transepithelial transport,MDCKII,,,,,human,mbds0003,v2007,2013-12-09 19:54:07
mbbd000000682,mbcd0001938,mbtp000001,mbrf0001076,,,,,substrate,,,,,ritonavir,+(0.1 microM),,MDR1-expressing MDCK cell; transepithelial transport,MDCKII,,,,,human,mbds0003,v2007,2013-12-09 19:54:06
mbbd000000683,mbcd0000746,mbtp000001,mbrf0001076,,,,,substrate,,,,,rhodamine 123,+(10 microM),,MDR1-expressing MDCK cell; transepithelial transport,MDCKII,,,,,human,mbds0003,v2007,2013-12-09 19:54:06
mbbd000000684,mbcd0002666,mbtp000001,mbrf0001076,,,,,substrate,,,,,ranitidine,+(100 microM),,MDR1-expressing MDCK cell; transepithelial transport,MDCKII,,,,,human,mbds0003,v2007,2013-12-09 19:54:08
mbbd000000685,mbcd0027018,mbtp000001,mbrf0001076,,,,,substrate,,,,,quinidine,+(1 microM),,MDR1-expressing MDCK cell; transepithelial transport,MDCKII,,,,,human,mbds0003,v2007,2013-12-09 19:54:08
mbbd000000686,mbcd0003096,mbtp000001,mbrf0001076,,,,,substrate,,,,,prednisolone,+(20 microM),,MDR1-expressing MDCK cell; transepithelial transport,MDCKII,,,,,human,mbds0003,v2007,2013-12-09 19:54:07
mbbd000000687,mbcd0002723,mbtp000001,mbrf0001076,,,,,substrate,,,,,morphine,+(1 microM),,MDR1-expressing MDCK cell; transepithelial transport,MDCKII,,,,,human,mbds0003,v2007,2013-12-09 19:54:08
mbbd000000688,mbcd0027669,mbtp000001,mbrf0001076,,,,,substrate,,,,,methylprednisolone,+(20 microM),,MDR1-expressing MDCK cell; transepithelial transport,MDCKII,,,,,human,mbds0003,v2007,2013-12-09 19:54:05
mbbd000000689,mbcd0002466,mbtp000001,mbrf0001076,,,,,substrate,,,,,etoposide,+(25 microM),,MDR1-expressing MDCK cell; transepithelial transport,MDCKII,,,,,human,mbds0003,v2007,2013-12-09 19:54:06
mbbd000000690,mbcd0025844,mbtp000001,mbrf0001076,,,,,substrate,,,,,doxorubicin,+(10 microM),,MDR1-expressing MDCK cell; transepithelial transport,MDCKII,,,,,human,mbds0003,v2007,2013-12-09 20:50:51
mbbd000000691,mbcd0001050,mbtp000001,mbrf0001076,,,,,substrate,,,,,digoxin,+(10 microM),,MDR1-expressing MDCK cell; transepithelial transport,MDCKII,,,,,human,mbds0003,v2007,2013-12-09 20:50:51
mbbd000000692,mbcd0000311,mbtp000001,mbrf0001076,,,,,substrate,,,,,cyclosporin A,+(0.1 microM),,MDR1-expressing MDCK cell; transepithelial transport,MDCKII,,,,,human,mbds0003,v2007,2013-12-09 20:50:51
mbbd000000693,mbcd0002667,mbtp000001,mbrf0001076,,,,,substrate,,,,,colchicine,+(25 microM),,MDR1-expressing MDCK cell; transepithelial transport,MDCKII,,,,,human,mbds0003,v2007,2013-12-09 20:50:51
mbbd000000694,mbcd0003876,mbtp000001,mbrf0001076,,,,,substrate,,,,,acebutolol,+(20 microM),,MDR1-expressing MDCK cell; transepithelial transport,MDCKII,,,,,human,mbds0003,v2007,2013-12-09 20:50:52
mbbd000000695,mbcd0001151,mbtp000001,mbrf0001076,,,,,substrate,,,,,vinblastine,+(0.1 microM),,Caco-2 cell; transepithelial transport,Caco-2,,,,,human,mbds0003,v2007,2013-12-09 20:50:52
mbbd000000696,mbcd0027062,mbtp000001,mbrf0001076,,,,,substrate,,,,,verapamil,+(0.1 microM),,Caco-2 cell; transepithelial transport,Caco-2,,,,,human,mbds0003,v2007,2013-12-09 20:50:52
mbbd000000697,mbcd0001532,mbtp000001,mbrf0001076,,,,,substrate,,,,,taxol,+(10 microM),,Caco-2 cell; transepithelial transport,Caco-2,,,,,human,mbds0003,v2007,2013-12-09 20:50:52
mbbd000000698,mbcd0000804,mbtp000001,mbrf0001076,,,,,substrate,,,,,talinolol,+(20 microM),,Caco-2 cell; transepithelial transport,Caco-2,,,,,human,mbds0003,v2007,2013-12-09 20:50:50
mbbd000000699,mbcd0001533,mbtp000001,mbrf0001076,,,,,substrate,,,,,saquinavir,+(20 microM),,Caco-2 cell; transepithelial transport,Caco-2,,,,,human,mbds0003,v2007,2013-12-09 20:50:50
mbbd000000700,mbcd0001938,mbtp000001,mbrf0001076,,,,,substrate,,,,,ritonavir,+(0.1 microM),,Caco-2 cell; transepithelial transport,Caco-2,,,,,human,mbds0003,v2007,2013-12-09 20:52:42
mbbd000000701,mbcd0000746,mbtp000001,mbrf0001076,,,,,substrate,,,,,rhodamine 123,+(10 microM),,Caco-2 cell; transepithelial transport,Caco-2,,,,,human,mbds0003,v2007,2013-12-09 20:52:42
mbbd000000702,mbcd0002666,mbtp000001,mbrf0001076,,,,,substrate,,,,,ranitidine,+(100 microM),,Caco-2 cell; transepithelial transport,Caco-2,,,,,human,mbds0003,v2007,2013-12-09 20:52:42
mbbd000000703,mbcd0027018,mbtp000001,mbrf0001076,,,,,substrate,,,,,quinidine,+(1 microM),,Caco-2 cell; transepithelial transport,Caco-2,,,,,human,mbds0003,v2007,2013-12-09 20:52:42
mbbd000000704,mbcd0003096,mbtp000001,mbrf0001076,,,,,substrate,,,,,prednisolone,+(20 microM),,Caco-2 cell; transepithelial transport,Caco-2,,,,,human,mbds0003,v2007,2013-12-09 20:52:43
mbbd000000705,mbcd0002723,mbtp000001,mbrf0001076,,,,,substrate,,,,,morphine,+(1 microM),,Caco-2 cell; transepithelial transport,Caco-2,,,,,human,mbds0003,v2007,2013-12-09 20:52:42
mbbd000000706,mbcd0027669,mbtp000001,mbrf0001076,,,,,substrate,,,,,methylprednisolone,+(20 microM),,Caco-2 cell; transepithelial transport,Caco-2,,,,,human,mbds0003,v2007,2013-12-09 20:52:42
mbbd000000707,mbcd0002466,mbtp000001,mbrf0001076,,,,,substrate,,,,,etoposide,+(25 microM),,Caco-2 cell; transepithelial transport,Caco-2,,,,,human,mbds0003,v2007,2013-12-09 20:52:42
mbbd000000708,mbcd0025844,mbtp000001,mbrf0001076,,,,,substrate,,,,,doxorubicin,+(10 microM),,Caco-2 cell; transepithelial transport,Caco-2,,,,,human,mbds0003,v2007,2013-12-09 20:52:41
mbbd000000709,mbcd0001050,mbtp000001,mbrf0001076,,,,,substrate,,,,,digoxin,+(10 microM),,Caco-2 cell; transepithelial transport,Caco-2,,,,,human,mbds0003,v2007,2013-12-09 20:52:41
mbbd000000710,mbcd0000311,mbtp000001,mbrf0001076,,,,,substrate,,,,,cyclosporin A,+(0.1 microM),,Caco-2 cell; transepithelial transport,Caco-2,,,,,human,mbds0003,v2007,2013-12-09 20:00:46
mbbd000000711,mbcd0002667,mbtp000001,mbrf0001076,,,,,substrate,,,,,colchicine,+(25 microM),,Caco-2 cell; transepithelial transport,Caco-2,,,,,human,mbds0003,v2007,2013-12-09 20:00:48
mbbd000000712,mbcd0003876,mbtp000001,mbrf0001076,,,,,substrate,,,,,acebutolol,+(20 microM),,Caco-2 cell; transepithelial transport,Caco-2,,,,,human,mbds0003,v2007,2013-12-09 20:00:49
mbbd000000713,mbcd0000001,mbtp000001,mbrf0001077,,,,,substrate,,,,,Org 34167,,,Caco-2 cell; transepithelial transport,Caco-2,,,,,human,mbds0003,v2007,2013-12-09 20:00:51
mbbd000000715,mbcd0000075,mbtp000001,mbrf0001077,,,,,non-substrate,,,,,Org 9935,,,Caco-2 cell; transepithelial transport,Caco-2,,,,,human,mbds0003,v2007,2013-12-09 20:00:44
mbbd000000716,mbcd0000016,mbtp000001,mbrf0001077,,,,,substrate,,,,,Org 23366,,,Caco-2 cell; transepithelial transport,Caco-2,,,,,human,mbds0003,v2007,2013-12-09 20:00:45
mbbd000000723,mbcd0000017,mbtp000001,mbrf0001077,,,,,substrate,,,,,Org 12962,,,Caco-2 cell; transepithelial transport,Caco-2,,,,,human,mbds0003,v2007,2013-12-09 20:52:22
mbbd000000724,mbcd0003893,mbtp000001,mbrf0001077,,,,,substrate,,,,,risperidone,,,Caco-2 cell; transepithelial transport,Caco-2,,,,,human,mbds0003,v2007,2013-12-09 20:52:22
mbbd000000725,mbcd0003013,mbtp000001,mbrf0001077,,,,,non-substrate,,,,,ibuprofen,,,Caco-2 cell; transepithelial transport,Caco-2,,,,,human,mbds0003,v2007,2013-12-09 20:52:21
mbbd000000726,mbcd0001353,mbtp000001,mbrf0001077,,,,,non-substrate,,,,,salicylic acid,,,Caco-2 cell; transepithelial transport,Caco-2,,,,,human,mbds0003,v2007,2013-12-09 20:52:22
mbbd000000727,mbcd0003025,mbtp000001,mbrf0001077,,,,,non-substrate,,,,,indomethacin,,,Caco-2 cell; transepithelial transport,Caco-2,,,,,human,mbds0003,v2007,2013-12-09 20:52:22
mbbd000000728,mbcd0027018,mbtp000001,mbrf0001077,,,,,substrate,,,,,quinidine,,,Caco-2 cell; transepithelial transport,Caco-2,,,,,human,mbds0003,v2007,2013-12-09 20:54:47
mbbd000000729,mbcd0003902,mbtp000001,mbrf0001077,,,,,non-substrate,,,,,acetylsalicylic acid,,,Caco-2 cell; transepithelial transport,Caco-2,,,,,human,mbds0003,v2007,2013-12-09 20:52:21
mbbd000000730,mbcd0003872,mbtp000001,mbrf0001077,,,,,non-substrate,,,,,acetaminophen,,,Caco-2 cell; transepithelial transport,Caco-2,,,,,human,mbds0003,v2007,2013-12-09 19:59:21
mbbd000000731,mbcd0003947,mbtp000001,mbrf0001077,,,,,substrate,,,,,clonidine,,,Caco-2 cell; transepithelial transport,Caco-2,,,,,human,mbds0003,v2007,2013-12-09 19:59:21
mbbd000000732,mbcd0014045,mbtp000001,mbrf0001077,,,,,substrate,,,,,domperidone,,,Caco-2 cell; transepithelial transport,Caco-2,,,,,human,mbds0003,v2007,2013-12-09 19:59:20
mbbd000000733,mbcd0002666,mbtp000001,mbrf0001077,,,,,non-substrate,,,,,ranitidine,,,Caco-2 cell; transepithelial transport,Caco-2,,,,,human,mbds0003,v2007,2013-12-09 19:59:21
mbbd000000734,mbcd0002985,mbtp000001,mbrf0001077,,,,,non-substrate,,,,,carbamazepine,,,Caco-2 cell; transepithelial transport,Caco-2,,,,,human,mbds0003,v2007,2013-12-09 19:59:20
mbbd000000735,mbcd0003081,mbtp000001,mbrf0001077,,,,,substrate,,,,,amitriptyline,,,Caco-2 cell; transepithelial transport,Caco-2,,,,,human,mbds0003,v2007,2013-12-09 19:59:20
mbbd000000736,mbcd0003898,mbtp000001,mbrf0001077,,,,,substrate,,,,,imipramine,,,Caco-2 cell; transepithelial transport,Caco-2,,,,,human,mbds0003,v2007,2013-12-09 19:59:19
mbbd000000737,mbcd0003879,mbtp000001,mbrf0001077,,,,,non-substrate,,,,,caffeine,,,Caco-2 cell; transepithelial transport,Caco-2,,,,,human,mbds0003,v2007,2013-12-09 19:59:19
mbbd000000739,mbcd0027062,mbtp000001,mbrf0001077,,,,,substrate,,,,,verapamil,,,Caco-2 cell; transepithelial transport,Caco-2,,,,,human,mbds0003,v2007,2013-12-09 20:57:59
mbbd000000741,mbcd0001248,mbtp000001,mbrf0001077,,,,,non-substrate,,,,,mannitol,,,Caco-2 cell; transepithelial transport,Caco-2,,,,,human,mbds0003,v2007,2013-12-09 20:13:20
mbbd000000742,mbcd0000482,mbtp000001,mbrf0001078,,,,,substrate,,,,,imatinib mesilate,,,MDR1-expressing LLC-PK1 cell; efflux,LLC-PK1,,,,,human,mbds0003,v2007,2013-12-09 20:54:18
mbbd000000743,mbcd0000311,mbtp000001,mbrf0001078,,=,,,inhibitor,72,40.0,%,,cyclosporin A,,,"MDR1-expressing LLC-PK1 cell; inhibition of imatinib mesilate uptake (imatinib mesilate: 10 microM, CsA: 10 microM)",LLC-PK1,mbcd0000482,,,,human,mbds0003,v2007,2013-12-09 20:54:18
mbbd000000746,mbcd0001532,mbtp000001,mbrf0001079,,,,,substrate,,,,,paclitaxel,,,MCF-7/Dox cell; drug resistance,MCF7,,,,,human,mbds0003,v2007,2013-12-09 20:54:18
mbbd000000747,mbcd0025844,mbtp000001,mbrf0001079,,,,,substrate,,,,,doxorubicin,,,MCF-7/Dox cell; drug resistance,MCF7,,,,,human,mbds0003,v2007,2013-12-09 20:54:18
mbbd000000759,mbcd0000311,mbtp000001,mbrf0001081,,~,,,inhibitor,1,160.0,%,,CsA,,,"K562/R7 cells; inhibition of Daunomycin efflux (Daunomycin: 10 microM, CyclosporinA: 2 microM)",K562/R7,mbcd0005183,,,,human,mbds0003,v2007,2013-12-09 20:04:34
mbbd000000763,mbcd0003096,mbtp000001,mbrf0001082,,=,,,substrate,86,12.5,,3.5,prednisolone,,,MDR1-expressing LLC-PK1 cell; transepithelial transport,LLC-PK1,,,,,human,mbds0003,v2007,2013-12-09 20:53:10
mbbd000000764,mbcd0003058,mbtp000001,mbrf0001082,,=,,,substrate,86,3.8,,1.2,prednisone,,,MDR1-expressing LLC-PK1 cell; transepithelial transport,LLC-PK1,,,,,human,mbds0003,v2007,2013-12-09 20:53:10
mbbd000000765,mbcd0027669,mbtp000001,mbrf0001082,,=,,,substrate,86,26.6,,7.0,methylprednisolone,,,MDR1-expressing LLC-PK1 cell; transepithelial transport,LLC-PK1,,,,,human,mbds0003,v2007,2013-12-09 20:53:10
mbbd000000766,mbcd0002959,mbtp000001,mbrf0001082,,=,,,substrate,86,3.7,,0.93,dexamethasone,,,MDR1-expressing LLC-PK1 cell; transepithelial transport,LLC-PK1,,,,,human,mbds0003,v2007,2013-12-09 20:53:10
mbbd000000767,mbcd0000088,mbtp000001,mbrf0001082,,=,,,substrate,86,2.4,,0.44,6beta-OH Cortisol; 6beta-hydroxycortisol,,,MDR1-expressing LLC-PK1 cell; transepithelial transport,LLC-PK1,,,,,human,mbds0003,v2007,2013-12-09 20:53:10
mbbd000000768,mbcd0000090,mbtp000001,mbrf0001082,,=,,,substrate,86,1.8,,0.69,6alpha-OH Cortisol; 6alpha-hydroxycortisol,,,MDR1-expressing LLC-PK1 cell; transepithelial transport,LLC-PK1,,,,,human,mbds0003,v2007,2013-12-09 20:53:10
mbbd000000769,mbcd0002635,mbtp000001,mbrf0001082,,=,,,substrate,86,3.6,,0.44,cortisol,,,MDR1-expressing LLC-PK1 cell; transepithelial transport,LLC-PK1,,,,,human,mbds0003,v2007,2013-12-09 20:53:10
mbbd000000770,mbcd0027348,mbtp000001,mbrf0001082,,=,,,substrate,86,2.3,,0.93,cortisone,,,MDR1-expressing LLC-PK1 cell; transepithelial transport,LLC-PK1,,,,,human,mbds0003,v2007,2013-12-09 20:03:02
mbbd000000771,mbcd0001079,mbtp000001,mbrf0001082,,=,,,substrate,86,8.3,,0.94,betamethasone,,,MDR1-expressing LLC-PK1 cell; transepithelial transport,LLC-PK1,,,,,human,mbds0003,v2007,2013-12-09 20:03:02
mbbd000000775,mbcd0001151,mbtp000001,mbrf0001084,,,,,substrate,,,,,vinblastine,,,MDR1-expressing MDCKII cell; transepithelial transport (basal to apical),MDCKII,,,,,human,mbds0003,v2007,2013-12-09 20:03:04
mbbd000000776,mbcd0002981,mbtp000001,mbrf0001084,,,,,substrate,,,,,mitoxantrone,,,MDR1-expressing MDCKII cell; transepithelial transport (basal to apical),MDCKII,,,,,human,mbds0003,v2007,2013-12-09 20:03:03
mbbd000000777,mbcd0001808,mbtp000001,mbrf0001084,,,,,inhibitor,,,,,GF120918,,,MDR1-expressing MDCKII cell; transepithelial transport (basal to apical),MDCKII,mbcd0001151,,,,human,mbds0003,v2007,2013-12-09 20:03:03
mbbd000000778,mbcd0001050,mbtp000001,mbrf0001084,,,,,substrate,,,,,digoxin,,,MDR1-expressing MDCKII cell; transepithelial transport (basal to apical),MDCKII,,,,,human,mbds0003,v2007,2013-12-09 20:06:10
mbbd000000779,mbcd0000339,mbtp000001,mbrf0001085,,,,,inhibitor,,,,,DAS,,,K562/R10 cell; increase in Doxorubicin intracellular accumulation (Doxorubicin: 5_10-6M),K562/R10,mbcd0025844,,,,human,mbds0003,v2007,2013-12-09 20:03:06
mbbd000000780,mbcd0000339,mbtp000001,mbrf0001085,,,,,inhibitor,,,,,DAS,,,K562/R10 cell; drug resistance (vinblastine),K562/R10,mbcd0001151,,,,human,mbds0003,v2007,2013-12-09 20:55:19
mbbd000000781,mbcd0027062,mbtp000001,mbrf0001086,,=,,,inhibitor,72,52.0,%,,Verapamil,,,"MDR1-expressing LLC-PK1 cell; inhibition of Doxorubicin transepithelial transport (basal to apical)(Doxorubicin: 3 microM, Verapamil: 20 microM)",LLC-PK1,mbcd0025844,,,,human,mbds0003,v2007,2013-12-09 20:55:18
mbbd000000782,mbcd0003923,mbtp000001,mbrf0001086,,~,,,non-inhibitor,1,100.0,%,5,TEA,,,"MDR1-expressing LLC-PK1 cell; inhibition of Doxorubicin transepithelial transport (basal to apical)(Doxorubicin: 3 microM, TEA: 100 microM)",LLC-PK1,mbcd0025844,,,,human,mbds0003,v2007,2013-12-09 20:55:18
mbbd000000783,mbcd0001092,mbtp000001,mbrf0001086,,~,,,non-inhibitor,1,85.0,%,10,Quinine,,,"MDR1-expressing LLC-PK1 cell; inhibition of Doxorubicin transepithelial transport (basal to apical) (Doxorubicin: 3 microM, Quinidine: 50 microM)",LLC-PK1,mbcd0025844,,,,human,mbds0003,v2007,2013-12-09 20:55:18
mbbd000000784,mbcd0001111,mbtp000001,mbrf0001086,,~,,,non-inhibitor,1,100.0,%,35,Cimetidine,,,"MDR1-expressing LLC-PK1 cell; inhibition of Doxorubicin transepithelial transport (basal to apical)(Doxorubicin: 3 microM, Cimetidine: 50 microM)",LLC-PK1,mbcd0025844,,,,human,mbds0003,v2007,2013-12-09 20:55:19
mbbd000000785,mbcd0027062,mbtp000001,mbrf0001087,,~,,,inhibitor,3,80.0,%,,Verapamil,,,"MDR1-expressing NIH3T3 cell; increase in Rhodamine 123 intracellular accumulation (R123: 150 microM, Verapamil: 2 microg/mL)",NIH-3T3,mbcd0000746,2,microg mL-1,,human,mbds0003,v2007,2013-12-09 20:55:19
mbbd000000786,mbcd0001731,mbtp000001,mbrf0001087,,~,,,inhibitor,3,60.0,%,,Triflupromazine,,,"MDR1-expressing Caco-2 cell; increase in Rhodamine 123 intracellular accumulation (R123: 150 microM, Triflupromazine: 20 microg/mL)",Caco-2,mbcd0000746,20,microg mL-1,,human,mbds0003,v2007,2013-12-09 20:55:19
mbbd000000787,mbcd0014705,mbtp000001,mbrf0001087,,~,,,inhibitor,3,80.0,%,,Protriptyline,,,"MDR1-expressing Caco-2 cell; increase in Rhodamine 123 intracellular accumulation (R123: 150 microM, Protriptyline: 0.25 microg/mL)",Caco-2,mbcd0000746,0.25,microg mL-1,,human,mbds0003,v2007,2013-12-09 20:55:19
mbbd000000788,mbcd0003915,mbtp000001,mbrf0001087,,~,,,inhibitor,3,80.0,%,,Promethazine,,,"MDR1-expressing NIH3T3 cell; increase in Rhodamine 123 intracellular accumulation (R123: 150 microM, Promethazine: 20 microg/mL)",NIH-3T3,mbcd0000746,20,microg mL-1,,human,mbds0003,v2007,2013-12-09 20:55:19
mbbd000000790,mbcd0001918,mbtp000001,mbrf0001087,,~,,,inhibitor,3,85.0,%,,Pimozide,,,"MDR1-expressing Caco-2 cell; increase in Rhodamine 123 intracellular accumulation (R123: 150 microM, Pimozine: 1 microg/mL)",Caco-2,mbcd0000746,1,microg mL-1,,human,mbds0003,v2007,2013-12-09 20:08:19
mbbd000000791,mbcd0002576,mbtp000001,mbrf0001087,,=,,,inhibitor,3,100.0,%,,Nicardipine,,,"MDR1-expressing NIH3T3 cell; increase in Rhodamine 123 intracellular accumulation (R123: 150 microM, Nicardipine: 2 microg/mL)",NIH-3T3,mbcd0000746,2,microg mL-1,,human,mbds0003,v2007,2013-12-09 20:08:19
mbbd000000792,mbcd0003913,mbtp000001,mbrf0001087,,~,,,inhibitor,3,90.0,%,,Chlorpromazine,,,"MDR1-expressing NIH3T3 cell; increase in Rhodamine 123 intracellular accumulation (R123: 150 microM, Chlorpromazine: 2.5 microg/mL)",NIH-3T3,mbcd0000746,2.5,microg mL-1,,human,mbds0003,v2007,2013-12-09 20:08:19
mbbd000000793,mbcd0027925,mbtp000001,mbrf0001087,,~,,,inhibitor,3,100.0,%,,Bepridil,,,"MDR1-expressing NIH3T3 cell; increase in Rhodamine 123 intracellular accumulation (R123: 150 microM, Bepridil: 5 microg/mL)",NIH-3T3,mbcd0000746,5,microg mL-1,,human,mbds0003,v2007,2013-12-09 20:08:19
mbbd000000794,mbcd0027062,mbtp000001,mbrf0001088,,=,,,inhibitor,25,4.2,microM,,Verapamil,,,G185 cell; inhibition of Daunorubicin efflux (Daunorubicin: ? microM) ,G185,mbcd0005183,,,,human,mbds0003,v2007,2013-12-09 20:08:17
mbbd000000795,mbcd0003021,mbtp000001,mbrf0001088,,=,,,inhibitor,25,11.4,microM,,L,,,G185 cell; inhibition of Daunorubicin efflux (Daunorubicin: ? microM) ,G185,mbcd0005183,,,,human,mbds0003,v2007,2013-12-09 20:08:17
mbbd000000796,mbcd0001369,mbtp000001,mbrf0001088,,=,,,inhibitor,25,43.0,microM,,DL,,,G185 cell; inhibition of Daunorubicin efflux (Daunorubicin: ? microM) ,G185,mbcd0005183,,,,human,mbds0003,v2007,2013-12-09 20:08:18
mbbd000000797,mbcd0000692,mbtp000001,mbrf0001089,,=,,,inhibitor,25,74.1,microM,,Piperine,,,Caco-2 cell; inhibition of Cyclosporin A transepithelial transport (basal to apical) (Cyclosporin A: 1 microM),Caco-2,mbcd0000311,,,,human,mbds0003,v2007,2013-12-09 20:08:18
mbbd000000798,mbcd0000692,mbtp000001,mbrf0001089,,=,,,inhibitor,25,15.5,microM,,Piperine,,,Caco-2 cell; inhibition of Digoxin transepithelial transport (basal to apical) (Digoxin: 5 microM),Caco-2,mbcd0001050,,,,human,mbds0003,v2007,2013-12-09 20:08:16
mbbd000000799,mbcd0001711,mbtp000001,mbrf0001090,,,,,non-inhibitor,,,,,O-desmethylvenlafaxine,,,L-MDR1 cell; cell accumulation of calcein,LLC-PK1,mbcd0029351,,,,human,mbds0003,v2007,2013-12-09 20:08:17
mbbd000000800,mbcd0000601,mbtp000001,mbrf0001090,,=,,,inhibitor,149,0.004,,0.005,N-desmethyl-venlafaxine,,,L-MDR1 cell; cell accumulation of calcein,LLC-PK1,mbcd0029351,,,,human,mbds0003,v2007,2013-12-09 20:09:28
mbbd000000801,mbcd0024640,mbtp000001,mbrf0001090,,=,,,inhibitor,149,0.01,,0.01,Venlafaxine,,,L-MDR1 cell; cell accumulation of calcein,LLC-PK1,mbcd0029351,,,,human,mbds0003,v2007,2013-12-09 20:09:29
mbbd000000802,mbcd0000334,mbtp000001,mbrf0001090,,=,,,inhibitor,149,0.49,,0.22,Desmethylsertraline,,,L-MDR1 cell; cell accumulation of calcein,LLC-PK1,mbcd0029351,,,,human,mbds0003,v2007,2013-12-09 20:09:30
mbbd000000803,mbcd0022892,mbtp000001,mbrf0001090,,=,,,inhibitor,25,31.8,microM,,Sertraline,,,L-MDR1 cell; cell accumulation of calcein,LLC-PK1,mbcd0029351,,,,human,mbds0003,v2007,2013-12-09 20:09:31
mbbd000000804,mbcd0009421,mbtp000001,mbrf0001090,,=,,,inhibitor,149,0.12,,0.03,reboxetine,,,L-MDR1 cell; cell accumulation of calcein,LLC-PK1,mbcd0029351,,,,human,mbds0003,v2007,2013-12-09 20:09:26
mbbd000000806,mbcd0024931,mbtp000001,mbrf0001090,,=,,,inhibitor,25,29.8,microM,,paroxetine,,,L-MDR1 cell; cell accumulation of calcein,LLC-PK1,mbcd0029351,,,,human,mbds0003,v2007,2013-12-09 20:09:27
mbbd000000807,mbcd0000923,mbtp000001,mbrf0001090,,=,,,inhibitor,149,0.07,,0.04,fluvoxamine,,,L-MDR1 cell; cell accumulation of calcein,LLC-PK1,mbcd0029351,,,,human,mbds0003,v2007,2013-12-09 20:09:28
mbbd000000808,mbcd0001725,mbtp000001,mbrf0001090,,=,,,inhibitor,149,0.08,,0.01,Norfluoxetine,,,L-MDR1 cell; cell accumulation of calcein,LLC-PK1,mbcd0029351,,,,human,mbds0003,v2007,2013-12-09 20:09:26
mbbd000000809,mbcd0022530,mbtp000001,mbrf0001090,,=,,,inhibitor,25,115.5,microM,,Fluoxetine,,,L-MDR1 cell; cell accumulation of calcein,LLC-PK1,mbcd0029351,,,,human,mbds0003,v2007,2013-12-09 20:09:26
mbbd000000811,mbcd0003877,mbtp000001,mbrf0001090,,=,,,inhibitor,149,0.05,,0.03,Citalopram,,,L-MDR1 cell; cell accumulation of calcein,LLC-PK1,mbcd0029351,,,,human,mbds0003,v2007,2013-12-09 20:57:43
mbbd000000812,mbcd0027018,mbtp000001,mbrf0001090,,=,,,inhibitor,25,33.8,microM,,Quinidine,,,L-MDR1 cell; cell accumulation of calcein,LLC-PK1,mbcd0029351,,,,human,mbds0003,v2007,2013-12-09 20:57:43
mbbd000000813,mbcd0027062,mbtp000001,mbrf0001090,,=,,,inhibitor,25,18.9,microM,,Verapamil,,,L-MDR1 cell; cell accumulation of calcein,LLC-PK1,mbcd0029351,,,,human,mbds0003,v2007,2013-12-09 20:57:43
mbbd000000814,mbcd0000547,mbtp000001,mbrf0001090,,=,,,inhibitor,25,0.18,microM,,LY335979,,,L-MDR1 cell; cell accumulation of calcein,LLC-PK1,mbcd0029351,,,,human,mbds0003,v2007,2013-12-09 20:57:44
mbbd000000815,mbcd0000721,mbtp000001,mbrf0001090,,=,,,inhibitor,149,1.32,,0.31,SDZ-PSC833,,,L-MDR1 cell; cell accumulation of calcein,LLC-PK1,mbcd0029351,,,,human,mbds0003,v2007,2013-12-09 20:57:44
mbbd000000816,mbcd0025844,mbtp000001,mbrf0001091,,=,,,substrate,17,3.0,microM,,Doxorubicin,,,reconstituted proteoliposomes; ATP hydrolysis,KB-V1,,0.1-100,microM,,human,mbds0003,v2007,2013-12-09 20:57:43
mbbd000000817,mbcd0002667,mbtp000001,mbrf0001091,,=,,,substrate,17,45.0,microM,,Colchicine,,,reconstituted proteoliposomes; ATP hydrolysis,KB-V1,,0.1-100,microM,,human,mbds0003,v2007,2013-12-09 20:57:43
mbbd000000818,mbcd0001372,mbtp000001,mbrf0001091,,=,,,substrate,17,10.0,microM,,Actinomycin D,,,reconstituted proteoliposomes; ATP hydrolysis,KB-V1,,0.1-100,microM,,human,mbds0003,v2007,2013-12-09 20:57:44
mbbd000000819,mbcd0001151,mbtp000001,mbrf0001092,,~,,,inhibitor,150,75.0,%,,Vinblastine,,,"MDR1-expressing LLC-PK1 cell; inhibition of Digoxin transepithelial transport (basal to apical)(Digoxin: 0.1microM, Vinblastine: 20 microM)",LLC-GA5-COL150,mbcd0001050,20,microM,,human,mbds0003,v2007,2013-12-09 20:57:44
mbbd000000820,mbcd0027018,mbtp000001,mbrf0001092,,~,,,inhibitor,150,50.0,%,,Quinidine,,,"MDR1-expressing LLC-PK1 cell; inhibition of Digoxin transepithelial transport (basal to apical) (Digoxin: 0.1microM, Quinidine: 20 microM)",LLC-GA5-COL150,mbcd0001050,20,microM,,human,mbds0003,v2007,2013-12-09 20:58:12
mbbd000000821,mbcd0001050,mbtp000001,mbrf0001092,,,,,substrate,,,,,digoxin,,,MDR1-expressing LLC-PK1 cell; transepithelial transport (basal to apical),LLC-PK1,,,,,human,mbds0003,v2007,2013-12-09 21:00:37
mbbd000000822,mbcd0001892,mbtp000001,mbrf0001093,,~,,,inhibitor,87,5.0,%,,Progesterone,net basal to apical transport after 3 hrs,,"MDR1-expressing LLC-PK1 cell; inhibition of Cortisol transepithelial transport (basal to apical) (Coltisol: 0.011? microM, Progesterone: 50 microM)",LLC-PK1,mbcd0002635,50,microM,,human,mbds0003,v2007,2013-12-09 20:54:32
mbbd000000823,mbcd0001892,mbtp000001,mbrf0001093,,,,,non-substrate,,,,,progesterone,,,MDR1-expressing LLC-PK1 cell; transepithelial transport (basal to apical),LLC-PK1,,,,,human,mbds0003,v2007,2013-12-09 20:58:12
mbbd000000824,mbcd0002635,mbtp000001,mbrf0001093,,,,,substrate,,,,,cortisol,,,MDR1-expressing LLC-PK1 cell; transepithelial transport (basal to apical),LLC-PK1,,,,,human,mbds0003,v2007,2013-12-09 21:00:33
mbbd000000825,mbcd0001675,mbtp000001,mbrf0001093,,,,,substrate,,,,,aldosterone,,,MDR1-expressing LLC-PK1 cell; transepithelial transport (basal to apical),LLC-PK1,,,,,human,mbds0003,v2007,2013-12-09 20:08:15
mbbd000000827,mbcd0000593,mbtp000001,mbrf0001095,,~,,,inhibitor,100,3.5,pmol/10^6 cells,,MS-073,,,"K562/ADM cell; increase in VCR intracellular accumulation (VCR: 0.03 microM, MS-073: 3 microM)",K562/ADM,mbcd0001135,3,microM,,human,mbds0003,v2007,2013-12-09 20:08:14
mbbd000000828,mbcd0000879,mbtp000001,mbrf0001096,,,,,inhibitor,,,,,Tween 80,,,"EHR2/DNR+ cells; inhibition of Daunorubicin efflux (Daunorubicin: 5 microM, Tween 80: 0.01 %(v/v)) ",EHR2/DNR+,,,,,human,mbds0003,v2007,2013-12-10 22:19:00
mbbd000000830,mbcd0000311,mbtp000001,mbrf0001097,,=,,,inhibitor,29,0.02,microM,,cyclosporin A,,,membrane from MDR1-expressing Sf9 cell; inhibition of Verapamil stimulated ATP hydrolysis,Sf9,,,,,human,mbds0003,v2007,2013-12-09 20:55:17
mbbd000000831,mbcd0001172,mbtp000001,mbrf0001098,,,,,substrate,,,,,ivermectin,,,MDR1-expressing LLC-PK1 cell; transepithelial transport (basal to apical),LLC-PK1,,,,,human,mbds0003,v2007,2013-12-09 20:57:29
mbbd000000832,mbcd0002959,mbtp000001,mbrf0001098,,,,,substrate,,,,,dexamethasone,,,MDR1-expressing LLC-PK1 cell; transepithelial transport (basal to apical),LLC-PK1,,,,,human,mbds0003,v2007,2013-12-09 20:55:17
mbbd000000833,mbcd0000247,mbtp000001,mbrf0001099,,=,,,inhibitor,25,2.06,microM,,cepharanthin,,,MDR1-expressing LLC-PK1 cell; inhibition of Daunorubicin transepithelial transport (basal to apical) (Daunorubicin: 0.1 microM),LLC-PK1,mbcd0005183,,,,human,mbds0003,v2007,2013-12-09 20:55:17
mbbd000000834,mbcd0000247,mbtp000001,mbrf0001099,,,,,substrate,,,,,cepharanthin,,,MDR1-expressing LLC-PK1 cell; transepithelial transport (basal to apical),LLC-PK1,,,,,human,mbds0003,v2007,2013-12-09 20:55:16
mbbd000000835,mbcd0001316,mbtp000001,mbrf0001100,,,,,substrate,,,,,FK506,,,MDR1-expressing LLC-PK1 cell; transepithelial transport of tacrolimus (basal to apical) (Tacrolimus: 6.2 microM),LLC-GA5-COL300,,,,,human,mbds0003,v2007,2013-12-09 20:55:15
mbbd000000836,mbcd0000311,mbtp000001,mbrf0001100,,=,,,substrate,16,8.4,microM,,Cyclosporin A,,,MDR1-expressing LLC-PK1 cell; transepithelial transport (basal to apical),LLC-PK1,,0-40,microM,,human,mbds0003,v2007,2013-12-09 20:55:16
mbbd000000837,mbcd0000703,mbtp000001,mbrf0001101,,=,,,inhibitor,3,55.0,%,,Pristinamycin IA,,,"Caco-2 cell; inhibition of Vinblastine transepithelial transport (basal to apical) (Vinblastine: 0.05 microM, Pristinamycin IA: 100 microM)",Caco-2,mbcd0001151,,,,human,mbds0003,v2007,2013-12-09 20:55:16
mbbd000000838,mbcd0000703,mbtp000001,mbrf0001101,,,,,substrate,,,,,pristinamycin IA,,,Caco-2 cell; transepithelial transport (basal to apical),Caco-2,,,,,human,mbds0003,v2007,2013-12-09 20:55:18
mbbd000000839,mbcd0001416,mbtp000001,mbrf0001102,,,,,inhibitor,,,,,Rifampicin,,,membrane from K562 R7 cell; inhibition of Azidopine photoaffinity labelling (Rifampicin: 200 microM),K562/R7,mbcd0000159,,,,human,mbds0003,v2007,2013-12-09 20:55:18
mbbd000000840,mbcd0000477,mbtp000001,mbrf0001103,,=,,,substrate,28,2.0,microM,0.5,OH-Dox,,,Doxorubicin resistant K562 cell; efflux,K562,,0.5-3,microM,,human,mbds0003,v2007,2013-12-09 20:13:43
mbbd000000841,mbcd0000191,mbtp000001,mbrf0001104,,,,,substrate,,,,,bisantrene,,,S1-B1-20 cells; efflux,S1-B1-20,,,,,human,mbds0003,v2007,2013-12-10 22:19:00
mbbd000000842,mbcd0026441,mbtp000001,mbrf0001105,,~,,,inhibitor,100,350.0,%,,TX100,,,"CEM/VLB1000 cell; increase in Vinblastine intracellular accumulation (Vinblastine: 1 microM, Triton X-100: 100 microM)",CEM/VLB1000,mbcd0001151,100,microM,,human,mbds0003,v2007,2013-12-09 20:13:44
mbbd000000843,mbcd0026441,mbtp000001,mbrf0001105,,,,,substrate,,,,,TX100,,,CEM and CEM/VLB1000 cell; intracellular accumulation,CEM,,,,,human,mbds0003,v2007,2013-12-09 20:13:46
mbbd000000845,mbcd0001505,mbtp000001,mbrf0001107,,,,,inhibitor,,,,,Estramustine,,,"SKVLB1 cells; 8-fold to 9-fold increase in Vinblastine intracellular accumulation (Vinblastine: 1 microM, Estramustine: 50 microM)",SKVLB1,,50,microM,,human,mbds0003,v2007,2013-11-18 20:31:42
mbbd000000846,mbcd0003109,mbtp000001,mbrf0001108,,=,,,inhibitor,72,40.0,%,,taurolithocholate,,,"P1(0.5) cell; inhibition of Rhodamine 123 efflux (R123: 5 microg/mL, TLCA: 200 microM)",PN1A 3T3,mbcd0000746,200,microM,,human,mbds0003,v2007,2013-12-10 22:19:00
mbbd000000847,mbcd0001664,mbtp000001,mbrf0001108,,=,,,non-inhibitor,72,88.0,%,,taurocholate,,,"P1(0.5) cell; inhibition of Rhodamine 123 efflux (R123: 5 microg/mL, TCA: 200 microM)",PN1A 3T3,mbcd0000746,200,microM,,human,mbds0003,v2007,2013-12-10 22:19:00
mbbd000000848,mbcd0000815,mbtp000001,mbrf0001108,,=,,,inhibitor,72,66.0,%,,taurochenodeoxycholate,,,"P1(0.5) cell; inhibition of Rhodamine 123 efflux (R123: 5 microg/mL, TCDC: 200 microM)",PN1A 3T3,mbcd0000746,200,microM,,human,mbds0003,v2007,2013-12-10 22:19:00
mbbd000000849,mbcd0001133,mbtp000001,mbrf0001109,,=,,,substrate,96,100.0,%,,toremifene,The Pgp ATPase activity measured in the presence of 10 microM verapamil (70 nmol/mg membrane protein/min) was taken as 100%,,MDR1-expressing Sf9 cell; ATP hydrolysis,Sf9,,40,microM,,human,mbds0003,v2007,2013-12-09 20:13:49
mbbd000000850,mbcd0000602,mbtp000001,mbrf0001109,,,,,substrate,,,,,N-desmethyltamoxifen,,,MDR1-expressing Sf9 cell; ATP hydrolysis,Sf9,,,,,human,mbds0003,v2007,2013-12-09 20:58:30
mbbd000000851,mbcd0000610,mbtp000001,mbrf0001109,,,,,substrate,,,,,nafoxidine,,,MDR1-expressing Sf9 cell; ATP hydrolysis,Sf9,,,,,human,mbds0003,v2007,2013-12-09 20:58:29
mbbd000000853,mbcd0000968,mbtp000001,mbrf0001109,,=,,,substrate,96,45.0,%,,diethylstilbestrol,The Pgp ATPase activity measured in the presence of 10 microM verapamil (70 nmol/mg membrane protein/min) was taken as 100%,,MDR1-expressing Sf9 cell; ATP hydrolysis,Sf9,,10,microM,,human,mbds0003,v2007,2013-12-09 20:58:29
mbbd000000854,mbcd0003905,mbtp000001,mbrf0001109,,,,,substrate,,,,,corticosterone,,,MDR1-expressing Sf9 cell; ATP hydrolysis,Sf9,,,,,human,mbds0003,v2007,2013-12-09 20:58:29
mbbd000000855,mbcd0017569,mbtp000001,mbrf0001109,,~,,,substrate,96,75.0,%,,clomifene,The Pgp ATPase activity measured in the presence of 10 microM verapamil (70 nmol/mg membrane protein/min) was taken as 100%,,MDR1-expressing Sf9 cell; ATP hydrolysis,Sf9,,30,microM,,human,mbds0003,v2007,2013-12-09 20:58:29
mbbd000000856,mbcd0000069,mbtp000001,mbrf0001109,,,,,substrate,,,,,4-hydroxytamoxifen,,,MDR1-expressing Sf9 cell; ATP hydrolysis,Sf9,,,,,human,mbds0003,v2007,2013-12-09 20:58:29
mbbd000000857,mbcd0003055,mbtp000001,mbrf0001109,,,,,substrate,,,,,beta-estradiol,,,MDR1-expressing Sf9 cell; ATP hydrolysis,Sf9,,,,,human,mbds0003,v2007,2013-12-09 20:58:29
mbbd000000858,mbcd0027062,mbtp000001,mbrf0001110,,=,,,inhibitor,3,60.0,%,,Verapamil,,,"Caco-2 cell; inhibition of Docetaxel transepithelial transport (basal to apical)(Docetaxel: 4 microM, Verapamil: 100 microM)",Caco-2,mbcd0027726,,,,human,mbds0003,v2007,2013-12-09 20:58:30
mbbd000000859,mbcd0027726,mbtp000001,mbrf0001110,,,,,substrate,,,,,docetaxel,,,Caco-2 cell; transepithelial transport (basal to apical),Caco-2,,,,,human,mbds0003,v2007,2013-12-09 20:58:30
mbbd000000860,mbcd0001299,mbtp000001,mbrf0001111,,~,,,inhibitor,100,210.0,%,,RU 486,,,"K562 R7 cell; increase in Doxorubicin intracellular accumulation (Doxorubicin: 10 microg/mL, RU486: 10 microM)",K562/R7,mbcd0025844,,,,human,mbds0003,v2007,2013-12-09 20:10:45
mbbd000000862,mbcd0027062,mbtp000001,mbrf0001112,,,,,inhibitor,,,,,Verapamil,,,"membrane from KB/V20C cell; inhibition of Azidopine photoaffinity labelling (Azidopine: 0.2 microM, Verapamil: 1 microM)",KB/V20C,mbcd0000159,,,,human,mbds0003,v2007,2013-12-09 20:10:45
mbbd000000865,mbcd0002337,mbtp000001,mbrf0001112,,,,,inhibitor,,,,,Terfenadine,,,"membrane from KB/V20C cell; inhibition of Azidopine photoaffinity labelling (Azidopine: 0.2 microM, Terfenadine: 100 microM)",KB/V20C,mbcd0000159,,,,human,mbds0003,v2007,2013-12-09 20:10:49
mbbd000000866,mbcd0002337,mbtp000001,mbrf0001112,,~,,,inhibitor,100,2.0,fold increase,,Terfenadine,2 to 3-fold,,"MCF-7/ADR cell; increase in Doxorubicin intracellular accumulation (Doxorubicin: 0-20 microM, Terfenadine: 5 microM)",MCF7/ADR,mbcd0025844,5,microM,,human,mbds0003,v2007,2013-12-09 20:10:46
mbbd000000867,mbcd0002338,mbtp000001,mbrf0001113,,,,,substrate,,,,,diltiazem,,,MDR1-expressing LLC-PK1 cell; transepithelial transport (basal to apical),LLC-PK1,,,,,human,mbds0003,v2007,2013-12-09 20:10:47
mbbd000000868,mbcd0000159,mbtp000001,mbrf0001113,,,,,substrate,,,,,azidopine,,,MDR1-expressing LLC-PK1 cell; transepithelial transport (basal to apical),LLC-PK1,,,,,human,mbds0003,v2007,2013-12-09 20:10:44
mbbd000000869,mbcd0001151,mbtp000001,mbrf0001114,,=,,,substrate,28,18.99,microM,5.55,Vinblastine,,,Caco-2 cell; transepithelial transport (basal to apical),Caco-2,,0-50,microM,,human,mbds0003,v2007,2013-12-09 20:10:44
mbbd000000870,mbcd0000558,mbtp000001,mbrf0001115,,,,,inhibitor,,,,,MA,Growth inhibition,,"MCF-7/ADR cell, Flow cytometry ; increase in Doxorubicin intracellular accumulation (Doxorubicin: 2 mg/mL, Megestrol acetate: 25 microM)",MCF7/ADR,mbcd0025844,3.0; 7.5; 12.0; 21.0,microM,,human,mbds0003,v2007,2013-12-09 20:58:00
mbbd000000871,mbcd0000558,mbtp000001,mbrf0001115,,,,,inhibitor,,,,,MA,Growth inhibition,,"HCT-116/VM46 cell, Flow cytometry ; increase in Doxorubicin intracellular accumulation (Doxorubicin: 2 mg/mL, Megestrol acetate: 50 microM)",HCT116/VM46,mbcd0025844,,,,human,mbds0003,v2007,2013-12-09 20:58:00
mbbd000000872,mbcd0003043,mbtp000001,mbrf0001116,,,,,substrate,,,,,MTX,,,CEM/MTX R cell; intracellular accumulation,CCRF-CEM,,,,,human,mbds0003,v2007,2013-12-09 20:58:00
mbbd000000873,mbcd0031693,mbtp000001,mbrf0001117,,,,,substrate,,,,,chlorpyrifos oxon,,,MDR1-expressing Sf9 cell; ATP hydrolysis,Sf9,,,,,human,mbds0003,v2007,2013-12-09 20:58:00
mbbd000000874,mbcd0028193,mbtp000001,mbrf0001117,,,,,non-substrate,,,,,chlorpyrifos,,,MDR1-expressing Sf9 cell; ATP hydrolysis,Sf9,,,,,human,mbds0003,v2007,2013-12-09 20:58:01
mbbd000000875,mbcd0001151,mbtp000001,mbrf0001118,,=,,,substrate,28,0.8,microM,,Vinblastine,,,reconstituted proteoliposomes; ATP hydrolysis,AA8,,0-100,microM,,human,mbds0003,v2007,2013-12-09 20:58:00
mbbd000000876,mbcd0027062,mbtp000001,mbrf0001118,,=,,,substrate,28,2.0,microM,,Verapamil,,,reconstituted proteoliposomes; ATP hydrolysis,AA8,,0-100,microM,,human,mbds0003,v2007,2013-12-09 20:58:01
mbbd000000877,mbcd0026585,mbtp000001,mbrf0001118,,=,,,substrate,28,1.0,microM,,Valinomycin,,,reconstituted proteoliposomes; ATP hydrolysis,AA8,,0-100,microM,,human,mbds0003,v2007,2013-12-09 20:58:01
mbbd000000878,mbcd0001092,mbtp000001,mbrf0001118,,=,,,substrate,28,10.0,microM,,Quinine,,,reconstituted proteoliposomes; ATP hydrolysis,AA8,,,,,human,mbds0003,v2007,2013-12-09 20:58:00
mbbd000000879,mbcd0001892,mbtp000001,mbrf0001118,,=,,,substrate,28,30.0,microM,,Progesterone,,,reconstituted proteoliposomes; ATP hydrolysis,AA8,,0-1000,microM,,human,mbds0003,v2007,2013-12-09 20:57:59
mbbd000000880,mbcd0000600,mbtp000001,mbrf0001118,,>,,,substrate,28,70.0,microM,,ALLN,,,reconstituted proteoliposomes; ATP hydrolysis,AA8,,,,,human,mbds0003,v2007,2013-12-09 20:02:59
mbbd000000885,mbcd0000373,mbtp000001,mbrf0001118,,=,,,substrate,28,6.0,microM,,Emetine,,,reconstituted proteoliposomes; ATP hydrolysis,AA8,,0-1000,microM,,human,mbds0003,v2007,2013-12-09 20:02:58
mbbd000000886,mbcd0000361,mbtp000001,mbrf0001118,,=,,,substrate,28,0.9,microM,,Dolastatin 10,,,reconstituted proteoliposomes; ATP hydrolysis,AA8,,1-12,microM,,human,mbds0003,v2007,2013-12-09 20:02:58
mbbd000000887,mbcd0001633,mbtp000001,mbrf0001119,,=,,,inhibitor,72,140.0,%,,Staurosporine,,,"MCF7/Adr cell; increase in Rhodamine 123 intracellular accumulation (R123: 1.66 microM, Staurosporine: 80 microM)",MCF7/ADR,mbcd0000746,,,,human,mbds0003,v2007,2013-12-09 20:02:58
mbbd000000889,mbcd0001316,mbtp000001,mbrf0001120,,=,,,inducer,111,3.2,fold increase,0.7,FK506,increase in protein level,,LS180 cell; Western,LS180,,,,,human,mbds0003,v2007,2013-12-09 20:03:01
mbbd000000890,mbcd0001416,mbtp000001,mbrf0001120,,=,,,inducer,111,16.2,fold increase,10.8,Rifampicin,increase in protein level,,LS180 cell; Western,LS180,,,,,human,mbds0003,v2007,2013-12-09 20:53:08
mbbd000000891,mbcd0001941,mbtp000001,mbrf0001120,,=,,,inducer,111,29.0,fold increase,3.3,Reserpine,increase in protein level,,LS180 cell; Western,LS180,,,,,human,mbds0003,v2007,2013-12-09 20:53:08
mbbd000000893,mbcd0003007,mbtp000001,mbrf0001120,,=,,,inducer,111,14.4,fold increase,3.6,Phenobarbital,increase in protein level,,LS180 cell; Western,LS180,,,,,human,mbds0003,v2007,2013-12-09 20:53:08
mbbd000000894,mbcd0001735,mbtp000001,mbrf0001120,,=,,,inducer,111,5.9,fold increase,1.7,Midazolam,increase in protein level,,LS180 cell; Western,LS180,,,,,human,mbds0003,v2007,2013-12-09 20:53:09
mbbd000000895,mbcd0028671,mbtp000001,mbrf0001120,,=,,,inducer,111,2.7,fold increase,0.3,Isosafrole,increase in protein level,,LS180 cell; Western,LS180,,,,,human,mbds0003,v2007,2013-12-09 20:53:09
mbbd000000896,mbcd0000937,mbtp000001,mbrf0001120,,=,,,inducer,111,2.0,fold increase,0.6,Erythromycin,increase in protein level,,LS180 cell; Western,LS180,,,,,human,mbds0003,v2007,2013-12-09 20:53:09
mbbd000000897,mbcd0002493,mbtp000001,mbrf0001120,,=,,,inducer,111,4.1,fold increase,1.3,Clotrimazole,increase in protein level,,LS180 cell; Western,LS180,,,,,human,mbds0003,v2007,2013-12-09 20:53:09
mbbd000000898,mbcd0002192,mbtp000001,mbrf0001120,,=,,,inducer,111,2.4,fold increase,0.7,Amiodarone,increase in protein level,,LS180 cell; Western,LS180,,,,,human,mbds0003,v2007,2013-12-09 20:53:07
mbbd000000899,mbcd0000042,mbtp000001,mbrf0001121,,=,,,non-inducer,98,1.07,fold increase,0.20,2-AAF,increase in mRNA level,,primary hepatocyte; Northern,primary hepatocytes,,,,,human,mbds0003,v2007,2013-12-09 20:53:07
mbbd000000900,mbcd0002539,mbtp000001,mbrf0001122,,,,,substrate,,,,,loperamide,,,MDR1-expressing LLC-PK1 cell; transepithelial transport (basal to apical),LLC-PK1,,,,,human,mbds0003,v2007,2013-12-09 19:58:35
mbbd000000901,mbcd0014045,mbtp000001,mbrf0001122,,,,,substrate,,,,,domperidone,,,MDR1-expressing LLC-PK1 cell; transepithelial transport (basal to apical),LLC-PK1,,,,,human,mbds0003,v2007,2013-12-09 19:58:34
mbbd000000906,mbcd0000348,mbtp000001,mbrf0001125,,=,,,inhibitor,72,257.0,%,,dihydrocytochalasin B,,,"MCF-7/ADR cells; increase in Vinblastine intracellular accumulation (Vinblastine: 0.01-0.02 microM, Dihydrocytochalasin B: 10 microM)",MCF7/ADR,mbcd0001151,10,microM,,human,mbds0003,v2007,2013-12-10 22:19:00
mbbd000000907,mbcd0000348,mbtp000001,mbrf0001125,,,,,substrate,,,,,dihydrocytochalasin B,,,membrane from MCF/ADR cell; ATP hydrolysis,MCF7,,,,,human,mbds0003,v2007,2014-01-27 21:28:32
mbbd000000908,mbcd0000312,mbtp000001,mbrf0001125,,=,,,inhibitor,72,190.0,%,,cytochalasine E,,,"MCF-7/ADR cells; increase in Vinblastine intracellular accumulation (Vinblastine: 0.01-0.02 microM, Cytochalasine E: 10 microM)",MCF7/ADR,mbcd0001151,10,microM,,human,mbds0003,v2007,2013-12-10 22:19:00
mbbd000000909,mbcd0000311,mbtp000001,mbrf0001126,,=,,,substrate,28,3.8,microM,,Cyclosporin A,,,Caco-2 cell; transepithelial transport (basal to apical),Caco-2,,0.1; 10,microM,,human,mbds0003,v2007,2013-12-09 19:58:39
mbbd000000910,mbcd0001151,mbtp000001,mbrf0001127,,=,,,inhibitor,17,14.6,microM,,vinblastine,,,MDR-P388 cell; increase in Calcein-AM intracellular accumulation (Calcein-AM: 0.25 microM),P388,mbcd0000212,,,,human,mbds0003,v2007,2013-12-10 22:19:00
mbbd000000911,mbcd0001151,mbtp000001,mbrf0001127,,=,,,inhibitor,17,34.0,microM,,vinblastine,,,MDR-CEM cell; increase in Calcein-AM intracellular accumulation (Calcein-AM: 0.25 microM),CEM,mbcd0000212,,,,human,mbds0003,v2007,2013-12-10 22:19:00
mbbd000000912,mbcd0000764,mbtp000001,mbrf0001127,,=,,,inhibitor,17,0.06,microM,,SDZ 280-446,,,MDR-P388 cell; increase in Calcein-AM intracellular accumulation (Calcein-AM: 0.25 microM),P388,mbcd0000212,,,,human,mbds0003,v2007,2013-12-10 22:19:00
mbbd000000913,mbcd0000764,mbtp000001,mbrf0001127,,=,,,inhibitor,17,0.22,microM,,SDZ 280-446,,,MDR-CEM cell; increase in Calcein-AM intracellular accumulation (Calcein-AM: 0.25 microM),CEM,mbcd0000212,,,,human,mbds0003,v2007,2013-12-10 22:19:00
mbbd000000914,mbcd0026257,mbtp000001,mbrf0001127,,=,,,inhibitor,17,14.4,microM,,quinacrine,,,MDR-CEM cell; increase in Calcein-AM intracellular accumulation (Calcein-AM: 0.25 microM),CEM,mbcd0000212,,,,human,mbds0003,v2007,2013-12-10 22:19:00
mbbd000000915,mbcd0000721,mbtp000001,mbrf0001127,,=,,,inhibitor,17,0.11,microM,,SDZ PSC 833,,,MDR-P388 cell; increase in Calcein-AM intracellular accumulation (Calcein-AM: 0.25 microM),P388,mbcd0000212,,,,human,mbds0003,v2007,2013-12-10 22:19:00
mbbd000000916,mbcd0000721,mbtp000001,mbrf0001127,,=,,,inhibitor,17,0.41,microM,,SDZ PSC 833,,,MDR-CEM cell; increase in Calcein-AM intracellular accumulation (Calcein-AM: 0.25 microM),CEM,mbcd0000212,,,,human,mbds0003,v2007,2013-12-10 22:19:00
mbbd000000917,mbcd0002192,mbtp000001,mbrf0001127,,=,,,inhibitor,17,12.8,microM,,amiodarone,,,MDR-CEM cell; increase in Calcein-AM intracellular accumulation (Calcein-AM: 0.25 microM),CEM,mbcd0000212,,,,human,mbds0003,v2007,2013-12-10 22:19:00
mbbd000000918,mbcd0000837,mbtp000001,mbrf0001128,,>,,,inhibitor,3,80.0,%,,Tetrachlorohydroquinone,,,"MDR1-expressing B16/F10 cell; inhibition of Doxorubicin efflux (Doxorubicin: 50 microM, Tetrachlorohydroquinone: 250 microM)",B16/F10,mbcd0025844,,,,human,mbds0003,v2007,2013-12-09 20:52:35
mbbd000000919,mbcd0026641,mbtp000001,mbrf0001128,,=,,,inhibitor,3,51.0,%,,Phenamiphos,51-80 % inhibition,,"MDR1-expressing B16/F10 cell; inhibition of Doxorubicin efflux (Doxorubicin: 50 microM, Phenamiphos: 250 microM)",B16/F10,mbcd0025844,,,,human,mbds0003,v2007,2013-12-09 20:52:35
mbbd000000920,mbcd0016573,mbtp000001,mbrf0001128,,>,,,inhibitor,3,80.0,%,,Parathion,,,"MDR1-expressing B16/F10 cell; inhibition of Doxorubicin efflux (Doxorubicin: 50 microM, Parathion: 250 microM)",B16/F10,mbcd0025844,,,,human,mbds0003,v2007,2013-12-09 20:00:03
mbbd000000921,mbcd0000522,mbtp000001,mbrf0001128,,=,,,inhibitor,3,51.0,%,,Leptophos,51-80 % inhibition,,"MDR1-expressing B16/F10 cell; inhibition of Doxorubicin efflux (Doxorubicin: 50 microM, Leptophoos: 250 microM)",B16/F10,mbcd0025844,,,,human,mbds0003,v2007,2013-12-09 21:00:53
mbbd000000922,mbcd0000475,mbtp000001,mbrf0001128,,>,,,inhibitor,3,80.0,%,,Hydramethylnon,,,"MDR1-expressing B16/F10 cell; inhibition of Doxorubicin efflux (Doxorubicin: 50 microM, Hydramethylnon: 8 microM)",B16/F10,mbcd0025844,,,,human,mbds0003,v2007,2013-12-09 21:00:53
mbbd000000923,mbcd0000470,mbtp000001,mbrf0001128,,>,,,inhibitor,3,80.0,%,,Heptachlor epoxide,,,"MDR1-expressing B16/F10 cell; inhibition of Doxorubicin efflux (Doxorubicin: 50 microM, Heptachlor epoxide: 250 microM)",B16/F10,mbcd0025844,,,,human,mbds0003,v2007,2013-12-09 20:00:02
mbbd000000924,mbcd0026080,mbtp000001,mbrf0001128,,>,,,inhibitor,3,80.0,%,,Heptachlor,,,"MDR1-expressing B16/F10 cell; inhibition of Doxorubicin efflux (Doxorubicin: 50 microM, Heptachlor: 250 microM)",B16/F10,mbcd0025844,,,,human,mbds0003,v2007,2013-12-09 20:00:06
mbbd000000925,mbcd0000416,mbtp000001,mbrf0001128,,=,,,inhibitor,3,31.0,%,,Fluvalinate,31-50 % inhibition,,"MDR1-expressing B16/F10 cell; inhibition of Doxorubicin efflux (Doxorubicin: 50 microM, Fluvalinate: 250 microM)",B16/F10,mbcd0025844,,,,human,mbds0003,v2007,2013-12-09 20:00:05
mbbd000000926,mbcd0027279,mbtp000001,mbrf0001128,,>,,,inhibitor,3,80.0,%,,Endosulfan,,,"MDR1-expressing B16/F10 cell; inhibition of Doxorubicin efflux (Doxorubicin: 50 microM, Endosulfan: 100 microM)",B16/F10,mbcd0025844,,,,human,mbds0003,v2007,2013-12-09 21:00:54
mbbd000000927,mbcd0027279,mbtp000001,mbrf0001128,,,,,substrate,,,,,endosulfan,,,MDR1-expressing B16/F10 cell; efflux,B16/F10,,,,,human,mbds0003,v2007,2013-12-09 20:00:04
mbbd000000928,mbcd0000341,mbtp000001,mbrf0001128,,>,,,inhibitor,3,80.0,%,,Dicapthon,,,"MDR1-expressing B16/F10 cell; inhibition of Doxorubicin efflux (Doxorubicin: 50 microM, Dicapthon: 250 microM)",B16/F10,mbcd0025844,,,,human,mbds0003,v2007,2013-12-09 20:00:08
mbbd000000929,mbcd0002493,mbtp000001,mbrf0001128,,=,,,inhibitor,3,51.0,%,,Clotrimazole,51-80 % inhibition,,"MDR1-expressing B16/F10 cell; inhibition of Doxorubicin efflux (Doxorubicin: 50 microM, Clotrimazole: 100 microM)",B16/F10,mbcd0025844,,,,human,mbds0003,v2007,2013-12-09 20:00:08
mbbd000000930,mbcd0000261,mbtp000001,mbrf0001128,,=,,,inhibitor,3,51.0,%,,Chlorthiophos I,51-80 % inhibition,,"MDR1-expressing B16/F10 cell; inhibition of Doxorubicin efflux (Doxorubicin: 50 microM, Chlorthiophos: 250 microM)",B16/F10,mbcd0025844,,,,human,mbds0003,v2007,2013-12-09 20:52:53
mbbd000000931,mbcd0028193,mbtp000001,mbrf0001128,,=,,,inhibitor,3,51.0,%,,Chlorpyrifos,51-80 % inhibition,,"MDR1-expressing B16/F10 cell; inhibition of Doxorubicin efflux (Doxorubicin: 50 microM, Chlorpyrifos: 250 microM)",B16/F10,mbcd0025844,,,,human,mbds0003,v2007,2013-12-09 20:52:53
mbbd000000932,mbcd0026145,mbtp000001,mbrf0001128,,>,,,inhibitor,3,80.0,%,,Chlordecone,,,"MDR1-expressing B16/F10 cell; inhibition of Doxorubicin efflux (Doxorubicin: 50 microM, Chlordecone: 250 microM)",B16/F10,mbcd0025844,,,,human,mbds0003,v2007,2013-12-09 20:52:54
mbbd000000933,mbcd0002999,mbtp000001,mbrf0001129,,,,,substrate,,,,,timolol,,,K562 and K562/ADR cell; uptake,K562,,,,,human,mbds0003,v2007,2013-12-09 20:52:54
mbbd000000934,mbcd0001512,mbtp000001,mbrf0001129,,,,,substrate,,,,,nadolol,,,K562 and K562/ADR cell; uptake,K562,,,,,human,mbds0003,v2007,2013-12-09 20:52:53
mbbd000000935,mbcd0000242,mbtp000001,mbrf0001129,,,,,substrate,,,,,celiprolol,,,K562 and K562/ADR cell; uptake,K562,,,,,human,mbds0003,v2007,2013-12-09 20:52:53
mbbd000000936,mbcd0003876,mbtp000001,mbrf0001129,,,,,substrate,,,,,acebutolol,,,Caco-2 cell; transepithelial transport (basal to apical),Caco-2,,,,,human,mbds0003,v2007,2013-12-09 20:52:53
mbbd000000937,mbcd0003876,mbtp000001,mbrf0001129,,,,,substrate,,,,,acebutolol,,,K562 and K562/ADR cell; uptake,K562,,,,,human,mbds0003,v2007,2013-12-09 20:52:53
mbbd000000938,mbcd0001151,mbtp000001,mbrf0001130,,=,,,inhibitor,72,44.0,%,,VLB,,,"plasma membrane from CEM/VLB1.0 cell; inhibition of Ivermectin binding (IVM: 0.2 microM, Vinblastine: 300-fold molar excess)",CEM/VLB1.0,mbcd0001172,,,,human,mbds0003,v2007,2013-12-09 20:52:53
mbbd000000939,mbcd0027062,mbtp000001,mbrf0001130,,=,,,inhibitor,72,25.0,%,,Verapamil,,,"plasma membrane from CEM/VLB1.0 cell; inhibition of IAAP photoaffinity labelling (IAAP: 0.02 microM, Verapamil: 100-fold molar excess)",CEM/VLB1.0,mbcd0029976,,,,human,mbds0003,v2007,2013-12-09 20:52:53
mbbd000000940,mbcd0000721,mbtp000001,mbrf0001130,,~,,,inhibitor,1,0.0,%,,SDZ-PSC 833,,,"plasma membrane from CEM/VLB1.0 cell; inhibition of IAAP photoaffinity labelling (IAAP: 0.02 microM, PSC-833: 100-fold molar excess)",CEM/VLB1.0,mbcd0029976,,,,human,mbds0003,v2007,2013-12-09 20:01:41
mbbd000000941,mbcd0001172,mbtp000001,mbrf0001130,,=,,,non-inhibitor,72,0.0,%,0,Ivermectin; IVM,,,"plasma membrane from CEM/VLB1.0 cell; inhibition of IAAP photoaffinity labelling (IAAP: 0.02 microM, IVM: 100-fold molar excess)",,,,,,human,mbds0003,v2007,2013-12-09 20:01:40
mbbd000000942,mbcd0001172,mbtp000001,mbrf0001130,,=,,,non-inhibitor,72,0.0,%,0,Ivermectin; IVM,,,"plasma membrane from CEM/VLB1.0 cell; inhibition of Vinblastine binding (Vinblastine: 0.2 microM, IVM: 300-fold molar excess)",,,,,,human,mbds0003,v2007,2013-12-09 20:01:43
mbbd000000943,mbcd0001172,mbtp000001,mbrf0001130,41,=,0.0106,microM,substrate,41,10.6,nM,,IVM,,,plasma membrane from CEM/VLB1.0 cell; binding,CEM,,0-200,nM,,human,mbds0003,v2007,2013-12-09 20:01:42
mbbd000000944,mbcd0000311,mbtp000001,mbrf0001130,,=,,,inhibitor,72,5.0,%,,cyclosporin A,,,"plasma membrane from CEM/VLB1.0 cell; inhibition of IAAP photoaffinity labelling (IAAP: 0.02 microM, CsA: 100-fold molar excess)",CEM/VLB1.0,mbcd0029976,,,,human,mbds0003,v2007,2013-12-09 20:01:44
mbbd000000945,mbcd0000311,mbtp000001,mbrf0001130,,=,,,non-inhibitor,72,0.0,%,0,Cyclosporin A,,,"plasma membrane from CEM/VLB1.0 cell; inhibition of Vinblastine binding (Vinblastine: 0.2 microM, CsA: 300-fold molar excess)",,,,,,human,mbds0003,v2007,2013-12-09 20:01:43
mbbd000000946,mbcd0000311,mbtp000001,mbrf0001130,,=,,,non-inhibitor,72,0.0,%,0,Cyclosporin A,,,"plasma membrane from CEM/VLB1.0 cell; inhibition of Ivermectin binding (IVM: 0.2 microM, CsA: 300-fold molar excess)",,,,,,human,mbds0003,v2007,2013-12-09 20:01:45
mbbd000000947,mbcd0003116,mbtp000001,mbrf0001131,,=,,,inhibitor,3,50.0,%,,Genistein,50-60 % inhibition,,"BALB/c-3T3-1000 cell (MDR1-transfected); inhibition of Rhodamine 123 efflux (R123: 10 microM, Genistein: 200 microM)",BALB/c-3T3-1000,mbcd0000746,,,,human,mbds0003,v2007,2013-12-09 20:01:44
mbbd000000948,mbcd0003116,mbtp000001,mbrf0001132,,~,,,inhibitor,100,66.0,%,5,Genistein,,,"H69/LX4 cell; increase in DNR intracellular accumulation (DNR: 0.5 microM, Genistein: 200 microM)",H69/LX4,mbcd0005183,200,microM,,human,mbds0003,v2007,2013-12-09 20:01:39
mbbd000000950,mbcd0027062,mbtp000001,mbrf0001134,,,,,inhibitor,,,,,Verapamil,12-fold increase of the red fluorescence emission band,,"K562 and K562/ADR cell, flow cytometry; inhibition of JC-1 uptake (JC-1: ca 0.1 microM, Verapamil: 5 microM)",K562; K562/ADR,mbcd0000497,50,microM,,human,mbds0003,v2007,2013-12-09 20:54:02
mbbd000000951,mbcd0000759,mbtp000001,mbrf0001134,,=,,,inhibitor,126,20.0,fold increase,,S9788,,,"K562 and K562/ADR cell, flow cytometry; inhibition of JC-1 uptake (JC-1: ca 0.1 microM, S9788: 5 microM); 20-fold increase of the red fluorescence emission band",K562; K562/ADR,mbcd0000497,5,microM,,human,mbds0003,v2007,2013-12-09 05:54:22
mbbd000000952,mbcd0000497,mbtp000001,mbrf0001134,,,,,substrate,,,,,JC-1,,,K562 and K562/ADR cell; spectrofliorimetric analysis (intracellular accumulation),K562,,,,,human,mbds0003,v2007,2013-12-09 20:53:30
mbbd000000953,mbcd0000311,mbtp000001,mbrf0001134,,,,,inhibitor,,,,,cyclosporin A,19-fold increase of the red fluorescence emission band,,"K562 and K562/ADR cell, flow cytometry; inhibition of JC-1 uptake (JC-1: ca 0.1 microM, CsA: 5 microM)",K562; K562/ADR,mbcd0000497,5,microM,,human,mbds0003,v2007,2013-12-09 20:54:01
mbbd000000954,mbcd0003923,mbtp000001,mbrf0001135,,,,,non-inhibitor,,,,,Tetraethylammonium,,,"MDR1-expressing LLC-PK1 cell; inhibition of Levofloxacin transepithelial transport (basal to apical) (Levofloxacin: 100 microM, TEA: 2500 microM)",LLC-PK1,,,,,human,mbds0003,v2007,2013-12-09 20:54:02
mbbd000000955,mbcd0027018,mbtp000001,mbrf0001135,,~,,,inhibitor,138,4.6,nmol/mg protein/60 min,0.4,Quinidine,,,"MDR1-expressing LLC-PK1 cell; inhibition of Levofloxacin transepithelial transport (basal to apical) (Levofloxacin: 100 microM, Quinidine: 50 microM)",LLC-PK1,mbcd0001470,,,,human,mbds0003,v2007,2013-12-09 20:54:03
mbbd000000956,mbcd0003146,mbtp000001,mbrf0001135,,,,,non-inhibitor,,,,,p-aminohippurate,,,"MDR1-expressing LLC-PK1 cell; inhibition of Levofloxacin transepithelial transport (basal to apical) (Levofloxacin: 100 microM, PAH: 2500 microM)",LLC-PK1,,,,,human,mbds0003,v2007,2013-12-09 20:54:02
mbbd000000957,mbcd0001470,mbtp000001,mbrf0001135,,~,,,inhibitor,100,140.0,%,,levofloxacin,,,"MDR1-expressing LLC-PK1 cell; inhibition of DU-6895a transepithelial transport (basal to apical) (DU-6895a: 100 microM, Levofloxacin: 3000 microM)",LLC-GA5-COL150,mbcd0031304,,,,human,mbds0003,v2007,2013-12-09 20:54:02
mbbd000000958,mbcd0001470,mbtp000001,mbrf0001135,,~,,,inhibitor,100,870.0,%,,levofloxacin,,,"MDR1-expressing LLC-PK1 cell; inhibition of Daunorubicin transepithelial transport (basal to apical) (Daunorubicin: 0.1 microM, Levofloxacin: 3000 microM)",LLC-GA5-COL150,mbcd0005183,,,,human,mbds0003,v2007,2013-12-09 20:53:29
mbbd000000959,mbcd0001470,mbtp000001,mbrf0001135,28,=,3000.0,microM,substrate,28,3.0,mM,,Levofloxacin,,,MDR1-expressing LLC-PK1 cell; transepithelial transport (basal to apical),LLC-PK1,,0.05-5,mM,,human,mbds0003,v2007,2013-12-09 20:53:30
mbbd000000960,mbcd0000311,mbtp000001,mbrf0001135,,~,,,inhibitor,100,140.0,%,,cyclosporin A,,,"MDR1-expressing LLC-PK1 cell; inhibition of Levofloxacin transepithelial transport (basal to apical) (Levofloxacin: 100 microM, CsA: 10 microM)",LLC-GA5-COL150,mbcd0001470,,,,human,mbds0003,v2007,2013-12-09 20:03:55
mbbd000000961,mbcd0001111,mbtp000001,mbrf0001135,,,,,non-inhibitor,,,,,Cimetidine,,,"MDR1-expressing LLC-PK1 cell; inhibition of Levofloxacin transepithelial transport (basal to apical) (Levofloxacin: 100 microM, Cimetidine: 2500 microM)",LLC-PK1,,,,,human,mbds0003,v2007,2013-12-09 20:03:53
mbbd000000962,mbcd0000594,mbtp000001,mbrf0001136,,,,,inhibitor,,,,,MS-209,,,"K562/ADM cell; increase in Doxorubicin intracellular accumulation (Doxorubicin: 0.05 microg/mL, MS-209: 3 microM)",K562/ADM,mbcd0025844,,,,human,mbds0003,v2007,2013-12-09 20:03:52
mbbd000000963,mbcd0000721,mbtp000001,mbrf0001137,,=,,,inhibitor,29,0.134,microM,,PSC 833,,,P-gp-MRP-16-Protein A complex; inhibition of ATPase activity (Verapamil),,,,,,human,mbds0003,v2007,2013-12-09 20:03:51
mbbd000000964,mbcd0000311,mbtp000001,mbrf0001138,,,,,substrate,,,,,cyclosporine,,,"in vivo, kidney transplant recipients; bowel biopsy; correlation between intestinal P-gp content and oral clearance",human intestinal cells,,,,,human,mbds0003,v2007,2013-11-26 01:55:29
mbbd000000965,mbcd0003024,mbtp000001,mbrf0001139,,=,,,substrate,28,20.0,microM,,Prazosin,,,membrane from P-gp expressing insect cell; ATP hydrolysis,High Five (BTI-TN5B1-4),,0-100,microM,,human,mbds0003,v2007,2014-03-04 00:45:10
mbbd000000966,mbcd0000034,mbtp000001,mbrf0001140,,=,,,inhibitor,3,800.0,%,,PBA,800-900 % inhibition,,"KB8-5 cell; increase in Vinblastine intracellular accumulation (Vinblastine: 0.0375 microM, PBA: 1 microM)",KB8-5,mbcd0001151,,,,human,mbds0003,v2007,2013-12-09 20:03:49
mbbd000000967,mbcd0027018,mbtp000001,mbrf0001141,,~,,,inhibitor,150,68.0,%,,Quinidine,,,"Caco-2 cell; inhibition of Saquinavir transepithelial transport (basal to apical) (Saquinavir: 5 microM, Quinidine: 5 microM)",Caco-2,mbcd0001533,,,,human,mbds0003,v2007,2013-12-09 20:03:48
mbbd000000968,mbcd0027018,mbtp000001,mbrf0001141,,~,,,inhibitor,150,55.0,%,,Quinidine,,,"Caco-2 cell; inhibition of Nelfinavir transepithelial transport (basal to apical) (Nelfinavir: 5 microM, Quinidine: 5 microM)",Caco-2,mbcd0026632,,,,human,mbds0003,v2007,2013-12-09 20:03:55
mbbd000000969,mbcd0027018,mbtp000001,mbrf0001141,,~,,,inhibitor,150,60.0,%,,Quinidine,,,"Caco-2 cell; inhibition of Indinavir transepithelial transport (basal to apical) (Indinavir: 5 microM, Quinidine: 5 microM)",Caco-2,mbcd0002323,,,,human,mbds0003,v2007,2013-12-09 20:03:55
mbbd000000970,mbcd0000721,mbtp000001,mbrf0001141,,~,,,inhibitor,150,68.0,%,,PSC-833,,,"Caco-2 cell; inhibition of Saquinavir transepithelial transport (basal to apical) (Saquinavir: 5 microM, PSC-833: 1 microM)",Caco-2,mbcd0001533,,,,human,mbds0003,v2007,2013-12-09 20:54:28
mbbd000000971,mbcd0000721,mbtp000001,mbrf0001141,,~,,,inhibitor,150,60.0,%,,PSC-833,,,"Caco-2 cell; inhibition of Nelfinavir transepithelial transport (basal to apical) (Nrlfinavir: 5 microM, PSC-833: 1 microM)",Caco-2,mbcd0026632,,,,human,mbds0003,v2007,2013-12-09 20:54:28
mbbd000000972,mbcd0000721,mbtp000001,mbrf0001141,,~,,,inhibitor,150,55.0,%,,PSC-833,,,"Caco-2 cell; inhibition of Indinavir transepithelial transport (basal to apical) (Indinavir: 5 microM, PSC-833: 1 microM)",Caco-2,mbcd0002323,,,,human,mbds0003,v2007,2013-12-09 20:54:28
mbbd000000973,mbcd0026632,mbtp000001,mbrf0001141,,,,,substrate,,,,,nelfinavir,,,MDR1-expressing LLC-PK1 cell; transepithelial transport (basal to apical),LLC-PK1,,,,,human,mbds0003,v2007,2013-12-09 20:54:28
mbbd000000974,mbcd0002323,mbtp000001,mbrf0001141,,,,,substrate,,,,,indinavir,,,MDR1-expressing LLC-PK1 cell; transepithelial transport (basal to apical),LLC-PK1,,,,,human,mbds0003,v2007,2013-12-09 20:54:30
mbbd000000975,mbcd0026045,mbtp000001,mbrf0001142,,,,,non-substrate,,,,,retinoic acid,,,MDR1-expressing LLC-PK1 cell; transepithelial transport (basal to apical),LLC-PK1,,,,,human,mbds0003,v2007,2013-12-09 20:54:32
mbbd000000976,mbcd0000169,mbtp000001,mbrf0001142,,,,,non-substrate,,,,,benzo(a)pyrene,,,MDR1-expressing LLC-PK1 cell; transepithelial transport (basal to apical),LLC-PK1,,,,,human,mbds0003,v2007,2013-12-09 20:54:32
mbbd000000977,mbcd0000212,mbtp000001,mbrf0001143,,=,,,substrate,28,0.12,microM,0.01,CAL-AM,,,K562/ADR cell; efflux,K562,,0.05-2,microM,,human,mbds0003,v2007,2013-12-09 20:54:32
mbbd000000978,mbcd0001532,mbtp000001,mbrf0001144,,=,,,substrate,28,16.5,microM,,Taxol,,,Caco-2 cell; transepithelial transport (basal to apical),Caco-2,,0.5-20,microM,,human,mbds0003,v2007,2013-12-09 20:54:32
mbbd000000979,mbcd0000544,mbtp000001,mbrf0001145,,,,,substrate,,,,,LU-49888,,,membrane from CEM5k cell; photoaffinity labeling,CEM-5k,,,,,human,mbds0003,v2007,2014-03-04 00:45:05
mbbd000000980,mbcd0000499,mbtp000001,mbrf0001145,,=,,,inhibitor,3,80.0,%,,K02,,,"membrane from CEM5k cell; inhibition of photolabeling by LU-49888 (LU-49888: 0.1 microM, K02: 10 microM)",CEM-5k,,,,,human,mbds0003,v2007,2014-03-04 00:45:05
mbbd000000981,mbcd0000499,mbtp000001,mbrf0001145,,=,,,inhibitor,3,74.0,%,,K02,,,"membrane from CEM5k cell; inhibition of photolabeling by Azidopine (Azidopine: 0.05 microM, K02: 10 microM)",CEM-5k,,,,,human,mbds0003,v2007,2014-03-04 00:45:05
mbbd000000982,mbcd0000499,mbtp000001,mbrf0001145,,,,,substrate,,,,,K02,,,MDR1-expressing MDCK cell; transepithelial transport (basal to apical),MDCK,,,,,human,mbds0003,v2007,2013-12-09 21:01:06
mbbd000000983,mbcd0000159,mbtp000001,mbrf0001145,,,,,substrate,,,,,azidopine,,,membrane from CEM5k cell; photoaffinity labeling,CEM-5k,,,,,human,mbds0003,v2007,2013-12-09 21:01:06
mbbd000000984,mbcd0000843,mbtp000001,mbrf0001146,,=,,,inhibitor,100,2.5,fold increase,,tetrandine; TET,,,"HCT15 cells; increase in Rhodamine 123 intracellular accumulation (R123: 4 microM, Tetrandine: 3 microM)",HCT15,mbcd0000746,3,microM,,human,mbds0003,v2007,2013-12-10 22:19:00
mbbd000000985,mbcd0000399,mbtp000001,mbrf0001146,,=,,,inhibitor,100,2.4,fold increase,,fangchinoline; FAN,,,"HCT15 cells; increase in Rhodamine 123 intracellular accumulation (R123: 4 microM, Fangchinoline: 3 microM)",HCT15,mbcd0000746,3,microM,,human,mbds0003,v2007,2013-12-10 22:19:00
mbbd000000986,mbcd0001151,mbtp000001,mbrf0001147,,~,,,inhibitor,138,27.0,%,2,Vinblastine,,,"MDR1-expressing LLC-PK1 cell; inhibition of TBuMA transepithelial transport (basal to apical)(TBuMA: 10 microM, Vinblastine: 2 microM)",LLC-PK1,mbcd0000864,,,,human,mbds0003,v2007,2013-12-09 21:01:05
mbbd000000987,mbcd0001567,mbtp000001,mbrf0001147,,,,,substrate,,,,,vecuronium,,,MDR1-expressing LLC-PK1 cell; transepithelial transport (basal to apical),LLC-PK1,,,,,human,mbds0003,v2007,2013-12-09 21:01:04
mbbd000000988,mbcd0000864,mbtp000001,mbrf0001147,,,,,substrate,,,,,TBuMA; tri-n-butylmethylammonium,,,MDR1-expressing LLC-PK1 cell; transepithelial transport (basal to apical),LLC-PK1,,,,,human,mbds0003,v2007,2013-12-09 21:01:04
mbbd000000989,mbcd0000160,mbtp000001,mbrf0001147,,,,,substrate,,,,,APM,,,MDR1-expressing LLC-PK1 cell; transepithelial transport (basal to apical),LLC-PK1,,,,,human,mbds0003,v2007,2013-12-09 21:01:03
mbbd000000990,mbcd0027062,mbtp000001,mbrf0001148,,~,,,inhibitor,72,45.0,%,,Verapamil,,,"HCT-8 cell; inhibition of Saquinavir transepithelial transport (basal to apical)(Saquinavir: 10 microM, Verapamil: 5 microM)",HCT8,mbcd0001533,,,,human,mbds0003,v2007,2013-12-09 20:16:52
mbbd000000991,mbcd0001533,mbtp000001,mbrf0001148,,~,,,inhibitor,72,45.0,%,,saquinavir,,,"HCT-8 cell; inhibition of Rhodamine 123 transepithelial transport (basal to apical) (R123: 13 microM, Saquinavir: 20microM)",HCT8,mbcd0000746,,,,human,mbds0003,v2007,2013-12-09 20:16:53
mbbd000000992,mbcd0001533,mbtp000001,mbrf0001148,,,,,substrate,,,,,saquinavir,,,HCT-8 cell; transepithelial transport (basal to apical),HCT8,,,,,human,mbds0003,v2007,2013-12-09 20:16:52
mbbd000000993,mbcd0000746,mbtp000001,mbrf0001148,,,,,substrate,,,,,R123,,,HCT-8 cell; transepithelial transport (basal to apical),HCT8,,,,,human,mbds0003,v2007,2013-12-09 20:16:52
mbbd000000994,mbcd0000311,mbtp000001,mbrf0001148,,~,,,inhibitor,72,55.0,%,,CsA,,,"HCT8-cell; inhibition of Saquinavir transepithelial transport (basal to apical)(Saquinavir: 10 microM, CsA: 4 microM)",HCT8,mbcd0001533,,,,human,mbds0003,v2007,2013-12-09 20:16:50
mbbd000000995,mbcd0000311,mbtp000001,mbrf0001148,,~,,,inhibitor,72,35.0,%,,CsA,,,"HCT8-cell; inhibition of Rhodamine 123 transepithelial transport (basal to apical)(R123: 13 microM, CsA: 5 microM)",HCT8,mbcd0000746,,,,human,mbds0003,v2007,2013-12-09 20:16:51
mbbd000000996,mbcd0000901,mbtp000001,mbrf0001149,,,,,non-substrate,,,,,vindoline,,,membrane from CEM/VLB100 cell; ATP hydrolysis,CCRF-CEM,,,,,human,mbds0003,v2007,2013-12-09 20:16:48
mbbd000000997,mbcd0001151,mbtp000001,mbrf0001149,,=,,,inhibitor,29,2.1,microM,,VLB,,,membrane from CEM/VLB100 cell; inhibition of ATPase activity (Verapamil),CEM/VLB100 ,mbcd0027062,,,,human,mbds0003,v2007,2013-12-09 20:16:49
mbbd000000999,mbcd0002989,mbtp000001,mbrf0001150,,,,,substrate,,,,,sparfloxacin,,,Caco-2 cell; transepithelial transport (basal to apical),Caco-2,,,,,human,mbds0003,v2007,2013-12-09 20:16:47
mbbd000001000,mbcd0000387,mbtp000001,mbrf0001151,,=,,,substrate,28,62.0,microM,,E217G,,,membrane vesicle from MDR1-expressing Sf9; uptake,Sf9,,0-200,microM,,human,mbds0003,v2007,2013-12-09 20:04:55
mbbd000001001,mbcd0000851,mbtp000001,mbrf0001152,,,,,inhibitor,,,,,Tiamulin,,,"CEM/VLB3.6 cell, Flow cytometry; increase in Daunomycin intracellular accumulation (Daunomycin: 1.9 microM, Tiamulin: 2 microM)",CEM/VLB3.6,mbcd0005183,,,,human,mbds0003,v2007,2013-12-09 20:04:54
mbbd000001002,mbcd0003076,mbtp000001,mbrf0001153,,=,,,inhibitor,72,240.0,%,,Naringenin,,,"Caco-2 cell; increase in Vinblastine transepithelial transpot (apical to basal)(Vinblastine: 0.01 microM, Naringenin: 855 microM)",Caco-2,mbcd0001151,,,,human,mbds0003,v2007,2013-12-09 20:04:53
mbbd000001004,mbcd0001735,mbtp000001,mbrf0001154,,~,,,inhibitor,72,55.0,%,,Midazolam,,,"Caco-2 cell; inhibition of Rhodamine 123 transepithelial transport (basal to apical)(R123: 5 microM, Midazolam: 100 microM) ",Caco-2,mbcd0000746,,,,human,mbds0003,v2007,2013-12-09 20:05:00
mbbd000001005,mbcd0001735,mbtp000001,mbrf0001154,,,,,substrate,,,,,midazolam,,,Caco-2 cell; transepithelial transport (basal to apical),Caco-2,,,,,human,mbds0003,v2007,2013-12-09 20:04:59
mbbd000001006,mbcd0017104,mbtp000001,mbrf0001154,,,,,non-substrate,,,,,ketoconazole,,,Caco-2 cell; transepithelial transport (basal to apical),Caco-2,,,,,human,mbds0003,v2007,2013-12-09 20:04:58
mbbd000001007,mbcd0000937,mbtp000001,mbrf0001154,,~,,,inhibitor,72,65.0,%,,Erythromycin,,,"Caco-2 cell; inhibition of Rhodamine 123 transepithelial transport (basal to apical) (R123: 5 microM, Erythromycin: 100 microM) ",Caco-2,mbcd0000746,,,,human,mbds0003,v2007,2013-12-09 20:04:56
mbbd000001008,mbcd0000937,mbtp000001,mbrf0001154,,,,,substrate,,,,,Erythromycin,,,Caco-2 cell; transepithelial transport (basal to apical),Caco-2,,,,,human,mbds0003,v2007,2013-12-09 20:05:02
mbbd000001009,mbcd0001135,mbtp000001,mbrf0001155,,=,,,inhibitor,70,148.0,microM,20,Vincristine,,,membrane from Vinblastine-induced Caco-2 cell; inhibition of Verapamil binding,,,,,,human,mbds0003,v2007,2013-12-09 20:05:01
mbbd000001010,mbcd0001135,mbtp000001,mbrf0001155,,=,,,inhibitor,79,0.47,microM,0.22,Vincristine,,,membrane from Vinblastine-induced Caco-2 cell; inhibition of Verapamil binding,,,,,,human,mbds0003,v2007,2013-12-09 20:54:56
mbbd000001011,mbcd0000804,mbtp000001,mbrf0001155,,=,,,inhibitor,70,1570.0,microM,636,rac-Talinolol,,,membrane from Vinblastine-induced Caco-2 cell; inhibition of Verapamil binding,,,,,,human,mbds0003,v2007,2013-12-09 20:54:56
mbbd000001012,mbcd0000804,mbtp000001,mbrf0001155,,=,,,inhibitor,79,72.0,microM,9.1,rac-Talinolol,,,membrane from Vinblastine-induced Caco-2 cell; inhibition of Verapamil binding,,,,,,human,mbds0003,v2007,2013-12-09 20:54:56
mbbd000001013,mbcd0000746,mbtp000001,mbrf0001155,,=,,,inhibitor,70,3.4,microM,3.6,R123,,,membrane from Vinblastine-induced Caco-2 cell; inhibition of Verapamil binding,,,,,,human,mbds0003,v2007,2013-12-09 20:54:57
mbbd000001014,mbcd0000746,mbtp000001,mbrf0001155,,=,,,inhibitor,79,0.11,microM,0.04,R123,,,membrane from Vinblastine-induced Caco-2 cell; inhibition of Verapamil binding,,,,,,human,mbds0003,v2007,2013-12-09 20:54:56
mbbd000001015,mbcd0002822,mbtp000001,mbrf0001155,,=,,,inhibitor,70,1750.0,microM,300,rac-Metoprolol,,,membrane from Vinblastine-induced Caco-2 cell; inhibition of Verapamil binding,,,,,,human,mbds0003,v2007,2013-12-09 20:54:56
mbbd000001016,mbcd0002822,mbtp000001,mbrf0001155,,=,,,inhibitor,79,200.0,microM,18,rac-Metoprolol,,,membrane from Vinblastine-induced Caco-2 cell; inhibition of Verapamil binding,,,,,,human,mbds0003,v2007,2013-12-09 20:54:56
mbbd000001017,mbcd0000721,mbtp000001,mbrf0001156,,=,,,inhibitor,25,1.06,microM,,SDZ PSC 833,,,MDR1-expressing LLC-PK1 cell; inhibition of Vinblastine transepithelial transport (basal to apical) (Vinblastine: 0.1 microM),LLC-PK1,mbcd0001151,,,,human,mbds0003,v2007,2013-12-09 20:54:56
mbbd000001018,mbcd0000721,mbtp000001,mbrf0001156,,=,,,inhibitor,25,0.291,microM,,SDZ PSC 833,,,MDR1-expressing LLC-PK1 cell; inhibition of Doxorubicin transepithelial transport (basal to apical) (Doxorubicin: 0.8 microM),LLC-PK1,mbcd0025844,,,,human,mbds0003,v2007,2013-12-09 20:54:55
mbbd000001019,mbcd0000721,mbtp000001,mbrf0001156,,,,,non-substrate,,,,,PSC833,,,MDR1-expressing LLC-PK1 cell; transepithelial transport (basal to apical),LLC-PK1,,,,,human,mbds0003,v2007,2013-12-09 20:54:55
mbbd000001020,mbcd0025844,mbtp000001,mbrf0001156,,,,,substrate,,,,,doxorubicin,,,MDR1-expressing LLC-PK1 cell; transepithelial transport (basal to apical),LLC-PK1,,,,,human,mbds0003,v2007,2013-12-09 20:03:26
mbbd000001021,mbcd0000311,mbtp000001,mbrf0001156,,=,,,inhibitor,25,3.66,microM,,cyclosporin,,,MDR1-expressing LLC-PK1 cell; inhibition of Doxorubicin transepithelial transport (basal to apical) (Digoxin: 0.8 microM),LLC-PK1,mbcd0025844,,,,human,mbds0003,v2007,2013-12-09 19:56:49
mbbd000001022,mbcd0027018,mbtp000001,mbrf0001157,,,,,substrate,,,,,quinidine,,,MDR1-expressing LLC-PK1 cell; transepithelial transport (basal to apical),LLC-PK1,,,,,human,mbds0003,v2007,2013-12-09 19:57:27
mbbd000001023,mbcd0001050,mbtp000001,mbrf0001157,,,,,substrate,,,,,digoxin,,,Caco-2 cell; transepithelial transport (basal to apical),Caco-2,,,,,human,mbds0003,v2007,2013-12-09 19:57:26
mbbd000001024,mbcd0027062,mbtp000001,mbrf0001158,,,,,inhibitor,,,,,Verapamil,,,"membrane from CEM/VLB100 cell; inhibition of Fluorescein-Colchicine transport (FL-Colchicin: 0.3 microM, Verapamil: 10 microM)",CEM/VLB100,mbcd0031381,,,,human,mbds0003,v2007,2013-12-09 20:08:56
mbbd000001025,mbcd0002667,mbtp000001,mbrf0001158,,=,,,substrate,28,1.33,microM,0.314,Colchicine,,,membrane from CEM/VLB100 cell; uptake,CCRF-CEM,,1,microM,,human,mbds0003,v2007,2013-12-09 20:08:54
mbbd000001026,mbcd0001151,mbtp000001,mbrf0001159,,~,,,inhibitor,100,525.0,%,30,Vinblastine,,,"CEM/VLB600 cell; increase in Colchicine intracellular accumulation (Colchicine: 0.0175 microM, Vinblastine: 100 microM)",CEM/VLB600,mbcd0002667,,,,human,mbds0003,v2007,2013-12-09 20:08:58
mbbd000001027,mbcd0027062,mbtp000001,mbrf0001159,,~,,,inhibitor,100,200.0,%,5,Verapamil,,,"CEM/VLB600 cell; increase in Colchicine intracellular accumulation (Colchicine: 0.0175 microM, Verapamil: 100 microM)",CEM/VLB600,mbcd0002667,,,,human,mbds0003,v2007,2013-12-09 20:08:57
mbbd000001028,mbcd0003074,mbtp000001,mbrf0001159,,~,,,inhibitor,100,225.0,%,10,glibenclamide,,,"CEM/VLB600 cell; increase in Colchicine intracellular accumulation (Colchicine: 0.0175 microM, Glibenclamide: 100 microM)",CEM/VLB600,mbcd0002667,,,,human,mbds0003,v2007,2013-12-09 20:03:30
mbbd000001029,mbcd0000311,mbtp000001,mbrf0001159,,~,,,inhibitor,100,480.0,%,10,cyclosporin,,,"CEM/VLB600 cell; increase in Colchicine intracellular accumulation (Colchicine: 0.0175 microM, CsA: 50 microM)",CEM/VLB600,mbcd0002667,,,,human,mbds0003,v2007,2013-12-09 20:03:29
mbbd000001030,mbcd0000193,mbtp000001,mbrf0001159,,,,,inhibitor,,,,,BM-223,,,"membrane from CEM/VLB600 cell; inhibition of Azidopine photoaffinity labelling (Azidopine: 0.016 microM, BM-223: 100 microM)",CEM/VLB600,mbcd0000159,,,,human,mbds0003,v2007,2013-12-09 20:14:45
mbbd000001031,mbcd0000193,mbtp000001,mbrf0001159,,~,,,inhibitor,100,500.0,%,10,BM-223,,,"CEM/VLB600 cell; increase in Colchicine intracellular accumulation (Colchicine: 0.0175 microM, BM-223: 100 microM)",CEM/VLB600,mbcd0002667,,,,human,mbds0003,v2007,2013-12-09 20:14:45
mbbd000001032,mbcd0021323,mbtp000001,mbrf0001159,,,,,inhibitor,,,,,BM-208,,,"membrane from CEM/VLB600 cell; inhibition of Azidopine photoaffinity labelling (Azidopine: 0.016 microM, BM-208: 100 microM)",CEM/VLB600,mbcd0000159,,,,human,mbds0003,v2007,2013-12-09 20:14:41
mbbd000001033,mbcd0021323,mbtp000001,mbrf0001159,,~,,,inhibitor,100,375.0,%,5,BM-208,,,"CEM/VLB600 cell; increase in Colchicine intracellular accumulation (Colchicine: 0.0175 microM, BM-208: 100 microM)",CEM/VLB600,mbcd0002667,,,,human,mbds0003,v2007,2013-12-09 20:51:18
mbbd000001034,mbcd0000596,mbtp000001,mbrf0001160,,,,,substrate,,,,,ADPA,,,membrane vesicle from A2780 and A2780AD cell; uptake,A2780,,,,,human,mbds0003,v2007,2013-12-09 20:14:39
mbbd000001035,mbcd0000721,mbtp000001,mbrf0001161,,=,,,inhibitor,29,1.3,microM,,PSC,,,CEM/VBL 100 cell; inhibition of Calcein-AM efflux,CEM/VLB100,mbcd0000212,,,,human,mbds0003,v2007,2013-12-09 20:14:40
mbbd000001036,mbcd0000337,mbtp000001,mbrf0001161,,=,,,inhibitor,29,2.3,microM,,DGP,,,CEM/VLB100 cell; inhibition of Calcein-AM efflux,CEM/VLB100,mbcd0000212,,,,human,mbds0003,v2007,2013-12-09 20:54:21
mbbd000001037,mbcd0000311,mbtp000001,mbrf0001161,,=,,,inhibitor,29,1.8,microM,,CysA,,,CEM/VLB100 cell; inhibition of Calcein-AM efflux,CEM/VLB100,mbcd0000212,,,,human,mbds0003,v2007,2013-12-09 20:14:37
mbbd000001038,mbcd0000203,mbtp000001,mbrf0001162,,,,,substrate,,,,,BTL,,,KB cell and KB-VJ300 cell; intracellular accumulation,KB,,,,,human,mbds0003,v2007,2013-12-09 20:54:24
mbbd000001039,mbcd0002337,mbtp000001,mbrf0001163,,=,,,non-inhibitor,3,112.0,%,4.1,terfenadine,,,"Caco-2 cell; inhibition of Digoxin transepithelial transport (basal to apical)(Digoxin: 5 microM, Terfenadine: 10 microM)",Caco-2,mbcd0001050,10,microM,,human,mbds0003,v2007,2013-11-17 07:05:35
mbbd000001040,mbcd0002337,mbtp000001,mbrf0001163,,,,,substrate,,,,,terfenadine,,,MDR1-expressing LLC-PK1 cell; transepithelial transport (basal to apical),LLC-PK1,,,,,human,mbds0003,v2007,2013-12-09 20:08:30
mbbd000001041,mbcd0002889,mbtp000001,mbrf0001163,,=,,,inhibitor,3,86.0,%,,Tamoxifen,,,"Caco-2 cell; inhibition of Digoxin transepithelial transport (basal to apical)(Digoxin: 5 microM, Tamoxifen: 100 microM)",Caco-2,mbcd0001050,100,microM,,human,mbds0003,v2007,2013-12-09 20:08:29
mbbd000001043,mbcd0007511,mbtp000001,mbrf0001163,,=,,,inhibitor,3,56.0,%,,Nifedipine,,,"Caco-2 cell; inhibition of Digoxin transepithelial transport (basal to apical) (Digoxin: 5 microM, Nifedipine: 100 microM)",Caco-2,mbcd0001050,100,microM,,human,mbds0003,v2007,2013-12-09 20:08:29
mbbd000001044,mbcd0007511,mbtp000001,mbrf0001163,,,,,non-substrate,,,,,nifedipine,,,MDR1-expressing LLC-PK1 cell; transepithelial transport (basal to apical),LLC-PK1,,,,,human,mbds0003,v2007,2013-12-09 20:08:29
mbbd000001045,mbcd0001735,mbtp000001,mbrf0001163,,=,,,inhibitor,3,74.0,%,,Midazolam,,,"Caco-2 cell; inhibition of Digoxin transepithelial transport (basal to apical)(Digoxin: 5 microM, Midazolam: 100 microM)",Caco-2,mbcd0001050,100,microM,,human,mbds0003,v2007,2013-12-09 20:08:29
mbbd000001046,mbcd0001735,mbtp000001,mbrf0001163,,,,,non-substrate,,,,,midazolam,,,MDR1-expressing LLC-PK1 cell; transepithelial transport (basal to apical),LLC-PK1,,,,,human,mbds0003,v2007,2013-12-09 20:08:29
mbbd000001047,mbcd0025591,mbtp000001,mbrf0001163,,=,,,inhibitor,3,65.0,%,,lovastatin,,,"Caco-2 cell; inhibition of Digoxin transepithelial transport (basal to apical) (Digoxin: 5 microM, Lovastatin: 100 microM)",Caco-2,mbcd0001050,100,microM,,human,mbds0003,v2007,2013-12-09 20:08:28
mbbd000001048,mbcd0025591,mbtp000001,mbrf0001163,,,,,substrate,,,,,lovastatin,,,MDR1-expressing LLC-PK1 cell; transepithelial transport (basal to apical),LLC-PK1,,,,,human,mbds0003,v2007,2013-12-09 20:08:32
mbbd000001049,mbcd0000937,mbtp000001,mbrf0001163,,=,,,inhibitor,3,101.0,%,,Erythromycin,,,"Caco-2 cell; inhibition of Digoxin transepithelial transport (basal to apical) (Digoxin: 5 microM, Erythromycin: 100 microM)",Caco-2,mbcd0001050,100,microM,,human,mbds0003,v2007,2013-12-09 20:08:31
mbbd000001050,mbcd0015049,mbtp000001,mbrf0001163,,,,,substrate,,,,,debrisoquine,,,MDR1-expressing LLC-PK1 cell; transepithelial transport (basal to apical),LLC-PK1,,,,,human,mbds0003,v2007,2013-12-09 20:57:46
mbbd000001051,mbcd0002635,mbtp000001,mbrf0001163,,=,,,inhibitor,3,56.0,%,15,cortisol,,,"Caco-2 cell; inhibition of Digoxin transepithelial transport (basal to apical)(Digoxin: 5 microM, Cortisol: 100 microM)",Caco-2,mbcd0001050,100,microM,,human,mbds0003,v2007,2013-11-17 07:05:35
mbbd000001052,mbcd0003000,mbtp000001,mbrf0001163,,=,,,inhibitor,3,24.0,%,,Chlorzoxazone,,,"Caco-2 cell; inhibition of Digoxin transepithelial transport (basal to apical)(Digoxin: 5 microM, Chlorzoxazone: 100 microM)",Caco-2,mbcd0001050,100,microM,,human,mbds0003,v2007,2013-12-09 20:57:46
mbbd000001053,mbcd0003879,mbtp000001,mbrf0001163,,=,,,inhibitor,3,36.0,%,11,caffeine,,,"Caco-2 cell; inhibition of Digoxin transepithelial transport (basal to apical) (Digoxin: 5 microM, Caffeine: 100 microM)",Caco-2,mbcd0001050,100,microM,,human,mbds0003,v2007,2013-12-09 20:57:47
mbbd000001054,mbcd0002192,mbtp000001,mbrf0001163,,=,,,inhibitor,3,78.0,%,,Amiodarone,,,"Caco-2 cell; inhibition of Digoxin transepithelial transport (basal to apical)(Digoxin: 5 microM, Amiodarone: 100 microM)",Caco-2,mbcd0001050,100,microM,,human,mbds0003,v2007,2013-12-09 20:57:47
mbbd000001055,mbcd0000088,mbtp000001,mbrf0001163,,=,,,inhibitor,3,57.0,%,16,6beta-hydroxycortisol,,,"Caco-2 cell; inhibition of Digoxin transepithelial transport (basal to apical)(Digoxin: 5 microM, 6beta-hydroxycortisol: 100 microM)",Caco-2,mbcd0001050,100,microM,,human,mbds0003,v2007,2013-11-17 07:05:36
mbbd000001057,mbcd0001797,mbtp000001,mbrf0001164,,=,,,substrate,85,11.1,,0.5,fexofenadine,,,MDR1-expressing MDCK cells; transepithelial transport (basal to apical),MDCK,,,,,human,mbds0003,v2007,2013-12-09 00:28:07
mbbd000001058,mbcd0001050,mbtp000001,mbrf0001164,,,,,substrate,,,,,digoxin,,,MDR1-expressing MDCK cell; transepithelial transport (basal to apical),MDCK,,,,,human,mbds0003,v2007,2013-12-09 20:57:47
mbbd000001059,mbcd0000311,mbtp000001,mbrf0001164,,,,,substrate,,,,,cyclosporine,,,MDR1-expressing MDCK cell; transepithelial transport (basal to apical),MDCK,,,,,human,mbds0003,v2007,2013-12-09 20:57:47
mbbd000001060,mbcd0000147,mbtp000001,mbrf0001165,,,,,substrate,,,,,asimadoline,,,MDR1-expressing LLC-PK1 cell; transepithelial transport (basal to apical),LLC-PK1,,,,,human,mbds0003,v2007,2013-12-09 20:06:16
mbbd000001061,mbcd0001151,mbtp000001,mbrf0001166,,,,,substrate,,,,,VLB,,,CCRF-CEM and MDR1-expressing CEM/VLB100 cells; cell accumulation,CEM/VLB100,,1,microM,,human,mbds0003,v2007,2013-11-12 05:11:45
mbbd000001064,mbcd0000547,mbtp000001,mbrf0001166,,,,,non-substrate,,,,,LY335979,,,Caco-2 cell; transepithelial transport (basal to apical),Caco-2,,30,microM,,human,mbds0003,v2007,2013-12-09 20:06:16
mbbd000001065,mbcd0000547,mbtp000001,mbrf0001166,,,,,non-substrate,,,,,LY335979,,,CCRF-CEM and MDR1-expressing CEM/VLB100 cells; cell accumulation,CEM/VLB100,,1,microM,,human,mbds0003,v2007,2013-11-12 05:11:45
mbbd000001066,mbcd0001797,mbtp000001,mbrf0001167,,,,,non-inhibitor,,,,,Fexofenadine,,,"Caco-2 cells; inhibition of Digoxin transepithelial transport (basal to apical) (Digoxin: 5 microM, Fexofenadine: 100 microM)",Caco-2,mbcd0001050,up to 100,microM,,human,mbds0003,v2007,2013-12-09 20:06:17
mbbd000001067,mbcd0001797,mbtp000001,mbrf0001167,,,,,substrate,,,,,fexofenadine,,,MDR1-expressing LLC-PK1 cell L-MDR1 cell line (LLC-PK1 cell derivative); transepithelial transport,LLC-PK1,,5,microM,,human,mbds0003,v2007,2013-12-08 08:52:03
mbbd000001068,mbcd0001316,mbtp000001,mbrf0001168,,~,,,inhibitor,25,1.3,microM,,FK506,,,Caco-2 cell; inhibition of Digoxin transepithelial transport (basal to apical),Caco-2,mbcd0001050,,,,human,mbds0003,v2007,2013-12-09 20:06:15
mbbd000001072,mbcd0000293,mbtp000001,mbrf0001168,,~,,,inhibitor,25,0.1,microM,,CP117227,,,Caco-2 cell; inhibition of Digoxin transepithelial transport (basal to apical),Caco-2,mbcd0001050,,,,human,mbds0003,v2007,2013-12-09 20:57:24
mbbd000001076,mbcd0000289,mbtp000001,mbrf0001168,,~,,,inhibitor,25,0.1,microM,,CP100356,,,Caco-2 cell; inhibition of Digoxin transepithelial transport (basal to apical),Caco-2,mbcd0001050,,,,human,mbds0003,v2007,2013-12-09 20:57:25
mbbd000001077,mbcd0002507,mbtp000001,mbrf0001169,,=,,,inhibitor,70,3200.0,microM,,pafenolol,,,membrane from Vinblastine-induced Caco-2 cell; inhibition of Verapamil binding ,,,,,,human,mbds0003,v2007,2013-12-09 20:57:25
mbbd000001078,mbcd0002507,mbtp000001,mbrf0001169,,=,,,inhibitor,79,5.5,microM,,pafenolol,,,membrane from Vinblastine-induced Caco-2 cell; inhibition of Verapamil binding ,,,,,,human,mbds0003,v2007,2013-12-09 20:57:23
mbbd000001079,mbcd0027062,mbtp000001,mbrf0001170,,,,,inhibitor,,,,,Verapamil,,,"Hs578T-Dox cell; increase in Calcein intracellular accumulation (Calcein: 50 mg/L, Verapamil: 10 microM)",Hs578T-Dox,mbcd0029351,,,,human,mbds0003,v2007,2013-12-09 20:57:24
mbbd000001080,mbcd0026732,mbtp000001,mbrf0001170,,,,,inhibitor,,,,,carvedilol,,,"Hs578T-Dox cell; increase in Calcein intracellular accumulation (Calcein: 50 mg/L, Carvedilol: 10 microM)",Hs578T-Dox,mbcd0029351,,,,human,mbds0003,v2007,2013-12-09 19:57:40
mbbd000001081,mbcd0027062,mbtp000001,mbrf0001171,,=,,,inhibitor,143,3.6,,,VER,,,Caco-2 cell; inhibition of Saquinavir transepithelial transport (basal to apical),Caco-2,mbcd0001533,500,microM,,human,mbds0003,v2007,2013-12-09 19:57:39
mbbd000001082,mbcd0001533,mbtp000001,mbrf0001171,,=,,,substrate,143,25.0,,,SQV,,,Caco-2 cell; transepithelial transport (basal to apical),Caco-2,,1,microM,,human,mbds0003,v2007,2013-12-09 19:57:38
mbbd000001083,mbcd0003120,mbtp000001,mbrf0001171,,=,,,non-inhibitor,143,20.0,,,QTN,,,Caco-2 cell; inhibition of Saquinavir transepithelial transport (basal to apical),Caco-2,mbcd0001533,250,microM,,human,mbds0003,v2007,2013-12-09 19:57:34
mbbd000001084,mbcd0000615,mbtp000001,mbrf0001171,,=,,,inhibitor,143,7.6,,,NAR,,,Caco-2 cell; inhibition of Saquinavir transepithelial transport (basal to apical),Caco-2,mbcd0001533,250,microM,,human,mbds0003,v2007,2013-12-09 19:57:43
mbbd000001085,mbcd0003076,mbtp000001,mbrf0001171,,=,,,non-inhibitor,143,17.3,,,NGN,,,Caco-2 cell; inhibition of Saquinavir transepithelial transport (basal to apical),Caco-2,mbcd0001533,250,microM,,human,mbds0003,v2007,2013-12-09 19:57:42
mbbd000001086,mbcd0022804,mbtp000001,mbrf0001171,,=,,,non-inhibitor,143,23.5,,,BEG,,,Caco-2 cell; inhibition of Saquinavir transepithelial transport (basal to apical),Caco-2,mbcd0001533,100,microM,,human,mbds0003,v2007,2013-12-09 19:57:41
mbbd000001092,mbcd0002323,mbtp000001,mbrf0001173,,,,,substrate,,,,,indinavir,,,Caco-2 cell; transepithelial transport (basal to apical),Caco-2,,,,,human,mbds0003,v2007,2013-12-09 20:55:10
mbbd000001093,mbcd0000311,mbtp000001,mbrf0001173,,~,,,inhibitor,138,1.3,nmol/4 hrs,0.2,CsA,,,Caco-2 cell; inhibition of Indinavir transepithelial transport (basal to apical),Caco-2,mbcd0002323,,,,human,mbds0003,v2007,2013-12-09 20:55:10
mbbd000001094,mbcd0001135,mbtp000001,mbrf0001174,,,,,substrate,,,,,vincristine,,,MDR1-expressing LLC-PK1 cell; intracellular accumulation,LLC-PK1,,,,,human,mbds0003,v2007,2013-12-09 20:52:23
mbbd000001095,mbcd0001151,mbtp000001,mbrf0001174,,=,,,substrate,28,99.4,microM,14.0,Vinblastine,,,MDR1-expressing LLC-PK1 cell; intracellular accumulation,LLC-PK1,,0.5-200,microM,,human,mbds0003,v2007,2013-12-09 20:52:23
mbbd000001096,mbcd0001532,mbtp000001,mbrf0001174,,,,,substrate,,,,,paclitaxel,,,MDR1-expressing LLC-PK1 cell; intracelullar accumulation,LLC-PK1,,,,,human,mbds0003,v2007,2013-12-09 20:52:23
mbbd000001097,mbcd0001664,mbtp000001,mbrf0001174,,,,,non-substrate,,,,,taurocholate,,,MDR1-expressing MDCKII cell; intracellular accumulation/efflux,MDCKII,,,,,human,mbds0003,v2007,2013-12-09 20:55:10
mbbd000001098,mbcd0002889,mbtp000001,mbrf0001174,,,,,non-substrate,,,,,tamoxifen,,,MDR1-expressing LLC-PK1 cell; intracellular accumulation,LLC-PK1,,,,,human,mbds0003,v2007,2013-12-09 20:52:24
mbbd000001099,mbcd0000746,mbtp000001,mbrf0001174,,,,,substrate,,,,,rhodamine 123,,,MDR1-expressing LLC-PK1 cell; intracellular accumulation,LLC-PK1,,,,,human,mbds0003,v2007,2013-12-09 20:52:24
mbbd000001100,mbcd0000357,mbtp000001,mbrf0001174,,,,,inhibitor,,,,,Ditekiren,non-inhibitor at <20 microM ditekiren,,"MDR1-expressing LLC-PK1 cell; increase in Calcein-AM intracellular accumulation (Calcein-AM: 1 microM, Ditekiren: 20 microM)",LLC-PK1,,20,microM,,human,mbds0003,v2007,2013-12-09 20:16:29
mbbd000001101,mbcd0005183,mbtp000001,mbrf0001174,,,,,substrate,,,,,daunomycin,,,MDR1-expressing LLC-PK1 cell; intracellular accumulation,LLC-PK1,,,,,human,mbds0003,v2007,2013-12-09 20:16:30
mbbd000001102,mbcd0000212,mbtp000001,mbrf0001174,,,,,substrate,,,,,calcein-AM,,,MDR1-expressing LLC-PK1 cell; intracellular accumulation,LLC-PK1,,,,,human,mbds0003,v2007,2013-12-09 20:16:26
mbbd000001103,mbcd0027726,mbtp000001,mbrf0001175,,,,,substrate,,,,,docetaxel,,,MDR1-expressing LLC-PK1 cell; transepithelial transport (basal to apical),LLC-PK1,,,,,human,mbds0003,v2007,2013-12-09 20:16:27
mbbd000001107,mbcd0002109,mbtp000001,mbrf0001177,,,,,inhibitor,,,,,Astemizole,100 (10) microM strongly (partially) inhibited Azidopine photoaffinity labelling,,"membrane from K562/DOX cell; inhibition of Azidopine photoaffinity labelling (Azidopine: 0.1 microM, Astemizole: 10 microM)",K562/DOX,,10,microM,,human,mbds0003,v2007,2013-12-09 20:16:31
mbbd000001108,mbcd0002109,mbtp000001,mbrf0001177,,,,,inhibitor,,,,,Astemizole,,,"K562/DOX cell; increase in Doxorubicin intracellular accumulation (Doxorubicin: 4 microM, Astemizole: 3 microM)",K562/DOX,mbcd0025844,3,microM,,human,mbds0003,v2007,2013-12-09 20:16:23
mbbd000001109,mbcd0027333,mbtp000001,mbrf0001178,,=,,,substrate,28,232.0,microM,7.9,Losartan,,,Caco-2 cell; transepithelial transport (basal to apical),Caco-2,,10-750,microM,,human,mbds0003,v2007,2013-12-09 20:16:24
mbbd000001110,mbcd0027333,mbtp000001,mbrf0001178,,=,,,substrate,28,403.2,microM,15.2,Losartan,,,MDR1-expressing MDCK cell; transepithelial transport (basal to apical),MDCK,,10-1500,microM,,human,mbds0003,v2007,2013-12-09 21:00:54
mbbd000001111,mbcd0000659,mbtp000001,mbrf0001179,,=,,,inhibitor,29,0.21,microM,,PAK-104P,,,K562/Adr cell; inhibition of Hydroxydoxorubicin efflux,K562/ADR,mbcd0000477,,,,human,mbds0003,v2007,2013-12-09 21:00:54
mbbd000001112,mbcd0001893,mbtp000001,mbrf0001180,,=,,,inhibitor,72,175.0,%,,Tangeretin,,,"MDR1-expressing LLC-PK1 cell; increase in Vinblastine uptake (Vinblastine: 0.02 microM, Tangeretin: 20 microM)",LLC-PK1,mbcd0001151,,,,human,mbds0003,v2007,2013-12-09 21:00:55
mbbd000001113,mbcd0003243,mbtp000001,mbrf0001180,,=,,,inhibitor,72,604.0,%,,Nobiletin,,,"MDR1-expressing LLC-PK1 cell; increase in Vinblastine uptake (Vinblastine: 0.02 microM, Nobiletin: 20 microM)",LLC-PK2,mbcd0001151,,,,human,mbds0003,v2007,2013-12-09 21:00:54
mbbd000001114,mbcd0002048,mbtp000001,mbrf0001180,,=,,,inhibitor,72,935.0,%,,HMF,,,"MDR1-expressing LLC-PK1 cell; increase in Vinblastine uptake (Vinblastine: 0.02 microM, HMF: 20 microM)",LLC-PK3,mbcd0001151,,,,human,mbds0003,v2007,2013-12-09 21:00:55
mbbd000001115,mbcd0001151,mbtp000001,mbrf0001181,,,,,inhibitor,,,,,Vinblastine,,,"membrane from MDR1-expressing LLC-PK1 cell; inhibition of Azidopine photoaffinity labelling (Azidopine: 0.4 microM, Vinblastine: 400 microM)",LLC-GA5-COL150,,,,,human,mbds0003,v2007,2013-12-09 21:00:55
mbbd000001116,mbcd0002191,mbtp000001,mbrf0001181,,=,,,inhibitor,25,3.3,microM,225,itraconazole,,,"MDR1-expressing LLC-PK1 cell; inhibition of Doxorubicin transepithelial transport (basal to apical) (Doxorubicin: 0.1 microM, Itraconazole: 100 microM)",LLC-PK1,mbcd0025844,0.5,microM,,human,mbds0003,v2007,2013-12-09 21:00:55
mbbd000001117,mbcd0002191,mbtp000001,mbrf0001181,,=,,,inhibitor,25,61.0,nM,0.4,itraconazole,,,"MDR1-expressing LLC-PK1 cell; inhibition of Vinblastine transepithelial transport (basal to apical) (Vinblastine: 0.1 microM, Itraconazole: 100 microM)",LLC-PK1,mbcd0001151,0.5,microM,,human,mbds0003,v2007,2013-12-09 21:00:55
mbbd000001118,mbcd0002191,mbtp000001,mbrf0001181,,>,,,inhibitor,25,1.0,mM,,itraconazole,,,"MDR1-expressing LLC-PK1 cell; inhibition of Digoxin transepithelial transport (basal to apical) (Digoxin: 0.1 microM, Itraconazole: 100 microM)",LLC-PK1,mbcd0001050,0.5,microM,,human,mbds0003,v2007,2013-12-09 21:00:54
mbbd000001119,mbcd0002191,mbtp000001,mbrf0001181,,,,,inhibitor,,,,,itraconazole,,,membrane from MDR1-expressing LLC-PK1 cell; inhibition of Azidopine photoaffinity labelling,LLC-GA5-COL150,,,,,human,mbds0003,v2007,2013-12-09 21:00:54
mbbd000001120,mbcd0025844,mbtp000001,mbrf0001181,,,,,inhibitor,,,,,doxorubicin,,,"membrane from MDR1-expressing LLC-PK1 cell; inhibition of Azidopine photoaffinity labelling (Azidopine: 0.4 microM, Doxorubicin: 400 microM)",LLC-GA5-COL150,,,,,human,mbds0003,v2007,2013-12-09 20:50:56
mbbd000001121,mbcd0001050,mbtp000001,mbrf0001181,,,,,inhibitor,,,,,Digoxin,,,"membrane from MDR1-expressing LLC-PK1 cell; inhibition of Azidopine photoaffinity labelling (Azidopine: 0.4 microM, Digoxin: 400 microM)",LLC-GA5-COL150,,,,,human,mbds0003,v2007,2013-12-09 20:50:56
mbbd000001122,mbcd0005183,mbtp000001,mbrf0001181,,,,,inhibitor,,,,,daunorubicin,,,"membrane from MDR1-expressing LLC-PK1 cell; inhibition of Azidopine photoaffinity labelling (Azidopine: 0.4 microM, Daunorubicin: 400 microM)",LLC-GA5-COL150,,,,,human,mbds0003,v2007,2013-12-09 20:50:56
mbbd000001123,mbcd0005183,mbtp000001,mbrf0001181,,,,,substrate,,,,,daunorubicin,,,MDR1-expressing LLC-PK1 cell; transepithelial transport (basal to apical),LLC-PK1,,,,,human,mbds0003,v2007,2013-12-09 20:50:56
mbbd000001124,mbcd0001050,mbtp000001,mbrf0001182,,~,,,inducer,97,350.0,%,3,Digoxin,,,LS180 cell; up-regulation of MDR1 mRNA,LS180 ,,1000,nM,,human,mbds0003,v2007,2013-12-09 20:50:56
mbbd000001125,mbcd0001050,mbtp000001,mbrf0001182,,~,,,inducer,97,440.0,%,80,Digoxin,,,Caco-2 cell; up-regulation of MDR1 mRNA,Caco-2,,1000,nM,,human,mbds0003,v2007,2013-12-09 20:50:57
mbbd000001129,mbcd0000048,mbtp000001,mbrf0001183,,~,,,inhibitor,1,65.0,%,,DM-beta-CyD,,,vinblastine-resistant Caco-2 (Caco-2R) cell monolayers; transepithelial transport of Rhodamine 123 (basal to apical),Caco-2,mbcd0000746,10,mM,,human,mbds0003,v2007,2013-11-24 07:52:24
mbbd000001132,mbcd0000311,mbtp000001,mbrf0001185,,,,,non-inhibitor,,,,,cyclosporin A,,,K562/ADR cell; cell accumulation of doxorubicin,K562/ADR,mbcd0025844,1,microM,,human,mbds0003,v2007,2013-12-09 19:52:49
mbbd000001133,mbcd0000937,mbtp000001,mbrf0001185,,,,,non-inhibitor,,,,,Erythromycin,,,K562/ADR cell; cell accumulation of doxorubicin,K562/ADR,mbcd0025844,1,mM,,human,mbds0003,v2007,2013-12-09 19:52:48
mbbd000001134,mbcd0028157,mbtp000001,mbrf0001185,,,,,non-inhibitor,,,,,Azithromycin,,,K562/ADR cell; cell accumulation of doxorubicin,K562/ADR,mbcd0025844,1,mM,,human,mbds0003,v2007,2013-12-09 19:52:47
mbbd000001137,mbcd0002889,mbtp000001,mbrf0001187,,=,,,inhibitor,25,29.0,microM,,Tamoxifen; TAM,,,Caco-2 cell; transepithelial transport of Rhodamine 123 (basal to apical),Caco-2,mbcd0000746,,,,human,mbds0003,v2007,2013-12-09 19:52:46
mbbd000001138,mbcd0002889,mbtp000001,mbrf0001187,,,,,non-substrate,,,,,tamoxifen; TAM,Prodrug of endoxifen,,Caco-2 cell; transepithelial transport,Caco-2,,100,microM,,human,mbds0003,v2007,2013-12-09 19:52:50
mbbd000001140,mbcd0000602,mbtp000001,mbrf0001187,,,,,non-substrate,,,,,N-desmethyltamoxifen,,,Caco-2 cell; transepithelial transport,Caco-2,,,,,human,mbds0003,v2007,2013-12-09 20:13:32
mbbd000001141,mbcd0001078,mbtp000001,mbrf0001188,,,,,substrate,,,,,gemcitabine,,,MDR1-expressing BROmdr cell; drug resistance,BRO,,,,,human,mbds0003,v2007,2013-12-09 20:13:32
mbbd000001142,mbcd0001078,mbtp000001,mbrf0001188,,,,,substrate,,,,,gemcitabine,,,2780AD cell; drug resistance,A2780,,,,,human,mbds0003,v2007,2013-12-09 20:13:31
mbbd000001143,mbcd0001078,mbtp000001,mbrf0001188,,,,,substrate,,,,,gemcitabine,,,MRD1-expressing SW1573/S1(1.1) cell; drug resistance,SW1573/S1(1.1),,,,,human,mbds0003,v2007,2014-01-17 20:49:27
mbbd000001144,mbcd0001078,mbtp000001,mbrf0001188,,,,,substrate,,,,,gemcitabine,,,2R160 cell; drug resistance,2R160,,,,,human,mbds0003,v2007,2014-01-17 20:49:27
mbbd000001145,mbcd0000303,mbtp000001,mbrf0001189,,,,,inhibitor,,,,,Curcumin I,,,human KB-V1 cell; increase in bodipy-FL-vinblastine intracellular accumulation,KB-V1,mbcd0031471,,,,human,mbds0003,v2007,2013-12-09 20:13:29
mbbd000001146,mbcd0000303,mbtp000001,mbrf0001189,,,,,inhibitor,,,,,Curcumin I,,,human KB-V1 cell; increase in Rhodamine 123 intracellular accumulation,KB-V1,mbcd0000746,,,,human,mbds0003,v2007,2013-12-09 20:50:50
mbbd000001147,mbcd0000303,mbtp000001,mbrf0001189,,,,,inhibitor,,,,,Curcumin I,,,human KB-V1 cell; increase in Calcein-AM intracellular accumulation,KB-V1,mbcd0000212,,,,human,mbds0003,v2007,2013-12-09 20:13:26
mbbd000001148,mbcd0000086,mbtp000001,mbrf0001190,,~,,,inhibitor,100,115.0,%,2,PMF,,,AML-2/D100 cell; increase in Rhodamine 123 intracellular accumulation,AML-2/D100,mbcd0000746,5,microM,,human,mbds0003,v2007,2013-12-09 20:13:33
mbbd000001149,mbcd0003120,mbtp000001,mbrf0001190,,=,,,inhibitor,25,52.5,microM,,Quercetin,,,AML-2/D100 cell; drug resistance (vincristine),AML-2/D100,mbcd0001135,,,,human,mbds0003,v2007,2013-12-09 20:50:53
mbbd000001150,mbcd0000063,mbtp000001,mbrf0001190,,=,,,inhibitor,25,6.3,microM,,"3,7-Dihydroxy-3',4'-dimethoxyflavone",,,AML-2/D100 cell; drug resistance (vincristine),AML-2/D100,mbcd0001135,,,,human,mbds0003,v2007,2013-12-09 20:58:21
mbbd000001151,mbcd0003217,mbtp000001,mbrf0001190,,=,,,inhibitor,25,19.6,microM,,"5,7,3',4'-Tetrahydroxyflavone",,,AML-2/D100 cell; drug resistance (vincristine),AML-2/D100,mbcd0001135,,,,human,mbds0003,v2007,2013-12-09 20:58:21
mbbd000001152,mbcd0000060,mbtp000001,mbrf0001190,,=,,,inhibitor,25,3.2,microM,,"3,5,7-Trihydroxy-3',4',5'-trimethoxyflavone",,,AML-2/D100 cell; drug resistance (vincristine),AML-2/D100,mbcd0001135,,,,human,mbds0003,v2007,2013-12-09 20:58:22
mbbd000001153,mbcd0000087,mbtp000001,mbrf0001190,,=,,,inhibitor,25,1.4,microM,,"5,7,4'-Trimethoxyflavone",,,AML-2/D100 cell; drug resistance (vincristine),AML-2/D100,mbcd0001135,,,,human,mbds0003,v2007,2013-12-09 20:58:22
mbbd000001154,mbcd0000084,mbtp000001,mbrf0001190,,=,,,inhibitor,25,0.9,microM,,"5,6,7,3',4',5'-Hexamethoxyflavone",,,AML-2/D100 cell; drug resistance (vincristine),AML-2/D100,mbcd0001135,,,,human,mbds0003,v2007,2013-12-09 20:58:19
mbbd000001155,mbcd0002084,mbtp000001,mbrf0001190,,=,,,inhibitor,25,3.2,microM,,"5,6,7,3',4'-Pentamethoxyflavone",,,AML-2/D100 cell; drug resistance (vincristine),AML-2/D100,mbcd0001135,,,,human,mbds0003,v2007,2013-12-09 20:58:19
mbbd000001156,mbcd0027062,mbtp000001,mbrf0001190,,=,,,inhibitor,25,0.4,microM,,Verapamil,,,AML-2/D100 cell; drug resistance (vincristine),AML-2/D100,mbcd0001135,,,,human,mbds0003,v2007,2013-12-09 20:58:21
mbbd000001157,mbcd0000062,mbtp000001,mbrf0001190,,=,,,inhibitor,25,1.9,microM,,"3,6,3',4'-Tetramethoxyflavone",,,AML-2/D100 cell; drug resistance (vincristine),AML-2/D100,mbcd0001135,,,,human,mbds0003,v2007,2013-12-09 20:58:20
mbbd000001158,mbcd0026844,mbtp000001,mbrf0001190,,=,,,inhibitor,25,1.2,microM,,"3',4'-Dimethoxyflavone",,,AML-2/D100 cell; drug resistance (vincristine),AML-2/D100,mbcd0001135,,,,human,mbds0003,v2007,2013-12-09 20:58:24
mbbd000001159,mbcd0000099,mbtp000001,mbrf0001190,,=,,,inhibitor,25,1.2,microM,,"7,3',4'-Trimethoxyflavone",,,AML-2/D100 cell; drug resistance (vincristine),AML-2/D100,mbcd0001135,,,,human,mbds0003,v2007,2013-12-09 20:58:23
mbbd000001160,mbcd0000086,mbtp000001,mbrf0001190,,=,,,inhibitor,25,0.4,microM,,PMF,,,AML-2/D100 cell; drug resistance (vincristine),AML-2/D100,mbcd0001135,,,,human,mbds0003,v2007,2013-12-09 20:14:52
mbbd000001162,mbcd0001316,mbtp000001,mbrf0001191,,,,,substrate,,,,,tacrolimus,,,Caco 2 cell; transepithelial transport,Caco-2,,,,,human,mbds0003,v2007,2013-12-09 20:14:52
mbbd000001164,mbcd0001416,mbtp000001,mbrf0001191,,,,,substrate,,,,,rifampicin,,,Caco 2 cell; transepithelial transport,Caco-2,,,,,human,mbds0003,v2007,2013-12-09 20:14:50
mbbd000001165,mbcd0000804,mbtp000001,mbrf0001191,,,,,substrate,,,,,talinolol,,,Caco 2 cell; transepithelial transport,Caco-2,,,,,human,mbds0003,v2007,2013-12-09 20:14:51
mbbd000001166,mbcd0003187,mbtp000001,mbrf0001191,,,,,substrate,,,,,topotecan,,,Caco 2 cell; transepithelial transport,Caco-2,,,,,human,mbds0003,v2007,2013-12-09 20:54:11
mbbd000001167,mbcd0001533,mbtp000001,mbrf0001191,,,,,substrate,,,,,saquinavir,,,Caco 2 cell; transepithelial transport,Caco-2,,,,,human,mbds0003,v2007,2013-12-09 20:54:11
mbbd000001168,mbcd0001050,mbtp000001,mbrf0001191,,,,,substrate,,,,,digoxin,,,Caco 2 cell; transepithelial transport,Caco-2,,,,,human,mbds0003,v2007,2013-12-09 20:14:48
mbbd000001169,mbcd0001532,mbtp000001,mbrf0001191,,,,,substrate,,,,,paclitaxel,,,Caco 2 cell; transepithelial transport,Caco-2,,,,,human,mbds0003,v2007,2013-12-09 20:14:49
mbbd000001170,mbcd0027062,mbtp000001,mbrf0001191,,,,,non-substrate,,,,,verapamil,,,Caco 2 cell; transepithelial transport,Caco-2,,,,,human,mbds0003,v2007,2013-12-09 21:00:38
mbbd000001175,mbcd0000311,mbtp000001,mbrf0001193,,~,,,inhibitor,1,70.0,%,,cyclosporin A,,,Caco2 cell; transepithelial transport of propranolol,Caco-2,mbcd0002488,,,,human,mbds0003,v2007,2013-12-09 21:00:38
mbbd000001176,mbcd0002488,mbtp000001,mbrf0001193,,,,,substrate,,,,,propranolol,,,Caco2 cell; transepithelial transport,Caco-2,,,,,human,mbds0003,v2007,2013-12-09 21:00:38
mbbd000001177,mbcd0000937,mbtp000001,mbrf0001194,,,,,substrate,,,,,erythromycin,,,MDR1-expressing MDCK cell; transepithelial transport,MDCK,,,,,human,mbds0003,v2007,2013-12-09 21:00:38
mbbd000001178,mbcd0001517,mbtp000001,mbrf0001195,,~,,,inhibitor,1,85.0,%,,Clarithromycin,,,MDR1-expressing LLC-GA5-COL150 cell; transepithelial transport of digoxin (apical to basal) (Digoxin: 20-30microM),LLC-GA5-COL150,,,,,human,mbds0003,v2007,2013-12-09 21:00:38
mbbd000001183,mbcd0001151,mbtp000001,mbrf0001196,,,,,substrate,,,,,vinblastine,,,P-gp transfected LNCaP cell; cell accumulation,LNCaP,,,,,human,mbds0003,v2007,2013-12-09 20:08:59
mbbd000001184,mbcd0001645,mbtp000001,mbrf0001196,,,,,substrate,,,,,DHT,,,P-gp transfected LNCaP cell (HeLa-AR and LNCaP prostate cancer cells); cellular accumulation assays,LNCaP; HeLa-AR,,,,,human,mbds0003,v2007,2013-11-24 23:54:39
mbbd000001185,mbcd0000843,mbtp000001,mbrf0001197,,,,,inhibitor,,,,,Tet,Growth inhibition,,KBV200 cell; drug resistance (vincristine),KBV200,mbcd0001135,,,,human,mbds0003,v2007,2013-12-09 20:09:00
mbbd000001186,mbcd0000171,mbtp000001,mbrf0001198,,=,,,inhibitor,25,2.8,microM,0.38,BPE3; benzoperimidine diethyl ester,,,K562/DX; inhibition of pirarubicin efflux,K562/DX,mbcd0030083,,,,human,mbds0003,v2007,2013-12-09 20:09:00
mbbd000001187,mbcd0000171,mbtp000001,mbrf0001198,,=,,,inhibitor,25,0.7,microM,0.16,BPE3; benzoperimidine diethyl ester,,,HL-60/VINC cell; inhibition of pirarubicin efflux,HL60/VINC,mbcd0030083,,,,human,mbds0003,v2007,2013-12-09 20:09:00
mbbd000001188,mbcd0000067,mbtp000001,mbrf0001199,,=,,,substrate,28,15.0,microM,,UK-294315,,,Caco2 cell; transepithelial transport,Caco-2,,,,,human,mbds0003,v2007,2013-12-09 20:09:01
mbbd000001198,mbcd0000772,mbtp000001,mbrf0001203,,,,,substrate,,,,,SVA,,,L-MDR1 cell; transepithelial transport,LLC-PK1,,,,,human,mbds0003,v2007,2013-12-09 20:57:31
mbbd000001199,mbcd0001194,mbtp000001,mbrf0001203,,,,,non-substrate,,,,,SV,,,L-MDR1 cell; transepithelial transport,LLC-PK1,,,,,human,mbds0003,v2007,2013-12-09 20:57:31
mbbd000001201,mbcd0000772,mbtp000001,mbrf0001203,,=,,,non-inhibitor,3,15.0,%,,SVA,,,L-MDR1 cell; transepithelial transport of vinblastine,LLC-PK1,mbcd0001938,50,microM,,human,mbds0003,v2007,2013-12-09 20:55:09
mbbd000001202,mbcd0001194,mbtp000001,mbrf0001203,,=,,,inhibitor,3,30.0,%,,SV,+(5 microM),,L-MDR1 cell; transepithelial transport of ritonavir,LLC-PK1,mbcd0001938,25,microM,,human,mbds0003,v2007,2013-12-09 20:55:10
mbbd000001203,mbcd0003243,mbtp000001,mbrf0001204,,=,,,non-inhibitor,89,101.0,%,1.4,NBL,,,LLC-GA5-COL150 cell; increase in saquinavir intracellular accumulation,LLC-GA5-COL150,mbcd0001533,20,microM,,human,mbds0003,v2007,2013-12-09 20:55:09
mbbd000001205,mbcd0001893,mbtp000001,mbrf0001204,,=,,,inhibitor,89,146.0,%,14,TAN,,,LLC-GA5-COL150 cell; increase in saquinavir intracellular accumulation,LLC-GA5-COL150,mbcd0001533,20,microM,,human,mbds0003,v2007,2013-12-09 20:55:10
mbbd000001207,mbcd0022804,mbtp000001,mbrf0001204,,=,,,inhibitor,89,159.0,%,5.5,BG,,,LLC-GA5-COL150 cell; increase in saquinavir intracellular accumulation,LLC-GA5-COL150,mbcd0001533,20,microM,,human,mbds0003,v2007,2013-12-09 20:55:10
mbbd000001210,mbcd0003154,mbtp000001,mbrf0001204,,=,,,non-inhibitor,89,111.0,%,9.3,Probenecid,,,LLC-GA5-COL150 cell; increase in saquinavir intracellular accumulation,LLC-GA5-COL150,mbcd0001533,5,mM,,human,mbds0003,v2007,2013-12-09 20:08:02
mbbd000001211,mbcd0002988,mbtp000001,mbrf0001204,,=,,,non-inhibitor,89,82.3,%,11,Sulfinpyrazone,,,LLC-GA5-COL150 cell; increase in saquinavir intracellular accumulation,LLC-GA5-COL150,mbcd0001533,5,mM,,human,mbds0003,v2007,2013-12-09 20:08:02
mbbd000001212,mbcd0002494,mbtp000001,mbrf0001204,,=,,,non-inhibitor,89,80.8,%,3.8,MK571,,,LLC-GA5-COL150 cell; increase in saquinavir intracellular accumulation,LLC-GA5-COL150,mbcd0001533,50,microM,,human,mbds0003,v2007,2013-12-09 20:08:00
mbbd000001213,mbcd0000311,mbtp000001,mbrf0001204,,=,,,inhibitor,89,380.0,%,24,CysA,,,LLC-GA5-COL150 cell; increase in saquinavir intracellular accumulation,LLC-GA5-COL150,mbcd0001533,20,microM,,human,mbds0003,v2007,2013-12-09 20:08:01
mbbd000001214,mbcd0027062,mbtp000001,mbrf0001204,,=,,,non-inhibitor,89,946.0,%,5.5,VER,,,LLC-GA5-COL150 cell; increase in saquinavir intracellular accumulation,LLC-GA5-COL150,mbcd0001533,100,microM,,human,mbds0003,v2007,2013-12-09 20:08:03
mbbd000001215,mbcd0003243,mbtp000001,mbrf0001204,,=,,,inhibitor,89,216.0,%,8.1,NBL,,,LLC-GA5-COL150 cell; increase in Vinblastine intracellular accumulation,LLC-GA5-COL150,mbcd0001151,20,microM,,human,mbds0003,v2007,2013-12-09 20:08:04
mbbd000001217,mbcd0001893,mbtp000001,mbrf0001204,,=,,,inhibitor,89,178.0,%,3.2,TAN,,,LLC-GA5-COL150 cell; increase in Vinblastine intracellular accumulation,LLC-GA5-COL150,mbcd0001151,20,microM,,human,mbds0003,v2007,2013-12-09 20:08:02
mbbd000001219,mbcd0022804,mbtp000001,mbrf0001204,,=,,,non-inhibitor,89,56.9,%,4.6,BG,,,LLC-GA5-COL150 cell; increase in Vinblastine intracellular accumulation,LLC-GA5-COL150,mbcd0001151,20,microM,,human,mbds0003,v2007,2013-12-09 20:08:05
mbbd000001222,mbcd0003154,mbtp000001,mbrf0001204,,=,,,non-inhibitor,89,56.7,%,1.0,Probenecid,,,LLC-GA5-COL150 cell; increase in Vinblastine intracellular accumulation,LLC-GA5-COL150,mbcd0001151,5,mM,,human,mbds0003,v2007,2013-12-09 19:52:44
mbbd000001223,mbcd0002988,mbtp000001,mbrf0001204,,=,,,non-inhibitor,89,40.5,%,1.7,Sulfinpyrazone,,,LLC-GA5-COL150 cell; increase in Vinblastine intracellular accumulation,LLC-GA5-COL150,mbcd0001151,5,mM,,human,mbds0003,v2007,2013-12-09 19:52:44
mbbd000001224,mbcd0002494,mbtp000001,mbrf0001204,,=,,,non-inhibitor,89,49.0,%,1.9,MK571,,,LLC-GA5-COL150 cell; increase in Vinblastine intracellular accumulation,LLC-GA5-COL150,mbcd0001151,50,microM,,human,mbds0003,v2007,2013-12-09 19:58:51
mbbd000001225,mbcd0000311,mbtp000001,mbrf0001204,,=,,,inhibitor,89,396.0,%,1,CysA,,,LLC-GA5-COL150 cell; increase in Vinblastine intracellular accumulation,LLC-GA5-COL150,mbcd0001151,20,microM,,human,mbds0003,v2007,2013-12-09 20:57:38
mbbd000001226,mbcd0027062,mbtp000001,mbrf0001204,,=,,,inhibitor,89,168.0,%,1.1,VER,,,LLC-GA5-COL150 cell; increase in Vinblastine intracellular accumulation,LLC-GA5-COL150,mbcd0001151,100,microM,,human,mbds0003,v2007,2013-12-09 20:57:37
mbbd000001227,mbcd0027677,mbtp000001,mbrf0001205,,=,,,non-inhibitor,100,72.3,%,16.7,1-NA,,,MCF-7/ADR cell; cell accumulation of 0.05micro daunomycin,MCF7/ADR,mbcd0005183,,,,human,mbds0003,v2007,2013-12-09 20:57:36
mbbd000001228,mbcd0000679,mbtp000001,mbrf0001205,,=,,,non-inhibitor,100,97.9,%,13.7,PA,,,MCF-7/ADR cell; cell accumulation of 0.05micro daunomycin,MCF7/ADR,mbcd0005183,,,,human,mbds0003,v2007,2013-12-09 19:52:42
mbbd000001229,mbcd0000172,mbtp000001,mbrf0001205,,=,,,non-inhibitor,100,90.3,%,8.0,BA,,,MCF-7/ADR cell; cell accumulation of 0.05micro daunomycin,MCF7/ADR,mbcd0005183,,,,human,mbds0003,v2007,2013-12-09 20:57:35
mbbd000001230,mbcd0000133,mbtp000001,mbrf0001205,,=,,,non-inhibitor,100,94.2,%,7.1,1-NIC,,,MCF-7/ADR cell; cell accumulation of 0.05micro daunomycin,MCF7/ADR,mbcd0005183,,,,human,mbds0003,v2007,2013-12-09 20:09:16
mbbd000001231,mbcd0000680,mbtp000001,mbrf0001205,,=,,,non-inhibitor,100,110.0,%,5.6,PEIC,,,MCF-7/ADR cell; cell accumulation of 0.05micro daunomycin,MCF7/ADR,mbcd0005183,,,,human,mbds0003,v2007,2013-12-09 20:09:18
mbbd000001232,mbcd0026443,mbtp000001,mbrf0001205,,=,,,inhibitor,100,209.0,%,24.7,BITC,,,MCF-7/ADR cell; cell accumulation of 0.05micro daunomycin,MCF7/ADR,mbcd0005183,,,,human,mbds0003,v2007,2013-12-09 20:09:19
mbbd000001233,mbcd0028378,mbtp000001,mbrf0001205,,=,,,inhibitor,100,487.0,%,26.7,1-NITC,,,MCF-7/ADR cell; cell accumulation of 0.05micro daunomycin,MCF7/ADR,mbcd0005183,,,,human,mbds0003,v2007,2013-12-09 19:56:46
mbbd000001234,mbcd0003129,mbtp000001,mbrf0001205,,=,,,inhibitor,100,198.0,%,63.1,PEITC,,,MCF-7/ADR cell; cell accumulation of 0.05micro daunomycin,MCF7/ADR,mbcd0005183,,,,human,mbds0003,v2007,2013-12-09 20:09:20
mbbd000001236,mbcd0027062,mbtp000001,mbrf0001205,,=,,,inhibitor,100,347.0,%,65.2,Verapamil,,,MCF-7/ADR cell; cell accumulation of 0.05micro daunomycin,MCF7/ADR,mbcd0005183,,,,human,mbds0003,v2007,2013-12-09 20:09:22
mbbd000001237,mbcd0001254,mbtp000001,mbrf0001206,,,,,substrate,,,,,epinastine,+(5 microM),,LLC-GA5-COL150 cell; transepithelial transport (basal to apical),LLC-GA5-COL150,,,,,human,mbds0003,v2007,2013-12-09 20:09:22
mbbd000001241,mbcd0001892,mbtp000001,mbrf0001209,,,,,non-substrate,,,,,progesterone,,,MDR1-expressing MDCK cell; transepithelial transport,MDCK,,,,,human,mbds0003,v2007,2013-12-09 19:59:29
mbbd000001242,mbcd0003055,mbtp000001,mbrf0001209,,,,,non-substrate,,,,,estradiol; beta-estradiol; 17 beta-estradiol,,,MDR1-expressing MDCK cell; transepithelial transport,MDCK,,,,,human,mbds0003,v2007,2013-12-09 20:09:16
mbbd000001243,mbcd0026802,mbtp000001,mbrf0001209,,=,,,non-substrate,85,1.3,,,norethindrone,,,MDR1-expressing MDCK cell monolayers; transepithelial transport,MDCK,,10,microM,,human,mbds0003,v2007,2013-11-17 07:59:29
mbbd000001244,mbcd0001673,mbtp000001,mbrf0001209,,=,,,substrate,85,11.0,,,estriol,,,MDR1-expressing MDCK cell; transepithelial transport,MDCK,,20,microM,,human,mbds0003,v2007,2013-12-09 20:09:06
mbbd000001245,mbcd0003211,mbtp000001,mbrf0001209,,=,,,substrate,85,6.6,,,estrone,,,MDR1-expressing MDCK cell monolayers; transepithelial transport,MDCK,,1,microM,,human,mbds0003,v2007,2013-11-17 07:59:28
mbbd000001246,mbcd0003119,mbtp000001,mbrf0001209,,=,,,substrate,85,3.2,,,ethynyl estradiol,,,MDR1-expressing MDCK cell; transepithelial transport,MDCK,,5,microM,,human,mbds0003,v2007,2013-12-09 20:54:10
mbbd000001247,mbcd0023123,mbtp000001,mbrf0001210,,,,,substrate,,,,,cerivastatin,,,L-MDR1 cell; transepithelial transport,LLC-PK1,,,,,human,mbds0003,v2007,2013-12-09 20:09:09
mbbd000001248,mbcd0000029,mbtp000001,mbrf0001211,,~,,,inhibitor,100,215.0,%,10,1-Monopalmitin,,,Caco-2 cell; Daunomycin accumulation,Caco-2,mbcd0005183,,,,human,mbds0003,v2007,2013-12-09 20:54:08
mbbd000001249,mbcd0000046,mbtp000001,mbrf0001211,,~,,,non-inhibitor,100,225.0,%,15,2-Monopalmitin,,,Caco-2 cell; Daunomycin accumulation,Caco-2,mbcd0005183,,,,human,mbds0003,v2007,2013-12-09 20:54:08
mbbd000001250,mbcd0000033,mbtp000001,mbrf0001211,,~,,,non-inhibitor,100,115.0,%,7,"1,2-Dipalmitin",,,Caco-2 cell; Daunomycin accumulation,Caco-2,mbcd0005183,,,,human,mbds0003,v2007,2013-12-09 20:14:57
mbbd000001251,mbcd0000035,mbtp000001,mbrf0001211,,~,,,non-inhibitor,100,115.0,%,7,"1,3-Dipalmitin",,,Caco-2 cell; Daunomycin accumulation,Caco-2,mbcd0005183,,,,human,mbds0003,v2007,2013-12-09 20:14:59
mbbd000001252,mbcd0000871,mbtp000001,mbrf0001211,,~,,,non-inhibitor,100,110.0,%,10,Tripalmitin,,,Caco-2 cell; Daunomycin accumulation,Caco-2,mbcd0005183,,,,human,mbds0003,v2007,2013-12-09 20:14:55
mbbd000001253,mbcd0001658,mbtp000001,mbrf0001211,,~,,,non-inhibitor,100,110.0,%,10,Palmitic Acid,,,Caco-2 cell; Daunomycin accumulation,Caco-2,mbcd0005183,,,,human,mbds0003,v2007,2013-12-09 20:52:22
mbbd000001254,mbcd0001660,mbtp000001,mbrf0001211,,~,,,non-inhibitor,100,120.0,%,1,Glycerol,,,Caco-2 cell; Daunomycin accumulation,Caco-2,mbcd0005183,,,,human,mbds0003,v2007,2013-12-09 20:14:53
mbbd000001255,mbcd0000661,mbtp000001,mbrf0001211,,~,,,non-inhibitor,100,105.0,%,5,Palmitic acid + Glycerol,,,Caco-2 cell; Daunomycin accumulation,Caco-2,mbcd0005183,,,,human,mbds0003,v2007,2013-12-09 20:14:54
mbbd000001257,mbcd0000030,mbtp000001,mbrf0001211,,~,,,inhibitor,100,275.0,%,50,1-Monopalmitolein,,,Caco-2 cell; Daunomycin accumulation,Caco-2,mbcd0005183,,,,human,mbds0003,v2007,2013-12-09 20:14:52
mbbd000001258,mbcd0000031,mbtp000001,mbrf0001211,,~,,,inhibitor,100,190.0,%,2,1-Monostearin,,,Caco-2 cell; Daunomycin accumulation,Caco-2,mbcd0005183,,,,human,mbds0003,v2007,2013-12-09 20:04:02
mbbd000001259,mbcd0000028,mbtp000001,mbrf0001211,,~,,,inhibitor,100,275.0,%,7,1-Monoolein,,,Caco-2 cell; Daunomycin accumulation,Caco-2,mbcd0005183,,,,human,mbds0003,v2007,2013-12-09 20:04:03
mbbd000001260,mbcd0000025,mbtp000001,mbrf0001211,,~,,,inhibitor,100,315.0,%,7,1-Monolinolein,,,Caco-2 cell; Daunomycin accumulation,Caco-2,mbcd0005183,,,,human,mbds0003,v2007,2013-12-09 20:54:45
mbbd000001262,mbcd0000023,mbtp000001,mbrf0001211,,~,,,inhibitor,100,140.0,%,15,1-Monocaprylin,,,Caco-2 cell; Daunomycin accumulation,Caco-2,mbcd0005183,,,,human,mbds0003,v2007,2013-12-09 20:54:45
mbbd000001263,mbcd0000022,mbtp000001,mbrf0001211,,~,,,inhibitor,100,175.0,%,25,1-Monocaprin,,,Caco-2 cell; Daunomycin accumulation,Caco-2,mbcd0005183,,,,human,mbds0003,v2007,2013-12-09 20:54:45
mbbd000001264,mbcd0000024,mbtp000001,mbrf0001211,,~,,,inhibitor,100,220.0,%,10,1-Monolaurin,,,Caco-2 cell; Daunomycin accumulation,Caco-2,mbcd0005183,,,,human,mbds0003,v2007,2013-12-09 20:54:46
mbbd000001265,mbcd0000027,mbtp000001,mbrf0001211,,~,,,inhibitor,100,210.0,%,10,1-Monomyristin,,,Caco-2 cell; Daunomycin accumulation,Caco-2,mbcd0005183,,,,human,mbds0003,v2007,2013-12-09 20:54:46
mbbd000001269,mbcd0001532,mbtp000001,mbrf0001212,,,,,substrate,,,,,paclitaxel,,,KB-TAX50 cell; drug resistance,KB/TAX50,,,,,human,mbds0003,v2007,2014-01-17 20:49:39
mbbd000001270,mbcd0001135,mbtp000001,mbrf0001212,,,,,substrate,,,,,vincristine,,,KB-TAX50 cell; drug resistance,KB/TAX50,,,,,human,mbds0003,v2007,2014-01-17 20:49:39
mbbd000001271,mbcd0002667,mbtp000001,mbrf0001212,,,,,substrate,,,,,colchicine,,,KB-TAX50 cell; drug resistance,KB/TAX50,,,,,human,mbds0003,v2007,2014-01-17 20:49:39
mbbd000001273,mbcd0001532,mbtp000001,mbrf0001212,,,,,substrate,,,,,paclitaxel,,,KB-VIN10 cell; drug resistance,KB/VIN10,,,,,human,mbds0003,v2007,2014-01-17 20:49:39
mbbd000001274,mbcd0001135,mbtp000001,mbrf0001212,,,,,substrate,,,,,vincristine,,,KB-VIN10 cell; drug resistance,KB/VIN10,,,,,human,mbds0003,v2007,2014-01-17 20:49:39
mbbd000001275,mbcd0002667,mbtp000001,mbrf0001212,,,,,substrate,,,,,colchicine,,,KB-VIN10 cell; drug resistance,KB/VIN10,,,,,human,mbds0003,v2007,2014-01-17 20:49:39
mbbd000001280,mbcd0027062,mbtp000001,mbrf0001213,,=,,,inhibitor,25,4.78,microM,,verapamil,,,MES-SA/DX5 cell; drug resistance (paclitaxel),MES-SA/DX5,mbcd0001532,,,,human,mbds0003,v2007,2013-12-10 22:19:00
mbbd000001281,mbcd0002823,mbtp000001,mbrf0001213,,=,,,inhibitor,25,5.33,microM,,S-verapamil,,,MES-SA/DX5 cell; drug resistance (paclitaxel),MES-SA/DX5,mbcd0001532,,,,human,mbds0003,v2007,2013-12-10 22:19:00
mbbd000001282,mbcd0027062,mbtp000001,mbrf0001213,,=,,,inhibitor,25,5.52,microM,,verapamil,,,MES-SA/DX5 cell; drug resistance (paclitaxel),MES-SA/DX5,mbcd0001532,,,,human,mbds0003,v2007,2013-12-10 22:19:00
mbbd000001286,mbcd0027062,mbtp000001,mbrf0001213,,=,,,inhibitor,25,2.21,microM,,verapamil,,,HCT15/CL02 cell; drug resistance (paclitaxel),HCT15/CL02,mbcd0001532,,,,human,mbds0003,v2007,2013-12-10 22:19:00
mbbd000001287,mbcd0002823,mbtp000001,mbrf0001213,,=,,,inhibitor,25,2.44,microM,,S-verapamil,,,HCT15/CL02 cell; drug resistance (paclitaxel),HCT15/CL02,mbcd0001532,,,,human,mbds0003,v2007,2013-12-10 22:19:00
mbbd000001288,mbcd0002298,mbtp000001,mbrf0001213,,=,,,inhibitor,25,2.58,microM,,R-verapamil,,,HCT15/CL02 cell; drug resistance (paclitaxel),HCT15/CL02,mbcd0001532,,,,human,mbds0003,v2007,2013-12-10 22:19:00
mbbd000001290,mbcd0000082,mbtp000001,mbrf0001215,,=,,,inhibitor,25,0.9,microM,,23,,,KB/MDR cell; increase in Vinblastine intracellular accumulation,KB/MDR,mbcd0001151,,,,human,mbds0003,v2007,2013-12-09 20:15:03
mbbd000001291,mbcd0004720,mbtp000001,mbrf0001215,,=,,,inhibitor,25,41.0,microM,,Baicalein,,,KB/MDR cell; increase in Vinblastine intracellular accumulation,KB/MDR,mbcd0001151,,,,human,mbds0003,v2007,2013-12-09 20:15:04
mbbd000001292,mbcd0001532,mbtp000001,mbrf0001216,,,,,substrate,,,,,taxol,,,R-HepG2 cell; drug resistance,HepG2,,,,,human,mbds0003,v2007,2013-12-09 20:15:01
mbbd000001293,mbcd0001117,mbtp000001,mbrf0001216,,,,,substrate,,,,,CDDP,,,R-HepG2 cell; drug resistance,HepG2,,,,,human,mbds0003,v2007,2013-12-09 20:15:02
mbbd000001294,mbcd0025844,mbtp000001,mbrf0001216,,,,,substrate,,,,,Dox,,,R-HepG2 cell; drug resistance,HepG2,,,,,human,mbds0003,v2007,2013-12-09 20:15:04
mbbd000001299,mbcd0002422,mbtp000001,mbrf0001220,,~,,,non-inhibitor,3,1.0,%,,Fumitremorgin C,-(10 microM),,MCF7/R cell; efflux of 3microM mitoxantrone,MCF7/R,mbcd0002981,,,,human,mbds0003,v2007,2013-12-09 20:15:00
mbbd000001300,mbcd0003154,mbtp000001,mbrf0001220,,~,,,non-inhibitor,3,1.0,%,,Probenecid,-(1mM),,MCF7/R cell; efflux of 3microM mitoxantrone,MCF7/R,mbcd0002981,,,,human,mbds0003,v2007,2013-12-09 19:53:58
mbbd000001301,mbcd0000721,mbtp000001,mbrf0001220,,~,,,inhibitor,3,45.0,%,1,PSC-833,+(2.5 microM),,MCF7/R cell; efflux of 3microM mitoxantrone,MCF7/R,mbcd0002981,,,,human,mbds0003,v2007,2013-12-09 19:53:59
mbbd000001303,mbcd0000648,mbtp000001,mbrf0001220,,~,,,inhibitor,3,40.0,%,2,Ortataxel,+(10 microM),,MCF7/R cell; efflux of mitoxantrone (Mitoxantrone: 3microM) ,MCF7/R,mbcd0002981,,,,human,mbds0003,v2007,2013-12-09 19:53:59
mbbd000001304,mbcd0000190,mbtp000001,mbrf0001221,,=,,,inhibitor,33,74.0,%,,VX-710,increase in uptake,,"A2780/Dx5b cell; increase in mitoxantrone intracellular accumulation (Mitoxantrone: 3 microM, VX-710: 2.5 microM)",A2780/Dx5b,mbcd0002981,,,,human,mbds0003,v2007,2013-12-09 19:53:59
mbbd000001305,mbcd0000841,mbtp000001,mbrf0001222,,,,,substrate,,,,,tetramethylrosamine,,,membrane vesicles from reconsituted PMPC proteoliposomes containing P-glycoprotein; efflux of Tetramethylrosamine,PMPC proteoliposomes,,,,,human,mbds0003,v2007,2013-11-24 23:55:08
mbbd000001306,mbcd0000768,mbtp000001,mbrf0001222,,=,,,inhibitor,29,0.45,micromol L-1,0.1,Mama5,,,membrane vesicles from MDR1-expressing CH^RB39 cells; efflux of Colchicine,CH^RB39,mbcd0002667,,,,human,mbds0003,v2007,2013-07-17 23:26:15
mbbd000001307,mbcd0001135,mbtp000001,mbrf0001223,,=,,,non-inhibitor,100,132.0,%,25,vincristine,,,"MDR1-expressing NIH-3T3 cell; increase in Calcein-AM intracellular accumulation (Calcein-AM: 0.5 microM, Vincristine: 200 microM)",NIH-3T3,mbcd0000212,,,,human,mbds0003,v2007,2013-12-09 19:54:00
mbbd000001308,mbcd0001151,mbtp000001,mbrf0001223,,=,,,inhibitor,100,12650.0,%,2834,Vinblastine,,,"MDR1-expressing NIH-3T3 cell; increase in Calcein-AM intracellular accumulation (Calcein-AM: 0.5 microM, Vinblastine: 70 microM)",NIH-3T3,mbcd0000212,,,,human,mbds0003,v2007,2013-12-09 19:53:55
mbbd000001309,mbcd0027062,mbtp000001,mbrf0001223,,=,,,inhibitor,100,8111.0,%,3721,Verapamil,,,"MDR1-expressing NIH-3T3 cell; increase in Calcein-AM intracellular accumulation (Calcein-AM: 0.5 microM, Verapamil: 75 microM)",NIH-3T3,mbcd0000212,,,,human,mbds0003,v2007,2013-12-09 19:53:57
mbbd000001310,mbcd0026585,mbtp000001,mbrf0001223,,=,,,inhibitor,100,16010.0,%,4820,Valinomycin,,,"MDR1-expressing NIH-3T3 cell; increase in Calcein-AM intracellular accumulation (Calcein-AM: 0.5 microM, Valinomycin: 10 microM)",NIH-3T3,mbcd0000212,,,,human,mbds0003,v2007,2013-12-09 20:50:50
mbbd000001311,mbcd0000878,mbtp000001,mbrf0001223,,=,,,inhibitor,100,10723.0,%,1405,Tween 20,,,"MDR1-expressing NIH-3T3 cell; increase in Calcein-AM intracellular accumulation (Calcein-AM: 0.5 microM, Tween 20: 1.4_10-3a%)",NIH-3T3,mbcd0000212,,,,human,mbds0003,v2007,2013-12-09 20:50:49
mbbd000001312,mbcd0003881,mbtp000001,mbrf0001223,,=,,,inhibitor,100,7210.0,%,,Trimipramine,,,"MDR1-expressing NIH-3T3 cell; increase in Calcein-AM intracellular accumulation (Calcein-AM: 0.5 microM, Trimipramine: 20 microM)",NIH-3T3,mbcd0000212,,,,human,mbds0003,v2007,2013-12-09 20:50:49
mbbd000001313,mbcd0018598,mbtp000001,mbrf0001223,,=,,,inhibitor,100,4810.0,%,,Tetracaine,,,"MDR1-expressing NIH-3T3 cell; increase in Calcein-AM intracellular accumulation (Calcein-AM: 0.5 microM, Tetracaine: 320 microM)",NIH-3T3,mbcd0000212,,,,human,mbds0003,v2007,2013-12-09 20:50:49
mbbd000001314,mbcd0001532,mbtp000001,mbrf0001223,,=,,,non-inhibitor,100,103.0,%,2,taxol,,,"MDR1-expressing NIH-3T3 cell; increase in Calcein-AM intracellular accumulation (Calcein-AM: 0.5 microM, Taxol: 20 microM)",NIH-3T3,mbcd0000212,,,,human,mbds0003,v2007,2013-12-09 20:50:49
mbbd000001315,mbcd0002889,mbtp000001,mbrf0001223,,=,,,inhibitor,100,469.0,%,260,Tamoxifen,,,"MDR1-expressing NIH-3T3 cell; increase in Calcein-AM intracellular accumulation (Calcein-AM: 0.5 microM, Tamoxifen: 20 microM)",NIH-3T3,mbcd0000212,,,,human,mbds0003,v2007,2013-12-09 20:50:49
mbbd000001316,mbcd0000721,mbtp000001,mbrf0001223,,=,,,inhibitor,100,18370.0,%,3180,PSC-833,,,"MDR1-expressing NIH-3T3 cell; increase in Calcein-AM intracellular accumulation (Calcein-AM: 0.5 microM, PSC-833: 8 microM)",NIH-3T3,mbcd0000212,,,,human,mbds0003,v2007,2013-12-09 20:50:49
mbbd000001317,mbcd0001941,mbtp000001,mbrf0001223,,=,,,inhibitor,100,7810.0,%,2880,Reserpine,,,"MDR1-expressing NIH-3T3 cell; increase in Calcein-AM intracellular accumulation (Calcein-AM: 0.5 microM, Reserpine: 40 microM)",NIH-3T3,mbcd0000212,,,,human,mbds0003,v2007,2013-12-09 20:17:54
mbbd000001319,mbcd0001092,mbtp000001,mbrf0001223,,=,,,inhibitor,100,2780.0,%,255,Quinine,,,"MDR1-expressing NIH-3T3 cell; increase in Calcein-AM intracellular accumulation (Calcein-AM: 0.5 microM, Quinine: 20 microM)",NIH-3T3,mbcd0000212,,,,human,mbds0003,v2007,2013-12-09 20:17:53
mbbd000001320,mbcd0027018,mbtp000001,mbrf0001223,,=,,,inhibitor,100,5774.0,%,1160,Quinidine,,,"MDR1-expressing NIH-3T3 cell; increase in Calcein-AM intracellular accumulation (Calcein-AM: 0.5 microM, Quinidine: 20 microM)",NIH-3T3,mbcd0000212,,,,human,mbds0003,v2007,2013-12-09 21:01:20
mbbd000001321,mbcd0003120,mbtp000001,mbrf0001223,,=,,,inhibitor,100,6185.0,%,2490,Quercetin,,,"MDR1-expressing NIH-3T3 cell; increase in Calcein-AM intracellular accumulation (Calcein-AM: 0.5 microM, Quercetin: 200 microM)",NIH-3T3,mbcd0000212,,,,human,mbds0003,v2007,2013-12-09 21:01:20
mbbd000001322,mbcd0000723,mbtp000001,mbrf0001223,,=,,,non-inhibitor,100,145.0,%,35,Puromycin,,,"MDR1-expressing NIH-3T3 cell; increase in Calcein-AM intracellular accumulation (Calcein-AM: 0.5 microM, Puromycin: 20 microM)",NIH-3T3,mbcd0000212,,,,human,mbds0003,v2007,2013-12-09 21:01:18
mbbd000001323,mbcd0002488,mbtp000001,mbrf0001223,,=,,,inhibitor,100,5152.0,%,,propranolol,,,"MDR1-expressing NIH-3T3 cell; increase in Calcein-AM intracellular accumulation (Calcein-AM: 0.5 microM, Propranolol: 500 microM)",NIH-3T3,mbcd0000212,,,,human,mbds0003,v2007,2013-12-09 21:01:19
mbbd000001324,mbcd0001892,mbtp000001,mbrf0001223,,=,,,inhibitor,100,660.0,%,176,Progesterone,,,"MDR1-expressing NIH-3T3 cell; increase in Calcein-AM intracellular accumulation (Calcein-AM: 0.5 microM, Progesterone: 10 microM)",NIH-3T3,mbcd0000212,,,,human,mbds0003,v2007,2013-12-09 21:01:21
mbbd000001325,mbcd0003058,mbtp000001,mbrf0001223,,=,,,inhibitor,100,881.0,%,,Prednisone,,,"MDR1-expressing NIH-3T3 cell; increase in Calcein-AM intracellular accumulation (Calcein-AM: 0.5 microM, Prednisone: 200 microM)",NIH-3T3,mbcd0000212,,,,human,mbds0003,v2007,2013-12-09 21:01:21
mbbd000001326,mbcd0003024,mbtp000001,mbrf0001223,,=,,,non-inhibitor,100,168.0,%,11,Prazosin,,,"MDR1-expressing NIH-3T3 cell; increase in Calcein-AM intracellular accumulation (Calcein-AM: 0.5 microM, Prazosin: 10 microM)",NIH-3T3,mbcd0000212,,,,human,mbds0003,v2007,2013-12-09 21:01:20
mbbd000001327,mbcd0000642,mbtp000001,mbrf0001223,,=,,,non-inhibitor,100,95.0,%,4,Oligomycin,,,"MDR1-expressing NIH-3T3 cell; increase in Calcein-AM intracellular accumulation (Calcein-AM: 0.5 microM, Oligomycin: 5 microM)",NIH-3T3,mbcd0000212,,,,human,mbds0003,v2007,2013-12-09 21:01:21
mbbd000001328,mbcd0003882,mbtp000001,mbrf0001223,,=,,,inhibitor,100,8332.0,%,1692,o-amsacrine,,,"MDR1-expressing NIH-3T3 cell; increase in Calcein-AM intracellular accumulation (Calcein-AM: 0.5 microM, o-Amsacrine: 5 microM)",NIH-3T3,mbcd0000212,,,,human,mbds0003,v2007,2013-12-09 21:01:21
mbbd000001329,mbcd0000630,mbtp000001,mbrf0001223,,=,,,inhibitor,100,11900.0,%,544,Nonidet P-40,,,"MDR1-expressing NIH-3T3 cell; increase in Calcein-AM intracellular accumulation (Calcein-AM: 0.5 microM, Nonidet P-40: 6_10-4a%)",NIH-3T3,mbcd0000212,,,,human,mbds0003,v2007,2013-12-09 21:01:22
mbbd000001330,mbcd0007511,mbtp000001,mbrf0001223,,=,,,inhibitor,100,8057.0,%,2147,Nifedipine,,,"MDR1-expressing NIH-3T3 cell; increase in Calcein-AM intracellular accumulation (Calcein-AM: 0.5 microM, Nifedipine: 125 microM)",NIH-3T3,mbcd0000212,,,,human,mbds0003,v2007,2013-12-09 20:57:40
mbbd000001331,mbcd0000998,mbtp000001,mbrf0001223,,=,,,non-inhibitor,100,116.0,%,22,Mitomycin,,,"MDR1-expressing NIH-3T3 cell; increase in Calcein-AM intracellular accumulation (Calcein-AM: 0.5 microM, Mitomycin C: 20 microM)",NIH-3T3,mbcd0000212,,,,human,mbds0003,v2007,2013-12-09 20:57:40
mbbd000001332,mbcd0002820,mbtp000001,mbrf0001223,,=,,,inhibitor,100,7180.0,%,,Mibefradil,,,"MDR1-expressing NIH-3T3 cell; increase in Calcein-AM intracellular accumulation (Calcein-AM: 0.5 microM, Mibefradil: 18 microM)",NIH-3T3,mbcd0000212,,,,human,mbds0003,v2007,2013-12-09 20:57:40
mbbd000001333,mbcd0020385,mbtp000001,mbrf0001223,,=,,,inhibitor,100,7150.0,%,,Maprotiline,,,"MDR1-expressing NIH-3T3 cell; increase in Calcein-AM intracellular accumulation (Calcein-AM: 0.5 microM, Maprotiline: 20 microM)",NIH-3T3,mbcd0000212,,,,human,mbds0003,v2007,2013-12-09 20:57:40
mbbd000001334,mbcd0000552,mbtp000001,mbrf0001223,,=,,,inhibitor,100,6703.0,%,1348,m-Amsacrine,,,"MDR1-expressing NIH-3T3 cell; increase in Calcein-AM intracellular accumulation (Calcein-AM: 0.5 microM, m-Amsacrine: 5 microM)",NIH-3T3,mbcd0000212,,,,human,mbds0003,v2007,2013-12-09 20:57:42
mbbd000001335,mbcd0003884,mbtp000001,mbrf0001223,,=,,,non-inhibitor,100,182.0,%,48,Lidocaine,,,"MDR1-expressing NIH-3T3 cell; increase in Calcein-AM intracellular accumulation (Calcein-AM: 0.5 microM, Lidocaine: 20 microM)",NIH-3T3,mbcd0000212,,,,human,mbds0003,v2007,2013-12-09 20:57:41
mbbd000001336,mbcd0017104,mbtp000001,mbrf0001223,,=,,,inhibitor,100,11022.0,%,2932,Ketoconazole,,,"MDR1-expressing NIH-3T3 cell; increase in Calcein-AM intracellular accumulation (Calcein-AM: 0.5 microM, Ketoconazole: 50 microM)",NIH-3T3,mbcd0000212,,,,human,mbds0003,v2007,2013-12-09 20:57:43
mbbd000001337,mbcd0001172,mbtp000001,mbrf0001223,,=,,,inhibitor,100,9727.0,%,1769,Ivermectin,,,"MDR1-expressing NIH-3T3 cell; increase in Calcein-AM intracellular accumulation (Calcein-AM: 0.5 microM, Ivermectin: 20 microM)",NIH-3T3,mbcd0000212,,,,human,mbds0003,v2007,2013-12-09 20:51:14
mbbd000001338,mbcd0003898,mbtp000001,mbrf0001223,,=,,,inhibitor,100,7930.0,%,,Imipramine,,,"MDR1-expressing NIH-3T3 cell; increase in Calcein-AM intracellular accumulation (Calcein-AM: 0.5 microM, Imipramine: 20 microM)",NIH-3T3,mbcd0000212,,,,human,mbds0003,v2007,2013-12-09 20:15:59
mbbd000001339,mbcd0000474,mbtp000001,mbrf0001223,,=,,,non-inhibitor,100,113.0,%,23,Hoechst 33342,,,"MDR1-expressing NIH-3T3 cell; increase in Calcein-AM intracellular accumulation (Calcein-AM: 0.5 microM, Hoechst 33342: 50 microM)",NIH-3T3,mbcd0000212,,,,human,mbds0003,v2007,2013-12-09 20:15:58
mbbd000001340,mbcd0001777,mbtp000001,mbrf0001223,,=,,,inhibitor,100,3710.0,%,,Haloperidol,,,"MDR1-expressing NIH-3T3 cell; increase in Calcein-AM intracellular accumulation (Calcein-AM: 0.5 microM, Haloperidol: 80 microM)",NIH-3T3,mbcd0000212,,,,human,mbds0003,v2007,2013-12-09 21:00:49
mbbd000001341,mbcd0000463,mbtp000001,mbrf0001223,,=,,,non-inhibitor,100,61.0,%,,Gramicidin D,,,"MDR1-expressing NIH-3T3 cell; increase in Calcein-AM intracellular accumulation (Calcein-AM: 0.5 microM, Gramicidin D: 10 microM)",NIH-3T3,mbcd0000212,,,,human,mbds0003,v2007,2013-12-09 21:00:49
mbbd000001342,mbcd0003116,mbtp000001,mbrf0001223,,=,,,inhibitor,100,218.0,%,48,Genistein,,,"MDR1-expressing NIH-3T3 cell; increase in Calcein-AM intracellular accumulation (Calcein-AM: 0.5 microM, Genistein: 40 microM)",NIH-3T3,mbcd0000212,,,,human,mbds0003,v2007,2013-12-09 21:00:49
mbbd000001343,mbcd0004758,mbtp000001,mbrf0001223,,=,,,inhibitor,100,1674.0,%,633,Galangin,,,"MDR1-expressing NIH-3T3 cell; increase in Calcein-AM intracellular accumulation (Calcein-AM: 0.5 microM, Galangin: 50 microM)",NIH-3T3,mbcd0000212,,,,human,mbds0003,v2007,2013-12-09 20:54:18
mbbd000001344,mbcd0002466,mbtp000001,mbrf0001223,,=,,,non-inhibitor,100,99.0,%,,Etoposide,,,"MDR1-expressing NIH-3T3 cell; increase in Calcein-AM intracellular accumulation (Calcein-AM: 0.5 microM, Etoposide: 200 microM)",NIH-3T3,mbcd0000212,,,,human,mbds0003,v2007,2013-12-09 20:54:12
mbbd000001345,mbcd0000373,mbtp000001,mbrf0001223,,=,,,inhibitor,100,2517.0,%,645,Emetine,,,"MDR1-expressing NIH-3T3 cell; increase in Calcein-AM intracellular accumulation (Calcein-AM: 0.5 microM, Emetine: 200 microM)",NIH-3T3,mbcd0000212,,,,human,mbds0003,v2007,2013-12-09 20:54:13
mbbd000001346,mbcd0002995,mbtp000001,mbrf0001223,,=,,,inhibitor,100,7960.0,%,,Desipramine,,,"MDR1-expressing NIH-3T3 cell; increase in Calcein-AM intracellular accumulation (Calcein-AM: 0.5 microM, Desipramine: 20 microM)",NIH-3T3,mbcd0000212,,,,human,mbds0003,v2007,2013-12-09 21:00:48
mbbd000001347,mbcd0000311,mbtp000001,mbrf0001223,,=,,,inhibitor,100,12370.0,%,2222,CsA,,,"MDR1-expressing NIH-3T3 cell; increase in Calcein-AM intracellular accumulation (Calcein-AM: 0.5 microM, Cyclosporin A: 10 microM)",NIH-3T3,mbcd0000212,,,,human,mbds0003,v2007,2013-12-09 21:00:48
mbbd000001348,mbcd0002667,mbtp000001,mbrf0001223,,=,,,non-inhibitor,100,92.0,%,,Colchicine,,,"MDR1-expressing NIH-3T3 cell; increase in Calcein-AM intracellular accumulation (Calcein-AM: 0.5 microM, Colchicine: 100 microM)",NIH-3T3,mbcd0000212,,,,human,mbds0003,v2007,2013-12-09 21:00:49
mbbd000001349,mbcd0019625,mbtp000001,mbrf0001223,,=,,,inhibitor,100,1048.0,%,190,Benzocaine,,,"MDR1-expressing NIH-3T3 cell; increase in Calcein-AM intracellular accumulation (Calcein-AM: 0.5 microM, Benzocaine: 20 microM)",NIH-3T3,mbcd0000212,,,,human,mbds0003,v2007,2013-12-09 21:00:49
mbbd000001350,mbcd0001372,mbtp000001,mbrf0001223,,=,,,inhibitor,100,445.0,%,248,Actinomycin D,,,"MDR1-expressing NIH-3T3 cell; increase in Calcein-AM intracellular accumulation (Calcein-AM: 0.5 microM, Actinomycin D: 40 microM)",NIH-3T3,mbcd0000212,,,,human,mbds0003,v2007,2013-12-09 20:14:10
mbbd000001356,mbcd0027062,mbtp000001,mbrf0001225,,=,,,inhibitor,25,8.44,microM,,Verapamil,,,Caco-2 cell; transepithelial transport of fexofenadine,Caco-2,mbcd0001797,,,,human,mbds0003,v2007,2013-12-09 20:14:11
mbbd000001357,mbcd0001797,mbtp000001,mbrf0001225,,,,,substrate,,,,,fexofenadine,,,Caco-2 cells; transepithelial transport,Caco-2,,,,,human,mbds0003,v2007,2013-12-08 08:56:23
mbbd000001358,mbcd0000283,mbtp000001,mbrf0001226,,=,,,substrate,17,257.0,nM,,Coelenterazine,,,KB 8-5-11 Rluc Cells; efflux,Rluc,,470,nM,,human,mbds0003,v2007,2013-12-09 20:14:09
mbbd000001359,mbcd0000726,mbtp000001,mbrf0001227,,,,,inhibitor,,,,,PND,,,K562/A02 cell; increase in Rhodamine 123 intracellular accumulation,K562/A02,mbcd0000746,,,,human,mbds0003,v2007,2013-12-09 20:14:08
mbbd000001360,mbcd0000726,mbtp000001,mbrf0001227,,,,,inhibitor,,,,,PND,Growth inhibition,,MCF-7/ADR cell; drug resistance (doxorubicin),MCF7/ADR,mbcd0025844,,,,human,mbds0003,v2007,2013-12-09 21:00:30
mbbd000001361,mbcd0000726,mbtp000001,mbrf0001227,,,,,inhibitor,,,,,PND,Growth inhibition,,K562/A02 cell; drug resistance (doxorubicin),K562/A02,mbcd0025844,,,,human,mbds0003,v2007,2013-12-09 21:00:30
mbbd000001362,mbcd0004764,mbtp000001,mbrf0001228,,,,,substrate,,,,,PCB-126,,,LLC-MDR1; transepithelial transport (basal to apical),LLC-PK1,,,,,human,mbds0003,v2007,2013-12-09 21:00:30
mbbd000001369,mbcd0000667,mbtp000001,mbrf0001230,,,,,substrate,,,,,pazufloxacin,,,K562/ADR cell; cell accumulation,K562,,,,,human,mbds0003,v2007,2013-12-09 21:00:30
mbbd000001370,mbcd0000472,mbtp000001,mbrf0001231,,,,,non-inhibitor,,,,,HA,,,MDR1-expressing MDCK cell; transepithelial transport of erythromycin,MDCK,mbcd0000937,2,mM,,human,mbds0003,v2007,2013-12-09 20:12:54
mbbd000001372,mbcd0000051,mbtp000001,mbrf0001231,,,,,non-inhibitor,,,,,CMPF,,,MDR1-expressing MDCK cell; transepithelial transport of erythromycin,MDCK,mbcd0000937,0.5; 1,mM,,human,mbds0003,v2007,2013-12-09 20:12:55
mbbd000001373,mbcd0000937,mbtp000001,mbrf0001231,,,,,substrate,,,,,Ery,,,MDR1-expressing MDCK cell; transepithelial transport,MDCK,,,,,human,mbds0003,v2007,2013-12-09 20:12:54
mbbd000001374,mbcd0005183,mbtp000001,mbrf0001232,,~,,,inducer,100,30.0,%,5,daunorubicin,,,MDR1-expressing MDCK cell; transepithelial transport of Hoechst 33342,MDCK,mbcd0000474,80,microM,,human,mbds0003,v2007,2013-12-09 20:12:52
mbbd000001375,mbcd0001808,mbtp000001,mbrf0001232,,=,,,inhibitor,25,0.14,mM,0.02,GF-120918,,,MDR1-expressing MDCK cell; transepithelial transport of Hoechst 33342,MDCK,mbcd0000474,2,microM,,human,mbds0003,v2007,2013-12-09 20:12:52
mbbd000001376,mbcd0005183,mbtp000001,mbrf0001232,,~,,,inhibitor,100,130.0,%,5,daunorubicin,,,MDR1-expressing MDCK cell; transepithelial transport of Rhodamine 123,MDCK,mbcd0000746,80,microM,,human,mbds0003,v2007,2013-12-09 20:12:53
mbbd000001377,mbcd0000474,mbtp000001,mbrf0001232,,~,,,non-inhibitor,100,100.0,%,5,Hoechst 33342,,,MDR1-expressing MDCK cell; transepithelial transport of Rhodamine 123,MDCK,mbcd0000746,5,microM,,human,mbds0003,v2007,2013-12-09 20:12:52
mbbd000001378,mbcd0001808,mbtp000001,mbrf0001232,,=,,,inhibitor,25,0.14,mM,0.03,GF-120918,,,MDR1-expressing MDCK cell; transepithelial transport of Rhodamine 123,MDCK,mbcd0000746,2,microM,,human,mbds0003,v2007,2013-12-09 20:12:52
mbbd000001379,mbcd0000474,mbtp000001,mbrf0001232,,,,,substrate,,,,,Hoechst 33342,,,MDR1-expressing MDCK cell; transepithelial transport,MDCK,,,,,human,mbds0003,v2007,2013-12-09 20:12:51
mbbd000001380,mbcd0000746,mbtp000001,mbrf0001232,,,,,substrate,,,,,rhodamine 123,,,MDR1-expressing MDCK cell; transepithelial transport,MDCK,,,,,human,mbds0003,v2007,2013-12-09 20:00:15
mbbd000001383,mbcd0002828,mbtp000001,mbrf0001234,,,,,substrate,,,,,imatinib,,,MDR1-transfected MDCKII cell; transepithelial transport,MDCKII,,,,,human,mbds0003,v2007,2013-12-09 20:00:17
mbbd000001384,mbcd0000796,mbtp000001,mbrf0001235,,,,,substrate,,,,,substance P,,,membrane vesicles prepared from human MDR1 transfected KB3-1 cell; uptake,KB3-1,,,,,human,mbds0003,v2007,2013-12-09 20:00:17
mbbd000001386,mbcd0000796,mbtp000001,mbrf0001235,,,,,substrate,,,,,substance P,,,membrane vesicles prepared from K562/ADM cell; uptake,K562,,,,,human,mbds0003,v2007,2013-12-09 20:00:17
mbbd000001388,mbcd0002241,mbtp000001,mbrf0001236,,=,,,inhibitor,25,1.7,microM,,Lopinavir,,,Caco-2 cell; inhibition of Rhodamine 123 efflux,Caco-2,mbcd0000746,,,,human,mbds0003,v2007,2013-12-09 20:00:17
mbbd000001389,mbcd0002104,mbtp000001,mbrf0001237,,,,,inhibitor,,,,,XR9576,Growth inhibition,,NCI/ADRRes cell; drug resistance (vinblastine),NCI/ADRRes,mbcd0001151,,,,human,mbds0003,v2007,2013-12-09 20:00:17
mbbd000001390,mbcd0000127,mbtp000001,mbrf0001238,,,,,inhibitor,,,,,ABA,Growth inhibition,,HepG2-DR cell; drug resistance (vinblastine),HepG2-DR,mbcd0001151,,,,human,mbds0003,v2007,2013-12-09 20:52:36
mbbd000001391,mbcd0000127,mbtp000001,mbrf0001238,,,,,inhibitor,,,,,ABA,Growth inhibition,,K562-DR cell; drug resistance (vinblastine),K562/DR,mbcd0001151,,,,human,mbds0003,v2007,2013-12-09 20:52:36
mbbd000001392,mbcd0001050,mbtp000001,mbrf0001239,,,,,substrate,,,,,digoxin,+(58.8nM),,LLC-GA5-COL150 cell; transepithelial transport (basal to apical),LLC-GA5-COL150,,,,,human,mbds0003,v2007,2013-12-09 20:58:28
mbbd000001393,mbcd0017980,mbtp000001,mbrf0001239,,,,,non-substrate,,,,,ciprofloxacin,-(2 microM),,LLC-GA5-COL150 cell; transepithelial transport (basal to apical),LLC-GA5-COL150,,,,,human,mbds0003,v2007,2013-12-09 20:52:36
mbbd000001394,mbcd0001470,mbtp000001,mbrf0001239,,,,,substrate,,,,,levofloxacin,+(5 microM),,LLC-GA5-COL150 cell; transepithelial transport (basal to apical),LLC-GA5-COL150,,,,,human,mbds0003,v2007,2013-12-09 20:52:36
mbbd000001395,mbcd0001038,mbtp000001,mbrf0001239,,,,,substrate,,,,,grepafloxacin,+(5 microM),,LLC-GA5-COL150 cell; transepithelial transport (basal to apical),LLC-GA5-COL150,,,,,human,mbds0003,v2007,2013-12-09 20:52:36
mbbd000001396,mbcd0003076,mbtp000001,mbrf0001240,,~,,,inhibitor,100,140.0,%,,Naringenin,,,MDR1-expressing MDCK cell; cell accumulation of colchicine,MDCK,mbcd0002667,100,microM,,human,mbds0003,v2007,2013-12-09 20:52:36
mbbd000001397,mbcd0003120,mbtp000001,mbrf0001240,,~,,,non-inhibitor,100,120.0,%,,Quercetin,,,MDR1-expressing MDCK cell; cell accumulation of colchicine,MDCK,mbcd0002667,100,microM,,human,mbds0003,v2007,2013-12-09 20:52:36
mbbd000001398,mbcd0003076,mbtp000001,mbrf0001240,,,,,substrate,,,,,naringenin,,,MDR1-expressing MDCK cell; cell accumulation,MDCK,,,,,human,mbds0003,v2007,2013-12-09 20:52:37
mbbd000001399,mbcd0003120,mbtp000001,mbrf0001240,,,,,substrate,,,,,quercetin,,,MDR1-expressing MDCK cell; cell accumulation,MDCK,,,,,human,mbds0003,v2007,2013-12-09 20:52:37
mbbd000001402,mbcd0001416,mbtp000001,mbrf0001243,,=,,,inducer,111,3.5,fold increase,2.1,Rifampin,increase in protein level,,"in vivo, quantitative immunohistochemistry; Western",,,,,,human,mbds0003,v2007,2013-12-09 20:13:11
mbbd000001404,mbcd0002104,mbtp000001,mbrf0001244,,,,,inhibitor,,,,,Tariquidar,,,P-gp positive tumor; Vinorelbine-induced cytotoxicity,tumour cells,,,,,human,mbds0003,v2007,2013-12-09 20:13:10
mbbd000001410,mbcd0024477,mbtp000001,mbrf0001245,,,,,non-substrate,,,,,sphingosine,,,Caco-2; cell accumulation (digoxin-sensitive),Caco-2,,,,,human,mbds0003,v2007,2013-12-09 20:13:25
mbbd000001411,mbcd0008620,mbtp000001,mbrf0001245,,,,,substrate,,,,,sphinganine,,,Caco-2; cell accumulation (digoxin-sensitive),Caco-2,,,,,human,mbds0003,v2007,2013-12-09 20:50:50
mbbd000001419,mbcd0001120,mbtp000001,mbrf0001248,,~,,,inhibitor,100,0.6,pmol/well,,Caspofungin,,,KB-V1 cell; cell accumulation of vinblastine,KB-V1,mbcd0001151,100,microM,,human,mbds0003,v2007,2013-12-09 20:50:50
mbbd000001420,mbcd0003126,mbtp000001,mbrf0001249,,~,,,substrate,83,0.4,microL min-1 (mg protein)-1,0.1,PRA,(+),,OATP_B1/MDR1 double transfected MDCK II cells; transepithelial transport (basal to apical),MDCKII,,,,,human,mbds0003,v2007,2013-11-26 21:53:24
mbbd000001421,mbcd0023123,mbtp000001,mbrf0001249,,~,,,substrate,83,0.65,microL min-1 (mg protein)-1,0.6,CER,(+),,OATPB1/MDR1 double transfected MDCK II cells; transepithelial transport (basal to apical),MDCKII,,,,,human,mbds0003,v2007,2013-11-26 21:53:24
mbbd000001422,mbcd0003075,mbtp000001,mbrf0001249,,~,,,substrate,83,0.3,microL min-1 (mg protein)-1,0.05,ES,(+),,OATP_B1/MDR1 double transfected MDCK II cells; transepithelial transport (basal to apical),MDCKII,,,,,human,mbds0003,v2007,2013-11-26 21:53:24
mbbd000001423,mbcd0000387,mbtp000001,mbrf0001249,,~,,,substrate,83,0.5,microL min-1 (mg protein)-1,0.05,EG,(+),,OATP_B1/MDR1 double transfected MDCK II cells; transepithelial transport (basal to apical),MDCKII,,,,,human,mbds0003,v2007,2013-11-26 21:53:24
mbbd000001426,mbcd0000772,mbtp000001,mbrf0001250,,>,,,non-inhibitor,25,100.0,microM,,Simvastatin acid,,,MDR1-expressing MDCK cell; inhibition of calcein-AM efflux,MDCK,mbcd0000212,,,,human,mbds0003,v2007,2013-12-09 20:57:57
mbbd000001428,mbcd0000542,mbtp000001,mbrf0001250,,>,,,non-inhibitor,25,100.0,microM,,Lovastatin acid,,,MDR1-expressing MDCK cell; inhibition of calcein-AM efflux,MDCK,mbcd0000212,,,,human,mbds0003,v2007,2013-12-09 20:57:57
mbbd000001429,mbcd0000154,mbtp000001,mbrf0001250,,=,,,inhibitor,25,14.0,microM,,Atorvastatin lactone,,,MDR1-expressing MDCK cell; inhibition of calcein-AM efflux,MDCK,mbcd0000212,,,,human,mbds0003,v2007,2013-12-09 20:57:57
mbbd000001431,mbcd0003126,mbtp000001,mbrf0001250,,>,,,non-inhibitor,25,100.0,microM,,Pravastatin,,,MDR1-expressing MDCK cell; inhibition of calcein-AM efflux,MDCK,mbcd0000212,,,,human,mbds0003,v2007,2013-12-09 20:10:20
mbbd000001432,mbcd0002985,mbtp000001,mbrf0001251,,,,,non-inhibitor,,,,,CBZ,,,MDR1-expressing LLC-PK1 cells; inhibition of cyclosporin A transcellular transport,LLC-PK1,mbcd0000311,224,microM,,human,mbds0003,v2007,2013-12-09 20:10:19
mbbd000001433,mbcd0002985,mbtp000001,mbrf0001251,,,,,non-substrate,,,,,CBZ,,,MDR1-expressing LLC-PK1 cells; transcellular transport,LLC-PK1,,,,,human,mbds0003,v2007,2013-12-09 20:10:19
mbbd000001434,mbcd0001511,mbtp000001,mbrf0001251,,,,,non-substrate,,,,,LEV,,,MDR1-expressing LLC-PK1 cells; transcellular transport,LLC-PK1,,,,,human,mbds0003,v2007,2013-12-09 20:10:23
mbbd000001435,mbcd0002996,mbtp000001,mbrf0001251,,,,,non-substrate,,,,,PHT,,,MDR1-expressing LLC-PK1 cells; transcellular transport,LLC-PK1,,,,,human,mbds0003,v2007,2013-12-09 20:10:23
mbbd000001436,mbcd0000311,mbtp000001,mbrf0001251,,,,,substrate,,,,,CsA; cyclosporin A,,,MDR1-expressing LLC-PK1 cells; transcellular transport,LLC-PK1,,,,,human,mbds0003,v2007,2013-12-09 20:10:21
mbbd000001437,mbcd0001511,mbtp000001,mbrf0001251,,,,,non-substrate,,,,,LEV,,,MDR1-expressing MDCKII cells; transcellular transport,MDCKII,,,,,human,mbds0003,v2007,2013-12-09 20:10:22
mbbd000001438,mbcd0002996,mbtp000001,mbrf0001251,,,,,non-substrate,,,,,PHT,,,MDR1-expressing MDCKII cells; transcellular transport,MDCKII,,,,,human,mbds0003,v2007,2013-12-09 20:10:19
mbbd000001439,mbcd0002104,mbtp000001,mbrf0001251,,,,,inhibitor,,,,,Tariquidar,(0.2) microM,,MDR1-expressing MDCKII cells; inhibition of cyclosporin A transcellular transport,MDCKII,mbcd0000311,,,,human,mbds0003,v2007,2013-12-09 20:10:19
mbbd000001440,mbcd0027062,mbtp000001,mbrf0001251,,,,,inhibitor,,,,,Verapamil,(200)microM,,MDR1-expressing MDCKII cells; inhibition of cyclosporin A transcellular transport,MDCKII,mbcd0000311,,,,human,mbds0003,v2007,2013-12-09 20:57:31
mbbd000001441,mbcd0000721,mbtp000001,mbrf0001251,,,,,inhibitor,,,,,PSC833,(30) microM,,MDR1-expressing MDCKII cells; inhibition of cyclosporin A transcellular transport,MDCKII,mbcd0000311,,,,human,mbds0003,v2007,2013-12-09 20:57:30
mbbd000001442,mbcd0000311,mbtp000001,mbrf0001251,,,,,substrate,,,,,CsA,,,MDR1-expressing MDCKII cells; transcellular transport,MDCKII,,,,,human,mbds0003,v2007,2013-12-09 20:57:30
mbbd000001443,mbcd0002666,mbtp000001,mbrf0001252,,=,,,substrate,103,14.8,%,4.7,ranitidine,,,Caco-2 cells; reduced net ranitidine secretion in the presence of MDR1 inhibitor verapamil (100 microM); transepithelial transport (basal to apical),Caco-2,,100,microM,,human,mbds0003,v2007,2013-11-11 03:52:51
mbbd000001444,mbcd0003146,mbtp000005,mbrf0001253,,=,,,substrate,28,880.0,micromol L-1,,PAH,,,membrane vesicle from MRP2-expressing HEK293 cell ; uptake,HEK293,,,,,human,mbds0003,v2007,2013-12-09 20:57:31
mbbd000001445,mbcd0000640,mbtp000005,mbrf0001253,,,,,substrate,,,,,OTA,,,membrane vesicle from MRP2-expressign HEK293 cell; uptake,HEK293,,,,,human,mbds0003,v2007,2013-12-09 20:57:31
mbbd000001446,mbcd0000640,mbtp000005,mbrf0001253,,=,,,inhibitor,25,58.0,micromol L-1,,OTA,,,membrane vesicles from MRP2-expressign HEK293 cells; inhibition of PAH uptake (PAH: 0.1 microM),,,,,,human,mbds0003,v2007,2012-04-04 22:10:06
mbbd000001447,mbcd0002494,mbtp000005,mbrf0001253,,=,,,inhibitor,25,4.0,micromol L-1,,MK571,,,membrane vesicles from MRP2-expressing HEK293 cells; inhibition of PAH uptake (PAH: 0.1 microM),,,,,,human,mbds0003,v2007,2012-04-04 22:10:06
mbbd000001448,mbcd0002917,mbtp000005,mbrf0001253,,=,,,inhibitor,25,3.3,microM,,Leukotriene C4,,,membrane vesicle from MRP2-expressign HEK cell; inhibition of PAH uptake (PAH: 0.1microM),HEK,mbcd0003146,,,,human,mbds0003,v2007,2013-12-09 20:57:32
mbbd000001449,mbcd0000884,mbtp000005,mbrf0001254,,,,,substrate,,,,,UDC-L-NBD,,,Hep G2 cell; secretion into apical vacuoles,HepG2,,,,,human,mbds0003,v2007,2013-12-09 20:57:31
mbbd000001450,mbcd0000547,mbtp000005,mbrf0001254,,=,,,non-inhibitor,8,0.26,,0.02,LY-335979,ratio of the number of apical vacuoles to the number of cells,,"Hep G2 cell; inhibition of Fluo-3 secretion into apical vacuoles (Fluo-3: 1 microM, LY335979: 10 microM)",HepG2,mbcd0003155,10,microM,,human,mbds0003,v2007,2013-12-09 20:09:09
mbbd000001452,mbcd0000253,mbtp000005,mbrf0001254,,,,,substrate,,,,,CGamF,,,Hep G2 cell; secretion into apical vacuoles,HepG2,,,,,human,mbds0003,v2007,2013-12-09 20:09:09
mbbd000001454,mbcd0000695,mbtp000005,mbrf0001003,,=,,,inhibitor,3,1.5,fold,,Pluronic L61,,,"MRP2-expressing MDCKII cell; inhibition of Vinblastine transepithelial transport (basal to apical)(Vinblastine: 2 microM, Pluronic L61: 0.1%)",MDCKII,mbcd0001151,0.1,%,,human,mbds0003,v2007,2013-12-09 20:09:07
mbbd000001455,mbcd0002988,mbtp000005,mbrf0001255,,,,,substrate,,,,,sulfinpyrazone,,,MRP2-expressing MDCKII cell; transepithelial transport (basal to apical),MDCKII,,,,,human,mbds0003,v2007,2013-12-09 20:09:08
mbbd000001456,mbcd0000442,mbtp000005,mbrf0001256,,,,,substrate,,,,,GS-B,,,MRP2-expressing COS-7 cell; excretion,COS7,,,,,human,mbds0003,v2007,2013-12-09 20:09:09
mbbd000001457,mbcd0000442,mbtp000005,mbrf0001256,,,,,substrate,,,,,GS-B,,,MRP2-expressing CHO-K1 cell; excretion,CHO,,,,,human,mbds0003,v2007,2013-12-09 20:09:09
mbbd000001458,mbcd0000441,mbtp000005,mbrf0001256,,,,,substrate,,,,,GS-MF,,,MRP2-expressing COS-7 cell; excretion,COS7,,,,,human,mbds0003,v2007,2013-12-09 20:09:04
mbbd000001459,mbcd0000441,mbtp000005,mbrf0001256,,,,,substrate,,,,,GS-MF,,,MRP2-expressing CHO-K1 cell; excretion,CHO,,,,,human,mbds0003,v2007,2013-12-09 20:09:05
mbbd000001460,mbcd0000800,mbtp000005,mbrf0001257,,,,,inducer,,,,,Sulforaphane,,,"in vitro, primary human hepatocyte; Northern and Western",human hepatocytes,,,,,human,mbds0003,v2007,2013-12-09 20:55:09
mbbd000001461,mbcd0000043,mbtp000005,mbrf0001258,,,,,substrate,,,,,PhIP,,,MRP2-expressing MDCK II cell; transepithelial transport (basal to apical),MDCKII,,,,,human,mbds0003,v2007,2013-12-09 20:55:09
mbbd000001462,mbcd0000627,mbtp000005,mbrf0001259,,,,,substrate,,,,,NNAL-O-glucuronide,,,membrane vesicle from MRP2-expressing HEK293T cell; uptake,HEK293T,,,,,human,mbds0003,v2007,2013-12-09 20:55:09
mbbd000001463,mbcd0001938,mbtp000005,mbrf0001260,,,,,inducer,,,,,ritonavir,,,"in vitro, primary hepatocyte; Northern",primary hepatocytes,,,,,human,mbds0003,v2007,2013-12-09 20:55:09
mbbd000001464,mbcd0013564,mbtp000005,mbrf0001261,,,,,inducer,,,,,oltipraz; OPZ,,,primary human hepatocytes,human hepatocytes,,50,microM,,human,mbds0003,v2007,2013-11-18 19:37:54
mbbd000001465,mbcd0001632,mbtp000005,mbrf0001262,,,,,inducer,,,,,Hyperforin,,,"in vitro, primary hepatocyte; Northern",primary hepatocytes,,,,,human,mbds0003,v2007,2013-12-09 20:55:08
mbbd000001466,mbcd0000466,mbtp000005,mbrf0001262,,,,,inducer,,,,,GW4064,,,HepG2 cell; Northern,HepG2,,,,,human,mbds0003,v2007,2013-12-09 20:55:08
mbbd000001467,mbcd0000254,mbtp000005,mbrf0001262,,,,,inducer,,,,,CDCA,,,HepG2 cell; Northern,HepG2,,,,,human,mbds0003,v2007,2013-12-09 20:55:08
mbbd000001468,mbcd0000819,mbtp000005,mbrf0001263,,,,,substrate,,,,,TLC-S,,,MRP2- and OATP-C-expressing MDCKII cell; transepithelial transport (basal to apical),MDCKII,,,,,human,mbds0003,v2007,2013-12-09 20:55:09
mbbd000001469,mbcd0003126,mbtp000005,mbrf0001263,,,,,substrate,,,,,pravastatin,,,MRP2- and OATP-C-expressing MDCKII cell; transepithelial transport (basal to apical),MDCKII,,,,,human,mbds0003,v2007,2013-12-09 20:55:09
mbbd000001470,mbcd0002988,mbtp000005,mbrf0001264,,~,,,inhibitor,145,45.0,%,,Sulfinpyrazone,,,"MRP2-expressing MDCKII cell; inhibition of Vinblastine transepithelial transport (basal to apical)(Vinblastine: 0.035 microM, Sulfinpyrazone: 1000 microM)",MDCKII,mbcd0001151,1,mM,,human,mbds0003,v2007,2013-12-09 20:07:58
mbbd000001475,mbcd0003007,mbtp000005,mbrf0001266,,,,,inducer,,,,,Phenobarbital,,,"in vitro, primary hepatocyte; Northern and Western; HepG2",HepG2,,,,,human,mbds0003,v2007,2013-10-15 21:36:29
mbbd000001476,mbcd0002466,mbtp000005,mbrf0001042,,=,,,substrate,28,616.54,microM,163.15,Etoposide,,,MRP2-expressing MDCKII cell; transepithelial transport (basal to apical),MDCKII,,1-500,microM,,human,mbds0003,v2007,2013-12-09 20:07:56
mbbd000001477,mbcd0001135,mbtp000005,mbrf0001267,,=,,,inhibitor,29,802.0,microM,,vincristine,,,MRP2-expressing MDCK cell; inhibition of Vinblastine transepithelial transport (basal to apical),MDCK,mbcd0001151,,,,human,mbds0003,v2007,2013-12-09 20:07:57
mbbd000001478,mbcd0001151,mbtp000005,mbrf0001267,,=,,,substrate,28,137.3,microM,33.6,Vinblastine,,,MRP2-expressing MDCK cell; transepithelial transport (basal to apical) in the presence of PSC-833,MDCK,,0-160,microM,,human,mbds0003,v2007,2013-12-09 20:07:58
mbbd000001479,mbcd0027062,mbtp000005,mbrf0001267,,,,,non-inhibitor,,,,,Verapamil,Ki=No inhibition,,MRP2-expressing MDCK cell; inhibition of Vinblastine transepithelial transport (basal to apical)(Verapamil: 50 microM),MDCK,mbcd0001151,,,,human,mbds0003,v2007,2013-12-09 20:07:58
mbbd000001480,mbcd0001941,mbtp000005,mbrf0001267,,=,,,inhibitor,29,295.0,microM,,Reserpine,,,MRP2-expressing MDCK cell; inhibition of Vinblastine transepithelial transport (basal to apical),MDCK,mbcd0001151,,,,human,mbds0003,v2007,2013-12-09 20:54:42
mbbd000001481,mbcd0027018,mbtp000005,mbrf0001267,,,,,non-inhibitor,,,,,Quinidine,Ki=No inhibition,,MRP2-expressing MDCK cell; inhibition of Vinblastine transepithelial transport (basal to apical)(Quinidine: 15 microM),MDCK,mbcd0001151,,,,human,mbds0003,v2007,2013-12-09 20:54:42
mbbd000001482,mbcd0002494,mbtp000005,mbrf0001267,,=,,,inhibitor,29,26.4,microM,,MK571,,,MRP2-expressing MDCK cell; inhibition of Vinblastine transepithelial transport (basal to apical),MDCK,mbcd0001151,,,,human,mbds0003,v2007,2013-12-09 20:54:42
mbbd000001483,mbcd0001808,mbtp000005,mbrf0001267,,,,,non-inhibitor,,,,,GF120918,Ki=No inhibition,,MRP2-expressing MDCK cell; inhibition of Vinblastine transepithelial transport (basal to apical)(GF120918: 12 microM),MDCK,mbcd0001151,,,,human,mbds0003,v2007,2013-12-09 20:54:41
mbbd000001484,mbcd0002466,mbtp000005,mbrf0001267,,=,,,inhibitor,29,756.0,microM,,Etoposide,,,MRP2-expressing MDCK cell; inhibition of Vinblastine transepithelial transport (basal to apical),MDCK,mbcd0001151,,,,human,mbds0003,v2007,2013-12-09 20:54:41
mbbd000001485,mbcd0005183,mbtp000005,mbrf0001267,,=,,,inhibitor,29,49.4,microM,,daunorubicin,,,MRP2-expressing MDCK cell; inhibition of Vinblastine transepithelial transport (basal to apical),MDCK,mbcd0001151,,,,human,mbds0003,v2007,2013-12-09 20:54:41
mbbd000001486,mbcd0000311,mbtp000005,mbrf0001267,,=,,,inhibitor,29,8.11,microM,,CsA,,,MRP2-expressing MDCK cell; inhibition of Vinblastine transepithelial transport (basal to apical),MDCK,mbcd0001151,,,,human,mbds0003,v2007,2013-12-09 20:54:40
mbbd000001487,mbcd0001533,mbtp000005,mbrf0001268,,,,,substrate,,,,,saquinavir,,,MRP2-expressing MDCKIi cell; transepithelial transport (basal to apical),MDCKII,,,,,human,mbds0003,v2007,2013-12-09 20:54:40
mbbd000001488,mbcd0001938,mbtp000005,mbrf0001269,,,,,substrate,,,,,ritonavir,,,MRP2-expressing MDCKII cells; transepithelial transport (basal to apical); GF120918 used to inhibit P-gp,MDCKII,,5,mM,,human,mbds0003,v2007,2012-04-04 22:10:06
mbbd000001489,mbcd0002323,mbtp000005,mbrf0001269,,,,,substrate,,,,,indinavir,,,MRP2-expressing MDCKII cell; transepithelial transport (basal to apical); GF120918 used to inhibit P-gp,MDCKII,,5,mM,,human,mbds0003,v2007,2012-04-04 22:10:06
mbbd000001490,mbcd0001197,mbtp000005,mbrf0001270,,,,,substrate,,,,,leucovorin,,,membrane vesicle from MRP2-expressing HEK293 cell; uptake (vesicle),HEK293,,,,,human,mbds0003,v2007,2013-12-09 20:05:24
mbbd000001491,mbcd0000002,mbtp000005,mbrf0001271,,,,,substrate,,,,,ECG,,,membrane vesicle from MRP2-expressing MDCKII cell; uptake,MDCKII,,,,,human,mbds0003,v2007,2013-12-09 20:05:25
mbbd000001492,mbcd0001151,mbtp000005,mbrf0001272,,~,,,inhibitor,100,190.0,%,10,VIN; vinblastine,,,MRP2-expressing MDCKII cells; inhibition of EGCG,MDCKII,mbcd0029142,50,microM,,human,mbds0003,v2007,2013-10-29 19:55:35
mbbd000001493,mbcd0003154,mbtp000005,mbrf0001272,,~,,,inhibitor,100,230.0,%,20,PRB; Probenecid,,,MRP2-expressing MDCKII cells; inhibition of EGCG,MDCKII,mbcd0029142,1,mM,,human,mbds0003,v2007,2013-10-17 22:36:09
mbbd000001494,mbcd0002494,mbtp000005,mbrf0001272,,~,,,inhibitor,100,400.0,%,5,MK; MK-571,,,MRP2-expressing MDCKII cells; inhibition of EGCG,MDCKII,mbcd0029142,50,microM,,human,mbds0003,v2007,2013-10-17 22:36:10
mbbd000001495,mbcd0000311,mbtp000005,mbrf0001272,,~,,,inhibitor,100,205.0,%,5,CsA; cyclosporin A,,,MRP2-expressing MDCKII cells; inhibition of EGCG,MDCKII,mbcd0029142,10,microM,,human,mbds0003,v2007,2013-10-17 22:36:02
mbbd000001496,mbcd0000076,mbtp000005,mbrf0001272,,,,,substrate,,,,,DiMeEGCG,,,MRP2-expressing MDCKII cells; uptake,MDCKII,,,,,human,mbds0003,v2007,2013-10-17 21:45:48
mbbd000001497,mbcd0000072,mbtp000005,mbrf0001272,,,,,substrate,,,,,MeEGCG,,,MRP2-expressing MDCKII cells; uptake,MDCKII,,,,,human,mbds0003,v2007,2013-10-17 21:45:49
mbbd000001498,mbcd0029142,mbtp000005,mbrf0001272,,,,,substrate,,,,,EGCG,,,MRP2-expressing MDCKII cells; uptake,MDCKII,,,,,human,mbds0003,v2007,2013-10-17 21:45:44
mbbd000001499,mbcd0000675,mbtp000005,mbrf0001273,,,,,substrate,,,,,phalloidin,,,MRP2-expressing MDCKII cell; transepithelial transport (basal to apical),MDCKII,,1,microM,,human,mbds0003,v2007,2013-12-09 20:05:24
mbbd000001500,mbcd0000056,mbtp000005,mbrf0001274,,=,,,substrate,28,35.1,microM,3.5,EE-G,,,membrane vesicle from MRP2-expressing Sf9 cell; uptake,Sf9,,,,,human,mbds0003,v2007,2013-12-09 20:51:12
mbbd000001501,mbcd0003007,mbtp000005,mbrf0001275,,=,,,inducer,97,3.0,fold,,phenobarbital,protein levels,,HepG2 hepatoma cells; MRP2 expresion Western blot,HepG2,,,,,human,mbds0003,v2007,2013-12-08 01:54:55
mbbd000001502,mbcd0001117,mbtp000005,mbrf0001275,,=,,,inducer,97,3.0,fold,,cisplatin,protein levels,,HepG2 hepatoma cells; MRP2 expresion Western blot,HepG2,,,,,human,mbds0003,v2007,2013-12-08 01:54:55
mbbd000001503,mbcd0000042,mbtp000005,mbrf0001275,,=,,,inducer,97,2.0,fold,,2-AAF,protein levels,,HepG2 hepatoma cells; MRP2 expresion Western blot,HepG2,,,,,human,mbds0003,v2007,2013-12-08 01:54:55
mbbd000001504,mbcd0001416,mbtp000005,mbrf0001276,,,,,inducer,,,,,rifampin,,,"in vivo, apical membrane of enterocyte; Northern and Immunohistochemistry",human duodenal enterocytes,,,,,human,mbds0003,v2007,2013-12-09 20:51:12
mbbd000001505,mbcd0003154,mbtp000005,mbrf0001277,,=,,,inhibitor,72,20.0,%,,Probenecid,(1)mM,,membrane vesicle from MRP6-expressing Sf9 cell; inhibition of NEM-GS,Sf9,mbcd0000603,,,,human,mbds0003,v2007,2013-12-09 20:51:12
mbbd000001506,mbcd0003034,mbtp000005,mbrf0001277,,~,,,inhibitor,3,100.0,%,,benzbromarone,,,membrane vesicle from MRP2-expressing Sf9 cell; inhibition of NEM-GS transport,Sf9,,30,microM,,human,mbds0003,v2007,2013-12-09 20:51:11
mbbd000001507,mbcd0000187,mbtp000005,mbrf0001278,,=,,,inhibitor,25,0.28,microM,,monoglucuronosylbilirubin,,,HepG2 cell; inhibition of LTC4 uptake (LTC4: 0.05 microM),HepG2,mbcd0002917,,,,human,mbds0003,v2007,2013-12-09 20:51:12
mbbd000001508,mbcd0004701,mbtp000005,mbrf0001278,,=,,,inhibitor,25,0.4,microM,,bisglucuronosylbilirubin,,,HepG2 cell; inhibition of LTC4 uptake (LTC4: 0.05 microM),HepG2,mbcd0002917,,,,human,mbds0003,v2007,2013-12-09 20:51:11
mbbd000001509,mbcd0002990,mbtp000005,mbrf0001279,,=,,,inhibitor,72,73.0,%,,GSSG,,,"membrane vesicle from MRP2-expressing MDCK cell; inhibition of DNP-SG uptake (DNP-SG: 0.015 microM, GSSG: 100 microM)",MDCKII,mbcd0030390,,,,human,mbds0003,v2007,2013-12-09 20:51:11
mbbd000001510,mbcd0003078,mbtp000005,mbrf0001279,,=,,,inhibitor,72,51.0,%,,GSH,,,"membrane vesicle from MRP2-expressing MDCK cell; inhibition of DNP-SG uptake (DNP-SG: 0.015 microM, GSH: 15 mM)",MDCKII,mbcd0030390,,,,human,mbds0003,v2007,2013-12-09 20:05:39
mbbd000001511,mbcd0003078,mbtp000005,mbrf0001279,,=,,,substrate,83,141.0,pmol (mg protein)-1 min-1,6.1,GSH,,,MRP2-expressing MDCKII cells; transepithelial transport (basal to apical),MDCKII,,,,,human,mbds0003,v2007,2013-11-21 01:53:19
mbbd000001512,mbcd0000047,mbtp000005,mbrf0001279,,=,,,substrate,28,70.0,microM,12,DNP-GS,,,membrane from MRP2-expressing MDCK cell; uptake,MDCKII,,12.5-250,microM,,human,mbds0003,v2007,2013-12-09 20:05:39
mbbd000001513,mbcd0002917,mbtp000005,mbrf0001280,,=,,,substrate,28,1.0,microM,0.1,LTC4,,,membrane vesicle from MRP2-expressing HEK-293 cell; uptake,HEK293,,,,,human,mbds0003,v2007,2013-12-09 20:05:39
mbbd000001514,mbcd0000387,mbtp000005,mbrf0001280,,=,,,substrate,28,7.2,microM,0.7,17beta glucuronosyl estradiol,,,membrane vesicle from MRP2-expressing HEK-293 cell; uptake,HEK293,,0.5-8,microM,,human,mbds0003,v2007,2013-12-09 20:05:38
mbbd000001515,mbcd0000465,mbtp000005,mbrf0001281,,,,,substrate,,,,,GPFXG,,,bile canalicular membrane vesicle; uptake,bile canalicular membrane vesicle,,,,,human,mbds0003,v2007,2013-12-09 20:05:37
mbbd000001516,mbcd0000369,mbtp000005,mbrf0001281,,=,,,substrate,28,14.1,microM,3.3,E-glu,,,bile canalicular membrane vesicle; uptake,bile canalicular membrane vesicle,,20,microM,,human,mbds0003,v2007,2013-12-09 20:05:38
mbbd000001517,mbcd0000047,mbtp000005,mbrf0001281,,=,,,substrate,28,193.0,microM,20,DNP-SG,,,bile canalicular membrane vesicle; uptake,bile canalicular membrane vesicle,,1,microM,,human,mbds0003,v2007,2013-12-09 20:05:38
mbbd000001518,mbcd0003043,mbtp000005,mbrf0001282,,,,,substrate,,,,,MTX,,,membrane vesicle from MRP2-expressing human ovarian carcinoma cell line 2008; uptake,human ovarian carcinoma cells,,,,,human,mbds0003,v2007,2013-11-24 23:55:08
mbbd000001519,mbcd0002494,mbtp000005,mbrf0001166,,~,,,inhibitor,88,0.3,pmol/min/mg protein,0.02,MK571,,,"membrane vesicle from MRP2-expressing MDCK cell; inhibition of LTC4 uptake (LTC4: 0.05 microM, MK571: 10 microM)",MDCK,mbcd0002917,10,microM,,human,mbds0003,v2007,2013-12-09 19:54:28
mbbd000001520,mbcd0000547,mbtp000005,mbrf0001166,,>,,,non-inhibitor,25,10.0,microM,,LY335979,,,"membrane vesicle from MRP2-expressing MDCK cell; inhibition of LTC4 uptake (LTC4: 0.05 microM, LY335979: 10 microM)",MDCK,mbcd0002917,,,,human,mbds0003,v2007,2013-12-09 20:51:21
mbbd000001521,mbcd0000311,mbtp000005,mbrf0001283,,=,,,inhibitor,29,21.0,microM,,CsA,,,membrane vesicle from MRP2-expressing HEK cell; inhibition of BMG uptake,HEK293,mbcd0000187,,,,human,mbds0003,v2007,2013-12-09 20:51:21
mbbd000001522,mbcd0000187,mbtp000005,mbrf0001283,,=,,,substrate,28,0.7,micromol L-1,0.2,MGB,,,membrane vesicles from MRP2-expressing HEK293 cells; uptake,HEK293,,,,,human,mbds0003,v2007,2013-11-24 23:12:55
mbbd000001523,mbcd0004701,mbtp000005,mbrf0001283,,=,,,substrate,28,0.9,micromol L-1,0.1,BGB,,,membrane vesicles from MRP2-expressing HEK293 cells; uptake,HEK293,,,,,human,mbds0003,v2007,2013-11-24 23:12:55
mbbd000001524,mbcd0000757,mbtp000005,mbrf0001284,,,,,substrate,,,,,S-decyl-glutathione,,,MRP2 reconstituted into proteoliposome; ATP hydrolysis,HEK293,,,,,human,mbds0003,v2007,2013-12-09 20:51:21
mbbd000001525,mbcd0002990,mbtp000005,mbrf0001284,,,,,substrate,,,,,glutathione disulfide,,,MRP2 reconstituted into proteoliposome; ATP hydrolysis,HEK293,,,,,human,mbds0003,v2007,2013-12-09 20:51:21
mbbd000001526,mbcd0003078,mbtp000005,mbrf0001284,,,,,substrate,,,,,glutathione,,,MRP2 reconstituted into proteoliposome; ATP hydrolysis,HEK293,,,,,human,mbds0003,v2007,2013-12-09 20:51:21
mbbd000001527,mbcd0001135,mbtp000005,mbrf0001285,,,,,substrate,,,,,VCR,,,MRP2-expressing LLC PK1 cell; intracellular accumulation,LLC-PK1,,,,,human,mbds0003,v2007,2013-12-09 20:51:21
mbbd000001528,mbcd0000721,mbtp000005,mbrf0001285,,=,,,inhibitor,29,28.9,microM,,PSC833,,,membrane vesicle from MRP2-expressing LLC PK1 cell; inhibition of LTC4 uptake,LLC-PK1,mbcd0002917,10,microM,,human,mbds0003,v2007,2013-12-09 20:51:21
mbbd000001529,mbcd0000721,mbtp000005,mbrf0001285,,=,,,inhibitor,25,0.098,microM,0.014,PSC833,,,"MRP2-expressing LLC PK1 cell; increase in Vincristine intracellular accumulation (Vincristine: 1 microM, PSC-833: 10 microM)",LLC-PK1,mbcd0001135,,,,human,mbds0003,v2007,2013-12-09 20:51:21
mbbd000001530,mbcd0000659,mbtp000005,mbrf0001285,,=,,,inhibitor,29,3.7,microM,,PAK-104P,,,membrane vesicle from MRP2-expressing LLC PK1 cell; inhibition of LTC4 uptake,LLC-PK1,mbcd0002917,5,microM,,human,mbds0003,v2007,2013-12-09 19:55:54
mbbd000001531,mbcd0000659,mbtp000005,mbrf0001285,,=,,,inhibitor,25,0.051,microM,0.007,PAK-104P,,,"MRP2-expressing LLC PK1 cell; increase in Vincristine intracellular accumulation (Vincristine: 1 microM, PAK-104P: 10 microM)",LLC-PK1,mbcd0001135,,,,human,mbds0003,v2007,2013-12-09 19:55:53
mbbd000001532,mbcd0002494,mbtp000005,mbrf0001285,,=,,,inhibitor,29,13.1,microM,,MK571,,,membrane vesicle from MRP2-expressing LLC PK1 cell; inhibition of LTC4 uptake,LLC-PK1,mbcd0002917,5,microM,,human,mbds0003,v2007,2013-12-09 19:55:52
mbbd000001533,mbcd0002494,mbtp000005,mbrf0001285,,=,,,inhibitor,25,0.083,microM,0.003,MK571,,,"MRP2-expressing LLC PK1 cell; increase in Vincristine intracellular accumulation (Vincristine: 1 microM, MK571: 10 microM)",LLC-PK1,mbcd0001135,,,,human,mbds0003,v2007,2013-12-09 19:55:51
mbbd000001534,mbcd0002917,mbtp000005,mbrf0001285,,=,,,substrate,28,0.26,microM,0.05,LTC4,,,membrane vesicle from MRP2-expressing LLC PK1 cell; uptake,LLC-PK1,,10-1600,nM,,human,mbds0003,v2007,2013-12-09 19:55:59
mbbd000001535,mbcd0000311,mbtp000005,mbrf0001285,,=,,,inhibitor,25,0.045,microM,0.004,CsA,,,"MRP2-expressing LLC PK1 cell; increase in Vincristine intracellular accumulation (Vincristine: 1 microM, CsA: 10 microM)",LLC-PK1,mbcd0001135,,,,human,mbds0003,v2007,2013-12-09 19:55:58
mbbd000001536,mbcd0000311,mbtp000005,mbrf0001285,,=,,,inhibitor,29,4.7,microM,,CsA,,,membrane vesicle from MRP2-expressing LLC PK1 cell; inhibition of LTC4 uptake,LLC-PK1,mbcd0002917,10,microM,,human,mbds0003,v2007,2013-12-09 19:55:57
mbbd000001537,mbcd0000047,mbtp000005,mbrf0001285,,,,,substrate,,,,,DNP-SG,,,membrane vesicle from MRP2-expressing LLC PK1 cell; uptake,LLC-PK1,,,,,human,mbds0003,v2007,2013-12-09 19:55:55
mbbd000001538,mbcd0000387,mbtp000005,mbrf0001286,,=,,,substrate,28,9.4,microM,1.1,E217betaG,,,brush-border membrane vesicle from Caco-2 cell; uptake,Caco-2,,0-30,microM,,human,mbds0003,v2007,2013-12-09 19:55:50
mbbd000001539,mbcd0000047,mbtp000005,mbrf0001286,,=,,,substrate,28,16.9,microM,7.2,DNP-SG,,,brush-border membrane vesicle from Caco-2 cell; uptake,Caco-2,,0-100,microM,,human,mbds0003,v2007,2013-12-09 19:55:50
mbbd000001540,mbcd0003120,mbtp000005,mbrf0001287,,=,,,inducer,97,133.0,%,5,quercetin,100% represents protein levels in solvent controls containing DMSO,,Caco-2 cell; compound 50 microM; Immunoblot analysis; 100% represents protein levels in solvent controls containing DMSO,,,50,microM,,human,mbds0003,v2007,2013-12-09 20:52:24
mbbd000001541,mbcd0020884,mbtp000005,mbrf0001288,,=,,,repressor,111,67.0,%,,Nocodazole,reduction in promoter activity,,promoter constructs in HepG2 cell; reporter gene activity,HepG2,,50,microM,,human,mbds0003,v2007,2013-12-09 20:52:24
mbbd000001542,mbcd0003154,mbtp000005,mbrf0001289,,~,,,inhibitor,138,70.0,%,,Probenecid,,,"membrane vesicle from MRP2-expressing Sf9 cell; inhibition of NEM-GS uptake (NEM-GS: 4 microM, Probenecid: <1000 microM)",Sf9,mbcd0000603,~800,microM,,human,mbds0003,v2007,2013-12-09 20:52:24
mbbd000001545,mbcd0003137,mbtp000005,mbrf0001289,,~,,,inhibitor,138,25.0,%,,Furosemide,,,"membrane vesicle from MRP2-expressing Sf9 cell; inhibition of NEM-GS uptake (NEM-GS: 4 microM, Furosemide: 5000 microM)",Sf9,mbcd0000603,~2.5,mM,,human,mbds0003,v2007,2013-12-09 20:52:25
mbbd000001546,mbcd0003109,mbtp000005,mbrf0001290,,~,,,inducer,98,1.4,fold increase,,TLCA sulfate,increase in mRNA level,,renal proximal tubular epithelial cell; RT-PCR,RPTEC,,100,microM,,human,mbds0003,v2007,2013-12-09 20:52:24
mbbd000001547,mbcd0000186,mbtp000005,mbrf0001290,,~,,,inducer,98,1.5,fold increase,,Bilirubin ditaurate,increase in mRNA level,,renal proximal tubular epithelial cell; RT-PCR,RPTEC,,100,microM,,human,mbds0003,v2007,2013-12-09 20:52:24
mbbd000001548,mbcd0003070,mbtp000005,mbrf0001291,,,,,substrate,,,,,DHEAS,(+),,OATP_B1/MRP2 double transfected LLC-PK1 cell; Transepithelical Transport (basal to apical),LLC-PK1,,,,,human,mbds0003,v2007,2013-12-09 20:52:25
mbbd000001549,mbcd0003075,mbtp000005,mbrf0001291,,,,,substrate,,,,,E1S,(+),,OATP_B1/MRP2 double transfected LLC-PK1 cell; Transepithelical Transport (basal to apical),LLC-PK1,,,,,human,mbds0003,v2007,2013-12-09 20:52:25
mbbd000001550,mbcd0000387,mbtp000005,mbrf0001291,,,,,substrate,,,,,E217betaG,(+),,OATP_B1/MRP2 double transfected LLC-PK1 cell; Transepithelical Transport (basal to apical),LLC-PK1,,,,,human,mbds0003,v2007,2013-12-09 19:57:50
mbbd000001551,mbcd0003126,mbtp000005,mbrf0001249,,~,,,substrate,83,3.8,microL min-1 (mg protein)-1,0.15,PRA,,,OATPB1/MRP2 double transfected MDCKII cells; transepithelial transport (basal to apical),MDCKII,,,,,human,mbds0003,v2007,2013-11-26 21:53:24
mbbd000001552,mbcd0023123,mbtp000005,mbrf0001249,,~,,,substrate,83,0.6,microL min-1 (mg protein)-1,0.05,CER,,,OATPB1/MRP2 double transfected MDCKII cells; transepithelial transport (basal to apical),MDCKII,,,,,human,mbds0003,v2007,2013-11-26 21:53:24
mbbd000001553,mbcd0003075,mbtp000005,mbrf0001249,,~,,,substrate,83,0.25,microL min-1 (mg protein)-1,0.05,ES,,,OATPB1/MRP2 double transfected MDCKII cells; transepithelial transport (basal to apical),MDCKII,,,,,human,mbds0003,v2007,2013-11-26 21:53:24
mbbd000001554,mbcd0000387,mbtp000005,mbrf0001249,,~,,,substrate,83,3.5,microL min-1 (mg protein)-1,0.1,EG,,,OATPB1/MRP2 double transfected MDCKII cells; transepithelial transport (basal to apical),MDCKII,,,,,human,mbds0003,v2007,2013-11-26 21:53:24
mbbd000001557,mbcd0000772,mbtp000005,mbrf0001250,,>,,,non-inhibitor,25,100.0,microM,,Simvastatin acid,,,MRP2-expressing MDCK cell; inhibition of calcein-AM efflux,MDCK,mbcd0000212,,,,human,mbds0003,v2007,2013-12-09 19:57:53
mbbd000001559,mbcd0000542,mbtp000005,mbrf0001250,,>,,,non-inhibitor,25,100.0,microM,,Lovastatin acid,,,MRP2-expressing MDCK cell; inhibition of calcein-AM efflux,MDCK,mbcd0000212,,,,human,mbds0003,v2007,2013-12-09 19:57:55
mbbd000001560,mbcd0000154,mbtp000005,mbrf0001250,,=,,,inhibitor,25,15.0,microM,,Atorvastatin lactone,,,MRP2-expressing MDCK cell; inhibition of calcein-AM efflux,MDCK,mbcd0000212,,,,human,mbds0003,v2007,2013-12-09 20:52:49
mbbd000001562,mbcd0003126,mbtp000005,mbrf0001250,,>,,,non-inhibitor,25,100.0,microM,,Pravastatin,,,MRP2-expressing MDCK cell; inhibition of calcein-AM efflux,MDCK,mbcd0000212,,,,human,mbds0003,v2007,2013-12-09 19:54:24
mbbd000001563,mbcd0001172,mbtp000005,mbrf0001292,,=,,,inhibitor,25,18.0,microM,,Ivermectin,,,Sf9 cells (membrane vesicles); inhibition of ATPase activity,Sf9,,,,,human,mbds0003,v2007,2013-12-09 19:54:25
mbbd000001564,mbcd0003074,mbtp000001,mbrf0001293,,,,,inhibitor,,,,,glyburide,,,PGP over-expressing A2780/Adr cell line,,,,,,human,mbds0010,,2012-11-02 19:44:56
mbbd000001565,mbcd0003074,mbtp000005,mbrf0001293,,=,,,inhibitor,72,230.0,%,,glyburide,(200)microM,,MRP2-expressing MDCK cells; inhibition of 5-carboxyfluorescein accumulation,,,,,,human,mbds0003,v2007,2013-12-09 20:52:49
mbbd000001566,mbcd0003025,mbtp000005,mbrf0001293,,=,,,inhibitor,72,210.0,%,,indomethacin,(200)microM,,MRP2-expressing MDCK cells; inhibition of 5-carboxyfluorescein accumulation,,,,,,human,mbds0003,v2007,2013-12-09 20:52:49
mbbd000001567,mbcd0003025,mbtp000005,mbrf0001293,,,,,non-inhibitor,,,,,indomethacin,,,MRP2-expressing MDCK cells; accumulation of substrate glyburide; 200 microM indomethacin,,,,,,human,mbds0003,v2007,2013-12-09 20:52:49
mbbd000001568,mbcd0003005,mbtp000005,mbrf0001294,,,,,substrate,,,,,olmesartan,,,human canalicular membrane vesicles (hCMV); transport,hCMV,,,,,human,mbds0003,v2007,2013-11-26 00:48:05
mbbd000001569,mbcd0003005,mbtp000005,mbrf0001294,,,,,substrate,,,,,olmesartan,,,MRP2-expressing vesicles (SOLVO) and human canalicular membrane vesicles (hCMVs); transport,hCMV,,,,,human,mbds0003,v2007,2014-03-04 00:44:27
mbbd000001570,mbcd0001511,mbtp000005,mbrf0001251,,,,,non-substrate,,,,,LEV,,,MRP2-expressing MDCKII cells; transcellular transport,MDCKII,,,,,human,mbds0003,v2007,2013-12-09 19:59:43
mbbd000001571,mbcd0002996,mbtp000005,mbrf0001251,,,,,substrate,,,,,PHT,,,MRP2-expressing MDCKII cells; transcellular transport; in only one of three experiments transport was observed,MDCKII,,,,,human,mbds0003,v2007,2013-11-12 06:39:00
mbbd000001572,mbcd0001151,mbtp000005,mbrf0001251,,,,,substrate,,,,,vinblastine,,,MRP2-expressing MDCKII cells; transcellular transport,MDCKII,,,,,human,mbds0003,v2007,2013-12-09 19:59:42
mbbd000001573,mbcd0002494,mbtp000005,mbrf0001295,,=,,,inhibitor,72,195.0,%,,MK-571,,,hMRP2-expressing MDCK2; increase cell accumulation of erythromycin,MDCKII,mbcd0000937,,,,human,mbds0003,v2007,2013-12-09 19:59:41
mbbd000001574,mbcd0002494,mbtp000005,mbrf0001295,,=,,,inhibitor,72,156.0,%,,MK-571,,,hMRP2-expressing MDCK2; increase cell accumulation of cyclosporine-A,MDCKII,mbcd0000311,,,,human,mbds0003,v2007,2013-12-09 19:59:39
mbbd000001575,mbcd0003154,mbtp000005,mbrf0001296,,=,,,inhibitor,29,42.2,microM,,probenacid,,,bile canalicular membrane vesicles; human liver CMVs; inhibition of SN38 uptake,,,,,,human,mbds0003,v2007,2013-12-09 19:59:38
mbbd000001581,mbcd0002988,mbtp000008,mbrf0001298,,=,,,inhibitor,72,18.0,%,,Sulfinpyrazone,"18 -> 83 % of control (clone#38), 30 -> 77 % of control (clone#77)",,"MRP3-expressing fibroblast from kidney of mdr1a/1b and mrp1 (-/-) mouse; increase in Etoposide intracellular accumulation (Etoposide: 2 microM, Sulfinpyrazone: 2000 microM)",fibroblast from kidney,mbcd0002466,,,,human,mbds0003,v2007,2013-12-09 20:53:24
mbbd000001582,mbcd0003154,mbtp000008,mbrf0001298,,=,,,inhibitor,72,18.0,%,,Probenecid,"18 -> 59 % of control (clone#38), 30 -> 58 % of control (clone#77)",,"MRP3-expressing fibroblast from kidney of mdr1a/1b and mrp1 (-/-) mouse; increase in Etoposide intracellular accumulation (Etoposide: 2 microM, Probenecid: 5000 microM)",fibroblast from kidney,mbcd0002466,,,,human,mbds0003,v2007,2013-12-09 19:54:54
mbbd000001583,mbcd0003025,mbtp000008,mbrf0001298,,=,,,inhibitor,72,18.0,%,,indomethacin,"18 -> 67 % of control (clone#38), 30 -> 64 % of control (clone#77)",,"MRP3-expressing fibroblast from kidney of mdr1a/1b and mrp1 (-/-) mouse; increase in Etoposide intracellular accumulation (Etoposide: 2 microM, Indomethacin: 500 microM)",fibroblast from kidney,mbcd0002466,,,,human,mbds0003,v2007,2013-12-09 19:54:55
mbbd000001584,mbcd0003078,mbtp000008,mbrf0001298,,,,,non-substrate,,,,,GSH,,,membrane vesicle from MRP3-expressing Sf9 cell; uptake,Sf9,,,,,human,mbds0003,v2007,2013-12-09 20:53:23
mbbd000001585,mbcd0000398,mbtp000008,mbrf0001298,,=,,,substrate,28,11.4,microM,2.6,Etoposide glucuronide,,,membrane vesicle from MRP3-expressing Sf9 cell; uptake,Sf9,,0.01-10,microM,,human,mbds0003,v2007,2013-12-09 20:53:23
mbbd000001586,mbcd0002466,mbtp000008,mbrf0001298,,,,,substrate,,,,,etoposide,,,MRP3-expressing fibroblast from kidney of mdr1a/1b and mrp1 (-/-) mouse; efflux,mouse kidney fibroblasts,,,,,human,mbds0003,v2007,2013-12-09 20:53:22
mbbd000001587,mbcd0000387,mbtp000008,mbrf0001298,,=,,,substrate,28,17.7,microM,2.6,E217betaG,,,membrane vesicle from MRP3-expressing Sf9 cell; uptake,Sf9,,,,,human,mbds0003,v2007,2013-12-09 20:53:23
mbbd000001588,mbcd0003034,mbtp000008,mbrf0001298,,=,,,inhibitor,72,18.0,%,,Benzbromarone,"18 -> 73 % of control (clone#38), 30 -> 67 % of control (clone#77)",,"MRP3-expressing fibroblast from kidney of mdr1a/1b and mrp1 (-/-) mouse; increase in Etoposide intracellular accumulation (Etoposide: 2 microM, Benzbromarone: 250 microM)",fibroblast from kidney,mbcd0002466,,,,human,mbds0003,v2007,2013-12-09 20:53:24
mbbd000001597,mbcd0003043,mbtp000008,mbrf0001299,,=,,,substrate,28,0.62,mM,0.23,Methotrexate,,,membrane vesicle from MRP3-expressing HEK293 cell; uptake,HEK293,,,,,human,mbds0003,v2007,2013-12-09 20:01:17
mbbd000001606,mbcd0000819,mbtp000008,mbrf0001300,,,,,substrate,,,,,TLC-S; taurolithocholate-S,,,membrane vesicle from MRP3-expressing Sf9 cell; uptake,Sf9,,,,,human,mbds0003,v2007,2014-02-26 06:31:16
mbbd000001607,mbcd0001664,mbtp000008,mbrf0001300,,,,,non-substrate,,,,,TC; taurocholate,,,membrane vesicle from MRP3-expressing Sf9 cell; uptake,Sf9,,,,,human,mbds0003,v2007,2013-12-09 20:52:19
mbbd000001608,mbcd0003043,mbtp000008,mbrf0001300,,=,,,inhibitor,29,1200.0,microM,,MTX,,,membrane vesicle from MRP3-expressing Sf9 cell; inhibition of E217_G uptake,Sf9,mbcd0000387,,,,human,mbds0003,v2007,2013-12-09 20:53:29
mbbd000001609,mbcd0000387,mbtp000008,mbrf0001300,,=,,,substrate,28,42.9,microM,4.3,E217betaG,,,membrane vesicle from MRP3-expressing Sf9 cell; uptake,Sf9,,50,nM,,human,mbds0003,v2007,2013-12-09 20:53:29
mbbd000001610,mbcd0000369,mbtp000008,mbrf0001300,,=,,,inhibitor,29,5.6,microM,,E3040 glucuronide,,,membrane vesicle from MRP3-expressing Sf9 cell; inhibition of E217_G uptake,Sf9,mbcd0000387,,,,human,mbds0003,v2007,2013-12-09 20:54:17
mbbd000001611,mbcd0000369,mbtp000008,mbrf0001300,,,,,substrate,,,,,E3040-glu,,,membrane vesicle from MRP3-expressing Sf9 cell; uptake,Sf9,,,,,human,mbds0003,v2007,2013-12-09 21:00:49
mbbd000001612,mbcd0000070,mbtp000008,mbrf0001300,,=,,,inhibitor,29,105.0,microM,,4-methylumbelliferone glucuronide,,,membrane vesicle from MRP3-expressing Sf9 cell; inhibition of E217_G uptake,Sf9,mbcd0000387,,,,human,mbds0003,v2007,2013-12-09 20:54:13
mbbd000001613,mbcd0000047,mbtp000008,mbrf0001300,,=,,,inhibitor,29,337.0,microM,,DNP-SG,,,membrane vesicle from MRP3-expressing Sf9 cell; inhibition of E217_G uptake,Sf9,mbcd0000387,,,,human,mbds0003,v2007,2013-12-09 20:54:13
mbbd000001614,mbcd0000819,mbtp000008,mbrf0001301,,=,,,inhibitor,72,8.0,%,,Taurolithocholic acid sulphate,,,"membrane vesicles from MRP3-expressing Sf9 cells ; inhibition of Etoposide glucuronide uptake (Etoposide glucuronide: 0.094 microM, TLC-S: 50.0 microM)",Sf9,mbcd0000398,,,,human,mbds0003,v2007,2013-12-09 20:54:13
mbbd000001615,mbcd0000819,mbtp000008,mbrf0001301,,=,,,inhibitor,72,8.0,%,,Taurolithocholic acid sulphate,(50)microM,,"membrane vesicle from MRP3-expressing Sf9 cell; inhibition of Etoposide glucuronide uptake (Etoposide glucuronide: 0.094 microM, TLCAS: 50 microM)",Sf9,mbcd0000398,,,,human,mbds0003,v2007,2013-12-09 20:54:13
mbbd000001616,mbcd0000817,mbtp000008,mbrf0001301,,=,,,inhibitor,72,9.0,%,,Taurodeoxycholate,(500)microM,,"membrane vesicle from MRP3-expressing Sf9 cell; inhibition of Etoposide glucuronide uptake (Etoposide glucuronide: 0.094 microM, TDCA: 500 microM)",Sf9,mbcd0000398,,,,human,mbds0003,v2007,2013-12-09 21:00:48
mbbd000001617,mbcd0000817,mbtp000008,mbrf0001301,,=,,,inhibitor,72,9.0,%,,Taurodeoxycholate,,,"membrane vesicles from MRP3-expressing Sf9 cells ; inhibition of Etoposide glucuronide uptake (Etoposide glucuronide: 0.094 microM, TDCA: 500.0 microM)",Sf9,mbcd0000398,,,,human,mbds0003,v2007,2013-12-09 21:00:48
mbbd000001618,mbcd0001664,mbtp000008,mbrf0001301,,=,,,inhibitor,72,55.0,%,,Taurocholate,,,"membrane vesicles from MRP3-expressing Sf9 cells ; inhibition of Etoposide glucuronide uptake (Etoposide glucuronide: 0.094 microM, TC: 500.0 microM)",Sf9,mbcd0000398,,,,human,mbds0003,v2007,2013-12-09 21:00:49
mbbd000001619,mbcd0001664,mbtp000008,mbrf0001301,,=,,,inhibitor,72,55.0,%,,Taurocholate,(500)microM,,"membrane vesicle from MRP3-expressing Sf9 cell; inhibition of Etoposide glucuronide uptake (Etoposide glucuronide: 0.094 microM, TCA: 500 microM)",Sf9,mbcd0000398,,,,human,mbds0003,v2007,2013-12-09 21:00:49
mbbd000001620,mbcd0000815,mbtp000008,mbrf0001301,,=,,,inhibitor,72,6.0,%,,Taurochenodeoxycholate,,,"membrane vesicles from MRP3-expressing Sf9 cells ; inhibition of Etoposide glucuronide uptake (Etoposide glucuronide: 0.094 microM, TCDC: 500.0 microM)",Sf9,mbcd0000398,,,,human,mbds0003,v2007,2013-12-09 20:15:55
mbbd000001621,mbcd0000815,mbtp000008,mbrf0001301,,=,,,inhibitor,72,6.0,%,,Taurochenodeoxycholate,(500)microM,,"membrane vesicle from MRP3-expressing Sf9 cell; inhibition of Etoposide glucuronide uptake (Etoposide glucuronide: 0.094 microM, TCDC: 500 microM)",Sf9,mbcd0000398,,,,human,mbds0003,v2007,2013-12-09 20:15:54
mbbd000001622,mbcd0002494,mbtp000008,mbrf0001301,,=,,,inhibitor,72,40.0,%,,MK571,,,"membrane vesicles from MRP3-expressing Sf9 cells ; inhibition of Etoposide glucuronide uptake (Etoposide glucuronide: 0.094 microM, MK-571: 20.0 microM)",Sf9,mbcd0000398,,,,human,mbds0003,v2007,2013-12-09 20:15:53
mbbd000001623,mbcd0002494,mbtp000008,mbrf0001301,,=,,,inhibitor,72,40.0,%,,MK571,(20)microM,,"membrane vesicle from MRP3-expressing Sf9 cell; inhibition of Etoposide glucuronide uptake (Etoposide glucuronide: 0.094 microM, MK571: 20 microM)",Sf9,mbcd0000398,,,,human,mbds0003,v2007,2013-12-09 20:15:52
mbbd000001624,mbcd0000534,mbtp000008,mbrf0001301,,=,,,inhibitor,72,24.0,%,,Lithocholic acid sulphate,,,"membrane vesicles from MRP3-expressing Sf9 cells ; inhibition of Etoposide glucuronide uptake (Etoposide glucuronide: 0.094 microM, LC-S: 20.0 microM)",Sf9,mbcd0000398,,,,human,mbds0003,v2007,2013-12-09 20:15:57
mbbd000001625,mbcd0000534,mbtp000008,mbrf0001301,,=,,,inhibitor,72,24.0,%,,Lithocholic acid sulphate,(20)microM,,"membrane vesicle from MRP3-expressing Sf9 cell; inhibition of Etoposide glucuronide uptake (Etoposide glucuronide: 0.094 microM, Lithocholic acid-sulfate: 20 microM)",Sf9,mbcd0000398,,,,human,mbds0003,v2007,2013-12-09 20:15:57
mbbd000001626,mbcd0000457,mbtp000008,mbrf0001301,,=,,,inhibitor,72,29.0,%,,Glycolithocholic acid sulphate,,,"membrane vesicles from MRP3-expressing Sf9 cells ; inhibition of Etoposide glucuronide uptake (Etoposide glucuronide: 0.094 microM, GLC-S: 20.0 microM)",Sf9,mbcd0000398,,,,human,mbds0003,v2007,2013-12-09 20:15:56
mbbd000001627,mbcd0000457,mbtp000008,mbrf0001301,,=,,,inhibitor,72,29.0,%,,Glycolithocholic acid sulphate,(20)microM,,"membrane vesicle from MRP3-expressing Sf9 cell; inhibition of Etoposide glucuronide uptake (Etoposide glucuronide: 0.094 microM, TDCA: 500 microM)",Sf9,mbcd0000398,,,,human,mbds0003,v2007,2013-12-09 20:15:56
mbbd000001628,mbcd0000455,mbtp000008,mbrf0001301,,=,,,inhibitor,72,30.0,%,,Glycocholate,,,"membrane vesicles from MRP3-expressing Sf9 cells ; inhibition of Etoposide glucuronide uptake (Etoposide glucuronide: 0.094 microM, GC: 500.0 microM)",Sf9,mbcd0000398,,,,human,mbds0003,v2007,2013-12-09 20:16:00
mbbd000001629,mbcd0000455,mbtp000008,mbrf0001301,,=,,,inhibitor,72,30.0,%,,Glycocholate,(500)microM,,"membrane vesicle from MRP3-expressing Sf9 cell; inhibition of Etoposide glucuronide uptake (Etoposide glucuronide: 0.094 microM, GC: 500 microM)",Sf9,mbcd0000398,,,,human,mbds0003,v2007,2013-12-09 20:15:59
mbbd000001630,mbcd0001021,mbtp000008,mbrf0001302,,=,,,inducer,111,1.82,fold increase,,omeprazole,increase in protein level,,HepG2 cell; Western,HepG2,,100,microM,,human,mbds0003,v2007,2013-12-09 21:01:26
mbbd000001631,mbcd0001021,mbtp000008,mbrf0001302,,=,,,inducer,98,2.36,fold increase,,omeprazole,increase in mRNA level,,HepG2 cell; RT-PCR,HepG2,,100,microM,,human,mbds0003,v2007,2013-12-09 21:01:27
mbbd000001632,mbcd0022340,mbtp000008,mbrf0001302,,=,,,inducer,98,3.26,fold increase,,beta-naphthoflavone,increase in mRNA level,,HepG2 cell; RT-PCR,HepG2,,10,microM,,human,mbds0003,v2007,2013-12-09 21:01:27
mbbd000001634,mbcd0003043,mbtp000008,mbrf0001303,,=,,,substrate,28,910.0,microM,,Methotrexate,,,MRP3-expressing MCF7 cell; uptake,MCF7,,,,,human,mbds0003,v2007,2013-12-09 21:01:25
mbbd000001635,mbcd0000440,mbtp000008,mbrf0001303,,=,,,substrate,28,2.9,microM,,15-d-PGJ2-SG,,,MRP3-expressing MCF7 cell; uptake,MCF7,,0.1-50,microM,,human,mbds0003,v2007,2013-12-09 21:01:25
mbbd000001636,mbcd0001197,mbtp000008,mbrf0001270,,,,,substrate,,,,,leucovorin,,,membrane vesicle from MRP3-expressing HEK293 cell; uptake (vesicle),HEK293,,,,,human,mbds0003,v2007,2013-12-09 21:01:26
mbbd000001637,mbcd0001664,mbtp000008,mbrf0001304,,=,,,inhibitor,25,40.0,microM,,Taurocholate,,,membrane vesicle from MRP3-expressing HEK cell; inhibition of E217_G uptake (E217_G: 0.4 microM),HEK,mbcd0000387,,,,human,mbds0003,v2007,2013-12-09 21:01:26
mbbd000001638,mbcd0001664,mbtp000008,mbrf0001304,,=,,,substrate,28,30.0,microM,9,Taurocholate,,,membrane vesicle from MRP3-expressing HEK cell; uptake,HEK293,,1-1000,microM,,human,mbds0003,v2007,2013-12-09 21:01:25
mbbd000001639,mbcd0000387,mbtp000008,mbrf0001304,,=,,,substrate,28,29.0,microM,,E217betaG,,,membrane vesicle from MRP3-expressing HEK cell; uptake,HEK293,,0.1-135,microM,,human,mbds0003,v2007,2013-12-09 21:01:25
mbbd000001640,mbcd0000056,mbtp000008,mbrf0001274,,=,,,substrate,28,9.2,microM,2.3,EE-G,,,membrane vesicle from MRP2-expressing Sf9 cell; uptake,Sf9,,0.2-200,microM,,human,mbds0003,v2007,2013-12-09 19:55:18
mbbd000001641,mbcd0001416,mbtp000005,mbrf0001275,,=,,,inducer,97,2.5,fold,,rifampicin,protein levels,,HepG2 hepatoma cells; MRP2 expresion Western blot,HepG2,,,,,human,mbds0010,,2013-12-08 01:54:55
mbbd000001642,mbcd0000042,mbtp000008,mbrf0001275,,=,,,inducer,97,1.5,fold,,2-AAF,protein levels,,HepG2 hepatoma cells; MRP2 mRNA; compound 100 microM,HepG2,,,,,human,mbds0003,v2007,2013-12-08 01:54:56
mbbd000001643,mbcd0000848,mbtp000008,mbrf0001305,,=,,,inhibitor,72,76.0,%,9,TXB2; thromboxane B2,,,membrane vesicle from MRP3-expressing Sf9 cells; inhibition of E217betaG transport,Sf9,mbcd0000387,20,microM,,human,mbds0003,v2007,2013-11-05 07:28:16
mbbd000001644,mbcd0000713,mbtp000008,mbrf0001305,,=,,,inhibitor,72,76.0,%,1,PGA1,,,membrane vesicle from MRP3-expressing Sf9 cells; inhibition of E217betaG transport,Sf9,mbcd0000387,20,microM,,human,mbds0003,v2007,2013-11-05 07:28:16
mbbd000001645,mbcd0003007,mbtp000008,mbrf0001306,,,,,inducer,,,,,PB,,,HepG2 cell; Northern,HepG2,,,,,human,mbds0003,v2007,2013-12-09 19:55:19
mbbd000001647,mbcd0020884,mbtp000008,mbrf0001288,,=,,,inducer,111,14.0,fold increase,,Nocodazole,increase in promoter activity,,promoter constructs in HepG2 cell; reporter gene activity,HepG2,,25,microM,,human,mbds0003,v2007,2013-12-09 19:55:19
mbbd000001648,mbcd0003043,mbtp000008,mbrf0001308,,<,,,inhibitor,72,10.0,%,,MTX,,,"membrane vesicles from HEK293T cells; inhibition of E217_G uptake (E217_G: 0.40 microM, MTX: 1000 microM)",HEK293T,mbcd0000387,,,,human,mbds0003,v2007,2013-12-09 20:17:52
mbbd000001649,mbcd0003043,mbtp000008,mbrf0001308,,,,,substrate,,,,,MTX,,,membrane vesicles from HEK293T cells; uptake,HEK293T,,,,,human,mbds0003,v2007,2013-12-09 20:17:51
mbbd000001650,mbcd0002917,mbtp000008,mbrf0001308,,,,,substrate,,,,,LTC4,,,membrane vesicles from HEK293T cells; uptake,HEK293T,,,,,human,mbds0003,v2007,2013-12-09 19:53:59
mbbd000001651,mbcd0003074,mbtp000008,mbrf0001293,,,,,substrate,,,,,glyburide,,,MRP3-expressing MDCK cells,MDCK,,,,,human,mbds0010,,2013-11-24 23:10:14
mbbd000001652,mbcd0003074,mbtp000008,mbrf0001293,,=,,,inhibitor,72,1350.0,%,,glyburide,(200)microM,,MRP3-expressing MDCK cells; inhibition of 5-carboxyfluorescein accumulation,,,,,,human,mbds0003,v2007,2013-12-09 20:00:37
mbbd000001653,mbcd0003025,mbtp000008,mbrf0001293,,=,,,inhibitor,72,350.0,%,,indomethacin,(200)microM,,MRP3-expressing MDCK cells; inhibition of 5-carboxyfluorescein accumulation,,,,,,human,mbds0003,v2007,2013-12-09 20:00:38
mbbd000001654,mbcd0003025,mbtp000008,mbrf0001293,,=,,,inhibitor,100,1.8,fold increase,,indomethacin,1.8-fold increase of glyburide accumulation,,MRP3-expressing MDCK cells; accumulation of substrate glyburide,,,,,,human,mbds0003,v2007,2013-12-09 20:00:41
mbbd000001655,mbcd0002981,mbtp000002,mbrf0001309,,,,,substrate,,,,,mitoxantrone,,,MCF-7 and MCF-7 AdVp3000 cell; intracellular accumulation,MCF7,,,,,human,mbds0003,v2007,2013-12-09 20:00:42
mbbd000001656,mbcd0002981,mbtp000002,mbrf0001309,,,,,substrate,,,,,mitoxantrone,,,S1 and S1-M1-80 cell; intracellular accumulation,S1,,,,,human,mbds0003,v2007,2013-12-09 20:00:38
mbbd000001657,mbcd0000496,mbtp000002,mbrf0001310,,,,,substrate,,,,,J-107088,,,BCRP-transfected PC-13 cell; intracellular accumulation,PC-13,,,,,human,mbds0003,v2007,2013-12-09 20:00:40
mbbd000001658,mbcd0003187,mbtp000002,mbrf0001311,,,,,substrate,,,,,TPT,,,T8 cell; increase in intracellular accumulation by GF120918,IGROV1,,,,,human,mbds0003,v2007,2013-12-09 19:53:58
mbbd000001659,mbcd0000779,mbtp000002,mbrf0001311,,,,,substrate,,,,,SN-38,,,T8 and MX3 cell; increase of cytotoxicity by GF120918,IGROV1,,,,,human,mbds0003,v2007,2013-12-09 19:53:58
mbbd000001661,mbcd0002091,mbtp000002,mbrf0001311,,,,,substrate,,,,,CPT-11,,,T8 and MX3 cell; increase of cytotoxicity by GF120918,IGROV1,,,,,human,mbds0003,v2007,2013-12-09 20:51:06
mbbd000001662,mbcd0001808,mbtp000002,mbrf0001311,,~,,,inhibitor,100,62.0,ng/mg protein,10,GF120918,cellular accumulation of TPT in T8 cells was 70 +/- 7 ng/mg protein at 2 microM GF120918,,"T8 and MX3 cell; increase in Topotecan intracellular accumulation (Topotecan: 1.9 microM, GF120918: 2 microM) ",MX3,mbcd0003187,2,microM,,human,mbds0003,v2007,2013-12-09 20:51:05
mbbd000001664,mbcd0000100,mbtp000002,mbrf0001311,,,,,substrate,,,,,9-AC,,,T8 and MX3 cell; increase of cytotoxicity by GF120918,IGROV1,,,,,human,mbds0003,v2007,2013-12-09 20:51:05
mbbd000001665,mbcd0000746,mbtp000002,mbrf0001312,,=,,,substrate,76,4.5,microM,,Rhodamine 123,,,membrane vesicle from BCRP-expressing Sf9 cell; ATP hydrolysis,Sf9,,,,,human,mbds0003,v2007,2013-12-09 20:51:05
mbbd000001666,mbcd0003024,mbtp000002,mbrf0001312,,=,,,substrate,76,1.0,microM,,Prazosin,,,membrane vesicle from BCRP-expressing Sf9 cell; ATP hydrolysis,Sf9,,0-100,microM,,human,mbds0003,v2007,2013-12-09 20:51:05
mbbd000001667,mbcd0002981,mbtp000002,mbrf0001312,,=,,,substrate,76,7.0,microM,,Mitoxantrone,,,membrane vesicle from BCRP-expressing Sf9 cell; ATP hydrolysis,Sf9,,10,nM,,human,mbds0003,v2007,2013-12-09 20:51:05
mbbd000001668,mbcd0002422,mbtp000002,mbrf0001312,,=,,,inhibitor,29,1.3,microM,,fumitremorgin C,,,membrane vesicle from BCRP-expressing Sf9 cell; inhibition of ATPase ,Sf9,,,,,human,mbds0003,v2007,2013-12-09 20:51:06
mbbd000001669,mbcd0025844,mbtp000002,mbrf0001312,,=,,,substrate,76,5.0,microM,,Doxorubicin,,,membrane vesicle from BCRP-expressing Sf9 cell; ATP hydrolysis,Sf9,,,,,human,mbds0003,v2007,2013-12-09 20:51:06
mbbd000001670,mbcd0005183,mbtp000002,mbrf0001312,,=,,,substrate,76,2.5,microM,,Daunorubicin,,,membrane vesicle from BCRP-expressing Sf9 cell; ATP hydrolysis,Sf9,,,,,human,mbds0003,v2007,2013-12-09 19:54:56
mbbd000001671,mbcd0000311,mbtp000002,mbrf0001312,,=,,,inhibitor,29,0.5,microM,,CsA,,,membrane vesicle from BCRP-expressing Sf9 cell; inhibition of ATPase ,Sf9,,,,,human,mbds0003,v2007,2013-12-09 19:54:57
mbbd000001672,mbcd0000780,mbtp000002,mbrf0001313,,=,,,substrate,28,26.0,microM,,SN-38-glucuronide,,,membrane vesicle from PC-6/SN2-5H; uptake,PC-6/SN2-5H,,30,microM,,human,mbds0003,v2007,2013-12-09 19:54:57
mbbd000001673,mbcd0000779,mbtp000002,mbrf0001313,,=,,,substrate,28,4.0,microM,,SN-38,,,membrane vesicle from PC-6/SN2-5H; uptake,PC-6/SN2-5H,,30,microM,,human,mbds0003,v2007,2013-12-09 19:54:57
mbbd000001674,mbcd0000474,mbtp000002,mbrf0001314,,,,,substrate,,,,,Hoechst 33342,,,BCRP-expressing MCF-7 cell; efflux,MCF7,,,,,human,mbds0003,v2007,2013-12-09 19:54:59
mbbd000001675,mbcd0003211,mbtp000002,mbrf0001315,,=,,,inhibitor,8,4.1,fold,,Estrone,reversal activity (ratio of IC50 values in the absence or presence of the steroid),,"BCRP-expressing K562 cells: flow cytometric analysis; inhibition of Topotecan efflux (Topotecan: 20 microM, Estrone: 10 microM)",K562,mbcd0003187,10,microM,,human,mbds0003,v2007,2013-11-11 03:52:51
mbbd000001676,mbcd0003055,mbtp000002,mbrf0001315,,,,,inhibitor,,,,,17beta-estradiol,,,"BCRP-expressing K562 cells: flow cytometric analysis; inhibition of Topotecan efflux (Topotecan: 20 microM, beta-Estradiol: 10 microM)",K562,mbcd0003187,,,,human,mbds0003,v2007,2013-10-14 18:22:47
mbbd000001677,mbcd0000779,mbtp000002,mbrf0001316,,,,,substrate,,,,,SN-38,,,Cytotoxicity,MT-4,,,,,human,mbds0003,v2007,2013-12-09 19:55:00
mbbd000001678,mbcd0002981,mbtp000002,mbrf0001316,,,,,substrate,,,,,mitoxantrone,,,Cytotoxicity,MT-4,,,,,human,mbds0003,v2007,2013-12-09 19:55:00
mbbd000001679,mbcd0002982,mbtp000002,mbrf0001316,,,,,substrate,,,,,3TC,,,Anti-HIV-1 activity,MT-4,,,,,human,mbds0003,v2007,2013-12-09 19:55:00
mbbd000001680,mbcd0002091,mbtp000002,mbrf0001316,,,,,substrate,,,,,CPT-11; 7-ethyl-10-4-(1-piperidino)-1-piperidino c,,,Cytotoxicity,MT-4,,,,,human,mbds0003,v2007,2013-12-09 20:06:22
mbbd000001681,mbcd0002466,mbtp000002,mbrf0001316,,,,,substrate,,,,,etoposide,,,Cytotoxicity,MT-4,,,,,human,mbds0003,v2007,2013-12-09 20:06:21
mbbd000001682,mbcd0025844,mbtp000002,mbrf0001316,,,,,substrate,,,,,DOX,,,Cytotoxicity,MT-4,,,,,human,mbds0003,v2007,2013-12-09 20:06:22
mbbd000001683,mbcd0001107,mbtp000002,mbrf0001316,,,,,substrate,,,,,AZT,,,Cytotoxicity,MT-4,,,,,human,mbds0003,v2007,2013-12-09 20:06:22
mbbd000001684,mbcd0001107,mbtp000002,mbrf0001316,,,,,substrate,,,,,AZT,,,Anti-HIV-1 activity,MT-4,,,,,human,mbds0003,v2007,2013-12-09 20:06:19
mbbd000001685,mbcd0001372,mbtp000002,mbrf0001316,,,,,substrate,,,,,actinomycin D,,,Cytotoxicity,MT-4,,,,,human,mbds0003,v2007,2013-12-09 20:06:18
mbbd000001686,mbcd0003187,mbtp000002,mbrf0001317,,,,,substrate,,,,,topotecan,,,BCRP-expressing K562 cell; drug resistance,K562,,,,,human,mbds0003,v2007,2013-12-09 20:06:20
mbbd000001697,mbcd0000779,mbtp000002,mbrf0001317,,,,,substrate,,,,,SN-38,,,BCRP-expressing K562 cell; drug resistance,K562,,,,,human,mbds0003,v2007,2013-12-09 20:57:25
mbbd000001698,mbcd0002981,mbtp000002,mbrf0001317,,,,,substrate,,,,,mitoxantrone,,,BCRP-expressing K562 cell; drug resistance,K562,,,,,human,mbds0003,v2007,2013-12-09 20:57:25
mbbd000001699,mbcd0003211,mbtp000002,mbrf0001317,,=,,,inhibitor,25,3.0,microM,,Estrone,,,BCRP-expressing K562 cell; drug resistance(Mitoxantrone),K562,,,,,human,mbds0003,v2007,2013-12-09 20:57:25
mbbd000001700,mbcd0003211,mbtp000002,mbrf0001317,,=,,,inhibitor,25,10.0,microM,,Estrone,,,BCRP-expressing K562 cell; drug resistance(SN-38),K562,,,,,human,mbds0003,v2007,2013-12-09 20:52:48
mbbd000001701,mbcd0003211,mbtp000002,mbrf0001317,,,,,inhibitor,,,,,Estrone,,,BCRP-expressing K562 cell; inhibition of topotecan uptake,K562,mbcd0003187,,,,human,mbds0003,v2007,2013-12-09 20:52:48
mbbd000001702,mbcd0000345,mbtp000002,mbrf0001317,,=,,,inhibitor,25,3.0,microM,,Diethylstilbestrol dipropionate,,,BCRP-expressing K562 cell; drug resistance(Mitoxantrone),K562,,,,,human,mbds0003,v2007,2013-12-09 20:52:49
mbbd000001703,mbcd0000345,mbtp000002,mbrf0001317,,=,,,inhibitor,25,3.0,microM,,Diethylstilbestrol dipropionate,,,BCRP-expressing K562 cell; drug resistance(SN-38),K562,,,,,human,mbds0003,v2007,2013-12-09 20:52:49
mbbd000001704,mbcd0000345,mbtp000002,mbrf0001317,,,,,inhibitor,,,,,Diethylstilbestrol dipropionate,,,BCRP-expressing K562 cell; inhibition of topotecan uptake,K562,mbcd0003187,,,,human,mbds0003,v2007,2013-12-09 19:54:02
mbbd000001705,mbcd0000968,mbtp000002,mbrf0001317,,=,,,inhibitor,25,0.5,microM,,Diethylstilbestrol,,,BCRP-expressing K562 cell; drug resistance(Mitoxantrone),K562,,,,,human,mbds0003,v2007,2013-12-09 19:54:02
mbbd000001706,mbcd0000968,mbtp000002,mbrf0001317,,=,,,inhibitor,25,0.5,microM,,Diethylstilbestrol,,,BCRP-expressing K562 cell; drug resistance(SN-38),K562,,,,,human,mbds0003,v2007,2013-12-09 20:52:48
mbbd000001707,mbcd0000968,mbtp000002,mbrf0001317,,,,,inhibitor,,,,,Diethylstilbestrol,,,BCRP-expressing K562 cell; inhibition of topotecan uptake,K562,mbcd0003187,,,,human,mbds0003,v2007,2013-12-09 20:52:48
mbbd000001708,mbcd0003001,mbtp000002,mbrf0001318,,,,,substrate,,,,,testosterone,,,inside-out membrane vesicles from BCRP-expressing Lactococcus lactis cells; ATPase assay,Lactococcus lactis,,,,,human,mbds0003,v2007,2013-11-24 23:55:09
mbbd000001709,mbcd0002889,mbtp000002,mbrf0001318,,,,,substrate,,,,,tamoxifen,,,inside-out membrane vesicles from BCRP-expressing Lactococcus lactis cells; ATPase assay,Lactococcus lactis,,,,,human,mbds0003,v2007,2013-11-24 23:55:10
mbbd000001710,mbcd0000746,mbtp000002,mbrf0001318,,,,,substrate,,,,,rhodamine 123,,,BCRP-expressing Lactococcus lactis cell; uptake,Lactococcus lactis,,,,,human,mbds0003,v2007,2013-12-09 19:59:33
mbbd000001712,mbcd0000474,mbtp000002,mbrf0001318,,,,,substrate,,,,,Hoechst 33342,,,membrane vesicle from BCRP-expressing Lactococcus lactis cell; uptake,Lactococcus lactis,,,,,human,mbds0003,v2007,2013-12-09 19:59:33
mbbd000001716,mbcd0003055,mbtp000002,mbrf0001318,,,,,substrate,,,,,estradiol,,,BCRP-expressing Lactococcus lactis cell; uptake,Lactococcus lactis,,,,,human,mbds0003,v2007,2013-12-09 19:59:35
mbbd000001717,mbcd0003055,mbtp000002,mbrf0001318,,,,,substrate,,,,,estradiol,,,inside-out membrane vesicle from BCRP-expressing Lactococcus lactis cell; ATPase assay,Lactococcus lactis,,,,,human,mbds0003,v2007,2013-12-09 19:59:34
mbbd000001718,mbcd0005183,mbtp000002,mbrf0001318,,,,,substrate,,,,,daunomycin,,,membrane vesicle from BCRP-expressing Lactococcus lactis cell; ATPase assay,Lactococcus lactis,,,,,human,mbds0003,v2007,2013-12-09 19:59:36
mbbd000001719,mbcd0001668,mbtp000002,mbrf0001318,,,,,substrate,,,,,cholesterol,,,inside-out membrane vesicles from BCRP-expressing Lactococcus lactis cells; ATPase assay,Lactococcus lactis,,,,,human,mbds0003,v2007,2013-11-24 23:15:12
mbbd000001720,mbcd0003126,mbtp000002,mbrf0001319,,=,,,inhibitor,72,76.0,%,,Pravastatin,(200)microM,,membrane vesicle from ABCG2-expressing P388 cell; inhibition of E1S,P388,mbcd0003075,,,,human,mbds0003,v2007,2013-12-09 20:52:23
mbbd000001721,mbcd0003043,mbtp000002,mbrf0001319,,,,,substrate,,,,,methotrexate,,,membrane vesicle from ABCG2-expressing P388 cell; uptake (vesicle),P388,,,,,human,mbds0003,v2007,2013-12-09 20:52:24
mbbd000001722,mbcd0003075,mbtp000002,mbrf0001319,,=,,,substrate,28,16.6,microM,3.4,E1S,,,membrane vesicle from ABCG2-expressing P388 cell; uptake (vesicle),P388,,52; 500,nM,,human,mbds0003,v2007,2013-12-09 20:52:23
mbbd000001723,mbcd0003211,mbtp000002,mbrf0001319,,=,,,inhibitor,72,56.0,%,,Estrone,(200)microM,,membrane vesicle from ABCG2-expressing P388 cell; inhibition of E1S,P388,mbcd0003075,,,,human,mbds0003,v2007,2013-12-09 20:52:23
mbbd000001724,mbcd0000387,mbtp000002,mbrf0001319,,,,,substrate,,,,,E217betaG,,,membrane vesicle from ABCG2-expressing P388 cell; uptake (vesicle),P388,,,,,human,mbds0003,v2007,2013-12-09 20:55:10
mbbd000001725,mbcd0025844,mbtp000002,mbrf0001319,,=,,,inhibitor,72,72.0,%,,doxorubicin,(1000)microM,,membrane vesicle from ABCG2-expressing P388 cell; inhibition of E1S,P388,mbcd0003075,,,,human,mbds0003,v2007,2013-12-09 20:52:23
mbbd000001731,mbcd0000071,mbtp000002,mbrf0001319,,,,,substrate,,,,,4-MUS,,,membrane vesicle from ABCG2-expressing P388 cell; uptake (vesicle),P388,,,,,human,mbds0003,v2007,2013-12-09 19:57:31
mbbd000001732,mbcd0000071,mbtp000002,mbrf0001319,,=,,,substrate,28,12.9,microM,2.1,4-MUS,,,membrane vesicle from ABCG2-expressing mouse lymphoma(P388)cell; uptake (vesicle),P388,,0.7; 5,microM,,human,mbds0003,v2007,2013-12-09 19:57:33
mbbd000001733,mbcd0000070,mbtp000002,mbrf0001319,,,,,substrate,,,,,4-MUG,,,membrane vesicle from ABCG2-expressing P388 cell; uptake (vesicle),P388,,,,,human,mbds0003,v2007,2013-12-09 19:57:32
mbbd000001734,mbcd0000070,mbtp000002,mbrf0001319,,=,,,inhibitor,72,84.0,%,,4-MUG,(500)microM,,membrane vesicle from ABCG2-expressing P388 cell; inhibition of E1S,P388,mbcd0003075,,,,human,mbds0003,v2007,2013-12-09 19:57:30
mbbd000001737,mbcd0003043,mbtp000002,mbrf0001320,,=,,,substrate,28,5.7,mM,,Methotrexate,,,membrane vesicle from ABCG2-expressing HEK-293 cell; uptake (vesicle),HEK293,,1-5000,nM,,human,mbds0003,v2007,2013-12-09 19:57:31
mbbd000001738,mbcd0000100,mbtp000002,mbrf0001321,,,,,substrate,,,,,9-AC,,,BCRP-expressing HEK293 cell; uptake,HEK293,,,,,human,mbds0003,v2007,2013-12-09 20:53:06
mbbd000001741,mbcd0003043,mbtp000002,mbrf0001270,,=,,,substrate,28,1.34,mM,0.18,MTX,,,membrane vesicles from ABCG2-R482-expressing HEK293 cells; uptake,HEK293,,100,microM,,human,mbds0003,v2007,2013-11-12 01:05:27
mbbd000001742,mbcd0003959,mbtp000002,mbrf0001270,,=,,,substrate,88,87.0,pmol mg-1 min-1,,FA,,,membrane vesicle from ABCG2-R482-expressing HEK293 cells; uptake,HEK293,,,,,human,mbds0003,v2007,2013-11-17 07:41:51
mbbd000001743,mbcd0000387,mbtp000002,mbrf0001270,,=,,,substrate,28,44.2,microM,4.3,E(2)17betaG,,,membrane vesicle from ABCG2-R482-expressing HEK293 cells; uptake,HEK293,,,,,human,mbds0003,v2007,2013-11-17 07:41:51
mbbd000001744,mbcd0000819,mbtp000002,mbrf0001322,,=,,,inhibitor,72,30.0,%,,taurolithocholate sulfate,(30)microM,,membrane vesicle from BCRP-expressing K562 cell; inhibition of E1S,K562,mbcd0003075,,,,human,mbds0003,v2007,2013-12-09 20:54:21
mbbd000001745,mbcd0003109,mbtp000002,mbrf0001322,,=,,,inhibitor,72,20.0,%,,Taurolithocholate,(30)microM,,membrane vesicle from BCRP-expressing K562 cell; inhibition of E1S,K562,mbcd0003075,,,,human,mbds0003,v2007,2013-12-09 20:14:45
mbbd000001746,mbcd0001664,mbtp000002,mbrf0001322,,=,,,inhibitor,72,70.0,%,,Taurocholate,(30)microM,,membrane vesicle from BCRP-expressing K562 cell; inhibition of E1S,K562,mbcd0003075,,,,human,mbds0003,v2007,2013-12-09 20:54:22
mbbd000001747,mbcd0002981,mbtp000002,mbrf0001322,,,,,substrate,,,,,MXR,,,BCRP-expressing LLC-PK1 cell; drug resistance,LLC-PK1,,,,,human,mbds0003,v2007,2013-12-09 20:54:23
mbbd000001748,mbcd0002422,mbtp000002,mbrf0001322,,,,,substrate,,,,,FTC,,,BCRP-expressing LLC-PK1 cell; drug resistance,LLC-PK1,,,,,human,mbds0003,v2007,2013-12-09 20:54:23
mbbd000001749,mbcd0003075,mbtp000002,mbrf0001322,,=,,,substrate,28,6.8,microM,1.4,E1S,,,membrane vesicle from BCRP-expressing K562 cell,K562,,50,nM,,human,mbds0003,v2007,2013-12-09 20:54:24
mbbd000001750,mbcd0003075,mbtp000002,mbrf0001322,,,,,substrate,,,,,E1S,,,BCRP-expressing LLC-PK1 cell,LLC-PK1,,,,,human,mbds0003,v2007,2013-12-09 20:09:01
mbbd000001751,mbcd0003211,mbtp000002,mbrf0001322,,=,,,inhibitor,72,70.0,%,,E1,(30)microM,,membrane vesicle from BCRP-expressing K562 cell; inhibition of E1S,K562,mbcd0003075,,,,human,mbds0003,v2007,2013-12-09 20:03:28
mbbd000001753,mbcd0002635,mbtp000002,mbrf0001322,,=,,,inhibitor,72,70.0,%,,cortisol,(30)microM,,membrane vesicle from BCRP-expressing K562 cell; inhibition of E1S,K562,mbcd0003075,,,,human,mbds0003,v2007,2013-12-09 20:03:24
mbbd000001754,mbcd0000779,mbtp000002,mbrf0001322,,=,,,inhibitor,72,40.0,%,,SN-38,(20)microM,,membrane vesicle from BCRP-expressing K562 cell; inhibition of E1S,K562,mbcd0003075,,,,human,mbds0003,v2007,2013-12-09 20:03:22
mbbd000001755,mbcd0000779,mbtp000002,mbrf0001322,,,,,substrate,,,,,SN-38,,,BCRP-expressing LLC-PK1 cell; drug resistance,LLC-PK1,,,,,human,mbds0003,v2007,2013-12-09 20:03:21
mbbd000001756,mbcd0000389,mbtp000002,mbrf0001322,,=,,,inhibitor,72,50.0,%,,E2S,(30)microM,,membrane vesicle from BCRP-expressing K562 cell; inhibition of E1S,K562,mbcd0003075,,,,human,mbds0003,v2007,2013-12-09 20:03:20
mbbd000001757,mbcd0000389,mbtp000002,mbrf0001322,,,,,substrate,,,,,E2S; 17beta-estradiol 3-sulfate,,,BCRP-expressing LLC-PK1 cell; efflux,LLC-PK1,,,,,human,mbds0003,v2007,2013-12-09 20:03:19
mbbd000001758,mbcd0003055,mbtp000002,mbrf0001322,,=,,,inhibitor,72,50.0,%,,E2,(30)microM,,membrane vesicle from BCRP-expressing K562 cell; inhibition of E1S,K562,mbcd0003075,,,,human,mbds0003,v2007,2013-12-09 20:03:30
mbbd000001760,mbcd0001808,mbtp000002,mbrf0001073,,~,,,inhibitor,103,33.0,%,2,GF120918,,,BCRP-expressing EPG85-257 cell; inhibition of C6-NBD-PS efflux,EPG85-257,mbcd0031470,10,microM,,human,mbds0003,v2007,2013-12-09 20:53:16
mbbd000001763,mbcd0001652,mbtp000002,mbrf0001323,,,,,substrate,,,,,flavopiridol,,,resistance; correlation hBCRPmRNA with flavopiridol induced apoptosis,MCF7,,,,,human,mbds0003,v2007,2013-12-09 20:53:16
mbbd000001764,mbcd0002981,mbtp000002,mbrf0001324,,=,,,inhibitor,72,50.0,%,,mitoxantrone,,,membrane vesicle from BCRP-expressing MCF7 cell; inhibition of MTX,MCF7,mbcd0003043,50,microM,,human,mbds0003,v2007,2013-12-09 20:53:17
mbbd000001767,mbcd0003043,mbtp000002,mbrf0001324,,=,,,substrate,28,681.0,microM,280,MTX,,,membrane vesicle from BCRP-expressing MCF7 cell; uptake (vesicle),MCF7,,0-2000,microM,,human,mbds0003,v2007,2013-12-09 20:53:16
mbbd000001768,mbcd0002422,mbtp000002,mbrf0001324,,~,,,inhibitor,3,60.0,%,,FTC,,,membrane vesicle from BCRP-expressing MCF7 cell; inhibition of MTX,MCF7,mbcd0003043,100,microM,,human,mbds0003,v2007,2013-12-09 20:04:00
mbbd000001769,mbcd0000779,mbtp000002,mbrf0001325,,,,,substrate,,,,,SN-38,,,BCRP-expressing PA317 cell; drug resistance,PA317,,,,,human,mbds0003,v2007,2013-12-09 20:53:15
mbbd000001770,mbcd0002981,mbtp000002,mbrf0001325,,,,,substrate,,,,,mitoxantrone,,,BCRP-expressing PA317 cell; drug resistance,PA317,,,,,human,mbds0003,v2007,2013-12-09 20:01:11
mbbd000001771,mbcd0002422,mbtp000002,mbrf0001325,,,,,inhibitor,,,,,Fumitremorgin C,Growth inhibition,,BCRP-expressing PA317 cell; drug resistance,PA317,mbcd0002981,,,,human,mbds0003,v2007,2013-12-09 20:01:11
mbbd000001772,mbcd0003211,mbtp000002,mbrf0001325,,,,,inhibitor,,,,,Estrone,Growth inhibition,,BCRP-expressing PA317 cell; drug resistance,PA317,mbcd0002981,,,,human,mbds0003,v2007,2013-12-09 19:58:57
mbbd000001773,mbcd0000746,mbtp000002,mbrf0001326,,,,,substrate,,,,,Rho123,,,BCRP-expressing oocyte cell; uptake,Xenopus laevis oocytes,,,,,human,mbds0003,v2007,2013-12-09 20:04:10
mbbd000001774,mbcd0002981,mbtp000002,mbrf0001326,,,,,substrate,,,,,MX,,,BCRP-expressing oocyte cell; uptake,Xenopus laevis oocytes,,,,,human,mbds0003,v2007,2013-12-09 20:01:13
mbbd000001775,mbcd0001652,mbtp000002,mbrf0001326,,,,,substrate,,,,,FLV,,,BCRP-expressing oocyte cell; uptake,Xenopus laevis oocytes,,,,,human,mbds0003,v2007,2013-12-09 20:01:12
mbbd000001776,mbcd0005183,mbtp000002,mbrf0001326,,,,,substrate,,,,,DNR,,,BCRP-expressing oocyte cell; uptake,Xenopus laevis oocytes,,,,,human,mbds0003,v2007,2013-12-09 20:01:16
mbbd000001777,mbcd0000779,mbtp000002,mbrf0001327,,,,,substrate,,,,,SN-38,,,"PC-6/SN2-5,PC-6/SN2-5H; inhibition of accumulation by antisense of BCRP",PC-6,,,,,human,mbds0003,v2007,2013-12-09 20:01:15
mbbd000001778,mbcd0003187,mbtp000002,mbrf0001328,,,,,substrate,,,,,TPT,,,MX3 cell and T8 cell; intracellular concentration of the drug is lower compared with IGROV1,IGROV1,,,,,human,mbds0003,v2007,2013-12-09 19:58:48
mbbd000001779,mbcd0002981,mbtp000002,mbrf0001328,,,,,substrate,,,,,MX,,,MX3 cell and T8 cell; intracellular concentration of the drug is lower compared with IGROV1,IGROV1,,,,,human,mbds0003,v2007,2013-12-09 19:58:46
mbbd000001780,mbcd0022617,mbtp000002,mbrf0001329,,=,,,inhibitor,100,344.0,%,70.7,Silymarin,,,"BCRP-expressing NCI-H460 cell; increase in mitoxantrone intracellular accumulation (Mitoxantrone: 20 microM, Silymarin: 50 microM)",NCI-H460,mbcd0002981,50,microM,,human,mbds0003,v2007,2013-12-09 20:50:58
mbbd000001781,mbcd0022617,mbtp000002,mbrf0001329,,=,,,inhibitor,100,302.0,%,60.9,Silymarin,,,"BCRP-expressing MCF-7 cell; increase in mitoxantrone intracellular accumulation (Mitoxantrone: 100 microM, Silymarin: 50 microM)",MCF7,mbcd0002981,50,microM,,human,mbds0003,v2007,2013-12-09 20:50:58
mbbd000001782,mbcd0027229,mbtp000002,mbrf0001329,,=,,,inhibitor,100,331.0,%,41.4,Silibin,,,"BCRP-expressing NCI-H460 cell; increase in mitoxantrone intracellular accumulation (Mitoxantrone: 20 microM, Silybin: 50 microM)",NCI-H460,mbcd0002981,50,microM,,human,mbds0003,v2007,2013-12-09 20:50:58
mbbd000001783,mbcd0027229,mbtp000002,mbrf0001329,,=,,,inhibitor,100,209.0,%,19.7,Silibin,,,"BCRP-expressing MCF-7 cell; increase in mitoxantrone intracellular accumulation (Mitoxantrone: 100 microM, Silybin: 50 microM)",MCF7,mbcd0002981,50,microM,,human,mbds0003,v2007,2013-12-09 20:50:58
mbbd000001784,mbcd0003120,mbtp000002,mbrf0001329,,=,,,inhibitor,100,233.0,%,18.4,Quercetin,,,"BCRP-expressing NCI-H460 cell; increase in mitoxantrone intracellular accumulation (Mitoxantrone: 20 microM, Quercetin: 50 microM)",NCI-H460,mbcd0002981,50,microM,,human,mbds0003,v2007,2013-12-09 20:50:57
mbbd000001785,mbcd0003120,mbtp000002,mbrf0001329,,=,,,inhibitor,100,206.0,%,18.3,Quercetin,,,"BCRP-expressing MCF-7 cell; increase in mitoxantrone intracellular accumulation (Mitoxantrone: 100 microM, Quercetin: 50 microM)",MCF7,mbcd0002981,50,microM,,human,mbds0003,v2007,2013-12-09 20:50:57
mbbd000001786,mbcd0004171,mbtp000002,mbrf0001329,,=,,,inhibitor,100,304.0,%,33.9,Phloretin,,,"BCRP-expressing NCI-H460 cell; increase in mitoxantrone intracellular accumulation (Mitoxantrone: 20 microM, Phloretin: 50 microM)",NCI-H460,mbcd0002981,50,microM,,human,mbds0003,v2007,2013-12-09 20:50:57
mbbd000001787,mbcd0004171,mbtp000002,mbrf0001329,,=,,,inhibitor,100,216.0,%,44.1,Phloretin,,,"BCRP-expressing MCF-7 cell; increase in mitoxantrone intracellular accumulation (Mitoxantrone: 100 microM, Phloretin: 50 microM)",MCF7,mbcd0002981,50,microM,,human,mbds0003,v2007,2013-12-09 20:50:57
mbbd000001788,mbcd0003076,mbtp000002,mbrf0001329,,=,,,inhibitor,100,338.0,%,28.0,Naringenin,,,"BCRP-expressing NCI-H460 cell; increase in mitoxantrone intracellular accumulation (Mitoxantrone: 20 microM, Naringenin: 50 microM)",NCI-H460,mbcd0002981,50,microM,,human,mbds0003,v2007,2013-12-09 20:50:58
mbbd000001789,mbcd0003076,mbtp000002,mbrf0001329,,=,,,inhibitor,100,46.4,%,345,Naringenin,,,"BCRP-expressing MCF-7 cell; increase in mitoxantrone intracellular accumulation (Mitoxantrone: 100 microM, Naringenin: 50 microM)",MCF7,mbcd0002981,50,microM,,human,mbds0003,v2007,2013-12-09 20:50:58
mbbd000001790,mbcd0003217,mbtp000002,mbrf0001329,,=,,,inhibitor,100,213.0,%,23.6,Luteolin,,,"BCRP-expressing NCI-H460 cell; increase in mitoxantrone intracellular accumulation (Mitoxantrone: 20 microM, Luteolin: 50 microM)",NCI-H460,mbcd0002981,50,microM,,human,mbds0003,v2007,2013-12-09 19:53:01
mbbd000001791,mbcd0003215,mbtp000002,mbrf0001329,,=,,,inhibitor,100,42.5,%,301,Kaempferol,,,"BCRP-expressing NCI-H460 cell; increase in mitoxantrone intracellular accumulation (Mitoxantrone: 20 microM, Kaempferol: 50 microM)",NCI-H460,mbcd0002981,50,microM,,human,mbds0003,v2007,2013-12-09 19:53:00
mbbd000001792,mbcd0003215,mbtp000002,mbrf0001329,,=,,,inhibitor,100,378.0,%,17.3,Kaempferol,,,"BCRP-expressing MCF-7 cell; increase in mitoxantrone intracellular accumulation (Mitoxantrone: 100 microM, Kaempferol: 50 microM)",MCF7,mbcd0002981,50,microM,,human,mbds0003,v2007,2013-12-09 19:52:58
mbbd000001793,mbcd0004749,mbtp000002,mbrf0001329,,=,,,inhibitor,100,305.0,%,55.8,Hesperetin,,,"BCRP-expressing NCI-H460 cell; increase in mitoxantrone intracellular accumulation (Mitoxantrone: 20 microM, Hesperetin: 50 microM)",NCI-H460,mbcd0002981,50,microM,,human,mbds0003,v2007,2013-12-09 19:52:55
mbbd000001794,mbcd0004749,mbtp000002,mbrf0001329,,=,,,inhibitor,100,362.0,%,55.2,Hesperetin,,,"BCRP-expressing MCF-7 cell; increase in mitoxantrone intracellular accumulation (Mitoxantrone: 100 microM, Hesperetin: 50 microM)",MCF7,mbcd0002981,50,microM,,human,mbds0003,v2007,2013-12-09 19:53:06
mbbd000001795,mbcd0003116,mbtp000002,mbrf0001329,,=,,,inhibitor,100,331.0,%,54.0,Genistein,,,"BCRP-expressing NCI-H460 cell; increase in mitoxantrone intracellular accumulation (Mitoxantrone: 20 microM, Genistein: 50 microM)",NCI-H460,mbcd0002981,50,microM,,human,mbds0003,v2007,2013-12-09 19:53:05
mbbd000001796,mbcd0003116,mbtp000002,mbrf0001329,,=,,,inhibitor,100,412.0,%,47.0,Genistein,,,"BCRP-expressing MCF-7 cell; increase in mitoxantrone intracellular accumulation (Mitoxantrone: 100 microM, Genistein: 50 microM)",MCF7,mbcd0002981,50,microM,,human,mbds0003,v2007,2013-12-09 19:53:04
mbbd000001797,mbcd0002422,mbtp000002,mbrf0001329,,=,,,inhibitor,100,404.0,%,40.4,FTC,,,"BCRP-expressing NCI-H460 cell; increase in mitoxantrone intracellular accumulation (Mitoxantrone: 20 microM, FTC: 50 microM)",NCI-H460,mbcd0002981,10,microM,,human,mbds0003,v2007,2013-12-09 19:53:02
mbbd000001798,mbcd0002422,mbtp000002,mbrf0001329,,=,,,inhibitor,100,439.0,%,89.8,FTC,,,"BCRP-expressing MCF-7 cell; increase in mitoxantrone intracellular accumulation (Mitoxantrone: 100 microM, FTC: 50 microM)",MCF7,mbcd0002981,10,microM,,human,mbds0003,v2007,2013-12-09 19:52:52
mbbd000001799,mbcd0023723,mbtp000002,mbrf0001329,,=,,,inhibitor,100,226.0,%,37.0,Fisetin,,,"BCRP-expressing NCI-H460 cell; increase in mitoxantrone intracellular accumulation (Mitoxantrone: 20 microM, Fisetin: 50 microM)",NCI-H460,mbcd0002981,50,microM,,human,mbds0003,v2007,2013-12-09 19:52:51
mbbd000001800,mbcd0023723,mbtp000002,mbrf0001329,,=,,,inhibitor,100,223.0,%,33.2,Fisetin,,,"BCRP-expressing MCF-7 cell; increase in mitoxantrone intracellular accumulation (Mitoxantrone: 100 microM, Fisetin: 50 microM)",MCF7,mbcd0002981,50,microM,,human,mbds0003,v2007,2013-12-09 21:01:02
mbbd000001801,mbcd0013632,mbtp000002,mbrf0001329,,=,,,inhibitor,100,297.0,%,23.1,Daidzein,,,"BCRP-expressing NCI-H460 cell; increase in mitoxantrone intracellular accumulation (Mitoxantrone: 20 microM, Daidzein: 50 microM)",NCI-H460,mbcd0002981,50,microM,,human,mbds0003,v2007,2013-12-09 21:01:02
mbbd000001802,mbcd0013632,mbtp000002,mbrf0001329,,=,,,inhibitor,100,215.0,%,13.1,Daidzein,,,"BCRP-expressing MCF-7 cell; increase in mitoxantrone intracellular accumulation (Mitoxantrone: 100 microM, Daidzein: 50 microM)",MCF7,mbcd0002981,50,microM,,human,mbds0003,v2007,2013-12-09 21:01:01
mbbd000001803,mbcd0003045,mbtp000002,mbrf0001329,,=,,,inhibitor,100,367.0,%,35.5,Chrysin,,,"BCRP-expressing NCI-H460 cell; increase in mitoxantrone intracellular accumulation (Mitoxantrone: 20 microM, Chrysin: 50 microM)",NCI-H460,mbcd0002981,50,microM,,human,mbds0003,v2007,2013-12-09 21:01:01
mbbd000001804,mbcd0003045,mbtp000002,mbrf0001329,,=,,,inhibitor,100,389.0,%,94.1,Chrysin,,,"BCRP-expressing MCF-7 cell; increase in mitoxantrone intracellular accumulation (Mitoxantrone: 100 microM, Chrysin: 50 microM)",MCF7,mbcd0002981,50,microM,,human,mbds0003,v2007,2013-12-09 21:01:02
mbbd000001805,mbcd0003026,mbtp000002,mbrf0001329,,=,,,inhibitor,100,463.0,%,59.7,Biochanin A,,,"BCRP-expressing NCI-H460 cell; increase in mitoxantrone intracellular accumulation (Mitoxantrone: 20 microM, Biochanin A: 50 microM)",NCI-H460,mbcd0002981,50,microM,,human,mbds0003,v2007,2013-12-09 21:01:02
mbbd000001806,mbcd0003026,mbtp000002,mbrf0001329,,=,,,inhibitor,100,440.0,%,99.5,Biochanin A,,,"BCRP-expressing MCF-7 cell; increase in mitoxantrone intracellular accumulation (Mitoxantrone: 100 microM, Biochanin A: 50 microM)",MCF7,mbcd0002981,50,microM,,human,mbds0003,v2007,2013-12-09 21:01:02
mbbd000001807,mbcd0003091,mbtp000002,mbrf0001329,,=,,,inhibitor,100,355.0,%,36.2,Apigenin,,,"BCRP-expressing NCI-H460 cell; increase in mitoxantrone intracellular accumulation (Mitoxantrone: 20 microM, Apigenin: 50 microM)",NCI-H460,mbcd0002981,50,microM,,human,mbds0003,v2007,2013-12-09 21:01:02
mbbd000001808,mbcd0003091,mbtp000002,mbrf0001329,,=,,,inhibitor,100,321.0,%,36.1,Apigenin,,,"BCRP-expressing MCF-7 cell; increase in mitoxantrone intracellular accumulation (Mitoxantrone: 100 microM, Apigenin: 50 microM)",MCF7,mbcd0002981,50,microM,,human,mbds0003,v2007,2013-12-09 21:01:01
mbbd000001809,mbcd0003125,mbtp000002,mbrf0001330,,=,,,inhibitor,25,0.4,microM,,ZD1839,,,BCRP-expressing Sf9 cell; efflux of Hoechst33342,Sf9,mbcd0000474,,,,human,mbds0003,v2007,2013-12-09 21:01:01
mbbd000001810,mbcd0003125,mbtp000002,mbrf0001330,,~,,,stimulator,1,120.0,%,,ZD1839,activity % of basal ATPase,,BCRP-expressing Sf9 cell; stimulation of ATPase activity (0.1~1 microM),Sf9,,,,,human,mbds0003,v2007,2014-03-04 00:28:49
mbbd000001811,mbcd0027062,mbtp000002,mbrf0001330,,>,,,inhibitor,25,50.0,microM,,Verapamil,,,BCRP-expressing Sf9 cell; efflux of Hoechst33342,Sf9,mbcd0000474,,,,human,mbds0003,v2007,2013-12-09 20:16:38
mbbd000001812,mbcd0002828,mbtp000002,mbrf0001330,,=,,,inhibitor,25,0.9,microM,,STI-571,,,BCRP-expressing Sf9 cell; efflux of Hoechst33342,Sf9,mbcd0000474,,,,human,mbds0003,v2007,2013-12-09 20:16:38
mbbd000001813,mbcd0002828,mbtp000002,mbrf0001330,,=,,,inhibitor,25,0.5,microM,,STI-571,,,BCRP-expressing Sf9 cell; inhibition of ATPase activity,Sf9,,,,,human,mbds0003,v2007,2013-12-09 20:16:39
mbbd000001816,mbcd0000371,mbtp000002,mbrf0001330,,=,,,inhibitor,25,0.2,microM,,EKI-785,,,BCRP-expressing Sf9 cell; efflux of Hoechst33342,Sf9,mbcd0000474,,,,human,mbds0003,v2007,2013-12-09 20:16:36
mbbd000001817,mbcd0000371,mbtp000002,mbrf0001330,,~,,,stimulator,1,130.0,%,,EKI-785,activity % of basal ATPase,,BCRP-expressing Sf9 cell; stimulation of ATPase activity (0.1~1 microM),Sf9,,,,,human,mbds0003,v2007,2014-03-04 00:28:49
mbbd000001818,mbcd0001533,mbtp000002,mbrf0001331,,=,,,inhibitor,25,19.5,microM,,saquinavir,,,BCRP-expressing HEK cell; increase in mitoxantrone intracellular accumulation,HEK,mbcd0002981,,,,human,mbds0003,v2007,2013-12-09 20:16:40
mbbd000001819,mbcd0001938,mbtp000002,mbrf0001331,,=,,,inhibitor,25,19.5,microM,,ritonavir,,,BCRP-expressing HEK cell; increase in mitoxantrone intracellular accumulation,HEK,mbcd0002981,,,,human,mbds0003,v2007,2013-12-09 20:16:41
mbbd000001820,mbcd0026632,mbtp000002,mbrf0001331,,=,,,inhibitor,25,12.5,microM,,Nelfinavir,,,BCRP-expressing HEK cell; increase in mitoxantrone intracellular accumulation,HEK,mbcd0002981,,,,human,mbds0003,v2007,2013-12-09 21:00:41
mbbd000001821,mbcd0002828,mbtp000002,mbrf0001332,,,,,substrate,,,,,imatinib,,,BCRP-expressing HEK293 cell; cell accumulation/inhibition study by Ko-143 efflux,HEK293,,,,,human,mbds0003,v2007,2013-12-09 21:00:41
mbbd000001822,mbcd0000482,mbtp000002,mbrf0001332,,,,,substrate,,,,,STI571,,,BCRP-expressing HEK cell; uptake,HEK293,,,,,human,mbds0003,v2007,2013-12-09 20:52:38
mbbd000001823,mbcd0003187,mbtp000002,mbrf0001333,,<,,,inhibitor,25,170.0,nM,,topotecan,,,BCRP-expressing SaoS2 cell; drug resistance(Imatinib mesylate),Saos-2,,,,,human,mbds0003,v2007,2013-12-09 21:00:41
mbbd000001824,mbcd0000779,mbtp000002,mbrf0001333,,=,,,inhibitor,25,176.0,nM,,SN-38,,,BCRP-expressing SaoS2 cell; drug resistance(Imatinib mesylate),Saos-2,,,,,human,mbds0003,v2007,2013-12-09 21:00:41
mbbd000001825,mbcd0000482,mbtp000002,mbrf0001333,,~,,,inhibitor,100,1800.0,%,,Imatinib mesylate,,,"BCRP-expressing SaoS2 cell; increase in Topotecan intracellular accumulation (Topotecan: 1 microM, Imanitib mesylate: 1 microM)",Saos-2,mbcd0003187,1,microM,,human,mbds0003,v2007,2013-12-09 21:00:41
mbbd000001829,mbcd0000779,mbtp000002,mbrf0001334,,,,,substrate,,,,,SN-38,,,BCRP-expressing PC-6 cell; uptake,PC-6,,,,,human,mbds0003,v2007,2013-12-09 21:00:40
mbbd000001835,mbcd0003076,mbtp000002,mbrf0001335,,,,,inhibitor,,,,,Naringenin,,,BCRP-expressing K562 cell; inhibition of topotecan uptake (Topotecan: 20 microM),K562,mbcd0003187,,,,human,mbds0003,v2007,2013-12-09 20:15:16
mbbd000001836,mbcd0003076,mbtp000002,mbrf0001335,,=,,,inhibitor,8,10.6,,0.30,Naringenin,Reversal index (ratio of IC50 measurements in the absence of reversing agents divided by levels in the presence of reversing agents),,BCRP-expressing K562 cell; drug resistance (Mitoxantrone),K562,mbcd0002981,10,microM,,human,mbds0003,v2007,2013-12-09 20:15:13
mbbd000001837,mbcd0003076,mbtp000002,mbrf0001335,,=,,,inhibitor,8,15.2,,0.92,Naringenin,Reversal index (ratio of IC50 measurements in the absence of reversing agents divided by levels in the presence of reversing agents),,BCRP-expressing K562 cell; drug resistance (SN-38),K562,mbcd0000779,10,microM,,human,mbds0003,v2007,2013-12-09 20:15:14
mbbd000001839,mbcd0003217,mbtp000002,mbrf0001335,,~,,,inhibitor,94,1.0,,,Luteolin,,,BCRP-expressing K562 cell; drug resistance (SN-38),K562,mbcd0000779,,,,human,mbds0003,v2007,2013-12-09 20:15:11
mbbd000001840,mbcd0003215,mbtp000002,mbrf0001335,,=,,,inhibitor,8,14.2,,0.95,Kaempferol,Reversal index (ratio of IC50 measurements in the absence of reversing agents divided by levels in the presence of reversing agents),,BCRP-expressing K562 cell; drug resistance (Mitoxantrone),K562,mbcd0002981,3,microM,,human,mbds0003,v2007,2013-12-09 19:54:35
mbbd000001841,mbcd0003215,mbtp000002,mbrf0001335,,=,,,inhibitor,8,21.5,,0.22,Kaempferol,Reversal index (ratio of IC50 measurements in the absence of reversing agents divided by levels in the presence of reversing agents),,BCRP-expressing K562 cell; drug resistance (SN-38),K562,mbcd0000779,3,microM,,human,mbds0003,v2007,2013-12-09 19:54:35
mbbd000001842,mbcd0004722,mbtp000002,mbrf0001335,,~,,,inhibitor,94,0.5,,,Kaempferide,,,BCRP-expressing K562 cell; drug resistance (SN-38),K562,mbcd0000779,,,,human,mbds0003,v2007,2013-12-09 19:54:35
mbbd000001843,mbcd0004749,mbtp000002,mbrf0001335,,~,,,inhibitor,94,3.0,,,Hesperetin,,,BCRP-expressing K562 cell; drug resistance (SN-38),K562,mbcd0000779,,,,human,mbds0003,v2007,2013-12-09 19:54:35
mbbd000001844,mbcd0003116,mbtp000002,mbrf0001335,,,,,substrate,,,,,genistein,,,BCRP-expressing K562 cell; cell accumulation,K562,,,,,human,mbds0003,v2007,2013-12-09 19:54:34
mbbd000001845,mbcd0003116,mbtp000002,mbrf0001335,,=,,,inhibitor,8,11.7,,0.4,Genistein,Reversal index (ratio of IC50 measurements in the absence of reversing agents divided by levels in the presence of reversing agents),,BCRP-expressing K562 cell; inhibition of topotecan uptake (Topotecan: 20 microM),K562,mbcd0003187,10,microM,,human,mbds0003,v2007,2013-12-09 19:54:33
mbbd000001846,mbcd0003116,mbtp000002,mbrf0001335,,~,,,inhibitor,94,4.0,,,Genistein,,,BCRP-expressing K562 cell; drug resistance (Mitoxantrone),K562,mbcd0002981,,,,human,mbds0003,v2007,2013-12-09 19:54:32
mbbd000001847,mbcd0003116,mbtp000002,mbrf0001335,,,,,inhibitor,,,,,Genistein,,,BCRP-expressing K562 cell; drug resistance (SN-38),K562,mbcd0000779,,,,human,mbds0003,v2007,2013-12-09 19:54:31
mbbd000001848,mbcd0003211,mbtp000002,mbrf0001335,,,,,inhibitor,,,,,Estrone,,,BCRP-expressing K562 cell; inhibition of topotecan uptake (Topotecan: 20 microM),K562,mbcd0003187,,,,human,mbds0003,v2007,2013-12-09 19:54:30
mbbd000001849,mbcd0003211,mbtp000002,mbrf0001335,,,,,inhibitor,,,,,Estrone,,,BCRP-expressing K562 cell; drug resistance (Mitoxantrone),K562,mbcd0002981,,,,human,mbds0003,v2007,2013-12-09 19:54:29
mbbd000001850,mbcd0003211,mbtp000002,mbrf0001335,,,,,inhibitor,,,,,Estrone,,,BCRP-expressing K562 cell; drug resistance (SN-38),K562,mbcd0000779,,,,human,mbds0003,v2007,2013-12-09 20:10:36
mbbd000001851,mbcd0003048,mbtp000002,mbrf0001335,,~,,,inhibitor,94,0.5,,,Diosmetin,,,BCRP-expressing K562 cell; drug resistance (SN-38),K562,mbcd0000779,,,,human,mbds0003,v2007,2013-12-09 20:10:37
mbbd000001852,mbcd0003045,mbtp000002,mbrf0001335,,~,,,inhibitor,94,4.0,,,Chrysin,,,BCRP-expressing K562 cell; drug resistance (SN-38),K562,mbcd0000779,,,,human,mbds0003,v2007,2013-12-09 20:10:39
mbbd000001853,mbcd0003091,mbtp000002,mbrf0001335,,~,,,inhibitor,94,0.5,,,Apigenin,,,BCRP-expressing K562 cell; drug resistance (SN-38),K562,mbcd0000779,,,,human,mbds0003,v2007,2013-12-09 20:10:40
mbbd000001854,mbcd0004715,mbtp000002,mbrf0001335,,=,,,inhibitor,8,9.71,,0.81,Acacetin,Reversal index (ratio of IC50 measurements in the absence of reversing agents divided by levels in the presence of reversing agents),,BCRP-expressing K562 cell; drug resistance (Mitoxantrone),K562,mbcd0002981,3,microM,,human,mbds0003,v2007,2013-12-09 20:10:41
mbbd000001855,mbcd0004715,mbtp000002,mbrf0001335,,=,,,inhibitor,8,21.4,,0.34,Acacetin,Reversal index (ratio of IC50 measurements in the absence of reversing agents divided by levels in the presence of reversing agents),,BCRP-expressing K562 cell; drug resistance (SN-38),K562,mbcd0000779,3,microM,,human,mbds0003,v2007,2013-12-09 20:03:01
mbbd000001856,mbcd0022900,mbtp000002,mbrf0001336,,=,,,inhibitor,25,10.0,microM,,Pantoprazole,,,membrane vesicle from BCRP-expressing Sf9 cell; inhibition of MTX uptake,Sf9,mbcd0003043,,,,human,mbds0003,v2007,2013-12-09 20:10:42
mbbd000001857,mbcd0001021,mbtp000002,mbrf0001336,,=,,,inhibitor,25,10.0,microM,,omeprazole,,,membrane vesicle from BCRP-expressing Sf9 cell; inhibition of MTX uptake,Sf9,mbcd0003043,,,,human,mbds0003,v2007,2013-12-09 20:03:05
mbbd000001858,mbcd0003043,mbtp000002,mbrf0001336,,,,,substrate,,,,,MTX,,,membrane vesicle from BCRP-expressing Sf9 cell; uptake,Sf9,,,,,human,mbds0003,v2007,2013-12-09 20:51:11
mbbd000001859,mbcd0000124,mbtp000002,mbrf0001337,,=,,,non-inhibitor,100,28.9,%,2.6,Albendazole Sulfoxide; ABZSO,,,Human BRCP transduced MDCKII subclones; inhibition of Mitoxantrone cellular accumulation,,,325,microM,,human,mbds0010,,2013-11-23 00:52:27
mbbd000001862,mbcd0003126,mbtp000002,mbrf0001249,,~,,,substrate,83,0.2,microL min-1 (mg protein)-1,0.1,PRA,(+),,OATP_B1/BCRP double transfected MDCK II cells; transepithelial transport (basal to apical),MDCKII,,,,,human,mbds0003,v2007,2013-11-26 21:53:24
mbbd000001863,mbcd0023123,mbtp000002,mbrf0001249,,~,,,substrate,83,0.2,microL min-1 (mg protein)-1,0.01,CER,(+),,OATP_B1/BCRP double transfected MDCK II cells; transepithelial transport (basal to apical),MDCKII,,,,,human,mbds0003,v2007,2013-11-26 21:53:24
mbbd000001864,mbcd0003075,mbtp000002,mbrf0001249,,~,,,substrate,83,2.25,microL min-1 (mg protein)-1,0.01,ES,(+),,OATP_B1/BCRP double transfected MDCK II cells; transepithelial transport (basal to apical),MDCKII,,,,,human,mbds0003,v2007,2013-11-26 21:53:24
mbbd000001865,mbcd0000387,mbtp000002,mbrf0001249,,~,,,substrate,83,0.4,microL min-1 (mg protein)-1,0.1,EG,(+),,OATP_B1/BCRP double transfected MDCK II cells; transepithelial transport (basal to apical),MDCKII,,,,,human,mbds0003,v2007,2013-11-26 21:53:24
mbbd000001866,mbcd0003252,mbtp000002,mbrf0001338,,=,,,inhibitor,29,105.0,microM,,Novobiocin,,,membrane vesicle from BCRP-expressing PC-6/SN2-5H2; inhibition of ATP-depdent uptake of topotecan,PC-6/SN2-5H2,mbcd0003187,160,nM,,human,mbds0003,v2007,2013-12-09 19:53:19
mbbd000001867,mbcd0003252,mbtp000002,mbrf0001293,,=,,,inhibitor,25,25.0,microM,,novobiocin,,,BCRP-expressing MCF7-MX cells; inhibition of mitoxantrone efflux,,,,,,human,mbds0003,v2007,2013-12-09 19:53:16
mbbd000001868,mbcd0003074,mbtp000002,mbrf0001293,,=,,,inhibitor,25,150.0,microM,,glyburide,,,BCRP-expressing MCF7-MX cells; inhibition of mitoxantrone efflux,,,,,,human,mbds0003,v2007,2013-12-09 19:53:21
mbbd000001869,mbcd0003252,mbtp000002,mbrf0001293,,=,,,inhibitor,100,3.0,fold increase,,novobiocin,3-fold increase of glyburide accumulation,,BCRP-expressing MCF7-MX cells; inhibition of glyburide accumulation,,,,,,human,mbds0003,v2007,2013-12-09 19:53:20
mbbd000001870,mbcd0001664,mbtp000010,mbrf0001339,,=,,,substrate,28,9.4,microM,1.2,Taurocholate,,,ASBT-expressing HEK293 cell; uptake,HEK293,,50,microM,,human,mbds0003,v2007,2013-12-09 20:50:59
mbbd000001871,mbcd0000050,mbtp000010,mbrf0001339,,~,,,inhibitor,29,10.0,microM,,2164U90,,,ASBT-expressing HEK293 cell; inhibition of Taurocholate accumulation,HEK293,mbcd0001664,,,,human,mbds0003,v2007,2013-12-09 20:50:59
mbbd000001872,mbcd0001664,mbtp000010,mbrf0001340,,=,,,substrate,33,20.1,microL / mg protein,2.4,taurocholic acid,,,ASBT-expressing HEK293 cell; uptake (pH 5.0),HEK293,,,,,human,mbds0003,v2007,2013-12-09 20:50:58
mbbd000001873,mbcd0001664,mbtp000010,mbrf0001340,,=,,,substrate,33,29.0,microL / mg protein,1.9,taurocholic acid,,,ASBT-expressing HEK293 cell; uptake (pH 7.4),HEK293,,,,,human,mbds0003,v2007,2013-12-09 20:50:59
mbbd000001874,mbcd0001612,mbtp000010,mbrf0001341,,=,,,inhibitor,116,75.0,microM,13.5,ursodeoxycholate,,,ASBT-expressing COS cell; inhibition of Taurocholate uptake,,,,,,human,mbds0003,v2007,2013-12-09 20:50:59
mbbd000001876,mbcd0000817,mbtp000010,mbrf0001341,,=,,,inhibitor,116,17.2,microM,3.1,taurodeoxycholate,,,ASBT-expressing COS cell; inhibition of Taurocholate uptake,,,,,,human,mbds0003,v2007,2013-12-09 20:50:59
mbbd000001877,mbcd0001664,mbtp000010,mbrf0001341,,=,,,substrate,16,13.3,microM,5.5,taurocholate,,,ASBT-expressing COS cell; uptake,COS,,,,,human,mbds0003,v2007,2013-12-09 20:50:59
mbbd000001878,mbcd0000815,mbtp000010,mbrf0001341,,=,,,inhibitor,116,6.1,microM,4.6,taurochenodeoxycholate,,,ASBT-expressing COS cell; inhibition of Taurocholate uptake,,,,,,human,mbds0003,v2007,2013-12-09 20:50:59
mbbd000001879,mbcd0000458,mbtp000010,mbrf0001341,,=,,,substrate,16,4.1,microM,0.7,glycoursodeoxycholate,,,ASBT-expressing COS cell; uptake,COS,,,,,human,mbds0003,v2007,2013-12-09 20:50:59
mbbd000001880,mbcd0000456,mbtp000010,mbrf0001341,,=,,,substrate,16,2.0,microM,0.4,glycodeoxycholate,,,ASBT-expressing COS cell; uptake,COS,,,,,human,mbds0003,v2007,2013-12-09 20:53:14
mbbd000001881,mbcd0001635,mbtp000010,mbrf0001341,,=,,,substrate,16,5.7,microM,1.6,glycochenodeoxycholate,,,ASBT-expressing COS cell; uptake,COS,,,,,human,mbds0003,v2007,2013-12-09 20:53:14
mbbd000001882,mbcd0001655,mbtp000010,mbrf0001341,,=,,,inhibitor,116,6.3,microM,2.5,deoxycholate,,,ASBT-expressing COS cell; inhibition of Taurocholate uptake,,,,,,human,mbds0003,v2007,2013-12-09 20:53:14
mbbd000001884,mbcd0000311,mbtp000010,mbrf0001341,,=,,,inhibitor,116,24.0,microM,5,cyclosporin A,,,ASBT-expressing COS cell; inhibition of Taurocholate uptake,,,,,,human,mbds0003,v2007,2013-12-09 19:57:54
mbbd000001885,mbcd0001640,mbtp000010,mbrf0001341,,=,,,inhibitor,116,41.5,microM,9.3,cholate,,,ASBT-expressing COS cells; inhibition of Taurocholate uptake,,,,,,human,mbds0003,v2007,2012-11-21 21:16:06
mbbd000001886,mbcd0001640,mbtp000010,mbrf0001341,,=,,,substrate,16,33.3,microM,12.8,cholate,,,ASBT-expressing COS cells; uptake,COS,,,,,human,mbds0003,v2007,2013-11-24 23:15:14
mbbd000001887,mbcd0000254,mbtp000010,mbrf0001341,,=,,,inhibitor,116,3.3,microM,1.6,chenodeoxycholate,,,ASBT-expressing COS cell; inhibition of Taurocholate uptake,,,,,,human,mbds0003,v2007,2013-12-09 19:57:51
mbbd000001888,mbcd0000201,mbtp000010,mbrf0001341,,=,,,inhibitor,116,144.0,microM,42,BSP,,,ASBT-expressing COS cell; inhibition of Taurocholate uptake,,,,,,human,mbds0003,v2007,2013-12-09 19:57:57
mbbd000001889,mbcd0003087,mbtp000009,mbrf0001342,28,=,2230.0,microM,substrate,28,2.23,mM,,vacv,,,PEPT1-expressing CHO cell; uptake (pH 7.9),CHO,,0.05,mM,,human,mbds0003,v2007,2013-12-09 19:57:56
mbbd000001890,mbcd0003087,mbtp000009,mbrf0001342,28,=,2690.0,microM,substrate,28,2.69,mM,,vacv,,,PEPT1-expressing CHO cell; uptake (pH 7.5),CHO,,0.05,mM,,human,mbds0003,v2007,2013-12-09 20:52:26
mbbd000001891,mbcd0003087,mbtp000009,mbrf0001342,28,=,5380.0,microM,substrate,28,5.38,mM,,vacv,,,PEPT1-expressing CHO cell; uptake (pH 6.8),CHO,,0.05,mM,,human,mbds0003,v2007,2013-12-09 20:52:26
mbbd000001892,mbcd0003087,mbtp000009,mbrf0001342,28,=,6640.0,microM,substrate,28,6.64,mM,,vacv,,,PEPT1-expressing CHO cell; uptake (pH 6.2),CHO,,0.05,mM,,human,mbds0003,v2007,2013-12-09 20:52:27
mbbd000001893,mbcd0003087,mbtp000009,mbrf0001342,28,=,7420.0,microM,substrate,28,7.42,mM,,vacv,,,PEPT1-expressing CHO cell; uptake (pH 5.5),CHO,,0.05,mM,,human,mbds0003,v2007,2013-12-09 20:52:27
mbbd000001897,mbcd0003494,mbtp000009,mbrf0001344,28,=,830.0,microM,substrate,28,830.0,mM,0.06,Glycylsarcosine,,,Caco-2 cell; uptake,Caco-2,,0-5,mM,,human,mbds0003,v2007,2013-12-09 20:52:26
mbbd000001898,mbcd0003494,mbtp000009,mbrf0001345,,=,,,inhibitor,72,135.0,%,,Glycylsarcosine,,,"Caco-2 cell; trans-stimulation of Sulpiride uptake (Surpiride: 100 microM, Gly-Sar: 1000 microM)",Caco-2,mbcd0030482,,,,human,mbds0003,v2007,2013-12-09 20:52:25
mbbd000001899,mbcd0003494,mbtp000009,mbrf0001345,,=,,,inhibitor,72,65.0,%,,Glycylsarcosine,,,"Caco-2 cell; inhibition of Sulpiride uptake (Surpiride: 100 microM, Gly-Sar: 1000 microM)",Caco-2,mbcd0030482,,,,human,mbds0003,v2007,2013-12-09 20:52:26
mbbd000001900,mbcd0003142,mbtp000009,mbrf0001345,,=,,,inhibitor,72,132.0,%,,Captopril,,,"Caco-2 cell; trans-stimulation of Sulpiride uptake (Sulpiride: 100 microM, Captopril: 1000 microM)",Caco-2,mbcd0030482,,,,human,mbds0003,v2007,2013-12-09 20:02:45
mbbd000001901,mbcd0003142,mbtp000009,mbrf0001345,,=,,,inhibitor,72,62.0,%,,Captopril,,,"Caco-2 cell; inhibition of Sulpiride uptake (Sulpiride: 100 microM, Captopril: 1000 microM)",Caco-2,mbcd0030482,,,,human,mbds0003,v2007,2013-12-09 20:02:47
mbbd000001902,mbcd0000308,mbtp000009,mbrf0001346,,=,,,substrate,28,21.9,microM,,Cyclo(Ser-Tyr),,,Caco-2 cell; uptake,Caco-2,,100,microM,,human,mbds0003,v2007,2013-12-09 20:02:43
mbbd000001903,mbcd0000307,mbtp000009,mbrf0001346,,=,,,substrate,28,118.0,microM,,Cyclo(Phe-Ser),,,Caco-2 cell; uptake,Caco-2,,100,microM,,human,mbds0003,v2007,2013-12-09 20:02:44
mbbd000001904,mbcd0000306,mbtp000009,mbrf0001346,,=,,,substrate,28,62.9,microM,,Cyclo(Gly-Tyr),,,Caco-2 cell; uptake,Caco-2,,100,microM,,human,mbds0003,v2007,2013-12-09 20:02:48
mbbd000001905,mbcd0000305,mbtp000009,mbrf0001346,,=,,,substrate,28,90.9,microM,,Cyclo(Gly-Phe),,,Caco-2 cell; uptake,Caco-2,,100,microM,,human,mbds0003,v2007,2013-12-09 20:02:48
mbbd000001906,mbcd0000512,mbtp000009,mbrf0001347,,=,,,inhibitor,29,280.0,microM,,L-Glu[acyclovir]-Sar,,,Caco-2 cell; inhibition of Gly-Sar uptake,Caco-2,mbcd0003494,,,,human,mbds0003,v2007,2013-12-09 20:02:47
mbbd000001907,mbcd0000511,mbtp000009,mbrf0001347,,=,,,inhibitor,29,210.0,microM,,L-Glu[1-(2-hydroxyethyl)thymine]-Sar,,,Caco-2 cell; inhibition of Gly-Sar uptake,Caco-2,mbcd0003494,,,,human,mbds0003,v2007,2013-12-09 20:02:48
mbbd000001908,mbcd0000906,mbtp000009,mbrf0001348,,=,,,inhibitor,72,40.0,%,,ZnSO4,(105)microM,,PEPT1-expressing Caco-2 cell; inhibition of Gly-Sar uptake,Caco-2,mbcd0003494,,,,human,mbds0003,v2007,2013-12-09 20:02:49
mbbd000001909,mbcd0003769,mbtp000009,mbrf0001349,,=,,,inhibitor,29,419.0,microM,,Lys-Ala,,,PEPT1-expressing HeLa cell; inhibition of Gly-Sar uptake,HeLa,mbcd0003494,,,,human,mbds0003,v2007,2013-12-09 20:02:49
mbbd000001910,mbcd0000148,mbtp000009,mbrf0001349,,=,,,inhibitor,29,108.0,microM,,Asp-Lys,,,PEPT1-expressing HeLa cell; inhibition of Gly-Sar uptake,HeLa,mbcd0003494,,,,human,mbds0003,v2007,2013-12-09 20:52:58
mbbd000001911,mbcd0003598,mbtp000009,mbrf0001349,,=,,,inhibitor,29,117.0,microM,,Ala-Lys,,,PEPT1-expressing HeLa cell; inhibition of Gly-Sar uptake,HeLa,mbcd0003494,,,,human,mbds0003,v2007,2013-12-09 20:52:57
mbbd000001912,mbcd0003764,mbtp000009,mbrf0001349,,=,,,inhibitor,29,78.0,microM,,Ala-Asp,,,PEPT1-expressing HeLa cell; inhibition of Gly-Sar uptake,HeLa,mbcd0003494,,,,human,mbds0003,v2007,2013-12-09 20:52:58
mbbd000001913,mbcd0003666,mbtp000009,mbrf0001350,,=,,,inhibitor,25,350.0,microM,,Cyclacillin,,,PEPT1-expressing HeLa cell; inhibition of Gly-Sar uptake (Gly-Sar: 25 microM),HeLa,mbcd0003494,,,,human,mbds0003,v2007,2013-12-09 20:52:58
mbbd000001914,mbcd0003666,mbtp000009,mbrf0001350,,=,,,inhibitor,25,600.0,microM,,Cyclacillin,,,Caco-2 cell; inhibition of Gly-Sar uptake (Gly-Sar: 5 microM),Caco-2,mbcd0003494,,,,human,mbds0003,v2007,2013-12-09 20:52:58
mbbd000001915,mbcd0003618,mbtp000009,mbrf0001350,,,,,substrate,,,,,cephalexin,,,PEPT1-expressing HeLa cell; uptake,HeLa,,,,,human,mbds0003,v2007,2013-12-09 20:52:58
mbbd000001916,mbcd0001472,mbtp000009,mbrf0001350,,=,,,inhibitor,25,870.0,microM,,Cefadroxil,,,PEPT1-expressing HeLa cell; inhibition of Gly-Sar uptake (Gly-Sar: 25 microM),HeLa,mbcd0003494,,,,human,mbds0003,v2007,2013-12-09 20:52:59
mbbd000001917,mbcd0001472,mbtp000009,mbrf0001350,,=,,,inhibitor,25,5400.0,microM,,Cefadroxil,,,Caco-2 cell; inhibition of Gly-Sar uptake (Gly-Sar: 5 microM),Caco-2,mbcd0003494,,,,human,mbds0003,v2007,2013-12-09 20:52:59
mbbd000001918,mbcd0003517,mbtp000009,mbrf0001351,,=,,,inhibitor,72,8.0,%,,Leu-Pro,,,"PEPT1-expressing HeLa cell; inhibition of Gly-Sar uptake (Gly-Sar: 20 microM, Leu-Pro: 10000 microM)",HeLa,mbcd0003494,,,,human,mbds0003,v2007,2013-12-09 20:53:03
mbbd000001919,mbcd0003642,mbtp000009,mbrf0001351,,=,,,inhibitor,72,7.0,%,,Gly-Pro,,,"PEPT1-expressing HeLa cell; inhibition of Gly-Sar uptake (Gly-Sar: 20 microM, Gly-Pro: 10000 microM)",HeLa,mbcd0003494,,,,human,mbds0003,v2007,2013-12-09 20:53:01
mbbd000001920,mbcd0000448,mbtp000009,mbrf0001351,,=,,,inhibitor,72,13.0,%,,Gly-Gly-Pro,,,"PEPT1-expressing HeLa cell; inhibition of Gly-Sar uptake (Gly-Sar: 20 microM, Gly-Gly-Pro: 10000 microM)",HeLa,mbcd0003494,,,,human,mbds0003,v2007,2013-12-09 20:04:04
mbbd000001921,mbcd0000447,mbtp000009,mbrf0001351,,=,,,inhibitor,72,10.0,%,,Gly-Gly-Ile,,,"PEPT1-expressing HeLa cell; inhibition of Gly-Sar uptake (Gly-Sar: 20 microM, Gly-Gly-Ile: 10000 microM)",HeLa,mbcd0003494,,,,human,mbds0003,v2007,2013-12-09 20:04:04
mbbd000001922,mbcd0003494,mbtp000009,mbrf0001351,28,=,290.0,microM,substrate,28,290.0,mM,0.04,Glycylsarcosine,,,PEPT1-expressing HeLa cell; uptake,HeLa,,30,microM,,human,mbds0003,v2007,2013-12-09 20:04:05
mbbd000001923,mbcd0003618,mbtp000009,mbrf0001351,,=,,,inhibitor,72,11.0,%,,Cephalexin,,,"PEPT1-expressing HeLa cell; inhibition of Gly-Sar uptake (Gly-Sar: 20 microM, Cephalexin: 10000 microM)",HeLa,mbcd0003494,,,,human,mbds0003,v2007,2013-12-09 20:04:05
mbbd000001924,mbcd0001472,mbtp000009,mbrf0001351,,=,,,inhibitor,72,27.0,%,,Cefadroxil,,,"PEPT1-expressing HeLa cell; inhibition of Gly-Sar uptake (Gly-Sar: 20 microM, Cephadroxil: 10000 microM)",HeLa,mbcd0003494,,,,human,mbds0003,v2007,2013-12-09 20:04:06
mbbd000001925,mbcd0000122,mbtp000009,mbrf0001351,,=,,,inhibitor,72,9.0,%,,Ala-Pro-Gly,,,"PEPT1-expressing HeLa cell; inhibition of Gly-Sar uptake (Gly-Sar: 20 microM, Ala-Pro-Gly: 10000 microM)",HeLa,mbcd0003494,,,,human,mbds0003,v2007,2013-12-09 20:14:56
mbbd000001926,mbcd0003493,mbtp000009,mbrf0001351,,=,,,inhibitor,72,8.0,%,,Ala-Pro,,,"PEPT1-expressing HeLa cell; inhibition of Gly-Sar uptake (Gly-Sar: 20 microM, Ala-Pro: 10000 microM)",HeLa,mbcd0003494,,,,human,mbds0003,v2007,2013-12-09 20:04:06
mbbd000001927,mbcd0001082,mbtp000009,mbrf0001352,,=,,,inhibitor,72,72.6,%,,Loracarbef,,,"Caco-2 cell; inhibition of Cefadroxil uptake (apical pH 5.5, Cefadroxil: 1000 microM, Loracarbef: 10000 microM)",Caco-2,mbcd0001472,,,,human,mbds0003,v2007,2013-12-09 20:04:06
mbbd000001928,mbcd0001082,mbtp000009,mbrf0001352,,=,,,inhibitor,72,60.3,%,,Loracarbef,,,"Caco-2 cell; inhibition of Cefadroxil uptake (apical pH 6.5, Cefadroxil: 1000 microM, Loracarbef: 10000 microM)",Caco-2,mbcd0001472,,,,human,mbds0003,v2007,2013-12-09 20:04:02
mbbd000001929,mbcd0003618,mbtp000009,mbrf0001352,,=,,,inhibitor,72,60.8,%,,Cephalexin,,,"Caco-2 cell; inhibition of Cefadroxil uptake (apical pH 5.5, Cefadroxil: 1000 microM, Cephalexin: 10000 microM)",Caco-2,mbcd0001472,,,,human,mbds0003,v2007,2013-12-09 20:04:02
mbbd000001930,mbcd0003618,mbtp000009,mbrf0001352,,=,,,inhibitor,72,54.7,%,,Cephalexin,,,"Caco-2 cell; inhibition of Cefadroxil uptake (apical pH 6.5, Cefadroxil: 1000 microM, Cephalexin: 10000 microM)",Caco-2,mbcd0001472,,,,human,mbds0003,v2007,2013-12-09 20:54:10
mbbd000001931,mbcd0003733,mbtp000009,mbrf0001352,,=,,,inhibitor,29,1310.0,microM,,Cefixime,,,Caco-2 cell; inhibition of Cefadroxil uptake,Caco-2,mbcd0001472,,,,human,mbds0003,v2007,2013-12-09 20:54:10
mbbd000001932,mbcd0001472,mbtp000009,mbrf0001352,,=,,,inhibitor,29,1450.0,microM,,Cefadroxil,,,Caco-2 cell; inhibition of Cefixim uptake,Caco-2,mbcd0003733,,,,human,mbds0003,v2007,2013-12-09 20:54:10
mbbd000001933,mbcd0001425,mbtp000009,mbrf0001352,,=,,,inhibitor,72,85.7,%,,Amoxicillin,,,"Caco-2 cell; inhibition of Cefadroxil uptake (apical pH 5.5, Cefadroxil: 1000 microM, Amoxicillin: 10000 microM)",Caco-2,mbcd0001472,,,,human,mbds0003,v2007,2013-12-09 20:54:10
mbbd000001934,mbcd0001425,mbtp000009,mbrf0001352,,=,,,inhibitor,72,62.9,%,,Amoxicillin,,,"Caco-2 cell; inhibition of Cefadroxil uptake (apical pH 6.5, Cefadroxil: 1000 microM, Amoxicillin: 10000 microM)",Caco-2,mbcd0001472,,,,human,mbds0003,v2007,2013-12-09 20:09:10
mbbd000001935,mbcd0003601,mbtp000009,mbrf0001353,,=,,,inhibitor,25,63.0,microM,,Ala-Ala,,,PEPT1-expressing CHO cell; inhibition of Gly-Sar uptake (Gly-Sar: 25000 microM),CHO,mbcd0003494,,,,human,mbds0003,v2007,2013-12-09 20:54:09
mbbd000001936,mbcd0003697,mbtp000009,mbrf0001353,,=,,,inhibitor,25,1400.0,microM,,Gly-Gly-Gly,,,PEPT1-expressing CHO cell; inhibition of Gly-Sar uptake (Gly-Sar: 25000 microM),CHO,mbcd0003494,,,,human,mbds0003,v2007,2013-12-09 20:54:09
mbbd000001937,mbcd0003618,mbtp000009,mbrf0001353,,=,,,inhibitor,25,5200.0,microM,,Cephalexin,,,PEPT1-expressing CHO cell; inhibition of Gly-Sar uptake (Gly-Sar: 25000 microM),CHO,mbcd0003494,,,,human,mbds0003,v2007,2013-12-09 20:54:09
mbbd000001938,mbcd0003622,mbtp000009,mbrf0001353,,=,,,inhibitor,25,10000.0,microM,,Ampicillin,,,PEPT1-expressing CHO cell; inhibition of Gly-Sar uptake (Gly-Sar: 25000 microM),CHO,mbcd0003494,,,,human,mbds0003,v2007,2013-12-09 20:54:09
mbbd000001939,mbcd0003554,mbtp000009,mbrf0001354,,=,,,inhibitor,29,710.0,microM,,Ceftibuten,,,PEPT1-expressing HeLa cell; inhibition of Gly-Sar uptake,HeLa,mbcd0003494,,,,human,mbds0003,v2007,2013-12-09 20:54:09
mbbd000001940,mbcd0003554,mbtp000009,mbrf0001354,,=,,,inhibitor,29,870.0,microM,,Ceftibuten,,,Caco-2 cell; inhibition of Gly-Sar uptake,Caco-2,mbcd0003494,,,,human,mbds0003,v2007,2013-12-09 19:59:04
mbbd000001941,mbcd0003733,mbtp000009,mbrf0001354,,=,,,inhibitor,3,44.0,%,,Cefixime,,,"PEPT1-expressing HeLa cell; inhibition of Gly-Sar uptake (Gly-Sar: 20 microM, Cefixime: 10000 microM)",HeLa,mbcd0003494,,,,human,mbds0003,v2007,2013-12-09 19:59:04
mbbd000001942,mbcd0003733,mbtp000009,mbrf0001354,,=,,,inhibitor,25,10000.0,microM,,Cefixime,,,Caco-2 cell; inhibition of Gly-Sar uptake (Gly-Sar: 5 microM),Caco-2,mbcd0003494,,,,human,mbds0003,v2007,2013-12-09 19:59:02
mbbd000001943,mbcd0001130,mbtp000009,mbrf0001354,,=,,,inhibitor,3,31.0,%,,Cefdinir,,,"PEPT1-expressing HeLa cell; inhibition of Gly-Sar uptake (Gly-Sar: 20 microM, Cefdinir: 10000 microM)",HeLa,mbcd0003494,,,,human,mbds0003,v2007,2013-12-09 19:59:03
mbbd000001944,mbcd0003494,mbtp000009,mbrf0001355,,,,,substrate,,,,,Gly-Sar,,,Xenopus laevis oocyte; uptake,Xenopus laevis oocytes,,,,,human,mbds0003,v2007,2013-12-09 19:59:00
mbbd000001945,mbcd0003688,mbtp000009,mbrf0001356,,=,,,inhibitor,29,300.0,microM,,Ala-psi[CS-N]-Pro,,,"Caco-2 cell; inhibition of Gly-Sar uptake, 96% trans conformation",Caco-2,mbcd0003494,,,,human,mbds0003,v2007,2013-12-09 19:59:01
mbbd000001946,mbcd0003718,mbtp000009,mbrf0001357,,=,,,stimulator,22,1.64,fold increase,0.34,Gly-Gln,1.64-fold (+/- 0.34) increase in Vmax from 20.7 +/- 1.4 to 34.0 +/- 4.7 nmol min-1 mg-1; Km remained unchanged at 4.2 +/- 0.4 mM,,Caco-2 cells; transport of Gly-Sar,Caco-2,mbcd0003494,,,,human,mbds0010,,2013-11-27 07:26:52
mbbd000001947,mbcd0003087,mbtp000009,mbrf0001358,,=,,,inhibitor,29,740.0,microM,,Valacyclovir,,,PEPT1-expressing HeLa cell; inhibition of Gly-Sar uptake,HeLa,mbcd0003494,,,,human,mbds0003,v2007,2013-12-09 19:59:00
mbbd000001948,mbcd0003087,mbtp000009,mbrf0001358,,=,,,inhibitor,29,490.0,microM,,Valacyclovir,,,Caco-2 cell; inhibition of Gly-Sar uptake,Caco-2,mbcd0003494,,,,human,mbds0003,v2007,2013-12-09 19:58:58
mbbd000001949,mbcd0003494,mbtp000009,mbrf0001358,28,=,510.0,microM,substrate,28,510.0,mM,0.03,Glycylsarcosine,,,Caco-2 cell; uptake,Caco-2,,10,microM,,human,mbds0003,v2007,2013-12-09 19:58:59
mbbd000001950,mbcd0003494,mbtp000009,mbrf0001358,28,=,450.0,microM,substrate,28,450.0,mM,0.13,Glycylsarcosine,,,PEPT1-expressing HeLa cell; uptake,HeLa,,10,microM,,human,mbds0003,v2007,2013-12-09 20:51:31
mbbd000001951,mbcd0031695,mbtp000009,mbrf0001359,25,=,3400.0,microM,inhibitor,25,3.4,mM,0.7,D-Val-ACV,,,"PEPT1-expressing CHO cell; inhibition of Gly-Sar uptake, D-form (Gly-Sar: 20 microM)",CHO,mbcd0003494,,,,human,mbds0003,v2007,2013-12-09 20:51:31
mbbd000001952,mbcd0003087,mbtp000009,mbrf0001359,25,=,1100.0,microM,inhibitor,25,1.1,mM,0.3,L-Val-ACV,,,"PEPT1-expressing CHO cell; inhibition of Gly-Sar uptake, L-form (Gly-Sar: 20 microM)",CHO,mbcd0003494,,,,human,mbds0003,v2007,2013-12-09 20:51:31
mbbd000001953,mbcd0003087,mbtp000009,mbrf0001359,28,=,292.0,microM,substrate,28,292.0,microM,55,L-Val-ACV,,,"Caco-2 cells; transepithelial transport (apical to basal), L-form",Caco-2,,0.01; 1,mM,,human,mbds0003,v2007,2014-06-23 23:06:35
mbbd000001954,mbcd0029604,mbtp000009,mbrf0001359,25,=,400.0,microM,inhibitor,25,0.4,mM,0.03,L-Val-AZT,,,PEPT1-expressing CHO cell; inhibition of Gly-Sar uptake (Gly-Sar: 20 microM),CHO,mbcd0003494,,,,human,mbds0003,v2007,2013-12-09 20:51:30
mbbd000001955,mbcd0000459,mbtp000009,mbrf0001359,25,=,1400.0,microM,inhibitor,25,1.4,mM,0.3,Gly-ACV,,,PEPT1-expressing CHO cell; inhibition of Gly-Sar uptake (Gly-Sar: 20 microM),CHO,mbcd0003494,,,,human,mbds0003,v2007,2013-12-09 20:51:28
mbbd000001956,mbcd0003498,mbtp000009,mbrf0001359,25,=,4500.0,microM,inhibitor,25,4.5,mM,0.7,Enalapril,,,PEPT1-expressing CHO cell; inhibition of Gly-Sar uptake (Gly-Sar: 20 microM),CHO,mbcd0003494,,,,human,mbds0003,v2007,2013-12-09 20:51:30
mbbd000001957,mbcd0003553,mbtp000009,mbrf0001359,25,=,15000.0,microM,inhibitor,25,15.0,mM,2,Cephradine,,,PEPT1-expressing CHO cell; inhibition of Gly-Sar uptake (Gly-Sar: 20 microM),CHO,mbcd0003494,,,,human,mbds0003,v2007,2013-12-09 20:51:30
mbbd000001958,mbcd0003087,mbtp000009,mbrf0001360,,=,,,inhibitor,29,4080.0,microM,,vacv,,,Xenopus laevis oocyte; inhibition of Gly-Sar uptake,Xenopus laevis oocytes,mbcd0003494,,,,human,mbds0003,v2007,2013-12-09 20:51:28
mbbd000001959,mbcd0003087,mbtp000009,mbrf0001360,28,=,5940.0,microM,substrate,28,5.94,mM,1.91,vacv,,,Xenopus laevis oocyte; uptake,Xenopus laevis oocytes,,0.1-25,mM,,human,mbds0003,v2007,2013-12-09 20:51:28
mbbd000001960,mbcd0003697,mbtp000009,mbrf0001360,,~,,,inhibitor,1,55.0,%,5,Gly-Gly-Gly,,,"Xenopus laevis oocyte; inhibition of VACV uptake (VACV: 0.2 microM, Gly-Gly-Gly: 10000 microM)",Xenopus laevis oocytes,mbcd0003087,,,,human,mbds0003,v2007,2013-12-09 20:00:27
mbbd000001961,mbcd0003494,mbtp000009,mbrf0001360,,~,,,inhibitor,1,55.0,%,5,glycylsarcosine,,,"Xenopus laevis oocyte; inhibition of VACV uptake (VACV: 0.2 microM, Gly-Sar: 10000 microM)",Xenopus laevis oocytes,mbcd0003087,,,,human,mbds0003,v2007,2013-12-09 20:00:28
mbbd000001962,mbcd0001472,mbtp000009,mbrf0001360,,~,,,inhibitor,1,50.0,%,5,Cefadroxil,,,"Xenopus laevis oocyte; inhibition of VACV uptake (VACV: 0.2 microM, Cefadroxil: 10000 microM)",Xenopus laevis oocytes,mbcd0003087,,,,human,mbds0003,v2007,2013-12-09 20:00:31
mbbd000001963,mbcd0022751,mbtp000009,mbrf0001360,,~,,,inhibitor,1,70.0,%,2,Carnosine,,,"Xenopus laevis oocyte; inhibition of VACV uptake (VACV: 0.2 microM, Carnosine: 10000 microM)",Xenopus laevis oocytes,mbcd0003087,,,,human,mbds0003,v2007,2013-12-09 20:00:32
mbbd000001964,mbcd0003494,mbtp000009,mbrf0001361,28,=,2100.0,microM,substrate,28,2.1,mM,0.5,Gly-Sar,,,PEPT1-overexpressing Caco-2 cells; uptake,Caco-2,,0.01-50,mM,,human,mbds0003,v2007,2013-11-19 19:58:24
mbbd000001965,mbcd0003494,mbtp000009,mbrf0001361,28,=,700.0,microM,substrate,28,0.7,mM,0.17,Gly-Sar,,,PEPT1-overexpressing Caco-2 cells; uptake,Caco-2,,0.01-50,mM,,human,mbds0003,v2007,2013-11-19 19:58:24
mbbd000001966,mbcd0003642,mbtp000009,mbrf0001362,,=,,,inhibitor,3,78.0,%,,Gly-Pro,,,"Caco-2 cell; inhibition of fMLP uptake (fMLP: 0.1 microM, Gly-Pro: 10000 microM)",Caco-2,mbcd0000419,,,,human,mbds0003,v2007,2013-12-09 20:00:25
mbbd000001967,mbcd0003630,mbtp000009,mbrf0001362,,=,,,inhibitor,3,93.0,%,,Gly-Leu,,,"Xenopus laevis oocyte; inhibition of fMLP uptake (fMLP: 0.12 microM, Gly-Leu: 10000 microM)",Xenopus laevis oocytes,mbcd0000419,,,,human,mbds0003,v2007,2013-12-09 20:00:26
mbbd000001968,mbcd0003630,mbtp000009,mbrf0001362,,=,,,inhibitor,3,93.0,%,,Gly-Leu,,,"Caco-2 cell; inhibition of fMLP uptake (fMLP: 0.1 microM, Gly-Leu: 10000 microM)",Caco-2,mbcd0000419,,,,human,mbds0003,v2007,2013-12-09 20:00:33
mbbd000001969,mbcd0000419,mbtp000009,mbrf0001362,,=,,,inhibitor,3,88.0,%,,Formyl-Met-Leu-Phe,,,"Xenopus laevis oocyte; inhibition of Gly-Sar uptake (Gly-Sar: 100 microM, fMLP: 1000 microM)",Xenopus laevis oocytes,mbcd0003494,,,,human,mbds0003,v2007,2013-12-09 20:57:25
mbbd000001970,mbcd0000419,mbtp000009,mbrf0001362,,,,,substrate,,,,,formyl-Met-Leu-Phe,,,Xenopus laevis oocyte; uptake,Xenopus laevis oocytes,,,,,human,mbds0003,v2007,2013-12-09 20:52:39
mbbd000001971,mbcd0022751,mbtp000009,mbrf0001362,,=,,,inhibitor,3,93.0,%,,Carnosine,,,"Caco-2 cell; inhibition of fMLP uptake (fMLP: 0.1 microM, Carnosine: 10000 microM)",Caco-2,mbcd0000419,,,,human,mbds0003,v2007,2013-12-09 20:52:39
mbbd000001972,mbcd0003883,mbtp000009,mbrf0001363,,=,,,inhibitor,25,151600.0,microM,,alpha-methyldopa,,,PEPT1-expressing CHO cell; inhibition of Gly-Sar uptake (Gly-Sar: 20 microM),CHO,mbcd0003494,,,,human,mbds0003,v2007,2013-12-09 20:52:38
mbbd000001973,mbcd0003904,mbtp000009,mbrf0001363,,=,,,inhibitor,25,141200.0,microM,,L-DOPA,,,PEPT1-expressing CHO cell; inhibition of Gly-Sar uptake (Gly-Sar: 20 microM),CHO,mbcd0003494,,,,human,mbds0003,v2007,2013-12-09 20:52:38
mbbd000001974,mbcd0003494,mbtp000009,mbrf0001363,28,=,500.0,microM,substrate,28,500.0,mM,0.1,Gly-Sar,,,PEPT1-expressing CHO cell; uptake,CHO,,0.01-50,mM,,human,mbds0003,v2007,2013-12-09 20:52:39
mbbd000001975,mbcd0003498,mbtp000009,mbrf0001363,,=,,,inhibitor,25,4500.0,microM,,Enalapril,,,PEPT1-expressing CHO cell; inhibition of Gly-Sar uptake (Gly-Sar: 20 microM),CHO,mbcd0003494,,,,human,mbds0003,v2007,2013-12-09 20:52:39
mbbd000001976,mbcd0003553,mbtp000009,mbrf0001363,,=,,,inhibitor,25,15300.0,microM,,Cephradine,,,PEPT1-expressing CHO cell; inhibition of Gly-Sar uptake (Gly-Sar: 20 microM),CHO,mbcd0003494,,,,human,mbds0003,v2007,2013-12-09 20:52:39
mbbd000001977,mbcd0003553,mbtp000009,mbrf0001363,,,,,substrate,,,,,cephradine,,,PEPT1-expressing CHO cell; uptake,CHO,,,,,human,mbds0003,v2007,2013-12-09 20:52:39
mbbd000001978,mbcd0003618,mbtp000009,mbrf0001363,,=,,,inhibitor,25,13700.0,microM,,Cephalexin,,,PEPT1-expressing CHO cell; inhibition of Gly-Sar uptake (Gly-Sar: 20 microM),CHO,mbcd0003494,,,,human,mbds0003,v2007,2013-12-09 20:52:38
mbbd000001979,mbcd0003618,mbtp000009,mbrf0001363,,,,,substrate,,,,,cephalexin,,,PEPT1-expressing CHO cell; uptake,CHO,,,,,human,mbds0003,v2007,2013-12-09 20:52:38
mbbd000001980,mbcd0001298,mbtp000009,mbrf0001363,,=,,,inhibitor,25,8200.0,microM,,Cefaclor,,,PEPT1-expressing CHO cell; inhibition of Gly-Sar uptake (Gly-Sar: 20 microM),CHO,mbcd0003494,,,,human,mbds0003,v2007,2013-12-09 19:56:45
mbbd000001981,mbcd0001298,mbtp000009,mbrf0001363,,,,,substrate,,,,,cefaclor,,,PEPT1-expressing CHO cell; uptake,CHO,,,,,human,mbds0003,v2007,2013-12-09 20:53:25
mbbd000001982,mbcd0003087,mbtp000009,mbrf0001364,28,=,1640.0,microM,substrate,28,1.64,mM,0.06,VACV,,,PEPT1-expressing CHO cell; uptake,CHO,,10,mM,,human,mbds0003,v2007,2013-12-09 19:56:43
mbbd000001983,mbcd0003637,mbtp000009,mbrf0001364,,>,,,inhibitor,3,80.0,%,,Leu-Leu,,,"PEPT1-expressing CHO cell; inhibition of VACV uptake (VACV: 20 microM, Leu-Leu: 10000 microM)",CHO,mbcd0003087,,,,human,mbds0003,v2007,2013-12-09 19:56:44
mbbd000001984,mbcd0003630,mbtp000009,mbrf0001364,,>,,,inhibitor,3,80.0,%,,Gly-Leu,,,"PEPT1-expressing CHO cell; inhibition of VACV uptake (VACV: 20 microM, Gly-Leu: 10000 microM)",CHO,mbcd0003087,,,,human,mbds0003,v2007,2013-12-09 19:56:47
mbbd000001985,mbcd0003634,mbtp000009,mbrf0001364,,>,,,inhibitor,3,80.0,%,,Gly-Gly,,,"PEPT1-expressing CHO cell; inhibition of VACV uptake (VACV: 20 microM, Gly-Gly: 10000 microM)",CHO,mbcd0003087,,,,human,mbds0003,v2007,2013-12-09 19:56:48
mbbd000001986,mbcd0003494,mbtp000009,mbrf0001364,,=,,,inhibitor,29,12800.0,microM,,Gly-Sar,,,PEPT1-expressing CHO cell; inhibition of VACV uptake,CHO,mbcd0003087,,,,human,mbds0003,v2007,2013-12-09 19:56:46
mbbd000001987,mbcd0003494,mbtp000009,mbrf0001364,28,=,3130.0,microM,substrate,28,3130.0,mM,1.09,Gly-Sar,,,PEPT1-expressing CHO cell; uptake,CHO,,10,mM,,human,mbds0003,v2007,2013-12-09 19:56:47
mbbd000001988,mbcd0003618,mbtp000009,mbrf0001364,,~,,,inhibitor,102,45.0,%,7,Cephalexin,,,"PEPT1-expressing CHO cell; inhibition of VACV uptake (VACV: 20 microM, Cephalexin: 10000 microM)",CHO,mbcd0003087,10,microM,,human,mbds0003,v2007,2013-12-09 19:56:40
mbbd000001989,mbcd0001472,mbtp000009,mbrf0001364,,=,,,inhibitor,29,9100.0,microM,,Cefadroxil,,,PEPT1-expressing CHO cell; inhibition of VACV uptake,CHO,mbcd0003087,,,,human,mbds0003,v2007,2013-12-09 20:09:16
mbbd000001990,mbcd0003622,mbtp000009,mbrf0001364,,~,,,inhibitor,102,50.0,%,3,Ampicillin,,,"PEPT1-expressing CHO cell; inhibition of VACV uptake (VAVC: 20 microM, Ampicillin: 10000 microM)",CHO,mbcd0003087,10,microM,,human,mbds0003,v2007,2013-12-09 20:03:36
mbbd000001991,mbcd0003601,mbtp000009,mbrf0001364,,>,,,inhibitor,3,80.0,%,,Ala-Ala,,,"PEPT1-expressing CHO cell; inhibition of VACV uptake (VAVC: 20 microM, Ala-Ala: 10000 microM)",,,,,,human,mbds0003,v2007,2013-12-09 20:03:33
mbbd000001992,mbcd0003539,mbtp000009,mbrf0001365,,,,,substrate,,,,,L-Phe-L-Pro,,,Xenopus laevis oocyte; uptake,Xenopus laevis oocytes,,,,,human,mbds0003,v2007,2013-12-09 20:57:38
mbbd000001993,mbcd0003765,mbtp000009,mbrf0001365,,,,,substrate,,,,,L-Phe-L-Phe,,,Xenopus laevis oocyte; uptake,Xenopus laevis oocytes,,,,,human,mbds0003,v2007,2013-12-09 19:52:43
mbbd000001994,mbcd0000514,mbtp000009,mbrf0001365,,,,,substrate,,,,,L-Phe-D-Pro,,,Xenopus laevis oocyte; uptake,Xenopus laevis oocytes,,,,,human,mbds0003,v2007,2013-12-09 20:57:38
mbbd000001995,mbcd0000510,mbtp000009,mbrf0001365,,~,,,inhibitor,72,20.0,%,,L-dopa-L-Phe,,,"Caco-2 cell; inhibition of Gly-Sar uptake (Gly-Sar: 20 microM, L-dopa-L-Phe: 1000 microM)",Caco-2,mbcd0003494,,,,human,mbds0003,v2007,2013-12-09 20:57:38
mbbd000001996,mbcd0000510,mbtp000009,mbrf0001365,,,,,substrate,,,,,L-dopa-L-Phe,,,Xenopus laevis oocyte; uptake,Xenopus laevis oocytes,,,,,human,mbds0003,v2007,2013-12-09 20:57:40
mbbd000001997,mbcd0000245,mbtp000009,mbrf0001366,,=,,,non-inhibitor,33,518.0,pmol/10^6 cells/5 min,19,Cephaloridine,,,"PEPT1-expressing HeLa cell; inhibition of Gly-Sar uptake (Gly-Sar: 50 microM, CER: 2500microM)",HeLa,mbcd0003494,,,,human,mbds0003,v2007,2013-12-09 20:57:39
mbbd000001998,mbcd0001075,mbtp000009,mbrf0001366,,=,,,non-inhibitor,33,537.0,pmol/10^6 cells/5 min,52,Ceftazidime,,,"PEPT1-expressing HeLa cell; inhibition of Gly-Sar uptake (Gly-Sar: 50 microM, Ceftatizime: 2500microM)",HeLa,mbcd0003494,,,,human,mbds0003,v2007,2013-12-09 20:57:34
mbbd000001999,mbcd0000232,mbtp000009,mbrf0001366,,=,,,inhibitor,72,76.0,%,,Cefoselis,,,"PEPT1-expressing HeLa cell; inhibition of Gly-Sar uptake (Gly-Sar: 50 microM, Cefoselis: 2500microM)",HeLa,mbcd0003494,,,,human,mbds0003,v2007,2013-12-09 19:52:41
mbbd000002000,mbcd0000229,mbtp000009,mbrf0001366,,=,,,non-inhibitor,33,477.0,pmol/10^6 cells/5 min,4,Cefluprenam,,,"PEPT1-expressing HeLa cell; inhibition of Gly-Sar uptake (Gly-Sar: 50 microM, Cefluprenam: 2500microM)",HeLa,mbcd0003494,,,,human,mbds0003,v2007,2013-12-09 19:59:48
mbbd000002001,mbcd0001591,mbtp000009,mbrf0001366,,=,,,non-inhibitor,33,598.0,pmol/10^6 cells/5 min,13,Cefepime,,,"PEPT1-expressing HeLa cell; inhibition of Gly-Sar uptake (Gly-Sar: 50 microM, Cefepime: 2500microM)",HeLa,mbcd0003494,,,,human,mbds0003,v2007,2013-12-09 19:59:49
mbbd000002002,mbcd0000235,mbtp000009,mbrf0001367,,>,,,inhibitor,29,30.0,mM,,cefsulodin,,,Caco-2; inhibition of Gly-Sar uptake (pH6.0),Caco-2,mbcd0003494,,,,human,mbds0003,v2007,2013-12-09 19:59:47
mbbd000002003,mbcd0003773,mbtp000009,mbrf0001367,,>,,,inhibitor,29,30.0,mM,,ceftriaxone,,,Caco-2; inhibition of Gly-Sar uptake (pH6.0),Caco-2,mbcd0003494,,,,human,mbds0003,v2007,2013-12-09 19:59:48
mbbd000002004,mbcd0003775,mbtp000009,mbrf0001367,,>,,,inhibitor,29,30.0,mM,,cefotaxime,,,Caco-2; inhibition of Gly-Sar uptake (pH6.0),Caco-2,mbcd0003494,,,,human,mbds0003,v2007,2013-12-09 19:59:46
mbbd000002005,mbcd0001075,mbtp000009,mbrf0001367,,>,,,inhibitor,29,10.0,mM,,Ceftazidime,,,Caco-2; inhibition of Gly-Sar uptake (pH6.0),Caco-2,mbcd0003494,,,,human,mbds0003,v2007,2013-12-09 19:59:47
mbbd000002006,mbcd0000092,mbtp000009,mbrf0001367,,>,,,inhibitor,29,30.0,mM,,6-aminopenicillanic acid,,,Caco-2; inhibition of Gly-Sar uptake (pH6.0),Caco-2,mbcd0003494,,,,human,mbds0003,v2007,2013-12-09 19:59:46
mbbd000002007,mbcd0003686,mbtp000009,mbrf0001367,,=,,,inhibitor,29,26.0,mM,,Cefuroxime,,,Caco-2; inhibition of Gly-Sar uptake (pH6.0),Caco-2,mbcd0003494,,,,human,mbds0003,v2007,2013-12-09 19:59:46
mbbd000002008,mbcd0001591,mbtp000009,mbrf0001367,,>,,,inhibitor,29,30.0,mM,,Cefepime,,,Caco-2; inhibition of Gly-Sar uptake (pH6.0),Caco-2,mbcd0003494,,,,human,mbds0003,v2007,2013-12-09 19:59:44
mbbd000002009,mbcd0003134,mbtp000009,mbrf0001367,,>,,,inhibitor,29,30.0,mM,,Benzylpenicillin,,,Caco-2; inhibition of Gly-Sar uptake (pH6.0),Caco-2,mbcd0003494,,,,human,mbds0003,v2007,2013-12-09 19:59:45
mbbd000002010,mbcd0003610,mbtp000009,mbrf0001367,,>,,,inhibitor,29,10.0,mM,,cephapirin,,,Caco-2; inhibition of Gly-Sar uptake (pH6.0),Caco-2,mbcd0003494,,,,human,mbds0003,v2007,2013-12-09 20:52:28
mbbd000002011,mbcd0003756,mbtp000009,mbrf0001367,,>,,,inhibitor,29,30.0,mM,,Cefpirome,,,Caco-2; inhibition of Gly-Sar uptake (pH6.0),Caco-2,mbcd0003494,,,,human,mbds0003,v2007,2013-12-09 20:52:27
mbbd000002012,mbcd0000231,mbtp000009,mbrf0001367,,=,,,inhibitor,29,22.0,mM,,cefodizime,,,Caco-2; inhibition of Gly-Sar uptake (pH6.0),Caco-2,mbcd0003494,,,,human,mbds0003,v2007,2013-12-09 20:52:28
mbbd000002015,mbcd0003681,mbtp000009,mbrf0001367,,>,,,inhibitor,29,10.0,mM,,Cephalothin,,,Caco-2; inhibition of Gly-Sar uptake (pH6.0),Caco-2,mbcd0003494,,,,human,mbds0003,v2007,2013-12-09 20:52:27
mbbd000002016,mbcd0000097,mbtp000009,mbrf0001367,,>,,,inhibitor,29,10.0,mM,,7-aminocephalosporanic acid,,,Caco-2; inhibition of Gly-Sar uptake (pH6.0),Caco-2,mbcd0003494,,,,human,mbds0003,v2007,2013-12-09 20:52:27
mbbd000002017,mbcd0003692,mbtp000009,mbrf0001367,,=,,,inhibitor,29,28.0,mM,,cefmetazole,,,Caco-2; inhibition of Gly-Sar uptake (pH6.0),Caco-2,mbcd0003494,,,,human,mbds0003,v2007,2013-12-09 20:52:27
mbbd000002018,mbcd0003720,mbtp000009,mbrf0001367,,=,,,inhibitor,29,12.0,mM,,oxacillin,,,Caco-2; inhibition of Gly-Sar uptake (pH6.0),Caco-2,mbcd0003494,,,,human,mbds0003,v2007,2013-12-09 20:52:27
mbbd000002019,mbcd0003019,mbtp000009,mbrf0001367,,=,,,inhibitor,29,8.1,mM,,Cefamandole,,,Caco-2; inhibition of Gly-Sar uptake (pH6.0),Caco-2,mbcd0003494,,,,human,mbds0003,v2007,2013-12-09 20:52:27
mbbd000002020,mbcd0003733,mbtp000009,mbrf0001367,,=,,,inhibitor,29,12.0,mM,,Cefixime,,,Caco-2; inhibition of Gly-Sar uptake (pH6.0),Caco-2,mbcd0003494,,,,human,mbds0003,v2007,2013-12-09 20:01:22
mbbd000002021,mbcd0003622,mbtp000009,mbrf0001367,,=,,,inhibitor,29,14.5,mM,,Ampicillin,,,Caco-2; inhibition of Gly-Sar uptake (pH6.0),Caco-2,mbcd0003494,,,,human,mbds0003,v2007,2013-12-09 20:01:23
mbbd000002022,mbcd0003806,mbtp000009,mbrf0001367,,=,,,inhibitor,29,3.0,mM,,cloxacillin,,,Caco-2; inhibition of Gly-Sar uptake (pH6.0),Caco-2,mbcd0003494,,,,human,mbds0003,v2007,2013-12-09 20:01:23
mbbd000002023,mbcd0000560,mbtp000009,mbrf0001367,,=,,,inhibitor,29,12.7,mM,,metampicillin,,,Caco-2; inhibition of Gly-Sar uptake (pH6.0),Caco-2,mbcd0003494,,,,human,mbds0003,v2007,2013-12-09 20:01:24
mbbd000002024,mbcd0001425,mbtp000009,mbrf0001367,,>,,,inhibitor,29,10.0,mM,,Amoxicillin,,,Caco-2; inhibition of Gly-Sar uptake (pH6.0),Caco-2,mbcd0003494,,,,human,mbds0003,v2007,2013-12-09 20:01:19
mbbd000002025,mbcd0003550,mbtp000009,mbrf0001367,,=,,,inhibitor,29,7.2,mM,,dicloxacillin,,,Caco-2; inhibition of Gly-Sar uptake (pH6.0),Caco-2,mbcd0003494,,,,human,mbds0003,v2007,2013-12-09 20:01:20
mbbd000002026,mbcd0003554,mbtp000009,mbrf0001367,,=,,,inhibitor,29,340.0,microM,,Ceftibuten,,,Caco-2; inhibition of Gly-Sar uptake (pH6.0),Caco-2,mbcd0003494,,,,human,mbds0003,v2007,2013-12-09 20:01:20
mbbd000002027,mbcd0003650,mbtp000009,mbrf0001367,,=,,,inhibitor,29,12.3,mM,,moxalactam,,,Caco-2; inhibition of Gly-Sar uptake (pH6.0),Caco-2,mbcd0003494,,,,human,mbds0003,v2007,2013-12-09 20:01:21
mbbd000002028,mbcd0003618,mbtp000009,mbrf0001367,,=,,,inhibitor,29,14.4,mM,,Cephalexin,,,Caco-2; inhibition of Gly-Sar uptake (pH6.0),Caco-2,mbcd0003494,,,,human,mbds0003,v2007,2013-12-09 20:01:25
mbbd000002030,mbcd0003666,mbtp000009,mbrf0001367,,=,,,inhibitor,29,500.0,microM,,Cyclacillin,,,Caco-2; inhibition of Gly-Sar uptake (pH6.0),Caco-2,mbcd0003494,,,,human,mbds0003,v2007,2013-12-09 20:52:50
mbbd000002031,mbcd0001298,mbtp000009,mbrf0001367,,>,,,inhibitor,29,10.0,mM,,Cefaclor,,,Caco-2; inhibition of Gly-Sar uptake (pH6.0),Caco-2,mbcd0003494,,,,human,mbds0003,v2007,2013-12-09 20:52:50
mbbd000002032,mbcd0001472,mbtp000009,mbrf0001367,,=,,,inhibitor,29,7.2,mM,,Cefadroxil,,,Caco-2; inhibition of Gly-Sar uptake (pH6.0),Caco-2,mbcd0003494,,,,human,mbds0003,v2007,2013-12-09 20:52:49
mbbd000002033,mbcd0000824,mbtp000009,mbrf0001368,,=,,,substrate,33,50.0,nL/oocyte,2.85,Temocaprilat,,,Xenopus laevis oocytes injected with hPEPT1 cRNA; uptake,Xenopus laevis oocytes,,,,,human,mbds0003,v2007,2013-12-10 22:21:07
mbbd000002034,mbcd0000823,mbtp000009,mbrf0001368,,=,,,substrate,33,519.0,nL/oocyte,87.9,Temocapril,,,Xenopus laevis oocytes injected with hPEPT1 cRNA; uptake,Xenopus laevis oocytes,,,,,human,mbds0003,v2007,2013-12-10 22:21:07
mbbd000002035,mbcd0003134,mbtp000009,mbrf0001368,,=,,,substrate,33,51.1,nL/oocyte,1.85,PCG,,,Xenopus laevis oocytes injected with hPEPT1 cRNA; uptake,Xenopus laevis oocytes,,,,,human,mbds0003,v2007,2013-12-10 22:21:07
mbbd000002036,mbcd0003061,mbtp000009,mbrf0001368,,=,,,non-substrate,33,12.3,nL/oocyte,1.3,Lisinopril,,,Xenopus laevis oocyte; uptake,Xenopus laevis oocytes,,,,,human,mbds0003,v2007,2013-12-10 22:21:07
mbbd000002037,mbcd0000406,mbtp000009,mbrf0001368,,=,,,substrate,33,23.8,nL/oocyte,4.66,FK089,,,Xenopus laevis oocytes injected with hPEPT1 cRNA; uptake,Xenopus laevis oocytes,,,,,human,mbds0003,v2007,2013-12-10 22:21:07
mbbd000002038,mbcd0000400,mbtp000009,mbrf0001368,,=,,,non-substrate,33,10.2,nL/oocyte,1.21,Faropenem,,,Xenopus laevis oocyte; uptake,Xenopus laevis oocytes,,,,,human,mbds0003,v2007,2013-12-10 22:21:07
mbbd000002039,mbcd0000375,mbtp000009,mbrf0001368,,=,,,substrate,33,8.49,nL/oocyte,1.15,Enalaprilat,,,Xenopus laevis oocytes injected with hPEPT1 cRNA; uptake,Xenopus laevis oocytes,,,,,human,mbds0003,v2007,2013-12-10 22:21:07
mbbd000002040,mbcd0003498,mbtp000009,mbrf0001368,,=,,,substrate,33,52.7,nL/oocyte,8.05,Enalapril,,,Xenopus laevis oocytes injected with hPEPT1 cRNA; uptake,Xenopus laevis oocytes,,,,,human,mbds0003,v2007,2013-12-10 22:21:07
mbbd000002041,mbcd0001564,mbtp000009,mbrf0001368,,=,,,non-substrate,33,3.88,nL/oocyte,0.9,Ceftizoxime,,,Xenopus laevis oocyte; uptake,Xenopus laevis oocytes,,,,,human,mbds0003,v2007,2013-12-10 22:21:07
mbbd000002042,mbcd0003554,mbtp000009,mbrf0001368,,=,,,substrate,33,22.6,nL/oocyte,3.2,Ceftibuten,,,Xenopus laevis oocytes injected with hPEPT1 cRNA; uptake,Xenopus laevis oocytes,,,,,human,mbds0003,v2007,2013-12-10 22:21:07
mbbd000002043,mbcd0003733,mbtp000009,mbrf0001368,,=,,,substrate,33,41.8,nL/oocyte,11.4,Cefixime,,,Xenopus laevis oocytes injected with hPEPT1 cRNA; uptake,Xenopus laevis oocytes,,,,,human,mbds0003,v2007,2013-12-10 22:21:07
mbbd000002044,mbcd0001130,mbtp000009,mbrf0001368,,=,,,substrate,33,16.8,nL/oocyte,4.03,Cefdinir,,,Xenopus laevis oocytes; uptake,Xenopus laevis oocytes,,,,,human,mbds0003,v2007,2013-12-10 22:21:07
mbbd000002045,mbcd0001472,mbtp000009,mbrf0001368,,=,,,substrate,33,48.3,nL/oocyte,6.32,Cefadroxil,,,Xenopus laevis oocytes injected with hPEPT1 cRNA; uptake,Xenopus laevis oocytes,,,,,human,mbds0003,v2007,2013-12-10 22:21:07
mbbd000002046,mbcd0022751,mbtp000009,mbrf0001368,,=,,,substrate,33,222.0,nL/oocyte,36.5,Carnosine,,,Xenopus laevis oocytes injected with hPEPT1 cRNA; uptake,Xenopus laevis oocytes,,,,,human,mbds0003,v2007,2013-12-10 22:21:07
mbbd000002047,mbcd0000129,mbtp000006,mbrf0001369,,~,,,inhibitor,102,70.0,%,,alpha-4-OH-cinnamate,,,Xenopus laevis oocyte; inhibition of pyruvate uptake; deoxyglucose was a negative control (100% pyruvate uptake),,,,,,human,mbds0003,v2007,2013-12-09 20:03:35
mbbd000002048,mbcd0000128,mbtp000006,mbrf0001369,,~,,,inhibitor,102,50.0,%,,alpha-3-OH-cinnamate,,,Xenopus laevis oocytes; % of control pyruvate (1 mM) uptake,,,,,,human,mbds0003,v2007,2012-10-30 00:00:06
mbbd000002049,mbcd0000327,mbtp000006,mbrf0001369,,~,,,non-inhibitor,102,100.0,%,,deoxyglucose,,,Xenopus laevis oocytes; % of control pyruvate (1 mM) uptake,,,,,,human,mbds0003,v2007,2012-10-30 00:00:06
mbbd000002050,mbcd0000358,mbtp000006,mbrf0001369,,~,,,inhibitor,102,35.0,%,,DL-alpha-hydroxybutyrate,,,Xenopus laevis oocytes; % of control pyruvate (1 mM) uptake; 78% inhibition,,,,,,human,mbds0003,v2007,2012-04-04 22:10:06
mbbd000002051,mbcd0000359,mbtp000006,mbrf0001369,,~,,,inhibitor,102,48.0,%,,DL-beta-hydroxybutyrate,,,Xenopus laevis oocytes; % of control pyruvate (1 mM) uptake; 65% inhibition,,,,,,human,mbds0003,v2007,2012-10-30 00:00:06
mbbd000002052,mbcd0001600,mbtp000006,mbrf0001369,,~,,,inhibitor,102,30.0,%,,gamma-hydroxybutyrate,,,Xenopus laevis oocytes; % of control pyruvate (1 mM) uptake; 85% inhibition,,,,,,human,mbds0003,v2007,2012-10-30 00:00:06
mbbd000002053,mbcd0001646,mbtp000006,mbrf0001369,,~,,,inhibitor,102,30.0,%,,D-lactate,,,Xenopus laevis oocytes; % of control pyruvate (1 mM) uptake,,,,,,human,mbds0003,v2007,2012-04-04 22:10:06
mbbd000002054,mbcd0000316,mbtp000006,mbrf0001369,,~,,,inhibitor,102,10.0,%,,L-lactate,,,Xenopus laevis oocytes; % of control pyruvate (1 mM) uptake; 100% inhibition,,,,,,human,mbds0003,v2007,2012-10-30 00:00:06
mbbd000002055,mbcd0000316,mbtp000006,mbrf0001369,,=,,,substrate,28,6.0,mM,,L-lactate,,,Xenopus laevis oocyte; uptake,Xenopus laevis oocytes,,,,,human,mbds0003,v2007,2013-12-09 20:53:24
mbbd000002056,mbcd0000909,mbtp000006,mbrf0001369,,=,,,substrate,28,2.5,mM,,pyruvate,,,Xenopus laevis oocyte; uptake,Xenopus laevis oocytes,,,,,human,mbds0003,v2007,2013-12-09 20:53:24
mbbd000002057,mbcd0001241,mbtp000006,mbrf0001370,,,,,non-substrate,,,,,nateglinide,,,Xenopus laevis oocytes,Xenopus laevis oocytes,,,,,human,mbds0003,v2007,2013-11-24 23:14:38
mbbd000002058,mbcd0000864,mbtp000007,mbrf0001371,,=,,,substrate,28,53.0,microM,13.9,TBuMA,,,Xenopus laevis oocyte; uptake,Xenopus laevis oocytes,,0-300,microM,,human,mbds0003,v2007,2013-12-09 20:53:25
mbbd000002060,mbcd0001239,mbtp000007,mbrf0001371,,~,,,inhibitor,33,530.0,fmol/oocyte min,200,Rocuronium,,,Xenopus laevis oocyte; inhibition of TBuMA uptake,Xenopus laevis oocytes,mbcd0000864,200,microM,,human,mbds0003,v2007,2013-12-09 20:05:10
mbbd000002061,mbcd0027018,mbtp000007,mbrf0001371,,~,,,inhibitor,33,530.0,fmol/oocyte min,190,Quinidine,,,Xenopus laevis oocyte; inhibition of TBuMA uptake,Xenopus laevis oocytes,mbcd0000864,200,microM,,human,mbds0003,v2007,2013-12-09 20:05:11
mbbd000002063,mbcd0000605,mbtp000007,mbrf0001371,,=,,,substrate,28,19.5,microM,7.3,NMQ,,,Xenopus laevis oocyte; uptake,Xenopus laevis oocytes,,0-200,microM,,human,mbds0003,v2007,2013-12-09 20:05:11
mbbd000002065,mbcd0000604,mbtp000007,mbrf0001371,,~,,,inhibitor,33,180.0,fmol/oocyte min,100,NMQD,,,Xenopus laevis oocyte; inhibition of TBuMA uptake,Xenopus laevis oocytes,mbcd0000864,200,microM,,human,mbds0003,v2007,2013-12-09 20:05:13
mbbd000002066,mbcd0000604,mbtp000007,mbrf0001371,,=,,,substrate,28,11.5,microM,2.1,NMQD,,,Xenopus laevis oocyte; uptake,Xenopus laevis oocytes,,0-100,microM,,human,mbds0003,v2007,2013-12-09 20:05:14
mbbd000002067,mbcd0000597,mbtp000007,mbrf0001371,,,,,substrate,,,,,APQ,,,Xenopus laevis oocyte; uptake,Xenopus laevis oocytes,,,,,human,mbds0003,v2007,2013-12-09 20:05:15
mbbd000002068,mbcd0000596,mbtp000007,mbrf0001371,,,,,substrate,,,,,APDA,,,Xenopus laevis oocyte; uptake,Xenopus laevis oocytes,,,,,human,mbds0003,v2007,2013-12-09 20:05:09
mbbd000002070,mbcd0000160,mbtp000007,mbrf0001371,,~,,,inhibitor,33,820.0,fmol/oocyte min,300,APM,,,Xenopus laevis oocyte; inhibition of TBuMA uptake,Xenopus laevis oocytes,mbcd0000864,200,microM,,human,mbds0003,v2007,2013-12-09 20:54:27
mbbd000002071,mbcd0000160,mbtp000007,mbrf0001371,,=,,,substrate,28,100.9,microM,43.0,APM,,,Xenopus laevis oocyte; uptake,Xenopus laevis oocytes,,0-200,microM,,human,mbds0003,v2007,2013-12-09 20:54:27
mbbd000002072,mbcd0003890,mbtp000007,mbrf0001372,,=,,,inhibitor,72,88.3,%,,GCV,,,"OCT1-expressing S2 cell; inhibition of TEA uptake (TEA: 5 microM, GCV: 1000 microM)",S2,mbcd0003923,,,,human,mbds0003,v2007,2013-12-09 20:54:26
mbbd000002073,mbcd0003890,mbtp000007,mbrf0001372,,=,,,substrate,28,516.2,microM,70.3,GCV,,,OCT1-expressing S2 cell; uptake,S2,,100,nM,,human,mbds0003,v2007,2013-12-09 20:54:26
mbbd000002074,mbcd0003916,mbtp000007,mbrf0001372,,=,,,inhibitor,72,88.4,%,,ACV,,,"OCT1-expressing S2 cell; inhibition of TEA uptake (TEA: 5 microM, ACV: 1000 microM)",S2,mbcd0003923,,,,human,mbds0003,v2007,2013-12-09 20:54:26
mbbd000002075,mbcd0003916,mbtp000007,mbrf0001372,,=,,,substrate,28,151.2,microM,22.1,ACV,,,OCT1-expressing S2 cell; uptake,S2,,50,nM,,human,mbds0003,v2007,2013-12-09 20:54:26
mbbd000002076,mbcd0000164,mbtp000007,mbrf0001373,,=,,,substrate,28,15.4,microM,5.6,Bamet-UD2,,,Xenopus laevis oocyte; uptake,Xenopus laevis oocytes,,0-100,microM,,human,mbds0003,v2007,2013-12-09 20:16:18
mbbd000002077,mbcd0000163,mbtp000007,mbrf0001373,,=,,,substrate,28,57.7,microM,12.0,Bamet-R2,,,Xenopus laevis oocyte; uptake,Xenopus laevis oocytes,,0-100,microM,,human,mbds0003,v2007,2013-12-09 20:52:35
mbbd000002078,mbcd0000719,mbtp000007,mbrf0001374,,=,,,inhibitor,72,68.9,%,,PGF2alpha,,,"OCT1-expressing S2 cell; inhibition of TEA uptake (TEA: 5 microM, PGF2_: 1000 microM)",S2,mbcd0003923,,,,human,mbds0003,v2007,2013-12-09 20:16:17
mbbd000002079,mbcd0000719,mbtp000007,mbrf0001374,28,=,0.477,microM,substrate,28,477.0,nM,33.1,PGF2alpha,,,OCT1-expressing S2 cell; uptake,S2,,5,nM,,human,mbds0003,v2007,2013-12-09 20:16:16
mbbd000002080,mbcd0001343,mbtp000007,mbrf0001374,,=,,,inhibitor,72,31.4,%,,PGE2,,,"OCT1-expressing S2 cell; inhibition of TEA uptake (TEA: 5 microM, PGE2: 1000 microM)",S2,mbcd0003923,,,,human,mbds0003,v2007,2013-12-09 20:07:40
mbbd000002081,mbcd0001343,mbtp000007,mbrf0001374,28,=,0.657,microM,substrate,28,0.657,nM,53.1,PGE2,,,OCT1-expressing S2 cell; uptake,S2,,5,nM,,human,mbds0003,v2007,2013-12-09 20:07:41
mbbd000002082,mbcd0000775,mbtp000007,mbrf0001375,,=,,,inhibitor,25,0.3,microM,,SKF550,,,OCT1-expressing HEK 293 cell; inhibition of MPP+ uptake (MPP+: 0.25 microM),HEK293,mbcd0003022,,,,human,mbds0003,v2007,2013-12-09 20:07:39
mbbd000002083,mbcd0001892,mbtp000007,mbrf0001375,,=,,,inhibitor,25,3.05,microM,,Progesterone,,,OCT1-expressing HEK293 cell; inhibition of MPP+ uptake (MPP+: 0.25 microM),HEK293,mbcd0003022,,,,human,mbds0003,v2007,2013-12-09 20:07:40
mbbd000002084,mbcd0003024,mbtp000007,mbrf0001375,,=,,,inhibitor,25,1.84,microM,,Prazosin,,,OCT1-expressing HEK 293 cell; inhibition of MPP+ uptake (MPP+: 0.25 microM),HEK293,mbcd0003022,,,,human,mbds0003,v2007,2013-12-09 20:07:39
mbbd000002085,mbcd0003971,mbtp000007,mbrf0001375,,=,,,inhibitor,25,2.72,microM,,PbA,,,OCT1-expressing HEK 293 cell; inhibition of MPP+ uptake (MPP+: 0.25 microM),HEK293,mbcd0003022,,,,human,mbds0003,v2007,2013-12-09 20:07:39
mbbd000002086,mbcd0000639,mbtp000007,mbrf0001375,,=,,,inhibitor,25,100.0,microM,,OMI,,,OCT1-expressing HEK293 cell; inhibition of MPP+ uptake (MPP+: 0.25 microM),HEK293,mbcd0003022,,,,human,mbds0003,v2007,2013-12-09 20:07:38
mbbd000002087,mbcd0000320,mbtp000007,mbrf0001375,,=,,,inhibitor,25,0.98,microM,,D22,,,OCT1-expressing HEK 293 cell; inhibition of MPP+ uptake (MPP+: 0.25 microM),HEK293,mbcd0003022,,,,human,mbds0003,v2007,2013-12-09 20:07:39
mbbd000002088,mbcd0003905,mbtp000007,mbrf0001375,,=,,,inhibitor,25,21.7,microM,,Corticosterone,,,OCT1-expressing HEK 293 cell; inhibition of MPP+ uptake (MPP+: 0.25 microM),HEK293,mbcd0003022,,,,human,mbds0003,v2007,2013-12-09 20:07:41
mbbd000002089,mbcd0003055,mbtp000007,mbrf0001375,,=,,,inhibitor,25,5.73,microM,,beta-oestradiol,,,OCT1-expressing HEK 293 cell; inhibition of MPP+ uptake (MPP+: 0.25 microM),HEK293,mbcd0003022,,,,human,mbds0003,v2007,2013-12-09 20:07:41
mbbd000002090,mbcd0003105,mbtp000007,mbrf0001376,,=,,,inhibitor,25,10.0,microM,,Phenformin,,,Xenopus laevis oocyte; inhibition of Cimetidine uptake (Cimetidine: 1 microM),Xenopus laevis oocytes,mbcd0001111,,,,human,mbds0003,v2007,2013-12-09 20:54:59
mbbd000002091,mbcd0003886,mbtp000007,mbrf0001376,,=,,,inhibitor,25,2010.0,microM,,Metformin,,,Xenopus laevis oocyte; inhibition of Cimetidine uptake (Cimetidine: 1 microM),Xenopus laevis oocytes,mbcd0001111,,,,human,mbds0003,v2007,2013-12-09 20:54:59
mbbd000002092,mbcd0003887,mbtp000007,mbrf0001377,,,,,substrate,,,,,agmatine,,,OCT1-expressing 293 cell; uptake,HEK293,,,,,human,mbds0003,v2007,2013-12-09 20:54:59
mbbd000002093,mbcd0003887,mbtp000007,mbrf0001377,,=,,,inhibitor,29,24000.0,microM,,Agmatine,,,OCT1-expressing 293 cell; inhibition of uptake of 0.1 microM MPP+,HEK293,mbcd0003022,,,,human,mbds0003,v2007,2013-12-09 20:54:59
mbbd000002094,mbcd0003022,mbtp000007,mbrf0001377,,=,,,substrate,16,32.0,microM,27-38 (95% CI),MPP+,,,OCT1-expressing 293 cells; uptake,HEK293,,,,,human,mbds0003,v2007,2013-11-10 07:36:04
mbbd000002099,mbcd0003923,mbtp000007,mbrf0001378,,=,,,inhibitor,25,168.0,microM,25.9,TEA,,,OCT1-expressing HeLa cell; inhibition of TEA uptake,,,,,,human,mbds0003,v2007,2013-12-09 20:54:59
mbbd000002125,mbcd0027062,mbtp000007,mbrf0001379,,,,,inhibitor,,,,,Verapamil,,,"Xenopus laevis oocyte; inhibition of MPP+ uptake (MPP+: 0.85 microM, Verapamil: 5000 microM)",Xenopus laevis oocytes,mbcd0003022,,,,human,mbds0003,v2007,2013-12-09 20:15:07
mbbd000002126,mbcd0001567,mbtp000007,mbrf0001379,,=,,,inhibitor,29,120.0,microM,,Vecuronium,,,Xenopus laevis oocyte; inhibition of MPP+ uptake,Xenopus laevis oocytes,mbcd0003022,,,,human,mbds0003,v2007,2013-12-09 20:15:10
mbbd000002127,mbcd0001667,mbtp000007,mbrf0001379,,=,,,inhibitor,33,292.0,fmol/oocyte/hr,9.00,Thymidine,,,"Xenopus laevis oocyte; inhibition of MPP+ uptake (MPP+: 0.85 microM, Thymidine: 5000 microM)",Xenopus laevis oocytes,mbcd0003022,5,mM,,human,mbds0003,v2007,2013-12-09 20:15:09
mbbd000002128,mbcd0003923,mbtp000007,mbrf0001379,,=,,,inhibitor,29,163.0,microM,,TEA,,,Xenopus laevis oocyte; inhibition of MPP+ uptake,Xenopus laevis oocytes,mbcd0003022,,,,human,mbds0003,v2007,2013-12-09 20:15:06
mbbd000002129,mbcd0001664,mbtp000007,mbrf0001379,,=,,,inhibitor,33,184.0,fmol/oocyte/hr,4.78,Taurocholate,,,"Xenopus laevis oocyte; inhibition of MPP+ uptake (MPP+: 0.15 microM, TCA: 5000 microM)",Xenopus laevis oocytes,mbcd0003022,5,mM,,human,mbds0003,v2007,2013-12-09 20:15:05
mbbd000002130,mbcd0001092,mbtp000007,mbrf0001379,,,,,inhibitor,,,,,Quinine,,,"Xenopus laevis oocyte; inhibition of MPP+ uptake (MPP+: 0.85 microM, Quinine: 1000 microM)",Xenopus laevis oocytes,mbcd0003022,,,,human,mbds0003,v2007,2013-12-09 21:00:58
mbbd000002131,mbcd0027018,mbtp000007,mbrf0001379,,,,,inhibitor,,,,,Quinidine,,,"Xenopus laevis oocyte; inhibition of MPP+ uptake (MPP+: 0.85 microM, Quinidine: 1000 microM)",Xenopus laevis oocytes,mbcd0003022,,,,human,mbds0003,v2007,2013-12-09 21:00:59
mbbd000002132,mbcd0003941,mbtp000007,mbrf0001379,,,,,inhibitor,,,,,Procainamide,,,"Xenopus laevis oocyte; inhibition of MPP+ uptake (MPP+: 0.85 microM, Procainamide: 5000 microM)",Xenopus laevis oocytes,mbcd0003022,,,,human,mbds0003,v2007,2013-12-09 21:00:55
mbbd000002133,mbcd0001566,mbtp000007,mbrf0001379,,~,,,inhibitor,33,20.0,fmol/oocyte/hr,,Pancuronium,,,"Xenopus laevis oocyte; inhibition of MPP+ uptake (MPP+: 0.85 microM, Pancuronium: 1000 microM)",Xenopus laevis oocytes,mbcd0003022,1,mM,,human,mbds0003,v2007,2013-12-09 21:00:57
mbbd000002134,mbcd0000607,mbtp000007,mbrf0001379,,~,,,inhibitor,33,80.0,fmol/oocyte/hr,,N1-methylnicotinamide,,,"Xenopus laevis oocyte; inhibition of MPP+ uptake (MPP+: 0.85 microM, NMN: 5000 microM)",Xenopus laevis oocytes,mbcd0003022,5,mM,,human,mbds0003,v2007,2013-12-09 21:01:01
mbbd000002135,mbcd0000490,mbtp000007,mbrf0001379,,=,,,inhibitor,33,178.0,fmol/oocyte/hr,20.9,Inosine,,,"Xenopus laevis oocyte; inhibition of MPP+ uptake (MPP+: 0.15 microM, Inosine: 1000 microM)",Xenopus laevis oocytes,mbcd0003022,1,mM,,human,mbds0003,v2007,2013-12-09 21:01:01
mbbd000002136,mbcd0000320,mbtp000007,mbrf0001379,,=,,,inhibitor,29,4.4,microM,,Decynium-22,,,Xenopus laevis oocyte; inhibition of MPP+ uptake,Xenopus laevis oocytes,mbcd0003022,,,,human,mbds0003,v2007,2013-12-09 21:01:00
mbbd000002137,mbcd0003947,mbtp000007,mbrf0001379,,,,,inhibitor,,,,,Clonidine,,,"Xenopus laevis oocyte; inhibition of MPP+ uptake (MPP+: 0.85 microM, Clonidine: 5000 microM)",Xenopus laevis oocytes,mbcd0003022,,,,human,mbds0003,v2007,2013-12-09 21:01:00
mbbd000002138,mbcd0001111,mbtp000007,mbrf0001379,,=,,,inhibitor,33,429.0,fmol/oocyte/hr,36.8,Cimetidine,,,"Xenopus laevis oocyte; inhibition of MPP+ uptake (MPP+: 0.85 microM, Cimetidine: 5000 microM)",Xenopus laevis oocytes,mbcd0003022,5,mM,,human,mbds0003,v2007,2013-12-09 21:00:55
mbbd000002139,mbcd0003945,mbtp000007,mbrf0001379,,~,,,inhibitor,33,250.0,fmol/oocyte/hr,40,Choline,,,"Xenopus laevis oocyte; inhibition of MPP+ uptake (MPP+: 0.85 microM, Choline: 1000 microM)",Xenopus laevis oocytes,mbcd0003022,1,mM,,human,mbds0003,v2007,2013-12-09 21:00:55
mbbd000002140,mbcd0003022,mbtp000007,mbrf0001379,,=,,,substrate,28,14.6,microM,4.39,MPP+,,,Xenopus laevis oocyte; uptake,Xenopus laevis oocytes,,0-500,microM,,human,mbds0003,v2007,2013-12-09 20:13:34
mbbd000002141,mbcd0003923,mbtp000007,mbrf0001380,,,,,substrate,,,,,TEA,not saturable,,Xenopus laevis oocyte; uptake,Xenopus laevis oocytes,,,,,human,mbds0003,v2007,2013-12-10 22:17:54
mbbd000002142,mbcd0000607,mbtp000007,mbrf0001380,,,,,substrate,,,,,NMN,not saturable,,Xenopus laevis oocyte; uptake,Xenopus laevis oocytes,,,,,human,mbds0003,v2007,2013-12-10 22:17:54
mbbd000002143,mbcd0003022,mbtp000007,mbrf0001380,,,,,substrate,,,,,MPP,not saturable,,Xenopus laevis oocyte; uptake,Xenopus laevis oocytes,,,,,human,mbds0003,v2007,2013-12-10 22:17:54
mbbd000002144,mbcd0027062,mbtp000007,mbrf0001381,,=,,,inhibitor,29,2.9,microM,,Verapamil,,,OCT1-expressing HeLa cell; inhibition of TEA uptake,HeLa,mbcd0003923,,,,human,mbds0003,v2007,2013-12-09 20:13:35
mbbd000002145,mbcd0001567,mbtp000007,mbrf0001381,,=,,,inhibitor,29,232.0,microM,,Vecuronium,,,OCT1-expressing HeLa cell; inhibition of TEA uptake,HeLa,mbcd0003923,,,,human,mbds0003,v2007,2013-12-09 20:13:35
mbbd000002146,mbcd0000844,mbtp000007,mbrf0001381,,=,,,inhibitor,29,7.46,microM,,Tetrapentylammonium,,,OCT1-expressing HeLa cell; inhibition of TEA uptake,HeLa,mbcd0003923,,,,human,mbds0003,v2007,2013-12-09 20:13:34
mbbd000002147,mbcd0003923,mbtp000007,mbrf0001381,,=,,,inhibitor,29,161.0,microM,,TEA,,,OCT1-expressing HeLa cell; inhibition of TEA uptake,HeLa,mbcd0003923,,,,human,mbds0003,v2007,2013-12-09 20:13:34
mbbd000002148,mbcd0003923,mbtp000007,mbrf0001381,,=,,,substrate,28,229.0,microM,78.4,TEA,,,OCT1-expressing HeLa cell; uptake,HeLa,,0-500,microM,,human,mbds0003,v2007,2013-12-09 20:13:36
mbbd000002149,mbcd0001092,mbtp000007,mbrf0001381,,=,,,inhibitor,29,22.9,microM,,Quinine,,,OCT1-expressing HeLa cell; inhibition of TEA uptake,HeLa,mbcd0003923,,,,human,mbds0003,v2007,2013-12-09 20:13:35
mbbd000002150,mbcd0027018,mbtp000007,mbrf0001381,,=,,,inhibitor,29,17.5,microM,,Quinidine,,,OCT1-expressing HeLa cell; inhibition of TEA uptake,HeLa,mbcd0003923,,,,human,mbds0003,v2007,2013-12-09 21:00:40
mbbd000002151,mbcd0003941,mbtp000007,mbrf0001381,,=,,,inhibitor,29,73.9,microM,,Procainamide,,,OCT1-expressing HeLa cell; inhibition of TEA uptake,HeLa,mbcd0003923,,,,human,mbds0003,v2007,2013-12-09 20:08:08
mbbd000002152,mbcd0000928,mbtp000007,mbrf0001381,,~,,,inhibitor,72,45.0,%,,Nicotine,,,"OCT1-expressing HeLa cell; inhibition of TEA uptake (TEA: 5 microM, Nicotine: 500 microM)",HeLa,mbcd0003923,,,,human,mbds0003,v2007,2013-12-09 21:00:40
mbbd000002153,mbcd0000607,mbtp000007,mbrf0001381,,=,,,inhibitor,29,7700.0,microM,,NMN,,,OCT1-expressing HeLa cell; inhibition of TEA uptake,HeLa,mbcd0003923,,,,human,mbds0003,v2007,2013-12-09 21:00:40
mbbd000002154,mbcd0001735,mbtp000007,mbrf0001381,,=,,,inhibitor,29,3.7,microM,,Midazolam,,,OCT1-expressing HeLa cell; inhibition of TEA uptake,HeLa,mbcd0003923,1-100,microM,,human,mbds0003,v2007,2013-12-09 21:00:40
mbbd000002155,mbcd0003933,mbtp000007,mbrf0001381,,~,,,inhibitor,72,30.0,%,,Dopamine,,,"OCT1-expressing HeLa cell; inhibition of TEA uptake (TEA: 5 microM, Dopamine: 5000 microM)",HeLa,mbcd0003923,,,,human,mbds0003,v2007,2013-12-09 21:00:40
mbbd000002156,mbcd0003141,mbtp000007,mbrf0001381,,~,,,inhibitor,72,30.0,%,,Disopyramide,(at a rough estimate) 30-40 % of control,,"OCT1-expressing HeLa cell; inhibition of TEA uptake (TEA: 5 microM, Disopyramide: 100 microM)",HeLa,mbcd0003923,,,,human,mbds0003,v2007,2013-12-09 21:00:40
mbbd000002157,mbcd0002995,mbtp000007,mbrf0001381,,=,,,inhibitor,29,5.36,microM,,Desipramine,,,OCT1-expressing HeLa cell; inhibition of TEA uptake,HeLa,mbcd0003923,,,,human,mbds0003,v2007,2013-12-09 21:00:40
mbbd000002158,mbcd0000320,mbtp000007,mbrf0001381,,=,,,inhibitor,29,2.73,microM,,Decynium-22,,,OCT1-expressing HeLa cell; inhibition of TEA uptake,HeLa,mbcd0003923,,,,human,mbds0003,v2007,2013-12-09 21:00:40
mbbd000002159,mbcd0003905,mbtp000007,mbrf0001381,,=,,,inhibitor,29,7.02,microM,,Corticosterone,,,OCT1-expressing HeLa cell; inhibition of TEA uptake,HeLa,mbcd0003923,,,,human,mbds0003,v2007,2013-12-09 21:00:40
mbbd000002160,mbcd0003947,mbtp000007,mbrf0001381,,=,,,inhibitor,29,0.55,microM,,Clonidine,,,OCT1-expressing HeLa cell; inhibition of TEA uptake,HeLa,mbcd0003923,,,,human,mbds0003,v2007,2013-12-09 20:10:29
mbbd000002161,mbcd0001111,mbtp000007,mbrf0001381,,=,,,inhibitor,29,166.0,microM,,Cimetidine,,,OCT1-expressing HeLa cell; inhibition of TEA uptake,HeLa,mbcd0003923,,,,human,mbds0003,v2007,2013-12-09 20:10:28
mbbd000002162,mbcd0001111,mbtp000007,mbrf0001381,,,,,substrate,,,,,cimetidine,,,OCT1-expressing HeLa cell; uptake,HeLa,,5,microM,weak substrate,human,mbds0003,v2007,2013-12-09 20:10:32
mbbd000002163,mbcd0003945,mbtp000007,mbrf0001381,,~,,,inhibitor,72,75.0,%,,Choline,,,"OCT1-expressing HeLa cell; inhibition of TEA uptake (TEA: 5 microM, Choline: 500 microM)",HeLa,mbcd0003923,,,,human,mbds0003,v2007,2013-12-09 20:10:31
mbbd000002164,mbcd0003083,mbtp000007,mbrf0001381,,~,,,inhibitor,72,60.0,%,,Amantadine,,,"OCT1-expressing HeLa cell; inhibition of TEA uptake (TEA: 5 microM, Amantadine: 100 microM)",HeLa,mbcd0003923,,,,human,mbds0003,v2007,2013-12-09 20:10:25
mbbd000002165,mbcd0003876,mbtp000007,mbrf0001381,,=,,,inhibitor,29,95.8,microM,,Acebutolol,,,OCT1-expressing HeLa cell; inhibition of TEA uptake,HeLa,mbcd0003923,,,,human,mbds0003,v2007,2013-12-09 20:10:24
mbbd000002166,mbcd0003022,mbtp000007,mbrf0001381,,=,,,inhibitor,29,12.3,microM,,MPP+,,,OCT1-expressing HeLa cell; inhibition of TEA uptake,HeLa,mbcd0003923,,,,human,mbds0003,v2007,2013-12-09 20:10:27
mbbd000002167,mbcd0000846,mbtp000007,mbrf0001382,,=,,,inhibitor,25,90.0,microM,,TPrA,,,OCT1-expressing HeLa cell; inhibition of TEA uptake (TEA: 10 microM),HeLa,mbcd0003923,,,,human,mbds0003,v2007,2013-12-09 20:10:26
mbbd000002168,mbcd0000839,mbtp000007,mbrf0001382,,=,,,inhibitor,25,3.0,microM,,THA,,,OCT1-expressing HeLa cell; inhibition of TEA uptake (TEA: 10 microM),HeLa,mbcd0003923,,,,human,mbds0003,v2007,2013-12-09 20:10:35
mbbd000002169,mbcd0000835,mbtp000007,mbrf0001382,,=,,,inhibitor,25,52.0,microM,,TBA,,,OCT1-expressing HeLa cell; inhibition of TEA uptake (TEA: 10 microM),HeLa,mbcd0003923,,,,human,mbds0003,v2007,2013-12-09 20:10:34
mbbd000002170,mbcd0027018,mbtp000007,mbrf0001382,,=,,,inhibitor,25,23.4,microM,,Quinidine,,,OCT1-expressing HeLa cell; inhibition of TEA uptake (TEA: 10 microM),HeLa,mbcd0003923,,,,human,mbds0003,v2007,2013-12-09 20:58:26
mbbd000002171,mbcd0000846,mbtp000007,mbrf0001383,,=,,,inhibitor,29,102.0,microM,,TPrA,,,Xenopus laevis oocyte; inhibition of MPP+ uptake,Xenopus laevis oocytes,mbcd0003022,,,,human,mbds0003,v2007,2013-12-09 20:58:26
mbbd000002172,mbcd0000844,mbtp000007,mbrf0001383,,~,,,non-inhibitor,102,100.0,%,10,TPeA,,,"Xenopus laevis oocyte; trans-stimulation of MPP+ uptake (MPP+: 1 microM, TPeA: 200 microM)",Xenopus laevis oocytes,,,,,human,mbds0003,v2007,2013-12-09 20:58:26
mbbd000002173,mbcd0000840,mbtp000007,mbrf0001383,,=,,,inhibitor,29,12400.0,microM,,TMA,,,Xenopus laevis oocyte; inhibition of MPP+ uptake,Xenopus laevis oocytes,mbcd0003022,,,,human,mbds0003,v2007,2013-12-09 20:58:26
mbbd000002174,mbcd0003923,mbtp000007,mbrf0001383,,=,,,inhibitor,29,158.0,microM,,TEA,,,Xenopus laevis oocyte; inhibition of MPP+ uptake,Xenopus laevis oocytes,mbcd0003022,,,,human,mbds0003,v2007,2013-12-09 20:58:25
mbbd000002175,mbcd0000835,mbtp000007,mbrf0001383,,=,,,inhibitor,29,29.6,microM,,TBA,,,Xenopus laevis oocyte; inhibition of MPP+ uptake,Xenopus laevis oocytes,mbcd0003022,,,,human,mbds0003,v2007,2013-12-09 20:58:26
mbbd000002176,mbcd0027018,mbtp000007,mbrf0001248,,=,,,inhibitor,72,20.0,%,,Quinidine,,,OCT1-expressing HeLa cell; inhibition of Tetraethyl ammonium uptake (Quinidine:100 microM),HeLa,mbcd0003923,,,,human,mbds0003,v2007,2013-12-09 20:58:25
mbbd000002177,mbcd0001120,mbtp000007,mbrf0001248,,=,,,inhibitor,72,30.0,%,,Caspofungin,,,OCT1-expressing HeLa cell; inhibition of Tetraethyl ammonium uptake (Caspofungin:100 microM),HeLa,mbcd0003923,,,,human,mbds0003,v2007,2013-12-09 20:58:25
mbbd000002180,mbcd0000909,mbtp000003,mbrf0001385,,=,,,inhibitor,29,26.0,mM,12,pyruvate,,,PGT-expressing HeLa cell; inhibition of PGE2 uptake,,,,,,human,mbds0003,v2007,2013-12-09 20:09:15
mbbd000002181,mbcd0001631,mbtp000003,mbrf0001385,,=,,,inhibitor,29,13.0,mM,4,Phosphoenolpyruvate,,,PGT-expressing HeLa cell; inhibition of PGE2 uptake,,,,,,human,mbds0003,v2007,2013-12-09 20:09:14
mbbd000002182,mbcd0000516,mbtp000003,mbrf0001385,,=,,,inhibitor,29,48.0,mM,12,lactate,,,PGT-expressing HeLa cell; inhibition of PGE2 uptake,,,,,,human,mbds0003,v2007,2013-12-09 20:09:14
mbbd000002183,mbcd0001637,mbtp000003,mbrf0001385,,=,,,inhibitor,29,15.0,mM,11,Glyceraldehyde-3-phosphate,,,PGT-expressing HeLa cell; inhibition of PGE2 uptake,,,,,,human,mbds0003,v2007,2013-12-09 20:09:13
mbbd000002184,mbcd0000438,mbtp000003,mbrf0001385,,=,,,inhibitor,29,31.0,mM,12,Glucose-6-phosphate,,,PGT-expressing HeLa cell; inhibition of PGE2 uptake,,,,,,human,mbds0003,v2007,2013-12-09 20:09:12
mbbd000002185,mbcd0001669,mbtp000003,mbrf0001385,,=,,,inhibitor,29,51.0,mM,21,"Fructose-1,6-diphosphate",,,PGT-expressing HeLa cell; inhibition of PGE2 uptake,,,,,,human,mbds0003,v2007,2013-12-09 20:09:11
mbbd000002186,mbcd0000036,mbtp000003,mbrf0001385,,=,,,inhibitor,29,57.0,mM,9,"1,3-Diphosphoglycerate",,,PGT-expressing HeLa cell; inhibition of PGE2 uptake,,,,,,human,mbds0003,v2007,2013-12-09 20:09:11
mbbd000002187,mbcd0000848,mbtp000003,mbrf0001386,77,=,0.182,microM,substrate,77,182.0,nM,,TXB2,,,PGT-expressing HeLa cell; uptake,HeLa,,500,nM,,human,mbds0003,v2007,2013-12-09 20:09:10
mbbd000002188,mbcd0000719,mbtp000003,mbrf0001386,77,=,0.092,microM,substrate,77,92.0,nM,,PGF2alpha,,,PGT-expressing HeLa cell; uptake,HeLa,,100,nM,,human,mbds0003,v2007,2013-12-09 20:09:10
mbbd000002189,mbcd0001343,mbtp000003,mbrf0001386,77,=,0.1,microM,substrate,77,0.1,nM,,PGE2,,,PGT-expressing HeLa cell; uptake,HeLa,,100,nM,,human,mbds0003,v2007,2013-12-09 20:09:10
mbbd000002190,mbcd0001267,mbtp000003,mbrf0001386,77,=,0.082,microM,substrate,77,82.0,nM,,PGE1,,,PGT-expressing HeLa cell; uptake,HeLa,,100,nM,,human,mbds0003,v2007,2013-12-09 20:57:58
mbbd000002191,mbcd0000714,mbtp000003,mbrf0001386,77,=,0.083,microM,substrate,77,83.0,nM,,PGD2,,,PGT-expressing HeLa cell; uptake,HeLa,,100,nM,,human,mbds0003,v2007,2013-12-09 20:57:58
mbbd000002192,mbcd0001441,mbtp000003,mbrf0001386,,,,,non-substrate,,,,,iloprost,,,PGT-expressing HeLa cell; uptake,HeLa,,,,,human,mbds0003,v2007,2013-12-09 20:57:58
mbbd000002193,mbcd0000719,mbtp000003,mbrf0001387,,=,,,inhibitor,29,0.023,microM,,PGF2,,,PGT-expressing HeLa cell; inhibition of PGE2 uptake,HeLa,mbcd0001343,,,,human,mbds0003,v2007,2013-12-09 20:57:58
mbbd000002194,mbcd0000714,mbtp000003,mbrf0001387,,=,,,inhibitor,29,0.038,microM,,PGD2,,,PGT-expressing HeLa cell; inhibition of PGE2 uptake,HeLa,mbcd0001343,,,,human,mbds0003,v2007,2013-12-09 20:57:58
mbbd000002197,mbcd0003075,mbtp000011,mbrf0001388,,,,,substrate,,,,,Estrone-3-sulfate,,,OATP-D-expressing HEK293 cell; uptake,HEK293,,,,,human,mbds0003,v2007,2013-12-09 20:57:58
mbbd000002199,mbcd0001664,mbtp000011,mbrf0001389,,=,,,inhibitor,33,40.0,%,,Taurocholate,,,Xenopus laevis oocyte; inhibition of PGE2 uptake (PGE2: 15 nM); compound 150 nM,,,,,,human,mbds0003,v2007,2013-12-09 20:57:57
mbbd000002201,mbcd0000719,mbtp000011,mbrf0001389,,=,,,inhibitor,33,0.0,%,,Prostaglandin F2alpha,,,Xenopus laevis oocyte; inhibition of PGE2 uptake (PGE2: 15 nM); compound 150 nM,,,,,,human,mbds0003,v2007,2013-12-09 20:05:08
mbbd000002205,mbcd0001267,mbtp000011,mbrf0001389,,=,,,inhibitor,33,0.0,%,,Prostaglandin E1,,,Xenopus laevis oocyte; inhibition of PGE2 uptake (PGE2: 15 nM); compound 150 nM,,,,,,human,mbds0003,v2007,2013-12-09 20:05:07
mbbd000002207,mbcd0000714,mbtp000011,mbrf0001389,,=,,,inhibitor,33,30.0,%,,Prostaglandin D2,,,Xenopus laevis oocyte; inhibition of PGE2 uptake (PGE2: 15 nM); compound 150 nM,,,,,,human,mbds0003,v2007,2013-12-09 20:05:08
mbbd000002209,mbcd0003146,mbtp000011,mbrf0001389,,=,,,inhibitor,33,30.0,%,,PAH,,,Xenopus laevis oocyte; inhibition of PGE2 uptake (PGE2: 15 nM); compound 150 nM,,,,,,human,mbds0003,v2007,2013-12-09 20:05:06
mbbd000002213,mbcd0000887,mbtp000011,mbrf0001390,,,,,non-substrate,,,,,unoprostone isopropyl ester,(-),,Xenopus laevis oocyte; uptake,Xenopus laevis oocytes,,,,,human,mbds0003,v2007,2013-12-09 20:54:24
mbbd000002216,mbcd0003075,mbtp000004,mbrf0001388,,,,,substrate,,,,,Estrone-3-sulfate,,,OATP-E-expressing HEK293 cell; uptake,HEK293,,,,,human,mbds0003,v2007,2013-12-09 20:54:25
mbbd000002218,mbcd0000984,mbtp000004,mbrf0001391,,~,,,inhibitor,72,30.0,%,,T3,,,"Xenopus laevis oocyte; inhibition of Taurocholate uptake (Taurochorate: 5 microM, T3: 50 microM) ",Xenopus laevis oocytes,mbcd0001664,,,,human,mbds0003,v2007,2013-12-09 20:54:25
mbbd000002219,mbcd0000984,mbtp000004,mbrf0001391,,=,,,substrate,28,0.9,microM,0.4,T3,,,Xenopus laevis oocyte; uptake,Xenopus laevis oocytes,,0.5-50,microM,,human,mbds0003,v2007,2013-12-09 20:54:25
mbbd000002220,mbcd0003957,mbtp000004,mbrf0001391,,~,,,inhibitor,72,15.0,%,,T4,,,"Xenopus laevis oocyte; inhibition of T3 uptake (T3: 1 microM, T4: 100 microM) ",Xenopus laevis oocytes,mbcd0000984,,,,human,mbds0003,v2007,2013-12-09 20:03:31
mbbd000002221,mbcd0003957,mbtp000004,mbrf0001391,,,,,substrate,,,,,T4,,,Xenopus laevis oocyte; uptake,Xenopus laevis oocytes,,,,,human,mbds0003,v2007,2013-12-09 20:03:31
mbbd000002222,mbcd0001664,mbtp000004,mbrf0001391,,~,,,inhibitor,72,55.0,%,,Taurocholate,,,"Xenopus laevis oocyte; inhibition of T3 uptake (T3: 1 microM, Taurochorate: 100 microM) ",Xenopus laevis oocytes,mbcd0000984,,,,human,mbds0003,v2007,2013-12-09 20:03:30
mbbd000002223,mbcd0001664,mbtp000004,mbrf0001391,,=,,,substrate,28,14.9,microM,3.3,Taurocholate,,,Xenopus laevis oocyte; uptake,Xenopus laevis oocytes,,3; 5,microM,,human,mbds0003,v2007,2013-12-09 20:03:31
mbbd000002224,mbcd0000201,mbtp000004,mbrf0001391,,~,,,inhibitor,72,15.0,%,,BSP,,,"Xenopus laevis oocyte; inhibition of Taurocholate uptake (Taurochorate: 5 microM, BSP: 50 microM) ",Xenopus laevis oocytes,mbcd0001664,,,,human,mbds0003,v2007,2013-12-09 20:03:30
mbbd000002227,mbcd0000887,mbtp000004,mbrf0001390,,,,,non-substrate,,,,,unoprostone isopropyl ester,(-),,Xenopus laevis oocyte; uptake,Xenopus laevis oocytes,,,,,human,mbds0003,v2007,2013-12-09 20:03:30
mbbd000002230,mbcd0001664,mbtp000012,mbrf0001392,,=,,,substrate,28,10.0,microM,5.5,Cholyl taurine,,,OATP-C-expressing HEK293 cell; uptake,HEK293,,,,,human,mbds0003,v2007,2013-12-09 20:53:17
mbbd000002231,mbcd0000749,mbtp000012,mbrf0001392,,~,,,inhibitor,72,20.0,%,,Rifamycin SV,,,"OATP-C-expressing HEK293 cell; inhibition of E217_G uptake (E217_G: 2 microM, Rifamycin SV: 50 microM) ",HEK293,mbcd0000387,,,,human,mbds0003,v2007,2013-12-09 20:53:17
mbbd000002232,mbcd0001416,mbtp000012,mbrf0001392,,~,,,inhibitor,72,20.0,%,,Rifampicin,,,"OATP-C-expressing HEK293 cell; inhibition of E217_G uptake (E217_G: 2 microM, Rifampicin: 75 microM) ",HEK293,mbcd0000387,,,,human,mbds0003,v2007,2013-12-09 20:53:20
mbbd000002233,mbcd0000487,mbtp000012,mbrf0001392,,~,,,inhibitor,72,5.0,%,,ICG,,,"OATP-C-expressing HEK293 cell; inhibition of E217_G uptake (E217_G: 2 microM, ICG: 10 microM) ",HEK293,mbcd0000387,,,,human,mbds0003,v2007,2013-12-09 20:53:19
mbbd000002234,mbcd0003075,mbtp000012,mbrf0001392,,=,,,substrate,28,12.5,microM,2.1,Estrone 3-sulfate,,,OATP-C-expressing HEK293 cell; uptake,HEK293,,,,,human,mbds0003,v2007,2013-12-09 20:53:17
mbbd000002236,mbcd0001640,mbtp000012,mbrf0001392,,=,,,substrate,28,11.4,microM,2.3,Cholate,,,OATP-C-expressing HEK293 cell; uptake,HEK293,,,,,human,mbds0003,v2007,2013-12-09 20:53:17
mbbd000002237,mbcd0000201,mbtp000012,mbrf0001392,,~,,,inhibitor,72,15.0,%,,BSP,,,"OATP-C-expressing HEK293 cell; inhibition of Bilirubin uptake (Bilirubin: 10 microM, BSP: 5 microM) ",HEK293,mbcd0004702,,,,human,mbds0003,v2007,2013-12-09 20:04:06
mbbd000002238,mbcd0000201,mbtp000012,mbrf0001392,,=,,,substrate,28,0.14,microM,0.03,BSP,,,OATP-C-expressing HEK293 cell; uptake,HEK293,,10-210; 1000,nM,,human,mbds0003,v2007,2013-12-09 20:53:21
mbbd000002239,mbcd0000187,mbtp000012,mbrf0001392,,=,,,substrate,28,0.1,microM,,Monoglucuronosyl bilirubin,,,OATP-C-expressing HEK293 cell; uptake,HEK293,,,,,human,mbds0003,v2007,2013-12-09 20:53:21
mbbd000002240,mbcd0004701,mbtp000012,mbrf0001392,,=,,,substrate,28,0.28,microM,0.13,Bisglucuronosyl bilirubin,,,OATP-C-expressing HEK293 cell; uptake,HEK293,,,,,human,mbds0003,v2007,2013-12-09 20:08:34
mbbd000002241,mbcd0004702,mbtp000012,mbrf0001392,,,,,substrate,,,,,bilirubin,,,OATP-C-expressing HEK293 cell; uptake,HEK293,,,,,human,mbds0003,v2007,2013-12-09 20:08:35
mbbd000002242,mbcd0000455,mbtp000012,mbrf0001393,,=,,,substrate,89,3.8,,,glycocholate,,,Xenopus laevis oocyte; uptake,Xenopus laevis oocytes,,10,microM,,human,mbds0003,v2007,2013-12-09 20:08:37
mbbd000002243,mbcd0000201,mbtp000012,mbrf0001393,,=,,,substrate,28,0.3,microM,0.1,BSP; bromosulfophthalein,,,Xenopus laevis oocyte; uptake,Xenopus laevis oocytes,,10,microM,,human,mbds0003,v2007,2013-12-09 20:08:37
mbbd000002244,mbcd0000199,mbtp000012,mbrf0001393,,=,,,substrate,89,12.0,,,BQ-123,,,Xenopus laevis oocyte; uptake,Xenopus laevis oocytes,,0.5,microM,,human,mbds0003,v2007,2013-12-09 20:08:39
mbbd000002245,mbcd0002041,mbtp000012,mbrf0001393,,=,,,substrate,89,3.5,,,DPDPE,,,Xenopus laevis oocyte; uptake,Xenopus laevis oocytes,,0.1,microM,,human,mbds0003,v2007,2013-12-09 20:08:40
mbbd000002246,mbcd0003043,mbtp000012,mbrf0001394,,=,,,substrate,28,25.0,microM,,MTX; methotrexate,,,Xenopus laevis oocyte; uptake,Xenopus laevis oocytes,,1,microM,,human,mbds0003,v2007,2013-12-09 20:08:42
mbbd000002247,mbcd0003075,mbtp000012,mbrf0001395,,=,,,inhibitor,29,0.0458,microM,,Estrone-3-sulfate,,,OATP-C-expressing HEK293 cell; inhibition of E217_G uptake,HEK293,mbcd0000387,,,,human,mbds0003,v2007,2013-12-09 20:08:42
mbbd000002248,mbcd0003075,mbtp000012,mbrf0001395,,=,,,substrate,28,5.34,microM,5.70,Estrone-3-sulfate,,,"Xenopus laevis oocytes; uptake; low affinity, high capacity component of a biphasic concentration dependence (compound concentrations are approximate)",Xenopus laevis oocytes,,3.6,nM,,human,mbds0003,v2007,2013-11-03 23:41:42
mbbd000002249,mbcd0003075,mbtp000012,mbrf0001395,28,=,0.094,microM,substrate,28,94.0,nM,53,Estrone-3-sulfate,,,"Xenopus laevis oocytes; uptake; high affinity, low capacity component of a biphasic concentration dependence (compound concentrations are approximate)",Xenopus laevis oocytes,,3.6,nM,,human,mbds0003,v2007,2013-11-03 23:41:42
mbbd000002250,mbcd0003075,mbtp000012,mbrf0001395,,=,,,substrate,28,7.0,microM,2.17,Estrone-3-sulfate,,,"OATP-C-expressing HEK293 cells; uptake; low affinity, high capacity component of a biphasic concentration dependence (compound concentrations are approximate)",HEK293,,0.1-10,microM,,human,mbds0003,v2007,2013-11-04 22:28:30
mbbd000002251,mbcd0003075,mbtp000012,mbrf0001395,28,=,0.0675,microM,substrate,28,67.5,nM,31.6,Estrone-3-sulfate,,,"OATP-C-expressing HEK293 cells; uptake; high affinity, low capacity component of a biphasic concentration dependence (compound concentrations are approximate)",HEK293,,10-100,nM,,human,mbds0003,v2007,2013-11-04 22:28:30
mbbd000002252,mbcd0000393,mbtp000012,mbrf0001395,,~,,,inhibitor,72,40.0,%,,Estrone-3-glucuronide,,,"OATP-C-expressing HEK293 cell; inhibition of E1S uptake (E1S: 0.04 microM, Estrone-3-glucuronide: 100 microM)",HEK293,mbcd0003075,,,,human,mbds0003,v2007,2013-12-09 20:57:26
mbbd000002253,mbcd0003211,mbtp000012,mbrf0001395,,~,,,inhibitor,72,40.0,%,,estrone,,,"OATP-C-expressing HEK293 cell; inhibition of E1S uptake (E1S: 0.04 microM, #Estrone: 100 microM)",HEK293,mbcd0003075,,,,human,mbds0003,v2007,2013-12-09 20:57:26
mbbd000002254,mbcd0000389,mbtp000012,mbrf0001395,,~,,,inhibitor,72,10.0,%,,estrone-3-sulfate,,,"OATP-C-expressing HEK293 cell; inhibition of E1S uptake (E1S: 0.04 microM, Estradiol-3-sulfate: 100 microM)",HEK293,mbcd0003075,,,,human,mbds0003,v2007,2013-12-09 20:57:26
mbbd000002255,mbcd0000388,mbtp000012,mbrf0001395,,~,,,inhibitor,72,40.0,%,,estradiol-17beta-glucuronide,,,"OATP-C-expressing HEK293 cell; inhibition of E1S uptake (E1S: 0.04 microM, E2 3SO4 17_G: 100 microM)",HEK293,mbcd0003075,,,,human,mbds0003,v2007,2013-12-09 20:57:25
mbbd000002256,mbcd0000387,mbtp000012,mbrf0001395,,<,,,inhibitor,72,1.0,%,,estradiol-17beta-glucuronide,(at a rough estimate) <1 % of control,,"OATP-C-expressing HEK293 cell; inhibition of E1S uptake (E1S: 0.04 microM, E217_G: 100 microM)",HEK293,mbcd0003075,,,,human,mbds0003,v2007,2013-12-09 20:57:25
mbbd000002257,mbcd0000387,mbtp000012,mbrf0001395,,=,,,inhibitor,29,4.43,microM,,estradiol-17beta-glucuronide,,,OATP-C-expressing HEK293 cell; inhibition of E217_G uptake,HEK293,mbcd0000387,,,,human,mbds0003,v2007,2013-12-09 20:57:25
mbbd000002258,mbcd0000387,mbtp000012,mbrf0001395,,=,,,substrate,28,3.71,microM,0.34,estradiol-17beta-glucuronide,,,OATP-C-expressing HEK293 cell; uptake,HEK293,,5.7,nM,,human,mbds0003,v2007,2013-12-09 20:57:26
mbbd000002259,mbcd0003055,mbtp000012,mbrf0001395,,~,,,inhibitor,72,35.0,%,,estradiol,,,"OATP-C-expressing HEK293 cell; inhibition of E1S uptake (E1S: 0.04 microM, beta-Estradiol: 100 microM)",HEK293,mbcd0003075,,,,human,mbds0003,v2007,2013-12-09 20:57:26
mbbd000002260,mbcd0000819,mbtp000012,mbrf0001263,,,,,substrate,,,,,TLC-S; taurolithocholate sulfate,,,MRP2- and OATP-C-expressing MDCKII cell; transepithelial transport (basal to apical),MDCKII,,,,,human,mbds0003,v2007,2013-12-09 20:06:24
mbbd000002261,mbcd0000164,mbtp000012,mbrf0001373,,=,,,substrate,28,9.7,microM,2.0,Bamet-UD2,,,Xenopus laevis oocyte; uptake,Xenopus laevis oocytes,,0-100,microM,,human,mbds0003,v2007,2013-12-09 20:06:25
mbbd000002262,mbcd0000163,mbtp000012,mbrf0001373,,=,,,substrate,28,10.0,microM,1.5,Bamet-R2,,,Xenopus laevis oocyte; uptake,Xenopus laevis oocytes,,0-100,microM,,human,mbds0003,v2007,2013-12-09 20:06:23
mbbd000002263,mbcd0000749,mbtp000012,mbrf0001396,,=,,,inhibitor,29,2.0,microM,,Rifamycin SV,,,Xenopus laevis oocyte; inhibition of BSP uptake,Xenopus laevis oocytes,mbcd0003035,,,,human,mbds0003,v2007,2013-12-09 20:06:23
mbbd000002264,mbcd0001416,mbtp000012,mbrf0001396,,=,,,inhibitor,29,17.0,microM,,Rifampicin,,,Xenopus laevis oocyte; inhibition of BSP uptake,Xenopus laevis oocytes,mbcd0003035,,,,human,mbds0003,v2007,2013-12-09 20:06:26
mbbd000002265,mbcd0001416,mbtp000012,mbrf0001396,,=,,,substrate,28,13.0,microM,3,Rifampicin,,,Xenopus laevis oocyte; uptake,Xenopus laevis oocytes,,10; 100,microM,,human,mbds0003,v2007,2013-12-09 20:06:26
mbbd000002266,mbcd0001533,mbtp000012,mbrf0001397,,~,,,inhibitor,72,10.0,%,,saquinavir,,,"OATP-C-expressing HeLa cell; inhibition of E217_G uptake (E217_G: 0.5 microM, Saquinavir: 100 microM)",HeLa,mbcd0000387,,,,human,mbds0003,v2007,2013-12-09 20:06:25
mbbd000002267,mbcd0001938,mbtp000012,mbrf0001397,,~,,,inhibitor,72,5.0,%,,ritonavir,,,"OATP-C-expressing HeLa cell; inhibition of E217_G uptake (E217_G: 0.5 microM, Ritonavir: 10 microM)",HeLa,mbcd0000387,,,,human,mbds0003,v2007,2013-12-09 20:06:26
mbbd000002268,mbcd0001416,mbtp000012,mbrf0001397,,~,,,inhibitor,72,10.0,%,,Rifampin,,,"OATP-C-expressing HeLa cell; inhibition of E217_G uptake (E217_G: 0.5 microM, Rifampicin: 10 microM) ",HeLa,mbcd0000387,,,,human,mbds0003,v2007,2013-12-09 20:06:22
mbbd000002269,mbcd0001416,mbtp000012,mbrf0001397,,=,,,substrate,28,1.5,microM,,Rifampin,,,OATP-C-expressing HeLa cell; uptake,HeLa,,0-32,microM,,human,mbds0003,v2007,2013-12-09 20:06:23
mbbd000002270,mbcd0026632,mbtp000012,mbrf0001397,,~,,,inhibitor,72,15.0,%,,Nelfinavir,,,"OATP-C-expressing HeLa cell; inhibition of E217_G uptake (E217_G: 0.5 microM, Nelfinavir: 10 microM)",HeLa,mbcd0000387,,,,human,mbds0003,v2007,2013-12-09 20:54:58
mbbd000002271,mbcd0002323,mbtp000012,mbrf0001397,,~,,,inhibitor,72,35.0,%,,Indinavir,,,"OATP-C-expressing HeLa cell; inhibition of E217_G uptake (E217_G: 0.5 microM, Indinavir: 10 microM) ",HeLa,mbcd0000387,,,,human,mbds0003,v2007,2013-12-09 20:54:57
mbbd000002272,mbcd0001632,mbtp000012,mbrf0001397,,~,,,inhibitor,72,10.0,%,,Hyperforin,,,"OATP-C-expressing HeLa cell; inhibition of E217_G uptake (E217_G: 0.5 microM, Hyperforin: 10 microM)",HeLa,mbcd0000387,,,,human,mbds0003,v2007,2013-12-09 20:54:58
mbbd000002273,mbcd0000311,mbtp000012,mbrf0001397,,~,,,inhibitor,72,5.0,%,,CyA,,,"OATP-C-expressing HeLa cell; inhibition of E217_G uptake (E217_G: 0.5 microM, CsA: 10microM)",HeLa,mbcd0000387,,,,human,mbds0003,v2007,2013-12-09 20:54:58
mbbd000002274,mbcd0000201,mbtp000012,mbrf0001397,,<,,,inhibitor,72,5.0,%,,BSP,(at a rough estimate) <5 % of control,,"OATP-C-expressing HeLa cell; inhibition of E217_G uptake (E217_G: 0.5 microM, BSP: 10 microM) ",HeLa,mbcd0000387,,,,human,mbds0003,v2007,2013-12-09 20:54:58
mbbd000002275,mbcd0000311,mbtp000012,mbrf0001398,,=,,,inhibitor,29,0.238,microM,,CsA,,,OATP2-expressing MDCKII cell; inhibition of Cerivastatin uptake,MDCKII,mbcd0023123,,,,human,mbds0003,v2007,2013-12-09 20:54:58
mbbd000002276,mbcd0000387,mbtp000012,mbrf0001399,,~,,,inhibitor,33,7.5,pmol/oocyte,0.5,E217betaG,+(100 microM),,Xenopus laevis oocyte; inhibition of UCB uptake (UCB: 10 microM),Xenopus laevis oocytes,mbcd0004702,,,,human,mbds0003,v2007,2013-12-09 20:54:59
mbbd000002277,mbcd0004702,mbtp000012,mbrf0001399,28,=,0.0076,microM,substrate,28,7.6,nM,1.2,UCB,,,Xenopus laevis oocyte; uptake,Xenopus laevis oocytes,,0-100,microM,,human,mbds0003,v2007,2013-12-09 20:54:59
mbbd000002278,mbcd0004702,mbtp000012,mbrf0001399,,~,,,inhibitor,33,0.45,pmol/oocyte,0.03,UCB,+(100 microM),,Xenopus laevis oocyte; inhibition of E217_G uptake (E217_G: 10 microM),Xenopus laevis oocytes,mbcd0000387,,,,human,mbds0003,v2007,2013-12-09 20:54:57
mbbd000002279,mbcd0000882,mbtp000012,mbrf0001400,,=,,,inhibitor,102,77.2,%,13.5,YGG,,,"Xenopus laevis oocyte; inhibition of E1S uptake (E1S: 0.004 microM, YGG: 1000 microM)",,,,,,human,mbds0003,v2007,2013-12-09 20:54:57
mbbd000002280,mbcd0003708,mbtp000012,mbrf0001400,,=,,,non-inhibitor,102,90.3,%,13.3,YdAG,,,"Xenopus laevis oocyte; inhibition of E1S uptake (E1S: 0.004 microM, YdAG: 1000 microM)",,,,,,human,mbds0003,v2007,2013-12-09 19:58:04
mbbd000002281,mbcd0001664,mbtp000012,mbrf0001400,,=,,,inhibitor,102,50.0,%,,taurocholate,,,Xenopus laevis oocyte; inhibition of DPDPE uptake (DPDPE: 0.02 microM),,,,,,human,mbds0003,v2007,2013-12-09 19:58:04
mbbd000002282,mbcd0027018,mbtp000012,mbrf0001400,,=,,,inhibitor,102,81.0,%,16.4,quinidine,,,"Xenopus laevis oocyte; inhibition of E1S uptake (E1S: 0.004 microM, Quinidine: 500 microM)",,,,,,human,mbds0003,v2007,2013-12-09 19:58:05
mbbd000002284,mbcd0000523,mbtp000012,mbrf0001400,,=,,,inhibitor,102,26.8,%,2.4,Leu-enkephalin,,,"Xenopus laevis oocyte; inhibition of E1S uptake (E1S: 0.004 microM, Leu-enkephalin: 1000 microM)",,,,,,human,mbds0003,v2007,2013-12-09 19:58:02
mbbd000002285,mbcd0000446,mbtp000012,mbrf0001400,,=,,,non-inhibitor,102,107.6,%,6.1,(Glycine)5,,,"Xenopus laevis oocyte; inhibition of E1S uptake (E1S: 0.004 microM, Gly5: 5000 microM)",,,,,,human,mbds0003,v2007,2013-12-09 19:58:02
mbbd000002286,mbcd0003533,mbtp000012,mbrf0001400,,=,,,non-inhibitor,102,127.4,%,12.9,(Glycine)4,,,"Xenopus laevis oocyte; inhibition of E1S uptake (E1S: 0.004 microM, Gly4: 5000 microM)",,,,,,human,mbds0003,v2007,2013-12-09 19:58:03
mbbd000002287,mbcd0003075,mbtp000012,mbrf0001400,,=,,,inhibitor,102,50.0,%,,estrone-3-sulfate,,,Xenopus laevis oocyte; inhibition of DPDPE uptake (DPDPE: 0.02 microM),,,,,,human,mbds0003,v2007,2013-12-09 19:58:03
mbbd000002288,mbcd0000328,mbtp000012,mbrf0001400,,=,,,inhibitor,102,62.5,%,4.4,des-tyrosine-DADLE,,,"Xenopus laevis oocyte; inhibition of E1S uptake (E1S: 0.004 microM, des-tyrosine DADLE: 1000 microM)",,,,,,human,mbds0003,v2007,2013-12-09 19:58:06
mbbd000002289,mbcd0000311,mbtp000012,mbrf0001400,,=,,,inhibitor,102,6.1,%,0.6,ciclosporin,,,"Xenopus laevis oocyte; inhibition of E1S uptake (E1S: 0.004 microM, CsA: 10 microM)",,,,,,human,mbds0003,v2007,2013-12-09 19:58:07
mbbd000002290,mbcd0004706,mbtp000012,mbrf0001400,,=,,,inhibitor,102,9.1,%,1.8,CCK-8,,,"Xenopus laevis oocyte; inhibition of E1S uptake (E1S: 0.004 microM, CCK-8: 100 microM)",,,,,,human,mbds0003,v2007,2013-12-09 20:51:22
mbbd000002292,mbcd0000201,mbtp000012,mbrf0001400,,=,,,inhibitor,102,8.0,%,0.7,BSP,,,"Xenopus laevis oocyte; inhibition of E1S uptake (E1S: 0.004 microM, BSP: 50 microM)",,,,,,human,mbds0003,v2007,2013-12-09 20:51:22
mbbd000002293,mbcd0000201,mbtp000012,mbrf0001400,,=,,,inhibitor,102,25.0,%,,BSP,,,Xenopus laevis oocyte; inhibition of DPDPE uptake (DPDPE: 0.02 microM),,,,,,human,mbds0003,v2007,2013-12-09 20:51:22
mbbd000002294,mbcd0000118,mbtp000012,mbrf0001400,,=,,,inhibitor,102,86.3,%,7.4,(Alanine)5,,,"Xenopus laevis oocyte; inhibition of E1S uptake (E1S: 0.004 microM, Ala5: 5000 microM)",,,,,,human,mbds0003,v2007,2013-12-09 20:51:23
mbbd000002295,mbcd0000117,mbtp000012,mbrf0001400,,=,,,non-inhibitor,102,118.7,%,8.9,(Alanine)4,,,"Xenopus laevis oocyte; inhibition of E1S uptake (E1S: 0.004 microM, Ala4: 5000 microM)",,,,,,human,mbds0003,v2007,2013-12-09 20:51:23
mbbd000002296,mbcd0002041,mbtp000012,mbrf0001400,,,,,substrate,,,,,DPDPE,+(0.02 microM),,Xenopus laevis oocyte; uptake,Xenopus laevis oocytes,,,,,human,mbds0003,v2007,2013-12-09 20:51:27
mbbd000002297,mbcd0000005,mbtp000012,mbrf0001400,,=,,,inhibitor,102,35.4,%,6.8,DADLE,,,"Xenopus laevis oocyte; inhibition of E1S uptake (E1S: 0.004 microM, DADLE: 1000 microM)",,,,,,human,mbds0003,v2007,2013-12-09 20:51:22
mbbd000002298,mbcd0000462,mbtp000012,mbrf0001401,,=,,,inhibitor,29,15.9,microM,,GL,,,Xenopus laevis oocyte; inhibition of E1S uptake,Xenopus laevis oocytes,mbcd0003075,,,,human,mbds0003,v2007,2013-12-09 20:51:22
mbbd000002300,mbcd0000675,mbtp000012,mbrf0001273,,=,,,substrate,67,1.3,microL mg-1 min-1,,phalloidin,,,OATP-C-expressing MDCKII cell; transepithelial transport (basal to apical),MDCKII,,1,microM,,human,mbds0003,v2007,2013-12-09 19:54:01
mbbd000002301,mbcd0000675,mbtp000012,mbrf0001273,,=,,,substrate,28,39.0,microM,11,Phalloidin,,,OATP-C-expressing HEK 293 cell; uptake,HEK293,,0.1,microM,,human,mbds0003,v2007,2013-12-09 19:54:00
mbbd000002302,mbcd0001316,mbtp000012,mbrf0001273,,=,,,inhibitor,25,3.7,microM,,FK506,,,OATP-C-expressing HEK 293 cells; inhibition of demethylphalloin uptake (demethylphalloin: 1 microM),HEK293,mbcd0000325,,,,human,mbds0003,v2007,2013-10-18 21:17:29
mbbd000002303,mbcd0000311,mbtp000012,mbrf0001273,,=,,,inhibitor,29,0.2,microM,,cyclosporin A,,,OATP-C-expressing HEK 293 cells; inhibition of demethylphalloin uptake (demethylphalloin: 1 microM),HEK293,mbcd0000325,200,nM,,human,mbds0003,v2007,2013-10-18 21:17:31
mbbd000002304,mbcd0000201,mbtp000012,mbrf0001273,,=,,,inhibitor,25,0.05,microM,,BSP,,,OATP-C-expressing HEK 293 cells; inhibition of demethylphalloin uptake (demethylphalloin: 1 microM),HEK293,mbcd0000325,,,,human,mbds0003,v2007,2013-10-18 21:17:32
mbbd000002305,mbcd0000143,mbtp000012,mbrf0001273,,=,,,inhibitor,25,1.0,microM,,Antamanide,,,OATP-C-expressing HEK 293 cells; inhibition of demethylphalloin uptake (demethylphalloin: 1 microM),HEK293,mbcd0000325,,,,human,mbds0003,v2007,2013-10-18 21:17:33
mbbd000002306,mbcd0000130,mbtp000012,mbrf0001273,,~,,,inhibitor,102,80.0,%,5,alpha-amanitin,,,OATP-C-expressing HEK 293 cells; inhibition of demethylphalloin uptake (demethylphalloin: 1 microM),HEK293,mbcd0000325,20,microM,weak inhibitor,human,mbds0003,v2007,2013-12-06 08:06:56
mbbd000002307,mbcd0000984,mbtp000012,mbrf0001402,,=,,,substrate,28,2.7,microM,1.1,triiodothyronine,,,Xenopus laevis oocytes; uptake,Xenopus laevis oocytes,,,,,human,mbds0003,v2007,2013-11-17 18:39:31
mbbd000002308,mbcd0003957,mbtp000012,mbrf0001402,,=,,,substrate,28,3.0,microM,1.3,thyroxine; T4,,,Xenopus laevis oocytes; uptake,Xenopus laevis oocytes,,10,microM,,human,mbds0003,v2007,2013-11-17 18:39:31
mbbd000002309,mbcd0000848,mbtp000012,mbrf0001402,,,,,substrate,,,,,thromboxane B2,,,Xenopus laevis oocyte; uptake,Xenopus laevis oocytes,,,,,human,mbds0003,v2007,2013-12-09 19:54:01
mbbd000002310,mbcd0001664,mbtp000012,mbrf0001402,,=,,,substrate,28,13.6,microM,5.6,Taurocholate,,,Xenopus laevis oocyte; uptake,Xenopus laevis oocytes,,0-100,microM,,human,mbds0003,v2007,2013-12-09 20:51:07
mbbd000002311,mbcd0001343,mbtp000012,mbrf0001402,,,,,substrate,,,,,PG E2; prostaglandin E2,,,Xenopus laevis oocyte; uptake,Xenopus laevis oocytes,,,,,human,mbds0003,v2007,2013-12-09 20:51:07
mbbd000002312,mbcd0000528,mbtp000012,mbrf0001402,,,,,substrate,,,,,leukotriene E4,,,Xenopus laevis oocyte; uptake,Xenopus laevis oocytes,,,,,human,mbds0003,v2007,2013-12-09 20:51:06
mbbd000002313,mbcd0002917,mbtp000012,mbrf0001402,,,,,substrate,,,,,leukotriene C4,,,Xenopus laevis oocyte; uptake,Xenopus laevis oocytes,,,,,human,mbds0003,v2007,2013-12-09 20:51:06
mbbd000002314,mbcd0000387,mbtp000012,mbrf0001402,,,,,substrate,,,,,estradiol-17beta-glucuronide,,,Xenopus laevis oocyte; uptake,Xenopus laevis oocytes,,,,,human,mbds0003,v2007,2013-12-09 20:51:06
mbbd000002316,mbcd0003957,mbtp000012,mbrf0001403,,=,,,substrate,33,2.38,pmol mg-1 min-1,0.58,T4; thyroxine,,,OATP-C-expressing 293c18 cell; uptake,HEK293c18,,,,,human,mbds0003,v2007,2013-12-09 20:51:06
mbbd000002317,mbcd0001664,mbtp000012,mbrf0001403,,~,,,inhibitor,33,0.4,pmol/mg/min,,Taurocholate,,,"OATP-C-expressing 293c18 cell; inhibition of Pravastatin uptake (Pravastatin: 0.5 microM, Taurocholate: 50 microM)",HEK293c18,mbcd0003126,50,microM,,human,mbds0003,v2007,2013-12-09 20:05:35
mbbd000002318,mbcd0001664,mbtp000012,mbrf0001403,,=,,,substrate,16,33.8,microM,,taurocholate,,,OATP-C-expressing 293c18 cell; uptake,HEK293c18,,0-150,microM,,human,mbds0003,v2007,2013-12-09 20:51:07
mbbd000002319,mbcd0001194,mbtp000012,mbrf0001403,,~,,,inhibitor,33,0.08,pmol/mg/min,,Simvastatin,,,"OATP-C-expressing 293c18 cell; inhibition of Taurocholate uptake (Taurocholate: 0.5 microM, Simvastatin: 50 microM)",HEK293c18,mbcd0001664,50,microM,,human,mbds0003,v2007,2013-12-09 20:51:07
mbbd000002320,mbcd0001194,mbtp000012,mbrf0001403,,>,,,inhibitor,3,95.0,%,,Simvastatin,,,"OATP-C-expressing 293c18 cell; inhibition of Pravastatin uptake (Pravastatin: 0.5 microM, Simvastatin: 50 microM)",HEK293c18,mbcd0003126,50,microM,,human,mbds0003,v2007,2013-12-09 19:55:01
mbbd000002321,mbcd0003126,mbtp000012,mbrf0001403,,=,,,substrate,16,33.7,microM,,Pravastatin,,,OATP-C-expressing 293c18 cell; uptake,HEK293c18,,0-150,microM,,human,mbds0003,v2007,2013-12-09 19:55:00
mbbd000002322,mbcd0025591,mbtp000012,mbrf0001403,,~,,,inhibitor,33,0.08,pmol/mg/min,,lovastatin,,,"OATP-C-expressing 293c18 cell; inhibition of Taurocholate uptake (Taurocholate: 0.5 microM, Lovastatin: 50 microM)",HEK293c18,mbcd0001664,50,microM,,human,mbds0003,v2007,2013-12-09 19:55:00
mbbd000002323,mbcd0025591,mbtp000012,mbrf0001403,,>,,,inhibitor,3,95.0,%,,lovastatin,,,"OATP-C-expressing 293c18 cell; inhibition of Pravastatin uptake (Pravastatin: 0.5 microM, Lovastatin: 50 microM)",HEK293c18,mbcd0003126,50,microM,,human,mbds0003,v2007,2013-12-09 19:55:00
mbbd000002325,mbcd0000195,mbtp000012,mbrf0001403,,~,,,inhibitor,33,0.07,pmol/mg/min,,BMS243887,,,"OATP-C-expressing 293c18 cell; inhibition of Taurocholate uptake (Taurocholate: 0.5 microM, BMS243887: 50 microM)",HEK293c18,mbcd0001664,50,microM,,human,mbds0003,v2007,2013-12-09 19:55:04
mbbd000002326,mbcd0000195,mbtp000012,mbrf0001403,,>,,,inhibitor,3,95.0,%,,BMS243887,,,"OATP-C-expressing 293c18 cell; inhibition of Pravastatin uptake (Pravastatin: 0.5 microM, BMS243887: 50 microM)",HEK293c18,mbcd0003126,50,microM,,human,mbds0003,v2007,2013-12-09 19:55:03
mbbd000002327,mbcd0000194,mbtp000012,mbrf0001403,,~,,,inhibitor,33,0.1,pmol/mg/min,,BMS241423,,,"OATP-C-expressing 293c18 cell; inhibition of Taurocholate uptake (Taurocholate: 0.5 microM, BMS241423: 50 microM)",HEK293c18,mbcd0001664,50,microM,,human,mbds0003,v2007,2013-12-09 19:55:02
mbbd000002328,mbcd0000194,mbtp000012,mbrf0001403,,>,,,inhibitor,3,95.0,%,,BMS241423,,,"OATP-C-expressing 293c18 cell; inhibition of Pravastatin uptake (Pravastatin: 0.5 microM, BMS241423: 50 microM)",HEK293c18,mbcd0003126,50,microM,,human,mbds0003,v2007,2013-12-09 19:55:09
mbbd000002329,mbcd0026093,mbtp000012,mbrf0001403,,~,,,inhibitor,33,0.085,pmol/mg/min,,Atorvastatin,,,"OATP-C-expressing 293c18 cell; inhibition of Taurocholate uptake (Taurocholate: 0.5 microM, Atorvastatin: 50 microM)",HEK293c18,mbcd0001664,50,microM,,human,mbds0003,v2007,2013-12-09 19:55:07
mbbd000002330,mbcd0026093,mbtp000012,mbrf0001403,,>,,,inhibitor,3,95.0,%,,Atorvastatin,,,"OATP-C-expressing 293c18 cell; inhibition of Pravastatin uptake (Pravastatin: 0.5 microM, Atorvastatin: 50 microM)",HEK293c18,mbcd0003126,50,microM,,human,mbds0003,v2007,2013-12-09 20:51:17
mbbd000002331,mbcd0000387,mbtp000012,mbrf0001404,,=,,,substrate,28,8.2,microM,,E217betaG,,,OATP-C-expressing HEK293 cell; uptake,HEK293,,1-10,microM,,human,mbds0003,v2007,2013-12-09 20:51:18
mbbd000002332,mbcd0001640,mbtp000012,mbrf0001404,,=,,,inhibitor,72,14.0,%,,cholate,,,"OATP-C-expressing HEK293 cell; inhibition of E217_G uptake (CA: 100 microM, E217_G: 1 microM)",HEK293,mbcd0000387,,,,human,mbds0003,v2007,2013-12-09 20:50:50
mbbd000002333,mbcd0000201,mbtp000012,mbrf0001404,,=,,,inhibitor,29,0.044,microM,,BSP,,,OATP-C-expressing HEK293 cell; inhibition of E217_G uptake,HEK293,mbcd0000387,,,,human,mbds0003,v2007,2013-12-09 20:51:18
mbbd000002334,mbcd0000187,mbtp000012,mbrf0001404,,,,,substrate,,,,,monoglucuronosyl bilirubin,,,OATP-C-expressing HEK293 cell; uptake,HEK293,,,,,human,mbds0003,v2007,2013-12-09 20:51:16
mbbd000002335,mbcd0027883,mbtp000012,mbrf0001404,,=,,,inhibitor,72,6.0,%,,DIDS,,,"OATP-C-expressing HEK293 cell; inhibition of E217_G uptake (DIDS: 50 microM, E217_G: 1 microM)",HEK293,mbcd0000387,,,,human,mbds0003,v2007,2013-12-09 20:51:16
mbbd000002336,mbcd0000693,mbtp000012,mbrf0001405,,,,,substrate,,,,,pitavastatin,,,OATP2-expressing HEK293 cell; cell accumulation,HEK293,,,,,human,mbds0003,v2007,2013-12-09 20:51:17
mbbd000002337,mbcd0003075,mbtp000012,mbrf0001405,,,,,substrate,,,,,E-sul,,,OATP2-expressing HEK293 cell; cell accumulation,HEK293,,,,,human,mbds0003,v2007,2013-12-09 20:51:17
mbbd000002338,mbcd0000387,mbtp000012,mbrf0001405,,,,,substrate,,,,,E217betaG,,,OATP2-expressing HEK293 cell; cell accumulation,HEK293,,,,,human,mbds0003,v2007,2013-12-09 20:51:16
mbbd000002339,mbcd0004706,mbtp000012,mbrf0001405,,,,,non-substrate,,,,,CCK-8,,,OATP2-expressing HEK293 cell; cell accumulation,HEK293,,,,,human,mbds0003,v2007,2014-02-22 06:45:19
mbbd000002340,mbcd0000875,mbtp000012,mbrf0001406,,=,,,inhibitor,72,5.0,%,,Troglitazone sulfate,(10)microM,,OATP-C-expressing Xenopus oocyte; inhibition of estrone-3-sulfate uptake (Estrone-3-sulfate: 9.2 nM),Xenopus laevis oocytes,mbcd0003075,,,,human,mbds0003,v2007,2013-12-09 19:56:27
mbbd000002341,mbcd0000875,mbtp000012,mbrf0001406,,,,,substrate,,,,,troglitazone sulfate,,,OATP-C-expressing Xenopus oocyte; cell accumulation,Xenopus laevis oocytes,,,,,human,mbds0003,v2007,2013-12-09 19:56:25
mbbd000002342,mbcd0000874,mbtp000012,mbrf0001406,,=,,,inhibitor,72,30.0,%,,M-2,(10)microM,,OATP-C-expressing Xenopus oocyte; inhibition of estrone-3-sulfate uptake (Estrone-3-sulfate: 9.2 nM),Xenopus laevis oocytes,mbcd0003075,,,,human,mbds0003,v2007,2013-12-09 19:56:30
mbbd000002343,mbcd0003895,mbtp000012,mbrf0001406,,=,,,inhibitor,72,35.0,%,,Troglitazone,(10)microM,,OATP-C-expressing Xenopus oocyte; inhibition of estrone-3-sulfate uptake (Estrone-3-sulfate: 9.2 nM),Xenopus laevis oocytes,mbcd0003075,,,,human,mbds0003,v2007,2013-12-09 19:56:28
mbbd000002344,mbcd0023111,mbtp000012,mbrf0001406,,=,,,inhibitor,72,60.0,%,,rosiglitazone,(10)microM,,OATP-C-expressing Xenopus oocyte; inhibition of estrone-3-sulfate uptake (Estrone-3-sulfate: 9.2 nM),Xenopus laevis oocytes,mbcd0003075,,,,human,mbds0003,v2007,2013-12-09 19:56:32
mbbd000002345,mbcd0000737,mbtp000012,mbrf0001406,,=,,,inhibitor,72,20.0,%,,M-3,(10)microM,,OATP-C-expressing Xenopus oocyte; inhibition of estrone-3-sulfate uptake (Estrone-3-sulfate: 9.2 nM),Xenopus laevis oocytes,mbcd0003075,,,,human,mbds0003,v2007,2013-12-09 19:56:31
mbbd000002346,mbcd0023126,mbtp000012,mbrf0001406,,=,,,inhibitor,72,70.0,%,,Pioglitazone,(10)microM,,OATP-C-expressing Xenopus oocyte; inhibition of estrone-3-sulfate uptake (Estrone-3-sulfate: 9.2 nM),Xenopus laevis oocytes,mbcd0003075,,,,human,mbds0003,v2007,2013-12-09 19:56:36
mbbd000002347,mbcd0003075,mbtp000012,mbrf0001406,,,,,substrate,,,,,estrone-3-sulfate,,,OATP-C-expressing Xenopus oocyte; cell accumulation; 30 min,Xenopus laevis oocytes,,3.6,nM,,human,mbds0003,v2007,2014-02-22 06:53:40
mbbd000002348,mbcd0000325,mbtp000012,mbrf0001407,,=,,,substrate,28,17.0,microM,,Demethylphalloin,,,Xenopus laevis oocyte; uptake,Xenopus laevis oocytes,,0-10,microM,,human,mbds0003,v2007,2013-12-09 19:56:24
mbbd000002349,mbcd0000779,mbtp000012,mbrf0001408,,,,,substrate,,,,,SN-38,+(0.16 microL/ocyte),,Xenopus laevis oocyte; uptake; 60 min,Xenopus laevis oocytes,,,,,human,mbds0003,v2007,2014-02-26 20:16:02
mbbd000002350,mbcd0000779,mbtp000012,mbrf0001408,,=,,,inhibitor,72,85.0,%,,SN-38,,,Xenopus laevis oocyte; inhibition of Estrone-3-sulfate uptake(Estrone-3-sulfate : 9.2nM),Xenopus laevis oocytes,mbcd0003075,,,,human,mbds0003,v2007,2013-12-09 20:52:18
mbbd000002351,mbcd0000780,mbtp000012,mbrf0001408,,~,,,inhibitor,102,50.0,%,4,SN-38G,,,Xenopus laevis oocyte; inhibition of Estrone-3-sulfate uptake(Estrone-3-sulfate : 9.2nM),Xenopus laevis oocytes,mbcd0003075,10,microM,,human,mbds0003,v2007,2013-12-09 20:52:18
mbbd000002352,mbcd0002091,mbtp000012,mbrf0001408,,=,,,inhibitor,72,60.0,%,,irinotecan,,,Xenopus laevis oocyte; inhibition of Estrone-3-sulfate uptake(Estrone-3-sulfate : 9.2nM),Xenopus laevis oocytes,mbcd0003075,,,,human,mbds0003,v2007,2013-12-09 20:52:17
mbbd000002354,mbcd0000780,mbtp000012,mbrf0001408,,,,,non-substrate,,,,,SN-38G,,,OATP1B1-expressing HEK293 cell; uptake after 5 min,HEK293,,10,microM,,human,mbds0003,v2007,2014-02-26 20:16:02
mbbd000002355,mbcd0002091,mbtp000012,mbrf0001408,,,,,non-substrate,,,,,irinotecan,,,OATP1B1-expressing HEK293 cell; uptake after 5 min,HEK293,,10,microM,,human,mbds0003,v2007,2014-02-26 20:16:02
mbbd000002356,mbcd0000780,mbtp000012,mbrf0001408,,~,,,non-inhibitor,102,87.0,%,4,SN-38G,,,OATP1B1 expressing HEK293 cells; inhibition of E1S uptake (SN38 G 10 microM),HEK293,mbcd0003075,10,microM,,human,mbds0003,v2007,2013-12-09 20:52:18
mbbd000002357,mbcd0000779,mbtp000012,mbrf0001408,,=,,,inhibitor,72,50.0,%,,SN-38,,,OATP1B1 expressing HEK293 cells; inhibition of E1S uptake (SN38 10 microM),HEK293,mbcd0003075,,,,human,mbds0003,v2007,2013-12-09 20:52:18
mbbd000002358,mbcd0002091,mbtp000012,mbrf0001408,,=,,,inhibitor,72,60.0,%,,irinotecan,,,OATP1B1 expressing HEK293 cells; inhibition of E1S uptake (irinotecan 10 microM),HEK293,mbcd0003075,,,,human,mbds0003,v2007,2013-12-09 20:52:17
mbbd000002360,mbcd0025591,mbtp000012,mbrf0001248,,=,,,inhibitor,72,40.0,%,,lovastatin,,,OATP1B1-expressing HeLa cell; inhibition of estradiol-17_-D-glucuronide uptake (Lovastatin:10 microM),HeLa,mbcd0000387,,,,human,mbds0003,v2007,2013-12-09 19:59:06
mbbd000002361,mbcd0001120,mbtp000012,mbrf0001248,,=,,,inhibitor,72,5.0,%,,Caspofungin,,,OATP1B1-expressing HeLa cell; inhibition of estradiol-17_-D-glucuronide uptake (Caspofungin:100 microM),HeLa,mbcd0000387,,,,human,mbds0003,v2007,2013-12-09 19:59:06
mbbd000002362,mbcd0001120,mbtp000012,mbrf0001248,,,,,substrate,,,,,caspofungin,,,OATP1B1-expressing Tet-on HeLa Cells; uptake,Tet-on HeLa,,,,,human,mbds0003,v2007,2013-12-09 19:59:05
mbbd000002363,mbcd0003126,mbtp000012,mbrf0001249,,,,,substrate,,,,,PRA,(+),,OATP_B1/MRP2 double transfected MDCK II cells; transepithelial transport (basal to apical),MDCKII,,,,,human,mbds0003,v2007,2013-11-26 21:53:24
mbbd000002364,mbcd0023123,mbtp000012,mbrf0001249,,,,,substrate,,,,,CER,(+),,OATP_B1/MRP2 double transfected MDCK II cells; transepithelial transport (basal to apical),MDCKII,,,,,human,mbds0003,v2007,2013-11-26 21:53:24
mbbd000002365,mbcd0003075,mbtp000012,mbrf0001249,,,,,substrate,,,,,ES,(+),,OATP_B1/MRP2 double transfected MDCK II cells; transepithelial transport (basal to apical),MDCKII,,,,,human,mbds0003,v2007,2013-11-26 21:53:24
mbbd000002366,mbcd0000387,mbtp000012,mbrf0001249,,,,,substrate,,,,,EG,(+),,OATP_B1/MRP2 double transfected MDCK II cells; transepithelial transportt (basal to apical),MDCKII,,,,,human,mbds0003,v2007,2013-11-26 21:53:24
mbbd000002367,mbcd0001194,mbtp000012,mbrf0001409,,,,,non-substrate,,,,,simvastatin,,,"OATP1B1-expressing HEK293 cells; uptake; SLCO1B1*5, *15 and *15+C1007G haplotype",HEK293,,,,,human,mbds0003,v2007,2013-12-10 22:19:00
mbbd000002368,mbcd0023123,mbtp000012,mbrf0001409,,,,,substrate,,,,,cerivastatin,,,OATP1B1-expressing HEK293 cells; uptake,HEK293,,,,,human,mbds0003,v2007,2013-12-10 22:19:00
mbbd000002369,mbcd0026093,mbtp000012,mbrf0001409,,=,,,substrate,28,12.4,microM,,atorvastatin,,,OATP1B1-expressing HEK293 cells; uptake,HEK293,,,,,human,mbds0003,v2007,2013-12-10 22:19:00
mbbd000002370,mbcd0003126,mbtp000012,mbrf0001409,,=,,,substrate,28,85.7,microM,,pravastatin,,,OATP1B1-expressing HEK293 cells; uptake,HEK293,,,,,human,mbds0003,v2007,2013-12-10 22:19:00
mbbd000002371,mbcd0000575,mbtp000012,mbrf0001410,,~,,,substrate,33,225.0,fmol oocyte-1 (30 min)-1,20,microcystin-LR,,,Xenopus laevis oocytes; 4 microM compound,Xenopus laevis oocytes,,,,,human,mbds0010,,2013-11-24 23:14:38
mbbd000002374,mbcd0000772,mbtp000012,mbrf0001250,,=,,,inhibitor,25,3.6,microM,,Simvastatin acid,,,OATP1B1-expressing HEK293 Cells; inhibition of estradiol-17_-glucuronide uptake(estradiol-17_-glucuronide:0.02microM),HEK293,mbcd0000387,,,,human,mbds0003,v2007,2013-12-09 20:52:40
mbbd000002376,mbcd0000542,mbtp000012,mbrf0001250,,=,,,inhibitor,25,4.0,microM,,Lovastatin acid,,,OATP1B1-expressing HEK293 Cells; inhibition of estradiol-17_-glucuronide uptake(estradiol-17_-glucuronide:0.02microM),HEK293,mbcd0000387,,,,human,mbds0003,v2007,2013-12-09 20:52:40
mbbd000002377,mbcd0000154,mbtp000012,mbrf0001250,,=,,,inhibitor,25,2.6,microM,,Atorvastatin lactone,,,OATP1B1-expressing HEK293 Cells; inhibition of estradiol-17_-glucuronide uptake(estradiol-17_-glucuronide:0.02microM),HEK293,mbcd0000387,,,,human,mbds0003,v2007,2013-12-09 20:52:40
mbbd000002379,mbcd0003126,mbtp000012,mbrf0001250,,>,,,non-inhibitor,25,100.0,microM,,Pravastatin,,,OATP1B1-expressing HEK293 Cells; inhibition of estradiol-17_-glucuronide uptake(estradiol-17_-glucuronide:0.02microM),HEK293,mbcd0000387,,,,human,mbds0003,v2007,2013-12-09 20:52:40
mbbd000002390,mbcd0000779,mbtp000012,mbrf0001408,,,,,substrate,,,,,SN-38,,,OATP1B1 expressing HEK293 cells; uptake after 5 min,HEK293,,10,microM,,human,mbds0003,v2007,2014-02-26 20:16:02
mbbd000002391,mbcd0003005,mbtp000012,mbrf0001294,,=,,,substrate,28,42.6,microM,28.6,olmesartan,,,OATP1B1-expressing Xenopus laevis oocytes; tranport,Xenopus laevis oocytes,,,,,human,mbds0003,v2007,2013-12-09 20:12:59
mbbd000002393,mbcd0002917,mbtp000013,mbrf0001413,,,,,substrate,,,,,leukotriene C4,,,OATP8-expressing HEK293 cell; uptake,HEK293,,,,,human,mbds0003,v2007,2013-12-09 20:12:58
mbbd000002394,mbcd0000387,mbtp000013,mbrf0001413,,=,,,substrate,28,5.4,microM,,E217betaG,,,OATP8-expressing HEK293 cell; uptake,HEK293,,1-10,microM,,human,mbds0003,v2007,2013-12-09 20:12:57
mbbd000002396,mbcd0000201,mbtp000013,mbrf0001413,,=,,,substrate,28,3.3,microM,,BSP,,,OATP8-expressing HEK293 cell; uptake,HEK293,,5,microM,,human,mbds0003,v2007,2013-12-09 20:12:57
mbbd000002398,mbcd0001664,mbtp000013,mbrf0001392,,,,,non-substrate,,,,,cholyl taurine,,,OATP8-expressing HEK293 cell; uptake,HEK293,,5,microM,,human,mbds0003,v2007,2014-02-22 07:06:59
mbbd000002399,mbcd0000749,mbtp000013,mbrf0001392,,~,,,inhibitor,72,35.0,%,,Rifamycin SV,,,"OATP8-expressing HEK293 cell; inhibition of E217_G uptake (E217_G: 2 microM, Rifamycin SV: 50 microM) ",HEK293,mbcd0000387,,,,human,mbds0003,v2007,2013-12-09 20:12:57
mbbd000002400,mbcd0001416,mbtp000013,mbrf0001392,,~,,,inhibitor,72,10.0,%,,Rifampicin,,,"OATP8-expressing HEK293 cell; inhibition of E217_G uptake (E217_G: 2 microM, Rifampicin: 75 microM) ",HEK293,mbcd0000387,,,,human,mbds0003,v2007,2013-12-09 19:55:42
mbbd000002401,mbcd0000487,mbtp000013,mbrf0001392,,~,,,non-inhibitor,102,90.0,%,4,ICG,,,"OATP8-expressing HEK293 cell; inhibition of E217_G uptake (E217_G: 2 microM, ICG: 10 microM) ",HEK293,mbcd0000387,10,microM,,human,mbds0003,v2007,2013-12-09 19:55:44
mbbd000002402,mbcd0003075,mbtp000013,mbrf0001392,,,,,non-substrate,,,,,estrone 3-sulfate,,,OATP8-expressing HEK293 cell; uptake,HEK293,,5,microM,,human,mbds0003,v2007,2014-02-22 06:31:12
mbbd000002404,mbcd0001640,mbtp000013,mbrf0001392,,,,,non-substrate,,,,,cholate,,,OATP8-expressing HEK293 cell; uptake,HEK293,,5,microM,,human,mbds0003,v2007,2013-12-09 19:55:47
mbbd000002405,mbcd0000187,mbtp000013,mbrf0001392,,=,,,substrate,28,0.5,microM,,Monoglucuronosyl bilirubin,,,OATP8-expressing HEK293 cell; uptake,HEK293,,,,,human,mbds0003,v2007,2013-12-09 19:55:49
mbbd000002406,mbcd0004701,mbtp000013,mbrf0001392,,,,,non-substrate,,,,,bisglucuronosyl bilirubin,,,OATP8-expressing HEK293 cell; uptake,HEK293,,,,,human,mbds0003,v2007,2013-12-09 19:55:45
mbbd000002407,mbcd0000984,mbtp000013,mbrf0001393,,=,,,substrate,89,2.6,,,Triiodothyronine,,,Xenopus laevis oocyte; uptake,Xenopus laevis oocytes,,10,microM,,human,mbds0003,v2007,2013-12-09 19:55:46
mbbd000002408,mbcd0003957,mbtp000013,mbrf0001393,,=,,,substrate,89,1.7,,,T4; thyroxine,,,Xenopus laevis oocyte; uptake,Xenopus laevis oocytes,,10,microM,,human,mbds0003,v2007,2013-12-09 19:55:39
mbbd000002409,mbcd0001664,mbtp000013,mbrf0001393,,=,,,substrate,89,3.0,,,taurocholate,,,Xenopus laevis oocyte; uptake,Xenopus laevis oocytes,,10,microM,,human,mbds0003,v2007,2013-12-09 19:55:40
mbbd000002410,mbcd0001442,mbtp000013,mbrf0001393,,=,,,substrate,89,5.9,,,ouabain,,,Xenopus laevis oocyte; uptake,Xenopus laevis oocytes,,200,microM,,human,mbds0003,v2007,2013-12-09 20:51:11
mbbd000002411,mbcd0002917,mbtp000013,mbrf0001393,,=,,,substrate,89,2.3,,,LTC4,,,Xenopus laevis oocyte; uptake,Xenopus laevis oocytes,,5,microM,,human,mbds0003,v2007,2013-12-09 20:51:10
mbbd000002412,mbcd0000455,mbtp000013,mbrf0001393,,=,,,substrate,89,3.3,,,glycocholate,,,Xenopus laevis oocyte; uptake,Xenopus laevis oocytes,,10,microM,,human,mbds0003,v2007,2013-12-09 20:51:11
mbbd000002413,mbcd0003075,mbtp000013,mbrf0001393,,=,,,substrate,89,2.3,,,estrone-3-sulfate,,,Xenopus laevis oocyte; uptake,Xenopus laevis oocytes,,10,microM,,human,mbds0003,v2007,2013-12-09 20:51:11
mbbd000002414,mbcd0000387,mbtp000013,mbrf0001393,,=,,,substrate,33,3.1,fmol oocyte-1 (30 min)-1,0.7,E217betaG,,,Xenopus laevis oocyte; uptake,Xenopus laevis oocytes,,10,microM,,human,mbds0003,v2007,2013-12-09 20:51:11
mbbd000002415,mbcd0001050,mbtp000013,mbrf0001393,,=,,,substrate,89,2.4,,,digoxin,,,Xenopus laevis oocyte; uptake,Xenopus laevis oocytes,,0.5,microM,,human,mbds0003,v2007,2013-12-09 20:51:11
mbbd000002416,mbcd0000324,mbtp000013,mbrf0001393,,=,,,substrate,89,1.4,,,deltorphin II,,,Xenopus laevis oocyte; uptake,Xenopus laevis oocytes,,50,microM,,human,mbds0003,v2007,2013-12-09 20:51:11
mbbd000002418,mbcd0000201,mbtp000013,mbrf0001393,,=,,,substrate,28,0.4,microM,0.1,BSP,,,Xenopus laevis oocyte; uptake,Xenopus laevis oocytes,,10,microM,,human,mbds0003,v2007,2013-12-09 20:51:10
mbbd000002419,mbcd0000199,mbtp000013,mbrf0001393,,=,,,substrate,89,33.0,,,BQ-123,,,Xenopus laevis oocyte; uptake,Xenopus laevis oocytes,,0.5,microM,,human,mbds0003,v2007,2013-12-09 20:51:10
mbbd000002420,mbcd0002041,mbtp000013,mbrf0001393,,=,,,substrate,89,10.3,,,DPDPE,,,Xenopus laevis oocyte; uptake,Xenopus laevis oocytes,,0.1,microM,,human,mbds0003,v2007,2013-12-09 19:57:44
mbbd000002421,mbcd0000984,mbtp000013,mbrf0001394,,=,,,substrate,28,6.4,microM,1.9,T3,,,Xenopus laevis oocyte; uptake,Xenopus laevis oocytes,,1,microM,,human,mbds0003,v2007,2014-02-26 21:08:39
mbbd000002422,mbcd0001664,mbtp000013,mbrf0001394,,=,,,substrate,28,5.8,microM,1.2,TCA; taurocholate,,,Xenopus laevis oocyte; uptake,Xenopus laevis oocytes,,1,microM,,human,mbds0003,v2007,2014-02-26 21:08:39
mbbd000002423,mbcd0003043,mbtp000013,mbrf0001394,,=,,,substrate,28,24.7,microM,5.1,MTX,,,Xenopus laevis oocytes; uptake,Xenopus laevis oocytes,,1,microM,,human,mbds0003,v2007,2014-02-26 21:08:39
mbbd000002425,mbcd0000201,mbtp000013,mbrf0001394,,~,,,inhibitor,33,0.15,pmol/oocyte/60 min,,BSP,,,"Xenopus laevis oocyte; inhibition of MTX uptake (MTX: 1 microM, BSP: 100 microM) ",Xenopus laevis oocytes,mbcd0003043,100,microM,,human,mbds0003,v2007,2013-12-09 19:57:45
mbbd000002426,mbcd0002041,mbtp000013,mbrf0001394,,,,,non-substrate,,,,,DPDPE; 2-D-penicillamine-5-D-penicillamine enkephalin,,,Xenopus laevis oocyte; uptake,Xenopus laevis oocytes,,10,microM,,human,mbds0003,v2007,2014-02-26 21:08:39
mbbd000002427,mbcd0001416,mbtp000013,mbrf0001414,,,,,substrate,,,,,rifampicin,,,OATP1B3/MRP2 double transfectant (MDCKII); transepithelial transport,MDCKII,,,,,human,mbds0003,v2007,2013-12-09 19:57:48
mbbd000002428,mbcd0003155,mbtp000013,mbrf0001414,,,,,substrate,,,,,Fluo-3,,,OATP1B3/MRP2 double transfectant (MDCKII); transepithelial transport,MDCKII,,,,,human,mbds0003,v2007,2013-12-09 19:57:49
mbbd000002430,mbcd0000387,mbtp000013,mbrf0001414,,,,,substrate,,,,,E217betaG,,,OATP1B3/MRP2 double transfectant (MDCKII); transepithelial transport,MDCKII,,,,,human,mbds0003,v2007,2013-12-09 20:51:20
mbbd000002431,mbcd0002917,mbtp000013,mbrf0001414,,,,,substrate,,,,,LTC4,,,OATP1B3/MRP2 double transfectant (MDCKII); transepithelial transport,MDCKII,,,,,human,mbds0003,v2007,2013-12-09 20:51:20
mbbd000002432,mbcd0000201,mbtp000013,mbrf0001414,,,,,substrate,,,,,BSP; sulfobromophthalein,,,OATP1B3/MRP2 double transfectant (MDCKII); transepithelial transport,MDCKII,,,,,human,mbds0003,v2007,2013-12-09 20:51:19
mbbd000002433,mbcd0004706,mbtp000013,mbrf0001415,,=,,,substrate,28,11.1,microM,2.9,CCK-8,,,Xenopus laevis oocytes; uptake,Xenopus laevis oocytes,,0.5-100,microM,,human,mbds0003,v2007,2013-11-23 21:15:04
mbbd000002434,mbcd0000749,mbtp000013,mbrf0001396,,=,,,inhibitor,29,3.0,microM,,Rifamycin SV,,,Xenopus laevis oocyte; inhibition of BSP uptake,Xenopus laevis oocytes,mbcd0003035,,,,human,mbds0003,v2007,2013-12-09 20:51:19
mbbd000002435,mbcd0001416,mbtp000013,mbrf0001396,,=,,,inhibitor,29,5.0,microM,,Rifampicin,,,Xenopus laevis oocyte; inhibition of BSP uptake,Xenopus laevis oocytes,mbcd0003035,,,,human,mbds0003,v2007,2013-12-09 20:51:19
mbbd000002436,mbcd0001416,mbtp000013,mbrf0001396,,=,,,substrate,28,2.3,microM,0.9,Rifampicin,,,Xenopus laevis oocyte; uptake,Xenopus laevis oocytes,,10; 100,microM,,human,mbds0003,v2007,2013-12-09 20:51:19
mbbd000002437,mbcd0000387,mbtp000013,mbrf0001399,,~,,,inhibitor,33,4.4,pmol/oocyte,0.8,E217betaG,+(100 microM),,Xenopus laevis oocyte; inhibition of UCB uptake (UCB: 10 microM),Xenopus laevis oocytes,mbcd0004702,,,,human,mbds0003,v2007,2013-12-09 20:51:19
mbbd000002438,mbcd0004702,mbtp000013,mbrf0001399,28,=,0.0391,microM,substrate,28,39.1,nM,6.4,UCB,,,Xenopus laevis oocyte; uptake,Xenopus laevis oocytes,,0-100,microM,,human,mbds0003,v2007,2013-12-09 20:51:20
mbbd000002439,mbcd0004702,mbtp000013,mbrf0001399,,~,,,inhibitor,33,0.53,pmol/oocyte,0.03,UCB,+(100 microM),,Xenopus laevis oocyte; inhibition of E217_G uptake (E217_G: 10 microM),Xenopus laevis oocytes,mbcd0000387,,,,human,mbds0003,v2007,2013-12-09 20:51:20
mbbd000002440,mbcd0000462,mbtp000013,mbrf0001401,,=,,,inhibitor,29,12.5,microM,,GL,,,Xenopus laevis oocyte; inhibition of BSP uptake,Xenopus laevis oocytes,mbcd0003035,,,,human,mbds0003,v2007,2013-12-09 19:53:11
mbbd000002441,mbcd0000462,mbtp000013,mbrf0001401,,~,,,inhibitor,3,100.0,%,,Glycyrrhizin,,,"Xenopus laevis oocyte; inhibition of E1S uptake (E1S: 0.05 microM, GL: 100 microM)",,,,,,human,mbds0003,v2007,2013-12-09 19:53:12
mbbd000002442,mbcd0000693,mbtp000013,mbrf0001405,,,,,substrate,,,,,pitavastatin,,,OATP8-expressing HEK293 cell; cell accumulation,HEK293,,,,,human,mbds0003,v2007,2013-12-09 19:53:10
mbbd000002443,mbcd0003075,mbtp000013,mbrf0001405,,,,,non-substrate,,,,,E-sul,,,OATP8-expressing HEK293 cell; cell accumulation,HEK293,,,,,human,mbds0003,v2007,2014-02-22 06:42:58
mbbd000002444,mbcd0000387,mbtp000013,mbrf0001405,,,,,substrate,,,,,E217betaG,,,OATP8-expressing HEK293 cell; cell accumulation,HEK293,,,,,human,mbds0003,v2007,2013-12-09 19:53:08
mbbd000002445,mbcd0004706,mbtp000013,mbrf0001405,,,,,substrate,,,,,CCK-8,,,OATP8-expressing HEK293 cell; cell accumulation,HEK293,,,,,human,mbds0003,v2007,2013-12-09 19:53:09
mbbd000002446,mbcd0000875,mbtp000013,mbrf0001406,,=,,,inhibitor,72,20.0,%,,Troglitazone sulfate,(10)microM,,OATP8-expressing Xenopus oocytes cell; inhibition of estrone-3-sulfate uptake (Estrone-3-sulfate: 9.2 nM),Xenopus laevis oocytes,mbcd0003075,,,,human,mbds0003,v2007,2013-12-09 19:53:06
mbbd000002447,mbcd0000737,mbtp000013,mbrf0001406,,=,,,inhibitor,72,60.0,%,,M-3,(10)microM,,OATP8-expressing Xenopus oocytes cell; inhibition of estrone-3-sulfate uptake (Estrone-3-sulfate: 9.2 nM),Xenopus laevis oocytes,mbcd0003075,,,,human,mbds0003,v2007,2013-12-09 19:53:07
mbbd000002448,mbcd0023126,mbtp000013,mbrf0001406,,=,,,inhibitor,72,65.0,%,,Pioglitazone,(10)microM,,OATP8-expressing Xenopus oocytes cell; inhibition of estrone-3-sulfate uptake (Estrone-3-sulfate: 9.2 nM),Xenopus laevis oocytes,mbcd0003075,,,,human,mbds0003,v2007,2013-12-09 19:53:13
mbbd000002449,mbcd0003075,mbtp000013,mbrf0001406,,,,,substrate,,,,,estrone-3-sulfate,,,OATP8-expressing Xenopus oocytes cell; cell accumulation; 120 min,Xenopus laevis oocytes,,3.6,nM,,human,mbds0003,v2007,2014-02-22 06:52:07
mbbd000002450,mbcd0000325,mbtp000013,mbrf0001407,,=,,,substrate,28,7.5,microM,,Demethylphalloin,,,Xenopus laevis oocyte; uptake,Xenopus laevis oocytes,,0-10,microM,,human,mbds0003,v2007,2013-12-09 20:16:34
mbbd000002451,mbcd0000779,mbtp000013,mbrf0001408,,,,,non-substrate,,,,,SN-38,-(0.09 microL/ocyte),,Xenopus laevis oocyte; uptake; 60 min,Xenopus laevis oocytes,,,,,human,mbds0003,v2007,2014-02-26 20:16:02
mbbd000002452,mbcd0001120,mbtp000013,mbrf0001248,,,,,non-substrate,,,,,caspofungin,,,OATP1B3-expressing Tet-on HeLa Cells; uptake,HeLa,,,,,human,mbds0003,v2007,2013-12-09 20:16:35
mbbd000002453,mbcd0000575,mbtp000013,mbrf0001410,,~,,,substrate,33,275.0,fmol oocyte-1 (30 min)-1,30,microcystin-LR,,,Xenopus laevis oocytes; 4 microM compound,Xenopus laevis oocytes,,,,,human,mbds0010,,2013-11-24 23:14:39
mbbd000002455,mbcd0003005,mbtp000013,mbrf0001294,,=,,,substrate,28,71.8,microM,21.6,olmesartan,,,OATP1B3-expressing Xenopus laevis oocytes; transport,Xenopus laevis oocytes,,,,,human,mbds0003,v2007,2013-12-09 20:16:32
mbbd000002456,mbcd0001664,mbtp000016,mbrf0001416,,=,,,substrate,33,13.0,pmol oocyte-1 h-1,4,taurocholate,,,OST-expressing oocytes cells; cell accumulation,Xenopus laevis oocytes,,20,microM,,human,mbds0003,v2007,2013-12-09 05:54:20
mbbd000002459,mbcd0001343,mbtp000016,mbrf0001416,,=,,,substrate,33,2.5,fmol oocyte-1 h-1,0.3,prostaglandin E2; PGE2,,,OST-expressing oocytes cells; cell accumulation,Xenopus laevis oocytes,,5,nM,,human,mbds0003,v2007,2013-12-09 05:54:20
mbbd000002460,mbcd0003075,mbtp000016,mbrf0001416,,=,,,substrate,33,110.0,fmol oocyte-1 h-1,10,estrone-3-sulfate,,,OST-expressing oocytes cells; cell accumulation,Xenopus laevis oocytes,,50,nM,,human,mbds0003,v2007,2013-12-09 05:54:20
mbbd000002461,mbcd0001050,mbtp000016,mbrf0001416,,=,,,substrate,33,260.0,fmol oocyte-1 h-1,40,digoxin,,,OST-expressing oocytes cells; cell accumulation,Xenopus laevis oocytes,,0.5,microM,,human,mbds0003,v2007,2013-12-09 05:54:20
mbbd000002589,mbcd0026093,mbtp000012,mbrf0001403,,,,,substrate,,,,,atorvastatin,,,transfected 293c18 cells,HEK293c18,,,,,human,mbds0010,,2013-12-09 06:40:44
mbbd000002656,mbcd0001094,mbtp000001,mbrf0001586,,,,,inhibitor,,,,,THC,,,HEK293-MDR1 cells; efflux of 1 microM calcein-AM; compound 50 microM,HEK293,mbcd0000212,50,microM,,human,mbds0010,,2013-11-17 19:23:41
mbbd000002657,mbcd0001094,mbtp000001,mbrf0001586,,,,,non-inhibitor,,,,,THC,,,HEK293-MDR1 cells; efflux of 1.5 microM Rh-123; compound 50 microM,HEK293,mbcd0000746,50,microM,,human,mbds0010,,2013-11-17 19:23:40
mbbd000002924,mbcd0004705,mbtp000001,mbrf0001600,,~,,,non-inducer,117,1.2,fold,0.05,telmisartan,,,LS180 cells; mRNA expression; RT-PCR; 1 week treatment,LS180,,10,microM,,human,mbds0010,,2013-12-13 22:01:20
mbbd000002925,mbcd0004705,mbtp000002,mbrf0001600,,=,,,inhibitor,25,16.9,microM,8.2,telmisartan,,,MDCKII-BCRP cells; transport of 1 microM PhA ,MDCKII,mbcd0029883,,,,human,mbds0010,,2013-11-17 19:30:49
mbbd000002926,mbcd0004705,mbtp000005,mbrf0001600,,=,,,inhibitor,25,25.4,microM,0.6,telmisartan,,,"MRP2 PREDIVEZ Kit (Solvo), Sf9 membrane vesicles; CDCF transport ",Sf9,mbcd0029372,,,,human,mbds0010,,2013-12-13 20:43:00
mbbd000002970,mbcd0020601,mbtp000002,mbrf0001570,,,,,substrate,,,,,camptotechin,,,BCRP overexpressing breast cancer cell line (MDA-MB-231),MDA-MB-231,,,,,human,mbds0010,,2013-11-12 20:35:04
mbbd000002994,mbcd0002352,mbtp000009,mbrf0001563,,=,,,substrate,28,6.54,mM,2.03,oseltamivir; tamiflu,,,uptake of oseltamivir (100 microM) by Caco-2 cells was measured at 37 deg C in HBSS,Caco-2,,100,microM,,human,mbds0010,,2013-11-17 19:38:06
mbbd000003233,mbcd0003099,mbtp000002,mbrf0001564,,,,,inhibitor,,,,,erlotinib,,,K562/BCRP cells; transport of mitoxantrone and SN-38; compound 1.5 microM,K562,,1.5,microM,,human,mbds0010,,2013-11-17 20:13:38
mbbd000003234,mbcd0003099,mbtp000001,mbrf0001537,,=,,,substrate,82,3.7,,,erlotinib,,,Polarized MDCKII cells stably expressing human MDR1 (ABCB1); also LLCPK-MDR1 monolayer cells,MDCKII,,,,,human,mbds0010,,2013-11-17 19:51:35
mbbd000003427,mbcd0001345,mbtp000001,mbrf0001586,,,,,inhibitor,,,,,Bup,,,HEK293-MDR1 cells; efflux of 1 microM calcein-AM; compound 50 microM,HEK293,mbcd0000212,50,microM,,human,mbds0010,,2013-11-17 19:23:40
mbbd000003506,mbcd0001056,mbtp000005,mbrf0001581,,~,,,inhibitor,3,50.0,%,,sorafenib,,,MDCKII cells; efflux of 5 microM docetaxel; compound 20 microM,MDCKII,mbcd0027726,20,microM,,human,mbds0010,,2013-11-17 20:16:15
mbbd000003556,mbcd0000960,mbtp000002,mbrf0001539,,,,,substrate,,,,,cladribine;2-CdA,,,MDCKII cells stably transduced with human ABCG2,MDCKII,,,,,human,mbds0010,,2013-11-17 19:53:16
mbbd000003619,mbcd0001441,mbtp000011,mbrf0001389,,=,,,non-substrate,89,1.33,,,illoprost,,,Xenopus laevis oocytes; 2.6 microM substrate,Xenopus laevis oocytes,,,,,human,mbds0003,v2007,2013-12-09 21:00:50
mbbd000003770,mbcd0009531,mbtp000012,mbrf0001590,,=,,,inhibitor,25,27.0,microM,,gemfibrozil,,,HEK293-OATP1B1 cells; uptake of oestradiol and 17beta-glucuronide; concentration-dependent inhibition; avg IC50,HEK293,mbcd0000387,,,,human,mbds0010,,2013-12-03 22:42:48
mbbd000003800,mbcd0027062,mbtp000012,mbrf0001551,,=,,,inhibitor,82,1.8,,,verapamil,,,MDCKII-OATP1B1 monolayers; uptake of 1 microM E2G; compound 10 microM,MDCKII,mbcd0000387,10,microM,,human,mbds0010,,2013-10-31 00:25:07
mbbd000003992,mbcd0028144,mbtp000001,mbrf0001497,,=,,,substrate,82,11.0,,,Eletriptan,,,LLC-MDR1,LLC,,10,microM,,human,mbds0010,,2013-11-17 19:48:19
mbbd000004004,mbcd0011439,mbtp000002,mbrf0001552,,,,,substrate,,,,,riluzole,,,human trophoblast cell line (BeWo),BeWo,,,,,human,mbds0010,,2013-11-17 20:12:12
mbbd000004030,mbcd0001611,mbtp000012,mbrf0001402,,,,,substrate,,,,,liotrix (4:1 mix of thyroxine and triiodothyronine,,,Xenopus laevis oocytes,Xenopus laevis oocytes,,,,,human,mbds0010,,2013-11-17 18:39:32
mbbd000004051,mbcd0000846,mbtp000007,mbrf0001378,,=,,,inhibitor,25,22.0,microM,4.1,TPrA,,,tetraethylammonium (TEA) transport in hOCT1-expressing HeLa cells,,,,,,human,mbds0003,v2007,2013-11-24 21:53:04
mbbd000004115,mbcd0003888,mbtp000001,mbrf0001048,,=,,,non-substrate,28,58.0,microM,31,Clozapine,,,"P-gp ATPase activity, a putative measure of P-gp affinity; human P-gp membranes from baculovirus-infected insect cells",insect cells,,,,,human,mbds0010,,2013-11-26 00:08:57
mbbd000004149,mbcd0000835,mbtp000007,mbrf0001378,,=,,,inhibitor,25,6.5,microM,1.5,TBA,,,tetraethylammonium (TEA) transport in hOCT1-expressing HeLa cells,,,,,,human,mbds0003,v2007,2013-11-24 21:53:04
mbbd000004175,mbcd0001343,mbtp000004,mbrf0001388,,~,,,substrate,8,6.0,,0.7,prostaglandin E2,,,HEK293 cells transfected with pcDNA3 vector; cell-to-medium ratio,HEK293,,,,,human,mbds0003,v2007,2013-12-09 20:51:20
mbbd000004177,mbcd0001343,mbtp000011,mbrf0001388,,~,,,substrate,8,1.2,,0.5,prostaglandin E2,,,HEK293 cells transfected with pcDNA3 vector; cell-to-medium ratio,HEK293,,,,,human,mbds0003,v2007,2013-12-09 20:51:20
mbbd000004178,mbcd0001343,mbtp000012,mbrf0001388,,~,,,substrate,8,4.5,,0.6,prostaglandin E2,,,HEK293 cells transfected with pcDNA3 vector; cell-to-medium ratio,HEK293,,,,,human,mbds0003,v2007,2013-12-09 20:51:21
mbbd000004317,mbcd0001374,mbtp000001,mbrf0001610,,~,,,inhibitor,25,200.0,microM,,ezetimibe,,,ABCB1-transfected MDCKII cells,MDCKII,,,,,human,mbds0010,,2013-11-17 20:49:28
mbbd000004474,mbcd0003922,mbtp000002,mbrf0001540,,,,,substrate,,,,,OXP,,,MDCKII cells - ABCG2,MDCKII,,,,,human,mbds0010,,2013-11-17 20:07:10
mbbd000004573,mbcd0001280,mbtp000005,mbrf0001569,,,,,substrate,,,,,sulfasalazine,,,Caco-2 cells,Caco-2,,,,,human,mbds0010,,2013-11-17 20:14:21
mbbd000004758,mbcd0002996,mbtp000005,mbrf0001251,,=,,,non-substrate,84,1.43,,,PHT,,,MDCK type II cells transfected with either human MRP2 (MDCKII-MRP2); in only one of three experiments transport was observed,MDCKII,,,,,human,mbds0010,,2013-11-12 20:49:13
mbbd000004788,mbcd0002493,mbtp000008,mbrf0001501,,,,,inducer,,,,,clotrimazole; clot.,,,HuH7 cells; compound 25 microM,HuH7,,10; 25,microM,,human,mbds0010,,2013-11-17 19:49:36
mbbd000004807,mbcd0003874,mbtp000012,mbrf0001593,,=,,,inhibitor,3,80.0,%,,NAC; N-acetyl cysteine,,,HeLa cells; uptake of BQ123; compound 10 nM,HeLa,mbcd0000199,10,nM,,human,mbds0010,,2013-11-17 20:17:48
mbbd000004918,mbcd0001323,mbtp000005,mbrf0001600,,,,,inducer,,,,,eprosartan,,,HuH-7 cells,HuH7,,,,,human,mbds0010,,2013-11-17 19:30:50
mbbd000004923,mbcd0001324,mbtp000012,mbrf0001273,,~,,,inhibitor,25,1.1,microM,,rapamycin,,,inhibition of demethylphalloin (1 microM) uptake; HEK-SLC21A6 cells,HEK293,mbcd0000325,,,,human,mbds0010,,2013-10-18 21:17:34
mbbd000004971,mbcd0003134,mbtp000004,mbrf0001388,,~,,,substrate,8,1.5,,0.5,benzylpenicillin,,,HEK293 cells transfected with pcDNA3 vector; cell-to-medium ratio,HEK293,,,,,human,mbds0003,v2007,2013-12-09 20:58:11
mbbd000004972,mbcd0003134,mbtp000011,mbrf0001388,,~,,,substrate,8,2.0,,0.5,benzylpenicillin,,,HEK293 cells transfected with pcDNA3 vector; cell-to-medium ratio,HEK293,,,,,human,mbds0003,v2007,2013-12-09 20:58:11
mbbd000004973,mbcd0003134,mbtp000012,mbrf0001388,,~,,,substrate,8,16.0,,1,benzylpenicillin,,,HEK293 cells transfected with pcDNA3 vector; cell-to-medium ratio,HEK293,,,,,human,mbds0003,v2007,2013-12-09 20:58:11
mbbd000005002,mbcd0003051,mbtp000012,mbrf0001400,,=,,,non-inhibitor,102,100.0,%,22.1,carnitine,,,inhibition of estrone-3-sulfate (4 nM) uptake by Xenopus laevis oocytes expressing OATP-C; compound 50 microM,,,,,,human,mbds0003,v2007,2013-11-24 21:53:04
mbbd000005013,mbcd0003138,mbtp000001,mbrf0001559,,=,,,substrate,28,1.2,mM,,nizatidine,,,Caco-2 cell monolayers,Caco-2,,,,,human,mbds0010,,2013-11-17 20:13:00
mbbd000005046,mbcd0007511,mbtp000008,mbrf0001501,,,,,non-inducer,,,,,nifedipine; nifed.,,,HuH7 cells; compound 25 microM,HuH7,,25,microM,,human,mbds0010,,2013-11-17 19:49:36
mbbd000005071,mbcd0001496,mbtp000001,mbrf0001061,,=,,,non-substrate,82,1.29,,,Naloxone,,,MDR1-MDCKII,MDCKII,,,,,human,mbds0010,,2013-11-17 06:52:45
mbbd000005158,mbcd0003146,mbtp000012,mbrf0001400,,=,,,non-inhibitor,102,106.7,%,5.7,PAH,,,inhibition of estrone-3-sulfate (4 nM) uptake by Xenopus laevis oocytes expressing OATP-C; compound 500 microM,,,,,,human,mbds0003,v2007,2013-11-24 21:53:04
mbbd000005225,mbcd0001241,mbtp000009,mbrf0001443,,,,,inhibitor,,,,,Nateglinide; AY4166,,,Caco-2 cells,Caco-2,mbcd0003494,0.5,mM,,human,mbds0010,,2013-11-10 04:15:55
mbbd000005305,mbcd0001030,mbtp000001,mbrf0001115,,,,,inhibitor,,,,,megestrol acetate; MA,Growth inhibition,,Growth inhibition,HCT116,mbcd0001372,3.0; 5.0; 8.6,microM,,human,mbds0010,,2013-11-04 22:13:42
mbbd000005398,mbcd0001190,mbtp000002,mbrf0001539,,,,,substrate,,,,,clofarabine,,,MDCKII cells stably transduced with human ABCG2,MDCKII,,,,,human,mbds0010,,2013-11-17 19:53:16
mbbd000005543,mbcd0019138,mbtp000012,mbrf0001590,,=,,,inhibitor,25,16.0,microM,,bezafibrate,,,HEK293-OATP1B1 cells; uptake of oestradiol and 17beta-glucuronide; concentration-dependent inhibition; avg IC50,HEK293,mbcd0000387,,,,human,mbds0010,,2013-12-03 22:42:48
mbbd000005554,mbcd0001485,mbtp000001,mbrf0001503,,,,,repressor,,,,,As2O3,,,Growth inhibition,K562,mbcd0030889,0.5-20,microM,,human,mbds0010,,2013-11-17 19:50:32
mbbd000005692,mbcd0012596,mbtp000008,mbrf0001501,,,,,inducer,,,,,metyrapone; metyr.,,,HuH7 cells; compound 1 mM,HuH7,,1,mM,,human,mbds0010,,2013-11-17 19:49:35
mbbd000005780,mbcd0001172,mbtp000002,mbrf0001605,,=,,,inhibitor,29,1.4,microM,,ivermectin,,,vesicular transport assay SB-ABCG2-HAM-PREDIVEZ-VT kit from Solvo,,mbcd0003075,1.85; 5.56; 16.7; 50,microM,,human,mbds0010,,2013-11-20 21:03:51
mbbd000005867,mbcd0000387,mbtp000004,mbrf0001388,,~,,,substrate,8,10.0,,1,estradiol-17beta-glucuronide,,,HEK293 cells transfected with pcDNA3 vector; cell-to-medium ratio,HEK293,,,,,human,mbds0003,v2007,2013-12-09 20:13:42
mbbd000005871,mbcd0000387,mbtp000011,mbrf0001388,,~,,,non-substrate,8,1.0,,,estradiol-17beta-glucuronide,,,HEK293 cells transfected with pcDNA3 vector; cell-to-medium ratio,HEK293,,,,,human,mbds0010,,2013-11-17 07:18:44
mbbd000005883,mbcd0015049,mbtp000001,mbrf0001163,,=,,,non-inhibitor,3,21.0,%,13,debrisoquine,,,Caco-2 cells; inhibition of digoxin transport,Caco-2,mbcd0001050,100,microM,,human,mbds0010,,2013-11-17 07:05:31
mbbd000005985,mbcd0025833,mbtp000001,mbrf0001607,,,,,substrate,,,,,sitagliptin,,,,,,,,,human,mbds0010,,2013-12-10 22:21:07
mbbd000006020,mbcd0027319,mbtp000005,mbrf0001581,,~,,,inhibitor,3,80.0,%,,sunitinib,,,MDCKII cells; efflux of 5 microM docetaxel; compound 20 microM,MDCKII,mbcd0027726,20,microM,,human,mbds0010,,2013-11-17 20:16:16
mbbd000006047,mbcd0001416,mbtp000008,mbrf0001501,,,,,inducer,,,,,rifampicin; rif.,,,HuH7 cells; compound 25 microM,HuH7,,25,microM,,human,mbds0010,,2013-11-17 19:49:35
mbbd000006307,mbcd0003959,mbtp000008,mbrf0001299,,=,,,substrate,28,1.96,mM,0.13,FA,,,MRP3-transfected human embryonic kidney HEK293 cell line (HEK/MRP3-5),HEK293,,,,,human,mbds0003,v2007,2013-11-24 23:12:57
mbbd000006362,mbcd0001194,mbtp000012,mbrf0001403,,,,,substrate,,,,,simvastatin,,,transfected 293c18 cells,HEK293c18,,,,,human,mbds0010,,2013-12-09 06:40:44
mbbd000006408,mbcd0002959,mbtp000005,mbrf0001275,,,,,non-inducer,,,,,dexamethasone,,,HepG2 hepatoma cells; MRP2 mRNA and protein,HepG2,,,,,human,mbds0010,,2013-11-17 07:11:35
mbbd000006454,mbcd0003043,mbtp000011,mbrf0001389,,=,,,non-substrate,89,1.0,,,Methotrexate,,,Xenopus laevis oocytes; 3 microM substrate,Xenopus laevis oocytes,,,,,human,mbds0003,v2007,2013-12-09 20:58:28
mbbd000006579,mbcd0002371,mbtp000001,mbrf0000013,67,=,0.56,,binder,,,,,1a,,B,Ratio of maximum velocity to that of Km value was determined by P-glycoprotein,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000006659,mbcd0002868,mbtp000001,mbrf0000013,67,=,0.96,,binder,,,,,3a,,B,Ratio of maximum velocity to that of Km value was determined by P-glycoprotein,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000006714,mbcd0002403,mbtp000001,mbrf0000013,67,=,1.1,,binder,,,,,18,,B,Ratio of maximum velocity to that of Km value was determined by P-glycoprotein,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000006736,mbcd0002575,mbtp000001,mbrf0000013,67,=,1.2,,binder,,,,,2a,,B,Ratio of maximum velocity to that of Km value was determined by P-glycoprotein,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000006764,mbcd0002360,mbtp000001,mbrf0000013,67,=,1.4,,binder,,,,,1c,,B,Ratio of maximum velocity to that of Km value was determined by P-glycoprotein,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000006912,mbcd0002857,mbtp000001,mbrf0000013,67,=,3.2,,binder,,,,,1b,,B,Ratio of maximum velocity to that of Km value was determined by P-glycoprotein,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000006944,mbcd0002123,mbtp000001,mbrf0000013,67,=,3.9,,binder,,,,,3b,,B,Ratio of maximum velocity to that of Km value was determined by P-glycoprotein,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000007132,mbcd0002585,mbtp000001,mbrf0000013,67,=,6.0,,binder,,,,,2c,,B,Ratio of maximum velocity to that of Km value was determined by P-glycoprotein,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000007268,mbcd0002268,mbtp000001,mbrf0000013,67,=,10.0,,binder,,,,,2b,,B,Ratio of maximum velocity to that of Km value was determined by P-glycoprotein,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000007424,mbcd0027062,mbtp000001,mbrf0000013,67,=,30.0,,binder,,,,,Verapamil,,B,Ratio of maximum velocity to that of Km value was determined by P-glycoprotein,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000007439,mbcd0027062,mbtp000001,mbrf0000052,100,=,32.0,%,inhibitor,100,32.0,%,,verapamil,,B,Effect on P-glycoprotein expressed in human KB-C2 cells assessed as increase in accumulation of rhodamine 123 at 2 uM,KB-C2,mbcd0000746,2,microM,,human,mbds0001,v12,2013-11-27 07:16:46
mbbd000007508,mbcd0001532,mbtp000001,mbrf0000013,67,=,50.0,,binder,,,,,Paclitaxel,,B,Ratio of maximum velocity to that of Km value was determined by P-glycoprotein,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000007622,mbcd0027062,mbtp000001,mbrf0000052,100,=,80.0,%,inhibitor,100,80.0,%,,verapamil,,B,Effect on P-glycoprotein expressed in human KB-C2 cells assessed as increase in accumulation of rhodamine 123 at 5 uM,KB-C2,mbcd0000746,5,microM,,human,mbds0001,v12,2013-11-27 07:16:47
mbbd000007815,mbcd0002385,mbtp000001,mbrf0000052,,,,,non-inhibitor,,,,,11,,B,no effect on the efflux of rhodamine 123 from KB-C2 cells at 60 min; cell. accumulation of rhodamine 123 increased to 114% in Pgp-overexpressing KB-C2 cells at 50 uM,KB-C2,mbcd0000746,50,microM,,human,mbds0001,v12,2013-10-13 19:34:28
mbbd000007883,mbcd0002384,mbtp000001,mbrf0000052,,,,,non-inhibitor,,,,,4,,B,no effect on the efflux of rhodamine 123 from KB-C2 cells at 60 min; cell. accumulation of rhodamine 123 increased to 134% in Pgp-overexpressing KB-C2 cells at 50 uM,KB-C2,mbcd0000746,50,microM,,human,mbds0001,v12,2013-10-13 19:34:28
mbbd000007929,mbcd0002089,mbtp000001,mbrf0000052,,,,,non-inhibitor,,,,,3,,B,no effect on the efflux of rhodamine 123 from KB-C2 cells at 60 min; cell. accumulation of rhodamine 123 increased to 169% in Pgp-overexpressing KB-C2 cells at 50 uM,KB-C2,mbcd0000746,50,microM,,human,mbds0001,v12,2013-10-13 19:34:28
mbbd000008189,mbcd0001532,mbtp000001,mbrf0000013,28,=,700.0,nM,binder,,,,,Paclitaxel,,B,Michaelis menton constant for human P-glycoprotein expressed in Sf9 cells,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000008370,mbcd0027062,mbtp000001,mbrf0000013,28,=,2000.0,nM,binder,,,,,Verapamil,,B,Michaelis menton constant for human P-glycoprotein expressed in Sf9 cells,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000008486,mbcd0002268,mbtp000001,mbrf0000013,28,=,4000.0,nM,binder,,,,,2b,,B,Michaelis menton constant for human P-glycoprotein expressed in Sf9 cells,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000008595,mbcd0002585,mbtp000001,mbrf0000013,28,=,8000.0,nM,binder,,,,,2c,,B,Michaelis menton constant for human P-glycoprotein expressed in Sf9 cells,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000008658,mbcd0002857,mbtp000001,mbrf0000013,28,=,11000.0,nM,binder,,,,,1b,,B,Michaelis menton constant for human P-glycoprotein expressed in Sf9 cells,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000008674,mbcd0002123,mbtp000001,mbrf0000013,28,=,12000.0,nM,binder,,,,,3b,,B,Michaelis menton constant for human P-glycoprotein expressed in Sf9 cells,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000008738,mbcd0002575,mbtp000001,mbrf0000013,28,=,20000.0,nM,binder,,,,,2a,,B,Michaelis menton constant for human P-glycoprotein expressed in Sf9 cells,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000008749,mbcd0002575,mbtp000001,mbrf0000013,22,=,23000.0,nM,binder,,,,,2a,,B,Maximum velocity against human P-glycoprotein expressed in Sf9 cells,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000008752,mbcd0002371,mbtp000001,mbrf0000013,22,=,23000.0,nM,binder,,,,,1a,,B,Maximum velocity against human P-glycoprotein expressed in Sf9 cells,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000008770,mbcd0002360,mbtp000001,mbrf0000013,28,=,28000.0,nM,binder,,,,,1c,,B,Michaelis menton constant for human P-glycoprotein expressed in Sf9 cells,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000008800,mbcd0001532,mbtp000001,mbrf0000013,22,=,35000.0,nM,binder,,,,,Paclitaxel,,B,Maximum velocity against human P-glycoprotein expressed in Sf9 cells,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000008801,mbcd0002403,mbtp000001,mbrf0000013,28,=,35000.0,nM,binder,,,,,18,,B,Michaelis menton constant for human P-glycoprotein expressed in Sf9 cells,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000008802,mbcd0002857,mbtp000001,mbrf0000013,22,=,35000.0,nM,binder,,,,,1b,,B,Maximum velocity against human P-glycoprotein expressed in Sf9 cells,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000008805,mbcd0002403,mbtp000001,mbrf0000013,22,=,39000.0,nM,binder,,,,,18,,B,Maximum velocity against human P-glycoprotein expressed in Sf9 cells,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000008809,mbcd0002371,mbtp000001,mbrf0000013,28,=,40000.0,nM,binder,,,,,1a,,B,Michaelis menton constant for human P-glycoprotein expressed in Sf9 cells,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000008810,mbcd0002360,mbtp000001,mbrf0000013,22,=,40000.0,nM,binder,,,,,1c,,B,Maximum velocity against human P-glycoprotein expressed in Sf9 cells,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000008811,mbcd0002268,mbtp000001,mbrf0000013,22,=,41000.0,nM,binder,,,,,2b,,B,Maximum velocity against human P-glycoprotein expressed in Sf9 cells,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000008819,mbcd0002585,mbtp000001,mbrf0000013,22,=,45000.0,nM,binder,,,,,2c,,B,Maximum velocity against human P-glycoprotein expressed in Sf9 cells,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000008822,mbcd0002123,mbtp000001,mbrf0000013,22,=,47000.0,nM,binder,,,,,3b,,B,Maximum velocity against human P-glycoprotein expressed in Sf9 cells,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000008823,mbcd0002868,mbtp000001,mbrf0000013,22,=,48000.0,nM,binder,,,,,3a,,B,Maximum velocity against human P-glycoprotein expressed in Sf9 cells,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000008843,mbcd0002868,mbtp000001,mbrf0000013,28,=,50000.0,nM,binder,,,,,3a,,B,Michaelis menton constant for human P-glycoprotein expressed in Sf9 cells,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000008879,mbcd0027062,mbtp000001,mbrf0000013,22,=,65000.0,nM,binder,,,,,Verapamil,,B,Maximum velocity against human P-glycoprotein expressed in Sf9 cells,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000009056,mbcd0002544,mbtp000001,mbrf0000069,,,,,inducer,,,,,Delavirdine,,B,Induction of ABCB1 activity,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000009059,mbcd0001868,mbtp000001,mbrf0000069,,,,,inducer,,,,,Efavirenz,,B,Induction of ABCB1 activity,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000009062,mbcd0002339,mbtp000001,mbrf0000069,,,,,inducer,,,,,Nevirapine,,B,Induction of ABCB1 activity,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000009090,mbcd0001795,mbtp000001,mbrf0000069,,,,,inducer,111,1.8,fold increase,,Etravirine,moderate inducer,B,Induction of ABCB1 activity; protein level,,,1,micromol L-1,,human,mbds0001,v12,2015-07-27 05:36:21
mbbd000009108,mbcd0027018,mbtp000001,mbrf0000074,,,,,inhibitor,,,,,quinidine,,A,"Inhibitors of transporters of clinical importance in the absorption and dispostion of drugs, MDR1",,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000009109,mbcd0027062,mbtp000001,mbrf0000074,,,,,inhibitor,,,,,verapamil,,A,"Inhibitors of transporters of clinical importance in the absorption and dispostion of drugs, MDR1",,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000009110,mbcd0002104,mbtp000001,mbrf0000074,,,,,inhibitor,,,,,tariquidar,,A,"Inhibitors of transporters of clinical importance in the absorption and dispostion of drugs, MDR1",,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000009112,mbcd0000311,mbtp000001,mbrf0000074,,,,,inhibitor,,,,,cyclosporine,,A,"Inhibitors of transporters of clinical importance in the absorption and dispostion of drugs, MDR1",,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000009169,mbcd0003143,mbtp000005,mbrf0000080,1,=,-1.0,%,inhibitor,104,-1.0,%,2,thioridazine,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:11
mbbd000009184,mbcd0002337,mbtp000005,mbrf0000080,1,=,3.0,%,inhibitor,104,3.0,%,1,terfenadine,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:12
mbbd000009185,mbcd0003064,mbtp000005,mbrf0000080,1,=,5.0,%,inhibitor,104,5.0,%,1,fendiline,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:12
mbbd000009186,mbcd0003035,mbtp000005,mbrf0000080,1,=,5.0,%,inhibitor,104,5.0,%,2,bromosulfalein,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:12
mbbd000009187,mbcd0000462,mbtp000005,mbrf0000080,1,=,5.0,%,inhibitor,104,5.0,%,1,glycyrrihizinic acid,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:12
mbbd000009188,mbcd0000487,mbtp000005,mbrf0000080,1,=,5.0,%,inhibitor,104,5.0,%,3,indocyanin green,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:13
mbbd000009189,mbcd0003021,mbtp000005,mbrf0000080,1,=,6.0,%,inhibitor,104,6.0,%,1,loratidine,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:13
mbbd000009190,mbcd0003122,mbtp000005,mbrf0000080,1,=,7.0,%,inhibitor,104,7.0,%,3,5-CFDA,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:13
mbbd000009191,mbcd0002889,mbtp000005,mbrf0000080,1,=,8.0,%,inhibitor,104,8.0,%,1,tomaxifen,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:13
mbbd000009192,mbcd0002494,mbtp000005,mbrf0000080,1,=,9.0,%,inhibitor,104,9.0,%,3,MK571,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:14
mbbd000009193,mbcd0003155,mbtp000005,mbrf0000080,1,=,9.0,%,inhibitor,104,9.0,%,2,Fluo-3,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:14
mbbd000009194,mbcd0003034,mbtp000005,mbrf0000080,1,=,11.0,%,inhibitor,104,11.0,%,1,benzbromarone,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:14
mbbd000009195,mbcd0000968,mbtp000005,mbrf0000080,1,=,11.0,%,inhibitor,104,11.0,%,1,diethylstilbestrol,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:14
mbbd000009196,mbcd0022617,mbtp000005,mbrf0000080,1,=,14.0,%,inhibitor,104,14.0,%,13,silymarin,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:15
mbbd000009197,mbcd0002493,mbtp000005,mbrf0000080,1,=,14.0,%,inhibitor,104,14.0,%,4,clotrimazole,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:15
mbbd000009198,mbcd0001416,mbtp000005,mbrf0000080,1,=,18.0,%,inhibitor,104,18.0,%,5,rifampicin,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:15
mbbd000009199,mbcd0001539,mbtp000005,mbrf0000080,1,=,25.0,%,inhibitor,104,25.0,%,6,chlorprothixene,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:15
mbbd000009200,mbcd0003109,mbtp000005,mbrf0000080,1,=,27.0,%,inhibitor,104,27.0,%,4,taurolithocholic acid,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:16
mbbd000009201,mbcd0002241,mbtp000005,mbrf0000080,1,=,33.0,%,inhibitor,104,33.0,%,12,lopinavir,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:16
mbbd000009202,mbcd0003121,mbtp000005,mbrf0000080,1,=,34.0,%,inhibitor,104,34.0,%,10,lansoprazole,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:16
mbbd000009203,mbcd0003033,mbtp000005,mbrf0000080,1,=,34.0,%,inhibitor,104,34.0,%,5,baicalin,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:16
mbbd000009204,mbcd0002109,mbtp000005,mbrf0000080,1,=,36.0,%,inhibitor,104,36.0,%,10,astemizole,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:17
mbbd000009205,mbcd0001941,mbtp000005,mbrf0000080,1,=,37.0,%,inhibitor,104,37.0,%,4,reserpine,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:17
mbbd000009206,mbcd0001808,mbtp000005,mbrf0000080,1,=,39.0,%,inhibitor,104,39.0,%,8,GF-120918,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:17
mbbd000009207,mbcd0000311,mbtp000005,mbrf0000080,1,=,40.0,%,inhibitor,104,40.0,%,7,cyclosporine-A,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:17
mbbd000009208,mbcd0002338,mbtp000005,mbrf0000080,1,=,40.0,%,inhibitor,104,40.0,%,13,diltiazem,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:18
mbbd000009209,mbcd0003120,mbtp000005,mbrf0000080,1,=,40.0,%,inhibitor,104,40.0,%,8,quercetin,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:18
mbbd000009210,mbcd0001533,mbtp000005,mbrf0000080,1,=,41.0,%,inhibitor,104,41.0,%,6,saquinavir,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:18
mbbd000009211,mbcd0003100,mbtp000005,mbrf0000080,1,=,42.0,%,inhibitor,104,42.0,%,13,dipyridamole,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:18
mbbd000009212,mbcd0003061,mbtp000005,mbrf0000080,1,=,43.0,%,inhibitor,104,43.0,%,12,lisinopril,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:19
mbbd000009213,mbcd0003062,mbtp000005,mbrf0000080,1,=,43.0,%,inhibitor,104,43.0,%,8,chelerythrine,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:19
mbbd000009214,mbcd0003060,mbtp000005,mbrf0000080,1,=,44.0,%,inhibitor,104,44.0,%,7,sanguinarine chloride,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:19
mbbd000009215,mbcd0000977,mbtp000005,mbrf0000080,1,=,46.0,%,inhibitor,104,46.0,%,10,israpidine,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:20
mbbd000009216,mbcd0003072,mbtp000005,mbrf0000080,1,=,46.0,%,inhibitor,104,46.0,%,11,celecoxib,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:20
mbbd000009217,mbcd0003027,mbtp000005,mbrf0000080,1,=,46.0,%,inhibitor,104,46.0,%,10,fenofibrate,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:20
mbbd000009218,mbcd0003146,mbtp000005,mbrf0000080,1,=,46.0,%,inhibitor,104,46.0,%,11,p-amino hippuric acid,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:20
mbbd000009219,mbcd0001322,mbtp000005,mbrf0000080,1,=,46.0,%,inhibitor,104,46.0,%,7,flupentixol,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:20
mbbd000009220,mbcd0002539,mbtp000005,mbrf0000080,1,=,46.0,%,inhibitor,104,46.0,%,7,loperamide,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:21
mbbd000009221,mbcd0003099,mbtp000005,mbrf0000080,1,=,47.0,%,inhibitor,104,47.0,%,7,erlotinib,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:21
mbbd000009222,mbcd0001938,mbtp000005,mbrf0000080,1,=,48.0,%,inhibitor,104,48.0,%,4,ritonavir,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:21
mbbd000009223,mbcd0003059,mbtp000005,mbrf0000080,1,=,50.0,%,inhibitor,104,50.0,%,8,morin,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:21
mbbd000009224,mbcd0003081,mbtp000005,mbrf0000080,1,=,51.0,%,inhibitor,104,51.0,%,4,amitriptyline,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:22
mbbd000009225,mbcd0003058,mbtp000005,mbrf0000080,1,=,51.0,%,inhibitor,104,51.0,%,5,prednisone,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:22
mbbd000009226,mbcd0002666,mbtp000005,mbrf0000080,1,=,52.0,%,inhibitor,104,52.0,%,6,ranitidine,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:22
mbbd000009227,mbcd0003119,mbtp000005,mbrf0000080,1,=,53.0,%,inhibitor,104,53.0,%,11,ethinylestradiol,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:22
mbbd000009228,mbcd0003032,mbtp000005,mbrf0000080,1,=,55.0,%,inhibitor,104,55.0,%,6,tinidazole,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:23
mbbd000009229,mbcd0020385,mbtp000005,mbrf0000080,1,=,56.0,%,inhibitor,104,56.0,%,12,maprotiline,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:23
mbbd000009230,mbcd0027062,mbtp000005,mbrf0000080,1,=,56.0,%,inhibitor,104,56.0,%,11,verapamil,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:23
mbbd000009231,mbcd0003118,mbtp000005,mbrf0000080,1,=,56.0,%,inhibitor,104,56.0,%,5,nystatin,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:24
mbbd000009232,mbcd0002995,mbtp000005,mbrf0000080,1,=,57.0,%,inhibitor,104,57.0,%,7,desipramine,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:24
mbbd000009233,mbcd0003089,mbtp000005,mbrf0000080,1,=,57.0,%,inhibitor,104,57.0,%,10,dextromethorphan,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:24
mbbd000009234,mbcd0002195,mbtp000005,mbrf0000080,1,=,58.0,%,inhibitor,104,58.0,%,11,propafenone,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:24
mbbd000009235,mbcd0002340,mbtp000005,mbrf0000080,1,=,58.0,%,inhibitor,104,58.0,%,14,chlorpromazine,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:25
mbbd000009236,mbcd0002576,mbtp000005,mbrf0000080,1,=,59.0,%,inhibitor,104,59.0,%,12,nicardipine,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:25
mbbd000009237,mbcd0001153,mbtp000005,mbrf0000080,1,=,59.0,%,inhibitor,104,59.0,%,15,atropine,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:25
mbbd000009238,mbcd0002994,mbtp000005,mbrf0000080,1,=,60.0,%,inhibitor,104,60.0,%,8,ergocristine,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:25
mbbd000009239,mbcd0003144,mbtp000005,mbrf0000080,1,=,60.0,%,inhibitor,104,60.0,%,9,amodiaquine,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:26
mbbd000009240,mbcd0001194,mbtp000005,mbrf0000080,1,=,61.0,%,inhibitor,104,61.0,%,11,simvastatin,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:26
mbbd000009241,mbcd0003031,mbtp000005,mbrf0000080,1,=,62.0,%,inhibitor,104,62.0,%,14,procyclidin,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:26
mbbd000009242,mbcd0003019,mbtp000005,mbrf0000080,1,=,63.0,%,inhibitor,104,63.0,%,7,cefamendole,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:26
mbbd000009243,mbcd0027018,mbtp000005,mbrf0000080,1,=,64.0,%,inhibitor,104,64.0,%,6,quinidine,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:26
mbbd000009244,mbcd0002192,mbtp000005,mbrf0000080,1,=,66.0,%,inhibitor,104,66.0,%,5,amiodarone,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:27
mbbd000009245,mbcd0002992,mbtp000005,mbrf0000080,1,=,66.0,%,inhibitor,104,66.0,%,15,tryptophan,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:27
mbbd000009246,mbcd0001472,mbtp000005,mbrf0000080,1,=,68.0,%,inhibitor,104,68.0,%,7,cefadroxil,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:27
mbbd000009247,mbcd0003117,mbtp000005,mbrf0000080,1,=,69.0,%,inhibitor,104,69.0,%,11,pramoxine,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:28
mbbd000009248,mbcd0002488,mbtp000005,mbrf0000080,1,=,69.0,%,inhibitor,104,69.0,%,9,propranolol,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:28
mbbd000009249,mbcd0000474,mbtp000005,mbrf0000080,1,=,70.0,%,inhibitor,104,70.0,%,16,hoechst 33342,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:28
mbbd000009250,mbcd0003022,mbtp000005,mbrf0000080,1,=,72.0,%,inhibitor,104,72.0,%,13,1-methyl-4-phenylpyridinium,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:28
mbbd000009251,mbcd0003149,mbtp000005,mbrf0000080,1,=,72.0,%,inhibitor,104,72.0,%,8,fusidic acid,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:29
mbbd000009252,mbcd0002822,mbtp000005,mbrf0000080,1,=,72.0,%,inhibitor,104,72.0,%,7,metoprolol,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:29
mbbd000009253,mbcd0002439,mbtp000005,mbrf0000080,1,=,73.0,%,inhibitor,104,73.0,%,17,Ko143,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:29
mbbd000009254,mbcd0003036,mbtp000005,mbrf0000080,1,=,73.0,%,inhibitor,104,73.0,%,9,flucloxacillin,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:29
mbbd000009255,mbcd0003000,mbtp000005,mbrf0000080,1,=,74.0,%,inhibitor,104,74.0,%,11,chlorzoxazone,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:30
mbbd000009256,mbcd0003125,mbtp000005,mbrf0000080,1,=,74.0,%,inhibitor,104,74.0,%,15,gefitinib,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:30
mbbd000009257,mbcd0000482,mbtp000005,mbrf0000080,1,=,74.0,%,inhibitor,104,74.0,%,9,imatinib mesylate,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:30
mbbd000009258,mbcd0001092,mbtp000005,mbrf0000080,1,=,75.0,%,inhibitor,104,75.0,%,10,quinine,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:31
mbbd000009259,mbcd0002831,mbtp000005,mbrf0000080,1,=,75.0,%,inhibitor,104,75.0,%,8,resveratrol,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:31
mbbd000009260,mbcd0003134,mbtp000005,mbrf0000080,1,=,76.0,%,inhibitor,104,76.0,%,15,benzylpenicillin,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:31
mbbd000009261,mbcd0017104,mbtp000005,mbrf0000080,1,=,76.0,%,inhibitor,104,76.0,%,6,ketoconazole,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:31
mbbd000009262,mbcd0001280,mbtp000005,mbrf0000080,1,=,77.0,%,inhibitor,104,77.0,%,11,sulfasalazine,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:31
mbbd000009263,mbcd0003092,mbtp000005,mbrf0000080,1,=,78.0,%,inhibitor,104,78.0,%,17,noscapine,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:32
mbbd000009264,mbcd0003024,mbtp000005,mbrf0000080,1,=,78.0,%,inhibitor,104,78.0,%,15,prazosine,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:32
mbbd000009266,mbcd0003112,mbtp000005,mbrf0000080,1,=,81.0,%,non-inhibitor,104,81.0,%,8,glipizide,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:32
mbbd000009267,mbcd0003111,mbtp000005,mbrf0000080,1,=,82.0,%,non-inhibitor,104,82.0,%,18,amiloride,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:33
mbbd000009268,mbcd0000080,mbtp000005,mbrf0000080,1,=,82.0,%,non-inhibitor,104,82.0,%,7,5-carboxyfluorescein,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:33
mbbd000009270,mbcd0003052,mbtp000005,mbrf0000080,1,=,83.0,%,non-inhibitor,104,83.0,%,14,phenacetin,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:33
mbbd000009271,mbcd0003068,mbtp000005,mbrf0000080,1,=,83.0,%,non-inhibitor,104,83.0,%,12,Ofloxacin,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:33
mbbd000009272,mbcd0003026,mbtp000005,mbrf0000080,1,=,84.0,%,non-inhibitor,104,84.0,%,5,biochanin A,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:34
mbbd000009273,mbcd0003051,mbtp000005,mbrf0000080,1,=,84.0,%,non-inhibitor,104,84.0,%,4,carnitine,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:34
mbbd000009274,mbcd0003069,mbtp000005,mbrf0000080,1,=,84.0,%,non-inhibitor,104,84.0,%,17,antipyrine,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:34
mbbd000009275,mbcd0003010,mbtp000005,mbrf0000080,1,=,86.0,%,non-inhibitor,104,86.0,%,17,ritanserine,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:35
mbbd000009276,mbcd0002985,mbtp000005,mbrf0000080,1,=,86.0,%,non-inhibitor,104,86.0,%,17,carbamazepine,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:35
mbbd000009277,mbcd0003011,mbtp000005,mbrf0000080,1,=,86.0,%,non-inhibitor,104,86.0,%,20,felodipine,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:35
mbbd000009278,mbcd0001664,mbtp000005,mbrf0000080,1,=,87.0,%,non-inhibitor,104,87.0,%,16,taurocholate,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:35
mbbd000009279,mbcd0025844,mbtp000005,mbrf0000080,1,=,87.0,%,non-inhibitor,104,87.0,%,15,doxorubicin,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:36
mbbd000009280,mbcd0003105,mbtp000005,mbrf0000080,1,=,88.0,%,non-inhibitor,104,88.0,%,10,phenformin,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:36
mbbd000009281,mbcd0001350,mbtp000005,mbrf0000080,1,=,88.0,%,non-inhibitor,104,88.0,%,14,tipranavir,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:36
mbbd000009282,mbcd0000937,mbtp000005,mbrf0000080,1,=,89.0,%,non-inhibitor,104,89.0,%,8,erythromycin,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:36
mbbd000009283,mbcd0000932,mbtp000005,mbrf0000080,1,=,89.0,%,non-inhibitor,104,89.0,%,8,tramadol,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:37
mbbd000009284,mbcd0002999,mbtp000005,mbrf0000080,1,=,91.0,%,non-inhibitor,104,91.0,%,11,timolol,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:37
mbbd000009285,mbcd0001111,mbtp000005,mbrf0000080,1,=,91.0,%,non-inhibitor,104,91.0,%,11,cemitidine,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:37
mbbd000009286,mbcd0002998,mbtp000005,mbrf0000080,1,=,92.0,%,non-inhibitor,104,92.0,%,2,naproxen,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:37
mbbd000009287,mbcd0003009,mbtp000005,mbrf0000080,1,=,92.0,%,non-inhibitor,104,92.0,%,12,rotenone,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:38
mbbd000009288,mbcd0002323,mbtp000005,mbrf0000080,1,=,93.0,%,non-inhibitor,104,93.0,%,10,indinavir,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:38
mbbd000009289,mbcd0003129,mbtp000005,mbrf0000080,1,=,94.0,%,non-inhibitor,104,94.0,%,8,phenylethyl isothiocyanate,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:38
mbbd000009290,mbcd0001221,mbtp000005,mbrf0000080,1,=,94.0,%,non-inhibitor,104,94.0,%,15,nitrofurantoin,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:38
mbbd000009291,mbcd0003091,mbtp000005,mbrf0000080,1,=,94.0,%,non-inhibitor,104,94.0,%,9,apigenin,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:39
mbbd000009292,mbcd0003131,mbtp000005,mbrf0000080,1,=,94.0,%,non-inhibitor,104,94.0,%,9,seglitide,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:39
mbbd000009293,mbcd0003008,mbtp000005,mbrf0000080,1,=,94.0,%,non-inhibitor,104,94.0,%,18,valproic acid,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:39
mbbd000009294,mbcd0003130,mbtp000005,mbrf0000080,1,=,94.0,%,non-inhibitor,104,94.0,%,13,hydrochlorothiazide,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:39
mbbd000009295,mbcd0002997,mbtp000005,mbrf0000080,1,=,94.0,%,non-inhibitor,104,94.0,%,22,terazosin,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:40
mbbd000009296,mbcd0003087,mbtp000005,mbrf0000080,1,=,94.0,%,non-inhibitor,104,94.0,%,12,valacyclovir,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:40
mbbd000009297,mbcd0003128,mbtp000005,mbrf0000080,1,=,96.0,%,non-inhibitor,104,96.0,%,22,sotalol,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:40
mbbd000009298,mbcd0003110,mbtp000005,mbrf0000080,1,=,96.0,%,non-inhibitor,104,96.0,%,18,adefovir,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:41
mbbd000009299,mbcd0002983,mbtp000005,mbrf0000080,1,=,96.0,%,non-inhibitor,104,96.0,%,10,isoniazid,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:41
mbbd000009300,mbcd0001797,mbtp000005,mbrf0000080,21,=,97.0,%,non-inhibitor,21,97.0,%,13,fexofenadine,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,Sf9,mbcd0030389,80,microM,,human,mbds0001,v12,2013-12-08 08:52:03
mbbd000009301,mbcd0003007,mbtp000005,mbrf0000080,1,=,98.0,%,non-inhibitor,104,98.0,%,11,phenobarbitol,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:41
mbbd000009302,mbcd0029079,mbtp000005,mbrf0000080,1,=,98.0,%,non-inhibitor,104,98.0,%,6,tranilast,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:42
mbbd000009303,mbcd0003090,mbtp000005,mbrf0000080,1,=,99.0,%,non-inhibitor,104,99.0,%,19,4-nitrophenyl glucuronide,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:42
mbbd000009304,mbcd0001050,mbtp000005,mbrf0000080,1,=,99.0,%,non-inhibitor,104,99.0,%,13,digoxin,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:42
mbbd000009305,mbcd0003073,mbtp000005,mbrf0000080,1,=,100.0,%,non-inhibitor,104,100.0,%,17,piroxicam,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:42
mbbd000009306,mbcd0000928,mbtp000005,mbrf0000080,1,=,101.0,%,non-inhibitor,104,101.0,%,13,nicotine,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:42
mbbd000009307,mbcd0002667,mbtp000005,mbrf0000080,1,=,101.0,%,non-inhibitor,104,101.0,%,8,colchicine,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:43
mbbd000009308,mbcd0003116,mbtp000005,mbrf0000080,1,=,101.0,%,non-inhibitor,104,101.0,%,6,genistein,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:43
mbbd000009309,mbcd0003037,mbtp000005,mbrf0000080,1,=,101.0,%,non-inhibitor,104,101.0,%,21,N-methylnicotinamide,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:43
mbbd000009310,mbcd0002091,mbtp000005,mbrf0000080,1,=,101.0,%,non-inhibitor,104,101.0,%,23,irinotecan,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:43
mbbd000009311,mbcd0000254,mbtp000005,mbrf0000080,1,=,101.0,%,non-inhibitor,104,101.0,%,13,chenodeoxycholic acid,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:44
mbbd000009312,mbcd0003083,mbtp000005,mbrf0000080,1,=,101.0,%,non-inhibitor,104,101.0,%,20,amantadine,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:44
mbbd000009313,mbcd0001021,mbtp000005,mbrf0000080,1,=,101.0,%,non-inhibitor,104,101.0,%,9,omeprazole,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:44
mbbd000009314,mbcd0003088,mbtp000005,mbrf0000080,1,=,102.0,%,non-inhibitor,104,102.0,%,14,chloroquine,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:44
mbbd000009315,mbcd0001107,mbtp000005,mbrf0000080,1,=,103.0,%,non-inhibitor,104,103.0,%,28,zidovudine,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:45
mbbd000009316,mbcd0001197,mbtp000005,mbrf0000080,1,=,103.0,%,non-inhibitor,104,103.0,%,11,leucovorin,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:45
mbbd000009317,mbcd0003097,mbtp000005,mbrf0000080,1,=,103.0,%,non-inhibitor,104,103.0,%,18,oxazepam,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:45
mbbd000009318,mbcd0003141,mbtp000005,mbrf0000080,1,=,104.0,%,non-inhibitor,104,104.0,%,20,disopyramide,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:46
mbbd000009319,mbcd0003142,mbtp000005,mbrf0000080,1,=,104.0,%,non-inhibitor,104,104.0,%,15,captopril,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:46
mbbd000009320,mbcd0003003,mbtp000005,mbrf0000080,1,=,106.0,%,non-inhibitor,104,106.0,%,16,bupropion,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:46
mbbd000009321,mbcd0001777,mbtp000005,mbrf0000080,1,=,106.0,%,non-inhibitor,104,106.0,%,9,haloperidol,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:46
mbbd000009322,mbcd0003140,mbtp000005,mbrf0000080,1,=,106.0,%,non-inhibitor,104,106.0,%,9,nandrolone,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:47
mbbd000009323,mbcd0003115,mbtp000005,mbrf0000080,1,=,107.0,%,non-inhibitor,104,107.0,%,16,trimethoprim,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:47
mbbd000009324,mbcd0003106,mbtp000005,mbrf0000080,1,=,108.0,%,non-inhibitor,104,108.0,%,13,flurbiprofen,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:47
mbbd000009325,mbcd0003139,mbtp000005,mbrf0000080,1,=,108.0,%,non-inhibitor,104,108.0,%,10,taxifolin,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:47
mbbd000009326,mbcd0003056,mbtp000005,mbrf0000080,1,=,109.0,%,non-inhibitor,104,109.0,%,11,tomoxetine,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:48
mbbd000009327,mbcd0003017,mbtp000005,mbrf0000080,1,=,109.0,%,non-inhibitor,104,109.0,%,11,mesalazine,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:48
mbbd000009328,mbcd0003016,mbtp000005,mbrf0000080,1,=,110.0,%,non-inhibitor,104,110.0,%,17,tetracycline,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:48
mbbd000009329,mbcd0003045,mbtp000005,mbrf0000080,1,=,110.0,%,non-inhibitor,104,110.0,%,13,chrysine,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:48
mbbd000009330,mbcd0003096,mbtp000005,mbrf0000080,1,=,110.0,%,non-inhibitor,104,110.0,%,12,prednisolone,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:49
mbbd000009331,mbcd0003138,mbtp000005,mbrf0000080,1,=,110.0,%,non-inhibitor,104,110.0,%,18,nizatidine,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:49
mbbd000009332,mbcd0003154,mbtp000005,mbrf0000080,1,=,110.0,%,non-inhibitor,104,110.0,%,27,probenecid,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:49
mbbd000009333,mbcd0002466,mbtp000005,mbrf0000080,1,=,110.0,%,non-inhibitor,104,110.0,%,23,etoposide,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:49
mbbd000009334,mbcd0001173,mbtp000005,mbrf0000080,1,=,111.0,%,non-inhibitor,104,111.0,%,21,medroxyprogesterone,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:50
mbbd000009335,mbcd0000070,mbtp000005,mbrf0000080,1,=,111.0,%,non-inhibitor,104,111.0,%,21,4-methylumbelliferone glucuronide,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:50
mbbd000009336,mbcd0001640,mbtp000005,mbrf0000080,1,=,112.0,%,non-inhibitor,104,112.0,%,13,cholic acid,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:50
mbbd000009337,mbcd0003030,mbtp000005,mbrf0000080,1,=,113.0,%,non-inhibitor,104,113.0,%,6,sulindac sulphone,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:50
mbbd000009338,mbcd0003002,mbtp000005,mbrf0000080,1,=,113.0,%,non-inhibitor,104,113.0,%,11,ritodrine,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:51
mbbd000009339,mbcd0003078,mbtp000005,mbrf0000080,1,=,116.0,%,non-inhibitor,104,116.0,%,27,reduced L-glutathione,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:51
mbbd000009340,mbcd0003095,mbtp000005,mbrf0000080,1,=,116.0,%,non-inhibitor,104,116.0,%,18,sulfanitran,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:51
mbbd000009341,mbcd0003137,mbtp000005,mbrf0000080,1,=,118.0,%,non-inhibitor,104,118.0,%,25,furosemide,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:48:51
mbbd000009342,mbcd0002991,mbtp000005,mbrf0000080,1,=,120.0,%,stimulator,104,120.0,%,11,ketoprofen,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:52:17
mbbd000009343,mbcd0002339,mbtp000005,mbrf0000080,1,=,121.0,%,stimulator,104,121.0,%,21,nevirapine,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:52:17
mbbd000009344,mbcd0003055,mbtp000005,mbrf0000080,1,=,123.0,%,stimulator,104,123.0,%,19,17beta-estradiol,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:52:17
mbbd000009345,mbcd0001892,mbtp000005,mbrf0000080,1,=,123.0,%,stimulator,104,123.0,%,20,progesterone,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:52:17
mbbd000009346,mbcd0002635,mbtp000005,mbrf0000080,1,=,124.0,%,stimulator,104,124.0,%,9,hydrocortisone,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:52:17
mbbd000009347,mbcd0002996,mbtp000005,mbrf0000080,1,=,125.0,%,stimulator,104,125.0,%,11,phenytoin,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:52:17
mbbd000009348,mbcd0003094,mbtp000005,mbrf0000080,1,=,125.0,%,stimulator,104,125.0,%,12,spironolactone,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:52:17
mbbd000009349,mbcd0003044,mbtp000005,mbrf0000080,1,=,126.0,%,stimulator,104,126.0,%,14,flutamide,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:52:17
mbbd000009350,mbcd0003043,mbtp000005,mbrf0000080,1,=,130.0,%,stimulator,104,130.0,%,24,methotrexate,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:52:17
mbbd000009351,mbcd0003013,mbtp000005,mbrf0000080,1,=,130.0,%,stimulator,104,130.0,%,29,ibuprofen,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:52:17
mbbd000009352,mbcd0001299,mbtp000005,mbrf0000080,1,=,134.0,%,stimulator,104,134.0,%,10,mifepristone,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:52:17
mbbd000009353,mbcd0003126,mbtp000005,mbrf0000080,1,=,135.0,%,stimulator,104,135.0,%,20,pravastatin,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:52:17
mbbd000009354,mbcd0003042,mbtp000005,mbrf0000080,1,=,136.0,%,stimulator,104,136.0,%,22,warfarin,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:52:17
mbbd000009355,mbcd0002990,mbtp000005,mbrf0000080,1,=,136.0,%,stimulator,104,136.0,%,29,oxidized L-glutathione,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:52:17
mbbd000009356,mbcd0002989,mbtp000005,mbrf0000080,1,=,138.0,%,stimulator,104,138.0,%,7,sparfloxacin,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:52:17
mbbd000009357,mbcd0003001,mbtp000005,mbrf0000080,1,=,140.0,%,stimulator,104,140.0,%,15,testosterone,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:52:17
mbbd000009358,mbcd0015247,mbtp000005,mbrf0000080,1,=,142.0,%,stimulator,104,142.0,%,11,glimepiride,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:52:17
mbbd000009359,mbcd0003012,mbtp000005,mbrf0000080,1,=,150.0,%,stimulator,104,150.0,%,16,acetaminophen glucuronide,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:52:17
mbbd000009360,mbcd0001527,mbtp000005,mbrf0000080,1,=,150.0,%,stimulator,104,150.0,%,24,budesonide,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:52:17
mbbd000009361,mbcd0002988,mbtp000005,mbrf0000080,1,=,150.0,%,stimulator,104,150.0,%,15,sulfinpyrazone,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:52:17
mbbd000009363,mbcd0003053,mbtp000005,mbrf0000080,1,=,151.0,%,stimulator,104,151.0,%,33,sulindac,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:52:17
mbbd000009364,mbcd0003077,mbtp000005,mbrf0000080,1,=,174.0,%,stimulator,104,174.0,%,19,gliclazide,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:52:17
mbbd000009365,mbcd0002981,mbtp000005,mbrf0000080,1,=,175.0,%,stimulator,104,175.0,%,47,mitoxantrone,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:52:17
mbbd000009366,mbcd0003113,mbtp000005,mbrf0000080,1,=,198.0,%,stimulator,104,198.0,%,20,diclofenac,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:52:17
mbbd000009367,mbcd0003076,mbtp000005,mbrf0000080,1,=,207.0,%,stimulator,104,207.0,%,28,naringenin,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:52:17
mbbd000009368,mbcd0003135,mbtp000005,mbrf0000080,1,=,224.0,%,stimulator,104,224.0,%,25,nitrendipine,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:52:17
mbbd000009369,mbcd0003075,mbtp000005,mbrf0000080,1,=,300.0,%,stimulator,104,300.0,%,67,estrone-3-sulphate,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:52:17
mbbd000009370,mbcd0003074,mbtp000005,mbrf0000080,1,=,304.0,%,stimulator,104,304.0,%,66,glibenclamide,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:52:17
mbbd000009371,mbcd0003025,mbtp000005,mbrf0000080,1,=,308.0,%,stimulator,104,308.0,%,23,Indomethacin,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:52:17
mbbd000009372,mbcd0003070,mbtp000005,mbrf0000080,1,=,395.0,%,stimulator,104,395.0,%,48,dehydroisoandrosterone-3-sulfate,ratio of the ATP-dependent E17G transport rate in the presence and absence of the test compound,B,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,,,,,,human,mbds0001,v12,2013-11-27 08:52:17
mbbd000009375,mbcd0002494,mbtp000005,mbrf0000080,25,=,10000.0,nM,inhibitor,25,10.0,microM,1.5,MK571,,B,Inhibition of human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles,,,,,,human,mbds0001,v12,2013-11-27 09:01:14
mbbd000009391,mbcd0002981,mbtp000005,mbrf0000074,,,,,substrate,,,,,mitoxantrone,,A,"Substrates of transporters of clinical importance in the absorption and dispostion of drugs, MRP2",,,,,,human,mbds0001,v12,2013-12-10 22:21:07
mbbd000009393,mbcd0002544,mbtp000005,mbrf0000074,,,,,inhibitor,,,,,delaviridine,,A,"Inhibitors of transporters of clinical importance in the absorption and dispostion of drugs, MRP2",,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000009420,mbcd0000780,mbtp000005,mbrf0000074,,,,,substrate,,,,,glucuronidated SN-38,,A,"Substrates of transporters of clinical importance in the absorption and dispostion of drugs, MRP2",,,,,,human,mbds0001,v12,2013-12-10 22:21:07
mbbd000009421,mbcd0001868,mbtp000005,mbrf0000074,,,,,inhibitor,,,,,efavirenz,,A,"Inhibitors of transporters of clinical importance in the absorption and dispostion of drugs, MRP2",,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000009422,mbcd0003029,mbtp000005,mbrf0000074,,,,,inhibitor,,,,,emtricitabine,,A,"Inhibitors of transporters of clinical importance in the absorption and dispostion of drugs, MRP2",,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000009431,mbcd0000311,mbtp000005,mbrf0000074,,,,,inhibitor,,,,,cyclosporine,,A,"Inhibitors of transporters of clinical importance in the absorption and dispostion of drugs, MRP2",,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000009448,mbcd0001868,mbtp000008,mbrf0000069,,,,,inducer,,,,,Efavirenz,,B,Induction of MRP3 activity,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000009452,mbcd0001795,mbtp000008,mbrf0000069,,,,,inducer,,,,,Etravirine,moderate inducer,B,Induction of MRP3 activity,,,0.1,micromol L-1,,human,mbds0001,v12,2015-07-27 05:36:21
mbbd000009454,mbcd0003029,mbtp000008,mbrf0000074,,,,,inhibitor,,,,,emtricitabine,,A,"Inhibitors of transporters of clinical importance in the absorption and dispostion of drugs, MPR3",,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000009457,mbcd0001868,mbtp000008,mbrf0000074,,,,,inhibitor,,,,,efavirenz,,A,"Inhibitors of transporters of clinical importance in the absorption and dispostion of drugs, MPR3",,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000009458,mbcd0002544,mbtp000008,mbrf0000074,,,,,inhibitor,,,,,delaviridine,,A,"Inhibitors of transporters of clinical importance in the absorption and dispostion of drugs, MPR3",,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000009756,mbcd0002293,mbtp000002,mbrf0000092,25,=,20700.0,nM,inhibitor,25,20.7,microM,11.1,2e,,B,Inhibition of BCRP expressed in MDCK cells by pheophorbide A assay,,,,,,human,mbds0001,v12,2012-10-26 18:21:13
mbbd000009804,mbcd0002422,mbtp000002,mbrf0000074,,,,,inhibitor,,,,,fumitre -morgin C,,A,"Inhibitors of transporters of clinical importance in the absorption and dispostion of drugs, BCRP",,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000009817,mbcd0003211,mbtp000002,mbrf0000074,,,,,inhibitor,,,,,oestrone,,A,"Inhibitors of transporters of clinical importance in the absorption and dispostion of drugs, BCRP",,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000009818,mbcd0003055,mbtp000002,mbrf0000074,,,,,inhibitor,,,,,17beta-oestradiol,,A,"Inhibitors of transporters of clinical importance in the absorption and dispostion of drugs, BCRP",,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000009841,mbcd0001868,mbtp000002,mbrf0000069,,,,,inducer,,,,,Efavirenz,,B,Induction of BCRP activity,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000009870,mbcd0001795,mbtp000002,mbrf0000069,,,,,inducer,111,3.5,fold increase,,Etravirine,strong inducer,B,Induction of BCRP activity; mRNA level,,,1,micromol L-1,,human,mbds0001,v12,2015-07-27 05:36:21
mbbd000010141,mbcd0003658,mbtp000009,mbrf0000105,150,=,10.7,%,substrate,150,10.7,%,1.5,BipR-OH,relative to the flux rate of 33.4 pmol s-1 cm-2 for Gly-Sar,B,Activity of human PEPT1 expressed in Xenopus laevis oocytes assessed as induction of transport-associated flux rate current at 1 mM at -60 mV membrane potential by two-electrode voltage clamp method; compared to the transport of Gly-Sar,Xenopus laevis oocytes,,1.0,mM,weak substrate,human,mbds0001,v12,2015-08-03 01:58:35
mbbd000010142,mbcd0003533,mbtp000009,mbrf0000108,39,=,15.0,%,non-substrate,39,15.0,%,,27,,F,Activation of human PEPT1 expressed in MDCK cells relative to Gly-Sar,MDCK,,,,,human,mbds0001,v12,2013-11-27 09:02:51
mbbd000010144,mbcd0003602,mbtp000009,mbrf0000108,120,=,20.0,%,substrate,120,20.0,%,,64,,F,Ratio of %GSmax to EC50 (which corresponds to Vmax/Km) for human PEPT1 activation; oligopeptides were tested for their ability to induce changes of membrane potential in PEPT1 vs mock transfected MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 21:35:45
mbbd000010147,mbcd0003536,mbtp000009,mbrf0000108,39,=,22.0,%,substrate,39,22.0,%,,14,,F,Activation of human PEPT1 expressed in MDCK cells relative to Gly-Sar,MDCK,,,,,human,mbds0001,v12,2013-11-27 09:02:51
mbbd000010149,mbcd0003632,mbtp000009,mbrf0000108,39,=,23.0,%,substrate,39,23.0,%,,38,,F,Activation of human PEPT1 expressed in MDCK cells relative to Gly-Sar,MDCK,,,,,human,mbds0001,v12,2013-11-27 09:02:51
mbbd000010150,mbcd0003672,mbtp000009,mbrf0000108,39,=,28.0,%,substrate,39,28.0,%,,43,,F,Activation of human PEPT1 expressed in MDCK cells relative to Gly-Sar,MDCK,,,,,human,mbds0001,v12,2013-11-27 09:02:51
mbbd000010151,mbcd0003602,mbtp000009,mbrf0000108,39,=,31.0,%,substrate,39,31.0,%,,64,,F,Activation of human PEPT1 expressed in MDCK cells relative to Gly-Sar,MDCK,,,,,human,mbds0001,v12,2013-11-27 09:02:51
mbbd000010153,mbcd0003606,mbtp000009,mbrf0000108,39,=,37.0,%,substrate,39,37.0,%,,79,,F,Activation of human PEPT1 expressed in MDCK cells relative to Gly-Sar,MDCK,,,,,human,mbds0001,v12,2013-11-27 09:02:51
mbbd000010154,mbcd0003627,mbtp000009,mbrf0000108,39,=,39.0,%,substrate,39,39.0,%,,54,,F,Activation of human PEPT1 expressed in MDCK cells relative to Gly-Sar,MDCK,,,,,human,mbds0001,v12,2013-11-27 09:02:51
mbbd000010156,mbcd0029007,mbtp000009,mbrf0000108,39,=,42.0,%,non-substrate,39,42.0,%,27,60,,F,Activation of human PEPT1 expressed in MDCK cells relative to Gly-Sar,MDCK,,,,,human,mbds0001,v12,2013-11-24 23:10:18
mbbd000010158,mbcd0003536,mbtp000009,mbrf0000108,120,=,46.0,%,substrate,120,46.0,%,,14,,F,Ratio of %GSmax to EC50 (which corresponds to Vmax/Km) for human PEPT1 activation; oligopeptides were tested for their ability to induce changes of membrane potential in PEPT1 vs mock transfected MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 21:35:45
mbbd000010159,mbcd0003578,mbtp000009,mbrf0000108,39,=,46.0,%,non-substrate,39,46.0,%,8,75,,F,Activation of human PEPT1 expressed in MDCK cells relative to Gly-Sar; oligopeptides were tested for their ability to induce changes of membrane potential in PEPT1 vs mock transfected MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 22:23:00
mbbd000010160,mbcd0003627,mbtp000009,mbrf0000108,120,=,50.0,%,substrate,120,50.0,%,,54,,F,Ratio of %GSmax to EC50 (which corresponds to Vmax/Km) for human PEPT1 activation; oligopeptides were tested for their ability to induce changes of membrane potential in PEPT1 vs mock transfected MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 21:35:45
mbbd000010161,mbcd0003580,mbtp000009,mbrf0000108,39,=,55.0,%,substrate,39,55.0,%,,22,,F,Activation of human PEPT1 expressed in MDCK cells relative to Gly-Sar,MDCK,,,,,human,mbds0001,v12,2013-11-27 09:02:51
mbbd000010164,mbcd0003711,mbtp000009,mbrf0000108,39,=,58.0,%,substrate,39,58.0,%,,70,,F,Activation of human PEPT1 expressed in MDCK cells relative to Gly-Sar,MDCK,,,,,human,mbds0001,v12,2013-11-27 09:02:51
mbbd000010166,mbcd0003738,mbtp000009,mbrf0000108,39,=,64.0,%,substrate,39,64.0,%,,7,,F,Activation of human PEPT1 expressed in MDCK cells relative to Gly-Sar,MDCK,,,,,human,mbds0001,v12,2013-11-27 09:02:51
mbbd000010167,mbcd0003734,mbtp000009,mbrf0000108,39,=,65.0,%,non-substrate,39,65.0,%,14,59,,F,Activation of human PEPT1 expressed in MDCK cells relative to Gly-Sar,MDCK,,,,,human,mbds0001,v12,2013-11-24 23:10:21
mbbd000010168,mbcd0003693,mbtp000009,mbrf0000108,39,=,69.0,%,substrate,39,69.0,%,,76,,F,Activation of human PEPT1 expressed in MDCK cells relative to Gly-Sar,MDCK,,,,,human,mbds0001,v12,2013-11-27 09:02:51
mbbd000010169,mbcd0003632,mbtp000009,mbrf0000108,120,=,70.0,%,substrate,120,70.0,%,,38,,F,Ratio of %GSmax to EC50 (which corresponds to Vmax/Km) for human PEPT1 activation; oligopeptides were tested for their ability to induce changes of membrane potential in PEPT1 vs mock transfected MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 21:35:45
mbbd000010170,mbcd0003701,mbtp000009,mbrf0000108,39,=,74.0,%,substrate,39,74.0,%,,80,,F,Activation of human PEPT1 expressed in MDCK cells relative to Gly-Sar,MDCK,,,,,human,mbds0001,v12,2013-11-27 09:02:51
mbbd000010171,mbcd0003788,mbtp000009,mbrf0000108,39,=,76.0,%,substrate,39,76.0,%,,61,,F,Activation of human PEPT1 expressed in MDCK cells relative to Gly-Sar,MDCK,,,,,human,mbds0001,v12,2013-11-27 09:02:51
mbbd000010172,mbcd0003626,mbtp000009,mbrf0000108,39,=,77.0,%,substrate,39,77.0,%,,16,,F,Activation of human PEPT1 expressed in MDCK cells relative to Gly-Sar,MDCK,,,,,human,mbds0001,v12,2013-11-27 09:02:51
mbbd000010173,mbcd0029531,mbtp000009,mbrf0000108,39,=,78.0,%,substrate,39,78.0,%,,57,,F,Activation of human PEPT1 expressed in MDCK cells relative to Gly-Sar,MDCK,,,,,human,mbds0001,v12,2013-11-27 09:02:51
mbbd000010174,mbcd0003652,mbtp000009,mbrf0000108,39,=,78.0,%,substrate,39,78.0,%,,33,,F,Activation of human PEPT1 expressed in MDCK cells relative to Gly-Sar,MDCK,,,,,human,mbds0001,v12,2013-11-27 09:02:51
mbbd000010175,mbcd0003798,mbtp000009,mbrf0000108,39,=,78.0,%,substrate,39,78.0,%,,15,,F,Activation of human PEPT1 expressed in MDCK cells relative to Gly-Sar,MDCK,,,,,human,mbds0001,v12,2013-11-27 09:02:51
mbbd000010176,mbcd0003700,mbtp000009,mbrf0000108,39,=,83.0,%,substrate,39,83.0,%,,32,,F,Activation of human PEPT1 expressed in MDCK cells relative to Gly-Sar,MDCK,,,,,human,mbds0001,v12,2013-11-27 09:02:51
mbbd000010177,mbcd0003782,mbtp000009,mbrf0000108,39,=,83.0,%,substrate,39,83.0,%,,20,,F,Activation of human PEPT1 expressed in MDCK cells relative to Gly-Sar,MDCK,,,,,human,mbds0001,v12,2013-11-27 09:02:51
mbbd000010179,mbcd0003545,mbtp000009,mbrf0000108,39,=,90.0,%,substrate,39,90.0,%,,8,,F,Activation of human PEPT1 expressed in MDCK cells relative to Gly-Sar,MDCK,,,,,human,mbds0001,v12,2013-11-27 09:02:51
mbbd000010180,mbcd0003600,mbtp000009,mbrf0000108,39,=,92.0,%,substrate,39,92.0,%,,67,,F,Activation of human PEPT1 expressed in MDCK cells relative to Gly-Sar,MDCK,,,,,human,mbds0001,v12,2013-11-27 09:02:51
mbbd000010181,mbcd0003614,mbtp000009,mbrf0000108,39,=,97.0,%,substrate,39,97.0,%,,17,,F,Activation of human PEPT1 expressed in MDCK cells relative to Gly-Sar,MDCK,,,,,human,mbds0001,v12,2013-11-27 09:02:51
mbbd000010182,mbcd0003797,mbtp000009,mbrf0000108,39,=,98.0,%,substrate,39,98.0,%,,66,,F,Activation of human PEPT1 expressed in MDCK cells relative to Gly-Sar,MDCK,,,,,human,mbds0001,v12,2013-11-27 09:02:51
mbbd000010183,mbcd0003703,mbtp000009,mbrf0000108,39,=,99.0,%,substrate,39,99.0,%,,72,,F,Activation of human PEPT1 expressed in MDCK cells relative to Gly-Sar,MDCK,,,,,human,mbds0001,v12,2013-11-27 09:02:51
mbbd000010184,mbcd0003784,mbtp000009,mbrf0000108,39,=,99.0,%,substrate,39,99.0,%,,81,,F,Activation of human PEPT1 expressed in MDCK cells relative to Gly-Sar,MDCK,,,,,human,mbds0001,v12,2013-11-27 09:02:51
mbbd000010185,mbcd0003510,mbtp000009,mbrf0000108,39,=,99.0,%,substrate,39,99.0,%,11,12,,F,Activation of human PEPT1 expressed in MDCK cells relative to Gly-Sar,MDCK,,,,,human,mbds0001,v12,2013-11-27 21:28:53
mbbd000010186,mbcd0003568,mbtp000009,mbrf0000108,120,=,100.0,%,substrate,120,100.0,%,,24,,F,Ratio of %GSmax to EC50 (which corresponds to Vmax/Km) for human PEPT1 activation; oligopeptides were tested for their ability to induce changes of membrane potential in PEPT1 vs mock transfected MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 21:35:45
mbbd000010187,mbcd0003580,mbtp000009,mbrf0000108,120,=,100.0,%,substrate,120,100.0,%,,22,,F,Ratio of %GSmax to EC50 (which corresponds to Vmax/Km) for human PEPT1 activation; oligopeptides were tested for their ability to induce changes of membrane potential in PEPT1 vs mock transfected MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 21:35:45
mbbd000010188,mbcd0003510,mbtp000009,mbrf0000108,120,=,100.0,%,substrate,120,100.0,%,,12,,F,Ratio of %GSmax to EC50 (which corresponds to Vmax/Km) for human PEPT1 activation; oligopeptides were tested for their ability to induce changes of membrane potential in PEPT1 vs mock transfected MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 21:28:52
mbbd000010189,mbcd0003652,mbtp000009,mbrf0000108,120,=,100.0,%,substrate,120,100.0,%,,33,,F,Ratio of %GSmax to EC50 (which corresponds to Vmax/Km) for human PEPT1 activation; oligopeptides were tested for their ability to induce changes of membrane potential in PEPT1 vs mock transfected MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 21:35:45
mbbd000010190,mbcd0003494,mbtp000009,mbrf0000108,39,=,101.0,%,substrate,39,101.0,%,,37,,F,Activation of human PEPT1 expressed in MDCK cells relative to Gly-Sar,MDCK,,,,,human,mbds0001,v12,2013-11-27 09:02:51
mbbd000010191,mbcd0003653,mbtp000009,mbrf0000108,39,=,102.0,%,substrate,39,102.0,%,,71,,F,Activation of human PEPT1 expressed in MDCK cells relative to Gly-Sar,MDCK,,,,,human,mbds0001,v12,2013-11-27 09:02:51
mbbd000010192,mbcd0003630,mbtp000009,mbrf0000108,39,=,103.0,%,substrate,39,103.0,%,,30,,F,Activation of human PEPT1 expressed in MDCK cells relative to Gly-Sar,MDCK,,,,,human,mbds0001,v12,2013-11-27 09:02:51
mbbd000010193,mbcd0003594,mbtp000009,mbrf0000108,39,=,104.0,%,non-substrate,39,104.0,%,30,58,,F,Activation of human PEPT1 expressed in MDCK cells relative to Gly-Sar,MDCK,,,,,human,mbds0001,v12,2013-11-24 23:10:28
mbbd000010194,mbcd0003765,mbtp000009,mbrf0000108,39,=,105.0,%,substrate,39,105.0,%,,56,,F,Activation of human PEPT1 expressed in MDCK cells relative to Gly-Sar,MDCK,,,,,human,mbds0001,v12,2013-11-27 09:02:51
mbbd000010195,mbcd0003737,mbtp000009,mbrf0000108,39,=,107.0,%,substrate,39,107.0,%,,13,,F,Activation of human PEPT1 expressed in MDCK cells relative to Gly-Sar,MDCK,,,,,human,mbds0001,v12,2013-11-27 09:02:51
mbbd000010196,mbcd0003569,mbtp000009,mbrf0000108,39,=,108.0,%,substrate,39,108.0,%,,53,,F,Activation of human PEPT1 expressed in MDCK cells relative to Gly-Sar,MDCK,,,,,human,mbds0001,v12,2013-11-27 09:02:51
mbbd000010197,mbcd0003637,mbtp000009,mbrf0000108,39,=,108.0,%,substrate,39,108.0,%,,44,,F,Activation of human PEPT1 expressed in MDCK cells relative to Gly-Sar,MDCK,,,,,human,mbds0001,v12,2013-11-27 09:02:51
mbbd000010198,mbcd0003794,mbtp000009,mbrf0000108,39,=,108.0,%,substrate,39,108.0,%,,65,,F,Activation of human PEPT1 expressed in MDCK cells relative to Gly-Sar,MDCK,,,,,human,mbds0001,v12,2013-11-27 09:02:51
mbbd000010199,mbcd0003697,mbtp000009,mbrf0000108,39,=,109.0,%,substrate,39,109.0,%,,26,,F,Activation of human PEPT1 expressed in MDCK cells relative to Gly-Sar,MDCK,,,,,human,mbds0001,v12,2013-11-27 09:02:51
mbbd000010200,mbcd0003547,mbtp000009,mbrf0000108,120,=,110.0,%,substrate,120,110.0,%,,18,,F,Ratio of %GSmax to EC50 (which corresponds to Vmax/Km) for human PEPT1 activation; oligopeptides were tested for their ability to induce changes of membrane potential in PEPT1 vs mock transfected MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 21:35:45
mbbd000010201,mbcd0003798,mbtp000009,mbrf0000108,120,=,110.0,%,substrate,120,110.0,%,,15,,F,Ratio of %GSmax to EC50 (which corresponds to Vmax/Km) for human PEPT1 activation; oligopeptides were tested for their ability to induce changes of membrane potential in PEPT1 vs mock transfected MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 21:35:45
mbbd000010202,mbcd0003547,mbtp000009,mbrf0000108,39,=,111.0,%,substrate,39,111.0,%,,18,,F,Activation of human PEPT1 expressed in MDCK cells relative to Gly-Sar,MDCK,,,,,human,mbds0001,v12,2013-11-27 09:02:51
mbbd000010203,mbcd0003628,mbtp000009,mbrf0000108,39,=,111.0,%,substrate,39,111.0,%,,34,,F,Activation of human PEPT1 expressed in MDCK cells relative to Gly-Sar,MDCK,,,,,human,mbds0001,v12,2013-11-27 09:02:51
mbbd000010204,mbcd0003642,mbtp000009,mbrf0000108,39,=,111.0,%,substrate,39,111.0,%,,36,,F,Activation of human PEPT1 expressed in MDCK cells relative to Gly-Sar,MDCK,,,,,human,mbds0001,v12,2013-11-27 09:02:51
mbbd000010205,mbcd0003634,mbtp000009,mbrf0000108,39,=,112.0,%,substrate,39,112.0,%,,25,,F,Activation of human PEPT1 expressed in MDCK cells relative to Gly-Sar,MDCK,,,,,human,mbds0001,v12,2013-11-27 09:02:51
mbbd000010206,mbcd0003568,mbtp000009,mbrf0000108,39,=,113.0,%,substrate,39,113.0,%,,24,,F,Activation of human PEPT1 expressed in MDCK cells relative to Gly-Sar,MDCK,,,,,human,mbds0001,v12,2013-11-27 09:02:51
mbbd000010207,mbcd0003504,mbtp000009,mbrf0000108,39,=,113.0,%,substrate,39,113.0,%,,31,,F,Activation of human PEPT1 expressed in MDCK cells relative to Gly-Sar,MDCK,,,,,human,mbds0001,v12,2013-11-27 09:02:51
mbbd000010208,mbcd0003492,mbtp000009,mbrf0000108,39,=,116.0,%,substrate,39,116.0,%,,63,,F,Activation of human PEPT1 expressed in MDCK cells relative to Gly-Sar,MDCK,,,,,human,mbds0001,v12,2013-11-27 09:02:51
mbbd000010209,mbcd0003598,mbtp000009,mbrf0000108,39,=,117.0,%,substrate,39,117.0,%,,5,,F,Activation of human PEPT1 expressed in MDCK cells relative to Gly-Sar,MDCK,,,,,human,mbds0001,v12,2013-11-27 09:02:51
mbbd000010210,mbcd0003810,mbtp000009,mbrf0000108,39,=,120.0,%,substrate,39,120.0,%,,55,,F,Activation of human PEPT1 expressed in MDCK cells relative to Gly-Sar,MDCK,,,,,human,mbds0001,v12,2013-11-27 09:02:51
mbbd000010211,mbcd0003696,mbtp000009,mbrf0000108,39,=,121.0,%,substrate,39,121.0,%,,46,,F,Activation of human PEPT1 expressed in MDCK cells relative to Gly-Sar,MDCK,,,,,human,mbds0001,v12,2013-11-27 09:02:51
mbbd000010212,mbcd0003654,mbtp000009,mbrf0000108,39,=,122.0,%,substrate,39,122.0,%,,19,,F,Activation of human PEPT1 expressed in MDCK cells relative to Gly-Sar,MDCK,,,,,human,mbds0001,v12,2013-11-27 09:02:51
mbbd000010213,mbcd0003665,mbtp000009,mbrf0000108,39,=,124.0,%,substrate,39,124.0,%,,23,,F,Activation of human PEPT1 expressed in MDCK cells relative to Gly-Sar,MDCK,,,,,human,mbds0001,v12,2013-11-27 09:02:51
mbbd000010214,mbcd0003764,mbtp000009,mbrf0000108,39,=,124.0,%,substrate,39,124.0,%,,4,,F,Activation of human PEPT1 expressed in MDCK cells relative to Gly-Sar,MDCK,,,,,human,mbds0001,v12,2013-11-27 09:02:51
mbbd000010215,mbcd0003635,mbtp000009,mbrf0000108,39,=,125.0,%,substrate,39,125.0,%,,39,,F,Activation of human PEPT1 expressed in MDCK cells relative to Gly-Sar,MDCK,,,,,human,mbds0001,v12,2013-11-27 09:02:51
mbbd000010216,mbcd0003601,mbtp000009,mbrf0000108,39,=,125.0,%,substrate,39,125.0,%,,3,,F,Activation of human PEPT1 expressed in MDCK cells relative to Gly-Sar,MDCK,,,,,human,mbds0001,v12,2013-11-27 09:02:51
mbbd000010217,mbcd0003673,mbtp000009,mbrf0000108,39,=,128.0,%,substrate,39,128.0,%,,41,,F,Activation of human PEPT1 expressed in MDCK cells relative to Gly-Sar,MDCK,,,,,human,mbds0001,v12,2013-11-27 09:02:51
mbbd000010218,mbcd0003731,mbtp000009,mbrf0000108,39,=,128.0,%,substrate,39,128.0,%,,29,,F,Activation of human PEPT1 expressed in MDCK cells relative to Gly-Sar,MDCK,,,,,human,mbds0001,v12,2013-11-27 09:02:51
mbbd000010219,mbcd0003791,mbtp000009,mbrf0000108,39,=,130.0,%,substrate,39,130.0,%,,47,,F,Activation of human PEPT1 expressed in MDCK cells relative to Gly-Sar,MDCK,,,,,human,mbds0001,v12,2013-11-27 09:02:51
mbbd000010220,mbcd0003694,mbtp000009,mbrf0000108,39,=,132.0,%,substrate,39,132.0,%,,42,,F,Activation of human PEPT1 expressed in MDCK cells relative to Gly-Sar,MDCK,,,,,human,mbds0001,v12,2013-11-27 09:02:51
mbbd000010221,mbcd0003519,mbtp000009,mbrf0000108,39,=,132.0,%,substrate,39,132.0,%,,51,,F,Activation of human PEPT1 expressed in MDCK cells relative to Gly-Sar,MDCK,,,,,human,mbds0001,v12,2013-11-27 09:02:51
mbbd000010222,mbcd0003636,mbtp000009,mbrf0000108,39,=,135.0,%,substrate,39,135.0,%,,6,,F,Activation of human PEPT1 expressed in MDCK cells relative to Gly-Sar,MDCK,,,,,human,mbds0001,v12,2013-11-27 09:02:51
mbbd000010223,mbcd0003746,mbtp000009,mbrf0000108,39,=,136.0,%,substrate,39,136.0,%,32,10,,F,Activation of human PEPT1 expressed in MDCK cells relative to Gly-Sar,MDCK,,,,,human,mbds0001,v12,2013-11-27 21:28:51
mbbd000010224,mbcd0000551,mbtp000009,mbrf0000108,39,=,138.0,%,substrate,39,138.0,%,,49,,F,Activation of human PEPT1 expressed in MDCK cells relative to Gly-Sar,MDCK,,,,,human,mbds0001,v12,2013-11-27 09:02:51
mbbd000010225,mbcd0003672,mbtp000009,mbrf0000108,120,=,150.0,%,substrate,120,150.0,%,,43,,F,Ratio of %GSmax to EC50 (which corresponds to Vmax/Km) for human PEPT1 activation; oligopeptides were tested for their ability to induce changes of membrane potential in PEPT1 vs mock transfected MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 21:35:45
mbbd000010226,mbcd0003492,mbtp000009,mbrf0000108,120,=,170.0,%,substrate,120,170.0,%,,63,,F,Ratio of %GSmax to EC50 (which corresponds to Vmax/Km) for human PEPT1 activation; oligopeptides were tested for their ability to induce changes of membrane potential in PEPT1 vs mock transfected MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 21:35:45
mbbd000010229,mbcd0003494,mbtp000009,mbrf0000108,120,=,190.0,%,substrate,120,190.0,%,,37,,F,Ratio of %GSmax to EC50 (which corresponds to Vmax/Km) for human PEPT1 activation; oligopeptides were tested for their ability to induce changes of membrane potential in PEPT1 vs mock transfected MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 21:35:45
mbbd000010230,mbcd0003697,mbtp000009,mbrf0000108,120,=,190.0,%,substrate,120,190.0,%,,26,,F,Ratio of %GSmax to EC50 (which corresponds to Vmax/Km) for human PEPT1 activation; oligopeptides were tested for their ability to induce changes of membrane potential in PEPT1 vs mock transfected MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 21:35:45
mbbd000010233,mbcd0003614,mbtp000009,mbrf0000108,120,=,230.0,%,substrate,120,230.0,%,,17,,F,Ratio of %GSmax to EC50 (which corresponds to Vmax/Km) for human PEPT1 activation; oligopeptides were tested for their ability to induce changes of membrane potential in PEPT1 vs mock transfected MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 21:35:45
mbbd000010234,mbcd0003665,mbtp000009,mbrf0000108,120,=,230.0,%,substrate,120,230.0,%,,23,,F,Ratio of %GSmax to EC50 (which corresponds to Vmax/Km) for human PEPT1 activation; oligopeptides were tested for their ability to induce changes of membrane potential in PEPT1 vs mock transfected MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 21:35:45
mbbd000010235,mbcd0003696,mbtp000009,mbrf0000108,120,=,230.0,%,substrate,120,230.0,%,,46,,F,Ratio of %GSmax to EC50 (which corresponds to Vmax/Km) for human PEPT1 activation; oligopeptides were tested for their ability to induce changes of membrane potential in PEPT1 vs mock transfected MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 21:35:45
mbbd000010236,mbcd0003634,mbtp000009,mbrf0000108,120,=,230.0,%,substrate,120,230.0,%,,25,,F,Ratio of %GSmax to EC50 (which corresponds to Vmax/Km) for human PEPT1 activation; oligopeptides were tested for their ability to induce changes of membrane potential in PEPT1 vs mock transfected MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 21:35:45
mbbd000010237,mbcd0003654,mbtp000009,mbrf0000108,120,=,240.0,%,substrate,120,240.0,%,,19,,F,Ratio of %GSmax to EC50 (which corresponds to Vmax/Km) for human PEPT1 activation; oligopeptides were tested for their ability to induce changes of membrane potential in PEPT1 vs mock transfected MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 21:35:45
mbbd000010238,mbcd0003737,mbtp000009,mbrf0000108,120,=,240.0,%,substrate,120,240.0,%,,13,,F,Ratio of %GSmax to EC50 (which corresponds to Vmax/Km) for human PEPT1 activation; oligopeptides were tested for their ability to induce changes of membrane potential in PEPT1 vs mock transfected MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 21:35:45
mbbd000010239,mbcd0003782,mbtp000009,mbrf0000108,120,=,270.0,%,substrate,120,270.0,%,,20,,F,Ratio of %GSmax to EC50 (which corresponds to Vmax/Km) for human PEPT1 activation; oligopeptides were tested for their ability to induce changes of membrane potential in PEPT1 vs mock transfected MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 21:35:45
mbbd000010240,mbcd0003700,mbtp000009,mbrf0000108,120,=,290.0,%,substrate,120,290.0,%,,32,,F,Ratio of %GSmax to EC50 (which corresponds to Vmax/Km) for human PEPT1 activation; oligopeptides were tested for their ability to induce changes of membrane potential in PEPT1 vs mock transfected MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 21:35:45
mbbd000010241,mbcd0003788,mbtp000009,mbrf0000108,120,=,300.0,%,substrate,120,300.0,%,,61,,F,Ratio of %GSmax to EC50 (which corresponds to Vmax/Km) for human PEPT1 activation; oligopeptides were tested for their ability to induce changes of membrane potential in PEPT1 vs mock transfected MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 21:35:45
mbbd000010242,mbcd0003731,mbtp000009,mbrf0000108,120,=,320.0,%,substrate,120,320.0,%,,29,,F,Ratio of %GSmax to EC50 (which corresponds to Vmax/Km) for human PEPT1 activation; oligopeptides were tested for their ability to induce changes of membrane potential in PEPT1 vs mock transfected MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 21:35:45
mbbd000010243,mbcd0003694,mbtp000009,mbrf0000108,120,=,350.0,%,substrate,120,350.0,%,,42,,F,Ratio of %GSmax to EC50 (which corresponds to Vmax/Km) for human PEPT1 activation; oligopeptides were tested for their ability to induce changes of membrane potential in PEPT1 vs mock transfected MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 21:35:45
mbbd000010244,mbcd0003600,mbtp000009,mbrf0000108,120,=,350.0,%,substrate,120,350.0,%,,67,,F,Ratio of %GSmax to EC50 (which corresponds to Vmax/Km) for human PEPT1 activation; oligopeptides were tested for their ability to induce changes of membrane potential in PEPT1 vs mock transfected MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 21:35:45
mbbd000010247,mbcd0003791,mbtp000009,mbrf0000108,120,=,410.0,%,substrate,120,410.0,%,,47,,F,Ratio of %GSmax to EC50 (which corresponds to Vmax/Km) for human PEPT1 activation; oligopeptides were tested for their ability to induce changes of membrane potential in PEPT1 vs mock transfected MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 21:35:45
mbbd000010248,mbcd0003703,mbtp000009,mbrf0000108,120,=,420.0,%,substrate,120,420.0,%,,72,,F,Ratio of %GSmax to EC50 (which corresponds to Vmax/Km) for human PEPT1 activation; oligopeptides were tested for their ability to induce changes of membrane potential in PEPT1 vs mock transfected MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 21:35:45
mbbd000010249,mbcd0003673,mbtp000009,mbrf0000108,120,=,460.0,%,substrate,120,460.0,%,,41,,F,Ratio of %GSmax to EC50 (which corresponds to Vmax/Km) for human PEPT1 activation; oligopeptides were tested for their ability to induce changes of membrane potential in PEPT1 vs mock transfected MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 21:35:45
mbbd000010250,mbcd0003784,mbtp000009,mbrf0000108,120,=,480.0,%,substrate,120,480.0,%,,81,,F,Ratio of %GSmax to EC50 (which corresponds to Vmax/Km) for human PEPT1 activation; oligopeptides were tested for their ability to induce changes of membrane potential in PEPT1 vs mock transfected MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 21:35:45
mbbd000010251,mbcd0003746,mbtp000009,mbrf0000108,120,=,500.0,%,substrate,120,500.0,%,,10,,F,Ratio of %GSmax to EC50 (which corresponds to Vmax/Km) for human PEPT1 activation; oligopeptides were tested for their ability to induce changes of membrane potential in PEPT1 vs mock transfected MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 21:28:52
mbbd000010252,mbcd0003504,mbtp000009,mbrf0000108,120,=,530.0,%,substrate,120,530.0,%,,31,,F,Ratio of %GSmax to EC50 (which corresponds to Vmax/Km) for human PEPT1 activation; oligopeptides were tested for their ability to induce changes of membrane potential in PEPT1 vs mock transfected MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 21:35:45
mbbd000010253,mbcd0003764,mbtp000009,mbrf0000108,120,=,540.0,%,substrate,120,540.0,%,,4,,F,Ratio of %GSmax to EC50 (which corresponds to Vmax/Km) for human PEPT1 activation; oligopeptides were tested for their ability to induce changes of membrane potential in PEPT1 vs mock transfected MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 21:35:45
mbbd000010254,mbcd0003598,mbtp000009,mbrf0000108,120,=,540.0,%,substrate,120,540.0,%,,5,,F,Ratio of %GSmax to EC50 (which corresponds to Vmax/Km) for human PEPT1 activation; oligopeptides were tested for their ability to induce changes of membrane potential in PEPT1 vs mock transfected MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 21:35:45
mbbd000010255,mbcd0003630,mbtp000009,mbrf0000108,120,=,620.0,%,substrate,120,620.0,%,,30,,F,Ratio of %GSmax to EC50 (which corresponds to Vmax/Km) for human PEPT1 activation; oligopeptides were tested for their ability to induce changes of membrane potential in PEPT1 vs mock transfected MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 21:35:45
mbbd000010256,mbcd0000551,mbtp000009,mbrf0000108,120,=,720.0,%,substrate,120,720.0,%,,49,,F,Ratio of %GSmax to EC50 (which corresponds to Vmax/Km) for human PEPT1 activation; oligopeptides were tested for their ability to induce changes of membrane potential in PEPT1 vs mock transfected MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 21:35:45
mbbd000010257,mbcd0003794,mbtp000009,mbrf0000108,120,=,770.0,%,substrate,120,770.0,%,,65,,F,Ratio of %GSmax to EC50 (which corresponds to Vmax/Km) for human PEPT1 activation; oligopeptides were tested for their ability to induce changes of membrane potential in PEPT1 vs mock transfected MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 21:35:45
mbbd000010258,mbcd0003626,mbtp000009,mbrf0000108,120,=,790.0,%,substrate,120,790.0,%,,16,,F,Ratio of %GSmax to EC50 (which corresponds to Vmax/Km) for human PEPT1 activation; oligopeptides were tested for their ability to induce changes of membrane potential in PEPT1 vs mock transfected MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 21:35:45
mbbd000010259,mbcd0003738,mbtp000009,mbrf0000108,120,=,830.0,%,substrate,120,830.0,%,,7,,F,Ratio of %GSmax to EC50 (which corresponds to Vmax/Km) for human PEPT1 activation; oligopeptides were tested for their ability to induce changes of membrane potential in PEPT1 vs mock transfected MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 21:35:45
mbbd000010260,mbcd0003628,mbtp000009,mbrf0000108,120,=,830.0,%,substrate,120,830.0,%,,34,,F,Ratio of %GSmax to EC50 (which corresponds to Vmax/Km) for human PEPT1 activation; oligopeptides were tested for their ability to induce changes of membrane potential in PEPT1 vs mock transfected MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 21:35:45
mbbd000010261,mbcd0003635,mbtp000009,mbrf0000108,120,=,870.0,%,substrate,120,870.0,%,,39,,F,Ratio of %GSmax to EC50 (which corresponds to Vmax/Km) for human PEPT1 activation; oligopeptides were tested for their ability to induce changes of membrane potential in PEPT1 vs mock transfected MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 21:35:45
mbbd000010262,mbcd0003642,mbtp000009,mbrf0000108,120,=,870.0,%,substrate,120,870.0,%,,36,,F,Ratio of %GSmax to EC50 (which corresponds to Vmax/Km) for human PEPT1 activation; oligopeptides were tested for their ability to induce changes of membrane potential in PEPT1 vs mock transfected MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 21:35:45
mbbd000010263,mbcd0003606,mbtp000009,mbrf0000108,120,=,950.0,%,substrate,120,950.0,%,,79,,F,Ratio of %GSmax to EC50 (which corresponds to Vmax/Km) for human PEPT1 activation; oligopeptides were tested for their ability to induce changes of membrane potential in PEPT1 vs mock transfected MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 21:35:45
mbbd000010264,mbcd0003519,mbtp000009,mbrf0000108,120,=,960.0,%,substrate,120,960.0,%,,51,,F,Ratio of %GSmax to EC50 (which corresponds to Vmax/Km) for human PEPT1 activation; oligopeptides were tested for their ability to induce changes of membrane potential in PEPT1 vs mock transfected MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 21:35:45
mbbd000010265,mbcd0003797,mbtp000009,mbrf0000108,120,=,1000.0,%,substrate,120,1000.0,%,,66,,F,Ratio of %GSmax to EC50 (which corresponds to Vmax/Km) for human PEPT1 activation; oligopeptides were tested for their ability to induce changes of membrane potential in PEPT1 vs mock transfected MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 21:35:45
mbbd000010266,mbcd0003701,mbtp000009,mbrf0000108,120,=,1000.0,%,substrate,120,1000.0,%,,80,,F,Ratio of %GSmax to EC50 (which corresponds to Vmax/Km) for human PEPT1 activation; oligopeptides were tested for their ability to induce changes of membrane potential in PEPT1 vs mock transfected MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 21:35:45
mbbd000010267,mbcd0003569,mbtp000009,mbrf0000108,120,=,1000.0,%,substrate,120,1000.0,%,,53,,F,Ratio of %GSmax to EC50 (which corresponds to Vmax/Km) for human PEPT1 activation; oligopeptides were tested for their ability to induce changes of membrane potential in PEPT1 vs mock transfected MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 21:35:45
mbbd000010268,mbcd0003810,mbtp000009,mbrf0000108,120,=,1100.0,%,substrate,120,1100.0,%,,55,,F,Ratio of %GSmax to EC50 (which corresponds to Vmax/Km) for human PEPT1 activation; oligopeptides were tested for their ability to induce changes of membrane potential in PEPT1 vs mock transfected MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 21:35:45
mbbd000010269,mbcd0003711,mbtp000009,mbrf0000108,120,=,1100.0,%,substrate,120,1100.0,%,,70,,F,Ratio of %GSmax to EC50 (which corresponds to Vmax/Km) for human PEPT1 activation; oligopeptides were tested for their ability to induce changes of membrane potential in PEPT1 vs mock transfected MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 21:35:45
mbbd000010270,mbcd0003653,mbtp000009,mbrf0000108,120,=,1110.0,%,substrate,120,1110.0,%,,71,,F,Ratio of %GSmax to EC50 (which corresponds to Vmax/Km) for human PEPT1 activation; oligopeptides were tested for their ability to induce changes of membrane potential in PEPT1 vs mock transfected MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 21:35:45
mbbd000010271,mbcd0003693,mbtp000009,mbrf0000108,120,=,1200.0,%,substrate,120,1200.0,%,,76,,F,Ratio of %GSmax to EC50 (which corresponds to Vmax/Km) for human PEPT1 activation; oligopeptides were tested for their ability to induce changes of membrane potential in PEPT1 vs mock transfected MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 21:35:45
mbbd000010272,mbcd0003637,mbtp000009,mbrf0000108,120,=,1400.0,%,substrate,120,1400.0,%,,44,,F,Ratio of %GSmax to EC50 (which corresponds to Vmax/Km) for human PEPT1 activation; oligopeptides were tested for their ability to induce changes of membrane potential in PEPT1 vs mock transfected MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 21:35:45
mbbd000010273,mbcd0003545,mbtp000009,mbrf0000108,120,=,1600.0,%,substrate,120,1600.0,%,,8,,F,Ratio of %GSmax to EC50 (which corresponds to Vmax/Km) for human PEPT1 activation; oligopeptides were tested for their ability to induce changes of membrane potential in PEPT1 vs mock transfected MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 21:35:45
mbbd000010274,mbcd0003601,mbtp000009,mbrf0000108,120,=,1700.0,%,substrate,120,1700.0,%,,3,,F,Ratio of %GSmax to EC50 (which corresponds to Vmax/Km) for human PEPT1 activation; oligopeptides were tested for their ability to induce changes of membrane potential in PEPT1 vs mock transfected MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 21:35:45
mbbd000010275,mbcd0003636,mbtp000009,mbrf0000108,120,=,1700.0,%,substrate,120,1700.0,%,,6,,F,Ratio of %GSmax to EC50 (which corresponds to Vmax/Km) for human PEPT1 activation; oligopeptides were tested for their ability to induce changes of membrane potential in PEPT1 vs mock transfected MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 21:35:45
mbbd000010276,mbcd0029531,mbtp000009,mbrf0000108,120,=,2900.0,%,substrate,120,2900.0,%,,57,,F,Ratio of %GSmax to EC50 (which corresponds to Vmax/Km) for human PEPT1 activation; oligopeptides were tested for their ability to induce changes of membrane potential in PEPT1 vs mock transfected MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 21:35:45
mbbd000010277,mbcd0003765,mbtp000009,mbrf0000108,120,=,3100.0,%,substrate,120,3100.0,%,,56,,F,Ratio of %GSmax to EC50 (which corresponds to Vmax/Km) for human PEPT1 activation; oligopeptides were tested for their ability to induce changes of membrane potential in PEPT1 vs mock transfected MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 21:35:45
mbbd000010283,mbcd0029531,mbtp000009,mbrf0000108,25,=,20000.0,nM,inhibitor,25,0.02,mM,,57,,F,competitive uptake of 10 microM Gly-Sar; binding affinity to human PEPT1 assessed as inhibition of [14C]Gly-Sar uptake in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 22:48:43
mbbd000010289,mbcd0029531,mbtp000009,mbrf0000108,17,=,30000.0,nM,substrate,17,0.03,mM,0.01,57,,F,Activation of human PEPT1 expressed in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 22:06:36
mbbd000010290,mbcd0003765,mbtp000009,mbrf0000108,17,=,30000.0,nM,substrate,17,0.03,mM,0.02,56,,F,Activation of human PEPT1 expressed in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 22:06:36
mbbd000010292,mbcd0003606,mbtp000009,mbrf0000108,17,=,40000.0,nM,substrate,17,0.04,mM,0.01,79,,F,Activation of human PEPT1 expressed in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 22:06:39
mbbd000010295,mbcd0003711,mbtp000009,mbrf0000108,17,=,50000.0,nM,substrate,17,0.05,mM,0.02,70,,F,Activation of human PEPT1 expressed in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 22:06:38
mbbd000010297,mbcd0003693,mbtp000009,mbrf0000108,17,=,60000.0,nM,substrate,17,0.06,mM,0.01,76,,F,Activation of human PEPT1 expressed in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 22:06:38
mbbd000010300,mbcd0003693,mbtp000009,mbrf0000108,25,=,60000.0,nM,inhibitor,25,0.06,mM,,76,,F,competitive uptake of 10 microM Gly-Sar; binding affinity to human PEPT1 assessed as inhibition of [14C]Gly-Sar uptake in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 22:48:43
mbbd000010302,mbcd0003545,mbtp000009,mbrf0000108,17,=,60000.0,nM,substrate,17,0.06,mM,0.01,8,,F,Activation of human PEPT1 expressed in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 22:06:32
mbbd000010305,mbcd0003569,mbtp000009,mbrf0000108,25,=,70000.0,nM,inhibitor,25,0.07,mM,,53,,F,competitive uptake of 10 microM Gly-Sar; binding affinity to human PEPT1 assessed as inhibition of [14C]Gly-Sar uptake in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 22:48:43
mbbd000010306,mbcd0003630,mbtp000009,mbrf0000108,25,=,70000.0,nM,inhibitor,25,0.07,mM,,30,,F,competitive uptake of 10 microM Gly-Sar; binding affinity to human PEPT1 assessed as inhibition of [14C]Gly-Sar uptake in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 22:48:43
mbbd000010307,mbcd0003701,mbtp000009,mbrf0000108,17,=,70000.0,nM,substrate,17,0.07,mM,0.02,80,,F,Activation of human PEPT1 expressed in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 22:06:39
mbbd000010309,mbcd0003636,mbtp000009,mbrf0000108,25,=,70000.0,nM,inhibitor,25,0.07,mM,,6,,F,competitive uptake of 10 microM Gly-Sar; binding affinity to human PEPT1 assessed as inhibition of [14C]Gly-Sar uptake in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 22:48:43
mbbd000010310,mbcd0003738,mbtp000009,mbrf0000108,17,=,80000.0,nM,substrate,17,0.08,mM,,7,,F,Activation of human PEPT1 expressed in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 22:06:32
mbbd000010311,mbcd0003765,mbtp000009,mbrf0000108,25,=,80000.0,nM,inhibitor,25,0.08,mM,,56,,F,competitive uptake of 10 microM Gly-Sar; binding affinity to human PEPT1 assessed as inhibition of [14C]Gly-Sar uptake in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 22:48:43
mbbd000010312,mbcd0003636,mbtp000009,mbrf0000108,17,=,80000.0,nM,substrate,17,0.08,mM,0.02,6,,F,Activation of human PEPT1 expressed in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 22:06:31
mbbd000010313,mbcd0003735,mbtp000009,mbrf0000108,25,=,80000.0,nM,inhibitor,25,0.08,mM,,69,,F,competitive uptake of 10 microM Gly-Sar; binding affinity to human PEPT1 assessed as inhibition of [14C]Gly-Sar uptake in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 22:48:43
mbbd000010314,mbcd0003601,mbtp000009,mbrf0000108,17,=,80000.0,nM,substrate,17,0.08,mM,0.01,3,,F,Activation of human PEPT1 expressed in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 22:06:28
mbbd000010315,mbcd0003637,mbtp000009,mbrf0000108,17,=,80000.0,nM,substrate,17,0.08,mM,0.03,44,,F,Activation of human PEPT1 expressed in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 22:06:33
mbbd000010320,mbcd0003711,mbtp000009,mbrf0000108,25,=,90000.0,nM,inhibitor,25,0.09,mM,,70,,F,competitive uptake of 10 microM Gly-Sar; binding affinity to human PEPT1 assessed as inhibition of [14C]Gly-Sar uptake in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 22:48:43
mbbd000010331,mbcd0003578,mbtp000009,mbrf0000108,25,=,100000.0,nM,inhibitor,25,0.1,mM,,75,,F,competitive uptake of 10 microM Gly-Sar; binding affinity to human PEPT1 assessed as inhibition of [14C]Gly-Sar uptake in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 22:48:43
mbbd000010332,mbcd0003653,mbtp000009,mbrf0000108,17,=,100000.0,nM,substrate,17,0.1,mM,0.05,71,,F,Activation of human PEPT1 expressed in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 22:06:38
mbbd000010333,mbcd0003626,mbtp000009,mbrf0000108,17,=,100000.0,nM,substrate,17,0.1,mM,0.02,16,,F,Activation of human PEPT1 expressed in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 22:06:25
mbbd000010334,mbcd0003606,mbtp000009,mbrf0000108,25,=,100000.0,nM,inhibitor,25,0.1,mM,,79,,F,competitive uptake of 10 microM Gly-Sar; binding affinity to human PEPT1 assessed as inhibition of [14C]Gly-Sar uptake in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 22:48:43
mbbd000010338,mbcd0003797,mbtp000009,mbrf0000108,17,=,100000.0,nM,substrate,17,0.1,mM,0.02,66,,F,Activation of human PEPT1 expressed in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 22:06:37
mbbd000010340,mbcd0003569,mbtp000009,mbrf0000108,17,=,110000.0,nM,substrate,17,0.11,mM,0.05,53,,F,Activation of human PEPT1 expressed in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 22:06:35
mbbd000010347,mbcd0003810,mbtp000009,mbrf0000108,17,=,110000.0,nM,substrate,17,0.11,mM,0.00,55,,F,Activation of human PEPT1 expressed in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 22:06:35
mbbd000010348,mbcd0003653,mbtp000009,mbrf0000108,25,=,110000.0,nM,inhibitor,25,0.11,mM,,71,,F,competitive uptake of 10 microM Gly-Sar; binding affinity to human PEPT1 assessed as inhibition of [14C]Gly-Sar uptake in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 22:48:43
mbbd000010350,mbcd0003635,mbtp000009,mbrf0000108,25,=,120000.0,nM,inhibitor,25,0.12,mM,,39,,F,competitive uptake of 10 microM Gly-Sar; binding affinity to human PEPT1 assessed as inhibition of [14C]Gly-Sar uptake in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 22:48:43
mbbd000010357,mbcd0003794,mbtp000009,mbrf0000108,25,=,130000.0,nM,inhibitor,25,0.13,mM,,65,,F,competitive uptake of 10 microM Gly-Sar; binding affinity to human PEPT1 assessed as inhibition of [14C]Gly-Sar uptake in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 22:48:43
mbbd000010358,mbcd0003642,mbtp000009,mbrf0000108,17,=,130000.0,nM,substrate,17,0.13,mM,0.03,36,,F,Activation of human PEPT1 expressed in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 22:06:30
mbbd000010359,mbcd0003628,mbtp000009,mbrf0000108,17,=,130000.0,nM,substrate,17,0.13,mM,0.01,34,,F,Activation of human PEPT1 expressed in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 22:06:29
mbbd000010369,mbcd0003519,mbtp000009,mbrf0000108,17,=,140000.0,nM,substrate,17,0.14,mM,0.06,51,,F,Activation of human PEPT1 expressed in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 22:06:34
mbbd000010370,mbcd0003794,mbtp000009,mbrf0000108,17,=,140000.0,nM,substrate,17,0.14,mM,0.02,65,,F,Activation of human PEPT1 expressed in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 22:06:37
mbbd000010374,mbcd0003635,mbtp000009,mbrf0000108,17,=,140000.0,nM,substrate,17,0.14,mM,0.01,39,,F,Activation of human PEPT1 expressed in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 22:06:30
mbbd000010382,mbcd0003626,mbtp000009,mbrf0000108,25,=,150000.0,nM,inhibitor,25,0.15,mM,,16,,F,competitive uptake of 10 microM Gly-Sar; binding affinity to human PEPT1 assessed as inhibition of [14C]Gly-Sar uptake in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 22:48:43
mbbd000010390,mbcd0003637,mbtp000009,mbrf0000108,25,=,170000.0,nM,inhibitor,25,0.17,mM,,44,,F,competitive uptake of 10 microM Gly-Sar; binding affinity to human PEPT1 assessed as inhibition of [14C]Gly-Sar uptake in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 22:48:43
mbbd000010393,mbcd0003810,mbtp000009,mbrf0000108,25,=,170000.0,nM,inhibitor,25,0.17,mM,,55,,F,competitive uptake of 10 microM Gly-Sar; binding affinity to human PEPT1 assessed as inhibition of [14C]Gly-Sar uptake in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 22:48:43
mbbd000010394,mbcd0003630,mbtp000009,mbrf0000108,17,=,170000.0,nM,substrate,17,0.17,mM,0.11,30,,F,Activation of human PEPT1 expressed in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 22:06:28
mbbd000010395,mbcd0003545,mbtp000009,mbrf0000108,25,=,170000.0,nM,inhibitor,25,0.17,mM,,8,,F,competitive uptake of 10 microM Gly-Sar; binding affinity to human PEPT1 assessed as inhibition of [14C]Gly-Sar uptake in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 22:48:43
mbbd000010396,mbcd0003628,mbtp000009,mbrf0000108,25,=,170000.0,nM,inhibitor,25,0.17,mM,,34,,F,competitive uptake of 10 microM Gly-Sar; binding affinity to human PEPT1 assessed as inhibition of [14C]Gly-Sar uptake in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 22:48:43
mbbd000010399,mbcd0000551,mbtp000009,mbrf0000108,17,=,190000.0,nM,substrate,17,0.19,mM,0.03,49,,F,Activation of human PEPT1 expressed in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 22:06:34
mbbd000010400,mbcd0003672,mbtp000009,mbrf0000108,17,=,190000.0,nM,substrate,17,0.19,mM,,43,,F,Activation of human PEPT1 expressed in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 22:06:33
mbbd000010406,mbcd0003504,mbtp000009,mbrf0000108,17,=,210000.0,nM,substrate,17,0.21,mM,0.05,31,,F,Activation of human PEPT1 expressed in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 22:06:28
mbbd000010408,mbcd0003784,mbtp000009,mbrf0000108,17,=,210000.0,nM,substrate,17,0.21,mM,0.04,81,,F,Activation of human PEPT1 expressed in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 22:06:39
mbbd000010409,mbcd0003701,mbtp000009,mbrf0000108,25,=,210000.0,nM,inhibitor,25,0.21,mM,,80,,F,competitive uptake of 10 microM Gly-Sar; binding affinity to human PEPT1 assessed as inhibition of [14C]Gly-Sar uptake in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 22:48:43
mbbd000010411,mbcd0003598,mbtp000009,mbrf0000108,17,=,220000.0,nM,substrate,17,0.22,mM,0.04,5,,F,Activation of human PEPT1 expressed in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 22:06:31
mbbd000010412,mbcd0003764,mbtp000009,mbrf0000108,17,=,230000.0,nM,substrate,17,0.23,mM,0.04,4,,F,Activation of human PEPT1 expressed in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 22:06:31
mbbd000010413,mbcd0003793,mbtp000009,mbrf0000108,25,=,230000.0,nM,inhibitor,25,0.23,mM,,1,,F,competitive uptake of 10 microM Gly-Sar; binding affinity to human PEPT1 assessed as inhibition of [14C]Gly-Sar uptake in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 22:48:43
mbbd000010414,mbcd0003784,mbtp000009,mbrf0000108,25,=,230000.0,nM,inhibitor,25,0.23,mM,,81,,F,competitive uptake of 10 microM Gly-Sar; binding affinity to human PEPT1 assessed as inhibition of [14C]Gly-Sar uptake in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 22:48:43
mbbd000010415,mbcd0003703,mbtp000009,mbrf0000108,17,=,240000.0,nM,substrate,17,0.24,mM,0.06,72,,F,Activation of human PEPT1 expressed in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 22:06:38
mbbd000010417,mbcd0003504,mbtp000009,mbrf0000108,25,=,240000.0,nM,inhibitor,25,0.24,mM,,31,,F,competitive uptake of 10 microM Gly-Sar; binding affinity to human PEPT1 assessed as inhibition of [14C]Gly-Sar uptake in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 22:48:43
mbbd000010422,mbcd0003601,mbtp000009,mbrf0000108,25,=,250000.0,nM,inhibitor,25,0.25,mM,,3,,F,competitive uptake of 10 microM Gly-Sar; binding affinity to human PEPT1 assessed as inhibition of [14C]Gly-Sar uptake in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 22:48:43
mbbd000010423,mbcd0003519,mbtp000009,mbrf0000108,25,=,250000.0,nM,inhibitor,25,0.25,mM,,51,,F,competitive uptake of 10 microM Gly-Sar; binding affinity to human PEPT1 assessed as inhibition of [14C]Gly-Sar uptake in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 22:48:43
mbbd000010424,mbcd0003500,mbtp000009,mbrf0000108,25,=,250000.0,nM,inhibitor,25,0.25,mM,,68,,F,competitive uptake of 10 microM Gly-Sar; binding affinity to human PEPT1 assessed as inhibition of [14C]Gly-Sar uptake in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 22:48:43
mbbd000010425,mbcd0003788,mbtp000009,mbrf0000108,17,=,250000.0,nM,substrate,17,0.25,mM,0.06,61,,F,Activation of human PEPT1 expressed in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 22:06:36
mbbd000010426,mbcd0003797,mbtp000009,mbrf0000108,25,=,260000.0,nM,inhibitor,25,0.26,mM,,66,,F,competitive uptake of 10 microM Gly-Sar; binding affinity to human PEPT1 assessed as inhibition of [14C]Gly-Sar uptake in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 22:48:43
mbbd000010427,mbcd0003738,mbtp000009,mbrf0000108,25,=,260000.0,nM,inhibitor,25,0.26,mM,,7,,F,competitive uptake of 10 microM Gly-Sar; binding affinity to human PEPT1 assessed as inhibition of [14C]Gly-Sar uptake in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 22:48:43
mbbd000010429,mbcd0003600,mbtp000009,mbrf0000108,17,=,260000.0,nM,substrate,17,0.26,mM,0.05,67,,F,Activation of human PEPT1 expressed in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 22:06:37
mbbd000010431,mbcd0003746,mbtp000009,mbrf0000108,17,=,270000.0,nM,substrate,17,0.27,mM,0.06,10,,F,Activation of human PEPT1 expressed in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-24 23:10:59
mbbd000010432,mbcd0003598,mbtp000009,mbrf0000108,25,=,280000.0,nM,inhibitor,25,0.28,mM,,5,,F,competitive uptake of 10 microM Gly-Sar; binding affinity to human PEPT1 assessed as inhibition of [14C]Gly-Sar uptake in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 22:48:43
mbbd000010434,mbcd0003700,mbtp000009,mbrf0000108,17,=,280000.0,nM,substrate,17,0.28,mM,0.07,32,,F,Activation of human PEPT1 expressed in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 22:06:29
mbbd000010435,mbcd0003673,mbtp000009,mbrf0000108,17,=,280000.0,nM,substrate,17,0.28,mM,0.03,41,,F,Activation of human PEPT1 expressed in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 22:06:32
mbbd000010443,mbcd0003782,mbtp000009,mbrf0000108,17,=,310000.0,nM,substrate,17,0.31,mM,0.15,20,,F,Activation of human PEPT1 expressed in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 22:06:26
mbbd000010444,mbcd0003798,mbtp000009,mbrf0000108,25,=,310000.0,nM,inhibitor,25,0.31,mM,,15,,F,competitive uptake of 10 microM Gly-Sar; binding affinity to human PEPT1 assessed as inhibition of [14C]Gly-Sar uptake in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 22:48:43
mbbd000010448,mbcd0003791,mbtp000009,mbrf0000108,17,=,320000.0,nM,substrate,17,0.32,mM,0.06,47,,F,Activation of human PEPT1 expressed in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 22:06:34
mbbd000010449,mbcd0003632,mbtp000009,mbrf0000108,17,=,330000.0,nM,substrate,17,0.33,mM,0.08,38,,F,Activation of human PEPT1 expressed in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 22:06:30
mbbd000010454,mbcd0003642,mbtp000009,mbrf0000108,25,=,330000.0,nM,inhibitor,25,0.33,mM,,36,,F,competitive uptake of 10 microM Gly-Sar; binding affinity to human PEPT1 assessed as inhibition of [14C]Gly-Sar uptake in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 22:48:43
mbbd000010455,mbcd0003703,mbtp000009,mbrf0000108,25,=,330000.0,nM,inhibitor,25,0.33,mM,,72,,F,competitive uptake of 10 microM Gly-Sar; binding affinity to human PEPT1 assessed as inhibition of [14C]Gly-Sar uptake in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 22:48:43
mbbd000010458,mbcd0003673,mbtp000009,mbrf0000108,25,=,340000.0,nM,inhibitor,25,0.34,mM,,41,,F,competitive uptake of 10 microM Gly-Sar; binding affinity to human PEPT1 assessed as inhibition of [14C]Gly-Sar uptake in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 22:48:43
mbbd000010463,mbcd0003694,mbtp000009,mbrf0000108,17,=,370000.0,nM,substrate,17,0.37,mM,0.04,42,,F,Activation of human PEPT1 expressed in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 22:06:33
mbbd000010465,mbcd0003791,mbtp000009,mbrf0000108,25,=,380000.0,nM,inhibitor,25,0.38,mM,,47,,F,competitive uptake of 10 microM Gly-Sar; binding affinity to human PEPT1 assessed as inhibition of [14C]Gly-Sar uptake in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 22:48:43
mbbd000010466,mbcd0003665,mbtp000009,mbrf0000108,25,=,380000.0,nM,inhibitor,25,0.38,mM,,23,,F,competitive uptake of 10 microM Gly-Sar; binding affinity to human PEPT1 assessed as inhibition of [14C]Gly-Sar uptake in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 22:48:43
mbbd000010467,mbcd0000551,mbtp000009,mbrf0000108,25,=,390000.0,nM,inhibitor,25,0.39,mM,,49,,F,competitive uptake of 10 microM Gly-Sar; binding affinity to human PEPT1 assessed as inhibition of [14C]Gly-Sar uptake in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 22:48:43
mbbd000010468,mbcd0003751,mbtp000009,mbrf0000114,25,=,390000.0,nM,inhibitor,25,0.39,mM,0.04,Val-OBz,,B,Inhibition of human PEPT1-mediated [3H]Gly-Sar uptake in human HeLa cells,,,,,,human,mbds0001,v12,2013-07-15 17:35:55
mbbd000010470,mbcd0003746,mbtp000009,mbrf0000108,25,=,390000.0,nM,inhibitor,25,0.39,mM,,10,,F,competitive uptake of 10 microM Gly-Sar; binding affinity to human PEPT1 assessed as inhibition of [14C]Gly-Sar uptake in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 22:48:43
mbbd000010471,mbcd0003654,mbtp000009,mbrf0000108,25,=,390000.0,nM,inhibitor,25,0.39,mM,,19,,F,competitive uptake of 10 microM Gly-Sar; binding affinity to human PEPT1 assessed as inhibition of [14C]Gly-Sar uptake in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 22:48:43
mbbd000010473,mbcd0003694,mbtp000009,mbrf0000108,25,=,400000.0,nM,inhibitor,25,0.4,mM,,42,,F,competitive uptake of 10 microM Gly-Sar; binding affinity to human PEPT1 assessed as inhibition of [14C]Gly-Sar uptake in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 22:48:43
mbbd000010474,mbcd0003731,mbtp000009,mbrf0000108,17,=,400000.0,nM,substrate,17,0.4,mM,0.06,29,,F,Activation of human PEPT1 expressed in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 22:06:28
mbbd000010479,mbcd0003614,mbtp000009,mbrf0000108,17,=,420000.0,nM,substrate,17,0.42,mM,0.08,17,,F,Activation of human PEPT1 expressed in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 22:06:26
mbbd000010483,mbcd0003737,mbtp000009,mbrf0000108,17,=,440000.0,nM,substrate,17,0.44,mM,,13,,F,Activation of human PEPT1 expressed in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 22:06:24
mbbd000010485,mbcd0003764,mbtp000009,mbrf0000108,25,=,450000.0,nM,inhibitor,25,0.45,mM,,4,,F,competitive uptake of 10 microM Gly-Sar; binding affinity to human PEPT1 assessed as inhibition of [14C]Gly-Sar uptake in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 22:48:43
mbbd000010487,mbcd0003536,mbtp000009,mbrf0000108,17,=,470000.0,nM,substrate,17,0.47,mM,0.36,14,,F,Activation of human PEPT1 expressed in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 22:06:24
mbbd000010491,mbcd0003634,mbtp000009,mbrf0000108,17,=,480000.0,nM,substrate,17,0.48,mM,0.18,25,,F,Activation of human PEPT1 expressed in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 22:06:27
mbbd000010494,mbcd0003654,mbtp000009,mbrf0000108,17,=,510000.0,nM,substrate,17,0.51,mM,0.05,19,,F,Activation of human PEPT1 expressed in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 22:06:26
mbbd000010495,mbcd0003614,mbtp000009,mbrf0000108,25,=,510000.0,nM,inhibitor,25,0.51,mM,,17,,F,competitive uptake of 10 microM Gly-Sar; binding affinity to human PEPT1 assessed as inhibition of [14C]Gly-Sar uptake in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 22:48:43
mbbd000010496,mbcd0003632,mbtp000009,mbrf0000108,25,=,520000.0,nM,inhibitor,25,0.52,mM,,38,,F,competitive uptake of 10 microM Gly-Sar; binding affinity to human PEPT1 assessed as inhibition of [14C]Gly-Sar uptake in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 22:48:43
mbbd000010497,mbcd0003580,mbtp000009,mbrf0000108,17,=,520000.0,nM,substrate,17,0.52,mM,0.05,22,,F,Activation of human PEPT1 expressed in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 22:06:27
mbbd000010499,mbcd0003696,mbtp000009,mbrf0000108,17,=,530000.0,nM,substrate,17,0.53,mM,0.05,46,,F,Activation of human PEPT1 expressed in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 22:06:33
mbbd000010501,mbcd0003494,mbtp000009,mbrf0000108,17,=,540000.0,nM,substrate,17,0.54,mM,0.20,37,,F,Activation of human PEPT1 expressed in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 22:06:30
mbbd000010502,mbcd0003665,mbtp000009,mbrf0000108,17,=,550000.0,nM,substrate,17,0.55,mM,0.28,23,,F,Activation of human PEPT1 expressed in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 22:06:27
mbbd000010503,mbcd0003697,mbtp000009,mbrf0000108,17,=,580000.0,nM,substrate,17,0.58,mM,0.06,26,,F,Activation of human PEPT1 expressed in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 22:06:27
mbbd000010505,mbcd0003547,mbtp000009,mbrf0000108,25,=,620000.0,nM,inhibitor,25,0.62,mM,,18,,F,competitive uptake of 10 microM Gly-Sar; binding affinity to human PEPT1 assessed as inhibition of [14C]Gly-Sar uptake in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 22:48:43
mbbd000010506,mbcd0003788,mbtp000009,mbrf0000108,25,=,620000.0,nM,inhibitor,25,0.62,mM,,61,,F,competitive uptake of 10 microM Gly-Sar; binding affinity to human PEPT1 assessed as inhibition of [14C]Gly-Sar uptake in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 22:48:43
mbbd000010507,mbcd0003510,mbtp000009,mbrf0000108,25,=,630000.0,nM,inhibitor,25,0.63,mM,,12,,F,competitive uptake of 10 microM Gly-Sar; binding affinity to human PEPT1 assessed as inhibition of [14C]Gly-Sar uptake in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 22:48:43
mbbd000010508,mbcd0003646,mbtp000009,mbrf0000114,25,=,630000.0,nM,inhibitor,25,0.63,mM,0.04,5b; Ile-3-HPG,,B,Inhibition of human PEPT1-mediated [3H]Gly-Sar uptake in human HeLa cells,,,,,,human,mbds0001,v12,2013-11-20 19:06:30
mbbd000010509,mbcd0003715,mbtp000009,mbrf0000114,25,=,1050000.0,nM,non-inhibitor,25,1.05,mM,0.13,Ile-OBz,,B,Inhibition of human PEPT1-mediated [3H]Gly-Sar uptake in human HeLa cells,,,,,,human,mbds0001,v12,2013-11-27 22:51:51
mbbd000010510,mbcd0003647,mbtp000009,mbrf0000114,25,=,650000.0,nM,inhibitor,25,0.65,mM,0.04,5a; L-Val-3-HPG,,B,Inhibition of human PEPT1-mediated [3H]Gly-Sar uptake in human HeLa cells,,,,,,human,mbds0001,v12,2013-11-20 19:06:30
mbbd000010511,mbcd0003568,mbtp000009,mbrf0000108,25,=,650000.0,nM,inhibitor,25,0.65,mM,,24,,F,competitive uptake of 10 microM Gly-Sar; binding affinity to human PEPT1 assessed as inhibition of [14C]Gly-Sar uptake in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 22:48:43
mbbd000010512,mbcd0003757,mbtp000009,mbrf0000108,25,=,660000.0,nM,inhibitor,25,0.66,mM,,50,,F,competitive uptake of 10 microM Gly-Sar; binding affinity to human PEPT1 assessed as inhibition of [14C]Gly-Sar uptake in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 22:48:43
mbbd000010513,mbcd0003798,mbtp000009,mbrf0000108,17,=,690000.0,nM,substrate,17,0.69,mM,0.28,15,,F,Activation of human PEPT1 expressed in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 22:06:25
mbbd000010514,mbcd0003492,mbtp000009,mbrf0000108,17,=,700000.0,nM,substrate,17,0.7,mM,0.16,63,,F,Activation of human PEPT1 expressed in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 22:06:36
mbbd000010515,mbcd0003782,mbtp000009,mbrf0000108,25,=,720000.0,nM,inhibitor,25,0.72,mM,,20,,F,competitive uptake of 10 microM Gly-Sar; binding affinity to human PEPT1 assessed as inhibition of [14C]Gly-Sar uptake in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 22:48:43
mbbd000010516,mbcd0003600,mbtp000009,mbrf0000108,25,=,730000.0,nM,inhibitor,25,0.73,mM,,67,,F,competitive uptake of 10 microM Gly-Sar; binding affinity to human PEPT1 assessed as inhibition of [14C]Gly-Sar uptake in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 22:48:43
mbbd000010518,mbcd0003652,mbtp000009,mbrf0000108,17,=,750000.0,nM,substrate,17,0.75,mM,0.37,33,,F,Activation of human PEPT1 expressed in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 22:06:29
mbbd000010520,mbcd0003492,mbtp000009,mbrf0000108,25,=,800000.0,nM,inhibitor,25,0.08,mM,,63,,F,competitive uptake of 10 microM Gly-Sar; binding affinity to human PEPT1 assessed as inhibition of [14C]Gly-Sar uptake in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 22:48:43
mbbd000010521,mbcd0003731,mbtp000009,mbrf0000108,25,=,810000.0,nM,inhibitor,25,0.81,mM,,29,,F,competitive uptake of 10 microM Gly-Sar; binding affinity to human PEPT1 assessed as inhibition of [14C]Gly-Sar uptake in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 22:48:43
mbbd000010522,mbcd0003737,mbtp000009,mbrf0000108,25,=,810000.0,nM,inhibitor,25,0.81,mM,,13,,F,competitive uptake of 10 microM Gly-Sar; binding affinity to human PEPT1 assessed as inhibition of [14C]Gly-Sar uptake in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 22:48:43
mbbd000010523,mbcd0003634,mbtp000009,mbrf0000108,25,=,820000.0,nM,inhibitor,25,0.82,mM,,25,,F,competitive uptake of 10 microM Gly-Sar; binding affinity to human PEPT1 assessed as inhibition of [14C]Gly-Sar uptake in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 22:48:43
mbbd000010524,mbcd0003696,mbtp000009,mbrf0000108,25,=,820000.0,nM,inhibitor,25,0.82,mM,,46,,F,competitive uptake of 10 microM Gly-Sar; binding affinity to human PEPT1 assessed as inhibition of [14C]Gly-Sar uptake in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 22:48:43
mbbd000010526,mbcd0003627,mbtp000009,mbrf0000108,17,=,850000.0,nM,substrate,17,0.85,mM,,54,,F,Activation of human PEPT1 expressed in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 22:06:35
mbbd000010531,mbcd0003672,mbtp000009,mbrf0000108,25,=,950000.0,nM,inhibitor,25,0.95,mM,,43,,F,competitive uptake of 10 microM Gly-Sar; binding affinity to human PEPT1 assessed as inhibition of [14C]Gly-Sar uptake in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 22:48:43
mbbd000010533,mbcd0003700,mbtp000009,mbrf0000108,25,=,980000.0,nM,inhibitor,25,0.98,mM,,32,,F,competitive uptake of 10 microM Gly-Sar; binding affinity to human PEPT1 assessed as inhibition of [14C]Gly-Sar uptake in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 22:48:43
mbbd000010535,mbcd0003510,mbtp000009,mbrf0000108,17,=,990000.0,nM,substrate,17,0.99,mM,,12,,F,Activation of human PEPT1 expressed in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 21:28:53
mbbd000010536,mbcd0003547,mbtp000009,mbrf0000108,17,=,1000000.0,nM,substrate,17,1.0,mM,0.17,18,,F,Activation of human PEPT1 expressed in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 22:06:26
mbbd000010541,mbcd0003697,mbtp000009,mbrf0000108,25,=,1070000.0,nM,inhibitor,25,1.07,mM,,26,,F,competitive uptake of 10 microM Gly-Sar; binding affinity to human PEPT1 assessed as inhibition of [14C]Gly-Sar uptake in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 22:48:43
mbbd000010542,mbcd0003568,mbtp000009,mbrf0000108,17,=,1100000.0,nM,substrate,17,1.1,mM,0.41,24,,F,Activation of human PEPT1 expressed in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 22:06:27
mbbd000010545,mbcd0003494,mbtp000009,mbrf0000108,25,=,1160000.0,nM,inhibitor,25,1.16,mM,,37,,F,competitive uptake of 10 microM Gly-Sar; binding affinity to human PEPT1 assessed as inhibition of [14C]Gly-Sar uptake in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 22:48:43
mbbd000010549,mbcd0003652,mbtp000009,mbrf0000108,25,=,1250000.0,nM,inhibitor,25,1.25,mM,,33,,F,competitive uptake of 10 microM Gly-Sar; binding affinity to human PEPT1 assessed as inhibition of [14C]Gly-Sar uptake in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 22:48:43
mbbd000010551,mbcd0003536,mbtp000009,mbrf0000108,25,=,1310000.0,nM,inhibitor,25,1.31,mM,,14,,F,competitive uptake of 10 microM Gly-Sar; binding affinity to human PEPT1 assessed as inhibition of [14C]Gly-Sar uptake in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 22:48:43
mbbd000010554,mbcd0003087,mbtp000009,mbrf0000114,25,=,1420000.0,nM,non-inhibitor,25,1.42,mM,0.18,valacyclovir,,B,Inhibition of human PEPT1-mediated [3H]Gly-Sar uptake in human HeLa cells,,,,,,human,mbds0001,v12,2013-11-27 09:08:01
mbbd000010557,mbcd0003602,mbtp000009,mbrf0000108,17,=,1600000.0,nM,substrate,17,1.6,mM,0.10,64,,F,Activation of human PEPT1 expressed in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 22:06:37
mbbd000010560,mbcd0003580,mbtp000009,mbrf0000108,25,=,1820000.0,nM,inhibitor,25,1.82,mM,,22,,F,competitive uptake of 10 microM Gly-Sar; binding affinity to human PEPT1 assessed as inhibition of [14C]Gly-Sar uptake in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 22:48:43
mbbd000010566,mbcd0003644,mbtp000009,mbrf0000114,25,=,2330000.0,nM,non-inhibitor,25,2.33,mM,0.45,5c; Phe-3-HPG,,B,Inhibition of human PEPT1-mediated [3H]Gly-Sar uptake in human HeLa cells,,,,,,human,mbds0001,v12,2013-11-20 19:06:30
mbbd000010575,mbcd0003627,mbtp000009,mbrf0000108,25,=,2990000.0,nM,inhibitor,25,2.99,mM,,54,,F,competitive uptake of 10 microM Gly-Sar; binding affinity to human PEPT1 assessed as inhibition of [14C]Gly-Sar uptake in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 22:48:43
mbbd000010576,mbcd0003683,mbtp000009,mbrf0000114,25,>,3000000.0,nM,non-inhibitor,25,3.0,mM,,Phe-OBz,,B,Inhibition of human PEPT1-mediated [3H]Gly-Sar uptake in human HeLa cells,,,,,,human,mbds0001,v12,2013-07-15 17:35:54
mbbd000010577,mbcd0003645,mbtp000009,mbrf0000114,25,>,3000000.0,nM,non-inhibitor,25,3.0,mM,,3-HPG,,B,Inhibition of human PEPT1-mediated [3H]Gly-Sar uptake in human HeLa cells,,,,,,human,mbds0001,v12,2013-07-15 17:35:54
mbbd000010583,mbcd0003611,mbtp000009,mbrf0000115,28,=,4200000.0,nM,substrate,28,4.2,mM,0.2,QSP,,B,Activity of human PepT1 expressed in Xenopus laevis oocytes assessed as induction of inward current; compound 5 mM,Xenopus laevis oocytes,,,,,human,mbds0001,v12,2013-11-24 23:14:40
mbbd000010590,mbcd0003734,mbtp000009,mbrf0000108,17,>,5000000.0,nM,non-substrate,17,5.0,mM,,59,,F,Activation of human PEPT1 expressed in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-24 23:11:05
mbbd000010591,mbcd0003594,mbtp000009,mbrf0000108,17,>,5000000.0,nM,non-substrate,17,5.0,mM,,58,,F,Activation of human PEPT1 expressed in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-24 23:11:05
mbbd000010603,mbcd0003800,mbtp000009,mbrf0000108,25,=,7200000.0,nM,inhibitor,25,7.2,mM,,45,,F,competitive uptake of 10 microM Gly-Sar; binding affinity to human PEPT1 assessed as inhibition of [14C]Gly-Sar uptake in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 22:48:43
mbbd000010608,mbcd0003805,mbtp000009,mbrf0000108,25,=,7310000.0,nM,inhibitor,25,7.31,mM,,9,,F,competitive uptake of 10 microM Gly-Sar; binding affinity to human PEPT1 assessed as inhibition of [14C]Gly-Sar uptake in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 22:48:43
mbbd000010612,mbcd0003515,mbtp000009,mbrf0000108,25,=,8110000.0,nM,inhibitor,25,8.11,mM,,11,,F,competitive uptake of 10 microM Gly-Sar; binding affinity to human PEPT1 assessed as inhibition of [14C]Gly-Sar uptake in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 22:48:43
mbbd000010616,mbcd0003625,mbtp000009,mbrf0000108,25,=,9110000.0,nM,inhibitor,25,9.11,mM,,77,,F,competitive uptake of 10 microM Gly-Sar; binding affinity to human PEPT1 assessed as inhibition of [14C]Gly-Sar uptake in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 22:48:43
mbbd000010617,mbcd0003594,mbtp000009,mbrf0000108,25,=,9160000.0,nM,inhibitor,25,9.16,mM,,58,,F,competitive uptake of 10 microM Gly-Sar; binding affinity to human PEPT1 assessed as inhibition of [14C]Gly-Sar uptake in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 22:48:43
mbbd000010626,mbcd0003725,mbtp000009,mbrf0000108,25,=,10900000.0,nM,inhibitor,25,10.9,mM,,48,,F,competitive uptake of 10 microM Gly-Sar; binding affinity to human PEPT1 assessed as inhibition of [14C]Gly-Sar uptake in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 22:48:43
mbbd000010631,mbcd0003734,mbtp000009,mbrf0000108,25,=,12300000.0,nM,inhibitor,25,12.3,mM,,59,,F,competitive uptake of 10 microM Gly-Sar; binding affinity to human PEPT1 assessed as inhibition of [14C]Gly-Sar uptake in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 22:48:43
mbbd000010644,mbcd0029007,mbtp000009,mbrf0000108,25,>,16000000.0,nM,inhibitor,25,16.0,mM,,60,,F,competitive uptake of 10 microM Gly-Sar; binding affinity to human PEPT1 assessed as inhibition of [14C]Gly-Sar uptake in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 22:48:43
mbbd000010645,mbcd0003803,mbtp000009,mbrf0000108,25,>,16000000.0,nM,inhibitor,25,16.0,mM,,62,,F,competitive uptake of 10 microM Gly-Sar; binding affinity to human PEPT1 assessed as inhibition of [14C]Gly-Sar uptake in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 22:48:43
mbbd000010646,mbcd0003602,mbtp000009,mbrf0000108,25,>,16000000.0,nM,inhibitor,25,16.0,mM,,64,,F,competitive uptake of 10 microM Gly-Sar; binding affinity to human PEPT1 assessed as inhibition of [14C]Gly-Sar uptake in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 22:48:43
mbbd000010654,mbcd0003685,mbtp000009,mbrf0000115,28,=,21400000.0,nM,substrate,28,21.4,mM,6.6,QCPac,,B,Activity of human PepT1 expressed in Xenopus laevis oocytes assessed as induction of inward current; compound 5 mM,Xenopus laevis oocytes,,,,,human,mbds0001,v12,2013-11-24 23:14:41
mbbd000010684,mbcd0003566,mbtp000009,mbrf0000108,,,,,non-substrate,,,,,21,,F,Activation of human PEPT1 expressed in MDCK cells relative to Gly-Sar,MDCK,,,,,human,mbds0001,v12,2013-11-24 23:11:08
mbbd000010685,mbcd0003820,mbtp000009,mbrf0000108,,,,,non-inhibitor,,,,,28,,F,competitive uptake of 10 microM Gly-Sar; binding affinity to human PEPT1 assessed as inhibition of [14C]Gly-Sar uptake in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 21:19:31
mbbd000010686,mbcd0003566,mbtp000009,mbrf0000108,,,,,non-substrate,,,,,21,,F,Ratio of %GSmax to EC50 (which corresponds to Vmax/Km) for human PEPT1 activation; oligopeptides were tested for their ability to induce changes of membrane potential in PEPT1 vs mock transfected MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-24 23:11:08
mbbd000010688,mbcd0003582,mbtp000009,mbrf0000108,,,,,non-inhibitor,,,,,74,,F,competitive uptake of 10 microM Gly-Sar; binding affinity to human PEPT1 assessed as inhibition of [14C]Gly-Sar uptake in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 21:19:31
mbbd000010695,mbcd0003786,mbtp000009,mbrf0000108,,,,,non-inhibitor,,,,,35,,F,competitive uptake of 10 microM Gly-Sar; binding affinity to human PEPT1 assessed as inhibition of [14C]Gly-Sar uptake in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 21:19:31
mbbd000010697,mbcd0003596,mbtp000009,mbrf0000108,,,,,non-substrate,,,,,73,,F,Activation of human PEPT1 expressed in MDCK cells relative to Gly-Sar; oligopeptides were tested for their ability to induce changes of membrane potential in PEPT1 vs mock transfected MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 22:22:59
mbbd000010700,mbcd0003500,mbtp000009,mbrf0000108,,,,,non-substrate,,,,,68,,F,Activation of human PEPT1 expressed in MDCK cells relative to Gly-Sar; oligopeptides were tested for their ability to induce changes of membrane potential in PEPT1 vs mock transfected MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-24 23:11:13
mbbd000010705,mbcd0003799,mbtp000009,mbrf0000108,,,,,non-substrate,,,,,40,,F,Activation of human PEPT1 expressed in MDCK cells relative to Gly-Sar; oligopeptides were tested for their ability to induce changes of membrane potential in PEPT1 vs mock transfected MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-24 23:11:13
mbbd000010709,mbcd0003745,mbtp000009,mbrf0000108,,,,,non-substrate,,,,,52,,F,Activation of human PEPT1 expressed in MDCK cells relative to Gly-Sar; oligopeptides were tested for their ability to induce changes of membrane potential in PEPT1 vs mock transfected MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-24 23:11:14
mbbd000010712,mbcd0003800,mbtp000009,mbrf0000108,,,,,non-substrate,,,,,45,,F,Activation of human PEPT1 expressed in MDCK cells relative to Gly-Sar; oligopeptides were tested for their ability to induce changes of membrane potential in PEPT1 vs mock transfected MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 22:22:56
mbbd000010713,mbcd0003735,mbtp000009,mbrf0000108,,,,,non-substrate,,,,,69,,F,Activation of human PEPT1 expressed in MDCK cells relative to Gly-Sar; oligopeptides were tested for their ability to induce changes of membrane potential in PEPT1 vs mock transfected MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-24 23:11:15
mbbd000010714,mbcd0001650,mbtp000009,mbrf0000074,,,,,substrate,,,,,bestatin,,A,"Substrates of transporters of clinical importance in the absorption and dispostion of drugs, PEPT1",,,,,,human,mbds0001,v12,2013-12-10 22:21:07
mbbd000010715,mbcd0003642,mbtp000009,mbrf0000074,,,,,inhibitor,,,,,glycyl-proline,,A,"Inhibitors of transporters of clinical importance in the absorption and dispostion of drugs, PEPT1",,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000010717,mbcd0003533,mbtp000009,mbrf0000108,,,,,non-substrate,,,,,27,,F,Activation of human PEPT1 expressed in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-24 23:11:15
mbbd000010720,mbcd0003533,mbtp000009,mbrf0000108,,,,,non-inhibitor,,,,,27,,F,competitive uptake of 10 microM Gly-Sar; binding affinity to human PEPT1 assessed as inhibition of [14C]Gly-Sar uptake in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 21:19:31
mbbd000010721,mbcd0003793,mbtp000009,mbrf0000108,,,,,non-substrate,,,,,1,,F,Activation of human PEPT1 expressed in MDCK cells relative to Gly-Sar; oligopeptides were tested for their ability to induce changes of membrane potential in PEPT1 vs mock transfected MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-24 23:11:15
mbbd000010722,mbcd0003579,mbtp000009,mbrf0000108,,,,,non-substrate,,,,,78,,F,Activation of human PEPT1 expressed in MDCK cells relative to Gly-Sar,MDCK,,,,,human,mbds0001,v12,2013-11-24 23:11:15
mbbd000010724,mbcd0003799,mbtp000009,mbrf0000108,,,,,non-inhibitor,,,,,40,,F,competitive uptake of 10 microM Gly-Sar; binding affinity to human PEPT1 assessed as inhibition of [14C]Gly-Sar uptake in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 21:19:31
mbbd000010728,mbcd0003142,mbtp000009,mbrf0000074,,,,,substrate,,,,,captopril,,A,"Substrates of transporters of clinical importance in the absorption and dispostion of drugs, PEPT1",,,,,,human,mbds0001,v12,2013-12-10 22:21:07
mbbd000010729,mbcd0003745,mbtp000009,mbrf0000108,,,,,non-inhibitor,,,,,52,,F,competitive uptake of 10 microM Gly-Sar; binding affinity to human PEPT1 assessed as inhibition of [14C]Gly-Sar uptake in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 21:19:31
mbbd000010730,mbcd0003625,mbtp000009,mbrf0000108,,,,,non-substrate,,,,,77,,F,Activation of human PEPT1 expressed in MDCK cells relative to Gly-Sar; oligopeptides were tested for their ability to induce changes of membrane potential in PEPT1 vs mock transfected MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-24 23:11:16
mbbd000010732,mbcd0003809,mbtp000009,mbrf0000108,,,,,non-substrate,,,,,2,,F,Activation of human PEPT1 expressed in MDCK cells relative to Gly-Sar; oligopeptides were tested for their ability to induce changes of membrane potential in PEPT1 vs mock transfected MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-24 23:11:16
mbbd000010733,mbcd0003803,mbtp000009,mbrf0000108,,,,,non-substrate,,,,,62,,F,Activation of human PEPT1 expressed in MDCK cells relative to Gly-Sar; oligopeptides were tested for their ability to induce changes of membrane potential in PEPT1 vs mock transfected MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-24 23:11:16
mbbd000010734,mbcd0003515,mbtp000009,mbrf0000108,,,,,non-substrate,,,,,11,,F,Activation of human PEPT1 expressed in MDCK cells relative to Gly-Sar; oligopeptides were tested for their ability to induce changes of membrane potential in PEPT1 vs mock transfected MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-24 23:11:17
mbbd000010737,mbcd0003596,mbtp000009,mbrf0000108,,,,,non-inhibitor,,,,,73,,F,competitive uptake of 10 microM Gly-Sar; binding affinity to human PEPT1 assessed as inhibition of [14C]Gly-Sar uptake in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 21:19:31
mbbd000010740,mbcd0003719,mbtp000009,mbrf0000115,,,,,substrate,,,,,PCQac,,B,Activity of human PepT1 expressed in Xenopus laevis oocytes assessed as induction of inward current; compound 5 mM,Xenopus laevis oocytes,,,,,human,mbds0001,v12,2013-11-24 23:14:41
mbbd000010743,mbcd0003579,mbtp000009,mbrf0000108,,,,,non-substrate,,,,,78,,F,Ratio of %GSmax to EC50 (which corresponds to Vmax/Km) for human PEPT1 activation; oligopeptides were tested for their ability to induce changes of membrane potential in PEPT1 vs mock transfected MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-24 23:11:17
mbbd000010744,mbcd0003618,mbtp000009,mbrf0000074,,,,,substrate,,,,,cephalexin,,A,"Substrates of transporters of clinical importance in the absorption and dispostion of drugs, PEPT1",,,,,,human,mbds0001,v12,2013-12-10 22:21:07
mbbd000010746,mbcd0003809,mbtp000009,mbrf0000108,,,,,non-inhibitor,,,,,2,,F,competitive uptake of 10 microM Gly-Sar; binding affinity to human PEPT1 assessed as inhibition of [14C]Gly-Sar uptake in MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 21:19:31
mbbd000010749,mbcd0003805,mbtp000009,mbrf0000108,,,,,non-substrate,,,,,9,,F,Activation of human PEPT1 expressed in MDCK cells relative to Gly-Sar; oligopeptides were tested for their ability to induce changes of membrane potential in PEPT1 vs mock transfected MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 22:23:01
mbbd000010750,mbcd0003582,mbtp000009,mbrf0000108,,,,,non-substrate,,,,,74,,F,Activation of human PEPT1 expressed in MDCK cells relative to Gly-Sar; oligopeptides were tested for their ability to induce changes of membrane potential in PEPT1 vs mock transfected MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-24 23:11:18
mbbd000010751,mbcd0003757,mbtp000009,mbrf0000108,,,,,non-substrate,,,,,50,,F,Activation of human PEPT1 expressed in MDCK cells relative to Gly-Sar; oligopeptides were tested for their ability to induce changes of membrane potential in PEPT1 vs mock transfected MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 22:22:57
mbbd000010752,mbcd0003725,mbtp000009,mbrf0000108,,,,,non-substrate,,,,,48,,F,Activation of human PEPT1 expressed in MDCK cells relative to Gly-Sar; oligopeptides were tested for their ability to induce changes of membrane potential in PEPT1 vs mock transfected MDCK cells,MDCK,,,,,human,mbds0001,v12,2013-11-27 22:22:57
mbbd000010878,mbcd0003880,mbtp000007,mbrf0000120,3,=,2.6,%,inhibitor,3,2.6,%,,terbutaline,,B,Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells at 100 uM by confocal microscopy,,,,,,human,mbds0001,v12,2013-11-27 09:08:01
mbbd000010928,mbcd0003008,mbtp000007,mbrf0000120,3,=,19.6,%,inhibitor,3,19.6,%,,valproic acid,,B,Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells at 100 uM by confocal microscopy,,,,,,human,mbds0001,v12,2013-11-27 09:08:01
mbbd000011077,mbcd0001092,mbtp000007,mbrf0000074,,,,,inhibitor,,,,,quinine,,A,"Inhibitors of transporters of clinical importance in the absorption and dispostion of drugs, OCT1",,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000011078,mbcd0003141,mbtp000007,mbrf0000074,,,,,inhibitor,,,,,disopyramide,,A,"Inhibitors of transporters of clinical importance in the absorption and dispostion of drugs, OCT1",,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000011079,mbcd0027018,mbtp000007,mbrf0000074,,,,,inhibitor,,,,,quinidine,,A,"Inhibitors of transporters of clinical importance in the absorption and dispostion of drugs, OCT1",,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000011081,mbcd0003965,mbtp000007,mbrf0000074,,,,,substrate,,,,,N-methylpyridinium,,A,"Substrates of transporters of clinical importance in the absorption and dispostion of drugs, OCT1",,,,,,human,mbds0001,v12,2013-12-10 22:21:07
mbbd000012275,mbcd0001795,mbtp000012,mbrf0000069,,,,,non-inducer,,,,,Etravirine,,B,Induction of SLCO1B1 activity,,,1,micromol L-1,,human,mbds0001,v12,2015-07-27 05:36:21
mbbd000012278,mbcd0001904,mbtp000012,mbrf0000074,,,,,substrate,,,,,repaglinide,,A,"Substrates of transporters of clinical importance in the absorption and dispostion of drugs, OATP1B1",,,,,,human,mbds0001,v12,2013-12-10 22:21:07
mbbd000012285,mbcd0001416,mbtp000012,mbrf0000074,,,,,inhibitor,,,,,rifampicin,,A,"Inhibitors of transporters of clinical importance in the absorption and dispostion of drugs, OATP1B1",,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000012286,mbcd0001938,mbtp000012,mbrf0000074,,,,,inhibitor,,,,,ritonavir,,A,"Inhibitors of transporters of clinical importance in the absorption and dispostion of drugs, OATP1B1",,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000012287,mbcd0000311,mbtp000012,mbrf0000074,,,,,inhibitor,,,,,cyclosporine,,A,"Inhibitors of transporters of clinical importance in the absorption and dispostion of drugs, OATP1B1",,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000012289,mbcd0001533,mbtp000012,mbrf0000074,,,,,inhibitor,,,,,saquinavir,,A,"Inhibitors of transporters of clinical importance in the absorption and dispostion of drugs, OATP1B1",,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000012290,mbcd0002241,mbtp000012,mbrf0000074,,,,,inhibitor,,,,,lopinavir,,A,"Inhibitors of transporters of clinical importance in the absorption and dispostion of drugs, OATP1B1",,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000012303,mbcd0003086,mbtp000013,mbrf0000074,,,,,substrate,,,,,valsartan,,A,"Substrates of transporters of clinical importance in the absorption and dispostion of drugs, OATP1B3",,,,,,human,mbds0001,v12,2013-12-10 22:21:07
mbbd000012305,mbcd0004707,mbtp000013,mbrf0000074,,,,,substrate,,,,,telmisartan glucuronide,,A,"Substrates of transporters of clinical importance in the absorption and dispostion of drugs, OATP1B3",,,,,,human,mbds0001,v12,2013-12-10 22:21:07
mbbd000012309,mbcd0002241,mbtp000013,mbrf0000074,,,,,inhibitor,,,,,lopinavir,,A,"Inhibitors of transporters of clinical importance in the absorption and dispostion of drugs, OATP1B3",,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000012310,mbcd0000311,mbtp000013,mbrf0000074,,,,,inhibitor,,,,,cyclosporine,,A,"Inhibitors of transporters of clinical importance in the absorption and dispostion of drugs, OATP1B3",,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000012312,mbcd0001416,mbtp000013,mbrf0000074,,,,,inhibitor,,,,,rifampicin,,A,"Inhibitors of transporters of clinical importance in the absorption and dispostion of drugs, OATP1B3",,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000012313,mbcd0001938,mbtp000013,mbrf0000074,,,,,inhibitor,,,,,ritonavir,,A,"Inhibitors of transporters of clinical importance in the absorption and dispostion of drugs, OATP1B3",,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000012364,mbcd0004752,mben000007,mbrf0000158,25,=,61.0,nM,inhibitor,25,61.0,nM,21,7j,,A,Inhibition of ethoxyresorufin O-deethylation (EROD) in bicistronic bacterial membranes epressing human cytochrome P450 1A1,Bicistronic bacterial membranes,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000012373,mbcd0004717,mben000007,mbrf0000164,28,=,90.0,nM,substrate,28,0.09,microM,,1,,A,Activity of human CYP1A1 by fluorogenic assay,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000012380,mbcd0004763,mben000007,mbrf0000158,25,=,140.0,nM,inhibitor,25,140.0,nM,30,7b,,A,Inhibition of ethoxyresorufin O-deethylation (EROD) in bicistronic bacterial membranes epressing human cytochrome P450 1A1,Bicistronic bacterial membranes,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000012386,mbcd0004724,mben000007,mbrf0000158,25,=,300.0,nM,inhibitor,25,300.0,nM,20,7a,,A,"Bicistronic membranes containing 5 nM of CYP1A2 were added to 0.1 M potassium phosphate buffer (pH 7.4) containing 2 microM ethoxyresorufin and varying concentrations of inhibitors. To measure CYP1A2 enzyme activity, ethoxyresorufin O-deethylation was determined",Bicistronic bacterial membranes,,,,,human,mbds0001,v12,2013-12-09 20:57:26
mbbd000012393,mbcd0004746,mben000007,mbrf0000158,25,=,610.0,nM,inhibitor,25,610.0,nM,40,7g,,A,Inhibition of ethoxyresorufin O-deethylation (EROD) in bicistronic bacterial membranes epressing human cytochrome P450 1A1,Bicistronic bacterial membranes,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000012398,mbcd0004729,mben000007,mbrf0000158,25,=,750.0,nM,inhibitor,25,750.0,nM,80,7d,,A,Inhibition of ethoxyresorufin O-deethylation (EROD) in bicistronic bacterial membranes epressing human cytochrome P450 1A1,Bicistronic bacterial membranes,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000012400,mbcd0002108,mben000007,mbrf0000158,25,=,830.0,nM,inhibitor,25,830.0,nM,120,7e,,A,Inhibition of ethoxyresorufin O-deethylation (EROD) in bicistronic bacterial membranes epressing human cytochrome P450 1A1,Bicistronic bacterial membranes,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000012404,mbcd0004748,mben000007,mbrf0000158,25,=,920.0,nM,inhibitor,25,920.0,nM,40,7c,,A,Inhibition of ethoxyresorufin O-deethylation (EROD) in bicistronic bacterial membranes epressing human cytochrome P450 1A1,Bicistronic bacterial membranes,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000012406,mbcd0004725,mben000007,mbrf0000158,25,=,980.0,nM,inhibitor,25,980.0,nM,220,7f,,A,Inhibition of ethoxyresorufin O-deethylation (EROD) in bicistronic bacterial membranes epressing human cytochrome P450 1A1,Bicistronic bacterial membranes,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000012407,mbcd0004716,mben000007,mbrf0000158,25,=,1100.0,nM,inhibitor,25,1100.0,nM,480,7h,,A,Inhibition of ethoxyresorufin O-deethylation (EROD) in bicistronic bacterial membranes epressing human cytochrome P450 1A1,Bicistronic bacterial membranes,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000012414,mbcd0004737,mben000007,mbrf0000158,25,=,1500.0,nM,inhibitor,25,1500.0,nM,230,9,,A,Inhibition of ethoxyresorufin O-deethylation (EROD) in bicistronic bacterial membranes epressing human cytochrome P450 1A1,Bicistronic bacterial membranes,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000012426,mbcd0004755,mben000007,mbrf0000158,25,=,6600.0,nM,inhibitor,25,6600.0,nM,200,7i,,A,Inhibition of ethoxyresorufin O-deethylation (EROD) in bicistronic bacterial membranes epressing human cytochrome P450 1A1,Bicistronic bacterial membranes,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000012428,mbcd0004717,mben000007,mbrf0000164,45,=,8800.0,M-1 s-1,substrate,45,8800.0,M-1 s-1,,1,,A,Ratio of Kcat to Km for human CYP1A1 by fluorogenic assay,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000012432,mbcd0004731,mben000007,mbrf0000158,25,=,15000.0,nM,inhibitor,25,15000.0,nM,,1b Oxyresveratrol,,A,Inhibition of ethoxyresorufin O-deethylation (EROD) in bicistronic bacterial membranes epressing human cytochrome P450 1A1,Bicistronic bacterial membranes,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000012443,mbcd0004732,mben000007,mbrf0000158,25,=,300000.0,nM,inhibitor,25,300000.0,nM,6300,11,,A,Inhibition of ethoxyresorufin O-deethylation (EROD) in bicistronic bacterial membranes epressing human cytochrome P450 1A1,Bicistronic bacterial membranes,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000015006,mbcd0004732,mben000005,mbrf0000158,25,>,2000000.0,nM,inhibitor,25,2000000.0,nM,,11,,A,Inhibition of ethoxyresorufin O-deethylation (EROD) in bicistronic bacterial membranes expressing human cytochrome P450 1A2,Bicistronic bacterial membranes,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000018608,mbcd0004752,mben000005,mbrf0000158,25,=,11.0,nM,inhibitor,25,11.0,nM,2,7j,,A,Inhibition of ethoxyresorufin O-deethylation (EROD) in bicistronic bacterial membranes expressing human cytochrome P450 1A2,Bicistronic bacterial membranes,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000022741,mbcd0004716,mben000005,mbrf0000158,25,=,290.0,nM,inhibitor,25,290.0,nM,110,7h,,A,Inhibition of ethoxyresorufin O-deethylation (EROD) in bicistronic bacterial membranes expressing human cytochrome P450 1A2,Bicistronic bacterial membranes,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000022777,mbcd0004755,mben000005,mbrf0000158,25,=,740.0,nM,inhibitor,25,740.0,nM,100,7i,,A,Inhibition of ethoxyresorufin O-deethylation (EROD) in bicistronic bacterial membranes expressing human cytochrome P450 1A2,Bicistronic bacterial membranes,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000022784,mbcd0004763,mben000005,mbrf0000158,25,=,930.0,nM,inhibitor,25,930.0,nM,120,7b,,A,Inhibition of ethoxyresorufin O-deethylation (EROD) in bicistronic bacterial membranes expressing human cytochrome P450 1A2,Bicistronic bacterial membranes,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000022858,mbcd0004724,mben000005,mbrf0000158,25,=,3100.0,nM,inhibitor,25,3100.0,nM,880,7a,,A,"Bicistronic membranes containing 5 nM of CYP1A2 were added to 0.1 M potassium phosphate buffer (pH 7.4) containing 2 microM ethoxyresorufin and varying concentrations of inhibitors. To measure CYP1A2 enzyme activity, ethoxyresorufin O-deethylation was determined",Bicistronic bacterial membranes,,,,,human,mbds0001,v12,2013-12-09 20:16:14
mbbd000022962,mbcd0004746,mben000005,mbrf0000158,25,=,5800.0,nM,inhibitor,25,5800.0,nM,1300,7g,,A,Inhibition of ethoxyresorufin O-deethylation (EROD) in bicistronic bacterial membranes expressing human cytochrome P450 1A2,Bicistronic bacterial membranes,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000022972,mbcd0002108,mben000005,mbrf0000158,25,=,6200.0,nM,inhibitor,25,6200.0,nM,960,7e,,A,Inhibition of ethoxyresorufin O-deethylation (EROD) in bicistronic bacterial membranes expressing human cytochrome P450 1A2,Bicistronic bacterial membranes,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000023166,mbcd0004731,mben000005,mbrf0000158,25,=,15000.0,nM,inhibitor,25,150000.0,nM,,1b Oxyresveratrol,,A,Inhibition of ethoxyresorufin O-deethylation (EROD) in bicistronic bacterial membranes expressing human cytochrome P450 1A2,Bicistronic bacterial membranes,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000023333,mbcd0004725,mben000005,mbrf0000158,25,=,31100.0,nM,inhibitor,25,31100.0,nM,2900,7f,,A,Inhibition of ethoxyresorufin O-deethylation (EROD) in bicistronic bacterial membranes expressing human cytochrome P450 1A2,Bicistronic bacterial membranes,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000023444,mbcd0004737,mben000005,mbrf0000158,25,=,64000.0,nM,inhibitor,25,64000.0,nM,5500,9,,A,Inhibition of ethoxyresorufin O-deethylation (EROD) in bicistronic bacterial membranes expressing human cytochrome P450 1A2,Bicistronic bacterial membranes,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000023546,mbcd0011356,mben000005,mbrf0000479,28,=,180000.0,nM,substrate,28,180.0,microM,0-430,2; nabumetone hydroxyimine,,A,Binding constant for compound binding to CYP1A2,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000023547,mbcd0004748,mben000005,mbrf0000158,25,=,198000.0,nM,inhibitor,25,198000.0,nM,14000,7c,,A,Inhibition of ethoxyresorufin O-deethylation (EROD) in bicistronic bacterial membranes expressing human cytochrome P450 1A2,Bicistronic bacterial membranes,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000023559,mbcd0004729,mben000005,mbrf0000158,25,=,570000.0,nM,inhibitor,25,570000.0,nM,1500,7d,,A,Inhibition of ethoxyresorufin O-deethylation (EROD) in bicistronic bacterial membranes expressing human cytochrome P450 1A2,Bicistronic bacterial membranes,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000031144,mbcd0004752,mben000008,mbrf0000158,25,=,2.0,nM,inhibitor,25,2.0,nM,1,7j,,A,Inhibition of ethoxyresorufin O-deethylation (EROD) in bicistronic bacterial membranes expressing human cytochrome P450 1B1,Bicistronic bacterial membranes,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000031158,mbcd0004724,mben000008,mbrf0000158,25,=,6.0,nM,inhibitor,25,6.0,nM,2,7a,,A,"Bicistronic membranes containing 5 nM of CYP1A2 were added to 0.1 M potassium phosphate buffer (pH 7.4) containing 2 microM ethoxyresorufin and varying concentrations of inhibitors. To measure CYP1A2 enzyme activity, ethoxyresorufin O-deethylation was determined",Bicistronic bacterial membranes,,,,,human,mbds0001,v12,2013-12-09 20:58:33
mbbd000031202,mbcd0004746,mben000008,mbrf0000158,25,=,97.0,nM,inhibitor,25,97.0,nM,30,7g,,A,Inhibition of ethoxyresorufin O-deethylation (EROD) in bicistronic bacterial membranes expressing human cytochrome P450 1B1,Bicistronic bacterial membranes,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000031214,mbcd0004725,mben000008,mbrf0000158,25,=,390.0,nM,inhibitor,25,390.0,nM,90,7f,,A,Inhibition of ethoxyresorufin O-deethylation (EROD) in bicistronic bacterial membranes expressing human cytochrome P450 1B1,Bicistronic bacterial membranes,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000031216,mbcd0004716,mben000008,mbrf0000158,25,=,460.0,nM,inhibitor,25,460.0,nM,80,7h,,A,Inhibition of ethoxyresorufin O-deethylation (EROD) in bicistronic bacterial membranes expressing human cytochrome P450 1B1,Bicistronic bacterial membranes,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000031220,mbcd0004737,mben000008,mbrf0000158,25,=,670.0,nM,inhibitor,25,670.0,nM,120,9,,A,Inhibition of ethoxyresorufin O-deethylation (EROD) in bicistronic bacterial membranes expressing human cytochrome P450 1B1,Bicistronic bacterial membranes,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000031222,mbcd0002108,mben000008,mbrf0000158,25,=,790.0,nM,inhibitor,25,790.0,nM,100,7e,,A,Inhibition of ethoxyresorufin O-deethylation (EROD) in bicistronic bacterial membranes expressing human cytochrome P450 1B1,Bicistronic bacterial membranes,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000031228,mbcd0004755,mben000008,mbrf0000158,25,=,2100.0,nM,inhibitor,25,2100.0,nM,260,7i,,A,Inhibition of ethoxyresorufin O-deethylation (EROD) in bicistronic bacterial membranes expressing human cytochrome P450 1B1,Bicistronic bacterial membranes,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000031231,mbcd0004729,mben000008,mbrf0000158,25,=,3000.0,nM,inhibitor,25,3000.0,nM,740,7d,,A,Inhibition of ethoxyresorufin O-deethylation (EROD) in bicistronic bacterial membranes expressing human cytochrome P450 1B1,Bicistronic bacterial membranes,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000031232,mbcd0004763,mben000008,mbrf0000158,25,=,3200.0,nM,inhibitor,25,3200.0,nM,560,7b,,A,Inhibition of ethoxyresorufin O-deethylation (EROD) in bicistronic bacterial membranes expressing human cytochrome P450 1B1,Bicistronic bacterial membranes,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000031234,mbcd0004732,mben000008,mbrf0000158,25,=,4900.0,nM,inhibitor,25,4900.0,nM,1300,11,,A,Inhibition of ethoxyresorufin O-deethylation (EROD) in bicistronic bacterial membranes expressing human cytochrome P450 1B1,Bicistronic bacterial membranes,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000031235,mbcd0004748,mben000008,mbrf0000158,25,=,17600.0,nM,inhibitor,25,17600.0,nM,480,7c,,A,Inhibition of ethoxyresorufin O-deethylation (EROD) in bicistronic bacterial membranes expressing human cytochrome P450 1B1,Bicistronic bacterial membranes,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000031236,mbcd0004731,mben000008,mbrf0000158,25,=,34000.0,nM,inhibitor,25,34000.0,nM,,1b Oxyresveratrol,,A,Inhibition of ethoxyresorufin O-deethylation (EROD) in bicistronic bacterial membranes expressing human cytochrome P450 1B1,Bicistronic bacterial membranes,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000037433,mbcd0003077,mben000006,mbrf0000531,22,=,12.1,pmol min-1 (pmol protein)-1,substrate,22,12.1,pmol min-1 pmol-1 CYP,,gliclazide,,A,Activity at recombinant CYP2C19 by Michaelis-Menten method,,mbcd0022746,,,,human,mbds0001,v12,2013-11-27 23:03:00
mbbd000038363,mbcd0003077,mben000006,mbrf0000531,22,=,14.9,pmol min-1 (pmol protein)-1,substrate,22,14.9,pmol min-1 pmol-1 CYP,,gliclazide,,A,Activity at recombinant CYP2C19 by Michaelis-Menten method,,mbcd0022962,,,,human,mbds0001,v12,2013-11-27 23:03:00
mbbd000041074,mbcd0022468,mben000006,mbrf0000526,25,=,210.0,nM,inhibitor,25,0.21,microM,0.03,38b,,A,Inhibitory concentration value against human cytochrome P-450 2C19,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000041886,mbcd0022787,mben000006,mbrf0000526,25,=,2000.0,nM,inhibitor,25,2.0,microM,0.22,38a,,A,Inhibitory concentration value against human cytochrome P-450 2C19,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000042307,mbcd0022593,mben000006,mbrf0000526,25,=,3200.0,nM,inhibitor,25,3.2,microM,0.2,57,,A,Inhibitory concentration value against human cytochrome P-450 2C19,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000043685,mbcd0022930,mben000006,mbrf0000526,25,=,12100.0,nM,inhibitor,25,12.1,microM,0.6,60,,A,Inhibitory concentration value against human cytochrome P-450 2C19,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000044362,mbcd0022783,mben000006,mbrf0000526,25,=,20100.0,nM,inhibitor,25,20.1,microM,2.2,9,,A,Inhibitory concentration value against human cytochrome P-450 2C19,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000044367,mbcd0022714,mben000006,mbrf0000526,25,=,22000.0,nM,inhibitor,25,22.0,microM,1.6,39a,,A,Inhibitory concentration value against human cytochrome P-450 2C19,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000044380,mbcd0003077,mben000006,mbrf0000531,28,=,24600.0,nM,substrate,28,24.6,microM,,gliclazide,,A,Activity at recombinant CYP2C19 assessed per picomole of enzyme by Michaelis-Menten method,,mbcd0022746,,,,human,mbds0001,v12,2013-11-27 23:03:00
mbbd000044381,mbcd0003077,mben000006,mbrf0000531,28,=,24800.0,nM,substrate,28,24.8,microM,,gliclazide,,A,Activity at recombinant CYP2C19 assessed per picomole of enzyme by Michaelis-Menten method,,mbcd0022962,,,,human,mbds0001,v12,2013-11-27 23:02:59
mbbd000044382,mbcd0022461,mben000006,mbrf0000526,25,=,24900.0,nM,inhibitor,25,24.9,microM,1.4,20,,A,Inhibitory concentration value against human cytochrome P-450 2C19,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000044787,mbcd0022790,mben000006,mbrf0000526,25,=,37200.0,nM,inhibitor,25,37.2,microM,3.4,36,,A,Inhibitory concentration value against human cytochrome P-450 2C19,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000045094,mbcd0022789,mben000006,mbrf0000526,25,=,40900.0,nM,inhibitor,25,40.9,microM,2.1,21,,A,Inhibitory concentration value against human cytochrome P-450 2C19,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000045109,mbcd0022459,mben000006,mbrf0000526,25,=,46400.0,nM,inhibitor,25,46.4,microM,4.2,59,,A,Inhibitory concentration value against human cytochrome P-450 2C19,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000045130,mbcd0022604,mben000006,mbrf0000526,25,=,53500.0,nM,inhibitor,25,53.5,microM,4.8,34,,A,Inhibitory concentration value against human cytochrome P-450 2C19,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000045136,mbcd0011356,mben000006,mbrf0000479,28,=,60000.0,nM,substrate,28,60.0,microM,30-90,2; nabumetone hydroxyimine,,A,Binding constant for compound binding to CYP2C19,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000045143,mbcd0022534,mben000006,mbrf0000526,25,=,62700.0,nM,inhibitor,25,62.7,microM,7.5,14,,A,Inhibitory concentration value against human cytochrome P-450 2C19,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000045147,mbcd0022460,mben000006,mbrf0000526,25,=,65200.0,nM,inhibitor,25,65.2,microM,5.8,13,,A,Inhibitory concentration value against human cytochrome P-450 2C19,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000045155,mbcd0023026,mben000006,mbrf0000531,29,=,79000.0,nM,inhibitor,29,79.0,microM,,NBPB,,A,Inhibition of CYP2C19,,,,,,human,mbds0001,v12,2013-11-27 23:02:58
mbbd000045206,mbcd0022711,mben000006,mbrf0000526,25,=,111200.0,nM,inhibitor,25,111.2,microM,6,16,,A,Inhibitory concentration value against human cytochrome P-450 2C19,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000045208,mbcd0028970,mben000006,mbrf0000526,25,=,118000.0,nM,inhibitor,25,118.0,microM,7,37a,,A,Inhibitory concentration value against human cytochrome P-450 2C19,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000045210,mbcd0022925,mben000006,mbrf0000526,25,=,122100.0,nM,inhibitor,25,122.1,microM,12.2,58a,,A,Inhibitory concentration value against human cytochrome P-450 2C19,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000045211,mbcd0022532,mben000006,mbrf0000526,25,=,122100.0,nM,inhibitor,25,122.1,microM,12.2,58b,,A,Inhibitory concentration value against human cytochrome P-450 2C19,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000045218,mbcd0028970,mben000006,mbrf0000526,25,=,175000.0,nM,inhibitor,25,175.0,microM,22,"37a,b",,A,Inhibitory concentration value against human cytochrome P-450 2C19,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000045220,mbcd0022578,mben000006,mbrf0000526,25,=,178000.0,nM,inhibitor,25,178.0,microM,13,7,,A,Inhibitory concentration value against human cytochrome P-450 2C19,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000045221,mbcd0022506,mben000006,mbrf0000526,25,=,182000.0,nM,inhibitor,25,182.0,microM,29,17,,A,Inhibitory concentration value against human cytochrome P-450 2C19,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000045232,mbcd0022781,mben000006,mbrf0000526,25,=,233000.0,nM,inhibitor,25,233.0,microM,21,38,,A,Inhibitory concentration value against human cytochrome P-450 2C19,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000045233,mbcd0022829,mben000006,mbrf0000531,29,=,250000.0,nM,inhibitor,29,250.0,microM,,NBN,,A,Inhibition of CYP2C19,,,,,,human,mbds0001,v12,2013-11-27 23:02:59
mbbd000045235,mbcd0028970,mben000006,mbrf0000526,25,=,279000.0,nM,inhibitor,25,279.0,microM,21,37b,,A,Inhibitory concentration value against human cytochrome P-450 2C19,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000045236,mbcd0022786,mben000006,mbrf0000526,25,>,300000.0,nM,inhibitor,25,300.0,microM,,61,,A,Inhibitory concentration value against human cytochrome P-450 2C19,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000045238,mbcd0007093,mben000006,mbrf0000526,25,>,300000.0,nM,inhibitor,25,300.0,microM,,31,,A,Inhibitory concentration value against human cytochrome P-450 2C19,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000045239,mbcd0022710,mben000006,mbrf0000526,25,>,300000.0,nM,inhibitor,25,300.0,microM,,62,,A,Inhibitory concentration value against human cytochrome P-450 2C19,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000052709,mbcd0003077,mben000006,mbrf0000531,,,,,inhibitor,,,,,gliclazide,,A,Inhibition of CYP2C19 assessed as decrease in catalytic reaction velocity at 100 uM by substrate-inhibition assay,,,100,microM,,human,mbds0001,v12,2013-11-27 23:03:01
mbbd000054353,mbcd0003077,mben000004,mbrf0000531,22,=,0.6,pmol min-1 (pmol protein)-1,substrate,22,0.6,pmol min-1 pmol-1 CYP,,gliclazide,,A,Activity at recombinant CYP2C9 by Michaelis-Menten method,,mbcd0022962,,,,human,mbds0001,v12,2013-11-27 23:02:59
mbbd000054355,mbcd0003077,mben000004,mbrf0000531,22,=,0.6,pmol min-1 (pmol protein)-1,substrate,22,0.6,pmol min-1 pmol-1 CYP,,gliclazide,,A,Activity at recombinant CYP2C9 by Michaelis-Menten method,,mbcd0022746,,,,human,mbds0001,v12,2013-11-27 23:03:00
mbbd000062230,mbcd0022468,mben000004,mbrf0000526,25,=,710.0,nM,inhibitor,25,0.71,microM,0.75,38b,,A,Inhibitory concentration against human cytochrome P-450 2C9,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000062790,mbcd0022593,mben000004,mbrf0000526,25,=,2100.0,nM,inhibitor,25,2.1,microM,0.2,57,,A,Inhibitory concentration against human cytochrome P-450 2C9,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000064155,mbcd0022787,mben000004,mbrf0000526,25,=,8900.0,nM,inhibitor,25,8.9,microM,1.5,38a,,A,Inhibitory concentration against human cytochrome P-450 2C9,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000064627,mbcd0022714,mben000004,mbrf0000526,25,=,11700.0,nM,inhibitor,25,11.7,microM,2.2,39a,,A,Inhibitory concentration against human cytochrome P-450 2C9,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000065612,mbcd0022930,mben000004,mbrf0000526,25,=,26900.0,nM,inhibitor,25,26.9,microM,2.9,60,,A,Inhibitory concentration against human cytochrome P-450 2C9,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000065669,mbcd0003077,mben000004,mbrf0000531,28,=,30000.0,nM,substrate,28,30.6,microM,,gliclazide,,A,Activity at recombinant CYP2C9 assessed per picomole of enzyme by Michaelis-Menten method,,mbcd0022746,,,,human,mbds0001,v12,2013-11-27 23:03:01
mbbd000066236,mbcd0003077,mben000004,mbrf0000531,28,=,40600.0,nM,substrate,28,40.6,microM,,gliclazide,,A,Activity at recombinant CYP2C9 assessed per picomole of enzyme by Michaelis-Menten method,,mbcd0022962,,,,human,mbds0001,v12,2013-11-27 23:02:59
mbbd000066239,mbcd0022604,mben000004,mbrf0000526,25,=,41800.0,nM,inhibitor,25,41.8,microM,5.2,34,,A,Inhibitory concentration against human cytochrome P-450 2C9,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000066363,mbcd0022460,mben000004,mbrf0000526,25,=,55200.0,nM,inhibitor,25,55.2,microM,7,13,,A,Inhibitory concentration against human cytochrome P-450 2C9,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000066391,mbcd0022459,mben000004,mbrf0000526,25,=,75200.0,nM,inhibitor,25,75.2,microM,8.2,59,,A,Inhibitory concentration against human cytochrome P-450 2C9,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000066396,mbcd0022925,mben000004,mbrf0000526,25,=,79500.0,nM,inhibitor,25,79.5,microM,8.9,58a,,A,Inhibitory concentration against human cytochrome P-450 2C9,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000066397,mbcd0022532,mben000004,mbrf0000526,25,=,79500.0,nM,inhibitor,25,79.5,microM,8.9,58b,,A,Inhibitory concentration against human cytochrome P-450 2C9,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000066404,mbcd0028970,mben000004,mbrf0000526,25,=,86200.0,nM,inhibitor,25,86.2,microM,13.8,37a,,A,Inhibitory concentration against human cytochrome P-450 2C9,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000066412,mbcd0022783,mben000004,mbrf0000526,25,=,93100.0,nM,inhibitor,25,93.1,microM,8.8,9,,A,Inhibitory concentration against human cytochrome P-450 2C9,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000066413,mbcd0022711,mben000004,mbrf0000526,25,=,96300.0,nM,inhibitor,25,96.3,microM,9.5,16,,A,Inhibitory concentration against human cytochrome P-450 2C9,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000066415,mbcd0022534,mben000004,mbrf0000526,25,=,98200.0,nM,inhibitor,25,98.2,microM,11.3,14,,A,Inhibitory concentration against human cytochrome P-450 2C9,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000066416,mbcd0022578,mben000004,mbrf0000526,25,=,99200.0,nM,inhibitor,25,99.2,microM,12.0,7,,A,Inhibitory concentration against human cytochrome P-450 2C9,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000066469,mbcd0022461,mben000004,mbrf0000526,25,=,123000.0,nM,inhibitor,25,123.0,microM,11,20,,A,Inhibitory concentration against human cytochrome P-450 2C9,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000066473,mbcd0028970,mben000004,mbrf0000526,25,=,141000.0,nM,inhibitor,25,141.0,microM,18,"37a,b",,A,Inhibitory concentration against human cytochrome P-450 2C9,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000066481,mbcd0022781,mben000004,mbrf0000526,25,=,208000.0,nM,inhibitor,25,208.0,microM,21,38,,A,Inhibitory concentration against human cytochrome P-450 2C9,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000066482,mbcd0022790,mben000004,mbrf0000526,25,=,223000.0,nM,inhibitor,25,223.0,microM,28,36,,A,Inhibitory concentration against human cytochrome P-450 2C9,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000066484,mbcd0022786,mben000004,mbrf0000526,25,>,300000.0,nM,inhibitor,25,300.0,microM,,61,,A,Inhibitory concentration against human cytochrome P-450 2C9,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000066485,mbcd0007093,mben000004,mbrf0000526,25,>,300000.0,nM,inhibitor,25,300.0,microM,,31,,A,Inhibitory concentration against human cytochrome P-450 2C9,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000066486,mbcd0022710,mben000004,mbrf0000526,25,>,300000.0,nM,inhibitor,25,300.0,microM,,62,,A,Inhibitory concentration against human cytochrome P-450 2C9,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000066490,mbcd0028970,mben000004,mbrf0000526,25,=,398000.0,nM,inhibitor,25,398.0,microM,49,37b,,A,Inhibitory concentration against human cytochrome P-450 2C9,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000066494,mbcd0022789,mben000004,mbrf0000526,25,>,400000.0,nM,inhibitor,25,400.0,microM,,21,,A,Inhibitory concentration against human cytochrome P-450 2C9,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000066495,mbcd0022506,mben000004,mbrf0000526,25,>,400000.0,nM,inhibitor,25,400.0,microM,,17,,A,Inhibitory concentration against human cytochrome P-450 2C9,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000067185,mbcd0003077,mben000004,mbrf0000531,,,,,inhibitor,,,,,gliclazide,,A,Inhibition of CYP2C9 assessed as decrease in catalytic reaction velocity at 200 uM by substrate-inhibition assay,,,200,microM,,human,mbds0001,v12,2013-11-27 23:03:01
mbbd000077465,mbcd0024252,mben000003,mbrf0000731,22,=,120000.0,(fluorescence units) min-1 (nmol protein)-1,substrate,22,1.2,*10^5 fluorescence units min-1 nmol-1 CYP,0.4,S-MDMA,,A,"Vmax for oxidation to 3,4-OH-MA by cytochrome P450 2D6 (wild type pSP19T7LT); expressed in 10E5 fluorescence units min-1 nmol-1 CYP",,,,,,human,mbds0001,v12,2013-12-09 05:48:48
mbbd000077466,mbcd0024750,mben000003,mbrf0000731,22,=,120000.0,(fluorescence units) min-1 (nmol protein)-1,substrate,22,1.2,*10^5 fluorescence units min-1 nmol-1 CYP,0.2,R/S-MDMA,,A,"Vmax for oxidation to 3,4-OH-MA by cytochrome P450 2D6 (wild type pSP19T7LT); expressed in 10E5 fluorescence units min-1 nmol-1 CYP",,,,,,human,mbds0001,v12,2013-12-09 05:48:48
mbbd000077467,mbcd0025069,mben000003,mbrf0000731,22,=,120000.0,(fluorescence units) min-1 (nmol protein)-1,substrate,22,1.2,*10^5 fluorescence units min-1 nmol-1 CYP,0.0,R-MDMA,,A,"Vmax for oxidation to 3,4-OH-MA by cytochrome P450 2D6 (wild type pSP19T7LT); expressed in 10E5 fluorescence units min-1 nmol-1 CYP",,,,,,human,mbds0001,v12,2013-12-09 05:48:48
mbbd000077468,mbcd0024757,mben000003,mbrf0000731,22,=,120000.0,(fluorescence units) min-1 (nmol protein)-1,substrate,22,1.2,*10^5 fluorescence units min-1 nmol-1 CYP,0.2,MDEA,,A,"Vmax for oxidation to 3,4-OH-MA by cytochrome P450 2D6 (wild type pSP19T7LT); expressed in 10E5 fluorescence units min-1 nmol-1 CYP",,,,,,human,mbds0001,v12,2013-12-09 05:48:48
mbbd000077554,mbcd0025060,mben000003,mbrf0000731,22,=,130000.0,(fluorescence units) min-1 (nmol protein)-1,substrate,22,1.3,*10^5 fluorescence units min-1 nmol-1 CYP,0.1,MDPA,,A,"Vmax for oxidation to 3,4-OH-MA by cytochrome P450 2D6 (wild type pSP19T7LT); expressed in 10E5 fluorescence units min-1 nmol-1 CYP",,,,,,human,mbds0001,v12,2013-12-09 05:48:48
mbbd000081595,mbcd0024865,mben000003,mbrf0000754,29,=,20.0,nM,inhibitor,29,0.02,microM,,CP-122721,,A,Binding affinity to human CYP2D6 using bufuralol as substrate,,mbcd0025521,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000081596,mbcd0025023,mben000003,mbrf0000754,29,=,520.0,nM,inhibitor,29,0.52,microM,,11 (diastereomeric mixture R/S = 36:1),,A,Binding affinity to human CYP2D6 using bufuralol as substrate,,mbcd0025521,,,,human,mbds0001,v12,2013-11-20 19:06:30
mbbd000082976,mbcd0024866,mben000003,mbrf0000754,3,=,41.8,%,inhibitor,3,41.8,%,,14 (diastereomeric mixture R/S = 1:9),,A,Inhibition of human CYP2D6 at 5 uM,,,,,,human,mbds0001,v12,2013-11-20 19:06:31
mbbd000082977,mbcd0025201,mben000003,mbrf0000754,3,=,42.0,%,inhibitor,3,42.0,%,,20 (diastereomeric mixture R/S = 1:5),,A,Inhibition of human CYP2D6 at 5 uM,,,,,,human,mbds0001,v12,2013-11-20 19:06:31
mbbd000082978,mbcd0025201,mben000003,mbrf0000754,3,=,42.0,%,inhibitor,3,42.0,%,,19 (diastereomeric mixture R/S = 3:1),,A,Inhibition of human CYP2D6 at 5 uM,,,,,,human,mbds0001,v12,2013-11-20 19:06:31
mbbd000082987,mbcd0025357,mben000003,mbrf0000754,3,=,43.1,%,inhibitor,3,43.1,%,,7,,A,Inhibition of human CYP2D6 at 5 uM,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000082999,mbcd0025518,mben000003,mbrf0000754,3,=,46.6,%,inhibitor,3,46.6,%,,6 (diastereomeric mixture R/S = 1:1),,A,Inhibition of human CYP2D6 at 5 uM,,,,,,human,mbds0001,v12,2013-11-20 19:06:31
mbbd000083086,mbcd0025354,mben000003,mbrf0000754,3,=,54.8,%,inhibitor,3,54.8,%,,4,,A,Inhibition of human CYP2D6 at 5 uM,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000083136,mbcd0025022,mben000003,mbrf0000754,3,=,64.1,%,inhibitor,3,64.1,%,,CJ-11974,,A,Inhibition of human CYP2D6 at 5 uM,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000083140,mbcd0025356,mben000003,mbrf0000754,3,=,65.9,%,inhibitor,3,65.9,%,,3 (diastereomeric mixture R/S = 1:1),,A,Inhibition of human CYP2D6 at 5 uM,,,,,,human,mbds0001,v12,2013-11-20 19:06:31
mbbd000083145,mbcd0025530,mben000003,mbrf0000754,3,=,66.4,%,inhibitor,3,66.4,%,,13 (diastereomeric mixture R/S = 5:4),,A,Inhibition of human CYP2D6 at 5 uM,,,,,,human,mbds0001,v12,2013-11-20 19:06:32
mbbd000083155,mbcd0025356,mben000003,mbrf0000754,29,=,840.0,nM,inhibitor,29,0.84,microM,,3 (diastereomeric mixture R/S = 1:1),,A,Binding affinity to human CYP2D6 using bufuralol as substrate,,mbcd0025521,,,,human,mbds0001,v12,2013-11-20 19:06:32
mbbd000083167,mbcd0024866,mben000003,mbrf0000754,3,=,73.0,%,inhibitor,3,73.0,%,,15 (diastereomeric mixture R/S = 49:1),,A,Inhibition of human CYP2D6 at 5 uM,,,,,,human,mbds0001,v12,2013-11-20 19:06:32
mbbd000083174,mbcd0025023,mben000003,mbrf0000754,3,=,74.2,%,inhibitor,3,74.2,%,,10 (diastereomeric mixture R/S = 1:1),,A,Inhibition of human CYP2D6 at 5 uM,,,,,,human,mbds0001,v12,2013-11-20 19:06:32
mbbd000083175,mbcd0024519,mben000003,mbrf0000754,3,=,74.2,%,inhibitor,3,74.2,%,,9 (diastereomeric mixture R/S = 1:1),,A,Inhibition of human CYP2D6 at 5 uM,,,,,,human,mbds0001,v12,2013-11-20 19:06:33
mbbd000083179,mbcd0025023,mben000003,mbrf0000754,3,=,75.9,%,inhibitor,3,75.9,%,,11 (diastereomeric mixture R/S = 36:1),,A,Inhibition of human CYP2D6 at 5 uM,,,,,,human,mbds0001,v12,2013-11-20 19:06:33
mbbd000083183,mbcd0024533,mben000003,mbrf0000754,3,=,76.5,%,inhibitor,3,76.5,%,,17 (diastereomeric mixture R/S = 10:1),,A,Inhibition of human CYP2D6 at 5 uM,,,,,,human,mbds0001,v12,2013-11-20 19:06:33
mbbd000083217,mbcd0024866,mben000003,mbrf0000754,3,=,81.0,%,inhibitor,3,81.0,%,,16 (diastereomeric mixture R/S = 1:1),,A,Inhibition of human CYP2D6 at 5 uM,,,,,,human,mbds0001,v12,2013-11-20 19:06:33
mbbd000083231,mbcd0024533,mben000003,mbrf0000754,3,=,85.4,%,inhibitor,3,85.4,%,,18 (diastereomeric mixture R/S = 1:5),,A,Inhibition of human CYP2D6 at 5 uM,,,,,,human,mbds0001,v12,2013-11-20 19:06:33
mbbd000083243,mbcd0025201,mben000003,mbrf0000754,3,=,90.0,%,inhibitor,3,90.0,%,,22 (diastereomeric mixture R/S = 1:3),,A,Inhibition of human CYP2D6 at 5 uM,,,,,,human,mbds0001,v12,2013-11-20 19:06:34
mbbd000083244,mbcd0025201,mben000003,mbrf0000754,3,=,90.0,%,inhibitor,3,90.0,%,,21 (diastereomeric mixture R/S = 5:1),,A,Inhibition of human CYP2D6 at 5 uM,,,,,,human,mbds0001,v12,2013-11-20 19:06:34
mbbd000083254,mbcd0025005,mben000003,mbrf0000754,3,=,92.9,%,inhibitor,3,92.9,%,,5 (diastereomeric mixture R/S = 1:1),,A,Inhibition of human CYP2D6 at 5 uM,,,,,,human,mbds0001,v12,2013-11-20 19:06:34
mbbd000083263,mbcd0024865,mben000003,mbrf0000754,3,=,95.6,%,inhibitor,3,95.6,%,,CP-122721,,A,Inhibition of human CYP2D6 at 5 uM,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000083264,mbcd0025183,mben000003,mbrf0000754,3,=,95.6,%,inhibitor,3,95.6,%,,2,,A,Inhibition of human CYP2D6 at 5 uM,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000083352,mbcd0025201,mben000003,mbrf0000754,29,=,120.0,nM,inhibitor,29,0.12,microM,,21 (diastereomeric mixture R/S = 5:1),,A,Binding affinity to human CYP2D6 using bufuralol as substrate,,mbcd0025521,,,,human,mbds0001,v12,2013-11-20 19:06:34
mbbd000083635,mbcd0025022,mben000003,mbrf0000754,29,=,420.0,nM,inhibitor,29,0.42,microM,,CJ-11974,,A,Binding affinity to human CYP2D6 using bufuralol as substrate,,mbcd0025521,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000083789,mbcd0024866,mben000003,mbrf0000754,29,=,660.0,nM,inhibitor,29,0.66,microM,,15 (diastereomeric mixture R/S = 49:1),,A,Binding affinity to human CYP2D6 using bufuralol as substrate,,mbcd0025521,,,,human,mbds0001,v12,2013-11-20 19:06:35
mbbd000083891,mbcd0025354,mben000003,mbrf0000754,29,=,1340.0,nM,inhibitor,29,1.34,microM,,4,,A,Binding affinity to human CYP2D6 using bufuralol as substrate,,mbcd0025521,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000083920,mbcd0025060,mben000003,mbrf0000731,28,=,1000.0,nM,substrate,28,1.0,microM,0.1,MDPA,,A,"Michaelis-Menten constant for oxidation to 3,4-OH-MA by cytochrome P450 2D6 (wild type pSP19T7LT)",,,,,,human,mbds0001,v12,2014-06-23 23:11:43
mbbd000084003,mbcd0024757,mben000003,mbrf0000731,28,=,1100.0,nM,substrate,28,1.1,microM,0.1,MDEA,,A,"Michaelis-Menten constant for oxidation to 3,4-OH-MA by cytochrome P450 2D6 (wild type pSP19T7LT)",,,,,,human,mbds0001,v12,2014-06-23 23:11:44
mbbd000084254,mbcd0024750,mben000003,mbrf0000731,28,=,1900.0,nM,substrate,28,1.9,microM,0.5,R/S-MDMA,,A,"Michaelis-Menten constant for oxidation to 3,4-OH-MA by cytochrome P450 2D6 (wild type pSP19T7LT)",,,,,,human,mbds0001,v12,2014-06-23 23:11:44
mbbd000084376,mbcd0025357,mben000003,mbrf0000754,29,=,2100.0,nM,inhibitor,29,2.1,microM,,7,,A,Binding affinity to human CYP2D6 using bufuralol as substrate,,mbcd0025521,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000084395,mbcd0024532,mben000003,mbrf0000754,28,=,2300.0,nM,substrate,28,2.3,microM,,(+)-1; CJ-17493,,A,Activity of CYP2D6 for N-dealkylation in human liver microsomes,,,,,,human,mbds0001,v12,2013-11-20 19:06:35
mbbd000084536,mbcd0025069,mben000003,mbrf0000731,28,=,2700.0,nM,substrate,28,2.7,microM,0.4,R-MDMA,,A,"Michaelis-Menten constant for oxidation to 3,4-OH-MA by cytochrome P450 2D6 (wild type pSP19T7LT)",,,,,,human,mbds0001,v12,2014-06-23 23:11:44
mbbd000084888,mbcd0024252,mben000003,mbrf0000731,28,=,3300.0,nM,substrate,28,3.3,microM,0.5,S-MDMA,,A,"Michaelis-Menten constant for oxidation to 3,4-OH-MA by cytochrome P450 2D6 (wild type pSP19T7LT)",,,,,,human,mbds0001,v12,2014-06-23 23:11:45
mbbd000085243,mbcd0025183,mben000003,mbrf0000754,29,=,70.0,nM,inhibitor,29,0.07,microM,,2,,A,Binding affinity to human CYP2D6 using bufuralol as substrate,,mbcd0025521,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000086611,mbcd0022714,mben000003,mbrf0000526,25,=,11300.0,nM,inhibitor,25,11.3,microM,2.6,39a,,A,Inhibitory concentration value against human cytochrome P-450 2D6,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000086956,mbcd0022468,mben000003,mbrf0000526,25,=,12900.0,nM,inhibitor,25,12.9,microM,1.9,38b,,A,Inhibitory concentration value against human cytochrome P-450 2D6,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000086995,mbcd0022593,mben000003,mbrf0000526,25,=,14400.0,nM,inhibitor,25,14.4,microM,0.9,57,,A,Inhibitory concentration value against human cytochrome P-450 2D6,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000087247,mbcd0024532,mben000003,mbrf0000754,28,=,16600.0,nM,substrate,28,16.6,microM,,(+)-1; CJ-17493,,A,Activity of CYP2D6 for hydroxylation in human liver microsomes,,,,,,human,mbds0001,v12,2013-11-20 19:06:35
mbbd000088375,mbcd0022930,mben000003,mbrf0000526,25,=,36300.0,nM,inhibitor,25,36.3,microM,4.4,60,,A,Inhibitory concentration value against human cytochrome P-450 2D6,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000088915,mbcd0011356,mben000003,mbrf0000479,28,=,90000.0,nM,substrate,28,90.0,microM,30-140,2; nabumetone hydroxyimine,,A,Binding constant for compound binding to CYP2D6,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000088917,mbcd0022783,mben000003,mbrf0000526,25,=,92500.0,nM,inhibitor,25,92.5,microM,10.8,9,,A,Inhibitory concentration value against human cytochrome P-450 2D6,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000088928,mbcd0022604,mben000003,mbrf0000526,25,=,98000.0,nM,inhibitor,25,98.0,microM,7.7,34,,A,Inhibitory concentration value against human cytochrome P-450 2D6,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000089047,mbcd0022787,mben000003,mbrf0000526,25,=,168000.0,nM,inhibitor,25,168.0,microM,16,38a,,A,Inhibitory concentration value against human cytochrome P-450 2D6,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000089052,mbcd0022790,mben000003,mbrf0000526,25,=,191000.0,nM,inhibitor,25,191.0,microM,30,36,,A,Inhibitory concentration value against human cytochrome P-450 2D6,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000089053,mbcd0022461,mben000003,mbrf0000526,25,=,193000.0,nM,inhibitor,25,193.0,microM,28,20,,A,Inhibitory concentration value against human cytochrome P-450 2D6,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000089056,mbcd0022781,mben000003,mbrf0000526,25,=,197000.0,nM,inhibitor,25,197.0,microM,21,38,,A,Inhibitory concentration value against human cytochrome P-450 2D6,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000089057,mbcd0022506,mben000003,mbrf0000526,25,=,199000.0,nM,inhibitor,25,199.0,microM,16,17,,A,Inhibitory concentration value against human cytochrome P-450 2D6,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000089067,mbcd0022532,mben000003,mbrf0000526,25,=,217000.0,nM,inhibitor,25,217.0,microM,20,58b,,A,Inhibitory concentration value against human cytochrome P-450 2D6,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000089068,mbcd0022925,mben000003,mbrf0000526,25,=,217000.0,nM,inhibitor,25,217.0,microM,20,58a,,A,Inhibitory concentration value against human cytochrome P-450 2D6,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000089070,mbcd0022711,mben000003,mbrf0000526,25,=,248000.0,nM,inhibitor,25,248.0,microM,35,16,,A,Inhibitory concentration value against human cytochrome P-450 2D6,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000089072,mbcd0022710,mben000003,mbrf0000526,25,=,277000.0,nM,inhibitor,25,277.0,microM,40,62,,A,Inhibitory concentration value against human cytochrome P-450 2D6,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000089075,mbcd0022789,mben000003,mbrf0000526,25,=,296000.0,nM,inhibitor,25,296.0,microM,66,21,,A,Inhibitory concentration value against human cytochrome P-450 2D6,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000089076,mbcd0022786,mben000003,mbrf0000526,25,=,297000.0,nM,inhibitor,25,297.0,microM,31,61,,A,Inhibitory concentration value against human cytochrome P-450 2D6,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000089078,mbcd0007093,mben000003,mbrf0000526,25,>,300000.0,nM,inhibitor,25,300.0,microM,,31,,A,Inhibitory concentration value against human cytochrome P-450 2D6,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000089080,mbcd0022459,mben000003,mbrf0000526,25,=,344000.0,nM,inhibitor,25,344.0,microM,43,59,,A,Inhibitory concentration value against human cytochrome P-450 2D6,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000089081,mbcd0022534,mben000003,mbrf0000526,25,=,387000.0,nM,inhibitor,25,387.0,microM,62,14,,A,Inhibitory concentration value against human cytochrome P-450 2D6,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000089082,mbcd0028970,mben000003,mbrf0000526,25,>,400000.0,nM,inhibitor,25,400.0,microM,,37a,,A,Inhibitory concentration value against human cytochrome P-450 2D6,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000089084,mbcd0031462,mben000003,mbrf0000526,25,>,400000.0,nM,inhibitor,25,400.0,microM,,37b,,A,Inhibitory concentration value against human cytochrome P-450 2D6,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000089091,mbcd0022578,mben000003,mbrf0000526,25,>,400000.0,nM,inhibitor,25,400.0,microM,,7,,A,Inhibitory concentration value against human cytochrome P-450 2D6,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000089094,mbcd0031463,mben000003,mbrf0000526,25,>,400000.0,nM,inhibitor,25,400.0,microM,,"37a,b",,A,Inhibitory concentration value against human cytochrome P-450 2D6,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000089095,mbcd0022460,mben000003,mbrf0000526,25,>,400000.0,nM,inhibitor,25,400.0,microM,,13,,A,Inhibitory concentration value against human cytochrome P-450 2D6,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000100999,mbcd0022930,mben000002,mbrf0000526,25,=,580.0,nM,inhibitor,25,0.58,microM,0.10,60,,A,Inhibitory concentration value against human cytochrome P-450 2E1,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000101006,mbcd0022468,mben000002,mbrf0000526,25,=,860.0,nM,inhibitor,25,0.86,microM,0.24,38b,,A,Inhibitory concentration value against human cytochrome P-450 2E1,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000101011,mbcd0022532,mben000002,mbrf0000526,25,=,4100.0,nM,inhibitor,25,4.1,microM,0.7,58b,,A,Inhibitory concentration value against human cytochrome P-450 2E1,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000101012,mbcd0022925,mben000002,mbrf0000526,25,=,4100.0,nM,inhibitor,25,4.1,microM,0.7,58a,,A,Inhibitory concentration value against human cytochrome P-450 2E1,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000101013,mbcd0022578,mben000002,mbrf0000526,25,=,4100.0,nM,inhibitor,25,4.1,microM,0.82,7,,A,Inhibitory concentration value against human cytochrome P-450 2E1,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000101014,mbcd0022790,mben000002,mbrf0000526,25,=,4200.0,nM,inhibitor,25,4.2,microM,1.1,36,,A,Inhibitory concentration value against human cytochrome P-450 2E1,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000101019,mbcd0022461,mben000002,mbrf0000526,25,=,6300.0,nM,inhibitor,25,6.3,microM,1.9,20,,A,Inhibitory concentration value against human cytochrome P-450 2E1,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000101020,mbcd0022783,mben000002,mbrf0000526,25,=,6900.0,nM,inhibitor,25,6.9,microM,2.1,9,,A,Inhibitory concentration value against human cytochrome P-450 2E1,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000101021,mbcd0022506,mben000002,mbrf0000526,25,=,7200.0,nM,inhibitor,25,7.2,microM,1.6,17,,A,Inhibitory concentration value against human cytochrome P-450 2E1,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000101030,mbcd0022604,mben000002,mbrf0000526,25,=,25500.0,nM,inhibitor,25,25.5,microM,3.9,34,,A,Inhibitory concentration value against human cytochrome P-450 2E1,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000101032,mbcd0022593,mben000002,mbrf0000526,25,=,31100.0,nM,inhibitor,25,31.1,microM,5.7,57,,A,Inhibitory concentration value against human cytochrome P-450 2E1,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000101033,mbcd0022460,mben000002,mbrf0000526,25,=,34300.0,nM,inhibitor,25,34.3,microM,7.1,13,,A,Inhibitory concentration value against human cytochrome P-450 2E1,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000101035,mbcd0011356,mben000002,mbrf0000479,28,=,40000.0,nM,substrate,28,40.0,microM,30-60,2; nabumetone hydroxyimine,,A,Binding constant for compound binding to CYP2E1,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000101037,mbcd0022787,mben000002,mbrf0000526,25,=,40200.0,nM,inhibitor,25,40.2,microM,18.1,38a,,A,Inhibitory concentration value against human cytochrome P-450 2E1,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000101040,mbcd0022786,mben000002,mbrf0000526,25,=,57900.0,nM,inhibitor,25,57.9,microM,12.5,61,,A,Inhibitory concentration value against human cytochrome P-450 2E1,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000101041,mbcd0022781,mben000002,mbrf0000526,25,=,77500.0,nM,inhibitor,25,77.5,microM,14.6,38,,A,Inhibitory concentration value against human cytochrome P-450 2E1,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000101042,mbcd0022459,mben000002,mbrf0000526,25,=,80000.0,nM,inhibitor,25,80.0,microM,10.2,59,,A,Inhibitory concentration value against human cytochrome P-450 2E1,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000101048,mbcd0022710,mben000002,mbrf0000526,25,=,109000.0,nM,inhibitor,25,109.0,microM,11,62,,A,Inhibitory concentration value against human cytochrome P-450 2E1,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000101050,mbcd0022714,mben000002,mbrf0000526,25,=,172000.0,nM,inhibitor,25,172.0,microM,52,39a,,A,Inhibitory concentration value against human cytochrome P-450 2E1,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000101053,mbcd0007093,mben000002,mbrf0000526,25,>,300000.0,nM,inhibitor,25,300.0,microM,,31,,A,Inhibitory concentration value against human cytochrome P-450 2E1,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000101054,mbcd0022789,mben000002,mbrf0000526,25,=,368000.0,nM,inhibitor,25,368.0,microM,79,21,,A,Inhibitory concentration value against human cytochrome P-450 2E1,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000101056,mbcd0028970,mben000002,mbrf0000526,25,>,400000.0,nM,inhibitor,25,400.0,microM,,37a,,A,Inhibitory concentration value against human cytochrome P-450 2E1,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000101061,mbcd0031462,mben000002,mbrf0000526,25,>,400000.0,nM,inhibitor,25,400.0,microM,,37b,,A,Inhibitory concentration value against human cytochrome P-450 2E1,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000101063,mbcd0022534,mben000002,mbrf0000526,25,>,400000.0,nM,inhibitor,25,400.0,microM,,14,,A,Inhibitory concentration value against human cytochrome P-450 2E1,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000101064,mbcd0022711,mben000002,mbrf0000526,25,>,400000.0,nM,inhibitor,25,400.0,microM,,16,,A,Inhibitory concentration value against human cytochrome P-450 2E1,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000101066,mbcd0031463,mben000002,mbrf0000526,25,>,400000.0,nM,inhibitor,25,400.0,microM,,"37a,b",,A,Inhibitory concentration value against human cytochrome P-450 2E1,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000101105,mbcd0002667,mben000001,mbrf0000841,28,=,5600.2,microM,substrate,64,-3.7482,microM-1,,Colchicine,,A,log (1/Km) value for human liver microsome cytochrome P450 3A4,,,,,,human,mbds0001,v12,2013-12-06 06:45:23
mbbd000101107,mbcd0025602,mben000001,mbrf0000841,28,=,3000.0,microM,substrate,64,-3.4771,microM-1,,Ethoxycoumarin,,A,log (1/Km) value for human liver microsome cytochrome P450 3A4,,,,,,human,mbds0001,v12,2013-12-06 06:45:23
mbbd000101111,mbcd0003895,mben000001,mbrf0000841,28,=,619.2,microM,substrate,64,-2.7918,microM-1,,Troglitazone,,A,log (1/Km) value for human liver microsome cytochrome P450 3A4,,,,,,human,mbds0001,v12,2013-12-06 06:45:23
mbbd000101112,mbcd0002985,mben000001,mbrf0000841,28,=,450.0,microM,substrate,64,-2.6532,microM-1,,Carbamazepine,,A,log (1/Km) value for human liver microsome cytochrome P450 3A4,,,,,,human,mbds0001,v12,2013-12-06 06:45:23
mbbd000101113,mbcd0002192,mben000001,mbrf0000841,28,=,310.0,microM,substrate,64,-2.4914,microM-1,,Amiodarone,,A,log (1/Km) value for human liver microsome cytochrome P450 3A4,,,,,,human,mbds0001,v12,2013-12-06 06:45:24
mbbd000101114,mbcd0027325,mben000001,mbrf0000841,28,=,300.0,microM,substrate,64,-2.4772,microM-1,,Senecionine,,A,log (1/Km) value for human liver microsome cytochrome P450 3A4,,,,,,human,mbds0001,v12,2013-12-06 06:45:24
mbbd000101115,mbcd0003877,mben000001,mbrf0000841,28,=,285.0,microM,substrate,64,-2.4548,microM-1,,Citalopram,,A,log (1/Km) value for human liver microsome cytochrome P450 3A4,,,,,,human,mbds0001,v12,2013-12-06 06:45:24
mbbd000101116,mbcd0028087,mben000001,mbrf0000841,28,=,265.0,microM,substrate,64,-2.4232,microM-1,,Alprazolam,,A,log (1/Km) value for human liver microsome cytochrome P450 3A4,,,,,,human,mbds0001,v12,2013-12-06 06:45:24
mbbd000101117,mbcd0026047,mben000001,mbrf0000841,28,=,252.6,microM,substrate,64,-2.4024,microM-1,,Pimobendan,,A,log (1/Km) value for human liver microsome cytochrome P450 3A4,,,,,,human,mbds0001,v12,2013-12-06 06:45:25
mbbd000101118,mbcd0028551,mben000001,mbrf0000841,28,=,245.5,microM,substrate,64,-2.3901,microM-1,,Zatosetron,,A,log (1/Km) value for human liver microsome cytochrome P450 3A4,,,,,,human,mbds0001,v12,2013-12-06 06:45:25
mbbd000101119,mbcd0008554,mben000001,mbrf0000841,28,=,170.0,microM,substrate,64,-2.2304,microM-1,,Dapsone,,A,log (1/Km) value for human liver microsome cytochrome P450 3A4,,,,,,human,mbds0001,v12,2013-12-06 06:45:25
mbbd000101120,mbcd0003000,mben000001,mbrf0000841,28,=,160.0,microM,substrate,64,-2.204,microM-1,,Chlorzoxazone,,A,log (1/Km) value for human liver microsome cytochrome P450 3A4,,,,,,human,mbds0001,v12,2013-12-06 06:45:26
mbbd000101121,mbcd0011364,mben000001,mbrf0000841,28,=,156.2,microM,substrate,64,-2.1938,microM-1,,Zileuton,,A,log (1/Km) value for human liver microsome cytochrome P450 3A4,,,,,,human,mbds0001,v12,2013-12-06 06:45:26
mbbd000101122,mbcd0028092,mben000001,mbrf0000841,28,=,154.6,microM,substrate,64,-2.1892,microM-1,,Flunitrazepam,,A,log (1/Km) value for human liver microsome cytochrome P450 3A4,,,,,,human,mbds0001,v12,2013-12-06 06:45:26
mbbd000101123,mbcd0026922,mben000001,mbrf0000841,28,=,125.0,microM,substrate,64,-2.0967,microM-1,,Bupivacaine,,A,log (1/Km) value for human liver microsome cytochrome P450 3A4,,,,,,human,mbds0001,v12,2013-12-06 06:45:26
mbbd000101124,mbcd0003948,mben000001,mbrf0000841,28,=,117.0,microM,substrate,64,-2.0682,microM-1,,Fentanyl,,A,log (1/Km) value for human liver microsome cytochrome P450 3A4,,,,,,human,mbds0001,v12,2013-12-06 06:45:27
mbbd000101125,mbcd0003898,mben000001,mbrf0000841,28,=,109.6,microM,substrate,64,-2.0398,microM-1,,Imipramine,,A,log (1/Km) value for human liver microsome cytochrome P450 3A4,,,,,,human,mbds0001,v12,2013-12-06 06:45:27
mbbd000101126,mbcd0001092,mben000001,mbrf0000841,28,=,106.0,microM,substrate,64,-2.0257,microM-1,,Quinine,,A,log (1/Km) value for human liver microsome cytochrome P450 3A4,,,,,,human,mbds0001,v12,2013-12-06 06:45:27
mbbd000101128,mbcd0002889,mben000001,mbrf0000841,28,=,98.0,microM,substrate,64,-1.9912,microM-1,,Tamoxifen,,A,log (1/Km) value for human liver microsome cytochrome P450 3A4,,,,,,human,mbds0001,v12,2013-12-06 06:45:27
mbbd000101129,mbcd0026923,mben000001,mbrf0000841,28,=,91.8,microM,substrate,64,-1.9628,microM-1,,Adinazolam,,A,log (1/Km) value for human liver microsome cytochrome P450 3A4,,,,,,human,mbds0001,v12,2013-12-06 06:45:28
mbbd000101130,mbcd0000815,mben000001,mbrf0000841,28,=,90.0,microM,substrate,64,-1.9542,microM-1,,Taurochenodeoxycholic acid,,A,log (1/Km) value for human liver microsome cytochrome P450 3A4,,,,,,human,mbds0001,v12,2013-12-06 06:45:28
mbbd000101131,mbcd0026837,mben000001,mbrf0000841,28,=,69.7,microM,substrate,64,-1.8432,microM-1,,Carteolol,,A,log (1/Km) value for human liver microsome cytochrome P450 3A4,,,,,,human,mbds0001,v12,2013-12-06 06:45:28
mbbd000101132,mbcd0003081,mben000001,mbrf0000841,28,=,69.3,microM,substrate,64,-1.8407,microM-1,,Amitriptyline,,A,log (1/Km) value for human liver microsome cytochrome P450 3A4,,,,,,human,mbds0001,v12,2013-12-06 06:45:28
mbbd000101133,mbcd0003888,mben000001,mbrf0000841,28,=,61.0,microM,substrate,64,-1.7853,microM-1,,Clozapine,,A,log (1/Km) value for human liver microsome cytochrome P450 3A4,,,,,,human,mbds0001,v12,2013-12-06 06:45:29
mbbd000101134,mbcd0000937,mben000001,mbrf0000841,28,=,61.0,microM,substrate,64,-1.7853,microM-1,,Erythromycin,,A,log (1/Km) value for human liver microsome cytochrome P450 3A4,,,,,,human,mbds0001,v12,2013-12-06 06:45:29
mbbd000101136,mbcd0001021,mben000001,mbrf0000841,28,=,49.0,microM,substrate,64,-1.6902,microM-1,,Omeprazole,,A,log (1/Km) value for human liver microsome cytochrome P450 3A4,,,,,,human,mbds0001,v12,2013-12-06 06:45:29
mbbd000101137,mbcd0001517,mben000001,mbrf0000841,28,=,48.7,microM,substrate,64,-1.6875,microM-1,,Clarithromycin,,A,log (1/Km) value for human liver microsome cytochrome P450 3A4,,,,,,human,mbds0001,v12,2013-12-06 06:45:29
mbbd000101138,mbcd0002466,mben000001,mbrf0000841,28,=,34.4,microM,substrate,64,-1.5366,microM-1,,Etoposide,,A,log (1/Km) value for human liver microsome cytochrome P450 3A4,,,,,,human,mbds0001,v12,2013-12-06 06:45:30
mbbd000101139,mbcd0000499,mben000001,mbrf0000841,28,=,30.5,microM,substrate,64,-1.4843,microM-1,,K 02,,A,log (1/Km) value for human liver microsome cytochrome P450 3A4,human liver microsome,,,,,human,mbds0001,v12,2013-12-06 06:45:30
mbbd000101140,mbcd0028167,mben000001,mbrf0000841,28,=,28.0,microM,substrate,64,-1.4472,microM-1,,Bromodichloromethane,,A,log (1/Km) value for human liver microsome cytochrome P450 3A4,,,,,,human,mbds0001,v12,2013-12-06 06:45:30
mbbd000101141,mbcd0028108,mben000001,mbrf0000841,28,=,24.7,microM,substrate,64,-1.3927,microM-1,,Vindesine,,A,log (1/Km) value for human liver microsome cytochrome P450 3A4,,,,,,human,mbds0001,v12,2013-12-06 06:45:30
mbbd000101142,mbcd0001777,mben000001,mbrf0000841,28,=,24.4,microM,substrate,64,-1.3874,microM-1,,Haloperidol,,A,log (1/Km) value for human liver microsome cytochrome P450 3A4,,,,,,human,mbds0001,v12,2013-12-06 06:45:31
mbbd000101143,mbcd0002959,mben000001,mbrf0000841,28,=,23.2,microM,substrate,64,-1.3655,microM-1,,Dexamethasone,,A,log (1/Km) value for human liver microsome cytochrome P450 3A4,,,,,,human,mbds0001,v12,2013-12-06 06:45:31
mbbd000101144,mbcd0002338,mben000001,mbrf0000841,28,=,23.0,microM,substrate,64,-1.3617,microM-1,,Diltiazem,,A,log (1/Km) value for human liver microsome cytochrome P450 3A4,,,,,,human,mbds0001,v12,2013-12-06 06:45:31
mbbd000101145,mbcd0028124,mben000001,mbrf0000841,28,=,22.0,microM,substrate,64,-1.3424,microM-1,,Ezlopitant alkene,,A,log (1/Km) value for human liver microsome cytochrome P450 3A4,,,,,,human,mbds0001,v12,2013-12-06 06:45:31
mbbd000101146,mbcd0001194,mben000001,mbrf0000841,28,=,20.9,microM,substrate,64,-1.3201,microM-1,,Simvastatin,,A,log (1/Km) value for human liver microsome cytochrome P450 3A4,,,,,,human,mbds0001,v12,2013-12-06 06:45:32
mbbd000101147,mbcd0001938,mben000001,mbrf0000841,28,=,20.0,microM,substrate,64,-1.301,microM-1,,Ritonavir,,A,log (1/Km) value for human liver microsome cytochrome P450 3A4,,,,,,human,mbds0001,v12,2013-12-06 06:45:32
mbbd000101148,mbcd0028083,mben000001,mbrf0000841,28,=,19.6,microM,substrate,64,-1.2923,microM-1,,Onapristone,,A,log (1/Km) value for human liver microsome cytochrome P450 3A4,,,,,,human,mbds0001,v12,2013-12-06 06:45:33
mbbd000101149,mbcd0002091,mben000001,mbrf0000841,28,=,18.4,microM,substrate,64,-1.2648,microM-1,,Irinotecan,,A,log (1/Km) value for human liver microsome cytochrome P450 3A4,,,,,,human,mbds0001,v12,2013-12-06 06:45:33
mbbd000101150,mbcd0001532,mben000001,mbrf0000841,28,=,18.0,microM,substrate,64,-1.2553,microM-1,,Taxol,,A,log (1/Km) value for human liver microsome cytochrome P450 3A4,,,,,,human,mbds0001,v12,2013-12-06 06:45:33
mbbd000101151,mbcd0002635,mben000001,mbrf0000841,28,=,15.2,microM,substrate,64,-1.1818,microM-1,,Cortisol,,A,log (1/Km) value for human liver microsome cytochrome P450 3A4,,,,,,human,mbds0001,v12,2013-12-06 06:45:33
mbbd000101152,mbcd0026618,mben000001,mbrf0000841,28,=,10.9,microM,substrate,64,-1.0373,microM-1,,Rifabutin,,A,log (1/Km) value for human liver microsome cytochrome P450 3A4,,,,,,human,mbds0001,v12,2013-12-06 06:45:34
mbbd000101153,mbcd0001299,mben000001,mbrf0000841,28,=,10.5,microM,substrate,64,-1.0212,microM-1,,Mifepristone,,A,log (1/Km) value for human liver microsome cytochrome P450 3A4,,,,,,human,mbds0001,v12,2013-12-06 06:45:34
mbbd000101154,mbcd0025613,mben000001,mbrf0000841,28,=,9.9,microM,substrate,64,-0.9955,microM-1,,Tazofelone,,A,log (1/Km) value for human liver microsome cytochrome P450 3A4,,,,,,human,mbds0001,v12,2013-12-06 06:45:34
mbbd000101155,mbcd0002337,mben000001,mbrf0000841,28,=,9.6,microM,substrate,64,-0.9823,microM-1,,Terfenadine,,A,log (1/Km) value for human liver microsome cytochrome P450 3A4,,,,,,human,mbds0001,v12,2013-12-06 06:45:34
mbbd000101156,mbcd0025672,mben000001,mbrf0000841,28,=,8.8,microM,substrate,64,-0.9445,microM-1,,Lilopristone,,A,log (1/Km) value for human liver microsome cytochrome P450 3A4,,,,,,human,mbds0001,v12,2013-12-06 06:45:35
mbbd000101157,mbcd0001324,mben000001,mbrf0000841,28,=,8.1,microM,substrate,64,-0.9069,microM-1,,Rapamycin,,A,log (1/Km) value for human liver microsome cytochrome P450 3A4,,,,,,human,mbds0001,v12,2013-12-06 06:45:35
mbbd000101158,mbcd0003011,mben000001,mbrf0000841,28,=,6.9,microM,substrate,64,-0.8388,microM-1,,Felodipine,,A,log (1/Km) value for human liver microsome cytochrome P450 3A4,,,,,,human,mbds0001,v12,2013-12-06 06:45:35
mbbd000101160,mbcd0001316,mben000001,mbrf0000841,28,=,6.2,microM,substrate,64,-0.7924,microM-1,,Tacrolimus,,A,log (1/Km) value for human liver microsome cytochrome P450 3A4,,,,,,human,mbds0001,v12,2013-12-06 06:45:36
mbbd000101161,mbcd0001918,mben000001,mbrf0000841,28,=,5.7,microM,substrate,64,-0.7559,microM-1,,Pimozide,,A,log (1/Km) value for human liver microsome cytochrome P450 3A4,,,,,,human,mbds0001,v12,2013-12-06 06:45:36
mbbd000101162,mbcd0000311,mben000001,mbrf0000841,28,=,4.0,microM,substrate,64,-0.6021,microM-1,,Cyclosporine,,A,log (1/Km) value for human liver microsome cytochrome P450 3A4,,,,,,human,mbds0001,v12,2013-12-06 06:45:36
mbbd000101163,mbcd0026066,mben000001,mbrf0000841,28,=,3.3,microM,substrate,64,-0.5185,microM-1,,1-Nitropyrene,,A,log (1/Km) value for human liver microsome cytochrome P450 3A4,,,,,,human,mbds0001,v12,2013-12-06 06:45:36
mbbd000101164,mbcd0028757,mben000001,mbrf0000841,28,=,1.8,microM,substrate,64,-0.2601,microM-1,,Tirilazad mesylate,,A,log (1/Km) value for human liver microsome cytochrome P450 3A4,,,,,,human,mbds0001,v12,2013-12-06 06:45:36
mbbd000101165,mbcd0002323,mben000001,mbrf0000841,28,=,1.3,microM,substrate,64,-0.1139,microM-1,,Indinavir,,A,log (1/Km) value for human liver microsome cytochrome P450 3A4,,,,,,human,mbds0001,v12,2013-12-06 06:45:37
mbbd000101166,mbcd0027726,mben000001,mbrf0000841,28,=,1.1,microM,substrate,64,-0.0414,microM-1,,Taxotere,,A,log (1/Km) value for human liver microsome cytochrome P450 3A4,,,,,,human,mbds0001,v12,2013-12-06 06:45:37
mbbd000101278,mbcd0024640,mben000001,mbrf0000841,28,=,0.81,microM,substrate,64,0.0899,microM-1,,Venlafaxine,,A,log (1/Km) value for human liver microsome cytochrome P450 3A4,,,,,,human,mbds0001,v12,2013-12-06 06:45:37
mbbd000101318,mbcd0003001,mben000001,mbrf0000849,67,=,0.15,nM-1 min-1,substrate,67,0.15,nM-1 min-1,,Testosterone,,A,Ratio of Vmax to Km for human recombinant CYP3A4,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000101535,mbcd0001533,mben000001,mbrf0000841,28,=,0.35,microM,substrate,64,0.4559,microM-1,,Saquinavir,,A,log (1/Km) value for human liver microsome cytochrome P450 3A4,,,,,,human,mbds0001,v12,2013-12-06 06:45:37
mbbd000101722,mbcd0026829,mben000001,mbrf0000849,67,=,0.77,nM-1 min-1,substrate,67,0.77,nM-1 min-1,,Deoxypodophyllotoxin,,A,Ratio of Vmax to Km for human recombinant CYP3A4,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000102340,mbcd0026829,mben000001,mbrf0000849,22,=,1.48,nmol min-1 (nmol protein)-1,substrate,22,1.48,nmol min-1 nmol-1 CYP,,Deoxypodophyllotoxin,,A,Activity of human recombinant CYP3A4 co-expressed in Escherichia coli with human p450 NADPH reductase assessed as conversion of deoxypodophyllotoxin to epipodophyllotoxin,,,,,,human,mbds0001,v12,2014-06-23 23:13:30
mbbd000104545,mbcd0002825,mben000001,mbrf0000849,1,=,4.38,%,inhibitor,1,4.38,%,,Miconazole,,A,Activity of human recombinant CYP3A4 assessed as conversion of testosterone to 6-beta-hydroxytestesterone at 25 uM after 60 mins in presence of 25 uM Miconazole,,mbcd0003001,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000104691,mbcd0026829,mben000001,mbrf0000849,1,=,4.85,%,inhibitor,1,4.85,%,,Deoxypodophyllotoxin,,A,Activity of human recombinant CYP3A4 assessed as conversion of testosterone to 6-beta-hydroxytestesterone at 25 uM after 60 mins in presence of 25 uM deoxypodophyllotoxin,,mbcd0003001,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000105448,mbcd0027251,mben000001,mbrf0000849,1,=,7.04,%,inhibitor,1,7.04,%,,Podophyllotoxin,,A,Activity of human recombinant CYP3A4 assessed as conversion of testosterone to 6-beta-hydroxytestesterone at 25 uM after 60 mins in presence of 25 uM podophyllotoxin,,mbcd0003001,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000105624,mbcd0027251,mben000001,mbrf0000849,1,=,7.82,%,inhibitor,1,7.82,%,,Podophyllotoxin,,A,Activity of human recombinant CYP3A4 assessed as conversion of testosterone to 6-beta-hydroxytestesterone at 25 uM after 60 mins in presence of 10 uM podophyllotoxin,,mbcd0003001,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000106044,mbcd0007577,mben000001,mbrf0000849,1,=,7.96,%,inhibitor,1,7.96,%,,Epipodophyllotoxin,,A,Activity of human recombinant CYP3A4 assessed as conversion of testosterone to 6-beta-hydroxytestesterone at 25 uM after 60 mins in presence of 10 uM epipodophyllotoxin,,mbcd0003001,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000106749,mbcd0026829,mben000001,mbrf0000849,1,=,10.4,%,inhibitor,1,10.4,%,,Deoxypodophyllotoxin,,A,Activity of human recombinant CYP3A4 assessed as conversion of testosterone to 6-beta-hydroxytestesterone at 25 uM after 60 mins in presence of 10 uM deoxypodophyllotoxin,,mbcd0003001,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000106751,mbcd0002825,mben000001,mbrf0000849,1,=,10.5,%,inhibitor,1,10.5,%,,Miconazole,,A,Activity of human recombinant CYP3A4 assessed as conversion of testosterone to 6-beta-hydroxytestesterone at 25 uM after 60 mins in presence of 10 uM Miconazole,,mbcd0003001,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000106927,mbcd0007577,mben000001,mbrf0000849,1,=,11.46,%,inhibitor,1,11.46,%,,Epipodophyllotoxin,,A,Activity of human recombinant CYP3A4 assessed as conversion of testosterone to 6-beta-hydroxytestesterone at 25 uM after 60 mins in presence of 25 uM epipodophyllotoxin,,mbcd0003001,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000110537,mbcd0003001,mben000001,mbrf0000849,22,=,30.3,nmol min-1 (nmol protein)-1,substrate,22,3.03,nmol min-1 nmol-1 CYP,,Testosterone,,A,Activity of human recombinant CYP3A4 co-expressed in Escherichia coli with human p450 NADPH reductase assessed as conversion of deoxypodophyllotoxin to epipodophyllotoxin,,,,,,human,mbds0001,v12,2013-11-27 23:10:23
mbbd000111081,mbcd0002825,mben000001,mbrf0000849,1,=,41.1,%,inhibitor,1,41.1,%,,Miconazole,,A,Activity of human recombinant CYP3A4 assessed as conversion of testosterone to 6-beta-hydroxytestesterone at 25 uM after 60 mins in presence of 1 uM Miconazole,,mbcd0003001,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000111094,mbcd0027251,mben000001,mbrf0000849,1,=,44.1,%,inhibitor,1,44.1,%,,Podophyllotoxin,,A,Activity of human recombinant CYP3A4 assessed as conversion of testosterone to 6-beta-hydroxytestesterone at 25 uM after 60 mins in presence of 1 uM podophyllotoxin,,mbcd0003001,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000111261,mbcd0026829,mben000001,mbrf0000849,1,=,61.0,%,inhibitor,1,61.0,%,,Deoxypodophyllotoxin,,A,Activity of human recombinant CYP3A4 assessed as conversion of testosterone to 6-beta-hydroxytestesterone at 25 uM after 60 mins in presence of 1 uM deoxypodophyllotoxin,,mbcd0003001,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000111346,mbcd0007577,mben000001,mbrf0000849,1,=,69.4,%,inhibitor,1,69.4,%,,Epipodophyllotoxin,,A,Activity of human recombinant CYP3A4 assessed as conversion of testosterone to 6-beta-hydroxytestesterone at 25 uM after 60 mins in presence of 1 uM epipodophyllotoxin,,mbcd0003001,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000111347,mbcd0031166,mben000001,mbrf0000849,1,=,69.6,%,inhibitor,1,69.6,%,,Demethylenedeoxypodophyllotoxin,,A,Activity of human recombinant CYP3A4 assessed as conversion of testosterone to 6-beta-hydroxytestesterone at 25 uM after 60 mins in presence of 10 uM demethylenedeoxypodophyllotoxin,,mbcd0003001,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000111348,mbcd0031166,mben000001,mbrf0000849,1,=,69.7,%,inhibitor,1,69.7,%,,Demethylenedeoxypodophyllotoxin,,A,Activity of human recombinant CYP3A4 assessed as conversion of testosterone to 6-beta-hydroxytestesterone at 25 uM after 60 mins in presence of 25 uM demethylenedeoxypodophyllotoxin,,mbcd0003001,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000111610,mbcd0031167,mben000001,mbrf0000849,1,=,95.0,%,non-inhibitor,1,95.0,%,,Demethylenepodophyllotoxin,,A,Activity of human recombinant CYP3A4 assessed as conversion of testosterone to 6-beta-hydroxytestesterone at 25 uM after 60 mins in presence of 1 uM demethylenepodophyllotoxin,,mbcd0003001,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000111643,mbcd0031167,mben000001,mbrf0000849,1,=,97.1,%,non-inhibitor,1,97.1,%,,Demethylenepodophyllotoxin,,A,Activity of human recombinant CYP3A4 assessed as conversion of testosterone to 6-beta-hydroxytestesterone at 25 uM after 60 mins in presence of 25 uM demethylenepodophyllotoxin,,mbcd0003001,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000111648,mbcd0031167,mben000001,mbrf0000849,1,=,98.7,%,non-inhibitor,1,98.7,%,,Demethylenepodophyllotoxin,,A,Activity of human recombinant CYP3A4 assessed as conversion of testosterone to 6-beta-hydroxytestesterone at 25 uM after 60 mins in presence of 10 uM demethylenepodophyllotoxin,,mbcd0003001,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000111730,mbcd0031166,mben000001,mbrf0000849,1,=,103.0,%,non-inhibitor,1,103.0,%,,Demethylenedeoxypodophyllotoxin,,A,Activity of human recombinant CYP3A4 assessed as conversion of testosterone to 6-beta-hydroxytestesterone at 25 uM after 60 mins in presence of 1 uM demethylenedeoxypodophyllotoxin,,mbcd0003001,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000112150,mbcd0026806,mben000001,mbrf0000934,28,=,377.2,ng mL-1,substrate,28,377.2,ng mL-1,,BILR 355,,A,Activity of human CYP3A4,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000113945,mbcd0026829,mben000001,mbrf0000849,28,=,1930.0,nM,substrate,28,1.93,microM,,Deoxypodophyllotoxin,,A,Activity of human recombinant CYP3A4 co-expressed in Escherichia coli with human p450 NADPH reductase assessed as conversion of deoxypodophyllotoxin to epipodophyllotoxin,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000118649,mbcd0022783,mben000001,mbrf0000526,25,=,6000.0,nM,inhibitor,25,6.0,microM,1.3,9,,A,Inhibitory concentration value against human cytochrome P-450 3A4,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000118667,mbcd0022593,mben000001,mbrf0000526,25,=,6300.0,nM,inhibitor,25,6.3,microM,1.4,57,,A,Inhibitory concentration value against human cytochrome P-450 3A4,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000122815,mbcd0022790,mben000001,mbrf0000526,25,=,13000.0,nM,inhibitor,25,13.0,microM,3.3,36,,A,Inhibitory concentration value against human cytochrome P-450 3A4,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000125339,mbcd0003001,mben000001,mbrf0000849,28,=,20500.0,nM,substrate,28,20.5,microM,,Testosterone,,A,Activity of human recombinant CYP3A4 co-expressed in Escherichia coli with human p450 NADPH reductase assessed as conversion of deoxypodophyllotoxin to epipodophyllotoxin,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000125387,mbcd0022460,mben000001,mbrf0000526,25,=,23900.0,nM,inhibitor,25,23.9,microM,7.3,13,,A,Inhibitory concentration value against human cytochrome P-450 3A4,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000126392,mbcd0022534,mben000001,mbrf0000526,25,=,27000.0,nM,inhibitor,25,27.0,microM,9.2,14,,A,Inhibitory concentration value against human cytochrome P-450 3A4,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000127288,mbcd0022789,mben000001,mbrf0000526,25,=,39100.0,nM,inhibitor,25,39.1,microM,12.8,21,,A,Inhibitory concentration value against human cytochrome P-450 3A4,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000127846,mbcd0022714,mben000001,mbrf0000526,25,=,47100.0,nM,inhibitor,25,47.1,microM,18.1,39a,,A,Inhibitory concentration value against human cytochrome P-450 3A4,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000128015,mbcd0028970,mben000001,mbrf0000526,25,=,51900.0,nM,inhibitor,25,51.9,microM,8.2,"37a,b",,A,Inhibitory concentration value against human cytochrome P-450 3A4,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000128029,mbcd0022711,mben000001,mbrf0000526,25,=,56900.0,nM,inhibitor,25,56.9,microM,19.2,16,,A,Inhibitory concentration value against human cytochrome P-450 3A4,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000128033,mbcd0022578,mben000001,mbrf0000526,25,=,57000.0,nM,inhibitor,25,57.0,microM,21.3,7,,A,Inhibitory concentration value against human cytochrome P-450 3A4,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000128041,mbcd0022787,mben000001,mbrf0000526,25,=,58700.0,nM,inhibitor,25,58.7,microM,15.3,38a,,A,Inhibitory concentration value against human cytochrome P-450 3A4,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000128058,mbcd0007093,mben000001,mbrf0000526,25,=,64700.0,nM,inhibitor,25,64.7,microM,13.7,31,,A,Inhibitory concentration value against human cytochrome P-450 3A4,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000128090,mbcd0022930,mben000001,mbrf0000526,25,=,75100.0,nM,inhibitor,25,75.1,microM,13.9,60,,A,Inhibitory concentration value against human cytochrome P-450 3A4,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000128096,mbcd0022781,mben000001,mbrf0000526,25,=,77500.0,nM,inhibitor,25,77.5,microM,14.6,38,,A,Inhibitory concentration value against human cytochrome P-450 3A4,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000128104,mbcd0022459,mben000001,mbrf0000526,25,=,79200.0,nM,inhibitor,25,79.2,microM,27.7,59,,A,Inhibitory concentration value against human cytochrome P-450 3A4,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000128111,mbcd0022461,mben000001,mbrf0000526,25,=,80900.0,nM,inhibitor,25,80.9,microM,13.2,20,,A,Inhibitory concentration value against human cytochrome P-450 3A4,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000128271,mbcd0022786,mben000001,mbrf0000526,25,=,109000.0,nM,inhibitor,25,109.0,microM,46,61,,A,Inhibitory concentration value against human cytochrome P-450 3A4,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000128274,mbcd0022506,mben000001,mbrf0000526,25,=,114000.0,nM,inhibitor,25,114.0,microM,25,17,,A,Inhibitory concentration value against human cytochrome P-450 3A4,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000128283,mbcd0022604,mben000001,mbrf0000526,25,=,139900.0,nM,inhibitor,25,139.9,microM,14.0,34,,A,Inhibitory concentration value against human cytochrome P-450 3A4,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000128285,mbcd0022710,mben000001,mbrf0000526,25,=,152000.0,nM,inhibitor,25,152.0,microM,70,62,,A,Inhibitory concentration value against human cytochrome P-450 3A4,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000128295,mbcd0011356,mben000001,mbrf0000479,28,=,200000.0,nM,substrate,28,200.0,microM,30-360,2; nabumetone hydroxyimine,,A,Binding constant for compound binding to CYP3A4,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000128304,mbcd0022925,mben000001,mbrf0000526,25,=,262000.0,nM,inhibitor,25,262.0,microM,63,58a,,A,Inhibitory concentration value against human cytochrome P-450 3A4,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000128305,mbcd0022532,mben000001,mbrf0000526,25,=,262000.0,nM,inhibitor,25,262.0,microM,63,58b,,A,Inhibitory concentration value against human cytochrome P-450 3A4,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000128322,mbcd0022468,mben000001,mbrf0000526,25,>,400000.0,nM,inhibitor,25,400.0,microM,,38b,,A,Inhibitory concentration value against human cytochrome P-450 3A4,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000128324,mbcd0028970,mben000001,mbrf0000526,25,>,400000.0,nM,inhibitor,25,400.0,microM,,37a,,A,Inhibitory concentration value against human cytochrome P-450 3A4,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000128327,mbcd0031462,mben000001,mbrf0000526,25,>,400000.0,nM,inhibitor,25,400.0,microM,,37b,,A,Inhibitory concentration value against human cytochrome P-450 3A4,,,,,,human,mbds0001,v12,2012-04-04 22:10:06
mbbd000133162,mbcd0000851,mben000001,mbrf0000159,,,,,inhibitor,,,,,Tiamulin,,A,Mechanism based inhibition of human cytochrome P450 3A4 measured by testosterone 6-beta hydroxylation,,,,,,human,mbds0001,v12,2013-12-10 22:19:00
mbbd000133272,mbcd0025672,mben000001,mbrf0000159,,,,,inhibitor,,,,,Lilopristone,,A,Mechanism based inhibition of human cytochrome P450 3A4 measured in vivo,,,,,,human,mbds0001,v12,2013-12-10 22:19:00
mbbd000137400,mbcd0001547,mbtp000002,mbrf0001603,,,,,inhibitor,,,,,dasatinib,,,ABCG2-expressing HEK293 cells; efflux of 200 nM BODIPY-prazosin; compound 10 microM,HEK293,mbcd0029889,10,microM,,human,mbds0010,,2013-11-17 20:21:56
mbbd000137434,mbcd0001151,mbtp000005,mbrf0001275,,,,,non-inducer,,,,,vinblastine,,,HepG2 hepatoma cells; MRP2 mRNA and protein,HepG2,,,,,human,mbds0010,,2013-11-17 07:11:37
mbbd000137765,mbcd0001280,mbtp000002,mbrf0001595,,=,,,inhibitor,25,0.6,microM,,sulfasalazine,,,BCRP membrane vesicles produced from transiently transfected HEK293-EBNA cells; uptake of 1 microM estrone-3-sulfate,HEK293,mbcd0003075,,,,human,mbds0010,,2013-11-17 20:18:28
mbbd000138113,mbcd0029098,mbtp000001,mbrf0001009,,=,,,substrate,81,10.7,,0.4,compound A,,,"cellular accumulation ratio (KB-3-1)/(KB-V1): KB-V1, a human MDR1 P-gp-overexpressing multidrug-resistant human epidermoid carcinoma cell line, and its parental cell line KB-3-1",KB-V1,,1,microM,,human,mbds0010,,2013-10-29 21:50:03
mbbd000138116,mbcd0029101,mbtp000001,mbrf0001009,,=,,,substrate,81,5.4,,0.6,compound D,,,"cellular accumulation ratio (KB-3-1)/(KB-V1): KB-V1, a human MDR1 P-gp-overexpressing multidrug-resistant human epidermoid carcinoma cell line, and its parental cell line KB-3-1",KB-V1,,1,microM,,human,mbds0010,,2013-10-29 21:50:03
mbbd000138117,mbcd0029102,mbtp000001,mbrf0001009,,=,,,substrate,81,1.6,,0.1,compound X,,,"cellular accumulation ratio (KB-3-1)/(KB-V1): KB-V1, a human MDR1 P-gp-overexpressing multidrug-resistant human epidermoid carcinoma cell line, and its parental cell line KB-3-1",KB-V1,,1,microM,weak substrate,human,mbds0010,,2013-10-29 21:50:03
mbbd000138118,mbcd0029103,mbtp000001,mbrf0001009,,=,,,non-substrate,81,1.2,,0.2,compound Y,,,"cellular accumulation ratio (KB-3-1)/(KB-V1): KB-V1, a human MDR1 P-gp-overexpressing multidrug-resistant human epidermoid carcinoma cell line, and its parental cell line KB-3-1",KB-V1,,1,microM,,human,mbds0010,,2013-10-29 21:50:03
mbbd000138119,mbcd0003888,mbtp000001,mbrf0001048,,=,,,non-substrate,22,15.1,nM mg-1 min-1,1.8,Clozapine,,,"P-gp ATPase activity, a putative measure of P-gp affinity; human P-gp membranes from baculovirus-infected insect cells",insect cells,,,,,human,mbds0010,,2013-11-26 00:08:57
mbbd000138120,mbcd0001018,mbtp000001,mbrf0001048,,=,,,substrate,22,6.9,nM mg-1 min-1,0.9,Olanzapine,,,"P-gp ATPase activity, a putative measure of P-gp affinity; human P-gp membranes from baculovirus-infected insect cells",insect cells,,,,,human,mbds0010,,2013-11-26 00:08:57
mbbd000138121,mbcd0027670,mbtp000001,mbrf0001048,,=,,,substrate,22,20.6,nM mg-1 min-1,2.6,Quetiapine,,,"P-gp ATPase activity, a putative measure of P-gp affinity; human P-gp membranes from baculovirus-infected insect cells",insect cells,,,,,human,mbds0010,,2013-11-26 00:08:57
mbbd000138122,mbcd0003005,mbtp000013,mbrf0001294,,=,,,substrate,8,15.6,microM,10.0,olmesartan,,,Xenopus laevis oocytes; 10 microM,Xenopus laevis oocytes,,,,,human,mbds0010,,2013-12-09 20:53:25
mbbd000138123,mbcd0003005,mbtp000012,mbrf0001294,,=,,,substrate,8,2.9,microM,1.0,olmesartan,,,Xenopus laevis oocytes; 10 microM,Xenopus laevis oocytes,,,,,human,mbds0010,,2013-12-09 20:53:25
mbbd000138126,mbcd0001105,mbtp000009,mbrf0001536,,=,,,inhibitor,29,0.17,mM,0.01,fosinopril,,,Caco-2; inhibition of Gly-Sar uptake,,,,,,human,mbds0010,,2013-12-09 20:00:59
mbbd000138127,mbcd0001136,mbtp000009,mbrf0001536,,=,,,inhibitor,29,0.96,mM,0.07,benazepril,,,Caco-2; inhibition of Gly-Sar uptake,,,,,,human,mbds0010,,2013-12-09 20:53:15
mbbd000138128,mbcd0001325,mbtp000009,mbrf0001536,,=,,,inhibitor,29,1.0,mM,0.1,quinapril,,,Caco-2; inhibition of Gly-Sar uptake,,,,,,human,mbds0010,,2013-12-09 20:09:43
mbbd000138129,mbcd0001119,mbtp000009,mbrf0001536,,=,,,inhibitor,29,1.7,mM,0.3,trandolapril,,,Caco-2; inhibition of Gly-Sar uptake,,,,,,human,mbds0010,,2013-12-09 20:09:42
mbbd000138130,mbcd0001569,mbtp000009,mbrf0001536,,=,,,inhibitor,29,2.2,mM,0.1,spirapril,,,Caco-2; inhibition of Gly-Sar uptake,,,,,,human,mbds0010,,2013-12-09 20:05:50
mbbd000138131,mbcd0001568,mbtp000009,mbrf0001536,,=,,,inhibitor,29,3.0,mM,0.3,cilazapril,,,Caco-2; inhibition of Gly-Sar uptake,,,,,,human,mbds0010,,2013-12-09 20:05:51
mbbd000138132,mbcd0000925,mbtp000009,mbrf0001536,,=,,,inhibitor,29,3.4,mM,0.2,ramipril,,,Caco-2; inhibition of Gly-Sar uptake,,,,,,human,mbds0010,,2013-12-09 20:58:10
mbbd000138133,mbcd0001215,mbtp000009,mbrf0001536,,=,,,inhibitor,29,5.0,mM,0.5,moexipril,,,Caco-2; inhibition of Gly-Sar uptake,,,,,,human,mbds0010,,2013-12-09 20:58:10
mbbd000138134,mbcd0001277,mbtp000009,mbrf0001536,,=,,,inhibitor,29,6.9,mM,1.5,perindopril,,,Caco-2; inhibition of Gly-Sar uptake,,,,,,human,mbds0010,,2013-12-09 20:05:56
mbbd000138135,mbcd0001325,mbtp000009,mbrf0001536,,=,,,inhibitor,29,0.71,mM,0.03,quinapril,,,inhibition of Gly-Sar uptake in HRPE-hPEPT1,,,,,,human,mbds0010,,2012-08-15 21:49:13
mbbd000138136,mbcd0001569,mbtp000009,mbrf0001536,,=,,,inhibitor,29,1.9,mM,0.2,spirapril,,,inhibition of Gly-Sar uptake in HRPE-hPEPT1,,,,,,human,mbds0010,,2012-08-15 21:49:13
mbbd000138137,mbcd0001136,mbtp000009,mbrf0001536,,=,,,substrate,29,0.91,mM,0.05,benazepril,,,inhibition of Gly-Sar uptake in HRPE-hPEPT1 cells (human retinal pigment epithelium cells),HRPE,,,,,human,mbds0010,,2013-11-26 01:55:29
mbbd000138138,mbcd0002981,mbtp000002,mbrf0001570,,,,,substrate,,,,,mitoxantrone,,,BCRP overexpressing breast cancer cell line (MDA-MB-231),MDA-MB-231,,,,,human,mbds0010,,2013-11-25 04:54:11
mbbd000138139,mbcd0001673,mbtp000001,mbrf0001209,,,,,inducer,,,,,estriol,,,P-gp expression at both the protein and mRNA level in vitro,,,,,,human,mbds0010,,2012-08-15 21:49:13
mbbd000138140,mbcd0003119,mbtp000001,mbrf0001209,,,,,inducer,,,,,ethynyl estradiol,,,P-gp expression at both the protein and mRNA level in vitro,,,,,,human,mbds0010,,2012-08-15 21:49:13
mbbd000138141,mbcd0011439,mbtp000002,mbrf0001552,,,,,inducer,,,,,riluzole,,,human trophoblast cell line (BeWo),BeWo,,,,,human,mbds0010,,2013-11-17 20:12:12
mbbd000138142,mbcd0001172,mbtp000002,mbrf0001605,,=,,,inhibitor,25,1.5,microM,,ivermectin,,,vesicular transport assay SB-ABCG2-HAM-PREDIVEZ-VT kit from Solvo; inhibition of estrone-3-sulfate transport,,mbcd0003075,,,,human,mbds0010,,2013-11-17 20:42:16
mbbd000138144,mbcd0000937,mbtp000001,mbrf0001142,,,,,substrate,,,,,erythromycin,,,LLC-PK1 cells,LLC-PK1,,,,,human,mbds0010,,2013-11-24 23:10:04
mbbd000138145,mbcd0001151,mbtp000001,mbrf0001147,,,,,substrate,,,,,vinblastine,,,LLC-PK1 cells (polarized pig kidney cells),LLC-PK1,,,,,human,mbds0010,,2013-11-24 23:10:04
mbbd000138146,mbcd0028099,mbtp000001,mbrf0001163,,=,,,inhibitor,3,63.0,%,6.3,1-hydroxymidazolam,,,Caco-2 cells; inhibition of digoxin transport; 100 microM,Caco-2,mbcd0001050,100,microM,,human,mbds0010,,2013-12-09 20:51:09
mbbd000138148,mbcd0017644,mbtp000001,mbrf0001163,,=,,,non-inhibitor,3,14.0,%,9.8,tolbutamide,,,Caco-2 cells; inhibition of digoxin transport; 100 microM,Caco-2,mbcd0001050,100,microM,,human,mbds0010,,2013-12-09 20:04:52
mbbd000138149,mbcd0001128,mbtp000001,mbrf0001163,,=,,,inhibitor,3,42.0,%,13,S-mephenytoin,,,Caco-2 cells; inhibition of digoxin transport; 100 microM,Caco-2,mbcd0001050,100,microM,,human,mbds0010,,2013-12-09 20:04:51
mbbd000138150,mbcd0003000,mbtp000001,mbrf0001163,,=,,,inhibitor,3,19.0,%,4.1,chlorzoxazone,,,Caco-2 cells; inhibition of digoxin transport; 10 microM,Caco-2,mbcd0001050,10,microM,,human,mbds0010,,2013-12-09 20:54:55
mbbd000138152,mbcd0027018,mbtp000001,mbrf0001163,,=,,,inhibitor,3,104.0,%,4.0,quinidine,,,Caco-2 cells; inhibition of digoxin transport; 10 microM,Caco-2,mbcd0001050,10,microM,,human,mbds0010,,2013-12-09 20:52:40
mbbd000138153,mbcd0000721,mbtp000001,mbrf0001163,,=,,,inhibitor,3,103.0,%,3.2,PSC-833,,,Caco-2 cells; inhibition of digoxin transport; 10 microM,Caco-2,mbcd0001050,10,microM,,human,mbds0010,,2013-12-09 20:52:41
mbbd000138154,mbcd0017104,mbtp000001,mbrf0001163,,=,,,inhibitor,3,100.0,%,8.2,ketoconazole,,,Caco-2 cells; inhibition of digoxin transport; 10 microM,Caco-2,mbcd0001050,10,microM,,human,mbds0010,,2013-12-09 20:52:40
mbbd000138155,mbcd0027062,mbtp000001,mbrf0001163,,=,,,inhibitor,3,90.0,%,12,verapamil,,,Caco-2 cells; inhibition of digoxin transport; 10 microM,Caco-2,mbcd0001050,10,microM,,human,mbds0010,,2013-12-09 20:52:40
mbbd000138156,mbcd0002192,mbtp000001,mbrf0001163,,=,,,inhibitor,3,72.0,%,9.8,amiodarone,,,Caco-2 cells; inhibition of digoxin transport; 10 microM,Caco-2,mbcd0001050,10,microM,,human,mbds0010,,2013-12-09 20:52:40
mbbd000138157,mbcd0025591,mbtp000001,mbrf0001163,,=,,,inhibitor,3,62.0,%,12,lovastatin,,,Caco-2 cells; inhibition of digoxin transport; 10 microM,Caco-2,mbcd0001050,10,microM,,human,mbds0010,,2013-12-09 20:52:40
mbbd000138158,mbcd0000937,mbtp000001,mbrf0001163,,=,,,inhibitor,3,50.0,%,6.0,erythromycin,,,Caco-2 cells; inhibition of digoxin transport; 10 microM,Caco-2,mbcd0001050,10,microM,,human,mbds0010,,2013-12-09 20:52:41
mbbd000138159,mbcd0001735,mbtp000001,mbrf0001163,,=,,,inhibitor,3,47.0,%,15,midazolam,,,Caco-2 cells; inhibition of digoxin transport; 10 microM,Caco-2,mbcd0001050,10,microM,,human,mbds0010,,2013-12-09 20:52:41
mbbd000138160,mbcd0002889,mbtp000001,mbrf0001163,,=,,,inhibitor,3,36.0,%,7.4,tamoxifen,,,Caco-2 cells; inhibition of digoxin transport; 10 microM,Caco-2,mbcd0001050,10,microM,,human,mbds0010,,2013-12-09 20:06:15
mbbd000138161,mbcd0007511,mbtp000001,mbrf0001163,,=,,,inhibitor,3,36.0,%,5.9,nifedipine,,,Caco-2 cells; inhibition of digoxin transport; 10 microM,Caco-2,mbcd0001050,10,microM,,human,mbds0010,,2013-12-09 20:06:15
mbbd000138163,mbcd0003879,mben000005,mbrf0001163,,,,,substrate,,,,,caffeine,,,,,,,,,human,mbds0010,,2012-08-15 21:49:13
mbbd000138164,mbcd0017644,mben000004,mbrf0001163,,,,,substrate,,,,,tolbutamide,,,,,,,,,human,mbds0010,,2012-08-15 21:49:13
mbbd000138165,mbcd0001128,mben000006,mbrf0001163,,,,,substrate,,,,,S-mephenytoin,,,,,,,,,human,mbds0010,,2012-08-15 21:49:13
mbbd000138166,mbcd0015049,mben000003,mbrf0001163,,,,,substrate,,,,,debrisoquine,,,,,,,,,human,mbds0010,,2012-08-15 21:49:13
mbbd000138167,mbcd0003000,mben000002,mbrf0001163,,,,,substrate,,,,,chlorzoxazone,,,,,,,,,human,mbds0010,,2012-08-15 21:49:13
mbbd000138168,mbcd0002337,mben000001,mbrf0001163,,,,,substrate,,,,,terfenadine,,,,,,,,,human,mbds0010,,2012-08-15 21:49:13
mbbd000138169,mbcd0027018,mben000001,mbrf0001163,,,,,substrate,,,,,quinidine,,,,,,,,,human,mbds0010,,2012-08-15 21:49:13
mbbd000138170,mbcd0000721,mben000001,mbrf0001163,,,,,substrate,,,,,PSC-833,,,,,,,,,human,mbds0010,,2012-08-15 21:49:13
mbbd000138171,mbcd0000721,mben000001,mbrf0001163,,,,,inhibitor,,,,,PSC-833,,,,,,,,,human,mbds0010,,2012-08-15 21:49:13
mbbd000138172,mbcd0017104,mben000001,mbrf0001163,,,,,inhibitor,,,,,ketoconazole,,,,,,,,,human,mbds0010,,2012-08-15 21:49:13
mbbd000138173,mbcd0027062,mben000001,mbrf0001163,,,,,substrate,,,,,verapamil,,,,,,,,,human,mbds0010,,2012-08-15 21:49:13
mbbd000138174,mbcd0002192,mben000001,mbrf0001163,,,,,substrate,,,,,amiodarone,,,,,,,,,human,mbds0010,,2012-08-15 21:49:13
mbbd000138175,mbcd0025591,mben000001,mbrf0001163,,,,,substrate,,,,,lovastatin,,,,,,,,,human,mbds0010,,2012-08-15 21:49:13
mbbd000138176,mbcd0000937,mben000001,mbrf0001163,,,,,substrate,,,,,erythromycin,,,,,,,,,human,mbds0010,,2012-08-15 21:49:13
mbbd000138177,mbcd0000937,mben000001,mbrf0001163,,,,,inhibitor,,,,,erythromycin,,,,,,,,,human,mbds0010,,2012-08-15 21:49:13
mbbd000138178,mbcd0001735,mben000001,mbrf0001163,,,,,substrate,,,,,midazolam,,,,,,,,,human,mbds0010,,2012-08-15 21:49:13
mbbd000138179,mbcd0002889,mben000001,mbrf0001163,,,,,substrate,,,,,tamoxifen,,,,,,,,,human,mbds0010,,2012-08-15 21:49:13
mbbd000138180,mbcd0007511,mben000001,mbrf0001163,,,,,substrate,,,,,nifedipine,,,,,,,,,human,mbds0010,,2012-08-15 21:49:13
mbbd000138181,mbcd0002635,mben000001,mbrf0001163,,,,,substrate,,,,,cortisol,,,,,,,,,human,mbds0010,,2012-08-15 21:49:13
mbbd000138190,mbcd0025591,mbtp000012,mbrf0001403,,,,,substrate,,,,,lovastatin,,,transfected 293c18 cells,HEK293c18,,,,,human,mbds0010,,2013-12-09 06:40:44
mbbd000138191,mbcd0003070,mbtp000012,mbrf0001403,,,,,substrate,,,,,DHEAS,,,transfected 293c18 cells,HEK293c18,,,,,human,mbds0010,,2013-12-09 06:40:44
mbbd000138192,mbcd0001050,mbtp000012,mbrf0001403,,,,,non-substrate,,,,,digoxin,,,transfected 293c18 cells,HEK293c18,,,,,human,mbds0010,,2013-12-09 06:40:44
mbbd000138193,mbcd0001675,mbtp000012,mbrf0001403,,,,,non-substrate,,,,,aldosterone,,,transfected 293c18 cells,HEK293c18,,,,,human,mbds0010,,2013-12-09 06:40:44
mbbd000138195,mbcd0000387,mbtp000012,mbrf0001388,,~,,,substrate,8,300.0,,5,estradiol-17beta-glucuronide,,,HEK293 cells transfected with pcDNA3 vector; cell-to-medium ratio,HEK293,,,,,human,mbds0010,,2013-12-09 20:53:16
mbbd000138196,mbcd0001343,mbtp000025,mbrf0001388,,~,,,substrate,8,3.0,,1,prostaglandin E2,,,HEK293 cells transfected with pcDNA3 vector; cell-to-medium ratio,HEK293,,,,,human,mbds0003,v2007,2013-12-09 20:53:15
mbbd000138197,mbcd0003134,mbtp000025,mbrf0001388,,~,,,substrate,8,1.0,,0.3,benzylpenicillin,,,HEK293 cells transfected with pcDNA3 vector; cell-to-medium ratio,HEK293,,,,,human,mbds0003,v2007,2013-12-09 20:53:16
mbbd000138199,mbcd0029117,mbtp000001,mbrf0001012,,=,,,substrate,87,20.2,,6.6,alpha-methyldigoxin,,,L-MDR1 cells (LLC-PK1 cells stably transfected with human MDR1 cDNA),LLC-PK1,,,,,human,mbds0010,,2013-10-17 21:16:28
mbbd000138201,mbcd0001050,mbtp000001,mbrf0001012,,=,,,substrate,87,11.7,,3.6,digoxin,,,L-MDR1 cells (LLC-PK1 cells stably transfected with human MDR1 cDNA),LLC-PK1,,,,,human,mbds0010,,2013-10-17 21:16:28
mbbd000138202,mbcd0001442,mbtp000001,mbrf0001012,,,,,non-substrate,,,,,ouabain,,,L-MDR1 cells (LLC-PK1 cells stably transfected with human MDR1 cDNA),LLC-PK1,,,,,human,mbds0010,,2013-10-17 21:16:28
mbbd000138203,mbcd0001197,mbtp000008,mbrf0001299,,=,,,substrate,28,1.74,mM,0.65,leucovorin,,,MRP3-transfected human embryonic kidney HEK293 cell line (HEK/MRP3-5),HEK293,,,,,human,mbds0003,v2007,2013-11-24 23:12:57
mbbd000138204,mbcd0003959,mbtp000008,mbrf0001299,,=,,,substrate,22,1.71,nM mg-1 min-1,0.05,FA,,,MRP3-transfected human embryonic kidney HEK293 cell line (HEK/MRP3-5),HEK293,,,,,human,mbds0010,,2013-11-24 23:12:57
mbbd000138205,mbcd0001197,mbtp000008,mbrf0001299,,=,,,substrate,22,3.63,nM mg-1 min-1,1.2,leucovorin,,,MRP3-transfected human embryonic kidney HEK293 cell line (HEK/MRP3-5),HEK293,,,,,human,mbds0010,,2013-11-24 23:12:58
mbbd000138206,mbcd0001777,mbtp000001,mbrf0001048,,=,,,non-substrate,28,33.0,microM,14.2,haloperidol,,,"P-gp ATPase activity, a putative measure of P-gp affinity; human P-gp membranes from baculovirus-infected insect cells",insect cells,,,,,human,mbds0010,,2013-11-26 00:08:57
mbbd000138209,mbcd0001777,mbtp000001,mbrf0001048,,=,,,non-substrate,22,8.9,nM mg-1 min-1,2.1,haloperidol,,,"P-gp ATPase activity, a putative measure of P-gp affinity; human P-gp membranes from baculovirus-infected insect cells",insect cells,,,,,human,mbds0010,,2013-11-26 00:08:57
mbbd000138210,mbcd0003893,mbtp000001,mbrf0001048,,=,,,substrate,22,16.8,nM mg-1 min-1,2.6,risperidone,,,"P-gp ATPase activity, a putative measure of P-gp affinity; human P-gp membranes from baculovirus-infected insect cells",insect cells,,,,,human,mbds0010,,2013-11-26 00:08:57
mbbd000138211,mbcd0002340,mbtp000001,mbrf0001048,,=,,,substrate,22,17.9,nM mg-1 min-1,2.5,chlorpromazine,,,"P-gp ATPase activity, a putative measure of P-gp affinity; human P-gp membranes from baculovirus-infected insect cells",insect cells,,,,,human,mbds0010,,2013-11-26 00:08:57
mbbd000138212,mbcd0001241,mbtp000006,mbrf0001370,,=,,,inhibitor,25,0.187,mM,,nateglinide,,,Xenopus laevis oocytes,,,,,,human,mbds0010,,2012-08-15 21:49:13
mbbd000138213,mbcd0003083,mbtp000001,mbrf0001061,,=,,,non-substrate,82,0.95,,,Amantadine,,,MDR1-MDCKII,MDCKII,,,,,human,mbds0010,,2013-11-17 06:52:45
mbbd000138214,mbcd0001287,mbtp000001,mbrf0001061,,=,,,non-substrate,82,0.95,,,Biperiden,,,MDR1-MDCKII,MDCKII,,,,,human,mbds0010,,2013-11-17 06:52:45
mbbd000138215,mbcd0002985,mbtp000001,mbrf0001061,,=,,,non-substrate,82,0.98,,,Carbamazepine,,,MDR1-MDCKII,MDCKII,,,,,human,mbds0010,,2013-11-17 06:52:46
mbbd000138216,mbcd0017921,mbtp000001,mbrf0001061,,=,,,non-substrate,82,0.92,,,Flumazenil,,,MDR1-MDCKII,MDCKII,,,,,human,mbds0010,,2013-11-17 06:52:46
mbbd000138217,mbcd0003898,mbtp000001,mbrf0001061,,=,,,non-substrate,82,1.05,,,Imipramine,,,MDR1-MDCKII,MDCKII,,,,,human,mbds0010,,2013-11-17 06:52:46
mbbd000138218,mbcd0027314,mbtp000001,mbrf0001061,,=,,,non-substrate,82,0.93,,,Ketamine,,,MDR1-MDCKII,MDCKII,,,,,human,mbds0010,,2013-11-17 06:52:46
mbbd000138219,mbcd0001042,mbtp000001,mbrf0001061,,=,,,non-substrate,82,0.97,,,Meprobamate,,,MDR1-MDCKII,MDCKII,,,,,human,mbds0010,,2013-11-17 06:52:47
mbbd000138220,mbcd0001226,mbtp000001,mbrf0001061,,=,,,non-substrate,82,1.04,,,Naltrexone,,,MDR1-MDCKII,MDCKII,,,,,human,mbds0010,,2013-11-17 06:52:47
mbbd000138221,mbcd0001618,mbtp000001,mbrf0001061,,=,,,non-substrate,82,1.17,,,Nitrazepam,,,MDR1-MDCKII,MDCKII,,,,,human,mbds0010,,2013-11-17 06:52:47
mbbd000138222,mbcd0000631,mbtp000001,mbrf0001061,,=,,,non-substrate,82,0.93,,,Nordazepam,,,MDR1-MDCKII,MDCKII,,,,,human,mbds0010,,2013-11-17 06:52:47
mbbd000138223,mbcd0001251,mbtp000001,mbrf0001061,,=,,,non-substrate,82,1.14,,,Scopolamine,,,MDR1-MDCKII,MDCKII,,,,,human,mbds0010,,2013-11-17 06:52:48
mbbd000138224,mbcd0014496,mbtp000001,mbrf0001061,,=,,,non-substrate,82,0.76,,,Selegiline,,,MDR1-MDCKII,MDCKII,,,,,human,mbds0010,,2013-11-17 06:52:48
mbbd000138225,mbcd0001204,mbtp000001,mbrf0001061,,=,,,non-substrate,82,1.48,,,Sumatriptan,,,MDR1-MDCKII,MDCKII,,,,,human,mbds0010,,2013-11-17 06:52:48
mbbd000138226,mbcd0009726,mbtp000001,mbrf0001061,,=,,,non-substrate,82,0.93,,,Tacrine,,,MDR1-MDCKII,MDCKII,,,,,human,mbds0010,,2013-11-17 06:52:48
mbbd000138227,mbcd0001682,mbtp000001,mbrf0001061,,=,,,non-substrate,82,1.01,,,Zimeldine,,,MDR1-MDCKII,MDCKII,,,,,human,mbds0010,,2013-11-17 06:52:49
mbbd000138228,mbcd0003081,mbtp000001,mbrf0001061,,=,,,non-substrate,82,1.34,,,Amitriptylline,,,MDR1-MDCKII,MDCKII,,,,,human,mbds0010,,2013-11-17 06:52:49
mbbd000138229,mbcd0026046,mbtp000001,mbrf0001061,,=,,,non-substrate,82,1.26,,,Bromocriptine,,,MDR1-MDCKII,MDCKII,,,,,human,mbds0010,,2013-11-17 06:52:49
mbbd000138230,mbcd0003932,mbtp000001,mbrf0001061,,=,,,non-substrate,82,0.95,,,Buspirone,,,MDR1-MDCKII,MDCKII,,,,,human,mbds0010,,2013-11-17 06:52:49
mbbd000138231,mbcd0002340,mbtp000001,mbrf0001061,,=,,,non-substrate,82,1.27,,,Chlorpromazine,,,MDR1-MDCKII,MDCKII,,,,,human,mbds0010,,2013-11-17 06:52:49
mbbd000138232,mbcd0001539,mbtp000001,mbrf0001061,,=,,,non-substrate,82,1.26,,,Chlorprothixene,,,MDR1-MDCKII,MDCKII,,,,,human,mbds0010,,2013-11-17 06:52:50
mbbd000138233,mbcd0003925,mbtp000001,mbrf0001061,,=,,,non-substrate,82,1.42,,,Clomipramine,,,MDR1-MDCKII,MDCKII,,,,,human,mbds0010,,2013-11-17 06:52:50
mbbd000138234,mbcd0002995,mbtp000001,mbrf0001061,,=,,,non-substrate,82,1.03,,,Desipramine,,,MDR1-MDCKII,MDCKII,,,,,human,mbds0010,,2013-11-17 06:52:50
mbbd000138235,mbcd0009851,mbtp000001,mbrf0001061,,=,,,non-substrate,82,1.15,,,Doxepin,,,MDR1-MDCKII,MDCKII,,,,,human,mbds0010,,2013-11-17 06:52:50
mbbd000138236,mbcd0022530,mbtp000001,mbrf0001061,,=,,,non-substrate,82,1.18,,,Fluoxetine,,,MDR1-MDCKII,MDCKII,,,,,human,mbds0010,,2013-11-17 06:52:51
mbbd000138237,mbcd0001214,mbtp000001,mbrf0001061,,=,,,non-substrate,82,0.88,,,Flurazepam,,,MDR1-MDCKII,MDCKII,,,,,human,mbds0010,,2013-11-17 06:52:51
mbbd000138238,mbcd0000923,mbtp000001,mbrf0001061,,=,,,non-substrate,82,1.2,,,Fluvoxamine,,,MDR1-MDCKII,MDCKII,,,,,human,mbds0010,,2013-11-17 06:52:51
mbbd000138239,mbcd0001777,mbtp000001,mbrf0001061,,=,,,non-substrate,82,1.04,,,Haloperidol,,,MDR1-MDCKII,MDCKII,,,,,human,mbds0010,,2013-11-17 06:52:51
mbbd000138240,mbcd0020385,mbtp000001,mbrf0001061,,=,,,non-substrate,82,1.05,,,Maprotiline,,,MDR1-MDCKII,MDCKII,,,,,human,mbds0010,,2013-11-17 06:52:52
mbbd000138241,mbcd0026438,mbtp000001,mbrf0001061,,=,,,non-substrate,82,1.21,,,Metergoline,,,MDR1-MDCKII,MDCKII,,,,,human,mbds0010,,2013-11-17 06:52:52
mbbd000138242,mbcd0001735,mbtp000001,mbrf0001061,,=,,,non-substrate,82,1.01,,,Midazolam,,,MDR1-MDCKII,MDCKII,,,,,human,mbds0010,,2013-11-17 06:52:52
mbbd000138243,mbcd0005617,mbtp000001,mbrf0001061,,=,,,non-substrate,82,1.39,,,Nortriptylene,,,MDR1-MDCKII,MDCKII,,,,,human,mbds0010,,2013-11-17 06:52:52
mbbd000138244,mbcd0003092,mbtp000001,mbrf0001061,,=,,,non-substrate,82,1.03,,,Noscapine,,,MDR1-MDCKII,MDCKII,,,,,human,mbds0010,,2013-11-17 06:52:53
mbbd000138245,mbcd0009152,mbtp000001,mbrf0001061,,=,,,non-substrate,82,1.47,,,Perphenazine,,,MDR1-MDCKII,MDCKII,,,,,human,mbds0010,,2013-11-17 06:52:53
mbbd000138246,mbcd0003031,mbtp000001,mbrf0001061,,=,,,non-substrate,82,0.95,,,Procyclidine,,,MDR1-MDCKII,MDCKII,,,,,human,mbds0010,,2013-11-17 06:52:53
mbbd000138247,mbcd0029111,mbtp000001,mbrf0001061,,=,,,non-substrate,82,0.88,,,Progabide,,,MDR1-MDCKII,MDCKII,,,,,human,mbds0010,,2013-11-17 06:52:53
mbbd000138248,mbcd0003913,mbtp000001,mbrf0001061,,=,,,non-substrate,82,1.15,,,Promazine,,,MDR1-MDCKII,MDCKII,,,,,human,mbds0010,,2013-11-17 06:52:53
mbbd000138249,mbcd0029107,mbtp000001,mbrf0001061,,=,,,non-substrate,82,1.15,,,Toxindole,oxindole?,,MDR1-MDCKII,MDCKII,,,,,human,mbds0010,,2013-11-17 06:52:54
mbbd000138250,mbcd0014354,mbtp000001,mbrf0001061,,=,,,non-substrate,82,0.94,,,Trazodone,,,MDR1-MDCKII,MDCKII,,,,,human,mbds0010,,2013-11-17 06:52:54
mbbd000138251,mbcd0003881,mbtp000001,mbrf0001061,,=,,,non-substrate,82,0.92,,,Trimipramine,,,MDR1-MDCKII,MDCKII,,,,,human,mbds0010,,2013-11-17 06:52:54
mbbd000138252,mbcd0027323,mbtp000001,mbrf0001061,,=,,,non-substrate,82,1.14,,,Zolpidem,,,MDR1-MDCKII,MDCKII,,,,,human,mbds0010,,2013-11-17 06:52:54
mbbd000138253,mbcd0028144,mbtp000001,mbrf0001061,,=,,,substrate,82,44.7,,,Eletriptan,,,MDR1-MDCKII,MDCKII,,,,,human,mbds0010,,2013-11-17 06:52:55
mbbd000138254,mbcd0004878,mbtp000001,mbrf0001061,,=,,,substrate,82,4.33,,,Methysergide,,,MDR1-MDCKII,MDCKII,,,,,human,mbds0010,,2013-11-17 06:52:55
mbbd000138255,mbcd0011125,mbtp000001,mbrf0001061,,=,,,substrate,82,2.17,,,Nalbuphine,,,MDR1-MDCKII,MDCKII,,,,,human,mbds0010,,2013-11-17 06:52:55
mbbd000138256,mbcd0001003,mbtp000001,mbrf0001061,,=,,,substrate,82,2.48,,,Zolmitriptan,,,MDR1-MDCKII,MDCKII,,,,,human,mbds0010,,2013-11-17 06:52:56
mbbd000138257,mbcd0001583,mbtp000001,mbrf0001061,,=,,,substrate,82,1.54,,,Levomeprazine,,,MDR1-MDCKII,MDCKII,,,,,human,mbds0010,,2013-11-17 06:52:56
mbbd000138258,mbcd0014705,mbtp000001,mbrf0001061,,=,,,substrate,82,2.37,,,Protriptylene,,,MDR1-MDCKII,MDCKII,,,,,human,mbds0010,,2013-11-17 06:52:56
mbbd000138259,mbcd0003893,mbtp000001,mbrf0001061,,=,,,substrate,82,1.61,,,Ripseridone,risperidone?,,MDR1-MDCKII,MDCKII,,,,,human,mbds0010,,2013-11-17 06:52:56
mbbd000138260,mbcd0003069,mbtp000001,mbrf0001061,,=,,,non-substrate,82,0.94,,,Antipyrine,,,MDR1-MDCKII,MDCKII,,,,,human,mbds0010,,2013-11-17 06:52:57
mbbd000138261,mbcd0003875,mbtp000001,mbrf0001061,,=,,,non-substrate,82,1.24,,,Atenolol,,,MDR1-MDCKII,MDCKII,,,,,human,mbds0010,,2013-11-17 06:52:57
mbbd000138262,mbcd0024951,mbtp000001,mbrf0001061,,=,,,non-substrate,82,0.93,,,Chlorpheneramine,,,MDR1-MDCKII,MDCKII,,,,,human,mbds0010,,2013-11-17 06:52:57
mbbd000138263,mbcd0003947,mbtp000001,mbrf0001061,,=,,,non-substrate,82,0.99,,,Clonidine,,,MDR1-MDCKII,MDCKII,,,,,human,mbds0010,,2013-11-17 06:52:57
mbbd000138264,mbcd0016160,mbtp000001,mbrf0001061,,=,,,non-substrate,82,0.84,,,Doxylamine,,,MDR1-MDCKII,MDCKII,,,,,human,mbds0010,,2013-11-17 06:52:58
mbbd000138265,mbcd0021164,mbtp000001,mbrf0001061,,=,,,non-substrate,82,0.91,,,Guanabenz,,,MDR1-MDCKII,MDCKII,,,,,human,mbds0010,,2013-11-17 06:52:58
mbbd000138266,mbcd0016560,mbtp000001,mbrf0001061,,=,,,non-substrate,82,1.23,,,Guanfacine,,,MDR1-MDCKII,MDCKII,,,,,human,mbds0010,,2013-11-17 06:52:58
mbbd000138267,mbcd0003025,mbtp000001,mbrf0001061,,=,,,non-substrate,82,0.97,,,Indomethacin,,,MDR1-MDCKII,MDCKII,,,,,human,mbds0010,,2013-11-17 06:52:58
mbbd000138268,mbcd0003884,mbtp000001,mbrf0001061,,=,,,non-substrate,82,0.83,,,Lidocaine,,,MDR1-MDCKII,MDCKII,,,,,human,mbds0010,,2013-11-17 06:52:58
mbbd000138269,mbcd0001248,mbtp000001,mbrf0001061,,=,,,non-substrate,82,0.88,,,Mannitol,,,MDR1-MDCKII,MDCKII,,,,,human,mbds0010,,2013-11-17 06:52:59
mbbd000138270,mbcd0005258,mbtp000001,mbrf0001061,,=,,,non-substrate,82,0.87,,,Mephentermine,,,MDR1-MDCKII,MDCKII,,,,,human,mbds0010,,2013-11-17 06:52:59
mbbd000138271,mbcd0002822,mbtp000001,mbrf0001061,,=,,,non-substrate,82,1.21,,,Metoprolol,,,MDR1-MDCKII,MDCKII,,,,,human,mbds0010,,2013-11-17 06:52:59
mbbd000138272,mbcd0013477,mbtp000001,mbrf0001061,,=,,,non-substrate,82,0.87,,,Mexilitene,mexiletine?,,MDR1-MDCKII,MDCKII,,,,,human,mbds0010,,2013-11-17 06:53:00
mbbd000138273,mbcd0003929,mbtp000001,mbrf0001061,,=,,,non-substrate,82,1.37,,,Oxprenolol,,,MDR1-MDCKII,MDCKII,,,,,human,mbds0010,,2013-11-17 06:53:00
mbbd000138274,mbcd0020501,mbtp000001,mbrf0001061,,=,,,non-substrate,82,1.41,,,Pheniramine,,,MDR1-MDCKII,MDCKII,,,,,human,mbds0010,,2013-11-17 06:53:00
mbbd000138275,mbcd0002488,mbtp000001,mbrf0001061,,=,,,non-substrate,82,1.04,,,Propranolol,,,MDR1-MDCKII,MDCKII,,,,,human,mbds0010,,2013-11-17 06:53:00
mbbd000138276,mbcd0001280,mbtp000001,mbrf0001061,,=,,,non-substrate,82,1.65,,,Sulfasalazine,,,MDR1-MDCKII,MDCKII,,,,,human,mbds0010,,2013-11-17 06:53:01
mbbd000138277,mbcd0003042,mbtp000001,mbrf0001061,,=,,,non-substrate,82,0.83,,,Warfarin,,,MDR1-MDCKII,MDCKII,,,,,human,mbds0010,,2013-11-17 06:53:01
mbbd000138278,mbcd0002238,mbtp000001,mbrf0001061,,=,,,non-substrate,82,1.01,,,Alprenolol,,,MDR1-MDCKII,MDCKII,,,,,human,mbds0010,,2013-11-17 06:53:01
mbbd000138279,mbcd0025521,mbtp000001,mbrf0001061,,=,,,non-substrate,82,0.78,,,Bufuralol,,,MDR1-MDCKII,MDCKII,,,,,human,mbds0010,,2013-11-17 06:53:01
mbbd000138280,mbcd0003956,mbtp000001,mbrf0001061,,=,,,non-substrate,82,1.29,,,Clemastine fumurate,,,MDR1-MDCKII,MDCKII,,,,,human,mbds0010,,2013-11-17 06:53:02
mbbd000138281,mbcd0011710,mbtp000001,mbrf0001061,,=,,,non-substrate,82,0.97,,,Cyclobenzaprine,,,MDR1-MDCKII,MDCKII,,,,,human,mbds0010,,2013-11-17 06:53:02
mbbd000138282,mbcd0012458,mbtp000001,mbrf0001061,,=,,,non-substrate,82,0.91,,,Diphenhydramine,,,MDR1-MDCKII,MDCKII,,,,,human,mbds0010,,2013-11-17 06:53:02
mbbd000138283,mbcd0029108,mbtp000001,mbrf0001061,,=,,,non-substrate,82,1.41,,,Doxapram,,,MDR1-MDCKII,MDCKII,,,,,human,mbds0010,,2013-11-17 06:53:02
mbbd000138284,mbcd0029109,mbtp000001,mbrf0001061,,=,,,non-substrate,82,1.45,,,Lorcainide,,,MDR1-MDCKII,MDCKII,,,,,human,mbds0010,,2013-11-17 06:53:02
mbbd000138285,mbcd0003915,mbtp000001,mbrf0001061,,=,,,non-substrate,82,1.27,,,Promethazine,,,MDR1-MDCKII,MDCKII,,,,,human,mbds0010,,2013-11-17 06:53:03
mbbd000138286,mbcd0029110,mbtp000001,mbrf0001061,,=,,,substrate,82,3.71,,,Acrivastine,,,MDR1-MDCKII,MDCKII,,,,,human,mbds0010,,2013-11-17 06:53:03
mbbd000138287,mbcd0003901,mbtp000001,mbrf0001061,,=,,,substrate,82,8.65,,,Cetirizine,,,MDR1-MDCKII,MDCKII,,,,,human,mbds0010,,2013-11-17 06:53:03
mbbd000138288,mbcd0001111,mbtp000001,mbrf0001061,,=,,,substrate,82,4.77,,,Cimetidine,,,MDR1-MDCKII,MDCKII,,,,,human,mbds0010,,2013-11-17 06:53:04
mbbd000138289,mbcd0001071,mbtp000001,mbrf0001061,,=,,,substrate,82,3.17,,,Famciclovir,,,MDR1-MDCKII,MDCKII,,,,,human,mbds0010,,2013-11-17 06:53:04
mbbd000138290,mbcd0002323,mbtp000001,mbrf0001061,,=,,,substrate,82,24.6,,,Indinavir,,,MDR1-MDCKII,MDCKII,,,,,human,mbds0010,,2013-11-17 06:53:04
mbbd000138291,mbcd0001170,mbtp000001,mbrf0001061,,=,,,substrate,82,8.85,,,Labetolol,,,MDR1-MDCKII,MDCKII,,,,,human,mbds0010,,2013-11-17 06:53:06
mbbd000138292,mbcd0003928,mbtp000001,mbrf0001061,,=,,,substrate,82,2.23,,,Neostigmine,,,MDR1-MDCKII,MDCKII,,,,,human,mbds0010,,2013-11-17 06:53:06
mbbd000138293,mbcd0019252,mbtp000001,mbrf0001061,,=,,,substrate,82,3.63,,,Pirenzapine,pirenzepine?,,MDR1-MDCKII,MDCKII,,,,,human,mbds0010,,2013-11-17 06:53:06
mbbd000138294,mbcd0003115,mbtp000001,mbrf0001061,,=,,,substrate,82,1.94,,,Trimethoprim,,,MDR1-MDCKII,MDCKII,,,,,human,mbds0010,,2013-11-17 06:53:06
mbbd000138295,mbcd0002383,mbtp000001,mbrf0001061,,=,,,substrate,82,29.0,,,Amprenavir,,,MDR1-MDCKII,MDCKII,,,,,human,mbds0010,,2013-11-17 06:53:07
mbbd000138296,mbcd0002109,mbtp000001,mbrf0001061,,=,,,substrate,82,2.22,,,Astemizole,,,MDR1-MDCKII,MDCKII,,,,,human,mbds0010,,2013-11-17 06:53:07
mbbd000138297,mbcd0002338,mbtp000001,mbrf0001061,,=,,,substrate,82,1.53,,,Diltiazem,,,MDR1-MDCKII,MDCKII,,,,,human,mbds0010,,2013-11-17 06:53:07
mbbd000138298,mbcd0014045,mbtp000001,mbrf0001061,,=,,,substrate,82,31.2,,,Domperidone,,,MDR1-MDCKII,MDCKII,,,,,human,mbds0010,,2013-11-17 06:53:07
mbbd000138299,mbcd0002539,mbtp000001,mbrf0001061,,=,,,substrate,82,9.94,,,Loperamide,,,MDR1-MDCKII,MDCKII,,,,,human,mbds0010,,2013-11-17 06:53:07
mbbd000138300,mbcd0001432,mbtp000001,mbrf0001061,,=,,,substrate,82,2.81,,,Mequitazine,,,MDR1-MDCKII,MDCKII,,,,,human,mbds0010,,2013-11-17 06:53:08
mbbd000138301,mbcd0026632,mbtp000001,mbrf0001061,,=,,,substrate,82,22.3,,,Nelfinivir,nelfinavir?,,MDR1-MDCKII,MDCKII,,,,,human,mbds0010,,2013-11-17 06:53:08
mbbd000138302,mbcd0001533,mbtp000001,mbrf0001061,,=,,,substrate,82,261.0,,,Saquinavir,,,MDR1-MDCKII,MDCKII,,,,,human,mbds0010,,2013-11-17 06:53:08
mbbd000138303,mbcd0002337,mbtp000001,mbrf0001061,,=,,,substrate,82,2.88,,,Terfenadine,,,MDR1-MDCKII,MDCKII,,,,,human,mbds0010,,2013-11-17 06:53:09
mbbd000138304,mbcd0027062,mbtp000001,mbrf0001061,,=,,,substrate,82,1.73,,,Verapamil,,,MDR1-MDCKII,MDCKII,,,,,human,mbds0010,,2013-11-17 06:53:09
mbbd000138306,mbcd0001533,mbtp000005,mbrf0001269,,,,,substrate,,,,,saquinavir,,,"polarized non-human (canine) MDCKII cell lines expressing human MRP1, MRP2, MRP3, MRP5; 5mM substrate; GF120918 used to inhibit P-gp human MRP1, MRP2, MRP3, MRP5",MDCKII,,,,,human,mbds0010,,2013-12-09 20:16:21
mbbd000138307,mbcd0003154,mbtp000005,mbrf0001269,,,,,inducer,,,,,probenacid,,,"polarized non-human (canine) MDCKII cell lines expressing human MRP1, MRP2, MRP3, MRP5; probenecid-enhanced efflux of HIV protease inhibitors human MRP1, MRP2, MRP3, MRP5",,,,,,human,mbds0010,,2013-12-09 20:16:20
mbbd000138308,mbcd0002988,mbtp000005,mbrf0001269,,,,,inducer,,,,,sulfinpyrazone,,,"polarized non-human (canine) MDCKII cell lines expressing human MRP1, MRP2, MRP3, MRP5; sulfinpyrazone-enhanced efflux of HIV protease inhibitors human MRP1, MRP2, MRP3, MRP5",,,,,,human,mbds0010,,2013-12-09 20:16:18
mbbd000138309,mbcd0001808,mbtp000005,mbrf0001269,,,,,non-inhibitor,,,,,GF120918,,,"polarized non-human (canine) MDCKII cell lines expressing human MRP1, MRP2, MRP3, MRP5; 5mM GF120918 human MRP1, MRP2, MRP3, MRP5",,,,,,human,mbds0010,,2013-12-09 20:16:18
mbbd000138310,mbcd0001938,mbtp000008,mbrf0001269,,,,,non-substrate,,,,,indinavir,,,"polarized non-human (canine) MDCKII cell lines expressing human MRP1, MRP2, MRP3, MRP5; 5mM substrate; GF120918 used to inhibit P-gp human MRP1, MRP2, MRP3, MRP5",MDCKII,,,,,human,mbds0010,,2013-12-09 19:52:45
mbbd000138311,mbcd0001533,mbtp000008,mbrf0001269,,,,,non-substrate,,,,,ritonavir,,,"polarized non-human (canine) MDCKII cell lines expressing human MRP1, MRP2, MRP3, MRP5; 5mM substrate; GF120918 used to inhibit P-gp human MRP1, MRP2, MRP3, MRP5",MDCKII,,,,,human,mbds0010,,2013-12-09 19:52:46
mbbd000138312,mbcd0003154,mbtp000008,mbrf0001269,,,,,non-substrate,,,,,saquinavir,,,"polarized non-human (canine) MDCKII cell lines expressing human MRP1, MRP2, MRP3, MRP5; 5mM substrate; GF120918 used to inhibit P-gp human MRP1, MRP2, MRP3, MRP5",MDCKII,,,,,human,mbds0010,,2013-12-09 19:52:46
mbbd000138313,mbcd0000844,mbtp000007,mbrf0001378,,=,,,inhibitor,25,1.8,microM,0.2,TPeA,,,tetraethylammonium (TEA) transport in hOCT1-expressing HeLa cells,,,,,,human,mbds0003,v2007,2013-11-24 21:53:04
mbbd000138314,mbcd0003947,mbtp000007,mbrf0001378,,=,,,inhibitor,25,0.71,microM,0.08,Clonidine,,,tetraethylammonium (TEA) transport in hOCT1-expressing HeLa cells,,,,,,human,mbds0003,v2007,2013-11-24 21:53:04
mbbd000138315,mbcd0002340,mbtp000007,mbrf0001378,,=,,,inhibitor,25,4.3,microM,0.16,Chlorpromazine,,,tetraethylammonium (TEA) transport in hOCT1-expressing HeLa cells,,,,,,human,mbds0003,v2007,2013-11-24 21:53:04
mbbd000138316,mbcd0027018,mbtp000007,mbrf0001378,,=,,,inhibitor,25,5.4,microM,0.22,Quinidine,,,tetraethylammonium (TEA) transport in hOCT1-expressing HeLa cells,,,,,,human,mbds0003,v2007,2013-11-24 21:53:04
mbbd000138317,mbcd0027888,mbtp000007,mbrf0001378,,=,,,inhibitor,25,7.7,microM,1.94,Crystal violet,,,tetraethylammonium (TEA) transport in hOCT1-expressing HeLa cells,,,,,,human,mbds0003,v2007,2013-11-24 21:53:04
mbbd000138318,mbcd0027318,mbtp000007,mbrf0001378,,=,,,inhibitor,25,9.7,microM,0.94,Pindolol,,,tetraethylammonium (TEA) transport in hOCT1-expressing HeLa cells,,,,,,human,mbds0003,v2007,2013-11-24 21:53:04
mbbd000138319,mbcd0003941,mbtp000007,mbrf0001378,,=,,,inhibitor,25,14.5,microM,0.83,Procainamide,,,tetraethylammonium (TEA) transport in hOCT1-expressing HeLa cells,,,,,,human,mbds0003,v2007,2013-11-24 21:53:04
mbbd000138320,mbcd0003022,mbtp000007,mbrf0001378,,=,,,inhibitor,25,15.7,microM,1.15,1-Methyl-4-phenylpyridinium,,,tetraethylammonium (TEA) transport in hOCT1-expressing HeLa cells,,,,,,human,mbds0003,v2007,2013-11-24 21:53:04
mbbd000138321,mbcd0003083,mbtp000007,mbrf0001378,,=,,,inhibitor,25,18.4,microM,2.42,Amantadine,,,tetraethylammonium (TEA) transport in hOCT1-expressing HeLa cells,,,,,,human,mbds0003,v2007,2013-11-24 21:53:04
mbbd000138322,mbcd0002666,mbtp000007,mbrf0001378,,=,,,inhibitor,25,21.7,microM,2.33,Ranitidine,,,tetraethylammonium (TEA) transport in hOCT1-expressing HeLa cells,,,,,,human,mbds0003,v2007,2013-11-24 21:53:04
mbbd000138323,mbcd0000928,mbtp000007,mbrf0001378,,=,,,inhibitor,25,53.2,microM,9.07,Nicotine,,,tetraethylammonium (TEA) transport in hOCT1-expressing HeLa cells,,,,,,human,mbds0003,v2007,2013-11-24 21:53:04
mbbd000138324,mbcd0000010,mbtp000007,mbrf0001378,,=,,,inhibitor,25,80.6,microM,3.2,1-(2-Hydroxyethyl)quinolinium,,,tetraethylammonium (TEA) transport in hOCT1-expressing HeLa cells,,,,,,human,mbds0003,v2007,2013-11-24 21:53:04
mbbd000138325,mbcd0007741,mbtp000007,mbrf0001378,,=,,,inhibitor,25,107.0,microM,6.7,Tyramine,,,tetraethylammonium (TEA) transport in hOCT1-expressing HeLa cells,,,,,,human,mbds0003,v2007,2013-11-24 21:53:04
mbbd000138326,mbcd0013197,mbtp000007,mbrf0001378,,=,,,inhibitor,25,434.0,microM,31.5,Thiamine,,,tetraethylammonium (TEA) transport in hOCT1-expressing HeLa cells,,,,,,human,mbds0003,v2007,2013-11-24 21:53:04
mbbd000138327,mbcd0003933,mbtp000007,mbrf0001378,,=,,,inhibitor,25,487.2,microM,43.3,Dopamine,,,tetraethylammonium (TEA) transport in hOCT1-expressing HeLa cells,,,,,,human,mbds0003,v2007,2013-11-24 21:53:04
mbbd000138328,mbcd0000309,mbtp000007,mbrf0001378,,=,,,inhibitor,25,544.0,microM,19.0,Cyclohexylamine,,,tetraethylammonium (TEA) transport in hOCT1-expressing HeLa cells,,,,,,human,mbds0003,v2007,2013-11-24 21:53:04
mbbd000138329,mbcd0000607,mbtp000007,mbrf0001378,,=,,,inhibitor,25,1035.0,microM,58.0,N1-Methylnicotinamide,,,tetraethylammonium (TEA) transport in hOCT1-expressing HeLa cells,,,,,,human,mbds0003,v2007,2013-11-24 21:53:04
mbbd000138330,mbcd0003907,mbtp000007,mbrf0001378,,=,,,inhibitor,25,3007.0,microM,27.2,Histamine,,,tetraethylammonium (TEA) transport in hOCT1-expressing HeLa cells,,,,,,human,mbds0003,v2007,2013-11-24 21:53:04
mbbd000138331,mbcd0003945,mbtp000007,mbrf0001378,,=,,,inhibitor,25,3540.0,microM,24.0,Choline,,,tetraethylammonium (TEA) transport in hOCT1-expressing HeLa cells,,,,,,human,mbds0003,v2007,2013-11-24 21:53:04
mbbd000138332,mbcd0000009,mbtp000007,mbrf0001378,,=,,,inhibitor,25,16.2,microM,1.4,1-(2-Hydroxyethyl)-4-phenylpyridinium,,,tetraethylammonium (TEA) transport in hOCT1-expressing HeLa cells,,,,,,human,mbds0003,v2007,2013-11-24 21:53:04
mbbd000138333,mbcd0000019,mbtp000007,mbrf0001378,,=,,,inhibitor,25,7.1,microM,1.1,1-Ethyl-4-phenylpyridinium,,,tetraethylammonium (TEA) transport in hOCT1-expressing HeLa cells,,,,,,human,mbds0003,v2007,2013-11-24 21:53:04
mbbd000138334,mbcd0000012,mbtp000007,mbrf0001378,,=,,,inhibitor,25,9.3,microM,0.6,1-(Phenyl)methyl-4-phenylpyridinium,,,tetraethylammonium (TEA) transport in hOCT1-expressing HeLa cells,,,,,,human,mbds0003,v2007,2013-11-24 21:53:04
mbbd000138335,mbcd0000008,mbtp000007,mbrf0001378,,=,,,inhibitor,25,31.1,microM,2.3,1-(2-Hydroxyethyl)-3-phenylpyridinium,,,tetraethylammonium (TEA) transport in hOCT1-expressing HeLa cells,,,,,,human,mbds0003,v2007,2013-11-24 21:53:04
mbbd000138336,mbcd0000018,mbtp000007,mbrf0001378,,=,,,inhibitor,25,28.3,microM,4.5,1-Ethyl-3-phenylpyridinium,,,tetraethylammonium (TEA) transport in hOCT1-expressing HeLa cells,,,,,,human,mbds0003,v2007,2013-11-24 21:53:04
mbbd000138337,mbcd0000011,mbtp000007,mbrf0001378,,=,,,inhibitor,25,5.5,microM,0.9,1-(Phenyl)methyl-3-phenylpyridinium,,,tetraethylammonium (TEA) transport in hOCT1-expressing HeLa cells,,,,,,human,mbds0003,v2007,2013-11-24 21:53:04
mbbd000138338,mbcd0000020,mbtp000007,mbrf0001378,,=,,,inhibitor,25,67.6,microM,11.2,1-Ethylquinolinium,,,tetraethylammonium (TEA) transport in hOCT1-expressing HeLa cells,,,,,,human,mbds0003,v2007,2013-11-24 21:53:04
mbbd000138339,mbcd0000654,mbtp000007,mbrf0001378,,=,,,inhibitor,25,14.3,microM,0.7,1-(Phenyl)methylquinolinium,,,tetraethylammonium (TEA) transport in hOCT1-expressing HeLa cells,,,,,,human,mbds0003,v2007,2013-11-24 21:53:04
mbbd000138340,mbcd0003963,mbtp000001,mbrf0001066,,,,,non-substrate,,,,,5-fluorouracil,,,Uptake comparison with MRD1-expressing variant (BC19),MCF7,,10,mM,,human,mbds0010,,2013-10-09 22:18:40
mbbd000138344,mbcd0001892,mbtp000002,mbrf0001318,,,,,substrate,,,,,progesterone,,,hBCRP expressed in the Gram-positive bacterium Lactococcus lactis; inside-out membrane vesicles of L. lactis,Lactococcus lactis,,,,,human,mbds0010,,2013-12-09 20:08:54
mbbd000138345,mbcd0000387,mbtp000016,mbrf0001416,,,,,non-substrate,,,,,estradiol 17beta-D-glucuronide,,,Xenopus laevis oocytes,Xenopus laevis oocytes,,57,nM,,human,mbds0010,,2013-11-17 19:45:31
mbbd000138346,mbcd0003146,mbtp000016,mbrf0001416,,,,,non-substrate,,,,,p-aminohippurate;PAH,,,Xenopus laevis oocytes,Xenopus laevis oocytes,,1,microM,,human,mbds0010,,2013-11-17 19:45:31
mbbd000138347,mbcd0002959,mbtp000001,mbrf0001497,,=,,,substrate,82,4.3,,,Dexamethasone,,,LLC-MDR1,LLC,,5,microM,,human,mbds0010,,2013-11-17 19:48:20
mbbd000138348,mbcd0001938,mbtp000001,mbrf0001497,,=,,,substrate,82,27.0,,,Ritonavir,,,LLC-MDR1,LLC,,5,microM,,human,mbds0010,,2013-11-17 19:48:20
mbbd000138349,mbcd0027062,mbtp000001,mbrf0001497,,=,,,substrate,82,4.9,,,Verapamil,,,LLC-MDR1,LLC,,0.5,microM,,human,mbds0010,,2013-11-17 19:48:20
mbbd000138353,mbcd0001197,mbtp000002,mbrf0001270,,,,,non-substrate,,,,,leucovorin,,,membrane vesicles prepared from HEK293 cells transfected with ABCG2 expression vector; 100 microM,HEK293,,,,,human,mbds0010,,2013-12-09 19:55:26
mbbd000138354,mbcd0003043,mbtp000002,mbrf0001270,,=,,,substrate,22,687.0,pmol mg-1 min-1,87,MTX,,,membrane vesicles prepared from HEK293 cells transfected with ABCG2 expression vector,HEK293,,,,,human,mbds0010,,2013-11-17 07:10:34
mbbd000138355,mbcd0000387,mbtp000002,mbrf0001270,,=,,,substrate,22,103.0,pmol mg-1 min-1,17,E(2)17betaG,,,membrane vesicles prepared from HEK293 cells transfected with ABCG2 expression vector,HEK293,,,,,human,mbds0010,,2013-11-17 07:10:34
mbbd000138356,mbcd0001267,mbtp000011,mbrf0001389,,=,,,substrate,28,48.5,nM,12.2,Prostaglandin E1,,,Xenopus laevis oocytes; 50 microM substrate,Xenopus laevis oocytes,,,,,human,mbds0003,v2007,2013-12-09 19:55:28
mbbd000138357,mbcd0001343,mbtp000011,mbrf0001389,,=,,,substrate,28,55.5,nM,6.7,Prostaglandin E2,,,Xenopus laevis oocytes; 15 microM substrate,Xenopus laevis oocytes,,,,,human,mbds0003,v2007,2013-12-09 19:55:30
mbbd000138358,mbcd0001664,mbtp000011,mbrf0001389,,=,,,non-substrate,89,0.8,,,Taurocholate,,,Xenopus laevis oocytes; 15 microM substrate,Xenopus laevis oocytes,,,,,human,mbds0003,v2007,2013-12-09 20:14:33
mbbd000138359,mbcd0000714,mbtp000011,mbrf0001389,,=,,,non-substrate,89,0.89,,,Prostaglandin D2,,,Xenopus laevis oocytes; 18 microM substrate,Xenopus laevis oocytes,,,,,human,mbds0003,v2007,2013-12-09 19:55:24
mbbd000138360,mbcd0001267,mbtp000011,mbrf0001389,,=,,,substrate,89,2.03,,,Prostaglandin E1,,,Xenopus laevis oocytes; 50 microM substrate,Xenopus laevis oocytes,,,,,human,mbds0010,,2013-12-09 20:50:55
mbbd000138361,mbcd0001343,mbtp000011,mbrf0001389,,=,,,substrate,89,3.61,,,Prostaglandin E2,,,Xenopus laevis oocytes; 15 microM substrate,Xenopus laevis oocytes,,,,,human,mbds0010,,2013-12-09 20:50:55
mbbd000138362,mbcd0000719,mbtp000011,mbrf0001389,,=,,,substrate,89,1.57,,,Prostaglandin F2alpha,,,Xenopus laevis oocytes; 13.7 microM substrate,Xenopus laevis oocytes,,,,,human,mbds0003,v2007,2013-12-09 20:50:56
mbbd000138363,mbcd0000848,mbtp000011,mbrf0001389,,=,,,non-substrate,89,1.11,,,Thromboxane B2,,,Xenopus laevis oocytes; 36 microM substrate,Xenopus laevis oocytes,,,,,human,mbds0003,v2007,2013-12-09 20:50:56
mbbd000138372,mbcd0003001,mbtp000001,mbrf0001196,,,,,non-substrate,,,,,testosterone,,,HeLa-AR and LNCaP prostate cancer cells; cellular accumulation assays,HeLa-AR,,,,,human,mbds0010,,2013-12-09 19:54:18
mbbd000138375,mbcd0003211,mbtp000001,mbrf0001209,,,,,inducer,,,,,estrone,,,P-gp expression at both the protein and mRNA level in vitro,,,,,,human,mbds0010,,2012-08-15 21:49:13
mbbd000138377,mbcd0029112,mbtp000001,mbrf0001245,,,,,substrate,,,,,8-sphingenine,,,Caco-2 cells,Caco-2,,,,,human,mbds0010,,2013-11-24 23:12:20
mbbd000138378,mbcd0029113,mbtp000001,mbrf0001245,,,,,substrate,,,,,"4,8-sphingadienine",,,Caco-2 cells,Caco-2,,,,,human,mbds0010,,2013-11-24 23:12:21
mbbd000138379,mbcd0029114,mbtp000001,mbrf0001245,,,,,substrate,,,,,"9-methyl-4,8-sphingadienine",,,Caco-2 cells,Caco-2,,,,,human,mbds0010,,2013-11-24 23:12:22
mbbd000138380,mbcd0003494,mbtp000009,mbrf0001368,,=,,,substrate,33,378.0,nL/oocyte,42.1,Gly-Sar,,,Xenopus laevis oocytes,Xenopus laevis oocytes,,,,,human,mbds0010,,2013-11-17 07:15:02
mbbd000138382,mbcd0001298,mbtp000009,mbrf0001368,,=,,,substrate,33,28.9,nL/oocyte,7.22,Cefaclor,,,Xenopus laevis oocytes,Xenopus laevis oocytes,,,,,human,mbds0010,,2013-11-17 07:15:02
mbbd000138403,mbcd0001892,mbtp000005,mbrf0001518,,>=,,,inhibitor,3,100.0,microM,,progesterone,,,intracellular CMF fluorescence in MDCK II/MRP2 cells,,,,,,human,mbds0010,,2012-08-15 21:49:13
mbbd000138404,mbcd0003005,mbtp000005,mbrf0001294,,~,,,substrate,33,1600.0,microL/mg protein/30 min,,olmesartan,,,human canalicular membrane vesicles (hCMVs) and MRP2-expressing membrane vesicles; 21 nM,hCMV,,,,,human,mbds0010,,2013-11-26 00:48:05
mbbd000138405,mbcd0001151,mbtp000005,mbrf0001251,,=,,,substrate,84,5.75,,,VBL,,,MDCK type II cells transfected with either human MRP2 (MDCKII-MRP2); 2 microM,MDCKII,,,,,human,mbds0010,,2013-12-09 20:52:25
mbbd000138409,mbcd0029104,mbtp000009,mbrf0001536,,=,,,inhibitor,29,0.047,mM,0.001,zofenopril,,,Caco-2; inhibition of Gly-Sar uptake,,,,,,human,mbds0010,,2013-12-09 20:57:33
mbbd000138410,mbcd0029105,mbtp000009,mbrf0001536,,=,,,inhibitor,29,6.0,mM,,quinaprilat,,,"Caco-2; Ki>3.16, extrapolated to Ki~6 due to limited solubility",,,,,,human,mbds0010,,2013-12-09 19:58:11
mbbd000138411,mbcd0003498,mbtp000009,mbrf0001536,,=,,,inhibitor,29,14.0,mM,1,enalapril,,,Caco-2; inhibition of Gly-Sar uptake,,,,,,human,mbds0010,,2013-12-09 19:58:10
mbbd000138412,mbcd0003061,mbtp000009,mbrf0001536,,=,,,non-inhibitor,29,23.0,mM,1,Lisinopril,,,Caco-2; inhibition of Gly-Sar uptake,,,,,,human,mbds0010,,2013-12-09 19:58:09
mbbd000138413,mbcd0003142,mbtp000009,mbrf0001536,,=,,,non-inhibitor,29,46.0,mM,2,captopril,,,Caco-2; inhibition of Gly-Sar uptake,,,,,,human,mbds0010,,2013-12-09 19:58:09
mbbd000138414,mbcd0029104,mbtp000009,mbrf0001536,,=,,,inhibitor,29,0.05,mM,0.01,zofenopril,,,inhibition of Gly-Sar uptake in HRPE-hPEPT1,,,,,,human,mbds0010,,2012-08-15 21:49:13
mbbd000138415,mbcd0003498,mbtp000009,mbrf0001536,,=,,,inhibitor,29,10.0,mM,1,enalapril,,,inhibition of Gly-Sar uptake in HRPE-hPEPT1,,,,,,human,mbds0010,,2012-08-15 21:49:13
mbbd000138416,mbcd0003142,mbtp000009,mbrf0001536,,=,,,non-inhibitor,29,43.0,mM,7,captopril,,,inhibition of Gly-Sar uptake in HRPE-hPEPT1,,,,,,human,mbds0010,,2012-08-15 21:49:13
mbbd000138417,mbcd0003494,mbtp000009,mbrf0001536,,=,,,substrate,29,0.72,mM,0.2,Gly-Sar,,,Caco-2; inhibition of Gly-Sar uptake,Caco-2,,,,,human,mbds0010,,2013-12-09 19:58:12
mbbd000138418,mbcd0003599,mbtp000009,mbrf0001536,,=,,,substrate,29,0.2,mM,0.01,Ala-Ala-Ala,,,Caco-2; inhibition of Gly-Sar uptake,Caco-2,,,,,human,mbds0010,,2013-12-09 20:54:07
mbbd000138419,mbcd0003493,mbtp000009,mbrf0001536,,=,,,substrate,29,0.14,mM,0.01,Ala-Pro,,,Caco-2; inhibition of Gly-Sar uptake,Caco-2,,,,,human,mbds0010,,2013-12-09 19:58:08
mbbd000138420,mbcd0003099,mbtp000002,mbrf0001537,,,,,substrate,,,,,erlotinib,,,IGROV1 human ovarian adenocarcinoma and the IGROV1-derived resistant T8 BCRP-expressing subline,IGROV1,,,,,human,mbds0010,,2013-11-24 23:56:47
mbbd000138421,mbcd0003099,mbtp000005,mbrf0001537,,,,,non-substrate,,,,,erlotinib,,,Polarized MDCKII cells stably expressing human MRP2 (ABCC2),MDCKII,,,,,human,mbds0010,,2013-11-17 19:51:35
mbbd000138422,mbcd0000960,mbtp000002,mbrf0001539,,=,,,substrate,28,2.3,mM,0.3,cladribine;2-CdA,,,Inside-out membrane vesicles were prepared from HEK293 cells (human embryonic kidney cells) ,HEK293,,,,,human,mbds0010,,2013-11-17 19:53:15
mbbd000138423,mbcd0000960,mbtp000002,mbrf0001539,,=,,,substrate,28,1.6,mM,0.1,cladribine;2-CdA,,,Inside-out membrane vesicles were prepared from Spodoptera frugiperda insect cells (Sf9),Sf9,,,,,human,mbds0010,,2013-11-17 19:53:15
mbbd000138424,mbcd0029116,mbtp000002,mbrf0001539,,=,,,substrate,28,148.0,microM,126-165,CdAMP;cladribine monophosphate;2-CdAMP,,,Inside-out membrane vesicles were prepared from Spodoptera frugiperda insect cells (Sf9),Sf9,,,,,human,mbds0010,,2013-11-17 19:53:15
mbbd000138425,mbcd0029116,mbtp000002,mbrf0001539,,=,,,substrate,22,775.0,pmol (mg protein)-1 min-1,578-984,CdAMP;cladribine monophosphate;2-CdAMP,,,Inside-out membrane vesicles were prepared from Spodoptera frugiperda insect cells (Sf9),Sf9,,,,,human,mbds0010,,2013-11-21 01:53:19
mbbd000138426,mbcd0003922,mbtp000002,mbrf0001540,,=,,,inhibitor,25,165.0,microM,0.61,OXP,,,MDCKII cells - ABCG2,MDCKII,,,,,human,mbds0010,,2013-11-17 20:07:10
mbbd000138430,mbcd0002985,mbtp000001,mbrf0001541,,,,,non-substrate,,,,,carbamazepine,,,Transwell assay with MDR1-transfected LLC cells,LLC-PK1,,,,,human,mbds0010,,2013-11-17 20:11:28
mbbd000138431,mbcd0003138,mbtp000002,mbrf0001559,,,,,non-substrate,,,,,nizatidine,,,Caco-2 cell monolayers,Caco-2,,,,,human,mbds0010,,2013-11-17 20:12:59
mbbd000138432,mbcd0003138,mbtp000005,mbrf0001559,,,,,non-substrate,,,,,nizatidine,,,Caco-2 cell monolayers,Caco-2,,,,,human,mbds0010,,2013-11-17 20:12:59
mbbd000138433,mbcd0003138,mbtp000001,mbrf0001559,,=,,,substrate,22,0.004,nmol cm-2 s-1,,nizatidine,,,Caco-2 cell monolayers,Caco-2,,,,,human,mbds0010,,2013-11-17 20:12:59
mbbd000138434,mbcd0002352,mbtp000009,mbrf0001563,,=,,,substrate,41,0.47,microL min-1 (mg protein)-1,0.517,oseltamivir; tamiflu,,,Caco-2 cells; uptake of oseltamivir (100 microM) was measured at 37 deg C in HBSS,Caco-2,,100,microM,,human,mbds0010,,2013-11-21 01:53:02
mbbd000138435,mbcd0002352,mbtp000009,mbrf0001563,,=,,,substrate,28,8.59,mM,1.98,oseltamivir; tamiflu,,,HeLa/PEPT1 cells,HeLa,,,,,human,mbds0010,,2013-11-17 19:38:06
mbbd000138436,mbcd0029106,mbtp000009,mbrf0001563,,=,,,non-substrate,8,0.034,microL 10 min-1 (mg protein)-1,0.002,Ro 64-0802,,,HeLa/PEPT1 cells; cell/medium ratio,HeLa,,,,,human,mbds0010,,2013-11-21 01:53:03
mbbd000138437,mbcd0002352,mbtp000009,mbrf0001563,,=,,,substrate,22,45.6,nM min-1 (mg protein)-1,12.0,oseltamivir; tamiflu,,,Caco-2 cells; uptake of oseltamivir (100 microM) was measured at 37 deg C in HBSS,Caco-2,,100,microM,,human,mbds0010,,2013-11-21 01:53:06
mbbd000138438,mbcd0002352,mbtp000009,mbrf0001563,,=,,,substrate,22,11.4,nM (10 min)-1 (mg protein)-1,1.68,oseltamivir; tamiflu,,,HeLa/PEPT1 cells,HeLa,,,,,human,mbds0010,,2013-11-21 01:54:27
mbbd000138439,mbcd0001280,mbtp000002,mbrf0001569,,,,,substrate,,,,,sulfasalazine,,,Caco-2 cells,Caco-2,,,,,human,mbds0010,,2013-11-17 20:14:20
mbbd000138440,mbcd0006203,mbtp000002,mbrf0001570,,,,,inhibitor,,,,,harmine,,,BCRP overexpressing breast cancer cell line (MDA-MB-231),,,,,,human,mbds0010,,2012-08-15 21:49:13
mbbd000138441,mbcd0006203,mbtp000001,mbrf0001570,,,,,non-inhibitor,,,,,harmine,,,The P-gp overexpressing cell line CEM ADR5000,,,,,,human,mbds0010,,2012-08-15 21:49:13
mbbd000138442,mbcd0029115,mbtp000001,mbrf0001607,,,,,substrate,,,,,vildagliptin,,,,,,,,,human,mbds0010,,2013-12-10 22:21:07
mbbd000138443,mbcd0001705,mbtp000001,mbrf0001607,,,,,substrate,,,,,saxagliptin,,,,,,,,,human,mbds0010,,2013-12-10 22:21:07
mbbd000138447,mbcd0025833,mben000015,mbrf0001607,,,,,non-substrate,,,,,sitagliptin,,,,,,,,,human,mbds0010,,2013-12-10 22:21:07
mbbd000138448,mbcd0029115,mben000015,mbrf0001607,,,,,non-substrate,,,,,vildagliptin,,,,,,,,,human,mbds0010,,2013-12-10 22:21:07
mbbd000138449,mbcd0001705,mben000015,mbrf0001607,,,,,substrate,,,,,saxagliptin,,,,,,,,,human,mbds0010,,2013-12-10 22:21:07
mbbd000138450,mbcd0025833,mben000014,mbrf0001607,,,,,substrate,,,,,sitagliptin,,,,,,,,,human,mbds0010,,2013-12-10 22:21:07
mbbd000138451,mbcd0029115,mben000014,mbrf0001607,,,,,non-substrate,,,,,vildagliptin,,,,,,,,,human,mbds0010,,2013-12-10 22:21:07
mbbd000138452,mbcd0001705,mben000014,mbrf0001607,,,,,non-substrate,,,,,saxagliptin,,,,,,,,,human,mbds0010,,2013-12-10 22:21:07
mbbd000138453,mbcd0001316,mbtp000001,mbrf0001610,,=,,,inhibitor,25,2.9,microM,,tacrolimus,,,ABCB1-transfected MDCKII cells,MDCKII,,,,,human,mbds0010,,2013-11-17 20:49:28
mbbd000138454,mbcd0001316,mbtp000005,mbrf0001610,,<=,,,non-inhibitor,25,50.0,microM,,tacrolimus,,,ABCC2-MDCKII,MDCKII,,,,,human,mbds0010,,2013-11-17 20:49:28
mbbd000138455,mbcd0001316,mbtp000012,mbrf0001610,,=,,,inhibitor,25,7.2,microM,,tacrolimus,,,inhibition of bromosulphthalein in OATP1B1 transfected HEK cells,HEK293,mbcd0003035,,,,human,mbds0010,,2013-11-17 20:49:29
mbbd000138456,mbcd0001316,mbtp000013,mbrf0001610,,=,,,inhibitor,25,2.04,microM,,tacrolimus,,,OATP-transfected HEK cells,HEK293,,,,,human,mbds0010,,2013-11-17 20:49:29
mbbd000138457,mbcd0001316,mbtp000012,mbrf0001610,,,,,non-substrate,,,,,tacrolimus,,,OATP-transfected HEK cells,HEK293,,,,,human,mbds0010,,2013-11-17 20:49:30
mbbd000138458,mbcd0001316,mbtp000013,mbrf0001610,,,,,non-substrate,,,,,tacrolimus,,,OATP-transfected HEK cells,HEK293,,,,,human,mbds0010,,2013-11-17 20:49:30
mbbd000138459,mbcd0027835,mbtp000001,mbrf0001866,,,,,inhibitor,,,,,Mefloquine,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138460,mbcd0001241,mbtp000006,mbrf0001370,,=,,,inhibitor,72,25.2,%,1.51,nateglinide,,,Inhibition of [14C]L-Lactic acid uptake by Caco-2 cells and MCT1-expressing oocytes,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138461,mbcd0003823,mbtp000006,mbrf0000119,,=,,,inhibitor,17,0.44,nM,0.18,1,,,Inhibition of MCT1 in activated T cells measuring intracellular and extracellular lactate,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138462,mbcd0000316,mbtp000006,mbrf0000119,,=,,,substrate,28,8.2,mM,2.0,L-lactate,,,"recombinant hMCT1 was cloned and expressed in the rat pancreatic cell line INS1, which has low endogenous expression of MCT1",INS1,,,,,human,mbds0010,,2013-11-24 23:56:47
mbbd000138463,mbcd0003075,mbtp000025,mbrf0001388,,=,,,substrate,28,5.0,nM,,Estrone-3-sulfate,,,HEK293 cells,HEK293,,,,,human,mbds0010,,2013-11-17 07:18:44
mbbd000138465,mbcd0000201,mbtp000025,mbrf0001393,,=,,,substrate,89,3.5,,,BSP,,,Xenopus laevis oocyte (transfected); BSP (10 microM),Xenopus laevis oocytes,,10,microM,,human,mbds0010,,2013-11-04 02:02:15
mbbd000138466,mbcd0001664,mbtp000025,mbrf0001393,,=,,,non-substrate,89,1.0,,,Taurocholate,,,Xenopus laevis oocyte (transfected); Taurocholate (10 microM),Xenopus laevis oocytes,,10,microM,,human,mbds0010,,2013-11-04 02:02:15
mbbd000138467,mbcd0000455,mbtp000025,mbrf0001393,,=,,,non-substrate,89,1.2,,,Glycocholate,,,Xenopus laevis oocyte (transfected); Glycocholate (10 microM),Xenopus laevis oocytes,,10,microM,,human,mbds0010,,2013-11-04 02:02:16
mbbd000138468,mbcd0003075,mbtp000025,mbrf0001393,,=,,,substrate,89,2.3,,,Estrone-3-sulfate,,,Xenopus laevis oocyte (transfected); Estrone-3-sulfate (10 microM),Xenopus laevis oocytes,,10,microM,,human,mbds0010,,2013-11-04 02:02:16
mbbd000138469,mbcd0000387,mbtp000025,mbrf0001393,,=,,,non-substrate,89,0.6,,,E217betaG,,,Xenopus laevis oocyte (transfected); E217betaG (10 microM),Xenopus laevis oocytes,,10,microM,,human,mbds0010,,2013-11-04 02:02:16
mbbd000138470,mbcd0003070,mbtp000025,mbrf0001393,,=,,,substrate,89,1.7,,,DHEAS,,,Xenopus laevis oocyte (transfected); DHEAS (10 microM),Xenopus laevis oocytes,,10,microM,,human,mbds0010,,2013-11-04 02:02:16
mbbd000138471,mbcd0001442,mbtp000025,mbrf0001393,,=,,,non-substrate,89,1.0,,,Ouabain,,,Xenopus laevis oocyte (transfected); Ouabain (200 microM),Xenopus laevis oocytes,,200,microM,,human,mbds0010,,2013-11-04 02:02:17
mbbd000138472,mbcd0001050,mbtp000025,mbrf0001393,,=,,,non-substrate,89,1.3,,,Digoxin,,,Xenopus laevis oocyte (transfected); Digoxin (0.5 microM),Xenopus laevis oocytes,,0.5,microM,,human,mbds0010,,2013-11-04 02:02:17
mbbd000138473,mbcd0000605,mbtp000025,mbrf0001393,,=,,,non-substrate,89,1.1,,,N-Methyl quinine,,,Xenopus laevis oocyte (transfected); N-Methyl quinine (10 microM),Xenopus laevis oocytes,,10,microM,,human,mbds0010,,2013-11-04 02:02:17
mbbd000138474,mbcd0002917,mbtp000025,mbrf0001393,,=,,,non-substrate,89,1.0,,,LTC4,,,Xenopus laevis oocyte (transfected); LTC4 (5 nmol L-1),Xenopus laevis oocytes,,5,microM,,human,mbds0010,,2013-11-04 02:02:18
mbbd000138475,mbcd0001343,mbtp000025,mbrf0001393,,=,,,non-substrate,89,1.0,,,PGE2,,,Xenopus laevis oocyte (transfected); PGE2 (20 nmol L-1),Xenopus laevis oocytes,,20,microM,,human,mbds0010,,2013-11-04 02:02:18
mbbd000138476,mbcd0000984,mbtp000025,mbrf0001393,,=,,,non-substrate,89,1.0,,,T3,,,Xenopus laevis oocyte (transfected); T3 (10 nmol L-1),Xenopus laevis oocytes,,10,microM,,human,mbds0010,,2013-11-04 02:02:19
mbbd000138477,mbcd0003957,mbtp000025,mbrf0001393,,=,,,non-substrate,89,1.0,,,T4,,,Xenopus laevis oocyte (transfected); T4 (10 nmol L-1),Xenopus laevis oocytes,,10,microM,,human,mbds0010,,2013-11-04 02:02:19
mbbd000138478,mbcd0000324,mbtp000025,mbrf0001393,,=,,,non-substrate,89,1.0,,,Deltorphin II,,,Xenopus laevis oocyte (transfected); Deltorphin II (50 microM),Xenopus laevis oocytes,,50,microM,,human,mbds0010,,2013-11-04 02:02:20
mbbd000138479,mbcd0002041,mbtp000025,mbrf0001393,,=,,,non-substrate,89,1.3,,,DPDPE,,,Xenopus laevis oocyte (transfected); DPDPE (0.1 microM),Xenopus laevis oocytes,,0.1,microM,,human,mbds0010,,2013-11-04 02:02:20
mbbd000138480,mbcd0000199,mbtp000025,mbrf0001393,,=,,,non-substrate,89,0.9,,,BQ-123,,,Xenopus laevis oocyte (transfected); BQ-123 (0.5 microM),Xenopus laevis oocytes,,0.5,microM,,human,mbds0010,,2013-11-04 02:02:20
mbbd000138481,mbcd0003075,mbtp000025,mbrf0001395,,=,,,substrate,28,9.04,microM,3.17,estrone-3-sulfate,,,HEK293 (transfected); pH 7.4; uptake; 4.8 nM; 30 min,HEK293,,,,,human,mbds0010,,2013-11-04 22:30:40
mbbd000138482,mbcd0000387,mbtp000025,mbrf0001395,,,,,non-substrate,,,,,estradiol-17beta-glucuronide,,,HEK293 (transfected); pH 7.4; uptake; 5.7 nM; 30 min,HEK293,,,,,human,mbds0010,,2013-11-04 22:30:40
mbbd000138483,mbcd0003075,mbtp000025,mbrf0001395,,=,,,substrate,22,531.0,pmol / mg protein / 30 min,92.7,estrone-3-sulfate,,,HEK293 (transfected); pH 7.4; uptake; 4.8 nM; 30 min,HEK293,,,,,human,mbds0010,,2013-11-04 22:30:41
mbbd000138484,mbcd0003055,mbtp000025,mbrf0001395,,~,,,non-inhibitor,72,70.0,%,,estradiol,data read from graph,,relative uptake; inhibition of estrone-3-sulfate (4 nM) uptake; 30 mins; inhibitor concentration 1 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138485,mbcd0003055,mbtp000025,mbrf0001395,,~,,,non-inhibitor,72,88.0,%,,estradiol,data read from graph,,relative uptake; inhibition of estrone-3-sulfate (4 nM) uptake; 30 mins; inhibitor concentration 10 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138486,mbcd0003055,mbtp000025,mbrf0001395,,~,,,inhibitor,72,60.0,%,,estradiol,data read from graph,,relative uptake; inhibition of estrone-3-sulfate (4 nM) uptake; 30 mins; inhibitor concentration 100 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138487,mbcd0000387,mbtp000025,mbrf0001395,,~,,,non-inhibitor,72,77.0,%,,estradiol-17beta-glucuronide,data read from graph,,relative uptake; inhibition of estrone-3-sulfate (4 nM) uptake; 30 mins; inhibitor concentration 1 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138488,mbcd0000387,mbtp000025,mbrf0001395,,~,,,non-inhibitor,72,101.0,%,,estradiol-17beta-glucuronide,data read from graph,,relative uptake; inhibition of estrone-3-sulfate (4 nM) uptake; 30 mins; inhibitor concentration 10 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138489,mbcd0000387,mbtp000025,mbrf0001395,,~,,,non-inhibitor,72,112.0,%,,estradiol-17beta-glucuronide,data read from graph,,relative uptake; inhibition of estrone-3-sulfate (4 nM) uptake; 30 mins; inhibitor concentration 100 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138490,mbcd0000389,mbtp000025,mbrf0001395,,~,,,non-inhibitor,72,85.0,%,,estradiol-3-sulphate,data read from graph,,relative uptake; inhibition of estrone-3-sulfate (4 nM) uptake; 30 mins; inhibitor concentration 1 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138491,mbcd0000389,mbtp000025,mbrf0001395,,~,,,non-inhibitor,72,70.0,%,,estradiol-3-sulphate,data read from graph,,relative uptake; inhibition of estrone-3-sulfate (4 nM) uptake; 30 mins; inhibitor concentration 10 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138492,mbcd0000389,mbtp000025,mbrf0001395,,~,,,inhibitor,72,45.0,%,,estradiol-3-sulphate,data read from graph,,relative uptake; inhibition of estrone-3-sulfate (4 nM) uptake; 30 mins; inhibitor concentration 100 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138493,mbcd0000388,mbtp000025,mbrf0001395,,~,,,non-inhibitor,72,85.0,%,,estradiol-17beta-glucuronide-sulphate,data read from graph,,relative uptake; inhibition of estrone-3-sulfate (4 nM) uptake; 30 mins; inhibitor concentration 1 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138494,mbcd0000388,mbtp000025,mbrf0001395,,~,,,non-inhibitor,72,95.0,%,,estradiol-17beta-glucuronide-sulphate,data read from graph,,relative uptake; inhibition of estrone-3-sulfate (4 nM) uptake; 30 mins; inhibitor concentration 10 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138495,mbcd0000388,mbtp000025,mbrf0001395,,~,,,non-inhibitor,72,120.0,%,,estradiol-17beta-glucuronide-sulphate,data read from graph,,relative uptake; inhibition of estrone-3-sulfate (4 nM) uptake; 30 mins; inhibitor concentration 100 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138496,mbcd0003211,mbtp000025,mbrf0001395,,~,,,non-inhibitor,72,130.0,%,,Estrone,data read from graph,,relative uptake; inhibition of estrone-3-sulfate (4 nM) uptake; 30 mins; inhibitor concentration 1 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138497,mbcd0003211,mbtp000025,mbrf0001395,,~,,,non-inhibitor,72,85.0,%,,Estrone,data read from graph,,relative uptake; inhibition of estrone-3-sulfate (4 nM) uptake; 30 mins; inhibitor concentration 10 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138498,mbcd0003211,mbtp000025,mbrf0001395,,~,,,inhibitor,72,45.0,%,,Estrone,data read from graph,,relative uptake; inhibition of estrone-3-sulfate (4 nM) uptake; 30 mins; inhibitor concentration 100 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138499,mbcd0000393,mbtp000025,mbrf0001395,,~,,,non-inhibitor,72,175.0,%,,Estrone-3-glucuronide,data read from graph,,relative uptake; inhibition of estrone-3-sulfate (4 nM) uptake; 30 mins; inhibitor concentration 1 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138500,mbcd0000393,mbtp000025,mbrf0001395,,~,,,non-inhibitor,72,140.0,%,,Estrone-3-glucuronide,data read from graph,,relative uptake; inhibition of estrone-3-sulfate (4 nM) uptake; 30 mins; inhibitor concentration 10 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138501,mbcd0000393,mbtp000025,mbrf0001395,,~,,,non-inhibitor,72,125.0,%,,Estrone-3-glucuronide,data read from graph,,relative uptake; inhibition of estrone-3-sulfate (4 nM) uptake; 30 mins; inhibitor concentration 100 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138502,mbcd0003075,mbtp000025,mbrf0001395,,~,,,non-inhibitor,72,85.0,%,,Estrone-3-sulphate,data read from graph,,relative uptake; inhibition of estrone-3-sulfate (4 nM) uptake; 30 mins; inhibitor concentration 1 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138503,mbcd0003075,mbtp000025,mbrf0001395,,~,,,inhibitor,72,45.0,%,,Estrone-3-sulphate,data read from graph,,relative uptake; inhibition of estrone-3-sulfate (4 nM) uptake; 30 mins; inhibitor concentration 10 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138504,mbcd0003075,mbtp000025,mbrf0001395,,~,,,inhibitor,72,25.0,%,,Estrone-3-sulphate,data read from graph,,relative uptake; inhibition of estrone-3-sulfate (4 nM) uptake; 30 mins; inhibitor concentration 100 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138505,mbcd0000749,mbtp000025,mbrf0001396,,=,,,inhibitor,72,89.0,%,,Rifamycin SV,,,Xenopus laevis oocytes (transfected); inhibition of BSP (350 nM) uptake; Rifamycin SV (10 microM),Xenopus laevis oocytes,mbcd0003035,10,microM,,human,mbds0010,,2013-11-04 02:41:38
mbbd000138506,mbcd0001416,mbtp000025,mbrf0001396,,=,,,inhibitor,72,15.0,%,,Rifampin,,,"Xenopus laevis oocytes (transfected); inhibition of BSP (350 nM) uptake, Rifampin (10 microM)",Xenopus laevis oocytes,mbcd0003035,10,microM,,human,mbds0010,,2013-11-04 02:41:38
mbbd000138507,mbcd0001664,mbtp000025,mbrf0001340,,=,,,substrate,22,1093.0,pmol / 2 min / mg protein,162,taurocholic acid,,,HEK293 (transfected); pH 5.0; substrate 0.2 - 10 microM; 2 min,HEK293,,,,,human,mbds0010,,2013-11-24 23:12:58
mbbd000138508,mbcd0003126,mbtp000025,mbrf0002051,,=,,,inhibitor,25,5.5,mM,,Pravastatin,,,HEK293 (transfected); relative uptake; substrate estrone-3-sulfate (4.76 nM); pH 5.5; pravastatin 1 mM - 20 mM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138511,mbcd0003075,mbtp000025,mbrf0001340,,=,,,substrate,22,2135.8,pmol / mg protein / min,410.3,Estrone-3-sulfate,,,HEK293 (transfected); pH 5.0; substrate 9.2 nM - 20 microM; 1 or 5 min,HEK293,,,,,human,mbds0010,,2013-11-24 23:12:58
mbbd000138512,mbcd0003075,mbtp000025,mbrf0001340,,=,,,substrate,22,300.5,pmol / mg protein / min,46.0,Estrone-3-sulfate,,,HEK293 (transfected); pH 7.4; substrate 9.2 nM - 20 microM; 1 or 5 min,HEK293,,,,,human,mbds0010,,2013-11-24 23:12:59
mbbd000138513,mbcd0003126,mbtp000025,mbrf0001340,,=,,,substrate,22,41.6,nmol / mg protein / 10 min,6.4,Pravastatin,,,HEK293 (transfected); pH 5.0; substrate 29.4 nM - 10 microM; 10 min,HEK293,,0.0294-10,microM,,human,mbds0010,,2014-02-22 06:09:18
mbbd000138514,mbcd0001664,mbtp000025,mbrf0001340,,=,,,substrate,33,13.1,microL / mg protein,1.35,taurocholic acid,,,HEK293 (transfected); pH 5.0; substrate 0.15 microM; 2 min; OATP-B specific uptake,HEK293,,0.15,microM,,human,mbds0010,,2013-11-24 23:12:59
mbbd000138515,mbcd0003075,mbtp000025,mbrf0001648,,=,,,substrate,33,204.0,microL / mg protein / 10 min,,Estrone-3-sulfate,,,HEK293 (transfected); OATP-B mediated uptake; pH 7.4; substrate concentration 12.8 nM,HEK293,,,,,human,mbds0010,,2013-11-24 23:12:59
mbbd000138516,mbcd0003074,mbtp000025,mbrf0001648,,=,,,substrate,33,53.0,microL / mg protein / 10 min,,Glibenclamide,,,HEK293 (transfected); OATP-B mediated uptake; pH 7.4; substrate concentration 10.1 nM,HEK293,,,,,human,mbds0010,,2013-11-24 23:13:00
mbbd000138517,mbcd0003074,mbtp000025,mbrf0001648,,=,,,substrate,22,112.0,pmol / mg protein / min,52.2,Glibenclamide,,,HEK293 (transfected); pH 7.4; 10 min; 10 nM,HEK293,,,,,human,mbds0010,,2013-11-24 23:13:00
mbbd000138518,mbcd0003075,mbtp000025,mbrf0001648,,=,,,substrate,22,184.0,pmol / mg protein / 20 s,53.5,Estrone-3-sulfate,,,HEK293 (transfected); pH 7.4; 10 min; 10 nM,HEK293,,,,,human,mbds0010,,2013-11-24 23:13:00
mbbd000138519,mbcd0003070,mbtp000025,mbrf0002483,,,,,substrate,,,,,DHEAS,,,,,,,,,human,mbds0010,,2013-12-11 05:34:05
mbbd000138520,mbcd0003075,mbtp000025,mbrf0002483,,,,,substrate,,,,,estrone-3-sulfate,,,,,,,,,human,mbds0010,,2013-12-11 05:34:05
mbbd000138521,mbcd0029146,mbtp000025,mbrf0002483,,,,,substrate,,,,,pregnenolone sulfate,,,,,,,,,human,mbds0010,,2013-12-11 05:34:05
mbbd000138522,mbcd0001343,mbtp000025,mbrf0002483,,,,,substrate,,,,,prostaglandin E2,,,,,,,,,human,mbds0010,,2013-12-11 05:34:05
mbbd000138523,mbcd0001549,mbtp000025,mbrf0002217,,=,,,substrate,28,72.0,microM,,aliskiren,,,HEK293 (transfected),HEK293,,,,,human,mbds0010,,2013-11-24 23:13:00
mbbd000138524,mbcd0001549,mbtp000025,mbrf0002217,,=,,,inhibitor,25,95.0,microM,,aliskiren,,,HEK293 (transfected),,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138525,mbcd0001050,mbtp000025,mbrf0002095,,,,,non-substrate,,,,,digoxin,,,HEK293 (transfected),HEK293,,,,,human,mbds0010,,2013-11-24 23:13:01
mbbd000138526,mbcd0001050,mbtp000025,mbrf0002095,,>,,,inhibitor,25,300.0,microM,,digoxin,,,HEK293 (transfected),,,,,,human,mbds0010,,2013-12-10 22:19:00
mbbd000138527,mbcd0000201,mbtp000025,mbrf0001660,,,,,substrate,,,,,BSP,later experiment shows no statisically significant pH dependance; pH range 4.5 - 7.4,,HeLa R1-11 (transfected); 2.5 microM BSP; 5 min; pH 7.4,HeLa R1-11,,,,,human,mbds0010,,2013-11-24 23:55:20
mbbd000138528,mbcd0003043,mbtp000025,mbrf0001660,,,,,non-substrate,,,,,MTX,"not statistically significant (P=0.08), but uptake is perceptible",,HeLa R1-11 (transfected); 2.5 microM substrate; 9 min; pH 5.5,HeLa R1-11,,,,,human,mbds0010,,2013-11-24 23:55:21
mbbd000138529,mbcd0003959,mbtp000025,mbrf0001660,,,,,non-substrate,,,,,folic acid,,,HeLa R1-11 (transfected); 2.5 microM substrate; 9 min; pH 5.5,HeLa R1-11,,,,,human,mbds0010,,2013-11-24 23:55:22
mbbd000138530,mbcd0029125,mbtp000025,mbrf0001660,,,,,substrate,,,,,pemetrexed,later experiment shows strong pH dependance; substrate pH 4.5 - 5.5; non-substrate > pH 6.5,,HeLa R1-11 (transfected); 2.5 microM substrate; 9 min; pH 5.5,HeLa R1-11,,2.5,microM,,human,mbds0010,,2013-11-24 23:55:22
mbbd000138531,mbcd0029126,mbtp000025,mbrf0001660,,,,,non-substrate,,,,,(6S)5-formylTHF,,,HeLa R1-11 (transfected); 2.5 microM substrate; 9 min; pH 5.5,HeLa R1-11,,,,,human,mbds0010,,2013-11-24 23:55:22
mbbd000138532,mbcd0001677,mbtp000025,mbrf0001660,,,,,non-substrate,,,,,(6S)5-methylTHF,,,HeLa R1-11 (transfected); 2.5 microM substrate; 9 min; pH 5.5,HeLa R1-11,,,,,human,mbds0010,,2013-11-24 23:55:22
mbbd000138533,mbcd0029125,mbtp000025,mbrf0001660,,=,,,substrate,28,307.1,microM,90.8,pemetrexed,,,HeLa R1-11 (transfected); 300 microM substrate; 4 min; pH 5.5,HeLa R1-11,,300,microM,,human,mbds0010,,2013-11-24 23:55:23
mbbd000138534,mbcd0029125,mbtp000025,mbrf0001660,,=,,,substrate,22,325.7,pmol / mg protein / min,28.9,pemetrexed,,,HeLa R1-11 (transfected); 300 microM substrate; 4 min; pH 5.5,HeLa R1-11,,300,microM,,human,mbds0010,,2013-11-24 23:55:23
mbbd000138535,mbcd0029125,mbtp000025,mbrf0001660,,=,,,substrate,28,348.0,microM,37,pemetrexed,Eadie-Hofstee analysis,,HeLa R1-11 (transfected); 300 microM substrate; 4 min; pH 5.5,HeLa R1-11,,300,microM,,human,mbds0010,,2013-11-24 23:55:23
mbbd000138536,mbcd0029125,mbtp000025,mbrf0001660,,=,,,substrate,22,336.0,pmol / mg protein / min,20,pemetrexed,Eadie-Hofstee analysis,,HeLa R1-11 (transfected); 300 microM substrate; 4 min; pH 5.5,HeLa R1-11,,300,microM,,human,mbds0010,,2013-11-24 23:55:23
mbbd000138537,mbcd0001445,mbtp000025,mbrf0001691,,=,,,substrate,33,47.9,pmol / min / mg,,Fluvastatin,,,HEK293 (transfected); substrate 1 microM; uptake,HEK293,,,,,human,mbds0010,,2013-11-24 23:13:01
mbbd000138538,mbcd0001445,mbtp000025,mbrf0001691,,,,,substrate,,,,,Fluvastatin,apparent Km 0.7 to 0.8 microM; non-linear regression,,HEK293 (transfected); substrate 1 microM; uptake,HEK293,,,,,human,mbds0010,,2013-11-24 23:13:01
mbbd000138539,mbcd0003075,mbtp000025,mbrf0001691,,=,,,substrate,28,10.2,microM,,estrone-3-sulfate,,,HEK293 (transfected); uptake,HEK293,,,,,human,mbds0010,,2013-11-24 23:13:02
mbbd000138540,mbcd0009531,mbtp000025,mbrf0001691,,~,,,inhibitor,72,40.0,%,,gemfibrozil,,,HEK293 (transfected); fluvastatin; inhibitor 100 micoM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138541,mbcd0009531,mbtp000025,mbrf0001691,,~,,,inhibitor,72,70.0,%,,gemfibrozil,,,HEK293 (transfected); fluvastatin; inhibitor 200 micoM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138542,mbcd0028129,mbtp000025,mbrf0001751,,=,,,substrate,28,202.0,microM,107,Bosentan,,,CHO (transfected); substrate 1 - 300 microM,CHO,,1-300,microM,,human,mbds0010,,2013-11-02 07:41:30
mbbd000138543,mbcd0028129,mbtp000025,mbrf0001751,,=,,,substrate,22,2.27,pmol / min / microg protein,0.69,Bosentan,,,CHO (transfected); substrate 1 - 300 microM,CHO,,1-300,microM,,human,mbds0010,,2013-11-02 07:41:30
mbbd000138544,mbcd0028129,mbtp000025,mbrf0001751,,=,,,substrate,67,0.011,microL / min / microg,,Bosentan,,,CHO (transfected); substrate 1 - 300 microM,CHO,,1-300,microM,,human,mbds0010,,2013-11-02 07:41:30
mbbd000138545,mbcd0029127,mbtp000025,mbrf0001751,,,,,non-substrate,,,,,Ro 48-5033,no detectable uptake,,CHO (transfected); substrate 1 - 300 microM,CHO,,1-300,microM,,human,mbds0010,,2013-11-02 07:41:29
mbbd000138546,mbcd0003075,mbtp000025,mbrf0001751,,=,,,substrate,8,1.7,,,E3S,,,CHO (transfected); uptake of known substrates for use as a control,CHO,,,,,human,mbds0010,,2013-11-02 07:41:29
mbbd000138547,mbcd0028129,mbtp000025,mbrf0001751,,,,,inhibitor,,,,,Bosentan,,,CHO (transfected); inhibition of E3S; data not shown,CHO,mbcd0003075,,,,human,mbds0010,,2013-11-02 07:41:29
mbbd000138548,mbcd0000311,mbtp000025,mbrf0001751,,,,,inhibitor,,,,,Cyclosporin A,,,CHO (transfected); inhibition of E3S; data not shown,CHO,mbcd0003075,,,,human,mbds0010,,2013-11-02 07:41:29
mbbd000138549,mbcd0001416,mbtp000025,mbrf0001751,,,,,inhibitor,,,,,rifampicin,,,CHO (transfected); inhibition of E3S; data not shown,CHO,mbcd0003075,,,,human,mbds0010,,2013-11-02 07:41:28
mbbd000138550,mbcd0002466,mbtp000025,mbrf0002112,,,,,substrate,,,,,etoposide,,,HEK293 (transfected); 1 microM substrate; 5 min,HEK293,,1,microM,,human,mbds0010,,2014-01-17 20:50:09
mbbd000138551,mbcd0002466,mbtp000025,mbrf0002112,,,,,substrate,,,,,etoposide,,,HEK293 (transfected); 10 microM substrate; 5 min,HEK293,,10,microM,,human,mbds0010,,2014-01-17 20:50:09
mbbd000138552,mbcd0001216,mbtp000025,mbrf0001976,,,,,non-substrate,,,,,NaFluo,"sodium salt, ratio 2:1 or 1:1 not specified in paper",,CHO (transfected); preliminary experiments,CHO,,,,,human,mbds0010,,2013-11-24 23:15:14
mbbd000138553,mbcd0003035,mbtp000025,mbrf0001660,,,,,inhibitor,,,,,BSP,abolished uptake of premetrexed,,substrate pemetrexed 50 microM; inhibition of uptake; BSP 5 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138554,mbcd0029125,mbtp000025,mbrf0001660,,~,,,inhibitor,29,350.0,microM,,pemetrexed,,,substrate pemetrexed 50 microM; inhibition of uptake,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138555,mbcd0029766,mbtp000025,mbrf0001660,,~,,,inhibitor,29,70.0,microM,,Raltitrexed,,,substrate pemetrexed 50 microM; inhibition of uptake,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138556,mbcd0003043,mbtp000025,mbrf0001660,,~,,,inhibitor,29,600.0,microM,,MTX,,,substrate pemetrexed 50 microM; inhibition of uptake,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138557,mbcd0001677,mbtp000025,mbrf0001660,,,,,non-inhibitor,,,,,(6S)5-methylTHF,,,substrate pemetrexed 50 microM; inhibition of uptake; (6S)5-methylTHF 600 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138558,mbcd0003959,mbtp000025,mbrf0001660,,,,,non-inhibitor,,,,,folic acid,,,substrate pemetrexed 50 microM; inhibition of uptake; folic acid 600 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138559,mbcd0029126,mbtp000025,mbrf0001660,,,,,non-inhibitor,,,,,(6S)5-formylTHF,,,substrate pemetrexed 50 microM; inhibition of uptake; (6S)5-formylTHF 600 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138560,mbcd0029129,mbtp000025,mbrf0001660,,,,,inhibitor,,,,,FCCP,shows pH dependance,,pH 5.5; substrate BSP,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138561,mbcd0029129,mbtp000025,mbrf0001660,,,,,inhibitor,,,,,FCCP,,,pH 5.5; substrate pemetrexed,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138562,mbcd0002323,mbtp000025,mbrf0002511,,,,,inhibitor,,,,,indinavir,,,inhibition of E3S uptake,,,,,,human,mbds0010,,2013-12-10 22:19:00
mbbd000138563,mbcd0001533,mbtp000025,mbrf0002511,,,,,inhibitor,,,,,saquinavir,,,inhibition of E3S uptake,,,,,,human,mbds0010,,2013-12-10 22:19:00
mbbd000138564,mbcd0001938,mbtp000025,mbrf0002511,,,,,inhibitor,,,,,ritonavir,,,inhibition of E3S uptake,,,,,,human,mbds0010,,2013-12-10 22:19:00
mbbd000138565,mbcd0001904,mbtp000025,mbrf0002236,,=,,,inhibitor,25,5.2,microM,,Repaglinide,,,HEK (transfected); inhibition of BSP uptake,HEK293,mbcd0003035,,,,human,mbds0010,,2013-11-04 03:00:42
mbbd000138566,mbcd0023111,mbtp000025,mbrf0002236,,=,,,inhibitor,25,5.2,microM,,Rosiglitazone,,,HEK (transfected); inhibition of BSP uptake,HEK293,mbcd0003035,,,,human,mbds0010,,2013-11-04 03:00:43
mbbd000138567,mbcd0003886,mbtp000025,mbrf0002236,,,,,non-inhibitor,,,,,Metformin,,,HEK (transfected); inhibition of BSP uptake,HEK293,mbcd0003035,,,,human,mbds0010,,2013-11-04 03:00:43
mbbd000138568,mbcd0029146,mbtp000025,mbrf0002365,,,,,inhibitor,,,,,pregnenolone sulfate,partial inhibitor,,Xenopus laevis oocyte (transfected); E3S substrate; 10 mins,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138569,mbcd0003070,mbtp000025,mbrf0001969,,=,,,substrate,28,9.0,microM,,DHEAS,,,CHO (transfected),CHO,,,,,human,mbds0010,,2013-11-24 23:15:14
mbbd000138570,mbcd0003070,mbtp000025,mbrf0001969,,=,,,substrate,22,85.0,pmol / min / mg,,DHEAS,,,CHO (transfected),CHO,,,,,human,mbds0010,,2013-11-24 23:15:15
mbbd000138571,mbcd0029146,mbtp000025,mbrf0001969,,,,,non-substrate,,,,,pregnenolone sulfate,,,CHO (transfected),CHO,,,,,human,mbds0010,,2013-11-24 23:15:15
mbbd000138585,mbcd0000875,mbtp000025,mbrf0001406,,,,,non-substrate,,,,,M1; troglitazone sulfate,,,Xenopus laevis oocytes (transfected); pH 7.4; M1 10 microM,Xenopus laevis oocytes,,,,,human,mbds0010,,2013-11-24 23:14:44
mbbd000138586,mbcd0001120,mbtp000025,mbrf0001248,,,,,non-substrate,,,,,caspofungin,,,HeLa cells (transfected); 1 hour; no statistically significant uptake,HeLa,,,,,human,mbds0010,,2013-11-24 23:55:19
mbbd000138587,mbcd0001797,mbtp000025,mbrf0002299,,=,,,non-substrate,140,0.0414,microL min-1 (mg protein)-1,0.0614,FEX,"OATP2B1-mediated uptake of FEX was only slightly observed, although not statistically significant",,HEK293 (transfected); FEX 10 microM; uptake; 10 mins,HEK293,,10,microM,weak substrate,human,mbds0010,,2013-12-09 01:09:30
mbbd000138588,mbcd0003075,mbtp000025,mbrf0002299,,=,,,substrate,140,10.8,microL / min / mg protein,1.0,E1S,,,HEK293 (transfected); probe substrate; uptake; 10 mins,HEK293,,,,,human,mbds0010,,2013-07-11 18:57:02
mbbd000138589,mbcd0029131,mbtp000025,mbrf0001883,,,,,substrate,,,,,UK 191005,,,,,,,,,human,mbds0010,,2014-02-21 02:50:32
mbbd000138590,mbcd0001239,mbtp000025,mbrf0001883,,,,,substrate,,,,,Rocuronium,,,,,,,,,human,mbds0010,,2014-02-21 02:50:32
mbbd000138591,mbcd0000604,mbtp000025,mbrf0001883,,,,,substrate,,,,,N-Methylquinidine,,,,,,,,,human,mbds0010,,2014-02-21 02:50:32
mbbd000138593,mbcd0001050,mbtp000025,mbrf0001883,,,,,substrate,,,,,Digoxin,,,,,,,,,human,mbds0010,,2014-02-21 02:50:32
mbbd000138594,mbcd0029132,mbtp000025,mbrf0001650,,,,,non-substrate,,,,,Y-700,The paper comments that there may be some contribution of OATP-B to Y-700 transport due to limited sensitivity of transfected HEK-293,,HEK293 (transfected); uptake; 10 mins; Y-700 5 microM,HEK293,,,,,human,mbds0010,,2013-11-24 23:13:02
mbbd000138595,mbcd0003075,mbtp000025,mbrf0002074,,=,,,substrate,28,20.9,microM,2.0,E1S,,,HEK293 (transfected); uptake; substrate concentration 0.1 microM; pH 7.4,HEK293,,0.1,microM,,human,mbds0010,,2013-11-04 02:36:18
mbbd000138596,mbcd0000693,mbtp000025,mbrf0002074,,=,,,substrate,28,1.17,microM,0.28,pitavastatin,,,HEK293 (transfected); uptake; substrate concentration 0.1 microM; pH 7.4,HEK293,,0.1,microM,,human,mbds0010,,2013-11-04 02:36:18
mbbd000138597,mbcd0000388,mbtp000025,mbrf0002074,,,,,non-substrate,,,,,E217betaG,,,HEK293 (transfected); uptake; substrate concentration 0.1 microM; pH 7.4; uptake: 7.51 +/- 0.49 and 9.72 +/-1.29 mircoL/mg protein by vector-transfected and OATP2B1-expressing cells for 5 min respectively,HEK293,,0.1,microM,,human,mbds0010,,2013-11-04 02:36:18
mbbd000138598,mbcd0003075,mbtp000025,mbrf0002074,,=,,,substrate,22,1196.0,pmol / min / mg protein,40,E1S,,,HEK293 (transfected); uptake; substrate concentration 0.1 microM; pH 7.4,HEK293,,0.1,microM,,human,mbds0010,,2013-11-04 02:36:18
mbbd000138599,mbcd0000693,mbtp000025,mbrf0002074,,=,,,substrate,22,7.36,pmol / min / mg protein,1.43,pitavastatin,,,HEK293 (transfected); uptake; substrate concentration 0.1 microM; pH 7.4,HEK293,,0.1,microM,,human,mbds0010,,2013-11-04 02:36:19
mbbd000138600,mbcd0000130,mbtp000025,mbrf0002576,,,,,non-substrate,,,,,amanitin,,,MDCKII (transfected); 0.7 microM amanitin; 30 min,MDCKII,,0.7,microM,,human,mbds0010,,2013-11-02 06:56:01
mbbd000138601,mbcd0000143,mbtp000025,mbrf0002576,,>,,,non-inhibitor,25,100.0,microM,,Antamanide,,,MDCKII (transfected); inhibition of BSP 0.5 microM uptake; 10 min,MDCKII,mbcd0003035,,,,human,mbds0010,,2013-11-02 06:56:02
mbbd000138602,mbcd0001532,mbtp000025,mbrf0002576,,=,,,inhibitor,25,25.0,microM,,Paclitaxel,cytotoxic concentration of inhibitor,,MDCKII (transfected); inhibition of BSP 0.5 microM uptake; 10 min,MDCKII,mbcd0003035,,,,human,mbds0010,,2013-11-02 06:56:02
mbbd000138603,mbcd0001416,mbtp000025,mbrf0002576,,=,,,inhibitor,25,90.0,microM,,Rifampicin,,,MDCKII (transfected); inhibition of BSP 0.5 microM uptake; 10 min,MDCKII,mbcd0003035,,,,human,mbds0010,,2013-11-02 06:56:02
mbbd000138604,mbcd0029133,mbtp000025,mbrf0002576,,=,,,inhibitor,25,1.0,microM,,Silibinin dihemisuccinate,,,MDCKII (transfected); inhibition of BSP 0.5 microM uptake; 10 min,MDCKII,mbcd0003035,,,,human,mbds0010,,2013-11-02 06:56:02
mbbd000138605,mbcd0023132,mbtp000025,mbrf0002576,,=,,,inhibitor,25,1.0,microM,,Montelukast,,,MDCKII (transfected); inhibition of BSP 0.5 microM uptake; 10 min,MDCKII,mbcd0003035,,,,human,mbds0010,,2013-11-02 06:56:02
mbbd000138606,mbcd0002494,mbtp000025,mbrf0002576,,=,,,inhibitor,25,0.2,microM,,MK571,,,MDCKII (transfected); inhibition of BSP 0.5 microM uptake; 10 min,MDCKII,mbcd0003035,,,,human,mbds0010,,2013-11-02 06:56:03
mbbd000138607,mbcd0000311,mbtp000025,mbrf0002576,,=,,,inhibitor,25,20.0,microM,,Cyclosporin A,,,MDCKII (transfected); inhibition of BSP 0.5 microM uptake; 10 min,MDCKII,mbcd0003035,,,,human,mbds0010,,2013-11-02 06:56:03
mbbd000138608,mbcd0001532,mbtp000025,mbrf0002576,,=,,,non-substrate,33,1.01,pmol / min / mg protein,0.04,Paclitaxel,,,MDCKII (transfected); drug uptake; 110 nM paclitaxel; 10 min,MDCKII,,110,nM,,human,mbds0010,,2013-11-02 06:56:03
mbbd000138609,mbcd0003134,mbtp000025,mbrf0002576,,=,,,non-substrate,33,0.43,pmol / min / mg protein,0.08,Penicillin G,,,MDCKII (transfected); drug uptake; 1.3 microM Penicillin G; 10 min,MDCKII,,1.3,microM,,human,mbds0010,,2013-11-02 06:56:04
mbbd000138610,mbcd0003074,mbtp000025,mbrf0001676,,,,,substrate,,,,,glibenclamide,,,HEK (transfected); 10 nM; pH 7.4; 5 min,HEK,,,,,human,mbds0010,,2013-11-24 23:13:02
mbbd000138611,mbcd0003075,mbtp000025,mbrf0001676,,,,,substrate,,,,,estrone-3-sulfate,,,HEK (transfected); 10 nM; pH 7.4; 5 min,HEK,,,,,human,mbds0010,,2013-11-24 23:13:03
mbbd000138612,mbcd0016436,mbtp000025,mbrf0001676,,,,,non-inhibitor,,,,,ginkgolide A,no statistical significance,,"HEK (transfected); substrate 10 nM; pH 7.4; 20 s; inhibitor concentrations tested 1, 10 and 100 microM",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138613,mbcd0012430,mbtp000025,mbrf0001676,,,,,non-inhibitor,,,,,ginkgolide B,no statistical significance,,"HEK (transfected); substrate 10 nM; pH 7.4; 20 s; inhibitor concentrations tested 1, 10 and 100 microM",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138614,mbcd0029134,mbtp000025,mbrf0001676,,,,,non-inhibitor,,,,,bilobalide,no statistical significance,,"HEK (transfected); substrate 10 nM; pH 7.4; 20 s; inhibitor concentrations tested 1, 10 and 100 microM",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138615,mbcd0029135,mbtp000025,mbrf0001676,,,,,non-inhibitor,,,,,ginkgolide C,no statistical significance,,HEK (transfected); substrate 10 nM; pH 7.4; 20 s; inhibitor concentrations tested 1 and 10 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138616,mbcd0029135,mbtp000025,mbrf0001676,,,,,inhibitor,,,,,ginkgolide C,,,HEK (transfected); substrate 10 nM; pH 7.4; 20 s; inhibitor concentrations tested 100 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138617,mbcd0029136,mbtp000025,mbrf0001676,,=,,,inhibitor,3,54.9,%,,kaempferol-3-glucoside,,,HEK (transfected); substrate 10 nM; pH 7.4; 20 s; inhibitor concentration 10 microM,,,,,,human,mbds0010,,2013-12-06 06:52:41
mbbd000138618,mbcd0029137,mbtp000025,mbrf0001676,,=,,,inhibitor,3,47.5,%,,isorhamnetin-3-glucoside,,,HEK (transfected); substrate 10 nM; pH 7.4; 20 s; inhibitor concentration 10 microM,,,,,,human,mbds0010,,2013-12-06 06:52:41
mbbd000138619,mbcd0029138,mbtp000025,mbrf0001676,,=,,,inhibitor,3,45.6,%,,Kaempferol-3-rutinoside,,,HEK (transfected); substrate 10 nM; pH 7.4; 20 s; inhibitor concentration 100 microM,,,,,,human,mbds0010,,2013-12-06 06:52:41
mbbd000138620,mbcd0029139,mbtp000025,mbrf0001676,,=,,,inhibitor,3,73.7,%,,quercetin-3-rhamnoside,,,HEK (transfected); substrate 10 nM; pH 7.4; 20 s; inhibitor concentration 100 microM,,,,,,human,mbds0010,,2013-12-06 06:52:42
mbbd000138621,mbcd0001628,mbtp000025,mbrf0001676,,=,,,inhibitor,3,34.6,%,,quercetin-3-rutinoside,,,HEK (transfected); substrate 10 nM; pH 7.4; 20 s; inhibitor concentration 100 microM,,,,,,human,mbds0010,,2013-12-06 06:52:42
mbbd000138622,mbcd0013807,mbtp000025,mbrf0001676,,=,,,inhibitor,3,27.2,%,,EC,,,HEK (transfected); substrate 10 nM; pH 7.4; 20 s; inhibitor concentration 10 microM,,,,,,human,mbds0010,,2013-12-06 06:52:42
mbbd000138623,mbcd0000002,mbtp000025,mbrf0001676,,=,,,inhibitor,3,66.6,%,,ECG,,,HEK (transfected); substrate 10 nM; pH 7.4; 20 s; inhibitor concentration 10 microM,,,,,,human,mbds0010,,2013-12-06 06:52:42
mbbd000138624,mbcd0029142,mbtp000025,mbrf0001676,,=,,,inhibitor,3,29.5,%,,EGCG,,,HEK (transfected); substrate 10 nM; pH 7.4; 20 s; inhibitor concentration 10 microM,,,,,,human,mbds0010,,2013-12-06 06:52:43
mbbd000138625,mbcd0029141,mbtp000025,mbrf0001676,,=,,,inhibitor,3,29.1,%,,EGC,,,HEK (transfected); substrate 10 nM; pH 7.4; 20 s; inhibitor concentration 100 microM,,,,,,human,mbds0010,,2013-12-06 06:52:43
mbbd000138626,mbcd0029140,mbtp000025,mbrf0001676,,=,,,inhibitor,3,31.7,%,,(+)-Catechin,,,HEK (transfected); substrate 10 nM; pH 7.4; 20 s; inhibitor concentration 100 microM,,,,,,human,mbds0010,,2013-12-06 06:52:43
mbbd000138627,mbcd0026093,mbtp000025,mbrf0002113,,~,,,inhibitor,72,10.0,%,,atorvastatin,,,"MDCKII (transfected); inhibition of E3S uptake (1 micromol/L, 0.5 microCi/mL); 5 min; inhibitor 50 microM",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138628,mbcd0000772,mbtp000025,mbrf0002113,,~,,,inhibitor,72,64.0,%,,simvastatin lactone,,,"MDCKII (transfected); inhibition of E3S uptake (1 micromol/L, 0.5 microCi/mL); 5 min; inhibitor 50 microM",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138629,mbcd0001194,mbtp000025,mbrf0002113,,~,,,inhibitor,72,16.0,%,,simvastatin acid,,,"MDCKII (transfected); inhibition of E3S uptake (1 micromol/L, 0.5 microCi/mL); 5 min; inhibitor 50 microM",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138630,mbcd0023123,mbtp000025,mbrf0002113,,~,,,inhibitor,72,54.0,%,,cerivastatin,,,"MDCKII (transfected); inhibition of E3S uptake (1 micromol/L, 0.5 microCi/mL); 5 min; inhibitor 50 microM",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138631,mbcd0003126,mbtp000025,mbrf0002113,,~,,,inhibitor,72,90.0,%,,pravastatin,,,"MDCKII (transfected); inhibition of E3S uptake (1 micromol/L, 0.5 microCi/mL); 5 min; inhibitor 50 microM",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138632,mbcd0025591,mbtp000025,mbrf0002113,,~,,,inhibitor,72,86.0,%,,lovastatin,,,"MDCKII (transfected); inhibition of E3S uptake (1 micromol/L, 0.5 microCi/mL); 5 min; inhibitor 50 microM",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138633,mbcd0001675,mbtp000025,mbrf0002113,,=,,,non-inhibitor,72,106.0,%,11,Aldosterone,,,"MDCKII (transfected); inhibition of E3S uptake (1 micromol/L, 0.5 microCi/mL); 5 min; inhibitor 100 microM",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138634,mbcd0026093,mbtp000025,mbrf0002113,,=,,,inhibitor,72,6.0,%,3,Atorvastatin,,,"MDCKII (transfected); inhibition of E3S uptake (1 micromol/L, 0.5 microCi/mL); 5 min; inhibitor 100 microM",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138635,mbcd0003072,mbtp000025,mbrf0002113,,=,,,non-inhibitor,72,83.0,%,3,Celecoxib,,,"MDCKII (transfected); inhibition of E3S uptake (1 micromol/L, 0.5 microCi/mL); 5 min; inhibitor 10 microM",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138636,mbcd0023123,mbtp000025,mbrf0002113,,=,,,inhibitor,72,25.0,%,4,Cerivastatin,,,"MDCKII (transfected); inhibition of E3S uptake (1 micromol/L, 0.5 microCi/mL); 5 min; inhibitor 100 microM",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138637,mbcd0029143,mbtp000025,mbrf0002113,,=,,,non-inhibitor,72,103.0,%,3,Cyclic guanosine monophosphate,,,"MDCKII (transfected); inhibition of E3S uptake (1 micromol/L, 0.5 microCi/mL); 5 min; inhibitor 10 microM",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138638,mbcd0001050,mbtp000025,mbrf0002113,,=,,,inhibitor,72,70.0,%,20,Digoxin,,,"MDCKII (transfected); inhibition of E3S uptake (1 micromol/L, 0.5 microCi/mL); 5 min; inhibitor 100 microM",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138639,mbcd0025706,mbtp000025,mbrf0002113,,=,,,non-inhibitor,72,79.0,%,5,Etoricoxib,,,"MDCKII (transfected); inhibition of E3S uptake (1 micromol/L, 0.5 microCi/mL); 5 min; inhibitor 10 microM",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138640,mbcd0009531,mbtp000025,mbrf0002113,,=,,,inhibitor,72,35.0,%,5,Gemfibrozil,,,"MDCKII (transfected); inhibition of E3S uptake (1 micromol/L, 0.5 microCi/mL); 5 min; inhibitor 100 microM",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138641,mbcd0003074,mbtp000025,mbrf0002113,,=,,,inhibitor,72,9.0,%,1,Glyburide,,,"MDCKII (transfected); inhibition of E3S uptake (1 micromol/L, 0.5 microCi/mL); 5 min; inhibitor 100 microM",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138642,mbcd0003025,mbtp000025,mbrf0002113,,=,,,inhibitor,72,60.0,%,14,Indomethacin,,,"MDCKII (transfected); inhibition of E3S uptake (1 micromol/L, 0.5 microCi/mL); 5 min; inhibitor 50 microM",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138643,mbcd0003914,mbtp000025,mbrf0002113,,=,,,inhibitor,72,62.0,%,6,Memantine,,,"MDCKII (transfected); inhibition of E3S uptake (1 micromol/L, 0.5 microCi/mL); 5 min; inhibitor 100 microM",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138644,mbcd0001129,mbtp000025,mbrf0002113,,=,,,inhibitor,72,57.0,%,4,Rofecoxib,,,"MDCKII (transfected); inhibition of E3S uptake (1 micromol/L, 0.5 microCi/mL); 5 min; inhibitor 10 microM",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138645,mbcd0003094,mbtp000025,mbrf0002113,,=,,,stimulator,72,134.0,%,9,Spironolactone,,,"MDCKII (transfected); inhibition of E3S uptake (1 micromol/L, 0.5 microCi/mL); 5 min; inhibitor 100 microM",,mbcd0003075,100,micromol L-1,,human,mbds0010,,2013-12-08 00:42:40
mbbd000138646,mbcd0027062,mbtp000025,mbrf0002113,,=,,,non-inhibitor,72,106.0,%,7,Verapamil,,,"MDCKII (transfected); inhibition of E3S uptake (1 micromol/L, 0.5 microCi/mL); 5 min; inhibitor 100 microM",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138647,mbcd0026093,mbtp000025,mbrf0002113,,=,,,inhibitor,17,0.39,microM,,atorvastatin,,,"MDCKII (transfected); inhibition of E3S uptake (1 micromol/L, 0.5 microCi/mL); 5 min",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138648,mbcd0023123,mbtp000025,mbrf0002113,,=,,,inhibitor,17,66.2,microM,,cerivastatin,,,"MDCKII (transfected); inhibition of E3S uptake (1 micromol/L, 0.5 microCi/mL); 5 min",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138649,mbcd0001194,mbtp000025,mbrf0002113,,=,,,inhibitor,17,84.7,microM,,simvastatin,,,"MDCKII (transfected); inhibition of E3S uptake (1 micromol/L, 0.5 microCi/mL); 5 min",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138650,mbcd0026093,mbtp000025,mbrf0002113,,=,,,inhibitor,29,0.69,microM,0.35,atorvastatin,,,MDCKII (transfected); inhibition of E3S uptake (10 microM to 0.1 microM); 5 min; atorvastatin (0.3 microM to 0.1 microM),,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138651,mbcd0026093,mbtp000025,mbrf0002113,,=,,,substrate,28,0.2,microM,0.1,atorvastatin,,,MDCKII (transfected); 10 min,MDCKII,,,,,human,mbds0010,,2013-11-24 23:11:22
mbbd000138652,mbcd0026093,mbtp000025,mbrf0002113,,=,,,substrate,22,30.5,pmol / min / mg protein,2.9,atorvastatin,,,MDCKII (transfected); 10 min,MDCKII,,,,,human,mbds0010,,2013-11-24 23:11:22
mbbd000138653,mbcd0003075,mbtp000025,mbrf0002113,,~,,,inhibitor,72,37.0,%,,E3S,,,MDCKII (transfected); 10 min; atorvastatin (1 microM); E3S (100 microM),,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138654,mbcd0003074,mbtp000025,mbrf0002113,,~,,,inhibitor,72,57.0,%,,glyburide,,,MDCKII (transfected); 10 min; atorvastatin (1 microM); glyburide (100 microM),,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138655,mbcd0001675,mbtp000025,mbrf0002349,,=,,,non-inhibitor,72,110.0,%,11,Aldosterone,no statistical significance,,MDCKII (transfected); E3S (1 microCi/ml; 1 microM); 5 min; substance 100 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138656,mbcd0001675,mbtp000025,mbrf0002349,,=,,,non-inhibitor,72,129.0,%,15,Aldosterone,no statistical significance,,MDCKII (transfected); E3S (1 microCi/ml; 1 microM); 5 min; substance 10 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138657,mbcd0029144,mbtp000025,mbrf0002349,,=,,,non-inhibitor,72,105.0,%,9,Androsterone,no statistical significance,,MDCKII (transfected); E3S (1 microCi/ml; 1 microM); 5 min; substance 10 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138658,mbcd0029144,mbtp000025,mbrf0002349,,=,,,stimulator,1,145.0,%,20,Androsterone,no statistical significance at 10 microM androsterone (P < 0.05),,MDCKII (transfected); E3S (1 microCi/ml; 1 microM); 5 min; substance 100 microM,,mbcd0003075,100,microM,,human,mbds0010,,2013-12-08 01:03:13
mbbd000138659,mbcd0027348,mbtp000025,mbrf0002349,,=,,,non-inhibitor,1,107.0,%,13,Cortisone,no statistical significance (P < 0.05),,MDCKII (transfected); E3S (1 microCi/ml; 1 microM); 5 min; substance 100 microM,,mbcd0003075,,,,human,mbds0010,,2013-12-08 01:03:14
mbbd000138660,mbcd0027348,mbtp000025,mbrf0002349,,=,,,non-inhibitor,1,125.0,%,15,Cortisone,no statistical significance (P < 0.05),,MDCKII (transfected); E3S (1 microCi/ml; 1 microM); 5 min; substance 10 microM,,mbcd0003075,,,,human,mbds0010,,2013-12-08 01:03:14
mbbd000138661,mbcd0003211,mbtp000025,mbrf0002349,,=,,,non-inhibitor,72,87.0,%,7,Estrone,no statistical significance,,MDCKII (transfected); E3S (1 microCi/ml; 1 microM); 5 min; substance 10 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138662,mbcd0003211,mbtp000025,mbrf0002349,,=,,,inhibitor,72,68.0,%,8,Estrone,statistical significance,,MDCKII (transfected); E3S (1 microCi/ml; 1 microM); 5 min; substance 100 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138663,mbcd0001673,mbtp000025,mbrf0002349,,=,,,inhibitor,72,43.0,%,10,Estriol,statistical significance,,MDCKII (transfected); E3S (1 microCi/ml; 1 microM); 5 min; substance 100 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138664,mbcd0001673,mbtp000025,mbrf0002349,,=,,,non-inhibitor,72,96.0,%,5,Estriol,no statistical significance,,MDCKII (transfected); E3S (1 microCi/ml; 1 microM); 5 min; substance 10 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138665,mbcd0003055,mbtp000025,mbrf0002349,,=,,,inhibitor,72,35.0,%,4,beta-Estradiol,statistical significance,,MDCKII (transfected); E3S (1 microCi/ml; 1 microM); 5 min; substance 10 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138666,mbcd0029148,mbtp000025,mbrf0002349,,=,,,non-inhibitor,72,83.0,%,15,Hydrocortisol,no statistical significance,,MDCKII (transfected); E3S (1 microCi/ml; 1 microM); 5 min; substance 100 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138667,mbcd0029148,mbtp000025,mbrf0002349,,=,,,non-inhibitor,72,92.0,%,7,Hydrocortisol,statistical significance,,MDCKII (transfected); E3S (1 microCi/ml; 1 microM); 5 min; substance 10 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138668,mbcd0011526,mbtp000025,mbrf0002349,,=,,,stimulator,1,168.0,%,12,Hydroxyprogesterone,statistical significance (P < 0.05),,MDCKII (transfected); E3S (1 microCi/ml; 1 microM); 5 min; substance 10 microM,,mbcd0003075,,,,human,mbds0010,,2013-12-08 01:03:14
mbbd000138669,mbcd0001299,mbtp000025,mbrf0002349,,=,,,inhibitor,72,7.0,%,1,Mifepristone,statistical significance,,MDCKII (transfected); E3S (1 microCi/ml; 1 microM); 5 min; substance 100 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138670,mbcd0001299,mbtp000025,mbrf0002349,,=,,,inhibitor,72,26.0,%,4,Mifepristone,statistical significance,,MDCKII (transfected); E3S (1 microCi/ml; 1 microM); 5 min; substance 10 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138671,mbcd0029145,mbtp000025,mbrf0002349,,=,,,non-inhibitor,1,129.0,%,4,Pregnenolone,no statistical significance (P < 0.05),,MDCKII (transfected); E3S (1 microCi/ml; 1 microM); 5 min; substance 50 microM,,mbcd0003075,50,microM,,human,mbds0010,,2013-12-08 01:03:15
mbbd000138672,mbcd0029145,mbtp000025,mbrf0002349,,=,,,stimulator,1,171.0,%,27,Pregnenolone,statistical significance (P < 0.05),,MDCKII (transfected); E3S (1 microCi/ml; 1 microM); 5 min; substance 10 microM,,mbcd0003075,10,microM,,human,mbds0010,,2013-12-08 01:03:15
mbbd000138673,mbcd0001892,mbtp000025,mbrf0002349,,=,,,non-inhibitor,72,66.0,%,5,Progesterone,no statistical significance,,MDCKII (transfected); E3S (1 microCi/ml; 1 microM); 5 min; substance 100 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138674,mbcd0001892,mbtp000025,mbrf0002349,,=,,,stimulator,1,186.0,%,14,Progesterone,no statistical significance at 100 microM progesterone (P < 0.05),,MDCKII (transfected); E3S (1 microCi/ml; 1 microM); 5 min; substance 10 microM,,mbcd0003075,10,microM,,human,mbds0010,,2013-12-08 01:03:15
mbbd000138675,mbcd0003001,mbtp000025,mbrf0002349,,=,,,inhibitor,72,27.0,%,4,Testosterone,statistical significance,,MDCKII (transfected); E3S (1 microCi/ml; 1 microM); 5 min; substance 100 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138676,mbcd0003001,mbtp000025,mbrf0002349,,=,,,non-inhibitor,72,84.0,%,8,Testosterone,no statistical significance,,MDCKII (transfected); E3S (1 microCi/ml; 1 microM); 5 min; substance 10 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138677,mbcd0003075,mbtp000025,mbrf0002349,,=,,,inhibitor,72,43.0,%,5,Estrone-3-sulfate,statistical significance,,MDCKII (transfected); E3S (1 microCi/ml; 1 microM); 5 min; substance 10 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138678,mbcd0000387,mbtp000025,mbrf0002349,,=,,,non-inhibitor,72,106.0,%,3,Estradiol-glucuronide,no statistical significance,,MDCKII (transfected); E3S (1 microCi/ml; 1 microM); 5 min; substance 10 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138679,mbcd0003070,mbtp000025,mbrf0002349,,=,,,inhibitor,72,70.0,%,2,DHEAS,statistical significance,,MDCKII (transfected); E3S (1 microCi/ml; 1 microM); 5 min; substance 10 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138680,mbcd0029146,mbtp000025,mbrf0002349,,=,,,inhibitor,72,28.0,%,7,Pregnenolone sulfate,statistical significance,,MDCKII (transfected); E3S (1 microCi/ml; 1 microM); 5 min; substance 10 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138681,mbcd0029147,mbtp000025,mbrf0002349,,=,,,non-inhibitor,72,83.0,%,15,Pregnenolone acetate,no statistical significance,,MDCKII (transfected); E3S (1 microCi/ml; 1 microM); 5 min; substance 10 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138682,mbcd0029144,mbtp000025,mbrf0002349,,=,,,non-inhibitor,1,121.0,%,5,Androsterone,no statistical significance (P < 0.05),,MDCKII (transfected); DHEAS (1 microCi/ml; 10 min; substance 100 microM,,mbcd0003070,100,microM,,human,mbds0010,,2013-12-08 01:03:15
mbbd000138683,mbcd0029144,mbtp000025,mbrf0002349,,=,,,stimulator,1,159.0,%,27,Androsterone,statistical significance (P < 0.05),,MDCKII (transfected); DHEAS (1 microCi/ml; 10 min; substance 10 microM,,mbcd0003070,10,microM,,human,mbds0010,,2013-12-08 01:03:16
mbbd000138684,mbcd0003211,mbtp000025,mbrf0002349,,=,,,stimulator,1,283.0,%,43,Estrone,statistical significance (P < 0.05),,MDCKII (transfected); DHEAS (1 microCi/ml; 10 min; substance 100 microM,,mbcd0003070,,,,human,mbds0010,,2013-12-08 01:03:16
mbbd000138685,mbcd0003211,mbtp000025,mbrf0002349,,=,,,stimulator,1,288.0,%,57,Estrone,statistical significance (P < 0.05),,MDCKII (transfected); DHEAS (1 microCi/ml; 10 min; substance 10 microM,,mbcd0003070,,,,human,mbds0010,,2013-12-08 01:03:16
mbbd000138686,mbcd0001673,mbtp000025,mbrf0002349,,=,,,non-inhibitor,72,78.0,%,13,Estriol,no statistical significance,,MDCKII (transfected); DHEAS (1 microCi/ml; 10 min; substance 100 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138687,mbcd0001673,mbtp000025,mbrf0002349,,=,,,non-inhibitor,72,108.0,%,8,Estriol,no statistical significance,,MDCKII (transfected); DHEAS (1 microCi/ml; 10 min; substance 10 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138688,mbcd0003055,mbtp000025,mbrf0002349,,=,,,stimulator,1,158.0,%,15,beta-Estradiol,statistical significance (P < 0.05),,MDCKII (transfected); DHEAS (1 microCi/ml; 10 min; substance 10 microM,,mbcd0003070,,,,human,mbds0010,,2013-12-08 01:03:16
mbbd000138689,mbcd0029148,mbtp000025,mbrf0002349,,=,,,non-inhibitor,1,158.0,%,35,Hydrocortisol,no statistical significance at 10 and 100 microM hydrocortisol (P < 0.05),,MDCKII (transfected); DHEAS (1 microCi/ml; 10 min; substance 100 microM,,mbcd0003070,,,,human,mbds0010,,2013-12-08 01:03:17
mbbd000138690,mbcd0029148,mbtp000025,mbrf0002349,,=,,,non-inhibitor,72,93.0,%,11,Hydrocortisol,no statistical significance,,MDCKII (transfected); DHEAS (1 microCi/ml; 10 min; substance 10 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138691,mbcd0001299,mbtp000025,mbrf0002349,,=,,,inhibitor,72,55.0,%,15,Mifepristone,statistical significance,,MDCKII (transfected); DHEAS (1 microCi/ml; 10 min; substance 100 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138692,mbcd0001299,mbtp000025,mbrf0002349,,=,,,inhibitor,72,69.0,%,10,Mifepristone,statistical significance,,MDCKII (transfected); DHEAS (1 microCi/ml; 10 min; substance 10 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138693,mbcd0029145,mbtp000025,mbrf0002349,,=,,,stimulator,1,179.0,%,14,Pregnenolone,statistical significance (P < 0.05),,MDCKII (transfected); DHEAS (1 microCi/ml; 10 min; substance 50 microM,,mbcd0003070,,,,human,mbds0010,,2013-12-08 01:03:17
mbbd000138694,mbcd0029145,mbtp000025,mbrf0002349,,=,,,stimulator,1,184.0,%,12,Pregnenolone,statistical significance (P < 0.05),,MDCKII (transfected); DHEAS (1 microCi/ml; 10 min; substance 10 microM,,mbcd0003070,,,,human,mbds0010,,2013-12-08 01:03:17
mbbd000138695,mbcd0001892,mbtp000025,mbrf0002349,,=,,,stimulator,1,303.0,%,36,Progesterone,statistical significance (P < 0.05),,MDCKII (transfected); DHEAS (1 microCi/ml; 10 min; substance 100 microM,,mbcd0003070,,,,human,mbds0010,,2013-12-08 01:03:17
mbbd000138696,mbcd0001892,mbtp000025,mbrf0002349,,=,,,stimulator,1,346.0,%,3,Progesterone,statistical significance (P < 0.05),,MDCKII (transfected); DHEAS (1 microCi/ml; 10 min; substance 10 microM,,mbcd0003070,,,,human,mbds0010,,2013-12-08 01:03:18
mbbd000138697,mbcd0003001,mbtp000025,mbrf0002349,,=,,,inhibitor,72,55.0,%,4,Testosterone,statistical significance,,MDCKII (transfected); DHEAS (1 microCi/ml; 10 min; substance 100 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138698,mbcd0003001,mbtp000025,mbrf0002349,,=,,,inhibitor,72,75.0,%,6,Testosterone,statistical significance,,MDCKII (transfected); DHEAS (1 microCi/ml; 10 min; substance 10 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138699,mbcd0003075,mbtp000025,mbrf0002349,,=,,,inhibitor,72,64.0,%,7,Estrone-3-sulfate,statistical significance,,MDCKII (transfected); DHEAS (1 microCi/ml; 10 min; substance 100 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138700,mbcd0003075,mbtp000025,mbrf0002349,,=,,,non-inhibitor,72,92.0,%,10,Estrone-3-sulfate,no statistical significance,,MDCKII (transfected); DHEAS (1 microCi/ml; 10 min; substance 10 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138701,mbcd0000387,mbtp000025,mbrf0002349,,=,,,non-inhibitor,72,95.0,%,13,Estradiol-glucuronide,no statistical significance,,MDCKII (transfected); DHEAS (1 microCi/ml; 10 min; substance 10 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138702,mbcd0029146,mbtp000025,mbrf0002349,,=,,,inhibitor,72,43.0,%,7,Pregnenolone sulfate,statistical significance,,MDCKII (transfected); DHEAS (1 microCi/ml; 10 min; substance 100 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138703,mbcd0011526,mbtp000025,mbrf0002349,,=,,,stimulator,1,241.0,%,6,Hydroxyprogesterone,statistical significance (P < 0.05),,MDCKII (transfected); DHEAS (1 microCi/ml; 10 min; substance 100 microM,,mbcd0003070,,,,human,mbds0010,,2013-12-08 01:03:18
mbbd000138704,mbcd0011526,mbtp000025,mbrf0002349,,=,,,stimulator,1,209.0,%,13,Hydroxyprogesterone,statistical significance (P < 0.05),,MDCKII (transfected); DHEAS (1 microCi/ml; 10 min; substance 10 microM,,mbcd0003070,,,,human,mbds0010,,2013-12-08 01:03:18
mbbd000138705,mbcd0029149,mbtp000025,mbrf0001700,,=,,,inhibitor,29,3.3,microM,,CI-1034,,,HEK (transfected); inhibition of BSP uptake,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138706,mbcd0004705,mbtp000025,mbrf0002389,,=,,,substrate,33,1.7,microL/5 min/mg protein,0.9,telmisartan,,,HEK293 (transfected); drug uptake,HEK293,,,,,human,mbds0010,,2013-12-13 22:01:14
mbbd000138707,mbcd0003086,mbtp000025,mbrf0002475,,=,,,non-substrate,33,0.627,microl / min / mg protein,0.092,valsartan,,,HEK293 (transfected); not significant in comparison to control 0.552 +/- 0.081 microl / min / mg protein,HEK293,,,,,human,mbds0010,,2013-11-24 23:13:03
mbbd000138708,mbcd0001448,mbtp000025,mbrf0001846,,=,,,substrate,28,2.4,microM,1.9,Rosuvastatin,,,HeLa (transfected),HeLa,,,,,human,mbds0010,,2013-11-24 23:55:19
mbbd000138709,mbcd0029150,mbtp000025,mbrf0002275,,,,,non-substrate,,,,,Atrasentan,,,,,,,,,human,mbds0010,,2013-11-24 23:56:46
mbbd000138710,mbcd0029833,mbtp000025,mbrf0001858,,=,,,non-substrate,33,0.077,pmol / oocyte /  h,0.012,TR-14035,Control: 0.076 +/- 0.009 pmol/oocyte/ h,,oocytes (transfected); pH 7.4; drug uptake,Xenopus laevis oocytes,,,,,human,mbds0010,,2013-11-24 23:56:47
mbbd000138711,mbcd0003075,mbtp000025,mbrf0001955,,=,,,substrate,28,1.56,microM,0.10,Estrone-3-sulfate,,,HEK293 (transfected); drug uptake; E3S 4.7 nM to 15 microM,HEK293,,,,,human,mbds0010,,2013-11-24 23:13:03
mbbd000138712,mbcd0003075,mbtp000025,mbrf0001955,,=,,,substrate,22,1.15,nmol / mg protein / 2 min,0.04,Estrone-3-sulfate,,,HEK293 (transfected); drug uptake; E3S 4.7 nM to 15 microM,HEK293,,,,,human,mbds0010,,2013-11-24 23:13:04
mbbd000138713,mbcd0003035,mbtp000025,mbrf0001955,,=,,,inhibitor,25,0.282,microM,0.062,BSP,,,HEK293 (transfected); inhibitor of drug uptake of E3S,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138714,mbcd0003070,mbtp000025,mbrf0001955,,=,,,inhibitor,25,8.6,microM,0.37,DHEAS,,,HEK293 (transfected); inhibitor of drug uptake of E3S,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138715,mbcd0003126,mbtp000025,mbrf0001955,,=,,,inhibitor,25,1.02,mM,0.10,Pravastatin,,,HEK293 (transfected); inhibitor of drug uptake of E3S,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138716,mbcd0003134,mbtp000025,mbrf0001955,,=,,,inhibitor,25,16.0,mM,3.4,Benzylpenicillin,,,HEK293 (transfected); inhibitor of drug uptake of E3S,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138717,mbcd0003146,mbtp000025,mbrf0001955,,~,,,inhibitor,72,40.0,%,,p-aminohippuric acid,read from graph,,HEK293 (transfected); pH 7.4; inhibition of drug uptake of E3S 4.7 nM; inhibitor 10 mM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138718,mbcd0003050,mbtp000025,mbrf0001955,,~,,,inhibitor,72,15.0,%,,Taurocholic acid,read from graph,,HEK293 (transfected); pH 7.4; inhibition of drug uptake of E3S 4.7 nM; inhibitor 1 mM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138719,mbcd0003154,mbtp000025,mbrf0001955,,~,,,inhibitor,72,25.0,%,,Probenecid,read from graph,,HEK293 (transfected); pH 7.4; inhibition of drug uptake of E3S 4.7 nM; inhibitor 1 mM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138720,mbcd0003025,mbtp000025,mbrf0001955,,~,,,inhibitor,72,5.0,%,,Indomethacin,read from graph,,HEK293 (transfected); pH 7.4; inhibition of drug uptake of E3S 4.7 nM; inhibitor 1 mM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138721,mbcd0019611,mbtp000025,mbrf0001955,,~,,,inhibitor,72,20.0,%,,Phenol red,read from graph,,HEK293 (transfected); pH 7.4; inhibition of drug uptake of E3S 4.7 nM; inhibitor 1 mM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138722,mbcd0027883,mbtp000025,mbrf0001955,,~,,,inhibitor,72,10.0,%,,DIDS,read from graph,,HEK293 (transfected); pH 7.4; inhibition of drug uptake of E3S 4.7 nM; inhibitor 1 mM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138723,mbcd0003923,mbtp000025,mbrf0001955,,~,,,non-inhibitor,72,95.0,%,,Tetraethylammonium,read from graph,,HEK293 (transfected); pH 7.4; inhibition of drug uptake of E3S 4.7 nM; inhibitor 10 mM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138724,mbcd0029154,mbtp000025,mbrf0001955,,~,,,inhibitor,72,75.0,%,,methylphenylpyridinium,read from graph,,HEK293 (transfected); pH 7.4; inhibition of drug uptake of E3S 4.7 nM; inhibitor 10 mM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138725,mbcd0003037,mbtp000025,mbrf0001955,,~,,,non-inhibitor,72,95.0,%,,N-methylnicotinamide,read from graph,,HEK293 (transfected); pH 7.4; inhibition of drug uptake of E3S 4.7 nM; inhibitor 10 mM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138726,mbcd0001111,mbtp000025,mbrf0001955,,~,,,inhibitor,72,50.0,%,,Cimetidine,read from graph,,HEK293 (transfected); pH 7.4; inhibition of drug uptake of E3S 4.7 nM; inhibitor 10 mM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138727,mbcd0001131,mbtp000025,mbrf0001955,,~,,,non-inhibitor,102,115.0,%,,Guanidine,read from graph,,HEK293 (transfected); pH 7.4; inhibition of drug uptake of E3S 4.7 nM; inhibitor 10 mM,,mbcd0003075,,,,human,mbds0010,,2013-12-08 00:42:40
mbbd000138728,mbcd0003941,mbtp000025,mbrf0001955,,~,,,non-inhibitor,72,100.0,%,,Procainamide,read from graph,,HEK293 (transfected); pH 7.4; inhibition of drug uptake of E3S 4.7 nM; inhibitor 10 mM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138729,mbcd0000516,mbtp000025,mbrf0001955,,~,,,non-inhibitor,72,100.0,%,,Lactic acid,read from graph,,HEK293 (transfected); pH 7.4; inhibition of drug uptake of E3S 4.7 nM; inhibitor 10 mM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138730,mbcd0001648,mbtp000025,mbrf0001955,,~,,,non-inhibitor,72,100.0,%,,Acetic acid,read from graph,,HEK293 (transfected); pH 7.4; inhibition of drug uptake of E3S 4.7 nM; inhibitor 10 mM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138731,mbcd0003008,mbtp000025,mbrf0001955,,~,,,inhibitor,72,10.0,%,,Valproic acid,read from graph,,HEK293 (transfected); pH 7.4; inhibition of drug uptake of E3S 4.7 nM; inhibitor 10 mM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138732,mbcd0029122,mbtp000025,mbrf0001955,,~,,,inhibitor,72,35.0,%,,Benzoic acid,read from graph,,HEK293 (transfected); pH 7.4; inhibition of drug uptake of E3S 4.7 nM; inhibitor 10 mM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138733,mbcd0001353,mbtp000025,mbrf0001955,,~,,,inhibitor,72,20.0,%,,Salicylic acid,read from graph,,HEK293 (transfected); pH 7.4; inhibition of drug uptake of E3S 4.7 nM; inhibitor 10 mM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138734,mbcd0014275,mbtp000025,mbrf0001955,,~,,,inhibitor,72,80.0,%,,Nicotinic acid,read from graph,,HEK293 (transfected); pH 7.4; inhibition of drug uptake of E3S 4.7 nM; inhibitor 10 mM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138735,mbcd0030025,mbtp000025,mbrf0001772,,=,,,substrate,28,4.0,microM,,CP-671305,,,HEK293 (transfected); 5 min; 0.5 - 64 microM,HEK293,,,,,human,mbds0010,,2013-11-24 23:13:04
mbbd000138736,mbcd0003005,mbtp000025,mbrf0002214,,,,,non-substrate,,,,,olmesartan,,,HEK293 (transfected); drug uptake; 0.1 microM; 6 min,HEK293,,,,,human,mbds0010,,2013-11-24 23:13:04
mbbd000138737,mbcd0025833,mbtp000025,mbrf0002464,,,,,non-substrate,,,,,Sitagliptin,data not shown in paper,,MDCKII cells (transfected),MDCKII,,,,,human,mbds0010,,2013-11-24 23:11:22
mbbd000138738,mbcd0029157,mbtp000025,mbrf0002200,,=,,,substrate,28,4.48,microM,1.35,M17055,,,HEK293 (transfected); pH 6.0,HEK293,,,,,human,mbds0010,,2013-11-24 23:13:04
mbbd000138739,mbcd0029157,mbtp000025,mbrf0002200,,=,,,substrate,22,248.0,pmol / mg protein / min,74,M17055,,,HEK293 (transfected); pH 6.0,HEK293,,,,,human,mbds0010,,2013-11-24 23:13:05
mbbd000138740,mbcd0029157,mbtp000025,mbrf0002200,,=,,,substrate,118,12.5,microL / mg protein / min,2.6,M17055,,,HEK293 (transfected); pH 6.0,HEK293,,,,,human,mbds0010,,2013-11-24 23:13:05
mbbd000138741,mbcd0029157,mbtp000025,mbrf0002200,,=,,,substrate,67,55.2,microL / mg protein / min,,M17055,,,HEK293 (transfected); pH 6.0,HEK293,,,,,human,mbds0010,,2013-11-24 23:13:05
mbbd000138742,mbcd0003035,mbtp000025,mbrf0002200,,=,,,inhibitor,29,1.47,microM,0.48,BSP,,,HEK293 (transfected); pH 6.0; 5 min; M17055 1.8 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138743,mbcd0003075,mbtp000025,mbrf0002200,,=,,,inhibitor,29,26.7,microM,3.6,Estrone-3-sulfate,,,HEK293 (transfected); pH 6.0; 5 min; M17055 1.8 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138744,mbcd0003126,mbtp000025,mbrf0002200,,=,,,inhibitor,29,114.0,microM,19,Pravastatin,,,HEK293 (transfected); pH 6.0; 5 min; M17055 1.8 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138745,mbcd0003137,mbtp000025,mbrf0002200,,=,,,inhibitor,29,19.6,microM,10.0,Furosemide,,,HEK293 (transfected); pH 6.0; 5 min; M17055 1.8 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138746,mbcd0000455,mbtp000025,mbrf0002200,,=,,,inhibitor,29,99.4,microM,16.2,Glycocholic acid,,,HEK293 (transfected); pH 6.0; 5 min; M17055 1.8 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138747,mbcd0003075,mbtp000025,mbrf0002200,,,,,inhibitor,,,,,Estrone-3-sulfate,data in graph,,HEK293 (transfected); pH 6.0; 5 min; M17055 1.8 microM; inhibitor 1mM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138748,mbcd0003126,mbtp000025,mbrf0002200,,,,,inhibitor,,,,,pravastatine,data in graph,,HEK293 (transfected); pH 6.0; 5 min; M17055 1.8 microM; inhibitor 1mM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138749,mbcd0003035,mbtp000025,mbrf0002200,,,,,inhibitor,,,,,BSP,data in graph,,HEK293 (transfected); pH 6.0; 5 min; M17055 1.8 microM; inhibitor 0.1 mM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138750,mbcd0003154,mbtp000025,mbrf0002200,,,,,inhibitor,,,,,Probenecid,data in graph,,HEK293 (transfected); pH 6.0; 5 min; M17055 1.8 microM; inhibitor 1 mM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138751,mbcd0027883,mbtp000025,mbrf0002200,,,,,inhibitor,,,,,DIDS,data in graph,,HEK293 (transfected); pH 6.0; 5 min; M17055 1.8 microM; inhibitor 1 mM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138752,mbcd0003137,mbtp000025,mbrf0002200,,,,,inhibitor,,,,,Furosemide,data in graph,,HEK293 (transfected); pH 6.0; 5 min; M17055 1.8 microM; inhibitor 1 mM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138753,mbcd0009261,mbtp000025,mbrf0002200,,,,,inhibitor,,,,,Bumetanid,data in graph,,HEK293 (transfected); pH 6.0; 5 min; M17055 1.8 microM; inhibitor 1 mM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138754,mbcd0009483,mbtp000025,mbrf0002200,,,,,inhibitor,,,,,Ethacrynic acid,data in graph,,HEK293 (transfected); pH 6.0; 5 min; M17055 1.8 microM; inhibitor 0.1 mM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138755,mbcd0001111,mbtp000025,mbrf0002200,,,,,non-inhibitor,,,,,Cimetidine,data in graph,,HEK293 (transfected); pH 6.0; 5 min; M17055 1.8 microM; inhibitor  mM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138756,mbcd0003923,mbtp000025,mbrf0002200,,,,,non-inhibitor,,,,,Tetraethylammonium,data in graph,,HEK293 (transfected); pH 6.0; 5 min; M17055 1.8 microM; inhibitor 1 mM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138757,mbcd0001640,mbtp000025,mbrf0002200,,,,,inhibitor,,,,,Cholic acid,data in graph,,HEK293 (transfected); pH 6.0; 5 min; M17055 1.8 microM; inhibitor 0.1 mM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138758,mbcd0000455,mbtp000025,mbrf0002200,,,,,inhibitor,,,,,Glycocholic acid,data in graph,,HEK293 (transfected); pH 6.0; 5 min; M17055 1.8 microM; inhibitor 0.1 mM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138759,mbcd0003050,mbtp000025,mbrf0002200,,,,,inhibitor,,,,,Taurocholic acid,data in graph,,HEK293 (transfected); pH 6.0; 5 min; M17055 1.8 microM; inhibitor 0.1 mM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138760,mbcd0000254,mbtp000025,mbrf0002200,,,,,inhibitor,,,,,chenodeoxycholic acid,data in graph,,HEK293 (transfected); pH 6.0; 5 min; M17055 1.8 microM; inhibitor 0.1 mM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138761,mbcd0001655,mbtp000025,mbrf0002200,,,,,inhibitor,,,,,deoxycholic acid,data in graph,,HEK293 (transfected); pH 6.0; 5 min; M17055 1.8 microM; inhibitor 0.1 mM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138762,mbcd0027721,mbtp000025,mbrf0002200,,,,,inhibitor,,,,,lithocholic acid,data in graph,,HEK293 (transfected); pH 6.0; 5 min; M17055 1.8 microM; inhibitor 0.1 mM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138763,mbcd0001612,mbtp000025,mbrf0002200,,,,,inhibitor,,,,,ursodeoxycholic acid,data in graph,,HEK293 (transfected); pH 6.0; 5 min; M17055 1.8 microM; inhibitor 0.1 mM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138764,mbcd0014270,mbtp000025,mbrf0001867,,,,,non-substrate,,,,,nafcillin,data not shown in paper,,Xenopus oocytes (transfected); Uptake of nafcillin (1 mM),Xenopus laevis oocytes,,,,,human,mbds0010,,2013-11-24 23:15:09
mbbd000138765,mbcd0001448,mbtp000025,mbrf0002327,,=,,,substrate,28,6.42,microM,1.03,Rosuvastatin,,,HEK293 (transfected); Rosuvastatin uptake; 1 min; 0.1 - 100 microM,HEK293,,,,,human,mbds0010,,2013-11-24 23:13:05
mbbd000138766,mbcd0001448,mbtp000025,mbrf0002327,,=,,,substrate,22,32.3,pmol / min / mg,4.9,Rosuvastatin,,,HEK293 (transfected); Rosuvastatin uptake; 1 min; 0.1 - 100 microM,HEK293,,,,,human,mbds0010,,2013-11-24 23:13:06
mbbd000138767,mbcd0001448,mbtp000025,mbrf0002327,,=,,,substrate,118,1.12,microl / min / mg,0.10,Rosuvastatin,,,HEK293 (transfected); Rosuvastatin uptake; 1 min; 0.1 - 100 microM,HEK293,,,,,human,mbds0010,,2013-11-24 23:13:06
mbbd000138768,mbcd0003075,mbtp000025,mbrf0002419,,=,,,substrate,28,19.1,microM,2.4,E1S,,,"FlpInTM-HEK293 cells (transfected); 0.25, 0.5 and 0.75 min",FlpInTM-HEK293,,,,,human,mbds0010,,2013-11-24 23:13:06
mbbd000138769,mbcd0003070,mbtp000025,mbrf0002419,,=,,,substrate,28,210.8,microM,46.3,DHEA-S,,,"FlpInTM-HEK293 cells (transfected); 0.25, 0.5 and 0.75 min",FlpInTM-HEK293,,,,,human,mbds0010,,2013-11-24 23:13:06
mbbd000138770,mbcd0003070,mbtp000025,mbrf0002419,,=,,,substrate,22,602.0,pmol / min / mg protein,112,DHEA-S,,,"FlpInTM-HEK293 cells (transfected); 0.25, 0.5 and 0.75 min",FlpInTM-HEK293,,,,,human,mbds0010,,2013-11-24 23:13:06
mbbd000138771,mbcd0003075,mbtp000025,mbrf0002419,,=,,,substrate,22,585.0,pmol / min / mg protein,57,E1S,,,"FlpInTM-HEK293 cells (transfected); 0.25, 0.5 and 0.75 min",FlpInTM-HEK293,,,,,human,mbds0010,,2013-11-24 23:13:07
mbbd000138772,mbcd0029158,mbtp000025,mbrf0002194,,,,,non-substrate,,,,,R-(-)-IBU,data not shown in paper; assay info omitted,,,,,1-500,microM,,human,mbds0010,,2013-12-11 05:34:05
mbbd000138773,mbcd0018339,mbtp000025,mbrf0002194,,,,,non-substrate,,,,,S-(+)-IBU,data not shown in paper; assay info omitted,,,,,1-500,microM,,human,mbds0010,,2013-12-11 05:34:05
mbbd000138774,mbcd0004707,mbtp000025,mbrf0001828,,=,,,substrate,28,1.09,microM,0.10,Tel-Glu,,,HEK293 (transfected); substrate 0.2 to 50 microM,HEK293,,,,,human,mbds0010,,2013-11-24 23:13:07
mbbd000138775,mbcd0004707,mbtp000025,mbrf0001828,,=,,,substrate,22,22.3,pmol / min / mg protein,1.0,Tel-Glu,,,HEK293 (transfected); substrate 0.2 to 50 microM,HEK293,,,,,human,mbds0010,,2013-11-24 23:13:07
mbbd000138776,mbcd0003075,mbtp000025,mbrf0001828,,=,,,substrate,25,223.0,microM,37,E-sul,,,HEK293 (transfected); substrate tel-glu,HEK293,,,,,human,mbds0010,,2013-11-24 23:13:07
mbbd000138777,mbcd0003075,mbtp000025,mbrf0001655,,=,,,substrate,28,17.8,microM,2.92,E3S,,,CHO (transfected); pH 8.0; 15 s,CHO,,,,,human,mbds0010,,2013-11-24 23:15:15
mbbd000138778,mbcd0003957,mbtp000025,mbrf0001655,,=,,,substrate,28,0.77,microM,0.18,T4,,,CHO (transfected); pH 8.0; 15 s,CHO,,,,,human,mbds0010,,2013-11-24 23:15:15
mbbd000138779,mbcd0003957,mbtp000025,mbrf0001655,,=,,,substrate,28,0.31,microM,0.09,T4,,,CHO (transfected); pH 6.5; 15 s,CHO,,,,,human,mbds0010,,2013-11-24 23:15:16
mbbd000138780,mbcd0003075,mbtp000025,mbrf0001655,,=,,,substrate,28,9.36,microM,0.93,E3S,,,CHO (transfected); pH 6.5; 15 s,CHO,,,,,human,mbds0010,,2013-11-24 23:15:16
mbbd000138781,mbcd0003075,mbtp000025,mbrf0001655,,=,,,substrate,22,1293.0,pmol / mg protein / min,51.13,E3S,,,CHO (transfected); pH 6.5; 15 s,CHO,,,,,human,mbds0010,,2013-11-24 23:15:16
mbbd000138782,mbcd0003957,mbtp000025,mbrf0001655,,=,,,substrate,22,5.76,pmol / mg protein / min,0.80,T4,,,CHO (transfected); pH 6.5; 15 s,CHO,,,,,human,mbds0010,,2013-11-24 23:15:16
mbbd000138783,mbcd0003957,mbtp000025,mbrf0001655,,=,,,substrate,22,7.28,pmol / mg protein / min,1.10,T4,,,CHO (transfected); pH 8.0; 15 s,CHO,,,,,human,mbds0010,,2013-11-24 23:15:17
mbbd000138784,mbcd0003075,mbtp000025,mbrf0001655,,=,,,substrate,22,1400.0,pmol / mg protein / min,114,E3S,,,CHO (transfected); pH 8.0; 15 s,CHO,,,,,human,mbds0010,,2013-11-24 23:15:17
mbbd000138785,mbcd0029159,mbtp000025,mbrf0002352,,,,,non-inhibitor,,,,,CP-724714,data not shown in paper,,"HEK293 (transfected); CP-724,714 1 nM - 100 microM; inhibition of uptake of probe substrate",,,,,,human,mbds0010,,2013-11-24 07:52:41
mbbd000138786,mbcd0003035,mbtp000025,mbrf0002067,,~,,,inhibitor,72,90.0,%,,BSP,,,COS cells (transfected); inhibition of estrone-3-sulfate 5 microM; pH 6.0; inhibitor 250 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138787,mbcd0000749,mbtp000025,mbrf0002067,,~,,,inhibitor,72,85.0,%,,rifamycin SV,,,COS cells (transfected); inhibition of estrone-3-sulfate 5 microM; pH 6.0; inhibitor 250 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138788,mbcd0000937,mbtp000025,mbrf0002067,,~,,,inhibitor,72,20.0,%,,erythromycin,,,COS cells (transfected); inhibition of estrone-3-sulfate 5 microM; pH 6.0; inhibitor 250 microM,,,,,weak inhibitor,human,mbds0010,,2013-11-21 02:36:50
mbbd000138789,mbcd0001517,mbtp000025,mbrf0002067,,~,,,inhibitor,72,22.0,%,,clarithromycin,,,COS cells (transfected); inhibition of estrone-3-sulfate 5 microM; pH 6.0; inhibitor 250 microM,,,,,weak inhibitor,human,mbds0010,,2013-11-24 22:15:13
mbbd000138790,mbcd0028157,mbtp000025,mbrf0002067,,~,,,inhibitor,72,10.0,%,,azithromycin,,,COS cells (transfected); inhibition of estrone-3-sulfate 5 microM; pH 6.0; inhibitor 250 microM,,,,,weak inhibitor,human,mbds0010,,2013-11-24 22:15:13
mbbd000138791,mbcd0003035,mbtp000025,mbrf0002067,,~,,,inhibitor,17,1.7,microM,,BSP,,,COS cells (transfected); inhibition of estrone-3-sulfate 1 microM; pH 6.0,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138792,mbcd0028157,mbtp000025,mbrf0002067,,>,,,inhibitor,17,1000.0,microM,,azithromycin,,,COS cells (transfected); inhibition of estrone-3-sulfate 1 microM; pH 6.0,,,,,weak inhibitor,human,mbds0010,,2013-11-24 22:15:12
mbbd000138793,mbcd0001517,mbtp000025,mbrf0002067,,>,,,inhibitor,17,1400.0,microM,,clarithromycin,,,COS cells (transfected); inhibition of estrone-3-sulfate 1 microM; pH 6.0,,,,,weak inhibitor,human,mbds0010,,2013-11-24 22:15:12
mbbd000138794,mbcd0000937,mbtp000025,mbrf0002067,,>,,,inhibitor,17,1100.0,microM,,erythromycin,,,COS cells (transfected); inhibition of estrone-3-sulfate 1 microM; pH 6.0,,,,,weak inhibitor,human,mbds0010,,2013-11-24 22:15:13
mbbd000138795,mbcd0028157,mbtp000025,mbrf0002067,,,,,non-substrate,,,,,azithromycin,,,COS cells (transfected); supplemental data fig. 10,COS,,,,,human,mbds0010,,2013-11-24 23:56:45
mbbd000138796,mbcd0001517,mbtp000025,mbrf0002067,,,,,non-substrate,,,,,clarithromycin,,,COS cells (transfected); supplemental data fig. 10,COS,,,,,human,mbds0010,,2013-11-24 23:56:45
mbbd000138797,mbcd0000242,mbtp000025,mbrf0002356,,=,,,non-substrate,33,45.7,nL / oocyte / 90 min,1.6,Celiprolol,"not statistically significant, control: water 33.8 +/- 4.8 nL / oocyte / 90 min",,Oocytes (transfected); celiprolol 1.0 microM; 90 min,Xenopus laevis oocytes,,,,,human,mbds0010,,2013-11-24 23:56:46
mbbd000138798,mbcd0029163,mbtp000025,mbrf0002232,,,,,non-substrate,,,,,8-FcA,,,CHO (transfected); 20 min; 10 microM; cellular accumulation,CHO,,,,,human,mbds0010,,2013-11-04 02:27:49
mbbd000138799,mbcd0000804,mbtp000025,mbrf0002296,,=,,,substrate,28,629.0,microM,780,Talinolol,,,X. laevis oocytes (transfected); pH 6.5; 120 min,Xenopus laevis oocytes,,,,,human,mbds0010,,2013-11-24 23:15:11
mbbd000138800,mbcd0000804,mbtp000025,mbrf0002296,,=,,,substrate,22,138.0,pmol / oocyte / 120 min,10,Talinolol,,,X. laevis oocytes (transfected); pH 6.5; 120 min,Xenopus laevis oocytes,,,,,human,mbds0010,,2013-11-24 23:15:11
mbbd000138801,mbcd0000615,mbtp000025,mbrf0002296,,>,,,non-inhibitor,25,2000.0,microM,,naringin,,,X. laevis oocytes (transfected); pH 6.5; inhibition of talinolol uptake; naringin 10 - 2000 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138802,mbcd0003120,mbtp000025,mbrf0001933,,=,,,inhibitor,29,8.7,microM,0.1,quercetin,,,HEK293 (transfected); inhibition of BSP transport,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138803,mbcd0003215,mbtp000025,mbrf0001933,,=,,,inhibitor,29,15.1,microM,7.8,kaempferol,,,HEK293 (transfected); inhibition of BSP transport,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138804,mbcd0003091,mbtp000025,mbrf0001933,,=,,,inhibitor,29,20.8,microM,8.0,apigenin,,,HEK293 (transfected); inhibition of BSP transport,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138805,mbcd0003091,mbtp000025,mbrf0001933,,=,,,inhibitor,25,13.9,microM,1.6,apigenin,,,HEK293 (transfected); inhibition of atorvastatin transport,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138806,mbcd0003120,mbtp000025,mbrf0001933,,=,,,inhibitor,25,14.1,microM,1.3,quercetin,,,HEK293 (transfected); inhibition of atorvastatin transport,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138807,mbcd0003215,mbtp000025,mbrf0001933,,=,,,inhibitor,25,20.7,microM,1.8,kaempferol,,,HEK293 (transfected); inhibition of atorvastatin transport,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138808,mbcd0003126,mbtp000025,mbrf0001794,,~,,,substrate,33,0.17,nL / min / oocyte,,pravastatin,read from graph,,Xenopus oocytes (transfected); Uptake of pravastatin (10 ?M); 180 min; pH 6.5,Xenopus laevis oocytes,,,,,human,mbds0010,,2013-11-24 23:15:09
mbbd000138809,mbcd0000746,mbtp000025,mbrf0001720,,,,,non-substrate,,,,,R123,,,HEK-293 (transfected); rhodamine 123 0 - 2 microM,HEK293,,,,,human,mbds0010,,2013-11-24 23:13:08
mbbd000138810,mbcd0029165,mbtp000025,mbrf0002131,,,,,substrate,,,,,TBPM-PI,,,Xenopus oocytes (transfected),Xenopus laevis oocytes,,,,,human,mbds0010,,2013-11-24 23:15:09
mbbd000138811,mbcd0029165,mbtp000025,mbrf0002131,,=,,,inhibitor,25,410.0,microM,,TBPM-PI,,,Xenopus oocytes (transfected); pH 6.0; Estrone-3-sulfate 10 nM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138812,mbcd0029166,mbtp000025,mbrf0002131,,,,,non-substrate,,,,,TBPM,,,Xenopus oocytes (transfected); pH 6.0,Xenopus laevis oocytes,,,,,human,mbds0010,,2013-11-24 23:15:10
mbbd000138813,mbcd0029165,mbtp000025,mbrf0002131,,>,,,substrate,28,1.0,mM,,TBPM-PI,,,Xenopus oocytes (transfected); pH 6.0,Xenopus laevis oocytes,,,,,human,mbds0010,,2013-11-24 23:15:10
mbbd000138814,mbcd0000615,mbtp000025,mbrf0001967,,,,,non-inhibitor,,,,,naringin,,,Xenopus oocytes (transfected); inhibition of uptake of pravastatin 10 microM; pH 6.5; naringin 1000 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138815,mbcd0000615,mbtp000025,mbrf0001967,,,,,inhibitor,,,,,naringin,,,Xenopus oocytes (transfected); inhibition of uptake of pitavastatin 1 microM; pH 6.5; naringin 1000 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138816,mbcd0029167,mbtp000025,mbrf0002434,,=,,,substrate,28,0.81,microM,0.06,BDE47,,,CHO (transfected),CHO,,,,,human,mbds0010,,2013-11-24 23:15:17
mbbd000138817,mbcd0029168,mbtp000025,mbrf0002434,,=,,,substrate,28,0.87,microM,0.22,BDE99,,,CHO (transfected),CHO,,,,,human,mbds0010,,2013-11-24 23:15:17
mbbd000138818,mbcd0029169,mbtp000025,mbrf0002434,,=,,,substrate,28,0.65,microM,0.07,BDE153,,,CHO (transfected),CHO,,,,,human,mbds0010,,2013-11-24 23:15:18
mbbd000138819,mbcd0029167,mbtp000025,mbrf0002434,,=,,,substrate,22,17.6,nmol / mg protein / min,1.1,BDE47,,,CHO (transfected),CHO,,,,,human,mbds0010,,2013-11-24 23:15:18
mbbd000138820,mbcd0029168,mbtp000025,mbrf0002434,,=,,,substrate,22,8.9,nmol / mg protein / min,0.9,BDE99,,,CHO (transfected),CHO,,,,,human,mbds0010,,2013-11-24 23:15:18
mbbd000138821,mbcd0029169,mbtp000025,mbrf0002434,,=,,,substrate,22,14.6,nmol / mg protein / min,3.1,BDE153,,,CHO (transfected),CHO,,,,,human,mbds0010,,2013-11-24 23:15:18
mbbd000138822,mbcd0029169,mbtp000025,mbrf0002434,,=,,,substrate,67,28.1,nL (mg protein)-1 min-1,8.1,BDE153,,,CHO (transfected),CHO,,,,,human,mbds0010,,2014-03-03 23:58:32
mbbd000138823,mbcd0029168,mbtp000025,mbrf0002434,,=,,,substrate,67,10.5,nL (mg protein)-1 min-1,1.6,BDE99,,,CHO (transfected),CHO,,,,,human,mbds0010,,2014-03-03 23:58:32
mbbd000138824,mbcd0029167,mbtp000025,mbrf0002434,,=,,,substrate,67,22.6,nL (mg protein)-1 min-1,1.1,BDE47,,,CHO (transfected),CHO,,,,,human,mbds0010,,2014-03-03 23:58:32
mbbd000138825,mbcd0003035,mbtp000025,mbrf0002056,,=,,,substrate,28,5.41,microM,3.76,BSP,,,HEK (transfected); 5 min,HEK293,,,,,human,mbds0010,,2013-11-02 07:50:09
mbbd000138826,mbcd0001416,mbtp000025,mbrf0002056,,=,,,inhibitor,25,80.5,microM,,rifampicin,,,HEK (transfected); inhibition of BSP uptake,HEK293,mbcd0003035,,,,human,mbds0010,,2013-11-03 21:46:34
mbbd000138827,mbcd0029170,mbtp000025,mbrf0002056,,,,,non-inhibitor,,,,,Gd-EOB-DTPA,,,HEK (transfected); inhibition of BSP 1 microM uptake,HEK293,,,,,human,mbds0010,,2013-11-02 07:50:08
mbbd000138828,mbcd0029170,mbtp000025,mbrf0002056,,,,,non-substrate,,,,,Gd-EOB-DTPA,,,HEK (transfected),HEK293,,,,,human,mbds0010,,2013-11-02 07:50:08
mbbd000138829,mbcd0000693,mbtp000025,mbrf0001843,,,,,substrate,,,,,pitavastatin,,,Xenopus oocytes (transfected); uptake of pitavastatin 1 microM,Xenopus laevis oocytes,,,,,human,mbds0010,,2013-11-24 23:15:10
mbbd000138830,mbcd0003033,mbtp000025,mbrf0002123,,=,,,inhibitor,3,83.7,%,15.4,BG,,,(trandfected); BG 10 microM; inhibition of ES,,,,,,human,mbds0010,,2013-12-06 06:52:43
mbbd000138831,mbcd0029171,mbtp000025,mbrf0002295,,=,,,inhibitor,25,23.0,microM,,latanoprost,,,HEK (transfected); inhibition of BSP (1 microM) uptake,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138832,mbcd0029172,mbtp000025,mbrf0002295,,=,,,inhibitor,25,88.0,microM,,latanoprost acid,,,HEK (transfected); inhibition of BSP (1 microM) uptake,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138833,mbcd0029172,mbtp000025,mbrf0002295,,,,,substrate,,,,,latanoprost acid,not saturable up to 125 microM; no Km value,,HEK (transfected); uptake of 15 microM is statistically significant,HEK,,,,weak substrate,human,mbds0010,,2013-11-24 23:13:08
mbbd000138834,mbcd0029171,mbtp000025,mbrf0002295,,,,,non-substrate,,,,,latanoprost,,,HEK (transfected); up to 500 microM,HEK,,,,,human,mbds0010,,2013-11-24 23:13:08
mbbd000138835,mbcd0003035,mbtp000025,mbrf0001773,,=,,,inhibitor,72,15.0,%,2,BSP,,,MDCKII (transfected); inhibition of E3S uptake; inhibitor concentration 100 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138836,mbcd0003126,mbtp000025,mbrf0001773,,=,,,inhibitor,72,17.0,%,6,Pravastatin,,,MDCKII (transfected); inhibition of E3S uptake; inhibitor concentration 5 mM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138837,mbcd0002383,mbtp000025,mbrf0001773,,=,,,non-inhibitor,72,94.0,%,7,Amprenavir,,,MDCKII (transfected); inhibition of E3S uptake; inhibitor concentration 10 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138838,mbcd0002051,mbtp000025,mbrf0001773,,=,,,inhibitor,72,33.0,%,2,Atazanavir,,,MDCKII (transfected); inhibition of E3S uptake; inhibitor concentration 10 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138839,mbcd0002634,mbtp000025,mbrf0001773,,=,,,inhibitor,72,26.0,%,1,Darunavir,,,MDCKII (transfected); inhibition of E3S uptake; inhibitor concentration 100 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138840,mbcd0002323,mbtp000025,mbrf0001773,,=,,,inhibitor,72,77.0,%,7,Indinavir,,,MDCKII (transfected); inhibition of E3S uptake; inhibitor concentration 10 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138841,mbcd0002241,mbtp000025,mbrf0001773,,=,,,inhibitor,72,18.0,%,2,Lopinavir,,,MDCKII (transfected); inhibition of E3S uptake; inhibitor concentration 10 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138842,mbcd0026632,mbtp000025,mbrf0001773,,=,,,inhibitor,72,25.0,%,8,Nelfinavir,,,MDCKII (transfected); inhibition of E3S uptake; inhibitor concentration 10 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138843,mbcd0001938,mbtp000025,mbrf0001773,,=,,,inhibitor,72,22.0,%,2,Ritonavir,,,MDCKII (transfected); inhibition of E3S uptake; inhibitor concentration 10 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138844,mbcd0001533,mbtp000025,mbrf0001773,,=,,,inhibitor,72,32.0,%,2,Saquinavir,,,MDCKII (transfected); inhibition of E3S uptake; inhibitor concentration 10 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138845,mbcd0001350,mbtp000025,mbrf0001773,,=,,,inhibitor,72,15.0,%,3,Tipranavir,,,MDCKII (transfected); inhibition of E3S uptake; inhibitor concentration 10 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138846,mbcd0001868,mbtp000025,mbrf0001773,,=,,,inhibitor,72,21.0,%,1,Efavirenz,,,MDCKII (transfected); inhibition of E3S uptake; inhibitor concentration 100 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138847,mbcd0001795,mbtp000025,mbrf0001773,,=,,,non-inhibitor,72,82.0,%,7,Etravirine,,,MDCKII (transfected); inhibition of E3S uptake; inhibitor concentration 100 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138848,mbcd0003124,mbtp000025,mbrf0001773,,=,,,non-inhibitor,72,96.0,%,3,Abacavir,,,MDCKII (transfected); inhibition of E3S uptake; inhibitor concentration 100 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138849,mbcd0003029,mbtp000025,mbrf0001773,,=,,,non-inhibitor,72,104.0,%,3,Emtricitabine,,,MDCKII (transfected); inhibition of E3S uptake; inhibitor concentration 100 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138850,mbcd0002982,mbtp000025,mbrf0001773,,=,,,non-inhibitor,72,100.0,%,4,Lamivudine,,,MDCKII (transfected); inhibition of E3S uptake; inhibitor concentration 100 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138851,mbcd0003028,mbtp000025,mbrf0001773,,=,,,non-inhibitor,72,100.0,%,4,Tenofovir,,,MDCKII (transfected); inhibition of E3S uptake; inhibitor concentration 100 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138852,mbcd0029174,mbtp000025,mbrf0001773,,=,,,non-inhibitor,72,88.0,%,3,Tenofovir DF,mixture of two compounds,,MDCKII (transfected); inhibition of E3S uptake; inhibitor concentration 100 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138853,mbcd0001107,mbtp000025,mbrf0001773,,=,,,non-inhibitor,72,103.0,%,5,Zidovudine,,,MDCKII (transfected); inhibition of E3S uptake; inhibitor concentration 100 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138854,mbcd0002051,mbtp000025,mbrf0001773,,,,,non-substrate,,,,,atazanavir,,,MDCKII (transfected); uptake; concentration 1 microM; pH 7.4,MDCKII,,,,,human,mbds0010,,2013-11-24 23:11:22
mbbd000138855,mbcd0001938,mbtp000025,mbrf0001773,,,,,non-substrate,,,,,ritonavir,,,MDCKII (transfected); uptake; concentration 1 microM; pH 7.4,MDCKII,,,,,human,mbds0010,,2013-11-24 23:11:23
mbbd000138856,mbcd0003035,mbtp000025,mbrf0001773,,=,,,inhibitor,25,6.0,microM,,BSP,,,MDCKII (transfected); inhibition of E3S uptake (1 microM),,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138857,mbcd0000749,mbtp000025,mbrf0001773,,=,,,inhibitor,25,2.7,microM,,Rifamycin SV,,,MDCKII (transfected); inhibition of E3S uptake (1 microM),,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138858,mbcd0002241,mbtp000025,mbrf0001773,,=,,,inhibitor,25,0.72,microM,,Lopinavir,,,MDCKII (transfected); inhibition of E3S uptake (1 microM),,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138859,mbcd0001350,mbtp000025,mbrf0001773,,=,,,inhibitor,25,0.88,microM,,Tipranavir,,,MDCKII (transfected); inhibition of E3S uptake (1 microM),,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138860,mbcd0026632,mbtp000025,mbrf0001773,,=,,,inhibitor,25,0.9,microM,,Nelfinavir,,,MDCKII (transfected); inhibition of E3S uptake (1 microM),,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138861,mbcd0001938,mbtp000025,mbrf0001773,,=,,,inhibitor,25,2.2,microM,,Ritonavir,,,MDCKII (transfected); inhibition of E3S uptake (1 microM),,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138862,mbcd0002051,mbtp000025,mbrf0001773,,=,,,inhibitor,25,3.6,microM,,Atazanavir,,,MDCKII (transfected); inhibition of E3S uptake (1 microM),,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138863,mbcd0001533,mbtp000025,mbrf0001773,,=,,,inhibitor,25,4.6,microM,,Saquinavir,,,MDCKII (transfected); inhibition of E3S uptake (1 microM),,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138864,mbcd0002634,mbtp000025,mbrf0001773,,=,,,inhibitor,25,26.0,microM,,Darunavir,,,MDCKII (transfected); inhibition of E3S uptake (1 microM),,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138865,mbcd0001868,mbtp000025,mbrf0001773,,=,,,inhibitor,25,9.6,microM,,Efavirenz,,,MDCKII (transfected); inhibition of E3S uptake (1 microM),,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138866,mbcd0003017,mbtp000025,mbrf0002291,,,,,non-inhibitor,,,,,mesalazine,,,"HEK293; inhibirion of 1 microM BSP; mesalazine 10, 50 and 100 microM",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138867,mbcd0003017,mbtp000025,mbrf0002291,,=,,,substrate,28,188.9,microM,50.5,mesalazine,,,HEK293 (transfected),HEK293,,,,,human,mbds0010,,2013-11-24 23:13:08
mbbd000138868,mbcd0003017,mbtp000025,mbrf0002291,,=,,,substrate,22,37.2,pmol / mg protein / min,3.6,mesalazine,,,HEK293 (transfected),HEK293,,,,,human,mbds0010,,2013-11-24 23:13:09
mbbd000138869,mbcd0003126,mbtp000025,mbrf0002291,,,,,inhibitor,,,,,Pravastatin,,,HEK293 (transfected); inhibition of mesalazine 20 microM; inhibitor 100 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138870,mbcd0003938,mbtp000025,mbrf0002291,,,,,non-inhibitor,,,,,Azathioprine,,,HEK293 (transfected); inhibition of mesalazine 20 microM; inhibitor 10 and 100 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138871,mbcd0001517,mbtp000025,mbrf0002291,,,,,non-inhibitor,,,,,clarithromycin,,,HEK293 (transfected); inhibition of mesalazine 20 microM; inhibitor 10 and 100 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138872,mbcd0001527,mbtp000025,mbrf0002291,,,,,inhibitor,,,,,budesonide,,,HEK293 (transfected); inhibition of mesalazine 20 microM; inhibitor 10 and 100 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138873,mbcd0000311,mbtp000025,mbrf0002291,,,,,inhibitor,,,,,cyclosporine,,,HEK293 (transfected); inhibition of mesalazine 20 microM; inhibitor 10 and 100 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138874,mbcd0001416,mbtp000025,mbrf0002291,,,,,inhibitor,,,,,rifampin,,,HEK293 (transfected); inhibition of mesalazine 20 microM; inhibitor 10 and 100 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138875,mbcd0029175,mbtp000025,mbrf0002568,,,,,substrate,,,,,19,,,Transfected CHO or HEK cells at 1 microM,HEK; CHO,,,,,human,mbds0010,,2013-11-24 23:13:09
mbbd000138876,mbcd0001549,mbtp000025,mbrf0002422,,,,,non-substrate,,,,,aliskiren,,,HEK293 (transfected); uptake of 2.5 or 10 microM aliskiren,HEK293,,,,,human,mbds0010,,2013-11-24 23:13:09
mbbd000138877,mbcd0002051,mbtp000025,mbrf0002199,,=,,,inhibitor,3,90.1,%,3.1,atazanavir,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138878,mbcd0026093,mbtp000025,mbrf0002199,,=,,,inhibitor,3,98.3,%,0.6,atorvastatin,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138879,mbcd0003035,mbtp000025,mbrf0002199,,=,,,inhibitor,3,69.3,%,9.0,bromosulfalein,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138880,mbcd0004706,mbtp000025,mbrf0002199,,=,,,inhibitor,3,60.1,%,10.8,cholecystokinin 8,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2013-11-23 21:09:53
mbbd000138881,mbcd0003100,mbtp000025,mbrf0002199,,=,,,inhibitor,3,83.1,%,4.0,dipryridamole,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138882,mbcd0003155,mbtp000025,mbrf0002199,,=,,,inhibitor,3,65.9,%,12.8,fluo-3,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138883,mbcd0001445,mbtp000025,mbrf0002199,,=,,,inhibitor,3,98.2,%,1.0,fluvastatin,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138884,mbcd0001635,mbtp000025,mbrf0002199,,=,,,inhibitor,3,65.3,%,6.9,glycochenodeoxycholate,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138885,mbcd0000456,mbtp000025,mbrf0002199,,=,,,inhibitor,3,53.8,%,8.4,glycodeoxycholate,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138886,mbcd0000487,mbtp000025,mbrf0002199,,=,,,inhibitor,3,79.2,%,4.0,indocyanine green,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138887,mbcd0002241,mbtp000025,mbrf0002199,,=,,,inhibitor,3,86.4,%,4.5,lopinavir,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138888,mbcd0001299,mbtp000025,mbrf0002199,,=,,,inhibitor,3,70.7,%,10.2,mifepristone,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138889,mbcd0002494,mbtp000025,mbrf0002199,,=,,,inhibitor,3,75.2,%,7.2,MK-571,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138890,mbcd0003059,mbtp000025,mbrf0002199,,=,,,inhibitor,3,71.3,%,5.9,morin,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138891,mbcd0003252,mbtp000025,mbrf0002199,,=,,,inhibitor,3,85.6,%,3.9,novobiocin,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138892,mbcd0000693,mbtp000025,mbrf0002199,,=,,,inhibitor,3,63.7,%,6.8,pitavastatin,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138893,mbcd0000749,mbtp000025,mbrf0002199,,=,,,inhibitor,3,74.8,%,9.8,rifamycin SV,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138894,mbcd0001938,mbtp000025,mbrf0002199,,=,,,inhibitor,3,93.6,%,1.5,ritonavir,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138895,mbcd0001448,mbtp000025,mbrf0002199,,=,,,inhibitor,3,51.2,%,10.9,rosuvastatin,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138896,mbcd0027229,mbtp000025,mbrf0002199,,=,,,inhibitor,3,74.0,%,7.1,silymarin,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138897,mbcd0001280,mbtp000025,mbrf0002199,,=,,,inhibitor,3,92.3,%,2.8,Sulfasalazine,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138898,mbcd0003050,mbtp000025,mbrf0002199,,=,,,inhibitor,3,96.2,%,1.4,taurocholate,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138899,mbcd0000817,mbtp000025,mbrf0002199,,=,,,inhibitor,3,85.3,%,4.2,taurodeoxycholate,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138900,mbcd0003109,mbtp000025,mbrf0002199,,=,,,inhibitor,3,94.6,%,3.0,taurolithocholate,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138901,mbcd0004705,mbtp000025,mbrf0002199,,=,,,inhibitor,3,94.9,%,1.2,telmisartan,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,HEK293,mbcd0003075,20,microM,,human,mbds0010,,2013-12-13 22:00:48
mbbd000138902,mbcd0001350,mbtp000025,mbrf0002199,,=,,,inhibitor,3,99.0,%,0.3,tipranavir,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138903,mbcd0000080,mbtp000025,mbrf0002199,,=,,,stimulator,3,-24.9,%,30.2,5-carboxyfluorescein diacetate,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2013-12-09 05:38:36
mbbd000138904,mbcd0003034,mbtp000025,mbrf0002199,,=,,,inhibitor,3,76.3,%,6.3,benzbromarone,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138905,mbcd0001527,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,30.3,%,25.1,budesonide,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138906,mbcd0023123,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,40.1,%,20.9,cerivastatin,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138907,mbcd0001517,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,5.1,%,12.3,clarithromycin,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138908,mbcd0000311,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,14.0,%,17.9,cyclosporin A,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2013-11-24 22:15:08
mbbd000138909,mbcd0003903,mbtp000025,mbrf0002199,,=,,,inhibitor,3,51.4,%,13.4,diazepam,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138910,mbcd0000968,mbtp000025,mbrf0002199,,=,,,inhibitor,3,68.1,%,9.6,diethylstilbestrol,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138911,mbcd0000387,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,-12.2,%,14.4,estradiol-17-beta-glucuronide,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138912,mbcd0003116,mbtp000025,mbrf0002199,,=,,,inhibitor,3,67.9,%,7.3,genistein,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138913,mbcd0001808,mbtp000025,mbrf0002199,,=,,,inhibitor,3,67.2,%,7.6,GF120918 (elacridar),,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138914,mbcd0003074,mbtp000025,mbrf0002199,,=,,,inhibitor,3,77.4,%,1.3,glibenclamide,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138915,mbcd0000462,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,28.7,%,9.7,glycyrrhizic acid,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138916,mbcd0001172,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,39.0,%,16.6,ivermectin,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138917,mbcd0002439,mbtp000025,mbrf0002199,,=,,,inhibitor,3,78.8,%,4.7,KO143,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138918,mbcd0025582,mbtp000025,mbrf0002199,,=,,,inhibitor,3,61.5,%,16.3,nefazodone,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138919,mbcd0026632,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,49.9,%,8.2,nelfinavir,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138920,mbcd0003118,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,23.4,%,21.1,Nystatin,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138921,mbcd0001532,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,30.8,%,20.6,paclitaxel,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138922,mbcd0000721,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,33.1,%,14.9,PSC833 (Valspodar),,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138923,mbcd0003120,mbtp000025,mbrf0002199,,=,,,inhibitor,3,72.6,%,12.2,quercetin,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138924,mbcd0001904,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,42.2,%,18.1,repaglinide,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138925,mbcd0001941,mbtp000025,mbrf0002199,,=,,,inhibitor,3,72.3,%,7.4,reserpine,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138926,mbcd0001416,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,21.2,%,12.5,rifampicin,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138927,mbcd0000815,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,47.2,%,19.9,taurochenodeoxycholate,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2013-11-24 22:15:08
mbbd000138928,mbcd0001151,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,-9.3,%,30.4,vinblastine,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138929,mbcd0003055,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,47.4,%,18.4,17beta-estradiol,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138930,mbcd0002383,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,-3.4,%,17.9,amprenavir,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138931,mbcd0002109,mbtp000025,mbrf0002199,,=,,,inhibitor,3,58.9,%,12.3,astemizole,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138932,mbcd0003033,mbtp000025,mbrf0002199,,=,,,inhibitor,3,59.1,%,12.4,baicalin,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138933,mbcd0003962,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,28.4,%,18.3,candesartan,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138934,mbcd0029182,mbtp000025,mbrf0002199,,=,,,stimulator,3,-41.5,%,17.2,coumestrol,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2013-12-09 05:38:34
mbbd000138935,mbcd0003113,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,19.6,%,13.4,diclofenac,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138936,mbcd0003099,mbtp000025,mbrf0002199,,=,,,inhibitor,3,93.7,%,1.6,erlotinib,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138937,mbcd0000937,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,-19.0,%,9.3,erythromycin,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138938,mbcd0003075,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,20.8,%,19.2,estrone-3-sulfate,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138939,mbcd0001374,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,-8.9,%,30.8,ezetimibe,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138940,mbcd0003044,mbtp000025,mbrf0002199,,=,,,inhibitor,3,65.8,%,13.5,flutamide,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138941,mbcd0009531,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,15.1,%,22.7,gemfibrozil,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138942,mbcd0000455,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,-9.8,%,33.2,glycocholic acid,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138943,mbcd0000474,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,12.7,%,20.3,hoechst 33342,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138944,mbcd0002323,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,17.8,%,29.2,indinavir,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138945,mbcd0003025,mbtp000025,mbrf0002199,,=,,,stimulator,3,-82.4,%,27.4,indometacin,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2013-12-09 05:38:32
mbbd000138946,mbcd0002191,mbtp000025,mbrf0002199,,=,,,inhibitor,3,59.8,%,14.5,itraconazole,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138947,mbcd0017104,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,44.0,%,16.2,ketoconazole,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138948,mbcd0003957,mbtp000025,mbrf0002199,,=,,,inhibitor,3,63.7,%,15.0,levothyroxin,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138949,mbcd0025591,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,-17.9,%,28.5,lovastatin,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138950,mbcd0002981,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,48.3,%,12.8,mitoxantrone,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138951,mbcd0002576,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,31.8,%,22.3,nicardipine,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138952,mbcd0007511,mbtp000025,mbrf0002199,,=,,,stimulator,3,-44.4,%,27.3,nifedipine,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2013-12-09 05:38:33
mbbd000138953,mbcd0003037,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,14.5,%,19.7,N-methylnicotinamide,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138954,mbcd0003005,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,-7.9,%,35.0,Olmesartan,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138955,mbcd0001442,mbtp000025,mbrf0002199,,=,,,stimulator,3,-24.1,%,29.0,ouabain,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2013-12-09 05:38:36
mbbd000138956,mbcd0003073,mbtp000025,mbrf0002199,,=,,,inhibitor,3,68.3,%,9.3,piroxicam,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138957,mbcd0003126,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,36.8,%,8.2,pravastatin,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138958,mbcd0001892,mbtp000025,mbrf0002199,,=,,,stimulator,3,-362.6,%,62.0,progesterone,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2013-12-09 05:38:31
mbbd000138959,mbcd0001092,mbtp000025,mbrf0002199,,=,,,stimulator,3,-22.9,%,34.2,quinine,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2013-12-09 05:38:37
mbbd000138960,mbcd0023111,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,10.0,%,15.0,mbcd0023111,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138961,mbcd0001533,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,11.5,%,24.3,saquinavir,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138962,mbcd0001194,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,47.4,%,14.2,simvastatin,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138963,mbcd0003094,mbtp000025,mbrf0002199,,=,,,stimulator,3,-82.0,%,25.0,spironolactone,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2013-12-09 05:38:32
mbbd000138964,mbcd0003016,mbtp000025,mbrf0002199,,=,,,inhibitor,3,51.1,%,9.9,tetracycline,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138965,mbcd0003008,mbtp000025,mbrf0002199,,=,,,inhibitor,3,61.9,%,8.0,valproic acid,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138966,mbcd0003086,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,12.3,%,26.2,valsartan,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138967,mbcd0001135,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,13.0,%,19.4,vincristine,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138968,mbcd0003022,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,2.4,%,24.8,1-methyl-4-phenyl-pyridinium,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138969,mbcd0003952,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,0.1,%,16.1,acarbose,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138970,mbcd0003916,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,-15.2,%,16.3,aciclovir,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138971,mbcd0003973,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,8.4,%,16.0,allopurinol,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138972,mbcd0003083,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,17.0,%,17.9,amantadine,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138973,mbcd0003081,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,-8.9,%,31.2,amitriptyline,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138974,mbcd0003144,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,43.4,%,18.0,amodiaquine,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138975,mbcd0003875,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,6.8,%,32.8,atenolol,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138976,mbcd0003056,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,16.3,%,35.0,atomoxetine,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138977,mbcd0001869,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,18.5,%,18.9,berberine,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138978,mbcd0001650,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,20.7,%,24.7,bestatin,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138979,mbcd0025521,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,-7.0,%,21.0,bufuralol,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138980,mbcd0003003,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,17.0,%,22.0,bupropion,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138981,mbcd0003932,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,-13.9,%,28.5,buspirone,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138982,mbcd0003879,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,3.2,%,27.3,caffeine,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138983,mbcd0003142,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,39.1,%,21.2,captopril,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138984,mbcd0002985,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,17.3,%,19.7,carbamazepine,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138985,mbcd0003051,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,15.5,%,17.2,carnitine,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138986,mbcd0001472,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,3.5,%,26.3,cefadroxil,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138987,mbcd0003019,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,2.7,%,20.9,cefamandole,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138988,mbcd0003901,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,29.9,%,15.4,cetirizine,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138989,mbcd0003062,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,13.1,%,21.9,chelerythrine,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138990,mbcd0003088,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,23.5,%,19.3,chloroquine,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138991,mbcd0002340,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,4.3,%,18.4,chlorpromazine,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138992,mbcd0001539,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,26.6,%,22.2,chlorprothixene,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138993,mbcd0003000,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,12.0,%,23.3,chlorzoxazone,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138994,mbcd0001640,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,20.2,%,19.6,cholic acid,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138995,mbcd0001111,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,-6.2,%,23.4,cimetidine,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138996,mbcd0002493,mbtp000025,mbrf0002199,,=,,,stimulator,3,-37.1,%,32.6,clotrimazole,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2013-12-09 05:38:34
mbbd000138997,mbcd0002667,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,24.4,%,9.3,colchicine,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138998,mbcd0029184,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,9.3,%,12.7,coumarin,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000138999,mbcd0013632,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,32.0,%,15.7,daidzein,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139000,mbcd0002995,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,-4.4,%,6.2,desipramine,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139001,mbcd0002959,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,-12.5,%,27.9,dexamethasone,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139002,mbcd0003089,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,15.9,%,18.8,dextromethorphan,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139003,mbcd0001050,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,32.1,%,14.5,digoxin,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139004,mbcd0002338,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,-9.1,%,24.5,Diltiazem,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139005,mbcd0003141,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,18.5,%,16.1,disopyramide,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139006,mbcd0015934,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,15.5,%,7.3,disulfiram,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139007,mbcd0000940,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,18.1,%,21.9,dofetilide,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139008,mbcd0003930,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,45.8,%,9.2,doxazosin,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139009,mbcd0025844,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,49.9,%,14.4,doxorubicin,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139010,mbcd0001868,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,43.2,%,15.0,efavirenz,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139011,mbcd0028144,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,0.4,%,9.6,eletriptan,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139012,mbcd0003029,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,20.7,%,20.7,emtricitabine,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139013,mbcd0003498,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,19.7,%,15.0,enalapril,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139014,mbcd0002466,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,6.8,%,23.9,etoposide,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139015,mbcd0003011,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,21.4,%,16.3,felodipine,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139016,mbcd0003064,mbtp000025,mbrf0002199,,=,,,stimulator,3,-118.7,%,31.0,fendiline,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2013-12-09 05:38:31
mbbd000139017,mbcd0003027,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,34.2,%,23.8,fenofibrate,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139018,mbcd0003948,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,11.7,%,17.8,fentanyl,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139019,mbcd0001797,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,-5.8,%,31.3,fexofenadine,,,HEK293; inhibitor 20 microM; substrate E3S 1.02 microM,HEK293,mbcd0003075,20,microM,,human,mbds0010,,2013-12-08 08:52:00
mbbd000139020,mbcd0023577,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,34.1,%,17.9,fluconazole,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139021,mbcd0022530,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,22.6,%,14.6,fluoxetine,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139022,mbcd0029185,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,9.5,%,30.8,flupenthixol,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139023,mbcd0000923,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,39.0,%,16.8,fluvoxamine,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139024,mbcd0004733,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,18.1,%,38.7,furafylline,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139025,mbcd0003137,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,34.5,%,14.4,furosemide,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139026,mbcd0003112,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,22.0,%,17.4,glipizide,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139027,mbcd0003642,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,24.1,%,25.7,glycyl proline,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139028,mbcd0029874,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,31.5,%,10.5,hygromycin,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139029,mbcd0003013,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,13.5,%,23.0,ibuprofen,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139030,mbcd0003898,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,16.9,%,23.0,imipramine,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139031,mbcd0002091,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,16.3,%,13.6,irinotecan,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139032,mbcd0002983,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,23.8,%,12.2,isoniazid,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139033,mbcd0000977,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,12.0,%,10.9,isradipine,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139034,mbcd0013986,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,13.6,%,26.2,lamotrigine,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139035,mbcd0003121,mbtp000025,mbrf0002199,,=,,,stimulator,3,-75.7,%,21.1,lansoprazole,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2013-12-09 05:38:32
mbbd000139036,mbcd0003061,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,19.2,%,19.2,lisinopril,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139037,mbcd0002539,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,19.6,%,28.8,loperamide,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139038,mbcd0003021,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,28.1,%,17.4,loratadine,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139039,mbcd0001128,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,32.9,%,24.5,mephenytoin,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139040,mbcd0003886,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,-4.5,%,24.5,metformin,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139041,mbcd0003043,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,-13.4,%,29.9,methotrexate,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139042,mbcd0018761,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,-1.6,%,8.4,methoxsalen,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139043,mbcd0002822,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,30.5,%,18.3,metoprolol,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139044,mbcd0001735,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,22.7,%,20.4,midazolam,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139045,mbcd0023049,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,27.5,%,10.1,moclobemide,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139046,mbcd0003076,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,32.4,%,22.3,naringenin,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139047,mbcd0000615,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,47.1,%,11.9,naringin,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139048,mbcd0000928,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,-16.5,%,16.2,nicotine,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139049,mbcd0001221,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,23.1,%,18.1,nitrofurantoin,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139050,mbcd0003965,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,12.8,%,21.5,"N-methylpyridinium, ASP+",,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139051,mbcd0000604,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,-10.3,%,23.6,N-methyl-quinidine,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139052,mbcd0023086,mbtp000025,mbrf0002199,,=,,,stimulator,3,-72.2,%,32.2,nootkatone,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2013-12-09 05:38:33
mbbd000139053,mbcd0001470,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,18.4,%,23.3,ofloxacin,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139054,mbcd0001243,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,11.3,%,23.3,omeprazole,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139055,mbcd0003920,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,-8.7,%,23.3,ondansetron,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139056,mbcd0003922,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,8.2,%,10.2,oxaliplatin,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139057,mbcd0003146,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,27.4,%,12.7,P-aminohippuric acid,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139058,mbcd0022900,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,17.3,%,21.2,pantoprazole,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139059,mbcd0024931,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,37.5,%,13.0,paroxetine,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139060,mbcd0003134,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,7.6,%,16.7,penicillin G,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139061,mbcd0000675,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,24.1,%,18.6,phalloidin,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139062,mbcd0003052,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,-0.1,%,22.4,phenacetin,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139063,mbcd0003105,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,16.7,%,26.6,phenformin,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139064,mbcd0003007,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,11.0,%,22.1,phenobarbital,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139065,mbcd0023817,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,15.1,%,20.8,phenylbutazone,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139066,mbcd0003129,mbtp000025,mbrf0002199,,=,,,stimulator,3,-32.0,%,19.5,phenylethyl isothiocyanate,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2013-12-09 05:38:35
mbbd000139067,mbcd0002996,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,11.1,%,33.5,phenytoin,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139068,mbcd0029179,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,10.8,%,24.9,pilsicainide,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139069,mbcd0027318,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,-10.8,%,27.9,pindolol,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139070,mbcd0023126,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,-9.9,%,30.4,pioglitazone,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139071,mbcd0003024,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,1.0,%,19.7,prazosin,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139072,mbcd0003096,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,27.6,%,17.2,Prednisolone,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139073,mbcd0003154,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,26.4,%,27.8,probenecid,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139074,mbcd0003941,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,17.8,%,29.8,procainamide,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139075,mbcd0002488,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,10.1,%,13.1,propranolol,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139076,mbcd0027018,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,-10.0,%,24.9,quinidine,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139077,mbcd0000961,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,41.6,%,15.4,ranolazine,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139078,mbcd0003060,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,15.0,%,24.4,sanguinarine,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139079,mbcd0025660,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,45.9,%,19.3,sildenafil,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139080,mbcd0003128,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,19.0,%,19.1,sotalol,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139081,mbcd0005282,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,17.1,%,26.4,sulfaphenazole,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139082,mbcd0002889,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,11.0,%,26.6,tamoxifen,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139083,mbcd0003028,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,23.3,%,19.8,tenofovir,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139084,mbcd0017123,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,3.7,%,22.8,terfenadine,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2013-11-24 22:15:08
mbbd000139085,mbcd0003001,mbtp000025,mbrf0002199,,=,,,stimulator,3,-175.1,%,36.5,testosterone,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2013-12-09 05:38:31
mbbd000139086,mbcd0003923,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,6.7,%,17.9,tetraethylammonium,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139087,mbcd0003942,mbtp000025,mbrf0002199,,=,,,stimulator,3,-25.5,%,28.8,Theophylline,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2013-12-09 05:38:36
mbbd000139088,mbcd0003143,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,21.5,%,18.7,thioridazine,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2013-11-24 22:15:09
mbbd000139089,mbcd0026048,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,16.2,%,15.0,thiotepa,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139090,mbcd0007935,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,23.0,%,25.2,ticlopidine,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139091,mbcd0017644,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,15.5,%,9.7,tolbutamide,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139092,mbcd0003187,mbtp000025,mbrf0002199,,=,,,stimulator,3,-39.2,%,30.9,topotecan,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2013-12-09 05:38:34
mbbd000139093,mbcd0020371,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,15.5,%,20.3,tranylcypromine,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2013-11-24 22:15:09
mbbd000139094,mbcd0026104,mbtp000025,mbrf0002199,,=,,,stimulator,3,-20.5,%,26.6,triazolam,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2013-12-09 05:38:38
mbbd000139095,mbcd0003115,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,35.1,%,12.6,trimethoprim,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139096,mbcd0003087,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,-7.3,%,15.2,valaciclovir,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139097,mbcd0029177,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,27.3,%,18.6,varenicline,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139098,mbcd0003042,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,31.6,%,19.3,warfarin,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139099,mbcd0027062,mbtp000025,mbrf0002199,,=,,,stimulator,3,-62.6,%,27.0,verapamil,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2013-12-09 05:38:33
mbbd000139100,mbcd0001107,mbtp000025,mbrf0002199,,=,,,non-inhibitor,3,4.7,%,16.2,zidovudine,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139101,mbcd0001416,mbtp000025,mbrf0002575,,=,,,inhibitor,72,100.0,%,,rifampin,,,HEK293 (transfected); rifampin 10 microM; inhibition of estrone sulfate,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139102,mbcd0030249,mbtp000025,mbrf0002575,,=,,,inhibitor,72,67.0,%,,indoxyl sulfate,,,HEK293 (transfected); indoxyl sulfate 400 microM; inhibition of estrone sulfate,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139103,mbcd0000051,mbtp000025,mbrf0002575,,=,,,inhibitor,72,82.0,%,,CMPF,,,HEK293 (transfected); CMPF 400 microM; inhibition of estrone sulfate,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139104,mbcd0029196,mbtp000025,mbrf0002085,,,,,non-substrate,,,,,99mTc-mebrofenin,"Tc salt of this compound; paper does not make it clear if compound is (1:1) or (2:1), (mebrofenin:Tc)",,Xenopus laevis oocytes (transfected); Uptake of 25 microM 99mTc-mebrofenin; 60 min,Xenopus laevis oocytes,,,,,human,mbds0010,,2013-12-09 20:53:05
mbbd000139105,mbcd0029339,mbtp000025,mbrf0002162,,=,,,substrate,28,10.7,microM,2.3,EE2-Sul,,,HEK-293 (transfected); 0.01-250 microM,HEK293,,,,,human,mbds0010,,2013-11-20 19:41:39
mbbd000139106,mbcd0029339,mbtp000025,mbrf0002162,,=,,,substrate,22,110.0,pmol / mg / min,7,EE2-Sul,,,HEK-293 (transfected); 0.01-250 microM,HEK293,,,,,human,mbds0010,,2013-11-20 19:41:40
mbbd000139107,mbcd0003075,mbtp000025,mbrf0002229,,,,,substrate,,,,,E-3-S,information in graph in paper,,HEK293 (transfected); drug uptake; pH 5.5 - 7.4 statistically significant uptake,HEK293,,,,,human,mbds0010,,2013-11-24 23:13:09
mbbd000139108,mbcd0001448,mbtp000025,mbrf0002229,,,,,substrate,,,,,rosuvastatin,information in graph in paper,,HEK293 (transfected); drug uptake; pH 5.5 - 7.4 statistically significant uptake,HEK293,,,,,human,mbds0010,,2013-11-24 23:13:10
mbbd000139109,mbcd0001445,mbtp000025,mbrf0002229,,,,,substrate,,,,,fluvastatin,information in graph in paper,,HEK293 (transfected); drug uptake; pH 5.5 - 7.4 statistically significant uptake,HEK293,,,,,human,mbds0010,,2013-11-24 23:13:10
mbbd000139110,mbcd0003126,mbtp000025,mbrf0002229,,,,,substrate,,,,,pravastatin,information in graph in paper,,HEK293 (transfected); drug uptake; pH 5.5 - 6.5 statistically significant uptake,HEK293,,,,,human,mbds0010,,2013-11-24 23:13:10
mbbd000139111,mbcd0026093,mbtp000025,mbrf0002229,,,,,substrate,,,,,atorvastatin,information in graph in paper,,HEK293 (transfected); drug uptake; pH 5.5 - 7.4 statistically significant uptake,HEK293,,,,,human,mbds0010,,2013-11-24 23:13:10
mbbd000139112,mbcd0023123,mbtp000025,mbrf0002229,,,,,substrate,,,,,cerivastatin,information in graph in paper,,HEK293 (transfected); drug uptake; pH 5.5 - 6.0 statistically significant uptake,HEK293,,,,,human,mbds0010,,2013-11-24 23:13:11
mbbd000139113,mbcd0000693,mbtp000025,mbrf0002229,,,,,substrate,,,,,pitavastatin,information in graph in paper,,HEK293 (transfected); drug uptake; pH 5.5 - 6.5 statistically significant uptake,HEK293,,,,,human,mbds0010,,2013-11-24 23:13:11
mbbd000139114,mbcd0025591,mbtp000025,mbrf0002229,,,,,non-substrate,,,,,lovastatin,information in graph in paper,,HEK293 (transfected); drug uptake; pH 5.5 - 7.4 not statistically significant uptake,HEK293,,,,,human,mbds0010,,2013-11-24 23:13:11
mbbd000139115,mbcd0001194,mbtp000025,mbrf0002229,,,,,non-substrate,,,,,simvastatin,information in graph in paper,,HEK293 (transfected); drug uptake; pH 5.5 - 7.4 not statistically significant uptake,HEK293,,,,,human,mbds0010,,2013-11-24 23:13:12
mbbd000139116,mbcd0029193,mbtp000025,mbrf0002102,,,,,non-substrate,,,,,CLF,,,CHO (transfected); CLF 1 microM; 1 or 5 min,CHO,,,,,human,mbds0010,,2013-11-04 21:58:46
mbbd000139117,mbcd0029193,mbtp000025,mbrf0002102,,,,,inhibitor,,,,,CLF,,,CHO (transfected); CLF 1 microM; 5 and 50 micoM; inhibition of estrone-3-sulfate 1.0 microM uptake,CHO,,,,,human,mbds0010,,2013-11-04 21:58:46
mbbd000139118,mbcd0001612,mbtp000025,mbrf0002407,,=,,,non-substrate,8,0.86,,,UDCA,,,HEK293 (transfected); substrate 100 microM (highest concentration tested),HEK293,,,,,human,mbds0010,,2013-11-24 23:13:12
mbbd000139119,mbcd0029194,mbtp000025,mbrf0002407,,=,,,non-substrate,8,0.98,,,norUDCA,,,HEK293 (transfected); substrate 100 microM (highest concentration tested),HEK293,,,,,human,mbds0010,,2013-11-24 23:13:12
mbbd000139120,mbcd0023132,mbtp000025,mbrf0002400,,,,,substrate,,,,,Montelukast,,,MDCKII (transfected),MDCKII,,,,,human,mbds0010,,2013-11-24 23:11:23
mbbd000139121,mbcd0001280,mbtp000025,mbrf0001887,,=,,,substrate,28,1.73,microM,0.30,sulphasalazine,,,"HEK293 (transfected); 2 min; substrate concentration 0.1, 0.3, 1.0, 3.0, 10, 30 and 100 microM",HEK293,,,,,human,mbds0010,,2013-11-24 23:13:13
mbbd000139122,mbcd0001280,mbtp000025,mbrf0001887,,=,,,substrate,22,9.72,microM,0.98,sulphasalazine,,,"HEK293 (transfected); 2 min; substrate concentration 0.1, 0.3, 1.0, 3.0, 10, 30 and 100 microM",HEK293,,,,,human,mbds0010,,2013-11-24 23:13:13
mbbd000139123,mbcd0001797,mbtp000025,mbrf0002111,,=,,,substrate,33,2.8,fold increase,,fexofenadine,"pH dependant, higher uptake at lower pH",,MDCKII (transfected); 100 nM fexofenadine; 3 min,MDCKII,,100,nM,,human,mbds0010,,2013-12-08 08:52:01
mbbd000139124,mbcd0013807,mbtp000025,mbrf0001894,,,,,non-inhibitor,,,,,EC,data in graph,,CHO (transfected); inhibition of 0.1 microM [3H]estrone- 3-sulfate; inhibitor 100 microM; 20 s,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139125,mbcd0029141,mbtp000025,mbrf0001894,,,,,non-inhibitor,,,,,EGC,data in graph,,CHO (transfected); inhibition of 0.1 microM [3H]estrone- 3-sulfate; inhibitor 100 microM; 20 s,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139126,mbcd0000002,mbtp000025,mbrf0001894,,=,,,inhibitor,25,35.9,microM,3.1,ECG,,,CHO (transfected); inhibition of 0.1 microM [3H]estrone- 3-sulfate,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139127,mbcd0029142,mbtp000025,mbrf0001894,,=,,,inhibitor,25,101.0,microM,9,EGCG,,,CHO (transfected); inhibition of 0.1 microM [3H]estrone- 3-sulfate,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139128,mbcd0029195,mbtp000025,mbrf0001905,,=,,,inhibitor,29,8.48,microM,1.62,ELT,,,HEK293/PDZK1 (transfected); inhibition of estrone-3-sulfate,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139129,mbcd0029195,mbtp000025,mbrf0001905,,,,,substrate,,,,,ELT,data in graph,,HEK293/PDZK1 (transfected); uptake of ELT; 30 min,HEK293/PDZK1,,,,,human,mbds0010,,2013-11-24 23:13:13
mbbd000139130,mbcd0029197,mbtp000019,mbrf0002596,,,,,inhibitor,,,,,ATB-BMPA,Ki values determined in paper are not specific to GLUT1,,human erythrocyte; inhibition of D-galactose uptake; tested at temperatures 20C and 0C,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139131,mbcd0029202,mbtp000019,mbrf0002591,,=,,,substrate,28,17.6,mM,,3-O-MG,two measurements made,,Xenopus laevis oocyte (transfected); uptake of 3-O-methyl-D-glucose,Xenopus laevis oocytes,,,,,human,mbds0010,,2013-11-24 23:14:45
mbbd000139132,mbcd0029202,mbtp000019,mbrf0002591,,=,,,substrate,28,16.9,mM,,3-O-MG,two measurements made,,Xenopus laevis oocyte (transfected); uptake of 3-O-methyl-D-glucose,Xenopus laevis oocytes,,,,,human,mbds0010,,2013-11-24 23:14:45
mbbd000139133,mbcd0029203,mbtp000019,mbrf0002591,,,,,inhibitor,,,,,D-GLC,data in graph,,Xenopus laevis oocyte (transfected); inhibition of the uptake of deGlc,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139134,mbcd0029204,mbtp000019,mbrf0002591,,,,,non-inhibitor,,,,,L-GLC,data in graph,,Xenopus laevis oocyte (transfected); inhibition of the uptake of deGlc,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139135,mbcd0029200,mbtp000019,mbrf0002591,,,,,inhibitor,,,,,D-MAN,data in graph,,Xenopus laevis oocyte (transfected); inhibition of the uptake of deGlc,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139136,mbcd0029205,mbtp000019,mbrf0002591,,,,,non-inhibitor,,,,,L-MAN,data in graph,,Xenopus laevis oocyte (transfected); inhibition of the uptake of deGlc,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139137,mbcd0029206,mbtp000019,mbrf0002591,,,,,non-inhibitor,,,,,D-ARA,data in graph,,Xenopus laevis oocyte (transfected); inhibition of the uptake of deGlc,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139138,mbcd0029207,mbtp000019,mbrf0002591,,,,,non-inhibitor,,,,,L-ARA,data in graph,,Xenopus laevis oocyte (transfected); inhibition of the uptake of deGlc,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139139,mbcd0029208,mbtp000019,mbrf0002591,,,,,non-inhibitor,,,,,D-XYL,data in graph,,Xenopus laevis oocyte (transfected); inhibition of the uptake of deGlc,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139140,mbcd0029209,mbtp000019,mbrf0002591,,,,,non-inhibitor,,,,,L-XYL,data in graph,,Xenopus laevis oocyte (transfected); inhibition of the uptake of deGlc,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139141,mbcd0029199,mbtp000019,mbrf0002591,,,,,non-inhibitor,,,,,D-FRU,data in graph,,Xenopus laevis oocyte (transfected); inhibition of the uptake of deGlc,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139142,mbcd0029211,mbtp000019,mbrf0002595,,=,,,inhibitor,41,49.0,nM,,CB,,,Dissociation constant for CB (labelled) interaction with GLUT1 in Proteoliposomes,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139143,mbcd0029211,mbtp000019,mbrf0002595,,=,,,inhibitor,41,28.0,nM,,CB,,,Dissociation constant for CB (labelled) interaction with GLUT1 in RBC membrane vesicles,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139144,mbcd0029203,mbtp000019,mbrf0002595,,=,,,substrate,41,32.0,mM,,D-glucose,,,apparent dissociation constant using CB (labelled) interaction with GLUT1 in red blood cell (RBC) membrane vesicles,human red blood cells,,,,,human,mbds0010,,2013-11-26 00:48:05
mbbd000139145,mbcd0029203,mbtp000019,mbrf0002595,,=,,,substrate,41,63.0,mM,,D-glucose,,,apparent dissociation constant using CB (labelled) interaction with GLUT1 in proteoliposomes,proteoliposomes,,,,,human,mbds0010,,2013-11-24 23:56:44
mbbd000139146,mbcd0025577,mbtp000019,mbrf0002595,,=,,,binder,41,0.64,M,,ethanol,,,apparent dissociation constant using CB (labelled) interaction with GLUT1 in proteoliposomes,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139147,mbcd0025577,mbtp000019,mbrf0002595,,=,,,binder,41,0.45,M,,ethanol,,,apparent dissociation constant using CB (labelled) interaction with GLUT1 in RBC membrane vesicles,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139148,mbcd0029198,mbtp000019,mbrf0002594,,,,,substrate,,,,,2-DOG,data in graph,,Xenopus laevis oocytes (transfected); wild type; 25 microM substrate,Xenopus laevis oocytes,,,,,human,mbds0010,,2013-11-24 23:14:45
mbbd000139149,mbcd0029202,mbtp000019,mbrf0002594,,,,,substrate,,,,,3-OMG,data in graph,,Xenopus laevis oocytes (transfected); wild type; 10 mM substrate,Xenopus laevis oocytes,,,,,human,mbds0010,,2013-11-24 23:14:45
mbbd000139150,mbcd0029198,mbtp000019,mbrf0002594,,=,,,substrate,33,42.4,pmol / oocyte / 30 min,2.0,2-DOG,data in graph,,Xenopus laevis oocytes (transfected); wild type,Xenopus laevis oocytes,,,,,human,mbds0010,,2013-11-24 23:14:46
mbbd000139151,mbcd0029212,mbtp000019,mbrf0002594,,=,,,inhibitor,29,16.0,mM,,Ethylideneglucose,data in graph,,Xenopus laevis oocytes (transfected); wild type; inhibition of 2-DOG uptake,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139152,mbcd0003975,mbtp000019,mbrf0002592,,=,,,inhibitor,41,2360.0,nM,690,forskolin,GLUT1 identified in tissue; adjusted for non-specific binding; action type is questionable,,erythrocyte; binding of labelled compound measured,,,,,,human,mbds0010,,2013-12-10 22:35:36
mbbd000139153,mbcd0029211,mbtp000019,mbrf0002592,,=,,,inhibitor,29,170.0,nM,30,cytochalasin B,GLUT1 identified in tissue; adjusted for non-specific binding; action type is questionable,,erythrocyte; inhibition of the binding of labelled compound forskolin,,,,,,human,mbds0010,,2013-12-10 22:35:36
mbbd000139154,mbcd0003975,mbtp000019,mbrf0002592,,=,,,inhibitor,29,2220.0,nM,660,forskolin,GLUT1 identified in tissue; adjusted for non-specific binding; action type is questionable,,erythrocyte; inhibition of the binding of labelled compound cytochalasin B,,,,,,human,mbds0010,,2013-12-10 22:35:36
mbbd000139155,mbcd0029211,mbtp000019,mbrf0002592,,=,,,inhibitor,41,190.0,nM,50,cytochalasin B,GLUT1 identified in tissue; adjusted for non-specific binding; action type is questionable,,erythrocyte; binding of labelled compound measured,,,,,,human,mbds0010,,2013-12-10 22:35:36
mbbd000139158,mbcd0003975,mbtp000019,mbrf0002592,,=,,,inhibitor,29,4400.0,nM,1700,forskolin,GLUT1 identified in tissue; adjusted for non-specific binding; action type is questionable,,brain; inhibition of the binding of labelled compound cytochalasin B,,,,,,human,mbds0010,,2013-12-10 22:35:36
mbbd000139159,mbcd0029211,mbtp000019,mbrf0002592,,=,,,inhibitor,41,130.0,nM,30,cytochalasin B,GLUT1 identified in tissue; adjusted for non-specific binding; action type is questionable,,brain; binding of labelled compound measured,,,,,,human,mbds0010,,2013-12-10 22:35:36
mbbd000139160,mbcd0003100,mbtp000019,mbrf0002592,,>,,,inhibitor,29,40.0,microM,,dipyridamole,GLUT1 identified in tissue; adjusted for non-specific binding; action type is questionable,,erythrocyte; inhibition of the binding of labelled compound cytochalasin B,,,,,,human,mbds0010,,2013-12-10 22:35:36
mbbd000139161,mbcd0004888,mbtp000019,mbrf0002592,,>,,,inhibitor,29,500.0,microM,,IBMX,GLUT1 identified in tissue; adjusted for non-specific binding; action type is questionable,,erythrocyte; inhibition of the binding of labelled compound cytochalasin B,,,,,,human,mbds0010,,2013-12-10 22:35:36
mbbd000139162,mbcd0029212,mbtp000019,mbrf0002590,,=,,,inhibitor,29,11.52,mM,2.21,Ethylidene glucose,,,Ethylidene glucose inhibition of 2-deoxy-D-glucose uptake of wild-type GLUT1-expressing Xenopus laevis oocytes; 0 - 100 mM inhibitor,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139163,mbcd0029211,mbtp000019,mbrf0002590,,=,,,inhibitor,29,8.86,*10^-7 M,0.26,Cytochalasin B,,,Ethylidene glucose inhibition of 2-deoxy-D-glucose uptake of wild-type GLUT1-expressing Xenopus laevis oocytes; 0 - 100 mM inhibitor,,,,,,human,mbds0010,,2013-11-20 21:27:04
mbbd000139164,mbcd0000327,mbtp000019,mbrf0002593,,,,,substrate,,,,,deoxyglucose,data in graph; figure 4,,CHO (transfected); substrate uptake; 0 - 10 min,CHO,,,,,human,mbds0010,,2013-11-24 23:15:19
mbbd000139165,mbcd0029213,mbtp000019,mbrf0002593,,,,,substrate,,,,,dehydroascorbic acid,data in graph; figure 4,,CHO (transfected); substrate uptake; 0 - 10 min,CHO,,,,,human,mbds0010,,2013-11-24 23:15:20
mbbd000139166,mbcd0003116,mbtp000019,mbrf0002593,,,,,inhibitor,,,,,Genistein,data in graph; figure 4; also inhibits binding of the inhibitor cytochalasin B,,CHO (transfected); inhibits both deoxyglucose and dehydroascorbic acid uptake,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139167,mbcd0029203,mbtp000019,mbrf0002597,,=,,,inhibitor,25,10.0,mM,,D-glucose,,,human erthrocytes; inhibition of D-glucose uptake,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139168,mbcd0029214,mbtp000019,mbrf0002597,,>,,,inhibitor,25,100.0,mM,,methyl beta-D-glucopyranoside,,,human erthrocytes; inhibition of D-glucose uptake,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139169,mbcd0029215,mbtp000019,mbrf0002597,,=,,,inhibitor,25,3.0,mM,0.3,Compound 3,,,human erthrocytes; inhibition of D-glucose uptake,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139170,mbcd0029217,mbtp000019,mbrf0002597,,=,,,inhibitor,25,3.0,mM,0.9,Compound 9,,,human erthrocytes; inhibition of D-glucose uptake,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139171,mbcd0029202,mbtp000019,mbrf0002597,,=,,,inhibitor,25,16.0,mM,6.0,3-O-methyl-D-glucose,,,human erthrocytes; inhibition of D-glucose uptake,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139172,mbcd0029216,mbtp000019,mbrf0002597,,=,,,inhibitor,25,0.065,mM,0.015,Compound 6,,,human erthrocytes; inhibition of D-glucose uptake,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139173,mbcd0029218,mbtp000019,mbrf0002597,,>,,,inhibitor,25,4.0,mM,,Compound 10,,,human erthrocytes; inhibition of D-glucose uptake,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139174,mbcd0029216,mbtp000019,mbrf0002597,,,,,non-substrate,,,,,Compound 6,,,human erthrocytes; drug uptake,human erthrocytes,,,,,human,mbds0010,,2013-11-24 23:56:44
mbbd000139175,mbcd0029203,mbtp000019,mbrf0002588,,=,,,inhibitor,25,10.0,mM,,D-Glucose,,,"human erythrocytes; inhibition of specific GLUTl-mediated, cytochalasin B-sensitive D-glucose uptake",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139176,mbcd0029223,mbtp000019,mbrf0002588,,~,,,inhibitor,25,52.0,mM,,Compound 2,,,"human erythrocytes; inhibition of specific GLUTl-mediated, cytochalasin B-sensitive D-glucose uptake",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139177,mbcd0029224,mbtp000019,mbrf0002588,,>,,,non-inhibitor,25,100.0,mM,,Compound 3,,,"human erythrocytes; inhibition of specific GLUTl-mediated, cytochalasin B-sensitive D-glucose uptake",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139178,mbcd0029225,mbtp000019,mbrf0002588,,>,,,non-inhibitor,25,100.0,mM,,Compound 4,,,"human erythrocytes; inhibition of specific GLUTl-mediated, cytochalasin B-sensitive D-glucose uptake",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139179,mbcd0029226,mbtp000019,mbrf0002588,,~,,,inhibitor,25,32.0,mM,,Compound 5,,,"human erythrocytes; inhibition of specific GLUTl-mediated, cytochalasin B-sensitive D-glucose uptake",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139180,mbcd0029227,mbtp000019,mbrf0002588,,~,,,inhibitor,25,42.0,mM,,Compound 6,,,"human erythrocytes; inhibition of specific GLUTl-mediated, cytochalasin B-sensitive D-glucose uptake",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139181,mbcd0029211,mbtp000019,mbrf0002589,,=,,,inhibitor,41,0.2,microM,0.01,CB,,,"reconstituted in vesicles; Equilibrium binding of CB in the absence and presence of speci¢ed concentrations of D-glucose, adenosine, or ATP; pH 7.4",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139182,mbcd0029211,mbtp000019,mbrf0002589,,=,,,inhibitor,41,0.2,microM,0.01,CB,,,"reconstituted in vesicles; Equilibrium binding of CB in the absence and presence of speci¢ed concentrations of D-glucose, adenosine, or ATP; pH 3.6",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139183,mbcd0029203,mbtp000019,mbrf0002589,,=,,,substrate,41,35.5,mM,0.9,Glucose,,,"human erythrocytes; GLUT1 reconstituted in vesicles; Equilibrium binding of CB in the absence and presence of specified concentrations of D-glucose, adenosine, or ATP; pH 7.4",human erythrocytes,,,,,human,mbds0010,,2013-11-26 01:55:30
mbbd000139184,mbcd0029203,mbtp000019,mbrf0002589,,=,,,substrate,41,17.3,mM,0.3,Glucose,,,"human erythrocytes; GLUT1 reconstituted in vesicles; Equilibrium binding of CB in the absence and presence of specified concentrations of D-glucose, adenosine, or ATP; pH 3.6",human erythrocytes,,,,,human,mbds0010,,2013-11-26 01:55:30
mbbd000139185,mbcd0029228,mbtp000019,mbrf0002589,,=,,,binder,41,2.98,mM,0.02,Adenosine,,,"reconstituted in vesicles; Equilibrium binding of CB in the absence and presence of speci¢ed concentrations of D-glucose, adenosine, or ATP; pH 7.4",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139186,mbcd0029228,mbtp000019,mbrf0002589,,=,,,binder,41,11.9,mM,0.1,Adenosine,,,"reconstituted in vesicles; Equilibrium binding of CB in the absence and presence of speci¢ed concentrations of D-glucose, adenosine, or ATP; pH 3.6",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139187,mbcd0029229,mbtp000019,mbrf0002589,,=,,,binder,41,30.0,mM,13.0,ATP,,,"reconstituted in vesicles; Equilibrium binding of CB in the absence and presence of speci¢ed concentrations of D-glucose, adenosine, or ATP; pH 7.4",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139188,mbcd0029229,mbtp000019,mbrf0002589,,=,,,binder,41,1.22,mM,0.29,ATP,,,"reconstituted in vesicles; Equilibrium binding of CB in the absence and presence of speci¢ed concentrations of D-glucose, adenosine, or ATP; pH 3.6",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139189,mbcd0003001,mbtp000025,mbrf0002199,,,,,non-inhibitor,,,,,testosterone,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139190,mbcd0003064,mbtp000025,mbrf0002199,,,,,non-inhibitor,,,,,fendiline,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139191,mbcd0001892,mbtp000025,mbrf0002199,,,,,non-inhibitor,,,,,progesterone,,,HEK293; inhibitor 20 microM; substrate E3S 1.04 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139192,mbcd0001131,mbtp000025,mbrf0001955,,,,,non-inhibitor,,,,,Guanidine,read from graph,,HEK293 (transfected); pH 7.4; inhibition of drug uptake of E3S 4.7 nM; inhibitor 10 mM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139193,mbcd0029148,mbtp000025,mbrf0002349,,,,,non-inhibitor,,,,,Hydrocortisol,no statistical significance,,MDCKII (transfected); DHEAS (1 microCi/ml; 10 min; substance 100 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139194,mbcd0029144,mbtp000025,mbrf0002349,,,,,non-inhibitor,,,,,Androsterone,no statistical significance,,MDCKII (transfected); DHEAS (1 microCi/ml; 10 min; substance 100 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139195,mbcd0027348,mbtp000025,mbrf0002349,,,,,non-inhibitor,,,,,Cortisone,no statistical significance,,MDCKII (transfected); E3S (1 microCi/ml; 1 microM); 5 min; substance 10 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139196,mbcd0027348,mbtp000025,mbrf0002349,,,,,non-inhibitor,,,,,Cortisone,no statistical significance,,MDCKII (transfected); E3S (1 microCi/ml; 1 microM); 5 min; substance 100 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139197,mbcd0029145,mbtp000025,mbrf0002349,,,,,non-inhibitor,,,,,Pregnenolone,no statistical significance,,MDCKII (transfected); E3S (1 microCi/ml; 1 microM); 5 min; substance 50 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139198,mbcd0001448,mbtp000024,mbrf0002571,,=,,,substrate,28,2.6,microM,,Rosuvastatin,,,rosuvastatin uptake in HeLa cells expressing OATP1A2,HeLa,,,,,human,mbds0010,,2013-11-24 23:55:19
mbbd000139199,mbcd0000640,mbtp000024,mbrf0002266,,,,,substrate,,,,,ochratoxin A,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139200,mbcd0019674,mbtp000024,mbrf0002266,,,,,substrate,,,,,Chlorambucil,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139201,mbcd0029234,mbtp000024,mbrf0001795,,=,,,inhibitor,25,0.27,microM,,T1AM,,,COS-1 cells; Inhibition of T3 uptake,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139202,mbcd0029234,mbtp000024,mbrf0001795,,=,,,inhibitor,25,2.1,microM,,T1AM,,,COS-1 cells; Inhibition of T4 uptake,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139203,mbcd0029234,mbtp000024,mbrf0001795,,,,,non-substrate,,,,,T1AM,,,COS-1 cells,COS1,,,,,human,mbds0010,,2013-12-09 06:43:10
mbbd000139204,mbcd0018125,mbtp000024,mbrf0002346,,=,,,substrate,100,12.0,% increase,,Hydroxyurea,,,Xenopus laevis oocytes,Xenopus laevis oocytes,,,,,human,mbds0010,,2013-12-08 00:42:40
mbbd000139205,mbcd0000920,mbtp000024,mbrf0002560,,=,,,inducer,117,9.0,fold,,Vitamin D3,,,Caco-2 cells; 500nM of Vitamin D3; 24 hours,,,,,,human,mbds0010,,2013-12-08 01:58:15
mbbd000139206,mbcd0008235,mbtp000024,mbrf0002215,,,,,non-substrate,,,,,MPA,,,HEK293T cells,HEK293T,,,,,human,mbds0010,,2013-11-24 23:13:13
mbbd000139207,mbcd0030373,mbtp000024,mbrf0002215,,,,,non-substrate,,,,,MPAG,,,HEK293T cells,HEK293T,,,,,human,mbds0010,,2013-11-24 23:13:14
mbbd000139208,mbcd0001533,mbtp000024,mbrf0002306,,=,,,substrate,28,36.4,microM,21.8,SQV,,,Xenopus laevis oocyte,Xenopus laevis oocytes,,,,,human,mbds0010,,2013-11-24 23:14:46
mbbd000139209,mbcd0003876,mbtp000024,mbrf0001651,,,,,substrate,,,,,Acebutolol,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139210,mbcd0003875,mbtp000024,mbrf0001651,,,,,substrate,,,,,Atenolol,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139211,mbcd0000242,mbtp000024,mbrf0001651,,,,,substrate,,,,,Celiprolol,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139212,mbcd0000804,mbtp000024,mbrf0001651,,,,,substrate,,,,,Talinolol,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139213,mbcd0017980,mbtp000024,mbrf0001651,,,,,substrate,,,,,Ciprofloxacin,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139214,mbcd0000615,mbtp000024,mbrf0001988,,=,,,inhibitor,25,3.6,microM,,Naringin,,,Inhibition of Fexofenadine uptake,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139215,mbcd0020086,mbtp000024,mbrf0001988,,=,,,inhibitor,25,2.7,microM,,Hesperidin,,,Inhibition of Fexofenadine uptake,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139216,mbcd0003017,mbtp000024,mbrf0002291,,,,,non-substrate,,,,,Mesalazine,,,HEK293 cells; Bromosulfophthalein uptake,HEK293,,,,,human,mbds0010,,2013-11-24 23:13:16
mbbd000139217,mbcd0029142,mbtp000024,mbrf0001894,,=,,,substrate,28,18.8,microM,2.7,EGCG,,,HEK293 or HeLa cells,HEK293; HeLa,,,,,human,mbds0010,,2013-11-24 23:13:16
mbbd000139218,mbcd0000002,mbtp000024,mbrf0001894,,=,,,substrate,28,10.4,microM,2,ECG,,,HEK293 or HeLa cells,HEK293; HeLa,,,,,human,mbds0010,,2013-11-24 23:13:16
mbbd000139219,mbcd0003075,mbtp000024,mbrf0001894,,=,,,substrate,28,16.1,microM,0.2,Estrone-3-sulfate,,,HEK293 or HeLa cells,HEK293; HeLa,,,,,human,mbds0010,,2013-11-24 23:13:17
mbbd000139220,mbcd0003075,mbtp000024,mbrf0001894,,=,,,substrate,22,640.0,pmol mg min-1,150,Estrone-3-sulfate,,,HEK293 or HeLa cells,HEK293; HeLa,,,,,human,mbds0010,,2013-11-24 23:13:17
mbbd000139221,mbcd0000002,mbtp000024,mbrf0001894,,=,,,inhibitor,25,10.2,microM,3.2,ECG,,,HEK293 or HeLa cells; Inhibition of Estrone-3-sulfate uptake,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139222,mbcd0029142,mbtp000024,mbrf0001894,,=,,,inhibitor,25,54.8,microM,12.8,EGCG,,,HEK293 or HeLa cells; Inhibition of Estrone-3-sulfate uptake,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139223,mbcd0029236,mbtp000024,mbrf0002505,,=,,,substrate,28,92.0,microM,15,Gd-B 20790,Gd3+ salt,,Xenopus laevis oocyte,Xenopus laevis oocytes,,,,,human,mbds0010,,2013-11-24 23:14:46
mbbd000139224,mbcd0029236,mbtp000024,mbrf0002505,,=,,,substrate,22,143.0,pmol (mg protein)-1 (15 s)-1,42,Gd-B 20790,Gd3+ salt,,Xenopus laevis oocyte,Xenopus laevis oocytes,,,,,human,mbds0010,,2013-11-24 23:14:46
mbbd000139225,mbcd0002634,mbtp000024,mbrf0001765,,,,,substrate,,,,,DRV,possible substrate,,Caco-2 cells,Caco-2,,,,,human,mbds0010,,2013-11-24 23:12:23
mbbd000139226,mbcd0029150,mbtp000024,mbrf0002275,,,,,substrate,,,,,Atrasentan,,,HeLa cells,HeLa,,,,,human,mbds0010,,2013-11-24 23:55:19
mbbd000139227,mbcd0012636,mbtp000024,mbrf0001837,,=,,,inhibitor,72,13.3,%,3.3,Enoxacin,,,Xenopus laevis oocyte; Levofloxacin (20 microM); Enoxacin (500 microM),,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139228,mbcd0012636,mbtp000024,mbrf0001837,,=,,,substrate,33,0.224,microL oocyte-1,0.019,Enoxacin,,,Xenopus laevis oocyte; Enoxacin (20 microM),Xenopus laevis oocytes,,,,,human,mbds0010,,2013-11-24 23:14:47
mbbd000139229,mbcd0001038,mbtp000024,mbrf0001837,,=,,,inhibitor,72,3.9,%,1.5,Grepafloxacin,,,Xenopus laevis oocyte; Levofloxacin (20 microM); Grepafloxacin (500 microM),,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139230,mbcd0029238,mbtp000024,mbrf0001837,,=,,,inhibitor,72,5.3,%,2.4,Moxifloxacin,,,Xenopus laevis oocyte; Levofloxacin (20 microM); Moxifloxacin (500 microM),,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139231,mbcd0017980,mbtp000024,mbrf0001837,,=,,,inhibitor,72,22.3,%,8.3,Ciprofloxacin,,,Xenopus laevis oocyte; Levofloxacin (20 microM); Ciprofloxacin (500 microM),,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139232,mbcd0021513,mbtp000024,mbrf0001837,,=,,,inhibitor,72,4.7,%,3.6,DR-3354,,,Xenopus laevis oocyte; Levofloxacin (20 microM); DR-3354 (500 microM),,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139233,mbcd0001470,mbtp000024,mbrf0001837,,=,,,inhibitor,72,8.6,%,4.3,Levofloxacin,,,Xenopus laevis oocyte; Levofloxacin (20 microM); Levofloxacin (500 microM),,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139234,mbcd0029239,mbtp000024,mbrf0001837,,=,,,substrate,33,0.575,microL oocyte-1,0.061,Gatifloxacin,,,Xenopus laevis oocyte; Gatifloxacin (20 microM),Xenopus laevis oocytes,,,,,human,mbds0010,,2013-11-24 23:14:47
mbbd000139235,mbcd0017980,mbtp000024,mbrf0001837,,=,,,substrate,33,0.173,microL oocyte-1,0.020,Ciprofloxacin,,,Xenopus laevis oocyte; Ciprofloxacin (20 microM),Xenopus laevis oocytes,,,,,human,mbds0010,,2013-11-24 23:14:47
mbbd000139236,mbcd0011365,mbtp000024,mbrf0001837,,=,,,substrate,33,0.119,microL oocyte-1,0.010,Norfloxacin,,,Xenopus laevis oocyte; Norfloxacin (20 microM),Xenopus laevis oocytes,,,,,human,mbds0010,,2013-11-24 23:14:47
mbbd000139237,mbcd0001378,mbtp000024,mbrf0001837,,=,,,substrate,33,0.475,microL oocyte-1,0.030,lomefloxacin,,,Xenopus laevis oocyte; lomefloxacin (20 microM),Xenopus laevis oocytes,,,,,human,mbds0010,,2013-11-24 23:14:48
mbbd000139238,mbcd0001038,mbtp000024,mbrf0001837,,=,,,substrate,28,173.0,microM,,Grepafloxacin,,,Xenopus laevis oocyte,Xenopus laevis oocytes,,,,,human,mbds0010,,2013-11-24 23:14:48
mbbd000139239,mbcd0021513,mbtp000024,mbrf0001837,,=,,,inhibitor,25,159.0,microM,,DR-3354,,,Xenopus laevis oocyte; Inhibition of Levofloxacin uptake,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139240,mbcd0001170,mbtp000024,mbrf0002356,,,,,substrate,,,,,Labetalol,,,Xenopus laevis oocyte,Xenopus laevis oocytes,,,,,human,mbds0010,,2013-11-24 23:14:48
mbbd000139241,mbcd0001512,mbtp000024,mbrf0002356,,,,,substrate,,,,,Nadolol,,,Xenopus laevis oocyte,Xenopus laevis oocytes,,,,,human,mbds0010,,2013-11-24 23:14:48
mbbd000139242,mbcd0003128,mbtp000024,mbrf0002356,,,,,substrate,,,,,Sotalol,,,Xenopus laevis oocyte,Xenopus laevis oocytes,,,,,human,mbds0010,,2013-11-24 23:14:49
mbbd000139243,mbcd0000242,mbtp000024,mbrf0002356,,=,,,substrate,28,20.5,microM,7.1,Celiprolol,,,Xenopus laevis oocyte,Xenopus laevis oocytes,,,,,human,mbds0010,,2013-11-24 23:14:49
mbbd000139244,mbcd0000242,mbtp000024,mbrf0002356,,=,,,substrate,22,2.83,pmol oocyte-1 (90 min)-1,0.69,Celiprolol,,,Xenopus laevis oocyte,Xenopus laevis oocytes,,,,,human,mbds0010,,2013-11-24 23:14:49
mbbd000139245,mbcd0000242,mbtp000024,mbrf0002356,,=,,,substrate,33,9.12,nL oocyte-1 (90 min)-1,1.81,Celiprolol,,,Xenopus laevis oocyte,Xenopus laevis oocytes,,,,,human,mbds0010,,2013-11-24 23:14:50
mbbd000139246,mbcd0029165,mbtp000024,mbrf0002131,,=,,,substrate,28,41.1,microM,,Tebipenem Pivoxil,,,Xenopus laevis oocyte,Xenopus laevis oocytes,,,,,human,mbds0010,,2013-11-24 23:14:50
mbbd000139247,mbcd0029833,mbtp000024,mbrf0001858,,=,,,substrate,33,1.25,pmol oocyte-1 h-1,0.34,TR-14035,,,Xenopus laevis oocyte,Xenopus laevis oocytes,,,,,human,mbds0010,,2013-11-24 23:14:50
mbbd000139248,mbcd0029833,mbtp000024,mbrf0001858,,=,,,substrate,28,3.31,microM,1.42,TR-14035,,,Xenopus laevis oocyte,Xenopus laevis oocytes,,,,,human,mbds0010,,2013-11-24 23:14:50
mbbd000139249,mbcd0000615,mbtp000024,mbrf0002422,,=,,,inhibitor,25,24.2,microM,2,Naringin,,,HEK293 cells; Inhibition of Fexofenadine uptake,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139250,mbcd0000615,mbtp000024,mbrf0002422,,=,,,inhibitor,25,75.5,microM,2,Naringin,,,HEK293 cells; Inhibition of Aliskiren uptake,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139251,mbcd0001616,mbtp000024,mbrf0001698,,=,,,inhibitor,25,4.2,microM,,Everolimus,,,Inhibition of Estrone-3-sulfate uptake,,mbcd0003075,,,,human,mbds0010,,2013-11-04 00:59:28
mbbd000139252,mbcd0001324,mbtp000024,mbrf0001698,,=,,,inhibitor,25,11.9,microM,,Sirolimus,,,Inhibition of Estrone-3-sulfate uptake,,mbcd0003075,,,,human,mbds0010,,2013-11-04 00:59:29
mbbd000139253,mbcd0001735,mbtp000024,mbrf0001844,,,,,non-substrate,,,,,Midazolam,,,Xenopus laevis oocyte,Xenopus laevis oocytes,,,,,human,mbds0010,,2013-11-24 23:14:50
mbbd000139255,mbcd0003120,mbtp000024,mbrf0001933,,=,,,inhibitor,25,13.5,microM,1.7,quercetin,,,HEK293; Inhibition of Atorvastatin uptake,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139256,mbcd0003091,mbtp000024,mbrf0001933,,=,,,inhibitor,25,9.3,microM,1.5,Apigenin,,,HEK293; Inhibition of Atorvastatin uptake,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139257,mbcd0003215,mbtp000024,mbrf0001933,,=,,,inhibitor,25,37.3,microM,1.6,Kaempferol,,,HEK293; Inhibition of Atorvastatin transport,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139258,mbcd0003120,mbtp000024,mbrf0001933,,=,,,inhibitor,29,22.0,microM,5.9,quercetin,,,HEK293; Inhibition of BSP uptake,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139259,mbcd0003215,mbtp000024,mbrf0001933,,=,,,inhibitor,29,25.2,microM,13,Kaempferol,,,HEK293; Inhibition of BSP uptake,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139260,mbcd0003091,mbtp000024,mbrf0001933,,=,,,inhibitor,29,32.4,microM,12.2,Apigenin,,,HEK293; Inhibition of BSP uptake,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139261,mbcd0001050,mbtp000024,mbrf0002095,,,,,non-substrate,,,,,Digoxin,,,HEK293 cells,HEK293,,,,,human,mbds0010,,2013-11-24 23:13:17
mbbd000139262,mbcd0000746,mbtp000024,mbrf0001720,,=,,,substrate,28,0.3,microM,0.1,R123,,,HEK293 cells expressing OATP1A2,HEK293,,,,,human,mbds0010,,2013-11-24 23:13:17
mbbd000139263,mbcd0000746,mbtp000024,mbrf0001720,,=,,,substrate,22,6.8,microM,0.5,R123,,,HEK293 cells expressing OATP1A2,HEK293,,,,,human,mbds0010,,2013-11-24 23:13:18
mbbd000139264,mbcd0029242,mbtp000024,mbrf0002092,,,,,inhibitor,,,,,PFO,"Likely inhibitor, not confirmed. PFC's inhibit OATP1A2 mediated E3S uptake is legth dependent.",,HEK293 cells; Inhibition of E3S uptake,,,,,,human,mbds0010,,2013-12-09 19:56:37
mbbd000139265,mbcd0029242,mbtp000024,mbrf0002092,,,,,non-substrate,,,,,PFO,,,HEK 293 cells,HEK293,,,,,human,mbds0010,,2013-11-24 23:13:18
mbbd000139266,mbcd0003146,mbtp000024,mbrf0001653,,,,,substrate,,,,,PAH,"Paper has a source for this info, however the source does not contail any mention of this compound.",,Xenopus laevis oocyte,Xenopus laevis oocytes,,,,,human,mbds0010,,2013-12-10 23:18:24
mbbd000139267,mbcd0003923,mbtp000024,mbrf0002302,,,,,non-substrate,,,,,tetraethylammonium,,,Xenopus laevis oocyte,Xenopus laevis oocytes,,,,,human,mbds0010,,2013-11-24 23:14:51
mbbd000139268,mbcd0008874,mbtp000024,mbrf0002302,,,,,non-substrate,,,,,Aspartate,,,Xenopus laevis oocyte,Xenopus laevis oocytes,,,,,human,mbds0010,,2013-11-24 23:14:51
mbbd000139269,mbcd0000047,mbtp000024,mbrf0002302,,,,,non-substrate,,,,,dinitrophenylglutathione,,,Xenopus laevis oocyte,Xenopus laevis oocytes,,,,,human,mbds0010,,2013-11-24 23:14:51
mbbd000139270,mbcd0001675,mbtp000024,mbrf0002302,,,,,non-substrate,,,,,Aldosterone,,,Xenopus laevis oocyte,Xenopus laevis oocytes,,,,,human,mbds0010,,2013-11-24 23:14:52
mbbd000139271,mbcd0002635,mbtp000024,mbrf0002302,,,,,non-substrate,,,,,Cortisol,,,Xenopus laevis oocyte,Xenopus laevis oocytes,,,,,human,mbds0010,,2013-11-24 23:14:52
mbbd000139272,mbcd0029244,mbtp000024,mbrf0002302,,,,,non-substrate,,,,,succinate,,,Xenopus laevis oocyte,Xenopus laevis oocytes,,,,,human,mbds0010,,2013-11-24 23:14:52
mbbd000139273,mbcd0029245,mbtp000024,mbrf0002505,,,,,non-substrate,,,,,Gd-EOB-DTPA,Gd3+ salt,,Xenopus laevis oocyte,Xenopus laevis oocytes,,,,,human,mbds0010,,2013-11-24 23:14:52
mbbd000139274,mbcd0026093,mbtp000024,mbrf0001933,,,,,substrate,,,,,Atorvastatin,,,Xenopus laevis oocyte; HeLa cells,Xenopus laevis oocytes; HeLa,,,,,human,mbds0010,,2013-11-24 23:14:53
mbbd000139275,mbcd0000864,mbtp000024,mbrf0001371,,,,,non-substrate,,,,,Tributylmethylammonium,,,Xenopus laevis oocyte; HeLa cells,Xenopus laevis oocytes; HeLa,,,,,human,mbds0010,,2013-11-24 23:14:53
mbbd000139276,mbcd0000984,mbtp000024,mbrf0001393,,=,,,substrate,89,2.3,,,T3,,,Xenopus laevis oocyte,Xenopus laevis oocytes,,10,microM,,human,mbds0010,,2013-11-04 02:02:20
mbbd000139277,mbcd0003957,mbtp000024,mbrf0001393,,=,,,substrate,89,2.3,,,T4,,,Xenopus laevis oocyte,Xenopus laevis oocytes,,10,microM,,human,mbds0010,,2013-11-04 02:02:21
mbbd000139278,mbcd0000605,mbtp000024,mbrf0001393,,=,,,substrate,89,34.0,,,N-methyl-quinine,,,Xenopus laevis oocyte,Xenopus laevis oocytes,,10,microM,,human,mbds0010,,2013-11-04 02:02:21
mbbd000139279,mbcd0002917,mbtp000024,mbrf0001393,,=,,,non-substrate,89,1.0,,,LTC4,,,Xenopus laevis oocyte,Xenopus laevis oocytes,,5,microM,,human,mbds0010,,2013-11-04 02:02:22
mbbd000139280,mbcd0001442,mbtp000024,mbrf0002302,,=,,,substrate,22,0.19,pmol oocyte-1 min,0.08,Ouabain,,,Xenopus laevis oocyte,Xenopus laevis oocytes,,,,,human,mbds0010,,2013-11-24 23:14:53
mbbd000139281,mbcd0003075,mbtp000024,mbrf0002302,,=,,,substrate,22,0.035,pmol oocyte-1 min,0.003,Estrone-3-sulfate,,,Xenopus laevis oocyte,Xenopus laevis oocytes,,,,,human,mbds0010,,2013-11-24 23:14:53
mbbd000139282,mbcd0000693,mbtp000024,mbrf0002087,,=,,,substrate,22,2.84,pmol h-1 oocyte-1,0.12,Pitavastatin,,,Xenopus laevis oocyte,Xenopus laevis oocytes,,,,,human,mbds0010,,2013-11-24 23:14:54
mbbd000139297,mbcd0029247,mbtp000006,mbrf0001996,,=,,,inhibitor,25,90.0,microM,,alpha-cyanocinnamate,,,Human erythrocyte,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139298,mbcd0000129,mbtp000006,mbrf0001996,,=,,,inhibitor,25,50.0,microM,,alpha-4-hydroxycinnamate,,,Human erythrocyte,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139299,mbcd0000128,mbtp000006,mbrf0001996,,=,,,inhibitor,25,250.0,microM,,alpha-3-hydroxycinnamate,,,Human erythrocyte,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139300,mbcd0029255,mbtp000006,mbrf0001996,,=,,,inhibitor,25,75.0,microM,,alpha-fluorocinnamate,,,Human erythrocyte,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139301,mbcd0029248,mbtp000006,mbrf0001996,,=,,,inhibitor,25,15.0,microM,,alpha-Cyano-beta-(1-phenylindol-3-yl) acrylate,,,Human erythrocyte,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139302,mbcd0029256,mbtp000006,mbrf0001996,,=,,,inhibitor,25,600.0,microM,,Cinnamic acid,,,Human erythrocyte,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139304,mbcd0012926,mbtp000006,mbrf0001996,,=,,,inhibitor,25,2.0,microM,,Niflumic  acid,,,Human erythrocyte,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139305,mbcd0004888,mbtp000006,mbrf0001996,,=,,,inhibitor,25,1000.0,microM,,3-Isobutyl-1-methylxanthine,,,Human erythrocyte,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139335,mbcd0000316,mbtp000006,mbrf0002093,,=,,,substrate,28,5.7,mM,1.2,L-Lactate,,,Xenopus laevis oocytes,Xenopus laevis oocytes,,0.2-75,mM,,human,mbds0010,,2013-11-23 00:52:27
mbbd000139336,mbcd0000909,mbtp000006,mbrf0002093,,=,,,substrate,28,1.2,mM,0.2,Pyruvate,,,Xenopus laevis oocytes,Xenopus laevis oocytes,,0.2-75,mM,,human,mbds0010,,2013-11-23 00:52:27
mbbd000139337,mbcd0001648,mbtp000006,mbrf0002099,,=,,,inhibitor,102,0.0,%,,Acetic acid,,,"Inhibition of L-Lactate (1.5 microM) uptake by CHO cells, inhibitor at 20mM",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139338,mbcd0029122,mbtp000006,mbrf0002099,,=,,,inhibitor,102,0.0,%,,Benzoic acid,,,"Inhibition of L-Lactate (1.5 microM) uptake by CHO cells, inhibitor at 20mM",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139339,mbcd0029158,mbtp000006,mbrf0002099,,=,,,inhibitor,102,35.3,%,6,R-Ibuprofen,,,"Inhibition of L-Lactate (1.5 microM) uptake by CHO cells, inhibitor at 0.2mM",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139340,mbcd0003013,mbtp000006,mbrf0002099,,=,,,inhibitor,102,50.5,%,4.4,Ibuprofen,,,"Inhibition of L-Lactate (1.5 microM) uptake by CHO cells, inhibitor at 0.2mM",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139341,mbcd0029267,mbtp000006,mbrf0002099,,=,,,inhibitor,102,75.7,%,6.3,R-Mandelic acid,,,"Inhibition of L-Lactate (1.5 microM) uptake by CHO cells, inhibitor at 20mM",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139342,mbcd0029268,mbtp000006,mbrf0002099,,=,,,inhibitor,102,2.9,%,8.2,S-Mandelic acid,,,"Inhibition of L-Lactate (1.5 microM) uptake by CHO cells, inhibitor at 20mM",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139343,mbcd0014275,mbtp000006,mbrf0002099,,=,,,inhibitor,102,14.5,%,5.4,Nicotinic Acid,,,"Inhibition of L-Lactate (1.5 microM) uptake by CHO cells, inhibitor at 20mM",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139344,mbcd0003126,mbtp000006,mbrf0002099,,=,,,inhibitor,102,2.5,%,1.7,Pravastatin,,,"Inhibition of L-Lactate (1.5 microM) uptake by CHO cells, inhibitor at 20mM",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139345,mbcd0029269,mbtp000006,mbrf0002099,,=,,,inhibitor,102,4.0,%,2.8,Propionic acid,,,"Inhibition of L-Lactate (1.5 microM) uptake by CHO cells, inhibitor at 20mM",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139346,mbcd0003008,mbtp000006,mbrf0002099,,=,,,inhibitor,102,21.5,%,6.5,Valproic Acid,,,"Inhibition of L-Lactate (1.5 microM) uptake by CHO cells, inhibitor at 20mM",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139347,mbcd0029270,mbtp000006,mbrf0002542,,=,,,substrate,28,0.22,mM,,XP13512,,,Xenopus oocytes,Xenopus laevis oocytes,,,,,human,mbds0010,,2013-11-24 23:15:08
mbbd000139348,mbcd0029271,mbtp000006,mbrf0002542,,=,,,substrate,28,9.0,mM,,Butyrate,,,Xenopus oocytes,Xenopus laevis oocytes,,,,,human,mbds0010,,2013-11-24 23:15:08
mbbd000139349,mbcd0029270,mbtp000006,mbrf0002542,,=,,,inhibitor,25,0.62,microM,,XP13512,,,Xenopus oocytes,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139350,mbcd0004171,mbtp000006,mbrf0002542,,=,,,inhibitor,29,28.0,microM,,Phloretin,,,Xenopus oocytes,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139352,mbcd0003076,mbtp000006,mbrf0002335,,=,,,inhibitor,25,23.4,microM,,Naringenin,,,"Caco-2 cells, uptake of labelled benzoic acid",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139353,mbcd0022617,mbtp000006,mbrf0002335,,=,,,inhibitor,25,30.2,microM,,Silybin,,,"Caco-2 cells, uptake of labelled benzoic acid",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139354,mbcd0003076,mbtp000006,mbrf0002335,,=,,,inhibitor,29,15.3,microM,,Naringenin,,,"Caco-2 cells, uptake of labelled benzoic acid",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139355,mbcd0022617,mbtp000006,mbrf0002335,,=,,,inhibitor,29,19.7,microM,,Silybin,,,"Caco-2 cells, uptake of labelled benzoic acid",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139356,mbcd0013346,mbtp000006,mbrf0002508,,,,,inhibitor,,,,,Lonidamine,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139357,mbcd0001353,mbtp000006,mbrf0001854,,,,,substrate,,,,,Salicylate,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139358,mbcd0026093,mbtp000006,mbrf0001854,,,,,substrate,,,,,Atorvastatin,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139360,mbcd0020955,mbtp000027,mbrf0002037,,=,,,substrate,33,64.5,microM,8.7,Leucine,,,uptake in HEK293 cells,HEK293,,,,,human,mbds0010,,2013-11-24 23:13:18
mbbd000139361,mbcd0020955,mbtp000027,mbrf0002037,,=,,,inhibitor,29,44.8,microM,5.3,Leucine,,,HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139362,mbcd0029274,mbtp000027,mbrf0002037,,=,,,inhibitor,29,78.3,microM,12.1,BCH,,,HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139363,mbcd0012192,mbtp000027,mbrf0002037,,=,,,inhibitor,29,90.7,microM,18.7,alpha-Methyl-L-tyrosine,,,HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139364,mbcd0029275,mbtp000027,mbrf0001673,,=,,,inhibitor,29,26.9,microM,1.1,3-fluoro-L-alpha-methyl-tyrosine,,,HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139365,mbcd0029275,mbtp000027,mbrf0001673,,=,,,substrate,28,45.6,microM,1.6,3-fluoro-L-alpha-methyl-tyrosine,,,"L-Leucine uptake in HEK293 cells, FAMT at 50 microM",HEK293,,,,,human,mbds0010,,2013-11-24 23:13:18
mbbd000139366,mbcd0029275,mbtp000027,mbrf0001673,,=,,,substrate,22,4.1,nmol mg-1 min-1,0.1,3-fluoro-L-alpha-methyl-tyrosine,,,"L-Leucine uptake in HEK293 cells, FAMT at 50 microM",HEK293,,,,,human,mbds0010,,2013-11-24 23:13:18
mbbd000139367,mbcd0029275,mbtp000027,mbrf0001673,,=,,,substrate,22,3.9,nmol mg-1 min-1,0.2,3-fluoro-L-alpha-methyl-tyrosine,,,"L-Leucine uptake in HEK293 cells, FAMT at 100 microM",HEK293,,,,,human,mbds0010,,2013-11-24 23:13:19
mbbd000139368,mbcd0029275,mbtp000027,mbrf0001673,,=,,,substrate,28,15.5,microM,1.8,3-fluoro-L-alpha-methyl-tyrosine,,,"L-Leucine uptake in HEK293 cells, FAMT at 100 microM",HEK293,,,,,human,mbds0010,,2013-11-24 23:13:19
mbbd000139369,mbcd0029276,mbtp000027,mbrf0002534,,=,,,inhibitor,102,24.9,%,1.7,D-leucine,,,Xenopus Oocytes,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139370,mbcd0029276,mbtp000027,mbrf0002534,,=,,,inhibitor,102,47.8,%,2.1,D-histidine,,,Xenopus Oocytes,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139371,mbcd0029277,mbtp000027,mbrf0002534,,=,,,inhibitor,102,59.2,%,2.1,D-methionine,,,Xenopus Oocytes,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139372,mbcd0029277,mbtp000027,mbrf0002412,,=,,,inhibitor,102,20.6,%,3.4,D-methionine,,,"Inhibition of Tryptophan uptake in fibroblast cell lines, 50nM of substrate",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139373,mbcd0029277,mbtp000027,mbrf0002412,,=,,,inhibitor,102,78.9,%,16.6,D-methionine,,,"Inhibition of Tryptophan uptake in fibroblast cell lines, 0.5mM of substrate",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139413,mbcd0003028,mbtp000022,mbrf0002098,,,,,substrate,,,,,tenofovir,,,,,,,,,human,mbds0010,,2013-12-10 22:21:07
mbbd000139414,mbcd0001938,mbtp000005,mbrf0002098,,,,,substrate,,,,,ritonavir,,,,,,,,,human,mbds0010,,2013-12-10 22:21:07
mbbd000139415,mbcd0001533,mbtp000005,mbrf0002098,,,,,substrate,,,,,saquinavir,,,,,,,,,human,mbds0010,,2013-12-10 22:21:07
mbbd000139416,mbcd0002988,mbtp000005,mbrf0002098,,,,,inhibitor,,,,,Sulfinpyrazone,,,MDCKII; enhanced MRP2-mediated saquinavir transport,,,,,,human,mbds0010,,2013-11-24 07:52:42
mbbd000139417,mbcd0002241,mbtp000005,mbrf0002528,,,,,substrate,,,,,LVR,,,MDCKII,MDCKII,,,,,human,mbds0010,,2013-10-16 22:45:08
mbbd000139418,mbcd0001117,mbtp000005,mbrf0001818,,,,,substrate,,,,,cisplatin,,,(CHO)-K1,CHO,,,,,human,mbds0010,,2013-12-09 06:42:00
mbbd000139419,mbcd0002917,mbtp000005,mbrf0001818,,=,,,substrate,28,0.24,microM,,LTC4,,,(CHO)-K1,CHO,,,,,human,mbds0010,,2013-11-24 22:21:28
mbbd000139420,mbcd0001135,mbtp000005,mbrf0001818,,,,,substrate,,,,,vincristine,,,(CHO)-K1,CHO,,,,,human,mbds0010,,2013-12-09 06:42:00
mbbd000139421,mbcd0000311,mbtp000005,mbrf0001295,,,,,substrate,,,,,cyclosporine-A,,,"MDCKII, SV40-HCEC",MDCK,,,,,human,mbds0010,,2013-11-24 23:11:24
mbbd000139422,mbcd0000937,mbtp000005,mbrf0001295,,,,,substrate,,,,,erythromycin,,,"MDCKII, SV40-HCEC",MDCKII; SV40-HCEC,,,,,human,mbds0010,,2013-10-16 22:45:09
mbbd000139423,mbcd0003070,mbtp000005,mbrf0001723,,,,,non-substrate,,,,,DHEAS,,,sf9 membrane vesicles,Sf9,,,,,human,mbds0010,,2013-11-24 23:54:40
mbbd000139425,mbcd0029339,mbtp000005,mbrf0001274,,,,,non-substrate,,,,,EE-S,,,sf9 membrane vesicles,Sf9,,,,,human,mbds0010,,2013-11-24 23:54:40
mbbd000139426,mbcd0029339,mbtp000005,mbrf0001274,,,,,stimulator,,,,,EE-S,,,"sf9 membrane vesicles; enhanced MRP2-mediated transport of ethacrynic acid glutathione, 17beta-estradiol-17beta-D-glucuronide and Ethinylestradiol-3-O-glucuronide",,,,,,human,mbds0010,,2013-11-27 07:26:52
mbbd000139431,mbcd0001135,mbtp000005,mbrf0001285,,=,,,substrate,9,8.02,,,VCR,,,LLC-PK1,LLC-PK1,,,,,human,mbds0010,,2013-11-24 23:10:04
mbbd000139432,mbcd0000779,mbtp000005,mbrf0001285,,=,,,substrate,9,6.28,,,SN-38,,,LLC-PK1,LLC-PK1,,,,,human,mbds0010,,2013-11-24 23:10:04
mbbd000139433,mbcd0001117,mbtp000005,mbrf0001285,,=,,,substrate,9,3.04,,,cisplatin,,,LLC-PK1,LLC-PK1,,,,,human,mbds0010,,2013-10-16 22:45:12
mbbd000139434,mbcd0025844,mbtp000005,mbrf0001285,,=,,,substrate,9,2.03,,,ADM,,,LLC-PK1,LLC-PK1,,,,,human,mbds0010,,2013-11-24 23:10:05
mbbd000139435,mbcd0002091,mbtp000005,mbrf0001285,,=,,,substrate,9,1.55,,,CPT-11,,,LLC-PK1,LLC-PK1,,,,,human,mbds0010,,2013-11-24 23:10:05
mbbd000139436,mbcd0002466,mbtp000005,mbrf0001285,,,,,non-substrate,,,,,etoposide,,,LLC-PK1,LLC-PK1,,,,,human,mbds0010,,2013-10-16 22:45:12
mbbd000139437,mbcd0002981,mbtp000005,mbrf0001285,,,,,non-substrate,,,,,MX,,,LLC-PK1,LLC-PK1,,,,,human,mbds0010,,2013-11-24 23:10:05
mbbd000139438,mbcd0001532,mbtp000005,mbrf0001285,,,,,non-substrate,,,,,Taxol,,,LLC-PK1,LLC-PK1,,,,,human,mbds0010,,2013-11-24 23:10:06
mbbd000139439,mbcd0029340,mbtp000005,mbrf0001285,,,,,non-substrate,,,,,Sb III,,,LLC-PK1,LLC-PK1,,,,,human,mbds0010,,2013-11-24 23:10:06
mbbd000139440,mbcd0029341,mbtp000005,mbrf0001285,,,,,non-substrate,,,,,As III,,,LLC-PK1,LLC-PK1,,,,,human,mbds0010,,2013-11-24 23:10:06
mbbd000139442,mbcd0003043,mbtp000005,mbrf0001847,,,,,substrate,,,,,MTX,,,LLC/PK1,LLC-PK1,,,,,human,mbds0010,,2013-11-24 23:10:07
mbbd000139443,mbcd0029343,mbtp000005,mbrf0001847,,,,,non-substrate,,,,,MTX-Glu2,,,LLC/PK1,LLC-PK1,,,,,human,mbds0010,,2013-11-24 23:10:07
mbbd000139444,mbcd0030392,mbtp000005,mbrf0001847,,,,,non-substrate,,,,,MTX-Glu3,,,LLC/PK1,LLC-PK1,,,,,human,mbds0010,,2013-11-24 23:10:07
mbbd000139445,mbcd0001151,mbtp000005,mbrf0001204,,,,,substrate,,,,,VBL,,,LLC-PK1,LLC-PK1,,,,,human,mbds0010,,2013-11-24 23:10:08
mbbd000139446,mbcd0001533,mbtp000005,mbrf0001204,,,,,substrate,,,,,saquinavir,,,LLC-PK1,LLC-PK1,,,,,human,mbds0010,,2013-10-16 22:45:06
mbbd000139447,mbcd0001893,mbtp000005,mbrf0001204,,=,,,non-inhibitor,89,108.0,%,2.0,TAN,,,LLC-PK1,LLC-PK1,mbcd0001151,20,microM,,human,mbds0010,,2013-10-15 02:09:50
mbbd000139448,mbcd0029344,mbtp000005,mbrf0001204,,=,,,non-inhibitor,89,105.0,%,3.3,HMF,,,LLC-PK1,LLC-PK1,mbcd0001151,20,microM,,human,mbds0010,,2013-10-15 02:09:49
mbbd000139449,mbcd0003243,mbtp000005,mbrf0001204,,=,,,inhibitor,89,128.0,%,1.9,NBL,,,LLC-PK1,LLC-PK1,mbcd0001151,20,microM,,human,mbds0010,,2013-10-15 02:09:49
mbbd000139450,mbcd0029345,mbtp000005,mbrf0001825,,,,,non-substrate,,,,,urate,,,sf9 membrane vesicles,Sf9,,,,,human,mbds0010,,2013-10-16 22:45:01
mbbd000139451,mbcd0002917,mbtp000005,mbrf0001289,,~,,,substrate,77,1.2,microM,0.2,LTC4,,,sf9 membrane vesicles,Sf9,,,,,human,mbds0010,,2013-11-24 23:54:40
mbbd000139452,mbcd0000603,mbtp000005,mbrf0001289,,~,,,substrate,77,2.5,mM,,NEM-GS,,,membrane vesicles from MRP2-expressing Sf9 cells; uptake,Sf9,,,,,human,mbds0003,v2007,2013-12-09 19:52:41
mbbd000139453,mbcd0003043,mbtp000005,mbrf0001289,,~,,,substrate,77,2.75,microM,0.25,methotrexate,,,membrane vesicles from MRP2-expressing Sf9 cells; uptake,Sf9,,,,,human,mbds0003,v2007,2013-12-09 20:52:45
mbbd000139456,mbcd0002988,mbtp000005,mbrf0001289,,~,,,stimulator,150,300.0,%,,Sulfinpyrazone,,,sf9 membrane vesicles; enhanced MRP2-mediated transport of NEM-GS at low concentrations,sf9,mbcd0000603,500,microM,,human,mbds0010,,2013-11-27 07:26:52
mbbd000139457,mbcd0002988,mbtp000005,mbrf0001289,,~,,,stimulator,138,320.0,%,,Sulfinpyrazone,,,sf9 membrane vesicles; inhibition of MRP2-mediated transport of NEM-GS at high concentrations,sf9,mbcd0000603,~600,microM,,human,mbds0010,,2013-11-27 07:26:52
mbbd000139458,mbcd0003134,mbtp000005,mbrf0001289,,~,,,stimulator,150,300.0,%,,penicillin G,,,sf9 membrane vesicles; enhanced MRP2-mediated transport of NEM-GS,sf9,mbcd0000603,5,mM,,human,mbds0010,,2013-11-27 07:26:52
mbbd000139459,mbcd0003025,mbtp000005,mbrf0001289,,~,,,stimulator,150,160.0,%,,indomethacin,,,sf9 membrane vesicles; enhanced MRP2-mediated transport of NEM-GS at low concentrations,sf9,mbcd0000603,~60,microM,,human,mbds0010,,2013-11-27 07:26:52
mbbd000139460,mbcd0003025,mbtp000005,mbrf0001289,,~,,,stimulator,138,160.0,%,,indomethacin,,,sf9 membrane vesicles; inhibition of MRP2-mediated transport of NEM-GS at high concentrations,sf9,mbcd0000603,~65,microM,,human,mbds0010,,2013-11-27 07:26:52
mbbd000139461,mbcd0003034,mbtp000005,mbrf0001289,,~,,,inhibitor,138,40.0,%,,Benzbromarone,,,sf9 membrane vesicles,sf9,mbcd0000603,~10,microM,,human,mbds0010,,2013-10-15 02:10:28
mbbd000139462,mbcd0025833,mbtp000005,mbrf0002464,,,,,non-substrate,,,,,Sitagliptin,,,sf9 membrane vesicles,Sf9,,,,,human,mbds0010,,2013-11-24 23:54:41
mbbd000139465,mbcd0000387,mbtp000005,mbrf0002456,,=,,,substrate,28,75.0,microM,7,E217G,,,sf9 membrane vesicles,Sf9,,,,,human,mbds0010,,2013-11-24 23:54:41
mbbd000139466,mbcd0029347,mbtp000005,mbrf0002456,,=,,,substrate,28,122.0,microM,23,E23G,,,sf9 membrane vesicles,Sf9,,,,,human,mbds0010,,2013-11-24 23:54:41
mbbd000139467,mbcd0001640,mbtp000005,mbrf0002456,,,,,stimulator,,,,,UDC,,,sf9 membrane vesicles; enhanced MRP2-mediated transport of E23G at low concentrations,,,,,,human,mbds0010,,2013-11-27 07:26:52
mbbd000139468,mbcd0001612,mbtp000005,mbrf0002456,,,,,inhibitor,,,,,UDC,,,sf9 membrane vesicles; inhibited MRP2-mediated transport of E23G at high concentrations,,,,,,human,mbds0010,,2013-11-24 07:53:10
mbbd000139469,mbcd0029348,mbtp000005,mbrf0002456,,,,,inducer,,,,,TUDC,,,sf9 membrane vesicles,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139470,mbcd0029348,mbtp000005,mbrf0002456,,,,,inhibitor,,,,,TUDC,,,sf9 membrane vesicles,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139471,mbcd0000458,mbtp000005,mbrf0002456,,,,,inducer,,,,,GUDC,,,sf9 membrane vesicles,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139473,mbcd0029348,mbtp000005,mbrf0002456,,=,,,substrate,28,127.0,microM,26,TUDC,,,sf9 membrane vesicles,Sf9,,,,,human,mbds0010,,2013-11-24 23:54:42
mbbd000139474,mbcd0003050,mbtp000005,mbrf0002456,,,,,substrate,,,,,taurocholate; TC,,,sf9 membrane vesicles,Sf9,,,,,human,mbds0010,,2013-10-16 22:45:03
mbbd000139475,mbcd0000819,mbtp000005,mbrf0002456,,,,,substrate,,,,,taurocholate-3-sulfate; TLCS,,,sf9 membrane vesicles,Sf9,,,,,human,mbds0010,,2013-10-16 22:45:03
mbbd000139476,mbcd0000047,mbtp000005,mbrf0002010,,,,,substrate,,,,,DNP-GS,,,MDCK membrane vesicles,MDCK,,,,,human,mbds0010,,2013-11-24 23:11:25
mbbd000139477,mbcd0029346,mbtp000005,mbrf0002010,,,,,substrate,,,,,PGA 1-GS,,,MDCK membrane vesicles,MDCKII,,,,,human,mbds0010,,2013-11-24 23:11:26
mbbd000139478,mbcd0001151,mbtp000005,mbrf0002010,,,,,substrate,,,,,vinblastine,,,MDCK membrane vesicles,MDCK,,,,,human,mbds0010,,2013-11-10 04:22:13
mbbd000139479,mbcd0005183,mbtp000005,mbrf0002010,,,,,non-substrate,,,,,daunorubicin,,,MDCK membrane vesicles,MDCK,,,,,human,mbds0010,,2013-11-10 04:22:14
mbbd000139481,mbcd0029347,mbtp000005,mbrf0001280,,=,,,substrate,28,7.2,microM,0.7,17beta-glucuronosyl estradiol,,,HEK-293 membrane vesicles,HEK293,,,,,human,mbds0010,,2013-11-24 23:13:19
mbbd000139482,mbcd0001267,mbtp000005,mbrf0001305,,,,,non-substrate,,,,,PGE1,,,sf9 membrane vesicles,Sf9,,,,,human,mbds0010,,2013-11-24 23:54:42
mbbd000139483,mbcd0001343,mbtp000005,mbrf0001305,,,,,non-substrate,,,,,PGE2,,,sf9 membrane vesicles,Sf9,,,,,human,mbds0010,,2013-11-24 23:54:42
mbbd000139484,mbcd0001343,mbtp000005,mbrf0001674,,,,,substrate,,,,,PGE2,,,sf21 membrane vesicles,Sf21,,,,,human,mbds0010,,2013-11-24 23:56:43
mbbd000139485,mbcd0001151,mbtp000005,mbrf0001255,,,,,substrate,,,,,vinblastine,,,MDCKII,MDCKII,,,,,human,mbds0010,,2013-10-16 22:45:02
mbbd000139486,mbcd0003078,mbtp000005,mbrf0001255,,,,,substrate,,,,,GSH,,,MDCKII,MDCKII,,,,,human,mbds0010,,2013-11-24 23:11:27
mbbd000139488,mbcd0003034,mbtp000005,mbrf0001255,,=,,,inhibitor,1,12.5,%,,Benzbromarone,,,MDCKII,MDCKII,mbcd0003078,25,microM,,human,mbds0010,,2013-10-15 02:10:02
mbbd000139489,mbcd0003154,mbtp000005,mbrf0001255,,=,,,inhibitor,1,12.5,%,,Probenecid,,,MDCKII,MDCKII,mbcd0003078,5,mM,,human,mbds0010,,2013-10-15 02:10:02
mbbd000139490,mbcd0002988,mbtp000005,mbrf0001255,,,,,stimulator,,,,,Sulfinpyrazone,~9-fold increase in flux,,MDCKII; enhanced MRP2-mediated transport of GSH at low concentrations,MDCKII,,0.8,mM,,human,mbds0010,,2013-11-27 07:26:52
mbbd000139491,mbcd0002988,mbtp000005,mbrf0001255,,~,,,inhibitor,1,40.0,%,,Sulfinpyrazone,,,MDCKII; inhibition of MRP2-mediated transport of GSH at high concentrations,MDCKII,mbcd0003078,0.8,mM,,human,mbds0010,,2013-11-24 08:05:30
mbbd000139492,mbcd0003025,mbtp000005,mbrf0001255,,,,,stimulator,,,,,indomethacin,,,MDCKII; enhanced MRP2-mediated transport of GSH at low concentrations,MDCKII,mbcd0003078,50,microM,,human,mbds0010,,2013-11-27 07:26:52
mbbd000139493,mbcd0003025,mbtp000005,mbrf0001255,,=,,,inhibitor,1,37.5,%,,indomethacin,,,MDCKII; inhibition of MRP2-mediated transport of GSH at high concentrations,MDCKII,mbcd0003078,400,microM,,human,mbds0010,,2013-11-24 08:05:30
mbbd000139494,mbcd0004706,mbtp000005,mbrf0001823,,=,,,substrate,28,8.1,microM,0.5,CCK-8,,,MDCKII membrane vesicles,MDCKII,,,,,human,mbds0010,,2013-11-24 23:11:27
mbbd000139495,mbcd0002466,mbtp000005,mbrf0001280,,=,,,inhibitor,25,1.2,microM,0.5,Etoposide,,,HEK-293 membrane vesicles,HEK293,,,,,human,mbds0010,,2013-11-20 20:30:43
mbbd000139496,mbcd0001135,mbtp000005,mbrf0001280,,=,,,inhibitor,25,18.7,microM,0.1,vincristine,,,MDCK,MDCK,,,,,human,mbds0010,,2013-10-15 01:42:52
mbbd000139497,mbcd0001117,mbtp000005,mbrf0001280,,=,,,inhibitor,25,24.2,microM,4.4,Cisplatin,,,HEK-293 membrane vesicles,HEK293,,,,,human,mbds0010,,2013-11-20 20:30:43
mbbd000139498,mbcd0025844,mbtp000005,mbrf0001280,,=,,,inhibitor,25,346.3,nM,48.1,doxorubicin,,,HEK-293 membrane vesicles,HEK293,,,,,human,mbds0010,,2013-11-20 20:30:43
mbbd000139499,mbcd0029350,mbtp000005,mbrf0001280,,=,,,inhibitor,25,18.8,nM,2.0,Epirubicin,,,HEK-293 membrane vesicles,HEK293,,,,,human,mbds0010,,2013-11-20 20:30:44
mbbd000139500,mbcd0001445,mbtp000005,mbrf0002304,,,,,non-substrate,,,,,fluvastatin,,,MDCKII cells,MDCKII,,,,,human,mbds0010,,2013-11-21 05:02:39
mbbd000139501,mbcd0003035,mbtp000005,mbrf0001414,,=,,,substrate,28,12.0,microM,,BSP,,,MDCKII,MDCKII,,,,,human,mbds0010,,2013-10-21 00:22:43
mbbd000139502,mbcd0003070,mbtp000005,mbrf0001414,,,,,substrate,,,,,DHEAS,,,MDCKII,MDCKII,,,,,human,mbds0010,,2013-10-21 00:22:45
mbbd000139503,mbcd0001416,mbtp000005,mbrf0001414,,=,,,inhibitor,100,50.0,%,,Rifampicin,,,HEK293-MRP2 membrane vesicles,HEK293,mbcd0002917,50,microM,,human,mbds0010,,2013-10-21 00:22:41
mbbd000139504,mbcd0000749,mbtp000005,mbrf0001414,,=,,,inhibitor,100,38.0,%,,Rifamycin SV,,,HEK293-MRP2 membrane vesicles,HEK293,mbcd0002917,50,microM,,human,mbds0010,,2013-10-21 00:22:39
mbbd000139505,mbcd0003043,mbtp000005,mbrf0001822,,=,,,substrate,28,480.0,microM,90,MTX,,,HEK293 membrane vesicles,HEK293,,,,,human,mbds0010,,2013-11-24 23:13:19
mbbd000139506,mbcd0001353,mbtp000005,mbrf0001822,,=,,,inhibitor,25,1760.0,microM,30,Salicylate,,,HEK293 membrane vesicles,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139507,mbcd0003073,mbtp000005,mbrf0001822,,=,,,inhibitor,25,257.0,microM,2,piroxicam,,,HEK293 membrane vesicles,HEK293,mbcd0003043,,,,human,mbds0010,,2013-10-15 02:10:39
mbbd000139508,mbcd0003013,mbtp000005,mbrf0001822,,=,,,inhibitor,25,930.0,microM,20,Ibuprofen,,,HEK293 membrane vesicles,HEK293,mbcd0003043,,,,human,mbds0010,,2013-10-15 02:10:39
mbbd000139509,mbcd0002998,mbtp000005,mbrf0001822,,=,,,inhibitor,25,609.0,microM,7,Naproxen,,,HEK293 membrane vesicles,HEK293,mbcd0003043,,,,human,mbds0010,,2013-10-15 02:10:39
mbbd000139510,mbcd0001175,mbtp000005,mbrf0001822,,=,,,inhibitor,25,38.0,microM,1,Sulindac,,,HEK293 membrane vesicles,HEK293,mbcd0003043,,,,human,mbds0010,,2013-10-15 02:10:15
mbbd000139511,mbcd0006583,mbtp000005,mbrf0001822,,=,,,inhibitor,25,494.0,microM,5,Tolmetin,,,HEK293 membrane vesicles,HEK293,mbcd0003043,,,,human,mbds0010,,2013-10-15 02:10:14
mbbd000139512,mbcd0027248,mbtp000005,mbrf0001822,,=,,,inhibitor,25,480.0,microM,2,etodolac,,,HEK293 membrane vesicles,HEK293,mbcd0003043,,,,human,mbds0010,,2013-10-15 02:10:15
mbbd000139513,mbcd0003113,mbtp000005,mbrf0001822,,=,,,inhibitor,25,97.0,microM,1,Diclofenac,,,HEK293 membrane vesicles,HEK293,mbcd0003043,,,,human,mbds0010,,2013-10-15 02:10:15
mbbd000139514,mbcd0003025,mbtp000005,mbrf0001822,,=,,,inhibitor,25,0.06,microM,0.01,indomethacin,low affinity (two-site competition model),,HEK293 membrane vesicles,HEK293,mbcd0003043,,,,human,mbds0010,,2013-10-15 02:10:15
mbbd000139515,mbcd0003025,mbtp000005,mbrf0001822,,=,,,inhibitor,25,46.0,microM,1,indomethacin,high affinity (two-site competition model),,HEK293 membrane vesicles,HEK293,mbcd0003043,,,,human,mbds0010,,2013-10-15 02:10:15
mbbd000139516,mbcd0002991,mbtp000005,mbrf0001822,,=,,,inhibitor,25,1.4,microM,0.1,Ketoprofen,low affinity (two-site competition model),,HEK293 membrane vesicles,HEK293,mbcd0003043,,,,human,mbds0010,,2013-10-15 02:10:15
mbbd000139517,mbcd0002991,mbtp000005,mbrf0001822,,=,,,inhibitor,25,470.0,microM,20,Ketoprofen,high affinity (two-site competition model),,HEK293 membrane vesicles,HEK293,mbcd0003043,,,,human,mbds0010,,2013-10-15 02:10:15
mbbd000139518,mbcd0003072,mbtp000005,mbrf0001822,,=,,,inhibitor,25,100.0,microM,2,celecoxib,,,HEK293 membrane vesicles,HEK293,mbcd0003043,,,,human,mbds0010,,2013-10-15 02:09:18
mbbd000139519,mbcd0023817,mbtp000005,mbrf0001822,,,,,stimulator,,,,,Phenylbutazone,,,HEK293 membrane vesicles; enhanced MRP2-mediated transport of MTX at low concentrations,HEK293,,,,,human,mbds0010,,2013-11-27 07:26:52
mbbd000139520,mbcd0023817,mbtp000005,mbrf0001822,,=,,,inhibitor,25,605.0,microM,4,Phenylbutazone,,,HEK293 membrane vesicles; inhibition of MRP2-mediated transport of MTX at high concentrations,HEK293,mbcd0003043,,,,human,mbds0010,,2013-11-24 08:05:30
mbbd000139522,mbcd0003154,mbtp000005,mbrf0001296,,=,,,inhibitor,29,35.7,microM,,probenacid,,,bile canalicular membrane vesicles; human liver CMVs; inhibition of SN38-Glu uptake,,,,,,human,mbds0010,,2013-12-09 20:08:52
mbbd000139523,mbcd0003146,mbtp000005,mbrf0002278,,=,,,substrate,28,5.0,mM,2,PAH,,,sf9 membrane vesicles,Sf9,,,,,human,mbds0010,,2013-11-24 23:54:42
mbbd000139524,mbcd0003146,mbtp000005,mbrf0002278,,=,,,substrate,28,2.1,mM,0.6,PAH,,,MDCKII membrane vesicles,MDCKII,,,,,human,mbds0010,,2013-11-24 23:11:27
mbbd000139525,mbcd0003154,mbtp000005,mbrf0002278,,=,,,stimulator,150,170.0,%,15,Probenecid,,,sf9 membrane vesicles; enhanced MRP2-mediated transport of PAH at low concentrations,sf9,mbcd0003146,10,microM,,human,mbds0010,,2013-11-27 07:26:52
mbbd000139526,mbcd0003154,mbtp000005,mbrf0002278,,=,,,inhibitor,150,68.0,%,14,Probenecid,,,sf9 membrane vesicles; inhibition of MRP2-mediated transport of PAH at high concentrations,sf9,mbcd0003146,1,mM,,human,mbds0010,,2013-11-24 08:05:31
mbbd000139527,mbcd0002988,mbtp000005,mbrf0002278,,=,,,stimulator,150,178.0,%,17,Sulfinpyrazone,,,sf9 membrane vesicles,sf9,mbcd0003146,10,microM,,human,mbds0010,,2013-11-27 07:26:52
mbbd000139528,mbcd0002494,mbtp000005,mbrf0002278,,=,,,inhibitor,150,1.0,%,21,MK571,,,sf9 membrane vesicles,sf9,mbcd0003146,1,mM,,human,mbds0010,,2013-10-15 02:09:16
mbbd000139529,mbcd0003100,mbtp000005,mbrf0002278,,=,,,inhibitor,150,68.0,%,21,Dipyridamole,,,sf9 membrane vesicles,sf9,mbcd0003146,25,microM,,human,mbds0010,,2013-10-15 02:09:17
mbbd000139530,mbcd0003086,mbtp000005,mbrf0002475,,=,,,substrate,28,30.4,microM,17.7,valsartan,,,LLC-PK1 membrane vesicles,LLC-PK1,,,,,human,mbds0010,,2013-10-16 22:45:05
mbbd000139531,mbcd0003005,mbtp000005,mbrf0002214,,=,,,substrate,28,14.9,microM,5.39,olmesartan,,,LLC-PK1,LLC-PK1,,,,,human,mbds0010,,2013-11-24 23:10:08
mbbd000139532,mbcd0003005,mbtp000005,mbrf0002214,,,,,substrate,,,,,olmesartan,,,MDCKII cells coexpressing OATP1B1/MRP2,MDCKII,,,,,human,mbds0010,,2013-11-24 23:11:27
mbbd000139533,mbcd0028129,mbtp000005,mbrf0002440,,=,,,inducer,33,404.0,%,,bosentan,,,sf9 membrane vesicles; enhanced MRP2-mediated E17G transport,Sf9,mbcd0000387,100,microM,,human,mbds0010,,2013-10-17 23:26:59
mbbd000139536,mbcd0000303,mbtp000005,mbrf0002374,,=,,,inhibitor,25,5.0,microM,,CUR,,,sf9 membrane vesicles; inhibited MRP2-mediated EASG transport,sf9,mbcd0029352,,,,human,mbds0010,,2013-11-24 07:53:08
mbbd000139537,mbcd0000303,mbtp000005,mbrf0002374,,,,,non-substrate,,,,,circumin; CUR,,,MDCKII,MDCKII,,,,,human,mbds0010,,2013-10-16 22:45:05
mbbd000139538,mbcd0000047,mbtp000005,mbrf0002374,,,,,substrate,,,,,DNPSG,,,MDCKII,MDCKII,,,,,human,mbds0010,,2013-11-24 23:11:28
mbbd000139539,mbcd0029351,mbtp000005,mbrf0002374,,,,,substrate,,,,,calcein,,,MDCKII,MDCKII,,,,,human,mbds0010,,2013-10-16 22:45:05
mbbd000139540,mbcd0029352,mbtp000005,mbrf0002374,,,,,substrate,,,,,EASG,,,sf9 membrane vesicles,Sf9,,,,,human,mbds0010,,2013-11-24 23:54:43
mbbd000139545,mbcd0029353,mbtp000005,mbrf0002254,,=,,,non-inhibitor,1,116.0,%,9,Nicotine-N-glucuronide,,,HEK293T membrane vesicles,HEK293T,mbcd0002917,100,microM,,human,mbds0010,,2013-10-29 23:14:03
mbbd000139546,mbcd0029354,mbtp000005,mbrf0002254,,=,,,non-inhibitor,1,106.0,%,4,Cotinine-N-glucuronide,,,HEK293T membrane vesicles,HEK293T,mbcd0002917,100,microM,,human,mbds0010,,2013-10-29 23:14:03
mbbd000139549,mbcd0001532,mbtp000005,mbrf0002507,,=,,,substrate,85,9.0,,0.6,paclitaxel,,,MDCKII-MRP2; compound 5 microM,MDCKII,,,,,human,mbds0010,,2013-11-24 23:11:28
mbbd000139550,mbcd0027726,mbtp000005,mbrf0002507,,,,,substrate,,,,,docetaxel,,,MDCKII-MRP2; compound 5 microM,MDCKII,,,,,human,mbds0010,,2013-11-24 23:11:28
mbbd000139551,mbcd0003154,mbtp000005,mbrf0002507,,,,,substrate,,,,,probenecid,,,"MDCKII; enhanced MRP2-mediated transport of paclitaxel, docetaxel, etoposide and vinblastine",MDCKII,,,,,human,mbds0010,,2013-11-24 07:52:47
mbbd000139552,mbcd0003155,mbtp000005,mbrf0001254,,,,,substrate,,,,,Fluo 3,,,Hep G2 cell; secretion into apical vacuoles,HepG2,,,,,human,mbds0003,v2007,2013-12-09 20:54:06
mbbd000139553,mbcd0000080,mbtp000005,mbrf0001254,,,,,substrate,,,,,CF,,,Hep G2 cell; secretion into apical vacuoles,HepG2,,,,,human,mbds0003,v2007,2013-12-09 20:54:06
mbbd000139557,mbcd0029357,mbtp000005,mbrf0001852,,,,,substrate,,,,,ACU154,,,MDCKII,MDCKII,,,,,human,mbds0010,,2013-10-16 22:45:08
mbbd000139558,mbcd0029358,mbtp000005,mbrf0001288,,~,,,repressor,111,30.0,%,,Trichostatin A,protein level % of control,,HepG2,HepG2,,1,microM,,human,mbds0010,,2013-10-15 01:42:29
mbbd000139559,mbcd0000042,mbtp000005,mbrf0001288,,=,,,inducer,111,2.4,fold increase,,2-AAF,increase in protein level,,HepG2,HepG2,,200,microM,,human,mbds0010,,2013-11-21 02:28:12
mbbd000139560,mbcd0013478,mbtp000005,mbrf0001287,,=,,,non-inducer,97,110.0,%,24,TCDD,100% represents protein levels in solvent controls containing DMSO,,Caco-2 cell; compound 10 nM; Immunoblot analysis; 100% represents protein levels in solvent controls containing DMSO,,,10,microM,,human,mbds0010,,2013-12-09 20:05:23
mbbd000139562,mbcd0023726,mbtp000005,mbrf0001287,,=,,,inducer,97,186.0,%,38,TBHQ,100% represents protein levels in solvent controls containing DMSO,,Caco-2 cell; compound 80 microM; Immunoblot analysis; 100% represents protein levels in solvent controls containing DMSO,,,80,microM,,human,mbds0010,,2013-12-09 20:05:23
mbbd000139563,mbcd0023726,mbtp000005,mbrf0002041,,,,,inducer,,,,,t-BHQ,,,HCT116,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139564,mbcd0017161,mbtp000005,mbrf0002041,,,,,inducer,,,,,PDTC,,,HCT116,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139566,mbcd0004707,mbtp000005,mbrf0001828,,,,,substrate,,,,,tel-glu,,,HEK293,HEK293,,,,,human,mbds0010,,2013-11-24 23:13:20
mbbd000139567,mbcd0001668,mbtp000005,mbrf0002287,,,,,inducer,,,,,Cholesterol,,,HepG2; MRP2 transport function,HepG2,,,,,human,mbds0010,,2013-11-24 22:15:06
mbbd000139568,mbcd0029359,mbtp000005,mbrf0001742,,=,,,substrate,28,4.2,microM,0.9,As(GS)3,,,HEK293 membrane vesicles,HEK293,,,,,human,mbds0010,,2014-01-17 20:50:09
mbbd000139569,mbcd0029360,mbtp000005,mbrf0001742,,=,,,substrate,28,1.7,microM,0.8,[(GS)2AsSe]-,,,HEK293 membrane vesicles,HEK293,,,,,human,mbds0010,,2013-11-24 23:13:20
mbbd000139570,mbcd0029361,mbtp000005,mbrf0002504,,=,,,substrate,28,10.0,microM,,CHB-SG,,,MCF7,MCF7,,,,,human,mbds0010,,2013-11-24 23:09:55
mbbd000139571,mbcd0002981,mbtp000005,mbrf0002026,,,,,substrate,,,,,mitoxantrone,unpublished data,,,,,,,,human,mbds0010,,2013-12-10 22:22:07
mbbd000139572,mbcd0003120,mbtp000005,mbrf0002042,,~,,,non-inhibitor,100,100.0,%,,Quercetin,,,MDCKII,MDCKII,mbcd0030390,,,,human,mbds0010,,2013-10-15 18:48:45
mbbd000139573,mbcd0003168,mbtp000005,mbrf0002042,,~,,,non-inhibitor,100,100.0,%,,Flavone,,,MDCKII,MDCKII,mbcd0030390,,,,human,mbds0010,,2013-10-15 18:48:45
mbbd000139574,mbcd0003139,mbtp000005,mbrf0002042,,~,,,non-inhibitor,100,100.0,%,,Taxifolin,,,MDCKII,MDCKII,mbcd0030390,,,,human,mbds0010,,2013-10-15 18:48:43
mbbd000139575,mbcd0029367,mbtp000005,mbrf0001860,,=,,,inhibitor,25,15.0,microM,,Robinetin,,,MDCKII,MDCKII,mbcd0029351,,,,human,mbds0010,,2013-10-15 22:12:54
mbbd000139576,mbcd0003040,mbtp000005,mbrf0001860,,=,,,inhibitor,25,22.2,microM,,Myricetin,,,MDCKII,MDCKII,mbcd0029351,,,,human,mbds0010,,2013-10-15 22:12:54
mbbd000139577,mbcd0029367,mbtp000005,mbrf0001860,,=,,,inhibitor,29,8.5,microM,,Robinetin,,,MDCKII,MDCKII,mbcd0029351,,,,human,mbds0010,,2013-10-15 22:12:54
mbbd000139578,mbcd0003168,mbtp000005,mbrf0001860,,>,,,non-inhibitor,25,50.0,microM,,Flavone,,,MDCKII,MDCKII,mbcd0029351,,,,human,mbds0010,,2013-10-15 22:12:54
mbbd000139579,mbcd0027296,mbtp000005,mbrf0001860,,>,,,non-inhibitor,25,50.0,microM,,3-Hydroxyflavone,,,MDCKII,MDCKII,mbcd0029351,,,,human,mbds0010,,2013-10-15 22:12:54
mbbd000139580,mbcd0029363,mbtp000005,mbrf0001860,,>,,,non-inhibitor,25,50.0,microM,,3'-Hydroxyflavone,,,MDCKII,MDCKII,mbcd0029351,,,,human,mbds0010,,2013-10-15 22:12:56
mbbd000139581,mbcd0029364,mbtp000005,mbrf0001860,,>,,,non-inhibitor,25,50.0,microM,,4'-Hydroxyflavone,,,MDCKII,MDCKII,mbcd0029351,,,,human,mbds0010,,2013-10-15 22:12:56
mbbd000139582,mbcd0003045,mbtp000005,mbrf0001860,,>,,,non-inhibitor,25,50.0,microM,,Chrysin,,,MDCKII,MDCKII,mbcd0029351,,,,human,mbds0010,,2013-10-15 22:12:56
mbbd000139583,mbcd0022645,mbtp000005,mbrf0001860,,>,,,non-inhibitor,25,50.0,microM,,"3,3'-Dihydroxyflavone",,,MDCKII,MDCKII,mbcd0029351,,,,human,mbds0010,,2013-10-15 22:12:56
mbbd000139584,mbcd0026912,mbtp000005,mbrf0001860,,>,,,non-inhibitor,25,50.0,microM,,"3,4'-Dihydroxyflavone",,,MDCKII,MDCKII,mbcd0029351,,,,human,mbds0010,,2013-10-15 22:12:56
mbbd000139585,mbcd0004758,mbtp000005,mbrf0001860,,>,,,non-inhibitor,25,50.0,microM,,Galangin,,,MDCKII,MDCKII,mbcd0029351,,,,human,mbds0010,,2013-10-15 22:12:56
mbbd000139586,mbcd0004720,mbtp000005,mbrf0001860,,>,,,non-inhibitor,25,50.0,microM,,Baicalein,,,MDCKII,MDCKII,mbcd0029351,,,,human,mbds0010,,2013-10-15 22:12:56
mbbd000139587,mbcd0003091,mbtp000005,mbrf0001860,,>,,,non-inhibitor,25,50.0,microM,,Apigenin,,,MDCKII,MDCKII,mbcd0029351,,,,human,mbds0010,,2013-10-15 22:12:56
mbbd000139588,mbcd0003076,mbtp000005,mbrf0001860,,>,,,non-inhibitor,25,50.0,microM,,Naringenin,,,MDCKII,MDCKII,mbcd0029351,,,,human,mbds0010,,2013-10-15 22:12:56
mbbd000139589,mbcd0022497,mbtp000005,mbrf0001860,,>,,,non-inhibitor,25,50.0,microM,,"3,3',4'-Trihydroxyflavone",,,MDCKII,MDCKII,mbcd0029351,,,,human,mbds0010,,2013-10-15 22:12:56
mbbd000139590,mbcd0003215,mbtp000005,mbrf0001860,,>,,,non-inhibitor,25,50.0,microM,,Kaempferol,,,MDCKII,MDCKII,mbcd0029351,,,,human,mbds0010,,2013-10-15 22:13:10
mbbd000139591,mbcd0023723,mbtp000005,mbrf0001860,,>,,,non-inhibitor,25,50.0,microM,,Fisetin,,,MDCKII,MDCKII,mbcd0029351,,,,human,mbds0010,,2013-10-15 22:13:10
mbbd000139592,mbcd0003217,mbtp000005,mbrf0001860,,>,,,non-inhibitor,25,50.0,microM,,Luteolin,,,MDCKII,MDCKII,mbcd0029351,,,,human,mbds0010,,2013-10-15 22:13:10
mbbd000139593,mbcd0004750,mbtp000005,mbrf0001860,,>,,,non-inhibitor,25,50.0,microM,,Eriodictyol,,,MDCKII,MDCKII,mbcd0029351,,,,human,mbds0010,,2013-10-15 22:13:10
mbbd000139594,mbcd0003059,mbtp000005,mbrf0001860,,>,,,non-inhibitor,25,50.0,microM,,Morin,,,MDCKII,MDCKII,mbcd0029351,,,,human,mbds0010,,2013-10-15 22:13:11
mbbd000139595,mbcd0003120,mbtp000005,mbrf0001860,,>,,,non-inhibitor,25,50.0,microM,,Quercetin,,,MDCKII,MDCKII,mbcd0029351,,,,human,mbds0010,,2013-10-15 22:13:11
mbbd000139596,mbcd0003139,mbtp000005,mbrf0001860,,>,,,non-inhibitor,25,50.0,microM,,Taxifolin,,,MDCKII,MDCKII,mbcd0029351,,,,human,mbds0010,,2013-10-15 22:13:11
mbbd000139597,mbcd0029140,mbtp000005,mbrf0001860,,>,,,non-inhibitor,25,50.0,microM,,Catechin,,,MDCKII,MDCKII,mbcd0029351,,,,human,mbds0010,,2013-10-15 22:13:11
mbbd000139598,mbcd0004715,mbtp000005,mbrf0001860,,>,,,non-inhibitor,25,50.0,microM,,Acacetin,,,MDCKII,MDCKII,mbcd0029351,,,,human,mbds0010,,2013-10-15 22:13:10
mbbd000139599,mbcd0004722,mbtp000005,mbrf0001860,,>,,,non-inhibitor,25,50.0,microM,,Kaempferide,,,MDCKII,MDCKII,mbcd0029351,,,,human,mbds0010,,2013-10-15 22:13:10
mbbd000139600,mbcd0029366,mbtp000005,mbrf0001860,,>,,,non-inhibitor,25,50.0,microM,,"5,7,3',4'-Tetramethoxyflavone",,,MDCKII,MDCKII,mbcd0029351,,,,human,mbds0010,,2013-10-15 22:13:06
mbbd000139601,mbcd0003048,mbtp000005,mbrf0001860,,>,,,non-inhibitor,25,50.0,microM,,Diosmetin,,,MDCKII,MDCKII,mbcd0029351,,,,human,mbds0010,,2013-10-15 22:13:06
mbbd000139602,mbcd0003041,mbtp000005,mbrf0001860,,>,,,non-inhibitor,25,50.0,microM,,Chrysoeriol,,,MDCKII,MDCKII,mbcd0029351,,,,human,mbds0010,,2013-10-15 22:13:06
mbbd000139603,mbcd0004718,mbtp000005,mbrf0001860,,>,,,non-inhibitor,25,50.0,microM,,Tamarixetin,,,MDCKII,MDCKII,mbcd0029351,,,,human,mbds0010,,2013-10-15 22:13:06
mbbd000139604,mbcd0004713,mbtp000005,mbrf0001860,,>,,,non-inhibitor,25,50.0,microM,,Isorhamnetin,,,MDCKII,MDCKII,mbcd0029351,,,,human,mbds0010,,2013-10-15 22:13:01
mbbd000139605,mbcd0029368,mbtp000005,mbrf0001958,,,,,substrate,,,,,M1,,,Caco-2,Caco-2,,,,,human,mbds0010,,2013-11-24 23:12:24
mbbd000139606,mbcd0029369,mbtp000005,mbrf0001958,,,,,substrate,,,,,M2,,,Caco-2,Caco-2,,,,,human,mbds0010,,2013-11-24 23:12:24
mbbd000139607,mbcd0029370,mbtp000005,mbrf0002175,,=,,,substrate,28,43.6,microM,7.4,quercetin 4'-beta-glucoside,,,Caco-2,Caco-2,,,,,human,mbds0010,,2013-10-16 22:45:09
mbbd000139608,mbcd0029371,mbtp000005,mbrf0002376,,,,,substrate,,,,,Genistin,,,Caco-2,Caco-2,,,,,human,mbds0010,,2013-12-10 22:19:00
mbbd000139609,mbcd0013807,mbtp000005,mbrf0002258,,,,,substrate,,,,,EC,,,Caco-2,Caco-2,,,,,human,mbds0010,,2013-11-24 23:12:24
mbbd000139610,mbcd0000002,mbtp000005,mbrf0001271,,,,,substrate,,,,,ECG,,,Caco-2,Caco-2,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139611,mbcd0004042,mbtp000005,mbrf0002039,,,,,substrate,,,,,phloridzin,,,MDCK,MDCKII,,,,,human,mbds0010,,2013-10-16 22:45:01
mbbd000139612,mbcd0001808,mbtp000005,mbrf0001731,,=,,,non-inhibitor,1,109.0,%,1,GF129018,,,A549 cells/sf9 membrane vesicles; no effect on MRP2-mediated calcein transport,A549; Sf9,mbcd0029351,,,,human,mbds0010,,2013-10-29 22:37:28
mbbd000139613,mbcd0001808,mbtp000005,mbrf0001731,,~,,,non-inhibitor,1,95.0,%,10,GF129018,,,A549 cells/sf9 membrane vesicles; no effect on MRP2-mediated CDCF transport,A549; Sf9,mbcd0029372,1,microM,,human,mbds0010,,2013-10-29 22:37:28
mbbd000139614,mbcd0001808,mbtp000005,mbrf0001731,,=,,,inhibitor,17,0.5,microM,0.2,GF129018,,,A549 cells/sf9 membrane vesicles; inhibited MRP2-mediated rhodamine-123 transport,A549; Sf9,mbcd0000746,,,,human,mbds0010,,2013-11-24 07:53:10
mbbd000139615,mbcd0002422,mbtp000005,mbrf0001731,,~,,,non-inhibitor,1,120.0,%,10,Fumitremorgin C,,,A549 cells/sf9 membrane vesicles; no effect on MRP2-mediated CDCF transport,A549; Sf9,mbcd0029372,100,microM,,human,mbds0010,,2013-11-24 22:14:57
mbbd000139616,mbcd0027062,mbtp000005,mbrf0001731,,,,,inhibitor,,,,,verapamil,,,A549 cells/sf9 membrane vesicles; inhibited MRP2-mediated rhodamine-123 transport,A549; Sf9,mbcd0000746,,,,human,mbds0010,,2013-11-24 07:53:10
mbbd000139617,mbcd0027062,mbtp000005,mbrf0001731,,,,,stimulator,,,,,verapamil,,,A549 cells/sf9 membrane vesicles; enhancedMRP2-mediated CDCF transport,A549; Sf9,,,,,human,mbds0010,,2013-11-27 07:26:52
mbbd000139618,mbcd0027062,mbtp000005,mbrf0001731,,~,,,non-inhibitor,1,133.0,%,4,Verapamil,,,A549 cells/sf9 membrane vesicles; no effect on MRP2-mediated calcein transport,A549; Sf9,mbcd0029351,,,,human,mbds0010,,2013-11-24 22:14:57
mbbd000139619,mbcd0000746,mbtp000005,mbrf0001731,,,,,substrate,,,,,rhodamine-123,,,A549 cells/sf9 membrane vesicles,A549; Sf9,,,,,human,mbds0010,,2013-10-29 22:37:28
mbbd000139620,mbcd0029351,mbtp000005,mbrf0001731,,,,,substrate,,,,,calcein,,,A549 cells/sf9 membrane vesicles,A549; Sf9,,,,,human,mbds0010,,2013-10-16 22:45:05
mbbd000139621,mbcd0029372,mbtp000005,mbrf0001731,,,,,substrate,,,,,CDCF,http://www.enzolifesciences.com/ENZ-52103/5-6-cdcfda-ultra-pure/,,A549 cells/sf9 membrane vesicles,A549; Sf9,,,,,human,mbds0010,,2013-10-29 22:37:28
mbbd000139622,mbcd0000311,mbtp000005,mbrf0001731,,,,,inhibitor,,,,,Cyclosporin A,,,A549 cells/sf9 membrane vesicles; inhibited MRP2-mediated CDCF transport,A549; Sf9,,,,,human,mbds0010,,2013-11-24 07:53:07
mbbd000139623,mbcd0002494,mbtp000005,mbrf0001731,,,,,inhibitor,,,,,MK571,,,A549 cells/sf9 membrane vesicles; inhibited MRP2-mediated CDCF transport,A549; Sf9,,,,,human,mbds0010,,2013-11-24 07:53:07
mbbd000139624,mbcd0003034,mbtp000005,mbrf0001731,,~,,,inhibitor,100,880.0,%,,Benzbromarone,,,A549 cells/sf9 membrane vesicles; inhibited MRP2-mediated CDCF transport,A549; Sf9,mbcd0029372,,,,human,mbds0010,,2013-11-24 07:53:08
mbbd000139625,mbcd0003113,mbtp000005,mbrf0002065,,,,,non-substrate,,,,,diclofenac,,,MDCKII,MDCKII,,,,,human,mbds0010,,2013-10-16 22:45:10
mbbd000139626,mbcd0003113,mbtp000005,mbrf0002065,,=,,,stimulator,138,2.6,fold increase,,Diclofenac,increase in transport,,MDCKII; enhanced MRP2-mediated paclitaxel transport,MDCKII,mbcd0001532,50,microM,,human,mbds0010,,2013-11-27 07:26:52
mbbd000139627,mbcd0003113,mbtp000005,mbrf0002065,,=,,,stimulator,138,2.0,fold increase,,Diclofenac,increase in transport,,MDCKII; enhanced MRP2-mediated docetaxel transport,MDCKII,mbcd0027726,50,microM,,human,mbds0010,,2013-11-27 07:26:52
mbbd000139628,mbcd0003113,mbtp000005,mbrf0002065,,=,,,stimulator,138,3.4,fold increase,,Diclofenac,increase in transport,,MDCKII; enhanced MRP2-mediated saquinavir transport,MDCKII,mbcd0001533,50,microM,,human,mbds0010,,2013-11-27 07:26:52
mbbd000139630,mbcd0003034,mbtp000005,mbrf0002065,,=,,,stimulator,138,3.3,fold increase,,Benzbromarone,increase in transport,,MDCKII; enhanced MRP2-mediated etoposide transport,MDCKII,mbcd0027726,,,,human,mbds0010,,2013-11-27 07:26:52
mbbd000139631,mbcd0027726,mbtp000005,mbrf0002065,,,,,substrate,,,,,docetaxel,,,MDCKII,MDCKII,,,,,human,mbds0010,,2013-10-16 22:45:08
mbbd000139632,mbcd0001532,mbtp000005,mbrf0002065,,,,,substrate,,,,,paclitaxel,,,MDCKII,MDCKII,,5,microM,,human,mbds0010,,2014-02-25 06:45:41
mbbd000139633,mbcd0003137,mbtp000005,mbrf0002065,,,,,non-inducer,,,,,Furosemide,,,MDCKII,MDCKII,,,,,human,mbds0010,,2013-10-15 00:41:45
mbbd000139634,mbcd0017644,mbtp000005,mbrf0002065,,,,,non-inducer,,,,,Tolbutamide,,,MDCKII,MDCKII,,,,,human,mbds0010,,2013-10-15 00:41:45
mbbd000139635,mbcd0003074,mbtp000005,mbrf0002065,,,,,non-inducer,,,,,glyburide,,,MDCKII,MDCKII,,,,,human,mbds0010,,2013-10-15 00:41:45
mbbd000139636,mbcd0003025,mbtp000005,mbrf0001495,,~,,,stimulator,150,250.0,%,,indomethacin,,,sf9 membrane vesicles; enhanced MRP2-mediated E217betaG transport,Sf9,mbcd0000387,10,microM,,human,mbds0010,,2013-11-27 07:26:52
mbbd000139637,mbcd0003095,mbtp000005,mbrf0001495,,~,,,stimulator,150,600.0,%,,Sulfanitran,,,sf9 membrane vesicles; enhanced MRP2-mediated E217betaG transport,Sf9,mbcd0000387,100,microM,,human,mbds0010,,2013-11-27 07:26:52
mbbd000139638,mbcd0003095,mbtp000005,mbrf0001495,,,,,stimulator,,,,,Sulfanitran,,,MDCKII; enhanced MRP2-mediated E217betaG transport,MDCKII,mbcd0000387,,,,human,mbds0010,,2013-11-27 07:26:52
mbbd000139639,mbcd0003134,mbtp000005,mbrf0001495,,~,,,non-inhibitor,150,110.0,%,,penicillin G,,,sf9 membrane vesicles; enhanced MRP2-mediated E217betaG transport,Sf9,mbcd0000387,100,microM,,human,mbds0010,,2013-10-11 20:00:40
mbbd000139640,mbcd0022900,mbtp000005,mbrf0001495,,~,,,non-inhibitor,150,800.0,%,,pantoprazole,,,sf9 membrane vesicles; enhanced MRP2-mediated E217betaG transport,Sf9,mbcd0000387,1,mM,,human,mbds0010,,2013-10-11 20:00:40
mbbd000139641,mbcd0003134,mbtp000005,mbrf0001495,,,,,non-substrate,,,,,penicillin G,,,MDCKII,MDCKII,,,,,human,mbds0010,,2013-10-11 20:00:41
mbbd000139642,mbcd0022900,mbtp000005,mbrf0001495,,,,,non-substrate,,,,,pantoprazole,,,MDCKII,MDCKII,,,,,human,mbds0010,,2013-10-11 20:00:40
mbbd000139643,mbcd0001021,mbtp000005,mbrf0001495,,~,,,non-inhibitor,150,700.0,%,,omeprazole,,,sf9 membrane vesicles; enhanced MRP2-mediated E217betaG transport,Sf9,mbcd0000387,1,mM,,human,mbds0010,,2013-10-11 20:00:40
mbbd000139644,mbcd0003121,mbtp000005,mbrf0001495,,~,,,non-inhibitor,150,500.0,%,,lansoprazole,,,sf9 membrane vesicles; enhanced MRP2-mediated E217betaG transport,Sf9,mbcd0000387,1,mM,,human,mbds0010,,2013-10-11 20:00:40
mbbd000139645,mbcd0003154,mbtp000005,mbrf0001495,,~,,,stimulator,150,200.0,%,,Probenecid,,,sf9 membrane vesicles; enhanced MRP2-mediated E217betaG transport,Sf9,mbcd0000387,100,microM,,human,mbds0010,,2013-11-27 07:26:52
mbbd000139646,mbcd0001533,mbtp000005,mbrf0001495,,~,,,stimulator,150,150.0,%,,saquinavir,,,sf9 membrane vesicles; enhanced MRP2-mediated E217betaG transport,Sf9,mbcd0000387,10,microM,,human,mbds0010,,2013-11-27 07:26:52
mbbd000139647,mbcd0003012,mbtp000005,mbrf0001495,,~,,,non-inhibitor,150,150.0,%,,acetaminophen glucuronide,,,sf9 membrane vesicles; enhanced MRP2-mediated E217betaG transport,Sf9,mbcd0000387,1,mM,,human,mbds0010,,2013-10-11 20:00:40
mbbd000139648,mbcd0003137,mbtp000005,mbrf0001495,,~,,,stimulator,150,200.0,%,,Furosemide,,,sf9 membrane vesicles; enhanced MRP2-mediated E217betaG transport,Sf9,mbcd0000387,100,microM,,human,mbds0010,,2013-11-27 07:26:52
mbbd000139649,mbcd0003095,mbtp000005,mbrf0001495,,=,,,inducer,33,253.0,%,10,Sulfanitran,,,sf9 membrane vesicles; enhanced MRP2-mediated 15 nM GS-DNP transport; compound 1 mM,Sf9,mbcd0000047,1,mM,,human,mbds0010,,2013-10-17 23:24:13
mbbd000139650,mbcd0003074,mbtp000005,mbrf0001495,,~,,,stimulator,150,500.0,%,,Glibenclamide,,,sf9 membrane vesicles; enhanced MRP2-mediated E217betaG transport,Sf9,mbcd0000387,100,microM,,human,mbds0010,,2013-11-27 07:26:52
mbbd000139651,mbcd0003050,mbtp000005,mbrf0001495,,~,,,stimulator,150,220.0,%,,taurocholate,,,sf9 membrane vesicles; enhanced MRP2-mediated E217betaG transport,Sf9,mbcd0000387,100,microM,,human,mbds0010,,2013-11-27 07:26:52
mbbd000139652,mbcd0000455,mbtp000005,mbrf0001495,,~,,,stimulator,150,450.0,%,,glycocholate,,,sf9 membrane vesicles; enhanced MRP2-mediated E217betaG transport,Sf9,mbcd0000387,100,microM,,human,mbds0010,,2013-11-27 07:26:52
mbbd000139653,mbcd0002990,mbtp000005,mbrf0001495,,~,,,inhibitor,150,90.0,%,,GSSG,,,sf9 membrane vesicles; inhibition of MRP2-mediated E217betaG transport,Sf9,mbcd0000387,100,microM,,human,mbds0010,,2013-10-11 20:00:40
mbbd000139654,mbcd0000047,mbtp000005,mbrf0001495,,~,,,inhibitor,150,80.0,%,,GS-DNP,,,sf9 membrane vesicles; inhibited MRP2-mediated E217betaG transport,Sf9,mbcd0000387,100,microM,,human,mbds0010,,2013-10-11 20:00:40
mbbd000139655,mbcd0003043,mbtp000005,mbrf0001495,,~,,,non-inhibitor,150,110.0,%,,MTX,,,sf9 membrane vesicles,Sf9,mbcd0000387,100,microM,,human,mbds0010,,2013-10-11 20:00:40
mbbd000139656,mbcd0003078,mbtp000005,mbrf0001495,,~,,,non-inhibitor,150,115.0,%,,GSH,,,sf9 membrane vesicles,Sf9,mbcd0000387,100,microM,,human,mbds0010,,2013-10-11 20:00:41
mbbd000139657,mbcd0002988,mbtp000005,mbrf0001495,,~,,,stimulator,150,600.0,%,,Sulfinpyrazone,,,sf9 membrane vesicles; enhanced MRP2-mediated E217betaG transport,Sf9,mbcd0000387,100,microM,,human,mbds0010,,2013-11-27 07:26:52
mbbd000139658,mbcd0003025,mbtp000005,mbrf0001495,,=,,,inducer,33,274.0,%,11,indomethacin,,,sf9 membrane vesicles; enhanced MRP2-mediated GS-DNP transport,Sf9,mbcd0000047,100,microM,,human,mbds0010,,2013-10-17 23:24:13
mbbd000139660,mbcd0003154,mbtp000005,mbrf0001495,,=,,,inhibitor,33,62.0,%,3,Probenecid,,,sf9 membrane vesicles; inhibition of MRP2-mediated GS-DNP transport,Sf9,mbcd0000047,1,mM,,human,mbds0010,,2013-10-11 00:47:00
mbbd000139661,mbcd0003043,mbtp000005,mbrf0001495,,=,,,inhibitor,33,83.0,%,1,MTX,,,sf9 membrane vesicles; inhibited MRP2-mediated GS-DNP transport,Sf9,mbcd0000047,2.2,mM,,human,mbds0010,,2013-10-11 20:00:41
mbbd000139662,mbcd0002988,mbtp000005,mbrf0001495,,=,,,inducer,33,152.0,%,2,Sulfinpyrazone,,,sf9 membrane vesicles; enhanced MRP2-mediated E217betaG transport,sf9,mbcd0000047,1,mM,,human,mbds0010,,2013-10-17 23:24:13
mbbd000139663,mbcd0003154,mbtp000005,mbrf0001495,,~,,,non-inducer,150,50.0,%,,Probenecid,,,sf9 membrane vesicles; inhibition of MRP2-mediated MTX transport,Sf9,mbcd0003043,1,mM,,human,mbds0010,,2013-10-11 20:00:41
mbbd000139664,mbcd0002990,mbtp000005,mbrf0001495,,~,,,non-inducer,150,50.0,%,,GSSG,,,sf9 membrane vesicles; inhibition of MRP2-mediated MTX transport,Sf9,mbcd0003043,1,mM,,human,mbds0010,,2013-10-11 20:00:41
mbbd000139854,mbcd0003043,mbtp000005,mbrf0001995,,=,,,substrate,28,1540.0,microM,250,MTX,,,HEK293 membrane vesicles,HEK293,,,,,human,mbds0010,,2013-11-24 23:13:20
mbbd000139855,mbcd0003154,mbtp000005,mbrf0001995,,=,,,inhibitor,29,0.171,microM,0.8,Probenecid,,,HEK293 membrane vesicles; inhibited MRP2-mediated MTX transport,HEK293,mbcd0003043,,,,human,mbds0010,,2014-03-04 00:28:58
mbbd000139856,mbcd0023817,mbtp000005,mbrf0001995,,~,,,stimulator,102,160.0,%,,Phenylbutazone,,,HEK293 membrane vesicles; enhancedMRP2-mediated MTX transport,HEK293,mbcd0003043,1,microM,,human,mbds0010,,2013-12-06 08:06:57
mbbd000139857,mbcd0003025,mbtp000005,mbrf0001995,,=,,,non-inhibitor,29,6.72,microM,1.22,indomethacin,,,HEK293 membrane vesicles,HEK293,mbcd0003146,,,,human,mbds0010,,2013-10-15 02:09:26
mbbd000139858,mbcd0001353,mbtp000005,mbrf0001995,,,,,non-inhibitor,,,,,Salicylate,,,HEK293 membrane vesicles,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139859,mbcd0003113,mbtp000005,mbrf0001995,,=,,,non-inhibitor,29,1.52,microM,0.07,Diclofenac,,,HEK293 membrane vesicles,HEK293,mbcd0003146,,,,human,mbds0010,,2013-10-15 02:09:25
mbbd000139860,mbcd0002991,mbtp000005,mbrf0001995,,=,,,non-inhibitor,29,0.89,microM,0.4,Ketoprofen,,,HEK293 membrane vesicles,HEK293,mbcd0003146,,,,human,mbds0010,,2013-10-15 02:09:44
mbbd000139861,mbcd0003013,mbtp000005,mbrf0001995,,=,,,non-inhibitor,29,1.38,microM,0.48,Ibuprofen,,,HEK293 membrane vesicles,HEK293,mbcd0003146,,,,human,mbds0010,,2013-10-15 02:09:44
mbbd000139862,mbcd0002998,mbtp000005,mbrf0001995,,=,,,non-inhibitor,29,1.18,microM,0.6,Naproxen,,,HEK293 membrane vesicles,HEK293,mbcd0003146,,,,human,mbds0010,,2013-10-15 02:09:44
mbbd000139863,mbcd0003134,mbtp000005,mbrf0001995,,,,,non-inhibitor,,,,,PCG,,,HEK293 membrane vesicles,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139864,mbcd0029374,mbtp000005,mbrf0001995,,=,,,inhibitor,29,26.6,microM,5.2,Diclofenac glucuronide,,,HEK293 membrane vesicles; inhibited MRP2-mediated MTX transport,HEK293,mbcd0003043,,,,human,mbds0010,,2014-03-04 00:28:59
mbbd000139865,mbcd0029375,mbtp000005,mbrf0001995,,,,,non-inhibitor,,,,,Naproxen-glucuronide,,,HEK293 membrane vesicles,HEK293,mbcd0003146,,,,human,mbds0010,,2013-10-15 02:09:43
mbbd000139866,mbcd0003007,mbtp000005,mbrf0002387,,=,,,inducer,97,220.0,%,,PB,,,HepaRG,HepaRG,,0.5,mM,,human,mbds0010,,2013-10-15 18:48:42
mbbd000139867,mbcd0022340,mbtp000005,mbrf0001670,,,,,inducer,,,,,BNF,,,human liver slices,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139868,mbcd0001416,mbtp000005,mbrf0001670,,,,,inducer,,,,,RIF,,,human liver slices,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139869,mbcd0003007,mbtp000005,mbrf0001670,,,,,inducer,,,,,PB,,,human liver slices,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139870,mbcd0029377,mbtp000005,mbrf0001925,,=,,,inducer,111,2.0,fold increase,,Gentamicin,increase in protein level,,MDCKII,MDCKII,,,,,human,mbds0010,,2013-11-21 02:28:13
mbbd000139871,mbcd0000441,mbtp000005,mbrf0001925,,,,,substrate,,,,,GS-MF,,,MDCKII,MDCKII,,,,,human,mbds0010,,2013-11-24 23:11:29
mbbd000139872,mbcd0029378,mbtp000005,mbrf0001925,,,,,inhibitor,,,,,CDNB-glutathione,,,MDCKII,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139873,mbcd0001038,mbtp000005,mbrf0002506,,,,,substrate,,,,,grepafloxacin,,,Caco-2,Caco-2,,,,,human,mbds0010,,2013-10-16 22:45:09
mbbd000139874,mbcd0017980,mbtp000005,mbrf0002506,,,,,non-substrate,,,,,ciprofloxacin,,,Caco-2,Caco-2,,,,,human,mbds0010,,2013-10-16 22:45:09
mbbd000139875,mbcd0001640,mbtp000005,mbrf0002506,,,,,substrate,,,,,cholic acid,,,Caco-2,Caco-2,,,,,human,mbds0010,,2013-10-16 22:45:09
mbbd000139876,mbcd0029379,mbtp000005,mbrf0002516,,,,,non-substrate,,,,,melamine,,,MDCKII,MDCKII,,,,,human,mbds0010,,2013-10-16 22:45:09
mbbd000139877,mbcd0003075,mbtp000005,mbrf0001263,,,,,non-substrate,,,,,E1S,,,MDCKII,MDCKII,,,,,human,mbds0010,,2013-11-24 23:11:29
mbbd000139878,mbcd0003070,mbtp000005,mbrf0001263,,,,,non-substrate,,,,,DHEAS,,,MDCKII,MDCKII,,,,,human,mbds0010,,2013-11-24 23:11:29
mbbd000139879,mbcd0001416,mbtp000005,mbrf0001291,,,,,substrate,,,,,Rifampicin,,,LLC-PK1,LLC-PK1,,,,,human,mbds0010,,2013-11-24 23:10:08
mbbd000139880,mbcd0000779,mbtp000005,mbrf0002358,,,,,substrate,,,,,SN-38,,,LS513 cells,LS513,,,,,human,mbds0010,,2013-11-26 00:18:20
mbbd000139881,mbcd0029380,mbtp000005,mbrf0001764,,,,,substrate,,,,,DON,,,LLCPK1 and MDCKII,LLC-PK1; MDCKII,,,,,human,mbds0010,,2013-12-09 20:57:55
mbbd000139882,mbcd0000187,mbtp000005,mbrf0001278,,,,,substrate,,,,,monoglucuronosylbilirubin,,,HepG2,HepG2,,,,,human,mbds0010,,2013-10-16 22:45:08
mbbd000139883,mbcd0004701,mbtp000005,mbrf0001278,,,,,substrate,,,,,bisglucuronosylbilirubin,,,HepG2,HepG2,,,,,human,mbds0010,,2013-10-16 22:45:10
mbbd000139884,mbcd0029381,mbtp000005,mbrf0002329,,,,,substrate,,,,,MED,,,HEK293,HEK293,,,,,human,mbds0010,,2013-11-04 00:17:09
mbbd000139885,mbcd0029193,mbtp000005,mbrf0002102,,=,,,substrate,28,3.3,microM,2,CLF,,,sf21 membrane vesicles,Sf21,,,,,human,mbds0010,,2013-11-04 21:58:45
mbbd000139886,mbcd0000937,mbtp000005,mbrf0002554,,,,,substrate,,,,,erythromycin,,,sf9 membrane vesicles,Sf9,,,,,human,mbds0010,,2013-10-16 22:45:08
mbbd000139887,mbcd0025734,mbtp000005,mbrf0002427,,,,,substrate,,,,,ZEA,,,MDCKII,MDCKII,,10,microM,,human,mbds0010,,2013-07-17 00:25:32
mbbd000139888,mbcd0029383,mbtp000005,mbrf0002427,,,,,substrate,,,,,alpha-ZOL,,,MDCKII,MDCKII,,10,microM,,human,mbds0010,,2013-07-17 00:25:33
mbbd000139889,mbcd0029384,mbtp000005,mbrf0002427,,,,,substrate,,,,,beta-ZOL,,,MDCKII,MDCKII,,10,microM,,human,mbds0010,,2013-07-17 00:25:33
mbbd000139890,mbcd0001117,mbtp000005,mbrf0001993,,,,,substrate,,,,,CDDP,,,sf9 membrane vesicles,Sf9,,,,,human,mbds0010,,2013-11-24 23:54:43
mbbd000139891,mbcd0026015,mbtp000005,mbrf0001993,,,,,substrate,,,,,HgCl2,,,sf9 membrane vesicles,Sf9,,,,,human,mbds0010,,2013-11-24 23:54:43
mbbd000139892,mbcd0001485,mbtp000005,mbrf0001993,,,,,inhibitor,,,,,As2O3,,,sf9 membrane vesicles,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139893,mbcd0000303,mbtp000005,mbrf0001770,,,,,inhibitor,,,,,CUR,,,sf9 membrane vesicles,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139894,mbcd0000303,mbtp000005,mbrf0001770,,,,,non-inhibitor,,,,,CUR,,,MDCKII,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139895,mbcd0029386,mbtp000005,mbrf0001770,,,,,inhibitor,,,,,DCUR,,,MDCKII and sf9 membrane vesicles,,,,,,human,mbds0010,,2013-12-09 20:10:05
mbbd000139896,mbcd0029387,mbtp000005,mbrf0001770,,,,,inhibitor,,,,,BDCUR,,,MDCKII and sf9 membrane vesicles,,,,,,human,mbds0010,,2013-12-09 20:10:06
mbbd000139897,mbcd0029056,mbtp000005,mbrf0001770,,,,,non-inhibitor,,,,,CAPE,,,MDCKII and sf9 membrane vesicles,,,,,,human,mbds0010,,2013-12-09 20:10:07
mbbd000139898,mbcd0029388,mbtp000005,mbrf0001770,,,,,non-inhibitor,,,,,CINN,,,MDCKII and sf9 membrane vesicles,,,,,,human,mbds0010,,2013-12-09 20:10:03
mbbd000139899,mbcd0029389,mbtp000005,mbrf0001770,,,,,non-inhibitor,,,,,CROT,,,MDCKII and sf9 membrane vesicles,,,,,,human,mbds0010,,2013-12-09 20:10:04
mbbd000139900,mbcd0029390,mbtp000005,mbrf0001770,,,,,non-inhibitor,,,,,HEX,,,MDCKII and sf9 membrane vesicles,,,,,,human,mbds0010,,2013-12-09 20:52:47
mbbd000139901,mbcd0029391,mbtp000005,mbrf0001770,,,,,inhibitor,,,,,CITR,,,sf9 membrane vesicles,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139902,mbcd0029391,mbtp000005,mbrf0001770,,,,,non-inhibitor,,,,,CITR,,,MDCKII,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139903,mbcd0029392,mbtp000005,mbrf0001770,,,,,non-inhibitor,,,,,ACRO,,,MDCKII and sf9 membrane vesicles,,,,,,human,mbds0010,,2013-12-09 20:52:46
mbbd000139904,mbcd0029393,mbtp000005,mbrf0001911,,,,,non-substrate,,,,,B[a]P-1-sulfate,,,MDCKII,MDCKII,,,,,human,mbds0010,,2013-11-24 23:11:29
mbbd000139905,mbcd0029394,mbtp000005,mbrf0001911,,,,,non-substrate,,,,,B[a]P-3-sulfate,,,MDCKII,MDCKII,,,,,human,mbds0010,,2013-11-24 23:11:30
mbbd000139906,mbcd0000693,mbtp000005,mbrf0001719,,,,,substrate,,,,,pitavastatin,,,MDCKII,MDCKII,,,,,human,mbds0010,,2013-10-16 22:45:09
mbbd000139907,mbcd0001448,mbtp000005,mbrf0002327,,,,,substrate,,,,,rosuvastatin,,,MDCKII,MDCKII,,,,,human,mbds0010,,2013-10-28 21:28:16
mbbd000139912,mbcd0027062,mbtp000005,mbrf0002584,,~,,,non-inhibitor,1,112.0,%,18,Verapamil,,,Caco-2,Caco-2,mbcd0029372,,,,human,mbds0010,,2013-10-15 18:48:44
mbbd000139913,mbcd0029372,mbtp000005,mbrf0002584,,,,,substrate,,,,,CDCF,,,Caco-2,Caco-2,,,,,human,mbds0010,,2013-11-24 23:12:24
mbbd000139914,mbcd0029395,mbtp000005,mbrf0002489,,,,,substrate,,,,,M3G,unpublished experiments,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139915,mbcd0003968,mbtp000005,mbrf0002566,,,,,non-substrate,,,,,creatinine,,,MDCK,MDCK,,,,,human,mbds0010,,2013-11-10 04:22:14
mbbd000139916,mbcd0000819,mbtp000005,mbrf0002530,,=,,,substrate,28,8.2,microM,1.3,TLC-S,,,HEK293 membrane vesicles,HEK293,,,,,human,mbds0010,,2013-11-24 23:13:21
mbbd000139917,mbcd0000913,mbtp000005,mbrf0001872,,,,,inducer,,,,,"1,25(OH)2D3",,,Caco-2,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139918,mbcd0029396,mbtp000005,mbrf0001872,,,,,inducer,,,,,1alpha(OH)D3,,,Caco-2,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139919,mbcd0029397,mbtp000005,mbrf0001872,,,,,inducer,,,,,1alpha(OH)D2,,,Caco-2,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139920,mbcd0029398,mbtp000005,mbrf0001872,,,,,inducer,,,,,25(OH)D3,,,Caco-2,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139921,mbcd0029399,mbtp000005,mbrf0002058,,,,,inducer,,,,,T2007,,,Caco-2,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139922,mbcd0029399,mbtp000005,mbrf0002058,,,,,non-substrate,,,,,T2007,,,Caco-2,Caco-2,,,,,human,mbds0010,,2013-11-24 23:12:25
mbbd000139923,mbcd0029400,mbtp000005,mbrf0002058,,,,,non-inducer,,,,,MMMDPB,,,Caco-2,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139924,mbcd0029400,mbtp000005,mbrf0002058,,,,,non-substrate,,,,,MMMDPB,,,Caco-2,Caco-2,,,,,human,mbds0010,,2013-11-24 23:12:25
mbbd000139925,mbcd0029401,mbtp000005,mbrf0002058,,,,,non-inducer,,,,,T2000,,,Caco-2,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139926,mbcd0029401,mbtp000005,mbrf0002058,,,,,non-substrate,,,,,T2000,,,Caco-2,Caco-2,,,,,human,mbds0010,,2013-11-24 23:12:25
mbbd000139927,mbcd0001416,mbtp000005,mbrf0001265,,,,,inducer,,,,,Rifampicin,,,HepG2 cells; RT-PCR and Western,,,,,,human,mbds0003,v2007,2013-12-09 20:53:13
mbbd000139928,mbcd0002493,mbtp000005,mbrf0001265,,,,,inducer,,,,,clotrimazol,,,HepG2 cells; RT-PCR and Western,,,,,,human,mbds0003,v2007,2013-12-09 20:53:13
mbbd000139929,mbcd0000146,mbtp000005,mbrf0001265,,,,,inducer,,,,,arsenite,,,HepG2 cells; RT-PCR and Western,,,,,,human,mbds0003,v2007,2013-12-09 20:53:14
mbbd000139930,mbcd0023726,mbtp000005,mbrf0001265,,,,,inducer,,,,,tBHQ,,,HepG2 cells; RT-PCR and Western,,,,,,human,mbds0003,v2007,2013-12-09 19:56:39
mbbd000139931,mbcd0029402,mbtp000005,mbrf0002183,,~,,,inducer,97,132.0,%,7,TO901317,,,HepG2,HepG2,,0.1,microM,,human,mbds0010,,2013-10-15 18:48:45
mbbd000139932,mbcd0029403,mbtp000005,mbrf0002183,,~,,,inducer,97,168.0,%,31,25-Hydroxycholesterol,,,HepG2,HepG2,,25,microM,,human,mbds0010,,2013-10-15 18:48:45
mbbd000139933,mbcd0001532,mbtp000005,mbrf0002507,,=,,,substrate,85,23.0,,6,paclitaxel,,,MDCKII-MRP2; compound 5 microM; with 500 microM probenacid,MDCKII,,,,,human,mbds0010,,2013-11-24 23:11:30
mbbd000139934,mbcd0027726,mbtp000005,mbrf0002507,,>,,,substrate,104,5.0,fold,,docetaxel,,,MDCKII-MRP2; compound 5 microM; with 500 microM probenacid 5-fold increase; approx. 3-fold reduction in cellular accumulation of docetaxel,MDCKII,,,,,human,mbds0010,,2013-11-24 23:11:30
mbbd000139935,mbcd0003154,mbtp000005,mbrf0002507,,,,,stimulator,,,,,Probenecid,,,"MDCKII; enhanced MRP2-mediated transport of paclitaxel, docetaxel, etoposide and vinblastine",MDCKII,,,,,human,mbds0010,,2013-11-27 07:26:52
mbbd000139936,mbcd0002466,mbtp000005,mbrf0002507,,,,,substrate,,,,,etoposide,,,MDCKII,MDCKII,,,,,human,mbds0010,,2013-10-16 22:45:11
mbbd000139937,mbcd0001151,mbtp000005,mbrf0002507,,,,,substrate,,,,,vinblastine,,,MDCKII,MDCKII,,,,,human,mbds0010,,2013-10-16 22:45:11
mbbd000139938,mbcd0029405,mbtp000005,mbrf0001881,,,,,inducer,,,,,GA-Me,,,HCT-8 and HCT-116,,,,,,human,mbds0010,,2013-11-29 08:11:08
mbbd000139939,mbcd0002544,mbtp000005,mbrf0000084,,~,,,inhibitor,3,96.0,%,,Delavirdine,,,MDCKII,MDCKII,,16.7,microM,,human,mbds0010,,2013-10-15 01:43:05
mbbd000139940,mbcd0001868,mbtp000005,mbrf0000084,,~,,,inhibitor,3,85.0,%,,efavirenz,,,MDCKII,MDCKII,,10,microM,,human,mbds0010,,2013-10-15 01:42:53
mbbd000139941,mbcd0002339,mbtp000005,mbrf0000084,,~,,,inhibitor,3,38.0,%,,Nevirapine,,,MDCKII,MDCKII,,10,microM,,human,mbds0010,,2013-10-15 01:42:53
mbbd000139942,mbcd0003124,mbtp000005,mbrf0000084,,~,,,inhibitor,3,40.0,%,,Abacavir,,,MDCKII,MDCKII,,10,microM,,human,mbds0010,,2013-10-15 01:42:53
mbbd000139943,mbcd0003029,mbtp000005,mbrf0000084,,~,,,inhibitor,3,55.0,%,,Emtricitabine,,,MDCKII,MDCKII,,10,microM,,human,mbds0010,,2013-10-15 01:42:53
mbbd000139944,mbcd0002982,mbtp000005,mbrf0000084,,~,,,inhibitor,3,38.0,%,,Lamivudine,,,MDCKII,MDCKII,,10,microM,,human,mbds0010,,2013-10-15 01:42:53
mbbd000139945,mbcd0003028,mbtp000005,mbrf0000084,,~,,,inhibitor,3,40.0,%,,Tenofovir,,,MDCKII,MDCKII,,10,microM,,human,mbds0010,,2013-10-15 01:42:53
mbbd000139949,mbcd0003154,mbtp000005,mbrf0001269,,~,,,stimulator,138,5.3,fold increase,,Probenecid,increase in transport,,MDCKII,MDCKII,mbcd0001533,1,mM,,human,mbds0010,,2013-11-27 07:26:52
mbbd000139950,mbcd0002988,mbtp000005,mbrf0001269,,~,,,stimulator,138,2.0,fold increase,,Sulfinpyrazone,increase in transport,,MDCKII,MDCKII,mbcd0001533,5,mM,,human,mbds0010,,2013-11-27 07:26:52
mbbd000139951,mbcd0002494,mbtp000005,mbrf0001269,,,,,non-inhibitor,,,,,MK571,,,MDCKII,MDCKII,mbcd0001533,50,microM,,human,mbds0010,,2013-10-15 02:10:01
mbbd000139952,mbcd0029061,mbtp000005,mbrf0001269,,,,,non-inhibitor,,,,,L-BSO,,,MDCKII,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139953,mbcd0000721,mbtp000005,mbrf0001269,,,,,non-inhibitor,,,,,PSC833,,,MDCKII-MRP2; inhibition of transport of 5 microM saquinavir; compound 10 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139955,mbcd0002241,mbtp000005,mbrf0001803,,,,,substrate,,,,,lopinavir,,,PBMC,PBMCs,,,,,human,mbds0010,,2013-10-16 22:45:07
mbbd000139956,mbcd0001938,mbtp000005,mbrf0002276,,~,,,inducer,98,5.5,fold increase,2,ritonavir,increase in transcript,,Primary human hepatocytes,Primary human hepatocytes,,10,microM,,human,mbds0010,,2013-11-21 02:28:14
mbbd000139957,mbcd0026632,mbtp000005,mbrf0002276,,~,,,inducer,98,4.5,fold increase,2,Nelfinavir,increase in transcript,,Primary human hepatocytes,Primary human hepatocytes,,25,microM,,human,mbds0010,,2013-11-21 02:28:14
mbbd000139958,mbcd0001416,mbtp000005,mbrf0002276,,~,,,inducer,98,6.5,fold increase,1.5,Rifampin,increase in transcript,,Primary human hepatocytes,Primary human hepatocytes,,25,microM,,human,mbds0010,,2013-11-21 02:28:15
mbbd000139959,mbcd0003959,mbtp000005,mbrf0002048,,,,,substrate,,,,,folic acid,,,,,,,,,human,mbds0010,,2013-12-10 22:21:07
mbbd000139960,mbcd0000047,mbtp000005,mbrf0002048,,=,,,substrate,28,6.5,microM,,Dinitrophenyl-SG,,,,,,,,,human,mbds0010,,2014-01-27 21:28:32
mbbd000139961,mbcd0000627,mbtp000005,mbrf0002048,,,,,substrate,,,,,NNAL-O-glucuronide,,,,,,,,,human,mbds0010,,2013-12-11 05:30:00
mbbd000139962,mbcd0029395,mbtp000005,mbrf0002048,,,,,substrate,,,,,Morphine 3-glucuronide,,,,,,,,,human,mbds0010,,2014-01-27 21:28:32
mbbd000139963,mbcd0003012,mbtp000005,mbrf0002048,,,,,substrate,,,,,Acetaminophen glucuronide,,,,,,,,,human,mbds0010,,2013-12-10 22:21:07
mbbd000139964,mbcd0003110,mbtp000005,mbrf0001718,,,,,non-substrate,,,,,adefovir,,,HEK293 membrane vesicles,HEK293,,,,,human,mbds0010,,2013-10-16 22:45:06
mbbd000139965,mbcd0029406,mbtp000005,mbrf0001718,,,,,non-substrate,,,,,cidofovir,,,HEK293 membrane vesicles,HEK293,,,,,human,mbds0010,,2013-10-16 22:45:06
mbbd000139968,mbcd0029315,mbtp000005,mbrf0001665,,,,,substrate,,,,,NNK,,,MDCK,MDCK,,,,,human,mbds0010,,2013-11-10 04:22:14
mbbd000139969,mbcd0026020,mbtp000005,mbrf0002132,,,,,non-substrate,,,,,acetochlor,,,sf9 membrane vesicles,Sf9,,,,,human,mbds0010,,2013-10-16 22:45:06
mbbd000139970,mbcd0029408,mbtp000005,mbrf0002132,,,,,non-substrate,,,,,alachlor,,,sf9 membrane vesicles,Sf9,,,,,human,mbds0010,,2013-10-16 22:45:03
mbbd000139971,mbcd0029409,mbtp000005,mbrf0002132,,,,,non-substrate,,,,,dimetachlor,,,sf9 membrane vesicles,Sf9,,,,,human,mbds0010,,2013-10-17 22:52:35
mbbd000139972,mbcd0029410,mbtp000005,mbrf0002132,,,,,non-substrate,,,,,metazachlor,,,sf9 membrane vesicles,Sf9,,,,,human,mbds0010,,2013-10-16 22:45:03
mbbd000139973,mbcd0029411,mbtp000005,mbrf0002132,,,,,non-substrate,,,,,metolachlor,,,sf9 membrane vesicles,Sf9,,,,,human,mbds0010,,2013-10-16 22:45:03
mbbd000139974,mbcd0029412,mbtp000005,mbrf0002132,,,,,non-substrate,,,,,propachlor,,,sf9 membrane vesicles,Sf9,,,,,human,mbds0010,,2013-10-16 22:45:03
mbbd000139975,mbcd0029413,mbtp000005,mbrf0002132,,,,,non-substrate,,,,,prynachlor,,,sf9 membrane vesicles,Sf9,,,,,human,mbds0010,,2013-10-16 22:45:03
mbbd000139976,mbcd0029414,mbtp000005,mbrf0002132,,,,,non-substrate,,,,,acetochlor-GSH,,,sf9 membrane vesicles,Sf9,,,,,human,mbds0010,,2013-10-16 22:45:03
mbbd000139977,mbcd0029415,mbtp000005,mbrf0002132,,,,,non-substrate,,,,,acetochlor-Cys,,,sf9 membrane vesicles,Sf9,,,,,human,mbds0010,,2013-10-16 22:45:02
mbbd000139978,mbcd0029416,mbtp000005,mbrf0002132,,,,,non-substrate,,,,,2-chloro-N-(2-methyl-6-ethylphenyl)acetamide-SG,,,sf9 membrane vesicles,Sf9,,,,,human,mbds0010,,2013-10-16 22:45:02
mbbd000139979,mbcd0029417,mbtp000005,mbrf0002132,,,,,non-substrate,,,,,2-chloro-N-(2-methyl-6-ethylphenyl)acetamide-Cys,,,sf9 membrane vesicles,Sf9,,,,,human,mbds0010,,2013-10-16 22:45:02
mbbd000139980,mbcd0002985,mbtp000005,mbrf0001755,,,,,inducer,,,,,CBZ,,,Human liver,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000139981,mbcd0002959,mbtp000005,mbrf0002350,,~,,,non-inducer,97,100.0,%,,Dexamethasone,,,A549,A549,,1,microM,,human,mbds0010,,2013-10-29 23:28:49
mbbd000139982,mbcd0002635,mbtp000005,mbrf0002350,,~,,,non-inducer,97,110.0,%,,Hydrocortisone,,,A549,A549,,1,microM,,human,mbds0010,,2013-10-29 23:28:49
mbbd000139983,mbcd0003058,mbtp000005,mbrf0002350,,~,,,inducer,97,134.0,%,9,Prednisone,,,A549,A549,,200,nM,,human,mbds0010,,2013-10-15 18:48:44
mbbd000139984,mbcd0029418,mbtp000005,mbrf0001734,,,,,substrate,,,,,NIV,,,MDCKII,MDCKII,,,,,human,mbds0010,,2013-11-24 23:11:30
mbbd000139985,mbcd0002091,mbtp000005,mbrf0002195,,,,,non-substrate,,,,,CPT-11,,,HepG2,HepG2,,,,,human,mbds0010,,2013-11-24 23:55:24
mbbd000139986,mbcd0000779,mbtp000005,mbrf0002195,,,,,non-substrate,,,,,SN-38,,,HepG2,HepG2,,,,,human,mbds0010,,2013-11-24 23:55:24
mbbd000139987,mbcd0029766,mbtp000005,mbrf0001282,,,,,substrate,,,,,ZD1694,,,Human ovarian carcinoma 2008,OV2008,,,,,human,mbds0010,,2013-10-16 22:45:11
mbbd000139988,mbcd0029420,mbtp000005,mbrf0001282,,,,,substrate,,,,,GW1843,,,Human ovarian carcinoma 2008,OV2008,,,,,human,mbds0010,,2013-10-16 22:45:11
mbbd000139989,mbcd0002091,mbtp000005,mbrf0001896,,,,,substrate,,,,,CPT-11,,,MDCKII,MDCKII,,,,,human,mbds0010,,2013-11-24 23:11:31
mbbd000139990,mbcd0029395,mbtp000005,mbrf0002587,,,,,substrate,,,,,M3G,,,sf9 membrane vesicles,Sf9,,,,,human,mbds0010,,2013-11-24 23:54:44
mbbd000139991,mbcd0029421,mbtp000005,mbrf0002587,,,,,non-substrate,,,,,M6G,,,sf9 membrane vesicles,Sf9,,,,,human,mbds0010,,2013-11-24 23:54:45
mbbd000139992,mbcd0029422,mbtp000005,mbrf0002585,,,,,substrate,,,,,gemifloxacin,,,MDCKII,MDCKII,,,,,human,mbds0010,,2013-10-16 22:45:10
mbbd000139993,mbcd0000029,mbtp000005,mbrf0002363,,=,,,repressor,111,19.0,%,,1-Monopalmitin,decrease in protein level,,Caco-2,Caco-2,,,,,human,mbds0010,,2013-10-15 01:42:38
mbbd000139994,mbcd0000031,mbtp000005,mbrf0002363,,=,,,repressor,111,35.0,%,,1-Monostearin,decrease in protein level,,Caco-2,Caco-2,,,,,human,mbds0010,,2013-10-15 01:42:37
mbbd000139995,mbcd0000028,mbtp000005,mbrf0002363,,,,,non-inducer,,,,,1-Monoolein,,,Caco-2,Caco-2,,,,,human,mbds0010,,2013-10-15 00:41:50
mbbd000139996,mbcd0003040,mbtp000005,mbrf0002494,,=,,,inhibitor,25,24.6,microM,1.3,Myricetin,,,MDCKII; inhibited MRP2-mediated vincristine transport,MDCKII,mbcd0029351,,,,human,mbds0010,,2013-11-24 07:53:10
mbbd000139997,mbcd0003622,mbtp000005,mbrf0002267,,,,,substrate,,,,,Ampicillin,,,,,,,,,human,mbds0010,,2013-12-10 22:21:07
mbbd000139998,mbcd0028157,mbtp000005,mbrf0002267,,,,,substrate,,,,,Azithromycin,,,,,,,,,human,mbds0010,,2013-12-10 22:21:07
mbbd000139999,mbcd0028157,mbtp000005,mbrf0002267,,,,,inhibitor,,,,,Azithromycin,,,,,,,,,human,mbds0010,,2013-12-10 22:21:07
mbbd000140000,mbcd0000231,mbtp000005,mbrf0002267,,,,,substrate,,,,,Cefodizime,,,,,,,,,human,mbds0010,,2013-12-10 22:21:07
mbbd000140001,mbcd0003773,mbtp000005,mbrf0002267,,,,,substrate,,,,,Ceftriaxone,,,,,,,,,human,mbds0010,,2013-12-10 22:21:07
mbbd000140002,mbcd0020601,mbtp000005,mbrf0002267,,,,,substrate,,,,,Camptothecin,,,,,,,,,human,mbds0010,,2013-12-10 22:21:07
mbbd000140003,mbcd0027733,mbtp000005,mbrf0002267,,,,,inhibitor,,,,,Lonafarnib,,,,,,,,,human,mbds0010,,2013-12-10 22:21:07
mbbd000140004,mbcd0003074,mbtp000005,mbrf0002267,,,,,inhibitor,,,,,Glibenclamide,,,,,,,,,human,mbds0010,,2013-12-10 22:21:07
mbbd000140005,mbcd0003110,mbtp000005,mbrf0002267,,,,,substrate,,,,,Adefovir,,,,,,,,,human,mbds0010,,2013-12-10 22:21:07
mbbd000140006,mbcd0029406,mbtp000005,mbrf0002267,,,,,substrate,,,,,Cidofovir,,,,,,,,,human,mbds0010,,2013-12-10 22:21:07
mbbd000140007,mbcd0026632,mbtp000005,mbrf0002267,,,,,substrate,,,,,Nelfinavir,,,,,,,,,human,mbds0010,,2013-12-10 22:21:07
mbbd000140008,mbcd0000824,mbtp000005,mbrf0002267,,,,,substrate,,,,,Temocaprilate,,,,,,,,,human,mbds0010,,2013-12-10 22:21:07
mbbd000140009,mbcd0003008,mbtp000005,mbrf0002267,,,,,substrate,,,,,Valproate,,,,,,,,,human,mbds0010,,2013-12-10 22:21:07
mbbd000140010,mbcd0003120,mbtp000005,mbrf0002555,,=,,,inhibitor,3,35.0,%,8,Quercetin,,,sf9 membrane vesicles,sf9,mbcd0029351,20,microM,,human,mbds0010,,2013-10-15 18:48:43
mbbd000140011,mbcd0001628,mbtp000005,mbrf0002555,,~,,,non-inhibitor,100,93.0,%,8,Rutin,,,sf9 membrane vesicles,sf9,mbcd0029351,,,,human,mbds0010,,2013-10-15 18:48:43
mbbd000140012,mbcd0003206,mbtp000005,mbrf0002555,,~,,,non-inhibitor,100,84.0,%,18,isoquercitrin,,,sf9 membrane vesicles,sf9,mbcd0029351,,,,human,mbds0010,,2013-10-15 18:48:43
mbbd000140013,mbcd0004718,mbtp000005,mbrf0002555,,,,,inducer,,,,,4'-O-methylquercetin,,,sf9 membrane vesicles,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140014,mbcd0004713,mbtp000005,mbrf0002555,,,,,inhibitor,,,,,3'-O-methylquercetin,,,sf9 membrane vesicles,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140015,mbcd0000800,mbtp000005,mbrf0002121,,,,,inducer,,,,,SF,,,HepG2 and Caco-2,,,,,,human,mbds0010,,2013-12-09 21:00:32
mbbd000140016,mbcd0029423,mbtp000005,mbrf0002121,,,,,inducer,,,,,ER,,,HepG2 and Caco-2,,,,,,human,mbds0010,,2013-12-09 21:00:32
mbbd000140017,mbcd0029424,mbtp000005,mbrf0002354,,,,,inducer,,,,,4PBA,,,MDCKII,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140018,mbcd0001612,mbtp000005,mbrf0002564,,,,,inducer,,,,,UDCA,,,Human cystic bile and duodenal tissue,Human cystic bile and duodenal tissue,,,,,human,mbds0010,,2013-10-15 21:36:29
mbbd000140019,mbcd0003043,mbtp000005,mbrf0001923,,,,,non-substrate,,,,,methotrexate,,,Xenopus laevis oocytes,Xenopus laevis oocytes,,1; 10; 100,microM,,human,mbds0010,,2014-02-25 06:18:51
mbbd000140020,mbcd0029425,mbtp000005,mbrf0002112,,,,,substrate,,,,,ezetimibe glucuronide,,,MDCK,MDCK,,,,,human,mbds0010,,2013-11-10 04:22:14
mbbd000140021,mbcd0002466,mbtp000005,mbrf0002112,,,,,substrate,,,,,etoposide,,,MDCK,MDCK,,,,,human,mbds0010,,2013-11-10 04:22:14
mbbd000140022,mbcd0029339,mbtp000005,mbrf0002162,,,,,non-substrate,,,,,EE2-Sul,,,sf9 membrane vesicles,Sf9,,,,,human,mbds0010,,2013-11-24 23:54:46
mbbd000140023,mbcd0001416,mbtp000005,mbrf0002333,,,,,inducer,,,,,RIF,,,Primary human hepatocytes,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140024,mbcd0003007,mbtp000005,mbrf0002333,,,,,inducer,,,,,PB,,,Primary human hepatocytes,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140025,mbcd0013564,mbtp000005,mbrf0002333,,,,,inducer,,,,,OPZ,,,Primary human hepatocytes,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140026,mbcd0003129,mbtp000005,mbrf0001738,,,,,substrate,,,,,PEITC,,,MDCKII,MDCKII,,,,,human,mbds0010,,2013-11-24 23:11:31
mbbd000140027,mbcd0000311,mbtp000005,mbrf0002391,,,,,substrate,,,,,CyA,,,Caco-2,Caco-2,,,,,human,mbds0010,,2013-11-24 23:12:25
mbbd000140028,mbcd0003126,mbtp000005,mbrf0002391,,~,,,inhibitor,1,20.0,%,10,Pravastatin,,,Caco-2; inhibited MRP2-mediated cyclosporin A transport,Caco-2,mbcd0000311,,,,human,mbds0010,,2013-11-24 07:53:10
mbbd000140029,mbcd0003120,mbtp000005,mbrf0002493,,=,,,inhibitor,25,7.3,microM,1.1,Quercetin,,,sf9 membrane vesicles; inhibition of MRP2-mediated LTC4 transport,sf9,mbcd0002917,,,,human,mbds0010,,2013-10-15 22:12:51
mbbd000140030,mbcd0003120,mbtp000005,mbrf0002493,,=,,,inhibitor,25,22.1,microM,2.3,Quercetin,,,sf9 membrane vesicles; inhibited MRP2-mediated CDCF transport,sf9,mbcd0029372,,,,human,mbds0010,,2013-10-30 00:00:36
mbbd000140031,mbcd0003120,mbtp000005,mbrf0002493,,=,,,inhibitor,25,7.3,microM,1.98,Quercetin,,,sf9 membrane vesicles; inhibition of MRP2-mediated E217betaG transport,sf9,mbcd0000387,,,,human,mbds0010,,2013-10-15 22:13:07
mbbd000140032,mbcd0003141,mbtp000005,mbrf0002493,,>,,,non-inhibitor,25,100.0,microM,,Disopyramide,,,sf9 membrane vesicles; LTC4 substrate; no activity,sf9,mbcd0002917,,,,human,mbds0010,,2013-10-30 00:00:35
mbbd000140033,mbcd0003872,mbtp000005,mbrf0002493,,,,,non-inhibitor,,,,,Paracetamol,,,sf9 membrane vesicles; LTC4 substrate; no activity,sf9,mbcd0002917,,,,human,mbds0010,,2013-10-30 00:00:35
mbbd000140034,mbcd0003025,mbtp000005,mbrf0002493,,=,,,inhibitor,25,243.6,microM,23.8,indomethacin,,,sf9 membrane vesicles; inhibited MRP2-mediated LTC4 transport,sf9,mbcd0002917,,,,human,mbds0010,,2013-10-30 00:00:36
mbbd000140035,mbcd0003025,mbtp000005,mbrf0002493,,=,,,inhibitor,25,75.7,microM,12.9,indomethacin,,,sf9 membrane vesicles; inhibited MRP2-mediated CDCF transport,sf9,mbcd0029372,,,,human,mbds0010,,2013-10-30 00:00:36
mbbd000140036,mbcd0003025,mbtp000005,mbrf0002493,,,,,stimulator,,,,,indomethacin,,,sf9 membrane vesicles; enhancedMRP2-mediated E217betaG transport,sf9,mbcd0000387,,,,human,mbds0010,,2013-11-27 07:26:52
mbbd000140037,mbcd0003113,mbtp000005,mbrf0002493,,=,,,inhibitor,25,233.6,microM,47.5,Diclofenac,,,sf9 membrane vesicles; inhibited MRP2-mediated LTC4 transport,sf9,mbcd0002917,,,,human,mbds0010,,2013-10-30 00:00:36
mbbd000140038,mbcd0003113,mbtp000005,mbrf0002493,,=,,,inhibitor,25,177.3,microM,15.0,Diclofenac,,,sf9 membrane vesicles; inhibited MRP2-mediated CDCF transport,sf9,mbcd0029372,,,,human,mbds0010,,2013-10-30 00:00:36
mbbd000140039,mbcd0003113,mbtp000005,mbrf0002493,,,,,stimulator,,,,,Diclofenac,,,sf9 membrane vesicles; enhancedMRP2-mediated E217betaG transport,sf9,mbcd0000387,,,,human,mbds0010,,2013-11-27 07:26:52
mbbd000140040,mbcd0003075,mbtp000005,mbrf0002493,,=,,,inhibitor,25,97.9,microM,19.4,Estrone-3-sulfate,,,sf9 membrane vesicles; inhibited MRP2-mediated LTC4 transport,sf9,mbcd0002917,,,,human,mbds0010,,2013-10-30 00:00:35
mbbd000140041,mbcd0003075,mbtp000005,mbrf0002493,,=,,,inhibitor,25,122.2,microM,11.4,Estrone-3-sulfate,,,sf9 membrane vesicles; inhibited MRP2-mediated CDCF transport,sf9,mbcd0029372,,,,human,mbds0010,,2013-10-30 00:00:35
mbbd000140042,mbcd0003075,mbtp000005,mbrf0002493,,,,,stimulator,,,,,Estrone-3-sulfate,,,sf9 membrane vesicles; enhancedMRP2-mediated E217betaG transport,sf9,mbcd0000387,,,,human,mbds0010,,2013-11-27 07:26:52
mbbd000140043,mbcd0001527,mbtp000005,mbrf0002493,,,,,non-inhibitor,,,,,budesonide,,,sf9 membrane vesicles; LTC4 substrate; no activity,sf9,mbcd0002917,,,,human,mbds0010,,2013-10-30 00:00:35
mbbd000140044,mbcd0001527,mbtp000005,mbrf0002493,,,,,stimulator,,,,,budesonide,,,sf9 membrane vesicles; enhancedMRP2-mediated CDCF transport,sf9,mbcd0029372,,,,human,mbds0010,,2013-11-27 07:26:52
mbbd000140045,mbcd0001527,mbtp000005,mbrf0002493,,=,,,inhibitor,25,60.3,microM,6.1,budesonide,,,sf9 membrane vesicles; inhibited MRP2-mediated E217betaG transport,sf9,mbcd0000387,,,,human,mbds0010,,2013-10-30 00:00:35
mbbd000140046,mbcd0003143,mbtp000005,mbrf0002493,,>,,,non-inhibitor,25,1000.0,microM,,Thioridazine,,,sf9 membrane vesicles; LTC4 substrate; no activity,sf9,mbcd0002917,,,,human,mbds0010,,2013-10-30 00:00:35
mbbd000140047,mbcd0003143,mbtp000005,mbrf0002493,,,,,stimulator,,,,,Thioridazine,,,sf9 membrane vesicles; enhancedMRP2-mediated CDCF transport,sf9,mbcd0029372,,,,human,mbds0010,,2013-11-27 07:26:52
mbbd000140048,mbcd0003143,mbtp000005,mbrf0002493,,=,,,inhibitor,25,40.9,microM,7.2,Thioridazine,,,sf9 membrane vesicles; inhibited MRP2-mediated E217betaG transport,sf9,mbcd0000387,,,,human,mbds0010,,2013-10-30 00:00:35
mbbd000140049,mbcd0003137,mbtp000005,mbrf0001927,,,,,stimulator,,,,,furosemide; FR,,,sf9 membrane vesicles; enhancedMRP2-mediated E217betaG transport,Sf9,mbcd0000387,,,,human,mbds0010,,2013-11-27 07:26:52
mbbd000140050,mbcd0003154,mbtp000005,mbrf0001927,,,,,stimulator,,,,,probenecid; PR,,,sf9 membrane vesicles; enhancedMRP2-mediated E217betaG transport,Sf9,mbcd0000387,,,,human,mbds0010,,2013-11-27 07:26:52
mbbd000140051,mbcd0003025,mbtp000005,mbrf0001927,,,,,stimulator,,,,,indomethacin; IM,,,sf9 membrane vesicles; enhancedMRP2-mediated E217betaG transport,Sf9,mbcd0000387,,,,human,mbds0010,,2013-11-27 07:26:52
mbbd000140052,mbcd0000455,mbtp000005,mbrf0001927,,,,,stimulator,,,,,GC,,,sf9 membrane vesicles; enhanced MRP2-mediated E217betaG transport,,,,,,human,mbds0010,,2013-11-27 07:26:52
mbbd000140053,mbcd0001635,mbtp000005,mbrf0001927,,,,,stimulator,,,,,GCDC,,,sf9 membrane vesicles; enhanced MRP2-mediated E217betaG transport,,,,,,human,mbds0010,,2013-11-27 07:26:52
mbbd000140054,mbcd0000817,mbtp000005,mbrf0001927,,,,,stimulator,,,,,TDC,,,sf9 membrane vesicles; enhanced MRP2-mediated E217betaG transport,,,,,,human,mbds0010,,2013-11-27 07:26:52
mbbd000140055,mbcd0000815,mbtp000005,mbrf0001927,,,,,stimulator,,,,,TCDC,,,sf9 membrane vesicles; enhanced MRP2-mediated E217betaG transport,,,,,,human,mbds0010,,2013-11-27 07:26:52
mbbd000140056,mbcd0000455,mbtp000005,mbrf0001927,,=,,,substrate,28,175.0,microM,25,GC,,,sf9 membrane vesicles,Sf9,,,,,human,mbds0010,,2013-11-24 23:54:47
mbbd000140057,mbcd0029372,mbtp000005,mbrf0002502,,,,,substrate,,,,,CDCF,,,sf9 membrane vesicles,Sf9,,,,,human,mbds0010,,2013-11-24 23:54:47
mbbd000140058,mbcd0001280,mbtp000005,mbrf0002502,,=,,,inhibitor,29,25.0,microM,15,Sulfasalazine,,,sf9 membrane vesicles; inhibited MRP2-mediated LTC4 transport,sf9,mbcd0002917,,,,human,mbds0010,,2013-11-24 07:53:08
mbbd000140059,mbcd0001280,mbtp000005,mbrf0002502,,=,,,inhibitor,29,16.0,microM,6,Sulfasalazine,,,sf9 membrane vesicles; inhibited MRP2-mediated CDCF transport,sf9,mbcd0029372,,,,human,mbds0010,,2013-11-24 07:53:08
mbbd000140060,mbcd0003034,mbtp000005,mbrf0002502,,=,,,inhibitor,29,24.0,microM,6,Benzbromarone,,,sf9 membrane vesicles; inhibited MRP2-mediated LTC4 transport,sf9,mbcd0002917,,,,human,mbds0010,,2013-11-24 07:53:09
mbbd000140061,mbcd0003034,mbtp000005,mbrf0002502,,=,,,inhibitor,29,4.4,microM,1.3,Benzbromarone,,,sf9 membrane vesicles; inhibited MRP2-mediated CDCF transport,sf9,mbcd0029372,,,,human,mbds0010,,2013-11-24 07:53:08
mbbd000140062,mbcd0000387,mbtp000005,mbrf0002502,,=,,,inhibitor,25,60.0,microM,18,E217betaG,,,sf9 membrane vesicles,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140063,mbcd0003113,mbtp000005,mbrf0002502,,=,,,inhibitor,25,95.0,microM,22,Diclofenac,,,sf9 membrane vesicles,sf9,mbcd0029372,,,,human,mbds0010,,2013-10-15 02:10:35
mbbd000140064,mbcd0001175,mbtp000005,mbrf0002502,,=,,,inhibitor,25,80.0,microM,13,Sulindac,,,sf9 membrane vesicles,sf9,mbcd0029372,,,,human,mbds0010,,2013-10-15 02:10:33
mbbd000140065,mbcd0000311,mbtp000005,mbrf0002502,,=,,,inhibitor,25,5.5,microM,2.4,Cyclosporin A,,,sf9 membrane vesicles,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140066,mbcd0003073,mbtp000005,mbrf0002502,,=,,,inhibitor,25,341.0,microM,87,piroxicam,,,sf9 membrane vesicles,sf9,mbcd0029372,,,,human,mbds0010,,2013-10-15 02:09:52
mbbd000140067,mbcd0003050,mbtp000005,mbrf0002502,,=,,,inhibitor,25,735.0,microM,194,taurocholate,,,sf9 membrane vesicles,sf9,mbcd0029372,,,,human,mbds0010,,2013-10-15 02:10:33
mbbd000140068,mbcd0003033,mbtp000005,mbrf0002502,,=,,,inhibitor,25,40.0,microM,9,Baicalin,,,sf9 membrane vesicles,sf9,mbcd0029372,,,,human,mbds0010,,2013-10-15 02:09:50
mbbd000140069,mbcd0000749,mbtp000005,mbrf0002502,,=,,,inhibitor,25,30.0,microM,14,Rifamycin SV,,,sf9 membrane vesicles,sf9,mbcd0029372,,,,human,mbds0010,,2013-10-15 02:10:14
mbbd000140070,mbcd0003137,mbtp000005,mbrf0002502,,=,,,inhibitor,25,249.0,microM,125,Furosemide,,,sf9 membrane vesicles,sf9,mbcd0029372,,,,human,mbds0010,,2013-10-15 02:10:01
mbbd000140071,mbcd0003043,mbtp000005,mbrf0002502,,=,,,inhibitor,25,2955.0,microM,951,Methotrexate,,,sf9 membrane vesicles,sf9,mbcd0029372,,,,human,mbds0010,,2013-10-15 02:09:21
mbbd000140072,mbcd0003035,mbtp000005,mbrf0002502,,=,,,inhibitor,25,4.6,microM,1.1,Bromosulfophtalein,,,sf9 membrane vesicles,sf9,mbcd0029372,,,,human,mbds0010,,2013-10-15 02:09:21
mbbd000140073,mbcd0003074,mbtp000005,mbrf0002502,,=,,,inhibitor,25,57.0,microM,19,Glybenclamide,,,sf9 membrane vesicles,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140074,mbcd0003012,mbtp000005,mbrf0002502,,=,,,inhibitor,25,559.0,microM,110,Acetaminophen-glucuronide,,,sf9 membrane vesicles,sf9,mbcd0029372,,,,human,mbds0010,,2013-10-15 02:09:31
mbbd000140075,mbcd0003013,mbtp000005,mbrf0002502,,=,,,inhibitor,25,412.0,microM,144,Ibuprofen,,,sf9 membrane vesicles,sf9,mbcd0029372,,,,human,mbds0010,,2013-10-15 02:09:21
mbbd000140076,mbcd0003116,mbtp000005,mbrf0002502,,=,,,inhibitor,25,64.0,microM,12,Genistein,,,sf9 membrane vesicles,sf9,mbcd0029372,,,,human,mbds0010,,2013-10-15 02:09:31
mbbd000140077,mbcd0002985,mbtp000005,mbrf0001941,,,,,non-substrate,,,,,carbamazepine; CBZ,,,MDCKII,MDCKII,,,,,human,mbds0010,,2013-10-16 22:45:04
mbbd000140078,mbcd0003008,mbtp000005,mbrf0001941,,,,,non-substrate,,,,,VPA,,,MDCKII,MDCKII,,,,,human,mbds0010,,2013-10-16 22:45:04
mbbd000140079,mbcd0001511,mbtp000005,mbrf0001941,,,,,non-substrate,,,,,levetiracetam; LEV,,,MDCKII,MDCKII,,,,,human,mbds0010,,2013-10-16 22:45:04
mbbd000140080,mbcd0002996,mbtp000005,mbrf0001941,,,,,non-substrate,,,,,phenytoin; PHT,,,MDCKII,MDCKII,,,,,human,mbds0010,,2013-10-16 22:45:10
mbbd000140081,mbcd0013986,mbtp000005,mbrf0001941,,,,,non-substrate,,,,,lamotrigine; LTG,,,MDCKII,MDCKII,,,,,human,mbds0010,,2013-10-16 22:45:10
mbbd000140082,mbcd0003007,mbtp000005,mbrf0001941,,,,,non-substrate,,,,,phenobarbital; PB,,,MDCKII,MDCKII,,,,,human,mbds0010,,2013-10-16 22:45:11
mbbd000140083,mbcd0029239,mbtp000005,mbrf0002257,,,,,substrate,,,,,gatifloxacin,,,MDCK,MDCK,,,,,human,mbds0010,,2013-11-10 04:22:15
mbbd000140084,mbcd0029350,mbtp000005,mbrf0001814,,~,,,repressor,117,80.0,%,2,Epi; epirubicin,,,Gene expression was calculated as a ratio of the band intensity of the studied gene to that in the internal standard (GAPDH),Caco-2,,10,microg mL-1,,human,mbds0010,,2013-10-18 19:02:20
mbbd000140085,mbcd0000455,mbtp000005,mbrf0001814,,~,,,repressor,117,55.0,%,1,GC; glycocholic acid,,,Gene expression was calculated as a ratio of the band intensity of the studied gene to that in the internal standard (GAPDH),Caco-2,,10,microg mL-1,,human,mbds0010,,2013-10-18 19:02:22
mbbd000140086,mbcd0002494,mbtp000005,mbrf0002518,,=,,,inhibitor,25,22.8,microM,,MK571,,,sf9 membrane vesicles,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140087,mbcd0017980,mbtp000005,mbrf0001656,,,,,non-substrate,,,,,ciprofloxacin,,,MDCKII,MDCKII,,,,,human,mbds0010,,2013-10-16 22:45:10
mbbd000140088,mbcd0029149,mbtp000005,mbrf0001700,,>,,,non-inhibitor,25,100.0,microM,,CI-1034,,,MDCK,MDCK,mbcd0000212,,,,human,mbds0010,,2013-10-15 18:48:42
mbbd000140089,mbcd0029149,mbtp000005,mbrf0001700,,=,,,inducer,97,510.0,%,100,CI-1034,,,human hepatocytes,human hepatocytes,,,,,human,mbds0010,,2013-10-15 18:48:42
mbbd000140090,mbcd0013555,mbtp000005,mbrf0001700,,,,,non-inducer,,,,,3MC,,,MDCK,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140091,mbcd0022340,mbtp000005,mbrf0001700,,,,,inducer,,,,,beta-NF,,,MDCK,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140092,mbcd0003007,mbtp000005,mbrf0001700,,=,,,inducer,97,196.0,%,40,PB,,,human hepatocytes,human hepatocytes,,,,,human,mbds0010,,2013-10-15 18:48:43
mbbd000140093,mbcd0001416,mbtp000005,mbrf0001700,,=,,,inducer,97,822.0,%,27,Rifampin,,,human hepatocytes,human hepatocytes,,,,,human,mbds0010,,2013-10-15 18:48:43
mbbd000140094,mbcd0029428,mbtp000005,mbrf0002567,,,,,non-substrate,,,,,GA,,,Caco2,Caco-2,,,,,human,mbds0010,,2013-11-24 23:12:26
mbbd000140095,mbcd0029429,mbtp000005,mbrf0002567,,,,,non-substrate,,,,,3-OH-GA,,,Caco2,Caco-2,,,,,human,mbds0010,,2013-11-24 23:12:26
mbbd000140096,mbcd0029430,mbtp000005,mbrf0002567,,,,,non-substrate,,,,,MMA,,,Caco2,Caco-2,,,,,human,mbds0010,,2013-11-24 23:12:26
mbbd000140097,mbcd0003139,mbtp000005,mbrf0001859,,,,,substrate,,,,,taxifolin,,,Caco-2,Caco-2,,,,,human,mbds0010,,2013-10-16 22:45:03
mbbd000140098,mbcd0005483,mbtp000005,mbrf0002583,,,,,non-inhibitor,,,,,IMA,,,Caco-2,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140099,mbcd0017104,mbtp000005,mbrf0002583,,~,,,inhibitor,100,305.0,%,25,Ketoconazole,,,Caco-2,Caco-2,mbcd0000640,,,,human,mbds0010,,2013-10-15 18:48:43
mbbd000140100,mbcd0001056,mbtp000005,mbrf0001741,,,,,substrate,,,,,sorafenib,,,LLCPK1,LLC-PK1,,,,,human,mbds0010,,2013-10-16 22:45:05
mbbd000140101,mbcd0027319,mbtp000005,mbrf0001741,,,,,non-substrate,,,,,sunitinib,,,LLCPK1,LLC-PK1,,,,,human,mbds0010,,2013-10-16 22:45:05
mbbd000140102,mbcd0029431,mbtp000005,mbrf0002265,,,,,inducer,,,,,4,,,HEK293,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140103,mbcd0002867,mbtp000005,mbrf0002265,,,,,inducer,,,,,11,,,HEK293,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140104,mbcd0029433,mbtp000005,mbrf0002265,,,,,inducer,,,,,12,,,HEK293,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140105,mbcd0029434,mbtp000005,mbrf0002265,,,,,inducer,,,,,13,,,HEK293,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140106,mbcd0029435,mbtp000005,mbrf0002265,,,,,inducer,,,,,14,,,HEK293,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140107,mbcd0029436,mbtp000005,mbrf0002265,,,,,inducer,,,,,15,,,HEK293,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140108,mbcd0029437,mbtp000005,mbrf0002265,,,,,inducer,,,,,16,,,HEK293,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140109,mbcd0029438,mbtp000005,mbrf0002265,,,,,inducer,,,,,17,,,HEK293,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140110,mbcd0029439,mbtp000005,mbrf0002265,,,,,non-inducer,,,,,23,,,HEK293,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140111,mbcd0002336,mbtp000005,mbrf0002265,,=,,,stimulator,33,513.0,%,,rimonabant,,,HEK293,HEK293,mbcd0000387,4,microM,,human,mbds0010,,2013-11-27 07:26:52
mbbd000140112,mbcd0029440,mbtp000005,mbrf0001829,,,,,inhibitor,,,,,CA-3-O-glucuronide,Supporting information,,sf9 membrane vesicles,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140113,mbcd0029441,mbtp000005,mbrf0001829,,,,,inhibitor,,,,,CA-4-O-glucuronide,Supporting information,,sf9 membrane vesicles,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140114,mbcd0029442,mbtp000005,mbrf0001829,,,,,inhibitor,,,,,CA-3-O-sulfate,Supporting information,,sf9 membrane vesicles,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140115,mbcd0029443,mbtp000005,mbrf0001829,,,,,non-inhibitor,,,,,CA-4-O-sulfate,Supporting information,,sf9 membrane vesicles,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140116,mbcd0029444,mbtp000005,mbrf0001829,,,,,inhibitor,,,,,DHCA-3-O-glucuronide,Supporting information,,sf9 membrane vesicles,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140117,mbcd0029445,mbtp000005,mbrf0001829,,,,,inhibitor,,,,,DHCA-4-O-glucuronide,Supporting information,,sf9 membrane vesicles,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140118,mbcd0029446,mbtp000005,mbrf0001829,,,,,non-inhibitor,,,,,DHCA-3-O-sulfate,Supporting information,,sf9 membrane vesicles,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140119,mbcd0029447,mbtp000005,mbrf0001829,,,,,non-inhibitor,,,,,DHCA-4-O-sulfate,Supporting information,,sf9 membrane vesicles,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140120,mbcd0029448,mbtp000005,mbrf0001829,,,,,inhibitor,,,,,DHFA-4-O-glucuronide,Supporting information,,sf9 membrane vesicles,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140121,mbcd0029449,mbtp000005,mbrf0001829,,,,,non-inhibitor,,,,,DHFA-4-O-sulfate,Supporting information,,sf9 membrane vesicles,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140122,mbcd0029450,mbtp000005,mbrf0001829,,,,,non-inhibitor,,,,,FA-4-O-glucuronide,Supporting information,,sf9 membrane vesicles,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140123,mbcd0029451,mbtp000005,mbrf0001829,,,,,non-inhibitor,,,,,FA-4-O-sulfate,Supporting information,,sf9 membrane vesicles,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140124,mbcd0029453,mbtp000005,mbrf0001829,,,,,inhibitor,,,,,IA-3-O-glucuornide,Supporting information,,sf9 membrane vesicles,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140125,mbcd0029452,mbtp000005,mbrf0001829,,,,,non-inhibitor,,,,,IA-3-O-sulfate,Supporting information,,sf9 membrane vesicles,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140126,mbcd0003033,mbtp000005,mbrf0002443,,,,,inhibitor,,,,,BG,,,Caco-2,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140127,mbcd0029454,mbtp000005,mbrf0001716,,,,,substrate,,,,,DMXAA-G,,,Caco-2,Caco-2,,,,,human,mbds0010,,2013-11-24 23:12:27
mbbd000140128,mbcd0000100,mbtp000005,mbrf0001321,,,,,non-substrate,,,,,9-AC,,,MDCKII,MDCKII,,,,,human,mbds0010,,2013-11-24 23:11:31
mbbd000140129,mbcd0029455,mbtp000005,mbrf0001321,,,,,non-substrate,,,,,9-NC,,,MDCKII,MDCKII,,,,,human,mbds0010,,2013-11-24 23:11:31
mbbd000140130,mbcd0029456,mbtp000005,mbrf0001855,,,,,substrate,,,,,H7G,,,sf9 membrane vesicles,Sf9,,,,,human,mbds0010,,2013-11-24 23:54:47
mbbd000140131,mbcd0029457,mbtp000005,mbrf0001855,,,,,substrate,,,,,H3'G,,,sf9 membrane vesicles,Sf9,,,,,human,mbds0010,,2013-11-24 23:54:47
mbbd000140132,mbcd0029458,mbtp000005,mbrf0002462,,,,,substrate,,,,,5GG,,,Caco-2,Caco-2,,,,,human,mbds0010,,2013-11-24 23:12:27
mbbd000140135,mbcd0003074,mbtp000005,mbrf0001293,,,,,inhibitor,,,,,glyburide,,,MDCK,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140136,mbcd0003074,mbtp000005,mbrf0001293,,,,,non-substrate,,,,,glyburide,,,MDCK,MDCK,,,,,human,mbds0010,,2013-11-24 23:11:31
mbbd000140137,mbcd0004903,mbtp000009,mbrf0002137,,,,,inhibitor,,,,,4-aminomethylbenzoic acid,,,Caco-2 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140138,mbcd0003552,mbtp000009,mbrf0002137,,=,,,substrate,88,43.5,pmol oocyte-1 (40 min)-1,3.8,ALA,,,pH 5.5,Xenopus laevis oocytes,,100,microM,,human,mbds0010,,2013-10-09 22:18:44
mbbd000140139,mbcd0004903,mbtp000009,mbrf0002137,,=,,,inhibitor,25,4.4,mM,1.5,AMBA; 4-Aminomethylbenzoic acid,,,Xenopus laevis oocytes,Xenopus laevis oocytes,mbcd0003494,0.1-40,mM,,human,mbds0010,,2013-11-10 04:15:56
mbbd000140140,mbcd0030510,mbtp000005,mbrf0001744,,,,,substrate,,,,,Enniatin B1; EBB-B1,,,Caco-2 cell line and MDCK II cells over-expressing Pgp,Caco-2,,,,,human,mbds0010,,2013-12-10 22:19:00
mbbd000140141,mbcd0001248,mbtp000009,mbrf0001939,,,,,non-substrate,,,,,Mannitol,,,transfected MDCK-hPept1 cells,MDCK,,,,,human,mbds0010,,2013-11-24 23:11:32
mbbd000140142,mbcd0003553,mbtp000009,mbrf0001939,,~,,,substrate,23,30.0,nm/sec,,Cephradine,,,stably transfected MDCK-hPept1 cells,MDCK,,,,,human,mbds0010,,2013-11-24 23:11:32
mbbd000140143,mbcd0003618,mbtp000009,mbrf0001939,,~,,,substrate,23,27.0,nm/sec,2,Cefalexin,,,stably transfected MDCK-hPept1 cells,MDCK,,,,,human,mbds0010,,2013-11-24 23:11:32
mbbd000140144,mbcd0001472,mbtp000009,mbrf0001939,,~,,,substrate,23,57.0,nm/sec,4,Cefadroxil,,,stably transfected MDCK-hPept1 cells,MDCK,,,,,human,mbds0010,,2013-11-24 23:11:32
mbbd000140145,mbcd0003061,mbtp000009,mbrf0001939,,~,,,substrate,23,27.0,nm/sec,1,Lisinopril,,,stably transfect MDCK-hPept1 cells,MDCK,,,,,human,mbds0010,,2013-11-24 23:11:33
mbbd000140146,mbcd0003733,mbtp000009,mbrf0001939,,~,,,substrate,23,30.0,nm/sec,3,Cifixime,,,staby transfect MDCK-hPept1 cells,MDCK,,,,,human,mbds0010,,2013-11-24 23:11:33
mbbd000140147,mbcd0001298,mbtp000009,mbrf0001939,,~,,,substrate,23,36.0,nm/sec,5,Cefaclor,,,stably transfected MDCK-hPept1 cells,MDCK,,,,,human,mbds0010,,2013-11-24 23:11:33
mbbd000140148,mbcd0003494,mbtp000009,mbrf0001939,,~,,,substrate,23,125.0,nm/sec,4,Gly-Sar,,,stably transfect MDCK-hPept1 cells,MDCK,,,,,human,mbds0010,,2013-11-24 23:11:33
mbbd000140149,mbcd0002822,mbtp000009,mbrf0001939,,~,,,substrate,23,116.0,nm/sec,12,Metoprolol,,,stably transfect MDCK-hPept1 cells,MDCK,,,,,human,mbds0010,,2013-11-24 23:11:34
mbbd000140150,mbcd0002959,mbtp000009,mbrf0001939,,~,,,substrate,23,123.0,nm/sec,8,Dexamethasone,,,MDCK-hPept1 cells,MDCK,,,,,human,mbds0010,,2013-11-24 23:11:34
mbbd000140151,mbcd0003137,mbtp000009,mbrf0001939,,~,,,substrate,23,20.0,nm/sec,1,Furosimide,,,MDCK-hPept1 cells,MDCK,,,,,human,mbds0010,,2013-11-24 23:11:34
mbbd000140152,mbcd0001280,mbtp000009,mbrf0001939,,~,,,substrate,23,16.0,nm/sec,1,Sulfasalazine,,,MDCK-hPept1 cells,MDCK,,,,,human,mbds0010,,2013-11-24 23:11:35
mbbd000140153,mbcd0029106,mbtp000009,mbrf0001918,,,,,non-substrate,,,,,oseltamivir carboxylate,,,placental cotyledons,placental cotyledon,,,,,human,mbds0010,,2013-11-26 01:55:30
mbbd000140154,mbcd0003554,mbtp000009,mbrf0002362,,=,,,inhibitor,29,0.34,mM,0.03,ceftibuten,,,Caco-2 cells,Caco-2,,,,,human,mbds0010,,2013-11-01 22:37:34
mbbd000140155,mbcd0003554,mbtp000009,mbrf0002362,,=,,,substrate,33,10.7,nmol/cm^2 2 h,1.3,ceftibuten,,,Caco-2 cells,Caco-2,,,,,human,mbds0010,,2013-11-01 22:37:34
mbbd000140156,mbcd0003666,mbtp000009,mbrf0002362,,=,,,inhibitor,29,0.5,mM,0.05,cyclacillin,,,Caco-2 cells,Caco-2,,,,,human,mbds0010,,2013-11-01 22:37:34
mbbd000140157,mbcd0003666,mbtp000009,mbrf0002362,,=,,,substrate,33,1.0,nmol / cm^2 2 h,0.1,cyclacillin,,,Caco-2 cells,Caco-2,,,,,human,mbds0010,,2013-11-01 22:37:34
mbbd000140158,mbcd0001472,mbtp000009,mbrf0002362,,=,,,inhibitor,29,7.2,mM,0.8,cefadroxil,,,Caco-2 cells,Caco-2,,,,,human,mbds0010,,2013-11-01 22:37:34
mbbd000140159,mbcd0001472,mbtp000009,mbrf0002362,,=,,,substrate,33,12.3,nmol / cm^2 2 h,0.7,cefadroxil,,,Caco-2 cells,Caco-2,,,,,human,mbds0010,,2013-11-01 22:37:34
mbbd000140160,mbcd0003019,mbtp000009,mbrf0002362,,=,,,inhibitor,29,8.1,mM,0.8,cefamandole,,,Caco-2 cells,Caco-2,,,,,human,mbds0010,,2013-11-01 22:37:34
mbbd000140161,mbcd0003019,mbtp000009,mbrf0002362,,=,,,substrate,33,0.2,nmol / cm^2 2 h,0.1,cefamandole,,,Caco-2 cells,Caco-2,,,,,human,mbds0010,,2013-11-01 22:37:34
mbbd000140162,mbcd0003553,mbtp000009,mbrf0002362,,=,,,inhibitor,29,9.8,mM,1.2,cephradine,,,Caco-2 cells,Caco-2,,,,,human,mbds0010,,2013-11-01 22:37:34
mbbd000140163,mbcd0003553,mbtp000009,mbrf0002362,,=,,,substrate,33,7.2,nmol / cm^2 2 h,0.4,cephradine,,,Caco-2 cells,Caco-2,,,,,human,mbds0010,,2013-11-01 22:37:34
mbbd000140164,mbcd0001298,mbtp000009,mbrf0002362,,~,,,inhibitor,29,11.0,mM,,cefaclor,,,Caco-2 cells,Caco-2,,,,,human,mbds0010,,2013-11-01 22:37:34
mbbd000140165,mbcd0001298,mbtp000009,mbrf0002362,,=,,,substrate,33,5.9,nmol / cm^2 2 h,0.3,cefaclor,,,Caco-2 cells,Caco-2,,,,,human,mbds0010,,2013-11-01 22:37:34
mbbd000140166,mbcd0029463,mbtp000009,mbrf0002362,,~,,,inhibitor,29,12.0,mM,,cefuroxime axetil,,,Caco-2 cells,Caco-2,,,,,human,mbds0010,,2013-11-01 22:37:34
mbbd000140167,mbcd0029463,mbtp000009,mbrf0002362,,=,,,substrate,33,6.9,nmol / cm^2 2 h,0.8,cefuroxime axetil,,,Caco-2 cells,Caco-2,,,,,human,mbds0010,,2013-11-01 22:37:34
mbbd000140168,mbcd0003733,mbtp000009,mbrf0002362,,=,,,inhibitor,29,12.0,mM,2,cefixime,,,Caco-2 cells,Caco-2,,,,,human,mbds0010,,2013-11-01 22:37:34
mbbd000140169,mbcd0003733,mbtp000009,mbrf0002362,,=,,,substrate,33,2.4,nmol / cm^2 2 h,0.2,cefixime,,,Caco-2 cells,Caco-2,,,,,human,mbds0010,,2013-11-01 22:37:34
mbbd000140170,mbcd0003681,mbtp000009,mbrf0002362,,~,,,inhibitor,29,14.0,mM,,cephalothin,,,Caco-2 cells,Caco-2,,,,,human,mbds0010,,2013-11-01 22:37:34
mbbd000140171,mbcd0003681,mbtp000009,mbrf0002362,,=,,,substrate,33,0.07,nmol / cm^2 2 h,0.03,cephalothin,,,Caco-2 cells,Caco-2,,,,,human,mbds0010,,2013-11-01 22:37:34
mbbd000140172,mbcd0003618,mbtp000009,mbrf0002362,,=,,,inhibitor,29,14.4,mM,2.4,cephalexin,,,Caco-2 cells,Caco-2,,,,,human,mbds0010,,2013-11-01 22:37:34
mbbd000140173,mbcd0003618,mbtp000009,mbrf0002362,,=,,,substrate,33,5.3,nmol / cm^2 2 h,0.7,cephalexin,,,Caco-2 cells,Caco-2,,,,,human,mbds0010,,2013-11-01 22:37:34
mbbd000140174,mbcd0003622,mbtp000009,mbrf0002362,,=,,,inhibitor,29,14.5,mM,1.7,ampicillin,,,Caco-2 cells,Caco-2,,,,,human,mbds0010,,2013-11-01 22:37:34
mbbd000140175,mbcd0003622,mbtp000009,mbrf0002362,,=,,,substrate,33,0.32,nmol / cm^2 2 h,0.08,ampicillin,,,Caco-2 cells,Caco-2,,,,,human,mbds0010,,2013-11-01 22:37:34
mbbd000140176,mbcd0003610,mbtp000009,mbrf0002362,,~,,,inhibitor,29,20.0,mM,,cefapirin,,,Caco-2 cells,Caco-2,,,,,human,mbds0010,,2013-11-01 22:37:34
mbbd000140177,mbcd0003610,mbtp000009,mbrf0002362,,=,,,non-substrate,33,0.19,nmol / cm^2 2 h,0.01,cefapirin,,,Caco-2 cells,Caco-2,,,,,human,mbds0010,,2013-11-01 22:37:34
mbbd000140178,mbcd0000231,mbtp000009,mbrf0002362,,=,,,inhibitor,29,22.0,mM,3,cefodizime,,,Caco-2 cells,Caco-2,,,,,human,mbds0010,,2013-11-01 22:37:34
mbbd000140179,mbcd0000231,mbtp000009,mbrf0002362,,=,,,substrate,33,0.28,nmol / cm^2 2 h,0.07,cefodizime,,,Caco-2 cells,Caco-2,,,,,human,mbds0010,,2013-11-01 22:37:34
mbbd000140180,mbcd0003686,mbtp000009,mbrf0002362,,=,,,inhibitor,29,26.0,mM,4,cefuroxime,,,Caco-2 cells,Caco-2,,,,,human,mbds0010,,2013-11-01 22:37:34
mbbd000140181,mbcd0003686,mbtp000009,mbrf0002362,,=,,,substrate,33,0.12,nmol / cm^2 2 h,0.01,cefuroxime,,,Caco-2 cells,Caco-2,,,,,human,mbds0010,,2013-11-01 22:37:34
mbbd000140182,mbcd0003692,mbtp000009,mbrf0002362,,=,,,inhibitor,29,28.0,mM,3,cefmetazole,,,Caco-2 cells,Caco-2,,,,,human,mbds0010,,2013-11-01 22:37:34
mbbd000140183,mbcd0003692,mbtp000009,mbrf0002362,,=,,,substrate,33,0.12,nmol / cm^2 2 h,0.02,cefmetazole,,,Caco-2 cells,Caco-2,,,,,human,mbds0010,,2013-11-01 22:37:34
mbbd000140184,mbcd0003134,mbtp000009,mbrf0002362,,~,,,inhibitor,29,40.0,mM,,benzylpenicillin,,,Caco-2 cells,Caco-2,,,,,human,mbds0010,,2013-11-01 22:37:34
mbbd000140185,mbcd0003773,mbtp000009,mbrf0002362,,~,,,inhibitor,29,40.0,mM,,ceftriaxone,,,Caco-2 cells,Caco-2,,,,,human,mbds0010,,2013-11-01 22:37:34
mbbd000140186,mbcd0003773,mbtp000009,mbrf0002362,,=,,,substrate,33,0.17,nmol / cm^2 2 h,0.03,ceftriaxone,,,Caco-2 cells,Caco-2,,,,,human,mbds0010,,2013-11-01 22:37:34
mbbd000140187,mbcd0003756,mbtp000009,mbrf0002362,,~,,,inhibitor,29,45.0,mM,,cefpirome,,,Caco-2 cells,Caco-2,,,,,human,mbds0010,,2013-11-01 22:37:34
mbbd000140188,mbcd0003756,mbtp000009,mbrf0002362,,=,,,substrate,33,0.17,nmol / cm^2 2 h,0.02,cefpirome,,,Caco-2 cells,Caco-2,,,,,human,mbds0010,,2013-11-01 22:37:34
mbbd000140189,mbcd0003775,mbtp000009,mbrf0002362,,~,,,inhibitor,29,50.0,mM,,cefotaxime,,,Caco-2 cells,Caco-2,,,,,human,mbds0010,,2013-11-01 22:37:34
mbbd000140190,mbcd0003775,mbtp000009,mbrf0002362,,=,,,substrate,33,0.1,nmol / cm^2 2 h,0.01,cefotaxime,,,Caco-2 cells,Caco-2,,,,,human,mbds0010,,2013-11-01 22:37:34
mbbd000140191,mbcd0001591,mbtp000009,mbrf0002362,,~,,,inhibitor,29,70.0,mM,,cefepime,,,Caco-2 cells,Caco-2,,,,,human,mbds0010,,2013-11-01 22:37:34
mbbd000140192,mbcd0000245,mbtp000009,mbrf0002362,,~,,,inhibitor,29,100.0,mM,,cephaloridine,,,Caco-2 cells,Caco-2,,,,,human,mbds0010,,2013-11-01 22:37:34
mbbd000140193,mbcd0000245,mbtp000009,mbrf0002362,,=,,,substrate,33,0.12,nmol / cm^2 2 h,0.02,cephaloridine,,,Caco-2 cells,Caco-2,,,,,human,mbds0010,,2013-11-01 22:37:34
mbbd000140194,mbcd0000235,mbtp000009,mbrf0002362,,~,,,inhibitor,29,150.0,mM,,cefsulodin,,,Caco-2 cells; inhibition of Gly-Sar uptake,Caco-2,mbcd0003494,,,,human,mbds0010,,2013-11-01 22:37:34
mbbd000140195,mbcd0000235,mbtp000009,mbrf0002362,,=,,,substrate,33,0.16,mM,0.05,cefsulodin,,,Caco-2 cells,Caco-2,,,,,human,mbds0010,,2013-11-01 22:37:34
mbbd000140196,mbcd0003819,mbtp000009,mbrf0000111,29,=,10000000.0,nM,inhibitor,29,10.0,mM,,cefoxitin; 89,,B,Caco-2 competition assay; uptake of 10 microM [14C]Gly-Sar,Caco-2,,,,,human,mbds0001,v12,2014-01-16 21:30:04
mbbd000140197,mbcd0003036,mbtp000009,mbrf0000111,29,=,3200000.0,nM,inhibitor,29,3.2,mM,,flucoxacillin; 99,,B,Caco-2 competition assay; uptake of 10 microM [14C]Gly-Sar,Caco-2,,,,,human,mbds0001,v12,2013-11-20 20:06:19
mbbd000140198,mbcd0030533,mbtp000009,mbrf0000111,29,=,15000000.0,nM,inhibitor,29,15.0,mM,,acidocillin; 101,,B,Caco-2 competition assay; uptake of 10 microM [14C]Gly-Sar,Caco-2,,,,,human,mbds0001,v12,2013-11-20 20:06:19
mbbd000140199,mbcd0003497,mbtp000009,mbrf0000111,29,~,31000000.0,nM,inhibitor,29,31.0,mM,,cefazoline; 103,,B,Caco-2 competition assay; uptake of 10 microM [14C]Gly-Sar,Caco-2,,,,,human,mbds0001,v12,2014-01-16 21:30:04
mbbd000140200,mbcd0003506,mbtp000009,mbrf0000111,29,~,61000000.0,nM,inhibitor,29,61.0,mM,,piperacillin; 105,,B,Caco-2 competition assay; uptake of 10 microM [14C]Gly-Sar,Caco-2,,,,,human,mbds0001,v12,2014-01-16 21:30:04
mbbd000140201,mbcd0003758,mbtp000009,mbrf0000111,29,~,110000000.0,nM,inhibitor,29,110.0,mM,,cefpodoxime; 106,,B,Caco-2 competition assay; uptake of 10 microM [14C]Gly-Sar,Caco-2,,,,,human,mbds0001,v12,2014-01-16 21:30:04
mbbd000140202,mbcd0003601,mbtp000009,mbrf0002450,,=,,,inhibitor,29,0.08,mM,0.01,ala-ala,,,Caco-2 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140203,mbcd0003087,mbtp000009,mbrf0002450,,=,,,inhibitor,29,0.49,mM,0.04,valacyclovir,,,Caco-2 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140204,mbcd0003494,mbtp000009,mbrf0002450,,=,,,inhibitor,29,1.1,mM,0.1,Gly-Sar,,,Caco-2 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140205,mbcd0003725,mbtp000009,mbrf0002450,,=,,,inhibitor,29,3.4,mM,0.7,lys-lys,,,Caco-2 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140206,mbcd0029464,mbtp000009,mbrf0002450,,=,,,inhibitor,29,2.5,mM,0.1,pro-arg,,,Caco-2 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140207,mbcd0003552,mbtp000009,mbrf0002450,,=,,,inhibitor,29,1.5,mM,0.01,gamma-aminolevulinic acid,,,Caco-2 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140208,mbcd0003602,mbtp000009,mbrf0002450,,=,,,inhibitor,29,14.0,mM,2,pro-ser,,,Caco-2 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140209,mbcd0003778,mbtp000009,mbrf0002450,,=,,,inhibitor,29,6.3,mM,1.6,ile-thiazolidide,,,Caco-2 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140210,mbcd0029465,mbtp000009,mbrf0002450,,=,,,inhibitor,29,9.8,mM,1.2,4-aminophenylacetic acid,,,Caco-2 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140211,mbcd0003142,mbtp000009,mbrf0002450,,>,,,inhibitor,29,30.0,mM,,captopril,,,Caco-2 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140212,mbcd0003498,mbtp000009,mbrf0002450,,=,,,inhibitor,29,12.0,mM,,enalapril,,,Caco-2 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140213,mbcd0001325,mbtp000009,mbrf0002450,,,,,inhibitor,,,,,quinapril,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140214,mbcd0029466,mbtp000009,mbrf0002450,,=,,,substrate,28,0.14,mM,,arphamenine A,,,Caco-2 cells,Caco-2,,,,,human,mbds0010,,2013-11-24 23:12:27
mbbd000140215,mbcd0029467,mbtp000009,mbrf0002746,,,,,substrate,,,,,LY544344,prodrug of LY354740,,Caco-2,Caco-2,,0.03; 3,mM,,human,mbds0010,,2013-11-02 05:23:10
mbbd000140216,mbcd0000946,mbtp000009,mbrf0002029,,~,,,substrate,33,3.4,nmol/mg protein/h,0.05,midodrine,,,Caco-2 cells,Caco-2,,1,mM,,human,mbds0010,,2013-11-22 20:30:33
mbbd000140217,mbcd0003494,mbtp000009,mbrf0001816,,=,,,substrate,28,1.38,mM,0.24,Gly-Sar,,,Caco-2 cells,Caco-2,,,,,human,mbds0010,,2013-11-24 23:12:28
mbbd000140218,mbcd0029474,mbtp000009,mbrf0002563,,=,,,substrate,28,160.0,micromol / L,,KPV,,,Caco-2 BBE,Caco-2,,0-1000,microM,,human,mbds0010,,2013-11-01 23:41:18
mbbd000140219,mbcd0000419,mbtp000009,mbrf0002742,,~,,,substrate,28,2.9,mM,,fMLP,,,KG-1,KG-1,,0.1-100,mM,,human,mbds0010,,2013-11-01 23:41:18
mbbd000140220,mbcd0029475,mbtp000009,mbrf0002472,,=,,,inhibitor,29,4.78,mM,0.24,Tri-DAP,,,inhibition of Gly-Sar,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140221,mbcd0001904,mbtp000009,mbrf0002044,,=,,,inhibitor,25,0.18,mM,0.01,Repaglinide,,,inhibition of Gly-Sar,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140222,mbcd0029476,mbtp000009,mbrf0002044,,=,,,inhibitor,25,7.69,mM,0.09,aspartame,,,inhibition of Gly-Sar,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140223,mbcd0001445,mbtp000009,mbrf0002044,,=,,,inhibitor,25,0.34,mM,0.04,fluvastatin,,,inhibition of Gly-Sar,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140224,mbcd0001130,mbtp000009,mbrf0002044,,,,,inhibitor,,,,,cefdinir,,,inhibition of Gly-Sar,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140225,mbcd0003126,mbtp000009,mbrf0002044,,,,,inhibitor,,,,,pravastatin,,,inhibition of Gly-Sar,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140226,mbcd0001425,mbtp000009,mbrf0002044,,,,,substrate,,,,,amoxicillin,,,inhibition of Gly-Sar; CHO-hPepT1 cells,CHO,,,,,human,mbds0010,,2013-11-26 01:55:29
mbbd000140227,mbcd0000925,mbtp000009,mbrf0002044,,,,,inhibitor,,,,,ramipril,,,inhibition of Gly-Sar,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140228,mbcd0009261,mbtp000009,mbrf0002044,,,,,inhibitor,,,,,bumetanide,,,inhibition of Gly-Sar,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140229,mbcd0001082,mbtp000009,mbrf0002044,,,,,inhibitor,,,,,loracarbef,,,inhibition of Gly-Sar,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140230,mbcd0001136,mbtp000009,mbrf0002044,,,,,inhibitor,,,,,benazepril,,,inhibition of Gly-Sar,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140231,mbcd0001277,mbtp000009,mbrf0002044,,,,,inhibitor,,,,,perindopril,,,inhibition of Gly-Sar,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140232,mbcd0003497,mbtp000009,mbrf0002044,,,,,inhibitor,,,,,cefazolin,,,inhibition of Gly-Sar,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140233,mbcd0001298,mbtp000009,mbrf0002044,,,,,inhibitor,,,,,cefaclor,,,inhibition of Gly-Sar,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140234,mbcd0000823,mbtp000009,mbrf0001654,,,,,substrate,,,,,temocapril,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140235,mbcd0003494,mbtp000009,mbrf0002005,,=,,,substrate,28,5.4,mM,,Gly-Sar,,,CHO-hPept1 cells,CHO,,,,,human,mbds0010,,2013-11-24 23:15:20
mbbd000140236,mbcd0003494,mbtp000009,mbrf0002005,,=,,,substrate,22,33.7,pmol / mg 30 mins,1.6,Gly-Sar,,,CHO-hPept1 cells,CHO,,,,,human,mbds0010,,2013-11-24 23:15:20
mbbd000140237,mbcd0029478,mbtp000009,mbrf0002005,,,,,inhibitor,,,,,acetaldehyde,,,inhibited Gly-Sar uptake; 2 week treatment reduced Gly-Sar uptake by ~50%,,,,,,human,mbds0010,,2013-11-23 00:52:26
mbbd000140238,mbcd0003642,mbtp000009,mbrf0002203,,,,,inhibitor,,,,,gly-pro,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140239,mbcd0022751,mbtp000009,mbrf0002203,,,,,substrate,,,,,carnosine,,,Caco-2 cells,Caco-2,,0.1,mM,,human,mbds0010,,2013-11-10 04:15:56
mbbd000140240,mbcd0003087,mbtp000009,mbrf0002203,,=,,,substrate,23,4.55,*10^6 cm/s,0.25,L-valacyclovir,,,Caco-2 monolayer,Caco-2,,,,,human,mbds0010,,2013-11-24 23:12:28
mbbd000140241,mbcd0029479,mbtp000009,mbrf0002203,,=,,,substrate,23,3.0,*10^6 cm/s,0.22,2b,,,Caco-2 monolayer,Caco-2,,,,,human,mbds0010,,2013-11-24 23:12:28
mbbd000140242,mbcd0029480,mbtp000009,mbrf0002203,,=,,,substrate,23,25.1,*10^6 cm/s,0.06,3b,,,Caco-2 monolayer,Caco-2,,,,,human,mbds0010,,2013-11-24 23:12:28
mbbd000140243,mbcd0029481,mbtp000009,mbrf0002203,,=,,,substrate,23,30.2,*10^6 cm/s,1.94,4b,,,Caco-2 monolayer,Caco-2,,,,,human,mbds0010,,2013-11-24 23:12:28
mbbd000140244,mbcd0003916,mbtp000009,mbrf0002203,,,,,non-substrate,,,,,acyclovir,,,Caco-2 cells; no inihibition of carnosine uptake,Caco-2,,5,mM,,human,mbds0010,,2013-11-24 22:14:57
mbbd000140245,mbcd0029482,mbtp000009,mbrf0002577,,,,,substrate,,,,,alafosfalin,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140246,mbcd0029483,mbtp000009,mbrf0002577,,>,,,non-substrate,29,10.0,mM,,pyrraline,,,hPept1 tranfect HeLa cells,HeLa,,,,,human,mbds0010,,2013-11-24 23:55:17
mbbd000140247,mbcd0003494,mbtp000009,mbrf0002577,,=,,,inhibitor,29,0.64,mM,0.02,Gly-Sar,,,hPept1 tranfect HeLa cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140248,mbcd0029484,mbtp000009,mbrf0002577,,=,,,inhibitor,29,0.27,mM,0.02,Ala-Pyrr,,,hPept1 tranfect HeLa cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140249,mbcd0029485,mbtp000009,mbrf0002577,,=,,,inhibitor,29,0.08,mM,0.01,Pyrr-Ala,,,hPept1 tranfect HeLa cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140250,mbcd0029486,mbtp000009,mbrf0001966,,=,,,inhibitor,29,0.65,mM,0.02,Anserine,,,hPept1 transfected HeLa cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140251,mbcd0029486,mbtp000009,mbrf0001966,,=,,,inhibitor,29,1.55,mM,0.02,Anserine,,,hPept1 Caco-2 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140252,mbcd0022751,mbtp000009,mbrf0001966,,=,,,inhibitor,29,1.7,mM,0.1,carnosine,,,hPept1 tranfected HeLa cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140255,mbcd0029487,mbtp000009,mbrf0002411,,=,,,inhibitor,25,8.7,mM,2.2,FruLys,,,inhibition of Gly-Sar uptake in Caco-2 cells,Caco-2,,,,,human,mbds0010,,2013-07-12 01:01:32
mbbd000140256,mbcd0029488,mbtp000009,mbrf0002411,,~,,,non-inhibitor,3,5.0,%,2,LAL; lysinoalanine,,,no inihibition on Gly-Sar uptake in Caco-2 cells,Caco-2,,10,mM,,human,mbds0010,,2013-10-09 22:18:34
mbbd000140257,mbcd0029489,mbtp000009,mbrf0002411,,~,,,inhibitor,3,15.0,%,2,CML,,,10mM substrate; inhibition of Gly Sar uptake in Caco-2 cells,Caco-2,,,,,human,mbds0010,,2013-07-12 01:01:32
mbbd000140258,mbcd0029490,mbtp000009,mbrf0002411,,~,,,inhibitor,3,36.0,%,5,HipCML,,,10mM substrate; inhibition of Gly Sar uptake in Caco-2 cells,Caco-2,,,,,human,mbds0010,,2013-07-12 01:01:32
mbbd000140259,mbcd0029491,mbtp000009,mbrf0002411,,~,,,inhibitor,3,34.0,%,4,HipFruLys,,,10mM substrate; inhibition of Gly Sar uptake in Caco-2 cells,Caco-2,,,,,human,mbds0010,,2013-07-12 01:01:33
mbbd000140260,mbcd0029492,mbtp000009,mbrf0002411,,~,,,inhibitor,3,16.0,%,4,HipLys,,,10mM substrate; inhibition of Gly Sar uptake in Caco-2 cells,Caco-2,,,,,human,mbds0010,,2013-07-12 01:01:33
mbbd000140261,mbcd0029493,mbtp000009,mbrf0002411,,~,,,inhibitor,3,76.0,%,2,gly-ala-phe,,,10mM substrate; inhibition of Gly Sar uptake in Caco-2 cells,Caco-2,,,,,human,mbds0010,,2013-07-12 01:01:34
mbbd000140262,mbcd0003598,mbtp000009,mbrf0002411,,=,,,inhibitor,25,0.31,mM,0.07,Ala-Lys,,,inhibition of Gly Sar uptake in Caco-2 cells,Caco-2,,,,,human,mbds0010,,2013-07-12 01:01:34
mbbd000140263,mbcd0029494,mbtp000009,mbrf0001853,,=,,,substrate,28,1.33,mM,,JBP485,,,HeLa - hPept1,HeLa,,,,,human,mbds0010,,2013-11-24 23:55:16
mbbd000140264,mbcd0029494,mbtp000009,mbrf0001853,,=,,,inhibitor,29,8.11,mM,,JBP485,,,inhibition of Gly Sar uptake in hPept1 transfected HeLa cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140265,mbcd0029494,mbtp000009,mbrf0001853,,=,,,substrate,22,1.75,nmol / mg protein / 3 min,,JBP485,optimum pH 5.8,,HeLa - hPept1,HeLa,,,,,human,mbds0010,,2013-11-24 23:55:16
mbbd000140266,mbcd0003494,mbtp000009,mbrf0001853,,=,,,substrate,28,1.03,mM,,Gly_Sar,,,hPept1 transfected HeLa cells,HeLa,,,,,human,mbds0010,,2013-11-24 23:55:16
mbbd000140267,mbcd0003494,mbtp000009,mbrf0001853,,=,,,substrate,22,1.86,nmol / mg protein / 3 min,,Gly_Sar,,,hPept1 transfected HeLa cells,HeLa,,,,,human,mbds0010,,2013-11-24 23:55:16
mbbd000140268,mbcd0003494,mbtp000009,mbrf0002544,,=,,,substrate,28,0.86,mM,,Gly_Sar,,,Pichia pastoris cells expressing PEPT1,Pichia pastoris,,,,,human,mbds0010,,2013-11-24 23:56:41
mbbd000140269,mbcd0002352,mbtp000009,mbrf0002544,,=,,,substrate,25,27.4,mM,,oseltamivir,,,inhibition of Gly-Sar uptake in Pichia pastoris cells expressing PEPT1,Pichia pastoris,,,,,human,mbds0010,,2013-11-24 23:56:41
mbbd000140270,mbcd0003494,mbtp000009,mbrf0002544,,=,,,substrate,22,24.7,microL / OD / min,2.4,Gly-Sar,,,Pichia pastoris cells expressing the Pept1 gene,Pichia pastoris,,,,,human,mbds0010,,2013-11-24 23:56:41
mbbd000140271,mbcd0003494,mbtp000009,mbrf0002544,,=,,,substrate,28,0.29,mM,,Glycosarcosine,,,"cDNA-transfected HeLa cells, 14C-label, pH 6.0",HeLa,,,,,human,mbds0010,,2013-11-24 23:55:15
mbbd000140272,mbcd0003494,mbtp000009,mbrf0002544,,=,,,substrate,41,2.21,mM,0.14,Gly-Sar,,,Pichia pastoris cells expressing the Pept1 gene,Pichia pastoris,,,,,human,mbds0010,,2013-11-24 23:56:36
mbbd000140273,mbcd0014341,mbtp000009,mbrf0002234,,,,,inhibitor,,,,,EIPA,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140275,mbcd0029495,mbtp000009,mbrf0002115,,~,,,non-substrate,33,0.5,microL (mg protein)-1,,Rebamipide,,,Xenopus laevis oocytes and HeLa cells; uptake after 10 min,HeLa,,250,microM,,human,mbds0010,,2013-10-30 23:42:32
mbbd000140276,mbcd0029496,mbtp000009,mbrf0002115,,=,,,non-inhibitor,33,92.9,%,11.5,Reb-Gly,,,Inhibitory Effect of Peptide Derivatives on [3H] Gly-Sar Uptake by HeLa Cells Expressing PEPT1,HeLa,mbcd0003494,500,microM,,human,mbds0010,,2013-10-30 23:42:33
mbbd000140277,mbcd0029497,mbtp000009,mbrf0002115,,=,,,non-inhibitor,33,90.9,%,8.2,Reb-Leu,,,Inhibitory Effect of Peptide Derivatives on [3H] Gly-Sar Uptake by HeLa Cells Expressing PEPT1,HeLa,mbcd0003494,500,microM,,human,mbds0010,,2013-10-30 23:42:33
mbbd000140278,mbcd0029498,mbtp000009,mbrf0002115,,=,,,non-inhibitor,33,100.0,%,12.1,Reb-Tyr,,,Inhibitory Effect of Peptide Derivatives on [3H] Gly-Sar Uptake by HeLa Cells Expressing PEPT1,HeLa,mbcd0003494,500,microM,,human,mbds0010,,2013-10-30 23:42:34
mbbd000140279,mbcd0029500,mbtp000009,mbrf0002115,,=,,,inhibitor,33,85.5,%,2.5,Ser(Reb)-Gly,,,Inhibitory Effect of Peptide Derivatives on [3H] Gly-Sar Uptake by HeLa Cells Expressing PEPT1,HeLa,mbcd0003494,500,microM,,human,mbds0010,,2013-10-30 23:42:32
mbbd000140280,mbcd0029501,mbtp000009,mbrf0002115,,=,,,inhibitor,33,68.4,%,3.0,Gly-Ser(Reb),,,Inhibitory Effect of Peptide Derivatives on [3H] Gly-Sar Uptake by HeLa Cells Expressing PEPT1,HeLa,mbcd0003494,250,microM,,human,mbds0010,,2013-10-30 23:42:32
mbbd000140281,mbcd0029502,mbtp000009,mbrf0002115,,=,,,inhibitor,33,76.1,%,6.2,Lys(Reb)-Gly,,,Inhibitory Effect of Peptide Derivatives on [3H] Gly-Sar Uptake by HeLa Cells Expressing PEPT1,HeLa,mbcd0003494,250,microM,,human,mbds0010,,2013-10-30 23:42:32
mbbd000140282,mbcd0029503,mbtp000009,mbrf0002115,,=,,,inhibitor,33,86.8,%,3.1,Gly-Lys(Reb),,,Inhibitory Effect of Peptide Derivatives on [3H] Gly-Sar Uptake by HeLa Cells Expressing PEPT1,HeLa,mbcd0003494,250,microM,,human,mbds0010,,2013-10-30 23:42:32
mbbd000140283,mbcd0003494,mbtp000009,mbrf0002115,,,,,substrate,,,,,Gly-Sar,,,Xenopus laevis oocytes,Xenopus laevis oocytes,,250,microM,,human,mbds0010,,2013-10-30 23:42:34
mbbd000140284,mbcd0001472,mbtp000009,mbrf0002115,,=,,,inhibitor,23,1.87,*10^-6 cm s-1,0.08,Cefadroxil,,,Caco-2 cell monolayers,Caco-2,mbcd0029500,20,mM,,human,mbds0010,,2013-11-20 21:44:59
mbbd000140285,mbcd0003733,mbtp000009,mbrf0002115,,=,,,inhibitor,23,1.91,*10^-6 cm s-1,0.07,cefixime,,,Caco-2 cell monolayers,Caco-2,mbcd0029500,2.5,mM,,human,mbds0010,,2013-11-20 21:44:59
mbbd000140286,mbcd0029504,mbtp000009,mbrf0002449,,=,,,inhibitor,29,3.4,microM,0.1,Bip-Pro,,,inhibition of [14C]Gly-Sar uptake in SKPT cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140287,mbcd0029504,mbtp000009,mbrf0002449,,=,,,inhibitor,29,7.8,microM,0.1,Bip-Pro,,,inhibition of Bip-[3H]Pro uptake in SKPT cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140288,mbcd0001472,mbtp000009,mbrf0002449,,=,,,inhibitor,29,5.2,microM,0.4,cefadroxil,,,inhibition of [14C]Gly-Sar uptake in SKPT cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140289,mbcd0001472,mbtp000009,mbrf0002449,,=,,,inhibitor,29,3.0,microM,1,cefadroxil,,,inhibition of Bip-[3H]Pro uptake in SKPT cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140290,mbcd0003552,mbtp000009,mbrf0002449,,=,,,inhibitor,29,230.0,microM,20,d-Aminolevulinic acid,,,inhibition of [14C]Gly-Sar uptake in SKPT cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140291,mbcd0003552,mbtp000009,mbrf0002449,,=,,,inhibitor,29,231.0,microM,90,d-Aminolevulinic acid,,,inhibition of Bip-[3H]Pro uptake in SKPT cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140292,mbcd0003725,mbtp000009,mbrf0002449,,=,,,inhibitor,29,75.0,microM,9,Lys-Lys,,,inhibition of [14C]Gly-Sar uptake in SKPT cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140293,mbcd0003725,mbtp000009,mbrf0002449,,=,,,inhibitor,29,12.0,microM,0.3,Lys-Lys,,,inhibition of Bip-[3H]Pro uptake in SKPT cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140294,mbcd0003494,mbtp000009,mbrf0002449,,=,,,substrate,3,36.0,%,5,Gly-Sar,,,Bip-[3H]Pro (4 nM) into SKPT cells was measured at pH 6.0 for 2 h at room temperature in the absence (control) or presence of inhibitors (all 100 microM),SKPT,,,,,human,mbds0010,,2013-12-09 20:51:25
mbbd000140295,mbcd0029504,mbtp000009,mbrf0002449,,=,,,substrate,3,86.0,%,1,Bip-Pro,,,Bip-[3H]Pro (4 nM) into SKPT cells was measured at pH 6.0 for 2 h at room temperature in the absence (control) or presence of inhibitors (all 100 microM),SKPT,,,,,human,mbds0010,,2013-12-09 20:51:25
mbbd000140296,mbcd0003601,mbtp000009,mbrf0002449,,=,,,substrate,33,15.0,%,1,ala-ala,,,Bip-[3H]Pro (4 nM) into SKPT cells was measured at pH 6.0 for 2 h at room temperature in the absence (control) or presence the inhibitor (100 microM),SKPT,,,,,human,mbds0010,,2013-11-24 23:56:40
mbbd000140297,mbcd0003723,mbtp000009,mbrf0002449,,=,,,non-substrate,3,0.0,%,3,Pro-Ala,,,Bip-[3H]Pro (4 nM) into SKPT cells was measured at pH 6.0 for 2 h at room temperature in the absence (control) or presence of inhibitors (all 100 microM),SKPT,,,,,human,mbds0010,,2013-12-09 20:51:25
mbbd000140298,mbcd0003725,mbtp000009,mbrf0002449,,=,,,substrate,3,54.0,%,2,lys-lys,,,Bip-[3H]Pro (4 nM) into SKPT cells was measured at pH 6.0 for 2 h at room temperature in the absence (control) or presence of inhibitors (all 100 microM),SKPT,,,,,human,mbds0010,,2013-12-09 20:51:25
mbbd000140299,mbcd0003764,mbtp000009,mbrf0002449,,=,,,substrate,3,81.0,%,1,Ala-asp,,,Bip-[3H]Pro (4 nM) into SKPT cells was measured at pH 6.0 for 2 h at room temperature in the absence (control) or presence of inhibitors (all 100 microM),SKPT,,,,,human,mbds0010,,2013-12-09 20:51:25
mbbd000140300,mbcd0003689,mbtp000009,mbrf0002449,,=,,,substrate,3,35.0,%,2,D-Phe-Ala,,,Bip-[3H]Pro (4 nM) into SKPT cells was measured at pH 6.0 for 2 h at room temperature in the absence (control) or presence of inhibitors (all 100 microM),SKPT,,,,,human,mbds0010,,2013-12-09 20:00:54
mbbd000140301,mbcd0003599,mbtp000009,mbrf0002449,,=,,,substrate,3,79.0,%,1,ala-ala-ala,,,Bip-[3H]Pro (4 nM) into SKPT cells was measured at pH 6.0 for 2 h at room temperature in the absence (control) or presence of inhibitors (all 100 microM),SKPT,,,,,human,mbds0010,,2013-12-09 20:00:55
mbbd000140302,mbcd0003552,mbtp000009,mbrf0002449,,=,,,substrate,3,22.0,%,3,d-Aminolevulinic acid,,,Bip-[3H]Pro (4 nM) into SKPT cells was measured at pH 6.0 for 2 h at room temperature in the absence (control) or presence of inhibitors (all 100 microM),SKPT,,,,,human,mbds0010,,2013-12-09 20:00:57
mbbd000140303,mbcd0001472,mbtp000009,mbrf0002449,,=,,,substrate,3,85.0,%,1,cefadroxil,,,Bip-[3H]Pro (4 nM) into SKPT cells was measured at pH 6.0 for 2 h at room temperature in the absence (control) or presence of inhibitors (all 100 microM),SKPT,,,,,human,mbds0010,,2013-12-09 20:00:58
mbbd000140304,mbcd0029506,mbtp000009,mbrf0002449,,,,,non-substrate,,,,,8-Aminooctanoic acid,,,Bip-[3H]Pro (4 nM) into SKPT cells was measured at pH 6.0 for 2 h at room temperature in the absence (control) or presence of inhibitors (all 100 microM),SKPT,,,,,human,mbds0010,,2013-12-09 20:00:52
mbbd000140305,mbcd0029507,mbtp000009,mbrf0002449,,=,,,inhibitor,3,62.0,%,1,Ala-4-nitroanilide,,,Bip-[3H]Pro (4 nM) into SKPT cells was measured at pH 6.0 for 2 h at room temperature in the absence (control) or presence of inhibitors (all 100 microM),,,,,,human,mbds0010,,2013-12-09 20:00:53
mbbd000140306,mbcd0027333,mbtp000009,mbrf0002050,,=,,,inhibitor,29,24.0,microM,1,losartan,,,inhibition of [14]Gly-Sar uptake in Caco-2 cells expressing PEPT1,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140307,mbcd0028570,mbtp000009,mbrf0002050,,=,,,inhibitor,29,230.0,microM,30,Irbesartan,,,inhibition of [14]Gly-Sar uptake in Caco-2 cells expressing PEPT1,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140308,mbcd0003086,mbtp000009,mbrf0002050,,=,,,inhibitor,29,390.0,microM,40,Valsartan,,,inhibition of [14]Gly-Sar uptake in Caco-2 cells expressing PEPT1,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140309,mbcd0001323,mbtp000009,mbrf0002050,,~,,,inhibitor,29,2200.0,microM,,eprosartan,,,inhibition of [14]Gly-Sar uptake in Caco-2 cells expressing PEPT1,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140310,mbcd0003494,mbtp000009,mbrf0002050,,=,,,substrate,28,1.1,mM,0.1,Gly-Sar,,,Caco-2 cells,Caco-2,,0-10,mM,,human,mbds0010,,2013-11-10 04:15:57
mbbd000140311,mbcd0003494,mbtp000009,mbrf0002050,,=,,,substrate,22,39.4,nmol / mg protein 10 min,1,Gly-Sar,,,Caco-2 cells,Caco-2,,0-10,mM,,human,mbds0010,,2013-11-10 04:15:57
mbbd000140312,mbcd0027333,mbtp000009,mbrf0002050,,~,,,non-substrate,33,19.5,nmol / 30 mins / 0.7*10^6 cells,0.5,Losartan,,,HeLa cells,HeLa,,1,mM,,human,mbds0010,,2013-11-10 04:16:06
mbbd000140313,mbcd0003086,mbtp000009,mbrf0002050,,~,,,non-substrate,33,2.9,nmol / 30 mins / 0.7*10^6 cells,0.2,Valsartan,,,HeLa cells,HeLa,,1,mM,,human,mbds0010,,2013-11-10 04:16:06
mbbd000140314,mbcd0001472,mbtp000009,mbrf0002050,,~,,,substrate,33,4.5,nmol / 30 mins / 0.7*10^6 cells,0.2,cefadroxil,,,HeLa cells,HeLa,,1,mM,,human,mbds0010,,2013-11-10 04:16:06
mbbd000140315,mbcd0000551,mbtp000009,mbrf0001343,,=,,,inhibitor,29,350.0,microM,90,Lys-Pro,,,"Inhibition of [14C]Gly-Sar uptake into Caco-2 cells (10 microM, pH 6.0, 10 min)",,,,,,human,mbds0003,v2007,2013-12-09 20:52:43
mbbd000140316,mbcd0029508,mbtp000009,mbrf0001343,,=,,,inhibitor,29,33.0,microM,1,Lys(Z)-Pro,,,"Inhibition of [14C]Gly-Sar uptake into Caco-2 cells (10 microM, pH 6.0, 10 min)",,,,,,human,mbds0003,v2007,2013-12-09 20:52:43
mbbd000140317,mbcd0029509,mbtp000009,mbrf0001343,,=,,,inhibitor,29,10.0,microM,1,Lys[Z(NO2)]-Pro,,,"Inhibition of [14C]Gly-Sar uptake into Caco-2 cells (10 microM, pH 6.0, 10 min)",,,,,,human,mbds0003,v2007,2013-12-09 20:52:43
mbbd000140318,mbcd0003494,mbtp000009,mbrf0001536,,=,,,inhibitor,29,0.72,mM,0.02,Gly-Sar,,,inhibition of [14-C] Gly-Sar uptake in Caco-2 cells (hPept1),,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140319,mbcd0003739,mbtp000009,mbrf0001536,,=,,,inhibitor,29,0.14,mM,0.01,Ala-Pro,,,inhibition of [14-C] Gly-Sar uptake in Caco-2 cells (hPept1),,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140320,mbcd0003599,mbtp000009,mbrf0001536,,=,,,inhibitor,29,0.2,mM,0.01,Ala-Ala-Ala,,,inhibition of [14-C] Gly-Sar uptake in Caco-2 cells (hPept1),,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140321,mbcd0029104,mbtp000009,mbrf0001536,,=,,,inhibitor,29,0.047,mM,0.001,zofenopril,,,inhibition of [14-C] Gly-Sar uptake in Caco-2 cells (hPept1),,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140322,mbcd0001105,mbtp000009,mbrf0001536,,=,,,inhibitor,29,0.17,mM,0.01,fosinopril,,,inhibition of [14-C] Gly-Sar uptake in Caco-2 cells (hPept1),,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140323,mbcd0001136,mbtp000009,mbrf0001536,,=,,,inhibitor,29,0.96,mM,0.07,Benazepril,,,inhibition of [14-C] Gly-Sar uptake in Caco-2 cells (hPept1),,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140324,mbcd0001325,mbtp000009,mbrf0001536,,=,,,inhibitor,29,1.0,mM,0.1,Quinapril,,,inhibition of [14-C] Gly-Sar uptake in Caco-2 cells (hPept1),,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140325,mbcd0001119,mbtp000009,mbrf0001536,,=,,,inhibitor,29,1.7,mM,0.3,trandolapril,,,inhibition of [14-C] Gly-Sar uptake in Caco-2 cells (hPept1),,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140326,mbcd0001569,mbtp000009,mbrf0001536,,=,,,inhibitor,29,2.2,mM,0.1,spirapril,,,inhibition of [14-C] Gly-Sar uptake in Caco-2 cells (hPept1),,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140327,mbcd0001568,mbtp000009,mbrf0001536,,=,,,inhibitor,29,3.0,mM,0.3,cilazapril,,,inhibition of [14-C] Gly-Sar uptake in Caco-2 cells (hPept1),,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140328,mbcd0000925,mbtp000009,mbrf0001536,,=,,,inhibitor,29,3.4,mM,0.2,Ramipril,,,inhibition of [14-C] Gly-Sar uptake in Caco-2 cells (hPept1),,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140329,mbcd0001215,mbtp000009,mbrf0001536,,=,,,inhibitor,29,5.0,mM,0.5,moexipril,,,inhibition of [14-C] Gly-Sar uptake in Caco-2 cells (hPept1),,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140330,mbcd0029105,mbtp000009,mbrf0001536,,~,,,inhibitor,29,6.0,mM,,quinaprilat,,,inhibition of [14-C] Gly-Sar uptake in Caco-2 cells (hPept1),,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140331,mbcd0001277,mbtp000009,mbrf0001536,,=,,,inhibitor,29,6.9,mM,1.5,perindopril,,,inhibition of [14-C] Gly-Sar uptake in Caco-2 cells (hPept1),,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140332,mbcd0003498,mbtp000009,mbrf0001536,,=,,,inhibitor,29,14.0,mM,1,enalapril,,,inhibition of [14-C] Gly-Sar uptake in Caco-2 cells (hPept1),,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140333,mbcd0003061,mbtp000009,mbrf0001536,,=,,,inhibitor,29,23.0,mM,1,lisinopril,,,inhibition of [14-C] Gly-Sar uptake in Caco-2 cells (hPept1),,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140334,mbcd0003142,mbtp000009,mbrf0001536,,=,,,inhibitor,29,46.0,mM,2,captopril,,,inhibition of [14-C] Gly-Sar uptake in Caco-2 cells (hPept1),,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140335,mbcd0029512,mbtp000009,mbrf0001930,,=,,,substrate,23,1.51,*10^6 cm/s,0.17,Lys-FITC-OH,"Gly-Sar concentration, 10 mM, permeability reduced to 0.71 +/- 0.08 in prescence of Gly-Sar",,"Transport of FITC Analogues in Caco-2 Cell Monolayers, apical to basal",Caco-2,,50,microM,,human,mbds0010,,2013-11-24 23:12:29
mbbd000140336,mbcd0029513,mbtp000009,mbrf0001930,,=,,,substrate,23,1.47,*10^6 cm/s,,Lys-FITC-OCH3,"Gly-Sar concentration, 10 mM, permeability reduced to 0.26 +/- 0.03 in prescence of Gly-Sar",,"Transport of FITC Analogues in Caco-2 Cell Monolayers, apical to basal",Caco-2,,50,microM,,human,mbds0010,,2013-11-24 23:12:29
mbbd000140337,mbcd0029514,mbtp000009,mbrf0001930,,=,,,substrate,23,0.12,*10^6 cm/s,0.02,Val-FITC-OCH3,"Gly-Sar concentration, 10 mM",,"Transport of FITC Analogues in Caco-2 Cell Monolayers, apical to basal",Caco-2,,50,microM,,human,mbds0010,,2013-11-24 23:12:29
mbbd000140338,mbcd0029515,mbtp000009,mbrf0002740,,=,,,substrate,28,4.3,mM,0.4,MDP; muramyl dipeptide,,,Caco-2 BBE,Caco-2,,0-10,mM,,human,mbds0010,,2013-11-11 03:52:51
mbbd000140339,mbcd0027417,mbtp000009,mbrf0002106,,=,,,substrate,23,0.12,*10^6 cm/s,0.06,Levovirin,,,Caco-2 Permeability,Caco-2,,,,,human,mbds0010,,2013-11-24 23:12:30
mbbd000140340,mbcd0012214,mbtp000009,mbrf0002106,,=,,,substrate,23,0.18,*10^6 cm/s,0.06,ribovirin,,,Caco-2 Permeability,Caco-2,,,,,human,mbds0010,,2013-11-24 23:12:30
mbbd000140341,mbcd0029516,mbtp000009,mbrf0002106,,=,,,substrate,23,5.7,*10^6 cm/s,1.99,LVV-5'-(L)-valine (R1518),,,Caco-2 Permeability,Caco-2,,,,,human,mbds0010,,2013-11-24 23:12:30
mbbd000140342,mbcd0029517,mbtp000009,mbrf0002106,,=,,,substrate,23,0.52,*10^6 cm/s,0.26,LVV-5'-(D)-valine,,,Caco-2 Permeability,Caco-2,,,,,human,mbds0010,,2013-11-24 23:12:30
mbbd000140343,mbcd0029518,mbtp000009,mbrf0002106,,=,,,substrate,23,1.46,*10^6 cm/s,1.09,LVV-5'-(L)-isoleucine,,,Caco-2 Permeability,Caco-2,,,,,human,mbds0010,,2013-11-24 23:12:31
mbbd000140344,mbcd0029519,mbtp000009,mbrf0002106,,=,,,substrate,23,1.17,*10^6 cm/s,0.57,LVV-5'-(L)-alanine,,,Caco-2 Permeability,Caco-2,,,,,human,mbds0010,,2013-11-24 23:12:31
mbbd000140345,mbcd0029520,mbtp000009,mbrf0002106,,=,,,substrate,23,0.88,*10^6 cm/s,0.17,LVV-5'-(L)-leucine,,,Caco-2 Permeability,Caco-2,,,,,human,mbds0010,,2013-11-24 23:12:31
mbbd000140346,mbcd0029521,mbtp000009,mbrf0002106,,=,,,substrate,23,0.5,*10^6 cm/s,0.39,LVV-5'-(L)-sarcosine,,,Caco-2 Permeability,Caco-2,,,,,human,mbds0010,,2013-11-24 23:12:31
mbbd000140347,mbcd0029522,mbtp000009,mbrf0002106,,=,,,non-substrate,23,0.14,*10^6 cm/s,0.07,LVV-5'-(L)-phenylalanine,,,Caco-2 Permeability,Caco-2,,,,,human,mbds0010,,2013-11-24 23:12:31
mbbd000140348,mbcd0029523,mbtp000009,mbrf0002106,,=,,,substrate,23,8.55,*10^6 cm/s,1.55,"LVV-2',3'-(L)-bis-valine",,,Caco-2 Permeability,Caco-2,,,,,human,mbds0010,,2013-11-24 23:12:32
mbbd000140349,mbcd0029524,mbtp000009,mbrf0002106,,=,,,substrate,23,3.42,*10^6 cm/s,0.18,LVV-5'-val-pro,,,Caco-2 Permeability,Caco-2,,,,,human,mbds0010,,2013-11-24 23:12:32
mbbd000140350,mbcd0029525,mbtp000009,mbrf0002106,,=,,,substrate,23,1.98,*10^6 cm/s,1.04,LVV-5'-pro-val,,,Caco-2 Permeability,Caco-2,,,,,human,mbds0010,,2013-11-24 23:12:32
mbbd000140351,mbcd0004903,mbtp000009,mbrf0002738,,~,,,inhibitor,28,3.0,mM,,4-AMBA,,,Xenopus laevis oocytes,Xenopus laevis oocytes,mbcd0031275,0-20,mM,,human,mbds0010,,2013-11-01 23:31:38
mbbd000140352,mbcd0029494,mbtp000009,mbrf0001884,,=,,,substrate,28,1.7,mM,0.2,JBP485,,,Caco-2; uptake,Caco-2,,0-5,mM,,human,mbds0010,,2013-11-04 22:03:19
mbbd000140353,mbcd0003494,mbtp000009,mbrf0001884,,=,,,substrate,22,11.5,nmol / mg protein / 10 min,0.3,Gly-Sar,,,Caco-2; uptake,Caco-2,,0-5,mM,,human,mbds0010,,2014-03-04 00:34:02
mbbd000140354,mbcd0029494,mbtp000009,mbrf0001884,,=,,,inhibitor,29,36.0,mM,3,JBP485,,,Inhibition constants (Ki) for different compounds in relation to the uptake of JBP485 and Gly-Sar,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140355,mbcd0029526,mbtp000009,mbrf0001884,,=,,,inhibitor,29,2.55,mM,0.13,JBP923,,,Inhibition constants (Ki) for different compounds in relation to the uptake of JBP485 and Gly-Sar,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140356,mbcd0003618,mbtp000009,mbrf0001884,,=,,,inhibitor,29,1.1,mM,0.11,CEX,,,Inhibition constants (Ki) for different compounds in relation to the uptake of JBP485 and Gly-Sar,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140357,mbcd0000311,mbtp000009,mbrf0001884,,,,,non-substrate,,,,,Cyclosporin A; CsA,,,Caco-2; effect on uptake rate of known substrate,Caco-2,,0.5,mM,,human,mbds0010,,2013-11-04 22:03:19
mbbd000140358,mbcd0029460,mbtp000009,mbrf0001782,,,,,substrate,,,,,valganciclovir,Prodrug of ganciclovir,,Xenopus laevis oocytes,Xenopus laevis oocytes,,10,mM,,human,mbds0010,,2013-11-02 07:20:38
mbbd000140359,mbcd0003087,mbtp000009,mbrf0002469,,=,,,substrate,28,2.26,mM,0.24,Valacyclovir,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140360,mbcd0003134,mbtp000009,mbrf0002469,,,,,substrate,,,,,Penicillin G,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140361,mbcd0029122,mbtp000009,mbrf0001971,,,,,inhibitor,,,,,benzoic acid,,,Caco-2 cells,Caco-2,mbcd0003554,20,microM,,human,mbds0010,,2013-11-10 04:15:57
mbbd000140372,mbcd0029535,mbtp000009,mbrf0001937,,=,,,substrate,25,0.807,mM,0.174,Phe-Sar,,,Inhibition of [3-H]Gly-Sar uptake; human pancreatic cancer AsPC-1 cells,AsPC-1,,,,,human,mbds0010,,2013-11-25 22:59:21
mbbd000140373,mbcd0003494,mbtp000009,mbrf0001937,,=,,,substrate,25,2.62,mM,1.99,Gly-Sar,,,Inhibition of [3-H]Gly-Sar uptake; human pancreatic cancer AsPC-1 cells,AsPC-1,,,,,human,mbds0010,,2013-11-25 22:59:21
mbbd000140374,mbcd0029536,mbtp000009,mbrf0001937,,=,,,substrate,25,0.274,mM,0.047,Bip(OMe)-Sar,,,Inhibition of [3-H]Gly-Sar uptake; human pancreatic cancer AsPC-1 cells,AsPC-1,,,,,human,mbds0010,,2013-11-25 22:59:21
mbbd000140375,mbcd0003494,mbtp000009,mbrf0001937,,=,,,substrate,17,0.608,mM,0.203,Gly-Sar,,,Half maximal peptide concentration for membrane pentential change; human pancreatic cancer AsPC-1 cells,AsPC-1,,,,,human,mbds0010,,2013-11-25 22:59:21
mbbd000140376,mbcd0029535,mbtp000009,mbrf0001937,,=,,,substrate,17,0.263,mM,0.131,Phe-Sar,,,Half maximal peptide concentration for membrane pentential change; human pancreatic cancer AsPC-1 cells,AsPC-1,,,,,human,mbds0010,,2013-11-25 22:59:21
mbbd000140377,mbcd0031696,mbtp000009,mbrf0002482,,=,,,substrate,17,178.0,microM,32,L-cephalexin,,,"membrane potential assay using FlexStation II in HeLa cells stably expressing PEPT1, dose-dependent membrane depolarization",HeLa,,,,,human,mbds0010,,2014-01-27 21:28:32
mbbd000140378,mbcd0003618,mbtp000009,mbrf0002482,,=,,,substrate,17,2.87,microM,3.15,D-cephalexin,,,"membrane potential assay using FlexStation II in HeLa cells stably expressing PEPT1, dose-dependent mem- brane depolarization",HeLa,,,,,human,mbds0010,,2013-11-24 23:55:15
mbbd000140384,mbcd0000823,mbtp000009,mbrf0002405,,,,,inhibitor,,,,,temocapril,Prodrug of temocaprilat,,Caco-2 cells,Caco-2,mbcd0003494,2,mM,,human,mbds0010,,2013-11-10 04:15:57
mbbd000140385,mbcd0003494,mbtp000009,mbrf0002305,,=,,,substrate,28,1.9,mM,0.4,Gly-Sar,,,"MDCK, Madin-Darby canine kidney cells; hPEPT1, human proton-coupled peptide transporter",MDCK,,,,,human,mbds0010,,2013-11-20 19:41:40
mbbd000140386,mbcd0003013,mbtp000009,mbrf0002305,,=,,,inhibitor,119,0.4,mM,0.1,ibuprofen,,,inhibition of uptake of [14C]Gly-Sar in MDCK/hPEPT1 cells,,,,,,human,mbds0010,,2013-12-06 23:49:58
mbbd000140387,mbcd0027248,mbtp000009,mbrf0002305,,,,,inhibitor,,,,,etodoloc,,,MDCK cells,MDCK,mbcd0003494,0.5,mM,,human,mbds0010,,2013-11-10 04:16:10
mbbd000140388,mbcd0029537,mbtp000009,mbrf0001685,,=,,,substrate,16,0.43,mM,0.04,Ile-Leu-Met,,,MDCK/hPEPT1 FLIPR Membrane Potential Assay,MDCK,,,,,human,mbds0010,,2013-12-09 20:08:13
mbbd000140389,mbcd0029538,mbtp000009,mbrf0001685,,=,,,substrate,16,0.47,mM,0.05,Phe-Leu-Ala,,,MDCK/hPEPT1 FLIPR Membrane Potential Assay,MDCK,,,,,human,mbds0010,,2013-12-09 20:08:14
mbbd000140390,mbcd0029539,mbtp000009,mbrf0001685,,=,,,substrate,16,0.49,mM,0.06,Cys-Asn-Met,,,MDCK/hPEPT1 FLIPR Membrane Potential Assay,MDCK,,,,,human,mbds0010,,2013-12-09 20:02:30
mbbd000140391,mbcd0029540,mbtp000009,mbrf0001685,,=,,,substrate,16,0.49,mM,0.07,Ser-Leu-Ala,,,MDCK/hPEPT1 FLIPR Membrane Potential Assay,MDCK,,,,,human,mbds0010,,2013-12-09 20:55:13
mbbd000140392,mbcd0029541,mbtp000009,mbrf0001685,,=,,,substrate,16,0.6,mM,0.05,Met-Glu-Tyr,,,MDCK/hPEPT1 FLIPR Membrane Potential Assay,MDCK,,,,,human,mbds0010,,2013-12-09 20:55:13
mbbd000140393,mbcd0029542,mbtp000009,mbrf0001685,,=,,,substrate,16,0.63,mM,0.09,Cys-Leu-Tyr,,,MDCK/hPEPT1 FLIPR Membrane Potential Assay,MDCK,,,,,human,mbds0010,,2013-12-09 20:55:13
mbbd000140394,mbcd0029543,mbtp000009,mbrf0001685,,=,,,substrate,16,0.63,mM,0.09,Val-Ser-Thr,,,MDCK/hPEPT1 FLIPR Membrane Potential Assay,MDCK,,,,,human,mbds0010,,2013-12-09 20:55:14
mbbd000140395,mbcd0029544,mbtp000009,mbrf0001685,,=,,,substrate,16,0.66,mM,0.06,Phe-Gly-Val,,,MDCK/hPEPT1 FLIPR Membrane Potential Assay,MDCK,,,,,human,mbds0010,,2013-12-09 20:55:14
mbbd000140396,mbcd0029545,mbtp000009,mbrf0001685,,=,,,substrate,16,0.69,mM,0.17,Gly-Tyr-Trp,,,MDCK/hPEPT1 FLIPR Membrane Potential Assay,MDCK,,,,,human,mbds0010,,2013-12-09 20:55:14
mbbd000140397,mbcd0029546,mbtp000009,mbrf0001685,,=,,,substrate,16,0.7,mM,0.07,Met-Leu-Asn,,,MDCK/hPEPT1 FLIPR Membrane Potential Assay,MDCK,,,,,human,mbds0010,,2013-12-09 20:55:13
mbbd000140398,mbcd0029547,mbtp000009,mbrf0001685,,=,,,substrate,16,2.41,mM,0.21,Ala-Ile-Asp,,,MDCK/hPEPT1 FLIPR Membrane Potential Assay,MDCK,,,,,human,mbds0010,,2013-12-09 20:55:14
mbbd000140399,mbcd0029548,mbtp000009,mbrf0001685,,=,,,substrate,16,2.53,mM,0.20,Ser-Ser-Ser,,,MDCK/hPEPT1 FLIPR Membrane Potential Assay,MDCK,,,,,human,mbds0010,,2013-12-09 20:55:14
mbbd000140400,mbcd0029549,mbtp000009,mbrf0001685,,=,,,substrate,16,2.6,mM,0.37,Gly-Thr-Asn,,,MDCK/hPEPT1 FLIPR Membrane Potential Assay,MDCK,,,,,human,mbds0010,,2013-12-09 20:01:03
mbbd000140401,mbcd0029550,mbtp000009,mbrf0001685,,=,,,substrate,16,2.63,mM,0.31,Ser-Asn-Asn,,,MDCK/hPEPT1 FLIPR Membrane Potential Assay,MDCK,,,,,human,mbds0010,,2013-12-09 20:01:02
mbbd000140402,mbcd0029551,mbtp000009,mbrf0001685,,=,,,substrate,16,2.66,mM,0.43,Arg-Ser-Ser,,,MDCK/hPEPT1 FLIPR Membrane Potential Assay,MDCK,,,,,human,mbds0010,,2013-12-09 20:01:01
mbbd000140403,mbcd0003697,mbtp000009,mbrf0001685,,=,,,substrate,16,2.76,mM,0.28,Gly-Gly-Gly,,,MDCK/hPEPT1 FLIPR Membrane Potential Assay,MDCK,,,,,human,mbds0010,,2013-12-09 20:01:00
mbbd000140404,mbcd0030525,mbtp000009,mbrf0001685,,=,,,substrate,16,2.95,mM,0.36,Ser-Cys-Glu,,,MDCK/hPEPT1 FLIPR Membrane Potential Assay,MDCK,,,,,human,mbds0010,,2013-12-09 20:01:06
mbbd000140405,mbcd0029552,mbtp000009,mbrf0001685,,=,,,substrate,16,3.03,mM,0.50,Asn-Gly-His,,,MDCK/hPEPT1 FLIPR Membrane Potential Assay,MDCK,,,,,human,mbds0010,,2013-12-09 19:54:03
mbbd000140406,mbcd0029553,mbtp000009,mbrf0001685,,=,,,substrate,16,3.22,mM,0.30,Asp-Cys-Asp,,,MDCK/hPEPT1 FLIPR Membrane Potential Assay,MDCK,,,,,human,mbds0010,,2013-12-09 20:01:05
mbbd000140407,mbcd0029554,mbtp000009,mbrf0001685,,=,,,substrate,16,3.31,mM,0.32,Gln-Glu-Ile,,,MDCK/hPEPT1 FLIPR Membrane Potential Assay,MDCK,,,,,human,mbds0010,,2013-12-09 20:01:04
mbbd000140408,mbcd0029555,mbtp000009,mbrf0001685,,=,,,substrate,16,0.75,mM,0.07,Thr-Met-Phe,,,MDCK/hPEPT1 FLIPR Membrane Potential Assay,MDCK,,,,,human,mbds0010,,2013-12-09 19:54:03
mbbd000140409,mbcd0029556,mbtp000009,mbrf0001685,,=,,,substrate,16,0.79,mM,0.10,Ser-Gln-Phe,,,MDCK/hPEPT1 FLIPR Membrane Potential Assay,MDCK,,,,,human,mbds0010,,2013-12-09 19:54:02
mbbd000140410,mbcd0029557,mbtp000009,mbrf0001685,,=,,,substrate,16,0.8,mM,0.08,Arg-Pro-Ser,,,MDCK/hPEPT1 FLIPR Membrane Potential Assay,MDCK,,,,,human,mbds0010,,2013-12-09 20:51:08
mbbd000140411,mbcd0029558,mbtp000009,mbrf0001685,,=,,,substrate,16,1.01,mM,0.10,Arg-Ile-Gln,,,MDCK/hPEPT1 FLIPR Membrane Potential Assay,MDCK,,,,,human,mbds0010,,2013-12-09 20:51:08
mbbd000140412,mbcd0029559,mbtp000009,mbrf0001685,,=,,,substrate,16,1.3,mM,0.22,Ala-Asp-Tyr,,,MDCK/hPEPT1 FLIPR Membrane Potential Assay,MDCK,,,,,human,mbds0010,,2013-12-09 20:51:08
mbbd000140413,mbcd0029560,mbtp000009,mbrf0001685,,=,,,substrate,16,1.25,mM,0.14,Gly-Gly-Leu,,,MDCK/hPEPT1 FLIPR Membrane Potential Assay,MDCK,,,,,human,mbds0010,,2013-12-09 20:05:52
mbbd000140414,mbcd0029561,mbtp000009,mbrf0001685,,=,,,substrate,16,1.67,mM,0.21,Trp-Pro-Tyr,,,MDCK/hPEPT1 FLIPR Membrane Potential Assay,MDCK,,,,,human,mbds0010,,2013-12-09 20:51:07
mbbd000140415,mbcd0029562,mbtp000009,mbrf0001685,,=,,,substrate,16,1.7,mM,0.17,Ala-Asn-Ser,,,MDCK/hPEPT1 FLIPR Membrane Potential Assay,MDCK,,,,,human,mbds0010,,2013-12-09 20:51:07
mbbd000140416,mbcd0029563,mbtp000009,mbrf0001685,,=,,,substrate,16,1.92,mM,0.16,Arg-Ile-Thr,,,MDCK/hPEPT1 FLIPR Membrane Potential Assay,MDCK,,,,,human,mbds0010,,2013-12-09 20:51:08
mbbd000140417,mbcd0029564,mbtp000009,mbrf0001685,,=,,,substrate,16,1.95,mM,0.23,His-Thr-Asn,,,MDCK/hPEPT1 FLIPR Membrane Potential Assay,MDCK,,,,,human,mbds0010,,2013-12-09 20:51:08
mbbd000140418,mbcd0029565,mbtp000009,mbrf0001685,,=,,,substrate,16,3.44,mM,0.38,Asn-Arg-Leu,,,MDCK/hPEPT1 FLIPR Membrane Potential Assay,MDCK,,,,,human,mbds0010,,2013-12-09 20:51:08
mbbd000140419,mbcd0029566,mbtp000009,mbrf0001685,,=,,,substrate,16,3.87,mM,0.60,Glu-Ser-Met,,,MDCK/hPEPT1 FLIPR Membrane Potential Assay,MDCK,,,,,human,mbds0010,,2013-12-09 20:51:08
mbbd000140420,mbcd0029567,mbtp000009,mbrf0001685,,=,,,substrate,16,5.82,mM,0.49,Leu-Leu-Asp,,,MDCK/hPEPT1 FLIPR Membrane Potential Assay,MDCK,,,,,human,mbds0010,,2013-12-09 21:01:28
mbbd000140421,mbcd0029568,mbtp000009,mbrf0001685,,=,,,substrate,16,11.4,mM,1.4,Glu-Glu-Glu,,,MDCK/hPEPT1 FLIPR Membrane Potential Assay,MDCK,,,,,human,mbds0010,,2013-12-09 21:01:28
mbbd000140422,mbcd0029569,mbtp000009,mbrf0001685,,=,,,substrate,16,13.5,mM,,Asp-Tyr-Thr,,,MDCK/hPEPT1 FLIPR Membrane Potential Assay,MDCK,,,,,human,mbds0010,,2013-12-09 21:01:29
mbbd000140423,mbcd0029570,mbtp000009,mbrf0001685,,=,,,substrate,16,16.0,mM,,Gly-Trp-Val,,,MDCK/hPEPT1 FLIPR Membrane Potential Assay,MDCK,,,,,human,mbds0010,,2013-12-09 21:01:29
mbbd000140424,mbcd0029571,mbtp000009,mbrf0001685,,=,,,substrate,16,21.1,mM,2.7,Asp-Arg-Arg,,,MDCK/hPEPT1 FLIPR Membrane Potential Assay,MDCK,,,,,human,mbds0010,,2013-12-09 21:01:27
mbbd000140425,mbcd0029572,mbtp000009,mbrf0001685,,=,,,substrate,16,22.0,mM,,Arg-His-Asp,,,MDCK/hPEPT1 FLIPR Membrane Potential Assay,MDCK,,,,,human,mbds0010,,2013-12-09 21:01:27
mbbd000140426,mbcd0029573,mbtp000009,mbrf0001685,,=,,,substrate,16,26.0,mM,,Trp-Glu-Asp,,,MDCK/hPEPT1 FLIPR Membrane Potential Assay,MDCK,,,,,human,mbds0010,,2013-12-09 21:01:28
mbbd000140427,mbcd0029574,mbtp000009,mbrf0001685,,=,,,substrate,16,28.0,mM,,Glu-Glu-Ser,,,MDCK/hPEPT1 FLIPR Membrane Potential Assay,MDCK,,,,,human,mbds0010,,2013-12-09 21:01:28
mbbd000140428,mbcd0029575,mbtp000009,mbrf0001685,,=,,,non-substrate,116,0.02,mM,,Met-Pro-Pro,,,[14C]Gly-Sar Uptake Competition in MDCK/hPEPT1 Cells,MDCK,,,,,human,mbds0010,,2013-11-24 23:11:46
mbbd000140429,mbcd0003714,mbtp000009,mbrf0001685,,=,,,inhibitor,116,0.08,mM,0.3,Trp-Trp-Trp,,,[14C]Gly-Sar Uptake Competition in MDCK/hPEPT1 Cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140430,mbcd0029577,mbtp000009,mbrf0001685,,=,,,non-substrate,116,1.8,mM,0.6,Leu-Asp-Trp,,,[14C]Gly-Sar Uptake Competition in MDCK/hPEPT1 Cells,MDCK,,,,,human,mbds0010,,2014-03-04 00:29:06
mbbd000140431,mbcd0029578,mbtp000009,mbrf0001685,,=,,,non-substrate,116,2.5,mM,1.5,Gly-Pro-Lys,,,[14C]Gly-Sar Uptake Competition in MDCK/hPEPT1 Cells,MDCK,,,,,human,mbds0010,,2014-03-04 00:29:06
mbbd000140432,mbcd0029579,mbtp000009,mbrf0001685,,=,,,non-substrate,116,4.0,mM,2,Pro-Trp-Ile,,,[14C]Gly-Sar Uptake Competition in MDCK/hPEPT1 Cells,MDCK,,,,,human,mbds0010,,2014-03-04 00:29:06
mbbd000140433,mbcd0029580,mbtp000009,mbrf0001685,,=,,,non-substrate,116,8.5,mM,3.2,Pro-Glu-Leu,,,[14C]Gly-Sar Uptake Competition in MDCK/hPEPT1 Cells,MDCK,,,,,human,mbds0010,,2014-03-04 00:29:06
mbbd000140434,mbcd0017980,mbtp000009,mbrf0001656,,,,,non-substrate,,,,,ciprofloxacin,,,MDCK cells,MDCK,,25,microM,,human,mbds0010,,2013-11-10 04:16:09
mbbd000140435,mbcd0029581,mbtp000009,mbrf0002147,,~,,,substrate,28,4.0,mM,,LDX,,,Gly-Sar uptake inhibition in CHO cells expressing hPepT1,CHO,,,,,human,mbds0010,,2013-11-24 23:15:20
mbbd000140436,mbcd0029583,mbtp000009,mbrf0001714,,=,,,inhibitor,3,31.0,%,8,cHPMPC,,,"inhibition of Uptake of 5 microM Gly-Sar (0.1 microM[3H]-Gly-Sar)in Na+ buffer at pH6 in Xenopus laevis oocytes overexpressing human PEPT1 (hPEPT1, SLC15A1) 10mM substrate",,,,,,human,mbds0010,,2013-12-09 19:55:33
mbbd000140437,mbcd0029584,mbtp000009,mbrf0001714,,=,,,inhibitor,3,76.0,%,3,2a,,,"inhibition of Uptake of 5 microM Gly-Sar (0.1 microM[3H]-Gly-Sar)in Na+ buffer at pH6 in Xenopus laevis oocytes overexpressing human PEPT1 (hPEPT1, SLC15A1) 10mM substrate",,,,,,human,mbds0010,,2013-12-09 19:55:34
mbbd000140438,mbcd0029587,mbtp000009,mbrf0001714,,=,,,inhibitor,3,36.0,%,9,2d,,,"inhibition of Uptake of 5 microM Gly-Sar (0.1 microM[3H]-Gly-Sar)in Na+ buffer at pH6 in Xenopus laevis oocytes overexpressing human PEPT1 (hPEPT1, SLC15A1) 10mM substrate",,,,,,human,mbds0010,,2013-12-09 19:55:31
mbbd000140439,mbcd0029588,mbtp000009,mbrf0001714,,=,,,inhibitor,3,67.0,%,3,3a,,,"inhibition of Uptake of 5 microM Gly-Sar (0.1 microM[3H]-Gly-Sar)in Na+ buffer at pH6 in Xenopus laevis oocytes overexpressing human PEPT1 (hPEPT1, SLC15A1) 10mM substrate",,,,,,human,mbds0010,,2013-12-09 20:51:18
mbbd000140440,mbcd0029589,mbtp000009,mbrf0001714,,=,,,inhibitor,3,76.0,%,5,3b,,,"inhibition of Uptake of 5 microM Gly-Sar (0.1 microM[3H]-Gly-Sar)in Na+ buffer at pH6 in Xenopus laevis oocytes overexpressing human PEPT1 (hPEPT1, SLC15A1) 10mM substrate",,,,,,human,mbds0010,,2013-12-09 21:01:17
mbbd000140441,mbcd0029592,mbtp000009,mbrf0001714,,=,,,inhibitor,3,97.0,%,1,6a,,,"inhibition of Uptake of 5 microM Gly-Sar (0.1 microM[3H]-Gly-Sar)in Na+ buffer at pH6 in Xenopus laevis oocytes overexpressing human PEPT1 (hPEPT1, SLC15A1) 10mM substrate",,,,,,human,mbds0010,,2013-12-09 19:56:21
mbbd000140442,mbcd0029593,mbtp000009,mbrf0001714,,=,,,inhibitor,3,97.0,%,1,6b,,,"inhibition of Uptake of 5 microM Gly-Sar (0.1 microM[3H]-Gly-Sar)in Na+ buffer at pH6 in Xenopus laevis oocytes overexpressing human PEPT1 (hPEPT1, SLC15A1) 10mM substrate",,,,,,human,mbds0010,,2013-12-09 19:56:21
mbbd000140443,mbcd0003087,mbtp000009,mbrf0001714,,=,,,substrate,3,94.0,%,2,7,,,"inhibition of Uptake of 5 microM Gly-Sar (0.1 microM[3H]-Gly-Sar)in Na+ buffer at pH6 in Xenopus laevis oocytes overexpressing human PEPT1 (hPEPT1, SLC15A1) 10mM substrate",Xenopus laevis oocytes,,,,,human,mbds0010,,2013-12-09 19:56:21
mbbd000140444,mbcd0029594,mbtp000009,mbrf0001714,,=,,,substrate,3,87.0,%,3,8,,,"inhibition of Uptake of 5 microM Gly-Sar (0.1 microM[3H]-Gly-Sar)in Na+ buffer at pH6 in Xenopus laevis oocytes overexpressing human PEPT1 (hPEPT1, SLC15A1) 10mM substrate",Xenopus laevis oocytes,,,,,human,mbds0010,,2013-12-09 19:56:21
mbbd000140445,mbcd0029585,mbtp000009,mbrf0001714,,,,,inhibitor,,,,,2b,,,"inhibition of Uptake of 5 microM Gly-Sar (0.1 microM[3H]-Gly-Sar)in Na+ buffer at pH6 in Xenopus laevis oocytes overexpressing human PEPT1 (hPEPT1, SLC15A1) 10mM substrate",,,,,,human,mbds0010,,2013-12-09 20:51:22
mbbd000140446,mbcd0029586,mbtp000009,mbrf0001714,,,,,inhibitor,,,,,2c,,,"inhibition of Uptake of 5 microM Gly-Sar (0.1 microM[3H]-Gly-Sar)in Na+ buffer at pH6 in Xenopus laevis oocytes overexpressing human PEPT1 (hPEPT1, SLC15A1) 10mM substrate",,,,,,human,mbds0010,,2013-12-09 19:56:21
mbbd000140447,mbcd0029590,mbtp000009,mbrf0001714,,,,,inhibitor,,,,,4,,,"inhibition of Uptake of 5 microM Gly-Sar (0.1 microM[3H]-Gly-Sar)in Na+ buffer at pH6 in Xenopus laevis oocytes overexpressing human PEPT1 (hPEPT1, SLC15A1) 10mM substrate",,,,,,human,mbds0010,,2013-12-09 19:56:20
mbbd000140448,mbcd0003552,mbtp000009,mbrf0002177,,=,,,substrate,33,20.0,pmol / min optical density,2,ALA,,,P. pastoris yeasts expressing PEPT2 and PEPT1,Pichia pastoris,,,,,human,mbds0010,,2013-11-24 23:56:36
mbbd000140449,mbcd0029595,mbtp000009,mbrf0002177,,,,,inhibitor,,,,,Und-ALA; undecanoyl-ALA,,,P. pastoris,Pichia pastoris,mbcd0003552,0.6,mM,,human,mbds0010,,2013-12-09 07:10:35
mbbd000140450,mbcd0001130,mbtp000009,mbrf0002337,,,,,substrate,,,,,cefdinir,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140451,mbcd0000406,mbtp000009,mbrf0002337,,,,,substrate,,,,,FK089,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140452,mbcd0029596,mbtp000009,mbrf0002337,,,,,substrate,,,,,methyldopa-L-phenylalanine,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140453,mbcd0029597,mbtp000009,mbrf0002337,,,,,substrate,,,,,L-dopa-L-phenylalanine,,,,,,,,,human,mbds0010,,2013-11-12 22:54:42
mbbd000140454,mbcd0015978,mbtp000009,mbrf0002237,,,,,substrate,,,,,NAAG,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140456,mbcd0003553,mbtp000009,mbrf0002736,,=,,,substrate,28,8.3,mM,,cephradine; CED,,,Caco-2; pH 6,Caco-2,,,,,human,mbds0010,,2013-10-31 21:54:55
mbbd000140457,mbcd0001298,mbtp000009,mbrf0002732,,=,,,substrate,28,7.6,mM,1.5,cefaclor; CCL,,,Caco-2; pH 6,Caco-2,,1-25,mM,,human,mbds0010,,2013-10-31 21:54:55
mbbd000140458,mbcd0003618,mbtp000009,mbrf0002733,,=,,,substrate,22,6.5,nmol min-1 (mg protein)-1,0.9,cephalexin; CEX,,,Caco-2; extracellular pH 6,Caco-2,,0.5-35,mM,,human,mbds0010,,2013-10-31 23:00:37
mbbd000140459,mbcd0003618,mbtp000009,mbrf0002733,,=,,,substrate,28,7.5,mM,2.8,cephalexin; CEX,,,Caco-2; extracellular pH 6,Caco-2,,0.5-35,mM,,human,mbds0010,,2013-10-31 23:00:37
mbbd000140460,mbcd0003554,mbtp000009,mbrf0002734,,=,,,substrate,28,0.5,mM,,ceftibuten; CETB,,,Caco-2; pH 5.5,Caco-2,,0.1-10.0,mM,,human,mbds0010,,2013-10-31 21:54:55
mbbd000140461,mbcd0003554,mbtp000009,mbrf0002736,,=,,,substrate,28,1.0,mM,,ceftibuten; CETB,,,Caco-2; pH 6,Caco-2,,,,,human,mbds0010,,2013-10-31 21:54:55
mbbd000140463,mbcd0003733,mbtp000009,mbrf0002736,,=,,,substrate,28,1.4,mM,,cefixime; CFIX,,,Caco-2; pH 6,Caco-2,,,,,human,mbds0010,,2013-10-31 21:54:56
mbbd000140464,mbcd0003733,mbtp000009,mbrf0002736,,=,,,substrate,28,17.0,mM,,cefixime; CFIX,,,Caco-2; pH 6,Caco-2,,1-50,mM,,human,mbds0010,,2013-10-31 21:54:55
mbbd000140465,mbcd0003666,mbtp000009,mbrf0002016,,=,,,inhibitor,3,93.7,%,2.1,ACPC,,,Inhibitory effects of various compounds on 36?M[3H]-Gly-Sar uptake into Caco-2 cells,Caco-2,mbcd0003494,5,mM,,human,mbds0010,,2013-11-01 23:09:42
mbbd000140466,mbcd0003622,mbtp000009,mbrf0002016,,=,,,inhibitor,3,26.3,%,4.7,ABPC,,,Inhibitory effects of various compounds on 36?M[3H]-Gly-Sar uptake into Caco-2 cells,Caco-2,mbcd0003494,20,mM,,human,mbds0010,,2013-11-01 23:09:42
mbbd000140467,mbcd0001298,mbtp000009,mbrf0002016,,=,,,inhibitor,3,47.3,%,4.8,CCL,,,Inhibitory effects of various compounds on 36?M[3H]-Gly-Sar uptake into Caco-2 cells,Caco-2,mbcd0003494,5,mM,,human,mbds0010,,2013-11-01 23:09:42
mbbd000140468,mbcd0001298,mbtp000009,mbrf0002016,,=,,,inhibitor,3,83.3,%,1.9,CCL,,,Inhibitory effects of various compounds on 36?M[3H]-Gly-Sar uptake into Caco-2 cells,Caco-2,mbcd0003494,10,mM,,human,mbds0010,,2013-11-01 23:09:42
mbbd000140469,mbcd0003553,mbtp000009,mbrf0002016,,=,,,inhibitor,3,74.0,%,3.4,CED,,,Inhibitory effects of various compounds on 36?M[3H]-Gly-Sar uptake into Caco-2 cells,Caco-2,mbcd0003494,20,mM,,human,mbds0010,,2013-11-01 23:09:42
mbbd000140470,mbcd0003618,mbtp000009,mbrf0002016,,=,,,inhibitor,3,71.2,%,2.7,CEX,,,Inhibitory effects of various compounds on 36?M[3H]-Gly-Sar uptake into Caco-2 cells,Caco-2,mbcd0003494,20,mM,,human,mbds0010,,2013-11-01 23:09:42
mbbd000140471,mbcd0003733,mbtp000009,mbrf0002016,,=,,,inhibitor,3,37.9,%,3.5,CFIX,,,Inhibitory effects of various compounds on 36?M[3H]-Gly-Sar uptake into Caco-2 cells,Caco-2,mbcd0003494,5,mM,,human,mbds0010,,2013-11-01 23:09:42
mbbd000140472,mbcd0003497,mbtp000009,mbrf0002016,,=,,,non-inhibitor,3,17.0,%,10.5,CEZ,,,Inhibitory effects of various compounds on 36?M[3H]-Gly-Sar uptake into Caco-2 cells,Caco-2,mbcd0003494,10,mM,,human,mbds0010,,2013-11-01 23:09:42
mbbd000140473,mbcd0003497,mbtp000009,mbrf0002016,,=,,,inhibitor,3,42.5,%,3.9,CEZ,,,Inhibitory effects of various compounds on 36?M[3H]-Gly-Sar uptake into Caco-2 cells,Caco-2,mbcd0003494,20,mM,,human,mbds0010,,2013-11-01 23:09:42
mbbd000140474,mbcd0020727,mbtp000009,mbrf0002016,,=,,,non-inhibitor,3,10.5,%,10.8,CTM,,,Inhibitory effects of various compounds on 36?M[3H]-Gly-Sar uptake into Caco-2 cells,Caco-2,mbcd0003494,20,mM,,human,mbds0010,,2013-11-01 23:09:42
mbbd000140475,mbcd0003905,mbtp000009,mbrf0002016,,=,,,non-substrate,140,0.0,,,corticosterone,carrier-mediated uptake clearance,,Caco-2,Caco-2,,,,,human,mbds0010,,2014-03-04 00:29:06
mbbd000140476,mbcd0001105,mbtp000009,mbrf0001752,,=,,,inhibitor,29,35.5,microM,,fosinopril,,,GlySar uptake was competitively inhibited by fosinopril in both Caco-2,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140477,mbcd0003494,mbtp000009,mbrf0001752,,=,,,substrate,141,16.5,nmol / mg protein / 10 min,0.9,Gly-Sar,,,Caco-2 cells,Caco-2,,,,,human,mbds0010,,2013-11-24 23:12:32
mbbd000140478,mbcd0003494,mbtp000009,mbrf0001752,,=,,,substrate,16,1015.0,microM,13,Gly-Sar,,,Caco-2 cells,Caco-2,,,,,human,mbds0010,,2013-11-24 23:12:33
mbbd000140479,mbcd0007683,mbtp000009,mbrf0002446,,,,,substrate,,,,,sulpiride,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140480,mbcd0003087,mbtp000009,mbrf0001782,,=,,,substrate,29,0.49,mM,0.04,valaciclovir,,,Caco-2 cells,Caco-2,,,,,human,mbds0010,,2013-12-08 01:46:50
mbbd000140481,mbcd0003087,mbtp000009,mbrf0001782,,=,,,substrate,29,0.74,mM,0.14,valaciclovir,,,hPEPT1-HeLa,HeLa,,,,,human,mbds0010,,2013-12-08 01:46:51
mbbd000140482,mbcd0029460,mbtp000009,mbrf0001782,,=,,,substrate,29,1.68,mM,0.30,valganciclovir,Prodrug of ganciclovir,,Caco-2 cells,Caco-2,,,,,human,mbds0010,,2013-12-08 01:46:51
mbbd000140483,mbcd0029460,mbtp000009,mbrf0001782,,=,,,substrate,29,2.71,mM,0.40,valganciclovir,Prodrug of ganciclovir,,hPEPT1-HeLa,HeLa,,,,,human,mbds0010,,2013-12-08 01:46:51
mbbd000140484,mbcd0029598,mbtp000009,mbrf0002002,,=,,,inhibitor,25,52.0,microM,9,PD 158473,,,Gly Sar uptake inhibition in CHO-PEPT1 cells,,,,,,human,mbds0010,,2013-07-10 21:10:36
mbbd000140485,mbcd0029598,mbtp000009,mbrf0002002,,=,,,substrate,28,107.0,microM,,PD 158473,,,Caco-2 cells,Caco-2,,,,,human,mbds0010,,2013-11-24 23:12:33
mbbd000140486,mbcd0013669,mbtp000009,mbrf0002002,,,,,inhibitor,,,,,Phe,,,"inhibition of PD158473 uptake in CHO-Pept1 cells , pH6.0, 15 minute incubation, 5mM substrate",CHO,mbcd0029598,5,mM,,human,mbds0010,,2013-11-11 03:59:22
mbbd000140487,mbcd0013669,mbtp000009,mbrf0002002,,=,,,inhibitor,29,147.0,microM,,L-Phe,,,"inhibition of PD158473 uptake in CHO-Pept1 cells , pH6.0, 15 minute incubation; 20, 40 and 60 microM substrate",CHO,mbcd0029598,5,mM,,human,mbds0010,,2013-07-10 21:46:58
mbbd000140488,mbcd0020955,mbtp000009,mbrf0002002,,,,,inhibitor,,,,,Leu,,,"inhibition of PD158473 uptake in CHO-Pept1 cells , pH6.0, 15 minute incubation, 5mM substrate",CHO,mbcd0029598,5,mM,,human,mbds0010,,2013-11-11 03:59:22
mbbd000140489,mbcd0029599,mbtp000009,mbrf0001893,,,,,non-substrate,,,,,gamma-iE-DAP,PEPT2 selective substrate,,,,,,,,human,mbds0010,,2013-11-24 03:25:24
mbbd000140490,mbcd0029165,mbtp000009,mbrf0001998,,,,,non-substrate,,,,,tebipenem pivoxyl,,,,,,,,,human,mbds0010,,2013-11-24 02:54:53
mbbd000140496,mbcd0029604,mbtp000009,mbrf0001361,,=,,,substrate,33,8.75,nmol (mg protein)-1 (30 min)-1,1.03,L-Val-AZT,,,PEPT1-overexpressing Caco-2 cells; uptake,Caco-2,,,,,human,mbds0010,,2013-12-09 05:54:21
mbbd000140498,mbcd0029605,mbtp000009,mbrf0002771,,,,,substrate,,,,,5'-O-L-valyl-gemcitabine,,,HeLa/hPEPT1 cells; uptake,HeLa,,,,,human,mbds0010,,2013-11-19 06:05:55
mbbd000140499,mbcd0029606,mbtp000009,mbrf0002772,,,,,substrate,,,,,5'-O-L-valyl floxuridine,,,HeLa/PEPT1 cells; uptake,HeLa,,,,,human,mbds0010,,2013-11-19 06:06:15
mbbd000140500,mbcd0000946,mbtp000009,mbrf0002029,,=,,,substrate,28,4.5,mM,1.3,midodrine,,,Caco-2 cells,Caco-2,,,,,human,mbds0010,,2013-11-02 05:47:00
mbbd000140501,mbcd0000946,mbtp000009,mbrf0002029,,=,,,inhibitor,25,2.8,mM,0.1,midodrine,,,Gly-Sar uptake inhibition in Caco-2 cells,Caco-2,mbcd0003494,,,,human,mbds0010,,2013-11-02 05:47:00
mbbd000140502,mbcd0029607,mbtp000009,mbrf0002029,,,,,substrate,,,,,DMAE-Val,,,Caco-2 cells,Caco-2,,0.5,mM,,human,mbds0010,,2013-11-10 04:15:58
mbbd000140503,mbcd0029608,mbtp000009,mbrf0002029,,,,,substrate,,,,,DMAE-Tyr,,,Caco-2 cells,Caco-2,,0.5,mM,,human,mbds0010,,2013-11-10 04:15:58
mbbd000140504,mbcd0029609,mbtp000009,mbrf0002029,,,,,substrate,,,,,DMAE-Cys,,,Caco-2 cells,Caco-2,,0.5,mM,,human,mbds0010,,2013-11-10 04:15:58
mbbd000140505,mbcd0029610,mbtp000009,mbrf0002029,,,,,substrate,,,,,DMAE-Glu,,,Caco-2 cells,Caco-2,,0.5,mM,,human,mbds0010,,2013-11-10 04:15:58
mbbd000140506,mbcd0029611,mbtp000009,mbrf0002029,,,,,non-substrate,,,,,DMAE-Ile,,,Caco-2 cells,Caco-2,,0.5,mM,,human,mbds0010,,2013-11-10 04:15:58
mbbd000140507,mbcd0029612,mbtp000009,mbrf0002029,,,,,non-substrate,,,,,DMAE-Phe,,,Caco-2 cells,Caco-2,,0.5,mM,,human,mbds0010,,2013-11-10 04:15:59
mbbd000140508,mbcd0029613,mbtp000009,mbrf0002029,,,,,non-substrate,,,,,DMAE-Pro,,,Caco-2 cells,Caco-2,,0.5,mM,,human,mbds0010,,2013-11-10 04:15:59
mbbd000140509,mbcd0029614,mbtp000009,mbrf0002029,,,,,non-substrate,,,,,DMAE-Lys,,,Caco-2 cells,Caco-2,,0.5,mM,,human,mbds0010,,2013-11-10 04:15:59
mbbd000140510,mbcd0029615,mbtp000009,mbrf0002251,,=,,,substrate,28,0.91,mM,,4a,,,Caco-2 cells,Caco-2,,,,,human,mbds0010,,2013-11-24 23:12:33
mbbd000140511,mbcd0029615,mbtp000009,mbrf0002251,,=,,,substrate,22,11.94,nmol / mg protein / 10 min,,4a,,,Caco-2 cells,Caco-2,,,,,human,mbds0010,,2013-11-24 23:12:33
mbbd000140514,mbcd0029618,mbtp000009,mbrf0002029,,~,,,substrate,33,1.5,nmol/mg protein/h,0.05,DMAE; desglymidodrine,,,Caco-2 cells,Caco-2,,,,,human,mbds0010,,2013-11-22 20:32:21
mbbd000140517,mbcd0029619,mbtp000009,mbrf0002556,,=,,,substrate,28,1.2,mM,0.2,NP-647,,,Caco-2 cell monolayers,Caco-2,,,,,human,mbds0010,,2013-11-24 23:12:34
mbbd000140518,mbcd0029619,mbtp000009,mbrf0002556,,=,,,substrate,22,2.2,microM / min,0.1,NP-647,,,Caco-2 cell monolayers,Caco-2,,,,,human,mbds0010,,2013-11-24 23:12:34
mbbd000140519,mbcd0003906,mbtp000009,mbrf0001756,,,,,inducer,,,,,cyclophosphamide,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140520,mbcd0003963,mbtp000009,mbrf0001756,,,,,inducer,,,,,5-fluoro uracil,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140521,mbcd0013669,mbtp000009,mbrf0001756,,,,,inducer,,,,,Phe,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140522,mbcd0003628,mbtp000009,mbrf0001756,,,,,inducer,,,,,Gly-Phe,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140523,mbcd0003648,mbtp000009,mbrf0000105,,=,,,inhibitor,3,20.3,%,6.3,TbtR-NH2,,,inhibition of Gly-Sar uptake,,mbcd0003494,1.0,mM,,human,mbds0010,,2015-08-03 01:58:35
mbbd000140524,mbcd0029620,mbtp000009,mbrf0000105,,=,,,inhibitor,3,10.4,%,2.3,BipR-OMe,,,inhibition of Gly-Sar uptake,,mbcd0003494,1.0,mM,,human,mbds0010,,2015-08-03 01:58:35
mbbd000140525,mbcd0029622,mbtp000009,mbrf0000105,,=,,,inhibitor,3,15.1,%,6.1,RWR-NH2,,,inhibition of Gly-Sar uptake,,mbcd0003494,1.0,mM,,human,mbds0010,,2015-08-03 01:58:35
mbbd000140526,mbcd0003821,mbtp000009,mbrf0000105,,=,,,non-inhibitor,3,-3.3,%,8.3,RBipR-NH2,,,inhibition of Gly-Sar uptake; hPEPT1 expressed by Xenopus laevis oocytes,Xenopus laevis oocytes,mbcd0003494,0.25 - 1.0,mM,,human,mbds0010,,2015-08-03 01:57:36
mbbd000140527,mbcd0003811,mbtp000009,mbrf0000105,,=,,,inhibitor,3,87.6,%,0.5,RWR-NHBn,suggested that RWR-NHBn can also impair membrane protein functions in an unspecific manner,,inhibition of Gly-Sar uptake,,mbcd0003494,,,,human,mbds0010,,2015-08-03 01:58:35
mbbd000140528,mbcd0003821,mbtp000009,mbrf0000105,,=,,,inhibitor,25,0.6,mM,,TbtR-NH2,,,inhibition of Gly-Sar uptake,,mbcd0003494,,,,human,mbds0010,,2015-08-03 01:58:35
mbbd000140529,mbcd0029622,mbtp000009,mbrf0000105,,=,,,inhibitor,25,2.7,mM,,RWR-NH2,,,inhibition of Gly-Sar uptake,,mbcd0003494,,,,human,mbds0010,,2015-08-03 01:58:35
mbbd000140530,mbcd0029621,mbtp000009,mbrf0000105,,=,,,inhibitor,28,3.7,mM,0.9,KWK-OH,,,inhibition of Gly-Sar uptake,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140531,mbcd0000235,mbtp000009,mbrf0001957,,>,,,non-substrate,29,20.0,mM,,cefesoludin,,,,,,,,,human,mbds0010,,2013-11-27 01:22:05
mbbd000140532,mbcd0003494,mbtp000009,mbrf0002773,,=,,,substrate,28,269.0,microM,67.9,Gly-Sar,,,Kinetic parameters for uptake mediated by wild type hPEPT1; HEK293 cells transfected with WT-hPEPT1,HEK293,,,,,human,mbds0010,,2013-11-25 22:59:21
mbbd000140533,mbcd0003494,mbtp000009,mbrf0002773,,=,,,substrate,22,3.14,nmol / mg protein / min,0.14,Gly-Sar,,,Kinetic parameters for uptake mediated by wild type hPEPT1; HEK293 cells transfected with WT-hPEPT1,HEK293,,,,,human,mbds0010,,2013-11-25 22:59:21
mbbd000140534,mbcd0029712,mbtp000009,mbrf0000114,,,,,non-substrate,,,,,3HPG,,,[3H]Gly-Sar uptake inhibition in HeLa/hPEPT1 cells,HeLa,,,,,human,mbds0010,,2013-11-24 23:55:14
mbbd000140539,mbcd0029482,mbtp000009,mbrf0002367,,=,,,inhibitor,29,0.19,mM,0.01,alafosfalin,,,Caco-2 cell (PEPT1) uptake competition assays with Gly-Sar,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140540,mbcd0003598,mbtp000009,mbrf0002367,,=,,,inhibitor,29,0.21,mM,0.02,ala-lys,,,Caco-2 cell (PEPT1) uptake competition assays with Gly-Sar,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140541,mbcd0003806,mbtp000009,mbrf0002367,,=,,,inhibitor,29,3.0,mM,1.0,cloxacillin,,,Caco-2 cell (PEPT1) uptake competition assays with Gly-Sar,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140542,mbcd0029626,mbtp000009,mbrf0002367,,,,,inhibitor,,,,,4-Toluenesulfonyl-ureido-carnosine,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140543,mbcd0029627,mbtp000009,mbrf0002367,,,,,inhibitor,,,,,"Val-2-bromo-5, 6-dichloro-1- (b-D-ribofuranosyl) b",,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140544,mbcd0029628,mbtp000009,mbrf0002367,,,,,substrate,,,,,Val-cytarabine,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140545,mbcd0001241,mbtp000009,mbrf0002367,,,,,inhibitor,,,,,nateglinide,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140546,mbcd0029629,mbtp000009,mbrf0002367,,,,,inhibitor,,,,,glibenclamide,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140547,mbcd0029630,mbtp000009,mbrf0002367,,,,,inhibitor,,,,,arphamenine B,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140548,mbcd0029631,mbtp000009,mbrf0002367,,,,,inhibitor,,,,,S-benzylcaptopril,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140549,mbcd0029632,mbtp000009,mbrf0002367,,,,,substrate,,,,,ceronapril,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140550,mbcd0003550,mbtp000009,mbrf0002367,,,,,inhibitor,,,,,dicloxacillin,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140551,mbcd0029633,mbtp000009,mbrf0002367,,,,,inhibitor,,,,,epicillin,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140552,mbcd0000560,mbtp000009,mbrf0002367,,,,,inhibitor,,,,,metampicillin,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140553,mbcd0003650,mbtp000009,mbrf0002367,,,,,inhibitor,,,,,moxalactam,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140554,mbcd0029635,mbtp000009,mbrf0002367,,,,,substrate,,,,,cephaloglycine,low affinity,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140555,mbcd0001075,mbtp000009,mbrf0002367,,,,,non-substrate,,,,,ceftazidime,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140556,mbcd0020727,mbtp000009,mbrf0002367,,,,,non-substrate,,,,,cefotiam,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140557,mbcd0000092,mbtp000009,mbrf0002367,,,,,non-substrate,,,,,6-amino penicillanic acid,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140558,mbcd0000097,mbtp000009,mbrf0002367,,,,,inhibitor,,,,,7-Aminocephalosporanic acid,low afiinity,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140559,mbcd0025577,mbtp000009,mbrf0001692,,=,,,inhibitor,3,36.0,%,,ethanol,no effect on Vmax,,inhibition of Gly-Sar transport,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140560,mbcd0029628,mbtp000009,mbrf0002208,,=,,,substrate,25,2.18,mM,0.12,Val-cytarabine,,,inhibition of Gly-Sar; Caco-2 cells,Caco-2,,,,,human,mbds0010,,2013-11-26 01:55:29
mbbd000140561,mbcd0000446,mbtp000009,mbrf0001747,,,,,inhibitor,,,,,pentaglycine,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140562,mbcd0025833,mbtp000009,mbrf0002464,,,,,non-substrate,,,,,sitagliptin,,,HEK293 cells,HEK293,,100,microM,,human,mbds0010,,2013-11-10 04:16:02
mbbd000140563,mbcd0003739,mbtp000009,mbrf0001926,,=,,,inhibitor,29,0.15,mM,0.02,H-ala-pro-OH,,,inhibition of [14C]Gly-Sar uptake in Caco-2 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140564,mbcd0003517,mbtp000009,mbrf0001926,,=,,,inhibitor,29,0.18,mM,0.01,H-leu-pro-OH,,,inhibition of [14C]Gly-Sar uptake in Caco-2 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140565,mbcd0003508,mbtp000009,mbrf0001926,,=,,,inhibitor,29,0.26,mM,0.01,H-glu-pro-OH,,,inhibition of [14C]Gly-Sar uptake in Caco-2 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140566,mbcd0003642,mbtp000009,mbrf0001926,,=,,,inhibitor,29,0.3,mM,0.02,H-gly-pro-OH,,,inhibition of [14C]Gly-Sar uptake in Caco-2 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140567,mbcd0029638,mbtp000009,mbrf0001926,,=,,,inhibitor,29,0.39,mM,0.05,H-arg-pro-OH,,,inhibition of [14C]Gly-Sar uptake in Caco-2 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140568,mbcd0003813,mbtp000009,mbrf0001926,,=,,,inhibitor,29,0.53,mM,0.03,H-tyr-pro-OH,,,inhibition of [14C]Gly-Sar uptake in Caco-2 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140569,mbcd0029639,mbtp000009,mbrf0001926,,=,,,inhibitor,29,0.54,mM,0.08,H-trp-pro-OH,,,inhibition of [14C]Gly-Sar uptake in Caco-2 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140570,mbcd0003492,mbtp000009,mbrf0001926,,=,,,inhibitor,29,1.2,mM,0.1,H-pro-pro-OH,,,inhibition of [14C]Gly-Sar uptake in Caco-2 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140571,mbcd0029640,mbtp000009,mbrf0001926,,=,,,inhibitor,29,2.5,mM,0.1,H-sar-pro-OH,,,inhibition of [14C]Gly-Sar uptake in Caco-2 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140572,mbcd0003739,mbtp000009,mbrf0001926,,=,,,inhibitor,29,15.0,mM,2,H-ala-D-pro-OH,,,inhibition of [14C]Gly-Sar uptake in Caco-2 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140573,mbcd0029641,mbtp000009,mbrf0001926,,>,,,inhibitor,29,20.0,mM,,H-ile-pyrrolidide,,,inhibition of [14C]Gly-Sar uptake in Caco-2 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140574,mbcd0003777,mbtp000009,mbrf0001926,,=,,,inhibitor,29,0.06,mM,0.01,H-ala-pip,,,inhibition of [14C]Gly-Sar uptake in Caco-2 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140575,mbcd0003788,mbtp000009,mbrf0001926,,=,,,inhibitor,29,0.47,mM,0.04,H-pro-leu,,,inhibition of [14C]Gly-Sar uptake in Caco-2 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140576,mbcd0003759,mbtp000009,mbrf0001926,,=,,,inhibitor,29,1.9,mM,0.1,H-pro-phe,,,inhibition of [14C]Gly-Sar uptake in Caco-2 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140577,mbcd0003723,mbtp000009,mbrf0001926,,=,,,inhibitor,29,9.5,mM,0.4,H-pro-ala,,,inhibition of [14C]Gly-Sar uptake in Caco-2 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140578,mbcd0003734,mbtp000009,mbrf0001926,,=,,,inhibitor,29,20.0,mM,1,H-pro-glu,,,inhibition of [14C]Gly-Sar uptake in Caco-2 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140579,mbcd0029007,mbtp000009,mbrf0001926,,=,,,inhibitor,29,22.0,mM,2,H-pro-gly,,,inhibition of [14C]Gly-Sar uptake in Caco-2 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140580,mbcd0029642,mbtp000009,mbrf0000109,,=,,,inhibitor,29,0.028,mM,,AF-LysGly,,,inhibitory potencies of [3H]-GlySar uptake in hPEPT1-CHO cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140581,mbcd0003768,mbtp000009,mbrf0000109,,=,,,inhibitor,29,0.035,mM,,AF-LysVal,,,inhibitory potencies of [3H]-GlySar uptake in hPEPT1-CHO cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140582,mbcd0003643,mbtp000009,mbrf0000109,,=,,,inhibitor,29,0.026,mM,,AF-LysSer,,,inhibitory potencies of [3H]-GlySar uptake in hPEPT1-CHO cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140583,mbcd0003807,mbtp000009,mbrf0000109,,=,,,inhibitor,29,0.024,mM,,AF-LysAla,,,inhibitory potencies of [3H]-GlySar uptake in hPEPT1-CHO cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140584,mbcd0029643,mbtp000009,mbrf0000109,,=,,,inhibitor,29,0.019,mM,,AF-LysGlyGly,,,inhibitory potencies of [3H]-GlySar uptake in hPEPT1-CHO cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140585,mbcd0022751,mbtp000009,mbrf0002019,,=,,,substrate,28,2.48,mM,,L-carnosine,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140586,mbcd0029406,mbtp000009,mbrf0001956,,=,,,inhibitor,29,10.8,mM,0.3,"cidofovir, HPMPC",,,Gly-Sar inhibition; competitive binding assay of cHPMPC methyl-ester dipeptide conjugates in DC5 cells over-expressing hPepT1,,,,,,human,mbds0010,,2013-11-20 19:41:40
mbbd000140587,mbcd0029583,mbtp000009,mbrf0001956,,=,,,inhibitor,29,10.7,mM,0.2,cHPMPC,,,Gly-Sar inhibition; competitive binding assay of cHPMPC methyl-ester dipeptide conjugates in DC5 cells over-expressing hPepT1,,,,,,human,mbds0010,,2013-11-20 19:41:40
mbbd000140588,mbcd0029584,mbtp000009,mbrf0001956,,=,,,inhibitor,29,2.7,mM,0.1,7,,,Gly-Sar inhibition; competitive binding assay of cHPMPC methyl-ester dipeptide conjugates in DC5 cells over-expressing hPepT1,,,,,,human,mbds0010,,2013-11-20 19:41:41
mbbd000140589,mbcd0029644,mbtp000009,mbrf0001956,,=,,,inhibitor,29,3.4,mM,0.2,9,,,Gly-Sar inhibition; competitive binding assay of cHPMPC methyl-ester dipeptide conjugates in DC5 cells over-expressing hPepT1,,,,,,human,mbds0010,,2013-11-20 19:41:41
mbbd000140590,mbcd0029645,mbtp000009,mbrf0001956,,=,,,inhibitor,29,5.4,mM,0.2,10,,,Gly-Sar inhibition; competitive binding assay of cHPMPC methyl-ester dipeptide conjugates in DC5 cells over-expressing hPepT1,,,,,,human,mbds0010,,2013-11-20 19:41:41
mbbd000140591,mbcd0029271,mbtp000009,mbrf0002097,,,,,inducer,,,,,butyrate,,,Caco-2 cells BBE,Caco-2,,1-20,mM,,human,mbds0010,,2013-11-10 04:16:00
mbbd000140592,mbcd0029647,mbtp000009,mbrf0002045,,>,,,non-substrate,25,1000.0,mM,,2a,"very weak inhibition, high IC50",,inhibition of GlySar uptake; Caco-2 cell monolayers,Caco-2,,,,,human,mbds0010,,2013-11-26 01:55:29
mbbd000140593,mbcd0029648,mbtp000009,mbrf0002045,,=,,,inhibitor,25,16.8,mM,0.9,2b,"very weak inhibition, high IC50",,inhibition of GlySar uptake,,,,,weak inhibitor,human,mbds0010,,2013-11-24 22:15:11
mbbd000140594,mbcd0029649,mbtp000009,mbrf0002045,,=,,,inhibitor,25,7.2,mM,1,2c,,,inhibition of GlySar uptake,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140595,mbcd0029650,mbtp000009,mbrf0002045,,=,,,inhibitor,25,0.2,mM,0.01,2d,,,inhibition of GlySar uptake,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140596,mbcd0029651,mbtp000009,mbrf0002045,,=,,,inhibitor,25,0.15,mM,0.01,2e,,,inhibition of GlySar uptake,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140597,mbcd0029652,mbtp000009,mbrf0002045,,=,,,inhibitor,25,6.0,mM,1,2f,,,inhibition of GlySar uptake,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140598,mbcd0029653,mbtp000009,mbrf0002045,,=,,,inhibitor,25,8.8,mM,0.8,2g,,,inhibition of GlySar uptake,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140599,mbcd0029654,mbtp000009,mbrf0002045,,=,,,inhibitor,25,9.0,mM,0.7,2h,,,inhibition of GlySar uptake,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140600,mbcd0029655,mbtp000009,mbrf0002383,,=,,,inhibitor,29,0.3,mM,0.04,H-Phe-Ser-Ala-OH,,,concentration dependent inhibition of 20 microM [14C]Gly-Sar uptake in Caco-2 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140601,mbcd0029656,mbtp000009,mbrf0002383,,=,,,inhibitor,29,0.22,mM,0.01,H-Phe-Ala-Ser-OH,,,concentration dependent inhibition of 20 microM [14C]Gly-Sar uptake in Caco-2 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140602,mbcd0029657,mbtp000009,mbrf0002383,,=,,,inhibitor,29,2.5,mM,0.3,H-d-Phe-Ser-Ala-OH,,,concentration dependent inhibition of 20 microM [14C]Gly-Sar uptake in Caco-2 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140603,mbcd0029658,mbtp000009,mbrf0002383,,~,,,inhibitor,29,12.0,mM,,H-d-Phe-Ala-Ser-OH,,,concentration dependent inhibition of 20 microM [14C]Gly-Sar uptake in Caco-2 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140604,mbcd0029659,mbtp000009,mbrf0002383,,=,,,inhibitor,29,0.22,mM,0.01,H-Val-Ser-Ala-OH,,,concentration dependent inhibition of 20 microM [14C]Gly-Sar uptake in Caco-2 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140605,mbcd0029660,mbtp000009,mbrf0002383,,~,,,inhibitor,29,25.0,mM,,H-d-Val-Ala-Ser-OH,,,concentration dependent inhibition of 20 microM [14C]Gly-Sar uptake in Caco-2 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140606,mbcd0029661,mbtp000009,mbrf0002383,,~,,,inhibitor,29,14.0,mM,,H-d-Val-Ser-Ala-OH,,,concentration dependent inhibition of 20 microM [14C]Gly-Sar uptake in Caco-2 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140607,mbcd0029662,mbtp000009,mbrf0002383,,=,,,inhibitor,29,0.42,mM,0.03,H-Tyr-Ser-Ala-OH,,,concentration dependent inhibition of 20 microM [14C]Gly-Sar uptake in Caco-2 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140608,mbcd0029663,mbtp000009,mbrf0002383,,~,,,inhibitor,29,18.0,mM,,H-d-Tyr-Ala-Ser-OH,,,concentration dependent inhibition of 20 microM [14C]Gly-Sar uptake in Caco-2 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140609,mbcd0029664,mbtp000009,mbrf0002383,,=,,,inhibitor,29,2.8,mM,0.4,H-d-Tyr-Ser-Ala-OH,,,concentration dependent inhibition of 20 microM [14C]Gly-Sar uptake in Caco-2 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140610,mbcd0029665,mbtp000009,mbrf0002383,,=,,,inhibitor,29,5.6,mM,1.6,H-Phe-d-Ser-Ala-OH,,,concentration dependent inhibition of 20 microM [14C]Gly-Sar uptake in Caco-2 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140611,mbcd0029666,mbtp000009,mbrf0002383,,=,,,inhibitor,29,0.34,mM,0.04,H-Phe-hSer-Ala-OH,,,concentration dependent inhibition of 20 microM [14C]Gly-Sar uptake in Caco-2 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140612,mbcd0029667,mbtp000009,mbrf0002383,,>,,,inhibitor,29,25.0,mM,,H-Phe-d-hSer-Ala-OH,,,concentration dependent inhibition of 20 microM [14C]Gly-Sar uptake in Caco-2 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140613,mbcd0029668,mbtp000009,mbrf0002383,,=,,,inhibitor,29,0.33,mM,0.04,H-Phe-Thr-Ala-OH,,,concentration dependent inhibition of 20 microM [14C]Gly-Sar uptake in Caco-2 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140614,mbcd0029669,mbtp000009,mbrf0002383,,>,,,inhibitor,29,25.0,mM,,H-Phe-d-Thr-Ala-OH,,,concentration dependent inhibition of 20 microM [14C]Gly-Sar uptake in Caco-2 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140615,mbcd0029670,mbtp000009,mbrf0002383,,=,,,inhibitor,29,0.24,mM,0.03,H-4-OEt-Phe-Ser-Ala-OH,,,concentration dependent inhibition of 20 microM [14C]Gly-Sar uptake in Caco-2 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140616,mbcd0029671,mbtp000009,mbrf0002383,,=,,,inhibitor,29,0.25,mM,0.02,H-4-Cl-Phe-Ser-Ala-OH,,,concentration dependent inhibition of 20 microM [14C]Gly-Sar uptake in Caco-2 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140617,mbcd0029672,mbtp000009,mbrf0002383,,=,,,inhibitor,29,0.28,mM,0.03,H-1-NaphthylAla-Ser-Ala-OH,,,concentration dependent inhibition of 20 microM [14C]Gly-Sar uptake in Caco-2 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140618,mbcd0029673,mbtp000009,mbrf0002383,,=,,,inhibitor,29,0.29,mM,0.02,H-2-NaphthylAla-Ser-Ala-OH,,,concentration dependent inhibition of 20 microM [14C]Gly-Sar uptake in Caco-2 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140619,mbcd0029674,mbtp000009,mbrf0002383,,=,,,inhibitor,29,0.3,mM,0.03,H-4-F-Phe-Ser-Ala-OH,,,concentration dependent inhibition of 20 microM [14C]Gly-Sar uptake in Caco-2 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140620,mbcd0029675,mbtp000009,mbrf0002383,,=,,,inhibitor,29,0.32,mM,0.01,"H-3,5-diCl-Phe-Ser-Ala-OH",,,concentration dependent inhibition of 20 microM [14C]Gly-Sar uptake in Caco-2 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140621,mbcd0029676,mbtp000009,mbrf0002383,,=,,,inhibitor,29,0.33,mM,0.04,H-Indan-1-ylGly-Ser-Ala-OH,,,concentration dependent inhibition of 20 microM [14C]Gly-Sar uptake in Caco-2 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140622,mbcd0029677,mbtp000009,mbrf0002383,,=,,,inhibitor,29,0.34,mM,0.03,H-2-Cl-Phe-Ser-Ala-OH,,,concentration dependent inhibition of 20 microM [14C]Gly-Sar uptake in Caco-2 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140623,mbcd0029678,mbtp000009,mbrf0002383,,=,,,inhibitor,29,0.37,mM,0.05,H-4-NH2 -Phe-Ser-Ala-OH,,,concentration dependent inhibition of 20 microM [14C]Gly-Sar uptake in Caco-2 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140624,mbcd0029679,mbtp000009,mbrf0002383,,=,,,inhibitor,29,0.38,mM,0.02,H-2-CN-Phe-Ser-Ala-OH,,,concentration dependent inhibition of 20 microM [14C]Gly-Sar uptake in Caco-2 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140625,mbcd0029680,mbtp000009,mbrf0002383,,=,,,inhibitor,29,0.38,mM,0.02,H-2-Me-Phe-Ser-Ala-OH,,,concentration dependent inhibition of 20 microM [14C]Gly-Sar uptake in Caco-2 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140626,mbcd0029681,mbtp000009,mbrf0002383,,=,,,inhibitor,29,0.43,mM,0.04,H-4-PhCO-Phe-Ser-Ala-OH,,,concentration dependent inhibition of 20 microM [14C]Gly-Sar uptake in Caco-2 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140627,mbcd0029682,mbtp000009,mbrf0002383,,=,,,inhibitor,29,0.45,mM,0.06,H-3-Cl-Phe-Ser-Ala-OH,,,concentration dependent inhibition of 20 microM [14C]Gly-Sar uptake in Caco-2 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140628,mbcd0003819,mbtp000009,mbrf0000111,,,,,substrate,,,,,cefoxitin; 89,,,Caco-2 cells,Caco-2,,,,,human,mbds0010,,2013-11-24 23:12:34
mbbd000140629,mbcd0003036,mbtp000009,mbrf0000111,,,,,substrate,,,,,flucoxacillin; 99,,,Caco-2 cells,Caco-2,,,,,human,mbds0010,,2013-11-24 23:12:34
mbbd000140630,mbcd0030533,mbtp000009,mbrf0000111,,,,,substrate,,,,,acidocillin; 101,,,Caco-2 cells,Caco-2,,,,,human,mbds0010,,2013-11-24 23:12:35
mbbd000140631,mbcd0003497,mbtp000009,mbrf0000111,,,,,substrate,,,,,cefazoline; 103,,,Caco-2 cells,Caco-2,,,,,human,mbds0010,,2013-11-24 23:12:35
mbbd000140632,mbcd0003506,mbtp000009,mbrf0000111,,,,,substrate,,,,,piperacillin; 105,,,Caco-2 cells,Caco-2,,,,,human,mbds0010,,2013-11-24 23:12:35
mbbd000140633,mbcd0003758,mbtp000009,mbrf0000111,,,,,substrate,,,,,cefpodoxime; 106,,,Caco-2 cells,Caco-2,,,,,human,mbds0010,,2013-11-24 23:12:35
mbbd000140634,mbcd0003601,mbtp000009,mbrf0002450,,,,,substrate,,,,,ala-ala,,,Caco-2 cells,Caco-2,,,,,human,mbds0010,,2013-11-24 23:12:36
mbbd000140635,mbcd0003087,mbtp000009,mbrf0002450,,,,,substrate,,,,,valacyclovir,,,Caco-2 cells,Caco-2,,,,,human,mbds0010,,2013-11-24 23:12:36
mbbd000140636,mbcd0003494,mbtp000009,mbrf0002450,,,,,substrate,,,,,Gly-Sar,,,Caco-2 cells,Caco-2,,,,,human,mbds0010,,2013-11-24 23:12:36
mbbd000140637,mbcd0003725,mbtp000009,mbrf0002450,,,,,substrate,,,,,lys-lys,,,Caco-2 cells,Caco-2,,,,,human,mbds0010,,2013-11-24 23:12:36
mbbd000140638,mbcd0029464,mbtp000009,mbrf0002450,,,,,substrate,,,,,pro-arg,,,Caco-2 cells,Caco-2,,,,,human,mbds0010,,2013-11-24 23:12:36
mbbd000140639,mbcd0003552,mbtp000009,mbrf0002450,,,,,substrate,,,,,gamma-aminolevulinic acid,,,Caco-2 cells,Caco-2,,,,,human,mbds0010,,2013-11-24 23:12:37
mbbd000140640,mbcd0003602,mbtp000009,mbrf0002450,,,,,substrate,,,,,pro-ser,,,Caco-2 cells,Caco-2,,,,,human,mbds0010,,2013-11-24 23:12:37
mbbd000140641,mbcd0003778,mbtp000009,mbrf0002450,,,,,substrate,,,,,ile-thiazolidide,,,Caco-2 cells,Caco-2,,,,,human,mbds0010,,2013-11-24 23:12:37
mbbd000140642,mbcd0029465,mbtp000009,mbrf0002450,,,,,substrate,,,,,4-aminophenylacetic acid,,,Caco-2 cells,Caco-2,,,,,human,mbds0010,,2013-11-24 23:12:37
mbbd000140643,mbcd0003498,mbtp000009,mbrf0002450,,,,,substrate,,,,,enalapril,,,Caco-2 cells,Caco-2,,,,,human,mbds0010,,2013-11-24 23:12:38
mbbd000140644,mbcd0003142,mbtp000009,mbrf0001536,,,,,substrate,,,,,captopril,,,inhibition of [14-C] Gly-Sar uptake in Caco-2 cells (hPept1),Caco-2,,,,,human,mbds0010,,2013-11-24 23:12:38
mbbd000140645,mbcd0029494,mbtp000009,mbrf0001884,,,,,substrate,,,,,JBP485,,,Caco-2 cells; Inhibition constants (Ki) for different compounds in relation to the uptake of JBP485 and Gly-Sar,Caco-2,,,,,human,mbds0010,,2013-11-25 22:59:21
mbbd000140646,mbcd0029526,mbtp000009,mbrf0001884,,,,,substrate,,,,,JBP923,,,Caco-2 cells; Inhibition constants (Ki) for different compounds in relation to the uptake of JBP485 and Gly-Sar,Caco-2,,,,,human,mbds0010,,2013-11-25 22:59:21
mbbd000140647,mbcd0003618,mbtp000009,mbrf0001884,,,,,substrate,,,,,CEX,,,Caco-2 cells; Inhibition constants (Ki) for different compounds in relation to the uptake of JBP485 and Gly-Sar,Caco-2,,,,,human,mbds0010,,2013-11-25 22:59:21
mbbd000140654,mbcd0029475,mbtp000009,mbrf0002472,,,,,substrate,,,,,Tri-DAP,,,inhibition of Gly-Sar; Caco2-BBE cells,Caco-2,,,,,human,mbds0010,,2013-11-26 01:55:29
mbbd000140655,mbcd0003494,mbtp000009,mbrf0002577,,,,,substrate,,,,,Gly-Sar,,,hPept1 tranfect HeLa cells,HeLa,,,,,human,mbds0010,,2013-11-24 23:55:13
mbbd000140656,mbcd0029484,mbtp000009,mbrf0002577,,,,,substrate,,,,,Ala-Pyrr,,,hPept1 tranfect HeLa cells,HeLa,,,,,human,mbds0010,,2013-11-24 23:55:13
mbbd000140657,mbcd0029485,mbtp000009,mbrf0002577,,,,,substrate,,,,,Pyrr-Ala,,,hPept1 tranfect HeLa cells,HeLa,,,,,human,mbds0010,,2013-11-24 23:55:13
mbbd000140658,mbcd0003552,mbtp000009,mbrf0002449,,,,,substrate,,,,,d-Aminolevulinic acid,,,inhibition of Bip-[3H]Pro uptake in SKPT cells,SKPT,,,,,human,mbds0010,,2013-11-24 23:56:36
mbbd000140659,mbcd0003725,mbtp000009,mbrf0002449,,,,,substrate,,,,,Lys-Lys,,,inhibition of [14C]Gly-Sar uptake in SKPT cells,SKPT,,,,,human,mbds0010,,2013-11-24 23:56:36
mbbd000140660,mbcd0027333,mbtp000009,mbrf0002050,,,,,substrate,,,,,losartan,,,inhibition of [14]Gly-Sar uptake in Caco-2 cells expressing PEPT1,Caco-2,,,,,human,mbds0010,,2013-11-24 23:12:38
mbbd000140661,mbcd0028570,mbtp000009,mbrf0002050,,,,,substrate,,,,,Irbesartan,,,inhibition of [14]Gly-Sar uptake in Caco-2 cells expressing PEPT1,Caco-2,,,,,human,mbds0010,,2013-11-24 23:12:38
mbbd000140662,mbcd0003086,mbtp000009,mbrf0002050,,,,,substrate,,,,,Valsartan,,,inhibition of [14]Gly-Sar uptake in Caco-2 cells expressing PEPT1,Caco-2,,,,,human,mbds0010,,2013-11-24 23:12:39
mbbd000140663,mbcd0001323,mbtp000009,mbrf0002050,,,,,substrate,,,,,eprosartan,,,inhibition of [14]Gly-Sar uptake in Caco-2 cells expressing PEPT1,Caco-2,,,,,human,mbds0010,,2013-11-24 23:12:39
mbbd000140664,mbcd0022751,mbtp000009,mbrf0001966,,,,,substrate,,,,,carnosine,,,hPept1 tranfected HeLa cells,HeLa,,,,,human,mbds0010,,2013-11-24 23:55:12
mbbd000140665,mbcd0029494,mbtp000009,mbrf0001853,,,,,substrate,,,,,JBP485,,,inhibition of Gly Sar uptake in hPept1 transfected HeLa cells,HeLa,,,,,human,mbds0010,,2013-11-24 23:55:12
mbbd000140666,mbcd0029504,mbtp000009,mbrf0002449,,,,,substrate,,,,,Bip-Pro,,,inhibition of [14C]Gly-Sar uptake in SKPT cells,SKPT,,,,,human,mbds0010,,2013-11-24 23:56:36
mbbd000140667,mbcd0003599,mbtp000009,mbrf0001536,,,,,substrate,,,,,Ala-Ala-Ala,,,inhibition of [14-C] Gly-Sar uptake in Caco-2 cells (hPept1),Caco-2,,,,,human,mbds0010,,2013-11-24 23:12:39
mbbd000140668,mbcd0029104,mbtp000009,mbrf0001536,,,,,substrate,,,,,zofenopril,,,inhibition of [14-C] Gly-Sar uptake in Caco-2 cells (hPept1),Caco-2,,,,,human,mbds0010,,2013-11-24 23:12:39
mbbd000140669,mbcd0001105,mbtp000009,mbrf0001536,,,,,substrate,,,,,fosinopril,,,inhibition of [14-C] Gly-Sar uptake in Caco-2 cells (hPept1),Caco-2,,,,,human,mbds0010,,2013-11-24 23:12:39
mbbd000140670,mbcd0001647,mbtp000007,mbrf0002741,,,,,substrate,,,,,acetylcholine; Ach,,,Xenopus laevis oocytes; uptake,Xenopus laevis oocytes,,5,microM,,human,mbds0010,,2013-11-01 23:38:30
mbbd000140672,mbcd0003022,mbtp000007,mbrf0001379,,=,,,substrate,22,3.69,pmol oocyte-1 hr-1,0.409,1-methyl-4-phenylpyridinium; MPP,,,Xenopus laevis oocytes; uptake,Xenopus laevis oocytes,,0-500,microM,,human,mbds0010,,2013-11-02 06:01:23
mbbd000140673,mbcd0003886,mbtp000007,mbrf0001792,,=,,,substrate,28,2.16,mM,0.36,metformin,,,CHO-K1; uptake,CHO,,0-10,mM,,human,mbds0010,,2013-12-09 06:42:00
mbbd000140674,mbcd0003922,mbtp000007,mbrf0001667,,=,,,substrate,100,18.2,pmol (mg protein)-1 hr-1,3.40,oxaliplatin,,,MDCK,MDCK,,6,microM,,human,mbds0010,,2013-11-21 01:53:19
mbbd000140678,mbcd0003886,mbtp000007,mbrf0001792,,=,,,substrate,22,4.84,nmol / mg protein / min,1.15,metformin,,,CHO cells that were stably transfected with OCT1,CHO,,,,,human,mbds0010,,2013-12-09 06:42:00
mbbd000140679,mbcd0003886,mbtp000007,mbrf0001792,,=,,,inhibitor,25,3.42,mM,0.77,metformin,,,inhibition of [3H]MPP uptake,CHO,mbcd0003022,,,,human,mbds0010,,2013-12-09 06:42:00
mbbd000140680,mbcd0002828,mbtp000007,mbrf0001234,,,,,substrate,,,,,imatinib,,,CCRF-CEM,CCRF-CEM,,5,microM,,human,mbds0010,,2013-11-04 00:13:07
mbbd000140681,mbcd0002995,mbtp000007,mbrf0002133,,=,,,inhibitor,102,5.5,%,0.3,desipramine,,,"inhibition of tetraethylammonium (TEA) uptake; The specific uptake was evaluated at 37?C and pH 8.5 for 20 min (DAPI, 1:M) or 10min ([14C]TEA, 3:M) in the presence of a test compound (0.2mM) or in its absence. The control values were 3.20 FI/mg protein and 132pmol/mg protein, respectively, for DAPI and TEA",,,,,,human,mbds0010,,2013-11-24 08:05:31
mbbd000140682,mbcd0027062,mbtp000007,mbrf0002133,,=,,,inhibitor,102,7.2,%,1.0,verapamil,,,"inhibition of 4',6-diamidino-2-phenylindol (DAPI) uptake; The specific uptake was evaluated at 37?C and pH 8.5 for 20 min (DAPI, 1:M) or 10min ([14C]TEA, 3:M) in the presence of a test compound (0.2mM) or in its absence. The control values were 3.20 FI/mg protein and 132pmol/mg protein, respectively, for DAPI and TEA",,,,,,human,mbds0010,,2013-11-24 07:58:19
mbbd000140683,mbcd0027062,mbtp000007,mbrf0002133,,=,,,inhibitor,102,4.7,%,0.1,verapamil,,,"inhibition of tetraethylammonium (TEA) uptake; The specific uptake was evaluated at 37?C and pH 8.5 for 20 min (DAPI, 1:M) or 10min ([14C]TEA, 3:M) in the presence of a test compound (0.2mM) or in its absence. The control values were 3.20 FI/mg protein and 132pmol/mg protein, respectively, for DAPI and TEA",,,,,,human,mbds0010,,2013-11-24 08:05:32
mbbd000140684,mbcd0012458,mbtp000007,mbrf0002133,,=,,,inhibitor,102,10.6,%,2.1,diphenhydramine,,,"inhibition of 4',6-diamidino-2-phenylindol (DAPI) uptake; The specific uptake was evaluated at 37?C and pH 8.5 for 20 min (DAPI, 1:M) or 10min ([14C]TEA, 3:M) in the presence of a test compound (0.2mM) or in its absence. The control values were 3.20 FI/mg protein and 132pmol/mg protein, respectively, for DAPI and TEA",,,,,,human,mbds0010,,2013-11-24 07:58:19
mbbd000140685,mbcd0012458,mbtp000007,mbrf0002133,,=,,,inhibitor,102,8.4,%,0.2,diphenhydramine,,,"inhibition of tetraethylammonium (TEA) uptake; The specific uptake was evaluated at 37?C and pH 8.5 for 20 min (DAPI, 1:M) or 10min ([14C]TEA, 3:M) in the presence of a test compound (0.2mM) or in its absence. The control values were 3.20 FI/mg protein and 132pmol/mg protein, respectively, for DAPI and TEA",,,,,,human,mbds0010,,2013-11-24 08:05:32
mbbd000140686,mbcd0002488,mbtp000007,mbrf0002133,,=,,,inhibitor,102,21.9,%,3.3,propanolol,,,"inhibition of 4',6-diamidino-2-phenylindol (DAPI) uptake; The specific uptake was evaluated at 37?C and pH 8.5 for 20 min (DAPI, 1:M) or 10min ([14C]TEA, 3:M) in the presence of a test compound (0.2mM) or in its absence. The control values were 3.20 FI/mg protein and 132pmol/mg protein, respectively, for DAPI and TEA",,,,,,human,mbds0010,,2013-11-24 07:58:19
mbbd000140687,mbcd0002488,mbtp000007,mbrf0002133,,=,,,inhibitor,102,25.5,%,0.4,propanolol,,,"inhibition of tetraethylammonium (TEA) uptake; The specific uptake was evaluated at 37?C and pH 8.5 for 20 min (DAPI, 1:M) or 10min ([14C]TEA, 3:M) in the presence of a test compound (0.2mM) or in its absence. The control values were 3.20 FI/mg protein and 132pmol/mg protein, respectively, for DAPI and TEA",,,,,,human,mbds0010,,2013-11-24 08:05:32
mbbd000140688,mbcd0003905,mbtp000007,mbrf0002133,,=,,,inhibitor,102,33.4,%,2.0,corticosterone,,,"inhibition of 4',6-diamidino-2-phenylindol (DAPI) uptake; The specific uptake was evaluated at 37?C and pH 8.5 for 20 min (DAPI, 1:M) or 10min ([14C]TEA, 3:M) in the presence of a test compound (0.2mM) or in its absence. The control values were 3.20 FI/mg protein and 132pmol/mg protein, respectively, for DAPI and TEA",,,,,,human,mbds0010,,2013-11-24 07:58:19
mbbd000140689,mbcd0003905,mbtp000007,mbrf0002133,,=,,,inhibitor,102,26.0,%,0.6,corticosterone,,,"inhibition of tetraethylammonium (TEA) uptake; The specific uptake was evaluated at 37?C and pH 8.5 for 20 min (DAPI, 1:M) or 10min ([14C]TEA, 3:M) in the presence of a test compound (0.2mM) or in its absence. The control values were 3.20 FI/mg protein and 132pmol/mg protein, respectively, for DAPI and TEA",,,,,,human,mbds0010,,2013-11-24 08:05:33
mbbd000140690,mbcd0003115,mbtp000007,mbrf0002133,,=,,,inhibitor,102,38.8,%,1.4,trimethoprim,,,"inhibition of 4',6-diamidino-2-phenylindol (DAPI) uptake; The specific uptake was evaluated at 37?C and pH 8.5 for 20 min (DAPI, 1:M) or 10min ([14C]TEA, 3:M) in the presence of a test compound (0.2mM) or in its absence. The control values were 3.20 FI/mg protein and 132pmol/mg protein, respectively, for DAPI and TEA",,,,,,human,mbds0010,,2013-11-24 07:58:19
mbbd000140691,mbcd0003115,mbtp000007,mbrf0002133,,=,,,inhibitor,102,30.4,%,0.2,trimethoprim,,,"inhibition of tetraethylammonium (TEA) uptake; The specific uptake was evaluated at 37?C and pH 8.5 for 20 min (DAPI, 1:M) or 10min ([14C]TEA, 3:M) in the presence of a test compound (0.2mM) or in its absence. The control values were 3.20 FI/mg protein and 132pmol/mg protein, respectively, for DAPI and TEA",,,,,,human,mbds0010,,2013-11-24 08:05:33
mbbd000140692,mbcd0002667,mbtp000007,mbrf0002133,,=,,,inhibitor,102,50.3,%,4.9,colchicine,,,"inhibition of 4',6-diamidino-2-phenylindol (DAPI) uptake; The specific uptake was evaluated at 37?C and pH 8.5 for 20 min (DAPI, 1:M) or 10min ([14C]TEA, 3:M) in the presence of a test compound (0.2mM) or in its absence. The control values were 3.20 FI/mg protein and 132pmol/mg protein, respectively, for DAPI and TEA",,,,,,human,mbds0010,,2013-11-24 07:58:19
mbbd000140693,mbcd0002667,mbtp000007,mbrf0002133,,=,,,inhibitor,102,64.6,%,2.5,colchicine,,,"inhibition of tetraethylammonium (TEA) uptake; The specific uptake was evaluated at 37?C and pH 8.5 for 20 min (DAPI, 1:M) or 10min ([14C]TEA, 3:M) in the presence of a test compound (0.2mM) or in its absence. The control values were 3.20 FI/mg protein and 132pmol/mg protein, respectively, for DAPI and TEA",,,,,,human,mbds0010,,2013-11-24 08:05:34
mbbd000140694,mbcd0001081,mbtp000007,mbrf0002133,,=,,,inhibitor,102,50.7,%,2.1,chloramphenicol,,,"inhibition of 4',6-diamidino-2-phenylindol (DAPI) uptake; The specific uptake was evaluated at 37?C and pH 8.5 for 20 min (DAPI, 1:M) or 10min ([14C]TEA, 3:M) in the presence of a test compound (0.2mM) or in its absence. The control values were 3.20 FI/mg protein and 132pmol/mg protein, respectively, for DAPI and TEA",,,,,,human,mbds0010,,2013-11-24 07:58:19
mbbd000140695,mbcd0001081,mbtp000007,mbrf0002133,,=,,,non-inhibitor,102,103.5,%,0.5,chloramphenicol,,,"inhibition of tetraethylammonium (TEA) uptake; The specific uptake was evaluated at 37?C and pH 8.5 for 20 min (DAPI, 1:M) or 10min ([14C]TEA, 3:M) in the presence of a test compound (0.2mM) or in its absence. The control values were 3.20 FI/mg protein and 132pmol/mg protein, respectively, for DAPI and TEA",,,,,,human,mbds0010,,2013-11-24 08:05:34
mbbd000140696,mbcd0029629,mbtp000007,mbrf0002133,,=,,,inhibitor,102,59.2,%,4.3,glibenclamide,,,"inhibition of 4',6-diamidino-2-phenylindol (DAPI) uptake; The specific uptake was evaluated at 37?C and pH 8.5 for 20 min (DAPI, 1:M) or 10min ([14C]TEA, 3:M) in the presence of a test compound (0.2mM) or in its absence. The control values were 3.20 FI/mg protein and 132pmol/mg protein, respectively, for DAPI and TEA",,,,,,human,mbds0010,,2013-11-24 07:58:19
mbbd000140697,mbcd0029629,mbtp000007,mbrf0002133,,=,,,non-inhibitor,102,98.3,%,2.9,glibenclamide,,,"inhibition of tetraethylammonium (TEA) uptake; The specific uptake was evaluated at 37?C and pH 8.5 for 20 min (DAPI, 1:M) or 10min ([14C]TEA, 3:M) in the presence of a test compound (0.2mM) or in its absence. The control values were 3.20 FI/mg protein and 132pmol/mg protein, respectively, for DAPI and TEA",,,,,,human,mbds0010,,2013-11-24 08:05:34
mbbd000140698,mbcd0029686,mbtp000007,mbrf0002133,,=,,,inhibitor,102,69.8,%,5.5,hemicholinium-3,,,"inhibition of 4',6-diamidino-2-phenylindol (DAPI) uptake; The specific uptake was evaluated at 37?C and pH 8.5 for 20 min (DAPI, 1:M) or 10min ([14C]TEA, 3:M) in the presence of a test compound (0.2mM) or in its absence. The control values were 3.20 FI/mg protein and 132pmol/mg protein, respectively, for DAPI and TEA",,,,,,human,mbds0010,,2013-11-24 07:58:19
mbbd000140699,mbcd0029686,mbtp000007,mbrf0002133,,=,,,non-inhibitor,102,98.5,%,1.2,hemicholinium-3,,,"inhibition of tetraethylammonium (TEA) uptake; The specific uptake was evaluated at 37?C and pH 8.5 for 20 min (DAPI, 1:M) or 10min ([14C]TEA, 3:M) in the presence of a test compound (0.2mM) or in its absence. The control values were 3.20 FI/mg protein and 132pmol/mg protein, respectively, for DAPI and TEA",,,,,,human,mbds0010,,2013-11-24 08:05:35
mbbd000140700,mbcd0023577,mbtp000007,mbrf0002133,,=,,,inhibitor,102,72.3,%,2.4,fluconazole,,,"inhibition of 4',6-diamidino-2-phenylindol (DAPI) uptake; The specific uptake was evaluated at 37?C and pH 8.5 for 20 min (DAPI, 1:M) or 10min ([14C]TEA, 3:M) in the presence of a test compound (0.2mM) or in its absence. The control values were 3.20 FI/mg protein and 132pmol/mg protein, respectively, for DAPI and TEA",,,,,,human,mbds0010,,2013-11-24 07:58:19
mbbd000140701,mbcd0023577,mbtp000007,mbrf0002133,,=,,,non-inhibitor,102,88.7,%,2.3,fluconazole,,,"inhibition of tetraethylammonium (TEA) uptake; The specific uptake was evaluated at 37?C and pH 8.5 for 20 min (DAPI, 1:M) or 10min ([14C]TEA, 3:M) in the presence of a test compound (0.2mM) or in its absence. The control values were 3.20 FI/mg protein and 132pmol/mg protein, respectively, for DAPI and TEA",,,,,,human,mbds0010,,2013-11-24 08:05:35
mbbd000140702,mbcd0010622,mbtp000007,mbrf0002133,,=,,,inhibitor,102,79.2,%,4.8,pyridoxine,,,"inhibition of 4',6-diamidino-2-phenylindol (DAPI) uptake; The specific uptake was evaluated at 37?C and pH 8.5 for 20 min (DAPI, 1:M) or 10min ([14C]TEA, 3:M) in the presence of a test compound (0.2mM) or in its absence. The control values were 3.20 FI/mg protein and 132pmol/mg protein, respectively, for DAPI and TEA",,,,,,human,mbds0010,,2013-11-24 07:58:19
mbbd000140703,mbcd0010622,mbtp000007,mbrf0002133,,=,,,non-inhibitor,102,91.8,%,6.5,pyridoxine,,,"inhibition of tetraethylammonium (TEA) uptake; The specific uptake was evaluated at 37?C and pH 8.5 for 20 min (DAPI, 1:M) or 10min ([14C]TEA, 3:M) in the presence of a test compound (0.2mM) or in its absence. The control values were 3.20 FI/mg protein and 132pmol/mg protein, respectively, for DAPI and TEA",,,,,,human,mbds0010,,2013-11-24 08:05:35
mbbd000140704,mbcd0002996,mbtp000007,mbrf0002133,,=,,,inhibitor,102,81.3,%,2.9,phenytoin,,,"inhibition of 4',6-diamidino-2-phenylindol (DAPI) uptake; The specific uptake was evaluated at 37?C and pH 8.5 for 20 min (DAPI, 1:M) or 10min ([14C]TEA, 3:M) in the presence of a test compound (0.2mM) or in its absence. The control values were 3.20 FI/mg protein and 132pmol/mg protein, respectively, for DAPI and TEA",,,,,,human,mbds0010,,2013-11-24 07:58:19
mbbd000140705,mbcd0002996,mbtp000007,mbrf0002133,,=,,,inhibitor,102,81.7,%,8.3,phenytoin,,,"inhibition of tetraethylammonium (TEA) uptake; The specific uptake was evaluated at 37?C and pH 8.5 for 20 min (DAPI, 1:M) or 10min ([14C]TEA, 3:M) in the presence of a test compound (0.2mM) or in its absence. The control values were 3.20 FI/mg protein and 132pmol/mg protein, respectively, for DAPI and TEA",,,,,,human,mbds0010,,2013-11-24 08:05:35
mbbd000140706,mbcd0014275,mbtp000007,mbrf0002133,,=,,,non-inhibitor,102,88.7,%,1.3,nicotinate,,,"inhibition of 4',6-diamidino-2-phenylindol (DAPI) uptake; The specific uptake was evaluated at 37?C and pH 8.5 for 20 min (DAPI, 1:M) or 10min ([14C]TEA, 3:M) in the presence of a test compound (0.2mM) or in its absence. The control values were 3.20 FI/mg protein and 132pmol/mg protein, respectively, for DAPI and TEA",,,,,,human,mbds0010,,2013-11-24 07:58:19
mbbd000140707,mbcd0014275,mbtp000007,mbrf0002133,,=,,,non-inhibitor,102,89.4,%,2.5,nicotinate,,,"inhibition of tetraethylammonium (TEA) uptake; The specific uptake was evaluated at 37?C and pH 8.5 for 20 min (DAPI, 1:M) or 10min ([14C]TEA, 3:M) in the presence of a test compound (0.2mM) or in its absence. The control values were 3.20 FI/mg protein and 132pmol/mg protein, respectively, for DAPI and TEA",,,,,,human,mbds0010,,2013-11-24 08:05:36
mbbd000140708,mbcd0029140,mbtp000007,mbrf0002133,,=,,,non-inhibitor,102,89.0,%,6.5,catechin,,,"inhibition of 4',6-diamidino-2-phenylindol (DAPI) uptake; The specific uptake was evaluated at 37?C and pH 8.5 for 20 min (DAPI, 1:M) or 10min ([14C]TEA, 3:M) in the presence of a test compound (0.2mM) or in its absence. The control values were 3.20 FI/mg protein and 132pmol/mg protein, respectively, for DAPI and TEA",,,,,,human,mbds0010,,2013-11-24 07:58:19
mbbd000140709,mbcd0029140,mbtp000007,mbrf0002133,,=,,,non-inhibitor,102,94.6,%,3.9,catechin,,,"inhibition of tetraethylammonium (TEA) uptake; The specific uptake was evaluated at 37?C and pH 8.5 for 20 min (DAPI, 1:M) or 10min ([14C]TEA, 3:M) in the presence of a test compound (0.2mM) or in its absence. The control values were 3.20 FI/mg protein and 132pmol/mg protein, respectively, for DAPI and TEA",,,,,,human,mbds0010,,2013-11-24 08:05:36
mbbd000140710,mbcd0029688,mbtp000007,mbrf0002133,,=,,,non-inhibitor,102,90.7,%,2.7,diaminobiotin,,,"inhibition of 4',6-diamidino-2-phenylindol (DAPI) uptake; The specific uptake was evaluated at 37?C and pH 8.5 for 20 min (DAPI, 1:M) or 10min ([14C]TEA, 3:M) in the presence of a test compound (0.2mM) or in its absence. The control values were 3.20 FI/mg protein and 132pmol/mg protein, respectively, for DAPI and TEA",,,,,,human,mbds0010,,2013-11-24 07:58:19
mbbd000140711,mbcd0029688,mbtp000007,mbrf0002133,,=,,,inhibitor,102,86.0,%,3.0,diaminobiotin,,,"inhibition of tetraethylammonium (TEA) uptake; The specific uptake was evaluated at 37?C and pH 8.5 for 20 min (DAPI, 1:M) or 10min ([14C]TEA, 3:M) in the presence of a test compound (0.2mM) or in its absence. The control values were 3.20 FI/mg protein and 132pmol/mg protein, respectively, for DAPI and TEA",,,,,,human,mbds0010,,2013-11-24 08:05:36
mbbd000140712,mbcd0007988,mbtp000007,mbrf0002133,,=,,,non-inhibitor,102,94.6,%,1.7,GABA,,,"inhibition of 4',6-diamidino-2-phenylindol (DAPI) uptake; The specific uptake was evaluated at 37?C and pH 8.5 for 20 min (DAPI, 1:M) or 10min ([14C]TEA, 3:M) in the presence of a test compound (0.2mM) or in its absence. The control values were 3.20 FI/mg protein and 132pmol/mg protein, respectively, for DAPI and TEA",,,,,,human,mbds0010,,2013-11-24 07:58:19
mbbd000140713,mbcd0007988,mbtp000007,mbrf0002133,,=,,,non-inhibitor,102,89.6,%,3.4,GABA,,,"inhibition of tetraethylammonium (TEA) uptake; The specific uptake was evaluated at 37?C and pH 8.5 for 20 min (DAPI, 1:M) or 10min ([14C]TEA, 3:M) in the presence of a test compound (0.2mM) or in its absence. The control values were 3.20 FI/mg protein and 132pmol/mg protein, respectively, for DAPI and TEA",,,,,,human,mbds0010,,2013-11-24 08:05:36
mbbd000140714,mbcd0003134,mbtp000007,mbrf0002133,,=,,,non-inhibitor,102,102.0,%,2.6,benzylpenicillin,,,"inhibition of 4',6-diamidino-2-phenylindol (DAPI) uptake; The specific uptake was evaluated at 37?C and pH 8.5 for 20 min (DAPI, 1:M) or 10min ([14C]TEA, 3:M) in the presence of a test compound (0.2mM) or in its absence. The control values were 3.20 FI/mg protein and 132pmol/mg protein, respectively, for DAPI and TEA",,,,,,human,mbds0010,,2013-11-24 07:58:19
mbbd000140715,mbcd0003134,mbtp000007,mbrf0002133,,=,,,non-inhibitor,102,94.5,%,0.9,benzylpenicillin,,,"inhibition of tetraethylammonium (TEA) uptake; The specific uptake was evaluated at 37?C and pH 8.5 for 20 min (DAPI, 1:M) or 10min ([14C]TEA, 3:M) in the presence of a test compound (0.2mM) or in its absence. The control values were 3.20 FI/mg protein and 132pmol/mg protein, respectively, for DAPI and TEA",,,,,,human,mbds0010,,2013-11-24 08:05:37
mbbd000140716,mbcd0003037,mbtp000007,mbrf0002133,,=,,,non-inhibitor,102,105.7,%,4.4,NMN,,,"inhibition of 4',6-diamidino-2-phenylindol (DAPI) uptake; The specific uptake was evaluated at 37?C and pH 8.5 for 20 min (DAPI, 1:M) or 10min ([14C]TEA, 3:M) in the presence of a test compound (0.2mM) or in its absence. The control values were 3.20 FI/mg protein and 132pmol/mg protein, respectively, for DAPI and TEA",,,,,,human,mbds0010,,2013-11-24 07:58:19
mbbd000140717,mbcd0003037,mbtp000007,mbrf0002133,,=,,,non-inhibitor,102,101.8,%,3.3,NMN,,,"inhibition of tetraethylammonium (TEA) uptake; The specific uptake was evaluated at 37?C and pH 8.5 for 20 min (DAPI, 1:M) or 10min ([14C]TEA, 3:M) in the presence of a test compound (0.2mM) or in its absence. The control values were 3.20 FI/mg protein and 132pmol/mg protein, respectively, for DAPI and TEA",,,,,,human,mbds0010,,2013-11-24 08:05:37
mbbd000140718,mbcd0001641,mbtp000007,mbrf0002133,,=,,,non-inhibitor,102,106.4,%,5.1,nicotinamide,,,"inhibition of 4',6-diamidino-2-phenylindol (DAPI) uptake; The specific uptake was evaluated at 37?C and pH 8.5 for 20 min (DAPI, 1:M) or 10min ([14C]TEA, 3:M) in the presence of a test compound (0.2mM) or in its absence. The control values were 3.20 FI/mg protein and 132pmol/mg protein, respectively, for DAPI and TEA",,,,,,human,mbds0010,,2013-11-24 07:58:19
mbbd000140719,mbcd0001641,mbtp000007,mbrf0002133,,=,,,non-inhibitor,102,91.8,%,4.2,nicotinamide,,,"inhibition of tetraethylammonium (TEA) uptake; The specific uptake was evaluated at 37?C and pH 8.5 for 20 min (DAPI, 1:M) or 10min ([14C]TEA, 3:M) in the presence of a test compound (0.2mM) or in its absence. The control values were 3.20 FI/mg protein and 132pmol/mg protein, respectively, for DAPI and TEA",,,,,,human,mbds0010,,2013-11-24 08:05:37
mbbd000140720,mbcd0001892,mbtp000007,mbrf0002133,,=,,,inhibitor,102,2.7,%,1.6,progesterone,,,"inhibition of 4',6-diamidino-2-phenylindol (DAPI) uptake; The specific uptake of DAPI (1:M) was evaluated at 37?C and pH 8.5 for 20min in the presence of a test compound (0.2mM) or in its absence. The control value was 3.20 FI/mg protein",,,,,,human,mbds0010,,2013-11-24 07:58:19
mbbd000140721,mbcd0003120,mbtp000007,mbrf0002133,,=,,,inhibitor,102,2.8,%,0.2,quercetin,,,"inhibition of 4',6-diamidino-2-phenylindol (DAPI) uptake; The specific uptake of DAPI (1:M) was evaluated at 37?C and pH 8.5 for 20min in the presence of a test compound (0.2mM) or in its absence. The control value was 3.20 FI/mg protein",,,,,,human,mbds0010,,2013-11-24 07:58:19
mbbd000140722,mbcd0003933,mbtp000007,mbrf0002133,,=,,,inhibitor,102,5.1,%,0.5,dopamine,,,"inhibition of 4',6-diamidino-2-phenylindol (DAPI) uptake; The specific uptake of DAPI (1:M) was evaluated at 37?C and pH 8.5 for 20min in the presence of a test compound (0.2mM) or in its absence. The control value was 3.20 FI/mg protein",,,,,,human,mbds0010,,2013-11-24 07:58:19
mbbd000140723,mbcd0003141,mbtp000007,mbrf0002133,,=,,,inhibitor,102,7.0,%,1.0,disopyramide,,,"inhibition of 4',6-diamidino-2-phenylindol (DAPI) uptake; The specific uptake of DAPI (1:M) was evaluated at 37?C and pH 8.5 for 20min in the presence of a test compound (0.2mM) or in its absence. The control value was 3.20 FI/mg protein",,,,,,human,mbds0010,,2013-11-24 07:58:19
mbbd000140724,mbcd0002338,mbtp000007,mbrf0002133,,=,,,inhibitor,102,7.9,%,1.7,diltiazem,,,"inhibition of 4',6-diamidino-2-phenylindol (DAPI) uptake; The specific uptake of DAPI (1:M) was evaluated at 37?C and pH 8.5 for 20min in the presence of a test compound (0.2mM) or in its absence. The control value was 3.20 FI/mg protein",,,,,,human,mbds0010,,2013-11-24 07:58:19
mbbd000140725,mbcd0009152,mbtp000007,mbrf0002133,,=,,,inhibitor,102,8.1,%,1.4,perphenazine,,,"inhibition of 4',6-diamidino-2-phenylindol (DAPI) uptake; The specific uptake of DAPI (1:M) was evaluated at 37?C and pH 8.5 for 20min in the presence of a test compound (0.2mM) or in its absence. The control value was 3.20 FI/mg protein",,,,,,human,mbds0010,,2013-11-24 07:58:19
mbbd000140726,mbcd0029689,mbtp000007,mbrf0002133,,=,,,inhibitor,102,9.8,%,1.5,propantheline,,,"inhibition of 4',6-diamidino-2-phenylindol (DAPI) uptake; The specific uptake of DAPI (1:M) was evaluated at 37?C and pH 8.5 for 20min in the presence of a test compound (0.2mM) or in its absence. The control value was 3.20 FI/mg protein",,,,,,human,mbds0010,,2013-11-24 07:58:19
mbbd000140727,mbcd0016500,mbtp000007,mbrf0002133,,=,,,inhibitor,102,16.8,%,1.8,serotonin,,,"inhibition of 4',6-diamidino-2-phenylindol (DAPI) uptake; The specific uptake of DAPI (1:M) was evaluated at 37?C and pH 8.5 for 20min in the presence of a test compound (0.2mM) or in its absence. The control value was 3.20 FI/mg protein",,,,,,human,mbds0010,,2013-11-24 07:58:19
mbbd000140728,mbcd0021691,mbtp000007,mbrf0002133,,=,,,inhibitor,102,25.7,%,2.3,norepinephrine,,,"inhibition of 4',6-diamidino-2-phenylindol (DAPI) uptake; The specific uptake of DAPI (1:M) was evaluated at 37?C and pH 8.5 for 20min in the presence of a test compound (0.2mM) or in its absence. The control value was 3.20 FI/mg protein",,,,,,human,mbds0010,,2013-11-24 07:58:19
mbbd000140729,mbcd0003894,mbtp000007,mbrf0002133,,=,,,inhibitor,102,25.8,%,1.0,metoclopramide,,,"inhibition of 4',6-diamidino-2-phenylindol (DAPI) uptake; The specific uptake of DAPI (1:M) was evaluated at 37?C and pH 8.5 for 20min in the presence of a test compound (0.2mM) or in its absence. The control value was 3.20 FI/mg protein",,,,,,human,mbds0010,,2013-11-24 07:58:19
mbbd000140730,mbcd0001869,mbtp000007,mbrf0002133,,=,,,inhibitor,102,28.8,%,6.5,berberine,,,"inhibition of 4',6-diamidino-2-phenylindol (DAPI) uptake; The specific uptake of DAPI (1:M) was evaluated at 37?C and pH 8.5 for 20min in the presence of a test compound (0.2mM) or in its absence. The control value was 3.20 FI/mg protein",,,,,,human,mbds0010,,2013-11-24 07:58:19
mbbd000140731,mbcd0003947,mbtp000007,mbrf0002133,,=,,,inhibitor,102,34.0,%,2.1,clonidine,,,"inhibition of 4',6-diamidino-2-phenylindol (DAPI) uptake; The specific uptake of DAPI (1:M) was evaluated at 37?C and pH 8.5 for 20min in the presence of a test compound (0.2mM) or in its absence. The control value was 3.20 FI/mg protein",,,,,,human,mbds0010,,2013-11-24 07:58:19
mbbd000140732,mbcd0003215,mbtp000007,mbrf0002133,,=,,,inhibitor,102,35.3,%,1.0,kaempferol,,,"inhibition of 4',6-diamidino-2-phenylindol (DAPI) uptake; The specific uptake of DAPI (1:M) was evaluated at 37?C and pH 8.5 for 20min in the presence of a test compound (0.2mM) or in its absence. The control value was 3.20 FI/mg protein",,,,,,human,mbds0010,,2013-11-24 07:58:19
mbbd000140733,mbcd0027348,mbtp000007,mbrf0002133,,=,,,inhibitor,102,35.6,%,0.8,cortisone,,,"inhibition of 4',6-diamidino-2-phenylindol (DAPI) uptake; The specific uptake of DAPI (1:M) was evaluated at 37?C and pH 8.5 for 20min in the presence of a test compound (0.2mM) or in its absence. The control value was 3.20 FI/mg protein",,,,,,human,mbds0010,,2013-11-24 07:58:19
mbbd000140734,mbcd0001243,mbtp000007,mbrf0002133,,=,,,inhibitor,102,35.9,%,1.8,omeprazole,,,"inhibition of 4',6-diamidino-2-phenylindol (DAPI) uptake; The specific uptake of DAPI (1:M) was evaluated at 37?C and pH 8.5 for 20min in the presence of a test compound (0.2mM) or in its absence. The control value was 3.20 FI/mg protein",,,,,,human,mbds0010,,2013-11-24 07:58:19
mbbd000140735,mbcd0027318,mbtp000007,mbrf0002133,,=,,,inhibitor,102,37.6,%,1.4,pindolol,,,"inhibition of 4',6-diamidino-2-phenylindol (DAPI) uptake; The specific uptake of DAPI (1:M) was evaluated at 37?C and pH 8.5 for 20min in the presence of a test compound (0.2mM) or in its absence. The control value was 3.20 FI/mg protein",,,,,,human,mbds0010,,2013-11-24 07:58:19
mbbd000140736,mbcd0001628,mbtp000007,mbrf0002133,,=,,,inhibitor,102,42.7,%,2.3,rutin,,,"inhibition of 4',6-diamidino-2-phenylindol (DAPI) uptake; The specific uptake of DAPI (1:M) was evaluated at 37?C and pH 8.5 for 20min in the presence of a test compound (0.2mM) or in its absence. The control value was 3.20 FI/mg protein",,,,,,human,mbds0010,,2013-11-24 07:58:19
mbbd000140737,mbcd0002635,mbtp000007,mbrf0002133,,=,,,inhibitor,102,50.0,%,1.4,hydrocortisone,,,"inhibition of 4',6-diamidino-2-phenylindol (DAPI) uptake; The specific uptake of DAPI (1:M) was evaluated at 37?C and pH 8.5 for 20min in the presence of a test compound (0.2mM) or in its absence. The control value was 3.20 FI/mg protein",,,,,,human,mbds0010,,2013-11-24 07:58:19
mbbd000140738,mbcd0003022,mbtp000007,mbrf0002133,,=,,,inhibitor,102,54.3,%,3.5,MPP,,,"inhibition of 4',6-diamidino-2-phenylindol (DAPI) uptake; The specific uptake of DAPI (1:M) was evaluated at 37?C and pH 8.5 for 20min in the presence of a test compound (0.2mM) or in its absence. The control value was 3.20 FI/mg protein",,,,,,human,mbds0010,,2013-11-24 07:58:19
mbbd000140739,mbcd0002985,mbtp000007,mbrf0002133,,=,,,inhibitor,102,56.2,%,4.0,carbamazepine,,,"inhibition of 4',6-diamidino-2-phenylindol (DAPI) uptake; The specific uptake of DAPI (1:M) was evaluated at 37?C and pH 8.5 for 20min in the presence of a test compound (0.2mM) or in its absence. The control value was 3.20 FI/mg protein",,,,,,human,mbds0010,,2013-11-24 07:58:19
mbbd000140740,mbcd0003076,mbtp000007,mbrf0002133,,=,,,inhibitor,102,58.7,%,1.1,naringenin,,,"inhibition of 4',6-diamidino-2-phenylindol (DAPI) uptake; The specific uptake of DAPI (1:M) was evaluated at 37?C and pH 8.5 for 20min in the presence of a test compound (0.2mM) or in its absence. The control value was 3.20 FI/mg protein",,,,,,human,mbds0010,,2013-11-24 07:58:19
mbbd000140741,mbcd0029691,mbtp000007,mbrf0002133,,=,,,inhibitor,102,59.1,%,2.5,NBMPR,,,"inhibition of 4',6-diamidino-2-phenylindol (DAPI) uptake; The specific uptake of DAPI (1:M) was evaluated at 37?C and pH 8.5 for 20min in the presence of a test compound (0.2mM) or in its absence. The control value was 3.20 FI/mg protein",,,,,,human,mbds0010,,2013-11-24 07:58:19
mbbd000140742,mbcd0003941,mbtp000007,mbrf0002133,,=,,,inhibitor,102,58.9,%,1.7,procainamide,,,"inhibition of 4',6-diamidino-2-phenylindol (DAPI) uptake; The specific uptake of DAPI (1:M) was evaluated at 37?C and pH 8.5 for 20min in the presence of a test compound (0.2mM) or in its absence. The control value was 3.20 FI/mg protein",,,,,,human,mbds0010,,2013-11-24 07:58:19
mbbd000140743,mbcd0003035,mbtp000007,mbrf0002133,,=,,,inhibitor,102,60.0,%,4.3,BSP,,,"inhibition of 4',6-diamidino-2-phenylindol (DAPI) uptake; The specific uptake of DAPI (1:M) was evaluated at 37?C and pH 8.5 for 20min in the presence of a test compound (0.2mM) or in its absence. The control value was 3.20 FI/mg protein",,,,,,human,mbds0010,,2013-11-24 07:58:19
mbbd000140744,mbcd0003884,mbtp000007,mbrf0002133,,=,,,inhibitor,102,60.4,%,3.5,lidocaine,,,"inhibition of 4',6-diamidino-2-phenylindol (DAPI) uptake; The specific uptake of DAPI (1:M) was evaluated at 37?C and pH 8.5 for 20min in the presence of a test compound (0.2mM) or in its absence. The control value was 3.20 FI/mg protein",,,,,,human,mbds0010,,2013-11-24 07:58:19
mbbd000140745,mbcd0003096,mbtp000007,mbrf0002133,,=,,,inhibitor,102,63.7,%,1.6,prednisolone,,,"inhibition of 4',6-diamidino-2-phenylindol (DAPI) uptake; The specific uptake of DAPI (1:M) was evaluated at 37?C and pH 8.5 for 20min in the presence of a test compound (0.2mM) or in its absence. The control value was 3.20 FI/mg protein",,,,,,human,mbds0010,,2013-11-24 07:58:19
mbbd000140746,mbcd0004042,mbtp000007,mbrf0002133,,=,,,inhibitor,102,66.9,%,3.8,phloridzin,,,"inhibition of 4',6-diamidino-2-phenylindol (DAPI) uptake; The specific uptake of DAPI (1:M) was evaluated at 37?C and pH 8.5 for 20min in the presence of a test compound (0.2mM) or in its absence. The control value was 3.20 FI/mg protein",,,,,,human,mbds0010,,2013-11-24 07:58:19
mbbd000140747,mbcd0001280,mbtp000007,mbrf0002133,,=,,,inhibitor,102,67.7,%,6.0,sulfasalazine,,,"inhibition of 4',6-diamidino-2-phenylindol (DAPI) uptake; The specific uptake of DAPI (1:M) was evaluated at 37?C and pH 8.5 for 20min in the presence of a test compound (0.2mM) or in its absence. The control value was 3.20 FI/mg protein",,,,,,human,mbds0010,,2013-11-24 07:58:19
mbbd000140748,mbcd0011455,mbtp000007,mbrf0002133,,=,,,inhibitor,102,68.3,%,1.7,primidone,,,"inhibition of 4',6-diamidino-2-phenylindol (DAPI) uptake; The specific uptake of DAPI (1:M) was evaluated at 37?C and pH 8.5 for 20min in the presence of a test compound (0.2mM) or in its absence. The control value was 3.20 FI/mg protein",,,,,,human,mbds0010,,2013-11-24 07:58:19
mbbd000140749,mbcd0001442,mbtp000007,mbrf0002133,,=,,,inhibitor,102,74.3,%,1.5,ouabain,,,"inhibition of 4',6-diamidino-2-phenylindol (DAPI) uptake; The specific uptake of DAPI (1:M) was evaluated at 37?C and pH 8.5 for 20min in the presence of a test compound (0.2mM) or in its absence. The control value was 3.20 FI/mg protein",,,,,,human,mbds0010,,2013-11-24 07:58:19
mbbd000140750,mbcd0029692,mbtp000007,mbrf0002133,,=,,,inhibitor,102,74.8,%,3.9,uridine,,,"inhibition of 4',6-diamidino-2-phenylindol (DAPI) uptake; The specific uptake of DAPI (1:M) was evaluated at 37?C and pH 8.5 for 20min in the presence of a test compound (0.2mM) or in its absence. The control value was 3.20 FI/mg protein",,,,,,human,mbds0010,,2013-11-24 07:58:19
mbbd000140751,mbcd0003075,mbtp000007,mbrf0002133,,=,,,inhibitor,102,75.6,%,4.3,estrone - 3 - sulfate,,,"inhibition of 4',6-diamidino-2-phenylindol (DAPI) uptake; The specific uptake of DAPI (1:M) was evaluated at 37?C and pH 8.5 for 20min in the presence of a test compound (0.2mM) or in its absence. The control value was 3.20 FI/mg protein",,,,,,human,mbds0010,,2013-11-24 07:58:19
mbbd000140752,mbcd0018332,mbtp000007,mbrf0002133,,=,,,inhibitor,102,77.1,%,7.4,mefenamate,,,"inhibition of 4',6-diamidino-2-phenylindol (DAPI) uptake; The specific uptake of DAPI (1:M) was evaluated at 37?C and pH 8.5 for 20min in the presence of a test compound (0.2mM) or in its absence. The control value was 3.20 FI/mg protein",,,,,,human,mbds0010,,2013-11-24 07:58:19
mbbd000140753,mbcd0001131,mbtp000007,mbrf0002133,,=,,,inhibitor,102,79.3,%,0.5,guanedine,,,"inhibition of 4',6-diamidino-2-phenylindol (DAPI) uptake; The specific uptake of DAPI (1:M) was evaluated at 37?C and pH 8.5 for 20min in the presence of a test compound (0.2mM) or in its absence. The control value was 3.20 FI/mg protein",,,,,,human,mbds0010,,2013-11-24 07:58:19
mbbd000140754,mbcd0029693,mbtp000007,mbrf0002133,,=,,,inhibitor,102,77.8,%,2.0,d-Desthiobiotin,,,"inhibition of 4',6-diamidino-2-phenylindol (DAPI) uptake; The specific uptake of DAPI (1:M) was evaluated at 37?C and pH 8.5 for 20min in the presence of a test compound (0.2mM) or in its absence. The control value was 3.20 FI/mg protein",,,,,,human,mbds0010,,2013-11-24 07:58:19
mbbd000140755,mbcd0003938,mbtp000007,mbrf0002133,,=,,,inhibitor,102,79.5,%,1.6,Azathioprine,,,"inhibition of 4',6-diamidino-2-phenylindol (DAPI) uptake; The specific uptake of DAPI (1:M) was evaluated at 37?C and pH 8.5 for 20min in the presence of a test compound (0.2mM) or in its absence. The control value was 3.20 FI/mg protein",,,,,,human,mbds0010,,2013-11-24 07:58:19
mbbd000140756,mbcd0001667,mbtp000007,mbrf0002133,,=,,,inhibitor,102,79.7,%,4.8,thymidine,,,"inhibition of 4',6-diamidino-2-phenylindol (DAPI) uptake; The specific uptake of DAPI (1:M) was evaluated at 37?C and pH 8.5 for 20min in the presence of a test compound (0.2mM) or in its absence. The control value was 3.20 FI/mg protein",,,,,,human,mbds0010,,2013-11-24 07:58:19
mbbd000140757,mbcd0003007,mbtp000007,mbrf0002133,,=,,,inhibitor,102,80.4,%,6.1,phenobarbital,,,"inhibition of 4',6-diamidino-2-phenylindol (DAPI) uptake; The specific uptake of DAPI (1:M) was evaluated at 37?C and pH 8.5 for 20min in the presence of a test compound (0.2mM) or in its absence. The control value was 3.20 FI/mg protein",,,,,,human,mbds0010,,2013-11-24 07:58:19
mbbd000140758,mbcd0001111,mbtp000007,mbrf0002133,,=,,,inhibitor,102,83.4,%,0.9,cimetidine,,,"inhibition of 4',6-diamidino-2-phenylindol (DAPI) uptake; The specific uptake of DAPI (1:M) was evaluated at 37?C and pH 8.5 for 20min in the presence of a test compound (0.2mM) or in its absence. The control value was 3.20 FI/mg protein",,,,,,human,mbds0010,,2013-11-24 07:58:19
mbbd000140759,mbcd0003907,mbtp000007,mbrf0002133,,=,,,inhibitor,102,83.5,%,2.7,histamine,,,"inhibition of 4',6-diamidino-2-phenylindol (DAPI) uptake; The specific uptake of DAPI (1:M) was evaluated at 37?C and pH 8.5 for 20min in the presence of a test compound (0.2mM) or in its absence. The control value was 3.20 FI/mg protein",,,,,,human,mbds0010,,2013-11-24 07:58:19
mbbd000140760,mbcd0017319,mbtp000007,mbrf0002133,,=,,,non-inhibitor,102,86.7,%,2.2,Sulfamethoxazole,,,"inhibition of 4',6-diamidino-2-phenylindol (DAPI) uptake; The specific uptake of DAPI (1:M) was evaluated at 37?C and pH 8.5 for 20min in the presence of a test compound (0.2mM) or in its absence. The control value was 3.20 FI/mg protein",,,,,,human,mbds0010,,2013-11-24 07:58:19
mbbd000140761,mbcd0003879,mbtp000007,mbrf0002133,,=,,,non-inhibitor,102,88.2,%,8.9,caffeine,,,"inhibition of 4',6-diamidino-2-phenylindol (DAPI) uptake; The specific uptake of DAPI (1:M) was evaluated at 37?C and pH 8.5 for 20min in the presence of a test compound (0.2mM) or in its absence. The control value was 3.20 FI/mg protein",,,,,,human,mbds0010,,2013-11-24 07:58:19
mbbd000140762,mbcd0029697,mbtp000007,mbrf0002133,,=,,,non-inhibitor,102,88.7,%,2.0,Dithioerythritol,,,"inhibition of 4',6-diamidino-2-phenylindol (DAPI) uptake; The specific uptake of DAPI (1:M) was evaluated at 37?C and pH 8.5 for 20min in the presence of a test compound (0.2mM) or in its absence. The control value was 3.20 FI/mg protein",,,,,,human,mbds0010,,2013-11-24 07:58:19
mbbd000140763,mbcd0029698,mbtp000007,mbrf0002133,,=,,,non-inhibitor,102,89.1,%,4.0,L-3-Methoxytyrosine,,,"inhibition of 4',6-diamidino-2-phenylindol (DAPI) uptake; The specific uptake of DAPI (1:M) was evaluated at 37?C and pH 8.5 for 20min in the presence of a test compound (0.2mM) or in its absence. The control value was 3.20 FI/mg protein",,,,,,human,mbds0010,,2013-11-24 07:58:19
mbbd000140764,mbcd0003137,mbtp000007,mbrf0002133,,=,,,non-inhibitor,102,90.1,%,5.1,furosemide,,,"inhibition of 4',6-diamidino-2-phenylindol (DAPI) uptake; The specific uptake of DAPI (1:M) was evaluated at 37?C and pH 8.5 for 20min in the presence of a test compound (0.2mM) or in its absence. The control value was 3.20 FI/mg protein",,,,,,human,mbds0010,,2013-11-24 07:58:19
mbbd000140765,mbcd0029699,mbtp000007,mbrf0002133,,=,,,non-inhibitor,102,91.2,%,3.8,tranexamate,,,"inhibition of 4',6-diamidino-2-phenylindol (DAPI) uptake; The specific uptake of DAPI (1:M) was evaluated at 37?C and pH 8.5 for 20min in the presence of a test compound (0.2mM) or in its absence. The control value was 3.20 FI/mg protein",,,,,,human,mbds0010,,2013-11-24 07:58:19
mbbd000140766,mbcd0029700,mbtp000007,mbrf0002133,,=,,,non-inhibitor,102,93.1,%,4.6,TPP,,,"inhibition of 4',6-diamidino-2-phenylindol (DAPI) uptake; The specific uptake of DAPI (1:M) was evaluated at 37?C and pH 8.5 for 20min in the presence of a test compound (0.2mM) or in its absence. The control value was 3.20 FI/mg protein",,,,,,human,mbds0010,,2013-11-24 07:58:19
mbbd000140767,mbcd0003512,mbtp000007,mbrf0002133,,=,,,non-inhibitor,102,93.4,%,2.1,5-aminovalerate,,,"inhibition of 4',6-diamidino-2-phenylindol (DAPI) uptake; The specific uptake of DAPI (1:M) was evaluated at 37?C and pH 8.5 for 20min in the presence of a test compound (0.2mM) or in its absence. The control value was 3.20 FI/mg protein",,,,,,human,mbds0010,,2013-11-24 07:58:19
mbbd000140768,mbcd0002988,mbtp000007,mbrf0002133,,=,,,non-inhibitor,102,93.9,%,2.5,Sulfinpyrazone,,,"inhibition of 4',6-diamidino-2-phenylindol (DAPI) uptake; The specific uptake of DAPI (1:M) was evaluated at 37?C and pH 8.5 for 20min in the presence of a test compound (0.2mM) or in its absence. The control value was 3.20 FI/mg protein",,,,,,human,mbds0010,,2013-11-24 07:58:19
mbbd000140769,mbcd0026528,mbtp000007,mbrf0002133,,=,,,non-inhibitor,102,94.2,%,2.5,ethosuximide,,,"inhibition of 4',6-diamidino-2-phenylindol (DAPI) uptake; The specific uptake of DAPI (1:M) was evaluated at 37?C and pH 8.5 for 20min in the presence of a test compound (0.2mM) or in its absence. The control value was 3.20 FI/mg protein",,,,,,human,mbds0010,,2013-11-24 07:58:19
mbbd000140770,mbcd0000311,mbtp000007,mbrf0002133,,=,,,non-inhibitor,102,94.5,%,4.7,cyclosporine A,,,"inhibition of 4',6-diamidino-2-phenylindol (DAPI) uptake; The specific uptake of DAPI (1:M) was evaluated at 37?C and pH 8.5 for 20min in the presence of a test compound (0.2mM) or in its absence. The control value was 3.20 FI/mg protein",,,,,,human,mbds0010,,2013-11-24 07:58:19
mbbd000140771,mbcd0017644,mbtp000007,mbrf0002133,,=,,,non-inhibitor,102,96.1,%,2.3,tolbutamide,,,"inhibition of 4',6-diamidino-2-phenylindol (DAPI) uptake; The specific uptake of DAPI (1:M) was evaluated at 37?C and pH 8.5 for 20min in the presence of a test compound (0.2mM) or in its absence. The control value was 3.20 FI/mg protein",,,,,,human,mbds0010,,2013-11-24 07:58:19
mbbd000140772,mbcd0003553,mbtp000007,mbrf0002133,,=,,,non-inhibitor,102,97.1,%,3.2,cephradine,,,"inhibition of 4',6-diamidino-2-phenylindol (DAPI) uptake; The specific uptake of DAPI (1:M) was evaluated at 37?C and pH 8.5 for 20min in the presence of a test compound (0.2mM) or in its absence. The control value was 3.20 FI/mg protein",,,,,,human,mbds0010,,2013-11-24 07:58:19
mbbd000140773,mbcd0003973,mbtp000007,mbrf0002133,,=,,,non-inhibitor,102,97.4,%,6.7,Allopurinol,,,"inhibition of 4',6-diamidino-2-phenylindol (DAPI) uptake; The specific uptake of DAPI (1:M) was evaluated at 37?C and pH 8.5 for 20min in the presence of a test compound (0.2mM) or in its absence. The control value was 3.20 FI/mg protein",,,,,,human,mbds0010,,2013-11-24 07:58:19
mbbd000140774,mbcd0029703,mbtp000007,mbrf0002133,,=,,,non-inhibitor,102,98.2,%,8.5,PABA,,,"inhibition of 4',6-diamidino-2-phenylindol (DAPI) uptake; The specific uptake of DAPI (1:M) was evaluated at 37?C and pH 8.5 for 20min in the presence of a test compound (0.2mM) or in its absence. The control value was 3.20 FI/mg protein",,,,,,human,mbds0010,,2013-11-24 07:58:19
mbbd000140775,mbcd0003008,mbtp000007,mbrf0002133,,=,,,non-inhibitor,102,98.8,%,5.0,valproate,,,"inhibition of 4',6-diamidino-2-phenylindol (DAPI) uptake; The specific uptake of DAPI (1:M) was evaluated at 37?C and pH 8.5 for 20min in the presence of a test compound (0.2mM) or in its absence. The control value was 3.20 FI/mg protein",,,,,,human,mbds0010,,2013-11-24 07:58:19
mbbd000140776,mbcd0029713,mbtp000007,mbrf0002133,,=,,,non-inhibitor,102,99.3,%,2.6,guanosine,,,"inhibition of 4',6-diamidino-2-phenylindol (DAPI) uptake; The specific uptake of DAPI (1:M) was evaluated at 37?C and pH 8.5 for 20min in the presence of a test compound (0.2mM) or in its absence. The control value was 3.20 FI/mg protein",,,,,,human,mbds0010,,2013-11-24 07:58:19
mbbd000140777,mbcd0001664,mbtp000007,mbrf0002133,,=,,,non-inhibitor,102,100.0,%,2.0,taurocholate,,,"inhibition of 4',6-diamidino-2-phenylindol (DAPI) uptake; The specific uptake of DAPI (1:M) was evaluated at 37?C and pH 8.5 for 20min in the presence of a test compound (0.2mM) or in its absence. The control value was 3.20 FI/mg protein",,,,,,human,mbds0010,,2013-11-24 07:58:19
mbbd000140778,mbcd0000910,mbtp000007,mbrf0002133,,=,,,non-inhibitor,102,101.2,%,7.4,biotin,,,"inhibition of 4',6-diamidino-2-phenylindol (DAPI) uptake; The specific uptake of DAPI (1:M) was evaluated at 37?C and pH 8.5 for 20min in the presence of a test compound (0.2mM) or in its absence. The control value was 3.20 FI/mg protein",,,,,,human,mbds0010,,2013-11-24 07:58:19
mbbd000140779,mbcd0006356,mbtp000007,mbrf0002133,,=,,,non-inhibitor,102,101.8,%,2.4,N-Ethylmaleimide,,,"inhibition of 4',6-diamidino-2-phenylindol (DAPI) uptake; The specific uptake of DAPI (1:M) was evaluated at 37?C and pH 8.5 for 20min in the presence of a test compound (0.2mM) or in its absence. The control value was 3.20 FI/mg protein",,,,,,human,mbds0010,,2013-11-24 07:58:19
mbbd000140780,mbcd0000840,mbtp000007,mbrf0002133,,=,,,non-inhibitor,102,103.9,%,3.9,TEA,,,"inhibition of 4',6-diamidino-2-phenylindol (DAPI) uptake; The specific uptake of DAPI (1:M) was evaluated at 37?C and pH 8.5 for 20min in the presence of a test compound (0.2mM) or in its absence. The control value was 3.20 FI/mg protein",,,,,,human,mbds0010,,2013-11-24 07:58:19
mbbd000140781,mbcd0003916,mbtp000007,mbrf0002133,,=,,,non-inhibitor,102,104.2,%,3.9,Acyclovir,,,"inhibition of 4',6-diamidino-2-phenylindol (DAPI) uptake; The specific uptake of DAPI (1:M) was evaluated at 37?C and pH 8.5 for 20min in the presence of a test compound (0.2mM) or in its absence. The control value was 3.20 FI/mg protein",,,,,,human,mbds0010,,2013-11-24 07:58:19
mbbd000140782,mbcd0003111,mbtp000007,mbrf0002133,,=,,,non-inhibitor,102,104.5,%,1.1,imidazole,,,"inhibition of 4',6-diamidino-2-phenylindol (DAPI) uptake; The specific uptake of DAPI (1:M) was evaluated at 37?C and pH 8.5 for 20min in the presence of a test compound (0.2mM) or in its absence. The control value was 3.20 FI/mg protein",,,,,,human,mbds0010,,2013-11-24 07:58:19
mbbd000140783,mbcd0029706,mbtp000007,mbrf0002133,,=,,,non-inhibitor,102,104.8,%,1.2,Pyridoxal 5'-phosphate,,,"inhibition of 4',6-diamidino-2-phenylindol (DAPI) uptake; The specific uptake of DAPI (1:M) was evaluated at 37?C and pH 8.5 for 20min in the presence of a test compound (0.2mM) or in its absence. The control value was 3.20 FI/mg protein",,,,,,human,mbds0010,,2014-02-27 03:13:57
mbbd000140784,mbcd0003942,mbtp000007,mbrf0002133,,=,,,non-inhibitor,102,105.3,%,6.1,Theophylline,,,"inhibition of 4',6-diamidino-2-phenylindol (DAPI) uptake; The specific uptake of DAPI (1:M) was evaluated at 37?C and pH 8.5 for 20min in the presence of a test compound (0.2mM) or in its absence. The control value was 3.20 FI/mg protein",,,,,,human,mbds0010,,2013-11-24 07:58:19
mbbd000140785,mbcd0017644,mbtp000007,mbrf0002133,,=,,,non-inhibitor,102,110.0,%,1.9,tolbutamide,,,"inhibition of 4',6-diamidino-2-phenylindol (DAPI) uptake; The specific uptake of DAPI (1:M) was evaluated at 37?C and pH 8.5 for 20min in the presence of a test compound (0.2mM) or in its absence. The control value was 3.20 FI/mg protein",,,,,,human,mbds0010,,2013-11-24 07:58:19
mbbd000140786,mbcd0003051,mbtp000007,mbrf0002133,,=,,,non-inhibitor,102,114.9,%,5.7,L-Carnitine,,,"inhibition of 4',6-diamidino-2-phenylindol (DAPI) uptake; The specific uptake of DAPI (1:M) was evaluated at 37?C and pH 8.5 for 20min in the presence of a test compound (0.2mM) or in its absence. The control value was 3.20 FI/mg protein",,,,,,human,mbds0010,,2013-11-24 07:58:19
mbbd000140787,mbcd0003146,mbtp000007,mbrf0002133,,=,,,inducer,102,121.4,%,3.6,PAH,,,"inhibition of 4',6-diamidino-2-phenylindol (DAPI) uptake; The specific uptake of DAPI (1:M) was evaluated at 37?C and pH 8.5 for 20min in the presence of a test compound (0.2mM) or in its absence. The control value was 3.20 FI/mg protein",,,,,,human,mbds0010,,2013-11-24 07:58:19
mbbd000140788,mbcd0000840,mbtp000007,mbrf0002133,,=,,,inducer,102,127.6,%,2.5,TMA,,,"inhibition of 4',6-diamidino-2-phenylindol (DAPI) uptake; The specific uptake of DAPI (1:M) was evaluated at 37?C and pH 8.5 for 20min in the presence of a test compound (0.2mM) or in its absence. The control value was 3.20 FI/mg protein",,,,,,human,mbds0010,,2013-11-24 07:58:19
mbbd000140789,mbcd0007800,mbtp000007,mbrf0002133,,=,,,inducer,102,140.6,%,5.2,spermine,,,"inhibition of 4',6-diamidino-2-phenylindol (DAPI) uptake; The specific uptake of DAPI (1:M) was evaluated at 37?C and pH 8.5 for 20min in the presence of a test compound (0.2mM) or in its absence. The control value was 3.20 FI/mg protein",,,,,,human,mbds0010,,2013-11-24 07:58:19
mbbd000140790,mbcd0003887,mbtp000007,mbrf0002165,,=,,,substrate,28,22.1,microM,2.5,YM155,,,uptake of [14 C]YM155 into the hOCT1-HEK,HEK,,,,,human,mbds0010,,2013-11-24 23:13:22
mbbd000140791,mbcd0003887,mbtp000007,mbrf0002165,,=,,,substrate,22,349.0,pmol / min / mg protein,33,YM155,,,uptake of [14 C]YM155 into the hOCT1-HEK,HEK,,,,,human,mbds0010,,2013-11-24 23:13:22
mbbd000140792,mbcd0003887,mbtp000007,mbrf0002165,,=,,,substrate,118,1.42,microL / min / mg protein,0.17,YM155,,,uptake of [14 C]YM155 into the hOCT1-HEK,HEK,,,,,human,mbds0010,,2013-11-24 23:13:22
mbbd000140793,mbcd0003022,mbtp000007,mbrf0002165,,=,,,inhibitor,25,30.4,microM,,MPP,,,"inhibition of YM155 uptake in hOCT1-HEK cells, substrate concentrations of YM155 (1 microM for hOCT1-HEK",,,,,,human,mbds0010,,2013-12-09 20:14:22
mbbd000140794,mbcd0001111,mbtp000007,mbrf0002165,,=,,,inhibitor,25,149.0,microM,,cimetidine,,,"inhibition of YM155 uptake in hOCT1-HEK cells, substrate concentrations of YM155 (1 microM for hOCT1-HEK",,,,,,human,mbds0010,,2013-12-09 20:14:21
mbbd000140795,mbcd0001508,mbtp000007,mbrf0002165,,=,,,inhibitor,25,62.4,microM,,tubocurarine,,,"inhibition of YM155 uptake in hOCT1-HEK cells, substrate concentrations of YM155 (1 microM for hOCT1-HEK",,,,,,human,mbds0010,,2013-12-09 20:14:21
mbbd000140796,mbcd0027018,mbtp000007,mbrf0002165,,=,,,inhibitor,25,7.11,microM,,quinidine,,,"inhibition of YM155 uptake in hOCT1-HEK cells, substrate concentrations of YM155 (1 microM for hOCT1-HEK",,,,,,human,mbds0010,,2013-12-09 20:14:21
mbbd000140797,mbcd0003024,mbtp000007,mbrf0002165,,=,,,inhibitor,25,1.56,microM,,prazosin,,,"inhibition of YM155 uptake in hOCT1-HEK cells, substrate concentrations of YM155 (1 microM for hOCT1-HEK",,,,,,human,mbds0010,,2013-12-09 20:14:20
mbbd000140798,mbcd0003905,mbtp000007,mbrf0002165,,=,,,inhibitor,25,8.89,microM,,corticosterone,,,"inhibition of YM155 uptake in hOCT1-HEK cells, substrate concentrations of YM155 (1 microM for hOCT1-HEK",,,,,,human,mbds0010,,2013-12-09 20:14:20
mbbd000140799,mbcd0027062,mbtp000007,mbrf0002165,,=,,,inhibitor,25,1.23,microM,,verapamil,,,"inhibition of YM155 uptake in hOCT1-HEK cells, substrate concentrations of YM155 (1 microM for hOCT1-HEK",,,,,,human,mbds0010,,2013-12-09 20:14:19
mbbd000140800,mbcd0003083,mbtp000007,mbrf0002165,,=,,,inhibitor,25,39.6,microM,,amantadine,,,"inhibition of YM155 uptake in hOCT1-HEK cells, substrate concentrations of YM155 (1 microM for hOCT1-HEK",,,,,,human,mbds0010,,2013-12-09 21:00:47
mbbd000140801,mbcd0003941,mbtp000007,mbrf0002165,,=,,,inhibitor,25,51.3,microM,,procainamide,,,"inhibition of YM155 uptake in hOCT1-HEK cells, substrate concentrations of YM155 (1 microM for hOCT1-HEK",,,,,,human,mbds0010,,2013-12-09 21:00:46
mbbd000140802,mbcd0003037,mbtp000007,mbrf0002165,,>,,,inhibitor,25,1000.0,microM,,N-methylnicotinamide,,,"inhibition of YM155 uptake in hOCT1-HEK cells, substrate concentrations of YM155 (1 microM for hOCT1-HEK",,,,,,human,mbds0010,,2013-12-09 21:00:46
mbbd000140803,mbcd0001117,mbtp000007,mbrf0002543,,,,,substrate,,,,,cisplatin,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140804,mbcd0002828,mbtp000007,mbrf0002543,,,,,substrate,,,,,imatinib,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140805,mbcd0011776,mbtp000007,mbrf0001708,,,,,non-substrate,,,,,carbo-Pt,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140806,mbcd0029718,mbtp000007,mbrf0001708,,,,,substrate,,,,,pico-Pt,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140807,mbcd0029719,mbtp000007,mbrf0001708,,,,,non-substrate,,,,,neda-Pt,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140808,mbcd0029720,mbtp000007,mbrf0001708,,,,,non-substrate,,,,,orma-Pt,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140809,mbcd0003022,mbtp000007,mbrf0002141,,=,,,substrate,22,441.0,pmol / min / 10^-6 cells,36,MPP+,,,uptake into human hepatocytes,human hepatocytes,,,,,human,mbds0010,,2013-11-24 23:56:35
mbbd000140810,mbcd0003022,mbtp000007,mbrf0002141,,=,,,substrate,22,369.0,pmol / min / 10^-6 cells,46,MPP+,,,"hepatocytes; cryopreserved, L-15 medium containing 10% DMSO, the suspension was stepwise frozen from ?20?Cto ?80?C before storage in liquid nitrogen",hepatocytes,,,,,human,mbds0010,,2013-12-09 20:15:46
mbbd000140811,mbcd0029711,mbtp000007,mbrf0001705,,,,,substrate,,,,,ASP; 4-Di-1-ASP,,,HEK293 cells,HEK293,,1,microM,,human,mbds0010,,2013-11-10 04:16:03
mbbd000140812,mbcd0021420,mbtp000007,mbrf0001705,,=,,,inhibitor,25,8.5,microM,1.4,tropisetron,,,inhibition of ASP+ 1 microM,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140813,mbcd0003920,mbtp000007,mbrf0001705,,=,,,inhibitor,25,63.0,microM,15.6,ondansetron,,,inhibition of ASP+ 1 microM HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140814,mbcd0003886,mbtp000007,mbrf0002163,,=,,,substrate,28,1.18,nmol / mg protein / min,0.18,metformin,,,metformin uptake in HEK293 cells stably transfected with human OCT1,HEK293,,,,,human,mbds0010,,2013-11-24 23:13:22
mbbd000140815,mbcd0003886,mbtp000007,mbrf0002163,,=,,,substrate,22,3.96,mM,0.44,metformin,,,metformin uptake in HEK293 cells stably transfected with human OCT1,HEK293,,,,,human,mbds0010,,2013-11-24 23:13:23
mbbd000140816,mbcd0002982,mbtp000007,mbrf0001778,,=,,,substrate,28,37.8,microM,13,lamivudine,wild type transporter,,uptake of lamivudine in oocytes expressing OCT1,Xenopus laevis oocytes,,,,,human,mbds0010,,2013-11-24 23:56:33
mbbd000140817,mbcd0002982,mbtp000007,mbrf0001778,,=,,,substrate,28,50.3,microM,14,lamivudine,P283L genetic variant,,uptake of lamivudine in oocytes expressing OCT1,Xenopus laevis oocytes,,,,,human,mbds0010,,2013-11-24 23:56:34
mbbd000140818,mbcd0002982,mbtp000007,mbrf0001778,,=,,,substrate,28,38.1,microM,15,lamivudine,P431L genetic variant,,uptake of lamivudine in oocytes expressing OCT1,Xenopus laevis oocytes,,,,,human,mbds0010,,2013-11-24 23:56:34
mbbd000140819,mbcd0002982,mbtp000007,mbrf0001778,,=,,,substrate,22,1653.0,fmol / min / oocyte,48,lamivudine,wild type transporter,,uptake of lamivudine in oocytes expressing OCT1,Xenopus laevis oocytes,,,,,human,mbds0010,,2013-11-24 23:56:34
mbbd000140820,mbcd0002982,mbtp000007,mbrf0001778,,=,,,substrate,22,327.0,fmol / min / oocyte,36,lamivudine,P283L genetic variant,,uptake of lamivudine in oocytes expressing OCT1,Xenopus laevis oocytes,,,,,human,mbds0010,,2013-11-24 23:56:35
mbbd000140821,mbcd0002982,mbtp000007,mbrf0001778,,=,,,substrate,22,855.0,fmol / min / oocyte,37,lamivudine,P431L genetic variant,,uptake of lamivudine in oocytes expressing OCT1,Xenopus laevis oocytes,,,,,human,mbds0010,,2013-11-24 23:56:35
mbbd000140822,mbcd0000932,mbtp000007,mbrf0002433,,=,,,inhibitor,25,30.3,micromol / L,3.1,tramadol,,,competition with ASP+ (4-(4-(dimeth- ylamino)styryl)-N-methylpyridinium iodide) uptake in HEK293 cells overexpressing OCT1,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140823,mbcd0029713,mbtp000007,mbrf0002433,,=,,,inhibitor,25,172.0,micromol / L,73,O-desmethyltramadol,,,competition with ASP+ (4-(4-(dimeth- ylamino)styryl)-N-methylpyridinium iodide) uptake in HEK293 cells overexpressing OCT1,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140824,mbcd0029713,mbtp000007,mbrf0002433,,=,,,substrate,28,149.0,microM,93,O-desmethyltramadol,,,HEK293 cells,HEK293,,0.5-100,microM,,human,mbds0010,,2013-11-10 04:16:03
mbbd000140825,mbcd0003094,mbtp000007,mbrf0002410,,=,,,inhibitor,3,89.4,%,2.01,spironolactone,,,OCT1 inhibition at 50mM ASP+ for fully functional OCT1- reference (NM_003057),HEK293,,,,,human,mbds0010,,2013-11-25 23:28:18
mbbd000140826,mbcd0003094,mbtp000007,mbrf0002410,,=,,,inhibitor,3,89.8,%,1.66,spironolactone,,,OCT1 inhibition at 50mM ASP+ for V408M (rs628031) genetic variant,HEK293,,,,,human,mbds0010,,2013-11-25 23:28:18
mbbd000140827,mbcd0003094,mbtp000007,mbrf0002410,,=,,,inhibitor,3,97.9,%,0.52,spironolactone,,,OCT1 inhibition at 50mM ASP+ for M420del (rs72552763) genetic variant,HEK293,,,,,human,mbds0010,,2013-11-25 23:28:18
mbbd000140828,mbcd0003094,mbtp000007,mbrf0002410,,=,,,inhibitor,3,100.0,%,0.20,spironolactone,,,OCT1 inhibition at 50mM ASP+ for R61C (rs12208357) genetic variant,HEK293,,,,,human,mbds0010,,2013-11-25 23:28:18
mbbd000140829,mbcd0027062,mbtp000007,mbrf0002410,,=,,,inhibitor,3,69.1,%,7.16,verapamil,,,OCT1 inhibition at 50mM ASP+ for fully functional OCT1- reference (NM_003057),HEK293,,,,,human,mbds0010,,2013-11-25 23:28:18
mbbd000140830,mbcd0027062,mbtp000007,mbrf0002410,,=,,,inhibitor,3,76.4,%,5.77,verapamil,,,OCT1 inhibition at 50mM ASP+ for V408M (rs628031) genetic variant,HEK293,,,,,human,mbds0010,,2013-11-25 23:28:18
mbbd000140831,mbcd0027062,mbtp000007,mbrf0002410,,=,,,inhibitor,3,96.5,%,4.21,verapamil,,,OCT1 inhibition at 50mM ASP+ for M420del (rs72552763) genetic variant,HEK293,,,,,human,mbds0010,,2013-11-25 23:28:18
mbbd000140832,mbcd0027062,mbtp000007,mbrf0002410,,=,,,inhibitor,3,100.0,%,1.07,verapamil,,,OCT1 inhibition at 50mM ASP+ for R61C (rs12208357) genetic variant,HEK293,,,,,human,mbds0010,,2013-11-25 23:28:18
mbbd000140833,mbcd0003930,mbtp000007,mbrf0002410,,=,,,inhibitor,3,77.5,%,2.86,doxazosin,,,OCT1 inhibition at 50mM ASP+ for fully functional OCT1- reference (NM_003057),HEK293,,,,,human,mbds0010,,2013-11-25 23:28:18
mbbd000140834,mbcd0003930,mbtp000007,mbrf0002410,,=,,,inhibitor,3,84.5,%,2.89,doxazosin,,,OCT1 inhibition at 50mM ASP+ for V408M (rs628031) genetic variant,HEK293,,,,,human,mbds0010,,2013-11-25 23:28:18
mbbd000140835,mbcd0003930,mbtp000007,mbrf0002410,,=,,,inhibitor,3,99.7,%,0.72,doxazosin,,,OCT1 inhibition at 50mM ASP+ for M420del (rs72552763) genetic variant,HEK293,,,,,human,mbds0010,,2013-11-25 23:28:18
mbbd000140836,mbcd0003930,mbtp000007,mbrf0002410,,=,,,inhibitor,3,100.0,%,0.52,doxazosin,,,OCT1 inhibition at 50mM ASP+ for R61C (rs12208357) genetic variant,HEK293,,,,,human,mbds0010,,2013-11-25 23:28:18
mbbd000140837,mbcd0003900,mbtp000007,mbrf0002410,,=,,,inhibitor,3,50.8,%,8.34,bucindolol,,,OCT1 inhibition at 50mM ASP+ for fully functional OCT1- reference (NM_003057),HEK293,,,,,human,mbds0010,,2013-11-25 23:28:18
mbbd000140838,mbcd0003900,mbtp000007,mbrf0002410,,=,,,inhibitor,3,61.2,%,3.77,bucindolol,,,OCT1 inhibition at 50mM ASP+ for V408M (rs628031) genetic variant,HEK293,,,,,human,mbds0010,,2013-11-25 23:28:18
mbbd000140839,mbcd0003900,mbtp000007,mbrf0002410,,=,,,inhibitor,3,84.7,%,2.64,bucindolol,,,OCT1 inhibition at 50mM ASP+ for M420del (rs72552763) genetic variant,HEK293,,,,,human,mbds0010,,2013-11-25 23:28:18
mbbd000140840,mbcd0003900,mbtp000007,mbrf0002410,,=,,,inhibitor,3,98.2,%,1.34,bucindolol,,,OCT1 inhibition at 50mM ASP+ for R61C (rs12208357) genetic variant,HEK293,,,,,human,mbds0010,,2013-11-25 23:28:18
mbbd000140841,mbcd0002995,mbtp000007,mbrf0002410,,=,,,inhibitor,3,74.7,%,7.56,desipramine,,,OCT1 inhibition at 50mM ASP+ for fully functional OCT1- reference (NM_003057),HEK293,,,,,human,mbds0010,,2013-11-25 23:28:18
mbbd000140842,mbcd0002995,mbtp000007,mbrf0002410,,=,,,inhibitor,3,68.6,%,4.88,desipramine,,,OCT1 inhibition at 50mM ASP+ for V408M (rs628031) genetic variant,HEK293,,,,,human,mbds0010,,2013-11-25 23:28:18
mbbd000140843,mbcd0002995,mbtp000007,mbrf0002410,,=,,,inhibitor,3,76.2,%,5.33,desipramine,,,OCT1 inhibition at 50mM ASP+ for M420del (rs72552763) genetic variant,HEK293,,,,,human,mbds0010,,2013-11-25 23:28:18
mbbd000140844,mbcd0002995,mbtp000007,mbrf0002410,,=,,,inhibitor,3,92.6,%,1.83,desipramine,,,OCT1 inhibition at 50mM ASP+ for R61C (rs12208357) genetic variant,HEK293,,,,,human,mbds0010,,2013-11-25 23:28:18
mbbd000140845,mbcd0002195,mbtp000007,mbrf0002410,,=,,,inhibitor,3,76.6,%,3.19,propafenone,,,OCT1 inhibition at 50mM ASP+ for fully functional OCT1- reference (NM_003057),HEK293,,,,,human,mbds0010,,2013-11-25 23:28:18
mbbd000140846,mbcd0002195,mbtp000007,mbrf0002410,,=,,,inhibitor,3,65.6,%,4.83,propafenone,,,OCT1 inhibition at 50mM ASP+ for V408M (rs628031) genetic variant,HEK293,,,,,human,mbds0010,,2013-11-25 23:28:18
mbbd000140847,mbcd0002195,mbtp000007,mbrf0002410,,=,,,inhibitor,3,82.5,%,4.86,propafenone,,,OCT1 inhibition at 50mM ASP+ for M420del (rs72552763) genetic variant,HEK293,,,,,human,mbds0010,,2013-11-25 23:28:17
mbbd000140848,mbcd0002195,mbtp000007,mbrf0002410,,=,,,inhibitor,3,93.4,%,1.58,propafenone,,,OCT1 inhibition at 50mM ASP+ for R61C (rs12208357) genetic variant,HEK293,,,,,human,mbds0010,,2013-11-25 23:28:17
mbbd000140849,mbcd0017104,mbtp000007,mbrf0002410,,=,,,inhibitor,3,56.7,%,5.33,ketoconazole,,,OCT1 inhibition at 50mM ASP+ for fully functional OCT1- reference (NM_003057),HEK293,,,,,human,mbds0010,,2013-11-25 23:28:17
mbbd000140850,mbcd0017104,mbtp000007,mbrf0002410,,=,,,inhibitor,3,50.5,%,5.93,ketoconazole,,,OCT1 inhibition at 50mM ASP+ for V408M (rs628031) genetic variant,HEK293,,,,,human,mbds0010,,2013-11-25 23:28:17
mbbd000140851,mbcd0017104,mbtp000007,mbrf0002410,,=,,,inhibitor,3,83.5,%,23.3,ketoconazole,,,OCT1 inhibition at 50mM ASP+ for M420del (rs72552763) genetic variant,HEK293,,,,,human,mbds0010,,2013-11-25 23:28:17
mbbd000140852,mbcd0017104,mbtp000007,mbrf0002410,,=,,,inhibitor,3,98.0,%,0.95,ketoconazole,,,OCT1 inhibition at 50mM ASP+ for R61C (rs12208357) genetic variant,HEK293,,,,,human,mbds0010,,2013-11-25 23:28:17
mbbd000140853,mbcd0002340,mbtp000007,mbrf0002410,,=,,,inhibitor,3,50.2,%,5.85,chlorpromazine,,,OCT1 inhibition at 50mM ASP+ for fully functional OCT1- reference (NM_003057),HEK293,,,,,human,mbds0010,,2013-11-25 23:28:17
mbbd000140854,mbcd0002340,mbtp000007,mbrf0002410,,=,,,inhibitor,3,48.0,%,6.35,chlorpromazine,,,OCT1 inhibition at 50mM ASP+ for V408M (rs628031) genetic variant,HEK293,,,,weak inhibitor,human,mbds0010,,2013-11-25 23:33:36
mbbd000140855,mbcd0002340,mbtp000007,mbrf0002410,,=,,,inhibitor,3,57.4,%,8.77,chlorpromazine,,,OCT1 inhibition at 50mM ASP+ for M420del (rs72552763) genetic variant,HEK293,,,,,human,mbds0010,,2013-11-25 23:28:17
mbbd000140856,mbcd0002340,mbtp000007,mbrf0002410,,=,,,inhibitor,3,87.3,%,1.62,chlorpromazine,,,OCT1 inhibition at 50mM ASP+ for R61C (rs12208357) genetic variant,HEK293,,,,,human,mbds0010,,2013-11-25 23:28:17
mbbd000140857,mbcd0003024,mbtp000007,mbrf0002410,,=,,,inhibitor,3,16.2,%,9.85,prazosin,,,OCT1 inhibition at 50mM ASP+ for fully functional OCT1- reference (NM_003057),HEK293,,,,weak inhibitor,human,mbds0010,,2013-11-25 23:32:13
mbbd000140858,mbcd0003024,mbtp000007,mbrf0002410,,=,,,inhibitor,3,10.7,%,13.1,prazosin,,,OCT1 inhibition at 50mM ASP+ for V408M (rs628031) genetic variant,HEK293,,,,weak inhibitor,human,mbds0010,,2013-11-25 23:32:13
mbbd000140859,mbcd0003024,mbtp000007,mbrf0002410,,=,,,inhibitor,3,37.0,%,8.73,prazosin,,,OCT1 inhibition at 50mM ASP+ for M420del (rs72552763) genetic variant,HEK293,,,,weak inhibitor,human,mbds0010,,2013-11-25 23:32:13
mbbd000140860,mbcd0003024,mbtp000007,mbrf0002410,,=,,,inhibitor,3,79.8,%,3.91,prazosin,,,OCT1 inhibition at 50mM ASP+ for R61C (rs12208357) genetic variant,HEK293,,,,,human,mbds0010,,2013-11-25 23:28:17
mbbd000140861,mbcd0003055,mbtp000007,mbrf0002410,,=,,,non-inhibitor,3,9.4,%,11.1,beta-estradiol,,,OCT1 inhibition at 50mM ASP+ for fully functional OCT1- reference (NM_003057),HEK293,,,,,human,mbds0010,,2013-11-25 23:28:17
mbbd000140862,mbcd0003055,mbtp000007,mbrf0002410,,=,,,inhibitor,3,12.4,%,10.2,beta-estradiol,,,OCT1 inhibition at 50mM ASP+ for V408M (rs628031) genetic variant,HEK293,,,,weak inhibitor,human,mbds0010,,2013-11-25 23:32:13
mbbd000140863,mbcd0003055,mbtp000007,mbrf0002410,,=,,,inhibitor,3,12.6,%,13.8,beta-estradiol,,,OCT1 inhibition at 50mM ASP+ for M420del (rs72552763) genetic variant,HEK293,,,,weak inhibitor,human,mbds0010,,2013-11-25 23:32:13
mbbd000140864,mbcd0003055,mbtp000007,mbrf0002410,,=,,,inhibitor,3,49.4,%,9.81,beta-estradiol,,,OCT1 inhibition at 50mM ASP+ for R61C (rs12208357) genetic variant,HEK293,,,,weak inhibitor,human,mbds0010,,2013-11-25 23:33:36
mbbd000140865,mbcd0003911,mbtp000007,mbrf0002410,,=,,,inhibitor,3,15.4,%,16.1,papaverine,,,OCT1 inhibition at 50mM ASP+ for fully functional OCT1- reference (NM_003057),HEK293,,,,weak inhibitor,human,mbds0010,,2013-11-25 23:32:13
mbbd000140866,mbcd0003911,mbtp000007,mbrf0002410,,=,,,inhibitor,3,16.2,%,8.29,papaverine,,,OCT1 inhibition at 50mM ASP+ for V408M (rs628031) genetic variant,HEK293,,,,weak inhibitor,human,mbds0010,,2013-11-25 23:32:13
mbbd000140867,mbcd0003911,mbtp000007,mbrf0002410,,=,,,inhibitor,3,39.6,%,9.37,papaverine,,,OCT1 inhibition at 50mM ASP+ for M420del (rs72552763) genetic variant,HEK293,,,,weak inhibitor,human,mbds0010,,2013-11-25 23:32:13
mbbd000140868,mbcd0003911,mbtp000007,mbrf0002410,,=,,,inhibitor,3,56.8,%,8.06,papaverine,,,OCT1 inhibition at 50mM ASP+ for R61C (rs12208357) genetic variant,HEK293,,,,,human,mbds0010,,2013-11-25 23:28:17
mbbd000140869,mbcd0000932,mbtp000007,mbrf0002410,,=,,,inhibitor,3,40.0,%,6.45,tramadol,,,OCT1 inhibition at 50mM ASP+ for fully functional OCT1- reference (NM_003057),HEK293,,,,weak inhibitor,human,mbds0010,,2013-11-25 23:33:36
mbbd000140870,mbcd0000932,mbtp000007,mbrf0002410,,=,,,inhibitor,3,45.1,%,6.25,tramadol,,,OCT1 inhibition at 50mM ASP+ for V408M (rs628031) genetic variant,HEK293,,,,weak inhibitor,human,mbds0010,,2013-11-25 23:33:36
mbbd000140871,mbcd0000932,mbtp000007,mbrf0002410,,=,,,inhibitor,3,53.9,%,5.84,tramadol,,,OCT1 inhibition at 50mM ASP+ for M420del (rs72552763) genetic variant,HEK293,,,,,human,mbds0010,,2013-11-25 23:28:17
mbbd000140872,mbcd0000932,mbtp000007,mbrf0002410,,=,,,inhibitor,3,57.7,%,11.5,tramadol,,,OCT1 inhibition at 50mM ASP+ for R61C (rs12208357) genetic variant,HEK293,,,,,human,mbds0010,,2013-11-25 23:28:17
mbbd000140873,mbcd0003115,mbtp000007,mbrf0002410,,=,,,inhibitor,3,27.0,%,13.8,trimethoprim,,,OCT1 inhibition at 50mM ASP+ for fully functional OCT1- reference (NM_003057),HEK293,,,,weak inhibitor,human,mbds0010,,2013-11-25 23:32:13
mbbd000140874,mbcd0003115,mbtp000007,mbrf0002410,,=,,,inhibitor,3,24.7,%,10.4,trimethoprim,,,OCT1 inhibition at 50mM ASP+ for V408M (rs628031) genetic variant,HEK293,,,,weak inhibitor,human,mbds0010,,2013-11-25 23:32:13
mbbd000140875,mbcd0003115,mbtp000007,mbrf0002410,,=,,,inhibitor,3,29.0,%,9.86,trimethoprim,,,OCT1 inhibition at 50mM ASP+ for M420del (rs72552763) genetic variant,HEK293,,,,weak inhibitor,human,mbds0010,,2013-11-25 23:32:13
mbbd000140876,mbcd0003115,mbtp000007,mbrf0002410,,=,,,inhibitor,3,43.0,%,7.56,trimethoprim,,,OCT1 inhibition at 50mM ASP+ for R61C (rs12208357) genetic variant,HEK293,,,,weak inhibitor,human,mbds0010,,2013-11-25 23:33:36
mbbd000140877,mbcd0027018,mbtp000007,mbrf0002410,,=,,,non-inhibitor,3,0.0,%,15.4,quinidine,,,OCT1 inhibition at 50mM ASP+ for fully functional OCT1- reference (NM_003057),HEK293,,,,,human,mbds0010,,2013-11-25 23:28:17
mbbd000140878,mbcd0027018,mbtp000007,mbrf0002410,,=,,,non-inhibitor,3,1.5,%,12.1,quinidine,,,OCT1 inhibition at 50mM ASP+ for V408M (rs628031) genetic variant,HEK293,,,,,human,mbds0010,,2013-11-25 23:28:17
mbbd000140879,mbcd0027018,mbtp000007,mbrf0002410,,=,,,inhibitor,3,20.3,%,11.3,quinidine,,,OCT1 inhibition at 50mM ASP+ for M420del (rs72552763) genetic variant,HEK293,,,,weak inhibitor,human,mbds0010,,2013-11-25 23:32:13
mbbd000140880,mbcd0027018,mbtp000007,mbrf0002410,,=,,,inhibitor,3,45.6,%,8.74,quinidine,,,OCT1 inhibition at 50mM ASP+ for R61C (rs12208357) genetic variant,HEK293,,,,weak inhibitor,human,mbds0010,,2013-11-25 23:33:36
mbbd000140881,mbcd0003947,mbtp000007,mbrf0002410,,=,,,inhibitor,3,41.0,%,16.9,clonidine,,,OCT1 inhibition at 50mM ASP+ for fully functional OCT1- reference (NM_003057),HEK293,,,,weak inhibitor,human,mbds0010,,2013-11-25 23:33:36
mbbd000140882,mbcd0003947,mbtp000007,mbrf0002410,,=,,,inhibitor,3,43.8,%,12.0,clonidine,,,OCT1 inhibition at 50mM ASP+ for V408M (rs628031) genetic variant,HEK293,,,,weak inhibitor,human,mbds0010,,2013-11-25 23:33:36
mbbd000140883,mbcd0003947,mbtp000007,mbrf0002410,,=,,,inhibitor,3,57.2,%,5.62,clonidine,,,OCT1 inhibition at 50mM ASP+ for M420del (rs72552763) genetic variant,HEK293,,,,,human,mbds0010,,2013-11-25 23:28:17
mbbd000140884,mbcd0003947,mbtp000007,mbrf0002410,,=,,,inhibitor,3,73.6,%,4.96,clonidine,,,OCT1 inhibition at 50mM ASP+ for R61C (rs12208357) genetic variant,HEK293,,,,,human,mbds0010,,2013-11-25 23:28:17
mbbd000140885,mbcd0003920,mbtp000007,mbrf0002410,,=,,,inhibitor,3,35.0,%,7.78,ondansetron,,,OCT1 inhibition at 50mM ASP+ for fully functional OCT1- reference (NM_003057),HEK293,,,,weak inhibitor,human,mbds0010,,2013-11-25 23:32:13
mbbd000140886,mbcd0003920,mbtp000007,mbrf0002410,,=,,,inhibitor,3,37.0,%,9.79,ondansetron,,,OCT1 inhibition at 50mM ASP+ for V408M (rs628031) genetic variant,HEK293,,,,weak inhibitor,human,mbds0010,,2013-11-25 23:32:13
mbbd000140887,mbcd0003920,mbtp000007,mbrf0002410,,=,,,inhibitor,3,42.2,%,8.52,ondansetron,,,OCT1 inhibition at 50mM ASP+ for M420del (rs72552763) genetic variant,HEK293,,,,weak inhibitor,human,mbds0010,,2013-11-25 23:33:36
mbbd000140888,mbcd0003920,mbtp000007,mbrf0002410,,=,,,inhibitor,3,56.4,%,7.31,ondansetron,,,OCT1 inhibition at 50mM ASP+ for R61C (rs12208357) genetic variant,HEK293,,,,,human,mbds0010,,2013-11-25 23:28:17
mbbd000140889,mbcd0003111,mbtp000007,mbrf0002410,,=,,,non-inhibitor,3,3.3,%,27.6,amiloride,,,OCT1 inhibition at 50mM ASP+ for fully functional OCT1- reference (NM_003057),HEK293,,,,,human,mbds0010,,2013-11-25 23:28:17
mbbd000140890,mbcd0003111,mbtp000007,mbrf0002410,,=,,,non-inhibitor,3,0.0,%,36.6,amiloride,,,OCT1 inhibition at 50mM ASP+ for V408M (rs628031) genetic variant,HEK293,,,,,human,mbds0010,,2013-11-25 23:28:17
mbbd000140891,mbcd0003111,mbtp000007,mbrf0002410,,=,,,inhibitor,3,31.6,%,26.0,amiloride,,,OCT1 inhibition at 50mM ASP+ for M420del (rs72552763) genetic variant,HEK293,,,,weak inhibitor,human,mbds0010,,2013-11-25 23:32:13
mbbd000140892,mbcd0003111,mbtp000007,mbrf0002410,,=,,,inhibitor,3,53.2,%,23.2,amiloride,,,OCT1 inhibition at 50mM ASP+ for R61C (rs12208357) genetic variant,HEK293,,,,,human,mbds0010,,2013-11-25 23:28:17
mbbd000140893,mbcd0003142,mbtp000007,mbrf0002410,,=,,,non-inhibitor,3,0.0,%,18.3,captopril,,,OCT1 inhibition at 50mM ASP+ for fully functional OCT1- reference (NM_003057),HEK293,,,,,human,mbds0010,,2013-11-25 23:28:17
mbbd000140894,mbcd0003142,mbtp000007,mbrf0002410,,=,,,non-inhibitor,3,0.0,%,15.8,captopril,,,OCT1 inhibition at 50mM ASP+ for V408M (rs628031) genetic variant,HEK293,,,,,human,mbds0010,,2013-11-25 23:28:17
mbbd000140895,mbcd0003142,mbtp000007,mbrf0002410,,=,,,non-inhibitor,3,0.0,%,16.4,captopril,,,OCT1 inhibition at 50mM ASP+ for M420del (rs72552763) genetic variant,HEK293,,,,,human,mbds0010,,2013-11-25 23:28:17
mbbd000140896,mbcd0003142,mbtp000007,mbrf0002410,,=,,,non-inhibitor,3,0.0,%,22.4,captopril,,,OCT1 inhibition at 50mM ASP+ for R61C (rs12208357) genetic variant,HEK293,,,,,human,mbds0010,,2013-11-25 23:28:17
mbbd000140897,mbcd0003902,mbtp000007,mbrf0002410,,=,,,non-inhibitor,3,0.0,%,11.8,acetylsalicylic acid,,,OCT1 inhibition at 50mM ASP+ for fully functional OCT1- reference (NM_003057),HEK293,,,,,human,mbds0010,,2013-11-25 23:28:17
mbbd000140898,mbcd0003902,mbtp000007,mbrf0002410,,=,,,non-inhibitor,3,0.0,%,15.9,acetylsalicylic acid,,,OCT1 inhibition at 50mM ASP+ for V408M (rs628031) genetic variant,HEK293,,,,,human,mbds0010,,2013-11-25 23:28:17
mbbd000140899,mbcd0003902,mbtp000007,mbrf0002410,,=,,,non-inhibitor,3,0.0,%,14.8,acetylsalicylic acid,,,OCT1 inhibition at 50mM ASP+ for M420del (rs72552763) genetic variant,HEK293,,,,,human,mbds0010,,2013-11-25 23:28:17
mbbd000140900,mbcd0003902,mbtp000007,mbrf0002410,,=,,,non-inhibitor,3,0.0,%,18.7,acetylsalicylic acid,,,OCT1 inhibition at 50mM ASP+ for R61C (rs12208357) genetic variant,HEK293,,,,,human,mbds0010,,2013-11-25 23:28:17
mbbd000140901,mbcd0003126,mbtp000007,mbrf0002410,,=,,,non-inhibitor,3,0.0,%,19.6,pravastatin,,,OCT1 inhibition at 50mM ASP+ for fully functional OCT1- reference (NM_003057),HEK293,,,,,human,mbds0010,,2013-11-25 23:28:17
mbbd000140902,mbcd0003126,mbtp000007,mbrf0002410,,=,,,non-inhibitor,3,0.0,%,9.70,pravastatin,,,OCT1 inhibition at 50mM ASP+ for V408M (rs628031) genetic variant,HEK293,,,,,human,mbds0010,,2013-11-25 23:28:17
mbbd000140903,mbcd0003126,mbtp000007,mbrf0002410,,=,,,non-inhibitor,3,0.0,%,15.6,pravastatin,,,OCT1 inhibition at 50mM ASP+ for M420del (rs72552763) genetic variant,HEK293,,,,,human,mbds0010,,2013-11-25 23:28:17
mbbd000140904,mbcd0003126,mbtp000007,mbrf0002410,,=,,,non-inhibitor,3,0.0,%,17.9,pravastatin,,,OCT1 inhibition at 50mM ASP+ for R61C (rs12208357) genetic variant,HEK293,,,,,human,mbds0010,,2013-11-25 23:28:17
mbbd000140905,mbcd0001280,mbtp000007,mbrf0002410,,=,,,non-inhibitor,3,1.5,%,24.3,sulfasalazine,,,OCT1 inhibition at 50mM ASP+ for fully functional OCT1- reference (NM_003057),HEK293,,,,,human,mbds0010,,2013-11-25 23:28:17
mbbd000140906,mbcd0001280,mbtp000007,mbrf0002410,,=,,,non-inhibitor,3,0.0,%,23.0,sulfasalazine,,,OCT1 inhibition at 50mM ASP+ for V408M (rs628031) genetic variant,HEK293,,,,,human,mbds0010,,2013-11-25 23:28:17
mbbd000140907,mbcd0001280,mbtp000007,mbrf0002410,,=,,,inhibitor,3,29.2,%,12.7,sulfasalazine,,,OCT1 inhibition at 50mM ASP+ for M420del (rs72552763) genetic variant,HEK293,,,,weak inhibitor,human,mbds0010,,2013-11-25 23:32:13
mbbd000140908,mbcd0001280,mbtp000007,mbrf0002410,,=,,,non-inhibitor,3,2.3,%,32.3,sulfasalazine,,,OCT1 inhibition at 50mM ASP+ for R61C (rs12208357) genetic variant,HEK293,,,,,human,mbds0010,,2013-11-25 23:28:17
mbbd000140909,mbcd0003037,mbtp000007,mbrf0002410,,=,,,non-inhibitor,3,0.0,%,16.0,N-1-methylnicotinamide,,,HEK293 cells; OCT1 inhibition at 50mM ASP+ for fully functional OCT1- reference (NM_003057),HEK293,,,,,human,mbds0010,,2013-11-25 23:28:17
mbbd000140910,mbcd0003037,mbtp000007,mbrf0002410,,=,,,non-inhibitor,3,0.0,%,11.6,N-1-methylnicotinamide,,,HEK293 cells; OCT1 inhibition at 50mM ASP+ for V408M (rs628031) genetic variant,HEK293,,,,,human,mbds0010,,2013-11-25 23:28:17
mbbd000140911,mbcd0003037,mbtp000007,mbrf0002410,,=,,,inhibitor,3,33.1,%,25.1,N-1-methylnicotinamide,,,HEK293 cells; OCT1 inhibition at 50mM ASP+ for M420del (rs72552763) genetic variant,HEK293,,,,weak inhibitor,human,mbds0010,,2013-11-25 23:32:13
mbbd000140912,mbcd0003037,mbtp000007,mbrf0002410,,=,,,inhibitor,3,92.8,%,12.9,N-1-methylnicotinamide,,,HEK293 cells; OCT1 inhibition at 50mM ASP+ for R61C (rs12208357) genetic variant,HEK293,,,,,human,mbds0010,,2013-11-25 23:28:17
mbbd000140913,mbcd0003886,mbtp000007,mbrf0002410,,=,,,non-inhibitor,3,0.0,%,12.5,metformin,,,HEK293 cells; OCT1 inhibition at 50mM ASP+ for fully functional OCT1- reference (NM_003057),HEK293,,,,,human,mbds0010,,2013-11-25 23:28:17
mbbd000140914,mbcd0003886,mbtp000007,mbrf0002410,,=,,,non-inhibitor,3,0.0,%,11.8,metformin,,,HEK293 cells; OCT1 inhibition at 50mM ASP+ for V408M (rs628031) genetic variant,HEK293,,,,,human,mbds0010,,2013-11-25 23:28:17
mbbd000140915,mbcd0003886,mbtp000007,mbrf0002410,,=,,,non-inhibitor,3,1.5,%,14.2,metformin,,,HEK293 cells; OCT1 inhibition at 50mM ASP+ for M420del (rs72552763) genetic variant,HEK293,,,,,human,mbds0010,,2013-11-25 23:28:17
mbbd000140916,mbcd0003886,mbtp000007,mbrf0002410,,=,,,inhibitor,3,11.9,%,35.5,metformin,,,HEK293 cells; OCT1 inhibition at 50mM ASP+ for R61C (rs12208357) genetic variant,HEK293,,,,weak inhibitor,human,mbds0010,,2013-11-25 23:32:13
mbbd000140917,mbcd0003923,mbtp000007,mbrf0002410,,=,,,non-inhibitor,3,0.0,%,23.4,tetraethylammonium,,,HEK293 cells; OCT1 inhibition at 50mM ASP+ for fully functional OCT1- reference (NM_003057),HEK293,,,,,human,mbds0010,,2013-11-25 23:28:17
mbbd000140918,mbcd0003923,mbtp000007,mbrf0002410,,=,,,non-inhibitor,3,0.0,%,17.4,tetraethylammonium,,,HEK293 cells; OCT1 inhibition at 50mM ASP+ for V408M (rs628031) genetic variant,HEK293,,,,,human,mbds0010,,2013-11-25 23:28:17
mbbd000140919,mbcd0003923,mbtp000007,mbrf0002410,,=,,,non-inhibitor,3,1.7,%,23.7,tetraethylammonium,,,HEK293 cells; OCT1 inhibition at 50mM ASP+ for M420del (rs72552763) genetic variant,HEK293,,,,,human,mbds0010,,2013-11-25 23:28:17
mbbd000140920,mbcd0003923,mbtp000007,mbrf0002410,,=,,,non-inhibitor,3,0.0,%,13.2,tetraethylammonium,,,HEK293 cells; OCT1 inhibition at 50mM ASP+ for R61C (rs12208357) genetic variant,HEK293,,,,,human,mbds0010,,2013-11-25 23:28:17
mbbd000140921,mbcd0029711,mbtp000007,mbrf0002410,,=,,,substrate,28,9.21,microM,0.9,ASP+,,,ASP+ uptake in HEK293 cells transfected with OCT1 reference,HEK293,,,,,human,mbds0010,,2013-11-24 23:13:23
mbbd000140922,mbcd0029711,mbtp000007,mbrf0002410,,=,,,substrate,28,8.81,microM,1.8,ASP+,,,ASP+ uptake in HEK293 cells transfected with V408M variant,HEK293,,,,,human,mbds0010,,2013-11-24 23:13:23
mbbd000140923,mbcd0029711,mbtp000007,mbrf0002410,,=,,,substrate,28,11.06,microM,1.4,ASP+,,,ASP+ uptake in HEK293 cells transfected with M420del variant,HEK293,,,,,human,mbds0010,,2013-11-24 23:13:24
mbbd000140924,mbcd0029711,mbtp000007,mbrf0002410,,=,,,substrate,28,5.64,microM,0.9,ASP+,,,ASP+ uptake in HEK293 cells transfected with R61C variant,HEK293,,,,,human,mbds0010,,2013-11-24 23:13:24
mbbd000140925,mbcd0029711,mbtp000007,mbrf0002410,,=,,,substrate,22,23900.0,RFU / min / mg protein,708,ASP+,,,ASP+ uptake in HEK293 cells transfected with OCT1 reference,HEK293,,,,,human,mbds0010,,2013-11-24 23:13:24
mbbd000140926,mbcd0029711,mbtp000007,mbrf0002410,,=,,,substrate,22,22200.0,RFU / min / mg protein,1350,ASP+,,,ASP+ uptake in HEK293 cells transfected with V408M variant,HEK293,,,,,human,mbds0010,,2013-11-24 23:13:24
mbbd000140927,mbcd0029711,mbtp000007,mbrf0002410,,=,,,substrate,22,21000.0,RFU / min / mg protein,850,ASP+,,,ASP+ uptake in HEK293 cells transfected with M420del variant,HEK293,,,,,human,mbds0010,,2013-11-24 23:13:25
mbbd000140928,mbcd0029711,mbtp000007,mbrf0002410,,=,,,substrate,22,6140.0,RFU / min / mg protein,260,ASP+,,,ASP+ uptake in HEK293 cells transfected with R61C variant,HEK293,,,,,human,mbds0010,,2013-11-24 23:13:25
mbbd000140929,mbcd0003886,mbtp000007,mbrf0002410,,=,,,substrate,28,5.45,microM,0.29,metformin,,,ASP+ uptake in HEK293 cells transfected with OCT1 reference,HEK293,,,,,human,mbds0010,,2013-11-24 23:13:25
mbbd000140930,mbcd0003886,mbtp000007,mbrf0002410,,=,,,substrate,28,6.36,microM,0.49,metformin,,,ASP+ uptake in HEK293 cells transfected with V408M variant,HEK293,,,,,human,mbds0010,,2013-11-24 23:13:25
mbbd000140931,mbcd0003886,mbtp000007,mbrf0002410,,=,,,substrate,28,5.19,microM,0.16,metformin,,,ASP+ uptake in HEK293 cells transfected with M420del variant,HEK293,,,,,human,mbds0010,,2013-11-24 23:13:26
mbbd000140932,mbcd0003886,mbtp000007,mbrf0002410,,=,,,substrate,22,31.9,RFU / min / mg protein,0.72,metformin,,,ASP+ uptake in HEK293 cells transfected with OCT1 reference,HEK293,,,,,human,mbds0010,,2013-11-24 23:13:26
mbbd000140933,mbcd0003886,mbtp000007,mbrf0002410,,=,,,substrate,22,34.2,RFU / min / mg protein,1.18,metformin,,,ASP+ uptake in HEK293 cells transfected with V408M variant,HEK293,,,,,human,mbds0010,,2013-11-24 23:13:26
mbbd000140934,mbcd0003886,mbtp000007,mbrf0002410,,=,,,substrate,22,11.6,RFU / min / mg protein,0.16,metformin,,,ASP+ uptake in HEK293 cells transfected with M420del variant,HEK293,,,,,human,mbds0010,,2013-11-24 23:13:27
mbbd000140935,mbcd0003094,mbtp000007,mbrf0002410,,=,,,inhibitor,25,3.08,microM,1.12,spironolactone,,,OCT1 inhibition at 50mM ASP+ for fully functional OCT1- reference (NM_003057),HEK293,,,,,human,mbds0010,,2013-11-25 23:28:18
mbbd000140936,mbcd0003094,mbtp000007,mbrf0002410,,=,,,inhibitor,25,0.36,microM,1.59,spironolactone,,,OCT1 inhibition at 50mM ASP+ for R61C (rs12208357) genetic variant,HEK293,,,,,human,mbds0010,,2013-11-25 23:28:18
mbbd000140937,mbcd0003094,mbtp000007,mbrf0002410,,=,,,inhibitor,25,2.45,microM,1.18,spironolactone,,,OCT1 inhibition at 50mM ASP+ for M420del (rs72552763) genetic variant,HEK293,,,,,human,mbds0010,,2013-11-25 23:28:18
mbbd000140938,mbcd0017104,mbtp000007,mbrf0002410,,=,,,inhibitor,25,7.4,microM,1.21,ketoconazole,,,OCT1 inhibition at 50mM ASP+ for fully functional OCT1- reference (NM_003057),HEK293,,,,,human,mbds0010,,2013-11-25 23:28:18
mbbd000140939,mbcd0017104,mbtp000007,mbrf0002410,,=,,,inhibitor,25,0.68,microM,1.26,ketoconazole,,,OCT1 inhibition at 50mM ASP+ for R61C (rs12208357) genetic variant,HEK293,,,,,human,mbds0010,,2013-11-25 23:28:18
mbbd000140940,mbcd0017104,mbtp000007,mbrf0002410,,=,,,inhibitor,25,2.7,microM,1.09,ketoconazole,,,OCT1 inhibition at 50mM ASP+ for M420del (rs72552763) genetic variant,HEK293,,,,,human,mbds0010,,2013-11-25 23:28:18
mbbd000140941,mbcd0027062,mbtp000007,mbrf0002410,,=,,,inhibitor,25,12.5,microM,1.10,verapamil,,,OCT1 inhibition at 50mM ASP+ for fully functional OCT1- reference (NM_003057),HEK293,,,,,human,mbds0010,,2013-11-25 23:28:18
mbbd000140942,mbcd0027062,mbtp000007,mbrf0002410,,=,,,inhibitor,25,2.38,microM,1.11,verapamil,,,OCT1 inhibition at 50mM ASP+ for R61C (rs12208357) genetic variant,HEK293,,,,,human,mbds0010,,2013-11-25 23:28:18
mbbd000140943,mbcd0027062,mbtp000007,mbrf0002410,,=,,,inhibitor,25,3.36,microM,1.19,verapamil,,,OCT1 inhibition at 50mM ASP+ for M420del (rs72552763) genetic variant,HEK293,,,,,human,mbds0010,,2013-11-25 23:28:18
mbbd000140944,mbcd0002195,mbtp000007,mbrf0002410,,=,,,inhibitor,25,14.1,microM,1.18,propafenone,,,OCT1 inhibition at 50mM ASP+ for fully functional OCT1- reference (NM_003057),HEK293,,,,,human,mbds0010,,2013-11-25 23:28:18
mbbd000140945,mbcd0002195,mbtp000007,mbrf0002410,,=,,,inhibitor,25,2.22,microM,1.17,propafenone,,,OCT1 inhibition at 50mM ASP+ for R61C (rs12208357) genetic variant,HEK293,,,,,human,mbds0010,,2013-11-25 23:28:18
mbbd000140946,mbcd0002195,mbtp000007,mbrf0002410,,=,,,inhibitor,25,10.3,microM,1.24,propafenone,,,OCT1 inhibition at 50mM ASP+ for M420del (rs72552763) genetic variant,HEK293,,,,,human,mbds0010,,2013-11-25 23:28:18
mbbd000140947,mbcd0003930,mbtp000007,mbrf0002410,,=,,,inhibitor,25,14.8,microM,1.22,doxazosin,,,OCT1 inhibition at 50mM ASP+ for fully functional OCT1- reference (NM_003057),HEK293,,,,,human,mbds0010,,2013-11-25 23:28:18
mbbd000140948,mbcd0003930,mbtp000007,mbrf0002410,,=,,,inhibitor,25,0.63,microM,1.25,doxazosin,,,OCT1 inhibition at 50mM ASP+ for R61C (rs12208357) genetic variant,HEK293,,,,,human,mbds0010,,2013-11-25 23:28:18
mbbd000140949,mbcd0003930,mbtp000007,mbrf0002410,,=,,,inhibitor,25,4.27,microM,1.15,doxazosin,,,OCT1 inhibition at 50mM ASP+ for M420del (rs72552763) genetic variant,HEK293,,,,,human,mbds0010,,2013-11-25 23:28:18
mbbd000140950,mbcd0003920,mbtp000007,mbrf0002410,,=,,,inhibitor,25,36.2,microM,1.40,ondansetron,,,OCT1 inhibition at 50mM ASP+ for fully functional OCT1- reference (NM_003057),HEK293,,,,,human,mbds0010,,2013-11-25 23:28:18
mbbd000140951,mbcd0003920,mbtp000007,mbrf0002410,,=,,,inhibitor,25,8.77,microM,1.26,ondansetron,,,OCT1 inhibition at 50mM ASP+ for R61C (rs12208357) genetic variant,HEK293,,,,,human,mbds0010,,2013-11-25 23:28:18
mbbd000140952,mbcd0003920,mbtp000007,mbrf0002410,,=,,,inhibitor,25,23.8,microM,1.26,ondansetron,,,OCT1 inhibition at 50mM ASP+ for M420del (rs72552763) genetic variant,HEK293,,,,,human,mbds0010,,2013-11-25 23:28:18
mbbd000140953,mbcd0002995,mbtp000007,mbrf0002410,,=,,,inhibitor,25,43.9,microM,1.44,desipramine,,,OCT1 inhibition at 50mM ASP+ for fully functional OCT1- reference (NM_003057),HEK293,,,,,human,mbds0010,,2013-11-25 23:28:18
mbbd000140954,mbcd0002995,mbtp000007,mbrf0002410,,=,,,inhibitor,25,14.7,microM,1.22,desipramine,,,OCT1 inhibition at 50mM ASP+ for R61C (rs12208357) genetic variant,HEK293,,,,,human,mbds0010,,2013-11-25 23:28:18
mbbd000140955,mbcd0002995,mbtp000007,mbrf0002410,,=,,,inhibitor,25,21.0,microM,1.32,desipramine,,,OCT1 inhibition at 50mM ASP+ for M420del (rs72552763) genetic variant,HEK293,,,,,human,mbds0010,,2013-11-25 23:28:18
mbbd000140956,mbcd0003024,mbtp000007,mbrf0002410,,=,,,inhibitor,25,50.9,microM,1.37,prazosin,,,OCT1 inhibition at 50mM ASP+ for fully functional OCT1- reference (NM_003057),HEK293,,,,,human,mbds0010,,2013-11-25 23:28:18
mbbd000140957,mbcd0003024,mbtp000007,mbrf0002410,,=,,,inhibitor,25,4.54,microM,1.26,prazosin,,,OCT1 inhibition at 50mM ASP+ for R61C (rs12208357) genetic variant,HEK293,,,,,human,mbds0010,,2013-11-25 23:28:18
mbbd000140958,mbcd0003024,mbtp000007,mbrf0002410,,=,,,inhibitor,25,4.81,microM,1.21,prazosin,,,OCT1 inhibition at 50mM ASP+ for M420del (rs72552763) genetic variant,HEK293,,,,,human,mbds0010,,2013-11-25 23:28:18
mbbd000140959,mbcd0002340,mbtp000007,mbrf0002410,,=,,,inhibitor,25,52.3,microM,1.23,chlorpromazine,,,OCT1 inhibition at 50mM ASP+ for fully functional OCT1- reference (NM_003057),HEK293,,,,,human,mbds0010,,2013-11-25 23:28:18
mbbd000140960,mbcd0002340,mbtp000007,mbrf0002410,,=,,,inhibitor,25,15.5,microM,1.34,chlorpromazine,,,OCT1 inhibition at 50mM ASP+ for R61C (rs12208357) genetic variant,HEK293,,,,,human,mbds0010,,2013-11-25 23:28:18
mbbd000140961,mbcd0002340,mbtp000007,mbrf0002410,,=,,,inhibitor,25,8.2,microM,1.15,chlorpromazine,,,OCT1 inhibition at 50mM ASP+ for M420del (rs72552763) genetic variant,HEK293,,,,,human,mbds0010,,2013-11-25 23:28:18
mbbd000140962,mbcd0027018,mbtp000007,mbrf0002410,,=,,,inhibitor,25,340.0,microM,1.62,quinidine,,,OCT1 inhibition at 50mM ASP+ for fully functional OCT1- reference (NM_003057),HEK293,,,,,human,mbds0010,,2013-11-25 23:28:18
mbbd000140963,mbcd0027018,mbtp000007,mbrf0002410,,=,,,inhibitor,25,20.5,microM,1.28,quinidine,,,OCT1 inhibition at 50mM ASP+ for R61C (rs12208357) genetic variant,HEK293,,,,,human,mbds0010,,2013-11-25 23:28:18
mbbd000140964,mbcd0027018,mbtp000007,mbrf0002410,,=,,,inhibitor,25,25.1,microM,1.22,quinidine,,,OCT1 inhibition at 50mM ASP+ for M420del (rs72552763) genetic variant,HEK293,,,,,human,mbds0010,,2013-11-25 23:28:18
mbbd000140965,mbcd0003900,mbtp000007,mbrf0002410,,=,,,inhibitor,25,15.1,microM,1.24,bucindolol,,,OCT1 inhibition at 50mM ASP+ for fully functional OCT1- reference (NM_003057),HEK293,,,,,human,mbds0010,,2013-11-25 23:28:18
mbbd000140966,mbcd0003900,mbtp000007,mbrf0002410,,=,,,inhibitor,25,1.18,microM,1.21,bucindolol,,,OCT1 inhibition at 50mM ASP+ for R61C (rs12208357) genetic variant,HEK293,,,,,human,mbds0010,,2013-11-25 23:28:18
mbbd000140967,mbcd0003900,mbtp000007,mbrf0002410,,=,,,inhibitor,25,13.4,microM,1.27,bucindolol,,,OCT1 inhibition at 50mM ASP+ for M420del (rs72552763) genetic variant,HEK293,,,,,human,mbds0010,,2013-11-25 23:28:18
mbbd000140968,mbcd0027062,mbtp000007,mbrf0002410,,=,,,inhibitor,25,0.62,microM,1.07,verapamil,,,OCT1 inhibition at 50mM metformin for fully functional OCT1- reference (NM_003057),HEK293,,,,,human,mbds0010,,2013-11-25 23:28:18
mbbd000140969,mbcd0027062,mbtp000007,mbrf0002410,,=,,,inhibitor,25,0.09,microM,1.87,verapamil,,,OCT1 inhibition at 50mM metformin for M420del (rs72552763) genetic variant,HEK293,,,,,human,mbds0010,,2013-11-25 23:28:18
mbbd000140970,mbcd0027062,mbtp000007,mbrf0002410,,=,,,inhibitor,25,0.63,microM,1.25,verapamil,,,OCT1 inhibition at 50mM metformin for V408M (rs628031) genetic variant,HEK293,,,,,human,mbds0010,,2013-11-25 23:28:18
mbbd000140971,mbcd0003081,mbtp000007,mbrf0002410,,=,,,inhibitor,25,6.99,microM,1.39,amitriptyline,,,OCT1 inhibition at 50mM metformin for fully functional OCT1- reference (NM_003057),HEK293,,,,,human,mbds0010,,2013-11-25 23:28:18
mbbd000140972,mbcd0003081,mbtp000007,mbrf0002410,,=,,,inhibitor,25,4.7,microM,1.56,amitriptyline,,,OCT1 inhibition at 50mM metformin for M420del (rs72552763) genetic variant,HEK293,,,,,human,mbds0010,,2013-11-25 23:28:18
mbbd000140973,mbcd0003081,mbtp000007,mbrf0002410,,=,,,inhibitor,25,4.55,microM,1.19,amitriptyline,,,OCT1 inhibition at 50mM metformin for V408M (rs628031) genetic variant,HEK293,,,,,human,mbds0010,,2013-11-25 23:28:18
mbbd000140974,mbcd0029629,mbtp000007,mbrf0002410,,=,,,inhibitor,25,199.0,microM,1.47,glibenclamide,,,OCT1 inhibition at 50mM metformin for fully functional OCT1- reference (NM_003057),HEK293,,,,,human,mbds0010,,2013-11-25 23:28:18
mbbd000140975,mbcd0029629,mbtp000007,mbrf0002410,,=,,,inhibitor,25,85.8,microM,1.97,glibenclamide,,,OCT1 inhibition at 50mM metformin for M420del (rs72552763) genetic variant,HEK293,,,,,human,mbds0010,,2013-11-25 23:28:18
mbbd000140976,mbcd0023126,mbtp000007,mbrf0002410,,=,,,inhibitor,25,185.0,microM,1.46,pioglitazone,,,OCT1 inhibition at 50mM metformin for fully functional OCT1- reference (NM_003057),HEK293,,,,,human,mbds0010,,2013-11-25 23:28:18
mbbd000140977,mbcd0023126,mbtp000007,mbrf0002410,,=,,,inhibitor,25,178.0,microM,2.62,pioglitazone,,,OCT1 inhibition at 50mM metformin for M420del (rs72552763) genetic variant,HEK293,,,,,human,mbds0010,,2013-11-25 23:28:18
mbbd000140978,mbcd0001194,mbtp000007,mbrf0002410,,=,,,inhibitor,25,89.0,microM,1.25,simvastatin,,,OCT1 inhibition at 50mM metformin for fully functional OCT1- reference (NM_003057),HEK293,,,,,human,mbds0010,,2013-11-25 23:28:18
mbbd000140979,mbcd0001194,mbtp000007,mbrf0002410,,=,,,inhibitor,25,26.5,microM,1.87,simvastatin,,,OCT1 inhibition at 50mM metformin for M420del (rs72552763) genetic variant,HEK293,,,,,human,mbds0010,,2013-11-25 23:28:18
mbbd000140980,mbcd0002995,mbtp000007,mbrf0002180,,,,,substrate,,,,,desipramine,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140981,mbcd0027062,mbtp000007,mbrf0002180,,,,,substrate,,,,,verapamil,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140982,mbcd0003947,mbtp000007,mbrf0002180,,,,,substrate,,,,,clonidine,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140983,mbcd0027018,mbtp000007,mbrf0002180,,,,,substrate,,,,,quinidine,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140984,mbcd0001092,mbtp000007,mbrf0002180,,,,,substrate,,,,,quinine,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140985,mbcd0003971,mbtp000007,mbrf0002180,,,,,substrate,,,,,phenoxybenzamine,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140986,mbcd0003024,mbtp000007,mbrf0002180,,,,,substrate,,,,,prazosin,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140987,mbcd0003941,mbtp000007,mbrf0002180,,,,,substrate,,,,,procainamide,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140988,mbcd0003876,mbtp000007,mbrf0002180,,,,,substrate,,,,,acebutolol,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140989,mbcd0003916,mbtp000007,mbrf0002180,,,,,substrate,,,,,aciclovir,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000140990,mbcd0001547,mbtp000007,mbrf0002745,,,,,non-substrate,,,,,dasatinib,,,KCL22,KCL22,,150,nM,,human,mbds0010,,2013-11-02 05:13:21
mbbd000140991,mbcd0003099,mbtp000007,mbrf0001698,,=,,,inhibitor,25,0.356,microM,,erlotinib,,,inhibition of metformin uptake,,mbcd0003886,,,,human,mbds0010,,2013-11-04 00:59:30
mbbd000140993,mbcd0001690,mbtp000007,mbrf0002747,,=,,,inhibitor,25,2.92,microM,0.90,nilotinib,,,HEK293,HEK293,mbcd0003886,,,,human,mbds0010,,2013-11-02 05:19:21
mbbd000141000,mbcd0003022,mbtp000007,mbrf0002236,,~,,,substrate,28,21.0,microM,,MPP+,,,MDCKII cells were stably transfected with the SLC22A1 cDNA and selected for a high expression of the uptake transporter OCT1,MDCKII,,,,,human,mbds0010,,2013-11-04 03:00:43
mbbd000141002,mbcd0001904,mbtp000007,mbrf0002236,,=,,,inhibitor,25,1.8,microM,,repaglinide,,,"Inhibitory effect of repaglinide, rosiglitazone, and metformin on OCT1- mediated MPP+ min incubation",MDCKII,mbcd0003022,,,,human,mbds0010,,2013-11-04 03:00:43
mbbd000141003,mbcd0023111,mbtp000007,mbrf0002236,,=,,,inhibitor,25,30.4,microM,,rosiglitazone,,,"Inhibitory effect of repaglinide, rosiglitazone, and metformin on OCT1- mediated MPP+ min incubation",MDCKII,mbcd0003022,,,,human,mbds0010,,2013-11-04 03:00:44
mbbd000141004,mbcd0001904,mbtp000007,mbrf0002236,,=,,,inhibitor,25,1.6,microM,,rapaglinide,,,Inhibitory effect of repaglinide and rosiglitazone on OCT1-mediated metformin (10 micromol/l) uptake after 10- min incubation,MDCKII,mbcd0003886,,,,human,mbds0010,,2013-11-04 03:00:44
mbbd000141005,mbcd0023111,mbtp000007,mbrf0002236,,=,,,inhibitor,25,6.9,microM,,rosiglitazone,,,Inhibitory effect of repaglinide and rosiglitazone on OCT1-mediated metformin (10 micromol/l) uptake after 10- min incubation,MDCKII,mbcd0003886,,,,human,mbds0010,,2013-11-04 03:00:44
mbbd000141006,mbcd0013986,mbtp000007,mbrf0001791,,=,,,substrate,28,62.0,microM,14,lamotrigine,,,human brain endothelial cells (hCMEC/D3) cells,hCMEC/D3,,,,,human,mbds0010,,2013-11-26 00:48:05
mbbd000141007,mbcd0013986,mbtp000007,mbrf0001791,,=,,,substrate,22,385.0,pmol / min / 10^6 cells,30,lamotrigine,,,human brain endothelial cells (hCMEC/D3) cells,hCMEC/D3,,,,,human,mbds0010,,2013-11-26 00:48:05
mbbd000141008,mbcd0027062,mbtp000007,mbrf0001791,,=,,,inhibitor,25,1.8,microM,1.2,verapamil,,,5 mM of [14C]-lamotrigine with inhibitor at 37 8C,,,,,,human,mbds0010,,2013-12-09 20:17:48
mbbd000141009,mbcd0003083,mbtp000007,mbrf0001791,,=,,,inhibitor,25,0.9,microM,1.7,amantadine,,,5 mM of [14C]-lamotrigine with inhibitor at 37 8C,,,,,,human,mbds0010,,2013-12-09 20:17:49
mbbd000141010,mbcd0003024,mbtp000007,mbrf0001791,,=,,,inhibitor,25,9.6,microM,1.3,prazosin,,,5 mM of [14C]-lamotrigine with inhibitor at 37 8C,,,,,,human,mbds0010,,2013-12-09 21:01:24
mbbd000141011,mbcd0027670,mbtp000007,mbrf0001791,,=,,,inhibitor,25,6.8,microM,1.0,quetiapine,,,5 mM of [14C]-lamotrigine with inhibitor at 37 8C,,,,,,human,mbds0010,,2013-12-09 21:01:24
mbbd000141012,mbcd0003886,mbtp000007,mbrf0002521,,=,,,substrate,28,1.47,mM,0.19,metformin,,,apparent uptake of [14C] metformin in HEK293 cells,HEK293,,0.01-5,mM,,human,mbds0010,,2013-11-04 00:06:19
mbbd000141013,mbcd0003886,mbtp000007,mbrf0002521,,=,,,substrate,22,396.0,pmol / mg protein / min,42,metformin,,,apparent uptake of [14C] metformin in HEK293 cells,HEK293,,,,,human,mbds0010,,2013-11-04 00:06:19
mbbd000141014,mbcd0001690,mbtp000007,mbrf0002409,,,,,non-substrate,,,,,nilotinib; AMN107,,,Mononuclear cells isolated from the blood of CML patients,CCRF-CEM,,0-2,microM,,human,mbds0010,,2014-02-19 23:50:42
mbbd000141015,mbcd0003024,mbtp000007,mbrf0002409,,,,,inhibitor,,,,,prazosin,,,,,,,,,human,mbds0010,,2021-06-05 20:25:54
mbbd000141017,mbcd0003941,mbtp000007,mbrf0002409,,=,,,inhibitor,25,90.0,microM,,procainamide,,,,,,,,,human,mbds0010,,2021-06-05 20:20:20
mbbd000141023,mbcd0003877,mbtp000007,mbrf0001669,,,,,substrate,,,,,citalopram,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141024,mbcd0003933,mbtp000007,mbrf0001669,,,,,substrate,,,,,dopamine,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141025,mbcd0021691,mbtp000007,mbrf0001669,,,,,substrate,,,,,norepinephrine,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141026,mbcd0001117,mbtp000007,mbrf0001667,,=,,,inhibitor,106,1.3,micromol / L,,cisplatin,7 hour exposure,,cytotoxicity of the platinum drugs in MDCK-MOCK and MDCK-hOCT1 cells,MDCK,,,,,human,mbds0010,,2013-11-02 06:07:29
mbbd000141027,mbcd0011776,mbtp000007,mbrf0001667,,=,,,inhibitor,106,1.1,micromol / L,,carboplatin,7 hour exposure,,cytotoxicity of the platinum drugs in MDCK-MOCK and MDCK-hOCT1 cells,MDCK,,,,,human,mbds0010,,2013-11-02 06:07:28
mbbd000141028,mbcd0003922,mbtp000007,mbrf0001667,,=,,,inhibitor,106,8.5,micromol / L,,oxaliplatin,7 hour exposure,,cytotoxicity of the platinum drugs in MDCK-MOCK and MDCK-hOCT1 cells,MDCK,,,,,human,mbds0010,,2013-11-02 06:07:28
mbbd000141029,mbcd0003922,mbtp000007,mbrf0001667,,=,,,inhibitor,106,8.0,micromol / L,,oxaliplatin,24 hour exposure,,cytotoxicity of the platinum drugs in MDCK-MOCK and MDCK-hOCT1 cells,MDCK,,,,,human,mbds0010,,2013-11-02 06:07:28
mbbd000141030,mbcd0003922,mbtp000007,mbrf0001667,,=,,,inhibitor,106,5.7,micromol / L,,oxaliplatin,72 hour exposure,,cytotoxicity of the platinum drugs in MDCK-MOCK and MDCK-hOCT1 cells,MDCK,,,,,human,mbds0010,,2013-11-02 06:07:28
mbbd000141031,mbcd0029718,mbtp000007,mbrf0002156,,=,,,inhibitor,136,6.74,,,picoplatin,toxicity tests,,"Modification factor (IC50 HEK-EV/IC50 HEK-transporter), HEK cells with and without OCT1 expression",,,,,,human,mbds0010,,2013-12-08 02:08:26
mbbd000141032,mbcd0003141,mbtp000007,mbrf0002156,,=,,,inhibitor,136,1.43,,,disopyramide,toxicity tests,,"Modification factor (IC50 HEK-EV/IC50 HEK-transporter), HEK cells with and without OCT1 expression, both Picoplatin + disopyramide",,,,,,human,mbds0010,,2013-12-08 02:08:27
mbbd000141033,mbcd0027084,mbtp000007,mbrf0002338,,=,,,substrate,16,0.8,microM,0.2,Et+,,,HEK293 cells; uptake into confluent cells overexpressing hOCT1,HEK293,,,,,human,mbds0010,,2013-11-26 01:55:30
mbbd000141034,mbcd0001111,mbtp000007,mbrf0002338,,=,,,inhibitor,25,2.83,mM,0.72,cimetidine,,,varying concentrations of known OCT substrates/inhibitors in combination with 1 ?M ethidium (Et+; hOCT1),,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141035,mbcd0001092,mbtp000007,mbrf0002338,,=,,,inhibitor,25,0.07,mM,0.01,quinine,,,varying concentrations of known OCT substrates/inhibitors in combination with 1 ?M ethidium (Et+; hOCT1),,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141036,mbcd0000840,mbtp000007,mbrf0002338,,=,,,inhibitor,25,7.41,mM,2.38,TEA+,,,varying concentrations of known OCT substrates/inhibitors in combination with 1 ?M ethidium (Et+; hOCT1),,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141037,mbcd0003022,mbtp000007,mbrf0002338,,=,,,inhibitor,25,0.39,mM,0.06,MPP+,,,varying concentrations of known OCT substrates/inhibitors in combination with 1 ?M ethidium (Et+; hOCT1),,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141038,mbcd0003945,mbtp000007,mbrf0002468,,=,,,inhibitor,25,16700.0,microM,,choline,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141039,mbcd0003968,mbtp000007,mbrf0002468,,>,,,inhibitor,25,20000.0,microM,,creatinine,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141040,mbcd0001131,mbtp000007,mbrf0002468,,=,,,substrate,25,5030.0,microM,,guanedine,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141041,mbcd0001647,mbtp000007,mbrf0002468,,=,,,inhibitor,25,580.0,microM,,acetylcholine,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141042,mbcd0003933,mbtp000007,mbrf0002468,,>,,,inhibitor,25,20000.0,microM,,dopamine,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141043,mbcd0003926,mbtp000007,mbrf0002468,,>,,,inhibitor,25,30000.0,microM,,epinephrine,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141044,mbcd0003907,mbtp000007,mbrf0002468,,>,,,inhibitor,25,20000.0,microM,,histamine,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141045,mbcd0021691,mbtp000007,mbrf0002468,,=,,,inhibitor,25,7100.0,microM,,norepinephrine,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141046,mbcd0016500,mbtp000007,mbrf0002468,,>,,,inhibitor,25,20000.0,microM,,serotonin,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141047,mbcd0003905,mbtp000007,mbrf0002468,,=,,,inhibitor,25,7.0,microM,,corticosterone,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141048,mbcd0003905,mbtp000007,mbrf0002468,,=,,,inhibitor,25,22.0,microM,,corticosterone,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141049,mbcd0001892,mbtp000007,mbrf0002468,,=,,,inhibitor,25,3.1,microM,,progesterone,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141050,mbcd0001343,mbtp000007,mbrf0002468,,=,,,inhibitor,28,0.66,microM,,prostaglandin E2,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141051,mbcd0000719,mbtp000007,mbrf0002468,,=,,,inhibitor,28,0.48,microM,,prostaglandin f2alpha,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141052,mbcd0003887,mbtp000007,mbrf0002468,,=,,,substrate,25,24000.0,microM,,agmatine,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141053,mbcd0001153,mbtp000007,mbrf0002468,,=,,,inhibitor,25,1.2,microM,,atropine,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141054,mbcd0003971,mbtp000007,mbrf0002468,,=,,,inhibitor,25,2.7,microM,,phenoxybenzamine,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141055,mbcd0003024,mbtp000007,mbrf0002468,,=,,,inhibitor,25,1.8,microM,,prazosin,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141056,mbcd0003876,mbtp000007,mbrf0002468,,=,,,inhibitor,25,96.0,microM,,acebutolol,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141057,mbcd0012458,mbtp000007,mbrf0002468,,=,,,inhibitor,25,3.4,microM,,diphenylhydramine,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141058,mbcd0001111,mbtp000007,mbrf0002468,,=,,,substrate,25,166.0,microM,,cimetidine,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141059,mbcd0002666,mbtp000007,mbrf0002468,,=,,,inhibitor,25,28.0,microM,,ranitidine,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141060,mbcd0003083,mbtp000007,mbrf0002468,,=,,,inhibitor,25,236.0,microM,,amantadine,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141061,mbcd0027314,mbtp000007,mbrf0002468,,=,,,inhibitor,25,115.0,microM,,ketamine,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141062,mbcd0003914,mbtp000007,mbrf0002468,,=,,,inhibitor,25,3.7,microM,,memantine,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141063,mbcd0029718,mbtp000007,mbrf0002468,,=,,,inhibitor,25,4.4,microM,,phencyclidine,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141064,mbcd0000928,mbtp000007,mbrf0002468,,=,,,inhibitor,25,186.0,microM,,nicotine,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141065,mbcd0020052,mbtp000007,mbrf0002468,,=,,,inhibitor,25,447.0,microM,,etilefrine,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141066,mbcd0000639,mbtp000007,mbrf0002468,,>,,,inhibitor,25,100.0,microM,,O-methylisoprenaline,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141067,mbcd0014419,mbtp000007,mbrf0002468,,=,,,inhibitor,25,81.0,microM,,dizocilpine,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141068,mbcd0027062,mbtp000007,mbrf0002468,,=,,,inhibitor,25,2.9,microM,,verapamil,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141069,mbcd0010628,mbtp000007,mbrf0002468,,=,,,inhibitor,25,15.0,microM,,r (-) disopyramide,,,,,,,,,human,mbds0010,,2013-11-20 19:13:42
mbbd000141070,mbcd0029738,mbtp000007,mbrf0002468,,=,,,inhibitor,25,30.0,microM,,s (+) disopyramide,,,,,,,,,human,mbds0010,,2013-11-20 19:14:31
mbbd000141071,mbcd0027018,mbtp000007,mbrf0002468,,=,,,substrate,25,18.0,microM,,quinidine,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141072,mbcd0001334,mbtp000007,mbrf0002468,,=,,,inhibitor,25,85.0,microM,,cocaine,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141073,mbcd0003877,mbtp000007,mbrf0002468,,=,,,inhibitor,25,2.8,microM,,citalopram,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141074,mbcd0001735,mbtp000007,mbrf0002468,,=,,,inhibitor,25,3.7,microM,,midazolam,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141075,mbcd0002995,mbtp000007,mbrf0002468,,=,,,inhibitor,25,5.4,microM,,desipramine,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141076,mbcd0003886,mbtp000007,mbrf0002468,,=,,,substrate,28,1470.0,microM,,metformin,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141077,mbcd0003886,mbtp000007,mbrf0002468,,=,,,substrate,25,2010.0,microM,,metformin,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141078,mbcd0003105,mbtp000007,mbrf0002468,,=,,,inhibitor,25,10153.0,microM,,phenformin,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141079,mbcd0028239,mbtp000007,mbrf0002468,,<,,,inhibitor,25,100.0,microM,,granisetron,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141080,mbcd0003920,mbtp000007,mbrf0002468,,<,,,inhibitor,25,100.0,microM,,ondansetron,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141081,mbcd0021420,mbtp000007,mbrf0002468,,<,,,inhibitor,25,100.0,microM,,tropisetron,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141082,mbcd0001092,mbtp000007,mbrf0002468,,=,,,substrate,25,13.0,microM,,quinine,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141083,mbcd0001092,mbtp000007,mbrf0002468,,=,,,substrate,25,23.0,microM,,quinine,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141084,mbcd0003916,mbtp000007,mbrf0002468,,=,,,substrate,28,151.0,microM,,aciclovir,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141085,mbcd0003890,mbtp000007,mbrf0002468,,=,,,substrate,28,516.0,microM,,ganciclovir,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141086,mbcd0001533,mbtp000007,mbrf0002468,,=,,,inhibitor,25,8.3,microM,,aquinavir,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141087,mbcd0002323,mbtp000007,mbrf0002468,,=,,,inhibitor,25,62.0,microM,,indinavir,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141088,mbcd0026632,mbtp000007,mbrf0002468,,=,,,inhibitor,25,22.0,microM,,nelfinavir,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141089,mbcd0001938,mbtp000007,mbrf0002468,,=,,,inhibitor,25,5.2,microM,,ritonavir,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141090,mbcd0001117,mbtp000007,mbrf0002468,,>,,,inhibitor,25,100.0,microM,,cisplatin,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141091,mbcd0002981,mbtp000007,mbrf0002468,,=,,,inhibitor,25,16.0,microM,,mitoxantrone,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141092,mbcd0001567,mbtp000007,mbrf0002468,,=,,,inhibitor,25,127.0,microM,,vecuronium,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141093,mbcd0001567,mbtp000007,mbrf0002468,,=,,,inhibitor,25,232.0,microM,,vecuronium,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141094,mbcd0024750,mbtp000007,mbrf0002468,,=,,,inhibitor,25,24.0,microM,,"3,4 methylenedioxymethamphetamine",,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141095,mbcd0001608,mbtp000007,mbrf0002468,,=,,,inhibitor,25,202.0,microM,,D-amphetamine,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141096,mbcd0003022,mbtp000007,mbrf0002468,,=,,,substrate,28,15.0,microM,,MPP,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141097,mbcd0003022,mbtp000007,mbrf0002468,,=,,,substrate,28,32.0,microM,,MPP,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141098,mbcd0000840,mbtp000007,mbrf0002468,,=,,,substrate,28,229.0,microM,,TEA,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141099,mbcd0000840,mbtp000007,mbrf0002468,,=,,,substrate,25,158.0,microM,,TEA,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141100,mbcd0000840,mbtp000007,mbrf0002468,,=,,,substrate,25,173.0,microM,,TEA,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141101,mbcd0003037,mbtp000007,mbrf0002468,,=,,,inhibitor,25,7700.0,microM,,N-methylnicotinamide,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141102,mbcd0000840,mbtp000007,mbrf0002468,,=,,,inhibitor,25,12400.0,microM,,tetramethylammonium,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141103,mbcd0000846,mbtp000007,mbrf0002468,,=,,,substrate,25,102.0,microM,,tetrapropylammonium,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141104,mbcd0000835,mbtp000007,mbrf0002468,,=,,,inhibitor,25,30.0,microM,,tetrabutylammonium,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141105,mbcd0000844,mbtp000007,mbrf0002468,,=,,,inhibitor,25,1.5,microM,,tetrapropylammonium,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141106,mbcd0000844,mbtp000007,mbrf0002468,,=,,,inhibitor,25,7.5,microM,,tetrapropylammonium,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141107,mbcd0000320,mbtp000007,mbrf0002468,,=,,,inhibitor,25,2.7,microM,,decynium-22,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141108,mbcd0001243,mbtp000007,mbrf0001901,,=,,,inhibitor,25,15.7,microM,3.8,omeprazole,,,IC50 values of OCT-mediated metformin transport,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141109,mbcd0029711,mbtp000007,mbrf0001901,,=,,,inhibitor,25,30.8,microM,8.8,pantoprazole,,,IC50 values of OCT-mediated metformin transport,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141110,mbcd0003121,mbtp000007,mbrf0001901,,=,,,inhibitor,25,35.8,microM,5.8,lansoprazole,,,IC50 values of OCT-mediated metformin transport,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141111,mbcd0023569,mbtp000007,mbrf0001901,,=,,,inhibitor,25,3.0,microM,1.7,rabeprazole,,,IC50 values of OCT-mediated metformin transport,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141112,mbcd0029724,mbtp000007,mbrf0001901,,=,,,inhibitor,25,23.3,microM,7.1,tanatoprazole,,,IC50 values of OCT-mediated metformin transport,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141113,mbcd0015049,mbtp000007,mbrf0001968,,=,,,substrate,28,5.9,microM,1.5,debrisoquine,,,"Effects of the common functional amino acid substitutions in OCT1 on the kinetics of debrisoquine uptake, reference wild type; T-REx(TM) cells (HEK293 cells genetically engineered to be used as hosts for targeted chromosomal integration)",HEK293,,,,,human,mbds0010,,2013-11-25 21:29:15
mbbd000141114,mbcd0015049,mbtp000007,mbrf0001968,,=,,,substrate,28,6.2,microM,3.5,debrisoquine,,,"Effects of the common functional amino acid substitutions in OCT1 on the kinetics of debrisoquine uptake, 61Cys variant; T-REx(TM) cells (HEK293 cells genetically engineered to be used as hosts for targeted chromosomal integration)",HEK293,,,,,human,mbds0010,,2013-11-25 21:29:15
mbbd000141115,mbcd0015049,mbtp000007,mbrf0001968,,=,,,substrate,28,2.6,microM,2.5,debrisoquine,,,"Effects of the common functional amino acid substitutions in OCT1 on the kinetics of debrisoquine uptake, 401Ser variant; T-REx(TM) cells (HEK293 cells genetically engineered to be used as hosts for targeted chromosomal integration)",HEK293,,,,,human,mbds0010,,2013-11-25 21:29:15
mbbd000141116,mbcd0015049,mbtp000007,mbrf0001968,,=,,,substrate,28,4.8,microM,1.5,debrisoquine,,,"Effects of the common functional amino acid substitutions in OCT1 on the kinetics of debrisoquine uptake, 420del variant; T-REx(TM) cells (HEK293 cells genetically engineered to be used as hosts for targeted chromosomal integration)",HEK293,,,,,human,mbds0010,,2013-11-25 21:29:15
mbbd000141117,mbcd0015049,mbtp000007,mbrf0001968,,=,,,substrate,22,41.9,pmol/min/mg,4.5,debrisoquine,,,"Effects of the common functional amino acid substitutions in OCT1 on the kinetics of debrisoquine uptake, reference wild type; T-REx(TM) cells (HEK293 cells genetically engineered to be used as hosts for targeted chromosomal integration)",HEK293,,,,,human,mbds0010,,2013-11-25 21:29:15
mbbd000141118,mbcd0015049,mbtp000007,mbrf0001968,,=,,,substrate,22,15.6,pmol/min/mg,0.5,debrisoquine,,,"Effects of the common functional amino acid substitutions in OCT1 on the kinetics of debrisoquine uptake, 61Cys variant; T-REx(TM) cells (HEK293 cells genetically engineered to be used as hosts for targeted chromosomal integration)",HEK293,,,,,human,mbds0010,,2013-11-25 21:29:15
mbbd000141119,mbcd0015049,mbtp000007,mbrf0001968,,=,,,substrate,22,3.6,pmol/min/mg,2.1,debrisoquine,,,"Effects of the common functional amino acid substitutions in OCT1 on the kinetics of debrisoquine uptake, 401Ser variant; T-REx(TM) cells (HEK293 cells genetically engineered to be used as hosts for targeted chromosomal integration)",HEK293,,,,,human,mbds0010,,2013-11-25 21:29:15
mbbd000141120,mbcd0015049,mbtp000007,mbrf0001968,,=,,,substrate,22,21.7,pmol/min/mg,1.1,debrisoquine,,,"Effects of the common functional amino acid substitutions in OCT1 on the kinetics of debrisoquine uptake, 420del variant; T-REx(TM) cells (HEK293 cells genetically engineered to be used as hosts for targeted chromosomal integration)",HEK293,,,,,human,mbds0010,,2013-11-25 21:29:15
mbbd000141121,mbcd0025833,mbtp000007,mbrf0001882,,,,,substrate,,,,,sitagliptin,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141122,mbcd0001111,mbtp000007,mbrf0001882,,=,,,inhibitor,25,158.0,microM,,cimetidine,,,inhibition of metformin uptake,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141123,mbcd0003099,mbtp000007,mbrf0001882,,=,,,inhibitor,25,0.4,microM,,erlotinib,,,inhibition of metformin uptake,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141124,mbcd0003125,mbtp000007,mbrf0001882,,=,,,inhibitor,25,1.1,microM,,gefitinib,,,inhibition of metformin uptake,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141125,mbcd0002828,mbtp000007,mbrf0001882,,=,,,inhibitor,25,1.5,microM,,imatinib,,,inhibition of metformin uptake,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141126,mbcd0003022,mbtp000007,mbrf0001882,,=,,,inhibitor,25,3.4,microM,,MPP+,,,inhibition of MPP+ uptake,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141127,mbcd0001690,mbtp000007,mbrf0001882,,=,,,inhibitor,25,2.9,microM,,nilotinib,,,inhibition of metformin uptake,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141128,mbcd0027018,mbtp000007,mbrf0001882,,=,,,inhibitor,25,55.0,microM,,quinidine,,,inhibition of metformin uptake,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141129,mbcd0025833,mbtp000007,mbrf0001882,,=,,,inhibitor,29,34.9,microM,,sitagliptin,,,inhibition of metformin uptake,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141130,mbcd0003022,mbtp000007,mbrf0001882,,=,,,inhibitor,29,34.4,microM,,MPP+,,,inhibition of MPP+ uptake,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141131,mbcd0001869,mbtp000007,mbrf0002079,,=,,,substrate,33,4.8,nmol/mg protein/60 min,0.8,berberine,,,MDCK-OCT1,MDCK,,,,,human,mbds0010,,2013-11-24 23:11:47
mbbd000141132,mbcd0001869,mbtp000007,mbrf0002079,,=,,,substrate,33,3.6,nmol/mg protein/60 min,0.6,berberine,,,MDCK-OCT1 in prescence of 1 microM zosuquidar trihydrochloride,MDCK,,,,,human,mbds0010,,2013-12-09 20:57:33
mbbd000141133,mbcd0001869,mbtp000007,mbrf0002079,,=,,,substrate,33,1.8,nmol/mg protein/60 min,0.5,berberine,,,MDCK-OCT1 in prescence of 5 microM zosuquidar trihydrochloride,MDCK,,,,,human,mbds0010,,2013-12-09 20:57:33
mbbd000141134,mbcd0001869,mbtp000007,mbrf0002079,,=,,,substrate,28,14.8,microM,3.3,berberine,,,MDCK-OCT1,MDCK,,,,,human,mbds0010,,2013-11-24 23:11:48
mbbd000141135,mbcd0001869,mbtp000007,mbrf0002079,,=,,,substrate,22,685.0,pmol / mg protein / min,124,berberine,,,MDCK-OCT1,MDCK,,,,,human,mbds0010,,2013-11-24 23:11:48
mbbd000141136,mbcd0027018,mbtp000007,mbrf0002406,,=,,,inhibitor,25,6.7,microM,2.0,quinidine,,,IC50 values for inhibition of hOCT1 mediated [3H]MPP+ uptake in X. laevis oocytes,,,,,,human,mbds0010,,2013-12-09 20:57:34
mbbd000141137,mbcd0002666,mbtp000007,mbrf0002406,,=,,,inhibitor,25,33.0,microM,5,ranitidine,,,IC50 values for inhibition of hOCT1 mediated [3H]MPP+ uptake in X. laevis oocytes,,,,,,human,mbds0010,,2013-12-09 20:57:34
mbbd000141138,mbcd0003950,mbtp000007,mbrf0002406,,=,,,inhibitor,25,28.0,microM,2,famotidine,,,IC50 values for inhibition of hOCT1 mediated [3H]MPP+ uptake in X. laevis oocytes,,,,,,human,mbds0010,,2013-12-09 20:57:34
mbbd000141139,mbcd0000840,mbtp000007,mbrf0002406,,=,,,inhibitor,25,216.0,microM,44,TEA,,,IC50 values for inhibition of hOCT1 mediated [3H]MPP+ uptake in X. laevis oocytes,,,,,,human,mbds0010,,2013-12-09 20:57:34
mbbd000141140,mbcd0003886,mbtp000007,mbrf0002406,,=,,,inhibitor,25,1231.0,microM,330,metformin,,,IC50 values for inhibition of hOCT1 mediated [3H]MPP+ uptake in X. laevis oocytes,,,,,,human,mbds0010,,2013-12-09 20:06:50
mbbd000141141,mbcd0002666,mbtp000007,mbrf0002406,,=,,,inhibitor,28,70.0,microM,9,ranitidine,,,hOCT1-mediated uptake of [3H]ranitidine,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141142,mbcd0001111,mbtp000007,mbrf0002193,,=,,,inhibitor,25,109.3,microM,4.4,cimetidine,,,cimetidine inhibited the cytotoxicity induced by 500 microM. HEK293 transfected with hOCT1,,,,,,human,mbds0010,,2013-12-09 20:06:51
mbbd000141143,mbcd0003094,mbtp000007,mbrf0000120,3,=,87.9,%,inhibitor,3,87.9,%,,spironolactone,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141144,mbcd0027062,mbtp000007,mbrf0000120,3,=,86.4,%,inhibitor,3,86.4,%,,verapamil,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141145,mbcd0003930,mbtp000007,mbrf0000120,3,=,85.6,%,inhibitor,3,85.6,%,,doxazosin,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141146,mbcd0003925,mbtp000007,mbrf0000120,3,=,85.3,%,inhibitor,3,85.3,%,,clomipramine,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141147,mbcd0002340,mbtp000007,mbrf0000120,3,=,85.1,%,inhibitor,3,85.1,%,,chlorpromazine,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141148,mbcd0003900,mbtp000007,mbrf0000120,3,=,84.6,%,inhibitor,3,84.6,%,,bucindolol,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141149,mbcd0002995,mbtp000007,mbrf0000120,3,=,84.3,%,inhibitor,3,84.3,%,,desipramine,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141150,mbcd0002195,mbtp000007,mbrf0000120,3,=,83.8,%,inhibitor,3,83.8,%,,propafenone,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141151,mbcd0003055,mbtp000007,mbrf0000120,3,=,83.5,%,inhibitor,3,83.5,%,,beta-estradiol,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141152,mbcd0003898,mbtp000007,mbrf0000120,3,=,82.8,%,inhibitor,3,82.8,%,,imipramine,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141153,mbcd0017104,mbtp000007,mbrf0000120,3,=,82.3,%,inhibitor,3,82.3,%,,ketoconazole,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141154,mbcd0003899,mbtp000007,mbrf0000120,3,=,79.4,%,inhibitor,3,79.4,%,,trihexyphenidyl,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141155,mbcd0003140,mbtp000007,mbrf0000120,3,=,79.3,%,inhibitor,3,79.3,%,,nandrolon,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141156,mbcd0003913,mbtp000007,mbrf0000120,3,=,79.2,%,inhibitor,3,79.2,%,,promazine,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141157,mbcd0003956,mbtp000007,mbrf0000120,3,=,78.8,%,inhibitor,3,78.8,%,,clemastine,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141158,mbcd0003081,mbtp000007,mbrf0000120,3,=,78.5,%,inhibitor,3,78.5,%,,amitriptyline,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141159,mbcd0026044,mbtp000007,mbrf0000120,3,=,78.1,%,inhibitor,3,78.1,%,,methoxyverapamil (+/-),,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141160,mbcd0003924,mbtp000007,mbrf0000120,3,=,77.6,%,inhibitor,3,77.6,%,,orphenadrine,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141161,mbcd0029094,mbtp000007,mbrf0000120,3,=,77.5,%,inhibitor,3,77.5,%,,gugglesteron,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141162,mbcd0003881,mbtp000007,mbrf0000120,3,=,77.2,%,inhibitor,3,77.2,%,,trimipramine,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141163,mbcd0002997,mbtp000007,mbrf0000120,3,=,77.0,%,inhibitor,3,77.0,%,,terazosin,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141164,mbcd0001153,mbtp000007,mbrf0000120,3,=,76.5,%,inhibitor,3,76.5,%,,atropine,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141165,mbcd0001904,mbtp000007,mbrf0000120,3,=,76.4,%,inhibitor,3,76.4,%,,repaglinide,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141166,mbcd0003949,mbtp000007,mbrf0000120,3,=,75.7,%,inhibitor,3,75.7,%,,oxybutynin,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141167,mbcd0003964,mbtp000007,mbrf0000120,3,=,74.3,%,inhibitor,3,74.3,%,,2-methoxyestradiol,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141168,mbcd0003948,mbtp000007,mbrf0000120,3,=,73.6,%,inhibitor,3,73.6,%,,fentanyl,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141169,mbcd0002539,mbtp000007,mbrf0000120,3,=,73.4,%,inhibitor,3,73.4,%,,loperamide,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141170,mbcd0002889,mbtp000007,mbrf0000120,3,=,72.1,%,inhibitor,3,72.1,%,,tamoxifen,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141171,mbcd0003915,mbtp000007,mbrf0000120,3,=,71.1,%,inhibitor,3,71.1,%,,promethazine,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141172,mbcd0001322,mbtp000007,mbrf0000120,3,=,71.0,%,inhibitor,3,71.0,%,,flupenthixol,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141173,mbcd0002493,mbtp000007,mbrf0000120,3,=,69.3,%,inhibitor,3,69.3,%,,clotrimazole,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141174,mbcd0003871,mbtp000007,mbrf0000120,3,=,69.0,%,inhibitor,3,69.0,%,,apomorphine,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141175,mbcd0003141,mbtp000007,mbrf0000120,3,=,68.8,%,inhibitor,3,68.8,%,,disopyramide,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141176,mbcd0003111,mbtp000007,mbrf0000120,3,=,68.7,%,inhibitor,3,68.7,%,,amiloride,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141177,mbcd0003882,mbtp000007,mbrf0000120,3,=,68.4,%,inhibitor,3,68.4,%,,amsacrine,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141178,mbcd0002723,mbtp000007,mbrf0000120,3,=,67.9,%,inhibitor,3,67.9,%,,morphine,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141179,mbcd0001777,mbtp000007,mbrf0000120,3,=,67.1,%,inhibitor,3,67.1,%,,haloperidole,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141180,mbcd0003910,mbtp000007,mbrf0000120,3,=,66.5,%,inhibitor,3,66.5,%,,prochlorperazine,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141181,mbcd0003911,mbtp000007,mbrf0000120,3,=,66.3,%,inhibitor,3,66.3,%,,papaverin,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141182,mbcd0002338,mbtp000007,mbrf0000120,3,=,65.5,%,inhibitor,3,65.5,%,,diltiazem,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141183,mbcd0003947,mbtp000007,mbrf0000120,3,=,65.4,%,inhibitor,3,65.4,%,,clonidine,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141184,mbcd0002337,mbtp000007,mbrf0000120,3,=,65.4,%,inhibitor,3,65.4,%,,terfenadine,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141185,mbcd0001539,mbtp000007,mbrf0000120,3,=,65.4,%,inhibitor,3,65.4,%,,chlorprothixene,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141186,mbcd0003889,mbtp000007,mbrf0000120,3,=,65.1,%,inhibitor,3,65.1,%,,androstene-dione,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141187,mbcd0003920,mbtp000007,mbrf0000120,3,=,63.8,%,inhibitor,3,63.8,%,,ondansetron,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141188,mbcd0027018,mbtp000007,mbrf0000120,3,=,62.9,%,inhibitor,3,62.9,%,,quinidine,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141189,mbcd0003897,mbtp000007,mbrf0000120,3,=,61.9,%,inhibitor,3,61.9,%,,fluphenazine,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141190,mbcd0003912,mbtp000007,mbrf0000120,3,=,61.6,%,inhibitor,3,61.6,%,,cyproterone,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141191,mbcd0003929,mbtp000007,mbrf0000120,3,=,61.5,%,inhibitor,3,61.5,%,,oxprenolol,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141192,mbcd0001092,mbtp000007,mbrf0000120,3,=,60.2,%,inhibitor,3,60.2,%,,quinine,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141193,mbcd0000932,mbtp000007,mbrf0000120,3,=,60.2,%,inhibitor,3,60.2,%,,tramadol,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141194,mbcd0003951,mbtp000007,mbrf0000120,3,=,59.5,%,inhibitor,3,59.5,%,,mepenzolate,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141195,mbcd0003914,mbtp000007,mbrf0000120,3,=,58.6,%,inhibitor,3,58.6,%,,memantine,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141196,mbcd0003115,mbtp000007,mbrf0000120,3,=,58.1,%,inhibitor,3,58.1,%,,trimethoprim,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141197,mbcd0003971,mbtp000007,mbrf0000120,3,=,56.7,%,inhibitor,3,56.7,%,,phenoxybenzamine,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141198,mbcd0001892,mbtp000007,mbrf0000120,3,=,55.7,%,inhibitor,3,55.7,%,,progesterone,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141199,mbcd0003024,mbtp000007,mbrf0000120,3,=,55.6,%,inhibitor,3,55.6,%,,prazosin,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 10 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141200,mbcd0002488,mbtp000007,mbrf0000120,3,=,55.4,%,inhibitor,3,55.4,%,,propanolol,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141201,mbcd0003894,mbtp000007,mbrf0000120,3,=,52.3,%,inhibitor,3,52.3,%,,metoclopramide,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141202,mbcd0003877,mbtp000007,mbrf0000120,3,=,52.0,%,inhibitor,3,52.0,%,,citalopram,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141203,mbcd0003021,mbtp000007,mbrf0000120,3,=,51.8,%,inhibitor,3,51.8,%,,loratadine,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141204,mbcd0003953,mbtp000007,mbrf0000120,3,=,51.5,%,inhibitor,3,51.5,%,,denopamine,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141205,mbcd0003909,mbtp000007,mbrf0000120,3,=,48.4,%,inhibitor,3,48.4,%,,mianserin,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141206,mbcd0003895,mbtp000007,mbrf0000120,3,=,48.2,%,inhibitor,3,48.2,%,,troglitazone,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141207,mbcd0003888,mbtp000007,mbrf0000120,3,=,47.5,%,inhibitor,3,47.5,%,,clozapine,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141208,mbcd0001050,mbtp000007,mbrf0000120,3,=,46.9,%,inhibitor,3,46.9,%,,digoxin,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141209,mbcd0003088,mbtp000007,mbrf0000120,3,=,46.0,%,inhibitor,3,46.0,%,,chloroquine,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141210,mbcd0001251,mbtp000007,mbrf0000120,3,=,43.9,%,inhibitor,3,43.9,%,,scopolamine,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141211,mbcd0001016,mbtp000007,mbrf0000120,3,=,43.4,%,inhibitor,3,43.4,%,,ipratropium,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141212,mbcd0002323,mbtp000007,mbrf0000120,3,=,43.0,%,inhibitor,3,43.0,%,,indinavir,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141213,mbcd0003876,mbtp000007,mbrf0000120,3,=,40.9,%,inhibitor,3,40.9,%,,acebutolol,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141214,mbcd0001226,mbtp000007,mbrf0000120,3,=,40.3,%,inhibitor,3,40.3,%,,naltrexone,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141215,mbcd0003893,mbtp000007,mbrf0000120,3,=,39.3,%,inhibitor,3,39.3,%,,risperidone,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141216,mbcd0001736,mbtp000007,mbrf0000120,3,=,39.1,%,inhibitor,3,39.1,%,,codeine,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141217,mbcd0002999,mbtp000007,mbrf0000120,3,=,39.0,%,inhibitor,3,39.0,%,,timolol,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141218,mbcd0001527,mbtp000007,mbrf0000120,3,=,38.2,%,inhibitor,3,38.2,%,,budesonide,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141219,mbcd0001170,mbtp000007,mbrf0000120,3,=,38.1,%,inhibitor,3,38.1,%,,labetalol,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141220,mbcd0001868,mbtp000007,mbrf0000120,3,=,37.0,%,inhibitor,3,37.0,%,,efavirenz,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141221,mbcd0003044,mbtp000007,mbrf0000120,3,=,34.1,%,inhibitor,3,34.1,%,,flutamide,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141222,mbcd0003905,mbtp000007,mbrf0000120,3,=,33.5,%,inhibitor,3,33.5,%,,corticosterone,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141223,mbcd0003959,mbtp000007,mbrf0000120,3,=,33.0,%,inhibitor,3,33.0,%,,folic acid,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141224,mbcd0002822,mbtp000007,mbrf0000120,3,=,32.4,%,inhibitor,3,32.4,%,,metoprolol,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141225,mbcd0002667,mbtp000007,mbrf0000120,3,=,31.9,%,inhibitor,3,31.9,%,,colchicine,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141226,mbcd0003083,mbtp000007,mbrf0000120,3,=,31.8,%,inhibitor,3,31.8,%,,amantadine,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141227,mbcd0003128,mbtp000007,mbrf0000120,3,=,31.8,%,inhibitor,3,31.8,%,,sotalol,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141228,mbcd0003954,mbtp000007,mbrf0000120,3,=,31.2,%,inhibitor,3,31.2,%,,esmolol,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141229,mbcd0003926,mbtp000007,mbrf0000120,3,=,29.1,%,inhibitor,3,29.1,%,,epinephrine (-),,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141230,mbcd0002666,mbtp000007,mbrf0000120,3,=,28.8,%,inhibitor,3,28.8,%,,ranitidine,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141231,mbcd0003931,mbtp000007,mbrf0000120,3,=,27.4,%,inhibitor,3,27.4,%,,doxycycline,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141232,mbcd0001175,mbtp000007,mbrf0000120,3,=,27.1,%,inhibitor,3,27.1,%,,sulindac,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141233,mbcd0003941,mbtp000007,mbrf0000120,3,=,26.5,%,inhibitor,3,26.5,%,,procainamide,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141234,mbcd0003043,mbtp000007,mbrf0000120,3,=,26.3,%,inhibitor,3,26.3,%,,methotrexate,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141235,mbcd0001416,mbtp000007,mbrf0000120,3,=,26.2,%,inhibitor,3,26.2,%,,rifampicin,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141236,mbcd0003932,mbtp000007,mbrf0000120,3,=,24.7,%,inhibitor,3,24.7,%,,buspirone,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141237,mbcd0003058,mbtp000007,mbrf0000120,3,=,23.3,%,inhibitor,3,23.3,%,,prednisone,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141238,mbcd0001194,mbtp000007,mbrf0000120,3,=,22.6,%,inhibitor,3,22.6,%,,simvastatin,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141239,mbcd0001117,mbtp000007,mbrf0000120,3,=,22.3,%,inhibitor,3,22.3,%,,cisplatin,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141240,mbcd0003904,mbtp000007,mbrf0000120,3,=,21.7,%,inhibitor,3,21.7,%,,levodopa,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141241,mbcd0003945,mbtp000007,mbrf0000120,3,=,21.3,%,inhibitor,3,21.3,%,,choline,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141242,mbcd0003068,mbtp000007,mbrf0000120,3,=,21.1,%,inhibitor,3,21.1,%,,ofloxacin,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141243,mbcd0003069,mbtp000007,mbrf0000120,3,=,20.7,%,inhibitor,3,20.7,%,,antipyrine,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141244,mbcd0003934,mbtp000007,mbrf0000120,3,=,20.7,%,inhibitor,3,20.7,%,,baclofen,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141245,mbcd0003622,mbtp000007,mbrf0000120,3,=,20.3,%,inhibitor,3,20.3,%,,ampicillin,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141246,mbcd0003927,mbtp000007,mbrf0000120,3,=,19.8,%,inhibitor,3,19.8,%,,carisoprodol,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141247,mbcd0003886,mbtp000007,mbrf0000120,3,=,19.6,%,inhibitor,3,19.6,%,,metformin,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141249,mbcd0001499,mbtp000007,mbrf0000120,3,=,19.5,%,inhibitor,3,19.5,%,,clindamycin,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141250,mbcd0003928,mbtp000007,mbrf0000120,3,=,19.4,%,inhibitor,3,19.4,%,,neostigmine,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141251,mbcd0003936,mbtp000007,mbrf0000120,3,=,17.0,%,inhibitor,3,17.0,%,,pilocarpine,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141252,mbcd0003937,mbtp000007,mbrf0000120,3,=,16.7,%,inhibitor,3,16.7,%,,ergotamine,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141253,mbcd0003960,mbtp000007,mbrf0000120,3,=,16.4,%,inhibitor,3,16.4,%,,meclizine,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141254,mbcd0029727,mbtp000007,mbrf0000120,3,=,15.6,%,inhibitor,3,15.6,%,,isoproterenol (+)-bitartrate R (-),,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141255,mbcd0003874,mbtp000007,mbrf0000120,3,=,15.5,%,inhibitor,3,15.5,%,,acetylcysteine,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141256,mbcd0003011,mbtp000007,mbrf0000120,3,=,15.5,%,inhibitor,3,15.5,%,,felodipine,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141257,mbcd0003918,mbtp000007,mbrf0000120,3,=,15.1,%,inhibitor,3,15.1,%,,gabapentin,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141258,mbcd0003498,mbtp000007,mbrf0000120,3,=,14.6,%,inhibitor,3,14.6,%,,enalapril,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141259,mbcd0003032,mbtp000007,mbrf0000120,3,=,14.2,%,inhibitor,3,14.2,%,,tinidazole,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141260,mbcd0000937,mbtp000007,mbrf0000120,3,=,14.0,%,inhibitor,3,14.0,%,,erythromycin,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141261,mbcd0003037,mbtp000007,mbrf0000120,3,=,13.9,%,inhibitor,3,13.9,%,,N1-methylnicotinamide,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141262,mbcd0001558,mbtp000007,mbrf0000120,3,=,13.9,%,inhibitor,3,13.9,%,,glucosamine,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141263,mbcd0003950,mbtp000007,mbrf0000120,3,=,13.9,%,inhibitor,3,13.9,%,,famotidine,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141264,mbcd0003958,mbtp000007,mbrf0000120,3,=,13.7,%,inhibitor,3,13.7,%,,bendroflumetazide,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141265,mbcd0003919,mbtp000007,mbrf0000120,3,=,13.7,%,inhibitor,3,13.7,%,,N-acetylprocainamide,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141266,mbcd0003968,mbtp000007,mbrf0000120,3,=,13.3,%,inhibitor,3,13.3,%,,creatinine,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141267,mbcd0003957,mbtp000007,mbrf0000120,3,=,12.7,%,inhibitor,3,12.7,%,,levothyroxine,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141268,mbcd0003921,mbtp000007,mbrf0000120,3,=,12.6,%,inhibitor,3,12.6,%,,metaproterenol,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141269,mbcd0003933,mbtp000007,mbrf0000120,3,=,11.8,%,inhibitor,3,11.8,%,,dopamine,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141270,mbcd0003137,mbtp000007,mbrf0000120,3,=,11.7,%,inhibitor,3,11.7,%,,furosemide,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141271,mbcd0003943,mbtp000007,mbrf0000120,3,=,11.6,%,inhibitor,3,11.6,%,,methimazole,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141272,mbcd0003890,mbtp000007,mbrf0000120,3,=,10.5,%,inhibitor,3,10.5,%,,ganciclovir,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141273,mbcd0003016,mbtp000007,mbrf0000120,3,=,10.4,%,inhibitor,3,10.4,%,,tetracycline,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141274,mbcd0002985,mbtp000007,mbrf0000120,3,=,8.4,%,inhibitor,3,8.4,%,,carbamazepine,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141275,mbcd0001111,mbtp000007,mbrf0000120,3,=,8.1,%,inhibitor,3,8.1,%,,cimetidine,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141276,mbcd0003973,mbtp000007,mbrf0000120,3,=,7.7,%,inhibitor,3,7.7,%,,allopurinol,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141277,mbcd0003072,mbtp000007,mbrf0000120,3,=,7.7,%,inhibitor,3,7.7,%,,celecoxib,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141278,mbcd0002466,mbtp000007,mbrf0000120,3,=,7.5,%,inhibitor,3,7.5,%,,etoposide,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141279,mbcd0001532,mbtp000007,mbrf0000120,3,=,7.1,%,inhibitor,3,7.1,%,,paclitaxel,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141280,mbcd0003944,mbtp000007,mbrf0000120,3,=,7.1,%,inhibitor,3,7.1,%,,vancomycin,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141281,mbcd0003000,mbtp000007,mbrf0000120,3,=,6.8,%,inhibitor,3,6.8,%,,chlorzoxazone,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141282,mbcd0003917,mbtp000007,mbrf0000120,3,=,6.5,%,inhibitor,3,6.5,%,,hydralazine,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141283,mbcd0003962,mbtp000007,mbrf0000120,3,=,6.3,%,inhibitor,3,6.3,%,,candesartan,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141284,mbcd0003013,mbtp000007,mbrf0000120,3,=,6.3,%,inhibitor,3,6.3,%,,ibuprofen,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141285,mbcd0003873,mbtp000007,mbrf0000120,3,=,5.6,%,inhibitor,3,5.6,%,,clodronic acid,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141286,mbcd0003955,mbtp000007,mbrf0000120,3,=,5.5,%,inhibitor,3,5.5,%,,eflornithine,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141287,mbcd0003126,mbtp000007,mbrf0000120,3,=,5.0,%,inhibitor,3,5.0,%,,pravastatin,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141288,mbcd0003903,mbtp000007,mbrf0000120,3,=,5.0,%,inhibitor,3,5.0,%,,diazepam,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141289,mbcd0001107,mbtp000007,mbrf0000120,3,=,4.7,%,inhibitor,3,4.7,%,,zidovudine,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141290,mbcd0003906,mbtp000007,mbrf0000120,3,=,4.7,%,inhibitor,3,4.7,%,,cyclophosfamide,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141291,mbcd0003969,mbtp000007,mbrf0000120,3,=,4.5,%,inhibitor,3,4.5,%,,arcaine,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141292,mbcd0003938,mbtp000007,mbrf0000120,3,=,4.2,%,inhibitor,3,4.2,%,,azathioprine,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141293,mbcd0003907,mbtp000007,mbrf0000120,3,=,4.1,%,inhibitor,3,4.1,%,,histamine,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141294,mbcd0003042,mbtp000007,mbrf0000120,3,=,4.0,%,inhibitor,3,4.0,%,,warfarin,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141295,mbcd0003952,mbtp000007,mbrf0000120,3,=,3.9,%,inhibitor,3,3.9,%,,acarbose,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141296,mbcd0000311,mbtp000007,mbrf0000120,3,=,3.5,%,inhibitor,3,3.5,%,,cyclosporin A,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141297,mbcd0003946,mbtp000007,mbrf0000120,3,=,2.4,%,inhibitor,3,2.4,%,,cysteamine,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141298,mbcd0003887,mbtp000007,mbrf0000120,3,=,2.1,%,inhibitor,3,2.1,%,,agmatine,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141299,mbcd0003908,mbtp000007,mbrf0000120,3,=,2.0,%,inhibitor,3,2.0,%,,zanamivir,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141301,mbcd0001081,mbtp000007,mbrf0000120,3,=,1.4,%,inhibitor,3,1.4,%,,chloramphenicol,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141302,mbcd0003963,mbtp000007,mbrf0000120,3,=,0.9,%,inhibitor,3,0.9,%,,5-fluorouracil,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141303,mbcd0003142,mbtp000007,mbrf0000120,3,=,0.4,%,inhibitor,3,0.4,%,,captopril,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141304,mbcd0003074,mbtp000007,mbrf0000120,3,=,0.3,%,inhibitor,3,0.3,%,,glybenclamide,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141305,mbcd0003027,mbtp000007,mbrf0000120,3,=,0.2,%,inhibitor,3,0.2,%,,fenofibrate,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141306,mbcd0029730,mbtp000007,mbrf0000120,3,=,-0.2,%,non-inhibitor,3,-0.2,%,,melagatran,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141307,mbcd0001248,mbtp000007,mbrf0000120,3,=,-1.4,%,non-inhibitor,3,-1.4,%,,mannitol,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141308,mbcd0003879,mbtp000007,mbrf0000120,3,=,-1.4,%,non-inhibitor,3,-1.4,%,,caffeine,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141309,mbcd0003618,mbtp000007,mbrf0000120,3,=,-1.9,%,non-inhibitor,3,-1.9,%,,cephalexin,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141310,mbcd0002996,mbtp000007,mbrf0000120,3,=,-2.0,%,non-inhibitor,3,-2.0,%,,phenytoin,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141311,mbcd0003884,mbtp000007,mbrf0000120,3,=,-2.3,%,non-inhibitor,3,-2.3,%,,lidocaine,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141312,mbcd0003885,mbtp000007,mbrf0000120,3,=,-2.4,%,non-inhibitor,3,-2.4,%,,normetanephrine (+/-),,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141313,mbcd0001280,mbtp000007,mbrf0000120,3,=,-3.7,%,non-inhibitor,3,-3.7,%,,sulfasalazine,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141314,mbcd0003113,mbtp000007,mbrf0000120,3,=,-3.7,%,non-inhibitor,3,-3.7,%,,diclofenac,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141315,mbcd0000928,mbtp000007,mbrf0000120,3,=,-3.7,%,non-inhibitor,3,-3.7,%,,nicotine,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141316,mbcd0003916,mbtp000007,mbrf0000120,3,=,-3.9,%,non-inhibitor,3,-3.9,%,,acyclovir,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141317,mbcd0003942,mbtp000007,mbrf0000120,3,=,-4.4,%,non-inhibitor,3,-4.4,%,,theophylline,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141318,mbcd0003875,mbtp000007,mbrf0000120,3,=,-4.6,%,non-inhibitor,3,-4.6,%,,atenolol,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141319,mbcd0003901,mbtp000007,mbrf0000120,3,=,-4.8,%,non-inhibitor,3,-4.8,%,,cetirizin,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141320,mbcd0003902,mbtp000007,mbrf0000120,3,=,-5.7,%,non-inhibitor,3,-5.7,%,,acetylsalicylic acid,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141321,mbcd0003007,mbtp000007,mbrf0000120,3,=,-6.0,%,non-inhibitor,3,-6.0,%,,phenobarbital,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141322,mbcd0003883,mbtp000007,mbrf0000120,3,=,-7.2,%,non-inhibitor,3,-7.2,%,,methyldopa,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141323,mbcd0003154,mbtp000007,mbrf0000120,3,=,-8.9,%,non-inhibitor,3,-8.9,%,,probenecid,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141324,mbcd0003872,mbtp000007,mbrf0000120,3,=,-9.2,%,non-inhibitor,3,-9.2,%,,paracetamol,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141325,mbcd0002991,mbtp000007,mbrf0000120,3,=,-9.4,%,non-inhibitor,3,-9.4,%,,ketoprofen,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141326,mbcd0003130,mbtp000007,mbrf0000120,3,=,-9.8,%,non-inhibitor,3,-9.8,%,,hydrochlortiazide,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141327,mbcd0001566,mbtp000007,mbrf0000120,3,=,-10.3,%,non-inhibitor,3,-10.3,%,,pancuronium,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141328,mbcd0003112,mbtp000007,mbrf0000120,3,=,-12.7,%,non-inhibitor,3,-12.7,%,,glipizide,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141329,mbcd0003940,mbtp000007,mbrf0000120,3,=,-17.9,%,non-inhibitor,3,-17.9,%,,propofol,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141330,mbcd0003050,mbtp000007,mbrf0000120,3,=,-19.1,%,non-inhibitor,3,-19.1,%,,sodium taurocholate,,B,"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP, 1 microM) uptake at human OCT1 expressed in HEK293 cells at 100 microM by confocal microscopy",HEK293,,,,,human,mbds0001,v12,2014-01-16 21:29:33
mbbd000141331,mbcd0003125,mbtp000007,mbrf0002453,,,,,inhibitor,,,,,gefitinib,,,HEK293,HEK293,mbcd0029884,1; 10; 100,microM,,human,mbds0010,,2013-10-30 22:02:19
mbbd000141332,mbcd0003125,mbtp000007,mbrf0002453,,,,,non-substrate,,,,,gefitinib,,,H322,H322,,0.1,microM,,human,mbds0010,,2013-10-30 22:02:19
mbbd000141333,mbcd0003024,mbtp000007,mbrf0002453,,=,,,inhibitor,25,4.2,microM,1.3,prazosin,,,inhibition of [3H]gefitinib uptake in H322 cells,H322,,,,,human,mbds0010,,2013-11-04 00:47:14
mbbd000141334,mbcd0003941,mbtp000007,mbrf0002453,,=,,,inhibitor,25,182.0,microM,1.3,procainamide,,,inhibition of [3H]gefitinib uptake in H322 cells,H322,,,,,human,mbds0010,,2013-11-04 00:47:14
mbbd000141335,mbcd0027062,mbtp000007,mbrf0002453,,=,,,inhibitor,25,59.0,microM,1.4,verapamil,,,inhibition of [3H]gefitinib uptake in H322 cells,H322,,,,,human,mbds0010,,2013-11-04 00:47:15
mbbd000141336,mbcd0029731,mbtp000007,mbrf0001757,,=,,,inhibitor,25,8.1,microM,1.2,cDPCP,87 fold decrease compared with MOCK-MDCK cells,,Cell growth inhibition assays for cDPCP (Left) and oxaliplatin (Right) in MDCK cells with and without hOCT1,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141337,mbcd0003922,mbtp000007,mbrf0001757,,=,,,inhibitor,25,3.3,microM,1.0,oxaliplatin,12 fold decrease in IC50 compared with mock MDCK cellls,,Cell growth inhibition assays for cDPCP (Left) and oxaliplatin (Right) in MDCK cells with and without hOCT1,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141338,mbcd0003886,mbtp000007,mbrf0002006,,=,,,substrate,28,907.0,microM,324,metformin,,,Kinetic parameters for the uptake of [14C]metformin and [14C]phenformin by human hepatocytes,human hepatocytes,,,,,human,mbds0010,,2013-11-24 23:56:31
mbbd000141339,mbcd0003105,mbtp000007,mbrf0002006,,=,,,substrate,28,12.5,microM,10.5,phenformin,,,Kinetic parameters for the uptake of [14C]metformin and [14C]phenformin by human hepatocytes,human hepatocytes,,,,,human,mbds0010,,2013-11-24 23:56:31
mbbd000141340,mbcd0003105,mbtp000007,mbrf0002006,,=,,,substrate,22,192.0,pmol / min / 10^6 cells,145,phenformin,,,Kinetic parameters for the uptake of [14C]metformin and [14C]phenformin by human hepatocytes,human hepatocytes,,,,,human,mbds0010,,2013-11-24 23:56:32
mbbd000141341,mbcd0003886,mbtp000007,mbrf0002006,,=,,,substrate,22,287.0,pmol / min / 10^6 cells,112,metformin,,,Kinetic parameters for the uptake of [14C]metformin and [14C]phenformin by human hepatocytes,human hepatocytes,,,,,human,mbds0010,,2013-11-24 23:56:32
mbbd000141342,mbcd0017598,mbtp000007,mbrf0002118,,=,,,substrate,28,36.4,microM,8.3,pentamidine,,,CHO-hOCT1 cells,CHO,,,,,human,mbds0010,,2013-11-24 23:15:21
mbbd000141343,mbcd0005862,mbtp000007,mbrf0002118,,=,,,substrate,28,6.1,microM,1.1,furamidine,,,CHO-hOCT1 cells,CHO,,,,,human,mbds0010,,2013-11-24 23:15:21
mbbd000141344,mbcd0017598,mbtp000007,mbrf0002118,,=,,,substrate,22,156.0,pmol / mg protein / min,3.7,pentamidine,,,CHO-hOCT1 cells,CHO,,,,,human,mbds0010,,2013-11-24 23:15:21
mbbd000141345,mbcd0005862,mbtp000007,mbrf0002118,,=,,,substrate,22,27.2,pmol / mg protein / min,1.3,furamidine,,,CHO-hOCT1 cells,CHO,,,,,human,mbds0010,,2013-11-24 23:15:21
mbbd000141346,mbcd0027018,mbtp000007,mbrf0002118,,=,,,inhibitor,25,5.7,microM,0.9,quinidine,,,Inhibition of hOCT1hOCT3-mediated [3H]MPP+ uptake in the respective hOCT-expressing CHO cells,,,,,,human,mbds0010,,2013-12-09 20:17:46
mbbd000141347,mbcd0017598,mbtp000007,mbrf0002118,,=,,,inhibitor,25,16.4,microM,1.7,pentamidine,,,Inhibition of hOCT1hOCT3-mediated [3H]MPP+ uptake in the respective hOCT-expressing CHO cells,,,,,,human,mbds0010,,2013-12-09 20:17:46
mbbd000141348,mbcd0005862,mbtp000007,mbrf0002118,,=,,,inhibitor,25,7.4,microM,0.9,furamidine,,,Inhibition of hOCT1hOCT3-mediated [3H]MPP+ uptake in the respective hOCT-expressing CHO cells,,,,,,human,mbds0010,,2013-12-09 20:17:44
mbbd000141349,mbcd0000840,mbtp000007,mbrf0002118,,=,,,inhibitor,25,469.7,microM,12.7,TEA,,,Inhibition of hOCT1hOCT3-mediated [3H]MPP+ uptake in the respective hOCT-expressing CHO cells,,,,,,human,mbds0010,,2013-12-09 20:17:43
mbbd000141350,mbcd0017598,mbtp000007,mbrf0002118,,=,,,inhibitor,25,46.2,microM,5.3,pentamidine,4.4 fold change from mock CHO cells,,Cytotoxicity of pentamidine and furamidine in CHO-hOCT1 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141351,mbcd0017598,mbtp000007,mbrf0002118,,=,,,inhibitor,25,109.9,microM,12.4,pentamidine,1.5 fold change from mock CHO cells,,Cytotoxicity of pentamidine and furamidine in CHO-hOCT1 cells + 1 microM ranitidine,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141352,mbcd0005862,mbtp000007,mbrf0002118,,=,,,inhibitor,25,7.3,microM,0.4,furamidine,9.3 fold change from mock CHO cells,,Cytotoxicity of pentamidine and furamidine in CHO-hOCT1 cells + 1 microM ranitidine,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141353,mbcd0005862,mbtp000007,mbrf0002118,,=,,,inhibitor,25,1.1,microM,0.05,furamidine,1.4 fold change from mock CHO cells,,Cytotoxicity of pentamidine and furamidine in CHO-hOCT1 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141354,mbcd0000840,mbtp000007,mbrf0001706,,=,,,substrate,28,206.0,microM,23,TEA,,,HEK-hOCT1 uptake of TEA,HEK,,,,,human,mbds0010,,2013-11-24 23:13:27
mbbd000141355,mbcd0000840,mbtp000007,mbrf0001706,,=,,,substrate,28,217.0,microM,27,TEA,,,HEK-hOCT1 uptake of TEA,HEK,,,,,human,mbds0010,,2013-11-24 23:13:27
mbbd000141356,mbcd0000840,mbtp000007,mbrf0001706,,=,,,substrate,28,208.0,microM,51,TEA,,,HEK-hOCT1 uptake of TEA,HEK,,,,,human,mbds0010,,2013-11-24 23:13:27
mbbd000141357,mbcd0000840,mbtp000007,mbrf0001706,,=,,,substrate,28,237.0,microM,20,TEA,,,HEK-hOCT1 uptake of TEA,HEK,,,,,human,mbds0010,,2013-11-24 23:13:28
mbbd000141358,mbcd0000840,mbtp000007,mbrf0001706,,=,,,substrate,22,52.0,cpm / min / well,10,TEA,,,HEK-hOCT1 uptake of TEA,HEK,,,,,human,mbds0010,,2013-11-24 23:13:28
mbbd000141359,mbcd0000840,mbtp000007,mbrf0001706,,=,,,substrate,22,61.0,cpm / min / well,9,TEA,,,HEK-hOCT1 uptake of TEA,HEK,,,,,human,mbds0010,,2013-11-24 23:13:28
mbbd000141360,mbcd0000840,mbtp000007,mbrf0001706,,=,,,substrate,22,60.0,cpm / min / well,6,TEA,,,HEK-hOCT1 uptake of TEA,HEK,,,,,human,mbds0010,,2013-11-24 23:13:29
mbbd000141361,mbcd0000840,mbtp000007,mbrf0001706,,=,,,substrate,22,67.0,cpm / min / well,6,TEA,,,HEK-hOCT1 uptake of TEA,HEK,,,,,human,mbds0010,,2013-11-24 23:13:29
mbbd000141362,mbcd0002298,mbtp000007,mbrf0002272,,=,,,inhibitor,29,0.05,microM,,R-verapamil,,,"hOCT1-MDCK cells, inhibition MPP+ transport",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141363,mbcd0002823,mbtp000007,mbrf0002272,,=,,,inhibitor,29,3.46,microM,,S-verapamil,,,"hOCT1-MDCK cells, inhibition MPP+ transport",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141364,mbcd0016517,mbtp000007,mbrf0002272,,=,,,inhibitor,29,0.46,microM,,S-atenolol,,,"hOCT1-MDCK cells, inhibition MPP+ transport",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141365,mbcd0029732,mbtp000007,mbrf0002272,,=,,,inhibitor,29,0.98,microM,,R-atenolol,,,"hOCT1-MDCK cells, inhibition MPP+ transport",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141366,mbcd0002877,mbtp000007,mbrf0002272,,=,,,inhibitor,29,0.95,microM,,R-propanolol,,,"hOCT1-MDCK cells, inhibition MPP+ transport",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141367,mbcd0001824,mbtp000007,mbrf0002272,,=,,,inhibitor,29,2.85,microM,,S-propanolol,,,"hOCT1-MDCK cells, inhibition MPP+ transport",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141368,mbcd0022655,mbtp000007,mbrf0002272,,=,,,inhibitor,29,1.71,microM,,"(1S,2S)-pseudoephedrine",,,"hOCT1-MDCK cells, inhibition MPP+ transport",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141369,mbcd0029733,mbtp000007,mbrf0002272,,=,,,inhibitor,29,1.12,microM,,"(1R,2R)-pseudoephedrine",,,"hOCT1-MDCK cells, inhibition MPP+ transport",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141370,mbcd0027018,mbtp000007,mbrf0002272,,=,,,inhibitor,29,6.33,microM,,quinidine,,,"hOCT1-MDCK cells, inhibition MPP+ transport",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141371,mbcd0001092,mbtp000007,mbrf0002272,,=,,,inhibitor,29,10.18,microM,,quinine,,,"hOCT1-MDCK cells, inhibition MPP+ transport",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141372,mbcd0018252,mbtp000007,mbrf0002272,,=,,,inhibitor,29,3.73,microM,,"S,S-fenoterol",,,"hOCT1-MDCK cells, inhibition MPP+ transport",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141373,mbcd0029734,mbtp000007,mbrf0002272,,=,,,inhibitor,29,12.6,microM,,"R,R-fenoterol",,,"hOCT1-MDCK cells, inhibition MPP+ transport",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141374,mbcd0029735,mbtp000007,mbrf0002272,,=,,,inhibitor,29,6.18,microM,,"S,R-fenoterol",,,"hOCT1-MDCK cells, inhibition MPP+ transport",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141375,mbcd0029736,mbtp000007,mbrf0002272,,=,,,inhibitor,29,13.2,microM,,"R,S-fenoterol",,,"hOCT1-MDCK cells, inhibition MPP+ transport",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141376,mbcd0029737,mbtp000007,mbrf0002272,,=,,,inhibitor,29,180.0,microM,,S-proterenol,,,"hOCT1-MDCK cells, inhibition MPP+ transport",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141377,mbcd0003972,mbtp000007,mbrf0002272,,=,,,inhibitor,29,120.0,microM,,R-proterenol,,,"hOCT1-MDCK cells, inhibition MPP+ transport",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141378,mbcd0003933,mbtp000007,mbrf0002272,,=,,,inhibitor,29,198.0,microM,,dopamine,,,"hOCT1-MDCK cells, inhibition MPP+ transport",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141379,mbcd0002340,mbtp000007,mbrf0002272,,=,,,inhibitor,29,4.3,microM,,chlorpromazine,,,"hOCT1-MDCK cells, inhibition MPP+ transport",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141380,mbcd0003941,mbtp000007,mbrf0002272,,=,,,inhibitor,29,14.0,microM,,procainamide,,,"hOCT1-MDCK cells, inhibition MPP+ transport",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141381,mbcd0010628,mbtp000007,mbrf0002272,,=,,,inhibitor,29,15.0,microM,,R-disopyramide,,,"hOCT1-MDCK cells, inhibition MPP+ transport",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141382,mbcd0029738,mbtp000007,mbrf0002272,,=,,,inhibitor,29,430.0,microM,,S-disopyramide,,,"hOCT1-MDCK cells, inhibition MPP+ transport",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141383,mbcd0013197,mbtp000007,mbrf0002272,,=,,,inhibitor,29,430.0,microM,,thiamine,,,"hOCT1-MDCK cells, inhibition MPP+ transport",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141384,mbcd0003124,mbtp000007,mbrf0002196,,=,,,inhibitor,25,0.072,nM,0.033,ABC,,,inhibition of MPP+ uptake in CHO cell lines,CHO,mbcd0003022,,,,human,mbds0010,,2013-11-02 06:32:51
mbbd000141385,mbcd0001107,mbtp000007,mbrf0002196,,=,,,inhibitor,25,0.155,nM,0.111,AZT,,,inhibition of MPP+ uptake in CHO cell lines,CHO,mbcd0003022,,,,human,mbds0010,,2013-11-02 06:32:51
mbbd000141386,mbcd0003029,mbtp000007,mbrf0002196,,=,,,inhibitor,25,0.02,nM,0.006,FTC,,,inhibition of MPP+ uptake in CHO cell lines,CHO,mbcd0003022,,,,human,mbds0010,,2013-11-02 06:32:51
mbbd000141387,mbcd0029174,mbtp000007,mbrf0002196,,=,,,inhibitor,25,0.854,nM,0.012,TDF,,,inhibition of MPP+ uptake in CHO cell lines,CHO,mbcd0003022,,,,human,mbds0010,,2013-11-02 06:32:51
mbbd000141388,mbcd0002982,mbtp000007,mbrf0002196,,=,,,substrate,67,8.03,microL (mg protein)-1 min-1,0.40,3TC; lamivudine,,,Kinetic parameters of 3TC uptake in CHO-hOCT1,CHO,,0-5,mM,,human,mbds0010,,2013-11-02 06:22:32
mbbd000141389,mbcd0003124,mbtp000007,mbrf0002196,,=,,,inhibitor,29,0.33,nM,0.280,ABC,,,Ki values of ABC inhibition of 3TC uptake in CHO cells,CHO,mbcd0002982,,,,human,mbds0010,,2013-11-02 06:32:52
mbbd000141390,mbcd0001107,mbtp000007,mbrf0002196,,=,,,inhibitor,29,0.021,nM,0.016,AZT,,,Ki values of AZT inhibition of 3TC uptake in CHO cells,CHO,mbcd0002982,,,,human,mbds0010,,2013-11-02 06:32:52
mbbd000141391,mbcd0029740,mbtp000007,mbrf0001978,,=,,,inhibitor,25,40.5,microM,,YM758,,,inhibition of MPP uptake in hOCT1-HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141392,mbcd0001153,mbtp000007,mbrf0001749,,=,,,inhibitor,25,1.2,microM,0.2,atropine,,,cationic drugs competing with the uptake of [3H]MPP+ in HEK cells transfected with hOCT1,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141393,mbcd0029741,mbtp000007,mbrf0001749,,=,,,inhibitor,25,16.0,microM,6,butylscopolamine,,,cationic drugs competing with the uptake of [3H]MPP+ in HEK cells transfected with hOCT1,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141394,mbcd0012458,mbtp000007,mbrf0001749,,=,,,inhibitor,25,3.4,microM,0.6,diphenhydramine,,,cationic drugs competing with the uptake of [3H]MPP+ in HEK cells transfected with hOCT1,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141395,mbcd0003947,mbtp000007,mbrf0001749,,=,,,inhibitor,25,6.5,microM,1.3,clonidine,,,cationic drugs competing with the uptake of [3H]MPP+ in HEK cells transfected with hOCT1,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141396,mbcd0020052,mbtp000007,mbrf0001749,,=,,,inhibitor,25,447.0,microM,57,etilefrine,,,cationic drugs competing with the uptake of [3H]MPP+ in HEK cells transfected with hOCT1,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141397,mbcd0001092,mbtp000007,mbrf0001749,,=,,,inhibitor,25,13.0,microM,0.8,quinine,,,cationic drugs competing with the uptake of [3H]MPP+ in HEK cells transfected with hOCT1,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141398,mbcd0002666,mbtp000007,mbrf0001749,,=,,,inhibitor,25,28.0,microM,2,ranitidine,,,cationic drugs competing with the uptake of [3H]MPP+ in HEK cells transfected with hOCT1,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141399,mbcd0002323,mbtp000007,mbrf0001439,,=,,,inhibitor,25,61.7,microM,18.4,indinavir,,,inhibitors inhibiting [14C]TEA uptake in hOCT1 DNA-transfected HeLa cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141400,mbcd0026632,mbtp000007,mbrf0001439,,=,,,inhibitor,25,21.8,microM,5.4,nelfinavir,,,inhibitors inhibiting [14C]TEA uptake in hOCT1 DNA-transfected HeLa cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141401,mbcd0001938,mbtp000007,mbrf0001439,,=,,,inhibitor,25,5.18,microM,1.21,ritonavir,,,inhibitors inhibiting [14C]TEA uptake in hOCT1 DNA-transfected HeLa cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141402,mbcd0001533,mbtp000007,mbrf0001439,,=,,,inhibitor,25,8.26,microM,1.64,saquinavir,,,inhibitors inhibiting [14C]TEA uptake in hOCT1 DNA-transfected HeLa cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141403,mbcd0029742,mbtp000008,mbrf0002392,,=,,,substrate,28,4.8,microM,0.9,enterodiol - GlcA,,,HEK293 cells transfected with hMRP3,HEK293,,,,,human,mbds0010,,2013-11-24 23:13:29
mbbd000141404,mbcd0029743,mbtp000008,mbrf0002392,,=,,,substrate,28,1.7,microM,0.3,enterolactone - GlcA,,,HEK293 cells transfected with hMRP3,HEK293,,,,,human,mbds0010,,2013-11-24 23:13:29
mbbd000141405,mbcd0029744,mbtp000008,mbrf0002392,,=,,,substrate,28,6.2,microM,0.3,secoisolariciresinol-GlcA,,,HEK293 cells transfected with hMRP3,HEK293,,,,,human,mbds0010,,2013-11-24 23:13:29
mbbd000141406,mbcd0029745,mbtp000008,mbrf0002392,,=,,,substrate,28,8.2,microM,0.9,genistein - GlcA,,,HEK293 cells transfected with hMRP3,HEK293,,,,,human,mbds0010,,2013-11-24 23:13:30
mbbd000141407,mbcd0029747,mbtp000008,mbrf0002392,,=,,,substrate,28,5.8,microM,0.7,equol - glucuronate,,,HEK293 cells transfected with hMRP3,HEK293,,,,,human,mbds0010,,2013-11-24 23:13:30
mbbd000141409,mbcd0025734,mbtp000008,mbrf0002427,,,,,non-substrate,,,,,zearalenone; ZEA,,,MDCKII,MDCKII,,10,microM,,human,mbds0010,,2013-07-17 00:25:32
mbbd000141410,mbcd0029383,mbtp000008,mbrf0002427,,,,,non-substrate,,,,,alpha-zearalenol; alpha-ZOL,,,MDCKII,MDCKII,,10,microM,,human,mbds0010,,2013-07-17 00:25:32
mbbd000141411,mbcd0000387,mbtp000008,mbrf0002254,,,,,substrate,,,,,E217(beta)G,,,HEK293T,HEK293T,,,,,human,mbds0010,,2013-10-29 22:56:14
mbbd000141413,mbcd0000369,mbtp000008,mbrf0002254,,~,,,inhibitor,25,5.0,microM,,E3040-gluconide,,,inhibition of E217(beta)G transport by MRP3,HEK293T,mbcd0000387,,,,human,mbds0010,,2013-10-29 23:14:03
mbbd000141414,mbcd0003043,mbtp000008,mbrf0002254,,,,,substrate,,,,,methotrexate,,,HEK293T,HEK293T,,,,,human,mbds0010,,2013-10-29 22:56:14
mbbd000141415,mbcd0029353,mbtp000008,mbrf0002254,,=,,,non-inhibitor,1,91.0,%,7,nicotine-N-glucuronate,,,Effect of nicotine glucuronides (100 microM) on MRP3-mediated transport of 3H-labeled E217(beta)G,HEK293T,mbcd0000387,100,microM,,human,mbds0010,,2013-10-29 23:14:03
mbbd000141416,mbcd0029354,mbtp000008,mbrf0002254,,=,,,non-inhibitor,1,107.0,%,6,cotinine-glucuronide,,,Effect of nicotine glucuronides (100 microM) on MRP3-mediated transport of 3H-labeled E217(beta)G,HEK293T,mbcd0000387,100,microM,,human,mbds0010,,2013-10-29 23:14:03
mbbd000141418,mbcd0002494,mbtp000008,mbrf0002254,,=,,,inhibitor,1,26.0,%,2,MK-571,,,Effect of MK-571 (12 microM) on MRP3-mediated transport of 3H-labeled E217(beta)G,HEK293T,mbcd0000387,12,microM,,human,mbds0010,,2013-12-09 19:55:21
mbbd000141419,mbcd0029353,mbtp000008,mbrf0002254,,=,,,non-inhibitor,1,101.0,%,4,nicotine-N-glucuronate,,,Effect of nicotine glucuronides (100 microM) on MRP3-mediated transport of 3H-labeled E217(beta)G in prescence of 3mM GSH,HEK293T,mbcd0000387,100,microM,,human,mbds0010,,2013-10-29 23:14:03
mbbd000141420,mbcd0029354,mbtp000008,mbrf0002254,,=,,,non-inhibitor,1,83.0,%,10,cotinine-glucuronide,,,Effect of nicotine glucuronides (100 microM) on MRP3-mediated transport of 3H-labeled E217(beta)G in prescence of 3mM GSH,HEK293T,mbcd0000387,100,microM,,human,mbds0010,,2013-10-29 23:14:03
mbbd000141422,mbcd0029353,mbtp000008,mbrf0002254,,=,,,non-inhibitor,1,89.0,%,8,nicotine-N-glucuronate,,,Effect of nicotine glucuronides (100 microM) on MRP3-mediated transport of 3H-labeled MTX,HEK293T,mbcd0003043,100,microM,,human,mbds0010,,2013-10-29 23:14:03
mbbd000141423,mbcd0029354,mbtp000008,mbrf0002254,,=,,,non-inhibitor,1,87.0,%,6,cotinine-glucuronide,,,Effect of nicotine glucuronides (100 microM) on MRP3-mediated transport of 3H-labeled MTX,HEK293T,mbcd0003043,100,microM,,human,mbds0010,,2013-10-29 23:14:03
mbbd000141425,mbcd0002494,mbtp000008,mbrf0002254,,=,,,inhibitor,1,0.0,%,2,MK-571,,,Effect of MK-571 (25 microM) on MRP3-mediated transport of 3H-labeled MTX,HEK293T,mbcd0003043,25,microM,,human,mbds0010,,2013-12-09 20:51:09
mbbd000141426,mbcd0002494,mbtp000008,mbrf0002254,,=,,,non-inhibitor,1,96.0,%,14,nicotine-N-glucuronate,,,Effect of nicotine glucuronides (100 microM) on MRP3-mediated transport of 3H-labeled MTX in prescence of 3mM GSH,HEK293T,mbcd0003043,100,microM,,human,mbds0010,,2013-10-29 23:14:03
mbbd000141427,mbcd0002494,mbtp000008,mbrf0002254,,=,,,non-inhibitor,1,95.0,%,5,cotinine-glucuronide,,,Effect of nicotine glucuronides (100 microM) on MRP3-mediated transport of 3H-labeled MTX in prescence of 3mM GSH,HEK293T,mbcd0003043,100,microM,,human,mbds0010,,2013-10-29 23:14:03
mbbd000141429,mbcd0004701,mbtp000008,mbrf0002489,,,,,substrate,,,,,bilirubin glucuronide,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141430,mbcd0002990,mbtp000008,mbrf0002489,,,,,substrate,,,,,GSSG,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141431,mbcd0003034,mbtp000008,mbrf0001587,,,,,inducer,,,,,benzmarone,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141432,mbcd0000311,mbtp000008,mbrf0000120,,=,,,inhibitor,25,631.5,nM,,cyclosporin A,,,"inhibition of GSH uptake, Benzmarone (50 microM)+GSH (2 mM)",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141433,mbcd0000534,mbtp000008,mbrf0002465,,=,,,inhibitor,25,7.3,microM,,lithocholate-S,,,etopside G uptake inhibition in sf9 vesicles,Sf9,,,,,human,mbds0010,,2013-11-26 01:37:01
mbbd000141434,mbcd0000457,mbtp000008,mbrf0002465,,=,,,inhibitor,25,10.6,microM,,glycolithocholate - S,,,etopside G uptake inhibition in sf9 vesicles,Sf9,,,,,human,mbds0010,,2013-11-26 01:37:01
mbbd000141436,mbcd0000819,mbtp000008,mbrf0002465,,=,,,inhibitor,25,9.1,microM,,taurolithocholate - S,,,etopside G uptake inhibition in sf9 vesicles,Sf9,,,,,human,mbds0010,,2013-11-26 01:37:01
mbbd000141437,mbcd0000819,mbtp000008,mbrf0002465,,=,,,inhibitor,25,11.0,microM,,taurolithocholate - S,,,E(2)17G uptake inhibitionin sf9 vesicles,Sf9,,,,,human,mbds0010,,2013-11-26 01:37:01
mbbd000141438,mbcd0003070,mbtp000008,mbrf0002465,,=,,,substrate,28,46.3,microM,7.3,Dehydroepiandrosterone-S,,,direct transport in MDCKII cells,MDCKII,,,,,human,mbds0010,,2013-11-24 23:11:48
mbbd000141439,mbcd0003070,mbtp000008,mbrf0002465,,,,,non-substrate,,,,,Dehydroepiandrosterone-S,not observed,,sf9 vesicles,Sf9,,,,,human,mbds0010,,2013-11-24 23:54:48
mbbd000141440,mbcd0003070,mbtp000008,mbrf0002465,,,,,non-inhibitor,,,,,Dehydroepiandrosterone-S,,,sf9 vesicles; etopside-G uptake modulation not observed (0-50 microM),Sf9,,,,,human,mbds0010,,2013-11-20 19:41:41
mbbd000141441,mbcd0029339,mbtp000008,mbrf0002465,,,,,non-substrate,,,,,Ethinylestradiol-S,,,sf9 vesicles,Sf9,,,,,human,mbds0010,,2013-11-24 23:54:48
mbbd000141442,mbcd0029339,mbtp000008,mbrf0002465,,,,,inducer,,,,,Ethinylestradiol-S,,,"sf9 vesicles; 2-100 microM: stimulated (<5?), 20 microM: decreased EEG Km ? 18?; Ethinylestradiol-G(EEG) uptake stimulation",Sf9,,,,,human,mbds0010,,2013-11-23 22:22:30
mbbd000141443,mbcd0029339,mbtp000008,mbrf0002465,,,,,inhibitor,,,,,Ethinylestradiol-S,,,"sf9 vesicles; 2-20 microM: stimulated (<4?), 100 microM: inhibited (>30%); E217G uptake",Sf9,,,,,human,mbds0010,,2013-11-20 19:41:42
mbbd000141444,mbcd0029339,mbtp000008,mbrf0002465,,,,,inducer,,,,,Ethinylestradiol-S,,,"Ethinylestradiol-G(EEG) uptake stimulation in sf9 vesicles, 2-100 microM: stimulated",Sf9,,,,,human,mbds0010,,2013-11-20 19:41:42
mbbd000141445,mbcd0029339,mbtp000008,mbrf0002465,,,,,inhibitor,,,,,Ethinylestradiol-S,,,"Ethinylestradiol-G(EEG) uptake stimulation in sf9 vesicles,  2-100 microM: stimulated(<5x), 20microM: decreasedEEG Km ~18x",Sf9,,,,,human,mbds0010,,2013-11-26 01:37:01
mbbd000141446,mbcd0000071,mbtp000008,mbrf0002465,,~,,,inducer,33,250.0,%,,4-Methylumbelliferone-S,,,"sf9 vesicles, E(2)17G uptake stimulation, 166 microM",Sf9,,,,,human,mbds0010,,2013-12-09 20:52:41
mbbd000141447,mbcd0000071,mbtp000008,mbrf0002465,,,,,inducer,,,,,4-Methylumbelliferone-S,,,sf9 vesicles; conc. dependent (?2.5? at 166 microM); E217G uptake stimulation,Sf9,,,,,human,mbds0010,,2013-11-26 01:37:01
mbbd000141448,mbcd0000071,mbtp000008,mbrf0002465,,,,,non-inducer,,,,,4-Methylumbelliferone-S,,,sf9 vesicles;  leukotriene C4 (LTCH) uptake stimulation,Sf9,,,,,human,mbds0010,,2013-11-26 01:37:01
mbbd000141449,mbcd0000387,mbtp000008,mbrf0002465,,=,,,substrate,28,42.9,microM,4.3,estradiol 17beta (betaDG),,,sf9 vesicles,Sf9,,,,,human,mbds0010,,2013-11-24 23:54:48
mbbd000141450,mbcd0000387,mbtp000008,mbrf0002465,,=,,,substrate,28,17.7,microM,2.6,estradiol 17beta (betaDG),,,sf9 vesicles,Sf9,,,,,human,mbds0010,,2013-11-24 23:54:48
mbbd000141451,mbcd0000387,mbtp000008,mbrf0002465,,~,,,substrate,28,27.5,microM,,estradiol 17beta (betaDG),,,sf9 vesicles,Sf9,,,,,human,mbds0010,,2013-11-24 23:54:49
mbbd000141452,mbcd0000387,mbtp000008,mbrf0002465,,~,,,substrate,28,25.6,microM,5.4,estradiol 17beta (betaDG),,,HEK293 vesicles,HEK293,,,,,human,mbds0010,,2013-11-24 23:13:30
mbbd000141453,mbcd0000387,mbtp000008,mbrf0002465,,~,,,substrate,28,24.2,microM,5.8,estradiol 17beta (betaDG),,,MDCKII vesicles,MDCKII,,,,,human,mbds0010,,2013-11-24 23:11:48
mbbd000141454,mbcd0000369,mbtp000008,mbrf0002465,,=,,,inhibitor,3,70.0,%,,E3040-G,,,"sf9 vesicles, methotrexate inhibition, concentration dependent",Sf9,,50,microM,,human,mbds0010,,2013-11-26 01:37:01
mbbd000141455,mbcd0000369,mbtp000008,mbrf0002465,,=,,,inhibitor,29,5.6,microM,1.0,E3040-G,,,"sf9 vesicles, E(2)17G inhibition",Sf9,,,,,human,mbds0010,,2013-11-26 01:37:01
mbbd000141456,mbcd0000070,mbtp000008,mbrf0002465,,=,,,inhibitor,29,105.0,microM,21,4-Methylumbelliferone-G,,,"sf9 vesicles, E(2)17G uptake inhibition",Sf9,,,,,human,mbds0010,,2013-11-26 01:37:01
mbbd000141457,mbcd0000070,mbtp000008,mbrf0002465,,~,,,inhibitor,3,30.0,%,21,4-Methylumbelliferone-G,,,"sf9 vesicles, E(2)17G uptake inhibition",Sf9,,50,microM,,human,mbds0010,,2013-11-26 01:37:01
mbbd000141458,mbcd0000398,mbtp000008,mbrf0002465,,=,,,substrate,28,11.4,microM,2.6,etoposide-G,,,sf9 vesicles,Sf9,,,,,human,mbds0010,,2013-11-24 23:54:50
mbbd000141459,mbcd0000056,mbtp000008,mbrf0002465,,=,,,substrate,28,9.2,microM,2.3,ethinylestradiol G,,,sf9 vesicles,Sf9,,,,,human,mbds0010,,2013-11-24 23:54:51
mbbd000141460,mbcd0000056,mbtp000008,mbrf0002465,,=,,,inhibitor,29,5.0,microM,0.6,ethinylestradiol G,,,"sf9 vesicles, inhibition of E(2)17G uptake",Sf9,,,,,human,mbds0010,,2014-02-26 06:49:20
mbbd000141461,mbcd0029756,mbtp000008,mbrf0002465,,<,,,inhibitor,25,1.0,microM,,NU/ICRF505-G,,,sf9 vesicles e(2)17G uptake inhibition,Sf9,,,,,human,mbds0010,,2013-11-26 01:37:01
mbbd000141462,mbcd0000187,mbtp000008,mbrf0002465,,,,,substrate,,,,,bilirubin-mono-G,,,MDCKII vesicles,MDCKII,,,,,human,mbds0010,,2014-03-01 06:22:55
mbbd000141463,mbcd0004701,mbtp000008,mbrf0002465,,,,,substrate,,,,,bilirubin-bis-G,,,MDCKII vesicles,MDCKII,,,,,human,mbds0010,,2014-03-01 06:22:55
mbbd000141464,mbcd0003012,mbtp000008,mbrf0002465,,~,,,inhibitor,25,2.0,mM,,acetaminophen - G,,,"sf9 vesicles, E(2)17G uptake inhibition",Sf9,,,,,human,mbds0010,,2013-11-26 01:37:01
mbbd000141465,mbcd0029395,mbtp000008,mbrf0002465,,~,,,substrate,28,0.75,mM,,morphine-3-G,,,sf9 vesicles,Sf9,,,,,human,mbds0010,,2013-11-24 23:54:51
mbbd000141466,mbcd0029395,mbtp000008,mbrf0002465,,~,,,inhibitor,29,290.0,microM,,morphine-3-G,,,"sf9 vesicles, E(2)17G uptake inhibition",Sf9,,,,,human,mbds0010,,2013-11-26 01:37:01
mbbd000141467,mbcd0029421,mbtp000008,mbrf0002465,,,,,non-substrate,,,,,morphine-6-G,,,HEK293 cells,HEK293,,,,,human,mbds0010,,2014-02-26 06:57:55
mbbd000141469,mbcd0003078,mbtp000008,mbrf0002465,,,,,non-substrate,,,,,GSH,,,sf9 vesicles,Sf9,,,,,human,mbds0010,,2013-11-24 23:54:52
mbbd000141470,mbcd0003078,mbtp000008,mbrf0002465,,,,,non-substrate,,,,,GSH,,,MDCKII cells,MDCKII,,,,,human,mbds0010,,2014-02-26 06:49:20
mbbd000141471,mbcd0003078,mbtp000008,mbrf0002465,,,,,non-substrate,,,,,GSH,,,ovarian carcinoma 2008 cells,human ovarian carcinoma 2008,,,,,human,mbds0010,,2014-02-26 06:49:20
mbbd000141472,mbcd0002917,mbtp000008,mbrf0002465,,=,,,substrate,28,5.3,microM,2.6,leukotriene C4,,,HEK293 cells,HEK293,,,,,human,mbds0010,,2013-11-24 23:13:31
mbbd000141473,mbcd0002917,mbtp000008,mbrf0002465,,,,,non-substrate,,,,,leukotriene C4,,,sf9 vesicles,Sf9,,,,,human,mbds0010,,2014-02-26 06:57:55
mbbd000141474,mbcd0000440,mbtp000008,mbrf0002465,,~,,,substrate,28,2.9,microM,,deoxyprostaglandin J2 - SG,,,MCF7 vesicles,MCF7,,,,,human,mbds0010,,2013-11-24 23:09:55
mbbd000141475,mbcd0000047,mbtp000008,mbrf0002465,,,,,substrate,,,,,dinitrophenol-SG,very poor uptake ~3x background,,sf9 vesicles,Sf9,,,,weak substrate,human,mbds0010,,2014-02-26 06:57:55
mbbd000141476,mbcd0000047,mbtp000008,mbrf0002465,,=,,,inhibitor,29,337.0,microM,41,dinitrophenol - SG,,,sf9 vesicles E(2)17G uptake inhibition,Sf9,,,,,human,mbds0010,,2013-11-26 01:37:01
mbbd000141477,mbcd0001080,mbtp000008,mbrf0002104,,,,,substrate,,,,,teniposide,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141478,mbcd0029762,mbtp000008,mbrf0002104,,,,,substrate,,,,,DACH,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141479,mbcd0026147,mbtp000008,mbrf0002454,,,,,inducer,,,,,BPA,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141480,mbcd0003028,mbtp000008,mbrf0002077,,,,,inhibitor,,,,,tenofovir,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141481,mbcd0002544,mbtp000008,mbrf0002313,,,,,inhibitor,,,,,delavirdine,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141482,mbcd0001868,mbtp000008,mbrf0002313,,,,,inhibitor,,,,,efavirenz,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141483,mbcd0003029,mbtp000008,mbrf0002313,,,,,inhibitor,,,,,emtricitabine,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141485,mbcd0001299,mbtp000005,mbrf0002460,,=,,,inducer,117,13.9,,5.84,Quinidine,,,T84 intestinal cell line; real-time PCR (TaqMan) following 72 h xenobiotic pre-treatment ,T84,,10,microM,,human,mbds0010,,2013-11-04 21:37:57
mbbd000141486,mbcd0029763,mbtp000008,mbrf0002157,,,,,substrate,,,,,trans-Resveratrol 3-glucuronide,,,sf9 cells,Sf9,,,,,human,mbds0010,,2013-11-24 23:54:54
mbbd000141487,mbcd0029764,mbtp000008,mbrf0002480,,=,,,inhibitor,25,708.0,nM,201,C-1305,,,HEK293 - MRP3,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141488,mbcd0003043,mbtp000008,mbrf0001733,,=,,,substrate,22,2930.0,pmol / mg / min,320,MTX,,,HEK293 - MRP3,HEK293,,,,,human,mbds0010,,2013-11-24 23:13:31
mbbd000141489,mbcd0003959,mbtp000008,mbrf0001733,,=,,,substrate,28,1.96,mM,0.05,folic acid,,,HEK293 - MRP3,HEK293,,,,,human,mbds0010,,2013-11-24 23:13:31
mbbd000141490,mbcd0003959,mbtp000008,mbrf0001733,,=,,,substrate,22,1.71,pmol / mg / min,0.05,folic acid,,,HEK293 - MRP3,HEK293,,,,,human,mbds0010,,2013-11-24 23:13:31
mbbd000141491,mbcd0001197,mbtp000008,mbrf0001733,,=,,,substrate,28,1.74,mM,0.65,leucovorin,,,HEK293 - MRP3,HEK293,,,,,human,mbds0010,,2013-11-24 23:13:32
mbbd000141492,mbcd0001197,mbtp000008,mbrf0001733,,=,,,substrate,22,3.63,pmol / mg / min,0.12,leucovorin,,,HEK293 - MRP3,HEK293,,,,,human,mbds0010,,2013-11-24 23:13:32
mbbd000141493,mbcd0002466,mbtp000008,mbrf0001299,,=,,,inhibitor,102,37.3,%,13,etoposide,,,Membrane vesicles prepared from HEK293/MRP3-5 cells were incubated at 37 deg C for 5 min in media containing 1.0 microM [3H]methotrexate with or without inhibitors,,,33,microM,,human,mbds0010,,2013-12-09 20:02:52
mbbd000141494,mbcd0002466,mbtp000008,mbrf0001299,,=,,,inhibitor,102,10.6,%,2.0,etoposide,,,Membrane vesicles prepared from HEK293/MRP3-5 cells were incubated at 37 deg C for 5 min in media containing 1.0 microM [3H]methotrexate with or without inhibitors,,,100,microM,,human,mbds0010,,2013-12-09 20:02:56
mbbd000141495,mbcd0002466,mbtp000008,mbrf0001299,,=,,,inhibitor,102,3.47,%,2.2,etoposide,,,Membrane vesicles prepared from HEK293/MRP3-5 cells were incubated at 37 deg C for 5 min in media containing 1.0 microM [3H]methotrexate with or without inhibitors; 300 microM compound,,,,,,human,mbds0003,v2007,2013-11-24 21:53:04
mbbd000141496,mbcd0001135,mbtp000008,mbrf0001299,,=,,,inhibitor,102,91.2,%,5.1,vincristine,,,Membrane vesicles prepared from HEK293/MRP3-5 cells were incubated at 37 deg C for 5 min in media containing 1.0 microM [3H]methotrexate with or without inhibitors,,,33,microM,,human,mbds0010,,2013-12-09 20:02:54
mbbd000141497,mbcd0001135,mbtp000008,mbrf0001299,,=,,,inhibitor,102,71.7,%,6.0,vincristine,,,Membrane vesicles prepared from HEK293/MRP3-5 cells were incubated at 37 deg C for 5 min in media containing 1.0 microM [3H]methotrexate with or without inhibitors,,,100,microM,,human,mbds0010,,2013-12-09 20:02:53
mbbd000141498,mbcd0001135,mbtp000008,mbrf0001299,,=,,,inhibitor,102,39.1,%,1.3,vincristine,,,Membrane vesicles prepared from HEK293/MRP3-5 cells were incubated at 37 deg C for 5 min in media containing 1.0 microM [3H]methotrexate with or without inhibitors; 300 microM compound,,,,,,human,mbds0003,v2007,2013-11-24 21:53:04
mbbd000141499,mbcd0025844,mbtp000008,mbrf0001299,,=,,,inhibitor,102,101.0,%,5.5,doxorubicin,,,Membrane vesicles prepared from HEK293/MRP3-5 cells were incubated at 37 deg C for 5 min in media containing 1.0 microM [3H]methotrexate with or without inhibitors,,,33,microM,,human,mbds0010,,2013-12-09 20:02:57
mbbd000141500,mbcd0025844,mbtp000008,mbrf0001299,,=,,,inhibitor,102,91.5,%,3.3,doxorubicin,,,Membrane vesicles prepared from HEK293/MRP3-5 cells were incubated at 37 deg C for 5 min in media containing 1.0 microM [3H]methotrexate with or without inhibitors,,,100,microM,,human,mbds0010,,2013-12-09 20:09:34
mbbd000141501,mbcd0025844,mbtp000008,mbrf0001299,,=,,,inhibitor,102,80.0,%,2.2,doxorubicin,,,Membrane vesicles prepared from HEK293/MRP3-5 cells were incubated at 37 deg C for 5 min in media containing 1.0 microM [3H]methotrexate with or without inhibitors; 300 microM compound,,,,,,human,mbds0003,v2007,2013-11-24 21:53:04
mbbd000141502,mbcd0000387,mbtp000008,mbrf0001299,,=,,,inhibitor,102,48.8,%,2.6,E217betaG,,,Membrane vesicles prepared from HEK293/MRP3-5 cells were incubated at 37 deg C for 5 min in media containing 1.0 microM [3H]methotrexate with or without inhibitors,,,11,microM,,human,mbds0010,,2013-12-09 20:09:35
mbbd000141503,mbcd0000387,mbtp000008,mbrf0001299,,=,,,inhibitor,102,20.9,%,1.4,E217betaG,,,Membrane vesicles prepared from HEK293/MRP3-5 cells were incubated at 37 deg C for 5 min in media containing 1.0 microM [3H]methotrexate with or without inhibitors,,,33,microM,,human,mbds0010,,2013-12-09 20:09:34
mbbd000141504,mbcd0000387,mbtp000008,mbrf0001299,,=,,,inhibitor,102,8.27,%,1.0,E217betaG,,,Membrane vesicles prepared from HEK293/MRP3-5 cells were incubated at 37 deg C for 5 min in media containing 1.0 microM [3H]methotrexate with or without inhibitors; 100 microM compound,,,,,,human,mbds0003,v2007,2013-11-24 21:53:04
mbbd000141505,mbcd0000455,mbtp000008,mbrf0001299,,=,,,inhibitor,102,47.1,%,11,glycocholate,,,Membrane vesicles prepared from HEK293/MRP3-5 cells were incubated at 37 deg C for 5 min in media containing 1.0 microM [3H]methotrexate with or without inhibitors,,,33,microM,,human,mbds0010,,2013-12-09 20:09:34
mbbd000141506,mbcd0000455,mbtp000008,mbrf0001299,,=,,,inhibitor,102,26.8,%,8.3,glycocholate,,,Membrane vesicles prepared from HEK293/MRP3-5 cells were incubated at 37 deg C for 5 min in media containing 1.0 microM [3H]methotrexate with or without inhibitors,,,100,microM,,human,mbds0010,,2013-12-09 20:09:34
mbbd000141507,mbcd0000455,mbtp000008,mbrf0001299,,=,,,inhibitor,102,10.4,%,0.5,glycocholate,,,Membrane vesicles prepared from HEK293/MRP3-5 cells were incubated at 37 deg C for 5 min in media containing 1.0 microM [3H]methotrexate with or without inhibitors; 300 microM compound,,,,,,human,mbds0003,v2007,2013-11-24 21:53:04
mbbd000141508,mbcd0001664,mbtp000008,mbrf0001299,,=,,,inhibitor,102,71.0,%,5.4,taurocholate,,,Membrane vesicles prepared from HEK293/MRP3-5 cells were incubated at 37 deg C for 5 min in media containing 1.0 microM [3H]methotrexate with or without inhibitors,,,33,microM,,human,mbds0010,,2013-12-09 20:09:33
mbbd000141509,mbcd0001664,mbtp000008,mbrf0001299,,=,,,inhibitor,102,43.9,%,3.5,taurocholate,,,Membrane vesicles prepared from HEK293/MRP3-5 cells were incubated at 37 deg C for 5 min in media containing 1.0 microM [3H]methotrexate with or without inhibitors,,,100,microM,,human,mbds0010,,2013-12-09 20:09:33
mbbd000141510,mbcd0001664,mbtp000008,mbrf0001299,,=,,,inhibitor,102,21.7,%,4.5,taurocholate,,,Membrane vesicles prepared from HEK293/MRP3-5 cells were incubated at 37 deg C for 5 min in media containing 1.0 microM [3H]methotrexate with or without inhibitors; 300 microM compound,,,,,,human,mbds0003,v2007,2013-11-24 21:53:04
mbbd000141511,mbcd0003078,mbtp000008,mbrf0001299,,=,,,inhibitor,102,115.0,%,17,glutathione,,,Membrane vesicles prepared from HEK293/MRP3-5 cells were incubated at 37 deg C for 5 min in media containing 1.0 microM [3H]methotrexate with or without inhibitors,,,111,microM,,human,mbds0010,,2013-12-09 20:58:03
mbbd000141512,mbcd0003078,mbtp000008,mbrf0001299,,=,,,inhibitor,102,93.7,%,5.1,glutathione,,,Membrane vesicles prepared from HEK293/MRP3-5 cells were incubated at 37 deg C for 5 min in media containing 1.0 microM [3H]methotrexate with or without inhibitors,,,333,microM,,human,mbds0010,,2013-12-09 20:58:02
mbbd000141513,mbcd0003078,mbtp000008,mbrf0001299,,=,,,inhibitor,102,87.0,%,12,glutathione,,,Membrane vesicles prepared from HEK293/MRP3-5 cells were incubated at 37 deg C for 5 min in media containing 1.0 microM [3H]methotrexate with or without inhibitors,,,1000,microM,,human,mbds0010,,2013-12-09 20:58:03
mbbd000141514,mbcd0029343,mbtp000008,mbrf0001299,,=,,,inhibitor,102,96.7,%,4.7,methotrexate Glu2,,,Membrane vesicles prepared from HEK293/MRP3-5 cells were incubated at 37 deg C for 5 min in media containing 1.0 microM [3H]methotrexate with or without inhibitors,,,33,microM,,human,mbds0010,,2013-12-09 20:58:02
mbbd000141515,mbcd0029343,mbtp000008,mbrf0001299,,=,,,inhibitor,102,87.3,%,3.8,methotrexate Glu2,,,Membrane vesicles prepared from HEK293/MRP3-5 cells were incubated at 37 deg C for 5 min in media containing 1.0 microM [3H]methotrexate with or without inhibitors,,,100,microM,,human,mbds0010,,2013-12-09 20:58:02
mbbd000141516,mbcd0029343,mbtp000008,mbrf0001299,,=,,,inhibitor,102,64.7,%,3.5,methotrexate Glu2,,,Membrane vesicles prepared from HEK293/MRP3-5 cells were incubated at 37 deg C for 5 min in media containing 1.0 microM [3H]methotrexate with or without inhibitors,,,300,microM,,human,mbds0010,,2013-12-09 20:58:02
mbbd000141517,mbcd0029766,mbtp000008,mbrf0001299,,=,,,inhibitor,102,73.4,%,8.0,ZD1694,,,Membrane vesicles prepared from HEK293/MRP3-5 cells were incubated at 37 deg C for 5 min in media containing 1.0 microM [3H]methotrexate with or without inhibitors,,,111,microM,,human,mbds0010,,2013-12-09 20:58:02
mbbd000141518,mbcd0029766,mbtp000008,mbrf0001299,,=,,,inhibitor,102,52.5,%,3.6,ZD1694,,,Membrane vesicles prepared from HEK293/MRP3-5 cells were incubated at 37 deg C for 5 min in media containing 1.0 microM [3H]methotrexate with or without inhibitors,,,333,microM,,human,mbds0010,,2013-12-09 20:58:01
mbbd000141519,mbcd0029766,mbtp000008,mbrf0001299,,=,,,inhibitor,102,31.7,%,0.1,ZD1694,,,Membrane vesicles prepared from HEK293/MRP3-5 cells were incubated at 37 deg C for 5 min in media containing 1.0 microM [3H]methotrexate with or without inhibitors,,,1000,microM,,human,mbds0010,,2013-12-09 20:58:01
mbbd000141520,mbcd0002494,mbtp000008,mbrf0001299,,=,,,inhibitor,102,31.1,%,5.9,MK571,,,Membrane vesicles prepared from HEK293/MRP3-5 cells were incubated at 37 deg C for 5 min in media containing 1.0 microM [3H]methotrexate with or without inhibitors,,,11,microM,,human,mbds0010,,2013-12-09 20:10:54
mbbd000141521,mbcd0002494,mbtp000008,mbrf0001299,,=,,,inhibitor,102,7.0,%,0.3,MK571,,,Membrane vesicles prepared from HEK293/MRP3-5 cells were incubated at 37 deg C for 5 min in media containing 1.0 microM [3H]methotrexate with or without inhibitors,,,33,microM,,human,mbds0010,,2013-12-09 20:10:53
mbbd000141522,mbcd0002494,mbtp000008,mbrf0001299,,=,,,inhibitor,102,2.3,%,0.7,MK571,,,Membrane vesicles prepared from HEK293/MRP3-5 cells were incubated at 37 deg C for 5 min in media containing 1.0 microM [3H]methotrexate with or without inhibitors; 100 microM compound,,,,,,human,mbds0003,v2007,2013-11-24 21:53:04
mbbd000141523,mbcd0003154,mbtp000008,mbrf0001299,,=,,,inhibitor,102,63.5,%,6.0,probenecid,,,Membrane vesicles prepared from HEK293/MRP3-5 cells were incubated at 37 deg C for 5 min in media containing 1.0 microM [3H]methotrexate with or without inhibitors,,,111,microM,,human,mbds0010,,2013-12-09 20:10:52
mbbd000141524,mbcd0003154,mbtp000008,mbrf0001299,,=,,,inhibitor,102,34.7,%,5.1,probenecid,,,Membrane vesicles prepared from HEK293/MRP3-5 cells were incubated at 37 deg C for 5 min in media containing 1.0 microM [3H]methotrexate with or without inhibitors,,,333,microM,,human,mbds0010,,2013-12-09 20:10:57
mbbd000141525,mbcd0003154,mbtp000008,mbrf0001299,,=,,,inhibitor,102,7.9,%,4.7,probenecid,,,Membrane vesicles prepared from HEK293/MRP3-5 cells were incubated at 37 deg C for 5 min in media containing 1.0 microM [3H]methotrexate with or without inhibitors; 1000 microM compound,,,,,,human,mbds0003,v2007,2013-11-24 21:53:04
mbbd000141526,mbcd0000659,mbtp000008,mbrf0001299,,=,,,inhibitor,102,59.2,%,10,PAK-104P,,,Membrane vesicles prepared from HEK293/MRP3-5 cells were incubated at 37 deg C for 5 min in media containing 1.0 microM [3H]methotrexate with or without inhibitors,,,11,microM,,human,mbds0010,,2013-12-09 20:10:56
mbbd000141527,mbcd0000659,mbtp000008,mbrf0001299,,=,,,inhibitor,102,23.5,%,1.5,PAK-104P,,,Membrane vesicles prepared from HEK293/MRP3-5 cells were incubated at 37 deg C for 5 min in media containing 1.0 microM [3H]methotrexate with or without inhibitors,,,33,microM,,human,mbds0010,,2013-12-09 20:10:55
mbbd000141528,mbcd0000659,mbtp000008,mbrf0001299,,=,,,inhibitor,102,3.0,%,0.9,PAK-104P,,,Membrane vesicles prepared from HEK293/MRP3-5 cells were incubated at 37 deg C for 5 min in media containing 1.0 microM [3H]methotrexate with or without inhibitors; 100 microM compound,,,,,,human,mbds0003,v2007,2013-11-24 21:53:04
mbbd000141529,mbcd0001589,mbtp000008,mbrf0001299,,=,,,inhibitor,102,69.4,%,9.3,ONO-1078,,,Membrane vesicles prepared from HEK293/MRP3-5 cells were incubated at 37 deg C for 5 min in media containing 1.0 microM [3H]methotrexate with or without inhibitors,,,3.3,microM,,human,mbds0010,,2013-12-09 20:10:50
mbbd000141530,mbcd0001589,mbtp000008,mbrf0001299,,=,,,inhibitor,102,15.3,%,6.9,ONO-1078,,,Membrane vesicles prepared from HEK293/MRP3-5 cells were incubated at 37 deg C for 5 min in media containing 1.0 microM [3H]methotrexate with or without inhibitors,,,11,microM,,human,mbds0010,,2013-12-09 20:58:32
mbbd000141531,mbcd0001589,mbtp000008,mbrf0001299,,=,,,inhibitor,102,2.9,%,1.0,ONO-1078,,,Membrane vesicles prepared from HEK293/MRP3-5 cells were incubated at 37 deg C for 5 min in media containing 1.0 microM [3H]methotrexate with or without inhibitors; 33 microM compound,,,,,,human,mbds0003,v2007,2013-11-24 21:53:04
mbbd000141532,mbcd0001589,mbtp000008,mbrf0001299,,=,,,inhibitor,102,0.0,%,,ONO-1078,,,Membrane vesicles prepared from HEK293/MRP3-5 cells were incubated at 37 deg C for 5 min in media containing 1.0 microM [3H]methotrexate with or without inhibitors,,,100,microM,,human,mbds0010,,2013-12-09 20:58:32
mbbd000141533,mbcd0000112,mbtp000008,mbrf0001299,,=,,,inhibitor,102,84.5,%,8.3,AG-A,,,Membrane vesicles prepared from HEK293/MRP3-5 cells were incubated at 37 deg C for 5 min in media containing 1.0 microM [3H]methotrexate with or without inhibitors,,,111,microM,,human,mbds0010,,2013-12-09 20:58:32
mbbd000141534,mbcd0000112,mbtp000008,mbrf0001299,,=,,,inhibitor,102,75.0,%,12,AG-A,,,Membrane vesicles prepared from HEK293/MRP3-5 cells were incubated at 37 deg C for 5 min in media containing 1.0 microM [3H]methotrexate with or without inhibitors,,,333,microM,,human,mbds0010,,2013-12-09 20:58:31
mbbd000141535,mbcd0000112,mbtp000008,mbrf0001299,,=,,,inhibitor,102,56.9,%,12,AG-A,,,Membrane vesicles prepared from HEK293/MRP3-5 cells were incubated at 37 deg C for 5 min in media containing 1.0 microM [3H]methotrexate with or without inhibitors; 1000 microM compound,,,,,,human,mbds0003,v2007,2013-11-24 21:53:04
mbbd000141536,mbcd0027062,mbtp000008,mbrf0001299,,=,,,inhibitor,102,86.9,%,4.9,verapamil,,,Membrane vesicles prepared from HEK293/MRP3-5 cells were incubated at 37 deg C for 5 min in media containing 1.0 microM [3H]methotrexate with or without inhibitors,,,111,microM,,human,mbds0010,,2013-12-09 20:58:32
mbbd000141537,mbcd0027062,mbtp000008,mbrf0001299,,=,,,inhibitor,102,57.5,%,7.5,verapamil,,,Membrane vesicles prepared from HEK293/MRP3-5 cells were incubated at 37 deg C for 5 min in media containing 1.0 microM [3H]methotrexate with or without inhibitors,,,333,microM,,human,mbds0010,,2013-12-09 20:58:32
mbbd000141538,mbcd0027062,mbtp000008,mbrf0001299,,=,,,inhibitor,102,32.1,%,7.5,verapamil,,,Membrane vesicles prepared from HEK293/MRP3-5 cells were incubated at 37 deg C for 5 min in media containing 1.0 microM [3H]methotrexate with or without inhibitors; 1000 microM compound,,,,,,human,mbds0003,v2007,2013-11-24 21:53:04
mbbd000141539,mbcd0000311,mbtp000008,mbrf0001299,,=,,,inhibitor,102,86.3,%,18,CsA,,,Membrane vesicles prepared from HEK293/MRP3-5 cells were incubated at 37 deg C for 5 min in media containing 1.0 microM [3H]methotrexate with or without inhibitors,,,1.1,microM,,human,mbds0010,,2013-12-09 20:58:32
mbbd000141540,mbcd0000311,mbtp000008,mbrf0001299,,=,,,inhibitor,102,77.2,%,17,CsA,,,Membrane vesicles prepared from HEK293/MRP3-5 cells were incubated at 37 deg C for 5 min in media containing 1.0 microM [3H]methotrexate with or without inhibitors,,,3.3,microM,,human,mbds0010,,2013-12-09 20:13:54
mbbd000141541,mbcd0000311,mbtp000008,mbrf0001299,,=,,,inhibitor,102,26.3,%,4.1,CsA,,,Membrane vesicles prepared from HEK293/MRP3-5 cells were incubated at 37 deg C for 5 min in media containing 1.0 microM [3H]methotrexate with or without inhibitors; 10 microM compound,,,,,,human,mbds0003,v2007,2013-11-24 21:53:04
mbbd000141542,mbcd0000721,mbtp000008,mbrf0001299,,=,,,inhibitor,102,91.8,%,5.8,PSC833,,,Membrane vesicles prepared from HEK293/MRP3-5 cells were incubated at 37 deg C for 5 min in media containing 1.0 microM [3H]methotrexate with or without inhibitors,,,1.1,microM,,human,mbds0010,,2013-12-09 20:13:57
mbbd000141543,mbcd0000721,mbtp000008,mbrf0001299,,=,,,inhibitor,102,86.2,%,13,PSC833,,,Membrane vesicles prepared from HEK293/MRP3-5 cells were incubated at 37 deg C for 5 min in media containing 1.0 microM [3H]methotrexate with or without inhibitors,,,3.3,microM,,human,mbds0010,,2013-12-09 20:13:55
mbbd000141544,mbcd0000721,mbtp000008,mbrf0001299,,=,,,inhibitor,102,61.4,%,1.3,PSC833,,,Membrane vesicles prepared from HEK293/MRP3-5 cells were incubated at 37 deg C for 5 min in media containing 1.0 microM [3H]methotrexate with or without inhibitors; 10 microM compound,,,,,,human,mbds0003,v2007,2013-11-24 21:53:04
mbbd000141545,mbcd0002988,mbtp000008,mbrf0002046,,,,,inhibitor,,,,,sulfinpyrazone,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141546,mbcd0003025,mbtp000008,mbrf0002046,,,,,inhibitor,,,,,indomethacin,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141547,mbcd0029769,mbtp000008,mbrf0002103,,,,,substrate,,,,,CLF,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141548,mbcd0001416,mbtp000008,mbrf0001833,,,,,inducer,,,,,rifampicin; RIF,,,HepG2 cells,HepG2,,25,microM,,human,mbds0010,,2013-11-10 04:16:07
mbbd000141550,mbcd0001135,mbtp000008,mbrf0001919,,=,,,non-substrate,132,1.1,,0.1,vincristine,The relative resistance factor was obtained by dividing the IC50 values for the wild-type or mutant MRP1-transfected cells by the IC50 value for cells transfected with the expression vector alone,,HEK298 transfected with MRP3 cells,HEK293,,,,,human,mbds0010,,2013-11-24 23:13:32
mbbd000141551,mbcd0002466,mbtp000008,mbrf0001919,,=,,,substrate,132,6.4,,1.9,VP-16,The relative resistance factor was obtained by dividing the IC50 values for the wild-type or mutant MRP1-transfected cells by the IC50 value for cells transfected with the expression vector alone,,HEK298 transfected with MRP3 cells,HEK293,,,,,human,mbds0010,,2013-11-24 23:13:32
mbbd000141552,mbcd0025844,mbtp000008,mbrf0001919,,=,,,non-substrate,132,0.87,,0.2,doxorubicin,The relative resistance factor was obtained by dividing the IC50 values for the wild-type or mutant MRP1-transfected cells by the IC50 value for cells transfected with the expression vector alone,,HEK298 transfected with MRP3 cells,HEK293,,,,,human,mbds0010,,2013-11-24 23:13:33
mbbd000141553,mbcd0029763,mbtp000008,mbrf0001953,,=,,,substrate,28,14.0,microM,2.2,Res-3-G,,,HEK298 - hMRP3,HEK293,,,,,human,mbds0010,,2013-11-24 23:13:33
mbbd000141554,mbcd0029763,mbtp000008,mbrf0001953,,=,,,substrate,22,72.0,pmol / mg / min,4.5,Res-3-G,,,HEK298 - hMRP3,HEK293,,,,,human,mbds0010,,2013-11-24 23:13:33
mbbd000141555,mbcd0029343,mbtp000008,mbrf0001560,,=,,,substrate,110,2.3,,1.7,MTX diglutamate,,,purified abcc3 in proteoliposomes,proteoliposomes,,,,,human,mbds0010,,2013-11-24 23:56:31
mbbd000141556,mbcd0029343,mbtp000008,mbrf0001560,,>,,,substrate,22,2.0,micromol / min / mg,1.7,MTX diglutamate,,,purified abcc3 in proteoliposomes,proteoliposomes,,,,,human,mbds0010,,2013-11-24 23:56:31
mbbd000141557,mbcd0002917,mbtp000008,mbrf0001560,,=,,,substrate,22,4.7,nmol / min / mg,0.8,LTC4,,,purified abcc3 in proteoliposomes,proteoliposomes,,,,,human,mbds0010,,2013-11-24 23:56:30
mbbd000141558,mbcd0002917,mbtp000008,mbrf0001560,,=,,,substrate,110,2.3,,0.5,LTC4,,,purified abcc3 in proteoliposomes,proteoliposomes,,,,,human,mbds0010,,2013-11-24 23:56:30
mbbd000141559,mbcd0002917,mbtp000008,mbrf0001560,,=,,,substrate,28,1.7,microM,0.3,LTC4,,,purified abcc3 in proteoliposomes,proteoliposomes,,,,,human,mbds0010,,2013-11-24 23:56:29
mbbd000141560,mbcd0000387,mbtp000008,mbrf0001784,,=,,,substrate,28,67.0,microM,,E2 17betaG,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141561,mbcd0000387,mbtp000008,mbrf0001784,,=,,,substrate,28,18.0,microM,,E2 17betaG,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141562,mbcd0000387,mbtp000008,mbrf0001784,,=,,,substrate,22,415.0,pmol / min / mg protein,,E2 17betaG,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141563,mbcd0000387,mbtp000008,mbrf0001784,,=,,,substrate,22,474.0,pmol / min / mg protein,,E2 17betaG,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141564,mbcd0000056,mbtp000008,mbrf0001784,,=,,,substrate,28,9.0,microM,,ethinylestradiol - glucuronide,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141565,mbcd0000056,mbtp000008,mbrf0001784,,=,,,substrate,22,138.0,pmol / min / mg protein,,ethinylestradiol - glucuronide,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141566,mbcd0000398,mbtp000008,mbrf0001784,,=,,,substrate,28,11.0,microM,,etoposide glucuronide,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141567,mbcd0000398,mbtp000008,mbrf0001784,,=,,,substrate,22,138.0,pmol / min / mg protein,,etoposide glucuronide,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141568,mbcd0003012,mbtp000008,mbrf0001784,,=,,,substrate,28,900.0,microM,,acetaminophen glucuronide,,,,,,,,,human,mbds0010,,2013-11-10 06:47:09
mbbd000141569,mbcd0003012,mbtp000008,mbrf0001784,,=,,,substrate,22,2100.0,pmol / min / mg protein,,acetaminophen glucuronide,,,,,,,,,human,mbds0010,,2013-11-10 06:47:09
mbbd000141570,mbcd0000387,mbtp000008,mbrf0001297,,=,,,substrate,28,25.6,microM,5.4,E2 17betaG,,,membrane vesicles prepared from HEK293/MRP3 cells,HEK293,,,,,human,mbds0003,v2007,2013-11-24 23:13:34
mbbd000141571,mbcd0000387,mbtp000008,mbrf0001297,,=,,,substrate,22,75.6,pmol / mg / min,5.9,E2 17betaG,,,membrane vesicles prepared from HEK293/MRP3 cells,HEK293,,,,,human,mbds0010,,2013-11-24 23:13:34
mbbd000141572,mbcd0000047,mbtp000008,mbrf0001297,,=,,,substrate,28,5.7,microM,1.7,DNP - SG,,,membrane vesicles prepared from HEK293/MRP3 cells,HEK293,,,,,human,mbds0003,v2007,2013-11-24 23:13:34
mbbd000141573,mbcd0000047,mbtp000008,mbrf0001297,,=,,,substrate,22,3.8,pmol / mg / min,0.1,DNP - SG,,,membrane vesicles prepared from HEK293/MRP3 cells,HEK293,,,,,human,mbds0010,,2013-11-24 23:13:34
mbbd000141574,mbcd0002917,mbtp000008,mbrf0001297,,=,,,substrate,28,5.3,microM,2.6,LTC4,,,membrane vesicles prepared from HEK293/MRP3 cells,HEK293,,,,,human,mbds0003,v2007,2013-11-24 23:13:35
mbbd000141575,mbcd0002917,mbtp000008,mbrf0001297,,=,,,substrate,22,20.2,pmol / mg / min,5.9,LTC4,,,membrane vesicles prepared from HEK293/MRP3 cells,HEK293,,,,,human,mbds0010,,2013-11-24 23:13:35
mbbd000141576,mbcd0003043,mbtp000008,mbrf0001297,,=,,,substrate,28,776.0,microM,319,methotrexate,,,membrane vesicles prepared from HEK293/MRP3 cells,HEK293,,,,,human,mbds0003,v2007,2013-11-24 23:13:35
mbbd000141577,mbcd0003043,mbtp000008,mbrf0001297,,=,,,substrate,22,288.0,pmol / mg / min,54,methotrexate,,,membrane vesicles prepared from HEK293/MRP3 cells,HEK293,,,,,human,mbds0010,,2013-11-24 23:13:36
mbbd000141578,mbcd0000455,mbtp000008,mbrf0001297,,=,,,substrate,28,248.0,microM,113,glycocholate,,,membrane vesicles prepared from HEK293/MRP3 cells,HEK293,,,,,human,mbds0003,v2007,2013-11-24 23:13:36
mbbd000141579,mbcd0000455,mbtp000008,mbrf0001297,,=,,,substrate,22,183.0,pmol / mg / min,34,glycocholate,,,membrane vesicles prepared from HEK293/MRP3 cells,HEK293,,,,,human,mbds0010,,2013-11-24 23:13:36
mbbd000141580,mbcd0029456,mbtp000008,mbrf0001855,,=,,,inhibitor,25,1.5,microM,0.3,H7G,,,inhibition of benzbromarone (100 mM),,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141581,mbcd0029456,mbtp000008,mbrf0001855,,=,,,inhibitor,3,79.0,%,4,H7G,,,inhibition of benzbromarone (100 mM),,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141582,mbcd0029457,mbtp000008,mbrf0001855,,=,,,inhibitor,25,3.4,microM,0.0,H3'G,,,inhibition of benzbromarone (100 mM),,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141583,mbcd0029457,mbtp000008,mbrf0001855,,=,,,inhibitor,3,98.0,%,4,H3'G,,,inhibition of benzbromarone (100 mM),,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141584,mbcd0001693,mbtp000008,mbrf0002573,,,,,substrate,,,,,trabectedin,,,Madin-Darby canine kidney cells,MDCK,,,,weak substrate,human,mbds0010,,2013-11-24 23:56:28
mbbd000141585,mbcd0001795,mbtp000008,mbrf0000069,25,=,5100.0,nM,inhibitor,25,5.1,micromol L-1,0.4,etravirine,strong inhibitor,,"MDCKII-MRP3, proliferation inhibition",MDCKII,,,,,human,mbds0010,,2015-07-27 05:36:21
mbbd000141586,mbcd0003122,mbtp000008,mbrf0001793,,,,,substrate,,,,,5-carboxyfuorescein diacetate,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141587,mbcd0029774,mbtp000008,mbrf0001793,,=,,,inhibitor,19,1.2,,0.3,3ATA,,,"inhibition of uptake of fluorescent CDFA, 6.25 microM",,,,,,human,mbds0010,,2013-12-09 20:16:43
mbbd000141588,mbcd0029774,mbtp000008,mbrf0001793,,=,,,inhibitor,19,1.4,,0.3,3ATA,,,"inhibition of uptake of fluorescent CDFA, 12.5 microM",,,,,,human,mbds0010,,2013-12-09 20:16:46
mbbd000141589,mbcd0029774,mbtp000008,mbrf0001793,,=,,,inhibitor,19,1.7,,0.4,3ATA,,,"inhibition of uptake of fluorescent CDFA, 25 microM",,,,,,human,mbds0010,,2013-12-09 20:16:45
mbbd000141590,mbcd0002494,mbtp000008,mbrf0001793,,=,,,inhibitor,19,1.5,,0.2,MK,,,"inhibition of uptake of fluorescent CDFA, 50 microM",,,,,,human,mbds0010,,2013-12-09 19:53:27
mbbd000141591,mbcd0002494,mbtp000008,mbrf0001793,,=,,,inhibitor,19,3.7,,0.1,MK,,,"inhibition of uptake of fluorescent CDFA, 100 microM",,,,,,human,mbds0010,,2013-12-09 19:53:28
mbbd000141592,mbcd0003154,mbtp000008,mbrf0001793,,=,,,inhibitor,19,6.0,,0.1,PRO,,,"inhibition of uptake of fluorescent CDFA, 1000 microM",,,,,,human,mbds0010,,2013-12-09 19:53:26
mbbd000141593,mbcd0001532,mbtp000008,mbrf0001721,,,,,substrate,,,,,paclitaxel,,,EVSA-T cells overexpressing MRP3,EVSA-T,,,,,human,mbds0010,,2013-11-24 23:56:28
mbbd000141594,mbcd0029775,mbtp000008,mbrf0001721,,,,,substrate,,,,,MMAE,,,EVSA-T cells overexpressing MRP3,EVSA-T,,,,,human,mbds0010,,2013-11-24 23:56:28
mbbd000141595,mbcd0000387,mbtp000008,mbrf0002329,,=,,,substrate,33,102.0,pmol / mg protein / 1.5 min,,E217betaG,,,HEK298 - MRP3 cells,HEK293,,,,,human,mbds0010,,2013-10-16 22:45:05
mbbd000141596,mbcd0029196,mbtp000008,mbrf0002329,,,,,substrate,,,,,MEB; Tc-99m mebrofenin,,,Membrane vesicles from HEK298 - MRP3 cells,HEK293,,0.4,nM,,human,mbds0010,,2013-11-17 21:06:14
mbbd000141597,mbcd0001868,mbtp000008,mbrf0002448,,=,,,substrate,25,57.3,microM,2.7,efivirenz,,,MDCKII-MRP3; inhibition of growth assay; untransfected MDCKII cells had IC50 value of 55.9 +/- 2.0,MDCKII,,,,,human,mbds0010,,2013-11-04 00:32:21
mbbd000141598,mbcd0029769,mbtp000008,mbrf0002102,,=,,,substrate,28,3.7,microM,1.0,CLF,,,sf21 insect cells - ABCC3,Sf21,,0.5-16,microM,,human,mbds0010,,2013-11-04 21:58:45
mbbd000141599,mbcd0029769,mbtp000008,mbrf0002102,,=,,,substrate,22,188.0,pmol / mg protein / min,55,CLF,,,sf21 insect cells - ABCC3,Sf21,,0.5-16,microM,,human,mbds0010,,2013-11-04 21:58:45
mbbd000141600,mbcd0000455,mbtp000008,mbrf0002081,,=,,,substrate,28,194.0,microM,23,G-CA,,,hMRP3 expressing membrane vesicles; Sf9 cells,Sf9,,,,,human,mbds0010,,2013-11-26 00:48:05
mbbd000141601,mbcd0000455,mbtp000008,mbrf0002081,,=,,,substrate,22,2562.0,pmol / mg protein / min,141,G-CA,,,hMRP3 expressing membrane vesicles; Sf9 cells,Sf9,,,,,human,mbds0010,,2013-11-26 00:48:05
mbbd000141602,mbcd0029777,mbtp000008,mbrf0002081,,=,,,substrate,28,329.0,microM,58,G-CA-1 beta ol,,,hMRP3 expressing membrane vesicles; Sf9 cells,Sf9,,,,,human,mbds0010,,2013-11-26 00:48:05
mbbd000141603,mbcd0029777,mbtp000008,mbrf0002081,,=,,,substrate,22,1220.0,pmol / mg protein / min,117,G-CA-1 beta ol,,,hMRP3 expressing membrane vesicles; Sf9 cells,Sf9,,,,,human,mbds0010,,2013-11-26 00:48:05
mbbd000141604,mbcd0029778,mbtp000008,mbrf0002081,,=,,,substrate,28,265.0,microM,42,G-CA-6 alpha-ol,,,hMRP3 expressing membrane vesicles; Sf9 cells,Sf9,,,,,human,mbds0010,,2013-11-26 00:48:05
mbbd000141605,mbcd0029778,mbtp000008,mbrf0002081,,=,,,substrate,22,2107.0,pmol / mg protein / min,117,G-CA-6 alpha-ol,,,hMRP3 expressing membrane vesicles; Sf9 cells,Sf9,,,,,human,mbds0010,,2013-11-26 00:48:05
mbbd000141606,mbcd0029779,mbtp000008,mbrf0002081,,=,,,substrate,28,110.0,microM,13,G-CDCA-1 beta-ol,,,hMRP3 expressing membrane vesicles; Sf9 cells,Sf9,,,,,human,mbds0010,,2013-11-26 00:48:05
mbbd000141607,mbcd0029779,mbtp000008,mbrf0002081,,=,,,substrate,22,1522.0,pmol / mg protein / min,68,G-CDCA-1 beta-ol,,,hMRP3 expressing membrane vesicles; Sf9 cells,Sf9,,,,,human,mbds0010,,2013-11-26 00:48:05
mbbd000141608,mbcd0029780,mbtp000008,mbrf0002081,,=,,,substrate,28,53.0,microM,12,G-CDCA - 1 alpha - ol,,,hMRP3 expressing membrane vesicles; Sf9 cells,Sf9,,,,,human,mbds0010,,2013-11-26 00:48:05
mbbd000141609,mbcd0029780,mbtp000008,mbrf0002081,,=,,,substrate,22,2041.0,pmol / mg protein / min,170,G-CDCA - 1 alpha - ol,,,hMRP3 expressing membrane vesicles; Sf9 cells,Sf9,,,,,human,mbds0010,,2013-11-26 00:48:05
mbbd000141610,mbcd0029781,mbtp000008,mbrf0002081,,=,,,substrate,28,93.0,microM,16,G-CA-Delta4-3-one,,,hMRP3 expressing membrane vesicles; Sf9 cells,Sf9,,,,,human,mbds0010,,2013-11-26 00:48:05
mbbd000141611,mbcd0029781,mbtp000008,mbrf0002081,,=,,,substrate,22,878.0,pmol / mg protein / min,52,G-CA-Delta4-3-one,,,hMRP3 expressing membrane vesicles; Sf9 cells,Sf9,,,,,human,mbds0010,,2013-11-26 00:48:06
mbbd000141612,mbcd0029782,mbtp000008,mbrf0002081,,=,,,substrate,28,4.0,microM,1,G-Delta5-3beta-S,,,hMRP3 expressing membrane vesicles; Sf9 cells,Sf9,,,,,human,mbds0010,,2013-11-26 00:48:06
mbbd000141613,mbcd0029782,mbtp000008,mbrf0002081,,=,,,substrate,22,191.0,pmol / mg protein / min,17,G-Delta5-3beta-S,,,hMRP3 expressing membrane vesicles; Sf9 cells,Sf9,,,,,human,mbds0010,,2013-11-26 00:48:06
mbbd000141614,mbcd0029783,mbtp000008,mbrf0001753,,=,,,inhibitor,25,200.0,microM,,compound 1,,,benzbromarone uptake inhibition,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141615,mbcd0029784,mbtp000008,mbrf0001753,,=,,,inhibitor,25,13.0,microM,,compound 2,,,benzbromarone uptake inhibition,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141616,mbcd0001533,mbtp000008,mbrf0001875,,=,,,non-substrate,25,22.7,microM,3.1,saquinavir,growth inhibition; control MDCKII cells had IC50 value of 24.0 +/- 3.2 microM,,MDCKII-MRP3 cells,MDCKII,,,,,human,mbds0010,,2013-12-09 02:51:34
mbbd000141617,mbcd0002634,mbtp000008,mbrf0001875,,=,,,non-substrate,25,343.7,microM,45.9,darunavir,growth inhibition; control MDCKII cells had IC50 value of 404.3 +/- 84.8 microM,,MDCKII-MRP3 cells,MDCKII,,,,,human,mbds0010,,2013-12-09 02:51:34
mbbd000141618,mbcd0001797,mbtp000008,mbrf0002744,,~,,,substrate,89,1.8,,,fexofenadine; FEX,,,Membrane vesicles from hMRP3-expressing HEK293 cells; uptake after 5 min,HEK293,,10,microM,,human,mbds0010,,2013-12-08 06:41:19
mbbd000141622,mbcd0001117,mbtp000008,mbrf0002270,,~,,,inducer,98,1.5,fold,,cisplatin,,,induced MRP3 mRNA expression in HepG2 cells,,,,,,human,mbds0010,,2013-10-12 00:50:29
mbbd000141623,mbcd0000462,mbtp000008,mbrf0002270,,,,,substrate,,,,,Glycyrrhizin,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141625,mbcd0000070,mbtp000008,mbrf0002235,,,,,substrate,,,,,4-MUG,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141626,mbcd0003043,mbtp000008,mbrf0001733,,=,,,substrate,28,0.62,mM,0.23,MTX,,,HEK293 - MRP3,HEK293,,,,,human,mbds0010,,2013-11-24 23:13:37
mbbd000141627,mbcd0003043,mbtp000008,mbrf0001733,,=,,,substrate,28,1.3,mM,0.2,MTX,,,HEK293 - MRP3,HEK293,,,,,human,mbds0010,,2013-11-24 23:13:37
mbbd000141628,mbcd0003043,mbtp000008,mbrf0001733,,=,,,substrate,22,430.0,pmol / mg / min,30,MTX,,,HEK293 - MRP3,HEK293,,,,,human,mbds0010,,2013-11-24 23:13:37
mbbd000141629,mbcd0000387,mbtp000012,mbrf0002116,,=,,,substrate,28,7.5,microM,3.9,E17betaG,,,"uptake into human hepatocytes expressing OATP-1B1/1B3, 2 hour incubation",human hepatocytes,,,,,human,mbds0010,,2013-11-24 23:56:28
mbbd000141630,mbcd0000387,mbtp000012,mbrf0002116,,=,,,substrate,28,6.6,microM,1.4,E17betaG,,,"uptake into human hepatocytes expressing OATP-1B1/1B3, 2 hour incubation",human hepatocytes,,,,,human,mbds0010,,2013-11-24 23:56:27
mbbd000141631,mbcd0000387,mbtp000012,mbrf0002116,,=,,,substrate,28,15.2,microM,1.0,E17betaG,,,"uptake into human hepatocytes expressing OATP-1B1/1B3, 2 hour incubation",human hepatocytes,,,,,human,mbds0010,,2013-11-24 23:56:27
mbbd000141632,mbcd0000387,mbtp000012,mbrf0002116,,=,,,substrate,28,22.0,microM,3.8,E17betaG,,,"uptake into human hepatocytes expressing OATP-1B1/1B3, 2 hour incubation",human hepatocytes,,,,,human,mbds0010,,2013-11-24 23:56:27
mbbd000141633,mbcd0000387,mbtp000012,mbrf0002116,,=,,,substrate,28,0.9,microM,0.7,E17betaG,,,"uptake into human hepatocytes expressing OATP-1B1/1B3, 2 hour incubation",human hepatocytes,,,,,human,mbds0010,,2013-11-24 23:56:27
mbbd000141634,mbcd0000387,mbtp000013,mbrf0002116,,=,,,substrate,28,7.5,microM,3.9,E17betaG,,,"uptake into human hepatocytes expressing OATP-1B1/1B3, 2 hour incubation",human hepatocytes,,,,,human,mbds0010,,2013-11-24 23:56:26
mbbd000141635,mbcd0000387,mbtp000013,mbrf0002116,,=,,,substrate,28,6.6,microM,1.4,E17betaG,,,"uptake into human hepatocytes expressing OATP-1B1/1B3, 2 hour incubation",human hepatocytes,,,,,human,mbds0010,,2013-11-24 23:56:26
mbbd000141636,mbcd0000387,mbtp000013,mbrf0002116,,=,,,substrate,28,15.2,microM,1.0,E17betaG,,,"uptake into human hepatocytes expressing OATP-1B1/1B3, 2 hour incubation",human hepatocytes,,,,,human,mbds0010,,2013-11-24 23:56:26
mbbd000141637,mbcd0000387,mbtp000013,mbrf0002116,,=,,,substrate,28,22.0,microM,3.8,E17betaG,,,"uptake into human hepatocytes expressing OATP-1B1/1B3, 2 hour incubation",human hepatocytes,,,,,human,mbds0010,,2013-11-24 23:56:25
mbbd000141638,mbcd0000387,mbtp000013,mbrf0002116,,=,,,substrate,28,0.9,microM,0.7,E17betaG,,,"uptake into human hepatocytes expressing OATP-1B1/1B3, 2 hour incubation",human hepatocytes,,,,,human,mbds0010,,2013-11-24 23:56:25
mbbd000141639,mbcd0000387,mbtp000012,mbrf0002116,,=,,,substrate,22,454.0,pmol / min / mg protein,76,E17betaG,,,"uptake into human hepatocytes expressing OATP-1B1/1B3, 2 hour incubation",human hepatocytes,,,,,human,mbds0010,,2013-11-24 23:56:24
mbbd000141640,mbcd0000387,mbtp000012,mbrf0002116,,=,,,substrate,22,155.0,pmol / min / mg protein,11,E17betaG,,,"uptake into human hepatocytes expressing OATP-1B1/1B3, 2 hour incubation",human hepatocytes,,,,,human,mbds0010,,2013-11-24 23:56:24
mbbd000141641,mbcd0000387,mbtp000012,mbrf0002116,,=,,,substrate,22,342.0,pmol / min / mg protein,9,E17betaG,,,"uptake into human hepatocytes expressing OATP-1B1/1B3, 2 hour incubation",human hepatocytes,,,,,human,mbds0010,,2013-11-24 23:56:23
mbbd000141642,mbcd0000387,mbtp000012,mbrf0002116,,=,,,substrate,22,566.0,pmol / min / mg protein,35,E17betaG,,,"uptake into human hepatocytes expressing OATP-1B1/1B3, 2 hour incubation",human hepatocytes,,,,,human,mbds0010,,2013-11-24 23:56:23
mbbd000141643,mbcd0000387,mbtp000012,mbrf0002116,,=,,,substrate,22,28.0,pmol / min / mg protein,4,E17betaG,,,"uptake into human hepatocytes expressing OATP-1B1/1B3, 2 hour incubation",human hepatocytes,,,,,human,mbds0010,,2013-11-24 23:56:23
mbbd000141644,mbcd0000387,mbtp000013,mbrf0002116,,=,,,substrate,22,454.0,pmol / min / mg protein,76,E17betaG,,,"uptake into human hepatocytes expressing OATP-1B1/1B3, 2 hour incubation",human hepatocytes,,,,,human,mbds0010,,2013-11-24 23:56:23
mbbd000141645,mbcd0000387,mbtp000013,mbrf0002116,,=,,,substrate,22,155.0,pmol / min / mg protein,11,E17betaG,,,"uptake into human hepatocytes expressing OATP-1B1/1B3, 2 hour incubation",human hepatocytes,,,,,human,mbds0010,,2013-11-24 23:56:22
mbbd000141646,mbcd0000387,mbtp000013,mbrf0002116,,=,,,substrate,22,342.0,pmol / min / mg protein,9,E17betaG,,,"uptake into human hepatocytes expressing OATP-1B1/1B3, 2 hour incubation",human hepatocytes,,,,,human,mbds0010,,2013-11-24 23:56:22
mbbd000141647,mbcd0000387,mbtp000013,mbrf0002116,,=,,,substrate,22,566.0,pmol / min / mg protein,35,E17betaG,,,"uptake into human hepatocytes expressing OATP-1B1/1B3, 2 hour incubation",human hepatocytes,,,,,human,mbds0010,,2013-11-24 23:56:22
mbbd000141648,mbcd0000387,mbtp000013,mbrf0002116,,=,,,substrate,22,28.0,pmol / min / mg protein,4,E17betaG,,,"uptake into human hepatocytes expressing OATP-1B1/1B3, 2 hour incubation",human hepatocytes,,,,,human,mbds0010,,2013-11-24 23:56:21
mbbd000141649,mbcd0000387,mbtp000012,mbrf0002116,,=,,,substrate,28,4.2,microM,0.4,E17betaG,,,"uptake into human hepatocytes expressing OATP-1B1/1B3, 6 hour incubation",human hepatocytes,,,,,human,mbds0010,,2013-11-24 23:56:21
mbbd000141650,mbcd0000387,mbtp000012,mbrf0002116,,=,,,substrate,28,10.5,microM,2.3,E17betaG,,,"uptake into human hepatocytes expressing OATP-1B1/1B3, 6 hour incubation",human hepatocytes,,,,,human,mbds0010,,2013-11-24 23:56:20
mbbd000141651,mbcd0000387,mbtp000012,mbrf0002116,,=,,,substrate,28,18.6,microM,3.5,E17betaG,,,"uptake into human hepatocytes expressing OATP-1B1/1B3, 6 hour incubation",human hepatocytes,,,,,human,mbds0010,,2013-11-24 23:56:20
mbbd000141652,mbcd0000387,mbtp000013,mbrf0002116,,=,,,substrate,28,4.2,microM,0.4,E17betaG,,,"uptake into human hepatocytes expressing OATP-1B1/1B3, 6 hour incubation",human hepatocytes,,,,,human,mbds0010,,2013-11-24 23:56:20
mbbd000141653,mbcd0000387,mbtp000013,mbrf0002116,,=,,,substrate,28,10.5,microM,2.3,E17betaG,,,"uptake into human hepatocytes expressing OATP-1B1/1B3, 6 hour incubation",human hepatocytes,,,,,human,mbds0010,,2013-11-24 23:56:20
mbbd000141654,mbcd0000387,mbtp000013,mbrf0002116,,=,,,substrate,28,18.6,microM,3.5,E17betaG,,,"uptake into human hepatocytes expressing OATP-1B1/1B3, 6 hour incubation",human hepatocytes,,,,,human,mbds0010,,2013-11-24 23:56:19
mbbd000141655,mbcd0000387,mbtp000012,mbrf0002116,,=,,,substrate,22,143.0,pmol / min / mg protein,4,E17betaG,,,"uptake into human hepatocytes expressing OATP-1B1/1B3, 2 hour incubation",human hepatocytes,,,,,human,mbds0010,,2013-11-24 23:56:19
mbbd000141656,mbcd0000387,mbtp000012,mbrf0002116,,=,,,substrate,22,243.0,pmol / min / mg protein,19,E17betaG,,,"uptake into human hepatocytes expressing OATP-1B1/1B3, 2 hour incubation",human hepatocytes,,,,,human,mbds0010,,2013-11-24 23:56:19
mbbd000141657,mbcd0000387,mbtp000012,mbrf0002116,,=,,,substrate,22,514.0,pmol / min / mg protein,33,E17betaG,,,"uptake into human hepatocytes expressing OATP-1B1/1B3, 2 hour incubation",human hepatocytes,,,,,human,mbds0010,,2013-11-24 23:56:19
mbbd000141658,mbcd0000387,mbtp000013,mbrf0002116,,=,,,substrate,22,143.0,pmol / min / mg protein,4,E17betaG,,,"uptake into human hepatocytes expressing OATP-1B1/1B3, 2 hour incubation",human hepatocytes,,,,,human,mbds0010,,2013-11-24 23:56:18
mbbd000141659,mbcd0000387,mbtp000013,mbrf0002116,,=,,,substrate,22,243.0,pmol / min / mg protein,19,E17betaG,,,"uptake into human hepatocytes expressing OATP-1B1/1B3, 2 hour incubation",human hepatocytes,,,,,human,mbds0010,,2013-11-24 23:56:18
mbbd000141660,mbcd0000387,mbtp000013,mbrf0002116,,=,,,substrate,22,514.0,pmol / min / mg protein,33,E17betaG,,,"uptake into human hepatocytes expressing OATP-1B1/1B3, 2 hour incubation",human hepatocytes,,,,,human,mbds0010,,2013-11-24 23:56:18
mbbd000141661,mbcd0000387,mbtp000012,mbrf0002116,,=,,,substrate,28,26.2,microM,19.8,E17betaG,,,"uptake into human hepatocytes expressing OATP-1B1/1B3, 24 hour incubation",human hepatocytes,,,,,human,mbds0010,,2013-11-24 23:56:17
mbbd000141662,mbcd0000387,mbtp000012,mbrf0002116,,=,,,substrate,28,12.0,microM,0.8,E17betaG,,,"uptake into human hepatocytes expressing OATP-1B1/1B3, 24 hour incubation",human hepatocytes,,,,,human,mbds0010,,2013-11-24 23:56:17
mbbd000141663,mbcd0000387,mbtp000012,mbrf0002116,,=,,,substrate,28,31.9,microM,3.8,E17betaG,,,"uptake into human hepatocytes expressing OATP-1B1/1B3, 24 hour incubation",human hepatocytes,,,,,human,mbds0010,,2013-11-24 23:56:17
mbbd000141664,mbcd0000387,mbtp000013,mbrf0002116,,=,,,substrate,28,26.2,microM,19.8,E17betaG,,,"uptake into human hepatocytes expressing OATP-1B1/1B3, 24 hour incubation",human hepatocytes,,,,,human,mbds0010,,2013-11-24 23:56:16
mbbd000141665,mbcd0000387,mbtp000013,mbrf0002116,,=,,,substrate,28,12.0,microM,0.8,E17betaG,,,"uptake into human hepatocytes expressing OATP-1B1/1B3, 24 hour incubation",human hepatocytes,,,,,human,mbds0010,,2013-11-24 23:56:15
mbbd000141666,mbcd0000387,mbtp000013,mbrf0002116,,=,,,substrate,28,31.9,microM,3.8,E17betaG,,,"uptake into human hepatocytes expressing OATP-1B1/1B3, 24 hour incubation",human hepatocytes,,,,,human,mbds0010,,2013-11-24 23:56:14
mbbd000141667,mbcd0000387,mbtp000012,mbrf0002116,,=,,,substrate,22,224.0,pmol / min / mg protein,81,E17betaG,,,"uptake into human hepatocytes expressing OATP-1B1/1B3, 2 hour incubation",human hepatocytes,,,,,human,mbds0010,,2013-11-24 23:56:14
mbbd000141668,mbcd0000387,mbtp000012,mbrf0002116,,=,,,substrate,22,177.0,pmol / min / mg protein,5,E17betaG,,,"uptake into human hepatocytes expressing OATP-1B1/1B3, 2 hour incubation",human hepatocytes,,,,,human,mbds0010,,2013-11-24 23:56:14
mbbd000141669,mbcd0000387,mbtp000012,mbrf0002116,,=,,,substrate,22,698.0,pmol / min / mg protein,34,E17betaG,,,"uptake into human hepatocytes expressing OATP-1B1/1B3, 2 hour incubation",human hepatocytes,,,,,human,mbds0010,,2013-11-24 23:56:13
mbbd000141670,mbcd0000387,mbtp000013,mbrf0002116,,=,,,substrate,22,224.0,pmol / min / mg protein,81,E17betaG,,,"uptake into human hepatocytes expressing OATP-1B1/1B3, 2 hour incubation",human hepatocytes,,,,,human,mbds0010,,2013-11-24 23:56:13
mbbd000141671,mbcd0000387,mbtp000013,mbrf0002116,,=,,,substrate,22,177.0,pmol / min / mg protein,5,E17betaG,,,"uptake into human hepatocytes expressing OATP-1B1/1B3, 2 hour incubation",human hepatocytes,,,,,human,mbds0010,,2013-11-24 23:56:12
mbbd000141672,mbcd0000387,mbtp000013,mbrf0002116,,=,,,substrate,22,698.0,pmol / min / mg protein,34,E17betaG,,,"uptake into human hepatocytes expressing OATP-1B1/1B3, 2 hour incubation",human hepatocytes,,,,,human,mbds0010,,2013-11-24 23:56:12
mbbd000141673,mbcd0026093,mbtp000012,mbrf0002404,,=,,,substrate,28,0.62,microM,0.45,atorvastatin,,,uptake into HEK293 - OATP1B1 cells,HEK293,,,,,human,mbds0010,,2013-11-24 23:13:37
mbbd000141674,mbcd0003126,mbtp000012,mbrf0002404,,=,,,substrate,28,29.0,microM,2.7,pravastatin,,,uptake into HEK293 - OATP1B1 cells,HEK293,,,,,human,mbds0010,,2013-11-24 23:13:38
mbbd000141675,mbcd0001445,mbtp000012,mbrf0002404,,=,,,substrate,28,12.0,microM,1.2,fluvastatin,,,uptake into HEK293 - OATP1B1 cells,HEK293,,,,,human,mbds0010,,2013-11-24 23:13:38
mbbd000141676,mbcd0000693,mbtp000012,mbrf0002404,,=,,,substrate,28,1.3,microM,0.29,pitavastatin,,,uptake into HEK293 - OATP1B1 cells,HEK293,,,,,human,mbds0010,,2013-11-24 23:13:38
mbbd000141677,mbcd0001448,mbtp000012,mbrf0002404,,=,,,substrate,28,9.0,microM,0.12,rosuvastatin,,,uptake into HEK293 - OATP1B1 cells,HEK293,,,,,human,mbds0010,,2013-11-24 23:13:39
mbbd000141678,mbcd0003075,mbtp000012,mbrf0002404,,=,,,substrate,28,0.28,microM,0.07,estrone 3 sulfate,,,uptake into HEK293 - OATP1B1 cells,HEK293,,,,,human,mbds0010,,2013-11-24 23:13:39
mbbd000141679,mbcd0003075,mbtp000012,mbrf0002404,,=,,,substrate,28,47.0,microM,26,estrone 3 sulfate,,,uptake into HEK293 - OATP1B1 cells,HEK293,,,,,human,mbds0010,,2013-11-24 23:13:39
mbbd000141680,mbcd0000387,mbtp000012,mbrf0002404,,=,,,substrate,28,5.5,microM,1.3,estradiol 17beta-glucuronide,,,uptake into HEK293 - OATP1B1 cells,HEK293,,,,,human,mbds0010,,2013-11-24 23:13:39
mbbd000141681,mbcd0000749,mbtp000012,mbrf0002404,,=,,,inhibitor,25,0.33,microM,0.080,rifamycin SV,,,inhibition of Atorvastatin uptake into HEK298-OATP1B1 tranfected cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141682,mbcd0000749,mbtp000012,mbrf0002404,,=,,,inhibitor,25,0.14,microM,0.076,rifamycin SV,,,inhibition of pravastatin uptake into HEK298-OATP1B1 tranfected cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141683,mbcd0000749,mbtp000012,mbrf0002404,,=,,,inhibitor,25,0.27,microM,0.014,rifamycin SV,,,inhibition of pitavastatin uptake into HEK298-OATP1B1 tranfected cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141684,mbcd0000749,mbtp000012,mbrf0002404,,=,,,inhibitor,25,0.053,microM,0.020,rifamycin SV,,,inhibition of rosuvastatin uptake into HEK298-OATP1B1 tranfected cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141685,mbcd0000749,mbtp000012,mbrf0002404,,=,,,inhibitor,25,1.1,microM,0.22,rifamycin SV,,,inhibition of estrone 3 sulfate uptake into HEK298-OATP1B1 tranfected cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141686,mbcd0000749,mbtp000012,mbrf0002404,,=,,,inhibitor,25,0.32,microM,0.05,rifamycin SV,,,inhibition of estradiol 17beta glucuronide uptake into HEK298-OATP1B1 tranfected cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141687,mbcd0009531,mbtp000012,mbrf0002404,,=,,,inhibitor,25,32.0,microM,4.2,gemfibrozil,,,inhibition of Atorvastatin uptake into HEK298-OATP1B1 tranfected cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141688,mbcd0009531,mbtp000012,mbrf0002404,,=,,,inhibitor,25,18.0,microM,1.7,gemfibrozil,,,inhibition of pravastatin uptake into HEK298-OATP1B1 tranfected cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141689,mbcd0009531,mbtp000012,mbrf0002404,,=,,,inhibitor,25,100.0,microM,28,gemfibrozil,,,inhibition of pitavastatin uptake into HEK298-OATP1B1 tranfected cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141690,mbcd0009531,mbtp000012,mbrf0002404,,=,,,inhibitor,25,19.0,microM,9.6,gemfibrozil,,,inhibition of rosuvastatin uptake into HEK298-OATP1B1 tranfected cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141691,mbcd0009531,mbtp000012,mbrf0002404,,>,,,inhibitor,25,300.0,microM,,gemfibrozil,,,inhibition of estrone 3 sulfate uptake into HEK298-OATP1B1 tranfected cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141692,mbcd0009531,mbtp000012,mbrf0002404,,=,,,inhibitor,25,42.0,microM,7.7,gemfibrozil,,,inhibition of estradiol 17beta glucuronide uptake into HEK298-OATP1B1 tranfected cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141693,mbcd0029785,mbtp000012,mbrf0002232,,=,,,substrate,28,2.9,microM,0.40,8-FcA,,,CHO-OATP1B1,CHO,,,,,human,mbds0010,,2013-11-04 02:27:49
mbbd000141694,mbcd0029785,mbtp000013,mbrf0002232,,=,,,substrate,28,1.8,microM,0.47,8-FcA,,,CHO-OATP1B3,CHO,,,,,human,mbds0010,,2013-11-04 02:46:08
mbbd000141695,mbcd0029785,mbtp000012,mbrf0002232,,=,,,substrate,22,0.2,pmol / min / cm^2,0.01,8-FcA,,,CHO-OATP1B1,CHO,,,,,human,mbds0010,,2013-11-04 02:27:50
mbbd000141696,mbcd0029785,mbtp000013,mbrf0002232,,=,,,substrate,22,0.33,pmol / min / cm^2,0.02,8-FcA,,,CHO-OATP1B3,CHO,,,,,human,mbds0010,,2013-11-04 02:46:08
mbbd000141697,mbcd0003035,mbtp000012,mbrf0002232,,=,,,inhibitor,25,0.18,microM,0.02,bromosulfophthalein,,,Inhibition of the OATP1B1-mediated transport of 2.5 microM 8-FcA,,,,,,human,mbds0010,,2013-11-04 02:46:13
mbbd000141699,mbcd0000311,mbtp000012,mbrf0002232,,=,,,inhibitor,25,0.25,microM,0.03,cyclosporin A,,,Inhibition of the OATP1B1-mediated transport of 2.5 microM 8-FcA,,,,,,human,mbds0010,,2013-11-04 02:46:13
mbbd000141700,mbcd0000311,mbtp000012,mbrf0002232,,=,,,inhibitor,29,0.24,microM,,cyclosporin A,,,Inhibition of the OATP1B1-mediated transport of 2.5 microM 8-FcA,,,,,,human,mbds0010,,2013-11-04 02:46:14
mbbd000141701,mbcd0000387,mbtp000012,mbrf0002232,,=,,,inhibitor,25,4.88,microM,0.87,estradiol 17beta d glucuronide,,,Inhibition of the OATP1B1-mediated transport of 2.5 microM 8-FcA,,,,,,human,mbds0010,,2013-11-04 02:46:14
mbbd000141703,mbcd0003075,mbtp000012,mbrf0002232,,=,,,inhibitor,25,0.053,microM,0.005,estrone 3 sulfate,,,Inhibition of the OATP1B1-mediated transport of 2.5 microM 8-FcA,,,,,,human,mbds0010,,2013-11-04 02:46:13
mbbd000141706,mbcd0003075,mbtp000012,mbrf0001691,,=,,,substrate,28,0.23,microM,,estrone 3 sulfate,,,"CHO cells; high affinity, low capacity component of a biphasic concentration dependence (compound concentrations are approximate)",CHO,,0.05-5,microM,,human,mbds0010,,2013-11-03 23:46:07
mbbd000141707,mbcd0003075,mbtp000012,mbrf0001691,,=,,,substrate,28,45.0,microM,,estrone 3 sulfate,,,"CHO cells; low affinity, high capacity component of a biphasic concentration dependence (compound concentrations are approximate)",CHO,,5-50,microM,,human,mbds0010,,2013-11-03 23:46:07
mbbd000141708,mbcd0029629,mbtp000012,mbrf0002232,,=,,,inhibitor,25,1.14,microM,0.13,glibenclamide,,,Inhibition of the OATP1B1-mediated transport of 2.5 microM 8-FcA,,,,,,human,mbds0010,,2013-11-04 02:46:13
mbbd000141709,mbcd0029629,mbtp000012,mbrf0002232,,=,,,inhibitor,29,0.75,microM,,glibenclamide,,,Inhibition of the OATP1B1-mediated transport of 2.5 microM 8-FcA,,,,,,human,mbds0010,,2013-11-04 02:46:12
mbbd000141710,mbcd0001416,mbtp000012,mbrf0002232,,=,,,inhibitor,25,0.99,microM,0.07,rifampicin,,,Inhibition of the OATP1B1-mediated transport of 2.5 microM 8-FcA,,,,,,human,mbds0010,,2013-11-04 02:46:12
mbbd000141712,mbcd0001416,mbtp000012,mbrf0002232,,=,,,inhibitor,29,0.48,microM,,rifampicin,,,Inhibition of the OATP1B1-mediated transport of 2.5 microM 8-FcA,,,,,,human,mbds0010,,2013-11-04 02:46:12
mbbd000141713,mbcd0003957,mbtp000012,mbrf0002232,,=,,,inhibitor,25,3.85,microM,0.88,thyroxine,,,Inhibition of the OATP1B1-mediated transport of 2.5 microM 8-FcA,,,,,,human,mbds0010,,2013-11-04 02:46:11
mbbd000141715,mbcd0003035,mbtp000013,mbrf0002232,,=,,,inhibitor,25,0.51,microM,0.02,bromosulfophthalein,,,Inhibition of the OATP1B3-mediated transport of 2.5 microM 8-FcA,,,,,,human,mbds0010,,2013-11-04 02:46:09
mbbd000141717,mbcd0000311,mbtp000013,mbrf0002232,,=,,,inhibitor,25,0.2,microM,0.02,cyclosporin A,,,Inhibition of the OATP1B3-mediated transport of 2.5 microM 8-FcA,,,,,,human,mbds0010,,2013-11-04 02:46:09
mbbd000141719,mbcd0000387,mbtp000013,mbrf0002232,,=,,,inhibitor,25,23.5,microM,1.59,estradiol 17beta d glucuronide,,,Inhibition of the OATP1B3-mediated transport of 2.5 microM 8-FcA,,,,,,human,mbds0010,,2013-11-04 02:46:09
mbbd000141720,mbcd0000387,mbtp000013,mbrf0001902,,=,,,substrate,28,15.8,microM,2.5,estradiol 17beta d glucuronide,,,CHO expressing OATP1B1,CHO,,2-50,microM,,human,mbds0010,,2013-11-23 21:43:11
mbbd000141721,mbcd0000387,mbtp000013,mbrf0002232,,=,,,inhibitor,29,24.6,microM,,estradiol 17beta d glucuronide,,,Inhibition of the OATP1B3-mediated transport of 2.5 microM 8-FcA,,,,,,human,mbds0010,,2013-11-04 02:46:10
mbbd000141722,mbcd0003075,mbtp000013,mbrf0002232,,=,,,inhibitor,25,20.1,microM,1.00,estrone 3 sulfate,,,Inhibition of the OATP1B3-mediated transport of 2.5 microM 8-FcA,,,,,,human,mbds0010,,2013-11-04 02:46:10
mbbd000141724,mbcd0029629,mbtp000013,mbrf0002232,,=,,,inhibitor,25,2.69,microM,0.12,glibenclamide,,,Inhibition of the OATP1B3-mediated transport of 2.5 microM 8-FcA,,,,,,human,mbds0010,,2013-11-04 02:46:10
mbbd000141725,mbcd0001416,mbtp000013,mbrf0002232,,=,,,inhibitor,25,0.65,microM,0.02,rifampicin,,,Inhibition of the OATP1B3-mediated transport of 2.5 microM 8-FcA,,,,,,human,mbds0010,,2013-11-04 02:46:10
mbbd000141727,mbcd0001416,mbtp000013,mbrf0002232,,=,,,inhibitor,29,1.45,microM,,rifampicin,,,Inhibition of the OATP1B3-mediated transport of 2.5 microM 8-FcA,,,,,,human,mbds0010,,2013-11-04 02:46:11
mbbd000141728,mbcd0003957,mbtp000013,mbrf0002232,,=,,,inhibitor,25,2.13,microM,0.17,thyroxine,,,Inhibition of the OATP1B3-mediated transport of 2.5 microM 8-FcA,,,,,,human,mbds0010,,2013-11-04 02:46:11
mbbd000141729,mbcd0003498,mbtp000012,mbrf0001715,,=,,,substrate,28,262.0,microM,35,enalapril,,,HEK293 OATP1B1 cells,HEK293,,,,,human,mbds0010,,2013-11-24 23:13:40
mbbd000141730,mbcd0003957,mbtp000013,mbrf0001715,,,,,substrate,,,,,enalapril,,,HEK293 OATP1B1 cells,HEK293,,,,,human,mbds0010,,2013-11-24 23:13:40
mbbd000141731,mbcd0029786,mbtp000012,mbrf0002231,,,,,substrate,,,,,FL-methotrexate,,,HEK293 cells,HEK293,,1,microM,,human,mbds0010,,2013-11-10 04:16:03
mbbd000141732,mbcd0000387,mbtp000012,mbrf0001689,,=,,,substrate,28,5.9,microM,1.2,Estradiol-17beta-glucuronide,,,CHO-OATP1B1 cells,CHO,,,,,human,mbds0010,,2013-11-24 23:15:22
mbbd000141733,mbcd0029787,mbtp000012,mbrf0001689,,=,,,inhibitor,29,374.0,microM,123,5 alpha androstane,competitive inhibitor,,CHO-OATP1B1 cells,,,,,,human,mbds0010,,2013-12-05 23:09:47
mbbd000141734,mbcd0019138,mbtp000012,mbrf0001689,,=,,,inhibitor,29,45.2,microM,5.9,bezafibrate,competitive inhibitor,,CHO-OATP1B1 cells,,,,,,human,mbds0010,,2013-12-05 23:09:46
mbbd000141735,mbcd0000254,mbtp000012,mbrf0001689,,=,,,inhibitor,29,3.4,microM,0.5,chenodeoxycholic acid,competitive inhibitor,,CHO-OATP1B1 cells,,,,,,human,mbds0010,,2013-12-05 23:09:46
mbbd000141736,mbcd0001640,mbtp000012,mbrf0001689,,=,,,inhibitor,29,25.0,microM,3.3,cholic acid,competitive inhibitor,,CHO-OATP1B1 cells,,,,,,human,mbds0010,,2013-12-05 23:09:46
mbbd000141737,mbcd0002493,mbtp000012,mbrf0001689,,=,,,inhibitor,29,7.6,microM,1.9,clotrimazole,competitive inhibitor,,CHO-OATP1B1 cells,,,,,,human,mbds0010,,2013-12-05 23:09:46
mbbd000141738,mbcd0029788,mbtp000012,mbrf0001689,,=,,,inhibitor,29,29.7,microM,5.7,dehydrocholic acid,competitive inhibitor,,CHO-OATP1B1 cells,,,,,,human,mbds0010,,2013-12-05 23:09:46
mbbd000141739,mbcd0001655,mbtp000012,mbrf0001689,,=,,,inhibitor,29,3.2,microM,0.5,deoxycholic acid,competitive inhibitor,,CHO-OATP1B1 cells,,,,,,human,mbds0010,,2013-12-05 23:09:46
mbbd000141740,mbcd0003055,mbtp000012,mbrf0001689,,=,,,inhibitor,29,3.3,microM,0.6,estradiol,competitive inhibitor,,CHO-OATP1B1 cells,CHO,,,,,human,mbds0010,,2013-12-05 23:09:46
mbbd000141741,mbcd0003075,mbtp000012,mbrf0001689,,=,,,inhibitor,29,0.2,microM,0.02,estrone 3 sulfate,competitive inhibitor,,CHO-OATP1B1 cells,,,,,,human,mbds0010,,2013-12-05 23:09:47
mbbd000141742,mbcd0003027,mbtp000012,mbrf0001689,,=,,,inhibitor,29,105.2,microM,26.7,fenofibrate,competitive inhibitor,,CHO-OATP1B1 cells,,,,,,human,mbds0010,,2013-12-05 23:09:47
mbbd000141743,mbcd0000455,mbtp000012,mbrf0001689,,=,,,inhibitor,29,22.2,microM,3.9,glycocholic acid,competitive inhibitor,,CHO-OATP1B1 cells,,,,,,human,mbds0010,,2013-12-05 23:09:47
mbbd000141744,mbcd0010886,mbtp000012,mbrf0001689,,=,,,inhibitor,29,0.3,microM,0.05,GW1929,competitive inhibitor,,CHO-OATP1B1 cells,,,,,,human,mbds0010,,2013-12-05 23:09:47
mbbd000141745,mbcd0000466,mbtp000012,mbrf0001689,,=,,,inhibitor,29,32.4,microM,6.7,GW4064,competitive inhibitor,,CHO-OATP1B1 cells,,,,,,human,mbds0010,,2013-12-05 23:09:47
mbbd000141746,mbcd0027721,mbtp000012,mbrf0001689,,=,,,inhibitor,29,1.2,microM,0.2,lithocholic acid,competitive inhibitor,,CHO-OATP1B1 cells,,,,,,human,mbds0010,,2013-12-05 23:09:47
mbbd000141747,mbcd0025591,mbtp000012,mbrf0001689,,=,,,inhibitor,29,12.7,microM,1.9,mevinolin,competitive inhibitor,,CHO-OATP1B1 cells,,,,,,human,mbds0010,,2013-12-05 23:09:47
mbbd000141748,mbcd0001299,mbtp000012,mbrf0001689,,=,,,inhibitor,29,2.2,microM,0.3,mifepristone,competitive inhibitor,,CHO-OATP1B1 cells,,,,,,human,mbds0010,,2013-12-05 23:09:47
mbbd000141749,mbcd0003126,mbtp000012,mbrf0001689,,=,,,inhibitor,29,21.8,microM,3.6,pravastatin,competitive inhibitor,,CHO-OATP1B1 cells,,,,,,human,mbds0010,,2013-12-05 23:09:47
mbbd000141750,mbcd0001664,mbtp000012,mbrf0001689,,=,,,inhibitor,29,11.4,microM,3.2,taurocholic acid,competitive inhibitor,,CHO-OATP1B1 cells,,,,,,human,mbds0010,,2013-12-05 23:09:47
mbbd000141751,mbcd0003957,mbtp000012,mbrf0001689,,=,,,inhibitor,29,3.5,microM,0.7,thyroxine,competitive inhibitor,,CHO-OATP1B1 cells,,,,,,human,mbds0010,,2013-12-05 23:09:47
mbbd000141752,mbcd0003895,mbtp000012,mbrf0001689,,=,,,inhibitor,29,1.0,microM,0.18,troglitazone,competitive inhibitor,,CHO-OATP1B1 cells,,,,,,human,mbds0010,,2013-12-05 23:09:47
mbbd000141753,mbcd0013017,mbtp000012,mbrf0001689,,=,,,inhibitor,29,1.6,microM,0.11,WY-14643,competitive inhibitor,,CHO-OATP1B1 cells,,,,,,human,mbds0010,,2013-12-05 23:10:15
mbbd000141754,mbcd0001904,mbtp000012,mbrf0002408,,=,,,inhibitor,3,63.0,%,3,repaglinide,,,human hepatocytes expressing both OATP1B1 and OATP1B3; Inhibition (>30%) of uptake of 1microM E217betaG into cryopreserved human hepatocytes by 20microM compounds,,,,,,human,mbds0010,,2013-11-24 07:52:52
mbbd000141755,mbcd0020017,mbtp000012,mbrf0002408,,=,,,inhibitor,3,57.0,%,12,capsazepine,,,human hepatocytes expressing both OATP1B1 and OATP1B3; Inhibition (>30%) of uptake of 1microM E217betaG into cryopreserved human hepatocytes by 20microM compounds,,,,,,human,mbds0010,,2013-11-24 07:52:53
mbbd000141756,mbcd0007987,mbtp000012,mbrf0002408,,=,,,inhibitor,3,53.0,%,19,zopiclone,,,human hepatocytes expressing both OATP1B1 and OATP1B3; Inhibition (>30%) of uptake of 1microM E217betaG into cryopreserved human hepatocytes by 20microM compounds,,,,,,human,mbds0010,,2013-11-24 07:52:53
mbbd000141757,mbcd0029790,mbtp000012,mbrf0002408,,=,,,inhibitor,3,52.0,%,5,bromocriptine mesylate,,,human hepatocytes expressing both OATP1B1 and OATP1B3; Inhibition (>30%) of uptake of 1microM E217betaG into cryopreserved human hepatocytes by 20microM compounds,,,,,,human,mbds0010,,2013-11-24 07:52:53
mbbd000141758,mbcd0003025,mbtp000012,mbrf0002408,,=,,,inhibitor,3,47.0,%,17,indomethacin,,,human hepatocytes expressing both OATP1B1 and OATP1B3; Inhibition (>30%) of uptake of 1microM E217betaG into cryopreserved human hepatocytes by 20microM compounds,,,,,,human,mbds0010,,2013-11-24 07:52:53
mbbd000141759,mbcd0023817,mbtp000012,mbrf0002408,,=,,,inhibitor,3,45.0,%,10,phenylbutazone,,,human hepatocytes expressing both OATP1B1 and OATP1B3; Inhibition (>30%) of uptake of 1microM E217betaG into cryopreserved human hepatocytes by 20microM compounds,,,,,,human,mbds0010,,2013-11-24 07:52:54
mbbd000141760,mbcd0017104,mbtp000012,mbrf0002408,,=,,,inhibitor,3,44.0,%,12,ketoconazole,,,human hepatocytes expressing both OATP1B1 and OATP1B3; Inhibition (>30%) of uptake of 1microM E217betaG into cryopreserved human hepatocytes by 20microM compounds,,,,,,human,mbds0010,,2013-11-24 07:52:54
mbbd000141761,mbcd0003021,mbtp000012,mbrf0002408,,=,,,inhibitor,3,41.0,%,20,loratadine,,,human hepatocytes expressing both OATP1B1 and OATP1B3; Inhibition (>30%) of uptake of 1microM E217betaG into cryopreserved human hepatocytes by 20microM compounds,,,,,,human,mbds0010,,2013-11-24 07:52:54
mbbd000141762,mbcd0014045,mbtp000012,mbrf0002408,,=,,,inhibitor,3,38.0,%,7,domperidon,,,human hepatocytes expressing both OATP1B1 and OATP1B3; Inhibition (>30%) of uptake of 1microM E217betaG into cryopreserved human hepatocytes by 20microM compounds,,,,,,human,mbds0010,,2013-11-24 07:52:54
mbbd000141763,mbcd0003911,mbtp000012,mbrf0002408,,=,,,inhibitor,3,37.0,%,2,papaverine,,,human hepatocytes expressing both OATP1B1 and OATP1B3; Inhibition (>30%) of uptake of 1microM E217betaG into cryopreserved human hepatocytes by 20microM compounds,,,,,,human,mbds0010,,2013-11-24 07:52:54
mbbd000141764,mbcd0025582,mbtp000012,mbrf0002408,,=,,,inhibitor,3,36.0,%,20,nefazodone,,,human hepatocytes expressing both OATP1B1 and OATP1B3; Inhibition (>30%) of uptake of 1microM E217betaG into cryopreserved human hepatocytes by 20microM compounds,,,,,,human,mbds0010,,2013-11-24 07:52:55
mbbd000141765,mbcd0029791,mbtp000012,mbrf0002408,,=,,,inhibitor,3,34.0,%,4,demeclocycline,,,human hepatocytes expressing both OATP1B1 and OATP1B3; Inhibition (>30%) of uptake of 1microM E217betaG into cryopreserved human hepatocytes by 20microM compounds,,,,,,human,mbds0010,,2013-11-24 07:52:55
mbbd000141766,mbcd0003094,mbtp000012,mbrf0002408,,=,,,inhibitor,3,34.0,%,20,spironolactone,,,human hepatocytes expressing both OATP1B1 and OATP1B3; Inhibition (>30%) of uptake of 1microM E217betaG into cryopreserved human hepatocytes by 20microM compounds,,,,,,human,mbds0010,,2013-11-24 07:52:55
mbbd000141767,mbcd0020658,mbtp000012,mbrf0002408,,=,,,inhibitor,3,31.0,%,9,clorgyline,,,human hepatocytes expressing both OATP1B1 and OATP1B3; Inhibition (>30%) of uptake of 1microM E217betaG into cryopreserved human hepatocytes by 20microM compounds,,,,,,human,mbds0010,,2013-11-24 07:52:55
mbbd000141768,mbcd0029792,mbtp000012,mbrf0002408,,=,,,inhibitor,3,30.0,%,6,dantrolene sodium,,,human hepatocytes expressing both OATP1B1 and OATP1B3; Inhibition (>30%) of uptake of 1microM E217betaG into cryopreserved human hepatocytes by 20microM compounds,,,,,,human,mbds0010,,2013-11-24 07:52:56
mbbd000141769,mbcd0021691,mbtp000012,mbrf0002408,,=,,,inhibitor,3,30.0,%,11,norepinephrine,,,human hepatocytes expressing both OATP1B1 and OATP1B3; Inhibition (>30%) of uptake of 1microM E217betaG into cryopreserved human hepatocytes by 20microM compounds,,,,,,human,mbds0010,,2013-11-24 07:52:56
mbbd000141770,mbcd0001904,mbtp000013,mbrf0002408,,=,,,inhibitor,3,63.0,%,3,repaglinide,,,human hepatocytes expressing both OATP1B1 and OATP1B3; Inhibition (>30%) of uptake of 1microM E217betaG into cryopreserved human hepatocytes by 20microM compounds,,,,,,human,mbds0010,,2013-11-24 07:52:56
mbbd000141771,mbcd0020017,mbtp000013,mbrf0002408,,=,,,inhibitor,3,57.0,%,12,capsazepine,,,human hepatocytes expressing both OATP1B1 and OATP1B3; Inhibition (>30%) of uptake of 1microM E217betaG into cryopreserved human hepatocytes by 20microM compounds,,,,,,human,mbds0010,,2013-11-24 07:52:56
mbbd000141772,mbcd0007987,mbtp000013,mbrf0002408,,=,,,inhibitor,3,53.0,%,19,zopiclone,,,human hepatocytes expressing both OATP1B1 and OATP1B3; Inhibition (>30%) of uptake of 1microM E217betaG into cryopreserved human hepatocytes by 20microM compounds,,,,,,human,mbds0010,,2013-11-24 07:52:57
mbbd000141773,mbcd0029790,mbtp000013,mbrf0002408,,=,,,inhibitor,3,52.0,%,5,bromocriptine mesylate,,,human hepatocytes expressing both OATP1B1 and OATP1B3; Inhibition (>30%) of uptake of 1microM E217betaG into cryopreserved human hepatocytes by 20microM compounds,,,,,,human,mbds0010,,2013-11-24 07:52:57
mbbd000141774,mbcd0003025,mbtp000013,mbrf0002408,,=,,,inhibitor,3,47.0,%,17,indomethacin,,,human hepatocytes expressing both OATP1B1 and OATP1B3; Inhibition (>30%) of uptake of 1microM E217betaG into cryopreserved human hepatocytes by 20microM compounds,,,,,,human,mbds0010,,2013-11-24 07:52:57
mbbd000141775,mbcd0023817,mbtp000013,mbrf0002408,,=,,,inhibitor,3,45.0,%,10,phenylbutazone,,,human hepatocytes expressing both OATP1B1 and OATP1B3; Inhibition (>30%) of uptake of 1microM E217betaG into cryopreserved human hepatocytes by 20microM compounds,,,,,,human,mbds0010,,2013-11-24 07:52:57
mbbd000141776,mbcd0017104,mbtp000013,mbrf0002408,,=,,,inhibitor,3,44.0,%,12,ketoconazole,,,human hepatocytes expressing both OATP1B1 and OATP1B3; Inhibition (>30%) of uptake of 1microM E217betaG into cryopreserved human hepatocytes by 20microM compounds,,,,,,human,mbds0010,,2013-11-24 07:52:58
mbbd000141777,mbcd0003021,mbtp000013,mbrf0002408,,=,,,inhibitor,3,41.0,%,20,loratadine,,,human hepatocytes expressing both OATP1B1 and OATP1B3; Inhibition (>30%) of uptake of 1microM E217betaG into cryopreserved human hepatocytes by 20microM compounds,,,,,,human,mbds0010,,2013-11-24 07:52:58
mbbd000141778,mbcd0014045,mbtp000013,mbrf0002408,,=,,,inhibitor,3,38.0,%,7,domperidon,,,human hepatocytes expressing both OATP1B1 and OATP1B3; Inhibition (>30%) of uptake of 1microM E217betaG into cryopreserved human hepatocytes by 20microM compounds,,,,,,human,mbds0010,,2013-11-24 07:52:58
mbbd000141779,mbcd0003911,mbtp000013,mbrf0002408,,=,,,inhibitor,3,37.0,%,2,papaverine,,,human hepatocytes expressing both OATP1B1 and OATP1B3; Inhibition (>30%) of uptake of 1microM E217betaG into cryopreserved human hepatocytes by 20microM compounds,,,,,,human,mbds0010,,2013-11-24 07:52:58
mbbd000141780,mbcd0025582,mbtp000013,mbrf0002408,,=,,,inhibitor,3,36.0,%,20,nefazodone,,,human hepatocytes expressing both OATP1B1 and OATP1B3; Inhibition (>30%) of uptake of 1microM E217betaG into cryopreserved human hepatocytes by 20microM compounds,,,,,,human,mbds0010,,2013-11-24 07:52:59
mbbd000141781,mbcd0029791,mbtp000013,mbrf0002408,,=,,,inhibitor,3,34.0,%,4,demeclocycline,,,human hepatocytes expressing both OATP1B1 and OATP1B3; Inhibition (>30%) of uptake of 1microM E217betaG into cryopreserved human hepatocytes by 20microM compounds,,,,,,human,mbds0010,,2013-11-24 07:52:59
mbbd000141782,mbcd0003094,mbtp000013,mbrf0002408,,=,,,inhibitor,3,34.0,%,20,spironolactone,,,human hepatocytes expressing both OATP1B1 and OATP1B3; Inhibition (>30%) of uptake of 1microM E217betaG into cryopreserved human hepatocytes by 20microM compounds,,,,,,human,mbds0010,,2013-11-24 07:52:59
mbbd000141783,mbcd0020658,mbtp000013,mbrf0002408,,=,,,inhibitor,3,31.0,%,9,clorgyline,,,human hepatocytes expressing both OATP1B1 and OATP1B3; Inhibition (>30%) of uptake of 1microM E217betaG into cryopreserved human hepatocytes by 20microM compounds,,,,,,human,mbds0010,,2013-11-24 07:52:59
mbbd000141784,mbcd0029792,mbtp000013,mbrf0002408,,=,,,inhibitor,3,30.0,%,6,dantrolene sodium,,,human hepatocytes expressing both OATP1B1 and OATP1B3; Inhibition (>30%) of uptake of 1microM E217betaG into cryopreserved human hepatocytes by 20microM compounds,,,,,,human,mbds0010,,2013-11-24 07:53:00
mbbd000141785,mbcd0021691,mbtp000013,mbrf0002408,,=,,,inhibitor,3,30.0,%,11,norepinephrine,,,human hepatocytes expressing both OATP1B1 and OATP1B3; Inhibition (>30%) of uptake of 1microM E217betaG into cryopreserved human hepatocytes by 20microM compounds,,,,,,human,mbds0010,,2013-11-24 07:53:00
mbbd000141786,mbcd0020017,mbtp000012,mbrf0002408,,=,,,inhibitor,29,14.0,microM,5,capsazepine,,,human hepatocytes expressing both OATP1B1 and OATP1B3; Inhibition (>30%) of uptake of 1microM E217betaG into cryopreserved human hepatocytes,,,,,,human,mbds0010,,2013-11-24 07:53:00
mbbd000141787,mbcd0020658,mbtp000012,mbrf0002408,,=,,,inhibitor,29,156.0,microM,23,clorgyline,,,human hepatocytes expressing both OATP1B1 and OATP1B3; Inhibition (>30%) of uptake of 1microM E217betaG into cryopreserved human hepatocytes,,,,,,human,mbds0010,,2013-11-24 07:53:00
mbbd000141788,mbcd0029792,mbtp000012,mbrf0002408,,=,,,inhibitor,29,40.0,microM,10,dantrolene sodium,,,human hepatocytes expressing both OATP1B1 and OATP1B3; Inhibition (>30%) of uptake of 1microM E217betaG into cryopreserved human hepatocytes,,,,,,human,mbds0010,,2013-11-24 07:53:01
mbbd000141789,mbcd0014045,mbtp000012,mbrf0002408,,=,,,inhibitor,29,74.0,microM,52,domperidon,,,human hepatocytes expressing both OATP1B1 and OATP1B3; Inhibition (>30%) of uptake of 1microM E217betaG into cryopreserved human hepatocytes,,,,,,human,mbds0010,,2013-11-24 07:53:01
mbbd000141791,mbcd0018094,mbtp000012,mbrf0002408,,=,,,inhibitor,29,61.0,microM,34,linopirdine,,,human hepatocytes expressing both OATP1B1 and OATP1B3; Inhibition (>30%) of uptake of 1microM E217betaG into cryopreserved human hepatocytes,,,,,,human,mbds0010,,2013-11-24 07:53:01
mbbd000141792,mbcd0003021,mbtp000012,mbrf0002408,,=,,,inhibitor,29,19.0,microM,5,loratadine,,,human hepatocytes expressing both OATP1B1 and OATP1B3; Inhibition (>30%) of uptake of 1microM E217betaG into cryopreserved human hepatocytes,,,,,,human,mbds0010,,2013-11-24 07:53:02
mbbd000141793,mbcd0025582,mbtp000012,mbrf0002408,,=,,,inhibitor,29,20.0,microM,7,nefazodone,,,human hepatocytes expressing both OATP1B1 and OATP1B3; Inhibition (>30%) of uptake of 1microM E217betaG into cryopreserved human hepatocytes,,,,,,human,mbds0010,,2013-11-24 07:53:02
mbbd000141794,mbcd0003911,mbtp000012,mbrf0002408,,=,,,inhibitor,29,65.0,microM,20,papaverine,,,human hepatocytes expressing both OATP1B1 and OATP1B3; Inhibition (>30%) of uptake of 1microM E217betaG into cryopreserved human hepatocytes,,,,,,human,mbds0010,,2013-11-24 07:53:03
mbbd000141795,mbcd0023817,mbtp000012,mbrf0002408,,=,,,inhibitor,29,43.0,microM,30,phenylbutazone,,,human hepatocytes expressing both OATP1B1 and OATP1B3; Inhibition (>30%) of uptake of 1microM E217betaG into cryopreserved human hepatocytes,,,,,,human,mbds0010,,2013-11-24 07:53:03
mbbd000141796,mbcd0003154,mbtp000012,mbrf0002408,,=,,,inhibitor,29,110.0,microM,40,probenecid,,,human hepatocytes expressing both OATP1B1 and OATP1B3; Inhibition (>30%) of uptake of 1microM E217betaG into cryopreserved human hepatocytes,,,,,,human,mbds0010,,2013-11-24 07:53:03
mbbd000141797,mbcd0007987,mbtp000012,mbrf0002408,,=,,,inhibitor,29,260.0,microM,497,zopiclone,,,human hepatocytes expressing both OATP1B1 and OATP1B3; Inhibition (>30%) of uptake of 1microM E217betaG into cryopreserved human hepatocytes,,,,,,human,mbds0010,,2013-11-24 07:53:03
mbbd000141798,mbcd0020017,mbtp000013,mbrf0002408,,=,,,inhibitor,29,14.0,microM,5,capsazepine,,,human hepatocytes expressing both OATP1B1 and OATP1B3; Inhibition (>30%) of uptake of 1microM E217betaG into cryopreserved human hepatocytes,,,,,,human,mbds0010,,2013-11-24 07:53:04
mbbd000141799,mbcd0020658,mbtp000013,mbrf0002408,,=,,,inhibitor,29,156.0,microM,23,clorgyline,,,human hepatocytes expressing both OATP1B1 and OATP1B3; Inhibition (>30%) of uptake of 1microM E217betaG into cryopreserved human hepatocytes,,,,,,human,mbds0010,,2013-11-24 07:53:04
mbbd000141800,mbcd0029792,mbtp000013,mbrf0002408,,=,,,inhibitor,29,40.0,microM,10,dantrolene sodium,,,human hepatocytes expressing both OATP1B1 and OATP1B3; Inhibition (>30%) of uptake of 1microM E217betaG into cryopreserved human hepatocytes,,,,,,human,mbds0010,,2013-11-24 07:53:04
mbbd000141801,mbcd0014045,mbtp000013,mbrf0002408,,=,,,inhibitor,29,74.0,microM,52,domperidon,,,human hepatocytes expressing both OATP1B1 and OATP1B3; Inhibition (>30%) of uptake of 1microM E217betaG into cryopreserved human hepatocytes,,,,,,human,mbds0010,,2013-11-24 07:53:04
mbbd000141802,mbcd0001797,mbtp000007,mbrf0002408,,<,,,non-inhibitor,3,30.0,%,,fexofenadine,,,human hepatocytes; Inhibition of uptake of 1microM MPP+ (substrate of OCT1) into cryopreserved human hepatocytes,human hepatocytes,mbcd0003022,20,microM,,human,mbds0010,,2013-12-08 07:22:54
mbbd000141803,mbcd0018094,mbtp000013,mbrf0002408,,=,,,inhibitor,29,61.0,microM,34,linopirdine,,,human hepatocytes expressing both OATP1B1 and OATP1B3; Inhibition (>30%) of uptake of 1microM E217betaG into cryopreserved human hepatocytes,,,,,,human,mbds0010,,2013-11-24 07:53:05
mbbd000141804,mbcd0003021,mbtp000013,mbrf0002408,,=,,,inhibitor,29,19.0,microM,5,loratadine,,,human hepatocytes expressing both OATP1B1 and OATP1B3; Inhibition (>30%) of uptake of 1microM E217betaG into cryopreserved human hepatocytes,,,,,,human,mbds0010,,2013-11-24 07:53:05
mbbd000141805,mbcd0025582,mbtp000013,mbrf0002408,,=,,,inhibitor,29,20.0,microM,7,nefazodone,,,human hepatocytes expressing both OATP1B1 and OATP1B3; Inhibition (>30%) of uptake of 1microM E217betaG into cryopreserved human hepatocytes,,,,,,human,mbds0010,,2013-11-24 07:53:05
mbbd000141806,mbcd0003911,mbtp000013,mbrf0002408,,=,,,inhibitor,29,65.0,microM,20,papaverine,,,human hepatocytes expressing both OATP1B1 and OATP1B3; Inhibition (>30%) of uptake of 1microM E217betaG into cryopreserved human hepatocytes,,,,,,human,mbds0010,,2013-11-24 07:53:06
mbbd000141807,mbcd0023817,mbtp000013,mbrf0002408,,=,,,inhibitor,29,43.0,microM,30,phenylbutazone,,,human hepatocytes expressing both OATP1B1 and OATP1B3; Inhibition (>30%) of uptake of 1microM E217betaG into cryopreserved human hepatocytes,,,,,,human,mbds0010,,2013-11-24 07:53:06
mbbd000141808,mbcd0003154,mbtp000013,mbrf0002408,,=,,,inhibitor,29,110.0,microM,40,probenecid,,,human hepatocytes expressing both OATP1B1 and OATP1B3; Inhibition (>30%) of uptake of 1microM E217betaG into cryopreserved human hepatocytes,,,,,,human,mbds0010,,2013-11-24 07:53:06
mbbd000141809,mbcd0007987,mbtp000013,mbrf0002408,,=,,,inhibitor,29,260.0,microM,497,zopiclone,,,human hepatocytes expressing both OATP1B1 and OATP1B3; Inhibition (>30%) of uptake of 1microM E217betaG into cryopreserved human hepatocytes,,,,,,human,mbds0010,,2013-11-24 07:53:06
mbbd000141810,mbcd0000387,mbtp000012,mbrf0001902,,=,,,substrate,28,5.4,microM,2.5,estradiol 17beta glucuronide,,,CHO expressing OATP1B1,CHO,,1-50,microM,,human,mbds0010,,2013-11-03 23:35:26
mbbd000141811,mbcd0003075,mbtp000012,mbrf0001902,,=,,,substrate,28,2.4,microM,0.8,estrone 3 sulfate,,,CHO expressing OATP1B1,CHO,,,,,human,mbds0010,,2013-11-03 23:35:26
mbbd000141812,mbcd0003155,mbtp000012,mbrf0001902,,=,,,substrate,28,2.3,microM,0.2,fluo-3,,,CHO expressing OATP1B1,CHO,,,,,human,mbds0010,,2013-11-03 23:35:27
mbbd000141813,mbcd0000387,mbtp000012,mbrf0001902,,=,,,substrate,22,360.0,pmol / mg / min,46,estradiol 17beta glucuronide,,,CHO expressing OATP1B1,CHO,,,,,human,mbds0010,,2013-11-03 23:35:27
mbbd000141814,mbcd0003075,mbtp000012,mbrf0001902,,=,,,substrate,22,340.0,pmol / mg / min,40,estrone 3 sulfate,,,CHO expressing OATP1B1,CHO,,,,,human,mbds0010,,2013-11-03 23:35:27
mbbd000141815,mbcd0003155,mbtp000012,mbrf0001902,,=,,,substrate,22,78.0,pmol / mg / min,21,fluo-3,,,CHO expressing OATP1B1,CHO,,,,,human,mbds0010,,2013-11-03 23:35:27
mbbd000141817,mbcd0003075,mbtp000013,mbrf0001902,,=,,,substrate,28,58.0,microM,20,estrone 3 sulfate,,,CHO expressing OATP1B1,CHO,,,,,human,mbds0010,,2013-11-03 23:35:28
mbbd000141818,mbcd0003155,mbtp000013,mbrf0001902,,=,,,substrate,28,3.1,microM,0.4,fluo-3,,,CHO expressing OATP1B1,CHO,,,,,human,mbds0010,,2013-11-03 23:35:28
mbbd000141819,mbcd0000387,mbtp000013,mbrf0001902,,=,,,substrate,22,360.0,pmol / mg / min,28,estradiol 17beta glucuronide,,,CHO expressing OATP1B1,CHO,,,,,human,mbds0010,,2013-11-03 23:35:29
mbbd000141820,mbcd0003075,mbtp000013,mbrf0001902,,=,,,substrate,22,1860.0,pmol / mg / min,325,estrone 3 sulfate,,,CHO expressing OATP1B1,CHO,,,,,human,mbds0010,,2013-11-03 23:35:29
mbbd000141821,mbcd0003155,mbtp000013,mbrf0001902,,=,,,substrate,22,630.0,pmol / mg / min,100,fluo-3,,,CHO expressing OATP1B1,CHO,,,,,human,mbds0010,,2013-11-03 23:35:29
mbbd000141822,mbcd0001416,mbtp000012,mbrf0001902,,=,,,inhibitor,25,1.5,microM,,rifampicin,,,inhibition of OATP1B1- and 1B3-mediated estradiol-17beta-glucuronide,CHO,,,,,human,mbds0010,,2013-11-23 21:43:23
mbbd000141823,mbcd0001532,mbtp000012,mbrf0001902,,=,,,inhibitor,25,0.03,microM,,paclitaxel,,,inhibition of OATP1B1- and 1B3-mediated estradiol-17beta-glucuronide,CHO,,,,,human,mbds0010,,2013-11-23 21:43:26
mbbd000141824,mbcd0001299,mbtp000012,mbrf0001902,,=,,,inhibitor,25,3.3,microM,,mifepristone,,,inhibition of OATP1B1- and 1B3-mediated estradiol-17beta-glucuronide,CHO,,,,,human,mbds0010,,2013-11-23 21:43:21
mbbd000141825,mbcd0025591,mbtp000012,mbrf0001902,,=,,,inhibitor,25,6.1,microM,,mevinolin,,,inhibition of OATP1B1- and 1B3-mediated estradiol-17beta-glucuronide,CHO,,,,,human,mbds0010,,2013-11-23 21:43:34
mbbd000141826,mbcd0002985,mbtp000012,mbrf0001902,,=,,,inhibitor,25,188.0,microM,,carbamazepine,,,inhibition of OATP1B1- and 1B3-mediated estradiol-17beta-glucuronide,CHO,,,,,human,mbds0010,,2013-11-23 21:43:29
mbbd000141827,mbcd0003895,mbtp000012,mbrf0001902,,=,,,inhibitor,25,1.2,microM,,troglitazone,,,inhibition of OATP1B1- and 1B3-mediated estradiol-17beta-glucuronide,CHO,,,,,human,mbds0010,,2013-11-23 21:43:32
mbbd000141828,mbcd0027721,mbtp000012,mbrf0001902,,=,,,inhibitor,25,0.7,microM,,lithocholate,,,inhibition of OATP1B1- and 1B3-mediated estradiol-17beta-glucuronide,CHO,,,,,human,mbds0010,,2013-11-23 21:43:36
mbbd000141829,mbcd0003055,mbtp000012,mbrf0001902,,=,,,inhibitor,25,3.9,microM,,estradiol,,,inhibition of OATP1B1- and 1B3-mediated estradiol-17beta-glucuronide,CHO,,,,,human,mbds0010,,2013-11-23 21:43:31
mbbd000141830,mbcd0002493,mbtp000012,mbrf0001902,,=,,,inhibitor,25,9.0,microM,,clotrimazole,,,inhibition of OATP1B1- and 1B3-mediated estradiol-17beta-glucuronide,CHO,,,,,human,mbds0010,,2013-11-23 21:43:28
mbbd000141831,mbcd0001416,mbtp000013,mbrf0001902,,=,,,inhibitor,25,2.6,microM,,rifampicin,,,inhibition of OATP1B1- and 1B3-mediated estradiol-17beta-glucuronide,CHO,,,,,human,mbds0010,,2013-11-23 21:43:23
mbbd000141832,mbcd0001532,mbtp000013,mbrf0001902,,=,,,inhibitor,25,0.5,microM,,paclitaxel,,,inhibition of OATP1B1- and 1B3-mediated estradiol-17beta-glucuronide,CHO,,,,,human,mbds0010,,2013-11-23 21:43:27
mbbd000141833,mbcd0001299,mbtp000013,mbrf0001902,,=,,,inhibitor,25,5.3,microM,,mifepristone,,,inhibition of OATP1B1- and 1B3-mediated estradiol-17beta-glucuronide,CHO,,,,,human,mbds0010,,2013-11-23 21:43:21
mbbd000141834,mbcd0025591,mbtp000013,mbrf0001902,,=,,,inhibitor,25,92.6,microM,,mevinolin,,,inhibition of OATP1B1- and 1B3-mediated estradiol-17beta-glucuronide,CHO,,,,,human,mbds0010,,2013-11-23 21:43:35
mbbd000141835,mbcd0002985,mbtp000013,mbrf0001902,,=,,,inhibitor,25,510.0,microM,,carbamazepine,,,inhibition of OATP1B1- and 1B3-mediated estradiol-17beta-glucuronide,CHO,,,,,human,mbds0010,,2013-11-23 21:43:29
mbbd000141836,mbcd0003895,mbtp000013,mbrf0001902,,=,,,inhibitor,25,15.7,microM,,troglitazone,,,inhibition of OATP1B1- and 1B3-mediated estradiol-17beta-glucuronide,CHO,,,,,human,mbds0010,,2013-11-23 21:43:32
mbbd000141837,mbcd0027721,mbtp000013,mbrf0001902,,=,,,inhibitor,25,6.8,microM,,lithocholate,,,inhibition of OATP1B1- and 1B3-mediated estradiol-17beta-glucuronide,CHO,,,,,human,mbds0010,,2013-11-23 21:43:36
mbbd000141838,mbcd0003055,mbtp000013,mbrf0001902,,=,,,inhibitor,25,12.9,microM,,estradiol,,,inhibition of OATP1B1- and 1B3-mediated estradiol-17beta-glucuronide,CHO,,,,,human,mbds0010,,2013-11-23 21:43:31
mbbd000141839,mbcd0000387,mbtp000012,mbrf0001902,,=,,,substrate,33,141.2,fmol / mg / 20 s,15.0,estradiol 17beta glucuronide,,,CHO-OATP1B1,CHO,,,,,human,mbds0010,,2013-11-04 02:52:17
mbbd000141840,mbcd0003075,mbtp000012,mbrf0001902,,=,,,substrate,33,760.9,fmol / mg / 20 s,30.3,estrone 3 sulfate,,,CHO-OATP1B1,CHO,,,,,human,mbds0010,,2013-11-04 02:52:17
mbbd000141841,mbcd0004706,mbtp000012,mbrf0001902,,=,,,substrate,33,5.9,fmol / mg / 20 s,0.4,CCK-8,,,CHO-OATP1B1,CHO,,,,,human,mbds0010,,2013-11-04 02:52:18
mbbd000141842,mbcd0002041,mbtp000012,mbrf0001902,,=,,,substrate,33,3.2,fmol / mg / 20 s,1.7,DPDPE,,,CHO-OATP1B1,CHO,,,,,human,mbds0010,,2013-11-04 02:52:18
mbbd000141843,mbcd0002466,mbtp000012,mbrf0001902,,=,,,substrate,33,216.0,fmol / mg / 20 s,50.4,etoposide,,,CHO-OATP1B1,CHO,,,,,human,mbds0010,,2013-11-04 02:52:18
mbbd000141844,mbcd0001532,mbtp000012,mbrf0001902,,=,,,substrate,33,166.5,fmol / mg / 20 s,22.9,paclitaxel,,,CHO-OATP1B1,CHO,,,,,human,mbds0010,,2013-11-04 02:52:18
mbbd000141845,mbcd0001664,mbtp000012,mbrf0001902,,=,,,substrate,33,5.2,fmol / mg / 20 s,1.5,taurocholate,,,CHO-OATP1B1,CHO,,,,,human,mbds0010,,2013-11-04 02:52:19
mbbd000141846,mbcd0003957,mbtp000012,mbrf0001902,,=,,,substrate,33,3.6,fmol / mg / 20 s,1.4,thyroxine,,,CHO-OATP1B1,CHO,,,,,human,mbds0010,,2013-11-04 02:52:19
mbbd000141847,mbcd0000387,mbtp000013,mbrf0001902,,=,,,substrate,33,40.7,fmol / mg / 20 s,6.1,estradiol 17beta glucuronide,,,CHO-OATP1B1,CHO,,,,,human,mbds0010,,2013-11-04 02:52:19
mbbd000141848,mbcd0003075,mbtp000013,mbrf0001902,,=,,,substrate,33,43.9,fmol / mg / 20 s,3.7,estrone 3 sulfate,,,CHO-OATP1B1,CHO,,,,,human,mbds0010,,2013-11-04 02:52:20
mbbd000141849,mbcd0004706,mbtp000013,mbrf0001902,,=,,,substrate,33,80.1,fmol / mg / 20 s,4.2,CCK-8,,,CHO-OATP1B1,CHO,,,,,human,mbds0010,,2013-11-04 02:52:20
mbbd000141850,mbcd0002041,mbtp000013,mbrf0001902,,=,,,substrate,33,21.8,fmol / mg / 20 s,2.2,DPDPE,,,CHO-OATP1B1,CHO,,,,,human,mbds0010,,2013-11-04 02:52:20
mbbd000141851,mbcd0002466,mbtp000013,mbrf0001902,,=,,,substrate,33,452.6,fmol / mg / 20 s,55.8,etoposide,,,CHO-OATP1B1; uptake of tracer compounds was determined under initial linear rates (20 s) ,CHO,,,,,human,mbds0010,,2014-02-25 06:13:51
mbbd000141852,mbcd0001532,mbtp000013,mbrf0001902,,=,,,substrate,33,173.8,fmol / mg / 20 s,24.2,paclitaxel,,,CHO-OATP1B1,CHO,,,,,human,mbds0010,,2013-11-04 02:52:21
mbbd000141853,mbcd0001664,mbtp000013,mbrf0001902,,=,,,substrate,33,30.1,fmol / mg / 20 s,4.1,taurocholate,,,CHO-OATP1B1,CHO,,,,,human,mbds0010,,2013-11-04 02:52:21
mbbd000141854,mbcd0003957,mbtp000013,mbrf0001902,,=,,,substrate,33,3.3,fmol / mg / 20 s,1.0,thyroxine,,,CHO-OATP1B1,CHO,,,,,human,mbds0010,,2013-11-04 02:52:21
mbbd000141855,mbcd0002493,mbtp000012,mbrf0001902,,=,,,inhibitor,3,27.69,%,,clotrimazole,,,CHO-OATP1B1; inhibition of estradiol 17beta glucuronide uptake; 50microM inhibitor concentration,CHO,mbcd0000387,,,,human,mbds0010,,2013-11-23 21:43:13
mbbd000141856,mbcd0002493,mbtp000012,mbrf0001902,,=,,,inhibitor,3,48.04,%,,clotrimazole,,,CHO-OATP1B1; inhibition of estradiol estrone 3 sulfate uptake; 50microM inhibitor concentration,CHO,mbcd0003075,,,,human,mbds0010,,2013-11-23 21:43:13
mbbd000141857,mbcd0002493,mbtp000012,mbrf0001902,,=,,,inhibitor,3,16.95,%,,clotrimazole,,,CHO-OATP1B1; inhibition of estradiol CCK-8 uptake; 50microM inhibitor concentration,CHO,mbcd0004706,,,,human,mbds0010,,2013-11-23 21:43:14
mbbd000141858,mbcd0002493,mbtp000012,mbrf0001902,,=,,,inhibitor,3,31.25,%,,clotrimazole,,,CHO-OATP1B1; inhibition of estradiol DPDPE uptake; 50microM inhibitor concentration,CHO,mbcd0002041,,,,human,mbds0010,,2013-11-23 21:43:15
mbbd000141859,mbcd0002493,mbtp000012,mbrf0001902,,=,,,inhibitor,3,34.58,%,,clotrimazole,,,CHO-OATP1B1; inhibition of estradiol etoposide uptake; 50microM inhibitor concentration,CHO,mbcd0002466,,,,human,mbds0010,,2013-11-23 21:43:16
mbbd000141860,mbcd0002493,mbtp000012,mbrf0001902,,=,,,inhibitor,3,9.97,%,,clotrimazole,,,CHO-OATP1B1; inhibition of estradiol paclitaxel uptake; 50microM inhibitor concentration,CHO,mbcd0001532,,,,human,mbds0010,,2013-11-23 21:43:16
mbbd000141861,mbcd0002493,mbtp000012,mbrf0001902,,=,,,inhibitor,3,26.92,%,,clotrimazole,,,CHO-OATP1B1; inhibition of estradiol taurocholate uptake; 50microM inhibitor concentration,CHO,mbcd0001664,,,,human,mbds0010,,2013-11-23 21:43:17
mbbd000141862,mbcd0002493,mbtp000012,mbrf0001902,,=,,,inhibitor,3,27.78,%,,clotrimazole,,,CHO-OATP1B1; inhibition of estradiol thyroxine uptake; 50microM inhibitor concentration,CHO,mbcd0026839,,,,human,mbds0010,,2013-11-23 21:43:17
mbbd000141863,mbcd0002493,mbtp000013,mbrf0001902,,=,,,inducer,3,254.3,%,,clotrimazole,,,CHO-OATP1B3; inhibition of estradiol 17beta glucuronide uptake; 50microM inhibitor concentration,CHO,mbcd0000387,,,,human,mbds0010,,2013-11-23 21:43:13
mbbd000141864,mbcd0002493,mbtp000013,mbrf0001902,,=,,,inducer,3,116.4,%,,clotrimazole,,,CHO-OATP1B3; inhibition of estradiol estrone 3 sulfate uptake; 50microM inhibitor concentration,CHO,mbcd0003075,,,,human,mbds0010,,2013-11-23 21:43:14
mbbd000141865,mbcd0002493,mbtp000013,mbrf0001902,,=,,,inhibitor,3,81.02,%,,clotrimazole,,,CHO-OATP1B3; inhibition of estradiol CCK-8 uptake; 50microM inhibitor concentration,CHO,mbcd0004706,,,,human,mbds0010,,2013-11-23 21:43:14
mbbd000141866,mbcd0002493,mbtp000013,mbrf0001902,,=,,,inhibitor,3,50.46,%,,clotrimazole,,,CHO-OATP1B3; inhibition of estradiol DPDPE uptake; 50microM inhibitor concentration,CHO,mbcd0002041,,,,human,mbds0010,,2013-11-23 21:43:15
mbbd000141867,mbcd0002493,mbtp000013,mbrf0001902,,=,,,inhibitor,3,56.89,%,,clotrimazole,,,CHO-OATP1B3; inhibition of estradiol etoposide uptake; 50microM inhibitor concentration,CHO,mbcd0002466,,,,human,mbds0010,,2013-11-23 21:43:16
mbbd000141868,mbcd0002493,mbtp000013,mbrf0001902,,=,,,inhibitor,3,9.44,%,,clotrimazole,,,CHO-OATP1B3; inhibition of estradiol paclitaxel uptake; 50microM inhibitor concentration,CHO,mbcd0001532,,,,human,mbds0010,,2013-11-23 21:43:16
mbbd000141869,mbcd0002493,mbtp000013,mbrf0001902,,=,,,inhibitor,3,54.82,%,,clotrimazole,,,CHO-OATP1B3; inhibition of estradiol taurocholate uptake; 50microM inhibitor concentration,CHO,mbcd0001664,,,,human,mbds0010,,2013-11-23 21:43:17
mbbd000141870,mbcd0002493,mbtp000013,mbrf0001902,,=,,,inhibitor,3,6.06,%,,clotrimazole,,,CHO-OATP1B3; inhibition of estradiol thyroxine uptake; 50microM inhibitor concentration,CHO,mbcd0026839,,,,human,mbds0010,,2013-11-23 21:43:18
mbbd000141871,mbcd0001416,mbtp000013,mbrf0001902,,~,,,inhibitor,33,10.0,%,,rifampicin,,,inhibition of 1 microM estradiol 17beta glucuronide uptake into OATP1B1 expressing CHO cells,CHO,,10,microM,,human,mbds0010,,2013-11-23 21:43:25
mbbd000141872,mbcd0001416,mbtp000013,mbrf0001902,,~,,,inhibitor,33,1.0,%,,rifampicin,,,inhibition of 1 microM estradiol 17beta glucuronide uptake into OATP1B1 expressing CHO cells,CHO,,100,microM,,human,mbds0010,,2013-11-23 21:43:25
mbbd000141873,mbcd0002996,mbtp000013,mbrf0001902,,~,,,non-inhibitor,33,92.0,%,,phenytoin,,,inhibition of 1 microM estradiol 17beta glucuronide uptake into OATP1B3 expressing CHO cells,CHO,,10,microM,,human,mbds0010,,2013-11-23 21:43:20
mbbd000141874,mbcd0002996,mbtp000013,mbrf0001902,,~,,,non-inhibitor,33,85.0,%,,phenytoin,,,inhibition of 1 microM estradiol 17beta glucuronide uptake into OATP1B3 expressing CHO cells,CHO,,100,microM,,human,mbds0010,,2013-11-23 21:43:20
mbbd000141875,mbcd0012596,mbtp000013,mbrf0001902,,~,,,non-inhibitor,33,92.0,%,,metyrapone,,,inhibition of 1 microM estradiol 17beta glucuronide uptake into OATP1B1 expressing CHO cells,CHO,,10,microM,,human,mbds0010,,2013-11-23 21:43:33
mbbd000141876,mbcd0012596,mbtp000013,mbrf0001902,,~,,,non-inhibitor,33,102.0,%,,metyrapone,,,inhibition of 1 microM estradiol 17beta glucuronide uptake into OATP1B1 expressing CHO cells,CHO,,100,microM,,human,mbds0010,,2013-11-23 21:43:34
mbbd000141877,mbcd0001532,mbtp000013,mbrf0001902,,~,,,inhibitor,33,70.0,%,,metyrapone,,,inhibition of 1 microM estradiol 17beta glucuronide uptake into OATP1B1 expressing CHO cells,CHO,,10,microM,,human,mbds0010,,2013-11-23 21:43:27
mbbd000141878,mbcd0001532,mbtp000013,mbrf0001902,,~,,,inhibitor,33,33.0,%,,metyrapone,,,inhibition of 1 microM estradiol 17beta glucuronide uptake into OATP1B1 expressing CHO cells,CHO,,100,microM,,human,mbds0010,,2013-11-23 21:43:27
mbbd000141879,mbcd0001299,mbtp000013,mbrf0001902,,~,,,inhibitor,33,40.0,%,,mifepristone,,,inhibition of 1 microM estradiol 17beta glucuronide uptake into OATP1B1 expressing CHO cells,CHO,,10,microM,,human,mbds0010,,2013-11-23 21:43:22
mbbd000141880,mbcd0001299,mbtp000013,mbrf0001902,,~,,,inhibitor,33,19.0,%,,mifepristone,,,inhibition of 1 microM estradiol 17beta glucuronide uptake into OATP1B1 expressing CHO cells,CHO,,100,microM,,human,mbds0010,,2013-11-23 21:43:22
mbbd000141881,mbcd0025591,mbtp000013,mbrf0001902,,~,,,inhibitor,33,68.0,%,,mevinolin,,,inhibition of 1 microM estradiol 17beta glucuronide uptake into OATP1B1 expressing CHO cells,CHO,,10,microM,,human,mbds0010,,2013-11-23 21:43:35
mbbd000141882,mbcd0025591,mbtp000013,mbrf0001902,,~,,,inhibitor,33,38.0,%,,mevinolin,,,inhibition of 1 microM estradiol 17beta glucuronide uptake into OATP1B1 expressing CHO cells,CHO,,100,microM,,human,mbds0010,,2013-11-23 21:43:35
mbbd000141883,mbcd0002493,mbtp000013,mbrf0001902,,~,,,inducer,33,162.0,%,,clotrimazole,,,inhibition of 1 microM estradiol 17beta glucuronide uptake into OATP1B3 expressing CHO cells,CHO,mbcd0000387,10,microM,,human,mbds0010,,2013-11-23 21:43:18
mbbd000141884,mbcd0002493,mbtp000013,mbrf0001902,,~,,,inducer,33,158.0,%,,clotrimazole,,,inhibition of 1 microM estradiol 17beta glucuronide uptake into OATP1B3 expressing CHO cells,CHO,mbcd0000387,100,microM,,human,mbds0010,,2013-11-23 21:43:18
mbbd000141885,mbcd0002985,mbtp000013,mbrf0001902,,~,,,non-inhibitor,33,83.0,%,,carbamazepine,,,inhibition of 1 microM estradiol 17beta glucuronide uptake into OATP1B3 expressing CHO cells,CHO,,10,microM,,human,mbds0010,,2013-11-23 21:43:19
mbbd000141886,mbcd0002985,mbtp000013,mbrf0001902,,~,,,non-inhibitor,33,84.0,%,,carbamazepine,,,inhibition of 1 microM estradiol 17beta glucuronide uptake into OATP1B3 expressing CHO cells,CHO,,100,microM,,human,mbds0010,,2013-11-23 21:43:20
mbbd000141887,mbcd0003895,mbtp000013,mbrf0001902,,~,,,inhibitor,33,56.0,%,,troglitazone,,,inhibition of 1 microM estradiol 17beta glucuronide uptake into OATP1B1 expressing CHO cells,CHO,,10,microM,,human,mbds0010,,2013-11-23 21:43:32
mbbd000141888,mbcd0003895,mbtp000013,mbrf0001902,,~,,,inhibitor,33,23.0,%,,troglitazone,,,inhibition of 1 microM estradiol 17beta glucuronide uptake into OATP1B1 expressing CHO cells,CHO,,100,microM,,human,mbds0010,,2013-11-23 21:43:33
mbbd000141889,mbcd0027721,mbtp000013,mbrf0001902,,~,,,non-inhibitor,33,92.0,%,,lithocholate,,,inhibition of 1 microM estradiol 17beta glucuronide uptake into OATP1B1 expressing CHO cells,CHO,,10,microM,,human,mbds0010,,2013-11-23 21:43:36
mbbd000141890,mbcd0027721,mbtp000013,mbrf0001902,,~,,,non-inhibitor,33,100.0,%,,lithocholate,,,inhibition of 1 microM estradiol 17beta glucuronide uptake into OATP1B1 expressing CHO cells,CHO,,100,microM,,human,mbds0010,,2013-11-23 21:43:36
mbbd000141891,mbcd0003055,mbtp000013,mbrf0001902,,~,,,non-inhibitor,33,79.0,%,,estradiol,,,inhibition of 1 microM estradiol 17beta glucuronide uptake into OATP1B3 expressing CHO cells,CHO,,10,microM,,human,mbds0010,,2013-11-23 21:43:20
mbbd000141892,mbcd0003055,mbtp000013,mbrf0001902,,~,,,inhibitor,33,58.0,%,,estradiol,,,inhibition of 1 microM estradiol 17beta glucuronide uptake into OATP1B3 expressing CHO cells,CHO,,100,microM,,human,mbds0010,,2013-11-23 21:43:21
mbbd000141893,mbcd0001416,mbtp000012,mbrf0001902,,~,,,inhibitor,33,14.0,%,,rifampicin,,,inhibition of 1 microM estradiol 17beta glucuronide uptake into OATP1B1 expressing CHO cells,CHO,,10,microM,,human,mbds0010,,2013-11-23 21:43:26
mbbd000141894,mbcd0001416,mbtp000012,mbrf0001902,,~,,,inhibitor,33,1.0,%,,rifampicin,,,inhibition of 1 microM estradiol 17beta glucuronide uptake into OATP1B1 expressing CHO cells,CHO,,100,microM,,human,mbds0010,,2013-11-23 21:43:26
mbbd000141895,mbcd0002996,mbtp000012,mbrf0001902,,~,,,non-inhibitor,33,110.0,%,,phenytoin,,,inhibition of 1 microM estradiol 17beta glucuronide uptake into OATP1B1 expressing CHO cells,CHO,,10,microM,,human,mbds0010,,2013-11-23 21:43:30
mbbd000141896,mbcd0002996,mbtp000012,mbrf0001902,,~,,,non-inhibitor,33,75.0,%,,phenytoin,,,inhibition of 1 microM estradiol 17beta glucuronide uptake into OATP1B1 expressing CHO cells,CHO,,100,microM,,human,mbds0010,,2013-11-23 21:43:30
mbbd000141897,mbcd0012596,mbtp000012,mbrf0001902,,~,,,non-inhibitor,33,80.0,%,,metyrapone,,,inhibition of 1 microM estradiol 17beta glucuronide uptake into OATP1B1 expressing CHO cells,CHO,,10,microM,,human,mbds0010,,2013-11-23 21:43:34
mbbd000141898,mbcd0012596,mbtp000012,mbrf0001902,,~,,,inhibitor,33,62.0,%,,metyrapone,,,inhibition of 1 microM estradiol 17beta glucuronide uptake into OATP1B1 expressing CHO cells,CHO,,100,microM,,human,mbds0010,,2013-11-23 21:43:34
mbbd000141899,mbcd0001532,mbtp000012,mbrf0001902,,~,,,inhibitor,33,18.0,%,,metyrapone,,,inhibition of 1 microM estradiol 17beta glucuronide uptake into OATP1B1 expressing CHO cells,CHO,,10,microM,,human,mbds0010,,2013-11-23 21:43:28
mbbd000141900,mbcd0001532,mbtp000012,mbrf0001902,,~,,,inhibitor,33,4.0,%,,metyrapone,,,inhibition of 1 microM estradiol 17beta glucuronide uptake into OATP1B1 expressing CHO cells,CHO,,100,microM,,human,mbds0010,,2013-11-23 21:43:28
mbbd000141901,mbcd0001299,mbtp000012,mbrf0001902,,~,,,inhibitor,33,37.0,%,,mifepristone,,,inhibition of 1 microM estradiol 17beta glucuronide uptake into OATP1B1 expressing CHO cells,CHO,,10,microM,,human,mbds0010,,2013-11-23 21:43:22
mbbd000141902,mbcd0001299,mbtp000012,mbrf0001902,,~,,,inhibitor,33,10.0,%,,mifepristone,,,inhibition of 1 microM estradiol 17beta glucuronide uptake into OATP1B1 expressing CHO cells,CHO,,100,microM,,human,mbds0010,,2013-11-23 21:43:23
mbbd000141903,mbcd0025591,mbtp000012,mbrf0001902,,~,,,inhibitor,33,24.0,%,,mevinolin,,,inhibition of 1 microM estradiol 17beta glucuronide uptake into OATP1B1 expressing CHO cells,CHO,,10,microM,,human,mbds0010,,2013-11-23 21:43:35
mbbd000141904,mbcd0025591,mbtp000012,mbrf0001902,,~,,,inhibitor,33,9.0,%,,mevinolin,,,inhibition of 1 microM estradiol 17beta glucuronide uptake into OATP1B1 expressing CHO cells,CHO,,100,microM,,human,mbds0010,,2013-11-23 21:43:36
mbbd000141905,mbcd0002493,mbtp000012,mbrf0001902,,~,,,inhibitor,33,68.0,%,,clotrimazole,,,inhibition of 1 microM estradiol 17beta glucuronide uptake into OATP1B1 expressing CHO cells,CHO,mbcd0000387,10,microM,,human,mbds0010,,2013-11-23 21:43:18
mbbd000141906,mbcd0002493,mbtp000012,mbrf0001902,,~,,,inhibitor,33,40.0,%,,clotrimazole,,,inhibition of 1 microM estradiol 17beta glucuronide uptake into OATP1B1 expressing CHO cells,CHO,mbcd0000387,100,microM,,human,mbds0010,,2013-11-23 21:43:19
mbbd000141907,mbcd0002985,mbtp000012,mbrf0001902,,~,,,inhibitor,33,70.0,%,,carbamazepine,,,inhibition of 1 microM estradiol 17beta glucuronide uptake into OATP1B1 expressing CHO cells,CHO,,10,microM,,human,mbds0010,,2013-11-23 21:43:29
mbbd000141908,mbcd0002985,mbtp000012,mbrf0001902,,~,,,inhibitor,33,56.0,%,,carbamazepine,,,inhibition of 1 microM estradiol 17beta glucuronide uptake into OATP1B1 expressing CHO cells,CHO,,100,microM,,human,mbds0010,,2013-11-23 21:43:29
mbbd000141909,mbcd0003895,mbtp000012,mbrf0001902,,~,,,inhibitor,33,12.0,%,,troglitazone,,,inhibition of 1 microM estradiol 17beta glucuronide uptake into OATP1B1 expressing CHO cells,CHO,,10,microM,,human,mbds0010,,2013-11-23 21:43:33
mbbd000141910,mbcd0003895,mbtp000012,mbrf0001902,,~,,,inhibitor,33,6.0,%,,troglitazone,,,inhibition of 1 microM estradiol 17beta glucuronide uptake into OATP1B1 expressing CHO cells,CHO,,100,microM,,human,mbds0010,,2013-11-23 21:43:33
mbbd000141911,mbcd0027721,mbtp000012,mbrf0001902,,~,,,inhibitor,33,24.0,%,,lithocholate,,,inhibition of 1 microM estradiol 17beta glucuronide uptake into OATP1B1 expressing CHO cells,CHO,,10,microM,,human,mbds0010,,2013-11-23 21:43:37
mbbd000141912,mbcd0027721,mbtp000012,mbrf0001902,,~,,,inhibitor,33,22.0,%,,lithocholate,,,inhibition of 1 microM estradiol 17beta glucuronide uptake into OATP1B1 expressing CHO cells,CHO,,100,microM,,human,mbds0010,,2013-11-23 21:43:37
mbbd000141913,mbcd0003055,mbtp000012,mbrf0001902,,~,,,inhibitor,33,26.0,%,,estradiol,,,inhibition of 1 microM estradiol 17beta glucuronide uptake into OATP1B1 expressing CHO cells,CHO,,10,microM,,human,mbds0010,,2013-11-23 21:43:31
mbbd000141914,mbcd0003055,mbtp000012,mbrf0001902,,~,,,inhibitor,33,8.0,%,,estradiol,,,inhibition of 1 microM estradiol 17beta glucuronide uptake into OATP1B1 expressing CHO cells,CHO,,100,microM,,human,mbds0010,,2013-11-23 21:43:31
mbbd000141915,mbcd0003035,mbtp000012,mbrf0002444,,=,,,substrate,28,1.2,microM,,bromosulphthalein; BSP,Concentrations and kinetics data not published,,HEK293 cells,HEK293,,,,,human,mbds0010,,2013-11-10 04:16:03
mbbd000141916,mbcd0004702,mbtp000012,mbrf0002444,,=,,,inhibitor,25,19.9,microM,,bilirubin,,,IC50 values for porphyrin inhibition of OATP1B1-mediated uptake of estradiol 17beta - d-glucuronide,,,,,,human,mbds0010,,2013-12-09 20:54:55
mbbd000141917,mbcd0029793,mbtp000012,mbrf0002444,,,,,non-inhibitor,,,,,bilirubin dimethyl ester,Detected inhibition for compound insufficient to calculate IC50,,IC50 values for porphyrin inhibition of OATP1B1-mediated uptake of estradiol 17beta - d-glucuronide,,,,,,human,mbds0010,,2013-12-09 20:54:55
mbbd000141918,mbcd0000186,mbtp000012,mbrf0002444,,=,,,inhibitor,25,0.005,microM,,bilirubin ditaurate,,,IC50 values for porphyrin inhibition of OATP1B1-mediated uptake of estradiol 17beta - d-glucuronide,,,,,,human,mbds0010,,2013-12-09 20:54:55
mbbd000141919,mbcd0029795,mbtp000012,mbrf0002444,,=,,,inhibitor,25,0.05,microM,,biliverdin,,,IC50 values for porphyrin inhibition of OATP1B1-mediated uptake of estradiol 17beta - d-glucuronide,,,,,,human,mbds0010,,2013-12-09 20:54:55
mbbd000141920,mbcd0029796,mbtp000012,mbrf0002444,,,,,non-inhibitor,,,,,biliverdin dimethylester,Detected inhibition for compound insufficient to calculate IC50,,IC50 values for porphyrin inhibition of OATP1B1-mediated uptake of estradiol 17beta - d-glucuronide,,,,,,human,mbds0010,,2013-12-09 20:54:28
mbbd000141921,mbcd0029797,mbtp000012,mbrf0002444,,,,,non-inhibitor,,,,,mesobilirubin,Detected inhibition for compound insufficient to calculate IC50,,IC50 values for porphyrin inhibition of OATP1B1-mediated uptake of estradiol 17beta - d-glucuronide,,,,,,human,mbds0010,,2013-12-09 20:54:28
mbbd000141922,mbcd0029798,mbtp000012,mbrf0002444,,,,,non-inhibitor,,,,,stercobilin,Detected inhibition for compound insufficient to calculate IC50,,IC50 values for porphyrin inhibition of OATP1B1-mediated uptake of estradiol 17beta - d-glucuronide,,,,,,human,mbds0010,,2013-12-09 20:54:27
mbbd000141923,mbcd0029799,mbtp000012,mbrf0002444,,,,,non-inhibitor,,,,,urobilirin,Detected inhibition for compound insufficient to calculate IC50,,IC50 values for porphyrin inhibition of OATP1B1-mediated uptake of estradiol 17beta - d-glucuronide,,,,,,human,mbds0010,,2013-12-09 20:54:27
mbbd000141924,mbcd0029885,mbtp000012,mbrf0002444,,=,,,inhibitor,25,0.08,microM,,chlorin e6,,,IC50 values for porphyrin inhibition of OATP1B1-mediated uptake of estradiol 17beta - d-glucuronide,,,,,,human,mbds0010,,2013-12-09 20:54:27
mbbd000141925,mbcd0029801,mbtp000012,mbrf0002444,,=,,,inhibitor,25,0.4,microM,,coporphyrin,,,IC50 values for porphyrin inhibition of OATP1B1-mediated uptake of estradiol 17beta - d-glucuronide,,,,,,human,mbds0010,,2013-12-09 20:04:14
mbbd000141926,mbcd0029802,mbtp000012,mbrf0002444,,=,,,inhibitor,25,1.1,microM,,deuteroporphyrin,,,IC50 values for porphyrin inhibition of OATP1B1-mediated uptake of estradiol 17beta - d-glucuronide,,,,,,human,mbds0010,,2013-12-09 20:04:13
mbbd000141927,mbcd0029803,mbtp000012,mbrf0002444,,,,,non-inhibitor,,,,,deuteroporphyrin dimethyl ester,Detected inhibition for compound insufficient to calculate IC50,,IC50 values for porphyrin inhibition of OATP1B1-mediated uptake of estradiol 17beta - d-glucuronide,,,,,,human,mbds0010,,2013-12-09 20:04:11
mbbd000141928,mbcd0029804,mbtp000012,mbrf0002444,,,,,non-inhibitor,,,,,etioporphyrin,Detected inhibition for compound insufficient to calculate IC50,,IC50 values for porphyrin inhibition of OATP1B1-mediated uptake of estradiol 17beta - d-glucuronide,,,,,,human,mbds0010,,2013-12-09 20:06:12
mbbd000141929,mbcd0030270,mbtp000012,mbrf0002444,,=,,,inhibitor,25,0.06,microM,,hematoporphyrin,,,IC50 values for porphyrin inhibition of OATP1B1-mediated uptake of estradiol 17beta - d-glucuronide,,,,,,human,mbds0010,,2013-12-09 20:06:11
mbbd000141930,mbcd0029806,mbtp000012,mbrf0002444,,,,,non-inhibitor,,,,,hematoporphyrin dimethyl ester,Detected inhibition for compound insufficient to calculate IC50,,IC50 values for porphyrin inhibition of OATP1B1-mediated uptake of estradiol 17beta - d-glucuronide,,,,,,human,mbds0010,,2013-12-09 20:57:48
mbbd000141931,mbcd0029807,mbtp000012,mbrf0002444,,=,,,inhibitor,25,1.4,microM,,mesoporphyrin,,,IC50 values for porphyrin inhibition of OATP1B1-mediated uptake of estradiol 17beta - d-glucuronide,,,,,,human,mbds0010,,2013-12-09 20:57:48
mbbd000141932,mbcd0029808,mbtp000012,mbrf0002444,,=,,,inhibitor,25,8.8,microM,,Cr(III) mesoporphyrin,,,IC50 values for porphyrin inhibition of OATP1B1-mediated uptake of estradiol 17beta - d-glucuronide,,,,,,human,mbds0010,,2013-12-09 20:57:48
mbbd000141933,mbcd0029808,mbtp000012,mbrf0002444,,=,,,inhibitor,25,1.2,microM,,Fe(III) mesoporphyrin,,,IC50 values for porphyrin inhibition of OATP1B1-mediated uptake of estradiol 17beta - d-glucuronide,,,,,,human,mbds0010,,2013-12-09 20:57:49
mbbd000141934,mbcd0029808,mbtp000012,mbrf0002444,,=,,,inhibitor,25,8.5,microM,,Sn(IV) mesoporphyrin,,,IC50 values for porphyrin inhibition of OATP1B1-mediated uptake of estradiol 17beta - d-glucuronide,,,,,,human,mbds0010,,2013-12-09 20:57:49
mbbd000141935,mbcd0029808,mbtp000012,mbrf0002444,,=,,,inhibitor,25,12.4,microM,,Zn(II) mesoporphyrin,,,IC50 values for porphyrin inhibition of OATP1B1-mediated uptake of estradiol 17beta - d-glucuronide,,,,,,human,mbds0010,,2013-12-09 20:57:50
mbbd000141936,mbcd0029812,mbtp000012,mbrf0002444,,,,,non-inhibitor,,,,,mesoporphyrin dimethyl ester,Detected inhibition for compound insufficient to calculate IC50,,IC50 values for porphyrin inhibition of OATP1B1-mediated uptake of estradiol 17beta - d-glucuronide,,,,,,human,mbds0010,,2013-12-09 20:57:50
mbbd000141937,mbcd0015671,mbtp000012,mbrf0002444,,=,,,inhibitor,25,66.6,microM,,protoporphyrin,,,IC50 values for porphyrin inhibition of OATP1B1-mediated uptake of estradiol 17beta - d-glucuronide,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000141938,mbcd0029813,mbtp000012,mbrf0002444,,,,,non-inhibitor,,,,,protoporphyrin dimethyl ester,Detected inhibition for compound insufficient to calculate IC50,,IC50 values for porphyrin inhibition of OATP1B1-mediated uptake of estradiol 17beta - d-glucuronide,,,,,,human,mbds0010,,2013-12-09 20:55:25
mbbd000141939,mbcd0029814,mbtp000012,mbrf0002444,,=,,,inhibitor,25,14.4,microM,,Cr(III) protoporphyrin,,,IC50 values for porphyrin inhibition of OATP1B1-mediated uptake of estradiol 17beta - d-glucuronide,,,,,,human,mbds0010,,2014-03-04 00:28:49
mbbd000141940,mbcd0029815,mbtp000012,mbrf0002444,,=,,,inhibitor,25,9.8,microM,,Fe(III) protoporphyrin,,,IC50 values for porphyrin inhibition of OATP1B1-mediated uptake of estradiol 17beta - d-glucuronide,,,,,,human,mbds0010,,2014-03-04 00:28:49
mbbd000141941,mbcd0029816,mbtp000012,mbrf0002444,,=,,,inhibitor,25,33.7,microM,,Mn(III) protoporphyrin,,,IC50 values for porphyrin inhibition of OATP1B1-mediated uptake of estradiol 17beta - d-glucuronide,,,,,,human,mbds0010,,2014-03-04 00:28:49
mbbd000141942,mbcd0029817,mbtp000012,mbrf0002444,,=,,,inhibitor,25,32.9,microM,,Sn(IV) protoporphyrin,,,IC50 values for porphyrin inhibition of OATP1B1-mediated uptake of estradiol 17beta - d-glucuronide,,,,,,human,mbds0010,,2014-03-04 00:28:49
mbbd000141943,mbcd0029818,mbtp000012,mbrf0002444,,=,,,inhibitor,25,17.9,microM,,Zn(II) protoporphyrin,,,IC50 values for porphyrin inhibition of OATP1B1-mediated uptake of estradiol 17beta - d-glucuronide,,,,,,human,mbds0010,,2014-03-04 00:28:49
mbbd000141944,mbcd0029819,mbtp000012,mbrf0002444,,=,,,inhibitor,25,4.7,microM,,N-methyl protoporphyrin,,,IC50 values for porphyrin inhibition of OATP1B1-mediated uptake of estradiol 17beta - d-glucuronide,,,,,,human,mbds0010,,2014-03-04 00:28:49
mbbd000141945,mbcd0029820,mbtp000012,mbrf0002444,,,,,non-inhibitor,,,,,Phthalocyanine,Detected inhibition for compound insufficient to calculate IC50,,IC50 values for porphyrin inhibition of OATP1B1-mediated uptake of estradiol 17beta - d-glucuronide,,,,,,human,mbds0010,,2013-12-09 20:10:00
mbbd000141946,mbcd0029821,mbtp000012,mbrf0002444,,,,,non-inhibitor,,,,,uroporphyrin,Detected inhibition for compound insufficient to calculate IC50,,IC50 values for porphyrin inhibition of OATP1B1-mediated uptake of estradiol 17beta - d-glucuronide,,,,,,human,mbds0010,,2013-12-09 19:58:00
mbbd000141947,mbcd0029170,mbtp000012,mbrf0002056,,=,,,substrate,28,0.7,mM,,gadoxetate; Gd-EOB-DTPA,,,HEK293,HEK293,,0-1.0,mM,,human,mbds0010,,2013-12-19 20:07:31
mbbd000141948,mbcd0029170,mbtp000013,mbrf0002056,,=,,,substrate,28,4.1,mM,,gadoxetate; Gd-EOB-DTPA,,,HEK293,HEK293,,0-1.0,mM,,human,mbds0010,,2013-12-19 20:07:31
mbbd000141949,mbcd0029149,mbtp000012,mbrf0001700,,=,,,inhibitor,29,2.0,microM,,CI-1034,,,HEK293,HEK293,mbcd0003035,1; 2; 4,microM,,human,mbds0010,,2013-10-15 17:53:22
mbbd000141950,mbcd0029149,mbtp000013,mbrf0001700,,=,,,inhibitor,29,1.8,microM,,CI-1034,,,HEK293,HEK293,mbcd0003035,1; 2; 4,microM,,human,mbds0010,,2013-10-15 17:53:22
mbbd000141951,mbcd0000575,mbtp000012,mbrf0001789,,=,,,substrate,17,214.0,nM,,MCLR,,,HEK293-OATP1B1 EC50 measured my PP inhibition,HEK293,,,,,human,mbds0010,,2013-11-24 23:13:40
mbbd000141952,mbcd0029826,mbtp000012,mbrf0001789,,>,,,substrate,17,5000.0,nM,,MCRR,,,HEK293-OATP1B1 EC50 measured my PP inhibition,HEK293,,,,,human,mbds0010,,2013-11-24 23:13:40
mbbd000141953,mbcd0029827,mbtp000012,mbrf0001789,,=,,,substrate,17,10.4,nM,,MCLW,,,HEK293-OATP1B1 EC50 measured my PP inhibition,HEK293,,,,,human,mbds0010,,2013-11-24 23:13:41
mbbd000141954,mbcd0029828,mbtp000012,mbrf0001789,,=,,,substrate,17,11.1,nM,,MCLF,,,HEK293-OATP1B1 EC50 measured my PP inhibition,HEK293,,,,,human,mbds0010,,2013-11-24 23:13:41
mbbd000141955,mbcd0000575,mbtp000013,mbrf0001789,,=,,,substrate,17,257.1,nM,,MCLR,,,HEK293-OATP1B1 EC50 measured my PP inhibition,HEK293,,,,,human,mbds0010,,2013-11-24 23:13:41
mbbd000141956,mbcd0029826,mbtp000013,mbrf0001789,,=,,,substrate,17,1267.0,nM,,MCRR,,,HEK293-OATP1B1 EC50 measured my PP inhibition,HEK293,,,,,human,mbds0010,,2013-11-24 23:13:41
mbbd000141957,mbcd0029827,mbtp000013,mbrf0001789,,=,,,substrate,17,4.0,nM,,MCLW,,,HEK293-OATP1B1 EC50 measured my PP inhibition,HEK293,,,,,human,mbds0010,,2013-11-24 23:13:41
mbbd000141958,mbcd0029828,mbtp000013,mbrf0001789,,=,,,substrate,17,3.7,nM,,MCLF,,,HEK293-OATP1B1 EC50 measured my PP inhibition,HEK293,,,,,human,mbds0010,,2013-11-24 23:13:42
mbbd000141959,mbcd0029829,mbtp000013,mbrf0001701,,=,,,substrate,16,0.53,microM,0.17,CDCA-NBD,,,HEK293-OATP1B3 transfected cells,HEK293,,,,,human,mbds0010,,2013-11-21 06:15:19
mbbd000141960,mbcd0029829,mbtp000013,mbrf0001701,,=,,,substrate,22,279.0,pmol / mg protein / min,117,CDCA-NBD,,,HEK293-OATP1B3 transfected cells,HEK293,,,,,human,mbds0010,,2013-11-21 06:15:19
mbbd000141961,mbcd0003963,mbtp000013,mbrf0001701,,=,,,non-inhibitor,33,106.3,%,3.6,5-fluorouracil,,,"inhibition of OATP1B3-mediated CDCA-NBD uptake, HEK298 transfected cells",HEK293,,5,microM,,human,mbds0010,,2013-11-21 06:15:20
mbbd000141962,mbcd0001381,mbtp000013,mbrf0001701,,=,,,non-inhibitor,33,104.6,%,5.6,cytarabine,,,"inhibition of OATP1B3-mediated CDCA-NBD uptake, HEK298 transfected cells",HEK293,,5,microM,,human,mbds0010,,2013-11-21 06:15:20
mbbd000141963,mbcd0029825,mbtp000013,mbrf0001701,,=,,,non-inhibitor,33,101.1,%,4.9,6-mercaptopurine,,,"inhibition of OATP1B3-mediated CDCA-NBD uptake, HEK298 transfected cells",HEK293,,5,microM,,human,mbds0010,,2013-11-21 06:15:20
mbbd000141964,mbcd0000960,mbtp000013,mbrf0001701,,=,,,non-inhibitor,33,103.3,%,5.2,2 chloro 2' deoxyadenosine,,,"inhibition of OATP1B3-mediated CDCA-NBD uptake, HEK298 transfected cells",HEK293,,5,microM,,human,mbds0010,,2013-11-21 06:15:21
mbbd000141966,mbcd0001078,mbtp000013,mbrf0001701,,=,,,non-inhibitor,33,105.8,%,6.6,gemcitabine,,,"inhibition of OATP1B3-mediated CDCA-NBD uptake, HEK298 transfected cells",HEK293,,5,microM,,human,mbds0010,,2013-11-21 06:15:21
mbbd000141967,mbcd0001135,mbtp000013,mbrf0001701,,=,,,non-inhibitor,33,90.0,%,5.8,vincristine,,,"inhibition of OATP1B3-mediated CDCA-NBD uptake, HEK298 transfected cells",HEK293,,5,microM,,human,mbds0010,,2013-11-21 06:15:21
mbbd000141968,mbcd0027726,mbtp000013,mbrf0001701,,=,,,non-inhibitor,33,81.9,%,11.1,docetaxel,,,"inhibition of OATP1B3-mediated CDCA-NBD uptake, HEK298 transfected cells",HEK293,,5,microM,,human,mbds0010,,2013-11-21 06:15:21
mbbd000141969,mbcd0001372,mbtp000013,mbrf0001701,,=,,,non-inhibitor,33,90.0,%,5.8,actinomycin D,,,"inhibition of OATP1B3-mediated CDCA-NBD uptake, HEK298 transfected cells",HEK293,,5,microM,,human,mbds0010,,2013-11-21 06:15:21
mbbd000141970,mbcd0011776,mbtp000013,mbrf0001701,,=,,,non-inhibitor,33,94.7,%,4.6,carboplatin,,,"inhibition of OATP1B3-mediated CDCA-NBD uptake, HEK298 transfected cells",HEK293,,5,microM,,human,mbds0010,,2013-11-21 06:15:21
mbbd000141971,mbcd0029830,mbtp000013,mbrf0001701,,=,,,non-inhibitor,33,96.6,%,6.0,2 fluoroadenine 9 beta D arabinofuranoside,,,"inhibition of OATP1B3-mediated CDCA-NBD uptake, HEK298 transfected cells",HEK293,,5,microM,,human,mbds0010,,2013-11-21 06:15:21
mbbd000141972,mbcd0002981,mbtp000013,mbrf0001701,,=,,,inhibitor,33,80.8,%,6.4,mitoxantrone,,,"inhibition of OATP1B3-mediated CDCA-NBD uptake, HEK298 transfected cells",HEK293,,5,microM,,human,mbds0010,,2013-11-21 06:15:21
mbbd000141973,mbcd0020601,mbtp000013,mbrf0001701,,=,,,inhibitor,33,85.3,%,6.8,camptothecin,,,"inhibition of OATP1B3-mediated CDCA-NBD uptake, HEK298 transfected cells",HEK293,,5,microM,,human,mbds0010,,2013-11-21 06:15:21
mbbd000141974,mbcd0003043,mbtp000013,mbrf0001701,,=,,,non-inhibitor,33,94.6,%,5.3,methotrexate,,,"inhibition of OATP1B3-mediated CDCA-NBD uptake, HEK298 transfected cells",HEK293,,5,microM,,human,mbds0010,,2013-11-21 06:15:22
mbbd000141975,mbcd0000998,mbtp000013,mbrf0001701,,=,,,non-inhibitor,33,90.8,%,5.9,mitomycin C,,,"inhibition of OATP1B3-mediated CDCA-NBD uptake, HEK298 transfected cells",HEK293,,5,microM,,human,mbds0010,,2013-11-21 06:15:22
mbbd000141976,mbcd0001532,mbtp000013,mbrf0001701,,=,,,inhibitor,33,72.7,%,6.5,paclitaxel,,,"inhibition of OATP1B3-mediated CDCA-NBD uptake, HEK298 transfected cells",HEK293,,5,microM,,human,mbds0010,,2013-11-21 06:15:22
mbbd000141977,mbcd0002091,mbtp000013,mbrf0001701,,=,,,non-inhibitor,33,92.4,%,12.7,irinotaxel,,,"inhibition of OATP1B3-mediated CDCA-NBD uptake, HEK298 transfected cells",HEK293,,5,microM,,human,mbds0010,,2013-11-21 06:15:22
mbbd000141978,mbcd0000779,mbtp000013,mbrf0001701,,=,,,inhibitor,33,54.8,%,26.8,SN-38,,,"inhibition of OATP1B3-mediated CDCA-NBD uptake, HEK298 transfected cells",HEK293,,5,microM,,human,mbds0010,,2013-11-21 06:15:22
mbbd000141979,mbcd0000201,mbtp000013,mbrf0001701,,=,,,inhibitor,33,36.1,%,4.1,BSP,,,"inhibition of OATP1B3-mediated CDCA-NBD uptake, HEK298 transfected cells",HEK293,,5,microM,,human,mbds0010,,2013-11-21 06:15:22
mbbd000141980,mbcd0003963,mbtp000013,mbrf0001701,,=,,,inhibitor,33,82.4,%,4.9,5-fluorouracil,,,"inhibition of OATP1B3-mediated CDCA-NBD uptake, HEK298 transfected cells",HEK293,,20,microM,,human,mbds0010,,2013-11-21 06:15:22
mbbd000141981,mbcd0001381,mbtp000013,mbrf0001701,,=,,,non-inhibitor,33,98.0,%,5.2,cytarabine,,,"inhibition of OATP1B3-mediated CDCA-NBD uptake, HEK298 transfected cells",HEK293,,20,microM,,human,mbds0010,,2013-11-21 06:15:22
mbbd000141982,mbcd0029825,mbtp000013,mbrf0001701,,=,,,non-inhibitor,33,107.7,%,4.6,6-mercaptopurine,,,"inhibition of OATP1B3-mediated CDCA-NBD uptake, HEK298 transfected cells",HEK293,,20,microM,,human,mbds0010,,2013-11-21 06:15:23
mbbd000141983,mbcd0000960,mbtp000013,mbrf0001701,,=,,,inhibitor,33,87.8,%,4.9,2 chloro 2' deoxyadenosine,,,"inhibition of OATP1B3-mediated CDCA-NBD uptake, HEK298 transfected cells",HEK293,,20,microM,,human,mbds0010,,2013-11-21 06:15:23
mbbd000141985,mbcd0001078,mbtp000013,mbrf0001701,,=,,,non-inhibitor,33,94.5,%,5.0,gemcitabine,,,"inhibition of OATP1B3-mediated CDCA-NBD uptake, HEK298 transfected cells",HEK293,,20,microM,,human,mbds0010,,2013-11-21 06:15:23
mbbd000141986,mbcd0001135,mbtp000013,mbrf0001701,,=,,,non-inhibitor,33,156.1,%,16.9,vincristine,,,"inhibition of OATP1B3-mediated CDCA-NBD uptake, HEK298 transfected cells",HEK293,,20,microM,,human,mbds0010,,2013-11-21 06:15:23
mbbd000141987,mbcd0027726,mbtp000013,mbrf0001701,,=,,,inhibitor,33,26.5,%,3.8,docetaxel,,,"inhibition of OATP1B3-mediated CDCA-NBD uptake, HEK298 transfected cells",HEK293,,20,microM,,human,mbds0010,,2013-11-21 06:15:23
mbbd000141988,mbcd0001372,mbtp000013,mbrf0001701,,=,,,inhibitor,33,61.2,%,3.9,actinomycin D,,,"inhibition of OATP1B3-mediated CDCA-NBD uptake, HEK298 transfected cells",HEK293,,20,microM,,human,mbds0010,,2013-11-21 06:15:23
mbbd000141989,mbcd0011776,mbtp000013,mbrf0001701,,=,,,non-inhibitor,33,98.9,%,4.5,carboplatin,,,"inhibition of OATP1B3-mediated CDCA-NBD uptake, HEK298 transfected cells",HEK293,,20,microM,,human,mbds0010,,2013-11-21 06:15:23
mbbd000141990,mbcd0029830,mbtp000013,mbrf0001701,,=,,,non-inhibitor,33,101.5,%,5.8,2 fluoroadenine 9 beta D arabinofuranoside,,,"inhibition of OATP1B3-mediated CDCA-NBD uptake, HEK298 transfected cells",HEK293,,20,microM,,human,mbds0010,,2013-11-21 06:15:24
mbbd000141991,mbcd0002981,mbtp000013,mbrf0001701,,=,,,inhibitor,33,53.7,%,3.4,mitoxantrone,,,"inhibition of OATP1B3-mediated CDCA-NBD uptake, HEK298 transfected cells",HEK293,,20,microM,,human,mbds0010,,2013-11-21 06:15:24
mbbd000141992,mbcd0020601,mbtp000013,mbrf0001701,,=,,,non-inhibitor,33,99.4,%,4.3,camptothecin,,,"inhibition of OATP1B3-mediated CDCA-NBD uptake, HEK298 transfected cells",HEK293,,20,microM,,human,mbds0010,,2013-11-21 06:15:24
mbbd000141993,mbcd0003043,mbtp000013,mbrf0001701,,=,,,inhibitor,33,78.3,%,4.2,methotrexate,,,"inhibition of OATP1B3-mediated CDCA-NBD uptake, HEK298 transfected cells",HEK293,,20,microM,,human,mbds0010,,2013-11-21 06:15:24
mbbd000141994,mbcd0000998,mbtp000013,mbrf0001701,,=,,,inhibitor,33,81.7,%,6.8,mitomycin C,,,"inhibition of OATP1B3-mediated CDCA-NBD uptake, HEK298 transfected cells",HEK293,,20,microM,,human,mbds0010,,2013-11-21 06:15:24
mbbd000141995,mbcd0001532,mbtp000013,mbrf0001701,,=,,,inhibitor,33,49.9,%,5.0,paclitaxel,,,"inhibition of OATP1B3-mediated CDCA-NBD uptake, HEK298 transfected cells",HEK293,,20,microM,,human,mbds0010,,2013-11-21 06:15:24
mbbd000141996,mbcd0002091,mbtp000013,mbrf0001701,,=,,,non-inhibitor,33,98.3,%,4.4,irinotaxel,,,"inhibition of OATP1B3-mediated CDCA-NBD uptake, HEK298 transfected cells",HEK293,,20,microM,,human,mbds0010,,2013-11-21 06:15:24
mbbd000141997,mbcd0000779,mbtp000013,mbrf0001701,,=,,,inhibitor,33,60.1,%,14.4,SN-38,,,"inhibition of OATP1B3-mediated CDCA-NBD uptake, HEK298 transfected cells",HEK293,,20,microM,,human,mbds0010,,2013-11-21 06:15:24
mbbd000141998,mbcd0000201,mbtp000013,mbrf0001701,,=,,,inhibitor,33,35.0,%,4.2,BSP,,,"inhibition of OATP1B3-mediated CDCA-NBD uptake, HEK298 transfected cells",HEK293,,20,microM,,human,mbds0010,,2013-11-21 06:15:24
mbbd000141999,mbcd0000387,mbtp000012,mbrf0002063,,=,,,substrate,33,4.8,pmol / min / mg protein,0.1,estradiol 17beta D glucuronide,,,"HEK298 cells, overexpressing OATP1B 1/3",HEK293,,,,,human,mbds0010,,2014-02-21 02:49:00
mbbd000142000,mbcd0000387,mbtp000013,mbrf0002063,,=,,,substrate,33,1.0,pmol / min / mg protein,0.1,estradiol 17beta D glucuronide,,,"HEK298 cells, overexpressing OATP1B 1/3",HEK293,,,,,human,mbds0010,,2014-02-21 02:49:00
mbbd000142003,mbcd0029831,mbtp000012,mbrf0002063,,=,,,inhibitor,25,2.2,microM,0.1,telaprevir,,,"HEK298 cells, overexpressing OATP1B 1/3  inhibition of 1 microM estradiol 17beta D glucuronide uptake",HEK293,,,,,human,mbds0010,,2014-02-21 02:22:05
mbbd000142004,mbcd0029831,mbtp000013,mbrf0002063,,=,,,inhibitor,25,6.8,microM,0.9,telaprevir,,,"HEK298 cells, overexpressing OATP1B 1/3  inhibition of 1 microM estradiol 17beta D glucuronide uptake",HEK293,,,,,human,mbds0010,,2014-02-21 02:22:05
mbbd000142005,mbcd0001448,mbtp000013,mbrf0001846,,=,,,substrate,28,9.8,microM,0.7,rosuvastatin,,,HeLa transfected OATP1B1 cells,HeLa,,,,,human,mbds0010,,2013-11-24 23:55:12
mbbd000142006,mbcd0000311,mbtp000013,mbrf0001846,,=,,,inhibitor,25,0.06,microM,,cyclosporine,,,HeLa cells - OATP1B3 inhibiting rosuvastatin uptake,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142007,mbcd0001664,mbtp000012,mbrf0001965,,=,,,substrate,28,42.2,microM,,TCA,,,uptake,Xenopus laevis oocytes,,10,microM,,human,mbds0010,,2013-10-09 22:18:44
mbbd000142008,mbcd0029832,mbtp000012,mbrf0001965,,=,,,inhibitor,29,8.0,microM,,BALU-1,graphical data,,inhibition of TCA uptake,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142009,mbcd0029196,mbtp000012,mbrf0002085,,=,,,substrate,28,1.68,microM,0.29,99m Tc mebrofenin,,,CHO-OATP1B1 transfected,CHO,,,,,human,mbds0010,,2013-11-24 23:15:22
mbbd000142010,mbcd0029196,mbtp000012,mbrf0002085,,=,,,substrate,22,385.9,pmol / mg protein / min,67.3,99m Tc mebrofenin,,,CHO-OATP1B1 transfected,CHO,,,,,human,mbds0010,,2013-11-24 23:15:22
mbbd000142011,mbcd0029196,mbtp000013,mbrf0002085,,=,,,substrate,28,2.57,microM,0.85,99m Tc mebrofenin,,,CHO-OATP1B3 transfected,CHO,,,,,human,mbds0010,,2013-11-24 23:15:23
mbbd000142012,mbcd0029196,mbtp000013,mbrf0002085,,=,,,substrate,22,371.5,pmol / mg protein / min,114.6,99m Tc mebrofenin,,,CHO-OATP1B3 transfected,CHO,,,,,human,mbds0010,,2013-11-24 23:15:23
mbbd000142013,mbcd0029196,mbtp000012,mbrf0002085,,=,,,inhibitor,25,3.16,microM,,99m Tc mebrofenin,,,inhibition of E3S uptake,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142014,mbcd0029196,mbtp000013,mbrf0002085,,=,,,inhibitor,25,2.35,microM,,99m Tc mebrofenin,,,inhibition of E3S uptake,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142015,mbcd0000575,mbtp000012,mbrf0001410,,=,,,substrate,16,7.0,microM,3,microcystin LR,,,xenopus oocytes expressing hOATP1B1,Xenopus laevis oocytes,,,,,human,mbds0010,,2013-11-24 23:15:08
mbbd000142016,mbcd0000575,mbtp000013,mbrf0001410,,=,,,substrate,16,9.0,microM,3,microcystin LR,,,xenopus oocytes expressing hOATP1B3,Xenopus laevis oocytes,,,,,human,mbds0010,,2013-11-24 23:15:08
mbbd000142017,mbcd0004702,mbtp000012,mbrf0001871,,=,,,substrate,28,8.0,microM,,bilirubin,,,HEK298 cells,HEK293,,,,,human,mbds0010,,2013-11-24 23:13:51
mbbd000142018,mbcd0004701,mbtp000012,mbrf0001871,,=,,,substrate,28,0.3,microM,,bisglucuronosyl bilirubin,,,HEK298 cells,HEK293,,,,,human,mbds0010,,2013-11-24 23:13:51
mbbd000142019,mbcd0003035,mbtp000012,mbrf0001871,,=,,,substrate,28,0.1,microM,,bromosulphthalein,,,HEK293 cells,HEK293,,,,,human,mbds0010,,2013-11-24 23:13:52
mbbd000142020,mbcd0001640,mbtp000012,mbrf0001871,,=,,,substrate,28,11.0,microM,,cholate,,,HEK298 cells,HEK293,,,,,human,mbds0010,,2013-11-24 23:13:52
mbbd000142021,mbcd0000164,mbtp000012,mbrf0001871,,=,,,substrate,28,10.0,microM,,bamet-UD2,,,XO,Xenopus laevis oocytes,,,,,human,mbds0010,,2013-11-24 23:15:11
mbbd000142022,mbcd0000163,mbtp000012,mbrf0001871,,=,,,substrate,28,10.0,microM,,bamet-R2,,,XO,Xenopus laevis oocytes,,,,,human,mbds0010,,2013-11-24 23:15:11
mbbd000142023,mbcd0003070,mbtp000012,mbrf0001871,,=,,,substrate,28,22.0,microM,,Dehydroepiandrosterone sulfate,,,HEK298 cells,HEK293,,,,,human,mbds0010,,2013-11-24 23:13:52
mbbd000142024,mbcd0000325,mbtp000012,mbrf0001871,,=,,,substrate,28,17.0,microM,,Demethylphalloin,,,XO,Xenopus laevis oocytes,,,,,human,mbds0010,,2013-11-24 23:15:12
mbbd000142025,mbcd0000387,mbtp000012,mbrf0001871,,=,,,substrate,28,8.0,microM,,estradiol 17beta glucuronide,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142026,mbcd0003075,mbtp000012,mbrf0001871,,=,,,substrate,28,0.2,microM,,estrone 3 sulfate,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142027,mbcd0003075,mbtp000012,mbrf0001871,,=,,,substrate,28,13.0,microM,,estrone 3 sulfate,,,HEK298 cells,HEK293,,,,,human,mbds0010,,2013-11-24 23:13:52
mbbd000142028,mbcd0000458,mbtp000012,mbrf0001871,,=,,,substrate,28,5.2,microM,,Glycoursodeoxycholate,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142029,mbcd0000187,mbtp000012,mbrf0001871,,=,,,substrate,28,0.1,microM,,monoglucoronosyl bilirubin,,,HEK298 cells,HEK293,,,,,human,mbds0010,,2013-11-24 23:13:53
mbbd000142030,mbcd0003005,mbtp000012,mbrf0001871,,=,,,substrate,28,42.6,microM,,olmesartan,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142031,mbcd0000675,mbtp000012,mbrf0001871,,=,,,substrate,28,39.0,microM,,phalloidin,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142032,mbcd0000693,mbtp000012,mbrf0001871,,=,,,substrate,28,3.0,microM,,pitavastatin,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142033,mbcd0003126,mbtp000012,mbrf0001871,,=,,,substrate,28,35.0,microM,,pravastatin,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142034,mbcd0001416,mbtp000012,mbrf0001871,,=,,,substrate,28,13.0,microM,,rifampicin,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142035,mbcd0001416,mbtp000012,mbrf0001871,,=,,,substrate,28,2.0,microM,,rifampicin,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142036,mbcd0001448,mbtp000012,mbrf0001871,,=,,,substrate,28,4.0,microM,,rosuvastatin,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142037,mbcd0001664,mbtp000012,mbrf0001871,,=,,,substrate,28,10.0,microM,,taurocholate,,,HEK298 cells,HEK293,,,,,human,mbds0010,,2013-11-24 23:13:53
mbbd000142038,mbcd0001664,mbtp000012,mbrf0001871,,=,,,substrate,28,14.0,microM,,taurocholate,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142039,mbcd0001664,mbtp000012,mbrf0001871,,=,,,substrate,28,34.0,microM,,taurocholate,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142040,mbcd0000815,mbtp000012,mbrf0001871,,=,,,substrate,28,7.5,microM,,Tauroursodeoxycholate,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142041,mbcd0003957,mbtp000012,mbrf0001871,,=,,,substrate,28,3.0,microM,,thyroxine (T4),,,,,,,,,human,mbds0010,,2013-07-16 19:05:33
mbbd000142042,mbcd0000984,mbtp000012,mbrf0001871,,=,,,substrate,28,2.7,microM,,Triodothyronine (T3),,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142043,mbcd0029833,mbtp000012,mbrf0001871,,=,,,substrate,28,7.5,microM,,TR-14035,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142044,mbcd0003086,mbtp000012,mbrf0001871,,=,,,substrate,28,1.4,microM,,valsartan,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142045,mbcd0000487,mbtp000013,mbrf0001917,,,,,substrate,,,,,ICG,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142046,mbcd0029834,mbtp000012,mbrf0001684,,,,,inhibitor,,,,,gemfibrozil 1 O beta glucuronide,potent inhibitor,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142047,mbcd0001904,mbtp000012,mbrf0001684,,,,,substrate,,,,,repaglinide,,,,,,,,,human,mbds0010,,2013-12-10 22:21:07
mbbd000142048,mbcd0001442,mbtp000012,mbrf0002179,,=,,,inhibitor,25,0.57,microM,0.1,ouabain,,,inhibition of Fluo-3 uptake in HEK298 transfected cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142049,mbcd0000201,mbtp000012,mbrf0002179,,=,,,inhibitor,25,0.65,microM,0.03,BSP,,,inhibition of Fluo-3 uptake in HEK298 transfected cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142050,mbcd0000201,mbtp000012,mbrf0002179,,~,,,inhibitor,28,0.5,microM,,BSP,,,inhibition of Fluo-3 uptake in HEK298 transfected cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142051,mbcd0001416,mbtp000012,mbrf0002179,,=,,,inhibitor,25,1.5,microM,0.13,rifampicin,,,inhibition of Fluo-3 uptake in HEK298 transfected cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142053,mbcd0017104,mbtp000012,mbrf0002179,,=,,,inhibitor,25,14.1,microM,1.07,ketoconazole,,,inhibition of Fluo-3 uptake in HEK298 transfected cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142054,mbcd0003070,mbtp000012,mbrf0002179,,=,,,inhibitor,25,20.6,microM,1.05,DHEAS,,,inhibition of Fluo-3 uptake in HEK298 transfected cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142055,mbcd0000387,mbtp000012,mbrf0002179,,=,,,inhibitor,25,21.0,microM,0.6,estradiol 17beta glucuronide,,,inhibition of Fluo-3 uptake in HEK298 transfected cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142057,mbcd0001050,mbtp000012,mbrf0002179,,=,,,inhibitor,25,41.8,microM,6.2,digoxin,,,inhibition of Fluo-3 uptake in HEK298 transfected cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142058,mbcd0000455,mbtp000012,mbrf0002179,,=,,,inhibitor,25,42.3,microM,1.1,glycocholate,,,inhibition of Fluo-3 uptake in HEK298 transfected cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142059,mbcd0003043,mbtp000012,mbrf0002179,,=,,,inhibitor,25,124.6,microM,1.26,methotrexate,,,inhibition of Fluo-3 uptake in HEK298 transfected cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142061,mbcd0000575,mbtp000013,mbrf0002040,,=,,,substrate,28,1.2,microM,,microcystin LR,,,uptake into HEK298-OATP1B3,HEK293,,,,,human,mbds0010,,2013-11-24 23:13:53
mbbd000142062,mbcd0001416,mbtp000013,mbrf0002040,,=,,,inhibitor,25,27.6,nM,6.51,rifampicin,,,"inhibition of microcystin LR (1microM) uptake, 2.5 microM inhibitor concentration",,,,,,human,mbds0010,,2013-12-09 20:04:42
mbbd000142063,mbcd0001416,mbtp000013,mbrf0002040,,=,,,inhibitor,25,60.6,nM,11.3,rifampicin,,,"inhibition of microcystin LR (1microM) uptake, 5 microM inhibitor concentration",,,,,,human,mbds0010,,2013-12-09 20:04:41
mbbd000142064,mbcd0001416,mbtp000013,mbrf0002040,,=,,,inhibitor,25,119.0,nM,23.2,rifampicin,,,"inhibition of microcystin LR (1microM) uptake, 10 microM inhibitor concentration",,,,,,human,mbds0010,,2013-12-09 20:04:46
mbbd000142065,mbcd0000201,mbtp000013,mbrf0002040,,=,,,inhibitor,25,7.52,nM,0.40,BSP,,,"inhibition of microcystin LR (1microM) uptake, 2.5 microM inhibitor concentration",,,,,,human,mbds0010,,2013-12-09 20:04:44
mbbd000142066,mbcd0000201,mbtp000013,mbrf0002040,,=,,,inhibitor,25,7.6,nM,0.67,BSP,,,"inhibition of microcystin LR (1microM) uptake, 5 microM inhibitor concentration",,,,,,human,mbds0010,,2013-12-09 20:04:44
mbbd000142067,mbcd0000201,mbtp000013,mbrf0002040,,=,,,inhibitor,25,19.3,nM,2.62,BSP,,,"inhibition of microcystin LR (1microM) uptake, 25 microM inhibitor concentration",,,,,,human,mbds0010,,2013-12-09 20:04:44
mbbd000142068,mbcd0000311,mbtp000013,mbrf0002040,,=,,,inhibitor,25,7.52,nM,1.35,CsA,,,"inhibition of microcystin LR (1microM) uptake, 10 nM inhibitor concentration",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142069,mbcd0000311,mbtp000013,mbrf0002040,,=,,,inhibitor,25,22.2,nM,9.30,CsA,,,"inhibition of microcystin LR (1microM) uptake, 100 nM inhibitor concentration",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142070,mbcd0000311,mbtp000013,mbrf0002040,,=,,,inhibitor,25,55.9,nM,17.8,CsA,,,"inhibition of microcystin LR (1microM) uptake, 200 nM inhibitor concentration",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142071,mbcd0029835,mbtp000012,mbrf0001916,,,,,substrate,,,,,nodularin,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142074,mbcd0018125,mbtp000012,mbrf0002346,,,,,substrate,,,,,hydroxyurea,,,Xenopus laevis oocytes,Xenopus laevis oocytes,,50,microM,,human,mbds0010,,2013-11-10 04:16:12
mbbd000142075,mbcd0018125,mbtp000013,mbrf0002346,,,,,substrate,,,,,hydroxyurea,,,Xenopus laevis oocytes,Xenopus laevis oocytes,,50,microM,,human,mbds0010,,2013-11-10 04:16:12
mbbd000142076,mbcd0001050,mbtp000013,mbrf0001767,,,,,substrate,,,,,digoxin,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142077,mbcd0000749,mbtp000013,mbrf0001767,,,,,inhibitor,,,,,rifamycin SV,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142078,mbcd0001550,mbtp000012,mbrf0001815,,,,,inhibitor,,,,,lapatinib,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142079,mbcd0029195,mbtp000012,mbrf0001658,,,,,inhibitor,,,,,eltrombopag,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142080,mbcd0001194,mbtp000012,mbrf0001658,,,,,substrate,,,,,simvastatin,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142081,mbcd0029837,mbtp000012,mbrf0002225,,=,,,inhibitor,25,18.2,microM,,GS-9451,,,inhibition of UGT1A1 uptake into CHO cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142082,mbcd0029837,mbtp000013,mbrf0002225,,=,,,inhibitor,25,10.8,microM,,GS-9451,,,inhibition of UGT1A1 uptake into CHO cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142083,mbcd0029838,mbtp000012,mbrf0002225,,=,,,inhibitor,25,0.16,microM,,GS-9256,,,inhibition of UGT1A1 uptake into CHO cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142084,mbcd0029838,mbtp000013,mbrf0002225,,=,,,inhibitor,25,0.15,microM,,GS-9256,,,inhibition of UGT1A1 uptake into CHO cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142085,mbcd0028555,mbtp000012,mbrf0001957,,,,,inhibitor,,,,,CCCP,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142086,mbcd0028555,mbtp000013,mbrf0001957,,,,,inhibitor,,,,,CCCP,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142087,mbcd0029839,mbtp000012,mbrf0002188,,=,,,inhibitor,25,5.1,microM,,compound 1,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142088,mbcd0029840,mbtp000012,mbrf0001696,,=,,,inhibitor,25,0.7,microM,,alisporivir,,,inhibition of bilirubin uptake,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142089,mbcd0029840,mbtp000013,mbrf0001696,,=,,,inhibitor,25,0.7,microM,,alisporivir,,,inhibition of bilirubin uptake,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142091,mbcd0022617,mbtp000012,mbrf0002310,,,,,inhibitor,,,,,silymarin,,,inhibition of rosuvastatin uptake,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142093,mbcd0029094,mbtp000013,mbrf0001951,,,,,inducer,,,,,gugglesterone,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142094,mbcd0003001,mbtp000013,mbrf0001888,,,,,substrate,,,,,testosterone,,,COS-7 cells expressing OATP1B3,COS7,,,,,human,mbds0010,,2013-11-24 23:56:12
mbbd000142095,mbcd0000130,mbtp000013,mbrf0002576,,=,,,substrate,28,3.7,microM,0.6,alpha AMA,,,MDCKII; uptake,MDCKII,,0.7,microM,,human,mbds0010,,2013-11-02 06:56:01
mbbd000142096,mbcd0003070,mbtp000013,mbrf0001751,,=,,,substrate,33,1.158,pmol / min microg,,DHEAS,,,OATP overexpressing CHO cells,CHO,,,,,human,mbds0010,,2013-11-02 07:41:28
mbbd000142097,mbcd0003042,mbtp000013,mbrf0001751,,=,,,substrate,33,0.116,pmol / min microg,,warfarin,,,OATP overexpressing CHO cells,CHO,,,,,human,mbds0010,,2013-11-02 07:41:28
mbbd000142098,mbcd0000387,mbtp000012,mbrf0001751,,=,,,substrate,33,0.417,pmol / min microg,,E17betaG,,,OATP overexpressing CHO cells,CHO,,,,,human,mbds0010,,2013-11-02 07:41:28
mbbd000142099,mbcd0003075,mbtp000012,mbrf0001751,,=,,,substrate,33,0.334,pmol / min microg,,E3S,,,OATP overexpressing CHO cells,CHO,,,,,human,mbds0010,,2013-11-02 07:33:28
mbbd000142100,mbcd0028129,mbtp000012,mbrf0001751,,=,,,substrate,28,141.0,microM,17,bosentan,,,hOATP expressing CHO cells,CHO,,0-300,microM,,human,mbds0010,,2013-11-02 07:33:28
mbbd000142101,mbcd0028129,mbtp000013,mbrf0001751,,=,,,substrate,28,44.0,microM,5,bosentan,,,hOATP expressing CHO cells,CHO,,0-300,microM,,human,mbds0010,,2013-11-02 07:33:28
mbbd000142102,mbcd0029127,mbtp000012,mbrf0001751,,=,,,substrate,28,166.0,microM,16,Ro 48-5033,,,hOATP expressing CHO cells,CHO,,,,,human,mbds0010,,2013-11-02 07:33:28
mbbd000142103,mbcd0029127,mbtp000013,mbrf0001751,,=,,,substrate,28,60.0,microM,17,Ro 48-5033,,,hOATP expressing CHO cells,CHO,,,,,human,mbds0010,,2013-11-02 07:33:29
mbbd000142104,mbcd0001416,mbtp000012,mbrf0001751,,=,,,inhibitor,25,3.2,microM,1.6,rifampicin,,,bosentan uptake inhibition into CHO-hOATP cells,CHO,mbcd0028129,,,,human,mbds0010,,2013-11-02 07:41:33
mbbd000142105,mbcd0001416,mbtp000013,mbrf0001751,,=,,,inhibitor,25,1.6,microM,0.8,rifampicin,,,bosentan uptake inhibition into CHO-hOATP cells,CHO,mbcd0028129,,,,human,mbds0010,,2013-11-02 07:41:33
mbbd000142106,mbcd0000311,mbtp000012,mbrf0001751,,=,,,inhibitor,25,0.3,microM,0.1,cyclosporin A,,,bosentan uptake inhibition into CHO-hOATP cells,CHO,mbcd0028129,,,,human,mbds0010,,2013-11-02 07:41:33
mbbd000142107,mbcd0000311,mbtp000013,mbrf0001751,,=,,,inhibitor,25,0.8,microM,0.2,cyclosporin A,,,bosentan uptake inhibition into CHO-hOATP cells,CHO,mbcd0028129,,,,human,mbds0010,,2013-11-02 07:41:33
mbbd000142108,mbcd0025660,mbtp000012,mbrf0001751,,=,,,inhibitor,25,1.5,microM,0.5,sildenafil,,,bosentan uptake inhibition into CHO-hOATP cells,CHO,mbcd0028129,,,,human,mbds0010,,2013-11-02 07:41:33
mbbd000142109,mbcd0025660,mbtp000013,mbrf0001751,,=,,,inhibitor,25,0.8,microM,0.3,sildenafil,,,bosentan uptake inhibition into CHO-hOATP cells,CHO,mbcd0028129,,,,human,mbds0010,,2013-11-02 07:41:32
mbbd000142110,mbcd0001416,mbtp000012,mbrf0001751,,~,,,inhibitor,25,50.0,microM,,rifampicin,,,Ro 48-5033 uptake inhibition into CHO-hOATP cells,CHO,mbcd0029127,,,,human,mbds0010,,2013-11-02 07:41:31
mbbd000142111,mbcd0001416,mbtp000013,mbrf0001751,,=,,,inhibitor,25,0.8,microM,0.4,rifampicin,,,Ro 48-5033 uptake inhibition into CHO-hOATP cells,CHO,mbcd0029127,,,,human,mbds0010,,2013-11-02 07:41:31
mbbd000142112,mbcd0000311,mbtp000012,mbrf0001751,,=,,,inhibitor,25,100.0,microM,,cyclosporin A,,,Ro 48-5033 uptake inhibition into CHO-hOATP cells,CHO,mbcd0029127,,,,human,mbds0010,,2013-11-02 07:41:31
mbbd000142113,mbcd0000311,mbtp000013,mbrf0001751,,=,,,inhibitor,25,0.5,microM,0.1,cyclosporin A,,,Ro 48-5033 uptake inhibition into CHO-hOATP cells,CHO,mbcd0029127,,,,human,mbds0010,,2013-11-02 07:41:31
mbbd000142114,mbcd0025660,mbtp000012,mbrf0001751,,=,,,inhibitor,25,100.0,microM,,sildenafil,,,Ro 48-5033 uptake inhibition into CHO-hOATP cells,CHO,mbcd0029127,,,,human,mbds0010,,2013-11-02 07:41:32
mbbd000142115,mbcd0025660,mbtp000013,mbrf0001751,,=,,,inhibitor,25,4.0,microM,1.3,sildenafil,,,Ro 48-5033 uptake inhibition into CHO-hOATP cells,CHO,mbcd0029127,,,,human,mbds0010,,2013-11-02 07:41:32
mbbd000142116,mbcd0001050,mbtp000012,mbrf0002095,,,,,non-substrate,,,,,digoxin,,,HEK293 cells,HEK293,,0.01-50,microM,,human,mbds0010,,2013-11-10 04:16:04
mbbd000142117,mbcd0001050,mbtp000013,mbrf0002095,,,,,non-substrate,,,,,digoxin,,,HEK293 cells,HEK293,,0.01-50,microM,,human,mbds0010,,2013-11-10 04:16:04
mbbd000142118,mbcd0001050,mbtp000012,mbrf0002095,,,,,inhibitor,,,,,digoxin,,,HEK293 cells,HEK293,mbcd0000387,0-1000,microM,,human,mbds0010,,2013-11-10 04:16:04
mbbd000142119,mbcd0001050,mbtp000013,mbrf0002095,,,,,inhibitor,,,,,digoxin,,,HEK293 cells,HEK293,mbcd0029176,0-1000,microM,,human,mbds0010,,2013-11-10 04:16:04
mbbd000142120,mbcd0001445,mbtp000012,mbrf0001691,,~,,,substrate,28,2.2,microM,,fluvastatin,1.4-3.5 microM,,uptake into CHO and HEK298 cells expressing OATP,HEK293; CHO,,,,,human,mbds0010,,2013-11-24 23:13:54
mbbd000142121,mbcd0001445,mbtp000013,mbrf0001691,,,,,substrate,,,,,fluvastatin,,,uptake into CHO and HEK298 cells expressing OATP,HEK293; CHO,,,,,human,mbds0010,,2013-11-24 23:13:54
mbbd000142122,mbcd0000693,mbtp000012,mbrf0002447,,=,,,substrate,28,4.8,microM,0.7,pitavastatin,,,HEK cells stably expressing OATP1B1,HEK,,,,,human,mbds0010,,2013-11-24 23:13:54
mbbd000142123,mbcd0000387,mbtp000012,mbrf0002447,,=,,,substrate,28,3.6,microM,0.9,estradiol 17beta glucuronide,,,HEK cells stably expressing OATP1B1,HEK,,,,,human,mbds0010,,2013-11-24 23:13:54
mbbd000142124,mbcd0026093,mbtp000012,mbrf0002447,,=,,,inhibitor,25,0.8,microM,0.3,atorvastatin,,,pitavastatin uptake inhibition into HEK-OATP1B1 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142125,mbcd0026093,mbtp000012,mbrf0002447,,=,,,inhibitor,25,0.6,microM,,atorvastatin,,,estradiol 17beta glucuronide uptake inhibition into HEK-OATP1B1 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142126,mbcd0026093,mbtp000012,mbrf0002447,,=,,,inhibitor,25,0.8,microM,,atorvastatin,,,estradiol 17beta glucuronide uptake inhibition into HEK-OATP1B1 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142127,mbcd0026093,mbtp000012,mbrf0002447,,=,,,inhibitor,25,1.6,microM,,atorvastatin,,,estrone 3 sulfate uptake inhibition into HEK-OATP1B1 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142128,mbcd0026093,mbtp000012,mbrf0002447,,=,,,inhibitor,25,2.4,microM,,atorvastatin,,,estrone 3 sulfate uptake inhibition into HEK-OATP1B1 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142129,mbcd0009531,mbtp000012,mbrf0002447,,=,,,inhibitor,25,38.0,microM,2,gemfibrozil,,,pitavastatin uptake inhibition into HEK-OATP1B1 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142130,mbcd0009531,mbtp000012,mbrf0002447,,=,,,inhibitor,25,11.0,microM,,gemfibrozil,,,estradiol 17beta glucuronide uptake inhibition into HEK-OATP1B1 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142131,mbcd0009531,mbtp000012,mbrf0002447,,=,,,inhibitor,25,44.0,microM,,gemfibrozil,,,estradiol 17beta glucuronide uptake inhibition into HEK-OATP1B1 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142132,mbcd0009531,mbtp000012,mbrf0002447,,=,,,inhibitor,25,130.0,microM,,gemfibrozil,,,estrone 3 sulfate uptake inhibition into HEK-OATP1B1 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142133,mbcd0009531,mbtp000012,mbrf0002447,,=,,,inhibitor,25,270.0,microM,,gemfibrozil,,,estrone 3 sulfate uptake inhibition into HEK-OATP1B1 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142134,mbcd0029629,mbtp000012,mbrf0002447,,=,,,inhibitor,25,2.2,microM,0.7,glibenclamide,,,pitavastatin uptake inhibition into HEK-OATP1B1 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142135,mbcd0029629,mbtp000012,mbrf0002447,,=,,,inhibitor,25,1.4,microM,,glibenclamide,,,estradiol 17beta glucuronide uptake inhibition into HEK-OATP1B1 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142136,mbcd0029629,mbtp000012,mbrf0002447,,=,,,inhibitor,25,14.0,microM,,glibenclamide,,,estradiol 17beta glucuronide uptake inhibition into HEK-OATP1B1 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142137,mbcd0029629,mbtp000012,mbrf0002447,,=,,,inhibitor,25,21.0,microM,,glibenclamide,,,estrone 3 sulfate uptake inhibition into HEK-OATP1B1 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142138,mbcd0029629,mbtp000012,mbrf0002447,,=,,,inhibitor,25,25.0,microM,,glibenclamide,,,estrone 3 sulfate uptake inhibition into HEK-OATP1B1 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142139,mbcd0027062,mbtp000012,mbrf0002447,,=,,,inhibitor,25,64.0,microM,15,verapamil,,,pitavastatin uptake inhibition into HEK-OATP1B1 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142140,mbcd0027062,mbtp000012,mbrf0002447,,=,,,inhibitor,25,32.0,microM,,verapamil,,,estradiol 17beta glucuronide uptake inhibition into HEK-OATP1B1 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142141,mbcd0027062,mbtp000012,mbrf0002447,,=,,,inhibitor,25,71.0,microM,,verapamil,,,estradiol 17beta glucuronide uptake inhibition into HEK-OATP1B1 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142142,mbcd0027062,mbtp000012,mbrf0002447,,>,,,inhibitor,25,600.0,microM,,verapamil,,,estrone 3 sulfate uptake inhibition into HEK-OATP1B1 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142144,mbcd0001194,mbtp000012,mbrf0002447,,=,,,inhibitor,25,6.0,microM,3.3,simvastatin,,,pitavastatin uptake inhibition into HEK-OATP1B1 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142145,mbcd0001194,mbtp000012,mbrf0002447,,=,,,inhibitor,25,4.4,microM,,simvastatin,,,estradiol 17beta glucuronide uptake inhibition into HEK-OATP1B1 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142146,mbcd0001194,mbtp000012,mbrf0002447,,=,,,inhibitor,25,5.6,microM,,simvastatin,,,estradiol 17beta glucuronide uptake inhibition into HEK-OATP1B1 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142147,mbcd0001194,mbtp000012,mbrf0002447,,=,,,inhibitor,25,11.0,microM,,simvastatin,,,estrone 3 sulfate uptake inhibition into HEK-OATP1B1 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142148,mbcd0001194,mbtp000012,mbrf0002447,,=,,,inhibitor,25,14.0,microM,,simvastatin,,,estrone 3 sulfate uptake inhibition into HEK-OATP1B1 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142149,mbcd0001416,mbtp000012,mbrf0002447,,=,,,inhibitor,25,2.2,microM,1.4,rifampicin,,,pitavastatin uptake inhibition into HEK-OATP1B1 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142150,mbcd0001416,mbtp000012,mbrf0002447,,=,,,inhibitor,25,0.3,microM,,rifampicin,,,estradiol 17beta glucuronide uptake inhibition into HEK-OATP1B1 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142151,mbcd0001416,mbtp000012,mbrf0002447,,=,,,inhibitor,25,0.9,microM,,rifampicin,,,estradiol 17beta glucuronide uptake inhibition into HEK-OATP1B1 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142152,mbcd0001416,mbtp000012,mbrf0002447,,=,,,inhibitor,25,2.3,microM,,rifampicin,,,estrone 3 sulfate uptake inhibition into HEK-OATP1B1 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142153,mbcd0001416,mbtp000012,mbrf0002447,,=,,,inhibitor,25,3.0,microM,,rifampicin,,,estrone 3 sulfate uptake inhibition into HEK-OATP1B1 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142154,mbcd0001938,mbtp000012,mbrf0002447,,=,,,inhibitor,25,1.0,microM,0.5,ritonavir,,,pitavastatin uptake inhibition into HEK-OATP1B1 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142155,mbcd0001938,mbtp000012,mbrf0002447,,=,,,inhibitor,25,0.7,microM,,ritonavir,,,estradiol 17beta glucuronide uptake inhibition into HEK-OATP1B1 cells,,,,,,human,mbds0010,,2013-11-19 22:46:13
mbbd000142156,mbcd0001938,mbtp000012,mbrf0002447,,=,,,inhibitor,25,1.0,microM,,ritonavir,,,estradiol 17beta glucuronide uptake inhibition into HEK-OATP1B1 cells,,,,,,human,mbds0010,,2013-11-19 22:46:13
mbbd000142157,mbcd0001938,mbtp000012,mbrf0002447,,=,,,inhibitor,25,8.6,microM,,ritonavir,,,estrone 3 sulfate uptake inhibition into HEK-OATP1B1 cells,,,,,,human,mbds0010,,2013-11-19 22:46:13
mbbd000142158,mbcd0001938,mbtp000012,mbrf0002447,,=,,,inhibitor,25,5.0,microM,,ritonavir,,,estrone 3 sulfate uptake inhibition into HEK-OATP1B1 cells,,,,,,human,mbds0010,,2013-11-19 22:46:13
mbbd000142159,mbcd0000311,mbtp000012,mbrf0002447,,=,,,inhibitor,25,0.7,microM,0.2,cyclosporine A,,,pitavastatin uptake inhibition into HEK-OATP1B1 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142160,mbcd0000311,mbtp000012,mbrf0002447,,=,,,inhibitor,25,0.7,microM,,cyclosporine A,,,estradiol 17beta glucuronide uptake inhibition into HEK-OATP1B1 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142161,mbcd0000311,mbtp000012,mbrf0002447,,=,,,inhibitor,25,1.1,microM,,cyclosporine A,,,estradiol 17beta glucuronide uptake inhibition into HEK-OATP1B1 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142162,mbcd0000311,mbtp000012,mbrf0002447,,=,,,inhibitor,25,1.3,microM,,cyclosporine A,,,estrone 3 sulfate uptake inhibition into HEK-OATP1B1 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142163,mbcd0000311,mbtp000012,mbrf0002447,,=,,,inhibitor,25,1.2,microM,,cyclosporine A,,,estrone 3 sulfate uptake inhibition into HEK-OATP1B1 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142165,mbcd0001640,mbtp000012,mbrf0002149,,=,,,substrate,28,11.0,microM,,cholic acid,endogenous substrate of OATP1B1,,HEK293 cells,HEK293,,,,,human,mbds0010,,2013-11-19 22:39:19
mbbd000142166,mbcd0000455,mbtp000012,mbrf0002149,,,,,substrate,,,,,glycocholic acid,endogenous substrate of OATP1B1,,XO,Xenopus laevis oocytes,,,,,human,mbds0010,,2013-11-19 22:39:18
mbbd000142167,mbcd0001635,mbtp000012,mbrf0002149,,,,,substrate,,,,,glycoursodeoxycholic acid,endogenous substrate of OATP1B1,,HEK293 cells,HEK293,,,,,human,mbds0010,,2013-11-19 22:39:19
mbbd000142168,mbcd0000819,mbtp000012,mbrf0002149,,,,,substrate,,,,,taurolithocholic acid 3 sulfate,endogenous substrate of OATP1B1,,MDCKII cells,MDCKII,,,,,human,mbds0010,,2013-11-19 22:39:18
mbbd000142169,mbcd0001664,mbtp000012,mbrf0002149,,=,,,substrate,28,34.0,microM,,taurocholic acid,endogenous substrate of OATP1B1,,HEK293c18 cells,HEK293c18,,,,,human,mbds0010,,2013-11-19 22:39:19
mbbd000142170,mbcd0001664,mbtp000012,mbrf0002149,,=,,,substrate,28,14.0,microM,,taurocholic acid,endogenous substrate of OATP1B1,,XO,Xenopus laevis oocytes,,,,,human,mbds0010,,2013-11-19 22:39:18
mbbd000142171,mbcd0001664,mbtp000012,mbrf0002149,,=,,,substrate,28,10.0,microM,,taurocholic acid,endogenous substrate of OATP1B1,,HEK293c18,HEK293c18,,,,,human,mbds0010,,2013-11-19 22:39:19
mbbd000142172,mbcd0000815,mbtp000012,mbrf0002149,,,,,substrate,,,,,tauroursodeoxycholic acid,endogenous substrate of OATP1B1,,HEK293,HEK293,,,,,human,mbds0010,,2013-11-19 22:39:19
mbbd000142173,mbcd0003957,mbtp000012,mbrf0002149,,,,,substrate,,,,,throxine,endogenous substrate of OATP1B1,,HEK293c18,HEK293c18,,,,,human,mbds0010,,2013-11-19 22:39:19
mbbd000142174,mbcd0003957,mbtp000012,mbrf0002149,,=,,,substrate,28,3.0,microM,,throxine,endogenous substrate of OATP1B1,,XO,Xenopus laevis oocytes,,,,,human,mbds0010,,2013-11-19 22:39:18
mbbd000142175,mbcd0000984,mbtp000012,mbrf0002149,,=,,,substrate,28,2.7,microM,,iodothyronine,endogenous substrate of OATP1B1,,XO,Xenopus laevis oocytes,,,,,human,mbds0010,,2013-11-19 22:39:18
mbbd000142176,mbcd0029843,mbtp000012,mbrf0002149,,,,,substrate,,,,,iodothyronine sulfate,endogenous substrate of OATP1B1,,COS1,COS1,,,,,human,mbds0010,,2013-11-19 22:39:19
mbbd000142177,mbcd0002917,mbtp000012,mbrf0002149,,,,,substrate,,,,,leukotriene C4,endogenous substrate of OATP1B1,,XO,Xenopus laevis oocytes,,,,,human,mbds0010,,2013-11-19 22:39:18
mbbd000142178,mbcd0000528,mbtp000012,mbrf0002149,,,,,substrate,,,,,leukotriene E4,endogenous substrate of OATP1B1,,XO,Xenopus laevis oocytes,,,,,human,mbds0010,,2013-11-19 22:39:18
mbbd000142179,mbcd0001343,mbtp000012,mbrf0002149,,,,,substrate,,,,,prostaglandin E2,endogenous substrate of OATP1B1,,XO,Xenopus laevis oocytes,,,,,human,mbds0010,,2013-11-19 22:39:18
mbbd000142180,mbcd0001343,mbtp000012,mbrf0002149,,,,,substrate,,,,,prostaglandin E2,endogenous substrate of OATP1B1,,HEK293,HEK293,,,,,human,mbds0010,,2013-11-19 22:39:19
mbbd000142181,mbcd0000848,mbtp000012,mbrf0002149,,,,,substrate,,,,,thromboxane B2,endogenous substrate of OATP1B1,,XO,Xenopus laevis oocytes,,,,,human,mbds0010,,2013-11-19 22:39:18
mbbd000142182,mbcd0004702,mbtp000012,mbrf0002149,,=,,,substrate,28,0.16,microM,,bilirubin,endogenous substrate of OATP1B1,,HEK293,HEK293,,,,,human,mbds0010,,2013-11-19 22:39:19
mbbd000142183,mbcd0004702,mbtp000012,mbrf0002149,,=,,,substrate,28,0.0076,microM,,bilirubin,endogenous substrate of OATP1B1,,XO,Xenopus laevis oocytes,,,,,human,mbds0010,,2013-11-19 22:39:18
mbbd000142184,mbcd0000187,mbtp000012,mbrf0002149,,=,,,substrate,28,0.1,microM,,bilirubin monoglucuronide,endogenous substrate of OATP1B1,,HEK293,HEK293,,,,,human,mbds0010,,2013-11-19 22:39:19
mbbd000142185,mbcd0004701,mbtp000012,mbrf0002149,,=,,,substrate,28,0.3,microM,,bilirubin diglucuronide,endogenous substrate of OATP1B1,,HEK293,HEK293,,,,,human,mbds0010,,2013-11-19 22:39:19
mbbd000142186,mbcd0004706,mbtp000012,mbrf0002149,,,,,substrate,,,,,CCK-8,endogenous substrate of OATP1B1,,HEK293,HEK293,,,,,human,mbds0010,,2013-11-19 22:39:19
mbbd000142187,mbcd0003070,mbtp000012,mbrf0002149,,=,,,substrate,28,22.0,microM,,DHEAS,endogenous substrate of OATP1B1,,HEK293,HEK293,,,,,human,mbds0010,,2013-11-19 22:39:19
mbbd000142188,mbcd0003070,mbtp000012,mbrf0002149,,,,,substrate,,,,,DHEAS,endogenous substrate of OATP1B1,,XO,Xenopus laevis oocytes,,,,,human,mbds0010,,2013-11-19 22:39:18
mbbd000142189,mbcd0000387,mbtp000012,mbrf0002149,,,,,substrate,,,,,E217betaG,endogenous substrate of OATP1B1,,XO,Xenopus laevis oocytes,,,,,human,mbds0010,,2013-11-19 22:39:18
mbbd000142190,mbcd0000387,mbtp000012,mbrf0002149,,=,,,substrate,28,8.2,microM,,E217betaG,endogenous substrate of OATP1B1,,HEK293,HEK293,,,,,human,mbds0010,,2013-11-19 22:39:19
mbbd000142191,mbcd0000387,mbtp000012,mbrf0002149,,=,,,substrate,28,9.7,microM,,E217betaG,endogenous substrate of OATP1B1,,XO,Xenopus laevis oocytes,,,,,human,mbds0010,,2013-11-19 22:39:18
mbbd000142192,mbcd0000387,mbtp000012,mbrf0002149,,=,,,substrate,28,3.7,microM,,E217betaG,endogenous substrate of OATP1B1,,XO,Xenopus laevis oocytes,,,,,human,mbds0010,,2013-11-19 22:39:18
mbbd000142194,mbcd0000387,mbtp000012,mbrf0002149,,=,,,substrate,28,28.0,microM,,E217betaG,endogenous substrate of OATP1B1,,MDCKII,MDCKII,,,,,human,mbds0010,,2013-11-19 22:39:19
mbbd000142195,mbcd0000387,mbtp000012,mbrf0002149,,=,,,substrate,28,8.3,microM,,E217betaG,endogenous substrate of OATP1B1,,HEK293,HEK293,,,,,human,mbds0010,,2013-11-19 22:39:19
mbbd000142196,mbcd0000387,mbtp000012,mbrf0002149,,=,,,substrate,28,6.3,microM,,E217betaG,endogenous substrate of OATP1B1,,HEK293,HEK293,,,,,human,mbds0010,,2013-11-19 22:39:19
mbbd000142198,mbcd0003075,mbtp000012,mbrf0002149,,=,,,substrate,28,0.2,microM,,estrone 3 sulfate,endogenous substrate of OATP1B1,,HEK293,HEK293,,,,,human,mbds0010,,2013-11-19 22:39:19
mbbd000142199,mbcd0003075,mbtp000012,mbrf0002149,,=,,,substrate,28,5.3,microM,,estrone 3 sulfate,endogenous substrate of OATP1B1,,XO,Xenopus laevis oocytes,,,,,human,mbds0010,,2013-11-19 22:39:18
mbbd000142200,mbcd0003075,mbtp000012,mbrf0002149,,=,,,substrate,28,13.0,microM,,estrone 3 sulfate,endogenous substrate of OATP1B1,,HEK293,HEK293,,,,,human,mbds0010,,2013-11-19 22:39:19
mbbd000142201,mbcd0003075,mbtp000012,mbrf0002149,,,,,substrate,,,,,estrone 3 sulfate,endogenous substrate of OATP1B1,,MDCKII,MDCKII,,,,,human,mbds0010,,2013-11-19 22:39:19
mbbd000142202,mbcd0003075,mbtp000012,mbrf0002149,,=,,,substrate,28,0.23,microM,,estrone 3 sulfate,endogenous substrate of OATP1B1,,HEK293,HEK293,,,,,human,mbds0010,,2013-11-19 22:39:19
mbbd000142203,mbcd0003075,mbtp000012,mbrf0002149,,=,,,substrate,28,0.45,microM,,estrone 3 sulfate,endogenous substrate of OATP1B1,,HEK293,HEK293,,,,,human,mbds0010,,2013-11-19 22:39:19
mbbd000142204,mbcd0003075,mbtp000012,mbrf0002149,,,,,substrate,,,,,estrone 3 sulfate,endogenous substrate of OATP1B1,,COS1,COS1,,,,,human,mbds0010,,2013-11-19 22:39:19
mbbd000142205,mbcd0003075,mbtp000012,mbrf0002149,,,,,substrate,,,,,estrone 3 sulfate,endogenous substrate of OATP1B1,,HEK cells Flp-In-293,HEK Flp-In-293,,,,,human,mbds0010,,2013-11-20 01:14:13
mbbd000142206,mbcd0003134,mbtp000012,mbrf0002149,,,,,substrate,,,,,benzylpenicillin,,,HEK293,HEK293,,,,,human,mbds0010,,2013-11-19 22:39:19
mbbd000142207,mbcd0029477,mbtp000012,mbrf0002149,,=,,,substrate,28,3.45,microM,,cefditoren,,,XO,Xenopus laevis oocytes,,,,,human,mbds0010,,2013-11-19 22:39:18
mbbd000142208,mbcd0010791,mbtp000012,mbrf0002149,,=,,,substrate,28,4.84,microM,,cefoperazone,,,XO,Xenopus laevis oocytes,,,,,human,mbds0010,,2013-11-19 22:39:18
mbbd000142209,mbcd0003497,mbtp000012,mbrf0002149,,=,,,substrate,28,20.8,microM,,cefazolin,,,XO,Xenopus laevis oocytes,,,,,human,mbds0010,,2013-11-19 22:39:18
mbbd000142210,mbcd0014270,mbtp000012,mbrf0002149,,=,,,substrate,28,11.1,microM,,nafcillin,,,XO,Xenopus laevis oocytes,,,,,human,mbds0010,,2013-11-19 22:39:18
mbbd000142211,mbcd0001416,mbtp000012,mbrf0002149,,=,,,substrate,28,13.0,microM,,rifampin,,,XO,Xenopus laevis oocytes,,,,,human,mbds0010,,2013-11-19 22:39:18
mbbd000142212,mbcd0001416,mbtp000012,mbrf0002149,,=,,,substrate,28,1.5,microM,,rifampin,,,HeLa,HeLa,,,,,human,mbds0010,,2013-11-19 22:39:19
mbbd000142213,mbcd0029844,mbtp000012,mbrf0002149,,,,,substrate,,,,,gimatecan,,,MDCKII,MDCKII,,,,,human,mbds0010,,2013-11-19 22:39:18
mbbd000142214,mbcd0000779,mbtp000012,mbrf0002149,,,,,substrate,,,,,SN-38,,,XO,Xenopus laevis oocytes,,,,,human,mbds0010,,2013-11-19 22:39:18
mbbd000142215,mbcd0029845,mbtp000012,mbrf0002149,,,,,substrate,,,,,pazopanib,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142216,mbcd0026093,mbtp000012,mbrf0002149,,=,,,substrate,28,12.4,microM,,atorvastatin,,,HEK293,HEK293,,,,,human,mbds0010,,2013-11-19 22:39:19
mbbd000142217,mbcd0023123,mbtp000012,mbrf0002149,,,,,substrate,,,,,cerivastatin,,,MDCKII,MDCKII,,,,,human,mbds0010,,2013-11-19 22:39:18
mbbd000142218,mbcd0023123,mbtp000012,mbrf0002149,,,,,substrate,,,,,cerivastatin,,,HEK293,HEK293,,,,,human,mbds0010,,2013-11-19 22:39:19
mbbd000142219,mbcd0029425,mbtp000012,mbrf0002149,,,,,substrate,,,,,ezetimibe glucuronide,,,HEK293,HEK293,,,,,human,mbds0010,,2013-11-19 22:39:19
mbbd000142220,mbcd0001445,mbtp000012,mbrf0002149,,=,,,substrate,28,2.4,microM,,fluvastatin,,,MDCKII,MDCKII,,,,,human,mbds0010,,2013-11-19 22:39:18
mbbd000142221,mbcd0001445,mbtp000012,mbrf0002149,,=,,,substrate,28,31.0,microM,,fluvastatin,,,XO,Xenopus laevis oocytes,,,,,human,mbds0010,,2013-11-19 22:39:18
mbbd000142222,mbcd0001445,mbtp000012,mbrf0002149,,=,,,substrate,28,1.4,microM,,fluvastatin,,,CHO,CHO,,,,,human,mbds0010,,2013-11-19 22:39:19
mbbd000142223,mbcd0001445,mbtp000012,mbrf0002149,,=,,,substrate,28,3.5,microM,,fluvastatin,,,CHO,CHO,,,,,human,mbds0010,,2013-11-19 22:39:19
mbbd000142224,mbcd0000693,mbtp000012,mbrf0002149,,=,,,substrate,28,3.0,microM,,pitavastatin,,,HEK293,HEK293,,,,,human,mbds0010,,2013-11-19 22:39:19
mbbd000142225,mbcd0000693,mbtp000012,mbrf0002149,,=,,,substrate,28,6.7,microM,,pitavastatin,,,XO,Xenopus laevis oocytes,,,,,human,mbds0010,,2013-11-19 22:39:18
mbbd000142226,mbcd0003126,mbtp000012,mbrf0002149,,=,,,substrate,28,6.7,microM,,pravastatin,,,HEK293,HEK293,,,,,human,mbds0010,,2013-11-19 22:39:19
mbbd000142227,mbcd0003126,mbtp000012,mbrf0002149,,=,,,substrate,28,11.5,microM,,pravastatin,,,XO,Xenopus laevis oocytes,,,,,human,mbds0010,,2013-11-19 22:39:18
mbbd000142228,mbcd0003126,mbtp000012,mbrf0002149,,=,,,substrate,28,24.0,microM,,pravastatin,,,MDCKII,MDCKII,,,,,human,mbds0010,,2013-11-19 22:39:18
mbbd000142229,mbcd0003126,mbtp000012,mbrf0002149,,=,,,substrate,28,86.0,microM,,pravastatin,,,HEK293,HEK293,,,,,human,mbds0010,,2013-11-19 22:39:19
mbbd000142230,mbcd0003126,mbtp000012,mbrf0002149,,=,,,substrate,28,58.0,microM,,pravastatin,,,XO,Xenopus laevis oocytes,,,,,human,mbds0010,,2013-11-19 22:39:18
mbbd000142231,mbcd0003126,mbtp000012,mbrf0002149,,=,,,substrate,28,109.0,microM,,pravastatin,,,HEK293,HEK293,,,,,human,mbds0010,,2013-11-19 22:39:19
mbbd000142232,mbcd0001448,mbtp000012,mbrf0002149,,=,,,substrate,28,7.3,microM,,rosuvastatin,,,XO,Xenopus laevis oocytes,,,,,human,mbds0010,,2013-11-19 22:39:18
mbbd000142233,mbcd0001448,mbtp000012,mbrf0002149,,,,,substrate,,,,,rosuvastatin,,,XO,Xenopus laevis oocytes,,,,,human,mbds0010,,2013-11-19 22:39:18
mbbd000142234,mbcd0001448,mbtp000012,mbrf0002149,,=,,,substrate,28,8.5,microM,,rosuvastatin,,,XO,Xenopus laevis oocytes,,,,,human,mbds0010,,2013-11-19 22:39:18
mbbd000142235,mbcd0001448,mbtp000012,mbrf0002149,,=,,,substrate,28,4.0,microM,,rosuvastatin,,,HeLa,HeLa,,,,,human,mbds0010,,2013-11-19 22:39:19
mbbd000142236,mbcd0001448,mbtp000012,mbrf0002149,,=,,,substrate,28,0.802,microM,,rosuvastatin,,,HEK293,HEK293,,,,,human,mbds0010,,2013-11-19 22:39:19
mbbd000142237,mbcd0003005,mbtp000012,mbrf0002149,,=,,,substrate,28,12.8,microM,,olmesartan,,,HEK293,HEK293,,,,,human,mbds0010,,2013-11-19 22:39:19
mbbd000142238,mbcd0003086,mbtp000012,mbrf0002149,,,,,substrate,,,,,valsartan,,,HEK293,HEK293,,,,,human,mbds0010,,2013-11-19 22:39:19
mbbd000142239,mbcd0003086,mbtp000012,mbrf0002149,,=,,,substrate,28,1.39,microM,,valsartan,,,HEK293,HEK293,,,,,human,mbds0010,,2013-11-19 22:39:19
mbbd000142240,mbcd0003086,mbtp000012,mbrf0002149,,=,,,substrate,28,17.8,microM,,valsartan,,,CHO,CHO,,,,,human,mbds0010,,2013-11-19 22:39:19
mbbd000142241,mbcd0000823,mbtp000012,mbrf0002149,,,,,substrate,,,,,temocapril,,,HEK293,HEK293,,,,,human,mbds0010,,2013-11-19 22:39:19
mbbd000142242,mbcd0010876,mbtp000012,mbrf0002149,,=,,,substrate,28,6.2,microM,,torsemide,,,HEK293,HEK293,,,,,human,mbds0010,,2013-11-19 22:39:19
mbbd000142243,mbcd0002634,mbtp000012,mbrf0002149,,,,,substrate,,,,,darunavir,,,XO,Xenopus laevis oocytes,,,,,human,mbds0010,,2013-11-19 22:39:18
mbbd000142244,mbcd0002241,mbtp000012,mbrf0002149,,,,,substrate,,,,,lopinavir,,,XO,Xenopus laevis oocytes,,,,,human,mbds0010,,2013-11-19 22:39:18
mbbd000142245,mbcd0001533,mbtp000012,mbrf0002149,,,,,substrate,,,,,saquinavir,,,XO,Xenopus laevis oocytes,,,,,human,mbds0010,,2013-11-19 22:39:18
mbbd000142246,mbcd0029357,mbtp000012,mbrf0002149,,,,,substrate,,,,,ACU154,,,MDCKII,MDCKII,,,,,human,mbds0010,,2013-11-19 22:39:18
mbbd000142247,mbcd0029150,mbtp000012,mbrf0002149,,,,,substrate,,,,,atrasentan,,,HeLa,HeLa,,,,,human,mbds0010,,2013-11-19 22:39:19
mbbd000142248,mbcd0003035,mbtp000012,mbrf0002149,,=,,,substrate,28,0.3,microM,,bromosulphthalein,,,XO,Xenopus laevis oocytes,,,,,human,mbds0010,,2013-11-19 22:39:18
mbbd000142249,mbcd0003035,mbtp000012,mbrf0002149,,=,,,substrate,28,2.4,microM,,bromosulphthalein,,,MDCKII,MDCKII,,,,,human,mbds0010,,2013-11-19 22:39:18
mbbd000142250,mbcd0003035,mbtp000012,mbrf0002149,,,,,substrate,,,,,bromosulphthalein,,,COS1,COS1,,,,,human,mbds0010,,2013-11-19 22:39:19
mbbd000142251,mbcd0000199,mbtp000012,mbrf0002149,,,,,substrate,,,,,BQ-123,,,XO,Xenopus laevis oocytes,,,,,human,mbds0010,,2013-11-19 22:39:18
mbbd000142252,mbcd0001120,mbtp000012,mbrf0002149,,,,,substrate,,,,,caspofungin,,,HeLa,HeLa,,,,,human,mbds0010,,2013-11-19 22:39:19
mbbd000142253,mbcd0000005,mbtp000012,mbrf0002149,,,,,substrate,,,,,DADLE,,,XO,Xenopus laevis oocytes,,,,,human,mbds0010,,2013-11-19 22:39:18
mbbd000142254,mbcd0002041,mbtp000012,mbrf0002149,,,,,substrate,,,,,DPDPE,,,XO,Xenopus laevis oocytes,,,,,human,mbds0010,,2013-11-19 22:39:18
mbbd000142255,mbcd0029339,mbtp000012,mbrf0002149,,=,,,substrate,28,0.087,microM,,EE2S,,,HEK293,HEK293,,,,,human,mbds0010,,2013-11-19 22:39:19
mbbd000142256,mbcd0029339,mbtp000012,mbrf0002149,,=,,,substrate,28,141.0,microM,,EE2S,,,HEK293,HEK293,,,,,human,mbds0010,,2013-11-19 22:39:19
mbbd000142257,mbcd0001797,mbtp000012,mbrf0002776,,,,,non-substrate,,,,,fexofenadine; FEX,no difference in basal-to-apical transcellular transport of FEX could be observed in vector-transfected control cells and single transfectants expressing OATP1B1,,MDCKII cells expressing OATP1B1,MDCKII,,5,microM,,human,mbds0010,,2013-12-08 08:52:01
mbbd000142258,mbcd0001652,mbtp000012,mbrf0002149,,,,,substrate,,,,,flavopiridol,,,HEK293,HEK293,,,,,human,mbds0010,,2013-11-19 22:39:19
mbbd000142259,mbcd0029849,mbtp000012,mbrf0002149,,,,,substrate,,,,,flavopiridol glucuronide,,,HEK293,HEK293,,,,,human,mbds0010,,2013-11-19 22:39:19
mbbd000142260,mbcd0029170,mbtp000012,mbrf0002149,,=,,,substrate,28,700.0,microM,,Gd-EOB-DTPA,,,HEK293,HEK293,,,,,human,mbds0010,,2013-12-19 20:07:31
mbbd000142261,mbcd0029850,mbtp000012,mbrf0002149,,,,,substrate,,,,,karenitecin,,,MDCKII,MDCKII,,,,,human,mbds0010,,2013-11-19 22:39:18
mbbd000142262,mbcd0003043,mbtp000012,mbrf0002149,,,,,substrate,,,,,methotrexate,,,XO,Xenopus laevis oocytes,,,,,human,mbds0010,,2013-11-19 22:39:18
mbbd000142263,mbcd0029851,mbtp000012,mbrf0002149,,,,,substrate,,,,,Mycophenolic acid-O-glucuronide,,,HEK293,HEK293,,,,,human,mbds0010,,2013-11-19 22:39:19
mbbd000142264,mbcd0029127,mbtp000012,mbrf0002149,,=,,,substrate,28,60.0,microM,,Ro 48-5033,,,CHO,CHO,,,,,human,mbds0010,,2013-11-19 22:39:19
mbbd000142265,mbcd0029852,mbtp000012,mbrf0002149,,=,,,substrate,28,1.93,microM,,SG8921G,,,HEK293,HEK293,,,,,human,mbds0010,,2013-11-19 22:39:19
mbbd000142266,mbcd0001324,mbtp000012,mbrf0002569,,,,,substrate,,,,,sirolimus,,,HEK293,HEK293,,,,,human,mbds0010,,2014-02-26 20:33:00
mbbd000142267,mbcd0000875,mbtp000012,mbrf0002149,,,,,substrate,,,,,troglitazone sulfate,,,XO,Xenopus laevis oocytes,,,,,human,mbds0010,,2013-11-19 22:39:18
mbbd000142268,mbcd0029740,mbtp000012,mbrf0002149,,,,,substrate,,,,,YM785,,,HEK293,HEK293,,,,,human,mbds0010,,2013-11-19 22:39:19
mbbd000142269,mbcd0029829,mbtp000012,mbrf0002149,,=,,,substrate,28,1.45,microM,,CDCA-NBD,,,HepG2,HepG2,,,,,human,mbds0010,,2013-11-19 22:39:19
mbbd000142270,mbcd0000253,mbtp000012,mbrf0002149,,,,,substrate,,,,,CGamF,,,CHO,CHO,,,,,human,mbds0010,,2013-11-19 22:39:19
mbbd000142271,mbcd0029769,mbtp000012,mbrf0002149,,,,,substrate,,,,,CLF,,,CHO,CHO,,,,,human,mbds0010,,2013-11-19 22:39:19
mbbd000142272,mbcd0029786,mbtp000012,mbrf0002149,,=,,,substrate,28,3.8,microM,,fluorescein - methotrexate,,,CHO,CHO,,,,,human,mbds0010,,2013-11-19 22:39:19
mbbd000142273,mbcd0029855,mbtp000012,mbrf0002149,,,,,substrate,,,,,arsenate,,,HEK293,HEK293,,,,,human,mbds0010,,2013-11-19 22:39:19
mbbd000142274,mbcd0000146,mbtp000012,mbrf0002149,,,,,substrate,,,,,arsenite,,,HEK293,HEK293,,,,,human,mbds0010,,2013-11-19 22:39:19
mbbd000142275,mbcd0029167,mbtp000012,mbrf0002149,,=,,,substrate,28,0.31,microM,,BDE47,,,CHO,CHO,,,,,human,mbds0010,,2013-11-19 22:39:19
mbbd000142276,mbcd0029168,mbtp000012,mbrf0002149,,=,,,substrate,28,0.91,microM,,BDE99,,,CHO,CHO,,,,,human,mbds0010,,2013-11-19 22:39:19
mbbd000142277,mbcd0029169,mbtp000012,mbrf0002149,,=,,,substrate,28,1.91,microM,,BDE153,,,CHO,CHO,,,,,human,mbds0010,,2013-11-19 22:39:19
mbbd000142278,mbcd0000675,mbtp000012,mbrf0002149,,,,,substrate,,,,,phalloidin,,,XO,Xenopus laevis oocytes,,,,,human,mbds0010,,2013-11-19 22:39:18
mbbd000142279,mbcd0023126,mbtp000012,mbrf0002149,,,,,inhibitor,,,,,pioglitazone,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142280,mbcd0023111,mbtp000012,mbrf0002149,,,,,inhibitor,,,,,rosiglitazone,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142281,mbcd0002241,mbtp000012,mbrf0002149,,=,,,inhibitor,25,0.5,microM,,lopinavir,,,CGamF inhibition in CHO cells,CHO,,,,,human,mbds0010,,2013-11-19 22:39:19
mbbd000142282,mbcd0002383,mbtp000012,mbrf0002149,,=,,,inhibitor,25,12.8,microM,,amprenavir,,,CGamF inhibition in CHO cells,CHO,,,,,human,mbds0010,,2013-11-19 22:39:19
mbbd000142283,mbcd0002051,mbtp000012,mbrf0002149,,=,,,inhibitor,25,1.5,microM,,atanazavir,,,CGamF inhibition in CHO cells,CHO,,,,,human,mbds0010,,2013-11-19 22:39:19
mbbd000142284,mbcd0002634,mbtp000012,mbrf0002149,,=,,,inhibitor,25,3.1,microM,,darunavir,,,CGamF inhibition in CHO cells,CHO,,,,,human,mbds0010,,2013-11-19 22:39:19
mbbd000142285,mbcd0000154,mbtp000012,mbrf0002149,,=,,,inhibitor,25,0.87,microM,,atorvastatin lactone,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142286,mbcd0001052,mbtp000012,mbrf0002149,,=,,,inhibitor,25,6.7,microM,,beclomethasone,,,,,,,,,human,mbds0010,,2013-11-19 22:39:18
mbbd000142287,mbcd0026046,mbtp000012,mbrf0002149,,=,,,inhibitor,25,0.7,microM,,bromocriptine,,,,,,,,,human,mbds0010,,2013-11-19 22:39:18
mbbd000142288,mbcd0001120,mbtp000012,mbrf0002149,,,,,inhibitor,,,,,caspofungin,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142289,mbcd0001517,mbtp000012,mbrf0002149,,,,,inhibitor,,,,,clarithromycin,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142290,mbcd0000311,mbtp000012,mbrf0002074,,=,,,inhibitor,29,0.242,microM,0.029,cyclosporin A,,,OATP1B1 uptake of pitavastatin inhibition,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142291,mbcd0001316,mbtp000012,mbrf0002074,,=,,,inhibitor,29,0.611,microM,0.069,tacrolimus,,,OATP1B1 uptake of pitavastatin inhibition,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142292,mbcd0001316,mbtp000012,mbrf0002074,,=,,,inhibitor,29,0.477,microM,0.030,rifampicin,,,OATP1B1 uptake of pitavastatin inhibition,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142293,mbcd0000749,mbtp000012,mbrf0002074,,=,,,inhibitor,29,0.171,microM,0.024,rifamycin SV,,,OATP1B1 uptake of pitavastatin inhibition,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142294,mbcd0017644,mbtp000012,mbrf0002074,,>,,,inhibitor,29,100.0,microM,,tolbutamide,,,OATP1B1 uptake of pitavastatin inhibition,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142295,mbcd0029629,mbtp000012,mbrf0002074,,=,,,inhibitor,29,0.746,microM,0.101,glibenclamide,,,OATP1B1 uptake of pitavastatin inhibition,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142296,mbcd0023577,mbtp000012,mbrf0002074,,>,,,inhibitor,29,100.0,microM,,fluconazole,,,OATP1B1 uptake of pitavastatin inhibition,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142297,mbcd0017104,mbtp000012,mbrf0002074,,=,,,inhibitor,29,19.2,microM,3.9,ketoconazole,,,OATP1B1 uptake of pitavastatin inhibition,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142298,mbcd0002191,mbtp000012,mbrf0002074,,>,,,inhibitor,29,100.0,microM,,itraconazole,,,OATP1B1 uptake of pitavastatin inhibition,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142299,mbcd0009531,mbtp000012,mbrf0002074,,=,,,inhibitor,29,25.2,microM,4.7,gemfibrozil,,,OATP1B1 uptake of pitavastatin inhibition,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142300,mbcd0029834,mbtp000012,mbrf0002074,,=,,,inhibitor,29,22.6,microM,5.8,gemfibrozil-O-glucuronide,,,OATP1B1 uptake of pitavastatin inhibition,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142301,mbcd0029859,mbtp000012,mbrf0002074,,>,,,inhibitor,29,300.0,microM,,gemfibrozil-M3,,,OATP1B1 uptake of pitavastatin inhibition,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142302,mbcd0013235,mbtp000012,mbrf0002074,,>,,,inhibitor,29,300.0,microM,,clofibrate,,,OATP1B1 uptake of pitavastatin inhibition,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142303,mbcd0021516,mbtp000012,mbrf0002074,,=,,,inhibitor,29,141.0,microM,22,ciprofibrate,,,OATP1B1 uptake of pitavastatin inhibition,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142304,mbcd0019138,mbtp000012,mbrf0002074,,=,,,inhibitor,29,68.6,microM,11.9,bezafibrate,,,OATP1B1 uptake of pitavastatin inhibition,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142305,mbcd0003027,mbtp000012,mbrf0002074,,>,,,inhibitor,29,300.0,microM,,fenofibrate,,,OATP1B1 uptake of pitavastatin inhibition,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142306,mbcd0001111,mbtp000012,mbrf0002074,,>,,,inhibitor,29,300.0,microM,,cimetidine,,,OATP1B1 uptake of pitavastatin inhibition,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142307,mbcd0002666,mbtp000012,mbrf0002074,,>,,,inhibitor,29,300.0,microM,,ranitidine,,,OATP1B1 uptake of pitavastatin inhibition,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142308,mbcd0003086,mbtp000012,mbrf0002074,,=,,,inhibitor,29,8.96,microM,1.33,valsartan,,,OATP1B1 uptake of pitavastatin inhibition,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142309,mbcd0004705,mbtp000012,mbrf0002074,,=,,,inhibitor,29,0.436,microM,0.043,telmisartan,,,OATP1B1-expressing HEK293 cells; uptake of pitavastatin; inhibition,HEK293,mbcd0000693,,,,human,mbds0010,,2013-12-13 22:01:07
mbbd000142310,mbcd0003000,mbtp000012,mbrf0002074,,>,,,inhibitor,29,100.0,microM,,chlorzoxazone,,,OATP1B1 uptake of pitavastatin inhibition,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142311,mbcd0002667,mbtp000012,mbrf0002074,,>,,,inhibitor,29,100.0,microM,,colchichine,,,OATP1B1 uptake of pitavastatin inhibition,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142312,mbcd0002996,mbtp000012,mbrf0002074,,>,,,inhibitor,29,100.0,microM,,phenytoin,,,OATP1B1 uptake of pitavastatin inhibition,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142313,mbcd0002996,mbtp000012,mbrf0002074,,=,,,inhibitor,29,8.26,microM,0.54,clarithromycin,,,OATP1B1 uptake of pitavastatin inhibition,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142314,mbcd0000937,mbtp000012,mbrf0002074,,=,,,inhibitor,29,11.6,microM,2.1,erythromycin,,,OATP1B1 uptake of pitavastatin inhibition,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142315,mbcd0002323,mbtp000012,mbrf0002074,,=,,,inhibitor,29,18.4,microM,1.9,indinavir,,,OATP1B1 uptake of pitavastatin inhibition,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142316,mbcd0001938,mbtp000012,mbrf0002074,,=,,,inhibitor,29,0.781,microM,0.048,ritonavir,,,OATP1B1 uptake of pitavastatin inhibition,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142317,mbcd0001533,mbtp000012,mbrf0002074,,=,,,inhibitor,29,1.59,microM,0.13,saquinavir,,,OATP1B1 uptake of pitavastatin inhibition,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142318,mbcd0003154,mbtp000012,mbrf0002074,,=,,,inhibitor,29,76.2,microM,7.1,probenecid,,,OATP1B1 uptake of pitavastatin inhibition,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142319,mbcd0003043,mbtp000012,mbrf0002074,,>,,,inhibitor,29,300.0,microM,,methotrexate,,,OATP1B1 uptake of pitavastatin inhibition,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142320,mbcd0001050,mbtp000012,mbrf0002074,,=,,,inhibitor,29,31.7,microM,3.0,digoxin,,,OATP1B1 uptake of pitavastatin inhibition,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142321,mbcd0002338,mbtp000012,mbrf0002074,,>,,,inhibitor,29,100.0,microM,,diltiazem,,,OATP1B1 uptake of pitavastatin inhibition,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142322,mbcd0027062,mbtp000012,mbrf0002074,,=,,,inhibitor,29,51.6,microM,15.9,verapamil,,,OATP1B1 uptake of pitavastatin inhibition,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142323,mbcd0003042,mbtp000012,mbrf0002074,,=,,,inhibitor,29,83.3,microM,9.7,warfarin,,,OATP1B1 uptake of pitavastatin inhibition,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142324,mbcd0001808,mbtp000012,mbrf0001551,,=,,,inhibitor,82,1.1,,,elacridar,,,"inhibited E2G, gimatecan and BNP1350 uptake",MDCKII,mbcd0000387,5,microM,,human,mbds0010,,2013-11-11 03:52:51
mbbd000142325,mbcd0002294,mbtp000012,mbrf0001551,,=,,,inhibitor,82,1.4,,,zosuquidar,,,"inhibited E2G, gimatecan and BNP1350 uptake",MDCKII,mbcd0000387,5,microM,,human,mbds0010,,2013-11-11 03:52:51
mbbd000142326,mbcd0000721,mbtp000012,mbrf0001551,,=,,,inhibitor,82,1.0,,,valspodar,,,"inhibited E2G, gimatecan and BNP1350 uptake",MDCKII,mbcd0000387,5,microM,,human,mbds0010,,2013-11-11 03:52:51
mbbd000142327,mbcd0022900,mbtp000012,mbrf0001551,,=,,,inhibitor,82,1.1,,,pantoprazole,,,"inhibited E2G, gimatecan and BNP1350 uptake",MDCKII,mbcd0000387,500,microM,,human,mbds0010,,2013-11-11 03:52:51
mbbd000142328,mbcd0029860,mbtp000012,mbrf0002149,,=,,,inhibitor,29,0.06,microM,,estropipate,IC50 or Ki (must check the original paper),,,,,,,,human,mbds0010,,2013-11-28 04:04:36
mbbd000142329,mbcd0029170,mbtp000012,mbrf0002149,,=,,,inhibitor,29,600.0,microM,,Gd-EOB-DTPA,IC50 or Ki (must check the original paper),,,,,,,,human,mbds0010,,2013-12-19 20:07:31
mbbd000142330,mbcd0003074,mbtp000012,mbrf0002149,,=,,,inhibitor,29,1.14,microM,,glyburide,IC50 or Ki (must check the original paper),,,,,,,,human,mbds0010,,2013-11-28 04:04:36
mbbd000142331,mbcd0001632,mbtp000012,mbrf0002149,,=,,,inhibitor,29,0.82,microM,,hyperforin,IC50 or Ki (must check the original paper),,,,,,,,human,mbds0010,,2013-11-28 04:04:34
mbbd000142332,mbcd0000487,mbtp000012,mbrf0002149,,=,,,inhibitor,29,0.112,microM,,indocyanine green,IC50 or Ki (must check the original paper),,,,,,,,human,mbds0010,,2013-11-28 04:04:34
mbbd000142333,mbcd0002091,mbtp000012,mbrf0001551,,~,,,inhibitor,100,85.0,%,5,irinotecan; CPT-11,,,Cellular accumulation of 1 microM E2G in MDCKII-OATP1B1 cells,MDCKII,mbcd0000387,100,microM,,human,mbds0010,,2013-12-09 20:17:19
mbbd000142334,mbcd0025591,mbtp000012,mbrf0002149,,=,,,inhibitor,29,6.1,microM,,lovastatin,IC50 or Ki (must check the original paper),,,,,,,,human,mbds0010,,2013-11-28 04:04:35
mbbd000142335,mbcd0006716,mbtp000012,mbrf0002149,,=,,,inhibitor,29,8.1,microM,,moricizine,IC50 or Ki (must check the original paper),,,,,,,,human,mbds0010,,2013-11-28 04:04:35
mbbd000142336,mbcd0012926,mbtp000012,mbrf0002149,,=,,,inhibitor,29,3.7,microM,,niflumic acid,IC50 or Ki (must check the original paper),,,,,,,,human,mbds0010,,2013-11-28 04:04:35
mbbd000142337,mbcd0029845,mbtp000012,mbrf0002149,,=,,,inhibitor,29,0.79,microM,,pazopanib,IC50 or Ki (must check the original paper),,,,,,,,human,mbds0010,,2013-11-28 04:04:35
mbbd000142338,mbcd0002831,mbtp000012,mbrf0002149,,=,,,inhibitor,29,11.2,microM,,resveratrol,IC50 or Ki (must check the original paper),,,,,,,,human,mbds0010,,2013-11-28 04:04:35
mbbd000142339,mbcd0001324,mbtp000012,mbrf0002569,,=,,,inhibitor,25,6.49,microM,,sirolimus,,,bromosulphthalein inhibition into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142340,mbcd0001324,mbtp000012,mbrf0002569,,=,,,inhibitor,25,2.11,microM,,sirolimus,,,bromosulphthalein inhibition into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142341,mbcd0028157,mbtp000012,mbrf0002524,,>,,,inhibitor,25,250.0,microM,,azithromycin,,,BSP inhibition into OATP expressing HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142342,mbcd0002996,mbtp000012,mbrf0002524,,=,,,inhibitor,25,96.0,microM,5,clarithromycin,,,BSP inhibition into OATP expressing HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142343,mbcd0000937,mbtp000012,mbrf0002524,,=,,,inhibitor,25,217.0,microM,19,erythromycin,,,BSP inhibition into OATP expressing HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142344,mbcd0028769,mbtp000012,mbrf0002524,,=,,,inhibitor,25,153.0,microM,4,roxithromycin,,,BSP inhibition into OATP expressing HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142345,mbcd0001376,mbtp000012,mbrf0002524,,=,,,inhibitor,25,121.0,microM,20,telithromycin,,,BSP inhibition into OATP expressing HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142346,mbcd0028157,mbtp000013,mbrf0002524,,,,,inhibitor,,,,,azithromycin,,,BSP inhibition into OATP expressing HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142347,mbcd0002996,mbtp000013,mbrf0002524,,=,,,inhibitor,25,32.0,microM,7,clarithromycin,,,BSP inhibition into OATP expressing HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142348,mbcd0000937,mbtp000013,mbrf0002524,,=,,,inhibitor,25,34.0,microM,14,erythromycin,,,BSP inhibition into OATP expressing HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142349,mbcd0028769,mbtp000013,mbrf0002524,,=,,,inhibitor,25,37.0,microM,6,roxithromycin,,,BSP inhibition into OATP expressing HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142350,mbcd0001376,mbtp000013,mbrf0002524,,=,,,inhibitor,25,11.0,microM,0.3,telithromycin,,,BSP inhibition into OATP expressing HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142351,mbcd0001416,mbtp000012,mbrf0002579,,=,,,inhibitor,29,4.42,microM,,rifampin,,,"oocytes overexpressing OATP1B1, inhibition of olmesartan uptake",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142352,mbcd0017104,mbtp000012,mbrf0002579,,=,,,inhibitor,29,66.1,microM,,ketoconazole,,,"oocytes overexpressing OATP1B1, inhibition of olmesartan uptake",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142353,mbcd0026093,mbtp000012,mbrf0002140,,=,,,substrate,28,0.93,microM,0.23,atorvastatin acid,,,OATP1B1 transfected HEK293 cells,HEK293,,,,,human,mbds0010,,2013-11-24 23:13:55
mbbd000142354,mbcd0026093,mbtp000012,mbrf0002140,,=,,,substrate,22,3.84,pmol / mg protein / min,0.27,atorvastatin acid,,,OATP1B1 transfected HEK293 cells,HEK293,,,,,human,mbds0010,,2013-11-24 23:13:55
mbbd000142355,mbcd0000311,mbtp000012,mbrf0002140,,=,,,inhibitor,25,0.021,microM,0.004,CsA,,,inhibition of atorvastatin uptake into OATP1B1 transfected HEK293 cells,,,,,,human,mbds0010,,2013-07-12 21:01:53
mbbd000142356,mbcd0001316,mbtp000012,mbrf0002140,,=,,,inhibitor,25,1.99,microM,0.42,tac,,,inhibition of atorvastatin uptake into OATP1B1 transfected HEK293 cells,,,,,,human,mbds0010,,2013-07-12 21:01:53
mbbd000142357,mbcd0003681,mbtp000012,mbrf0001735,,>,,,inhibitor,25,10000.0,microM,,cephalothin,,,inhibition of LCA-NDB uptake into HEK293 cells expressing OATP,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142358,mbcd0003497,mbtp000012,mbrf0001735,,>,,,inhibitor,25,10000.0,microM,,cefazolin,,,inhibition of LCA-NDB uptake into HEK293 cells expressing OATP,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142359,mbcd0003692,mbtp000012,mbrf0001735,,>,,,inhibitor,25,10000.0,microM,,cefmetazole,,,inhibition of LCA-NDB uptake into HEK293 cells expressing OATP,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142360,mbcd0003134,mbtp000012,mbrf0001735,,>,,,inhibitor,25,4900.0,microM,,penicillin,,,inhibition of LCA-NDB uptake into HEK293 cells expressing OATP,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142361,mbcd0010791,mbtp000012,mbrf0001735,,>,,,inhibitor,25,10000.0,microM,,cefaperazone,,,inhibition of LCA-NDB uptake into HEK293 cells expressing OATP,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142362,mbcd0003775,mbtp000012,mbrf0001735,,>,,,inhibitor,25,10000.0,microM,,cefotaxime,,,inhibition of LCA-NDB uptake into HEK293 cells expressing OATP,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142363,mbcd0003618,mbtp000012,mbrf0001735,,>,,,inhibitor,25,10000.0,microM,,cephalexin,,,inhibition of LCA-NDB uptake into HEK293 cells expressing OATP,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142364,mbcd0001298,mbtp000012,mbrf0001735,,>,,,inhibitor,25,1000.0,microM,,cefaclor,,,inhibition of LCA-NDB uptake into HEK293 cells expressing OATP,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142365,mbcd0003622,mbtp000012,mbrf0001735,,>,,,inhibitor,25,10000.0,microM,,ampicillin,,,inhibition of LCA-NDB uptake into HEK293 cells expressing OATP,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142366,mbcd0003773,mbtp000012,mbrf0001735,,=,,,inhibitor,25,470.0,microM,,ceftriaxone,,,inhibition of LCA-NDB uptake into HEK293 cells expressing OATP,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142367,mbcd0013187,mbtp000012,mbrf0001735,,>,,,inhibitor,25,100.0,microM,,meropenem,,,inhibition of LCA-NDB uptake into HEK293 cells expressing OATP,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142368,mbcd0000937,mbtp000012,mbrf0001735,,>,,,inhibitor,25,100.0,microM,,erythromycin,,,inhibition of LCA-NDB uptake into HEK293 cells expressing OATP,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142369,mbcd0028769,mbtp000012,mbrf0001735,,>,,,inhibitor,25,100.0,microM,,roxythromycin,,,inhibition of LCA-NDB uptake into HEK293 cells expressing OATP,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142370,mbcd0002996,mbtp000012,mbrf0001735,,=,,,inhibitor,25,75.0,microM,,clarithromycin,,,inhibition of LCA-NDB uptake into HEK293 cells expressing OATP,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142371,mbcd0003016,mbtp000012,mbrf0001735,,>,,,inhibitor,25,100.0,microM,,tetracycline,,,inhibition of LCA-NDB uptake into HEK293 cells expressing OATP,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142372,mbcd0029861,mbtp000012,mbrf0001735,,>,,,inhibitor,25,100.0,microM,,minocyclin,,,inhibition of LCA-NDB uptake into HEK293 cells expressing OATP,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142373,mbcd0010468,mbtp000012,mbrf0001735,,>,,,inhibitor,25,100.0,microM,,kanamycin,,,inhibition of LCA-NDB uptake into HEK293 cells expressing OATP,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142374,mbcd0011365,mbtp000012,mbrf0001735,,>,,,inhibitor,25,100.0,microM,,norfloxacin,,,inhibition of LCA-NDB uptake into HEK293 cells expressing OATP,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142375,mbcd0001470,mbtp000012,mbrf0001735,,>,,,inhibitor,25,100.0,microM,,levofloxacin,,,inhibition of LCA-NDB uptake into HEK293 cells expressing OATP,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142376,mbcd0002989,mbtp000012,mbrf0001735,,>,,,inhibitor,25,100.0,microM,,sparfloxacin,,,inhibition of LCA-NDB uptake into HEK293 cells expressing OATP,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142377,mbcd0003068,mbtp000012,mbrf0001735,,>,,,inhibitor,25,100.0,microM,,ofloxacin,,,inhibition of LCA-NDB uptake into HEK293 cells expressing OATP,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142378,mbcd0002191,mbtp000012,mbrf0001735,,>,,,inhibitor,25,100.0,microM,,itraconazole,,,inhibition of LCA-NDB uptake into HEK293 cells expressing OATP,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142379,mbcd0023577,mbtp000012,mbrf0001735,,>,,,inhibitor,25,100.0,microM,,fluconazole,,,inhibition of LCA-NDB uptake into HEK293 cells expressing OATP,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142380,mbcd0001416,mbtp000012,mbrf0001735,,=,,,inhibitor,25,8.8,microM,,rifampicin,,,inhibition of LCA-NDB uptake into HEK293 cells expressing OATP,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142381,mbcd0002983,mbtp000012,mbrf0001735,,>,,,inhibitor,25,1000.0,microM,,isoniazide,,,inhibition of LCA-NDB uptake into HEK293 cells expressing OATP,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142382,mbcd0008222,mbtp000012,mbrf0001735,,>,,,inhibitor,25,1000.0,microM,,aztreonam,,,inhibition of LCA-NDB uptake into HEK293 cells expressing OATP,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142383,mbcd0003681,mbtp000013,mbrf0001735,,=,,,inhibitor,25,1600.0,microM,,cephalothin,,,inhibition of LCA-NDB uptake into HEK293 cells expressing OATP,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142384,mbcd0003497,mbtp000013,mbrf0001735,,=,,,inhibitor,25,3900.0,microM,,cefazolin,,,inhibition of LCA-NDB uptake into HEK293 cells expressing OATP,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142385,mbcd0003692,mbtp000013,mbrf0001735,,=,,,inhibitor,25,5200.0,microM,,cefmetazole,,,inhibition of LCA-NDB uptake into HEK293 cells expressing OATP,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142386,mbcd0003134,mbtp000013,mbrf0001735,,=,,,inhibitor,25,5000.0,microM,,penicillin,,,inhibition of LCA-NDB uptake into HEK293 cells expressing OATP,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142387,mbcd0010791,mbtp000013,mbrf0001735,,=,,,inhibitor,25,2800.0,microM,,cefaperazone,,,inhibition of LCA-NDB uptake into HEK293 cells expressing OATP,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142388,mbcd0003775,mbtp000013,mbrf0001735,,=,,,inhibitor,25,2400.0,microM,,cefotaxime,,,inhibition of LCA-NDB uptake into HEK293 cells expressing OATP,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142389,mbcd0003618,mbtp000013,mbrf0001735,,>,,,inhibitor,25,10000.0,microM,,cephalexin,,,inhibition of LCA-NDB uptake into HEK293 cells expressing OATP,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142390,mbcd0001298,mbtp000013,mbrf0001735,,>,,,inhibitor,25,1000.0,microM,,cefaclor,,,inhibition of LCA-NDB uptake into HEK293 cells expressing OATP,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142391,mbcd0003622,mbtp000013,mbrf0001735,,>,,,inhibitor,25,10000.0,microM,,ampicillin,,,inhibition of LCA-NDB uptake into HEK293 cells expressing OATP,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142392,mbcd0003773,mbtp000013,mbrf0001735,,=,,,inhibitor,25,100.0,microM,,ceftriaxone,,,inhibition of LCA-NDB uptake into HEK293 cells expressing OATP,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142393,mbcd0013187,mbtp000013,mbrf0001735,,>,,,inhibitor,25,100.0,microM,,meropenem,,,inhibition of LCA-NDB uptake into HEK293 cells expressing OATP,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142394,mbcd0000937,mbtp000013,mbrf0001735,,=,,,inhibitor,25,27.0,microM,,erythromycin,,,inhibition of LCA-NDB uptake into HEK293 cells expressing OATP,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142395,mbcd0028769,mbtp000013,mbrf0001735,,=,,,inhibitor,25,75.0,microM,,roxythromycin,,,inhibition of LCA-NDB uptake into HEK293 cells expressing OATP,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142396,mbcd0002996,mbtp000013,mbrf0001735,,=,,,inhibitor,25,56.0,microM,,clarithromycin,,,inhibition of LCA-NDB uptake into HEK293 cells expressing OATP,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142397,mbcd0003016,mbtp000013,mbrf0001735,,>,,,inhibitor,25,100.0,microM,,tetracycline,,,inhibition of LCA-NDB uptake into HEK293 cells expressing OATP,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142398,mbcd0029861,mbtp000013,mbrf0001735,,>,,,inhibitor,25,100.0,microM,,minocyclin,,,inhibition of LCA-NDB uptake into HEK293 cells expressing OATP,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142399,mbcd0010468,mbtp000013,mbrf0001735,,>,,,inhibitor,25,100.0,microM,,kanamycin,,,inhibition of LCA-NDB uptake into HEK293 cells expressing OATP,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142400,mbcd0011365,mbtp000013,mbrf0001735,,>,,,inhibitor,25,100.0,microM,,norfloxacin,,,inhibition of LCA-NDB uptake into HEK293 cells expressing OATP,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142401,mbcd0001470,mbtp000013,mbrf0001735,,>,,,inhibitor,25,100.0,microM,,levofloxacin,,,inhibition of LCA-NDB uptake into HEK293 cells expressing OATP,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142402,mbcd0002989,mbtp000013,mbrf0001735,,>,,,inhibitor,25,100.0,microM,,sparfloxacin,,,inhibition of LCA-NDB uptake into HEK293 cells expressing OATP,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142403,mbcd0003068,mbtp000013,mbrf0001735,,>,,,inhibitor,25,100.0,microM,,ofloxacin,,,inhibition of LCA-NDB uptake into HEK293 cells expressing OATP,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142404,mbcd0002191,mbtp000013,mbrf0001735,,>,,,inhibitor,25,100.0,microM,,itraconazole,,,inhibition of LCA-NDB uptake into HEK293 cells expressing OATP,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142405,mbcd0023577,mbtp000013,mbrf0001735,,>,,,inhibitor,25,100.0,microM,,fluconazole,,,inhibition of LCA-NDB uptake into HEK293 cells expressing OATP,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142406,mbcd0001416,mbtp000013,mbrf0001735,,=,,,inhibitor,25,3.9,microM,,rifampicin,,,inhibition of LCA-NDB uptake into HEK293 cells expressing OATP,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142407,mbcd0002983,mbtp000013,mbrf0001735,,>,,,inhibitor,25,1000.0,microM,,isoniazide,,,inhibition of LCA-NDB uptake into HEK293 cells expressing OATP,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142408,mbcd0008222,mbtp000013,mbrf0001735,,>,,,inhibitor,25,1000.0,microM,,aztreonam,,,inhibition of LCA-NDB uptake into HEK293 cells expressing OATP,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142409,mbcd0003126,mbtp000012,mbrf0001649,,=,,,substrate,28,83.9,microM,,pravastatin,,,HEK293 cells expressing OATP1B1,HEK293,,,,,human,mbds0010,,2013-11-24 23:13:55
mbbd000142410,mbcd0003120,mbtp000012,mbrf0001649,,=,,,inhibitor,25,15.9,microM,1.4,quercetin,,,inhibition of pravastatin uptake into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142411,mbcd0003120,mbtp000012,mbrf0001649,,=,,,inhibitor,29,17.9,microM,4.6,quercetin,,,inhibition of estrone 3 sulfate uptake into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142412,mbcd0001241,mbtp000012,mbrf0002171,,=,,,substrate,28,51.6,microM,,nateglinide,,,cryopreserved human hepatocytes,human hepatocytes,,,,,human,mbds0010,,2013-11-24 23:56:11
mbbd000142413,mbcd0001241,mbtp000012,mbrf0002171,,=,,,substrate,22,337.0,pmol / mg / min,,nateglinide,,,cryopreserved human hepatocytes,human hepatocytes,,,,,human,mbds0010,,2013-11-24 23:56:11
mbbd000142414,mbcd0001241,mbtp000012,mbrf0002171,,=,,,inhibitor,131,95.6,%,32.6,nateglinide,OATP1B3 coexpressed in tissue,,"inhibition of estrone 3 sulfate uptake into crypreserved human hepatocytes, inhibitor concentration of 3microM",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142415,mbcd0001241,mbtp000012,mbrf0002171,,=,,,inhibitor,131,96.7,%,35.5,nateglinide,OATP1B3 coexpressed in tissue,,"inhibition of estrone 3 sulfate uptake into crypreserved human hepatocytes, inhibitor concentration of 10microM",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142416,mbcd0001241,mbtp000012,mbrf0002171,,=,,,inhibitor,131,80.7,%,44.4,nateglinide,OATP1B3 coexpressed in tissue,,"inhibition of estrone 3 sulfate uptake into crypreserved human hepatocytes, inhibitor concentration of 30microM",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142417,mbcd0001241,mbtp000012,mbrf0002171,,=,,,inhibitor,131,59.3,%,26.7,nateglinide,OATP1B3 coexpressed in tissue,,"inhibition of estrone 3 sulfate uptake into crypreserved human hepatocytes, inhibitor concentration of 100microM",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142418,mbcd0001241,mbtp000012,mbrf0002171,,=,,,inhibitor,131,39.8,%,22.3,nateglinide,OATP1B3 coexpressed in tissue,,"inhibition of estrone 3 sulfate uptake into crypreserved human hepatocytes, inhibitor concentration of 300microM",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142419,mbcd0001904,mbtp000012,mbrf0002171,,=,,,inhibitor,131,67.7,%,20,repaglinide,OATP1B3 coexpressed in tissue,,"inhibition of estrone 3 sulfate uptake into crypreserved human hepatocytes, inhibitor concentration of 3microM",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142420,mbcd0001904,mbtp000012,mbrf0002171,,=,,,inhibitor,131,48.4,%,21.3,repaglinide,OATP1B3 coexpressed in tissue,,"inhibition of estrone 3 sulfate uptake into crypreserved human hepatocytes, inhibitor concentration of 10microM",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142421,mbcd0001904,mbtp000012,mbrf0002171,,=,,,inhibitor,131,35.5,%,10.2,repaglinide,OATP1B3 coexpressed in tissue,,"inhibition of estrone 3 sulfate uptake into crypreserved human hepatocytes, inhibitor concentration of 30microM",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142422,mbcd0001904,mbtp000012,mbrf0002171,,=,,,inhibitor,131,19.7,%,1.2,repaglinide,OATP1B3 coexpressed in tissue,,"inhibition of estrone 3 sulfate uptake into crypreserved human hepatocytes, inhibitor concentration of 100microM",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142423,mbcd0001904,mbtp000012,mbrf0002171,,=,,,inhibitor,131,8.31,%,2.43,repaglinide,OATP1B3 coexpressed in tissue,,"inhibition of estrone 3 sulfate uptake into crypreserved human hepatocytes, inhibitor concentration of 300microM",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142424,mbcd0001416,mbtp000012,mbrf0002171,,=,,,inhibitor,131,25.8,%,5.2,rifampicin,OATP1B3 coexpressed in tissue,,"inhibition of estrone 3 sulfate uptake into crypreserved human hepatocytes, inhibitor concentration of 300microM",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142425,mbcd0001241,mbtp000013,mbrf0002171,,=,,,inhibitor,131,86.7,%,18.8,nateglinide,OATP1B1 coexpressed in tissue,,"inhibition of CCK uptake into crypreserved human hepatocytes, inhibitor concentration of 1microM",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142426,mbcd0001241,mbtp000013,mbrf0002171,,=,,,inhibitor,131,77.3,%,10.2,nateglinide,OATP1B1 coexpressed in tissue,,"inhibition of CCK uptake into crypreserved human hepatocytes, inhibitor concentration of 3microM",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142427,mbcd0001241,mbtp000013,mbrf0002171,,=,,,inhibitor,131,61.2,%,12.8,nateglinide,OATP1B1 coexpressed in tissue,,"inhibition of CCK uptake into crypreserved human hepatocytes, inhibitor concentration of 10microM",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142428,mbcd0001241,mbtp000013,mbrf0002171,,=,,,inhibitor,131,38.8,%,24.1,nateglinide,OATP1B1 coexpressed in tissue,,"inhibition of CCK uptake into crypreserved human hepatocytes, inhibitor concentration of 30microM",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142429,mbcd0001241,mbtp000013,mbrf0002171,,=,,,inhibitor,131,22.2,%,13.2,nateglinide,OATP1B1 coexpressed in tissue,,"inhibition of CCK uptake into crypreserved human hepatocytes, inhibitor concentration of 100microM",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142430,mbcd0001904,mbtp000013,mbrf0002171,,=,,,inhibitor,131,91.7,%,8.8,repaglinide,OATP1B1 coexpressed in tissue,,"inhibition of CCK uptake into crypreserved human hepatocytes, inhibitor concentration of 0.3microM",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142431,mbcd0001904,mbtp000013,mbrf0002171,,=,,,inhibitor,131,61.5,%,13.2,repaglinide,OATP1B1 coexpressed in tissue,,"inhibition of CCK uptake into crypreserved human hepatocytes, inhibitor concentration of 1microM",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142432,mbcd0001904,mbtp000013,mbrf0002171,,=,,,inhibitor,131,55.6,%,5.5,repaglinide,OATP1B1 coexpressed in tissue,,"inhibition of CCK uptake into crypreserved human hepatocytes, inhibitor concentration of 3microM",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142433,mbcd0001904,mbtp000013,mbrf0002171,,=,,,inhibitor,131,38.8,%,15.5,repaglinide,OATP1B1 coexpressed in tissue,,"inhibition of CCK uptake into crypreserved human hepatocytes, inhibitor concentration of 10microM",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142434,mbcd0001904,mbtp000013,mbrf0002171,,=,,,inhibitor,131,26.8,%,22.0,repaglinide,OATP1B1 coexpressed in tissue,,"inhibition of CCK uptake into crypreserved human hepatocytes, inhibitor concentration of 30microM",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142435,mbcd0001416,mbtp000013,mbrf0002171,,=,,,inhibitor,131,14.9,%,25.9,rifampicin,OATP1B1 coexpressed in tissue,,"inhibition of CCK uptake into crypreserved human hepatocytes, inhibitor concentration of 300microM",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142436,mbcd0020432,mbtp000012,mbrf0002328,,>,,,inhibitor,25,100.0,microM,,2-aminobenzenesulfonamide,,,inhibition of fluorescein methotrexate uptake into OATP expressing CHO cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142437,mbcd0029862,mbtp000012,mbrf0002328,,>,,,inhibitor,25,100.0,microM,,aconitine,,,inhibition of fluorescein methotrexate uptake into OATP expressing CHO cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142438,mbcd0001052,mbtp000012,mbrf0002328,,=,,,inhibitor,25,6.7,microM,1.2,beclomethasone,,,inhibition of fluorescein methotrexate uptake into OATP expressing CHO cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142439,mbcd0026046,mbtp000012,mbrf0002328,,=,,,inhibitor,25,0.7,microM,0.08,bromocryptine,,,inhibition of fluorescein methotrexate uptake into OATP expressing CHO cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142440,mbcd0003142,mbtp000012,mbrf0002328,,,,,non-inhibitor,,,,,captopril,,,inhibition of fluorescein methotrexate uptake into OATP expressing CHO cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142441,mbcd0028790,mbtp000012,mbrf0002328,,=,,,inhibitor,25,0.8,microM,0.2,ergocryptine,,,inhibition of fluorescein methotrexate uptake into OATP expressing CHO cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142442,mbcd0029860,mbtp000012,mbrf0002328,,=,,,inhibitor,25,0.06,microM,0.01,estropipate,,,inhibition of fluorescein methotrexate uptake into OATP expressing CHO cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142443,mbcd0007735,mbtp000012,mbrf0002328,,>,,,inhibitor,25,100.0,microM,,etomidate,,,inhibition of fluorescein methotrexate uptake into OATP expressing CHO cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142444,mbcd0013319,mbtp000012,mbrf0002328,,=,,,inhibitor,25,34.5,microM,6.8,fipexide,,,inhibition of fluorescein methotrexate uptake into OATP expressing CHO cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142445,mbcd0011583,mbtp000012,mbrf0002328,,>,,,inhibitor,25,100.0,microM,,metronidazole,,,inhibition of fluorescein methotrexate uptake into OATP expressing CHO cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142446,mbcd0006716,mbtp000012,mbrf0002328,,=,,,inhibitor,25,8.1,microM,1.9,moricizine,,,inhibition of fluorescein methotrexate uptake into OATP expressing CHO cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142447,mbcd0012926,mbtp000012,mbrf0002328,,=,,,inhibitor,25,3.7,microM,1.4,niflumic acid,,,inhibition of fluorescein methotrexate uptake into OATP expressing CHO cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142448,mbcd0000925,mbtp000012,mbrf0002328,,=,,,inhibitor,25,4.0,microM,0.5,ramipril,,,inhibition of fluorescein methotrexate uptake into OATP expressing CHO cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142449,mbcd0001904,mbtp000012,mbrf0002328,,=,,,inhibitor,25,1.1,microM,0.2,repaglinide,,,inhibition of fluorescein methotrexate uptake into OATP expressing CHO cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142450,mbcd0002831,mbtp000012,mbrf0002328,,=,,,inhibitor,25,11.2,microM,2.0,resveratrol,,,inhibition of fluorescein methotrexate uptake into OATP expressing CHO cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142451,mbcd0001416,mbtp000012,mbrf0002328,,=,,,inhibitor,25,1.3,microM,0.2,rifampicin,,,inhibition of fluorescein methotrexate uptake into OATP expressing CHO cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142452,mbcd0012729,mbtp000012,mbrf0002328,,,,,non-inhibitor,,,,,trifluridine,,,inhibition of fluorescein methotrexate uptake into OATP expressing CHO cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142453,mbcd0017670,mbtp000012,mbrf0002328,,=,,,inhibitor,25,12.5,microM,1.9,ursolic acid,,,inhibition of fluorescein methotrexate uptake into OATP expressing CHO cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142454,mbcd0020432,mbtp000013,mbrf0002328,,>,,,inhibitor,25,100.0,microM,,2-aminobenzenesulfonamide,,,inhibition of fluorescein methotrexate uptake into OATP expressing CHO cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142455,mbcd0029862,mbtp000013,mbrf0002328,,,,,non-inhibitor,,,,,aconitine,,,inhibition of fluorescein methotrexate uptake into OATP expressing CHO cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142456,mbcd0001052,mbtp000013,mbrf0002328,,=,,,inhibitor,25,1.4,microM,0.4,beclomethasone,,,inhibition of fluorescein methotrexate uptake into OATP expressing CHO cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142457,mbcd0026046,mbtp000013,mbrf0002328,,=,,,inhibitor,25,1.8,microM,0.3,bromocryptine,,,inhibition of fluorescein methotrexate uptake into OATP expressing CHO cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142458,mbcd0003142,mbtp000013,mbrf0002328,,,,,non-inhibitor,,,,,captopril,,,inhibition of fluorescein methotrexate uptake into OATP expressing CHO cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142459,mbcd0028790,mbtp000013,mbrf0002328,,=,,,inhibitor,25,2.2,microM,1.2,ergocryptine,,,inhibition of fluorescein methotrexate uptake into OATP expressing CHO cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142460,mbcd0029860,mbtp000013,mbrf0002328,,=,,,inhibitor,25,19.3,microM,6.3,estropipate,,,inhibition of fluorescein methotrexate uptake into OATP expressing CHO cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142461,mbcd0007735,mbtp000013,mbrf0002328,,>,,,inhibitor,25,100.0,microM,,etomidate,,,inhibition of fluorescein methotrexate uptake into OATP expressing CHO cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142462,mbcd0013319,mbtp000013,mbrf0002328,,>,,,inhibitor,25,100.0,microM,,fipexide,,,inhibition of fluorescein methotrexate uptake into OATP expressing CHO cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142463,mbcd0011583,mbtp000013,mbrf0002328,,>,,,inhibitor,25,100.0,microM,,metronidazole,,,inhibition of fluorescein methotrexate uptake into OATP expressing CHO cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142464,mbcd0006716,mbtp000013,mbrf0002328,,=,,,inhibitor,25,2.7,microM,0.4,moricizine,,,inhibition of fluorescein methotrexate uptake into OATP expressing CHO cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142465,mbcd0012926,mbtp000013,mbrf0002328,,=,,,inhibitor,25,22.0,microM,6.8,niflumic acid,,,inhibition of fluorescein methotrexate uptake into OATP expressing CHO cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142466,mbcd0000925,mbtp000013,mbrf0002328,,=,,,inhibitor,25,3.3,microM,0.3,ramipril,,,inhibition of fluorescein methotrexate uptake into OATP expressing CHO cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142467,mbcd0001904,mbtp000013,mbrf0002328,,=,,,inhibitor,25,4.8,microM,0.7,repaglinide,,,inhibition of fluorescein methotrexate uptake into OATP expressing CHO cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142468,mbcd0002831,mbtp000013,mbrf0002328,,=,,,inhibitor,25,23.7,microM,2.5,resveratrol,,,inhibition of fluorescein methotrexate uptake into OATP expressing CHO cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142469,mbcd0001416,mbtp000013,mbrf0002328,,=,,,inhibitor,25,1.5,microM,0.5,rifampicin,,,inhibition of fluorescein methotrexate uptake into OATP expressing CHO cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142470,mbcd0012729,mbtp000013,mbrf0002328,,,,,non-inhibitor,,,,,trifluridine,,,inhibition of fluorescein methotrexate uptake into OATP expressing CHO cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142471,mbcd0017670,mbtp000013,mbrf0002328,,=,,,inhibitor,25,2.3,microM,0.03,ursolic acid,,,inhibition of fluorescein methotrexate uptake into OATP expressing CHO cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142472,mbcd0029786,mbtp000012,mbrf0002328,,=,,,substrate,28,3.8,microM,0.7,FMTX,,,CHO expressing OATP,CHO,,,,,human,mbds0010,,2013-11-24 23:15:23
mbbd000142473,mbcd0029786,mbtp000012,mbrf0002328,,=,,,substrate,22,961.0,fluorescence units/mg/min,198,FMTX,,,CHO expressing OATP,CHO,,,,,human,mbds0010,,2013-11-24 23:15:23
mbbd000142474,mbcd0029786,mbtp000013,mbrf0002328,,=,,,substrate,28,7.9,microM,2.0,FMTX,,,CHO expressing OATP,CHO,,,,,human,mbds0010,,2013-11-24 23:15:24
mbbd000142475,mbcd0029786,mbtp000013,mbrf0002328,,=,,,substrate,22,4772.0,fluorescence units/mg/min,709,FMTX,,,CHO expressing OATP,CHO,,,,,human,mbds0010,,2013-11-24 23:15:24
mbbd000142476,mbcd0001892,mbtp000013,mbrf0002328,,=,,,inducer,17,0.2,microM,,progesterone,,,stimulated OATP1B1 uptake of FMTX,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142477,mbcd0001892,mbtp000012,mbrf0002328,,=,,,inhibitor,25,5.4,microM,1.9,progesterone,,,stimulated OATP1B1 uptake of FMTX,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142478,mbcd0001216,mbtp000012,mbrf0002328,,=,,,substrate,28,38.0,microM,5,fluorescein,,,CHO expressing OATP,CHO,,,,,human,mbds0010,,2013-11-24 23:15:24
mbbd000142479,mbcd0001216,mbtp000013,mbrf0002328,,=,,,substrate,28,82.0,microM,10,fluorescein,,,CHO expressing OATP,CHO,,,,,human,mbds0010,,2013-11-24 23:15:24
mbbd000142480,mbcd0000002,mbtp000013,mbrf0001894,,=,,,substrate,28,34.1,microM,2.9,ECG; epicatechin gallate,,,Uptake into OATP expressing Caco-2 cells; 100 microM compound,Caco-2,,,,,human,mbds0010,,2013-11-24 23:12:40
mbbd000142481,mbcd0029142,mbtp000013,mbrf0001894,,=,,,substrate,28,13.2,microM,1.4,EGCG; epigallocatechin gallate,,,Uptake into OATP expressing Caco-2 cells; 100 microM compound,Caco-2,,,,,human,mbds0010,,2013-11-24 23:12:40
mbbd000142482,mbcd0000002,mbtp000012,mbrf0001894,,=,,,inhibitor,25,58.6,microM,15.1,ECG; epicatechin gallate,,,inhibition of estrone 3 sulfate Uptake into OATP expressing Caco-2 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142483,mbcd0029142,mbtp000012,mbrf0001894,,=,,,inhibitor,25,7.8,microM,0.9,EGCG; epigallocatechin gallate,,,inhibition of estrone 3 sulfate Uptake into OATP expressing Caco-2 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142484,mbcd0000002,mbtp000012,mbrf0001894,,,,,non-substrate,,,,,ECG; epicatechin gallate,,,Uptake into OATP expressing Caco-2 cells; 100 microM compound,Caco-2,,,,,human,mbds0010,,2013-11-24 23:12:40
mbbd000142485,mbcd0029142,mbtp000012,mbrf0001894,,,,,non-substrate,,,,,EGCG; epigallocatechin gallate,,,Uptake into OATP expressing Caco-2 cells; 100 microM compound,Caco-2,,,,,human,mbds0010,,2013-11-24 23:12:40
mbbd000142486,mbcd0002241,mbtp000012,mbrf0002758,,=,,,inhibitor,3,85.8,%,,lopinavir,,,HEK cells Flp-In-293; inhibition of estradiol 17beta glucuronide uptake,,mbcd0000387,20,microM,,human,mbds0010,,2013-11-20 01:14:13
mbbd000142487,mbcd0001938,mbtp000012,mbrf0002758,,=,,,inhibitor,3,92.3,%,,ritonavir,,,HEK cells Flp-In-293; inhibition of estradiol 17beta glucuronide uptake,,mbcd0000387,20,microM,,human,mbds0010,,2013-11-20 01:14:13
mbbd000142488,mbcd0002383,mbtp000012,mbrf0002758,,=,,,inhibitor,3,79.3,%,,amprenavir,,,HEK cells Flp-In-293; inhibition of estradiol 17beta glucuronide uptake,,mbcd0000387,20,microM,,human,mbds0010,,2013-11-20 01:14:13
mbbd000142494,mbcd0029150,mbtp000013,mbrf0002275,,,,,substrate,,,,,atrasentan,,,HeLa cells,HeLa,,10,nM,,human,mbds0010,,2013-11-10 04:16:07
mbbd000142495,mbcd0027726,mbtp000013,mbrf0002751,,~,,,substrate,102,225.0,%,,docetaxel,,,Xenopus laevis oocytes; uptake study using radiolabelled docetaxel,Xenopus laevis oocytes,,20,nM,,human,mbds0010,,2014-02-26 23:09:01
mbbd000142496,mbcd0000937,mbtp000013,mbrf0001870,,,,,substrate,,,,,enalapril,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142497,mbcd0001797,mbtp000013,mbrf0002299,,=,,,substrate,28,108.0,microM,11,FEX,The uptake of FEX in OATP1B3-expressing cells was significantly greater than that in vector-transfected cells (P < 0.005),,HEK293 cells,HEK293,,10,microM,,human,mbds0010,,2013-12-08 06:41:19
mbbd000142498,mbcd0001797,mbtp000013,mbrf0002299,,=,,,inhibitor,29,205.0,microM,72,FEX,,,HEK293 cells inhibition of 0.1 microM E2-17betaG uptake,HEK293,mbcd0030389,,,,human,mbds0010,,2013-11-17 22:22:36
mbbd000142499,mbcd0001445,mbtp000013,mbrf0002304,,=,,,substrate,28,7.0,microM,2.5,fluvastatin,,,ABCC2-OATP1B3 double transfected MDCKII cells,MDCKII,,,,,human,mbds0010,,2013-11-21 05:02:42
mbbd000142500,mbcd0001445,mbtp000013,mbrf0002304,,=,,,substrate,22,53.6,pmol/mg protein/min,11.0,fluvastatin,,,ABCC2-OATP1B3 double transfected MDCKII cells,MDCKII,,,,,human,mbds0010,,2013-11-21 05:02:42
mbbd000142501,mbcd0002828,mbtp000013,mbrf0001870,,,,,substrate,,,,,imatinib,,,,,,,,,human,mbds0010,,2013-11-21 05:31:21
mbbd000142502,mbcd0003043,mbtp000013,mbrf0001870,,=,,,substrate,28,24.7,microM,,methotrexate,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142503,mbcd0001532,mbtp000013,mbrf0002751,,=,,,substrate,28,6.79,microM,3.44,paclitaxel,,,Xenopus laevis oocytes; uptake study using radiolabelled paclitaxel; 20 nM and 2 microM paclitaxel,Xenopus laevis oocytes,,20,nM,,human,mbds0010,,2014-02-26 23:10:54
mbbd000142504,mbcd0000693,mbtp000013,mbrf0001870,,=,,,substrate,28,3.3,microM,,pitavastatin,,,,,,,,,human,mbds0010,,2013-11-21 05:31:22
mbbd000142505,mbcd0004705,mbtp000013,mbrf0002389,,=,,,substrate,28,0.81,microM,0.18,telmisartan,,,HEK293 (transfected); drug uptake,HEK293,,,,,human,mbds0010,,2013-12-13 21:59:07
mbbd000142506,mbcd0000779,mbtp000013,mbrf0001701,,,,,substrate,,,,,SN-38,,,HEK293-OATP1B3 transfected cells,HEK293,,5,microM,,human,mbds0010,,2013-11-21 06:15:19
mbbd000142507,mbcd0000387,mbtp000012,mbrf0001903,,=,,,substrate,28,7.0,microM,1,estradiol 17beta glucuronide,,,CHO cells transfected with OATP,CHO,,,,,human,mbds0010,,2013-11-24 23:15:25
mbbd000142508,mbcd0017670,mbtp000012,mbrf0001903,,=,,,inhibitor,16,20.0,microM,11,ursolic acid,,,CHO cells transfected with OATP inhibition of e217betaG uptake,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142509,mbcd0029468,mbtp000012,mbrf0001903,,=,,,inhibitor,16,13.0,microM,3,oleanolic acid,,,CHO cells transfected with OATP inhibition of e217betaG uptake,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142510,mbcd0029863,mbtp000012,mbrf0001903,,=,,,inhibitor,16,36.0,microM,19,compound 4,,,CHO cells transfected with OATP inhibition of e217betaG uptake,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142511,mbcd0029864,mbtp000012,mbrf0001903,,=,,,inhibitor,16,15.0,microM,6,compound 6,,,CHO cells transfected with OATP inhibition of e217betaG uptake,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142512,mbcd0003075,mbtp000012,mbrf0001903,,=,,,substrate,28,0.5,microM,0.1,estrone 3 sulfate,,,CHO cells transfected with OATP,CHO,,,,,human,mbds0010,,2013-11-24 23:15:25
mbbd000142513,mbcd0017670,mbtp000012,mbrf0001903,,=,,,inhibitor,16,0.8,microM,0.1,ursolic acid,,,CHO cells transfected with OATP inhibition of e3s uptake,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142514,mbcd0029468,mbtp000012,mbrf0001903,,=,,,inhibitor,16,0.7,microM,0.1,oleanolic acid,,,CHO cells transfected with OATP inhibition of e3s uptake,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142515,mbcd0029863,mbtp000012,mbrf0001903,,=,,,inhibitor,16,1.3,microM,0.3,compound 4,,,CHO cells transfected with OATP inhibition of e3s uptake,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142516,mbcd0029864,mbtp000012,mbrf0001903,,=,,,inhibitor,16,0.8,microM,0.2,compound 6,,,CHO cells transfected with OATP inhibition of e3s uptake,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142517,mbcd0000387,mbtp000012,mbrf0001903,,=,,,substrate,22,175.0,pmol / mg / min,11,estradiol 17beta glucuronide,,,CHO cells transfected with OATP,CHO,,,,,human,mbds0010,,2013-11-24 23:15:26
mbbd000142518,mbcd0017670,mbtp000012,mbrf0001903,,=,,,inhibitor,141,217.0,pmol / mg / min,60,ursolic acid,,,CHO cells transfected with OATP inhibition of e217betaG uptake,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142519,mbcd0029468,mbtp000012,mbrf0001903,,=,,,inhibitor,141,117.0,pmol / mg / min,10,oleanolic acid,,,CHO cells transfected with OATP inhibition of e217betaG uptake,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142520,mbcd0029863,mbtp000012,mbrf0001903,,=,,,inhibitor,141,258.0,pmol / mg / min,86,compound 4,,,CHO cells transfected with OATP inhibition of e217betaG uptake,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142521,mbcd0029864,mbtp000012,mbrf0001903,,=,,,inhibitor,141,92.0,pmol / mg / min,18,compound 6,,,CHO cells transfected with OATP inhibition of e217betaG uptake,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142522,mbcd0003075,mbtp000012,mbrf0001903,,=,,,substrate,22,96.0,pmol / mg / min,10,estrone 3 sulfate,,,CHO cells transfected with OATP,CHO,,,,,human,mbds0010,,2013-11-24 23:15:27
mbbd000142523,mbcd0017670,mbtp000012,mbrf0001903,,=,,,inhibitor,141,105.0,pmol / mg / min,8,ursolic acid,,,CHO cells transfected with OATP inhibition of e3s uptake,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142524,mbcd0029468,mbtp000012,mbrf0001903,,=,,,inhibitor,141,85.0,pmol / mg / min,5,oleanolic acid,,,CHO cells transfected with OATP inhibition of e3s uptake,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142525,mbcd0029863,mbtp000012,mbrf0001903,,=,,,inhibitor,141,102.0,pmol / mg / min,10,compound 4,,,CHO cells transfected with OATP inhibition of e3s uptake,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142526,mbcd0029864,mbtp000012,mbrf0001903,,=,,,inhibitor,141,93.0,pmol / mg / min,8,compound 6,,,CHO cells transfected with OATP inhibition of e3s uptake,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142527,mbcd0000387,mbtp000012,mbrf0001903,,=,,,substrate,28,16.0,microM,9,estradiol 17beta glucuronide,,,CHO cells transfected with OATP,CHO,,,,,human,mbds0010,,2013-11-24 23:15:27
mbbd000142528,mbcd0017670,mbtp000012,mbrf0001903,,,,,non-inhibitor,,,,,ursolic acid,,,CHO cells transfected with OATP inhibition of e217betaG uptake,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142529,mbcd0029468,mbtp000012,mbrf0001903,,,,,non-inhibitor,,,,,oleanolic acid,,,CHO cells transfected with OATP inhibition of e217betaG uptake,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142530,mbcd0029863,mbtp000012,mbrf0001903,,,,,non-inhibitor,,,,,compound 4,,,CHO cells transfected with OATP inhibition of e217betaG uptake,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142531,mbcd0029864,mbtp000012,mbrf0001903,,=,,,inhibitor,16,17.0,microM,5,compound 6,,,CHO cells transfected with OATP inhibition of e217betaG uptake,,,25,microM,,human,mbds0010,,2013-11-23 22:11:21
mbbd000142532,mbcd0003075,mbtp000012,mbrf0001903,,=,,,substrate,28,93.0,microM,38,estrone 3 sulfate,,,CHO cells transfected with OATP,CHO,,,,,human,mbds0010,,2013-11-24 23:15:28
mbbd000142533,mbcd0017670,mbtp000012,mbrf0001903,,,,,inhibitor,,,,,ursolic acid,,,CHO cells transfected with OATP inhibition of e3s uptake,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142536,mbcd0029864,mbtp000012,mbrf0001903,,=,,,inhibitor,16,15.0,microM,3,compound 6,,,CHO cells transfected with OATP inhibition of e3s uptake,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142537,mbcd0029864,mbtp000012,mbrf0001903,,=,,,inhibitor,16,18.0,microM,9,compound 6,,,CHO cells transfected with OATP inhibition of e217betaG uptake,,,50,microM,,human,mbds0010,,2013-11-23 22:11:22
mbbd000142538,mbcd0000387,mbtp000012,mbrf0001903,,=,,,substrate,22,280.0,microM,45,estradiol 17beta glucuronide,,,CHO cells transfected with OATP,CHO,,,,,human,mbds0010,,2013-11-24 23:15:28
mbbd000142542,mbcd0029864,mbtp000012,mbrf0001903,,=,,,inhibitor,141,188.0,microM,40,compound 6,,,CHO cells transfected with OATP inhibition of e217betaG uptake,,,25,microM,,human,mbds0010,,2013-11-23 22:11:21
mbbd000142543,mbcd0003075,mbtp000012,mbrf0001903,,=,,,substrate,22,2120.0,microM,340,estrone 3 sulfate,,,CHO cells transfected with OATP,CHO,,,,,human,mbds0010,,2013-11-24 23:15:28
mbbd000142545,mbcd0029468,mbtp000012,mbrf0001903,,,,,non-inhibitor,,,,,oleanolic acid,,,CHO cells transfected with OATP inhibition of e3s uptake,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142547,mbcd0029864,mbtp000012,mbrf0001903,,=,,,inhibitor,141,1070.0,microM,50,compound 6,,,CHO cells transfected with OATP inhibition of e3s uptake,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142548,mbcd0029864,mbtp000012,mbrf0001903,,=,,,inhibitor,141,83.0,microM,9,compound 6,,,CHO cells transfected with OATP inhibition of e217betaG uptake,,,50,microM,,human,mbds0010,,2013-11-23 22:11:23
mbbd000142549,mbcd0000575,mbtp000012,mbrf0002218,,=,,,inhibitor,25,5.0,nM,51,LR,,,growth inhibition on OATP transfected HeLa cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142550,mbcd0029828,mbtp000012,mbrf0002218,,=,,,inhibitor,25,0.4,nM,0.1,LF,,,growth inhibition on OATP transfected HeLa cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142551,mbcd0029827,mbtp000012,mbrf0002218,,=,,,inhibitor,25,0.3,nM,0.1,LW,,,growth inhibition on OATP transfected HeLa cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142552,mbcd0029826,mbtp000012,mbrf0002218,,=,,,inhibitor,25,3800.0,nM,2300,RR,,,growth inhibition on OATP transfected HeLa cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142553,mbcd0029865,mbtp000012,mbrf0002218,,=,,,inhibitor,25,90.0,nM,20,YR,,,growth inhibition on OATP transfected HeLa cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142554,mbcd0029866,mbtp000012,mbrf0002218,,=,,,inhibitor,25,2.2,nM,0.6,okadaic acid,,,growth inhibition on OATP transfected HeLa cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142555,mbcd0000575,mbtp000013,mbrf0002218,,=,,,inhibitor,25,39.0,nM,8,LR,,,growth inhibition on OATP transfected HeLa cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142556,mbcd0029828,mbtp000013,mbrf0002218,,=,,,inhibitor,25,0.9,nM,0.9,LF,,,growth inhibition on OATP transfected HeLa cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142557,mbcd0029827,mbtp000013,mbrf0002218,,=,,,inhibitor,25,0.5,nM,0.4,LW,,,growth inhibition on OATP transfected HeLa cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142558,mbcd0029826,mbtp000013,mbrf0002218,,=,,,inhibitor,25,580.0,nM,400,RR,,,growth inhibition on OATP transfected HeLa cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142559,mbcd0029865,mbtp000013,mbrf0002218,,=,,,inhibitor,25,45.0,nM,30,YR,,,growth inhibition on OATP transfected HeLa cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142560,mbcd0029866,mbtp000013,mbrf0002218,,=,,,inhibitor,25,3.0,nM,1.2,okadaic acid,,,growth inhibition on OATP transfected HeLa cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142561,mbcd0029867,mbtp000012,mbrf0002282,,=,,,inhibitor,25,5.3,microM,1.1,Remogliflozin Etabonate,,,estradiol 17beta glucuronide uptake inhibition into CHO-OATP1B1 cell line,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142562,mbcd0029868,mbtp000012,mbrf0002282,,=,,,inhibitor,25,25.0,microM,2.3,Remogliflozin,,,estradiol 17beta glucuronide uptake inhibition into CHO-OATP1B1 cell line,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142563,mbcd0029869,mbtp000012,mbrf0002282,,=,,,inhibitor,25,14.0,microM,1.5,GSK279782,,,estradiol 17beta glucuronide uptake inhibition into CHO-OATP1B1 cell line,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142564,mbcd0002051,mbtp000012,mbrf0002199,,=,,,inhibitor,3,95.0,%,6.7,atazanavir,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142565,mbcd0026093,mbtp000012,mbrf0002199,,=,,,inhibitor,3,96.0,%,1.1,atorvastatin,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142566,mbcd0003035,mbtp000012,mbrf0002199,,=,,,inhibitor,3,94.1,%,3.2,bromosulfalein,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142567,mbcd0004706,mbtp000012,mbrf0002199,,=,,,inhibitor,3,89.3,%,3.0,cholecystokinin 8,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142568,mbcd0003100,mbtp000012,mbrf0002199,,=,,,inhibitor,3,91.9,%,3.2,dipyridamole,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142569,mbcd0003155,mbtp000012,mbrf0002199,,=,,,inhibitor,3,93.9,%,1.2,fluo-3,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142570,mbcd0001445,mbtp000012,mbrf0002199,,=,,,inhibitor,3,80.1,%,11.2,fluvastatin,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142571,mbcd0000458,mbtp000012,mbrf0002199,,=,,,inhibitor,3,80.2,%,5.9,glycochenodeoxycholate,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142572,mbcd0000487,mbtp000012,mbrf0002199,,=,,,inhibitor,3,86.1,%,5.8,indocyanine green,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142573,mbcd0002241,mbtp000012,mbrf0002199,,=,,,inhibitor,3,85.8,%,7.3,lopinavir,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142574,mbcd0001299,mbtp000012,mbrf0002199,,=,,,inhibitor,3,81.2,%,5.1,mifepristone,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142575,mbcd0002494,mbtp000012,mbrf0002199,,=,,,inhibitor,3,88.5,%,2.5,MK-571,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142576,mbcd0003059,mbtp000012,mbrf0002199,,=,,,inhibitor,3,85.2,%,4.0,morin,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142577,mbcd0003252,mbtp000012,mbrf0002199,,=,,,inhibitor,3,58.1,%,6.8,novobiocin,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142578,mbcd0000693,mbtp000012,mbrf0002199,,=,,,inhibitor,3,97.4,%,0.6,pitavastatin,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142579,mbcd0000749,mbtp000012,mbrf0002199,,=,,,inhibitor,3,95.4,%,1.5,rifamycin SV,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142580,mbcd0001938,mbtp000012,mbrf0002199,,=,,,inhibitor,3,92.3,%,2.9,ritonavir,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142581,mbcd0001448,mbtp000012,mbrf0002199,,=,,,inhibitor,3,71.4,%,6.8,rosuvastatin,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142582,mbcd0022617,mbtp000012,mbrf0002199,,=,,,inhibitor,3,94.5,%,4.4,silymarin,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142583,mbcd0001280,mbtp000012,mbrf0002199,,=,,,inhibitor,3,92.1,%,3.1,sulfasalazine,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142584,mbcd0001664,mbtp000012,mbrf0002199,,=,,,inhibitor,3,93.0,%,3.6,taurocholate,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142585,mbcd0000817,mbtp000012,mbrf0002199,,=,,,inhibitor,3,93.0,%,3.6,taurodeoxycholate,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142586,mbcd0000819,mbtp000012,mbrf0002199,,=,,,inhibitor,3,97.8,%,1.1,taurolithocholate,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142587,mbcd0004705,mbtp000012,mbrf0002199,,=,,,inhibitor,3,109.4,%,2.5,telmisartan,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,HEK293,mbcd0000387,20,microM,,human,mbds0010,,2013-12-13 22:00:54
mbbd000142588,mbcd0001350,mbtp000012,mbrf0002199,,=,,,inhibitor,3,89.5,%,3.0,tipranavir,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142589,mbcd0003122,mbtp000012,mbrf0002199,,=,,,inhibitor,3,70.7,%,11.1,5-carboxyfluorescein diacetate,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142590,mbcd0003034,mbtp000012,mbrf0002199,,=,,,inhibitor,3,86.6,%,6.6,benzbromarone,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142591,mbcd0001527,mbtp000012,mbrf0002199,,=,,,inhibitor,3,73.2,%,6.6,budesonide,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142592,mbcd0023123,mbtp000012,mbrf0002199,,=,,,inhibitor,3,73.6,%,20.4,cerivastatin,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142593,mbcd0002996,mbtp000012,mbrf0002199,,=,,,inhibitor,3,73.1,%,10.4,clarithromycin,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142594,mbcd0000311,mbtp000012,mbrf0002199,,=,,,inhibitor,3,96.8,%,1.5,cyclosporin A,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142595,mbcd0003903,mbtp000012,mbrf0002199,,=,,,inhibitor,3,51.6,%,19.4,diazepam,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142596,mbcd0000968,mbtp000012,mbrf0002199,,=,,,inhibitor,3,62.1,%,12.9,diethylstilbestrol,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142597,mbcd0000387,mbtp000012,mbrf0002199,,=,,,inhibitor,3,67.9,%,9.7,estradiol 17beta glucuronide,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142598,mbcd0003116,mbtp000012,mbrf0002199,,=,,,inhibitor,3,84.9,%,11.6,genistein,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142599,mbcd0001808,mbtp000012,mbrf0002199,,=,,,inhibitor,3,94.4,%,0.9,GF120918 (elacridar),,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142600,mbcd0029629,mbtp000012,mbrf0002199,,=,,,inhibitor,3,92.4,%,2.9,glibenclamide,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142601,mbcd0000462,mbtp000012,mbrf0002199,,=,,,inhibitor,3,65.8,%,9.7,glycyrrhizic acid,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142602,mbcd0001172,mbtp000012,mbrf0002199,,=,,,inhibitor,3,64.7,%,18.6,ivermectin,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142603,mbcd0002439,mbtp000012,mbrf0002199,,=,,,inhibitor,3,59.3,%,12.5,KO143,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142604,mbcd0025582,mbtp000012,mbrf0002199,,=,,,inhibitor,3,12.0,%,24.9,nefazodone,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142605,mbcd0026632,mbtp000012,mbrf0002199,,=,,,inhibitor,3,71.3,%,7.4,neflinavir,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142606,mbcd0003118,mbtp000012,mbrf0002199,,=,,,inhibitor,3,69.3,%,11.2,nystatin,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142607,mbcd0001532,mbtp000012,mbrf0002199,,=,,,inhibitor,3,71.6,%,6.4,paclitaxel,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142608,mbcd0000721,mbtp000012,mbrf0002199,,=,,,inhibitor,3,96.3,%,1.8,PSC833 (valspodar),,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142609,mbcd0003120,mbtp000012,mbrf0002199,,=,,,inhibitor,3,77.0,%,10.8,quercetin,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142610,mbcd0001904,mbtp000012,mbrf0002199,,=,,,inhibitor,3,88.4,%,2.9,repaglinide,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142611,mbcd0001941,mbtp000012,mbrf0002199,,=,,,inhibitor,3,67.2,%,12.3,reserpine,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142612,mbcd0001416,mbtp000012,mbrf0002199,,=,,,inhibitor,3,88.3,%,3.9,rifampicin,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142613,mbcd0000815,mbtp000012,mbrf0002199,,=,,,inhibitor,3,89.5,%,2.4,taurochenodeoxycholate,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142615,mbcd0003055,mbtp000012,mbrf0002199,,=,,,inhibitor,3,102.8,%,5.9,17beta-estradiol,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142616,mbcd0002383,mbtp000012,mbrf0002199,,=,,,inhibitor,3,79.3,%,4.3,amprenavir,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142617,mbcd0002109,mbtp000012,mbrf0002199,,=,,,inhibitor,3,22.3,%,20.5,astemizole,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142618,mbcd0003033,mbtp000012,mbrf0002199,,=,,,inhibitor,3,27.6,%,17.4,baicalin,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142619,mbcd0003962,mbtp000012,mbrf0002199,,=,,,inhibitor,3,52.1,%,20.1,candesartan,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142620,mbcd0029182,mbtp000012,mbrf0002199,,=,,,inhibitor,3,73.2,%,10.6,coumestrol,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142621,mbcd0003113,mbtp000012,mbrf0002199,,=,,,inhibitor,3,77.9,%,7.8,diclofenac,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142622,mbcd0003099,mbtp000012,mbrf0002199,,=,,,inhibitor,3,10.6,%,18.6,erlotinib,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142623,mbcd0000937,mbtp000012,mbrf0002199,,=,,,inhibitor,3,58.8,%,9.1,erythromycin,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142624,mbcd0003075,mbtp000012,mbrf0002199,,=,,,inhibitor,3,98.1,%,2.6,estrone-3-sulfate,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142625,mbcd0001374,mbtp000012,mbrf0002199,,=,,,inhibitor,3,55.5,%,11.5,ezetimibe,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142626,mbcd0003044,mbtp000012,mbrf0002199,,=,,,inhibitor,3,6.8,%,24.1,flutamide,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142627,mbcd0009531,mbtp000012,mbrf0002199,,=,,,inhibitor,3,59.3,%,10.7,gemfibrozil,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142628,mbcd0000455,mbtp000012,mbrf0002199,,=,,,inhibitor,3,66.4,%,4.5,glycocholic acid,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142629,mbcd0000474,mbtp000012,mbrf0002199,,=,,,inhibitor,3,48.1,%,14.2,hoechst 33342,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142630,mbcd0002323,mbtp000012,mbrf0002199,,=,,,inhibitor,3,71.9,%,25.0,indinavir,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142631,mbcd0003025,mbtp000012,mbrf0002199,,=,,,inhibitor,3,88.6,%,4.5,indometacin,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142632,mbcd0002191,mbtp000012,mbrf0002199,,=,,,inhibitor,3,22.3,%,10.7,itraconazole,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142633,mbcd0017104,mbtp000012,mbrf0002199,,=,,,inhibitor,3,53.6,%,18.7,ketoconazole,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142634,mbcd0003957,mbtp000012,mbrf0002199,,=,,,non-inhibitor,3,-13.1,%,24.3,levothyroxin,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2013-12-09 05:38:38
mbbd000142635,mbcd0025591,mbtp000012,mbrf0002199,,=,,,inhibitor,3,66.5,%,4.5,lovastatin,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142636,mbcd0002981,mbtp000012,mbrf0002199,,=,,,inhibitor,3,27.2,%,18.2,mitoxantrone,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142637,mbcd0002576,mbtp000012,mbrf0002199,,=,,,inhibitor,3,65.1,%,7.6,nicardipine,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142638,mbcd0007511,mbtp000012,mbrf0002199,,=,,,inhibitor,3,63.7,%,18.8,nifedipine,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142639,mbcd0003037,mbtp000012,mbrf0002199,,=,,,inhibitor,3,71.4,%,5.7,N-methylnicotinamide,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142640,mbcd0003005,mbtp000012,mbrf0002199,,=,,,inhibitor,3,60.4,%,22.7,Olmesartan,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142641,mbcd0001442,mbtp000012,mbrf0002199,,=,,,inhibitor,3,50.5,%,19.8,ouabain,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142642,mbcd0003073,mbtp000012,mbrf0002199,,=,,,inhibitor,3,16.2,%,16.3,piroxicam,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142643,mbcd0003126,mbtp000012,mbrf0002199,,=,,,inhibitor,3,52.2,%,12.6,pravastatin,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142644,mbcd0001892,mbtp000012,mbrf0002199,,=,,,inhibitor,3,63.9,%,12.1,progesterone,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142645,mbcd0001092,mbtp000012,mbrf0002199,,=,,,inhibitor,3,54.0,%,11.9,quinine,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142646,mbcd0023111,mbtp000012,mbrf0002199,,=,,,inhibitor,3,79.1,%,4.7,mbcd0023111,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142647,mbcd0001533,mbtp000012,mbrf0002199,,=,,,inhibitor,3,63.8,%,8.5,saquinavir,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142648,mbcd0001194,mbtp000012,mbrf0002199,,=,,,inhibitor,3,73.1,%,13.1,simvastatin,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142649,mbcd0003094,mbtp000012,mbrf0002199,,=,,,inhibitor,3,88.3,%,2.6,spironolactone,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142650,mbcd0003016,mbtp000012,mbrf0002199,,=,,,inhibitor,3,22.1,%,19.7,tetracycline,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142651,mbcd0003008,mbtp000012,mbrf0002199,,=,,,inhibitor,3,25.2,%,17.9,valproic acid,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142652,mbcd0003086,mbtp000012,mbrf0002199,,=,,,inhibitor,3,62.2,%,21.1,valsartan,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142653,mbcd0001135,mbtp000012,mbrf0002199,,=,,,inhibitor,3,3.9,%,19.3,vincristine,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142654,mbcd0003022,mbtp000012,mbrf0002199,,=,,,inhibitor,3,14.2,%,18.2,1-methyl-4-phenyl-pyridinium,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142655,mbcd0003952,mbtp000012,mbrf0002199,,=,,,inhibitor,3,14.9,%,22.6,acarbose,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142656,mbcd0003916,mbtp000012,mbrf0002199,,=,,,inhibitor,3,2.3,%,18.2,aciclovir,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142657,mbcd0003973,mbtp000012,mbrf0002199,,=,,,stimulator,3,-35.6,%,53.0,allopurinol,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2013-12-09 05:38:35
mbbd000142658,mbcd0003083,mbtp000012,mbrf0002199,,=,,,inhibitor,3,26.4,%,32.5,amantadine,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142659,mbcd0003081,mbtp000012,mbrf0002199,,=,,,inhibitor,3,10.5,%,23.4,amitriptyline,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142660,mbcd0003144,mbtp000012,mbrf0002199,,=,,,inhibitor,3,24.2,%,13.9,amodiaquine,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142661,mbcd0003875,mbtp000012,mbrf0002199,,=,,,inhibitor,3,20.6,%,16.6,atenolol,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142662,mbcd0003056,mbtp000012,mbrf0002199,,=,,,non-inhibitor,3,-7.5,%,39.1,atomoxetine,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142663,mbcd0001869,mbtp000012,mbrf0002199,,=,,,inhibitor,3,32.0,%,25.7,berberine,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142664,mbcd0001650,mbtp000012,mbrf0002199,,=,,,inhibitor,3,10.9,%,13.0,bestatin,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142665,mbcd0025521,mbtp000012,mbrf0002199,,=,,,non-inhibitor,3,-13.9,%,20.7,bufuralol,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142666,mbcd0003003,mbtp000012,mbrf0002199,,=,,,inhibitor,3,8.5,%,32.1,bupropion,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142667,mbcd0003932,mbtp000012,mbrf0002199,,=,,,inhibitor,3,33.3,%,8.6,buspirone,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142668,mbcd0003879,mbtp000012,mbrf0002199,,=,,,non-inhibitor,3,-1.8,%,31.9,caffeine,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142669,mbcd0003142,mbtp000012,mbrf0002199,,=,,,inhibitor,3,18.6,%,12.8,captopril,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142670,mbcd0002985,mbtp000012,mbrf0002199,,=,,,inhibitor,3,13.3,%,37.2,carbamazepine,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142671,mbcd0003051,mbtp000012,mbrf0002199,,=,,,inhibitor,3,36.6,%,12.6,carnitine,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142672,mbcd0001472,mbtp000012,mbrf0002199,,=,,,inhibitor,3,9.4,%,21.8,cefadroxil,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142673,mbcd0003019,mbtp000012,mbrf0002199,,=,,,inhibitor,3,30.2,%,12.4,cefamandole,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142674,mbcd0003901,mbtp000012,mbrf0002199,,=,,,inhibitor,3,35.7,%,14.4,cetirizine,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142675,mbcd0003062,mbtp000012,mbrf0002199,,=,,,non-inhibitor,3,-0.7,%,17.2,chelerythrine,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142676,mbcd0003088,mbtp000012,mbrf0002199,,=,,,non-inhibitor,3,-1.4,%,22.7,chloroquine,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142677,mbcd0002340,mbtp000012,mbrf0002199,,=,,,inhibitor,3,27.1,%,13.8,chlorpromazine,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142678,mbcd0001539,mbtp000012,mbrf0002199,,=,,,inhibitor,3,24.0,%,20.5,chlorprothixene,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142679,mbcd0003000,mbtp000012,mbrf0002199,,=,,,inhibitor,3,20.1,%,20.4,chlorzoxazone,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142680,mbcd0001640,mbtp000012,mbrf0002199,,=,,,inhibitor,3,41.6,%,20.2,cholic acid,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142681,mbcd0001111,mbtp000012,mbrf0002199,,=,,,inhibitor,3,40.3,%,21.2,cimetidine,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142682,mbcd0002493,mbtp000012,mbrf0002199,,=,,,inhibitor,3,32.3,%,15.3,clotrimazole,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142683,mbcd0002667,mbtp000012,mbrf0002199,,=,,,inhibitor,3,45.2,%,13.2,colchicine,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142684,mbcd0029184,mbtp000012,mbrf0002199,,=,,,inhibitor,3,7.6,%,22.0,coumarin,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142685,mbcd0013632,mbtp000012,mbrf0002199,,=,,,inhibitor,3,35.0,%,34.1,daidzein,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142686,mbcd0002995,mbtp000012,mbrf0002199,,=,,,inhibitor,3,25.9,%,27.3,desipramine,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142687,mbcd0002959,mbtp000012,mbrf0002199,,=,,,inhibitor,3,10.7,%,17.9,dexamethasone,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142688,mbcd0003089,mbtp000012,mbrf0002199,,=,,,inhibitor,3,36.3,%,15.5,dextromethorphan,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142689,mbcd0001050,mbtp000012,mbrf0002199,,=,,,inhibitor,3,36.0,%,21.8,digoxin,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142690,mbcd0002338,mbtp000012,mbrf0002199,,=,,,inhibitor,3,3.2,%,10.8,Diltiazem,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142691,mbcd0003141,mbtp000012,mbrf0002199,,=,,,inhibitor,3,47.5,%,19.1,disopyramide,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142692,mbcd0015934,mbtp000012,mbrf0002199,,=,,,inhibitor,3,8.5,%,29.0,disulfiram,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142693,mbcd0000940,mbtp000012,mbrf0002199,,=,,,inhibitor,3,1.0,%,27.4,dofetilide,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142694,mbcd0003930,mbtp000012,mbrf0002199,,=,,,inhibitor,3,28.8,%,14.0,doxazosin,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142695,mbcd0025844,mbtp000012,mbrf0002199,,=,,,non-inhibitor,3,-5.8,%,25.7,doxorubicin,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142696,mbcd0001868,mbtp000012,mbrf0002199,,=,,,inhibitor,3,40.9,%,21.8,efavirenz,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142697,mbcd0028144,mbtp000012,mbrf0002199,,=,,,inhibitor,3,31.7,%,33.7,eletriptan,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142698,mbcd0003029,mbtp000012,mbrf0002199,,=,,,inhibitor,3,6.4,%,43.7,emtricitabine,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142699,mbcd0003498,mbtp000012,mbrf0002199,,=,,,non-inhibitor,3,-7.5,%,34.8,enalapril,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142700,mbcd0002466,mbtp000012,mbrf0002199,,=,,,inhibitor,3,42.2,%,9.2,etoposide,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142701,mbcd0003011,mbtp000012,mbrf0002199,,=,,,inhibitor,3,36.6,%,16.9,felodipine,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142702,mbcd0003064,mbtp000012,mbrf0002199,,=,,,inhibitor,3,15.0,%,22.8,fendiline,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142703,mbcd0003027,mbtp000012,mbrf0002199,,=,,,inhibitor,3,5.4,%,23.0,fenofibrate,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142704,mbcd0003948,mbtp000012,mbrf0002199,,=,,,stimulator,3,-53.3,%,42.2,fentanyl,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2013-12-09 05:38:33
mbbd000142705,mbcd0001797,mbtp000012,mbrf0002199,,=,,,non-inhibitor,3,28.9,%,13.7,fexofenadine,,,inhibition of 0.52 microM E217betaG at 20 microM inhibitor concentration into HEK293 cells,HEK293,mbcd0030389,20,microM,,human,mbds0010,,2013-12-08 08:52:00
mbbd000142706,mbcd0023577,mbtp000012,mbrf0002199,,=,,,inhibitor,3,7.4,%,29.0,fluconazole,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142707,mbcd0022530,mbtp000012,mbrf0002199,,=,,,inhibitor,3,21.8,%,40.0,fluoxetine,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142708,mbcd0001322,mbtp000012,mbrf0002199,,=,,,inhibitor,3,30.2,%,17.1,flupenthixol,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142709,mbcd0000923,mbtp000012,mbrf0002199,,=,,,inhibitor,3,43.8,%,11.3,fluvoxamine,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142710,mbcd0004733,mbtp000012,mbrf0002199,,=,,,non-inhibitor,3,-14.7,%,47.1,furafylline,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142711,mbcd0003137,mbtp000012,mbrf0002199,,=,,,inhibitor,3,23.4,%,35.7,furosemide,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142712,mbcd0003112,mbtp000012,mbrf0002199,,=,,,inhibitor,3,1.1,%,23.4,glipizide,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142713,mbcd0003642,mbtp000012,mbrf0002199,,=,,,non-inhibitor,3,-8.4,%,28.1,glycyl proline,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142714,mbcd0029874,mbtp000012,mbrf0002199,,=,,,inhibitor,3,32.8,%,20.5,hygromycin,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142715,mbcd0003013,mbtp000012,mbrf0002199,,=,,,inhibitor,3,47.3,%,15.7,ibuprofen,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142716,mbcd0003898,mbtp000012,mbrf0002199,,=,,,inhibitor,3,26.9,%,21.0,imipramine,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142717,mbcd0002091,mbtp000012,mbrf0002199,,=,,,inhibitor,3,40.5,%,13.1,irinotecan,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142718,mbcd0002983,mbtp000012,mbrf0002199,,=,,,inhibitor,3,29.9,%,11.4,isoniazid,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142719,mbcd0000977,mbtp000012,mbrf0002199,,=,,,inhibitor,3,47.5,%,17.7,isradipine,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142720,mbcd0013986,mbtp000012,mbrf0002199,,=,,,inhibitor,3,24.9,%,23.2,lamotrigine,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142721,mbcd0003121,mbtp000012,mbrf0002199,,=,,,inhibitor,3,31.4,%,24.8,lansoprazole,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142722,mbcd0003061,mbtp000012,mbrf0002199,,=,,,inhibitor,3,4.6,%,19.8,lisinopril,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142723,mbcd0002539,mbtp000012,mbrf0002199,,=,,,inhibitor,3,32.5,%,24.3,loperamide,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142724,mbcd0003021,mbtp000012,mbrf0002199,,=,,,inhibitor,3,43.5,%,12.1,loratadine,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142725,mbcd0001128,mbtp000012,mbrf0002199,,=,,,non-inhibitor,3,-5.7,%,38.3,mephenytoin,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142726,mbcd0003886,mbtp000012,mbrf0002199,,=,,,non-inhibitor,3,-3.3,%,21.3,metformin,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142727,mbcd0003043,mbtp000012,mbrf0002199,,=,,,inhibitor,3,27.4,%,24.7,methotrexate,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142728,mbcd0018761,mbtp000012,mbrf0002199,,=,,,inhibitor,3,38.1,%,14.3,methoxsalen,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142729,mbcd0002822,mbtp000012,mbrf0002199,,=,,,inhibitor,3,28.1,%,29.1,metoprolol,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142730,mbcd0001735,mbtp000012,mbrf0002199,,=,,,inhibitor,3,32.9,%,37.6,midazolam,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142731,mbcd0023049,mbtp000012,mbrf0002199,,=,,,inhibitor,3,1.7,%,33.1,moclobemide,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142732,mbcd0003076,mbtp000012,mbrf0002199,,=,,,inhibitor,3,34.8,%,6.6,naringenin,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142733,mbcd0000615,mbtp000012,mbrf0002199,,=,,,inhibitor,3,34.0,%,25.8,naringin,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142734,mbcd0000928,mbtp000012,mbrf0002199,,=,,,inhibitor,3,6.9,%,14.7,nicotine,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142735,mbcd0001221,mbtp000012,mbrf0002199,,=,,,inhibitor,3,23.3,%,21.5,nitrofurantoin,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142736,mbcd0003965,mbtp000012,mbrf0002199,,=,,,inhibitor,3,27.9,%,26.2,"N-methylpyridinium, ASP+",,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142737,mbcd0000604,mbtp000012,mbrf0002199,,=,,,non-inhibitor,3,-6.1,%,36.4,N-methyl-quinidine,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142738,mbcd0023086,mbtp000012,mbrf0002199,,=,,,inhibitor,3,25.6,%,20.1,nootkatone,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142739,mbcd0001470,mbtp000012,mbrf0002199,,=,,,non-inhibitor,3,-8.2,%,26.2,ofloxacin,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142740,mbcd0001243,mbtp000012,mbrf0002199,,=,,,inhibitor,3,15.9,%,13.5,omeprazole,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142741,mbcd0003920,mbtp000012,mbrf0002199,,=,,,inhibitor,3,4.8,%,16.6,ondansetron,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142742,mbcd0003922,mbtp000012,mbrf0002199,,=,,,inhibitor,3,13.0,%,17.5,oxaliplatin,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142743,mbcd0003146,mbtp000012,mbrf0002199,,=,,,inhibitor,3,30.1,%,26.9,P-aminohippuric acid,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142744,mbcd0029711,mbtp000012,mbrf0002199,,=,,,inhibitor,3,15.2,%,24.8,pantoprazole,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142745,mbcd0024931,mbtp000012,mbrf0002199,,=,,,inhibitor,3,33.0,%,28.4,paroxetine,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142746,mbcd0003134,mbtp000012,mbrf0002199,,=,,,inhibitor,3,8.8,%,12.4,penicillin G,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142747,mbcd0000675,mbtp000012,mbrf0002199,,=,,,inhibitor,3,26.1,%,8.6,phalloidin,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142748,mbcd0003052,mbtp000012,mbrf0002199,,=,,,inhibitor,3,34.2,%,13.1,phenacetin,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142749,mbcd0003105,mbtp000012,mbrf0002199,,=,,,inhibitor,3,34.5,%,13.4,phenformin,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142750,mbcd0003007,mbtp000012,mbrf0002199,,=,,,non-inhibitor,3,-3.9,%,37.9,phenobarbital,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142751,mbcd0023817,mbtp000012,mbrf0002199,,=,,,inhibitor,3,25.1,%,13.1,phenylbutazone,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142752,mbcd0003129,mbtp000012,mbrf0002199,,=,,,non-inhibitor,3,-16.4,%,25.1,phenylethyl isothiocyanate,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142753,mbcd0002996,mbtp000012,mbrf0002199,,=,,,inhibitor,3,25.4,%,21.1,phenytoin,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142754,mbcd0029179,mbtp000012,mbrf0002199,,=,,,inhibitor,3,11.2,%,40.8,pilsicainide,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142755,mbcd0027318,mbtp000012,mbrf0002199,,=,,,stimulator,3,-24.7,%,32.3,pindolol,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2013-12-09 05:38:36
mbbd000142756,mbcd0023126,mbtp000012,mbrf0002199,,=,,,inhibitor,3,21.9,%,26.5,pioglitazone,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142757,mbcd0003024,mbtp000012,mbrf0002199,,=,,,inhibitor,3,25.1,%,17.6,prazosin,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142758,mbcd0003096,mbtp000012,mbrf0002199,,=,,,inhibitor,3,2.3,%,37.1,Prednisolone,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142759,mbcd0003154,mbtp000012,mbrf0002199,,=,,,inhibitor,3,35.2,%,22.8,probenecid,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142760,mbcd0003941,mbtp000012,mbrf0002199,,=,,,inhibitor,3,21.6,%,30.3,procainamide,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142761,mbcd0002488,mbtp000012,mbrf0002199,,=,,,inhibitor,3,8.9,%,31.0,propranolol,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142762,mbcd0027018,mbtp000012,mbrf0002199,,=,,,inhibitor,3,43.3,%,13.4,quinidine,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142763,mbcd0000961,mbtp000012,mbrf0002199,,=,,,inhibitor,3,4.3,%,39.1,ranolazine,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142764,mbcd0003060,mbtp000012,mbrf0002199,,=,,,non-inhibitor,3,-0.2,%,17.2,sanguinarine,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142765,mbcd0025660,mbtp000012,mbrf0002199,,=,,,inhibitor,3,22.2,%,23.9,sildenafil,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142766,mbcd0003128,mbtp000012,mbrf0002199,,=,,,inhibitor,3,46.4,%,7.6,sotalol,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142767,mbcd0005282,mbtp000012,mbrf0002199,,=,,,inhibitor,3,16.9,%,18.3,sulfaphenazole,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142768,mbcd0002889,mbtp000012,mbrf0002199,,=,,,inhibitor,3,25.6,%,16.6,tamoxifen,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142769,mbcd0003028,mbtp000012,mbrf0002199,,=,,,inhibitor,3,18.4,%,38.2,tenofovir,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142770,mbcd0017123,mbtp000012,mbrf0002199,,=,,,inhibitor,3,42.7,%,14.8,terfenadine,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142771,mbcd0003001,mbtp000012,mbrf0002199,,=,,,inhibitor,3,33.2,%,15.9,testosterone,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142772,mbcd0003923,mbtp000012,mbrf0002199,,=,,,inhibitor,3,25.9,%,20.5,tetraethylammonium,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142773,mbcd0003942,mbtp000012,mbrf0002199,,=,,,inhibitor,3,0.8,%,27.0,Theophylline,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142774,mbcd0003143,mbtp000012,mbrf0002199,,=,,,inhibitor,3,26.1,%,11.2,thioridazine,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142775,mbcd0026048,mbtp000012,mbrf0002199,,=,,,stimulator,3,-40.3,%,45.2,thiotepa,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2013-12-09 05:38:34
mbbd000142776,mbcd0007935,mbtp000012,mbrf0002199,,=,,,inhibitor,3,19.4,%,14.9,ticlopidine,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142777,mbcd0017644,mbtp000012,mbrf0002199,,=,,,inhibitor,3,9.1,%,11.8,tolbutamide,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142778,mbcd0003187,mbtp000012,mbrf0002199,,=,,,inhibitor,3,36.7,%,19.2,topotecan,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142779,mbcd0020371,mbtp000012,mbrf0002199,,=,,,non-inhibitor,3,-9.5,%,42.2,tranylcypromine,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142780,mbcd0026104,mbtp000012,mbrf0002199,,=,,,inhibitor,3,45.7,%,14.4,triazolam,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142781,mbcd0003115,mbtp000012,mbrf0002199,,=,,,inhibitor,3,24.7,%,21.8,trimethoprim,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142782,mbcd0003087,mbtp000012,mbrf0002199,,=,,,inhibitor,3,8.3,%,14.6,valaciclovir,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142783,mbcd0029177,mbtp000012,mbrf0002199,,=,,,inhibitor,3,24.7,%,46.4,varenicline,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142784,mbcd0003042,mbtp000012,mbrf0002199,,=,,,inhibitor,3,27.8,%,25.9,warfarin,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142785,mbcd0027062,mbtp000012,mbrf0002199,,=,,,inhibitor,3,40.3,%,22.2,verapamil,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142786,mbcd0003072,mbtp000012,mbrf0002199,,=,,,non-inhibitor,3,-3.3,%,18.4,celecoxib,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142787,mbcd0001107,mbtp000012,mbrf0002199,,=,,,inhibitor,3,9.5,%,30,zidovudine,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142788,mbcd0002051,mbtp000013,mbrf0002199,,=,,,inhibitor,3,92.6,%,4.0,atazanavir,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142789,mbcd0026093,mbtp000013,mbrf0002199,,=,,,inhibitor,3,74.4,%,16.2,atorvastatin,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142790,mbcd0003035,mbtp000013,mbrf0002199,,=,,,inhibitor,3,74.9,%,3.9,bromosulfalein,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142791,mbcd0004706,mbtp000013,mbrf0002199,,=,,,inhibitor,3,96.9,%,3.7,cholecystokinin 8,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142792,mbcd0003100,mbtp000013,mbrf0002199,,=,,,inhibitor,3,91.8,%,5.6,dipyridamole,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142793,mbcd0003155,mbtp000013,mbrf0002199,,=,,,inhibitor,3,88.5,%,1.3,fluo-3,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142794,mbcd0001445,mbtp000013,mbrf0002199,,=,,,inhibitor,3,76.0,%,4.7,fluvastatin,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142795,mbcd0000458,mbtp000013,mbrf0002199,,=,,,inhibitor,3,72.0,%,8.5,glycochenodeoxycholate,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142796,mbcd0000487,mbtp000013,mbrf0002199,,=,,,inhibitor,3,100.1,%,2.5,indocyanine green,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142797,mbcd0002241,mbtp000013,mbrf0002199,,=,,,inhibitor,3,84.6,%,8.1,lopinavir,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142798,mbcd0001299,mbtp000013,mbrf0002199,,=,,,inhibitor,3,80.3,%,6.5,mifepristone,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142799,mbcd0002494,mbtp000013,mbrf0002199,,=,,,inhibitor,3,80.7,%,8.9,MK-571,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142800,mbcd0003059,mbtp000013,mbrf0002199,,=,,,inhibitor,3,78.5,%,6.4,morin,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142801,mbcd0003252,mbtp000013,mbrf0002199,,=,,,inhibitor,3,84.2,%,2.1,novobiocin,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142802,mbcd0000693,mbtp000013,mbrf0002199,,=,,,inhibitor,3,94.3,%,1.4,pitavastatin,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142803,mbcd0000749,mbtp000013,mbrf0002199,,=,,,inhibitor,3,101.4,%,2.4,rifamycin SV,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142804,mbcd0001938,mbtp000013,mbrf0002199,,=,,,inhibitor,3,85.1,%,7.5,ritonavir,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142805,mbcd0001448,mbtp000013,mbrf0002199,,=,,,inhibitor,3,55.4,%,16.0,rosuvastatin,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142806,mbcd0022617,mbtp000013,mbrf0002199,,=,,,inhibitor,3,88.5,%,9.2,silymarin,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142807,mbcd0001280,mbtp000013,mbrf0002199,,=,,,inhibitor,3,72.1,%,7.0,sulfasalazine,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142808,mbcd0001664,mbtp000013,mbrf0002199,,=,,,inhibitor,3,95.5,%,0.9,taurocholate,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142809,mbcd0000817,mbtp000013,mbrf0002199,,=,,,inhibitor,3,61.4,%,9.8,taurodeoxycholate,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142810,mbcd0000819,mbtp000013,mbrf0002199,,=,,,inhibitor,3,89.8,%,3.9,taurolithocholate,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142811,mbcd0004705,mbtp000013,mbrf0002199,,=,,,inhibitor,3,91.5,%,7.2,telmisartan,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,HEK293,mbcd0000387,20,microM,,human,mbds0010,,2013-12-13 22:01:01
mbbd000142812,mbcd0001350,mbtp000013,mbrf0002199,,=,,,inhibitor,3,109.0,%,1.1,tipranavir,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142813,mbcd0003122,mbtp000013,mbrf0002199,,=,,,inhibitor,3,71.1,%,5.0,5-carboxyfluorescein diacetate,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142814,mbcd0003034,mbtp000013,mbrf0002199,,=,,,inhibitor,3,19.5,%,13.7,benzbromarone,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142815,mbcd0001527,mbtp000013,mbrf0002199,,=,,,inhibitor,3,79.0,%,4.1,budesonide,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142816,mbcd0023123,mbtp000013,mbrf0002199,,=,,,inhibitor,3,68.1,%,7.9,cerivastatin,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142817,mbcd0002996,mbtp000013,mbrf0002199,,=,,,inhibitor,3,53.8,%,4.1,clarithromycin,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142818,mbcd0000311,mbtp000013,mbrf0002199,,=,,,inhibitor,3,103.7,%,1.6,cyclosporin A,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142819,mbcd0003903,mbtp000013,mbrf0002199,,=,,,inhibitor,3,9.3,%,21.4,diazepam,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142820,mbcd0000968,mbtp000013,mbrf0002199,,=,,,inhibitor,3,31.1,%,15.3,diethylstilbestrol,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142821,mbcd0000387,mbtp000013,mbrf0002199,,=,,,inhibitor,3,69.0,%,8.0,estradiol 17beta glucuronide,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142822,mbcd0003116,mbtp000013,mbrf0002199,,=,,,non-inhibitor,3,-5.0,%,35.2,genistein,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142823,mbcd0001808,mbtp000013,mbrf0002199,,=,,,inhibitor,3,37.4,%,17.1,GF120918 (elacridar),,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142824,mbcd0029629,mbtp000013,mbrf0002199,,=,,,inhibitor,3,49.3,%,7.2,glibenclamide,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142825,mbcd0000462,mbtp000013,mbrf0002199,,=,,,inhibitor,3,90.9,%,3.4,glycyrrhizic acid,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142826,mbcd0001172,mbtp000013,mbrf0002199,,=,,,inhibitor,3,55.2,%,9.4,ivermectin,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142827,mbcd0002439,mbtp000013,mbrf0002199,,=,,,inhibitor,3,24.2,%,4.6,KO143,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142828,mbcd0025582,mbtp000013,mbrf0002199,,=,,,inhibitor,3,61.4,%,7.1,nefazodone,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142829,mbcd0026632,mbtp000013,mbrf0002199,,=,,,inhibitor,3,59.3,%,14.6,neflinavir,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142830,mbcd0003118,mbtp000013,mbrf0002199,,=,,,inhibitor,3,74.9,%,8.5,nystatin,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142831,mbcd0001532,mbtp000013,mbrf0002199,,=,,,inhibitor,3,62.1,%,12.3,paclitaxel,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142832,mbcd0000721,mbtp000013,mbrf0002199,,=,,,inhibitor,3,93.9,%,0.7,PSC833 (valspodar),,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142833,mbcd0003120,mbtp000013,mbrf0002199,,=,,,inhibitor,3,21.6,%,7.9,quercetin,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142834,mbcd0001904,mbtp000013,mbrf0002199,,=,,,inhibitor,3,83.2,%,7.1,repaglinide,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142835,mbcd0001941,mbtp000013,mbrf0002199,,=,,,inhibitor,3,25.4,%,12.8,reserpine,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142836,mbcd0001416,mbtp000013,mbrf0002199,,=,,,inhibitor,3,101.7,%,1.9,rifampicin,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142837,mbcd0000815,mbtp000013,mbrf0002199,,=,,,inhibitor,3,82.4,%,4.4,taurochenodeoxycholate,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142839,mbcd0003055,mbtp000013,mbrf0002199,,=,,,inhibitor,3,39.3,%,10.3,17beta-estradiol,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142840,mbcd0002383,mbtp000013,mbrf0002199,,=,,,inhibitor,3,16.3,%,21.0,amprenavir,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142841,mbcd0002109,mbtp000013,mbrf0002199,,=,,,inhibitor,3,24.4,%,10.2,astemizole,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142842,mbcd0003033,mbtp000013,mbrf0002199,,=,,,inhibitor,3,20.9,%,19.0,baicalin,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142843,mbcd0003962,mbtp000013,mbrf0002199,,=,,,inhibitor,3,28.6,%,5.3,candesartan,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142844,mbcd0029182,mbtp000013,mbrf0002199,,=,,,stimulator,3,-21.1,%,14.0,coumestrol,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2013-12-09 05:38:37
mbbd000142845,mbcd0003113,mbtp000013,mbrf0002199,,=,,,inhibitor,3,27.3,%,7.4,diclofenac,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142846,mbcd0003099,mbtp000013,mbrf0002199,,=,,,inhibitor,3,27.5,%,38.8,erlotinib,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142847,mbcd0000937,mbtp000013,mbrf0002199,,=,,,inhibitor,3,45.8,%,19.2,erythromycin,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142848,mbcd0003075,mbtp000013,mbrf0002199,,=,,,inhibitor,3,10.1,%,18.3,estrone-3-sulfate,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142849,mbcd0001374,mbtp000013,mbrf0002199,,=,,,inhibitor,3,1.5,%,26.0,ezetimibe,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142850,mbcd0003044,mbtp000013,mbrf0002199,,=,,,inhibitor,3,9.0,%,3.5,flutamide,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142851,mbcd0009531,mbtp000013,mbrf0002199,,=,,,inhibitor,3,14.4,%,19.8,gemfibrozil,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142852,mbcd0000455,mbtp000013,mbrf0002199,,=,,,inhibitor,3,29.0,%,13.5,glycocholic acid,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142853,mbcd0000474,mbtp000013,mbrf0002199,,=,,,inhibitor,3,67.0,%,4.3,hoechst 33342,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142854,mbcd0002323,mbtp000013,mbrf0002199,,=,,,inhibitor,3,18.1,%,9.5,indinavir,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142855,mbcd0003025,mbtp000013,mbrf0002199,,=,,,inhibitor,3,48.6,%,11.7,indometacin,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142856,mbcd0002191,mbtp000013,mbrf0002199,,=,,,non-inhibitor,3,-2.3,%,28.8,itraconazole,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142857,mbcd0017104,mbtp000013,mbrf0002199,,=,,,inhibitor,3,24.7,%,15.4,ketoconazole,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142858,mbcd0003957,mbtp000013,mbrf0002199,,=,,,inhibitor,3,11.4,%,5.0,levothyroxin,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142859,mbcd0025591,mbtp000013,mbrf0002199,,=,,,inhibitor,3,21.3,%,16.0,lovastatin,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142860,mbcd0002981,mbtp000013,mbrf0002199,,=,,,inhibitor,3,67.9,%,7.3,mitoxantrone,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142861,mbcd0002576,mbtp000013,mbrf0002199,,=,,,inhibitor,3,10.1,%,18.1,nicardipine,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142862,mbcd0007511,mbtp000013,mbrf0002199,,=,,,stimulator,3,-21.0,%,23.9,nifedipine,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2013-12-09 05:38:37
mbbd000142863,mbcd0003037,mbtp000013,mbrf0002199,,=,,,non-inhibitor,3,-0.5,%,13.8,N-methylnicotinamide,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142864,mbcd0003005,mbtp000013,mbrf0002199,,=,,,inhibitor,3,37.0,%,8.7,Olmesartan,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142865,mbcd0001442,mbtp000013,mbrf0002199,,=,,,inhibitor,3,20.5,%,5.0,ouabain,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142866,mbcd0003073,mbtp000013,mbrf0002199,,=,,,inhibitor,3,23.5,%,7.5,piroxicam,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142867,mbcd0003126,mbtp000013,mbrf0002199,,=,,,inhibitor,3,5.4,%,19.3,pravastatin,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142868,mbcd0001892,mbtp000013,mbrf0002199,,=,,,inhibitor,3,33.4,%,4.0,progesterone,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142869,mbcd0001092,mbtp000013,mbrf0002199,,=,,,non-inhibitor,3,-1.3,%,13.6,quinine,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142870,mbcd0023111,mbtp000013,mbrf0002199,,=,,,stimulator,3,-32.1,%,20.8,rosiglitazone,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2013-12-09 05:38:35
mbbd000142871,mbcd0001533,mbtp000013,mbrf0002199,,=,,,inhibitor,3,6.6,%,26.5,saquinavir,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142872,mbcd0001194,mbtp000013,mbrf0002199,,=,,,inhibitor,3,29.3,%,26.9,simvastatin,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142873,mbcd0003094,mbtp000013,mbrf0002199,,=,,,stimulator,3,-34.2,%,4.0,spironolactone,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2013-12-09 05:38:35
mbbd000142874,mbcd0003016,mbtp000013,mbrf0002199,,=,,,inhibitor,3,29.5,%,11.1,tetracycline,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142875,mbcd0003008,mbtp000013,mbrf0002199,,=,,,inhibitor,3,9.6,%,24.7,valproic acid,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142876,mbcd0003086,mbtp000013,mbrf0002199,,=,,,inhibitor,3,33.7,%,4.7,valsartan,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142877,mbcd0001135,mbtp000013,mbrf0002199,,=,,,inhibitor,3,59.8,%,9.8,vincristine,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142878,mbcd0003022,mbtp000013,mbrf0002199,,=,,,inhibitor,3,10.8,%,30.3,1-methyl-4-phenyl-pyridinium,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142879,mbcd0003952,mbtp000013,mbrf0002199,,=,,,inhibitor,3,17.7,%,5.6,acarbose,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142880,mbcd0003916,mbtp000013,mbrf0002199,,=,,,non-inhibitor,3,-2.0,%,14.7,aciclovir,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142881,mbcd0003973,mbtp000013,mbrf0002199,,=,,,inhibitor,3,10.8,%,30.3,allopurinol,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142882,mbcd0003083,mbtp000013,mbrf0002199,,=,,,inhibitor,3,10.0,%,17.0,amantadine,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142883,mbcd0003081,mbtp000013,mbrf0002199,,=,,,inhibitor,3,22.0,%,8.4,amitriptyline,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142884,mbcd0003144,mbtp000013,mbrf0002199,,=,,,inhibitor,3,28.2,%,15.4,amodiaquine,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142885,mbcd0003875,mbtp000013,mbrf0002199,,=,,,inhibitor,3,7.1,%,12.8,atenolol,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142886,mbcd0003056,mbtp000013,mbrf0002199,,=,,,inhibitor,3,31.6,%,5.0,atomoxetine,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142887,mbcd0001869,mbtp000013,mbrf0002199,,=,,,inhibitor,3,19.4,%,3.6,berberine,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142888,mbcd0001650,mbtp000013,mbrf0002199,,=,,,inhibitor,3,31.8,%,9.3,bestatin,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142889,mbcd0025521,mbtp000013,mbrf0002199,,=,,,inhibitor,3,23.8,%,21.2,bufuralol,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142890,mbcd0003003,mbtp000013,mbrf0002199,,=,,,inhibitor,3,7.2,%,14.5,bupropion,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142891,mbcd0003932,mbtp000013,mbrf0002199,,=,,,non-inhibitor,3,-5.6,%,7.5,buspirone,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142892,mbcd0003879,mbtp000013,mbrf0002199,,=,,,inhibitor,3,22.1,%,19.5,caffeine,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142893,mbcd0003142,mbtp000013,mbrf0002199,,=,,,inhibitor,3,4.0,%,11.1,captopril,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142894,mbcd0002985,mbtp000013,mbrf0002199,,=,,,inhibitor,3,23.2,%,18.7,carbamazepine,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142895,mbcd0003051,mbtp000013,mbrf0002199,,=,,,non-inhibitor,3,-9.3,%,29.5,carnitine,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142896,mbcd0001472,mbtp000013,mbrf0002199,,=,,,inhibitor,3,21.0,%,13.9,cefadroxil,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142897,mbcd0003019,mbtp000013,mbrf0002199,,=,,,inhibitor,3,16.5,%,21.2,cefamandole,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142898,mbcd0003901,mbtp000013,mbrf0002199,,=,,,inhibitor,3,40.3,%,2.0,cetirizine,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142899,mbcd0003062,mbtp000013,mbrf0002199,,=,,,inhibitor,3,24.9,%,11.0,chelerythrine,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142900,mbcd0003088,mbtp000013,mbrf0002199,,=,,,non-inhibitor,3,-7.2,%,13.2,chloroquine,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142901,mbcd0002340,mbtp000013,mbrf0002199,,=,,,inhibitor,3,22.8,%,19.4,chlorpromazine,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142902,mbcd0001539,mbtp000013,mbrf0002199,,=,,,non-inhibitor,3,-6.9,%,19.0,chlorprothixene,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142903,mbcd0003000,mbtp000013,mbrf0002199,,=,,,non-inhibitor,3,-1.0,%,41.4,chlorzoxazone,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142904,mbcd0001640,mbtp000013,mbrf0002199,,=,,,inhibitor,3,40.8,%,10.4,cholic acid,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142905,mbcd0001111,mbtp000013,mbrf0002199,,=,,,inhibitor,3,24.8,%,12.5,cimetidine,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142906,mbcd0002493,mbtp000013,mbrf0002199,,=,,,stimulator,3,-120.4,%,13.2,clotrimazole,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2013-12-09 05:38:32
mbbd000142907,mbcd0002667,mbtp000013,mbrf0002199,,=,,,non-inhibitor,3,-3.9,%,6.4,colchicine,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142908,mbcd0029184,mbtp000013,mbrf0002199,,=,,,inhibitor,3,38.2,%,17.2,coumarin,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142909,mbcd0013632,mbtp000013,mbrf0002199,,=,,,inhibitor,3,0.7,%,12.7,daidzein,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142910,mbcd0002995,mbtp000013,mbrf0002199,,=,,,inhibitor,3,3.2,%,12.4,desipramine,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142911,mbcd0002959,mbtp000013,mbrf0002199,,=,,,inhibitor,3,34.2,%,12.4,dexamethasone,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142912,mbcd0003089,mbtp000013,mbrf0002199,,=,,,stimulator,3,-21.9,%,33.6,dextromethorphan,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2013-12-09 05:38:37
mbbd000142913,mbcd0001050,mbtp000013,mbrf0002199,,=,,,non-inhibitor,3,-4.7,%,12.4,digoxin,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142914,mbcd0002338,mbtp000013,mbrf0002199,,=,,,inhibitor,3,4.1,%,4.5,Diltiazem,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142915,mbcd0003141,mbtp000013,mbrf0002199,,=,,,inhibitor,3,8.6,%,12.9,disopyramide,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142916,mbcd0015934,mbtp000013,mbrf0002199,,=,,,non-inhibitor,3,-3.8,%,10.5,disulfiram,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142917,mbcd0000940,mbtp000013,mbrf0002199,,=,,,inhibitor,3,19.9,%,4.8,dofetilide,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142918,mbcd0003930,mbtp000013,mbrf0002199,,=,,,non-inhibitor,3,-17.3,%,31.0,doxazosin,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142919,mbcd0025844,mbtp000013,mbrf0002199,,=,,,inhibitor,3,26.6,%,12.7,doxorubicin,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142920,mbcd0001868,mbtp000013,mbrf0002199,,=,,,inhibitor,3,18.2,%,18.6,efavirenz,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142921,mbcd0028144,mbtp000013,mbrf0002199,,=,,,inhibitor,3,2.8,%,9.9,eletriptan,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142922,mbcd0003029,mbtp000013,mbrf0002199,,=,,,inhibitor,3,17.1,%,13.6,emtricitabine,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142923,mbcd0003498,mbtp000013,mbrf0002199,,=,,,inhibitor,3,4.1,%,21.7,enalapril,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142924,mbcd0002466,mbtp000013,mbrf0002199,,=,,,inhibitor,3,8.5,%,12.2,etoposide,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142925,mbcd0003011,mbtp000013,mbrf0002199,,=,,,inhibitor,3,18.4,%,11.2,felodipine,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142926,mbcd0003064,mbtp000013,mbrf0002199,,=,,,inhibitor,3,20.4,%,21.4,fendiline,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142927,mbcd0003027,mbtp000013,mbrf0002199,,=,,,non-inhibitor,3,-10.8,%,18.2,fenofibrate,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142928,mbcd0003948,mbtp000013,mbrf0002199,,=,,,inhibitor,3,22.6,%,6.4,fentanyl,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142929,mbcd0001797,mbtp000013,mbrf0002199,,=,,,non-inhibitor,3,6.0,%,21.1,fexofenadine,,,inhibition of 1.04 microM E217betaG at 20 microM inhibitor concentration into HEK293 cells,HEK293,mbcd0030389,20,microM,,human,mbds0010,,2013-12-08 08:52:00
mbbd000142930,mbcd0023577,mbtp000013,mbrf0002199,,=,,,inhibitor,3,7.5,%,24.1,fluconazole,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142931,mbcd0022530,mbtp000013,mbrf0002199,,=,,,inhibitor,3,14.3,%,6.3,fluoxetine,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142932,mbcd0001322,mbtp000013,mbrf0002199,,=,,,inhibitor,3,13.5,%,4.4,flupenthixol,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142933,mbcd0000923,mbtp000013,mbrf0002199,,=,,,inhibitor,3,29.2,%,7.6,fluvoxamine,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142934,mbcd0004733,mbtp000013,mbrf0002199,,=,,,inhibitor,3,0.7,%,36.8,furafylline,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142935,mbcd0003137,mbtp000013,mbrf0002199,,=,,,inhibitor,3,22.3,%,12.6,furosemide,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142936,mbcd0003112,mbtp000013,mbrf0002199,,=,,,inhibitor,3,25.2,%,14.3,glipizide,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142937,mbcd0003642,mbtp000013,mbrf0002199,,=,,,inhibitor,3,9.6,%,8.2,glycyl proline,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142938,mbcd0029874,mbtp000013,mbrf0002199,,=,,,non-inhibitor,3,-4.2,%,9.7,hygromycin,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142939,mbcd0003013,mbtp000013,mbrf0002199,,=,,,non-inhibitor,3,-6.6,%,21.5,ibuprofen,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142940,mbcd0003898,mbtp000013,mbrf0002199,,=,,,non-inhibitor,3,-2.4,%,13.8,imipramine,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142941,mbcd0002091,mbtp000013,mbrf0002199,,=,,,inhibitor,3,26.9,%,12.6,irinotecan,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142942,mbcd0002983,mbtp000013,mbrf0002199,,=,,,inhibitor,3,18.7,%,21.5,isoniazid,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142943,mbcd0000977,mbtp000013,mbrf0002199,,=,,,inhibitor,3,7.7,%,34.5,isradipine,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142944,mbcd0013986,mbtp000013,mbrf0002199,,=,,,inhibitor,3,14.5,%,30.3,lamotrigine,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142945,mbcd0003121,mbtp000013,mbrf0002199,,=,,,inhibitor,3,23.3,%,14.8,lansoprazole,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142946,mbcd0003061,mbtp000013,mbrf0002199,,=,,,inhibitor,3,9.0,%,14.3,lisinopril,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142947,mbcd0002539,mbtp000013,mbrf0002199,,=,,,inhibitor,3,32.4,%,11.6,loperamide,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142948,mbcd0003021,mbtp000013,mbrf0002199,,=,,,inhibitor,3,45.0,%,10.4,loratadine,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142949,mbcd0001128,mbtp000013,mbrf0002199,,=,,,non-inhibitor,3,-0.6,%,13.4,mephenytoin,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142950,mbcd0003886,mbtp000013,mbrf0002199,,=,,,inhibitor,3,19.6,%,3.1,metformin,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142951,mbcd0003043,mbtp000013,mbrf0002199,,=,,,inhibitor,3,17.2,%,3.9,methotrexate,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142952,mbcd0018761,mbtp000013,mbrf0002199,,=,,,inhibitor,3,8.9,%,14.0,methoxsalen,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142953,mbcd0002822,mbtp000013,mbrf0002199,,=,,,inhibitor,3,19.8,%,20.5,metoprolol,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142954,mbcd0001735,mbtp000013,mbrf0002199,,=,,,inhibitor,3,6.7,%,7.1,midazolam,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142955,mbcd0023049,mbtp000013,mbrf0002199,,=,,,non-inhibitor,3,-3.3,%,9.3,moclobemide,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142956,mbcd0003076,mbtp000013,mbrf0002199,,=,,,stimulator,3,-57.2,%,21.1,naringenin,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2013-12-09 05:38:33
mbbd000142957,mbcd0000615,mbtp000013,mbrf0002199,,=,,,inhibitor,3,37.7,%,16.8,naringin,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142958,mbcd0000928,mbtp000013,mbrf0002199,,=,,,inhibitor,3,11.0,%,22.0,nicotine,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142959,mbcd0001221,mbtp000013,mbrf0002199,,=,,,non-inhibitor,3,-1.5,%,21.8,nitrofurantoin,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142960,mbcd0003965,mbtp000013,mbrf0002199,,=,,,non-inhibitor,3,-2.3,%,12.3,"N-methylpyridinium, ASP+",,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142961,mbcd0000604,mbtp000013,mbrf0002199,,=,,,inhibitor,3,21.0,%,12.8,N-methyl-quinidine,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142962,mbcd0023086,mbtp000013,mbrf0002199,,=,,,non-inhibitor,3,-3.2,%,18.8,nootkatone,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142963,mbcd0001470,mbtp000013,mbrf0002199,,=,,,inhibitor,3,24.5,%,24.7,ofloxacin,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142964,mbcd0001243,mbtp000013,mbrf0002199,,=,,,inhibitor,3,29.5,%,6.1,omeprazole,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142965,mbcd0003920,mbtp000013,mbrf0002199,,=,,,non-inhibitor,3,-3.6,%,24.0,ondansetron,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142966,mbcd0003922,mbtp000013,mbrf0002199,,=,,,inhibitor,3,9.9,%,15.7,oxaliplatin,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142967,mbcd0003146,mbtp000013,mbrf0002199,,=,,,inhibitor,3,23.7,%,9.4,P-aminohippuric acid,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142968,mbcd0029711,mbtp000013,mbrf0002199,,=,,,inhibitor,3,23.4,%,21.3,pantoprazole,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142969,mbcd0024931,mbtp000013,mbrf0002199,,=,,,inhibitor,3,12.7,%,13.2,paroxetine,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142970,mbcd0003134,mbtp000013,mbrf0002199,,=,,,inhibitor,3,40.9,%,20.1,penicillin G,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142971,mbcd0000675,mbtp000013,mbrf0002199,,=,,,inhibitor,3,36.2,%,10.8,phalloidin,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142972,mbcd0003052,mbtp000013,mbrf0002199,,=,,,non-inhibitor,3,-0.9,%,17.4,phenacetin,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142973,mbcd0003105,mbtp000013,mbrf0002199,,=,,,non-inhibitor,3,-2.3,%,38.8,phenformin,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142974,mbcd0003007,mbtp000013,mbrf0002199,,=,,,inhibitor,3,7.3,%,9.2,phenobarbital,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142975,mbcd0023817,mbtp000013,mbrf0002199,,=,,,inhibitor,3,17.0,%,7.5,phenylbutazone,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142976,mbcd0003129,mbtp000013,mbrf0002199,,=,,,inhibitor,3,12.3,%,1.7,phenylethyl isothiocyanate,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142977,mbcd0002996,mbtp000013,mbrf0002199,,=,,,inhibitor,3,20.2,%,5.9,phenytoin,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142978,mbcd0029179,mbtp000013,mbrf0002199,,=,,,non-inhibitor,3,-16.8,%,13.4,pilsicainide,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142979,mbcd0027318,mbtp000013,mbrf0002199,,=,,,inhibitor,3,24.5,%,15.2,pindolol,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142980,mbcd0023126,mbtp000013,mbrf0002199,,=,,,inhibitor,3,5.6,%,30.7,pioglitazone,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142981,mbcd0003024,mbtp000013,mbrf0002199,,=,,,inhibitor,3,36.1,%,12.9,prazosin,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142982,mbcd0003096,mbtp000013,mbrf0002199,,=,,,inhibitor,3,9.6,%,21.0,Prednisolone,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142983,mbcd0003154,mbtp000013,mbrf0002199,,=,,,inhibitor,3,22.0,%,11.9,probenecid,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142984,mbcd0003941,mbtp000013,mbrf0002199,,=,,,inhibitor,3,3.4,%,6.3,procainamide,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142985,mbcd0002488,mbtp000013,mbrf0002199,,=,,,inhibitor,3,12.8,%,17.5,propranolol,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142986,mbcd0027018,mbtp000013,mbrf0002199,,=,,,inhibitor,3,37.2,%,13.6,quinidine,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142987,mbcd0000961,mbtp000013,mbrf0002199,,=,,,non-inhibitor,3,-14.9,%,1.7,ranolazine,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142988,mbcd0003060,mbtp000013,mbrf0002199,,=,,,inhibitor,3,2.9,%,9.0,sanguinarine,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142989,mbcd0025660,mbtp000013,mbrf0002199,,=,,,inhibitor,3,30.8,%,13.7,sildenafil,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142990,mbcd0003128,mbtp000013,mbrf0002199,,=,,,inhibitor,3,6.6,%,10.4,sotalol,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142991,mbcd0005282,mbtp000013,mbrf0002199,,=,,,inhibitor,3,0.7,%,21.1,sulfaphenazole,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142992,mbcd0002889,mbtp000013,mbrf0002199,,=,,,inhibitor,3,28.5,%,24.5,tamoxifen,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142993,mbcd0003028,mbtp000013,mbrf0002199,,=,,,inhibitor,3,33.6,%,7.8,tenofovir,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142994,mbcd0017123,mbtp000013,mbrf0002199,,=,,,inhibitor,3,33.3,%,13.0,terfenadine,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142995,mbcd0003001,mbtp000013,mbrf0002199,,=,,,inhibitor,3,37.4,%,14.8,testosterone,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142996,mbcd0003923,mbtp000013,mbrf0002199,,=,,,inhibitor,3,4.9,%,9.8,tetraethylammonium,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142997,mbcd0003942,mbtp000013,mbrf0002199,,=,,,inhibitor,3,2.5,%,9.3,Theophylline,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142998,mbcd0003143,mbtp000013,mbrf0002199,,=,,,inhibitor,3,25.2,%,3.5,thioridazine,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000142999,mbcd0026048,mbtp000013,mbrf0002199,,=,,,inhibitor,3,0.6,%,17.9,thiotepa,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143000,mbcd0007935,mbtp000013,mbrf0002199,,=,,,inhibitor,3,0.2,%,35.9,ticlopidine,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143001,mbcd0017644,mbtp000013,mbrf0002199,,=,,,inhibitor,3,5.8,%,9.2,tolbutamide,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143002,mbcd0003187,mbtp000013,mbrf0002199,,=,,,inhibitor,3,17.3,%,17.0,topotecan,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143003,mbcd0020371,mbtp000013,mbrf0002199,,=,,,non-inhibitor,3,-9.3,%,12.1,tranylcypromine,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143004,mbcd0026104,mbtp000013,mbrf0002199,,=,,,inhibitor,3,18.7,%,16.1,triazolam,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143005,mbcd0003115,mbtp000013,mbrf0002199,,=,,,inhibitor,3,18.8,%,10.9,trimethoprim,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143006,mbcd0003087,mbtp000013,mbrf0002199,,=,,,inhibitor,3,6.6,%,18.2,valaciclovir,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143007,mbcd0029177,mbtp000013,mbrf0002199,,=,,,inhibitor,3,0.8,%,9.6,varenicline,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143008,mbcd0003042,mbtp000013,mbrf0002199,,=,,,non-inhibitor,3,-3.2,%,17.8,warfarin,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143009,mbcd0027062,mbtp000013,mbrf0002199,,=,,,non-inhibitor,3,-9.0,%,14.8,verapamil,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143010,mbcd0003072,mbtp000013,mbrf0002199,,=,,,inhibitor,3,22.3,%,6.1,celecoxib,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143011,mbcd0001107,mbtp000013,mbrf0002199,,=,,,inhibitor,3,7.1,%,2.5,zidovudine,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143012,mbcd0000456,mbtp000012,mbrf0002199,,=,,,inhibitor,3,85.0,%,3.5,glycodeoxycholate,,,inhibition of 0.52microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143013,mbcd0000456,mbtp000013,mbrf0002199,,=,,,inhibitor,3,79.0,%,4.4,glycodeoxycholate,,,inhibition of 1.04microM E217betaG at 20microM inhibitor concentration into HEK293 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143014,mbcd0000387,mbtp000012,mbrf0002199,,=,,,substrate,28,12.2,microM,5.94,estradiol-17beta-glucoronide,,,HEK293 cells,HEK293,,,,,human,mbds0010,,2013-11-24 23:13:55
mbbd000143015,mbcd0000387,mbtp000012,mbrf0002199,,=,,,substrate,22,15.44,pmol / mg  / min,3.44,estradiol 17beta glucuronide,,,HEK293 cells,HEK293,,,,,human,mbds0010,,2013-11-24 23:13:56
mbbd000143016,mbcd0000387,mbtp000013,mbrf0002199,,=,,,substrate,28,11.69,microM,3.80,estradiol-17beta-glucoronide,,,HEK293 cells,HEK293,,,,,human,mbds0010,,2013-11-24 23:13:56
mbbd000143017,mbcd0000387,mbtp000013,mbrf0002199,,=,,,substrate,22,10.12,pmol / mg  / min,1.78,estradiol 17beta glucuronide,,,HEK293 cells,HEK293,,,,,human,mbds0010,,2013-11-24 23:13:56
mbbd000143018,mbcd0026093,mbtp000012,mbrf0002199,,=,,,substrate,28,0.77,microM,0.24,atorvastatin,,,HEK293 cells,HEK293,,,,,human,mbds0010,,2013-11-24 23:13:56
mbbd000143019,mbcd0026093,mbtp000012,mbrf0002199,,=,,,substrate,22,6.61,pmol / mg  / min,1.24,atorvastatin,,,HEK293 cells,HEK293,,,,,human,mbds0010,,2013-11-24 23:13:57
mbbd000143020,mbcd0026093,mbtp000013,mbrf0002199,,=,,,substrate,28,0.73,microM,1.45,atorvastatin,,,HEK293 cells,HEK293,,,,,human,mbds0010,,2013-11-24 23:13:57
mbbd000143021,mbcd0026093,mbtp000013,mbrf0002199,,=,,,substrate,22,2.29,pmol / mg  / min,1.45,atorvastatin,,,HEK293 cells,HEK293,,,,,human,mbds0010,,2013-11-24 23:13:57
mbbd000143022,mbcd0029876,mbtp000002,mbrf0002461,,=,,,inhibitor,25,3.7,nM,3.7,hCPT; Homocamptothecin,,,MCF-7 Cell line. IC50 values measured in presence of 5microM FTC,,,,,,human,mbds0010,,2013-12-09 20:13:37
mbbd000143023,mbcd0029877,mbtp000002,mbrf0002461,,=,,,inhibitor,25,2.0,nM,0.1,BN80915,,,MCF-7 Cell line. IC50 values measured in presence of 5microM FTC,,,,,,human,mbds0010,,2013-12-09 20:13:38
mbbd000143024,mbcd0029350,mbtp000002,mbrf0001760,,,,,substrate,,,,,Epirubicin,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143025,mbcd0029879,mbtp000002,mbrf0002345,,,,,substrate,,,,,Dirithromycin,,,Human BRCP-G cDNA from cell line S1-M1 expressed in L.lactis bacteria. BRCP-G is a mutant form with amino acid at position 482 changed from R to G,Lactococcus lactis,,,,,human,mbds0010,,2013-12-09 20:13:39
mbbd000143026,mbcd0000937,mbtp000002,mbrf0002345,,,,,substrate,,,,,Erythromycin,,,Human BRCP-G mutant from cell line S1-M1 expressed in L.lactis,Lactococcus lactis,,,,,human,mbds0010,,2013-12-09 20:13:40
mbbd000143027,mbcd0003016,mbtp000002,mbrf0002345,,,,,substrate,,,,,Tetracycline,,,Human BRCP-G mutant expressed in L.lactis,Lactococcus lactis,,,,,human,mbds0010,,2013-12-09 20:13:40
mbbd000143028,mbcd0026257,mbtp000002,mbrf0002345,,,,,substrate,,,,,Quinacrine,,,Human BRCP-G mutant expressed in L.lactis,Lactococcus lactis,,,,,human,mbds0010,,2013-12-09 20:13:40
mbbd000143029,mbcd0003068,mbtp000002,mbrf0002345,,,,,substrate,,,,,Ofloxacin,,,Human BRCP-G mutant expressed in L.lactis,Lactococcus lactis,,,,,human,mbds0010,,2013-12-09 20:13:41
mbbd000143030,mbcd0003681,mbtp000002,mbrf0002345,,,,,substrate,,,,,Cephalothin,,,Human BRCP-G mutant expressed in L.lactis,Lactococcus lactis,,,,,human,mbds0010,,2013-12-09 20:58:27
mbbd000143031,mbcd0001416,mbtp000002,mbrf0002345,,,,,substrate,,,,,Rifampicin,,,Human BRCP-G mutant expressed in L.lactis,Lactococcus lactis,,,,,human,mbds0010,,2013-12-09 20:58:27
mbbd000143032,mbcd0001640,mbtp000002,mbrf0002345,,,,,substrate,,,,,Cholate,,,Human BRCP-G mutant expressed in L.lactis,Lactococcus lactis,,,,,human,mbds0010,,2013-12-09 20:58:27
mbbd000143033,mbcd0001655,mbtp000002,mbrf0002345,,,,,substrate,,,,,Deoxycholate,,,Human BRCP-G mutant expressed in L.lactis,Lactococcus lactis,,,,,human,mbds0010,,2013-12-09 20:58:26
mbbd000143034,mbcd0001664,mbtp000002,mbrf0002345,,,,,substrate,,,,,Taurocholate,,,Human BRCP-G mutant expressed in L.lactis,Lactococcus lactis,,,,,human,mbds0010,,2013-12-09 20:50:59
mbbd000143035,mbcd0000817,mbtp000002,mbrf0002345,,,,,substrate,,,,,Taurodeoxycholate,,,Human BRCP-G expressed in L.lactis,Lactococcus lactis,,,,,human,mbds0010,,2013-12-09 20:58:26
mbbd000143036,mbcd0001635,mbtp000002,mbrf0002345,,,,,substrate,,,,,Glycochenodeoxycholate,,,Human BRCP-G expressed in L.lactis,Lactococcus lactis,,,,,human,mbds0010,,2013-12-09 20:58:26
mbbd000143049,mbcd0029881,mbtp000002,mbrf0001947,,,,,non-substrate,,,,,VX710,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143050,mbcd0001808,mbtp000002,mbrf0001947,,,,,non-substrate,,,,,GF120918,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143051,mbcd0002104,mbtp000002,mbrf0001947,,,,,non-substrate,,,,,Tariquidar,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143052,mbcd0000648,mbtp000002,mbrf0001947,,,,,non-substrate,,,,,Ortataxel,Bay59-8862,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143053,mbcd0029882,mbtp000002,mbrf0001947,,,,,non-substrate,,,,,TRA96023,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143054,mbcd0029883,mbtp000002,mbrf0002055,,=,,,substrate,25,0.9,microM,0.1,PhA; Pheophorbide A,,,ABCG2-transfected HEK-293 cells. Specific binding determined by absorbance measurements of photosensitiser fluorescence in presence and absence of 10 microM fumitremorgin C (ABCG2 inhibitor). Cytotoxicity assay,HEK293,,,,,human,mbds0010,,2013-11-24 23:13:58
mbbd000143055,mbcd0029884,mbtp000002,mbrf0002055,,=,,,substrate,25,4.5,microM,0.7,MPPa; Pyropheophorbide a methyl ester,,,ABCG2-transfected HEK-293 cells. Specific binding determined by absorbance measuremnts of photosensitiser fluorescence in absence and resence of 10 microM fumitremorgin C (ABCG2 inhibitor). Cytotoxicity assay,HEK293,,,,,human,mbds0010,,2013-11-24 23:13:58
mbbd000143056,mbcd0029885,mbtp000002,mbrf0002055,,=,,,substrate,25,9.0,microM,1.4,Ce6; Chlorin e6,,,ABCG2-transfected HEK-293 cells. Specific binding determined by absorbance measurements of photosensitiser fluorescence in presence and absence of 10 microM fumitremorgin C (ABCG2 inhibitor). Cytotoxicity assay,HEK293,,,,,human,mbds0010,,2013-11-24 23:13:58
mbbd000143057,mbcd0029886,mbtp000002,mbrf0002055,,=,,,non-substrate,25,2.5,microM,0.7,m-THPC; meso-tetra(3-hydroxyphenyl)chlorin,,,ABCG2-transfected HEK-293 cells. Specific binding determined by absorbance measurements of photosensitiser fluorescence in presence and absence of 10 microM fumitremorgin C (ABCG2 inhibitor). Cytotoxicity assay,HEK293,,,,,human,mbds0010,,2013-11-24 23:13:58
mbbd000143058,mbcd0002981,mbtp000002,mbrf0001890,,,,,substrate,,,,,Mitoxantrone,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143059,mbcd0003043,mbtp000002,mbrf0001890,,,,,substrate,,,,,Methotrexate,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143060,mbcd0000779,mbtp000002,mbrf0001890,,,,,substrate,,,,,SN-38,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143061,mbcd0003187,mbtp000002,mbrf0001890,,,,,substrate,,,,,Topotecan,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143062,mbcd0029952,mbtp000002,mbrf0001890,,,,,substrate,,,,,NB-506,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143063,mbcd0000496,mbtp000002,mbrf0001890,,,,,substrate,,,,,J-107088,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143064,mbcd0001652,mbtp000002,mbrf0001890,,,,,substrate,,,,,Flavopiridol,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143065,mbcd0001111,mbtp000002,mbrf0001890,,,,,substrate,,,,,Cimetidine,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143066,mbcd0029883,mbtp000002,mbrf0001890,,,,,substrate,,,,,Pheophorbide A,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143067,mbcd0000043,mbtp000002,mbrf0001890,,,,,substrate,,,,,PhIP,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143068,mbcd0003075,mbtp000002,mbrf0001890,,,,,substrate,,,,,estrone 3-sulfate,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143069,mbcd0029888,mbtp000002,mbrf0001890,,,,,substrate,,,,,17beta-estradiol sulfate,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143070,mbcd0000387,mbtp000002,mbrf0001890,,,,,substrate,,,,,17beta-estradiol 17-(beta-D-glucuronide),,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143071,mbcd0003959,mbtp000002,mbrf0001890,,,,,substrate,,,,,Folic acid,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143072,mbcd0015671,mbtp000002,mbrf0001890,,,,,substrate,,,,,Protoporthyrin IX,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143073,mbcd0029889,mbtp000002,mbrf0001890,,,,,substrate,,,,,BODIPY-Prazosin,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143074,mbcd0000474,mbtp000002,mbrf0001890,,,,,substrate,,,,,Hoechst 33342,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143075,mbcd0000124,mbtp000002,mbrf0001337,,~,,,substrate,138,50.0,%,,Albendazole Sulfoxide; ABZSO,,,Human BRCP-transduced MDCKII subclones. Transepithelial transport was measured after 4 hours by measuring percentage of drug in opposite compartment by HPLC. Translocation from basolateral to apical compartment,MDCKII,,10,microM,,human,mbds0010,,2013-12-09 20:57:41
mbbd000143076,mbcd0026840,mbtp000002,mbrf0001337,,=,,,substrate,143,29.0,,,Oxfendazole; OXF,,,Human BRCP transduced MDCKII subclones; transepithelial transport,MDCKII,,10,microM,,human,mbds0010,,2013-11-24 23:11:50
mbbd000143077,mbcd0001221,mbtp000002,mbrf0001774,,~,,,substrate,138,27.0,%,2,Nitrofurantoin,,,Human BRCP-transduced MDCKII subclones. Transepithelial transport from basolateral to apical compartment measured via measuring percentage of drug in opposite compartment after 4 hours by HPLC. 10microM drug present,MDCKII,,10,microM,,human,mbds0010,,2013-12-09 20:57:41
mbbd000143078,mbcd0003125,mbtp000002,mbrf0002213,,~,,,inhibitor,29,1.01,micromol L-1,0.09,Gefitinib,,,Using plasma membrane vesicles of BCRP-overexpressing PC-6/SN2-5H cells,,,,,,human,mbds0010,,2013-12-09 20:57:42
mbbd000143079,mbcd0001052,mbtp000002,mbrf0002418,,=,,,inhibitor,72,40.4,%,3.2,Beclomethasone,,,MEF3.8-BRCP cell line. Inhibitory potency measyred relative to reference inhibitor Ko-138,MEF3.8,mbcd0002981,20,microM,,human,mbds0010,,2013-12-09 20:57:42
mbbd000143080,mbcd0001512,mbtp000002,mbrf0002418,,=,,,inhibitor,72,2.8,%,4.3,Ursodeoxycholic acid,,,MEF3.8-BRCP cell line. Inhibitory potency measyred relative to reference inhibitor Ko-138,MEF3.8,mbcd0002981,50,microM,,human,mbds0010,,2013-12-09 20:04:15
mbbd000143081,mbcd0001050,mbtp000002,mbrf0002418,,=,,,inhibitor,72,45.1,%,1.7,Digoxin,,,MEF3.8-BRCP cell line. Inhibitory potency measyred relative to reference inhibitor Ko-138,MEF3.8,mbcd0002981,50,microM,,human,mbds0010,,2013-12-09 20:04:16
mbbd000143082,mbcd0001675,mbtp000002,mbrf0002418,,=,,,non-inhibitor,72,-3.2,%,5,Aldosterone,,,MEF3.8-BRCP cell line; Inhibitory potency measyred relative to reference inhibitor Ko-138,MEF3.8,mbcd0002981,50,microM,,human,mbds0010,,2013-12-09 05:42:48
mbbd000143083,mbcd0003096,mbtp000002,mbrf0002418,,=,,,non-inhibitor,72,-2.9,%,1.6,Prednisolone,,,MEF3.8-BRCP cell line; Inhibitory potency measyred relative to reference inhibitor Ko-138,MEF3.8,mbcd0002981,50,microM,,human,mbds0010,,2013-12-09 05:42:48
mbbd000143084,mbcd0002635,mbtp000002,mbrf0002418,,=,,,non-inhibitor,72,-0.4,%,1.8,Hydorcortisone,,,MEF3.8-BRCP cell line; Inhibitory potency measyred relative to reference inhibitor Ko-138,MEF3.8,mbcd0002981,50,microM,,human,mbds0010,,2013-12-09 05:42:48
mbbd000143085,mbcd0029880,mbtp000002,mbrf0002418,,=,,,inhibitor,72,0.5,%,1.5,Dexamethasone 21-phosphate,,,MEF3.8-BRCP cell line. Inhibitory potency measyred relative to reference inhibitor Ko-138,MEF3.8,mbcd0002981,50,microM,,human,mbds0010,,2013-12-09 20:04:18
mbbd000143086,mbcd0003058,mbtp000002,mbrf0002418,,=,,,inhibitor,72,7.4,%,1.6,Prednisone,,,MEF3.8-BRCP cell line. Inhibitory potency measyred relative to reference inhibitor Ko-138,MEF3.8,mbcd0002981,50,microM,,human,mbds0010,,2013-12-09 20:04:16
mbbd000143087,mbcd0002959,mbtp000002,mbrf0002418,,=,,,inhibitor,72,13.2,%,2.4,Dexamethasone,,,MEF3.8-BRCP cell line. Inhibitory potency measyred relative to reference inhibitor Ko-138,MEF3.8,mbcd0002981,50,microM,,human,mbds0010,,2013-12-09 20:04:17
mbbd000143088,mbcd0027758,mbtp000002,mbrf0002418,,=,,,inhibitor,72,15.3,%,4.3,Triamcinolone,,,MEF3.8-BRCP cell line. Inhibitory potency measyred relative to reference inhibitor Ko-138,MEF3.8,mbcd0002981,50,microM,,human,mbds0010,,2013-12-09 20:04:19
mbbd000143089,mbcd0003905,mbtp000002,mbrf0002418,,=,,,inhibitor,72,20.7,%,4,Corticosterone,,,MEF3.8-BRCP cell line. Inhibitory potency measyred relative to reference inhibitor Ko-138,MEF3.8,mbcd0002981,50,microM,,human,mbds0010,,2013-12-09 20:04:20
mbbd000143090,mbcd0027669,mbtp000002,mbrf0002418,,=,,,inhibitor,72,21.5,%,2.2,6alpha-methylprednisolone,,,MEF3.8-BRCP cell line. Inhibitory potency measyred relative to reference inhibitor Ko-138,MEF3.8,mbcd0002981,50,microM,,human,mbds0010,,2013-12-09 20:54:15
mbbd000143091,mbcd0026840,mbtp000002,mbrf0001337,,=,,,inhibitor,100,112.7,%,1.2,Oxfendazole; OXF,,,Human BRCP transduced MDCKII subclones; measured percentage inhibition of Mitoxantrone transport from basolateral to apical compartment,,,325,microM,,human,mbds0010,,2013-12-09 20:54:13
mbbd000143092,mbcd0003125,mbtp000002,mbrf0002522,,~,,,substrate,28,100.0,nmol L-1,,Iressa; Gefitinib,,,A431-ABCG2 membranes; Km value of ATase activation by Iressa,A431,,,,,human,mbds0010,,2013-11-24 23:56:07
mbbd000143093,mbcd0003125,mbtp000002,mbrf0002522,,=,,,substrate,22,38.9,nmol Pi (mg protein)-1 min-1,2,Iressa,,,A431-ABCG2 membranes; Vmax of vanadate-sensitiveATPase activity,A431,,,,,human,mbds0010,,2013-12-09 20:54:16
mbbd000143094,mbcd0000311,mbtp000002,mbrf0002261,,=,,,inhibitor,134,3.11,log scale,0.789-12.2 (95% CI),Cyclosporin A,,,Wild-type BRCP expressing AML cells; Mitoxantrone (BRCP substrate) IC50s measured; RMF=IC50(drug)/IC50(drug + inhibitor),HEK293,mbcd0002981,2.5,micromol L-1,,human,mbds0010,,2013-12-09 20:54:33
mbbd000143095,mbcd0029890,mbtp000002,mbrf0002011,,~,,,substrate,33,9.0,microL mg-1,1.5,ME3277,,,Uptake of ME3277 by membrane vesicles; BRCP-expressing LLC-PK1 cells examined for 10 minutes,LLC-PK1,,100,microM,,human,mbds0010,,2013-12-09 20:54:17
mbbd000143096,mbcd0002576,mbtp000002,mbrf0002285,,=,,,inhibitor,17,6.97,microM,1.25,Nicardipine,,,BCRP expressing MCF-7/MX100 cells; EC50 values for increasing Mitoxantrone(BRCP substrate) accumulation inside cells,,,,,,human,mbds0010,,2013-12-09 20:54:17
mbbd000143097,mbcd0029891,mbtp000002,mbrf0002285,,=,,,inhibitor,17,9.82,microM,1.39,Niguldipine,,,BRCP expressing MCF-7/MX 100 cells; EC50 values for increasing Mitoxantrone(BRCP substrate) accumulation inside cells,,,,,,human,mbds0010,,2013-12-09 20:54:17
mbbd000143098,mbcd0003135,mbtp000002,mbrf0002285,,=,,,inhibitor,17,22.1,microM,10.2,Nitrendipine,,,BRCP expressing MCF-7/MX 100 cells; EC50 values for increasing Mitoxantrone(BRCP substrate) accumulation inside cells,,,,,,human,mbds0010,,2013-12-09 20:54:17
mbbd000143100,mbcd0019766,mbtp000002,mbrf0002285,,~,,,inhibitor,20,310.0,%,20,Compound Ia,,,BCRP expressing MCF-7 cells; measuring 30min accumulation of mitoxantrone within cells by flow cytometry as percentage of control with no inhibitor present; Ia at concentration of 2.5 microM,,,,,,human,mbds0010,,2013-12-09 21:00:48
mbbd000143101,mbcd0029892,mbtp000002,mbrf0002285,,~,,,inhibitor,20,290.0,%,10,Compound Ib,,,BCRP expressing MCF-7 cells; measuring 30 min accumulation of mitoxantrone within cells by flow cytometry as a percentage of control,,,2.5,microM,,human,mbds0010,,2013-12-09 19:59:52
mbbd000143102,mbcd0029893,mbtp000002,mbrf0002285,,~,,,inhibitor,20,350.0,%,150,Compound Ic,,,BCRP-expressing MCF-7 cells; measuring 30 min accumulation of mitoxantrone within cells by flow cytometry as a percentage of control,,,2.5,microM,,human,mbds0010,,2013-12-09 19:59:51
mbbd000143103,mbcd0029894,mbtp000002,mbrf0002285,,~,,,inhibitor,20,320.0,%,90,Compound Id,,,BCRP- expressing MCF-7 cells; measuring 30 min accumulation of mitoxantrone within cells by flow cytometry as a percentage of control,,,2.5,microM,,human,mbds0010,,2013-12-09 19:59:50
mbbd000143104,mbcd0029895,mbtp000002,mbrf0002285,,~,,,inhibitor,20,220.0,%,90,Compound Ie,,,BCRP- expressing MCF-7 cells; measuring 30 min accumulation of mitoxantrone within cells by flow cytometry as a percentage of control,,,2.5,microM,,human,mbds0010,,2013-12-09 19:59:58
mbbd000143105,mbcd0029896,mbtp000002,mbrf0002285,,~,,,inhibitor,20,300.0,%,100,Compound If,,,BCRP- expressing MCF-7 cells; measured 30 min accumulation of mitoxantrone within cells by flow cytometry as a percentage of control,,,2.5,microM,,human,mbds0010,,2013-12-09 19:59:56
mbbd000143106,mbcd0029897,mbtp000002,mbrf0002285,,~,,,inhibitor,20,310.0,%,60,Compound Ig,,,BCRP- expressing MCF-7 cells; measured 30 min accumulation of mitoxantrone within cells by flow cytometry as a percentage of control,,,2.5,microM,,human,mbds0010,,2013-12-09 19:59:55
mbbd000143107,mbcd0029898,mbtp000002,mbrf0002285,,~,,,inhibitor,20,200.0,%,60,Compound Ii,,,BCRP-expressing MCF-7 cells; measured 30 min accumulation of Mitoxantrone within cells by flow cytometry as a percentage of control,,,2.5,microM,,human,mbds0010,,2013-12-09 19:59:53
mbbd000143108,mbcd0029890,mbtp000002,mbrf0002285,,~,,,inhibitor,20,260.0,%,30,Compound Ij,,,BCRP-expressing MCF-7 cells; measured 30 min accumulation of mitoxantrone within cells by flow cytometry as a percentage of control,,,2.5,microM,,human,mbds0010,,2013-12-09 20:00:00
mbbd000143109,mbcd0029900,mbtp000002,mbrf0002285,,~,,,inhibitor,20,240.0,%,30,Compound Ik,,,BCRP-expressing MCF-7 cells; measured 30 min mitoxantrone accumulation within cells by flow cytometry as a percentage of control,,,2.5,microM,,human,mbds0010,,2013-12-09 19:59:59
mbbd000143110,mbcd0029901,mbtp000002,mbrf0002285,,~,,,inhibitor,20,280.0,%,10,Compound Il,,,BCRP-expressing MCF-7 cells; measured 30 min mitoxantrone accumulation within cells as a percentage of control,,,2.5,microM,,human,mbds0010,,2013-12-09 20:52:52
mbbd000143111,mbcd0029902,mbtp000002,mbrf0002285,,~,,,inhibitor,20,350.0,%,50,Compound Im,,,BCRP-expressing MCF-7 cells; measured 30 min mitoxantrone accumulation within cells by flow cytometry as a percentage of control,,,2.5,microM,,human,mbds0010,,2013-12-09 20:52:52
mbbd000143112,mbcd0029903,mbtp000002,mbrf0002285,,~,,,inhibitor,20,310.0,%,40,Compound In,,,BCRP-expressing MCF-7 cells; measured 30 min mitoxantrone accumulation within cells by flow cytometry as a percetage of the control,,,2.5,microM,,human,mbds0010,,2013-12-09 20:52:52
mbbd000143113,mbcd0029904,mbtp000002,mbrf0002285,,~,,,inhibitor,20,280.0,%,80,Compound Io,,,BCRP-expressing MCF-7 cells; measured 30 min mitoxantrone accumulation within cells by flow cytometry as a percentage of control,,,2.5,microM,,human,mbds0010,,2013-12-09 20:52:52
mbbd000143114,mbcd0029905,mbtp000002,mbrf0002285,,~,,,inhibitor,20,390.0,%,80,Compound IIa,,,BCRP-expressing MCF-7 cells; measured 30 min mitoxantrone accumulation within cells by flow cytometry as a percentage of control,,,2.5,microM,,human,mbds0010,,2013-12-09 20:52:51
mbbd000143115,mbcd0029906,mbtp000002,mbrf0002285,,~,,,inhibitor,20,480.0,%,30,Compound IIb,,,BCRP- expressing MCF-7 cells; measured 30min Mitoxantrone accumulation within cells as a percentage of control,,,2.5,microM,,human,mbds0010,,2013-12-09 20:52:51
mbbd000143116,mbcd0029907,mbtp000002,mbrf0002285,,~,,,inhibitor,20,300.0,%,20,Compound IIc,,,BCRP-expressing MCF-7 cells; measured 30 min Mitoxantrone accumulation within cells by flow cytometry as a percentage of control,,,2.5,microM,,human,mbds0010,,2013-12-09 20:52:51
mbbd000143117,mbcd0029908,mbtp000002,mbrf0002285,,~,,,inhibitor,20,540.0,%,90,Compound IId,,,BCRP-expressing MCF-7 cells; measured 30min Mitoxantrone accumulation within cells by flow cytometry as a percentage of control,,,2.5,microM,,human,mbds0010,,2013-12-09 20:52:51
mbbd000143118,mbcd0029909,mbtp000002,mbrf0002285,,~,,,inhibitor,20,240.0,%,40,Compound IIe,,,BCRP-expressing MCF-7 cells; measured Mitoxantrone accumulation with cells by flow cytometry as a percentage of controll,,,2.5,microM,,human,mbds0010,,2013-12-09 20:52:50
mbbd000143119,mbcd0029910,mbtp000002,mbrf0002285,,~,,,inhibitor,20,370.0,%,40,Compound IIf,,,BCRP-expressing MCF-7 cells; measured 30 min Mitoxantrone accumulation within cells by flow cytometry as a percentage of control,,,2.5,microM,,human,mbds0010,,2013-12-09 20:52:51
mbbd000143120,mbcd0029911,mbtp000002,mbrf0002285,,~,,,inhibitor,20,250.0,%,20,Compound IIi,,,BCRP-expressing MCF-7 cells; measured 30 min mitoxantrone accumulation within cells by flow cytometry as a percentage of control,,,2.5,microM,,human,mbds0010,,2013-12-09 19:58:20
mbbd000143121,mbcd0029912,mbtp000002,mbrf0002285,,~,,,inhibitor,20,240.0,%,10,Compound IIm,,,BCRP-expressing MCF-7 cells; measured 30 min Mitoxantrone accumulation within cells as a percetqage of control,,,2.5,microM,,human,mbds0010,,2013-12-09 19:58:20
mbbd000143122,mbcd0029913,mbtp000002,mbrf0002285,,~,,,inhibitor,20,330.0,%,40,Compound IIn,,,BCRP-expressing MCF-7 cells; measured 30 min mitoxantrone accumulation within cells as a percentage of control,,,2.5,microM,,human,mbds0010,,2013-12-09 19:58:23
mbbd000143123,mbcd0029914,mbtp000002,mbrf0002285,,~,,,inhibitor,20,440.0,%,50,Compound IIo,,,BCRP-expressing MCF-7 cells; measured 30min mitoxantrone accumulation within cells as a percentage of control,,,2.5,microM,,human,mbds0010,,2013-12-09 19:58:21
mbbd000143124,mbcd0029902,mbtp000002,mbrf0002285,,=,,,inhibitor,17,3.71,microM,0.85,Compound Im,,,BCRP expressing MCF-7/MX 100 cells; EC50 values for increasing mitoxantrone accumulation inside cells,,,,,,human,mbds0010,,2013-12-09 19:58:17
mbbd000143125,mbcd0029906,mbtp000002,mbrf0002285,,=,,,inhibitor,17,3.8,microM,0.64,Compound IIb,,,BCRP expressing MCF-7/MX 100 cells; EC50 values for increasing mitoxantrone accumulation inside cells,,,,,,human,mbds0010,,2013-12-09 19:58:16
mbbd000143126,mbcd0029394,mbtp000002,mbrf0002513,,~,,,substrate,138,980.0,pmol cm-2,20,BP-3-Sulfate,,,Human CaCO-2 cell line; transport across apical membranes measured after 6 hours,Caco-2,,5,microM,,human,mbds0010,,2013-12-09 19:58:19
mbbd000143127,mbcd0029916,mbtp000002,mbrf0002513,,~,,,substrate,138,325.0,pmol cm-2,25,BP-3-Glucuronide,,,Human TC7 cells (CaCO-2 subclone); transport across apical membrane measured after 6 hours,Caco-2,,5,microM,,human,mbds0010,,2013-12-09 19:58:18
mbbd000143128,mbcd0003168,mbtp000002,mbrf0002311,,=,,,inhibitor,25,2.8,microM,1.6,Flavone,,,Wild-type ABCG2 transfected HEK-293 cells in presence of 5microM L-1 mitoxantrone,,,,,,human,mbds0010,,2013-12-09 19:58:26
mbbd000143129,mbcd0027296,mbtp000002,mbrf0002311,,=,,,inhibitor,25,8.1,microM,1.9,3-OH-flavone,,,Wild-type ABCG2 transfected HEK-293 cells in presence of 5microM L-1 mitoxantrone,,,,,,human,mbds0010,,2013-12-09 19:58:24
mbbd000143130,mbcd0022349,mbtp000002,mbrf0002311,,=,,,inhibitor,25,7.1,microM,0.3,7-OH-flavone,,,Wild-type ABCG2 transfected HEK-293 cells in presence of 5microM L-1 mitoxantrone,,,,,,human,mbds0010,,2013-12-09 20:52:32
mbbd000143131,mbcd0003045,mbtp000002,mbrf0002311,,=,,,inhibitor,25,4.6,microM,0.5,Chrysin,,,Wild-type ABCG2 transfected HEK-293 cells in presence of 5microM L-1 mitoxantrone,,,,,,human,mbds0010,,2013-12-09 20:52:32
mbbd000143132,mbcd0022552,mbtp000002,mbrf0002311,,=,,,inhibitor,25,3.0,microM,0.9,Tectochrysin,,,Wild-type ABCG2 transfected HEK-293 cells in presence of 5microM L-1 mitoxantrone,,,,,,human,mbds0010,,2013-12-09 20:52:31
mbbd000143133,mbcd0003238,mbtp000002,mbrf0002311,,=,,,inhibitor,25,0.29,microM,0.06,6-Prenylchrysin,,,Wild type ABCG2 transfected HEK-293 cells in presence of 5microM L-1 mitoxantrone,,,,,,human,mbds0010,,2013-12-09 20:52:32
mbbd000143134,mbcd0029917,mbtp000002,mbrf0002311,,=,,,inhibitor,25,0.78,microM,0.15,"6-(1,1-Dimethylallyl)chrysin",,,Wild-type ABCG2 transfected HEK-293 cells in presence of 5microM L-1 mitoxantrone,,,,,,human,mbds0010,,2013-12-09 20:52:31
mbbd000143135,mbcd0029918,mbtp000002,mbrf0002311,,=,,,inhibitor,25,0.89,microM,0.31,8-Prenylchrysin,,,Wild-type ABCG2 transfected HEK-293 cells in presence of 5microM L-1 mitoxantrone,,,,,,human,mbds0010,,2013-12-09 20:52:31
mbbd000143136,mbcd0029919,mbtp000002,mbrf0002311,,=,,,inhibitor,25,1.4,microM,0.5,"8-(1,1-Dimethylallyl)chrysin",,,Wild-type ABCG2 transfected HEK-293 cells in presence of 5microM L-1 mitoxantrone,,,,,,human,mbds0010,,2013-12-09 20:52:31
mbbd000143137,mbcd0029920,mbtp000002,mbrf0002311,,=,,,inhibitor,25,1.0,microM,0.4,6-Geranylchrysin,,,Wild-type ABCG2 transfected HEK-293 cells in presence of 5microM L-1 mitoxantrone,,,,,,human,mbds0010,,2013-12-09 20:52:31
mbbd000143138,mbcd0029921,mbtp000002,mbrf0002311,,>,,,inhibitor,25,10.0,microM,,6-Farnesylchrysin,,,Wild-type ABCG2 transfected HEK-293 cells in presence of 5microM mitoxantrone,,,,,,human,mbds0010,,2013-12-09 20:52:32
mbbd000143139,mbcd0029922,mbtp000002,mbrf0002311,,=,,,inhibitor,25,2.1,microM,0.5,"6,8-Digeranylchrysin",,,Wild-type  ABCG2 transfected HEK-293 cells in presence of 5microM L-1 mitoxantrone,,,,,,human,mbds0010,,2013-12-09 20:52:32
mbbd000143140,mbcd0001808,mbtp000002,mbrf0002311,,=,,,inhibitor,25,0.31,microM,0.14,GF120918,,,Wild type transfected H EK-293 cells in presence of 5microM L-1 mitoxantrone,,,,,,human,mbds0010,,2013-12-09 20:03:44
mbbd000143141,mbcd0003091,mbtp000002,mbrf0002311,,~,,,inhibitor,3,65.0,%,5,Apigenin,,,Wild-type ABCG2 transfected HEK-293 cells; intracellular mitoxantrone accumulation as a percentage of control(empty vector),,,20,microM,,human,mbds0010,,2013-11-23 22:11:26
mbbd000143142,mbcd0004758,mbtp000002,mbrf0002311,,~,,,inhibitor,3,60.0,%,5,Gelangin,,,Wild-type ABCG2 transfected HEK-293 cells; intracelluar mitoxantrone accumulation as a percentage of control,,,20,microM,,human,mbds0010,,2013-12-09 20:03:42
mbbd000143143,mbcd0003116,mbtp000002,mbrf0002311,,~,,,inhibitor,3,50.0,%,5,Genistein,,,Wild-type ABCG2 transfected HEK-293 cells; intracellular mitoxantrone accumulation as a percentage of control,,,20,microM,,human,mbds0010,,2013-12-09 20:03:40
mbbd000143144,mbcd0003096,mbtp000002,mbrf0002311,,~,,,inhibitor,3,30.0,%,4,Naringenin,,,Wild-type ABCG2 transfected HEK-293 cells; intracellular mitoxantrone accumulation as a percentage of control,,,20,microM,,human,mbds0010,,2013-12-09 20:03:39
mbbd000143145,mbcd0003238,mbtp000002,mbrf0002311,,~,,,inhibitor,3,80.0,%,5,6-Prenylchrysin,,,Wild type HEK-293 transfected cells; intracellular mitoxantrone accumulation as a percentage of control,,,5,microM,,human,mbds0010,,2013-12-09 20:03:38
mbbd000143146,mbcd0022552,mbtp000002,mbrf0002311,,~,,,inhibitor,3,55.0,%,2,Tectochrysin,,,Wild type ABCG2 transfected HEK-293 cells; intracellular mitoxantrone accumulation as a percentage of control,,,20,microM,,human,mbds0010,,2013-12-09 20:03:38
mbbd000143147,mbcd0001808,mbtp000002,mbrf0002311,,~,,,inhibitor,3,90.0,%,5,GF120918,,,Wild-type ABCG2 trasfected HEK-293 cells; intracelular mitoxantroe accumulation as a percentage of control,,,5,microM,,human,mbds0010,,2013-12-09 20:03:38
mbbd000143148,mbcd0000693,mbtp000002,mbrf0001719,,=,,,substrate,28,5.73,microM,1.52,Pitavastatin,,,BCRP-transfected HEK-293 cells; ATP dependant uptake of Pitavastatin,HEK293,,,,,human,mbds0010,,2013-11-24 23:13:59
mbbd000143149,mbcd0000693,mbtp000002,mbrf0001719,,=,,,substrate,22,1106.0,pmol min-1  mg-1,79,Pitavastatin,,,BCRP- trasnfected HEK-293 cells; ATP dependant uptake of Pitavastatin,HEK293,,,,,human,mbds0010,,2013-12-09 20:03:45
mbbd000143150,mbcd0000693,mbtp000002,mbrf0001719,,~,,,substrate,33,490.0,microL (mg protein)-1,20,Pitavastatin,,,Uptake into human BCRP-expressing membrane vesicles; 5 minutes; inpresence of ATP; HEK293 cells,HEK293,,0.1,microM,,human,mbds0010,,2013-11-26 00:48:05
mbbd000143151,mbcd0023123,mbtp000002,mbrf0001719,,~,,,substrate,33,35.0,microL (mg protein)-1,,Cerivastatin,,,Uptake into human BRCP-expressing membrane vesicles; 5 minutes; inpresence of ATP; HEK293 cells,HEK293,,0.1,microM,,human,mbds0010,,2013-11-26 00:48:05
mbbd000143152,mbcd0001445,mbtp000002,mbrf0001719,,~,,,substrate,33,280.0,microL (mg protein)-1,10,Fluvastatin,,,Uptake into BCRP-expressing membrane vesicles; 5 minutes; in presence of ATP; HEK293 cells,HEK293,,5,microM,,human,mbds0010,,2013-11-26 00:48:05
mbbd000143153,mbcd0003126,mbtp000002,mbrf0001719,,~,,,substrate,33,7.5,microL (mg protein)-1,0.5,Pravastatin,,,Uptake into BCRP-expressing membrane vesicles; 5 minutes; in presence of ATP; HEK293 cells,HEK293,,0.1,microM,,human,mbds0010,,2013-11-26 00:48:05
mbbd000143154,mbcd0003075,mbtp000002,mbrf0001719,,~,,,substrate,33,1010.0,microL (mg protein)-1,5,estrone-3-sulfate,,,Uptake into BCRP-expressing membrane vesicles; 2 minutes; in presence of ATP; HEK293 cells,HEK293,,0.1,microM,,human,mbds0010,,2013-11-26 00:48:05
mbbd000143155,mbcd0001448,mbtp000002,mbrf0001719,,~,,,substrate,33,390.0,microL (mg protein)-1,10,Rosuvastatin,,,Uptake into BCRP-expressing membrane vesicles; 5 minutes; in presence of ATP; HEK293 cells,HEK293,,0.1,microM,,human,mbds0010,,2013-11-26 00:48:05
mbbd000143156,mbcd0026093,mbtp000002,mbrf0001719,,=,,,inhibitor,29,14.3,microM,1.9,Atorvastatin,,,Inhibition of ATP-dependant uptake of 0.1microM estrone-3-sulfate by human BCRP for 1 minute,,,,,,human,mbds0010,,2013-12-09 20:54:25
mbbd000143157,mbcd0023123,mbtp000002,mbrf0001719,,=,,,inhibitor,29,18.1,microM,2.5,Cerivastatin,,,Inhibition of ATP-dependant 0.1microM estrone-3-sulfate uptake for 1 minute,,,,,,human,mbds0010,,2013-12-09 20:54:25
mbbd000143158,mbcd0001445,mbtp000002,mbrf0001719,,=,,,inhibitor,29,5.43,microM,0.27,Fluvastatin,,,Inhibition of ATP-dependant uptake of 0.1microM estrone-3-sulfate for 1 minute,,,,,,human,mbds0010,,2013-12-09 20:54:25
mbbd000143159,mbcd0000693,mbtp000002,mbrf0001719,,=,,,inhibitor,29,2.92,microM,0.35,Pitavastatin,,,Inhibition of ATP-dependant uptake of 0.1microM estrone-3-sulfate for 1 minute,,,,,,human,mbds0010,,2013-12-09 20:54:25
mbbd000143160,mbcd0003126,mbtp000002,mbrf0001719,,>,,,inhibitor,29,300.0,microM,,Pravastatin,,,Inhibition of ATP-dependant uptake of 0.1microM estrone-3-sulfate for 1 minute,,,,,,human,mbds0010,,2013-12-09 20:01:28
mbbd000143161,mbcd0001448,mbtp000002,mbrf0001719,,=,,,inhibitor,29,15.4,microM,2.4,Rosuvastatin,,,Inhibition of ATP-dependant uptake of 0.1microM estrone-3-sulfate for 1 minute,,,,,,human,mbds0010,,2013-12-09 20:01:27
mbbd000143162,mbcd0000772,mbtp000002,mbrf0001719,,=,,,inhibitor,29,18.0,microM,4.3,Simvastatin acid,,,Inhibition of ATP-dependant uptake of 0.1microM estrone-3-sulfate fro 1 minute,,,,,,human,mbds0010,,2013-12-09 20:01:31
mbbd000143163,mbcd0003091,mbtp000002,mbrf0001921,,=,,,inhibitor,17,1.66,microM,0.55,Apigenin,,,EC50 value for increasing mitoxantrone accumulation within MCF-7/MX100 cells,,,,,,human,mbds0010,,2013-12-09 20:01:29
mbbd000143164,mbcd0003045,mbtp000002,mbrf0001921,,=,,,inhibitor,17,0.39,microM,0.13,Chrysin,,,EB50 value for increasing mitoxantrone accumulation within MCF-7/MX100 cells,,,,,,human,mbds0010,,2013-12-09 20:01:33
mbbd000143165,mbcd0003168,mbtp000002,mbrf0001921,,=,,,inhibitor,17,3.99,microM,1.78,Flavone,,,EC50 value for increasing mitoxantrone accumulation within MCF-7/MX100 cells,,,,,,human,mbds0010,,2013-12-09 20:01:32
mbbd000143166,mbcd0004758,mbtp000002,mbrf0001921,,=,,,inhibitor,17,1.21,microM,0.27,Galangin,,,EC50 values for increasing mitoxantrone accumulation within MCF-7/MX100 cells,,,,,,human,mbds0010,,2013-12-09 20:01:35
mbbd000143167,mbcd0003215,mbtp000002,mbrf0001921,,=,,,inhibitor,17,6.04,microM,0.09,Kaempferol,,,EC50 values for increasing mitoxantrone accumulation within MCF-7/MX100 cells,,,,,,human,mbds0010,,2013-12-09 20:01:34
mbbd000143168,mbcd0029923,mbtp000002,mbrf0001921,,=,,,inhibitor,17,1.41,microM,0.26,"5,7-Dimethoxyflavone",,,EC50 values for increasing mitoxantrone accumulation within MCF-7/MX100 cells,,,,,,human,mbds0010,,2013-12-09 20:01:27
mbbd000143169,mbcd0004738,mbtp000002,mbrf0001921,,=,,,inhibitor,17,0.07,microM,0.02,"7,8-Benzoflavone",,,EC50 values for increasing mitoxantrone accumulation within MCF-7/MX100 cells,,,,,,human,mbds0010,,2013-12-09 20:01:27
mbbd000143170,mbcd0004720,mbtp000002,mbrf0001921,,=,,,inhibitor,17,1.21,microM,0.35,Baicalein,,,EC50 values for increasing accumulation of Mitoxantrone within MCF-7/MX100 cells,,,,,,human,mbds0010,,2013-12-09 20:53:26
mbbd000143171,mbcd0029924,mbtp000002,mbrf0001921,,=,,,inhibitor,17,1.09,microM,0.41,"5,6,7-Trimethoxyflavone",,,EC50 values for increasing mitoxantrone accumulation within MCF-7/MX100 cells,,,,,,human,mbds0010,,2013-12-09 20:53:27
mbbd000143172,mbcd0027257,mbtp000002,mbrf0001921,,=,,,inhibitor,17,20.1,microM,4.3,"7,8-Dihydroxyflavone",,,EC50 values for increasing mitoxantrone accumulation within MCF-7/MX100 cells,,,,,,human,mbds0010,,2013-12-09 20:53:26
mbbd000143173,mbcd0029925,mbtp000002,mbrf0001921,,=,,,inhibitor,17,0.45,microM,0.25,"6,4'-Dimethoxy-3-hydroxy-flavone",,,EC50 values for increasing mitoxantrone accumulation within MCF-7/MX100 cells,,,,,,human,mbds0010,,2013-12-09 20:53:26
mbbd000143174,mbcd0022934,mbtp000002,mbrf0001921,,=,,,inhibitor,17,0.09,microM,0.05,2'-hydroxy-alpha-napthoflavone,,,EC50 values for increasing mitoxantrone accumulation within MCF-7/X100 cells,,,,,,human,mbds0010,,2013-12-09 20:05:16
mbbd000143175,mbcd0004722,mbtp000002,mbrf0001921,,=,,,inhibitor,17,1.02,microM,0.33,Kaempferide,,,EC50 values for increasing mitoxantrone accumulation within MCF-7/MX100 cells,,,,,,human,mbds0010,,2013-12-09 20:53:28
mbbd000143176,mbcd0029926,mbtp000002,mbrf0001921,,=,,,inhibitor,17,0.61,microM,0.15,8-Methylflavone,,,EC50 values for increasing mitoxantrone accumulation within MCF-7/MX100cells,,,,,,human,mbds0010,,2013-12-09 20:53:27
mbbd000143177,mbcd0003026,mbtp000002,mbrf0001921,,=,,,inhibitor,17,1.62,microM,1.02,Biochanin A,,,EC50 values for increasing mitoxantrone accumulation within MCF-7/MX100 cells,,,,,,human,mbds0010,,2013-12-09 20:53:28
mbbd000143178,mbcd0013632,mbtp000002,mbrf0001921,,=,,,inhibitor,17,57.3,microM,15.8,Daidzein,,,EC50 values for increasing mitoxantrone accumulation within MCF-7/MX100 cells,,,,,,human,mbds0010,,2013-12-09 20:53:26
mbbd000143179,mbcd0003116,mbtp000002,mbrf0001921,,=,,,inhibitor,17,14.9,microM,2.69,Genistein,,,EC50 values for increasing mitoxantrone accumulation within MCF-7/MX100 cells,,,,,,human,mbds0010,,2013-12-09 20:53:26
mbbd000143180,mbcd0029927,mbtp000002,mbrf0001921,,=,,,inhibitor,17,24.6,microM,5.21,Flavanone,,,EC50 values for mitoxantrone accumulation within MCF-7/MX100 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143181,mbcd0004749,mbtp000002,mbrf0001921,,=,,,inhibitor,17,12.4,microM,2.21,Hesperetin,,,EC50 values for increasing mitoxantrone accumulation within MCF-7/MX100 cells,,,,,,human,mbds0010,,2013-12-09 19:53:44
mbbd000143182,mbcd0027229,mbtp000002,mbrf0001921,,=,,,inhibitor,17,183.0,microM,21.7,Silybin,,,EC50 values for mitoxantrone accumulation within MCF-7/MX100 cells,,,,,,human,mbds0010,,2013-12-09 19:53:43
mbbd000143183,mbcd0029928,mbtp000002,mbrf0001921,,=,,,inhibitor,17,16.3,microM,4.25,7-Methoxyflavanone,,,EB50 values for mitoxantrone accumulation within MCF-7/MX100 cells,,,,,,human,mbds0010,,2013-12-09 19:53:42
mbbd000143184,mbcd0003076,mbtp000002,mbrf0001921,,=,,,inhibitor,17,32.0,microM,3.22,Naringenin,,,EC50 values for mitoxantrone accumulation within MCF-7/MX100 cells,,,,,,human,mbds0010,,2013-12-09 19:57:28
mbbd000143185,mbcd0029929,mbtp000002,mbrf0001921,,=,,,inhibitor,17,11.7,microM,2.17,Chalcone,,,EC50 values for mitoxantrone accumulation within MCF-7/MX100 cells,,,,,,human,mbds0010,,2013-12-09 19:53:48
mbbd000143186,mbcd0029930,mbtp000002,mbrf0001921,,=,,,inhibitor,17,5.67,microM,4.74,"6,2',3'-Trimethoxyflavanone",,,EC50 values for increasing mitoxantrone accumulation within MCF-7/MX100 cells,,,,,,human,mbds0010,,2013-12-09 19:53:46
mbbd000143187,mbcd0029931,mbtp000002,mbrf0001921,,=,,,inhibitor,17,14.2,microM,1.48,"6,2',3'-7-Hydroxyflavanone",,,EC50 values for increasig mitoxantrone accumulation within BCRP-overexpressing MCF-7/MX100 cells,,,,,,human,mbds0010,,2013-12-09 19:53:45
mbbd000143188,mbcd0029932,mbtp000002,mbrf0001997,,~,,,substrate,33,57.0,%,2,Aflatoxin B1,,,Transepithelial transport in BCRP-transduced MDCK-II cells; transport from basolateral to apical compartment; measured percentage of radioactivity present in monolayer after 4h incubation,MDCKII,,2,microM,,human,mbds0010,,2013-12-09 19:53:42
mbbd000143189,mbcd0029933,mbtp000002,mbrf0001997,,~,,,substrate,33,50.0,%,2,"2-amino-3-methylimidazo[4,5-f]quinoline; IQ",,,Transepithelial transport in BCRP-transduced MDCK-II cells; transport from basolateral to apical compartment; measured percentage of radioactivity present in monolayer after 4h incubation,MDCKII,,2,microM,,human,mbds0010,,2013-12-09 19:53:41
mbbd000143190,mbcd0029309,mbtp000002,mbrf0001997,,~,,,substrate,33,25.0,%,,"3-amino-1,4-dimethyl-5H-pyrido[4,3-b]indole",,,Transepithelial transport in BCRP-transduced MDCK-II cells; transport from basolateral to apical compartment; measured percentage of radioactivity present after 4h incubation,MDCKII,,,,,human,mbds0010,,2013-12-09 20:51:04
mbbd000143191,mbcd0029420,mbtp000002,mbrf0002107,,=,,,substrate,135,43.1,fold,,GW1843,,,HEK/BCRP-R482 cell line; measured after 4 hours; IC50 ratio (fold increase),HEK,,,,,human,mbds0010,,2013-11-24 23:13:59
mbbd000143192,mbcd0029766,mbtp000002,mbrf0002107,,=,,,substrate,135,11.8,fold,,Tomudex,,,HEK/BCRP-R482 cell line; measured after 4 hours; IC50 ratio (fold increase),HEK,,,,,human,mbds0010,,2013-11-24 23:14:00
mbbd000143193,mbcd0003043,mbtp000002,mbrf0002107,,=,,,substrate,100,29.0,pmol/10^7 cells,3.5,Methotrexate,,,HEK/BCRP-R482 and HEK/BCRP-G482 cell lines; measured after 24 hours,HEK,,,,,human,mbds0010,,2013-11-24 23:13:59
mbbd000143194,mbcd0002576,mbtp000002,mbrf0001946,,=,,,inhibitor,25,4.8,microM,1.3,Nicardipine,,,BCRP-tranfected HEK/482R cells; BCRP-mediated MX efflux,HEK293,mbcd0002981,,,,human,mbds0010,,2013-11-17 22:13:08
mbbd000143195,mbcd0003100,mbtp000002,mbrf0001946,,=,,,inhibitor,25,6.4,microM,0.9,Dipyridamole,,,BCRP-tranfected HEK/482R cells; BCRP-mediated MX efflux,HEK293,mbcd0002981,,,,human,mbds0010,,2013-11-17 22:13:08
mbbd000143196,mbcd0026854,mbtp000002,mbrf0001946,,=,,,inhibitor,25,13.7,microM,3.8,Nimodipine,,,BCRP-tranfected HEK/482R cells; BCRP-mediated MX efflux,HEK293,mbcd0002981,,,,human,mbds0010,,2013-11-17 22:13:09
mbbd000143197,mbcd0003135,mbtp000002,mbrf0001946,,~,,,non-substrate,103,50.0,fmol / 0.5*10^6 cells,3,Nitrendipine,,,BCRP-transfected HEK/482R cells; intracellular concentrations calculated based on radioactivity within the cells,HEK293,,10,nM,,human,mbds0010,,2013-12-09 20:51:04
mbbd000143198,mbcd0003100,mbtp000002,mbrf0001946,,~,,,substrate,103,14.0,fmol / 0.5*10^6 cells,3,Dipyridamole,,,BCRP-transfected HEK/482R cells; intracelular concentrations calculated based on radioactivity within the cells,HEK293,,,,,human,mbds0010,,2013-12-09 20:51:04
mbbd000143199,mbcd0029937,mbtp000002,mbrf0002087,,,,,non-substrate,,,,,Pitavastatin Lactone,,,Membrane vesicles (SB BCRP HAM Sf9 VT Membrane or SB BCRP M VT Membrane (Mammalian)),SB BCRP HAM Sf9 VT Membrane; SB BCRP M VT Membrane (Mammalian),,1-100,microM,,human,mbds0010,,2013-10-09 22:18:43
mbbd000143200,mbcd0000693,mbtp000002,mbrf0002087,,,,,substrate,,,,,Pitavastatin,,,Membrane vesicles (SB BCRP HAM Sf9 VT Membrane or SB BCRP M VT Membrane (Mammalian)),SB BCRP HAM Sf9 VT Membrane; SB BCRP M VT Membrane (Mammalian),,1-120,microM,,human,mbds0010,,2013-10-09 22:18:43
mbbd000143201,mbcd0000779,mbtp000002,mbrf0001313,,=,,,substrate,28,116.0,microM,,SN-38,,,membrane vesicles of PC-6 cells,PC-6,,,,,human,mbds0010,,2013-11-24 23:56:07
mbbd000143202,mbcd0002091,mbtp000002,mbrf0002458,,,,,substrate,,,,,Irinotecan,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143203,mbcd0000779,mbtp000002,mbrf0001313,,=,,,substrate,22,152.0,pmol mg-1 min-1,,SN-38,,,membrane vesicles of PC-6 cells,PC-6,,,,,human,mbds0010,,2013-11-24 23:56:07
mbbd000143204,mbcd0029938,mbtp000002,mbrf0001906,,~,,,substrate,9,2.0,,,SN 22,,,Drug resistace ratio from (IC50HEK293-ABCG2)/(IC50HEK293),HEK293,,,,,human,mbds0010,,2013-11-24 23:14:00
mbbd000143205,mbcd0000779,mbtp000002,mbrf0001906,,~,,,substrate,9,28.0,,,SN 38,,,Drug resistance ration from (IC50HEK293-ABCG2)/(IC50HEK293),HEK293,,,,,human,mbds0010,,2013-11-24 23:14:00
mbbd000143206,mbcd0029939,mbtp000002,mbrf0001906,,~,,,substrate,9,2.0,,,SN 343,,,Drug resistance ratio from (IC50HEK293-ABCG2)/(IC50HEK293),HEK293,,,,,human,mbds0010,,2013-11-24 23:14:00
mbbd000143207,mbcd0029940,mbtp000002,mbrf0001906,,~,,,substrate,9,1.5,,,SN 348,,,Drug resistance ratio from (IC50HEK293-ABCG2)/(IC50HEK293),HEK293,,,,,human,mbds0010,,2013-11-24 23:14:01
mbbd000143208,mbcd0029941,mbtp000002,mbrf0001906,,~,,,substrate,9,2.0,,,SN 349,,,Drug resistance ratio from (IC50HEK293-ABCG2)/(IC50HEK293),HEK293,,,,,human,mbds0010,,2013-11-24 23:14:01
mbbd000143209,mbcd0029942,mbtp000002,mbrf0001906,,~,,,substrate,9,1.0,,,SN 351,,,Drug resistance ratio from (IC50HEK293-ABCG2)/(IC50HEK293),HEK293,,,,,human,mbds0010,,2013-11-24 23:14:01
mbbd000143210,mbcd0029943,mbtp000002,mbrf0001906,,~,,,substrate,9,3.0,,,SB 352,,,Drug resistance ratio from (IC50HEK293-ABCG2)/(IC50HEK293),HEK293,,,,,human,mbds0010,,2013-11-24 23:14:01
mbbd000143211,mbcd0029944,mbtp000002,mbrf0001906,,~,,,substrate,9,1.5,,,SN 353,,,Drug resistance ratio from (IC50HEK293-ABCG2)/(IC50HEK293),HEK293,,,,,human,mbds0010,,2013-12-06 23:47:58
mbbd000143212,mbcd0029945,mbtp000002,mbrf0001906,,~,,,substrate,9,52.0,,,SN 355,,,Drug resistance ratio from (IC50HEK293-ABCG2)/(IC50HEK293),HEK293,,,,,human,mbds0010,,2013-11-24 23:14:02
mbbd000143213,mbcd0029946,mbtp000002,mbrf0001906,,~,,,substrate,9,4.0,,,SN 364,,,Drug resistance ratio from (IC50HEK293-ABCG2)/(IC50HEK293),HEK293,,,,,human,mbds0010,,2013-11-24 23:14:02
mbbd000143214,mbcd0029947,mbtp000002,mbrf0001906,,~,,,substrate,9,9.0,,,SN 392,,,Drug resistance ratio from (IC50HEK293-ABCG2)/(IC50HEK293),HEK293,,,,,human,mbds0010,,2013-11-24 23:14:02
mbbd000143215,mbcd0029948,mbtp000002,mbrf0001906,,~,,,substrate,9,2.0,,,SN 397,,,Drug resistance ratio from (IC50HEK293-ABCG2)/(IC50HEK293),HEK293,,,,,human,mbds0010,,2013-11-24 23:14:03
mbbd000143216,mbcd0029949,mbtp000002,mbrf0001906,,~,,,substrate,9,20.0,,,SN 398,,,Drug resistance ratio from (IC50HEK293-ABCG2)/(IC50HEK293),HEK293,,,,,human,mbds0010,,2013-11-24 23:14:03
mbbd000143217,mbcd0029950,mbtp000002,mbrf0001906,,~,,,substrate,9,2.0,,,SN 443,,,Drug resistance ratio from (IC50HEK293-ABCG2)/(IC50HEK293),HEK293,,,,,human,mbds0010,,2013-11-24 23:14:03
mbbd000143218,mbcd0029951,mbtp000002,mbrf0001906,,~,,,substrate,9,1.5,,,SN 444,,,Drug resistance ratio from (IC50HEK293-ABCG2)/(IC50HEK293),HEK293,,,,,human,mbds0010,,2013-11-24 23:14:03
mbbd000143219,mbcd0005183,mbtp000002,mbrf0001989,,,,,substrate,,,,,Daunorubicin,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143220,mbcd0025844,mbtp000002,mbrf0001989,,,,,substrate,,,,,Doxorubicin,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143221,mbcd0001941,mbtp000002,mbrf0001989,,,,,substrate,,,,,Reserpine,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143222,mbcd0000100,mbtp000002,mbrf0002537,,,,,substrate,,,,,9-Aminocamptothecin,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143223,mbcd0000191,mbtp000002,mbrf0001309,,>,,,non-inhibitor,25,100.0,microM,,Bisantrene,,,BCRP-transduced MCF-7 AdVp 3000 cell line,,,,,,human,mbds0010,,2013-12-09 20:58:16
mbbd000143224,mbcd0029877,mbtp000002,mbrf0002426,,,,,substrate,,,,,Diflomotecan,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143225,mbcd0025844,mbtp000002,mbrf0002537,,,,,substrate,,,,,Doxorubicin,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143226,mbcd0005183,mbtp000002,mbrf0002537,,,,,substrate,,,,,Daunomycin,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143228,mbcd0029350,mbtp000002,mbrf0001437,,=,,,substrate,8,400.0,,5,Epirubicin,,,Ratio of relatvie resistance from IC50(resistant cells)/IC50(parental cells); S1-M1-80 cell line developed from S1 subclone exposed to increasing concentrations of mitoxantrone,S1-M1-80,,,,,human,mbds0010,,2013-12-09 20:58:16
mbbd000143229,mbcd0002466,mbtp000002,mbrf0002537,,,,,substrate,,,,,Etoposide,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143230,mbcd0001652,mbtp000002,mbrf0002537,,,,,substrate,,,,,Flavopiridol,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143231,mbcd0002091,mbtp000002,mbrf0002537,,,,,substrate,,,,,Irinotecan; CPT-11,,,,,,,,,human,mbds0010,,2013-12-10 22:21:07
mbbd000143232,mbcd0000496,mbtp000002,mbrf0002537,,,,,substrate,,,,,J-107088,,,,,,,,,human,mbds0010,,2013-12-10 22:21:07
mbbd000143233,mbcd0003043,mbtp000002,mbrf0002537,,,,,substrate,,,,,Methotrexate,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143234,mbcd0002981,mbtp000002,mbrf0002537,,,,,substrate,,,,,Mitoxantrone,,,,,,,,,human,mbds0010,,2013-12-10 22:21:07
mbbd000143235,mbcd0029952,mbtp000002,mbrf0002537,,,,,substrate,,,,,NB-506,,,,,,,,,human,mbds0010,,2013-12-10 22:21:07
mbbd000143236,mbcd0000779,mbtp000002,mbrf0002537,,,,,substrate,,,,,SN-38,,,,,,,,,human,mbds0010,,2013-12-10 22:21:07
mbbd000143237,mbcd0002828,mbtp000002,mbrf0002537,,,,,substrate,,,,,Imatinib; ST1-571; Gleevec,,,,,,,,,human,mbds0010,,2014-01-27 21:28:32
mbbd000143238,mbcd0001080,mbtp000002,mbrf0002537,,,,,substrate,,,,,Teniposide,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143239,mbcd0003187,mbtp000002,mbrf0002537,,,,,substrate,,,,,Topotecan,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143240,mbcd0002982,mbtp000002,mbrf0002537,,,,,substrate,,,,,Lamivudine,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143241,mbcd0001107,mbtp000002,mbrf0002537,,,,,substrate,,,,,Zidovudine,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143242,mbcd0002831,mbtp000002,mbrf0001929,,=,,,substrate,20,62.0,AU,13,Resveratrol,,,BCRP- transduced K562 cells; fluorescence of 5000 cells after exposure to 5microM Mitoxantrone by flow cytometry,K562,,30,microM,,human,mbds0010,,2013-12-09 20:57:55
mbbd000143243,mbcd0013632,mbtp000002,mbrf0001929,,=,,,substrate,20,69.0,AU,16,Daidzein,,,BCRP-transduced K562 cells; fluorescence of 5000 cells after exposure to 5microM Mitoxantrone by flow cytometry,K562,,30,microM,,human,mbds0010,,2013-12-09 20:57:55
mbbd000143244,mbcd0004749,mbtp000002,mbrf0001929,,=,,,substrate,20,67.0,AU,16,Hesperetin,,,BCRP-transduced K562 cells; fluorescence of 5000 cells after exposure to 5microM Mitoxantrone by flow cytometry,K562,,30,microM,,human,mbds0010,,2013-12-09 20:57:53
mbbd000143245,mbcd0003120,mbtp000002,mbrf0001929,,=,,,substrate,20,60.0,AU,13,Quercetin,,,BCRP-transduced K562 cells; fluorescence of 5000 cells after exposure to 5microM Mitoxantrone by flow cytometry,K562,,30,microM,,human,mbds0010,,2013-12-09 20:57:54
mbbd000143246,mbcd0022617,mbtp000002,mbrf0001929,,=,,,substrate,20,63.0,AU,19,Silymarin,,,BCRP-transduced K562 cells; fluorescence of 5000 cells after exposure to 5microM Mitoxantrone by flow cytometry,K562,,30,microM,,human,mbds0010,,2013-12-09 20:57:54
mbbd000143247,mbcd0029883,mbtp000002,mbrf0002537,,,,,substrate,,,,,Pheophorbide A,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143248,mbcd0000043,mbtp000002,mbrf0002537,,,,,substrate,,,,,PhIP,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143249,mbcd0000474,mbtp000002,mbrf0002537,,,,,substrate,,,,,Hoechst 33342,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143250,mbcd0000746,mbtp000002,mbrf0002537,,,,,substrate,,,,,Rhodamine,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143251,mbcd0029953,mbtp000002,mbrf0002537,,,,,inhibitor,,,,,Cl 1033,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143252,mbcd0002422,mbtp000002,mbrf0002537,,,,,inhibitor,,,,,Fumitremorgin C,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143253,mbcd0002828,mbtp000002,mbrf0002537,,,,,inhibitor,,,,,Imatinib,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143254,mbcd0022900,mbtp000002,mbrf0002537,,,,,inhibitor,,,,,Pantoprazole,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143255,mbcd0003024,mbtp000002,mbrf0002537,,,,,inhibitor,,,,,Prazosin,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143256,mbcd0001941,mbtp000002,mbrf0002537,,,,,inhibitor,,,,,Reserpine,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143257,mbcd0003125,mbtp000002,mbrf0002537,,,,,inhibitor,,,,,Gefitinib,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143258,mbcd0000311,mbtp000002,mbrf0001712,,=,,,inhibitor,17,4.3,microM,1.9,Cyclosporin A,,,BCRP-expressing HEK cells; EC50 values for BCRP -mediated efflux of pheophorbide A,,,,,,human,mbds0010,,2013-12-09 20:08:51
mbbd000143259,mbcd0001316,mbtp000002,mbrf0001712,,=,,,inhibitor,17,3.6,microM,1.8,Tacrolimus,,,BCRP-expressing HEK cells; EC50 values for BCRP-mediated efflux of Pheophorbide A,,,,,,human,mbds0010,,2013-12-09 20:08:51
mbbd000143260,mbcd0001324,mbtp000002,mbrf0001712,,=,,,inhibitor,17,1.9,microM,0.4,Sirolimus,,,BCRP-expressing HEK cells; EC50 values for BCRP-mediated efflux of Pheophorbide A,,,,,,human,mbds0010,,2013-12-09 20:57:28
mbbd000143261,mbcd0001448,mbtp000002,mbrf0001679,,=,,,substrate,28,10.8,microM,1.1,Rosuvastatin,,,Km for high-affinity site on BCRP for Rosuvastatin; MXR-M-VT membranes,MXR-M-VT,,,,,human,mbds0010,,2013-11-26 00:18:20
mbbd000143262,mbcd0001448,mbtp000002,mbrf0001679,,=,,,substrate,28,307.0,microM,89.4,Rosuvastatin,,,Km for low-affinity site on BRCP for Rosuvastatin; MXR-M-VT membranes,MXR-M-VT,,,,,human,mbds0010,,2013-11-26 00:18:20
mbbd000143263,mbcd0017980,mbtp000002,mbrf0002289,,~,,,substrate,138,15.0,%,,Ciprofloxacin,,,Human BCRP-transduced MDCK-II subclones; transepithelial transport from basolateral to apical compartment; measured percentage of drug in opposite compartment after 4 hours,MDCKII,,10,microM,,human,mbds0010,,2013-12-09 20:57:28
mbbd000143264,mbcd0003068,mbtp000002,mbrf0002289,,~,,,substrate,138,25.0,%,,Ofloxacin,,,Human BCRP-transduced MDCK-II subclones; transepithelial transport from basolateral to apical compartment; measured percentage of drug in opposite compartment after 4 hours,MDCKII,,,,,human,mbds0010,,2013-12-09 20:57:28
mbbd000143265,mbcd0011365,mbtp000002,mbrf0002289,,~,,,substrate,138,7.0,%,0.5,Norfloxacin,,,Human BCRP-transduced MDCK-II subclones; transepithelial transport from basolateral to apical compartment; measured percentage of drug in opposite compartment after 4 hours,MDCKII,,,,,human,mbds0010,,2013-11-24 23:11:53
mbbd000143266,mbcd0017980,mbtp000002,mbrf0002289,,~,,,substrate,20,50.0,AU,5,Ciprofloxacin,,,MDCK-II cells; Fluorescence measures the intracellular accumulation of Mitoxantrone upon preincubation of fluoroquinolone,MDCKII,,100,microM,,human,mbds0010,,2013-11-25 22:56:44
mbbd000143267,mbcd0003068,mbtp000002,mbrf0002289,,~,,,substrate,20,60.0,AU,2,Ofloxacin,,,MDCK-II cells; Fluorescence measures the intracellular accumulation of mitoxantrone upon preincubation with fluoroquinolone,MDCKII,,200,microM,,human,mbds0010,,2013-11-25 22:59:21
mbbd000143268,mbcd0011365,mbtp000002,mbrf0002289,,~,,,substrate,20,49.0,AU,5,Norfloxacin,,,MDCK-II cells; Fluorescence measures the intracellular accumulation of Mitoxantrone upon preincubation with fluoroquinolone,MDCKII,,200,microM,,human,mbds0010,,2013-11-25 22:59:21
mbbd000143269,mbcd0002439,mbtp000002,mbrf0002289,,~,,,inhibitor,20,150.0,AU,25,Ko 143,,,Fluorescence measures the intracellular accumulation of Mitoxantrone following preincubation with the inhibitor,,,1,microM,,human,mbds0010,,2013-12-09 20:57:28
mbbd000143270,mbcd0003074,mbtp000002,mbrf0001293,,~,,,substrate,81,2.6,,,Glyburide,,,BCRP-overexpressing MCF7/MX cells; measured intracellular accumulation after 20 minutes as a percentage of that at time 0 with presence and absence of BCRP inhibitor Novobiocin,MCF7/MX,,,,,human,mbds0010,,2013-11-24 23:09:56
mbbd000143271,mbcd0002422,mbtp000002,mbrf0001781,,=,,,inhibitor,25,0.79,microM,0.01,Fumitremorgin C,,,ABCG2-overexpressing NCI-H460 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143272,mbcd0003211,mbtp000002,mbrf0001781,,=,,,inhibitor,25,10.7,microM,,Estrone,,,ABCG2-overexpressing NCI-H460 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143273,mbcd0003252,mbtp000002,mbrf0001781,,=,,,inhibitor,25,12.6,microM,,Novobiocin,,,ABCG2-overexpressing NCI-H460 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143274,mbcd0001941,mbtp000002,mbrf0001781,,=,,,inhibitor,25,11.8,microM,,Reserpine,,,ABCG2-overexpressing NCI-H460 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143275,mbcd0002104,mbtp000002,mbrf0001781,,=,,,inhibitor,25,3.2,microM,,Tariquidar,,,ABCG2-overexpressing NCI-H460 cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143276,mbcd0029954,mbtp000002,mbrf0001781,,=,,,inhibitor,25,2.23,microM,0.25,Eupatin,,,ABCG2-overexpressing NCI-H460 cells; IC50 values measured from Dose-response curve of a pheophorbide assay,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143277,mbcd0029955,mbtp000002,mbrf0001781,,,,,inhibitor,,,,,Eupatoretin,,,NCI-H460 cells,NCI-H460,mbcd0029883,10,microM,,human,mbds0010,,2013-11-20 20:56:24
mbbd000143278,mbcd0003223,mbtp000002,mbrf0001781,,,,,inhibitor,,,,,Cosmosiin,,,NCI-H460 cells,NCI-H460,mbcd0029883,10,microM,,human,mbds0010,,2013-11-20 20:57:22
mbbd000143279,mbcd0002981,mbtp000002,mbrf0002536,,,,,substrate,,,,,Mitoxantrone,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143280,mbcd0003187,mbtp000002,mbrf0002536,,,,,substrate,,,,,Topotecan,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143281,mbcd0002091,mbtp000002,mbrf0002536,,,,,substrate,,,,,Irinotecan,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143282,mbcd0025844,mbtp000002,mbrf0002536,,,,,substrate,,,,,Doxorubicin,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143283,mbcd0005183,mbtp000002,mbrf0002536,,,,,substrate,,,,,Daunorubicin,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143284,mbcd0029350,mbtp000002,mbrf0002536,,,,,substrate,,,,,Epirubicin,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143285,mbcd0029956,mbtp000002,mbrf0002536,,,,,substrate,,,,,Idarubicinol,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143286,mbcd0001652,mbtp000002,mbrf0002536,,,,,substrate,,,,,Flavopiridol,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143287,mbcd0029953,mbtp000002,mbrf0002536,,,,,substrate,,,,,Cl 1033,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143288,mbcd0003043,mbtp000002,mbrf0002536,,,,,substrate,,,,,Methotrexate,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143289,mbcd0003024,mbtp000002,mbrf0002536,,,,,substrate,,,,,Prazosin,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143290,mbcd0029957,mbtp000002,mbrf0002536,,,,,substrate,,,,,Indolocarbazole,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143291,mbcd0029952,mbtp000002,mbrf0002536,,,,,substrate,,,,,NB-506,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143292,mbcd0000496,mbtp000002,mbrf0002536,,,,,substrate,,,,,J-107088,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143293,mbcd0001107,mbtp000002,mbrf0002536,,,,,substrate,,,,,Zidovudine,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143294,mbcd0002982,mbtp000002,mbrf0002536,,,,,substrate,,,,,Lamivudine,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143295,mbcd0000746,mbtp000002,mbrf0002536,,,,,substrate,,,,,Rhodamine 123,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143296,mbcd0029889,mbtp000002,mbrf0002536,,,,,substrate,,,,,BODIPY-Prazosin,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143297,mbcd0000474,mbtp000002,mbrf0002536,,,,,substrate,,,,,Hoechst 33342,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143298,mbcd0029883,mbtp000002,mbrf0002536,,,,,substrate,,,,,Pheophorbide A,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143299,mbcd0015671,mbtp000002,mbrf0002536,,,,,substrate,,,,,Protoporthyrin IX,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143300,mbcd0002422,mbtp000002,mbrf0002536,,,,,inhibitor,,,,,Fumitremorgin C,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143301,mbcd0002439,mbtp000002,mbrf0002536,,,,,inhibitor,,,,,Ko143,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143302,mbcd0001808,mbtp000002,mbrf0002536,,,,,inhibitor,,,,,GF120918,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143303,mbcd0001652,mbtp000002,mbrf0002536,,,,,inhibitor,,,,,Flavopiridol,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143304,mbcd0029953,mbtp000002,mbrf0002536,,,,,inhibitor,,,,,Cl 1033,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143305,mbcd0003125,mbtp000002,mbrf0002536,,,,,inhibitor,,,,,Iressa,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143306,mbcd0003252,mbtp000002,mbrf0002536,,,,,inhibitor,,,,,Novobiocin,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143307,mbcd0001941,mbtp000002,mbrf0002536,,,,,inhibitor,,,,,Reserpine,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143308,mbcd0000190,mbtp000002,mbrf0002536,,,,,inhibitor,,,,,Biricodar,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143309,mbcd0029959,mbtp000002,mbrf0002536,,,,,inhibitor,,,,,VX 853,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143310,mbcd0000968,mbtp000002,mbrf0002536,,,,,inhibitor,,,,,Diethylstilbestrol,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143311,mbcd0003211,mbtp000002,mbrf0002536,,,,,inhibitor,,,,,Estrone,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143312,mbcd0002889,mbtp000002,mbrf0002536,,,,,inhibitor,,,,,Tamoixifen,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143313,mbcd0029960,mbtp000002,mbrf0002536,,,,,inhibitor,,,,,TAG-11,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143314,mbcd0029961,mbtp000002,mbrf0002536,,,,,inhibitor,,,,,TAG-139,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143315,mbcd0001133,mbtp000002,mbrf0002536,,,,,inhibitor,,,,,Toremifene,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143316,mbcd0029962,mbtp000002,mbrf0001657,,=,,,substrate,135,3.8,fold,,AG 337,,,HEK293/ABCG2-R482 cell line; growth inhibition after 72 hours exposure to the drug; IC50 ratio,HEK293,,,,,human,mbds0010,,2013-11-24 23:14:04
mbbd000143317,mbcd0029963,mbtp000002,mbrf0001657,,=,,,substrate,135,1.7,fold,,AG 331,,,HEK293/ABCG2-R482 cell line; growth inhibition after 72 hours exposure to the drug; IC50 ratio,HEK293,,,,weak substrate,human,mbds0010,,2013-11-24 23:14:04
mbbd000143318,mbcd0029964,mbtp000002,mbrf0001657,,=,,,substrate,135,5.9,fold,,AG 377,,,HEK293/ABCG2-R482 cell line; growth inhibition after 72 hours exposure to the drug; IC50 ratio,HEK293,,,,,human,mbds0010,,2013-11-24 23:14:04
mbbd000143319,mbcd0026481,mbtp000002,mbrf0001657,,=,,,substrate,135,6.3,fold,,Trimetrexate,,,HEK293/ABCG2-R482 cell line; growth inhibition after 72 hours exposure to the drug; IC50 ratio,HEK293,,,,,human,mbds0010,,2013-11-24 23:14:04
mbbd000143320,mbcd0029965,mbtp000002,mbrf0001657,,=,,,substrate,135,1.6,fold,,Piritrexim,,,HEK293/ABCG2-R482 cell line; growth inhibition after 72 hours exposure to the drug; IC50 ratio,HEK293,,,,weak substrate,human,mbds0010,,2013-11-24 23:14:05
mbbd000143321,mbcd0016826,mbtp000002,mbrf0001657,,=,,,substrate,135,6.8,fold,,Pyrimethamine,,,HEK293/ABCG2-R482 cell line; growth inhibition after 72 hours exposure to the drug; IC50 ratio,HEK293,,,,,human,mbds0010,,2013-11-24 23:14:05
mbbd000143322,mbcd0029966,mbtp000002,mbrf0001657,,=,,,non-substrate,135,0.9,fold,,Metoprine,,,HEK293/ABCG2-R482 cell line; growth inhibition after 72 hours exposure to the drug; IC50 ratio,HEK293,,,,,human,mbds0010,,2013-11-24 23:14:05
mbbd000143323,mbcd0025844,mbtp000002,mbrf0001657,,=,,,substrate,135,2.5,fold,,Doxorubicin,,,HEK293/ABCG2-R482 cell line; growth inhibition after 72 hours exposure to the drug; IC50 ratio,HEK293,,,,,human,mbds0010,,2013-11-24 23:14:05
mbbd000143324,mbcd0001532,mbtp000002,mbrf0001657,,=,,,substrate,135,24.3,fold,,Paclitaxel,,,HEK293/ABCG2-R482 cell line; growth inhibition after 72 hours exposure to the drug; IC50 ratio,HEK293,,,,,human,mbds0010,,2013-11-24 23:14:05
mbbd000143325,mbcd0001117,mbtp000002,mbrf0001657,,=,,,non-substrate,135,0.7,fold,,Cisplatinum,,,HEK293/ABCG2-R482 cell line; growth inhibition after 72 hours exposure to the drug; IC50 ratio,HEK293,,,,,human,mbds0010,,2013-11-24 23:14:06
mbbd000143326,mbcd0003963,mbtp000002,mbrf0001657,,=,,,substrate,135,1.4,fold,,5-Fluorouracil,,,HEK293/ABCG2-R482 cell line; growth inhibition after 72 hours exposure to the drug; IC50 ratio,HEK293,,,,weak substrate,human,mbds0010,,2013-11-24 23:14:06
mbbd000143327,mbcd0003043,mbtp000002,mbrf0001657,,=,,,substrate,135,59.4,fold,,Methotrexate,,,ABCG2-overexpressing MCF-7/MR cell line; growth inhibition after 72 hours exposure to the drug; IC50 ratio,MCF7/MR,,,,,human,mbds0010,,2013-11-24 23:09:57
mbbd000143328,mbcd0002981,mbtp000002,mbrf0001657,,=,,,substrate,135,34.2,fold,,Mitoxantrone,,,ABCG2-overexpressing MCF-7/MR cell line; growth inhibition after 72 hours exposure to the drug; IC50 ratio,MCF7/MR,,,,,human,mbds0010,,2013-11-24 23:09:57
mbbd000143329,mbcd0001135,mbtp000002,mbrf0001657,,=,,,substrate,135,22.0,fold,,Vincristine,,,ABCG2-overexpressing MCF-7/MR cell line; growth inhibition after 72 hours exposure to the drug; IC50 ratio,MCF7/MR,,,,,human,mbds0010,,2013-11-24 23:09:57
mbbd000143330,mbcd0001151,mbtp000002,mbrf0001657,,=,,,substrate,135,43.0,fold,,Vinblastine,,,ABCG2-overexpressing MCF-7/MR cell line; growth inhibition after 72 hours exposure to the drug; IC50 ratio,MCF7/MR,,,,,human,mbds0010,,2013-11-24 23:09:58
mbbd000143331,mbcd0026481,mbtp000002,mbrf0001657,,=,,,non-substrate,135,1.0,fold,,Trimetrexate,,,ABCG2-overexpressing MCF-7/MR cell line; growth inhibition after 72 hours exposure to the drug; IC50 ratio,MCF7/MR,,,,,human,mbds0010,,2013-11-24 23:09:58
mbbd000143332,mbcd0025844,mbtp000002,mbrf0001657,,=,,,substrate,135,8.3,fold,,Doxorubicin,,,ABCG2-overexpressing MCF-7/MR cell line; growth inhibition after 72 hours exposure to the drug; IC50 ratio,MCF7/MR,,,,,human,mbds0010,,2013-11-24 23:09:58
mbbd000143333,mbcd0000482,mbtp000002,mbrf0002484,,,,,inhibitor,,,,,Imatinib Mesylate,,,Cells taken from CML patients,CML CD34+,mbcd0002981,5,microM,,human,mbds0010,,2013-10-09 22:18:32
mbbd000143334,mbcd0000482,mbtp000002,mbrf0002484,,,,,non-substrate,,,,,Imatinib Mesylate,,,Cells taken from CML patients,CML CD34+,,5,microM,,human,mbds0010,,2013-10-09 22:18:35
mbbd000143335,mbcd0001830,mbtp000002,mbrf0002088,,=,,,inhibitor,25,444.0,microM,84,XR 9577,,,BCRP-overexpressing MCF-7/MX cell line; mitxantrone cell viability assay; incubation for 72 hours,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143336,mbcd0002875,mbtp000002,mbrf0002088,,=,,,inhibitor,25,50.0,microM,6,WK-X-34,,,BCRP-overexpressing MCF-7/MX cell line; mitoxantrone cell viability assay; incubation for 72 hours,,,,,,human,mbds0010,,2013-11-21 00:16:44
mbbd000143337,mbcd0001937,mbtp000002,mbrf0002088,,=,,,inhibitor,25,76.0,microM,6,WK-X-50,,,BCRP-overexpressing MCF-7/MX cell line; mitoxantrone cell viability assay; inbcubation for 72 hours,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143338,mbcd0029968,mbtp000002,mbrf0002088,,=,,,inhibitor,25,43.0,microM,15,WK-X-84,,,BCRP-overexpressing MCF-7/MX cell line; mitoxantrone cell viability assay; incubation for 72 hours,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143339,mbcd0000311,mbtp000002,mbrf0002088,,=,,,inhibitor,25,2.0,microM,0.8,Cyclosporin A,,,BCRP-overexpressing MCF-7/MX cell line;  mitoxantrone cell viability assay; incubation for 72 hours,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143340,mbcd0002875,mbtp000002,mbrf0002202,,=,,,inhibitor,25,26.5,microM,4.6,WK-X-34,,,BCRP-overexpressing MCF-7/MX cells; measured inhibition of mitoxantrone accuulation,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143341,mbcd0005183,mbtp000002,mbrf0002533,,=,,,substrate,14,10.4,*10^-6 cm s-1,,Daunorubicin,,,MDCK II/ABCG2 cell line; apical to basolateral compartment; transport in low passage cells,MDCKII,,10,microM,,human,mbds0010,,2013-11-24 23:11:53
mbbd000143342,mbcd0002981,mbtp000002,mbrf0002533,,=,,,substrate,14,2.0,*10^-6 cm s-1,,Mitoxantrone,,,MDCK II/ABCG2 cell line; apical to basolateral compartment; transport in low passage cells ,MDCKII,,10,microM,,human,mbds0010,,2013-11-24 23:11:53
mbbd000143343,mbcd0029953,mbtp000002,mbrf0002533,,=,,,substrate,14,1.6,*10^-6 cm s-1,,Cl 1033,,,MDCK II/ABCG2 cell line; apical to basolateral compartment; transport in low passage cells,MDCKII,,10,microM,,human,mbds0010,,2013-11-24 23:11:54
mbbd000143344,mbcd0003187,mbtp000002,mbrf0002533,,=,,,substrate,14,5.1,*10^-6 cm s-1,,Topotecan,,,MDCK II/ABCG2 cell line; apical to basolateral compartment; transport in low passage cells,MDCKII,,10,microM,,human,mbds0010,,2013-11-24 23:11:54
mbbd000143345,mbcd0000779,mbtp000002,mbrf0002533,,=,,,substrate,14,5.8,*10^-6 cm s-1,,SN-38,,,MDCK II/ABCG2 cell line; apical to basolateral compartment transport; transport in low passage cells,MDCKII,,10,microM,,human,mbds0010,,2013-11-24 23:11:54
mbbd000143346,mbcd0003024,mbtp000002,mbrf0002533,,~,,,substrate,14,3.2,*10^-6 cm s-1,1.5,Prazosin,,,MDCK II/ABCG2 cell line; transport from apical to basolateral compartment,MDCKII,,10,microM,,human,mbds0010,,2013-11-24 23:11:54
mbbd000143347,mbcd0003024,mbtp000002,mbrf0002533,,~,,,substrate,104,1.7,,0.5,Prazosin,,,MDCK II/ABCG2 cell line; transport from apical to basolateral compartment,MDCKII,,,,,human,mbds0010,,2013-11-24 23:11:55
mbbd000143348,mbcd0029969,mbtp000002,mbrf0002309,,~,,,inhibitor,20,25.0,AU,4,Rg3 100,,,BCRP -overexpressing MCF-7/MX cell line; Fluorescence of Mitoxantrone for efflux; Control fluorescence ~ 9,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143349,mbcd0029970,mbtp000002,mbrf0002309,,~,,,inhibitor,20,33.0,AU,5,Rh2 20,,,BCRP-overexpressing MCF-7/MX cell line; fluorescence of Mitoxantrone for efflux; Control fluorescence~9,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143350,mbcd0029971,mbtp000002,mbrf0002309,,~,,,inhibitor,20,38.0,AU,2,PPD20,,,BCRP-overexpressing MCF-7/MX cell line; fluorescence of mitoxantrone for efflux;  control fluorescence ~ 9,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143351,mbcd0029972,mbtp000002,mbrf0002309,,~,,,inhibitor,20,11.0,AU,4,Rg1 100,,,BCRP-overexpressing MCF-7/MX cell line; fluorescence of mitoxantrone for efflux; control fluorescence ~ 9,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143352,mbcd0029973,mbtp000002,mbrf0002309,,~,,,inhibitor,20,10.0,AU,4,Rh1 50,,,BCRP-overexpressing MCF-7/MX cell line; fluorescence of mitoxantrone for efflux; control fluorescence ~ 9,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143353,mbcd0029974,mbtp000002,mbrf0002309,,~,,,inhibitor,20,21.0,AU,4,PPT 20,,,BCRP-overexpressing MCF-7/MX cell line; fluorescence of mitoxantrone efflux; control fluorescence ~ 9,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143354,mbcd0029975,mbtp000002,mbrf0002000,,,,,substrate,,,,,Phytoporphyrin,,,HEK293 cells,HEK293,,10,microM,,human,mbds0010,,2013-11-10 04:16:05
mbbd000143355,mbcd0029976,mbtp000002,mbrf0002246,,,,,substrate,,,,,Iodoarylazidoprazosin,,,MCF7 cells,MCF7,,1.5,nM,,human,mbds0010,,2013-11-10 04:16:09
mbbd000143357,mbcd0000303,mbtp000002,mbrf0001817,,=,,,inhibitor,25,19.8,microM L-1,0.4,Curcumin I,,,ABCG2-transduced HEK-293 cell line; cytotoxicity from a MTT assay,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143358,mbcd0029386,mbtp000002,mbrf0001817,,=,,,inhibitor,25,27.2,microM L-1,0.1,Curcumin II,,,ABCG2 transduced HEK-293 cell line; cytotoxicity from a MTT assay,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143359,mbcd0029978,mbtp000002,mbrf0001817,,=,,,inhibitor,25,29.5,microM L-1,1.9,Curcumin III,,,ABCG2 transduced HEK-293 cell line; cytotoxicity from a MTT assay,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143360,mbcd0000303,mbtp000002,mbrf0001817,,,,,non-substrate,,,,,Curcumin I,,,uptake,MCF7,,0.2; 10,microM,,human,mbds0010,,2013-10-09 22:18:40
mbbd000143361,mbcd0029386,mbtp000002,mbrf0001817,,,,,non-substrate,,,,,Curcumin II,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143362,mbcd0029978,mbtp000002,mbrf0001817,,,,,non-substrate,,,,,Curcumin III,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143363,mbcd0003043,mbtp000002,mbrf0002242,,=,,,substrate,28,1.3,mM,0.2,Methotrexate,,,ABCG2 transduced HEK-293 cell line,HEK293,,,,,human,mbds0010,,2013-11-24 23:14:06
mbbd000143364,mbcd0003043,mbtp000002,mbrf0002242,,=,,,substrate,22,0.7,ng (mg protein)-1 min-1,0.1,Methotrexate,,,ABCG2 transduced HEK-293 cell line,HEK293,,,,,human,mbds0010,,2013-11-24 23:14:06
mbbd000143365,mbcd0002831,mbtp000002,mbrf0002242,,~,,,substrate,138,30.0,%,1,Resveratrol,,,MDCK-II/ABCG2 cell lin; pH 6.0,MDCKII,,,,,human,mbds0010,,2013-11-24 23:11:55
mbbd000143366,mbcd0003187,mbtp000002,mbrf0002242,,~,,,substrate,138,20.0,%,0.5,Topotecan,,,MDCK II/ABCG2 cell line; pH 7.4,MDCKII,,,,,human,mbds0010,,2013-11-24 23:11:55
mbbd000143367,mbcd0029979,mbtp000002,mbrf0001836,,=,,,substrate,132,22.0,,,JNJ 7706621,,,Resistance factor (IC50 HEK-293/ABCG2)/(IC50HEK-293),HEK293,,,,,human,mbds0010,,2014-02-25 08:23:47
mbbd000143368,mbcd0002981,mbtp000002,mbrf0001836,,=,,,substrate,132,20.0,,,Mitoxantrone,,,Resistance factor (IC50 HEK-293/ABCG2)/(IC50HEK-293),HEK293,,,,,human,mbds0010,,2014-02-25 08:23:48
mbbd000143369,mbcd0003187,mbtp000002,mbrf0001836,,=,,,substrate,132,5.6,,,Topotecan,,,The cross-resistance profile of the HeLa-6621 cells was determined in a 48-hour cell proliferation assay,HEK293,,,,,human,mbds0010,,2014-02-25 08:23:47
mbbd000143370,mbcd0001652,mbtp000002,mbrf0001836,,=,,,substrate,132,1.4,,,Flavopiridol,,,The cross-resistance profile of the HeLa-6621 cells was determined in a 48-hour cell proliferation assay,HEK293,,,,weak substrate,human,mbds0010,,2014-02-25 08:23:47
mbbd000143371,mbcd0025844,mbtp000002,mbrf0001836,,=,,,substrate,132,2.5,,,Doxorubicin,,,The cross-resistance profile of the HeLa-6621 cells was determined in a 48-hour cell proliferation assay,HEK293,,,,weak substrate,human,mbds0010,,2014-02-25 08:23:47
mbbd000143372,mbcd0001151,mbtp000002,mbrf0001836,,=,,,non-substrate,132,1.0,,,Vinblastine,,,The cross-resistance profile of the HeLa-6621 cells was determined in a 48-hour cell proliferation assay,HEK293,,,,,human,mbds0010,,2014-02-25 08:23:47
mbbd000143373,mbcd0001532,mbtp000002,mbrf0001836,,=,,,substrate,132,3.0,,,Paclitaxel,,,Resistance factor (IC50 HEK-293/ABCG2)/(IC50HEK-293),HEK293,,,,weak substrate,human,mbds0010,,2014-02-25 08:23:48
mbbd000143374,mbcd0003043,mbtp000002,mbrf0001733,,=,,,substrate,28,1.34,mM,0.18,Methotrexate,,,Wild-type BCRP transduced HEK-293 cells,HEK293,,,,,human,mbds0010,,2013-11-25 22:16:54
mbbd000143375,mbcd0003043,mbtp000002,mbrf0001733,,=,,,substrate,22,687.0,pmol mg-1 min-1,87,Methotrexate,,,Wild-type BCRP transduced HEK-293 cells,HEK293,,,,,human,mbds0010,,2013-11-24 23:14:08
mbbd000143376,mbcd0001197,mbtp000002,mbrf0001733,,,,,non-substrate,,,,,Leucovorin,,,wild-type ABCG2 transfected HEK293 cells,HEK293,,,,,human,mbds0010,,2013-11-25 22:16:54
mbbd000143377,mbcd0003959,mbtp000002,mbrf0001733,,=,,,substrate,22,87.0,pmol (mg protein)-1 min-1,,Folic Acid,,,"Initial rate of folic acid transport in the presence of 100 microM folic acid and 4mM ATP, using isolated membrane vesicles; wild-type ABCG2 transfected HEK293 cells ",HEK293,,100,microM,,human,mbds0010,,2013-11-25 22:59:21
mbbd000143378,mbcd0029420,mbtp000002,mbrf0001733,,=,,,substrate,94,43.0,AU,,GW1843,,,Wild type BCRP transduced HEK-293 cell line; anti-folate resistance level,HEK293,,,,,human,mbds0010,,2013-11-24 23:14:09
mbbd000143379,mbcd0029766,mbtp000002,mbrf0001733,,=,,,substrate,94,11.8,AU,,Raltitrexed,,,Wild type BCRP transduced HEK-293 cell line; anti-folate resistance level,HEK293,,,,,human,mbds0010,,2013-11-24 23:14:10
mbbd000143380,mbcd0025627,mbtp000002,mbrf0002233,,~,,,substrate,33,4.5,pmol mg-1,0.25,Riboflavin,,,BCRP -expressing Sf9 cell line; in presence of ATP,Sf9,,,,,human,mbds0010,,2013-11-24 03:25:32
mbbd000143383,mbcd0002422,mbtp000002,mbrf0002379,,=,,,inhibitor,25,0.47,microM,,Fumitremorgin C,,,BCRP-overexpressing MDCK II cell line,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143384,mbcd0002439,mbtp000002,mbrf0002379,,=,,,inhibitor,25,0.01,microM,,Ko143,,,BCRP -over-expressing MDCK II cell line,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143385,mbcd0002383,mbtp000002,mbrf0002379,,=,,,inhibitor,25,181.0,microM,,Amprenavir,,,BCRP- overexpressing MDCK II cell line,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143386,mbcd0002051,mbtp000002,mbrf0002379,,=,,,inhibitor,25,69.1,microM,,Atazanavir,,,BCRP-overexpressing MDCK II cell line,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143387,mbcd0002241,mbtp000002,mbrf0002379,,=,,,inhibitor,25,7.66,microM,,Lopinavir,,,BCRP-overexpressing MDCK II cell line,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143388,mbcd0026632,mbtp000002,mbrf0002379,,=,,,inhibitor,25,13.5,microM,,Nelfinavir,,,BCRP -overexpressing MDCK-II cell line,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143389,mbcd0001533,mbtp000002,mbrf0002379,,=,,,inhibitor,25,27.4,microM,,Saquinavir,,,BCRP-overexpressing MDCK II cell line,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143390,mbcd0002544,mbtp000002,mbrf0002379,,=,,,inhibitor,25,18.7,microM,,Delavirdine,,,BCRP-overexpressing MDCK II cell line,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143391,mbcd0001868,mbtp000002,mbrf0002379,,=,,,inhibitor,25,20.6,microM,,Efavirenz,,,BCRP- overexpressing MDCK-II cell line,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143392,mbcd0003124,mbtp000002,mbrf0002379,,=,,,inhibitor,25,385.0,microM,,Abacavir,,,BCRP - overexpressing MDCK II cell line,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143393,mbcd0002383,mbtp000002,mbrf0002379,,~,,,inhibitor,19,2.0,,0.1,Amprenavir,,,Ph A efflux assay measured by flow cytometry; BCRP-MDCK II cell line,,,100,microM,,human,mbds0010,,2013-11-23 22:11:26
mbbd000143394,mbcd0002051,mbtp000002,mbrf0002379,,~,,,inhibitor,19,4.0,,0.1,Atazanavir,,,Ph A efflux assay measured by flow cytometry; BCRP-MDCK II cell line,,,,,,human,mbds0010,,2013-11-23 22:11:25
mbbd000143395,mbcd0002323,mbtp000002,mbrf0002379,,~,,,inhibitor,19,1.0,,,Indinavir,,,Ph A efflux assay measured by flow cytometry; BCRP-MDCK II cell line,,,50,microM,,human,mbds0010,,2013-11-24 02:54:43
mbbd000143396,mbcd0002241,mbtp000002,mbrf0002379,,~,,,inhibitor,19,4.0,,0.5,Lopinavir,,,Ph A efflux assay measured by flo cytometry; BCRP-MDCK II cell line,,,20,microM,,human,mbds0010,,2013-11-24 02:54:47
mbbd000143397,mbcd0026632,mbtp000002,mbrf0002379,,~,,,inhibitor,19,3.75,,1,Nelfinavir,,,Ph A efflux assay measured by flow cytometry; BCRP-MDCK II cell line,,,20,microM,,human,mbds0010,,2013-11-24 02:54:52
mbbd000143398,mbcd0001938,mbtp000002,mbrf0002379,,~,,,inhibitor,19,1.5,,0.2,Ritonavir,,,Ph A efflux assay measured by flow cytometry; BCRP-MDCK II celll line,,,5,microM,,human,mbds0010,,2013-11-24 03:25:29
mbbd000143399,mbcd0001533,mbtp000002,mbrf0002379,,~,,,inhibitor,19,4.5,,0.5,Saquinavir,,,Ph A efflux assay measured by flow cytometry; BCRP-MDCK II cell line,,,50,microM,,human,mbds0010,,2013-11-24 03:25:31
mbbd000143400,mbcd0001350,mbtp000002,mbrf0002379,,~,,,inhibitor,19,2.0,,0.2,Tiprinavir,,,Ph A efflux assay measured by flow cytometry; BCRP-MDCK-II cell line,,,20,microM,,human,mbds0010,,2013-11-24 06:37:36
mbbd000143401,mbcd0002544,mbtp000002,mbrf0002379,,~,,,inhibitor,19,6.0,,1,Delavirdine,,,Ph A efflux assay measured by flow cytometry; BCRP-MDCK II cell line,,,100,microM,,human,mbds0010,,2013-11-23 22:22:26
mbbd000143402,mbcd0001868,mbtp000002,mbrf0002379,,~,,,inhibitor,19,5.7,,0.5,Efavirenz,,,Ph A efflux assay measured by flow cytometry; BCRP-MDCK II cell line,,,50,microM,,human,mbds0010,,2013-12-09 07:14:50
mbbd000143403,mbcd0003124,mbtp000002,mbrf0002379,,~,,,inhibitor,19,3.0,,0.1,Abacavir,,,Ph A efflux assay measured by flow cytometry; BCRP-MDCK II cell line,,,500,microM,,human,mbds0010,,2013-11-23 22:11:25
mbbd000143404,mbcd0029982,mbtp000002,mbrf0002379,,~,,,inhibitor,19,1.0,,0.1,Didanosine,,,Ph A efflux assay measured by flow cytometry; BCRP-MDCK II cell line,,,500,microM,,human,mbds0010,,2013-11-23 22:22:27
mbbd000143405,mbcd0003029,mbtp000002,mbrf0002379,,~,,,inhibitor,19,1.0,,,Emtricitabine,,,Ph A efflux assay measured by flow cytometry; BCRP-MDCK II cell line,,,1000,microM,,human,mbds0010,,2013-12-09 07:13:35
mbbd000143406,mbcd0002982,mbtp000002,mbrf0002379,,~,,,inhibitor,19,1.2,,0.1,Lamivudine,,,Ph A efflux assay measured by flow cytometry; BCRP-MDCK II cell line,,,1000,microM,,human,mbds0010,,2013-11-24 02:54:45
mbbd000143407,mbcd0029983,mbtp000002,mbrf0002379,,~,,,inhibitor,19,1.1,,0.1,Stavudine,,,Ph A efflux assay measured by flow cytometry; BCRP-MDCK II cel line,,,1000,microM,,human,mbds0010,,2013-11-24 03:25:33
mbbd000143408,mbcd0003028,mbtp000002,mbrf0002379,,~,,,inhibitor,19,1.1,,0.1,Tenofovir,,,Ph A efflux assay measured by flow cytometry; BCRP-MDCK II cell line,,,1000,microM,,human,mbds0010,,2013-11-24 06:37:36
mbbd000143409,mbcd0001355,mbtp000002,mbrf0002379,,~,,,inhibitor,19,1.2,,0.1,Zalcitabine,,,Ph A efflux assay measured using flow cytometry; BCRP-MDCK II cell line,,,500,microM,,human,mbds0010,,2013-11-24 06:37:40
mbbd000143410,mbcd0001107,mbtp000002,mbrf0002379,,~,,,inhibitor,19,2.0,,0.2,Zidovudine,,,Ph A efflux assay measured using flow cytometry; BCRP-MDCK II cell line,,,500,microM,,human,mbds0010,,2013-11-24 06:37:40
mbbd000143411,mbcd0000311,mbtp000002,mbrf0001891,,=,,,inhibitor,25,26.1,microM,,Cyclosporine A,,,BCRP- overexpressing MDCK II cell line,,,,,,human,mbds0010,,2013-11-20 18:11:06
mbbd000143412,mbcd0000311,mbtp000002,mbrf0001891,,,,,non-substrate,,,,,Cyclosporin A; CsA,,,Membrane vesicles (SB BCRP HAM Sf9 VT Membrane or SB BCRP M VT Membrane (Mammalian)); uptake,SB BCRP HAM Sf9 VT Membrane; SB BCRP M VT Membrane (Mammalian),,0-20,microM,,human,mbds0010,,2013-10-09 22:18:42
mbbd000143413,mbcd0000311,mbtp000002,mbrf0001891,,=,,,inhibitor,29,7.8,microM,,Cyclosporin A,,,BCRP-MDCK II cell line; membrane vesicular transport assay; inhibition constant for BCRP mediated MTX efflux,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143414,mbcd0003125,mbtp000002,mbrf0001802,,=,,,substrate,17,1.13,hours,0.39,Gefitinib,,,BCRP- transduced hek-293 cell line; measurements of cellular efflux,HEK293,,10,microM,,human,mbds0010,,2013-11-24 23:14:11
mbbd000143415,mbcd0003125,mbtp000002,mbrf0001802,,~,,,substrate,138,20.0,% initial radioactivity,0.5,Gefitinib,,,BCRP-HEK-293 cell line; cellular efflux after 4 hours,HEK293,,1,microM,,human,mbds0010,,2013-11-24 23:14:12
mbbd000143416,mbcd0003099,mbtp000002,mbrf0001802,,~,,,substrate,138,10.5,% initial radioactivity,0.2,Erlotinib,,,BCRP-HEK-293 cell line; cellular efflux after 2 hours incubation,HEK293,,10,microM,,human,mbds0010,,2013-12-09 07:12:57
mbbd000143417,mbcd0029850,mbtp000002,mbrf0002221,,,,,substrate,,,,,BNP 1350,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143418,mbcd0029986,mbtp000002,mbrf0002221,,,,,substrate,,,,,Exatecan Mesylate,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143419,mbcd0029988,mbtp000002,mbrf0002221,,,,,substrate,,,,,UCN-01,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143420,mbcd0002981,mbtp000002,mbrf0002221,,,,,substrate,,,,,Mitoxantrone,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143421,mbcd0005183,mbtp000002,mbrf0002221,,,,,substrate,,,,,Daunorubicin,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143422,mbcd0025844,mbtp000002,mbrf0002221,,,,,substrate,,,,,Doxorubicin,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143423,mbcd0029350,mbtp000002,mbrf0002221,,,,,substrate,,,,,Epirubicin,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143424,mbcd0000191,mbtp000002,mbrf0002221,,,,,substrate,,,,,Bisantrene,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143425,mbcd0001652,mbtp000002,mbrf0002221,,,,,substrate,,,,,Flavopiridol,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143426,mbcd0002466,mbtp000002,mbrf0002221,,,,,substrate,,,,,Etoposide,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143427,mbcd0001080,mbtp000002,mbrf0002221,,,,,substrate,,,,,Teniposide,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143428,mbcd0000100,mbtp000002,mbrf0002221,,,,,substrate,,,,,9-aminocamptothecin,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143429,mbcd0003187,mbtp000002,mbrf0002221,,,,,substrate,,,,,Topotecan,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143430,mbcd0002091,mbtp000002,mbrf0002221,,,,,substrate,,,,,Irinotecan,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143431,mbcd0000779,mbtp000002,mbrf0002221,,,,,substrate,,,,,SN-38,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143432,mbcd0029877,mbtp000002,mbrf0002221,,,,,substrate,,,,,Diflomotecan,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143433,mbcd0029876,mbtp000002,mbrf0002221,,,,,substrate,,,,,Homocamptothecin,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143434,mbcd0000496,mbtp000002,mbrf0002221,,,,,substrate,,,,,J-107088,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143435,mbcd0029952,mbtp000002,mbrf0002221,,,,,substrate,,,,,NB-506,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143436,mbcd0029420,mbtp000002,mbrf0002221,,,,,substrate,,,,,GW1843,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143437,mbcd0029766,mbtp000002,mbrf0002221,,,,,substrate,,,,,Tomudex,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143438,mbcd0002828,mbtp000002,mbrf0002221,,,,,substrate,,,,,Imatinib,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143439,mbcd0003125,mbtp000002,mbrf0002221,,,,,substrate,,,,,Gefitinib,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143440,mbcd0029953,mbtp000002,mbrf0002221,,,,,substrate,,,,,Cl 1033,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143441,mbcd0029883,mbtp000002,mbrf0002221,,,,,substrate,,,,,Pheophorbide A,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143442,mbcd0029989,mbtp000002,mbrf0002221,,,,,substrate,,,,,Pheophorbide A methyl ester,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143443,mbcd0029885,mbtp000002,mbrf0002221,,,,,substrate,,,,,Chlorin e6,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143444,mbcd0015671,mbtp000002,mbrf0002221,,,,,substrate,,,,,Protoporthyrin IX,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143445,mbcd0002422,mbtp000002,mbrf0002221,,,,,inhibitor,,,,,Fumitremorgin C,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143446,mbcd0002439,mbtp000002,mbrf0002221,,,,,inhibitor,,,,,Ko 143,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143447,mbcd0000311,mbtp000002,mbrf0002221,,,,,inhibitor,,,,,Cyclosporin A,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143448,mbcd0001316,mbtp000002,mbrf0002221,,,,,inhibitor,,,,,Tacrolimus,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143449,mbcd0001324,mbtp000002,mbrf0002221,,,,,inhibitor,,,,,Sirolimus,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143450,mbcd0003125,mbtp000002,mbrf0002221,,,,,inhibitor,,,,,Gefitinib,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143451,mbcd0002828,mbtp000002,mbrf0002221,,,,,inhibitor,,,,,Imatinib,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143452,mbcd0001808,mbtp000002,mbrf0002221,,,,,inhibitor,,,,,Elacridar,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143453,mbcd0002104,mbtp000002,mbrf0002221,,,,,inhibitor,,,,,Tariquidar,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143454,mbcd0000190,mbtp000002,mbrf0002221,,,,,inhibitor,,,,,Biricodar,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143455,mbcd0003045,mbtp000002,mbrf0002221,,,,,inhibitor,,,,,Chrysin,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143456,mbcd0003238,mbtp000002,mbrf0002221,,,,,inhibitor,,,,,6-prenylchrysin,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143457,mbcd0022552,mbtp000002,mbrf0002221,,,,,inhibitor,,,,,Tectochrysin,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143458,mbcd0003076,mbtp000002,mbrf0002221,,,,,inhibitor,,,,,Naringenin,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143459,mbcd0003120,mbtp000002,mbrf0002221,,,,,inhibitor,,,,,Quercetin,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143460,mbcd0004715,mbtp000002,mbrf0002221,,,,,inhibitor,,,,,Acacetin,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143461,mbcd0022617,mbtp000002,mbrf0002221,,,,,inhibitor,,,,,Silymarin,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143462,mbcd0003116,mbtp000002,mbrf0002221,,,,,inhibitor,,,,,Genistein,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143463,mbcd0003055,mbtp000002,mbrf0002221,,,,,inhibitor,,,,,17-beta-estradiol,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143464,mbcd0003211,mbtp000002,mbrf0002221,,,,,inhibitor,,,,,Estrone,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143465,mbcd0002889,mbtp000002,mbrf0002221,,,,,inhibitor,,,,,Tamoxifen,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143466,mbcd0000648,mbtp000002,mbrf0002221,,,,,inhibitor,,,,,Ortataxel,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143467,mbcd0003252,mbtp000002,mbrf0002221,,,,,inhibitor,,,,,Novobiocin,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143468,mbcd0001941,mbtp000002,mbrf0002221,,,,,inhibitor,,,,,Reserpine,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143469,mbcd0000303,mbtp000002,mbrf0002221,,,,,inhibitor,,,,,Curcumin,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143470,mbcd0003100,mbtp000002,mbrf0002221,,,,,inhibitor,,,,,Dipyridamole,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143471,mbcd0003135,mbtp000002,mbrf0002221,,,,,inhibitor,,,,,Nitrendipine,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143472,mbcd0002875,mbtp000002,mbrf0002221,,,,,inhibitor,,,,,WK-X-54,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143473,mbcd0026854,mbtp000002,mbrf0002221,,,,,inhibitor,,,,,Nimodipine,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143474,mbcd0000099,mbtp000002,mbrf0002527,,~,,,inhibitor,93,500.0,microM-1,,"3',4',7-trimethoxyflavone",,,K562/BCRP cell line; inhibitory effect on BCRP-mediated SN-38 resistance; RI50 value is concentration of inhibitor causing 2-fold reduction in IC50 value,,,,,,human,mbds0010,,2013-12-09 20:08:34
mbbd000143475,mbcd0004715,mbtp000002,mbrf0002527,,~,,,inhibitor,93,30.0,microM-1,,Acacetin,,,K562/BCRP cell line; inhibitory effect on BCRP-mediated SN-38 resistance; RI50 value is concentration of inhibitor causing 2-fold reduction in IC50 value,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143476,mbcd0003048,mbtp000002,mbrf0002527,,~,,,inhibitor,93,100.0,microM-1,,Diosmetin,,,K562/BCRP cell line; inhibitory effect on BCRP-mediated SN-38 resistance; RI50 value is concentration of inhibitor causing 2-fold reduction in IC50 value,,,,,,human,mbds0010,,2013-12-09 19:54:46
mbbd000143477,mbcd0003091,mbtp000002,mbrf0002527,,~,,,inhibitor,93,8.0,microM-1,,Apigenin,,,K562/BCRP cell line; inhibitory effect on BCRP-mediated SN-38 resistance; RI50 value is concentration of inhibitor causing 2-fold reduction in IC50 value,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143478,mbcd0003045,mbtp000002,mbrf0002527,,~,,,inhibitor,93,4.0,microM-1,,Chrysin,,,K562/BCRP cell line; inhibitory effect on BCRP-mediated SN-38 resistance; RI50 value is concentration of inhibitor causing 2-fold reduction in IC50 value,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143479,mbcd0003217,mbtp000002,mbrf0002527,,~,,,inhibitor,93,1.0,microM-1,,Luteolin,,,K562/BCRP cell line; inhibitory effect on BCRP-mediated SN-38 resistance; RI50 value is concentration of inhibitor causing 2-fold reduction in IC50 value,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143480,mbcd0029990,mbtp000002,mbrf0002527,,~,,,inhibitor,93,1.0,microM-1,,Luteolin-4-O-glucoside,,,K562/BCRP cell line; inhibitory effect on BCRP-mediated SN-38 resistance; RI50 value is concentration of inhibitor causing a 2-fold reduction in IC50 value,,,,,,human,mbds0010,,2013-12-09 20:51:24
mbbd000143481,mbcd0004722,mbtp000002,mbrf0002527,,~,,,inhibitor,93,11.0,microM-1,,Kaempferide,,,K562/BCRP cell line; inhibitory effect on BCRP-mediated SN-38 resistance; RI50 value is concentration of inhibitor causing 2-fold reduction in IC50 value,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143482,mbcd0003215,mbtp000002,mbrf0002527,,~,,,inhibitor,93,2.0,microM-1,,Kaempferol,,,K562/BCRP cell line; inhibitory effect on BCRP-mediated SN-38 resistance; RI50 value is concentration if inhibitor causing 2-fold reduction in IC50 value,,,,,,human,mbds0010,,2013-12-09 20:51:24
mbbd000143483,mbcd0004758,mbtp000002,mbrf0002527,,~,,,inhibitor,93,1.0,microM-1,,Galangin,,,K562/BCRP cell line; inhibitory effect on BCRP-mediated SN-38 resistance; RI50 value is concentration of inhibitor causing 2-fold reduction in IC50 value,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143484,mbcd0003040,mbtp000002,mbrf0002527,,~,,,inhibitor,93,0.5,microM-1,,Myricetin,,,K562/BCRP cell line; inhibitory effect on BCRP-mediated SN-38 resistance; RI50 value is concentration of inhibitor causing 2-fold reduction in IC50 value,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143485,mbcd0004749,mbtp000002,mbrf0002527,,~,,,inhibitor,93,3.0,microM-1,,Hesperetin,,,K562/BCRP cell line; inhibitory effect on BCRP-mediated SN-38 resistance; RI50 value is concentration of inhibitor causing 2-fold reduction in IC50 value,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143486,mbcd0029991,mbtp000002,mbrf0002527,,~,,,inhibitor,93,1.0,microM-1,,Naringenin-7-O-glucoside,,,K562/BCRP cell line; inhibitory effect on BCRP-mediated SN-38 resistance; RI50 value is concentration of inhibitor causing 2-fold reduction in IC50 value,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143487,mbcd0003116,mbtp000002,mbrf0002527,,~,,,inhibitor,93,2.0,microM-1,,Genistein,,,K562/BCRP cell line; inhibitory effect on BCRP-mediated SN-38 resistance; RI50 value is concentration of inhibitor causing 2-fold reduction in IC50 value,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143488,mbcd0013632,mbtp000002,mbrf0002527,,~,,,inhibitor,93,0.3,microM-1,,Daidzein,,,K562/BCRP cell line; inhibitory effect on BCRP-mediated SN-38 resistance; RI50 value is concentration of inhibitor causing 2-fold reduction in IC50 value,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143489,mbcd0029992,mbtp000002,mbrf0002527,,~,,,inhibitor,93,10.0,microM-1,,"3,4-dimethoxychalcone",,,K562/BCRP cell line; inhibitory effect on BCRP-mediated SN-38 resistance; RI50 value is concentration of inhibitor causing 2-fold reduction in IC50 value,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143490,mbcd0029383,mbtp000002,mbrf0002527,,~,,,inhibitor,93,4.0,microM-1,,alpha-Zearalenol,,,K562/BCRP cell line; inhibitory effect on BCRP-mediated SN-38 resistance; RI50 value is concentration of inhibitor causing 2-fold reduction in IC50 value,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143491,mbcd0029384,mbtp000002,mbrf0002527,,~,,,inhibitor,93,1.0,microM-1,,beat-Zearalenol,,,K562/BCRP cell line; inhibitory effect on BCRP-mediated SN-38 resistance; RI50 value is concentration of inhibitor causing 2-fold reduction in IC50 value,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143492,mbcd0027229,mbtp000002,mbrf0002527,,~,,,inhibitor,93,0.2,microM,,Silybin,,,K562/BCRP cell line; inhibitory effect on BCRP-mediated SN-38 resistance; RI50 value is concentration of inhibitor causing 2-fold reduction in IC50 value,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143493,mbcd0029995,mbtp000002,mbrf0001693,,,,,substrate,,,,,HPPH; Photochlor,,,BCC1 cells,BCC1,,0.4-0.8,microM,,human,mbds0010,,2013-11-10 04:16:00
mbbd000143494,mbcd0015671,mbtp000002,mbrf0001693,,,,,substrate,,,,,Protoporthyrin IX,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143495,mbcd0029996,mbtp000002,mbrf0001693,,,,,substrate,,,,,Verteporfin; BPD-MA,,,BCC1 cells,BCC1,,0.2,microM,,human,mbds0010,,2013-11-10 04:16:01
mbbd000143496,mbcd0030152,mbtp000002,mbrf0001693,,,,,non-substrate,,,,,HPPH-galactose conjugate,,,BCC1 cells,BCC1,,0.8,microM,,human,mbds0010,,2013-11-10 04:16:01
mbbd000143497,mbcd0029764,mbtp000002,mbrf0002480,,=,,,substrate,25,2113.0,nM,226,C-1305,,,Wild type ABCG2 transfected HEK-293 cell line; after 72 hours exposure,HEK293,,,,,human,mbds0010,,2013-11-24 23:14:13
mbbd000143498,mbcd0029999,mbtp000002,mbrf0002480,,=,,,substrate,25,523.0,nM,75,C-1311,,,Wild type ABCG2 transfected HEK-293 cell line; after 72 hours exposure,HEK293,,,,,human,mbds0010,,2013-11-24 23:14:13
mbbd000143499,mbcd0002981,mbtp000002,mbrf0002480,,=,,,substrate,25,121.0,nM,5,Mitoxantrone,,,Wild type ABCG2 transfected HEK-293 cell line; after 72 hour exposure,HEK293,,,,,human,mbds0010,,2013-11-24 23:14:13
mbbd000143500,mbcd0002982,mbtp000002,mbrf0001652,,=,,,substrate,28,216.5,microM,58,Lamivudine,,,ABCG2-overexpressing MDCK cells,MDCK,,0-1000,microM,,human,mbds0010,,2014-01-17 20:50:22
mbbd000143502,mbcd0002982,mbtp000002,mbrf0001652,,=,,,substrate,22,20.42,nmol h-1 (10^6 cells)-1,2.9,Lamivudine,,,ABCG2-overexpressing MDCK cell line,MDCK,,,,,human,mbds0010,,2013-11-24 23:11:56
mbbd000143503,mbcd0017104,mbtp000002,mbrf0001907,,=,,,inhibitor,25,15.3,microM,6.5,Ketoconazole,,,Wild-type BCRP-overexpressing HEK cell line; inhibition of BCRP-mediated Ph A efflux,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143504,mbcd0017104,mbtp000002,mbrf0001907,,=,,,inhibitor,129,6.38,,,Ketoconazole,,,Wild type BCRP-overexpressing HEK cell line; relative resistance from (EC50-HEK cells)/(EC50-HEK/BCRP cells) for Topotecan toxicity in presence of inhibitor,,,5,microM,,human,mbds0010,,2013-12-09 06:25:28
mbbd000143505,mbcd0002191,mbtp000002,mbrf0001907,,=,,,inhibitor,129,5.04,,,Itraconazole,,,Wild type BCRP-overexpressing HEK cell line; relative resistance from (EC50-HEK cells)/(EC50-HEK/BCRP cells) for Topotecan toxicity in presence of inhibitor,,,2,microM,,human,mbds0010,,2013-12-09 06:24:42
mbbd000143506,mbcd0000482,mbtp000002,mbrf0002178,,~,,,inhibitor,3,100.0,%,,Imatinib Mesylate,transport completely inhibited,,human bone marrow mononuclear cells incubated with Hoechst in the presence or absence of varying concentrations of imatinib,human bone marrow,,0.8,microM,,human,mbds0010,,2013-11-10 02:55:40
mbbd000143507,mbcd0000482,mbtp000002,mbrf0002178,,,,,substrate,,,,,Imatinib Mesylate,,,ABCG2-overexpressing K562 cells,K562,,200,nM,,human,mbds0010,,2013-11-10 02:55:40
mbbd000143508,mbcd0001690,mbtp000002,mbrf0002178,,~,,,inhibitor,3,100.0,%,,Nilotinib,transport completely inhibited,,human bone marrow mononuclear cells incubated with Hoechst in the presence or absence of varying concentrations of nilotinib,human bone marrow,,100,nM,,human,mbds0010,,2013-11-10 02:55:40
mbbd000143509,mbcd0001690,mbtp000002,mbrf0002178,,,,,substrate,,,,,Nilotinib,,,ABCG2-overexpressing K562 cells,K562,,200,nM,,human,mbds0010,,2013-11-10 02:55:41
mbbd000143510,mbcd0021308,mbtp000002,mbrf0002368,,=,,,inhibitor,25,5.5,micromol L-1,0.7,Bisindolylmaleimide I,,,ABCG2-overexpressing HEK-293 cell line; results from at least 2 independant experiments,HEK293,,,,,human,mbds0010,,2013-11-20 21:26:18
mbbd000143511,mbcd0030000,mbtp000002,mbrf0002368,,=,,,inhibitor,25,5.5,micromol L-1,0.7,Bisindolylmaleimide II,,,ABCG2-overexpressing HEK-293 cell line; results from at least 2 independant experiments,HEK293,,,,,human,mbds0010,,2013-11-04 21:53:09
mbbd000143512,mbcd0030001,mbtp000002,mbrf0002368,,=,,,inhibitor,25,10.3,micromol L-1,0.6,Bisindolylmaleimide III,,,ABCG2-overexpressing HEK-293 cell line; results from at least 2 independant experiments,HEK293,,,,,human,mbds0010,,2013-11-04 21:53:09
mbbd000143513,mbcd0030002,mbtp000002,mbrf0002368,,=,,,inhibitor,25,10.7,micromol L-1,0.4,Bisindolylmaleimide IV,,,ABCG2-overexpressing HEK-293 cell line; results from at least 2 independant experiments,HEK293,,,,,human,mbds0010,,2013-11-04 21:53:09
mbbd000143514,mbcd0030003,mbtp000002,mbrf0002368,,=,,,inhibitor,25,10.5,micromol L-1,0.7,Bisindolylmaleimide V,,,ABCG2-overexpressing HEK-293 cell line; results from at least 2 indepedant experiments,HEK293,,,,,human,mbds0010,,2013-11-04 21:53:09
mbbd000143515,mbcd0030004,mbtp000002,mbrf0002368,,=,,,inhibitor,25,3.2,micromol L-1,3.2,Bisindolylmaleimide VI,,,ABCG2-overexpressing HEK-293 cell line; results from at least 2 independant experiments,HEK293,,,,,human,mbds0010,,2013-11-04 21:53:10
mbbd000143516,mbcd0030005,mbtp000002,mbrf0002368,,=,,,inhibitor,25,12.5,micromol L-1,4,Bisindolylmaleimide VII,,,ABCG2-overexpressing HEK-293 cell line; results from at least 2 independant experiments,HEK293,,,,,human,mbds0010,,2013-11-04 21:53:10
mbbd000143517,mbcd0030006,mbtp000002,mbrf0002368,,=,,,inhibitor,25,6.5,micromol L-1,0.7,Bisindolylmaleimide VIII,,,ABCG2-overexpressing HEK-293 cell line; results from at least 2 independant experiments,HEK293,,,,,human,mbds0010,,2013-11-04 21:53:10
mbbd000143518,mbcd0026369,mbtp000002,mbrf0002368,,=,,,inhibitor,25,7.3,micromol L-1,2.3,Bisindolylmaleimide IX,,,ABCG2-overexpressing HEK-293 cell line; results from at least 2 independatn experiments,HEK293,,,,,human,mbds0010,,2013-11-04 21:53:11
mbbd000143519,mbcd0030007,mbtp000002,mbrf0002368,,=,,,inhibitor,25,3.5,micromol L-1,0.9,Bisindolylmaleimide X,,,ABCG2-overexpressing HEK-293 cell line; results from at least 2 experiments,HEK293,,,,,human,mbds0010,,2013-11-04 21:53:11
mbbd000143520,mbcd0030008,mbtp000002,mbrf0002368,,=,,,inhibitor,25,6.5,micromol L-1,0.7,Bisindolylmaleimide XI,,,ABCG2-overexpressing HEK-293 cell line; results from at least 2 independant experiments,HEK293,,,,,human,mbds0010,,2013-11-04 21:53:11
mbbd000143521,mbcd0030009,mbtp000002,mbrf0002368,,=,,,inhibitor,25,0.08,micromol L-1,0.007,Go9676,,,ABCG2-overexpressing HEK-293 cell line; results from at least 2 independant experiments,HEK293,,,,,human,mbds0010,,2013-11-04 21:53:12
mbbd000143522,mbcd0030010,mbtp000002,mbrf0002368,,=,,,inhibitor,25,1.2,micromol L-1,0.5,Go7874,,,ABCG2-overexpressing HEK-293 cell line; results from at least 2 independant experiments,HEK293,,,,,human,mbds0010,,2013-11-04 21:53:12
mbbd000143523,mbcd0030011,mbtp000002,mbrf0002368,,=,,,inhibitor,25,0.5,micromol L-1,0.07,K252a,,,ABCG2-overexpressing HEK-293 cell line; results from at least 2 independant experiments,HEK293,,,,,human,mbds0010,,2013-11-04 21:53:12
mbbd000143524,mbcd0030012,mbtp000002,mbrf0002368,,=,,,inhibitor,25,4.7,micromol L-1,0.6,K252c,,,ABCG2-overexpressing cell line; results from at least 2 independant experiments,HEK293,,,,,human,mbds0010,,2013-11-04 21:53:12
mbbd000143525,mbcd0030013,mbtp000002,mbrf0002368,,=,,,inhibitor,25,7.5,micromol L-1,2.1,KT5720,,,ABCG2-overexpressing HEK-293 cell line; results from at least 2 different experiments,HEK293,,,,,human,mbds0010,,2013-11-04 21:53:12
mbbd000143526,mbcd0030014,mbtp000002,mbrf0002368,,=,,,inhibitor,25,5.5,micromol L-1,0.7,KT5823,,,ABCG2-overexpressing cell line; results from at least 2 independant experiments,HEK293,,,,,human,mbds0010,,2013-11-04 21:53:13
mbbd000143527,mbcd0030015,mbtp000002,mbrf0002368,,=,,,inhibitor,25,52.5,micromol L-1,3.5,Arcyriaflavin A,,,ABCG2 -overexpressing HEK-293 cell line; results from at least 2 independant experiments,HEK293,,,,,human,mbds0010,,2013-11-04 21:53:13
mbbd000143528,mbcd0030016,mbtp000002,mbrf0002368,,=,,,inhibitor,25,3.7,micromol L-1,2.5,PKC412,,,ABCG2-overexpressing HEK-293 cell line; results from at least 2 different experiments,HEK293,,,,,human,mbds0010,,2013-11-04 21:53:13
mbbd000143529,mbcd0030017,mbtp000002,mbrf0002368,,=,,,inhibitor,25,0.6,micromol L-1,0.1,SB-218078,,,ABCG2-overexpressing HEK-293 cell line; results from at least 2 independant experiments,HEK293,,,,,human,mbds0010,,2013-11-04 21:53:13
mbbd000143530,mbcd0030018,mbtp000002,mbrf0002368,,=,,,inhibitor,25,1.3,micromol L-1,0.6,CDK4I,,,ABCG2-overexpressing HEK-293 cell line; results from at least 2 independant experiments,HEK293,,,,,human,mbds0010,,2013-11-04 21:53:14
mbbd000143531,mbcd0021308,mbtp000002,mbrf0002368,,,,,non-substrate,,,,,Bisindolylmaleimide I,,,Cytotoxicity assays comparing IC50 values between BCRP1-expressing and control cells,HEK293,,,,,human,mbds0010,,2013-11-04 21:53:08
mbbd000143532,mbcd0030000,mbtp000002,mbrf0002368,,,,,non-substrate,,,,,Bisindolylmaleimide II,,,Cytotoxicity assays comparing IC50 values between BCRP1-expressing and control cells,HEK293,,,,,human,mbds0010,,2013-10-09 22:18:36
mbbd000143533,mbcd0030001,mbtp000002,mbrf0002368,,,,,non-substrate,,,,,Bisindolylmaleimide III,,,Cytotoxicity assays comparing IC50 values between BCRP1-expressing and control cells,HEK293,,,,,human,mbds0010,,2013-10-09 22:18:36
mbbd000143534,mbcd0030002,mbtp000002,mbrf0002368,,,,,non-substrate,,,,,Bisindolylmaleimide IV,,,Cytotoxicity assays comparing IC50 values between BCRP1-expressing and control cells,HEK293,,,,,human,mbds0010,,2013-10-09 22:18:36
mbbd000143535,mbcd0030003,mbtp000002,mbrf0002368,,,,,non-substrate,,,,,Bisindolylmaleimide V,,,Cytotoxicity assays comparing IC50 values between BCRP1-expressing and control cells,HEK293,,,,,human,mbds0010,,2013-10-09 22:18:36
mbbd000143536,mbcd0030004,mbtp000002,mbrf0002368,,,,,non-substrate,,,,,Bisindolylmaleimide VI,,,Cytotoxicity assays comparing IC50 values between BCRP1-expressing and control cells,HEK293,,,,,human,mbds0010,,2013-10-09 22:18:36
mbbd000143537,mbcd0030005,mbtp000002,mbrf0002368,,,,,non-substrate,,,,,Bisindolylmaleimide VII,,,Cytotoxicity assays comparing IC50 values between BCRP1-expressing and control cells,HEK293,,,,,human,mbds0010,,2013-10-09 22:18:36
mbbd000143538,mbcd0030006,mbtp000002,mbrf0002368,,,,,non-substrate,,,,,Bisindolylmaleimide VIII,,,Cytotoxicity assays comparing IC50 values between BCRP1-expressing and control cells,HEK293,,,,,human,mbds0010,,2013-10-09 22:18:36
mbbd000143539,mbcd0026369,mbtp000002,mbrf0002368,,,,,non-substrate,,,,,Bisindolylmaleimide IX,,,Cytotoxicity assays comparing IC50 values between BCRP1-expressing and control cells,HEK293,,,,,human,mbds0010,,2013-11-04 21:53:08
mbbd000143540,mbcd0030007,mbtp000002,mbrf0002368,,,,,non-substrate,,,,,Bisindolylmaleimide X,,,Cytotoxicity assays comparing IC50 values between BCRP1-expressing and control cells,HEK293,,,,,human,mbds0010,,2013-10-09 22:18:36
mbbd000143541,mbcd0030008,mbtp000002,mbrf0002368,,,,,non-substrate,,,,,Bisindolylmaleimide XI,,,Cytotoxicity assays comparing IC50 values between BCRP1-expressing and control cells,HEK293,,,,,human,mbds0010,,2013-10-09 22:18:36
mbbd000143542,mbcd0030009,mbtp000002,mbrf0002368,,,,,non-substrate,,,,,Go9676,,,Cytotoxicity assays comparing IC50 values between BCRP1-expressing and control cells,HEK293,,,,,human,mbds0010,,2013-10-09 22:18:36
mbbd000143543,mbcd0030010,mbtp000002,mbrf0002368,,,,,non-substrate,,,,,Go7874,,,Cytotoxicity assays comparing IC50 values between BCRP1-expressing and control cells,HEK293,,,,,human,mbds0010,,2013-10-09 22:18:37
mbbd000143544,mbcd0030011,mbtp000002,mbrf0002368,,,,,non-substrate,,,,,K252a,,,Cytotoxicity assays comparing IC50 values between BCRP1-expressing and control cells,HEK293,,,,,human,mbds0010,,2013-10-09 22:18:37
mbbd000143545,mbcd0030012,mbtp000002,mbrf0002368,,,,,non-substrate,,,,,K252c,,,Cytotoxicity assays comparing IC50 values between BCRP1-expressing and control cells,HEK293,,,,,human,mbds0010,,2013-10-09 22:18:37
mbbd000143546,mbcd0030013,mbtp000002,mbrf0002368,,,,,non-substrate,,,,,KT5720,,,Cytotoxicity assays comparing IC50 values between BCRP1-expressing and control cells,HEK293,,,,,human,mbds0010,,2013-10-09 22:18:37
mbbd000143547,mbcd0030014,mbtp000002,mbrf0002368,,,,,non-substrate,,,,,KT5823,,,Cytotoxicity assays comparing IC50 values between BCRP1-expressing and control cells,HEK293,,,,,human,mbds0010,,2013-10-09 22:18:37
mbbd000143548,mbcd0030015,mbtp000002,mbrf0002368,,,,,non-substrate,,,,,Arcyriaflavin A,,,Cytotoxicity assays comparing IC50 values between BCRP1-expressing and control cells,HEK293,,,,,human,mbds0010,,2013-10-09 22:18:38
mbbd000143549,mbcd0030016,mbtp000002,mbrf0002368,,,,,non-substrate,,,,,PKC412,,,Cytotoxicity assays comparing IC50 values between BCRP1-expressing and control cells,HEK293,,,,,human,mbds0010,,2013-10-09 22:18:38
mbbd000143550,mbcd0030017,mbtp000002,mbrf0002368,,,,,non-substrate,,,,,SB-218078,,,Cytotoxicity assays comparing IC50 values between BCRP1-expressing and control cells,HEK293,,,,,human,mbds0010,,2013-10-09 22:18:38
mbbd000143551,mbcd0030018,mbtp000002,mbrf0002368,,,,,non-substrate,,,,,CDK4I,,,Cytotoxicity assays comparing IC50 values between BCRP1-expressing and control cells,HEK293,,,,,human,mbds0010,,2013-10-09 22:18:38
mbbd000143552,mbcd0027062,mbtp000002,mbrf0002224,,=,,,inhibitor,81,4.1,fold increase,,Verapamil,,,accumulation expressed as ratio mitoxantrone with inhibitor/mitoxantrone only; ratios normalized to that obtained with Ko143 (100% inhibition),Saos-2,mbcd0002981,50,microM,,human,mbds0010,,2013-11-17 23:10:24
mbbd000143553,mbcd0001038,mbtp000002,mbrf0002274,,=,,,substrate,138,251.0,microL (mg protein)-1,38,Grepafloxacin,,,hBCRP-expressing MDCK-II cell line; transcellular transport from basal to apical compartment at 180 minute,MDCKII,,,,,human,mbds0010,,2013-11-24 23:11:56
mbbd000143554,mbcd0030019,mbtp000002,mbrf0002274,,=,,,substrate,138,166.0,microL (mg protein)-1,25,Ulifloxacin,,,hBCRP-expressing MDCK-II cell line; transcellular transport from basal to apical compartment at 180 minutes,MDCKII,,,,,human,mbds0010,,2013-11-24 23:11:56
mbbd000143555,mbcd0030020,mbtp000002,mbrf0002439,,=,,,substrate,25,24.0,nM,6.4,TH-337,,,BCRP-expressing HEK-293 cell line,HEK293,,,,,human,mbds0010,,2013-11-24 23:14:13
mbbd000143556,mbcd0030021,mbtp000002,mbrf0002439,,=,,,substrate,25,0.9,nM,0.1,TH-482,,,BCRP-expressing HEK-293 cell line,HEK293,,,,,human,mbds0010,,2013-11-24 23:14:14
mbbd000143557,mbcd0030022,mbtp000002,mbrf0002439,,=,,,substrate,25,2.5,nM,0.3,TH-494,,,BCRP-expressing HEK-293 cell line,HEK293,,,,,human,mbds0010,,2013-11-24 23:14:14
mbbd000143558,mbcd0030023,mbtp000002,mbrf0002439,,=,,,substrate,25,2.0,nM,0.1,Combretastatin A-4,,,BCRP- expressing HEK-293 cell line,HEK293,,,,,human,mbds0010,,2013-11-24 23:14:14
mbbd000143559,mbcd0005183,mbtp000002,mbrf0002439,,=,,,substrate,25,2.0,nM,0.1,Daunorubicin,,,BCRP-expressing HEK-293 cell line,HEK293,,,,,human,mbds0010,,2013-11-24 23:14:14
mbbd000143560,mbcd0002981,mbtp000002,mbrf0002439,,=,,,substrate,25,31.0,nM,1.2,Mitoxantrone,,,BCRP-expressing HEK-293 cell line,HEK293,,,,,human,mbds0010,,2013-11-24 23:14:14
mbbd000143561,mbcd0013632,mbtp000002,mbrf0001974,,=,,,substrate,23,53.2,microL hour-1 well-1,4.1,Daidzein,,,MDCKII/hBCRP cell line; transcellular transport from basolateral to apical compartment,MDCKII,,,,,human,mbds0010,,2013-11-24 23:11:57
mbbd000143562,mbcd0003116,mbtp000002,mbrf0001974,,=,,,substrate,23,28.8,microL hour-1 well-1,1,Genistein,,,MDCKII/hBRCP cell line; transcellular transport from basolateral to apical compartment,MDCKII,,,,,human,mbds0010,,2013-11-24 23:11:57
mbbd000143563,mbcd0029182,mbtp000002,mbrf0001974,,=,,,substrate,23,10.2,microL hour-1 well-1,0.6,Coumestrol,,,MDCKII/hBCRP cell line; transcellulartransport from basolateral to apical compartment,MDCKII,,,,,human,mbds0010,,2013-11-24 23:11:57
mbbd000143564,mbcd0030025,mbtp000002,mbrf0001772,,,,,substrate,,,,,CP 671305,,,MDCKII cells,MDCKII,,2,microM,,human,mbds0010,,2013-11-10 04:16:10
mbbd000143565,mbcd0003005,mbtp000002,mbrf0002214,,,,,non-substrate,,,,,Olmesartan,,,MDCKII cells coexpressing OATP1B1/BCRP,MDCKII,,,,,human,mbds0010,,2013-11-24 23:11:57
mbbd000143566,mbcd0000878,mbtp000002,mbrf0001783,,~,,,inhibitor,33,155.0,%,10,Tween 20,,,BCRP-MDCKII cell line; cellular uptake of mitoxantrone after 2 hours as a percentage of control,,,100,microM,,human,mbds0010,,2013-11-24 06:37:38
mbbd000143567,mbcd0030026,mbtp000002,mbrf0001783,,~,,,inhibitor,33,130.0,%,5,Span 20,,,BCRP/MDCKII cell line; cellular uptake of mitoxantrone after 2 hours as a percentage of control,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143568,mbcd0030027,mbtp000002,mbrf0001783,,~,,,inhibitor,33,155.0,%,10,Brij 30,,,BCRP/MDCKII cell line; cellular uptake of mitoxantrone after 2 hours as a percentage of control,,,100,microM,,human,mbds0010,,2013-11-23 22:11:29
mbbd000143569,mbcd0000695,mbtp000002,mbrf0001783,,~,,,inhibitor,33,170.0,%,15,Pluronic P85,,,BCRP/MDCKII cell line; cellular uptake of mitoxantrone after 2 hours as a percentage of control,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143570,mbcd0030028,mbtp000002,mbrf0002255,,,,,inhibitor,,,,,Cannabinol; CBN,,,MEF3.8 cells,MEF3.8,mbcd0002981,50,microM,,human,mbds0010,,2013-11-10 04:16:10
mbbd000143571,mbcd0001094,mbtp000002,mbrf0002255,,,,,inhibitor,,,,,(Delta)9-tetrahydrocannabinol; THC,,,MEF3.8 cells,MEF3.8,mbcd0002981,10; 50,microM,,human,mbds0010,,2013-11-10 04:16:11
mbbd000143572,mbcd0003074,mbtp000002,mbrf0002096,,,,,substrate,,,,,Glyburide,,,Placental brush border membrane vesicles,Placental brush border membrane vesicles,,120,mM,,human,mbds0010,,2013-10-09 22:18:43
mbbd000143573,mbcd0002195,mbtp000002,mbrf0002432,,=,,,inhibitor,17,37.9,microM,,Compound 1a,,,ABCG2-transfected HEK cell line; mitoxantrone intracellular accumulation studies,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143574,mbcd0001742,mbtp000002,mbrf0002432,,=,,,inhibitor,17,33.5,microM,,Compound 1b,,,ABCG2-transfected HEK cell line; mitoxantrone intracellular accumulation studies,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143575,mbcd0002105,mbtp000002,mbrf0002432,,=,,,inhibitor,17,30.7,microM,,Compound 1c,,,ABCG2- transfected HEK cell line; mitoxantrone accumulation studies,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143576,mbcd0002672,mbtp000002,mbrf0002432,,=,,,inhibitor,17,36.4,microM,,1d,,,ABCG2-transfected cell line; mitoxantrone accumulation studies,HEK293,mbcd0002981,,,,human,mbds0010,,2013-12-09 06:44:36
mbbd000143577,mbcd0002850,mbtp000002,mbrf0002432,,=,,,inhibitor,17,440.0,microM,,Compound 1e,,,ABCG2 transfected cell line; mitoxantrone intracellular accumulation studies,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143578,mbcd0002401,mbtp000002,mbrf0002432,,=,,,inhibitor,17,4.62,microM,,Compound 1f,,,ABCG2 transfected HEK cell line; mitoxantrone intracellular accumulation studies,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143579,mbcd0030030,mbtp000002,mbrf0002432,,=,,,inhibitor,17,47.1,microM,,Compound 1g,,,ABCG2 transfected HEK cell line; mitoxantrone intracellular accumulation studies,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143580,mbcd0002345,mbtp000002,mbrf0002432,,=,,,inhibitor,17,34.0,microM,,Compound 1h,,,ABCG2 trasnfected HEK cell line; mitoxantrone intracellular accumulation studies,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143581,mbcd0002838,mbtp000002,mbrf0002432,,=,,,inhibitor,17,12.9,microM,,Compound 1i,,,ABCG2 transfected HEK cell line; mitoxantrone intracellular accumulation studies,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143582,mbcd0002505,mbtp000002,mbrf0002432,,=,,,inhibitor,17,13.9,microM,,Compound 1j,,,ABCG2 transfected HEK cell line; mitoxantrone intracellular accumulation studies,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143583,mbcd0002675,mbtp000002,mbrf0002432,,=,,,inhibitor,17,15.2,microM,,Compound 1k,,,ABCG2 transfected HEK cell line; mitoxantrone intracellular accumulation studies,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143584,mbcd0002579,mbtp000002,mbrf0002432,,=,,,inhibitor,17,14.1,microM,,Compound 1l,,,ABCG2 transfected HEK cell line; mitoxantrone intracellular accumulation studies,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143585,mbcd0030031,mbtp000002,mbrf0002432,,=,,,inhibitor,17,31.9,microM,,Compound 1m,,,ABCG2 transfected cell line; mitoxantrone intracellular accumulation studies,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143586,mbcd0001902,mbtp000002,mbrf0002432,,=,,,inhibitor,17,600.0,microM,,Compound 2a,,,ABCG2 transfected HEK cell line; mitoxantrone intracellular accumulation studies,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143587,mbcd0002927,mbtp000002,mbrf0002432,,=,,,inhibitor,17,58.8,microM,,Compound 2b,,,ABCG2 transfected cell line; mitoxantrone intracellular accumulation studies,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143588,mbcd0002843,mbtp000002,mbrf0002432,,=,,,inhibitor,17,98.3,microM,,Compound 2c,,,ABCG2 transfected cell line; mitoxantrone intracellular accumulation studies,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143589,mbcd0002520,mbtp000002,mbrf0002432,,=,,,inhibitor,17,3.3,microM,,Compound 3,,,ABCG2 transfected HEK cell linel; mitoxantrone intracellular accumulation studies,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143590,mbcd0002275,mbtp000002,mbrf0002432,,=,,,inhibitor,17,37.3,microM,,Compound 4,,,ABCG2 HEK cell line; mitoxantrone intracellular accumulation studies,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143591,mbcd0001752,mbtp000002,mbrf0002432,,=,,,inhibitor,17,4.21,microM,,Compound 5a,,,ABCG2 transfected HEK cell line; mitoxantrone intracellular accumulation studies,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143592,mbcd0002350,mbtp000002,mbrf0002432,,=,,,inhibitor,17,1.5,microM,,Compound 5b,,,ABCG2 transfected HEK cell line; mitoxantrone intracellular accumulation studies,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143593,mbcd0002369,mbtp000002,mbrf0002432,,=,,,inhibitor,17,3.81,microM,,Compound 5c,,,ABCG2 transfected HEK cell line; mitoxantrone intracellular accumulation studies,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143594,mbcd0002697,mbtp000002,mbrf0002432,,=,,,inhibitor,17,1.24,microM,,Compound 5d,,,ABCG2 transfected HEK cell line; mitoxantrone intracellular accumulation studies,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143595,mbcd0002864,mbtp000002,mbrf0002432,,=,,,inhibitor,17,3.68,microM,,Compound 6,,,ABCG2 transfected HEK cell line; mitoxantrone intracellular accumulation studies,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143596,mbcd0001652,mbtp000002,mbrf0002061,,=,,,substrate,25,0.2821,micromol L-1,0.0148,Flavopiridol,,,HEK-293/ABCG2-482-R5 cell line,HEK293,,,,,human,mbds0010,,2013-11-24 23:14:15
mbbd000143597,mbcd0002981,mbtp000002,mbrf0002061,,=,,,substrate,25,0.4574,micromol L-1,0.3924,Mitoxantrone,,,HEK-293/ABCG2-482-R5 cell line,HEK293,,,,,human,mbds0010,,2013-11-24 23:14:15
mbbd000143598,mbcd0000779,mbtp000002,mbrf0002061,,=,,,substrate,25,0.1282,micromol L-1,0.0021,SN-38,,,HEK-293/ABCG2-482-R5 cell line,HEK293,,,,,human,mbds0010,,2013-11-24 23:14:15
mbbd000143599,mbcd0001117,mbtp000002,mbrf0002061,,=,,,substrate,25,1.3265,micromol L-1,0.2001,Cisplatin,,,HEK-293/ABCG2-482-R5 cell line,HEK293,,,,,human,mbds0010,,2013-11-24 23:14:16
mbbd000143600,mbcd0003099,mbtp000002,mbrf0002061,,,,,inhibitor,,,,,Erlotinib,,,HEK293 cells,HEK293,mbcd0002981,2.5; 10,microM,,human,mbds0010,,2013-11-10 04:16:05
mbbd000143601,mbcd0016031,mbtp000002,mbrf0001915,,=,,,substrate,25,8.54,microM,1.13,Vitamin K3,,,HEK-293/ABCG2-R482 cell line; cytotoxicity,HEK293,,,,,human,mbds0010,,2013-10-30 22:19:49
mbbd000143602,mbcd0016031,mbtp000002,mbrf0001915,,=,,,inhibitor,25,20.25,microM,,Vitamin K3,,,MCF-7 FLV1000,MCF7 FLV1000,mbcd0002981,30,microM,,human,mbds0010,,2013-12-09 06:52:46
mbbd000143603,mbcd0028598,mbtp000002,mbrf0001915,,=,,,substrate,25,2.96,microM,0.87,Plumbagin,,,HEK-293/ABCG2-R482 cell line; cytotoxicity,HEK293,,,,,human,mbds0010,,2013-10-30 22:19:49
mbbd000143604,mbcd0028598,mbtp000002,mbrf0001915,,=,,,inhibitor,25,7.88,microM,,Plumbagin,,,MCF-7 FLV1000,MCF7 FLV1000,mbcd0002981,30,microM,,human,mbds0010,,2013-12-09 06:52:46
mbbd000143605,mbcd0005274,mbtp000002,mbrf0001800,,~,,,inhibitor,1,85.0,%,15,NSC 11668,,,ABCG2 overexpressing NCI-H460/MX20 cell line; measured for ability to accumulate intracellular Pheophorbide A as a percentage of the FTC response,,,10,microM,,human,mbds0010,,2013-11-24 02:54:50
mbbd000143606,mbcd0007646,mbtp000002,mbrf0001800,,~,,,inhibitor,1,76.0,%,5,NSC 19139,,,ABCG2 overexpressing NCI-H460/MX20 cell line; measured for ability to accumulate intracellular Pheophorbide A as a percentage of the FTC response,,,10,microM,,human,mbds0010,,2013-11-24 02:54:50
mbbd000143607,mbcd0030033,mbtp000002,mbrf0001800,,~,,,inhibitor,1,62.0,%,10,NSC 23471,,,ABCG2 overexpressing NCI-H460/MX20 cell line; measured for ability to accumulate intracellular Pheophorbide A as a percentage of the FTC response,,,10,microM,,human,mbds0010,,2013-11-24 02:54:50
mbbd000143608,mbcd0011095,mbtp000002,mbrf0001800,,~,,,inhibitor,1,67.0,%,10,NSC 120688,,,ABCG2 overexpressing NCI-H460/MX20 cell line; measured for ability to accumulate intracellular Pheophorbide A as a percentage of the FTC response,,,10,microM,,human,mbds0010,,2013-11-24 02:54:50
mbbd000143609,mbcd0021325,mbtp000002,mbrf0001800,,~,,,inhibitor,1,78.0,%,15,NSC 303769,,,ABCG2 overexpressing NCI-H460/MX20 cell line; measured for ability to accumulate intracellular Pheophorbide A as a percentage of the FTC response,,,10,microM,,human,mbds0010,,2013-11-24 02:54:51
mbbd000143610,mbcd0010918,mbtp000002,mbrf0001800,,~,,,inhibitor,1,65.0,%,5,NSC 306698,,,ABCG2 overexpressing NCI-H460/MX20 cell line; measured for ability to accumulate intracellular Pheophorbide A as a percentage of the FTC response,,,10,microM,,human,mbds0010,,2013-11-24 02:54:51
mbbd000143611,mbcd0030034,mbtp000002,mbrf0001800,,~,,,inhibitor,1,68.0,%,8,NSC 320852,,,ABCG2 overexpressing NCI-H460/MX20 cell line; measured for ability to accumulate intracellular Pheophorbide A as a percentage of the FTC response,,,10,microM,,human,mbds0010,,2013-11-24 02:54:51
mbbd000143612,mbcd0021406,mbtp000002,mbrf0001800,,~,,,inhibitor,1,65.0,%,7,NSC 375985,,,ABCG2 overexpressing NCI-H460/MX20 cell line; measured for ability to accumulate intracellular Pheophorbide A as a percentage of the FTC response,,,10,microM,,human,mbds0010,,2013-11-24 02:54:51
mbbd000143613,mbcd0000349,mbtp000002,mbrf0001800,,~,,,inhibitor,1,72.0,%,10,NSC 409663,,,ABCG2 overexpressing NCI-H460/MX20 cell line; measured for ability to accumulate intracellular Pheophorbide A as a percentage of the FTC response,,,10,microM,,human,mbds0010,,2013-11-24 02:54:52
mbbd000143614,mbcd0005274,mbtp000002,mbrf0001800,,=,,,substrate,25,4.5,microM,,NSC 11668,,,ABCG2-overexpressing MCF-7 FLV1000 cells,MCF7 FLV1000,,,,,human,mbds0010,,2013-11-24 23:09:58
mbbd000143615,mbcd0007646,mbtp000002,mbrf0001800,,=,,,substrate,25,2.6,microM,,NSC 19139,,,ABCG2-overexpressing MCF-7 FLV1000 cells,MCF7 FLV1000,,,,,human,mbds0010,,2013-11-24 23:09:59
mbbd000143616,mbcd0030037,mbtp000002,mbrf0001800,,=,,,substrate,25,4.3,microM,,NSC 120668,,,ABCG2-overexpressing MCF-7 FLV1000 cells,MCF7 FLV1000,,,,,human,mbds0010,,2013-11-24 23:09:59
mbbd000143617,mbcd0021406,mbtp000002,mbrf0001800,,=,,,substrate,25,3.7,microM,,NSC 375985,,,ABCG2-overexpressing MCF-7 FLV1000 cells,MCF7 FLV1000,,,,,human,mbds0010,,2013-11-24 23:09:59
mbbd000143618,mbcd0030038,mbtp000002,mbrf0001800,,=,,,substrate,25,3.9,microM,,NSC 168201,,,ABCG2-overexpressing MCF-7 FLV1000 cells,MCF7 FLV1000,,,,,human,mbds0010,,2013-11-24 23:09:59
mbbd000143619,mbcd0030039,mbtp000002,mbrf0001799,,=,,,substrate,25,8.97,microM,1.6,NSC 73306,,,ABCG2 - R482-HEK293 cell line,HEK293,,,,,human,mbds0010,,2013-11-24 23:14:16
mbbd000143620,mbcd0002981,mbtp000002,mbrf0001799,,=,,,substrate,25,155.6,microM,10.1,Mitoxantrone,,,ABCG2 - R482-HEK293 cell line,HEK293,,,,,human,mbds0010,,2013-11-24 23:14:16
mbbd000143621,mbcd0029844,mbtp000002,mbrf0002514,,,,,substrate,,,,,Gimatecan,,,Competition assay with Methotrexate; Membrane vesicles of Sf9 cells,Sf9,,0.01; 0.1; 2,microM,,human,mbds0010,,2013-10-09 22:18:44
mbbd000143622,mbcd0029844,mbtp000002,mbrf0002514,,~,,,inhibitor,33,10.0,%,10,Gimatecan,,,Sf9-BCRP membrane vesicles; Effect of gimatecan on ATP-dependent transport of methotrexate by BCRP as a percentage of control,,,0.1,microM,,human,mbds0010,,2013-11-24 02:25:36
mbbd000143623,mbcd0001550,mbtp000002,mbrf0002452,,=,,,substrate,21,0.071,pmol min-1 cm-2,0.002,Lapatinib,,,BCRP-MDCKII cell line; transport assay over 90 minutes from basolateral to apical compartment,MDCKII,,3,microM,,human,mbds0010,,2013-11-24 23:11:58
mbbd000143624,mbcd0001550,mbtp000002,mbrf0002452,,=,,,inhibitor,25,0.025,microM,,Lapatinib,,,BCRP-MDCKII cell line; inhibition assessed by determining basolateral to apical transport of Cimetidine across MDCKII-BCRP monolayers,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143625,mbcd0029953,mbtp000002,mbrf0001798,,,,,substrate,,,,,Canertinib,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143626,mbcd0000482,mbtp000002,mbrf0001798,,,,,inhibitor,,,,,Imatinib Mesylate,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143627,mbcd0000482,mbtp000002,mbrf0001798,,,,,substrate,,,,,Imatinib Mesylate,interactions are concentration dependant,,,,,<1,microM,,human,mbds0010,,2013-11-12 04:41:37
mbbd000143628,mbcd0000482,mbtp000002,mbrf0001798,,,,,non-substrate,,,,,Imatinib Mesylate,Interactions are concentration dependant,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143629,mbcd0001690,mbtp000002,mbrf0001798,,,,,substrate,,,,,Nilotinib,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143630,mbcd0001690,mbtp000002,mbrf0001798,,,,,inhibitor,,,,,Nilotinib,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143631,mbcd0003125,mbtp000002,mbrf0001798,,,,,inhibitor,,,,,Gefitinib,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143632,mbcd0003125,mbtp000002,mbrf0001798,,,,,substrate,,,,,Gefitinib,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143633,mbcd0003099,mbtp000002,mbrf0001798,,,,,substrate,,,,,Erlotinib,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143634,mbcd0030041,mbtp000002,mbrf0002739,,,,,inhibitor,,,,,Tryprostatin A; TPS-A,,,MCF7,MCF7,mbcd0002981,1; 10; 50,microM,,human,mbds0010,,2013-11-01 23:33:39
mbbd000143635,mbcd0007655,mbtp000002,mbrf0001805,,,,,substrate,,,,,Leflunomide; LEF,,,BCRP-HAM-Sf9 ,HAM-Sf9,,,,,human,mbds0010,,2013-11-04 03:13:03
mbbd000143636,mbcd0030042,mbtp000002,mbrf0001805,,,,,substrate,,,,,A771726,,,BCRP-HAM-Sf9 ,HAM-Sf9,,,,,human,mbds0010,,2013-11-04 03:13:03
mbbd000143637,mbcd0030042,mbtp000002,mbrf0001805,,,,,inhibitor,,,,,A771726,,,PLB985-BCRP cells,PLB985,mbcd0000474,,,,human,mbds0010,,2013-11-04 03:13:04
mbbd000143638,mbcd0007655,mbtp000002,mbrf0001805,,,,,inhibitor,,,,,Leflunomide; LEF,,,PLB985-BCRP cells,PLB985,mbcd0000474,,,,human,mbds0010,,2013-11-04 03:13:04
mbbd000143639,mbcd0026020,mbtp000002,mbrf0002132,,,,,non-substrate,,,,,acetochlor,,,MCF7-MX cells; ATPase assay for a selected human cell line overexpressing BCRP,MCF7/MX,,,,,human,mbds0010,,2013-12-09 06:53:20
mbbd000143640,mbcd0029408,mbtp000002,mbrf0002132,,,,,non-substrate,,,,,alachlor,,,MCF7-MX cells; ATPase assay for a selected human cell line overexpressing BCRP,MCF7/MX,,,,,human,mbds0010,,2013-12-09 06:53:20
mbbd000143641,mbcd0029409,mbtp000002,mbrf0002132,,,,,non-substrate,,,,,Dimetachlor,,,MCF7-MX cells; ATPase assay for a selected human cell line overexpressing BCRP,MCF7/MX,,,,,human,mbds0010,,2013-12-09 06:53:20
mbbd000143642,mbcd0029410,mbtp000002,mbrf0002132,,,,,non-substrate,,,,,Metazachlor,,,MCF7-MX cells; ATPase assay for a selected human cell line overexpressing BCRP,MCF7/MX,,,,,human,mbds0010,,2013-12-09 06:53:20
mbbd000143643,mbcd0029411,mbtp000002,mbrf0002132,,,,,non-substrate,,,,,Metolachlor,,,MCF7-MX cells; ATPase assay for a selected human cell line overexpressing BCRP,MCF7/MX,,,,,human,mbds0010,,2013-12-09 06:53:20
mbbd000143644,mbcd0029412,mbtp000002,mbrf0002132,,,,,non-substrate,,,,,Propachlor,,,MCF7-MX cells; ATPase assay for a selected human cell line overexpressing BCRP,MCF7/MX,,,,,human,mbds0010,,2013-12-09 06:53:20
mbbd000143645,mbcd0029413,mbtp000002,mbrf0002132,,,,,non-substrate,,,,,Prynachlor,,,MCF7-MX cells; ATPase assay for a selected human cell line overexpressing BCRP,MCF7/MX,,,,,human,mbds0010,,2013-12-09 06:53:20
mbbd000143646,mbcd0004749,mbtp000002,mbrf0002086,,,,,non-substrate,,,,,Hesperetin,hesperetin was metabolized into hesperetin 7-O-glucuronide and hesperetin 7-O sulfate,,Caco-2 cell monolayer system,Caco-2,,10,microM,,human,mbds0010,,2013-10-31 19:30:02
mbbd000143647,mbcd0029456,mbtp000002,mbrf0002086,,=,,,substrate,21,14.3,pmol min-1 monolayer-1,3.7,Hesperetin 7-O-Glucuronide,hesperetin metabolite,,Caco-2 cell monolayer system; 10 microM hesperetin; BCRP inhibitor Ko143 (5 microM),Caco-2,,,,,human,mbds0010,,2013-12-09 20:10:08
mbbd000143648,mbcd0030050,mbtp000002,mbrf0002086,,=,,,substrate,21,2.1,pmol min-1 monolayer-1,0.8,Hesperetin 7-O-Sulfate,hesperetin metabolite,,Caco-2 cell monolayer system; 10 microM hesperetin; BCRP inhibitor Ko143 (5 microM),Caco-2,,,,,human,mbds0010,,2013-12-09 20:10:09
mbbd000143649,mbcd0003074,mbtp000002,mbrf0002186,,=,,,substrate,107,0.32,,0.06,Glyburide,,,fetal and maternal perfusates; concentration ratio after 180 minutes; human placental cotyledon,human placental cotyledon,,,,,human,mbds0010,,2013-11-26 00:48:05
mbbd000143650,mbcd0001547,mbtp000002,mbrf0001801,,=,,,substrate,25,25.0,nmol L-1,,Dasatinib,,,ABCG2-overexpressing K562 cell line,K562,,,,,human,mbds0010,,2013-11-24 23:56:04
mbbd000143651,mbcd0030051,mbtp000002,mbrf0002001,,=,,,inhibitor,100,204.6,%,20.4,Chalcone 1,,,MDA-MB-231/R cell line; mitoxantrone accumulation as a percentage of control,,,5,microM,,human,mbds0010,,2013-11-23 22:11:30
mbbd000143652,mbcd0030052,mbtp000002,mbrf0002001,,=,,,inhibitor,100,332.7,%,19.9,Chalcone 2,,,MDA-MB-231/R cell line; mitoxantrone accumulation as a percentage of control,,,5,microM,,human,mbds0010,,2013-11-23 22:11:33
mbbd000143653,mbcd0030053,mbtp000002,mbrf0002001,,=,,,inhibitor,100,211.3,%,29.4,Chalcone 3,,,MDA-MB-231/R cell line; mitoxantrone accumulation as a percentage of control,,,5,microM,,human,mbds0010,,2013-11-23 22:11:33
mbbd000143654,mbcd0030054,mbtp000002,mbrf0002001,,=,,,inhibitor,100,295.4,%,37.4,Chalcone 4,,,MDA-MB-231/R cell line; mitoxantrone accumulation as a percentage of control,,,5,microM,,human,mbds0010,,2013-11-23 22:11:33
mbbd000143655,mbcd0030055,mbtp000002,mbrf0002001,,=,,,inhibitor,100,315.3,%,38.6,Chalcone 5,,,MDA-MB-231/R cell line; mitoxantrone accumulation as a percentage of control,,,5,microM,,human,mbds0010,,2013-11-23 22:11:34
mbbd000143656,mbcd0030056,mbtp000002,mbrf0002001,,=,,,inhibitor,100,323.9,%,61.7,Chalcone 14,,,MDA-MB-231/R cell line; mitoxantrone accumulation as a percentage of control,,,5,microM,,human,mbds0010,,2013-11-23 22:11:32
mbbd000143657,mbcd0002508,mbtp000002,mbrf0002001,,=,,,inhibitor,100,370.4,%,42,Chalcone 6,,,MDA-MB-231/R cell line; mitoxantrone accumulation as a percentage of control,,,5,microM,,human,mbds0010,,2013-11-23 22:11:35
mbbd000143658,mbcd0030057,mbtp000002,mbrf0002001,,=,,,inhibitor,100,315.5,%,25.4,Chalcone 7,,,MDA-MB-231/R cell line; mitoxantrone accumulation as a percentage of control,,,5,microM,,human,mbds0010,,2013-11-23 22:11:35
mbbd000143659,mbcd0030058,mbtp000002,mbrf0002001,,=,,,inhibitor,100,231.2,%,8.9,Chalcone 8,,,MDA-MB-231/R cell line; mitoxantrone accumulation as a percentage of control,,,5,microM,,human,mbds0010,,2013-11-23 22:11:35
mbbd000143660,mbcd0030059,mbtp000002,mbrf0002001,,=,,,inhibitor,100,265.7,%,42.6,Chalcone 9,,,MDA-MB-231/R cell line; mitoxantrone accumulation as a percentage of control,,,5,microM,,human,mbds0010,,2013-11-23 22:11:36
mbbd000143661,mbcd0030060,mbtp000002,mbrf0002001,,=,,,inhibitor,100,254.2,%,19.3,Chalcone 10,,,MDA-MB-231/R cell line; mitoxantrone accumulation as a percentage of control,,,5,microM,,human,mbds0010,,2013-11-23 22:11:31
mbbd000143662,mbcd0030061,mbtp000002,mbrf0002001,,=,,,inhibitor,100,286.0,%,50.1,Chalcone 11,,,MDA-MB-231/R cell line; mitoxantrone accumulation as a percentage of control,,,5,microM,,human,mbds0010,,2013-11-23 22:11:31
mbbd000143663,mbcd0020414,mbtp000002,mbrf0002001,,=,,,inhibitor,100,184.5,%,31.3,Chalcone 12,,,MDA-MB-231/R cell line; mitoxantrone accumulation as a percentage of control,,,5,microM,,human,mbds0010,,2013-11-23 22:11:31
mbbd000143664,mbcd0030062,mbtp000002,mbrf0002001,,=,,,inhibitor,100,270.4,%,29.3,Chalcone 13,,,MDA-MB-231/R cell line; mitoxantrone accumulation as a percentage of control,,,5,microM,,human,mbds0010,,2013-11-23 22:11:31
mbbd000143665,mbcd0030063,mbtp000002,mbrf0002001,,=,,,inhibitor,100,344.1,%,77.7,Chalcone 15,,,MDA-MB-231/R cell line; mitoxantrone accumulation as a percentage of control,,,5,microM,,human,mbds0010,,2013-11-23 22:11:32
mbbd000143666,mbcd0030064,mbtp000002,mbrf0002001,,=,,,inhibitor,100,359.0,%,79.8,Chalcone 16,,,MDA-MB-231/R cell line; mitoxantrone accumulation as a percentage of control,,,5,microM,,human,mbds0010,,2013-11-23 22:11:32
mbbd000143667,mbcd0030065,mbtp000002,mbrf0002001,,=,,,inhibitor,100,354.4,%,69.1,Chalcone 17,,,MDA-MB-231/R cell line; mitoxantrone accumulation as a percentage of control,,,5,microM,,human,mbds0010,,2013-11-23 22:11:32
mbbd000143668,mbcd0030051,mbtp000002,mbrf0002001,,~,,,inhibitor,96,7.0,nmol min-1 mg-1,0.8,Chalcone 1,,,MDA-MB-231/R cell line; effect of chalcone on vanadate-sensitive BCRP ATPase activity in crude membranes,,,10,microM,,human,mbds0010,,2013-11-24 07:52:32
mbbd000143669,mbcd0030052,mbtp000002,mbrf0002001,,~,,,inhibitor,96,6.0,nmol min-1 mg-1,2,Chalcone 2,,,MDA-MB-231/R cell line; effect of chalcone on vanadate-sensitive BCRP ATPase activity in crude membranes,,,10,microM,,human,mbds0010,,2013-11-24 07:52:32
mbbd000143670,mbcd0030053,mbtp000002,mbrf0002001,,~,,,inhibitor,96,5.5,nmol min-1 mg-1,1.5,Chalcone 3,,,MDA-MB-231/R cell line; effect of chalcone on vanadate-sensitive BCRP ATPase activity in crude membranes,,,10,microM,,human,mbds0010,,2013-11-24 07:52:32
mbbd000143671,mbcd0030054,mbtp000002,mbrf0002001,,~,,,inhibitor,96,8.0,nmol min-1 mg-1,2,Chalcone 4,,,MDA-MB-231/R cell line; effect of chalcone on vanadate-sensitive BCRP ATPase activity in crude membranes,,,10,microM,,human,mbds0010,,2013-11-24 07:52:33
mbbd000143672,mbcd0030055,mbtp000002,mbrf0002001,,~,,,inhibitor,96,12.0,nmol min-1 mg-1,1.5,Chalcone 5,,,MDA-MB-231/R cell line; effect of chalcone on vanadate-sensitive BCRP ATPase activity in crude membranes,,,10,microM,,human,mbds0010,,2013-11-24 07:52:33
mbbd000143673,mbcd0030056,mbtp000002,mbrf0002001,,~,,,inhibitor,96,10.0,nmol min-1 mg-1,1,Chalcone 14,,,MDA-MB-231/R cell line; effect of chalcone on vanadate-sensitive BCRP ATPase activity in crude membranes,,,10,microM,,human,mbds0010,,2013-11-24 07:52:33
mbbd000143674,mbcd0002508,mbtp000002,mbrf0002001,,~,,,inhibitor,96,9.5,nmol min-1 mg-1,1,Chalcone 6,,,MDA-MB-231/R cell line; effect of chalcone on vanadate-sensitive BCRP ATPase activity in crude membranes,,,10,microM,,human,mbds0010,,2013-11-24 07:52:33
mbbd000143675,mbcd0030057,mbtp000002,mbrf0002001,,~,,,inhibitor,96,6.5,nmol min-1 mg-1,0.5,Chalcone 7,,,MDA-MB-231/R cell line; effect of chalcone on vanadate-sensitive BCRP ATPase activity in crude membranes,,,10,microM,,human,mbds0010,,2013-11-24 07:52:34
mbbd000143676,mbcd0030058,mbtp000002,mbrf0002001,,~,,,inhibitor,96,4.5,nmol min-1 mg-1,1,Chalcone 8,,,MDA-MB-231/R cell line; effect of chalcone on vanadate-sensitive BCRP ATPase activity in crude membranes,,,10,microM,,human,mbds0010,,2013-11-24 07:52:34
mbbd000143677,mbcd0030059,mbtp000002,mbrf0002001,,~,,,inhibitor,96,7.5,nmol min-1 mg-1,1,Chalcone 9,,,MDA-MB-231/R cell line; effect of chalcone on vanadate-sensitive BCRP ATPase activity in crude membranes,,,10,microM,,human,mbds0010,,2013-11-24 07:52:34
mbbd000143678,mbcd0030060,mbtp000002,mbrf0002001,,~,,,inhibitor,96,4.5,nmol min-1 mg-1,1,Chalcone 10,,,MDA-MB-231/R cell line; effect of chalcone on vanadate-sensitive BCRP ATPase activity in crude membranes,,,10,microM,,human,mbds0010,,2013-11-24 07:52:34
mbbd000143679,mbcd0030061,mbtp000002,mbrf0002001,,~,,,inhibitor,96,5.8,nmol min-1 mg-1,1.5,Chalcone 11,,,MDA-MB-231/R cell line; effect of chalcone on vanadate-sensitive BCRP ATPase activity in crude membranes,,,10,microM,,human,mbds0010,,2013-11-24 07:52:35
mbbd000143680,mbcd0020414,mbtp000002,mbrf0002001,,~,,,inhibitor,96,7.5,nmol min-1 mg-1,1,Chalcone 12,,,MDA-MB-231/R cell line; effect of chalcone on vanadate-sensitive BCRP ATPase activity in crude membranes,,,10,microM,,human,mbds0010,,2013-11-24 07:52:35
mbbd000143681,mbcd0030062,mbtp000002,mbrf0002001,,~,,,inhibitor,96,9.0,nmol min-1 mg-1,1,Chalcone 13,,,MDA-MB-231/R cell line; effect of chalcone on vanadate-sensitive BCRP ATPase activity in crude membranes,,,10,microM,,human,mbds0010,,2013-11-24 07:52:35
mbbd000143682,mbcd0030063,mbtp000002,mbrf0002001,,~,,,inhibitor,96,9.0,nmol min-1 mg-1,2,Chalcone 15,,,MDA-MB-231/R cell line; effect of chalcone on vanadate-sensitive BCRP ATPase activity in crude membranes,,,10,microM,,human,mbds0010,,2013-11-24 07:52:35
mbbd000143683,mbcd0030064,mbtp000002,mbrf0002001,,~,,,inhibitor,96,8.5,nmol min-1 mg-1,1,Chalcone 16,,,MDA-MB-231/R cell line; effect of chalcone on vanadate-sensitive BCRP ATPase activity in crude membranes,,,10,microM,,human,mbds0010,,2013-11-24 07:52:36
mbbd000143684,mbcd0030065,mbtp000002,mbrf0002001,,~,,,inhibitor,96,10.0,nmol min-1 mg-1,0.5,Chalcone 17,,,MDA-MB-231/R cell line; effect of chalcone on vanadate-sensitive BCRP ATPase activity in crude membranes,,,10,microM,,human,mbds0010,,2013-11-24 07:52:36
mbbd000143685,mbcd0030066,mbtp000002,mbrf0001797,,>,,,substrate,28,500.0,microM,,Belotecan,,,MDCKII/BCRP cell line; parameter for secretory transport (Basal to Apical),MDCKII,,,,,human,mbds0010,,2013-11-24 23:11:58
mbbd000143686,mbcd0030066,mbtp000002,mbrf0001797,,~,,,substrate,138,180.0,nmol cm-2 min-1,5,Belotecan,,,MDCKII/BCRP cell line; rate of secretory transport (basal to apical),MDCKII,,500,microM,,human,mbds0010,,2013-12-08 02:33:02
mbbd000143687,mbcd0003187,mbtp000002,mbrf0001797,,=,,,substrate,28,213.28,microM,30.14,Topotecan,,,MDCKII/BCRP cell line; parameter for secretory transport (Basal to Apical),MDCKII,,,,,human,mbds0010,,2013-11-24 23:11:59
mbbd000143688,mbcd0003187,mbtp000002,mbrf0001797,,~,,,substrate,138,150.0,nmol cm-2 min-1,10,Topotecan,,,MDCKII/BCRP cell line; rate of secretory transport (basal to apical),MDCKII,,500,microM,,human,mbds0010,,2013-12-08 02:33:02
mbbd000143689,mbcd0000043,mbtp000002,mbrf0001949,,=,,,substrate,107,0.72,,0.09,PhIP,,,perfusion of human term placenta,perfused human placenta,,2,microM,,human,mbds0010,,2013-11-26 01:55:30
mbbd000143690,mbcd0000100,mbtp000002,mbrf0002160,,,,,substrate,,,,,9-aminocamptothecin,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143691,mbcd0003124,mbtp000002,mbrf0002160,,,,,substrate,,,,,Abacavir,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143692,mbcd0000191,mbtp000002,mbrf0002160,,,,,substrate,,,,,Bisantrene,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143693,mbcd0029850,mbtp000002,mbrf0002160,,,,,substrate,,,,,BNP 1350,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143694,mbcd0029885,mbtp000002,mbrf0002160,,,,,substrate,,,,,Chlorin e6,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143695,mbcd0029953,mbtp000002,mbrf0002160,,,,,substrate,,,,,Cl 1033,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143696,mbcd0017980,mbtp000002,mbrf0002160,,,,,substrate,,,,,Ciprofloxacin,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143697,mbcd0000960,mbtp000002,mbrf0002160,,,,,substrate,,,,,Cladribine,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143698,mbcd0005183,mbtp000002,mbrf0002160,,,,,substrate,,,,,Daunorubicin,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143699,mbcd0029877,mbtp000002,mbrf0002160,,,,,substrate,,,,,Diflomotecan,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143700,mbcd0003100,mbtp000002,mbrf0002160,,,,,substrate,,,,,Dipyridamole,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143701,mbcd0025844,mbtp000002,mbrf0002160,,,,,substrate,,,,,Doxorubicin,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143702,mbcd0029986,mbtp000002,mbrf0002160,,,,,substrate,,,,,DX 8961f,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143703,mbcd0029350,mbtp000002,mbrf0002160,,,,,substrate,,,,,Epirubicin,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143704,mbcd0003099,mbtp000002,mbrf0002160,,,,,substrate,,,,,Erlotinib,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143705,mbcd0002466,mbtp000002,mbrf0002160,,,,,substrate,,,,,Etoposide,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143706,mbcd0001652,mbtp000002,mbrf0002160,,,,,substrate,,,,,Flavopiridol,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143707,mbcd0003125,mbtp000002,mbrf0002160,,,,,substrate,,,,,Gefitinib,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143708,mbcd0029844,mbtp000002,mbrf0002160,,,,,substrate,,,,,Gimatecan,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143709,mbcd0003074,mbtp000002,mbrf0002160,,,,,substrate,,,,,Glyburide,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143710,mbcd0029420,mbtp000002,mbrf0002160,,,,,substrate,,,,,GW1843,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143711,mbcd0029876,mbtp000002,mbrf0002160,,,,,substrate,,,,,Homocamptothecin,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143712,mbcd0002828,mbtp000002,mbrf0002160,,,,,substrate,,,,,Imatinib,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143713,mbcd0000496,mbtp000002,mbrf0002160,,,,,substrate,,,,,J-107088,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143714,mbcd0029979,mbtp000002,mbrf0002160,,,,,substrate,,,,,JNJ 7706621,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143715,mbcd0007655,mbtp000002,mbrf0002160,,,,,substrate,,,,,Leflunomide,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143716,mbcd0003043,mbtp000002,mbrf0002160,,,,,substrate,,,,,Methotrexate,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143717,mbcd0002981,mbtp000002,mbrf0002160,,,,,substrate,,,,,Mitoxantrone,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143718,mbcd0029952,mbtp000002,mbrf0002160,,,,,substrate,,,,,NB-506,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143719,mbcd0026632,mbtp000002,mbrf0002160,,,,,substrate,,,,,Nelfinavir,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143720,mbcd0001221,mbtp000002,mbrf0002160,,,,,substrate,,,,,Nitorfurantoin,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143721,mbcd0011365,mbtp000002,mbrf0002160,,,,,substrate,,,,,Norfloxacin,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143722,mbcd0003068,mbtp000002,mbrf0002160,,,,,substrate,,,,,Ofloxacin,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143723,mbcd0003005,mbtp000002,mbrf0002160,,,,,substrate,,,,,Olmesartan,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143724,mbcd0029883,mbtp000002,mbrf0002160,,,,,substrate,,,,,Pheophorbide A,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143725,mbcd0000693,mbtp000002,mbrf0002160,,,,,substrate,,,,,Pitavastatin,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143726,mbcd0015671,mbtp000002,mbrf0002160,,,,,substrate,,,,,Protoporthyrin IX,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143727,mbcd0030067,mbtp000002,mbrf0002160,,,,,substrate,,,,,Pyropheophorbide A,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143728,mbcd0000779,mbtp000002,mbrf0002160,,,,,substrate,,,,,SN 38,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143729,mbcd0001280,mbtp000002,mbrf0002160,,,,,substrate,,,,,Sulfasalazine,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143730,mbcd0001080,mbtp000002,mbrf0002160,,,,,substrate,,,,,Teniposide,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143731,mbcd0029766,mbtp000002,mbrf0002160,,,,,substrate,,,,,Tomudex,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143732,mbcd0003187,mbtp000002,mbrf0002160,,,,,substrate,,,,,Topotecan,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143733,mbcd0029988,mbtp000002,mbrf0002160,,,,,substrate,,,,,UCN-01,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143734,mbcd0001107,mbtp000002,mbrf0002160,,,,,substrate,,,,,Zidovudine,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143735,mbcd0003055,mbtp000002,mbrf0002160,,,,,inhibitor,,,,,17-beta-estradiol,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143736,mbcd0003238,mbtp000002,mbrf0002160,,,,,inhibitor,,,,,6-prenylchrysin,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143737,mbcd0003124,mbtp000002,mbrf0002160,,,,,inhibitor,,,,,Abacavir,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143738,mbcd0004715,mbtp000002,mbrf0002160,,,,,inhibitor,,,,,Acacetin,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143739,mbcd0002383,mbtp000002,mbrf0002160,,,,,inhibitor,,,,,Amprenavir,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143740,mbcd0002051,mbtp000002,mbrf0002160,,,,,inhibitor,,,,,Atazanavir,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143741,mbcd0000190,mbtp000002,mbrf0002160,,,,,inhibitor,,,,,Biricodar,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143742,mbcd0003045,mbtp000002,mbrf0002160,,,,,inhibitor,,,,,Chrysin,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143743,mbcd0029953,mbtp000002,mbrf0002160,,,,,inhibitor,,,,,Cl 1033,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143744,mbcd0000303,mbtp000002,mbrf0002160,,,,,inhibitor,,,,,Curcumin,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143745,mbcd0000311,mbtp000002,mbrf0002160,,,,,inhibitor,,,,,Cyclosporin A,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143746,mbcd0002544,mbtp000002,mbrf0002160,,,,,inhibitor,,,,,Delavirdine,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143747,mbcd0000968,mbtp000002,mbrf0002160,,,,,inhibitor,,,,,Diethylstilbestrol,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143748,mbcd0003100,mbtp000002,mbrf0002160,,,,,inhibitor,,,,,Dipyridamole,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143749,mbcd0001868,mbtp000002,mbrf0002160,,,,,inhibitor,,,,,Efavirenz,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143750,mbcd0001808,mbtp000002,mbrf0002160,,,,,inhibitor,,,,,Elacridar,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143751,mbcd0003211,mbtp000002,mbrf0002160,,,,,inhibitor,,,,,Estrone,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143752,mbcd0002422,mbtp000002,mbrf0002160,,,,,inhibitor,,,,,Fumitremorgin C,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143753,mbcd0003125,mbtp000002,mbrf0002160,,,,,inhibitor,,,,,Gefitinib,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143754,mbcd0003116,mbtp000002,mbrf0002160,,,,,inhibitor,,,,,Genistein,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143755,mbcd0002828,mbtp000002,mbrf0002160,,,,,inhibitor,,,,,Imatinib,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143756,mbcd0002439,mbtp000002,mbrf0002160,,,,,inhibitor,,,,,Ko 143,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143757,mbcd0002241,mbtp000002,mbrf0002160,,,,,inhibitor,,,,,Lopinavir,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143758,mbcd0003096,mbtp000002,mbrf0002160,,,,,inhibitor,,,,,Naringenin,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143759,mbcd0026632,mbtp000002,mbrf0002160,,,,,inhibitor,,,,,Nelfinavir,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143760,mbcd0002576,mbtp000002,mbrf0002160,,,,,inhibitor,,,,,Nicardipine,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143761,mbcd0026854,mbtp000002,mbrf0002160,,,,,inhibitor,,,,,Nimodipine,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143762,mbcd0003135,mbtp000002,mbrf0002160,,,,,inhibitor,,,,,Nitrendipine,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143763,mbcd0003252,mbtp000002,mbrf0002160,,,,,inhibitor,,,,,Novobiocin,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143764,mbcd0000648,mbtp000002,mbrf0002160,,,,,inhibitor,,,,,Ortataxel,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143765,mbcd0022900,mbtp000002,mbrf0002160,,,,,inhibitor,,,,,Pantoprazole,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143766,mbcd0003120,mbtp000002,mbrf0002160,,,,,inhibitor,,,,,Quercetin,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143767,mbcd0001941,mbtp000002,mbrf0002160,,,,,inhibitor,,,,,Reserpine,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143768,mbcd0001938,mbtp000002,mbrf0002160,,,,,inhibitor,,,,,Ritonavir,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143769,mbcd0001448,mbtp000002,mbrf0002160,,,,,inhibitor,,,,,Rosuvastatin,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143770,mbcd0001533,mbtp000002,mbrf0002160,,,,,inhibitor,,,,,Saquinavir,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143771,mbcd0022617,mbtp000002,mbrf0002160,,,,,inhibitor,,,,,Silymarin,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143772,mbcd0001324,mbtp000002,mbrf0002160,,,,,inhibitor,,,,,Sirolimus,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143773,mbcd0001316,mbtp000002,mbrf0002160,,,,,inhibitor,,,,,Tacrolimus,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143774,mbcd0002889,mbtp000002,mbrf0002160,,,,,inhibitor,,,,,Tamoxifen,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143775,mbcd0002104,mbtp000002,mbrf0002160,,,,,inhibitor,,,,,Tariquidar,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143776,mbcd0030041,mbtp000002,mbrf0002160,,,,,inhibitor,,,,,Tryprostatin A,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143777,mbcd0002875,mbtp000002,mbrf0002160,,,,,inhibitor,,,,,WK-X-34,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143778,mbcd0029968,mbtp000002,mbrf0002424,,=,,,inhibitor,100,283.0,%,,Aurone 1,,,MDA-MB-231/R MX cell line; intracellulat mitoxantrone accumulation as a percentage of control,,,5,microM,,human,mbds0010,,2013-11-24 07:52:24
mbbd000143779,mbcd0030069,mbtp000002,mbrf0002424,,=,,,inhibitor,100,275.0,%,,Aurone 2,,,MDA-MB-231/R MX cell line; intracellulat mitoxantrone accumulation as a percentage of control,,,5,microM,,human,mbds0010,,2013-11-24 07:52:25
mbbd000143780,mbcd0030070,mbtp000002,mbrf0002424,,=,,,inhibitor,100,275.0,%,,Aurone 3,,,MDA-MB-231/R MX cell line; intracellulat mitoxantrone accumulation as a percentage of control,,,5,microM,,human,mbds0010,,2013-11-24 07:52:25
mbbd000143781,mbcd0030071,mbtp000002,mbrf0002424,,=,,,inhibitor,100,233.0,%,,Aurone 4,,,MDA-MB-231/R MX cell line; intracellulat mitoxantrone accumulation as a percentage of control,,,5,microM,,human,mbds0010,,2013-11-24 07:52:25
mbbd000143782,mbcd0030072,mbtp000002,mbrf0002424,,=,,,inhibitor,100,235.0,%,,Aurone 5,,,MDA-MB-231/R MX cell line; intracellulat mitoxantrone accumulation as a percentage of control,,,5,microM,,human,mbds0010,,2013-11-24 07:52:25
mbbd000143783,mbcd0030073,mbtp000002,mbrf0002424,,=,,,inhibitor,100,273.0,%,,Aurone 6,,,MDA-MB-231/R MX cell line; intracellulat mitoxantrone accumulation as a percentage of control,,,5,microM,,human,mbds0010,,2013-11-24 07:52:26
mbbd000143784,mbcd0030075,mbtp000002,mbrf0002424,,=,,,inhibitor,100,263.0,%,,Aurone 7,,,MDA-MB-231/R MX cell line; intracellulat mitoxantrone accumulation as a percentage of control,,,5,microM,,human,mbds0010,,2013-11-24 07:52:26
mbbd000143785,mbcd0030075,mbtp000002,mbrf0002424,,=,,,inhibitor,100,251.0,%,,Aurone 8,,,MDA-MB-231/R MX cell line; intracellulat mitoxantrone accumulation as a percentage of control,,,5,microM,,human,mbds0010,,2013-11-24 07:52:26
mbbd000143786,mbcd0030076,mbtp000002,mbrf0002424,,=,,,inhibitor,100,294.0,%,,Aurone 9,,,MDA-MB-231/R MX cell line; intracellulat mitoxantrone accumulation as a percentage of control,,,5,microM,,human,mbds0010,,2013-11-24 07:52:26
mbbd000143787,mbcd0030077,mbtp000002,mbrf0002424,,=,,,inhibitor,100,278.0,%,,Aurone 10,,,MDA-MB-231/R MX cell line; intracellulat mitoxantrone accumulation as a percentage of control,,,5,microM,,human,mbds0010,,2013-11-24 07:52:26
mbbd000143788,mbcd0030078,mbtp000002,mbrf0002424,,=,,,inhibitor,100,321.0,%,,Aurone 11,,,MDA-MB-231/R MX cell line; intracellulat mitoxantrone accumulation as a percentage of control,,,5,microM,,human,mbds0010,,2013-11-24 07:52:27
mbbd000143789,mbcd0030079,mbtp000002,mbrf0002424,,=,,,inhibitor,100,291.0,%,,Aurone 12,,,MDA-MB-231/R MX cell line; intracellulat mitoxantrone accumulation as a percentage of control,,,5,microM,,human,mbds0010,,2013-11-24 07:52:27
mbbd000143790,mbcd0030080,mbtp000002,mbrf0002424,,=,,,inhibitor,100,268.0,%,,Aurone 13,,,MDA-MB-231/R MX cell line; intracellulat mitoxantrone accumulation as a percentage of control,,,5,microM,,human,mbds0010,,2013-11-24 07:52:27
mbbd000143791,mbcd0030081,mbtp000002,mbrf0002424,,=,,,inhibitor,100,358.0,%,,Aurone 14,,,MDA-MB-231/R MX cell line; intracellulat mitoxantrone accumulation as a percentage of control,,,5,microM,,human,mbds0010,,2013-11-24 07:52:27
mbbd000143792,mbcd0030082,mbtp000002,mbrf0002424,,=,,,inhibitor,100,187.0,%,,Aurone 15,,,MDA-MB-231/R MX cell line; intracellulat mitoxantrone accumulation as a percentage of control,,,5,microM,,human,mbds0010,,2013-11-24 07:52:28
mbbd000143793,mbcd0003963,mbtp000002,mbrf0001777,,=,,,substrate,135,10.58,,,5-Fu; 5-Fluorouracil,,,PA317/Tet-on/TRE-BCRP cell line; expression of BCRP regulated by doxycycline; 6 mg L-1 doxycycline induction for 24 hours,PA317/Tet-on/TRE-BCRP,,,,,human,mbds0010,,2013-11-20 23:18:55
mbbd000143794,mbcd0003043,mbtp000002,mbrf0001777,,=,,,substrate,135,8.6,,,MTX; Methotrexate,,,PA317/Tet-on/TRE-BCRP cell line; expression of BCRP regulated by doxycycline; 6 mg L-1 doxycycline induction for 24 hours,PA317/Tet-on/TRE-BCRP,,,,,human,mbds0010,,2013-11-20 23:18:55
mbbd000143795,mbcd0030889,mbtp000002,mbrf0001777,,=,,,substrate,135,17.3,,,ADM; Adriamycin,,,PA317/Tet-on/TRE-BCRP cell line; expression of BCRP regulated by doxycycline; 6 mg L-1 doxycycline induction for 24 hours,PA317/Tet-on/TRE-BCRP,,,,,human,mbds0010,,2014-02-25 07:04:19
mbbd000143796,mbcd0030083,mbtp000002,mbrf0001777,,=,,,substrate,135,15.8,,,THP; Pirarubicin,,,PA317/Tet-on/TRE-BCRP cell line; expression of BCRP regulated by doxycycline; 6 mg L-1 doxycycline induction for 24 hours,PA317/Tet-on/TRE-BCRP,,,,,human,mbds0010,,2013-11-20 23:18:56
mbbd000143797,mbcd0002466,mbtp000002,mbrf0001777,,=,,,substrate,135,17.6,,,VP-16; Etoposide,,,PA317/Tet-on/TRE-BCRP cell line; expression of BCRP regulated by doxycycline; 6 mg L-1 doxycycline induction for 24 hours,PA317/Tet-on/TRE-BCRP,,,,,human,mbds0010,,2013-11-20 23:18:56
mbbd000143798,mbcd0002981,mbtp000002,mbrf0001777,,=,,,substrate,135,82.8,,,MX; Mitoxantrone,,,PA317/Tet-on/TRE-BCRP cell line; expression of BCRP regulated by doxycycline; 6 mg L-1 doxycycline induction for 24 hours,PA317/Tet-on/TRE-BCRP,,,,,human,mbds0010,,2013-11-20 23:18:56
mbbd000143799,mbcd0001532,mbtp000002,mbrf0001777,,=,,,non-substrate,135,1.07,,,Taxol; Paclitaxel,,,PA317/Tet-on/TRE-BCRP cell line; expression of BCRP regulated by doxycycline; 6 mg L-1 doxycycline induction for 24 hours,PA317/Tet-on/TRE-BCRP,,,,,human,mbds0010,,2013-11-20 23:18:56
mbbd000143800,mbcd0001117,mbtp000002,mbrf0001777,,=,,,non-substrate,135,1.3,,,DDP; Cisplatin,,,PA317/Tet-on/TRE-BCRP cell line; expression of BCRP regulated by doxycycline; 6 mg L-1 doxycycline induction for 24 hours,PA317/Tet-on/TRE-BCRP,,,,,human,mbds0010,,2013-11-20 23:18:57
mbbd000143801,mbcd0028108,mbtp000002,mbrf0001777,,=,,,non-substrate,135,1.12,,,VDS; Vindesine,,,PA317/Tet-on/TRE-BCRP cell line; expression of BCRP regulated by doxycycline; 6 mg L-1 doxycycline induction for 24 hours,PA317/Tet-on/TRE-BCRP,,,,,human,mbds0010,,2013-11-20 23:18:57
mbbd000143802,mbcd0000998,mbtp000002,mbrf0001777,,=,,,non-substrate,135,1.72,,,MMC; Mitomycin C,,,PA317/Tet-on/TRE-BCRP cell line; expression of BCRP regulated by doxycycline; 6 mg L-1 doxycycline induction for 24 hours,PA317/Tet-on/TRE-BCRP,,,,,human,mbds0010,,2013-11-20 23:18:57
mbbd000143803,mbcd0001135,mbtp000002,mbrf0001777,,=,,,non-substrate,135,4.03,,,VCR; Vincristine,,,PA317/Tet-on/TRE-BCRP cell line; expression of BCRP regulated by doxycycline; 6 mg L-1 doxycycline induction for 24 hours,PA317/Tet-on/TRE-BCRP,,,,,human,mbds0010,,2013-11-20 23:18:58
mbbd000143804,mbcd0001172,mbtp000002,mbrf0002049,,~,,,inhibitor,108,310.0,Units of fluorescence,20,Ivermectin,,,human ABCG2 transduced MDCK II cell line; Mitoxantrone intracellular accumulation,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143805,mbcd0030084,mbtp000002,mbrf0002049,,~,,,inhibitor,108,100.0,Units of Fluorescence,5,Selamectin,,,human ABCG2 transduced MDCK II cell line; Mitoxantrone intracellular accumulation,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143806,mbcd0001172,mbtp000002,mbrf0001777,,=,,,inhibitor,3,95.02,%,7.65,Ivermectin,,,human ABCG2 transduced MDCK II cell line,,,,,,human,mbds0010,,2013-12-06 07:26:13
mbbd000143807,mbcd0030084,mbtp000002,mbrf0001777,,=,,,inhibitor,3,32.21,%,5.47,Selamectin,,,human ABCG2 transduced MDCK II cell line,,,,,,human,mbds0010,,2013-12-06 07:26:13
mbbd000143808,mbcd0001550,mbtp000002,mbrf0001543,,~,,,inhibitor,100,1.75,pmol (10^5 cells)-1,0.05,Lapatinib,,,ABCG2-482-R5 transfected HEK-293 cell line; mitoxantrone intracellular accumulation,,,1,microM,,human,mbds0010,,2013-11-24 02:54:46
mbbd000143809,mbcd0001550,mbtp000002,mbrf0001543,,~,,,inhibitor,96,50.0,nmol min-1 (mg protein)-1,2,Lapatinib,,,High Five insect cells infected with the recombinant baculovirus carrying the human ABCG2 cDNAs,,,10,microM,,human,mbds0010,,2013-11-24 02:54:46
mbbd000143810,mbcd0002439,mbtp000002,mbrf0002541,,=,,,inhibitor,25,0.07,microM,,Ko 143,,,BCRP over-expressing drug resistance cell line MCF7/MX100,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143811,mbcd0003893,mbtp000002,mbrf0002541,,=,,,inhibitor,25,38.1,microM,,Risperidone,,,BCRP over-expressing drug resistance cell line MCF7/MX100,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143812,mbcd0030085,mbtp000002,mbrf0002541,,=,,,inhibitor,25,51.0,microM,,Paliperidone,,,BCRP over-expressing drug resistance cell line MCF7/MX100,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143813,mbcd0001018,mbtp000002,mbrf0002541,,>,,,inhibitor,25,100.0,microM,,Olanzapine,,,BCRP over-expressing drug resistance cell line MCF7/MX100,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143814,mbcd0027670,mbtp000002,mbrf0002541,,=,,,inhibitor,25,66.1,microM,,Quetiapine,,,BCRP over-expressing drug resistance cell line MCF7/MX100,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143815,mbcd0003888,mbtp000002,mbrf0002541,,=,,,inhibitor,25,42.0,microM,,Clozapine,,,BCRP over-expressing drug resistance cell line MCF7/MX100,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143816,mbcd0002340,mbtp000002,mbrf0002541,,=,,,inhibitor,25,52.2,microM,,Chlorpromazine,,,BCRP over-expressing drug resistance cell line MCF7/MX100,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143817,mbcd0001777,mbtp000002,mbrf0002541,,>,,,inhibitor,25,100.0,microM,,Haloperidol,,,BCRP over-expressing drug resistance cell line MCF7/MX100,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143818,mbcd0002439,mbtp000002,mbrf0002541,,~,,,inhibitor,20,1100.0,%,20,Ko 143,,,BCRP over-expressing drug resistance cell line MCF7/MX100; Intracellular mitoxantrone accumulation as a percentage of control,,,1000,nM,,human,mbds0010,,2013-11-24 02:54:45
mbbd000143819,mbcd0003893,mbtp000002,mbrf0002541,,~,,,inhibitor,20,200.0,%,10,Risperidone,,,BCRP over-expressing drug resistance cell line MCF7/MX100; Intracellular mitoxantrone accumulation as a percentage of control,,,0.25,microM,,human,mbds0010,,2013-11-24 03:25:28
mbbd000143820,mbcd0030085,mbtp000002,mbrf0002541,,~,,,inhibitor,20,140.0,%,5,Paliperidone,,,BCRP over-expressing drug resistance cell line MCF7/MX100; Intracellular mitoxantrone accumulation as a percentage of control,,,100,microM,,human,mbds0010,,2013-12-10 22:38:48
mbbd000143821,mbcd0001018,mbtp000002,mbrf0002541,,~,,,inhibitor,20,100.0,%,,Olanzapine,,,BCRP over-expressing drug resistance cell line MCF7/MX100; Intracellular mitoxantrone accumulation as a percentage of control,,,100,microM,,human,mbds0010,,2013-11-24 02:54:53
mbbd000143822,mbcd0027670,mbtp000002,mbrf0002541,,~,,,inhibitor,20,200.0,%,10,Quetiapine,,,BCRP over-expressing drug resistance cell line MCF7/MX100; Intracellular mitoxantrone accumulation as a percentage of control,,,100,microM,,human,mbds0010,,2013-11-24 03:25:26
mbbd000143823,mbcd0003888,mbtp000002,mbrf0002541,,~,,,inhibitor,20,200.0,%,20,Clozapine,,,BCRP over-expressing drug resistance cell line MCF7/MX100; Intracellular mitoxantrone accumulation as a percentage of control,,,100,microM,,human,mbds0010,,2013-11-23 22:11:37
mbbd000143824,mbcd0003113,mbtp000002,mbrf0002065,,~,,,substrate,138,50.0,%,5,Diclofenac,,,BCRP-transduced MDCK-II cell line; percentage of radioactivity translocated from basolateral to apical compartment after 4 hours,MDCKII,,5,microM,,human,mbds0010,,2013-11-24 23:11:59
mbbd000143825,mbcd0003113,mbtp000002,mbrf0002065,,=,,,inhibitor,25,78.0,microM,,Diclofenac,,,inside-out Sf9-BCRP plasma membrane vesicles; inhibition of BCRP-mediated transport of MTX; pH 7.4,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143826,mbcd0027319,mbtp000002,mbrf0001545,,~,,,inhibitor,20,1000.0,AU,,Sunitinib,,,ABCG2-expressing Arg482-HEK-293; ABCG2 cell line;  Effect of sunitinib on the accumulation of 1 microM pheophorbide A,,,10,microM,,human,mbds0010,,2013-12-09 21:03:09
mbbd000143827,mbcd0027319,mbtp000002,mbrf0001545,,=,,,substrate,25,1.33,microM,,Sunitinib,,,MCF-7 FLV1000 cell line,MCF7 FLV1000,,,,,human,mbds0010,,2013-11-24 23:10:00
mbbd000143828,mbcd0002563,mbtp000002,mbrf0002139,,=,,,inhibitor,17,1.56,microM,,MC18,,,Madin-Darby Canine Kidney (MDCK) cell line overexpressing BCRP by Calcein-AMassay,MDCK,,,,,human,mbds0010,,2013-11-20 19:41:42
mbbd000143829,mbcd0001465,mbtp000002,mbrf0002139,,=,,,substrate,17,31.0,microM,4.6,Bicalutamide,,,BCRP-transfected MDCK II cell line; monitoring Calcein accumulation in transfected MDCK cells,MDCKII,,,,,human,mbds0010,,2013-11-24 23:11:59
mbbd000143830,mbcd0001652,mbtp000002,mbrf0002395,,=,,,substrate,25,0.3127,microM,0.0265,Flavopiridol,cell survival,,ABCG2-482-R5 overexpressing HEK-293 cell line,HEK293,,,,,human,mbds0010,,2013-11-21 02:19:17
mbbd000143831,mbcd0002981,mbtp000002,mbrf0002395,,=,,,substrate,25,0.4123,microM,0.0263,Mitoxantrone,cell survival,,ABCG2-482-R5 overexpressing HEK-293 cell line,HEK293,,,,,human,mbds0010,,2013-11-21 02:19:18
mbbd000143832,mbcd0000779,mbtp000002,mbrf0002395,,=,,,substrate,25,0.1446,microM,0.0562,SN-38,cell survival,,ABCG2-482-R5 overexpressing HEK-293 cell line,HEK293,,,,,human,mbds0010,,2013-11-21 02:19:18
mbbd000143833,mbcd0001117,mbtp000002,mbrf0002395,,=,,,substrate,25,1.4873,microM,0.3117,Cisplatin,cell survival,,ABCG2-482-R5 overexpressing HEK-293 cell line,HEK293,,,,,human,mbds0010,,2013-11-21 02:19:18
mbbd000143834,mbcd0011472,mbtp000002,mbrf0002395,,~,,,inhibitor,100,1.75,pmol (10^5 cells)-1,0.1,AG1478,,,ABCG2-482-R5 overexpressing HEK-293 cell line; intracellular mitoxantrone accumulation,HEK293,,10,microM,,human,mbds0010,,2013-12-09 07:12:57
mbbd000143835,mbcd0011472,mbtp000002,mbrf0002395,,~,,,substrate,96,65.0,nmol Pi (mg protein)-1 min-1,5,AG1478,,,Vi-sensitive ATPase activity of ABCG2 in the membrane vesicles of High Five insect cells stimulated,High Five insect cells,,5,microM,,human,mbds0010,,2013-12-09 07:14:18
mbbd000143836,mbcd0001021,mbtp000002,mbrf0001548,,=,,,inhibitor,25,17.6,micromol L-1,,Omeprazole,,,"BCRP-expressing membrane vesicles, which express human BCRP on their membranes in an inside-out manner",,,,,,human,mbds0010,,2013-12-09 20:11:58
mbbd000143837,mbcd0003121,mbtp000002,mbrf0001548,,=,,,inhibitor,25,14.4,micromol L-1,,Lansoprazole,,,"BCRP-expressing membrane vesicles, which express human BCRP on their membranes in an inside-out manner",,,,,,human,mbds0010,,2013-12-09 20:11:58
mbbd000143838,mbcd0023569,mbtp000002,mbrf0001548,,=,,,inhibitor,25,8.5,micromol L-1,,Rabeprazole,,,"BCRP-expressing membrane vesicles, which express human BCRP on their membranes in an inside-out manner",,,,,,human,mbds0010,,2013-12-09 20:11:58
mbbd000143839,mbcd0022900,mbtp000002,mbrf0001548,,=,,,inhibitor,25,5.5,micromol L-1,,Pantoprazole,,,"BCRP-expressing membrane vesicles, which express human BCRP on their membranes in an inside-out manner",,,,,,human,mbds0010,,2013-12-09 20:11:57
mbbd000143840,mbcd0001021,mbtp000002,mbrf0001548,,~,,,inhibitor,3,10.0,%,,Omeprazole,,,"BCRP-expressing membrane vesicles, which express human BCRP on their membranes in an inside-out; Inhibitory effects of (BCRP)-mediated uptake of 100 mM methotrexate (MTX)",,,100,micromol L-1,,human,mbds0010,,2013-12-09 20:56:36
mbbd000143841,mbcd0003121,mbtp000002,mbrf0001548,,=,,,inhibitor,3,12.0,%,,Lansoprazole,,,"BCRP-expressing membrane vesicles, which express human BCRP on their membranes in an inside-out; Inhibitory effects of (BCRP)-mediated uptake of 100 mM methotrexate (MTX)",,,100,micromol L-1,,human,mbds0010,,2013-12-09 20:56:36
mbbd000143842,mbcd0023569,mbtp000002,mbrf0001548,,~,,,inhibitor,3,10.0,%,,Rabeprazole,,,"BCRP-expressing membrane vesicles, which express human BCRP on their membranes in an inside-out; Inhibitory effects of (BCRP)-mediated uptake of 100 mM methotrexate (MTX)",,,100,micromol L-1,,human,mbds0010,,2013-12-09 20:56:35
mbbd000143843,mbcd0022900,mbtp000002,mbrf0001548,,~,,,inhibitor,3,8.0,%,,Pantoprazole,,,"BCRP-expressing membrane vesicles, which express human BCRP on their membranes in an inside-out; Inhibitory effects of (BCRP)-mediated uptake of 100 mM methotrexate (MTX)",,,100,micromol L-1,,human,mbds0010,,2013-12-10 22:39:21
mbbd000143844,mbcd0023975,mbtp000002,mbrf0001686,,~,,,inhibitor,25,1.4,microM,,HhAntag691,,,ABCG2- overexpressing MDCK II cell line,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143845,mbcd0023975,mbtp000002,mbrf0001686,,~,,,inhibitor,108,90.0,% increase,,HhAntag691,,,HEK293/ABCG2 cells,HEK293,mbcd0029889,20,microM,,human,mbds0010,,2013-12-07 00:13:55
mbbd000143846,mbcd0002828,mbtp000002,mbrf0001740,,,,,substrate,,,,,Imatinib,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143847,mbcd0002828,mbtp000002,mbrf0001740,,,,,inhibitor,,,,,Imatinib,inhibition at relatively high concentrations only,,,,,,,,human,mbds0010,,2013-11-18 20:09:19
mbbd000143848,mbcd0001690,mbtp000002,mbrf0001740,,,,,substrate,,,,,Nilotinib,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143849,mbcd0001690,mbtp000002,mbrf0001740,,,,,inhibitor,,,,,Nilotinib,Inhibition at high concentrations only,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143850,mbcd0003125,mbtp000002,mbrf0001740,,,,,substrate,,,,,Gefitinib,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143851,mbcd0003125,mbtp000002,mbrf0001740,,,,,inhibitor,,,,,Gefitinib,inhibition at high concentration only,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143852,mbcd0003099,mbtp000002,mbrf0001740,,,,,substrate,,,,,Erlotinib,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143853,mbcd0003099,mbtp000002,mbrf0001740,,,,,inhibitor,,,,,Erlotinib,Inhibition at high concentrations only,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143854,mbcd0029953,mbtp000002,mbrf0001740,,,,,substrate,,,,,Canertinib,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143855,mbcd0029953,mbtp000002,mbrf0001740,,,,,inhibitor,,,,,Canertinib,Inhibition at high concentrations only,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143856,mbcd0001652,mbtp000002,mbrf0001740,,,,,substrate,,,,,Flavopiridol,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143857,mbcd0001652,mbtp000002,mbrf0001740,,,,,inhibitor,,,,,Flavopiridol,Inhibition at high concentrations only,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143858,mbcd0029961,mbtp000002,mbrf0001740,,,,,inhibitor,,,,,TAG 139,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143859,mbcd0003116,mbtp000002,mbrf0001740,,,,,inhibitor,,,,,Genistein,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143860,mbcd0003096,mbtp000002,mbrf0001740,,,,,inhibitor,,,,,Naringenin,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143861,mbcd0004715,mbtp000002,mbrf0001740,,,,,inhibitor,,,,,Acacetin,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143862,mbcd0003215,mbtp000002,mbrf0001740,,,,,inhibitor,,,,,Kaempferol,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143863,mbcd0030087,mbtp000002,mbrf0001740,,,,,inhibitor,,,,,YHO-13351,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143864,mbcd0030088,mbtp000002,mbrf0001740,,,,,inhibitor,,,,,YHO-13177,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143865,mbcd0030089,mbtp000002,mbrf0002561,,=,,,substrate,25,0.05,microM,0.022,Becatecarin,,,wild-type ABCG2-transfected (R-2) HEK-293 cell line,HEK293,,,,,human,mbds0010,,2013-11-24 23:14:16
mbbd000143866,mbcd0030089,mbtp000002,mbrf0002561,,=,,,inhibitor,95,0.28,microM,,Becatecarin,,,Crude membranes from MCF-7 FLV1000 cells incubated with 20 microM becatecarin,,,,,,human,mbds0010,,2013-12-07 01:06:07
mbbd000143867,mbcd0001808,mbtp000002,mbrf0002420,,,,,inhibitor,,,,,Elacridar,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143868,mbcd0002104,mbtp000002,mbrf0002420,,,,,inhibitor,,,,,Tariquidar,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143869,mbcd0003163,mbtp000002,mbrf0002420,,,,,inhibitor,,,,,GF 120918 analogue,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143870,mbcd0002241,mbtp000002,mbrf0002420,,,,,inhibitor,,,,,Lopinavir,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143871,mbcd0026632,mbtp000002,mbrf0002420,,,,,inhibitor,,,,,Nelfinavir,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143872,mbcd0002828,mbtp000002,mbrf0002420,,,,,inhibitor,,,,,Gleevec,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143873,mbcd0003125,mbtp000002,mbrf0002420,,,,,inhibitor,,,,,ZD 1839,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143874,mbcd0000371,mbtp000002,mbrf0002420,,,,,inhibitor,,,,,EKI-785,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143875,mbcd0022617,mbtp000002,mbrf0002420,,,,,inhibitor,,,,,Silymarin,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143876,mbcd0004749,mbtp000002,mbrf0002420,,,,,inhibitor,,,,,Hesperetin,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143877,mbcd0003120,mbtp000002,mbrf0002420,,,,,inhibitor,,,,,Quercetin,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143878,mbcd0013632,mbtp000002,mbrf0002420,,,,,inhibitor,,,,,Daidzein,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143879,mbcd0003026,mbtp000002,mbrf0002420,,,,,inhibitor,,,,,Biochanin A,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143880,mbcd0003045,mbtp000002,mbrf0002420,,,,,inhibitor,,,,,Chrysin,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143881,mbcd0022552,mbtp000002,mbrf0002420,,,,,inhibitor,,,,,Tectochrysin,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143882,mbcd0003238,mbtp000002,mbrf0002420,,,,,inhibitor,,,,,6-Prenylchrysin,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143883,mbcd0002422,mbtp000002,mbrf0002420,,,,,inhibitor,,,,,Fumitremorgin C,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143884,mbcd0002439,mbtp000002,mbrf0002420,,,,,inhibitor,,,,,Ko 143,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143885,mbcd0003252,mbtp000002,mbrf0002420,,,,,inhibitor,,,,,Novobiocin,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143886,mbcd0001107,mbtp000002,mbrf0002420,,,,,substrate,,,,,Zidovudine,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143887,mbcd0002982,mbtp000002,mbrf0002420,,,,,substrate,,,,,Lamivudine,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143888,mbcd0003124,mbtp000002,mbrf0002420,,,,,substrate,,,,,Abacavir,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143889,mbcd0001448,mbtp000002,mbrf0002240,,,,,substrate,,,,,Rosuvastatin,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143890,mbcd0000693,mbtp000002,mbrf0002240,,,,,substrate,,,,,Pitavastatin,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143891,mbcd0023123,mbtp000002,mbrf0002240,,,,,substrate,,,,,Cerivastatin,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143892,mbcd0029932,mbtp000002,mbrf0002240,,,,,substrate,,,,,Aflatoxin B1,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143893,mbcd0000043,mbtp000002,mbrf0002240,,,,,substrate,,,,,"2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine",,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143894,mbcd0030090,mbtp000002,mbrf0002240,,,,,substrate,,,,,"2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline; MeIQx",,,,,,,,,human,mbds0010,,2013-11-20 19:06:36
mbbd000143895,mbcd0029933,mbtp000002,mbrf0002240,,,,,substrate,,,,,"2-amino-3-methylimidazo[4,5-f]quinoline; IQ",,,,,,,,,human,mbds0010,,2013-11-20 19:06:36
mbbd000143896,mbcd0029309,mbtp000002,mbrf0002240,,,,,substrate,,,,,"3-amino-1,4-dimethyl-5H-pyrido[4,3-b]indole; Trp-P-1",,,,,,,,,human,mbds0010,,2013-11-20 19:06:36
mbbd000143897,mbcd0017980,mbtp000002,mbrf0002240,,,,,substrate,,,,,Ciprofloxacin,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143898,mbcd0003068,mbtp000002,mbrf0002240,,,,,substrate,,,,,Ofloxacin,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143899,mbcd0011365,mbtp000002,mbrf0002240,,,,,substrate,,,,,Norfloxacin,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143900,mbcd0000937,mbtp000002,mbrf0002240,,,,,substrate,,,,,Erythromycin,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143901,mbcd0001221,mbtp000002,mbrf0002240,,,,,substrate,,,,,Nitrofurantoin,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143902,mbcd0000159,mbtp000002,mbrf0002240,,,,,substrate,,,,,Azidpine,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143903,mbcd0003100,mbtp000002,mbrf0002240,,,,,substrate,,,,,Dipyridamole,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143904,mbcd0001280,mbtp000002,mbrf0002240,,,,,substrate,,,,,Sulfasalazine,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143905,mbcd0001111,mbtp000002,mbrf0002240,,,,,substrate,,,,,Cimetidine,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143906,mbcd0025627,mbtp000002,mbrf0002240,,,,,substrate,,,,,Riboflavin,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143907,mbcd0016031,mbtp000002,mbrf0002240,,,,,substrate,,,,,Vitamin K3,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143908,mbcd0003074,mbtp000002,mbrf0002240,,,,,substrate,,,,,Glyburide,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143909,mbcd0030091,mbtp000002,mbrf0002775,,,,,substrate,,,,,d-Luciferin,,,HEK293 cells stably transfected with wt ABCG2/BCRP,HEK293,,,,,human,mbds0010,,2013-12-07 00:57:51
mbbd000143910,mbcd0002824,mbtp000002,mbrf0002228,,=,,,inhibitor,17,20.0,microM,,PB28,,,BCRP- overexpressing MDCK II cell line,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143911,mbcd0002252,mbtp000002,mbrf0002228,,=,,,inhibitor,17,90.0,microM,,MC18,,,BCRP- overexpressing MDCK II cell line,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143912,mbcd0003234,mbtp000002,mbrf0002228,,=,,,inhibitor,17,73.0,microM,,MC70,,,BCRP- overexpressing MDCK II cell line,MDCKII,mbcd0000746,,,,human,mbds0010,,2013-10-15 22:29:26
mbbd000143913,mbcd0030092,mbtp000002,mbrf0002228,,=,,,inhibitor,17,0.56,microM,0.02,Compound 6a,,,BCRP-overexpressing MDCK II cell line,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143914,mbcd0030093,mbtp000002,mbrf0002228,,=,,,inhibitor,17,55.0,microM,3,Compound 7a,,,BCRP-overexpressing MDCK II cell line,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143915,mbcd0030094,mbtp000002,mbrf0002228,,=,,,inhibitor,17,0.31,microM,0.02,Compound 8a,,,BCRP-overexpressing MDCK II cell line,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143916,mbcd0030095,mbtp000002,mbrf0002228,,=,,,inhibitor,17,1.2,microM,0.4,Compound 9a,,,BCRP-overexpressing MDCK II cell line,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143917,mbcd0030096,mbtp000002,mbrf0002228,,=,,,inhibitor,17,25.0,microM,2.8,Compound 6b,,,BCRP-overexpressing MDCK II cell line,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143918,mbcd0030097,mbtp000002,mbrf0002228,,=,,,inhibitor,17,0.34,microM,0.05,Compound 8b,,,BCRP-overexpressing MDCK II cell line,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143919,mbcd0030098,mbtp000002,mbrf0002228,,=,,,inhibitor,17,2.3,microM,0.8,Compound 9b,,,BCRP-overexpressing MDCK II cell line,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143920,mbcd0030099,mbtp000002,mbrf0002228,,=,,,inhibitor,17,30.0,microM,2.1,Compound 6c,,,BCRP-overexpressing MDCK II cell line,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143921,mbcd0030100,mbtp000002,mbrf0002228,,=,,,inhibitor,17,7.0,microM,0.65,Compound 8c,,,BCRP-overexpressing MDCK II cell line,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143922,mbcd0030101,mbtp000002,mbrf0002228,,=,,,inhibitor,17,15.0,microM,1.1,Compound 6d,,,BCRP-overexpressing MDCK II cell line,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143923,mbcd0030102,mbtp000002,mbrf0002228,,=,,,inhibitor,17,0.24,microM,0.07,Compound 8d,,,BCRP-overexpressing MDCK II cell line,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143924,mbcd0030103,mbtp000002,mbrf0002228,,=,,,inhibitor,17,73.0,microM,3,Compound 6e,,,BCRP-overexpressing MDCK II cell line,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143925,mbcd0030104,mbtp000002,mbrf0002228,,=,,,inhibitor,17,3.9,microM,0.6,Compound 8e,,,BCRP-overexpressing MDCK II cell line,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143926,mbcd0030105,mbtp000002,mbrf0002228,,=,,,inhibitor,17,15.0,microM,1.2,Compound 8f,,,BCRP-overexpressing MDCK II cell line,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143927,mbcd0030106,mbtp000002,mbrf0002228,,=,,,inhibitor,17,2.5,microM,0.6,Compound 8g,,,BCRP-overexpressing MDCK II cell line,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143928,mbcd0030107,mbtp000002,mbrf0002228,,=,,,inhibitor,17,90.0,microM,4.2,Compound 8h,,,BCRP-overexpressing MDCK II cell line,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143929,mbcd0030108,mbtp000002,mbrf0002228,,=,,,inhibitor,17,52.0,microM,2.5,Compound 8i,,,BCRP-overexpressing MDCK II cell line,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143930,mbcd0030109,mbtp000002,mbrf0002228,,=,,,inhibitor,17,22.0,microM,1.5,Compound 6j,,,BCRP-overexpressing MDCK II cell line,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143931,mbcd0030110,mbtp000002,mbrf0002228,,=,,,inhibitor,17,0.46,microM,0.07,Compound 8j,,,BCRP-overexpressing MDCK II cell line,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143932,mbcd0030111,mbtp000002,mbrf0002228,,=,,,inhibitor,17,25.0,microM,3,Compound 6k,,,BCRP-overexpressing MDCK II cell line,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143933,mbcd0030112,mbtp000002,mbrf0002228,,=,,,inhibitor,17,75.0,microM,1.5,Compound 8k,,,BCRP-overexpressing MDCK II cell line,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143934,mbcd0030113,mbtp000002,mbrf0002228,,=,,,inhibitor,17,30.0,microM,4,Compound 9k,,,BCRP-overexpressing MDCK II cell line,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143935,mbcd0030114,mbtp000002,mbrf0002228,,=,,,inhibitor,17,12.7,microM,2.1,Compound 6l,,,BCRP-overexpressing MDCK II cell line,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143936,mbcd0030115,mbtp000002,mbrf0002228,,=,,,inhibitor,17,2.0,microM,0.8,Compound 8l,,,BCRP-overexpressing MDCK II cell line,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143937,mbcd0030116,mbtp000002,mbrf0002228,,=,,,inhibitor,17,29.0,microM,1.2,Compound 6m,,,BCRP-overexpressing MDCK II cell line,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143938,mbcd0030117,mbtp000002,mbrf0002228,,=,,,inhibitor,17,12.0,microM,1.2,Compound 8m,,,BCRP-overexpressing MDCK II cell line,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143939,mbcd0030118,mbtp000002,mbrf0002228,,=,,,inhibitor,17,5.4,microM,0.4,Compound 8n,,,BCRP-overexpressing MDCK II cell line,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143940,mbcd0030119,mbtp000002,mbrf0002228,,=,,,inhibitor,17,17.0,microM,0.8,Compound 8p,,,BCRP-overexpressing MDCK II cell line,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143941,mbcd0030120,mbtp000002,mbrf0002228,,=,,,substrate,14,38.0,*10^-6 cm s-1,,CP-724714,,,BCRP-overexpressing MDCK II cell line; Drug transport measurements from basolateral to apical compartment,MDCKII,,2,microM,,human,mbds0010,,2013-11-24 23:11:59
mbbd000143942,mbcd0003187,mbtp000002,mbrf0001555,,=,,,substrate,25,5.132,microM,,Topotecan,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143943,mbcd0003187,mbtp000002,mbrf0001555,,=,,,substrate,25,5.132,microM,2.024,Topotecan,,,ABCG2-overexpressing S1-M1-80 cell line,S1-M1-80,,,,,human,mbds0010,,2013-11-24 23:56:04
mbbd000143944,mbcd0025844,mbtp000002,mbrf0001555,,=,,,substrate,25,6.845,microM,1.035,Doxorubicin,,,ABCG2-overexpressing S1-M1-80 cell line,S1-M1-80,,,,,human,mbds0010,,2013-11-24 23:56:03
mbbd000143945,mbcd0027319,mbtp000002,mbrf0001555,,~,,,inhibitor,100,80.0,%,10,Sunitinib,,,ABCG2-overexpressing S1-M1-80 cell line; intracellular Rhodamine 123 accumulation as a percentage of control value of 10 (relative values),,,2.5,microM,,human,mbds0010,,2014-03-04 00:29:00
mbbd000143946,mbcd0001868,mbtp000002,mbrf0002448,,=,,,inhibitor,25,55.2,microM,2.5,Efavirenz,,,BCRP-MDCKII cell line,MDCKII,,,,,human,mbds0010,,2013-11-04 00:32:22
mbbd000143947,mbcd0001868,mbtp000002,mbrf0002448,,~,,,inducer,117,3.0,,1,Efavirenz,,,ABC-transporter mRNA expression in LS180 cells compared to medium control after 4 weeks,LS180,,10,microM,,human,mbds0010,,2013-11-04 00:32:22
mbbd000143950,mbcd0003882,mbtp000002,mbrf0002192,,,,,non-substrate,,,,,m-AMSA,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143951,mbcd0000841,mbtp000002,mbrf0002192,,,,,non-substrate,,,,,Tetramethylrosamine,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143952,mbcd0025844,mbtp000002,mbrf0002192,,,,,non-substrate,,,,,Doxorubicin,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143953,mbcd0002981,mbtp000002,mbrf0002192,,,,,substrate,,,,,Mitoxantrone,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143954,mbcd0000779,mbtp000002,mbrf0002192,,,,,substrate,,,,,SN-38,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143955,mbcd0029883,mbtp000002,mbrf0002192,,,,,substrate,,,,,Pheophorbide A,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143956,mbcd0003043,mbtp000002,mbrf0002192,,,,,substrate,,,,,Methotrexate,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143957,mbcd0030121,mbtp000002,mbrf0002192,,=,,,substrate,25,3.22,microM,0.18,C 1309,,,ABCG2-Overexpressing A549/K1.5 Cell line,A549/K1.5,,,,,human,mbds0010,,2013-11-24 23:56:03
mbbd000143958,mbcd0030122,mbtp000002,mbrf0002192,,=,,,substrate,25,2.41,microM,1.1,C 1336,,,ABCG2-Overexpressing A549/K1.5 Cell line,A549/K1.5,,,,,human,mbds0010,,2013-11-24 23:56:03
mbbd000143959,mbcd0030123,mbtp000002,mbrf0002192,,=,,,substrate,25,1.22,microM,0.07,C 1310,,,ABCG2-Overexpressing A549/K1.5 Cell line,A549/K1.5,,,,,human,mbds0010,,2013-11-24 23:56:03
mbbd000143960,mbcd0030124,mbtp000002,mbrf0002192,,=,,,substrate,25,0.25,microM,0.01,C 1584,,,ABCG2-Overexpressing A549/K1.5 Cell line,A549/K1.5,,,,,human,mbds0010,,2013-11-24 23:56:03
mbbd000143961,mbcd0030125,mbtp000002,mbrf0002192,,=,,,substrate,25,0.7,microM,0.03,C 1371,,,ABCG2-Overexpressing A549/K1.5 Cell line,A549/K1.5,,,,,human,mbds0010,,2013-11-24 23:56:02
mbbd000143962,mbcd0030126,mbtp000002,mbrf0002192,,=,,,substrate,25,1.0,microM,0.25,C 1335,,,ABCG2-Overexpressing A549/K1.5 Cell line,A549/K1.5,,,,,human,mbds0010,,2013-11-24 23:56:02
mbbd000143963,mbcd0030127,mbtp000002,mbrf0002192,,=,,,substrate,25,31.26,microM,2.55,C 1419,,,ABCG2-Overexpressing A549/K1.5 Cell line,A549/K1.5,,,,,human,mbds0010,,2013-11-24 23:56:02
mbbd000143964,mbcd0030128,mbtp000002,mbrf0002192,,=,,,substrate,25,17.17,microM,1.95,C 1492,,,ABCG2-Overexpressing A549/K1.5 Cell line,A549/K1.5,,,,,human,mbds0010,,2013-11-24 23:56:02
mbbd000143965,mbcd0029999,mbtp000002,mbrf0002192,,=,,,substrate,25,2.34,microM,0.05,C 1311,,,ABCG2-Overexpressing A549/K1.5 Cell line,A549/K1.5,,,,,human,mbds0010,,2013-11-24 23:56:01
mbbd000143966,mbcd0030129,mbtp000002,mbrf0002192,,=,,,substrate,25,9.83,microM,1.44,C 1633,,,ABCG2-Overexpressing A549/K1.5 Cell line,A549/K1.5,,,,,human,mbds0010,,2013-11-24 23:56:01
mbbd000143967,mbcd0030130,mbtp000002,mbrf0002192,,=,,,non-substrate,25,3.46,microM,0.16,C 1315,,,ABCG2-Overexpressing A549/K1.5 Cell line,A549/K1.5,,,,,human,mbds0010,,2013-11-24 23:56:00
mbbd000143968,mbcd0030131,mbtp000002,mbrf0002192,,=,,,non-substrate,25,2.51,microM,0.17,C 1558,,,ABCG2-Overexpressing A549/K1.5 Cell line,A549/K1.5,,,,,human,mbds0010,,2013-11-24 23:55:59
mbbd000143969,mbcd0030132,mbtp000002,mbrf0002192,,=,,,non-substrate,25,3.07,microM,0.8,C 1554,,,ABCG2-Overexpressing A549/K1.5 Cell line,A549/K1.5,,,,,human,mbds0010,,2013-11-24 23:55:59
mbbd000143970,mbcd0030133,mbtp000002,mbrf0002192,,=,,,non-substrate,25,18.27,microM,2.4,C 1213,,,ABCG2-Overexpressing A549/K1.5 Cell line,A549/K1.5,,,,,human,mbds0010,,2013-11-24 23:55:59
mbbd000143971,mbcd0030134,mbtp000002,mbrf0002192,,=,,,non-substrate,25,2.13,microM,0.62,C 2018,,,ABCG2-Overexpressing A549/K1.5 Cell line,A549/K1.5,,,,,human,mbds0010,,2013-11-24 23:55:59
mbbd000143972,mbcd0030135,mbtp000002,mbrf0002192,,=,,,non-substrate,25,1.93,microM,0.84,C 1212,,,ABCG2-Overexpressing A549/K1.5 Cell line,A549/K1.5,,,,,human,mbds0010,,2013-11-24 23:55:58
mbbd000143973,mbcd0030136,mbtp000002,mbrf0002192,,=,,,non-substrate,25,1.25,microM,0.11,C 1375,,,ABCG2-Overexpressing A549/K1.5 Cell line,A549/K1.5,,,,,human,mbds0010,,2013-11-24 23:55:58
mbbd000143974,mbcd0030137,mbtp000002,mbrf0002192,,=,,,non-substrate,25,2.38,microM,0.12,C 1415,,,ABCG2-Overexpressing A549/K1.5 Cell line,A549/K1.5,,,,,human,mbds0010,,2013-11-24 23:55:57
mbbd000143975,mbcd0030138,mbtp000002,mbrf0002192,,=,,,non-substrate,25,3.09,microM,0.74,C 1503,,,ABCG2-Overexpressing A549/K1.5 Cell line,A549/K1.5,,,,,human,mbds0010,,2013-11-24 23:55:56
mbbd000143976,mbcd0030139,mbtp000002,mbrf0002192,,=,,,non-substrate,25,0.68,microM,0.06,C 1379,,,ABCG2-Overexpressing A549/K1.5 Cell line,A549/K1.5,,,,,human,mbds0010,,2013-11-24 23:55:56
mbbd000143977,mbcd0030140,mbtp000002,mbrf0002192,,=,,,non-substrate,25,1.21,microM,0.65,C 1176,,,ABCG2-Overexpressing A549/K1.5 Cell line,A549/K1.5,,,,,human,mbds0010,,2013-11-24 23:55:56
mbbd000143978,mbcd0030141,mbtp000002,mbrf0002192,,=,,,non-substrate,25,0.97,microM,0.08,C 1330,,,ABCG2-Overexpressing A549/K1.5 Cell line,A549/K1.5,,,,,human,mbds0010,,2013-11-24 23:55:56
mbbd000143979,mbcd0030142,mbtp000002,mbrf0002192,,=,,,non-substrate,25,0.56,microM,0.002,C 1266,,,ABCG2-Overexpressing A549/K1.5 Cell line,A549/K1.5,,,,,human,mbds0010,,2013-11-24 23:55:55
mbbd000143980,mbcd0030143,mbtp000002,mbrf0002377,,=,,,substrate,25,0.75,microM,,Compound 8,,,BCRP- KBH5.0 cell line,KBH5.0,,,,,human,mbds0010,,2013-11-24 23:55:55
mbbd000143981,mbcd0030144,mbtp000002,mbrf0002377,,=,,,substrate,25,0.75,microM,,Compound 11,,,BCRP- KBH5.0 cell line,KBH5.0,,,,,human,mbds0010,,2013-11-24 23:55:55
mbbd000143982,mbcd0030145,mbtp000002,mbrf0002377,,=,,,substrate,25,0.28,microM,,Compound 14,,,BCRP- KBH5.0 cell line,KBH5.0,,,,,human,mbds0010,,2013-11-24 23:55:55
mbbd000143983,mbcd0003187,mbtp000002,mbrf0001561,,=,,,substrate,25,11.116,micromol L-1,0.635,Topotecan,,,ABCG2-overexpressing cell line S1-M1-80,S1-M1-80,,,,,human,mbds0010,,2013-11-24 23:55:53
mbbd000143984,mbcd0030146,mbtp000002,mbrf0001561,,=,,,inhibitor,25,1.398,micromol L-1,,Vandetanib,,,ABCG2-overexpressing cell line S1-M1-80,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143985,mbcd0003187,mbtp000002,mbrf0002540,,=,,,substrate,25,206.0,nmol L-1,17.4,Topotecan,,,BCRP -overexpressing Human NSCLC PC-9 cell line,NSCLC PC-9,,,,,human,mbds0010,,2013-11-24 23:55:53
mbbd000143986,mbcd0003125,mbtp000002,mbrf0002540,,=,,,inhibitor,25,26.8,nmol L-1,4.4,Gefitinib,,,BCRP -overexpressing Human NSCLC PC-9 cell line,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143987,mbcd0003125,mbtp000002,mbrf0002540,,~,,,substrate,100,0.1,nmol,0.01,Gefitinib,,,BCRP -overexpressing Human NSCLC PC-9 cell line;Reduction of intracellular gefitinib concentration after 10 minutes incubation,NSCLC PC-9,,0.5,micromol L-1,,human,mbds0010,,2013-11-24 23:55:53
mbbd000143988,mbcd0001539,mbtp000002,mbrf0001668,,=,,,inhibitor,3,78.0,%,,Chlorprotixene,,,Saos-2/wtABCG2 cell line; percentage inhibition of mitoxantrone accumulation,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143989,mbcd0000311,mbtp000002,mbrf0001668,,=,,,inhibitor,3,78.0,%,,Cyclosporin A,,,Saos-2/wtABCG2 cell line; percentage inhibition of mitoxantrone accumulation,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143990,mbcd0000968,mbtp000002,mbrf0001668,,=,,,inhibitor,3,96.0,%,,Diethylstilbestrol,,,Saos-2/wtABCG2 cell line; percentage inhibition of mitoxantrone accumulation,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143991,mbcd0003011,mbtp000002,mbrf0001668,,=,,,inhibitor,3,68.0,%,,Dipyridamole,,,Saos-2/wtABCG2 cell line; percentage inhibition of mitoxantrone accumulation,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143992,mbcd0001322,mbtp000002,mbrf0001668,,=,,,inhibitor,3,73.0,%,,Flupentixol,,,Saos-2/wtABCG2 cell line; percentage inhibition of mitoxantrone accumulation,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143993,mbcd0001808,mbtp000002,mbrf0001668,,=,,,inhibitor,3,96.0,%,,GF120918,,,Saos-2/wtABCG2 cell line; percentage inhibition of mitoxantrone accumulation,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143994,mbcd0000977,mbtp000002,mbrf0001668,,=,,,inhibitor,3,56.0,%,,Isradipine,,,Saos-2/wtABCG2 cell line; percentage inhibition of mitoxantrone accumulation,,,,,,human,mbds0010,,2013-11-20 18:11:06
mbbd000143995,mbcd0002539,mbtp000002,mbrf0001668,,=,,,inhibitor,3,62.0,%,,Loperamide,,,Saos-2/wtABCG2 cell line; percentage inhibition of mitoxantrone accumulation,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143996,mbcd0002241,mbtp000002,mbrf0001668,,=,,,inhibitor,3,66.0,%,,Lopinavir,,,Saos-2/wtABCG2 cell line; percentage inhibition of mitoxantrone accumulation,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143997,mbcd0002494,mbtp000002,mbrf0001668,,=,,,inhibitor,3,70.0,%,,MK-571,,,Saos-2/wtABCG2 cell line; percentage inhibition of mitoxantrone accumulation,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143998,mbcd0003120,mbtp000002,mbrf0001668,,=,,,inhibitor,3,59.0,%,,Quercetin,,,Saos-2/wtABCG2 cell line; percentage inhibition of mitoxantrone accumulation,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000143999,mbcd0001941,mbtp000002,mbrf0001668,,=,,,inhibitor,3,64.0,%,,Reserpine,,,Saos-2/wtABCG2 cell line; percentage inhibition of mitoxantrone accumulation,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144000,mbcd0001938,mbtp000002,mbrf0001668,,=,,,inhibitor,3,59.0,%,,Ritonavir,,,Saos-2/wtABCG2 cell line; percentage inhibition of mitoxantrone accumulation,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144001,mbcd0001533,mbtp000002,mbrf0001668,,=,,,inhibitor,3,67.0,%,,Saquinavir,,,Saos-2/wtABCG2 cell line; percentage inhibition of mitoxantrone accumulation,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144002,mbcd0022617,mbtp000002,mbrf0001668,,=,,,inhibitor,3,52.0,%,,Silymarin,,,Saos-2/wtABCG2 cell line; percentage inhibition of mitoxantrone accumulation,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144003,mbcd0002889,mbtp000002,mbrf0001668,,=,,,inhibitor,3,64.0,%,,Tamoxifen,,,Saos-2/wtABCG2 cell line; percentage inhibition of mitoxantrone accumulation,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144004,mbcd0002337,mbtp000002,mbrf0001668,,=,,,inhibitor,3,51.0,%,,Terfenadine,,,Saos-2/wtABCG2 cell line; percentage inhibition of mitoxantrone accumulation,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144005,mbcd0003143,mbtp000002,mbrf0001668,,=,,,inhibitor,3,69.0,%,,Thioridazine,,,Saos-2/wtABCG2 cell line; percentage inhibition of mitoxantrone accumulation,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144006,mbcd0002192,mbtp000002,mbrf0001668,,=,,,inhibitor,3,63.0,%,,Amiodarone,,,Saos-2/wtABCG2 cell line; percentage inhibition of mitoxantrone accumulation,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144007,mbcd0003055,mbtp000002,mbrf0001668,,=,,,inhibitor,3,58.0,%,,17-beta-estradiol,,,Saos-2/wtABCG2 cell line; percentage inhibition of mitoxantrone accumulation,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144008,mbcd0002340,mbtp000002,mbrf0001668,,=,,,inhibitor,3,63.0,%,,Chlorpromazine,,,Saos-2/wtABCG2 cell line; percentage inhibition of mitoxantrone accumulation,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144009,mbcd0001172,mbtp000002,mbrf0001668,,=,,,inhibitor,3,102.0,%,,Ivermectin,,,Saos-2/wtABCG2 cell line; percentage inhibition of mitoxantrone accumulation,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144010,mbcd0003034,mbtp000002,mbrf0001668,,=,,,inhibitor,3,133.0,%,,Benzbromarone,,,Saos-2/wtABCG2 cell line; percentage inhibition of mitoxantrone accumulation,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144011,mbcd0003091,mbtp000002,mbrf0001668,,=,,,inhibitor,3,102.0,%,,Apigenin,,,Saos-2/wtABCG2 cell line; percentage inhibition of mitoxantrone accumulation,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144012,mbcd0003026,mbtp000002,mbrf0001668,,=,,,inhibitor,3,125.0,%,,Biochanin A,,,Saos-2/wtABCG2 cell line; percentage inhibition of mitoxantrone accumulation,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144013,mbcd0003045,mbtp000002,mbrf0001668,,=,,,inhibitor,3,106.0,%,,Chrysin,,,Saos-2/wtABCG2 cell line; percentage inhibition of mitoxantrone accumulation,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144014,mbcd0002994,mbtp000002,mbrf0001668,,=,,,inhibitor,3,115.0,%,,Ergocristine,,,Saos-2/wtABCG2 cell line; percentage inhibition of mitoxantrone accumulation,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144015,mbcd0003011,mbtp000002,mbrf0001668,,=,,,inhibitor,3,92.0,%,,Felodipine,,,Saos-2/wtABCG2 cell line; percentage inhibition of mitoxantrone accumulation,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144016,mbcd0003125,mbtp000002,mbrf0001668,,=,,,inhibitor,3,100.0,%,,Gefitinib,,,Saos-2/wtABCG2 cell line; percentage inhibition of mitoxantrone accumulation,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144017,mbcd0003116,mbtp000002,mbrf0001668,,=,,,inhibitor,3,58.0,%,,Genistein,,,Saos-2/wtABCG2 cell line; percentage inhibition of mitoxantrone accumulation,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144018,mbcd0003074,mbtp000002,mbrf0001668,,=,,,inhibitor,3,92.0,%,,Glibenclamide,,,Saos-2/wtABCG2 cell line; percentage inhibition of mitoxantrone accumulation,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144019,mbcd0000482,mbtp000002,mbrf0001668,,=,,,inhibitor,3,100.0,%,,Imatinib mesylate,,,Saos-2/wtABCG2 cell line; percentage inhibition of mitoxantrone accumulation,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144020,mbcd0017104,mbtp000002,mbrf0001668,,=,,,inhibitor,3,80.0,%,,Ketoconazole,,,Saos-2/wtABCG2 cell line; percentage inhibition of mitoxantrone accumulation,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144021,mbcd0002439,mbtp000002,mbrf0001668,,=,,,inhibitor,3,97.0,%,,Ko143,,,Saos-2/wtABCG2 cell line; percentage inhibition of mitoxantrone accumulation,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144022,mbcd0001173,mbtp000002,mbrf0001668,,=,,,inhibitor,3,63.0,%,,Medroxyprogesterone,,,Saos-2/wtABCG2 cell line; percentage inhibition of mitoxantrone accumulation,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144023,mbcd0001299,mbtp000002,mbrf0001668,,=,,,inhibitor,3,53.0,%,,Mifepristone,,,Saos-2/wtABCG2 cell line; percentage inhibition of mitoxantrone accumulation,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144024,mbcd0002576,mbtp000002,mbrf0001668,,=,,,inhibitor,3,101.0,%,,Nicardipine,,,Saos-2/wtABCG2 cell line; percentage inhibition of mitoxantrone accumulation,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144025,mbcd0003135,mbtp000002,mbrf0001668,,=,,,inhibitor,3,75.0,%,,Nitrendipine,,,Saos-2/wtABCG2 cell line; percentage inhibition of mitoxantrone accumulation,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144026,mbcd0001194,mbtp000002,mbrf0001668,,=,,,inhibitor,3,64.0,%,,Simvastatin,,,Saos-2/wtABCG2 cell line; percentage inhibition of mitoxantrone accumulation,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144027,mbcd0001350,mbtp000002,mbrf0001668,,=,,,inhibitor,3,92.0,%,,Tipranavir,,,Saos-2/wtABCG2 cell line; percentage inhibition of mitoxantrone accumulation,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144028,mbcd0027062,mbtp000002,mbrf0001668,,=,,,inhibitor,3,71.0,%,,Verapamil,,,Saos-2/wtABCG2 cell line; percentage inhibition of mitoxantrone accumulation,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144029,mbcd0003144,mbtp000002,mbrf0001668,,=,,,inhibitor,3,51.0,%,,Amodiaquine,,,Saos-2/wtABCG2 cell line; percentage inhibition of mitoxantrone accumulation,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144030,mbcd0002422,mbtp000002,mbrf0001668,,=,,,inhibitor,3,77.0,%,,Fumitremorgin C,,,Saos-2/wtABCG2 cell line; percentage inhibition of mitoxantrone accumulation,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144031,mbcd0000474,mbtp000002,mbrf0001668,,=,,,inhibitor,3,60.0,%,,Hoechst 33342,,,Saos-2/wtABCG2 cell line; percentage inhibition of mitoxantrone accumulation,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144032,mbcd0002981,mbtp000002,mbrf0001668,,,,,inhibitor,,,,,Mitoxantrone,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144033,mbcd0003096,mbtp000002,mbrf0001668,,=,,,inhibitor,3,57.0,%,,Naringenin,,,Saos-2/wtABCG2 cell line; percentage inhibition of mitoxantrone accumulation,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144034,mbcd0001021,mbtp000002,mbrf0001668,,=,,,inhibitor,3,56.0,%,,Omeprazole,,,Saos-2/wtABCG2 cell line; percentage inhibition of mitoxantrone accumulation,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144035,mbcd0003024,mbtp000002,mbrf0001668,,=,,,inhibitor,3,68.0,%,,Prazosin,,,Saos-2/wtABCG2 cell line; percentage inhibition of mitoxantrone accumulation,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144036,mbcd0001892,mbtp000002,mbrf0001668,,=,,,inhibitor,3,56.0,%,,Progesterone,,,Saos-2/wtABCG2 cell line; percentage inhibition of mitoxantrone accumulation,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144037,mbcd0030147,mbtp000002,mbrf0002209,,>,,,inhibitor,25,24.0,microM,,PZ-39,,,ABCG2-overexpressing HEK-293 cell line,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144038,mbcd0030147,mbtp000002,mbrf0002209,,~,,,inhibitor,100,3.5,fold increase,0.5,PZ-39,,,ABCG2-overexpressing HEK-293 cell line; measuring fold change in intracellular mitoxantrone accumulation following 30 minute incubation,,,3.3,microM,,human,mbds0010,,2014-03-04 00:29:00
mbbd000144039,mbcd0030148,mbtp000002,mbrf0002209,,~,,,inhibitor,100,3.0,fold increase,0.4,C6,,,ABCG2-overexpressing HEK-293 cell line; measuring fold change in intracellular mitoxantrone accumulation,,,3,microM,,human,mbds0010,,2014-03-04 00:29:00
mbbd000144040,mbcd0030149,mbtp000002,mbrf0002209,,~,,,inhibitor,100,2.5,fold increase,0.2,C8,,,ABCG2-overexpressing HEK-293 cell line; measuring fold change in intracellular mitoxantrone accumulation,,,3,microM,,human,mbds0010,,2014-03-04 00:29:00
mbbd000144041,mbcd0030150,mbtp000002,mbrf0002209,,~,,,inhibitor,100,3.2,fold increase,0.2,E2,,,HEK293 cells,HEK293,mbcd0002981,3,microM,,human,mbds0010,,2013-11-10 04:16:05
mbbd000144042,mbcd0003125,mbtp000002,mbrf0002244,,=,,,substrate,14,1906.0,nm s-1,,Gefitinib,,,BCRP-overexpressing MDCK II cell line; drug transport from basolateral to apical compartment,MDCKII,,1,microM,,human,mbds0010,,2013-11-24 23:12:00
mbbd000144043,mbcd0030146,mbtp000002,mbrf0002244,,=,,,substrate,14,1848.0,nm s-1,,Vandetanib,,,BCRP-overexpressing MDCK II cell line; drug transport from basolateral to apical compartment,MDCKII,,1,microM,,human,mbds0010,,2013-11-24 23:12:00
mbbd000144044,mbcd0003125,mbtp000002,mbrf0002244,,=,,,inhibitor,17,3.0,microM,,Gefitinib,,,Caco-2 cell line; mitoxantrone trnsport inhibition,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144045,mbcd0030146,mbtp000002,mbrf0002244,,=,,,inhibitor,3,1.2,microM,,Vandetanib,,,Caco-2 cell line; mitoxantrone transport inhibition,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144046,mbcd0029345,mbtp000002,mbrf0001745,,~,,,substrate,100,0.3,pmol oocyte-1 (120 min)-1,0.01,Urate,,,urate accumulation data from Xenopus oocytes injected with mRNA encoding ABCG2,Xenopus laevis oocytes,,,,,human,mbds0010,,2013-11-24 23:15:09
mbbd000144049,mbcd0030153,mbtp000002,mbrf0002062,,=,,,inhibitor,25,4.57,microM,0.05,Enniatin B,,,(ABCG2)-transfected subclone MDA-MB-231/bcrp cell line,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144050,mbcd0030154,mbtp000002,mbrf0002062,,=,,,inhibitor,25,4.0,microM,0.76,Beauvericin,,,(ABCG2)-transfected subclone MDA-MB-231/bcrp cell line,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144051,mbcd0003078,mbtp000002,mbrf0002529,,,,,substrate,,,,,Gutathione; GSH,,,Intracellular GSH production was stimulated by 15dPGJ2 and efflux was measured in a competition assay with Hoechst33342,MDA 1586,,,,,human,mbds0010,,2013-10-09 22:18:41
mbbd000144052,mbcd0003026,mbtp000002,mbrf0002401,,,,,inhibitor,,,,,Biochanin A,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144053,mbcd0003045,mbtp000002,mbrf0002401,,,,,inhibitor,,,,,Chrysin,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144054,mbcd0003116,mbtp000002,mbrf0002401,,,,,substrate,,,,,Genistein,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144055,mbcd0003215,mbtp000002,mbrf0002401,,,,,inhibitor,,,,,Kaempferol,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144056,mbcd0003096,mbtp000002,mbrf0002401,,,,,inhibitor,,,,,Naringenin,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144057,mbcd0003120,mbtp000002,mbrf0002401,,,,,substrate,,,,,Quercetin,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144058,mbcd0030155,mbtp000002,mbrf0001924,,=,,,inhibitor,25,6.9,microM,0.5,botryllamide G,,,ABCG2-overexpressing NCI-H460 MX20 cell line,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144059,mbcd0030156,mbtp000002,mbrf0001924,,=,,,inhibitor,25,11.2,microM,0.6,Botryllamide B,,,ABCG2-overexpressing NCI-H460 MX20 cell line,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144060,mbcd0030157,mbtp000002,mbrf0001924,,=,,,inhibitor,25,16.4,microM,2.3,Botryllamide D,,,ABCG2-overexpressing NCI-H460 MX20 cell line,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144061,mbcd0030158,mbtp000002,mbrf0001924,,=,,,inhibitor,25,16.7,microM,0.8,Botryllamide F,,,ABCG2-overexpressing NCI-H460 MX20 cell line,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144062,mbcd0030159,mbtp000002,mbrf0001924,,=,,,inhibitor,25,33.4,microM,6.7,Botryllamide A,,,ABCG2-overexpressing NCI-H460 MX20 cell line,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144063,mbcd0003125,mbtp000002,mbrf0002487,,=,,,inhibitor,123,19.0,,,Gefitinib,,,"HEK293/ABCG2/fLuc stable cell line; signal-to-background (S/B) ratio of the light output from each compound divided by that from the control well was calculated; S/B ratio serves as an indicator of the potency of ABCG2 inhibition, the mechanism by which BLI signal is enhanced",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144064,mbcd0006203,mbtp000002,mbrf0002487,,=,,,inhibitor,123,8.9,,,Harmine,,,"HEK293/ABCG2/fLuc stable cell line; signal-to-background (S/B) ratio of the light output from each compound divided by that from the control well was calculated; S/B ratio serves as an indicator of the potency of ABCG2 inhibition, the mechanism by which BLI signal is enhanced",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144065,mbcd0003024,mbtp000002,mbrf0002487,,=,,,inhibitor,123,8.4,,,Prazosin,,,"HEK293/ABCG2/fLuc stable cell line; signal-to-background (S/B) ratio of the light output from each compound divided by that from the control well was calculated; S/B ratio serves as an indicator of the potency of ABCG2 inhibition, the mechanism by which BLI signal is enhanced",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144066,mbcd0003100,mbtp000002,mbrf0002487,,=,,,inhibitor,123,7.1,,,Dipyridamole,,,"HEK293/ABCG2/fLuc stable cell line; signal-to-background (S/B) ratio of the light output from each compound divided by that from the control well was calculated; S/B ratio serves as an indicator of the potency of ABCG2 inhibition, the mechanism by which BLI signal is enhanced",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144067,mbcd0000303,mbtp000002,mbrf0002487,,=,,,inhibitor,123,6.3,,,Curcumin,,,"HEK293/ABCG2/fLuc stable cell line; signal-to-background (S/B) ratio of the light output from each compound divided by that from the control well was calculated; S/B ratio serves as an indicator of the potency of ABCG2 inhibition, the mechanism by which BLI signal is enhanced",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144068,mbcd0026632,mbtp000002,mbrf0002487,,=,,,inhibitor,123,6.1,,,nelfinavir mesylate,,,"HEK293/ABCG2/fLuc stable cell line; signal-to-background (S/B) ratio of the light output from each compound divided by that from the control well was calculated; S/B ratio serves as an indicator of the potency of ABCG2 inhibition, the mechanism by which BLI signal is enhanced",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144069,mbcd0029891,mbtp000002,mbrf0002487,,=,,,inhibitor,123,5.9,,,niguldipine,,,"HEK293/ABCG2/fLuc stable cell line; signal-to-background (S/B) ratio of the light output from each compound divided by that from the control well was calculated; S/B ratio serves as an indicator of the potency of ABCG2 inhibition, the mechanism by which BLI signal is enhanced",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144070,mbcd0025627,mbtp000002,mbrf0002487,,=,,,inhibitor,123,5.4,,,riboflavin,,,"HEK293/ABCG2/fLuc stable cell line; signal-to-background (S/B) ratio of the light output from each compound divided by that from the control well was calculated; S/B ratio serves as an indicator of the potency of ABCG2 inhibition, the mechanism by which BLI signal is enhanced",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144071,mbcd0001941,mbtp000002,mbrf0002487,,=,,,inhibitor,123,5.4,,,reserpine,,,"HEK293/ABCG2/fLuc stable cell line; signal-to-background (S/B) ratio of the light output from each compound divided by that from the control well was calculated; S/B ratio serves as an indicator of the potency of ABCG2 inhibition, the mechanism by which BLI signal is enhanced",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144072,mbcd0004749,mbtp000002,mbrf0002487,,=,,,inhibitor,123,5.0,,,hesperetin,,,"HEK293/ABCG2/fLuc stable cell line; signal-to-background (S/B) ratio of the light output from each compound divided by that from the control well was calculated; S/B ratio serves as an indicator of the potency of ABCG2 inhibition, the mechanism by which BLI signal is enhanced",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144073,mbcd0027689,mbtp000002,mbrf0002487,,=,,,inhibitor,123,20.6,,,Glafenine,,,"HEK293/ABCG2/fLuc stable cell line; signal-to-background (S/B) ratio of the light output from each compound divided by that from the control well was calculated; S/B ratio serves as an indicator of the potency of ABCG2 inhibition, the mechanism by which BLI signal is enhanced",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144074,mbcd0005410,mbtp000002,mbrf0002487,,=,,,inhibitor,123,20.0,,,tracazolate,,,"HEK293/ABCG2/fLuc stable cell line; signal-to-background (S/B) ratio of the light output from each compound divided by that from the control well was calculated; S/B ratio serves as an indicator of the potency of ABCG2 inhibition, the mechanism by which BLI signal is enhanced",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144075,mbcd0015709,mbtp000002,mbrf0002487,,=,,,inhibitor,123,16.9,,,calcimycin,,,"HEK293/ABCG2/fLuc stable cell line; signal-to-background (S/B) ratio of the light output from each compound divided by that from the control well was calculated; S/B ratio serves as an indicator of the potency of ABCG2 inhibition, the mechanism by which BLI signal is enhanced",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144076,mbcd0030160,mbtp000002,mbrf0002487,,=,,,inhibitor,123,15.9,,,doxazosin mesylate,,,"HEK293/ABCG2/fLuc stable cell line; signal-to-background (S/B) ratio of the light output from each compound divided by that from the control well was calculated; S/B ratio serves as an indicator of the potency of ABCG2 inhibition, the mechanism by which BLI signal is enhanced",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144077,mbcd0029996,mbtp000002,mbrf0002487,,=,,,inhibitor,123,11.3,,,verteporfin,,,"HEK293/ABCG2/fLuc stable cell line; signal-to-background (S/B) ratio of the light output from each compound divided by that from the control well was calculated; S/B ratio serves as an indicator of the potency of ABCG2 inhibition, the mechanism by which BLI signal is enhanced",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144078,mbcd0030161,mbtp000002,mbrf0002487,,=,,,inhibitor,123,11.2,,,flavoxate hydrochloride,,,"HEK293/ABCG2/fLuc stable cell line; signal-to-background (S/B) ratio of the light output from each compound divided by that from the control well was calculated; S/B ratio serves as an indicator of the potency of ABCG2 inhibition, the mechanism by which BLI signal is enhanced",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144079,mbcd0030027,mbtp000002,mbrf0002487,,=,,,inhibitor,123,11.1,,,Brij 30,,,"HEK293/ABCG2/fLuc stable cell line; signal-to-background (S/B) ratio of the light output from each compound divided by that from the control well was calculated; S/B ratio serves as an indicator of the potency of ABCG2 inhibition, the mechanism by which BLI signal is enhanced",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144080,mbcd0026257,mbtp000002,mbrf0002487,,=,,,inhibitor,123,10.6,,,quinacrine,,,"HEK293/ABCG2/fLuc stable cell line; signal-to-background (S/B) ratio of the light output from each compound divided by that from the control well was calculated; S/B ratio serves as an indicator of the potency of ABCG2 inhibition, the mechanism by which BLI signal is enhanced",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144081,mbcd0030162,mbtp000002,mbrf0002487,,=,,,inhibitor,123,9.6,,,dihydroergotamine mesylate,,,"HEK293/ABCG2/fLuc stable cell line; signal-to-background (S/B) ratio of the light output from each compound divided by that from the control well was calculated; S/B ratio serves as an indicator of the potency of ABCG2 inhibition, the mechanism by which BLI signal is enhanced",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144082,mbcd0008152,mbtp000002,mbrf0002487,,=,,,inhibitor,123,8.8,,,harmaline,,,"HEK293/ABCG2/fLuc stable cell line; signal-to-background (S/B) ratio of the light output from each compound divided by that from the control well was calculated; S/B ratio serves as an indicator of the potency of ABCG2 inhibition, the mechanism by which BLI signal is enhanced",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144083,mbcd0030163,mbtp000002,mbrf0002487,,=,,,inhibitor,123,7.9,,,clebopride maleate,,,"HEK293/ABCG2/fLuc stable cell line; signal-to-background (S/B) ratio of the light output from each compound divided by that from the control well was calculated; S/B ratio serves as an indicator of the potency of ABCG2 inhibition, the mechanism by which BLI signal is enhanced",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144084,mbcd0004713,mbtp000002,mbrf0002487,,=,,,inhibitor,123,7.0,,,isorhamnetin,,,"HEK293/ABCG2/fLuc stable cell line; signal-to-background (S/B) ratio of the light output from each compound divided by that from the control well was calculated; S/B ratio serves as an indicator of the potency of ABCG2 inhibition, the mechanism by which BLI signal is enhanced",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144085,mbcd0012083,mbtp000002,mbrf0002487,,=,,,inhibitor,123,6.7,,,clebopride,,,"HEK293/ABCG2/fLuc stable cell line; signal-to-background (S/B) ratio of the light output from each compound divided by that from the control well was calculated; S/B ratio serves as an indicator of the potency of ABCG2 inhibition, the mechanism by which BLI signal is enhanced",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144086,mbcd0003009,mbtp000002,mbrf0002487,,=,,,inhibitor,123,6.7,,,rotenone,,,"HEK293/ABCG2/fLuc stable cell line; signal-to-background (S/B) ratio of the light output from each compound divided by that from the control well was calculated; S/B ratio serves as an indicator of the potency of ABCG2 inhibition, the mechanism by which BLI signal is enhanced",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144087,mbcd0030164,mbtp000002,mbrf0002487,,=,,,inhibitor,123,6.7,,,clomiphene citrate,,,"HEK293/ABCG2/fLuc stable cell line; signal-to-background (S/B) ratio of the light output from each compound divided by that from the control well was calculated; S/B ratio serves as an indicator of the potency of ABCG2 inhibition, the mechanism by which BLI signal is enhanced",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144088,mbcd0025660,mbtp000002,mbrf0002487,,=,,,inhibitor,123,6.6,,,sildenafil,,,"HEK293/ABCG2/fLuc stable cell line; signal-to-background (S/B) ratio of the light output from each compound divided by that from the control well was calculated; S/B ratio serves as an indicator of the potency of ABCG2 inhibition, the mechanism by which BLI signal is enhanced",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144089,mbcd0022727,mbtp000002,mbrf0002487,,=,,,inhibitor,123,6.4,,,emodin,,,"HEK293/ABCG2/fLuc stable cell line; signal-to-background (S/B) ratio of the light output from each compound divided by that from the control well was calculated; S/B ratio serves as an indicator of the potency of ABCG2 inhibition, the mechanism by which BLI signal is enhanced",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144090,mbcd0030165,mbtp000002,mbrf0002487,,=,,,inhibitor,123,6.3,,,flubendazole,,,"HEK293/ABCG2/fLuc stable cell line; signal-to-background (S/B) ratio of the light output from each compound divided by that from the control well was calculated; S/B ratio serves as an indicator of the potency of ABCG2 inhibition, the mechanism by which BLI signal is enhanced",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144091,mbcd0012596,mbtp000002,mbrf0002487,,=,,,inhibitor,123,6.3,,,flubendazole,,,"HEK293/ABCG2/fLuc stable cell line; signal-to-background (S/B) ratio of the light output from each compound divided by that from the control well was calculated; S/B ratio serves as an indicator of the potency of ABCG2 inhibition, the mechanism by which BLI signal is enhanced",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144092,mbcd0030166,mbtp000002,mbrf0002487,,=,,,inhibitor,123,6.3,,,Periciazine,,,"HEK293/ABCG2/fLuc stable cell line; signal-to-background (S/B) ratio of the light output from each compound divided by that from the control well was calculated; S/B ratio serves as an indicator of the potency of ABCG2 inhibition, the mechanism by which BLI signal is enhanced",HEK293,mbcd0003043,,,,human,mbds0010,,2013-12-09 07:04:49
mbbd000144093,mbcd0030167,mbtp000002,mbrf0002487,,=,,,inhibitor,123,6.2,,,isoreserpine,,,"HEK293/ABCG2/fLuc stable cell line; signal-to-background (S/B) ratio of the light output from each compound divided by that from the control well was calculated; S/B ratio serves as an indicator of the potency of ABCG2 inhibition, the mechanism by which BLI signal is enhanced",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144094,mbcd0012778,mbtp000002,mbrf0002487,,=,,,inhibitor,123,6.2,,,acepromazine,,,"HEK293/ABCG2/fLuc stable cell line; signal-to-background (S/B) ratio of the light output from each compound divided by that from the control well was calculated; S/B ratio serves as an indicator of the potency of ABCG2 inhibition, the mechanism by which BLI signal is enhanced",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144095,mbcd0003044,mbtp000002,mbrf0002487,,=,,,inhibitor,123,6.1,,,flutamide,,,"HEK293/ABCG2/fLuc stable cell line; signal-to-background (S/B) ratio of the light output from each compound divided by that from the control well was calculated; S/B ratio serves as an indicator of the potency of ABCG2 inhibition, the mechanism by which BLI signal is enhanced",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144096,mbcd0030168,mbtp000002,mbrf0002487,,=,,,inhibitor,123,6.0,,,gambogic acid,,,"HEK293/ABCG2/fLuc stable cell line; signal-to-background (S/B) ratio of the light output from each compound divided by that from the control well was calculated; S/B ratio serves as an indicator of the potency of ABCG2 inhibition, the mechanism by which BLI signal is enhanced",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144097,mbcd0021750,mbtp000002,mbrf0002487,,=,,,inhibitor,123,5.8,,,piperacetazine,,,"HEK293/ABCG2/fLuc stable cell line; signal-to-background (S/B) ratio of the light output from each compound divided by that from the control well was calculated; S/B ratio serves as an indicator of the potency of ABCG2 inhibition, the mechanism by which BLI signal is enhanced",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144098,mbcd0001581,mbtp000002,mbrf0002487,,=,,,inhibitor,123,5.7,,,digitoxin,,,"HEK293/ABCG2/fLuc stable cell line; signal-to-background (S/B) ratio of the light output from each compound divided by that from the control well was calculated; S/B ratio serves as an indicator of the potency of ABCG2 inhibition, the mechanism by which BLI signal is enhanced",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144099,mbcd0030169,mbtp000002,mbrf0002487,,=,,,inhibitor,123,5.6,,,acetophenazine maleate,,,"HEK293/ABCG2/fLuc stable cell line; signal-to-background (S/B) ratio of the light output from each compound divided by that from the control well was calculated; S/B ratio serves as an indicator of the potency of ABCG2 inhibition, the mechanism by which BLI signal is enhanced",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144100,mbcd0004771,mbtp000002,mbrf0002487,,=,,,inhibitor,123,5.6,,,eupatorin,,,"HEK293/ABCG2/fLuc stable cell line; signal-to-background (S/B) ratio of the light output from each compound divided by that from the control well was calculated; S/B ratio serves as an indicator of the potency of ABCG2 inhibition, the mechanism by which BLI signal is enhanced",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144101,mbcd0030170,mbtp000002,mbrf0002487,,=,,,inhibitor,123,5.4,,,estrone hemisuccinate,,,"HEK293/ABCG2/fLuc stable cell line; signal-to-background (S/B) ratio of the light output from each compound divided by that from the control well was calculated; S/B ratio serves as an indicator of the potency of ABCG2 inhibition, the mechanism by which BLI signal is enhanced",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144102,mbcd0030171,mbtp000002,mbrf0002487,,=,,,inhibitor,123,5.4,,,raloxifene hydrochloride,,,"HEK293/ABCG2/fLuc stable cell line; signal-to-background (S/B) ratio of the light output from each compound divided by that from the control well was calculated; S/B ratio serves as an indicator of the potency of ABCG2 inhibition, the mechanism by which BLI signal is enhanced",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144103,mbcd0000642,mbtp000002,mbrf0002487,,,,,inhibitor,,,,,oligomycin,,,"HEK293/ABCG2/fLuc stable cell line; signal-to-background (S/B) ratio of the light output from each compound divided by that from the control well was calculated; S/B ratio serves as an indicator of the potency of ABCG2 inhibition, the mechanism by which BLI signal is enhanced",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144104,mbcd0030172,mbtp000002,mbrf0002201,,,,,inhibitor,,,,,JA1-51,,,HCT116 cells,HCT116,mbcd0002981,10,microM,,human,mbds0010,,2013-11-10 04:16:02
mbbd000144105,mbcd0003129,mbtp000002,mbrf0002372,,,,,substrate,,,,,Phenethyl isothiocyanate,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144106,mbcd0000779,mbtp000002,mbrf0002510,,=,,,substrate,135,262.0,,,SN 38,,,SN-38-resistant PC-6/SN2-5H2 cell line,PC-6/SN2-5H2,,,,,human,mbds0010,,2013-11-24 23:55:52
mbbd000144107,mbcd0029945,mbtp000002,mbrf0002510,,=,,,substrate,135,105.0,,,SN 355,,,SN-38-resistant PC-6/SN2-5H2 cell line,PC-6/SN2-5H2,,,,,human,mbds0010,,2013-11-24 23:55:52
mbbd000144108,mbcd0029947,mbtp000002,mbrf0002510,,=,,,substrate,135,55.0,,,SN 392,,,SN-38-resistant PC-6/SN2-5H2 cell line,PC-6/SN2-5H2,,,,,human,mbds0010,,2013-11-24 23:55:52
mbbd000144109,mbcd0029949,mbtp000002,mbrf0002510,,=,,,substrate,135,213.0,,,SN 398,,,SN-38-resistant PC-6/SN2-5H2 cell line,PC-6/SN2-5H2,,,,,human,mbds0010,,2013-11-24 23:55:52
mbbd000144110,mbcd0030173,mbtp000002,mbrf0002510,,,,,inhibitor,,,,,TAG-5,,,,,,,,,human,mbds0010,,2013-12-05 21:58:34
mbbd000144111,mbcd0029960,mbtp000002,mbrf0002510,,,,,inhibitor,,,,,TAG-11,,,,,,,,,human,mbds0010,,2013-12-05 21:58:34
mbbd000144112,mbcd0030175,mbtp000002,mbrf0002510,,,,,inhibitor,,,,,TAG-72,,,,,,,,,human,mbds0010,,2013-12-05 02:25:20
mbbd000144113,mbcd0030176,mbtp000002,mbrf0002510,,,,,inhibitor,,,,,TAG-126,,,,,,,,,human,mbds0010,,2013-12-05 21:58:34
mbbd000144114,mbcd0029961,mbtp000002,mbrf0002510,,,,,inhibitor,,,,,TAG-139,,,,,,,,,human,mbds0010,,2013-12-05 21:58:34
mbbd000144115,mbcd0030178,mbtp000002,mbrf0002091,,=,,,substrate,129,47.0,,,NSC107392,,,ABCG2- overexpressing HEK-293 cell line; Relative resistance values were calculated by dividing the IC50 for each compound in the ABCG2-transfected cells by the IC50 for each compound in the empty vector-transfected cells,HEK293,,,,,human,mbds0010,,2013-12-09 20:52:33
mbbd000144116,mbcd0030179,mbtp000002,mbrf0002091,,=,,,substrate,129,98.0,,,NSC 265473,,,ABCG2- overexpressing HEK-293 cell line; Relative resistance values were calculated by dividing the IC50 for each compound in the ABCG2-transfected cells by the IC50 for each compound in the empty vector-transfected cells,HEK293,,,,,human,mbds0010,,2013-12-09 20:52:33
mbbd000144117,mbcd0025729,mbtp000002,mbrf0002091,,=,,,substrate,129,37.0,,,NSC 349156,,,ABCG2- overexpressing HEK-293 cell line; Relative resistance values were calculated by dividing the IC50 for each compound in the ABCG2-transfected cells by the IC50 for each compound in the empty vector-transfected cells,HEK293,,,,,human,mbds0010,,2013-12-09 19:56:42
mbbd000144118,mbcd0030180,mbtp000002,mbrf0002091,,=,,,inhibitor,3,78.0,%,,NSC 24048,,,"Crude membranes from MCF-7 FLV1000 cell line; measuring their ability to prevent binding of the radiolabeled, photo-cross-linkable analog of prazosin, [125I]IAAP, to ABCG2; results reported as the percentage inhibition of ABCG2 labeling",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144119,mbcd0030181,mbtp000002,mbrf0002091,,=,,,inhibitor,3,85.0,%,,NSC 45384,,,"Crude membranes from MCF-7 FLV1000 cell line; measuring their ability to prevent binding of the radiolabeled, photo-cross-linkable analog of prazosin, [125I]IAAP, to ABCG2; results reported as the percentage inhibition of ABCG2 labeling",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144120,mbcd0030182,mbtp000002,mbrf0002091,,=,,,inhibitor,3,81.0,%,,NSC103054,,,"Crude membranes from MCF-7 FLV1000 cell line; measuring their ability to prevent binding of the radiolabeled, photo-cross-linkable analog of prazosin, [125I]IAAP, to ABCG2; results reported as the percentage inhibition of ABCG2 labeling",,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144121,mbcd0030183,mbtp000002,mbrf0002091,,=,,,inhibitor,3,15.0,%,,NSC 636795,,,"Crude membranes from MCF-7 FLV1000 cell line; measuring their ability to prevent binding of the radiolabeled, photo-cross-linkable analog of prazosin, [125I]IAAP, to ABCG2; results reported as the percentage inhibition of ABCG2 labeling",,,,,,human,mbds0010,,2014-03-04 00:28:49
mbbd000144122,mbcd0000594,mbtp000002,mbrf0001886,,,,,inhibitor,,,,,Dofequidar fumarate,,,Membrane vesicles of Sf9 insect cells,Sf9,mbcd0003043,1-30,microM,,human,mbds0010,,2013-10-09 22:18:32
mbbd000144123,mbcd0030185,mbtp000002,mbrf0002353,,,,,substrate,,,,,4-nitrophenyl sulfate,,,BeWo cells,BeWo,,1,microM,,human,mbds0010,,2013-11-10 04:16:01
mbbd000144124,mbcd0030186,mbtp000002,mbrf0002353,,,,,substrate,,,,,acetaminophen sulfate,,,BeWo cells,BeWo,,250,microM,,human,mbds0010,,2013-11-10 04:16:01
mbbd000144125,mbcd0030187,mbtp000002,mbrf0002129,,=,,,substrate,17,1.1,microM,,Malvidin,,,human BCRP transporter-expressing Spodoptera frugiperda (Sf9) ovarian cell line,Sf9,,,,,human,mbds0010,,2013-11-24 23:54:54
mbbd000144126,mbcd0010117,mbtp000002,mbrf0002129,,=,,,substrate,17,3.3,microM,,Petunidin,,,human BCRP transporter-expressing Spodoptera frugiperda (Sf9) ovarian cell line,Sf9,,,,,human,mbds0010,,2013-11-24 23:54:54
mbbd000144127,mbcd0030188,mbtp000002,mbrf0002129,,=,,,substrate,17,6.3,microM,,malvidin-3-galactoside,,,human BCRP transporter-expressing Spodoptera frugiperda (Sf9) ovarian cell line,Sf9,,,,,human,mbds0010,,2013-11-24 23:54:55
mbbd000144128,mbcd0030189,mbtp000002,mbrf0002129,,=,,,substrate,17,12.0,microM,,"malvidin-3,5-diglucoside",,,human BCRP transporter-expressing Spodoptera frugiperda (Sf9) ovarian cell line,Sf9,,,,,human,mbds0010,,2013-11-24 23:54:55
mbbd000144129,mbcd0030190,mbtp000002,mbrf0002129,,=,,,substrate,17,15.0,microM,,cyanidin-3-galactoside,,,human BCRP transporter-expressing Spodoptera frugiperda (Sf9) ovarian cell line,Sf9,,,,,human,mbds0010,,2013-11-24 23:54:55
mbbd000144130,mbcd0030191,mbtp000002,mbrf0002129,,=,,,substrate,17,45.0,microM,,peonidin-3- glucoside,,,human BCRP transporter-expressing Spodoptera frugiperda (Sf9) ovarian cell line,Sf9,,,,,human,mbds0010,,2013-11-24 23:54:55
mbbd000144131,mbcd0030192,mbtp000002,mbrf0002129,,=,,,substrate,17,119.0,microM,,cyanidin-3-glucoside,,,human BCRP transporter-expressing Spodoptera frugiperda (Sf9) ovarian cell line,Sf9,,,,,human,mbds0010,,2013-11-24 23:54:55
mbbd000144132,mbcd0030193,mbtp000002,mbrf0002129,,=,,,inhibitor,25,5.0,microM,,Cyanidin,,,Membrane vesicles in the inside-out orientation prepared from overexpressing human BCRP transporter baculovirus-infected Sf9 cell line,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144133,mbcd0030194,mbtp000002,mbrf0002129,,=,,,inhibitor,17,4.0,microM,,peonidin,,,Membrane vesicles in the inside-out orientation prepared from overexpressing human BCRP transporter baculovirus-infected Sf9 cell line,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144134,mbcd0030195,mbtp000002,mbrf0002129,,=,,,inhibitor,25,83.0,microM,,"cyanidin-3,5-diglucoside",,,Membrane vesicles in the inside-out orientation prepared from overexpressing human BCRP transporter baculovirus-infected Sf9 cell line,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144135,mbcd0030187,mbtp000002,mbrf0002129,,=,,,inhibitor,25,3.0,microM,,Malvidin,Inhibitory activity at high concentrations only,,Membrane vesicles in the inside-out orientation prepared from overexpressing human BCRP transporter baculovirus-infected Sf9 cell line,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144136,mbcd0030196,mbtp000002,mbrf0002129,,=,,,inhibitor,25,17.0,microM,,pelargonidin,,,Membrane vesicles in the inside-out orientation prepared from overexpressing human BCRP transporter baculovirus-infected Sf9 cell line,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144137,mbcd0030197,mbtp000002,mbrf0002129,,=,,,inhibitor,25,13.0,microM,,delphinidin,,,Membrane vesicles in the inside-out orientation prepared from overexpressing human BCRP transporter baculovirus-infected Sf9 cell line,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144138,mbcd0010117,mbtp000002,mbrf0002129,,=,,,inhibitor,25,5.0,microM,,petunidin,Inhibitory activity at high concentrations only,,Membrane vesicles in the inside-out orientation prepared from overexpressing human BCRP transporter baculovirus-infected Sf9 cell line,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144139,mbcd0030198,mbtp000002,mbrf0002129,,=,,,inhibitor,25,47.0,microM,,delphinidin-3-glucoside,,,Membrane vesicles in the inside-out orientation prepared from overexpressing human BCRP transporter baculovirus-infected Sf9 cell line,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144140,mbcd0030199,mbtp000002,mbrf0002129,,=,,,inhibitor,25,95.0,microM,,cyanidin-3-rutinoside,,,Membrane vesicles in the inside-out orientation prepared from overexpressing human BCRP transporter baculovirus-infected Sf9 cell line,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144141,mbcd0030200,mbtp000002,mbrf0002129,,=,,,inhibitor,25,43.0,microM,,malvidin-3-glucoside,,,Membrane vesicles in the inside-out orientation prepared from overexpressing human BCRP transporter baculovirus-infected Sf9 cell line,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144142,mbcd0030201,mbtp000002,mbrf0002129,,=,,,inhibitor,25,130.0,microM,,"pelargonidin-3,5- diglucoside",,,Membrane vesicles in the inside-out orientation prepared from overexpressing human BCRP transporter baculovirus-infected Sf9 cell line,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144143,mbcd0030188,mbtp000002,mbrf0002129,,=,,,inhibitor,25,31.0,microM,,malvidin-3-galactoside,Inhibitory activity at high concentrations only,,Membrane vesicles in the inside-out orientation prepared from overexpressing human BCRP transporter baculovirus-infected Sf9 cell line,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144144,mbcd0003235,mbtp000002,mbrf0000092,,=,,,inhibitor,25,8.71,microM,2.37,Compound 1a,,,stably transfected MDCK BCRP cell line; measurements from a flow cytometry Pheophorbide A assay,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144145,mbcd0003204,mbtp000002,mbrf0000092,,=,,,inhibitor,25,9.08,microM,3.29,Compound 1b,,,stably transfected MDCK BCRP cell line; measurements from a flow cytometry Pheophorbide A assay,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144146,mbcd0003213,mbtp000002,mbrf0000092,,=,,,inhibitor,25,2.61,microM,2.61,Compound 1c,,,stably transfected MDCK BCRP cell line; measurements from a flow cytometry Pheophorbide A assay,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144147,mbcd0003167,mbtp000002,mbrf0000092,,=,,,inhibitor,25,74.1,microM,13.9,Compound 1d,,,stably transfected MDCK BCRP cell line; measurements from a flow cytometry Pheophorbide A assay,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144148,mbcd0003166,mbtp000002,mbrf0000092,,=,,,inhibitor,25,58.4,microM,13.6,Compound 1e,,,stably transfected MDCK BCRP cell line; measurements from a flow cytometry Pheophorbide A assay,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144149,mbcd0003205,mbtp000002,mbrf0000092,,=,,,inhibitor,25,46.4,microM,12.9,Compound 1f,,,stably transfected MDCK BCRP cell line; measurements from a flow cytometry Pheophorbide A assay,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144150,mbcd0002719,mbtp000002,mbrf0000092,,=,,,inhibitor,25,45.7,microM,21.9,Compound 2a,,,stably transfected MDCK BCRP cell line; measurements from a flow cytometry Pheophorbide A assay,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144151,mbcd0002924,mbtp000002,mbrf0000092,,=,,,inhibitor,25,40.0,microM,11.1,Compound 2a,,,stably transfected MDCK BCRP cell line; measurements from a flow cytometry Pheophorbide A assay,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144152,mbcd0001851,mbtp000002,mbrf0000092,,=,,,inhibitor,25,4.38,microM,1.7,Compound 2c,,,stably transfected MDCK BCRP cell line; measurements from a flow cytometry Pheophorbide A assay,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144153,mbcd0002561,mbtp000002,mbrf0000092,,=,,,inhibitor,25,20.9,microM,10.4,Compound 2d,,,stably transfected MDCK BCRP cell line; measurements from a flow cytometry Pheophorbide A assay,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144154,mbcd0002293,mbtp000002,mbrf0000092,,=,,,inhibitor,25,20.7,microM,11.1,Compound 2e,,,stably transfected MDCK BCRP cell line; measurements from a flow cytometry Pheophorbide A assay,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144155,mbcd0002876,mbtp000002,mbrf0000092,,=,,,inhibitor,25,98.2,microM,11.2,Compound 2f,,,stably transfected MDCK BCRP cell line; measurements from a flow cytometry Pheophorbide A assay,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144156,mbcd0003267,mbtp000002,mbrf0000092,,=,,,inhibitor,25,6.98,microM,3.11,Compound 3,,,stably transfected MDCK BCRP cell line; measurements from a flow cytometry Pheophorbide A assay,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144157,mbcd0002875,mbtp000002,mbrf0000092,,=,,,inhibitor,25,0.86,microM,0.13,Compound 4a,,,stably transfected MDCK BCRP cell line; measurements from a flow cytometry Pheophorbide A assay,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144158,mbcd0030202,mbtp000002,mbrf0000092,,=,,,inhibitor,25,0.63,microM,0.29,Compound 4b,,,stably transfected MDCK BCRP cell line; measurements from a flow cytometry Pheophorbide A assay,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144159,mbcd0003266,mbtp000002,mbrf0000092,,=,,,inhibitor,25,0.5,microM,0.08,Compound 5,,,stably transfected MDCK BCRP cell line; measurements from a flow cytometry Pheophorbide A assay,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144160,mbcd0002439,mbtp000002,mbrf0000092,,=,,,inhibitor,25,0.074,microM,0.016,Ko 143,,,stably transfected MDCK BCRP cell line; measurements from a flow cytometry Pheophorbide A assay,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144161,mbcd0003252,mbtp000002,mbrf0000092,,=,,,inhibitor,25,104.0,microM,12,Novobiocin,,,stably transfected MDCK BCRP cell line; measurements from a flow cytometry Pheophorbide A assay,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144162,mbcd0002104,mbtp000002,mbrf0000092,,=,,,inhibitor,25,0.85,microM,0.07,XR 9576,,,stably transfected MDCK BCRP cell line; measurements from a flow cytometry Pheophorbide A assay,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144163,mbcd0001808,mbtp000002,mbrf0000092,,=,,,inhibitor,25,0.43,microM,0.03,GF120918,,,stably transfected MDCK BCRP cell line; measurements from a flow cytometry Pheophorbide A assay,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144164,mbcd0003125,mbtp000002,mbrf0000092,,=,,,inhibitor,25,1.26,microM,0.23,Gefitinib,,,stably transfected MDCK BCRP cell line; measurements from a flow cytometry Pheophorbide A assay,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144165,mbcd0002828,mbtp000002,mbrf0000092,,=,,,inhibitor,25,3.38,microM,1.9,Imatinib,,,stably transfected MDCK BCRP cell line; measurements from a flow cytometry Pheophorbide A assay,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144166,mbcd0026911,mbtp000002,mbrf0002182,,,,,substrate,,,,,Hypericin,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144167,mbcd0026911,mbtp000002,mbrf0002182,,,,,inducer,,,,,Hypericin,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144168,mbcd0003259,mbtp000002,mbrf0000094,25,>,100000.0,nM,inhibitor,25,100.0,microM,,Compound 15,,B,ABCG2 expressed in human NCI-H460/MX20 cell line; PhA assay; intracellular fluorescence intensity was read and normalized to cells treated with the ABCG2 inhibitor fumitremorgin C; accumulation of substrate pheophorbide-A,NCI-H460/MX20,,,,,human,mbds0001,v12,2013-11-20 20:06:19
mbbd000144169,mbcd0003258,mbtp000002,mbrf0000094,25,=,25200.0,nM,inhibitor,25,25.2,microM,1.7,Compound 16,,B,ABCG2 expressed in human NCI-H460/MX20 cell line; PhA assay; intracellular fluorescence intensity was read and normalized to cells treated with the ABCG2 inhibitor fumitremorgin C; accumulation of substrate pheophorbide-A,NCI-H460/MX20,,,,,human,mbds0001,v12,2013-11-20 20:06:19
mbbd000144170,mbcd0003253,mbtp000002,mbrf0000094,25,>,100000.0,nM,inhibitor,25,100.0,microM,,Cmpound 17,,B,ABCG2 expressed in human NCI-H460/MX20 cell line; PhA assay; intracellular fluorescence intensity was read and normalized to cells treated with the ABCG2 inhibitor fumitremorgin C; accumulation of substrate pheophorbide-A,NCI-H460/MX20,,,,,human,mbds0001,v12,2013-11-20 20:06:19
mbbd000144171,mbcd0003255,mbtp000002,mbrf0000094,25,>,100000.0,nM,inhibitor,25,100.0,microM,,Compound 18,,B,ABCG2 expressed in human NCI-H460/MX20 cell line; PhA assay; intracellular fluorescence intensity was read and normalized to cells treated with the ABCG2 inhibitor fumitremorgin C; accumulation of substrate pheophorbide-A,NCI-H460/MX20,,,,,human,mbds0001,v12,2013-11-20 20:06:19
mbbd000144172,mbcd0003254,mbtp000002,mbrf0000094,25,>,100000.0,nM,inhibitor,25,100.0,microM,,Compound 9,,B,ABCG2 expressed in human NCI-H460/MX20 cell line; PhA assay; intracellular fluorescence intensity was read and normalized to cells treated with the ABCG2 inhibitor fumitremorgin C; accumulation of substrate pheophorbide-A,NCI-H460/MX20,,,,,human,mbds0001,v12,2013-11-20 20:06:19
mbbd000144173,mbcd0003260,mbtp000002,mbrf0000094,25,>,100000.0,nM,inhibitor,25,100.0,microM,,Compound 8,,B,ABCG2 expressed in human NCI-H460/MX20 cell line; PhA assay; intracellular fluorescence intensity was read and normalized to cells treated with the ABCG2 inhibitor fumitremorgin C; accumulation of substrate pheophorbide-A,NCI-H460/MX20,,,,,human,mbds0001,v12,2013-11-20 20:06:19
mbbd000144174,mbcd0003257,mbtp000002,mbrf0000094,25,=,15400.0,nM,inhibitor,25,15.4,microM,1.0,Compound 19,,B,ABCG2 expressed in human NCI-H460/MX20 cell line; PhA assay; intracellular fluorescence intensity was read and normalized to cells treated with the ABCG2 inhibitor fumitremorgin C; accumulation of substrate pheophorbide-A,NCI-H460/MX20,,,,,human,mbds0001,v12,2013-11-20 20:06:19
mbbd000144175,mbcd0003256,mbtp000002,mbrf0000094,25,=,6400.0,nM,inhibitor,25,6.4,microM,0.8,Compound 20,,B,ABCG2 expressed in human NCI-H460/MX20 cell line; PhA assay; intracellular fluorescence intensity was read and normalized to cells treated with the ABCG2 inhibitor fumitremorgin C; accumulation of substrate pheophorbide-A,NCI-H460/MX20,,,,,human,mbds0001,v12,2013-11-20 20:06:19
mbbd000144176,mbcd0003261,mbtp000002,mbrf0000094,25,=,18800.0,nM,inhibitor,25,18.8,microM,1.2,Compound 21,,B,ABCG2 expressed in human NCI-H460/MX20 cell line; PhA assay; intracellular fluorescence intensity was read and normalized to cells treated with the ABCG2 inhibitor fumitremorgin C; accumulation of substrate pheophorbide-A,NCI-H460/MX20,,,,,human,mbds0001,v12,2013-11-20 20:06:19
mbbd000144177,mbcd0003262,mbtp000002,mbrf0000094,25,=,11100.0,nM,inhibitor,25,11.1,microM,1.2,Compound 22,,B,ABCG2 expressed in human NCI-H460/MX20 cell line; PhA assay; intracellular fluorescence intensity was read and normalized to cells treated with the ABCG2 inhibitor fumitremorgin C; accumulation of substrate pheophorbide-A,NCI-H460/MX20,,,,,human,mbds0001,v12,2013-11-20 20:06:19
mbbd000144178,mbcd0003263,mbtp000002,mbrf0000094,25,=,23200.0,nM,inhibitor,25,23.2,microM,2.5,Compound 23,,B,ABCG2 expressed in human NCI-H460/MX20 cell line; PhA assay; intracellular fluorescence intensity was read and normalized to cells treated with the ABCG2 inhibitor fumitremorgin C; accumulation of substrate pheophorbide-A,NCI-H460/MX20,,,,,human,mbds0001,v12,2013-11-20 20:06:19
mbbd000144179,mbcd0003264,mbtp000002,mbrf0000094,25,>,100000.0,nM,inhibitor,25,100.0,microM,,Compound 24,,B,ABCG2 expressed in human NCI-H460/MX20 cell line; PhA assay; intracellular fluorescence intensity was read and normalized to cells treated with the ABCG2 inhibitor fumitremorgin C; accumulation of substrate pheophorbide-A,NCI-H460/MX20,,,,,human,mbds0001,v12,2013-11-20 20:06:19
mbbd000144180,mbcd0030203,mbtp000002,mbrf0002263,,~,,,substrate,103,5.0,pmol mL-1,,Sphingosine 1-phosphate,,,E2-stimulated release of S1P from MCF-7 cells; release measured in presence of ABCC1-specific inhibitor MK571,MCF7,,,,,human,mbds0010,,2013-11-24 23:10:00
mbbd000144181,mbcd0001309,mbtp000002,mbrf0002286,,,,,non-substrate,,,,,Temozolomide,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144182,mbcd0003890,mbtp000002,mbrf0002286,,,,,substrate,,,,,ganciclovir; GCV,,,Competition assay with Hoechst33342,CLB05,,100,microg ml-1,,human,mbds0010,,2013-10-09 22:18:35
mbbd000144183,mbcd0030204,mbtp000002,mbrf0002248,,,,,substrate,,,,,Phosphatidylserine,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144184,mbcd0030205,mbtp000002,mbrf0002248,,,,,substrate,,,,,Lyso-Tracker Green,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144185,mbcd0003078,mbtp000002,mbrf0001699,,=,,,substrate,105,2.5,fold increase,,Glutathione,,,Human ABCG2 was expressed in the yeast strain S. cerevisiae mutant; inducible yeast model was grown in galactose for expression of plasma membrane-bound ABCG2,Saccharomyces cerevisiae,,,,,human,mbds0010,,2013-12-06 23:55:57
mbbd000144186,mbcd0029339,mbtp000002,mbrf0002162,,~,,,substrate,33,4.5,pmol mg-1 (2 min)-1,0.5,17-alpha-ethinylestradiol-3-O-sulfate,,,BCRP-overexpressing Sf9 membrane vesicles,Sf9,,,,,human,mbds0010,,2013-11-24 23:54:56
mbbd000144187,mbcd0029339,mbtp000002,mbrf0002162,,=,,,substrate,28,307.0,microM,143,17-alpha-ethinylestradiol-3-O-sulfate,,,BCRP-overexpressing Sf9 membrane vesicles,Sf9,,,,,human,mbds0010,,2013-11-24 23:54:56
mbbd000144188,mbcd0013632,mbtp000002,mbrf0002473,,=,,,inhibitor,48,5.62,,0.04,Daidzein,,,BCRP-expressing membrane vesicles,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144189,mbcd0001634,mbtp000002,mbrf0002473,,=,,,inhibitor,48,4.54,,0.05,Daidzin,,,BCRP-expressing membrane vesicles,,,,,,human,mbds0010,,2013-11-20 21:24:53
mbbd000144190,mbcd0004091,mbtp000002,mbrf0002473,,=,,,inhibitor,48,5.69,,0.06,Formononetin,,,BCRP-expressing membrane vesicles,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144191,mbcd0030207,mbtp000002,mbrf0002473,,=,,,inhibitor,48,4.86,,0.05,Ononin,,,BCRP-expressing membrane vesicles,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144192,mbcd0030208,mbtp000002,mbrf0002473,,=,,,inhibitor,48,5.96,,0.05,"4',7-Dimethoxyisoflavone",,,BCRP-expressing membrane vesicles,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144193,mbcd0030209,mbtp000002,mbrf0002473,,=,,,inhibitor,48,3.37,,0.14,Daidzein-7-glucuronide,,,BCRP-expressing membrane vesicles,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144194,mbcd0030210,mbtp000002,mbrf0002473,,=,,,inhibitor,48,5.41,,0.06,Daidzein-4'-sulfate,,,BCRP-expressing membrane vesicles,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144195,mbcd0003116,mbtp000002,mbrf0002473,,=,,,inhibitor,48,6.62,,0.06,Genistein,,,BCRP-expressing membrane vesicles,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144196,mbcd0029371,mbtp000002,mbrf0002473,,=,,,inhibitor,48,5.37,,0.05,Genistin,,,BCRP-expressing membrane vesicles,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144197,mbcd0003026,mbtp000002,mbrf0002473,,=,,,inhibitor,48,6.3,,0.07,Biochanin A,,,BCRP-expressing membrane vesicles,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144198,mbcd0030212,mbtp000002,mbrf0002473,,=,,,inhibitor,48,5.57,,0.05,Sissotrin,,,BCRP-expressing membrane vesicles,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144199,mbcd0012714,mbtp000002,mbrf0002473,,=,,,inhibitor,48,5.7,,0.09,"4',7-Dimethoxy-5-hydroxyisoflavone",,,BCRP-expressing membrane vesicles,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144200,mbcd0030213,mbtp000002,mbrf0002473,,=,,,inhibitor,48,5.38,,0.06,Sophoricoside,,,BCRP-expressing membrane vesicles,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144201,mbcd0030214,mbtp000002,mbrf0002473,,=,,,inhibitor,48,6.4,,0.07,Prunetin,,,BCRP-expressing membrane vesicles,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144202,mbcd0030215,mbtp000002,mbrf0002473,,=,,,inhibitor,48,5.99,,0.05,Glycitein,,,BCRP-expressing membrane vesicles,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144203,mbcd0030216,mbtp000002,mbrf0002473,,=,,,inhibitor,48,5.46,,0.06,BCRP-expressing membrane vesicles,,,BCRP-expressing membrane vesicles,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144204,mbcd0030217,mbtp000002,mbrf0002473,,=,,,inhibitor,48,6.31,,0.06,"4',6,7-Trimethoxyisoflavone",,,BCRP-expressing membrane vesicles,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144205,mbcd0030218,mbtp000002,mbrf0002473,,=,,,inhibitor,48,5.57,,0.07,"3',4',7-Trihydroxyisoflavone",,,BCRP-expressing membrane vesicles,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144206,mbcd0030219,mbtp000002,mbrf0002473,,=,,,inhibitor,48,6.07,,0.06,5-Methyl-7-methoxyisoflavone,,,BCRP-expressing membrane vesicles,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144207,mbcd0030220,mbtp000002,mbrf0002473,,=,,,inhibitor,48,5.88,,0.05,Ipriflavone,,,BCRP-expressing membrane vesicles,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144208,mbcd0029182,mbtp000002,mbrf0002473,,=,,,inhibitor,48,7.2,,0.05,Coumestrol,,,BCRP-expressing membrane vesicles,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144209,mbcd0030221,mbtp000002,mbrf0002473,,=,,,inhibitor,48,5.4,,0.05,Coumestrin,,,BCRP-expressing membrane vesicles,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144210,mbcd0002051,mbtp000002,mbrf0002060,,=,,,inhibitor,25,22.3,microM,,Atazanavir,,,BCRP-overexpressing MCF-7/MR cell line; IC50s were calculated from sulphorhodamine B- or XTT-determined growth curves; grown for 72-96 h in the presence of a concentration range of an established substrate,MCF7,,,,,human,mbds0010,,2013-12-09 06:51:30
mbbd000144211,mbcd0002241,mbtp000002,mbrf0002060,,=,,,inhibitor,25,12.7,microM,,Lopinavir,,,BCRP-overexpressing MCF-7/MR cell line; IC50s were calculated from sulphorhodamine B- or XTT-determined growth curves; grown for 72-96 h in the presence of a concentration range of an established substrate,MCF7,,,,,human,mbds0010,,2013-12-09 06:51:30
mbbd000144212,mbcd0001938,mbtp000002,mbrf0002060,,=,,,inhibitor,25,33.9,microM,,Ritonavir,,,BCRP-overexpressing MCF-7/MR cell line; IC50s were calculated from sulphorhodamine B- or XTT-determined growth curves; grown for 72-96 h in the presence of a concentration range of an established substrate,MCF7,,,,,human,mbds0010,,2013-12-09 06:51:30
mbbd000144214,mbcd0001172,mbtp000002,mbrf0001605,,=,,,inhibitor,25,1.0,microM,,Ivermectin,,,PLB985-BCRP cell line,PLB985,mbcd0000474,,,,human,mbds0010,,2013-11-17 20:42:16
mbbd000144215,mbcd0001172,mbtp000002,mbrf0001605,,~,,,inhibitor,3,75.0,%,,Ivermectin,,,PLB985-BCRP cell line,PLB985,mbcd0000474,10,microM,,human,mbds0010,,2013-11-20 21:03:51
mbbd000144216,mbcd0003003,mbtp000002,mbrf0002226,,=,,,substrate,28,0.6,microM,0.4,Bupropion,,,Placental brush border membrane vesicles from human placenta; stimulation of ATP hydrolysis in membranes expressing BCRP transporter,human placental cells,,,,,human,mbds0010,,2013-11-24 23:55:51
mbbd000144217,mbcd0003003,mbtp000002,mbrf0002226,,=,,,substrate,22,6.0,nmol Pi (mg protein)-1 min-1,0.8,Bupropion,,,Placental brush border membrane vesicles from human placenta; stimulation of ATP hydrolysis in membranes expressing BCRP transporter,human placental cells,,,,,human,mbds0010,,2013-11-24 23:55:51
mbbd000144218,mbcd0030222,mbtp000002,mbrf0002226,,,,,non-substrate,,,,,OH-bupropion; hydroxybupropion,,,Placental brush border membrane vesicles,Placental brush border membrane vesicles,,0.05-3,microM,,human,mbds0010,,2013-10-09 22:18:43
mbbd000144219,mbcd0003207,mbtp000002,mbrf0000089,25,=,11900.0,nM,inhibitor,25,11.9,microM,1.8,naphthopyrone 3,,B,ABCG2-overexpressing NCI-H460 MX20 cell line; high throughput assay measuring accumulation of the ABCG2 specific substrate pheophorbide a (PhA),NCI-H460/MX20,,,,,human,mbds0001,v12,2013-12-09 06:54:11
mbbd000144220,mbcd0003244,mbtp000002,mbrf0000089,25,=,5900.0,nM,inhibitor,25,5.9,microM,0.5,naphthopyrone 5,,B,ABCG2-overexpressing NCI-H460 MX20 cell line; high throughput assay measuring accumulation of the ABCG2 specific substrate pheophorbide a (PhA),NCI-H460/MX20,,,,,human,mbds0001,v12,2013-12-09 06:54:11
mbbd000144221,mbcd0003226,mbtp000002,mbrf0000089,25,=,12800.0,nM,inhibitor,25,12.8,microM,0.4,8; TMC-256C1,,B,ABCG2-overexpressing NCI-H460 MX20 cell line; high throughput assay measuring accumulation of the ABCG2 specific substrate pheophorbide a (PhA),NCI-H460/MX20,,,,,human,mbds0001,v12,2013-12-09 06:54:11
mbbd000144222,mbcd0003219,mbtp000002,mbrf0000089,25,=,9000.0,nM,inhibitor,25,9.0,microM,0.8,9; comaparvin,,B,ABCG2-overexpressing NCI-H460 MX20 cell line; high throughput assay measuring accumulation of the ABCG2 specific substrate pheophorbide a (PhA),NCI-H460/MX20,,,,,human,mbds0001,v12,2013-12-09 06:54:11
mbbd000144223,mbcd0003208,mbtp000002,mbrf0000089,25,>,20000.0,nM,inhibitor,25,20.0,microM,,10; 6-methoxycomaparvin,,B,ABCG2-overexpressing NCI-H460 MX20 cell line; high throughput assay measuring accumulation of the ABCG2 specific substrate pheophorbide a (PhA),NCI-H460/MX20,,,,,human,mbds0001,v12,2013-12-09 06:54:11
mbbd000144224,mbcd0003245,mbtp000002,mbrf0000089,25,=,16600.0,nM,inhibitor,25,16.6,microM,4.1,11; 6-methoxycomaparvin 5-methyl ether,,B,ABCG2-overexpressing NCI-H460 MX20 cell line; high throughput assay measuring accumulation of the ABCG2 specific substrate pheophorbide a (PhA),NCI-H460/MX20,,,,,human,mbds0001,v12,2013-12-09 06:54:11
mbbd000144225,mbcd0030223,mbtp000002,mbrf0001680,,=,,,inhibitor,25,7.94,microM,1.27,Compound 5,,,MDCK BCRP cell line; Hoechst 33342 assay,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144226,mbcd0030225,mbtp000002,mbrf0001680,,=,,,inhibitor,25,1.96,microM,0.3,Compound 6,,,MDCK BCRP cell line; Hoechst 33342 assay,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144227,mbcd0030225,mbtp000002,mbrf0001680,,=,,,inhibitor,25,14.1,microM,3.7,Compound 7,,,MDCK BCRP cell line; Hoechst 33342 assay,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144228,mbcd0030226,mbtp000002,mbrf0001680,,=,,,inhibitor,25,11.9,microM,1.2,Compound 8,,,MDCK BCRP cell line; Hoechst 33342 assay,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144229,mbcd0030227,mbtp000002,mbrf0001680,,=,,,inhibitor,25,1.39,microM,0.26,Compound 9,,,MDCK BCRP cell line; Hoechst 33342 assay,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144230,mbcd0030228,mbtp000002,mbrf0001680,,=,,,inhibitor,25,3.47,microM,0.38,Compound 10,,,MDCK BCRP cell line; Hoechst 33342 assay,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144231,mbcd0030229,mbtp000002,mbrf0001680,,=,,,inhibitor,25,12.9,microM,2.9,Compound 11,,,MDCK BCRP cell line; Hoechst 33342 assay,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144232,mbcd0030230,mbtp000002,mbrf0001680,,=,,,inhibitor,25,6.51,microM,0.23,Compound 12,,,MDCK BCRP cell line; Hoechst 33342 assay,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144233,mbcd0030231,mbtp000002,mbrf0001680,,=,,,inhibitor,25,5.56,microM,0.64,Compound 13,,,MDCK BCRP cell line; Hoechst 33342 assay,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144234,mbcd0030202,mbtp000002,mbrf0001680,,=,,,inhibitor,25,1.25,microM,0.24,Compound 14,,,MDCK BCRP cell line; Hoechst 33342 assay,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144235,mbcd0001830,mbtp000002,mbrf0001680,,=,,,inhibitor,25,0.701,microM,0.136,XR9577,,,MDCK BCRP cell line; Hoechst 33342 assay,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144236,mbcd0002422,mbtp000002,mbrf0002122,,=,,,inhibitor,25,1.04,microM,1.23,Fumitremorgin C,,,BCRP-overexpressing MDCK cell line; Inhibition of BCRP-mediated effect on accumulation of mitoxantrone,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144237,mbcd0002981,mbtp000002,mbrf0002122,,=,,,substrate,25,2.5,microM,0.2,Mitoxantrone,,,BCRP -overexpressing MDCK cell line,MDCK,,,,,human,mbds0010,,2013-11-24 23:12:00
mbbd000144238,mbcd0003187,mbtp000002,mbrf0002122,,=,,,substrate,25,13.82,microM,0.91,Topotecan,,,BCRP-overexpressing MDCK cell line,MDCK,,,,,human,mbds0010,,2013-11-24 23:12:00
mbbd000144239,mbcd0030067,mbtp000002,mbrf0002009,,=,,,substrate,126,2.82,,,Pyropheophorbide A,,,HEK-293 428R (ABCG2 positive) cell line; fluorescence change mediated by the TKI IM in the two cell lines HEK-293 PcDNA (ABCG2 negative) and HEK-293 428R (ABCG2 positive) is expressed as the (fractional) change relative to the fluorescence due to the PS alone,HEK293,,,,,human,mbds0010,,2013-11-24 23:14:17
mbbd000144240,mbcd0029995,mbtp000002,mbrf0002009,,=,,,substrate,126,2.99,,,HPPH,,,HEK-293 428R (ABCG2 positive) cell line; fluorescence change mediated by the TKI IM in the two cell lines HEK-293 PcDNA (ABCG2 negative) and HEK-293 428R (ABCG2 positive) is expressed as the (fractional) change relative to the fluorescence due to the PS alone,HEK293,,,,,human,mbds0010,,2013-11-24 23:14:18
mbbd000144241,mbcd0030232,mbtp000002,mbrf0002009,,=,,,substrate,126,1.42,,,Compound 3,,,HEK-293 428R (ABCG2 positive) cell line; fluorescence change mediated by the TKI IM in the two cell lines HEK-293 PcDNA (ABCG2 negative) and HEK-293 428R (ABCG2 positive) is expressed as the (fractional) change relative to the fluorescence due to the PS alone,HEK293,,,,,human,mbds0010,,2013-11-24 23:14:18
mbbd000144242,mbcd0030233,mbtp000002,mbrf0002009,,=,,,substrate,25,2.5,microM,,Compound 4,,,HEK-293 428R (ABCG2 positive) cell line; fluorescence change mediated by the TKI IM in the two cell lines HEK-293 PcDNA (ABCG2 negative) and HEK-293 428R (ABCG2 positive) is expressed as the (fractional) change relative to the fluorescence due to the PS alone,HEK293,,,,,human,mbds0010,,2013-11-24 23:14:18
mbbd000144243,mbcd0030234,mbtp000002,mbrf0002009,,=,,,substrate,25,1.84,microM,,Compound 15,,,HEK-293 428R (ABCG2 positive) cell line; fluorescence change mediated by the TKI IM in the two cell lines HEK-293 PcDNA (ABCG2 negative) and HEK-293 428R (ABCG2 positive) is expressed as the (fractional) change relative to the fluorescence due to the PS alone,HEK293,,,,,human,mbds0010,,2013-11-24 23:14:18
mbbd000144244,mbcd0030235,mbtp000002,mbrf0002184,,=,,,substrate,25,1.6,microM,0.1,"1; (2E)-3-(3-hydroxy-4-methoxyphenyl)-1-(3,4,5-trimethoxyphenyl)prop-2-en-1-one",,,BCRP-overexpressing MCF-7+Top cell line; incubation time of 48 hours,MCF7,,,,,human,mbds0010,,2013-11-24 23:10:00
mbbd000144245,mbcd0030235,mbtp000002,mbrf0002184,,~,,,inhibitor,3,60.0,%,5,"1; (2E)-3-(3-hydroxy-4-methoxyphenyl)-1-(3,4,5-trimethoxyphenyl)prop-2-en-1-one",,,BCRP-overexpressing MCF-7+Top cell line; Mitoxantrone assay: % inhibition of BCRP drug transporters,,,,,,human,mbds0010,,2013-11-20 19:06:37
mbbd000144246,mbcd0030236,mbtp000002,mbrf0002184,,=,,,substrate,25,18.0,microM,1.2,Complex 2,,,BCRP-overexpressing MCF-7+Top cell line; incubation time of 48 hours,MCF7,,,,,human,mbds0010,,2013-11-24 23:10:00
mbbd000144247,mbcd0030236,mbtp000002,mbrf0002184,,~,,,inhibitor,3,50.0,%,2,Complex 2,,,BCRP-overexpressing MCF-7+Top cell line; Mitoxantrone assay: % inhibition of BCRP drug transporters,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144248,mbcd0030237,mbtp000002,mbrf0001954,,=,,,inhibitor,25,19.13,microM,,Apatinib,,,ABCG2-overexpressing MCF-7/ FLV1000 cell line,,,,,,human,mbds0010,,2013-11-20 18:27:27
mbbd000144249,mbcd0030237,mbtp000002,mbrf0001954,,~,,,substrate,96,55.0,nmol min-1 (mg protein)-1,5,Apatinib,,,beryllium fluoride (BeFx)-sensitive ABCG2 ATPase activity in membrane vesicles of High Five insect cells,High Five insect cells,,2.5,microM,,human,mbds0010,,2013-11-25 04:54:13
mbbd000144250,mbcd0001550,mbtp000002,mbrf0002187,,~,,,inhibitor,3,85.0,%,20,lapatinib,,,H358  cell line; Flow cytometry data showing the effect of lapatinib on mitoxantrone (MXR) efflux through BCRP,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144251,mbcd0001056,mbtp000002,mbrf0002417,,~,,,substrate,100,90.0,%,5,Sorafenib,,,BCRP-expressing MDCK-II cell line; intracellular accumulation as a percentage of control,MDCKII,,,,,human,mbds0010,,2013-11-24 23:12:01
mbbd000144252,mbcd0007655,mbtp000002,mbrf0001713,,,,,substrate,,,,,leflunomide,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144253,mbcd0030042,mbtp000002,mbrf0001713,,,,,substrate,,,,,A771726,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144254,mbcd0030238,mbtp000002,mbrf0002089,,,,,substrate,,,,,Danofloxacin-mesylate; DM,,,Caco-2 cells,Caco-2,,10,microM,,human,mbds0010,,2013-11-10 04:16:00
mbbd000144255,mbcd0030239,mbtp000002,mbrf0002429,,=,,,substrate,14,15.4,*10^-6 cm s-1,3.2,enrofloxacin,,,Human BCRP- overexpressing MDCK II cell line; ?Papp values for transepithelial transport from basolateral to apical compartment,MDCKII,,10,microM,,human,mbds0010,,2013-11-24 23:12:01
mbbd000144256,mbcd0001038,mbtp000002,mbrf0002274,,~,,,substrate,138,2500.0,pmol (mg protein)-1,100,Grepafloxacin,,,hBCRP expressing MDCK-II cell line; transcellular transport from basal-to-apical direction after 180 minutes incubation,MDCKII,,10,microM,,human,mbds0010,,2013-11-24 23:12:01
mbbd000144257,mbcd0030019,mbtp000002,mbrf0002274,,~,,,substrate,138,1700.0,pmol (mg protein)-1,200,Ulifloxacin,,,hBCRP expressing MDCK-II cell line; transcellular transport from basal-to-apical direction after 180 minutes incubation,MDCKII,,10,microM,,human,mbds0010,,2013-11-24 23:12:01
mbbd000144258,mbcd0000159,mbtp000002,mbrf0002246,,,,,substrate,,,,,Azidopine,,,MCF7 cells,MCF7,,25,nM,,human,mbds0010,,2013-11-10 04:16:09
mbbd000144259,mbcd0026833,mbtp000002,mbrf0001861,,,,,substrate,,,,,Alfuzosin,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144260,mbcd0030240,mbtp000002,mbrf0001874,,~,,,inhibitor,25,80.0,nM,,PZ-8,,,MCF7/ AdVp3000 cell line; IC50 for sensitizing mitoxantrone resistance,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144261,mbcd0030241,mbtp000002,mbrf0001874,,~,,,inhibitor,25,70.0,nM,,PZ- 16,,,MCF7/ AdVp3000 cell line; IC50 for sensitizing mitoxantrone resistance,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144262,mbcd0030242,mbtp000002,mbrf0001874,,=,,,inhibitor,25,12.94,microM,,PZ-34,,,HEK293/ABCG2 cell line; IC50 for for sensitization of mitoxantrone resistance,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144263,mbcd0030243,mbtp000002,mbrf0001874,,>,,,inhibitor,25,20.0,microM,,PZ-38,,,HEK293/ABCG2 cell line; IC50 for for sensitization of mitoxantrone resistance,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144264,mbcd0001795,mbtp000002,mbrf0000069,25,=,6000.0,nM,inhibitor,25,6.0,micromol L-1,0.9,Etravirine,strong inhibitor,B,BCRP-overexpressiing MDCK-II cell line; Inhibition of BCRP assessed as cell growth inhibition by calcein and pheophorbide A efflux assays,,,,,,human,mbds0001,v12,2015-07-27 05:36:21
mbbd000144265,mbcd0007267,mbtp000002,mbrf0002164,,,,,substrate,,,,,BMS-536924,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144266,mbcd0001190,mbtp000002,mbrf0002437,,~,,,substrate,100,700.0,pmol (mg protein)-1,,clofarabine,,,ABCG2-expressing Saos2 cells; intracellular accumulation after 120 minutes incubation,Saos-2,,10,micromol L-1,,human,mbds0010,,2013-12-09 06:56:31
mbbd000144267,mbcd0003024,mbtp000002,mbrf0002324,,~,,,substrate,138,80.0,%,5,Prazosin,,,BCRP-expressing MDCK II cell line; Percentage of initial concentration (C0) obtained in basolateral compartment at end of incubation after concentration equilibrium assay after 120 miutes incubation,MDCKII,,,,,human,mbds0010,,2013-11-24 23:12:02
mbbd000144268,mbcd0030244,mbtp000002,mbrf0002324,,~,,,substrate,138,92.0,%,,Befloxatone,,,BCRP-expressing MDCK II cell line; Percentage of initial concentration (C0) obtained in basolateral compartment at end of incubation after concentration equilibrium assay after 120 miutes incubation,MDCKII,,,,,human,mbds0010,,2013-11-24 23:12:02
mbbd000144269,mbcd0025666,mbtp000002,mbrf0002094,,=,,,inducer,117,8.2,,,Romidepsin,Relative ABCG2 expression shown after normalization with GAPDH,,"Human colon cancer cell line S1, a derivative of LS180; Quantitative realtime PCR was performed to quantify the fold change of ABCG2 transcript expression",S1,,10,ng mL-1,,human,mbds0010,,2013-12-06 23:45:24
mbbd000144270,mbcd0030245,mbtp000002,mbrf0002386,,=,,,inhibitor,25,15.7,micromol L-1,5.7,elvitegravir,,,MDCKII-BCRP cell line; PhA flow cytometry efflux assay,,,,,,human,mbds0010,,2013-11-24 02:54:47
mbbd000144271,mbcd0030245,mbtp000002,mbrf0002386,,=,,,inducer,111,1.6,,0.4,elvitegravir,,,ABCB1 mRNA expression in ABCG2 cells compared with medium control; Expression data were normalized to reference gene GU; Induction of ABCG2 mRNA,,,10,micromol L-1,,human,mbds0010,,2013-12-10 22:42:16
mbbd000144272,mbcd0030246,mbtp000002,mbrf0002386,,=,,,inhibitor,25,236.7,microM L-1,93.3,vicriviroc,,,MDCKII-BCRP cell line; PhA flow cytometry efflux assay,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144273,mbcd0001684,mbtp000002,mbrf0002386,,=,,,inducer,111,1.7,,0.4,maraviroc,,,ABCB1 mRNA expression in ABCG2 cells compared with medium control; Expression data were normalized to reference gene GU; Induction of ABCG2 mRNA,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144274,mbcd0025660,mbtp000002,mbrf0002499,,,,,inhibitor,,,,,Sildenafil,,,"HEK293, MCF7 and S1-M1-80 cells",HEK293; MCF7; S1-M1-80,mbcd0002981,10; 50,microM,,human,mbds0010,,2013-11-10 04:16:06
mbbd000144275,mbcd0024640,mbtp000002,mbrf0002025,,=,,,inducer,97,161.0,%,13.9,Venlafaxine,,,BCRP expression at the protein level in human brain endothelial cells (HBMEC);drug treatment in the HBMEC for 1 h; displayed as a percentage of control,,,50,microM,,human,mbds0010,,2013-11-24 06:37:40
mbbd000144276,mbcd0030247,mbtp000002,mbrf0002430,,=,,,inhibitor,25,45.8,microM,2.6,Nutlin-3a,,,Saos-2-BCRP cell line,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144277,mbcd0030247,mbtp000002,mbrf0002430,,=,,,non-substrate,104,0.04,,,Nutlin-3a,,,MDCKII-BCRP cell line; bidirectional transport studies using BCRP over-expressing and pcDNA3.1 vector control MDCKII cells; Nutlin- 3a concentrations from either the apical or basolateral compartment were measured by LC-MS/MS; efflux ratio calculated from REBCRP/REpcDNA3.1,MDCKII,,,,,human,mbds0010,,2013-11-20 19:41:43
mbbd000144278,mbcd0004887,mbtp000002,mbrf0001690,,=,,,inhibitor,25,40.0,microM,1,kynurenic acid,,,HEK293-BCRP expressing cell line,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144279,mbcd0000472,mbtp000002,mbrf0001690,,=,,,inhibitor,25,3670.0,microM,170,hippuric acid,,,HEK293-BCRP expressing cell line,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144280,mbcd0030249,mbtp000002,mbrf0001690,,=,,,inhibitor,25,770.0,microM,120,indoxyl sulfate,,,HEK293-BCRP expressing cell line,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144281,mbcd0030088,mbtp000002,mbrf0001821,,>,,,inhibitor,25,10.0,micromol L-1,,YHO-13177,,,HCT116/ BCRP cell line,HCT116,,,,,human,mbds0010,,2013-10-30 19:52:37
mbbd000144282,mbcd0030087,mbtp000002,mbrf0001821,,,,,inhibitor,,,,,YHO-13351,YHO-13351 is a prodrug of YHO-13177,,HCT116/ BCRP cell line,HCT116,,,,,human,mbds0010,,2013-10-30 19:52:36
mbbd000144283,mbcd0029125,mbtp000002,mbrf0002320,,=,,,substrate,28,0.39,mM,0.08,pemetrexed; PMX,,,Membrane vesicles of HEK293 cells; pH 5.2,HEK293,,0-4000,microM,,human,mbds0010,,2013-10-09 22:18:43
mbbd000144284,mbcd0001690,mbtp000002,mbrf0002220,,=,,,inhibitor,25,93.2,microM,,Tasigna,,,ABCG2-HEK cell line,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144285,mbcd0030251,mbtp000002,mbrf0002220,,,,,substrate,,,,,BODIPY FL Tasigna,,,HEK293 cells,HEK293,,0.25,microM,,human,mbds0010,,2013-11-10 04:16:05
mbbd000144286,mbcd0030252,mbtp000002,mbrf0001769,,,,,substrate,,,,,barasertib-hQPA; AZD1152-HQPA,,,OCI-AML6.2 cells,OCI-AML6.2,,300,nM,,human,mbds0010,,2013-11-10 04:16:11
mbbd000144287,mbcd0030253,mbtp000002,mbrf0002347,,~,,,substrate,138,70.0,%,5,URB 937,,,MDCKII-ABCG2 cell line; Transepithelial transport from the basolateral to the apical compartment after 4h incubation,MDCKII,,,,,human,mbds0010,,2013-11-24 23:12:02
mbbd000144288,mbcd0029271,mbtp000002,mbrf0002279,,~,,,substrate,138,85.0,%,2,butyrate; BT,,,IEC-6 cell line; butyrate efflux affected by ABCG2 potent inhibitor Ko 143  (as percentage of control with no inhibitor present),IEC-6,,10,microM,,human,mbds0010,,2013-11-03 22:22:25
mbbd000144289,mbcd0000692,mbtp000002,mbrf0001688,,~,,,inhibitor,3,90.0,%,,Piperine,,,Mitoxantrone-treated MCF-7/DOX cell line; percentage inhibition of fluorescent dye; Inhibition efficiency was calculated by the formula (fluorescence intensity of piperine treated resistant cells - fluorescence intensity of untreated resistant cells)/(fluorescence intensity of sensitive cells - fluorescence intensity of untreated resistant cells),,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144290,mbcd0000692,mbtp000002,mbrf0001688,,~,,,inhibitor,3,90.0,%,,Piperine,,,Mitoxantrone-treated MCF-7/DOX cell line; percentage inhibition of fluorescent dye; Inhibition efficiency was calculated by the formula (fluorescence intensity of piperine treated resistant cells - fluorescence intensity of untreated resistant cells)/(fluorescence intensity of sensitive cells - fluorescence intensity of untreated resistant cells); after 6h incubation,,,50,microM,,human,mbds0010,,2013-11-24 03:25:21
mbbd000144291,mbcd0029150,mbtp000002,mbrf0002380,,=,,,inhibitor,25,59.8,microM,11,Atrasentan,,,MDCK-II/BCRP- cell line; pheophorbide A flow cytometry efflux assay,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144292,mbcd0029150,mbtp000002,mbrf0002380,,~,,,inducer,111,1.5,,1,Atrasentan,,,adenocarcinoma cells (LS180); mRNA expression after 4 days compared to untreated medium control,,,50,microM,,human,mbds0010,,2013-11-23 22:11:27
mbbd000144293,mbcd0029271,mbtp000002,mbrf0002279,,~,,,substrate,138,60.0,%,2,butyrate; BT,,,MDA-MB-231; butyrate efflux affected by ABCG2 potent inhibitor Ko 143  (as percentage of control with no inhibitor present),MDA-MB-231,,10,microM,,human,mbds0010,,2013-11-03 22:22:26
mbbd000144294,mbcd0003916,mbtp000002,mbrf0002083,,=,,,substrate,100,5.0,fold,,Acyclovir,,,HEK293/BCRP cell line; Increase in Intracellular accumulation in presence of ABCG2 potent inhibitor FTC; Intracellular acyclovir accumulation was assessed using a liquid scintillation counter,HEK293,,,,,human,mbds0010,,2013-12-10 22:19:00
mbbd000144296,mbcd0030256,mbtp000005,mbrf0002582,,,,,non-substrate,,,,,Biochanin A sulfate,,,MDCK/MRP2 cells,MDCK,,,,,human,mbds0010,,2013-11-10 02:15:07
mbbd000144297,mbcd0003026,mbtp000002,mbrf0002582,,,,,non-substrate,,,,,biochanin A,,,BCRP-overexpressing MCF7/MX100 cells; 10 microM FTC was used as a BCRP inhibitor,MCF7/MX100,,,,,human,mbds0010,,2013-11-10 02:15:06
mbbd000144298,mbcd0030257,mbtp000002,mbrf0001728,,=,,,inhibitor,25,13.67,microM,10.44,Compound 5,,,HEK/ABCG2-482-R2 cell line; mitoxantrone assay,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144299,mbcd0030259,mbtp000002,mbrf0001728,,=,,,inhibitor,25,16.67,microM,14.17,Compound 7,,,HEK/ABCG2-482-R2 cell line; mitoxantrone assay,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144300,mbcd0030260,mbtp000002,mbrf0002351,,,,,substrate,,,,,Lurtotecan,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144301,mbcd0027084,mbtp000002,mbrf0002351,,,,,substrate,,,,,Ethidium,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144302,mbcd0000723,mbtp000002,mbrf0002351,,,,,substrate,,,,,Puromycin,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144303,mbcd0030261,mbtp000002,mbrf0002351,,,,,substrate,,,,,BCECF-AM,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144304,mbcd0030262,mbtp000002,mbrf0002351,,,,,substrate,,,,,CPT-11,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144305,mbcd0000779,mbtp000002,mbrf0002351,,,,,substrate,,,,,7-ethyl-10-hydroxycamptothecin,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144306,mbcd0003110,mbtp000002,mbrf0002351,,,,,substrate,,,,,PMEA,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144307,mbcd0000169,mbtp000002,mbrf0002351,,,,,substrate,,,,,benzo[a]pyrene,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144309,mbcd0030263,mbtp000002,mbrf0002351,,,,,substrate,,,,,E3040S,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144310,mbcd0030264,mbtp000002,mbrf0002351,,,,,substrate,,,,,ST 1976,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144311,mbcd0030265,mbtp000002,mbrf0002351,,,,,substrate,,,,,ST 1587,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144312,mbcd0003129,mbtp000002,mbrf0002351,,,,,substrate,,,,,PEITC,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144313,mbcd0003070,mbtp000002,mbrf0002351,,,,,substrate,,,,,dehydroepiandrosterone-sulfate,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144314,mbcd0000640,mbtp000002,mbrf0002351,,,,,substrate,,,,,ochratoxin A,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144316,mbcd0000124,mbtp000002,mbrf0002351,,,,,substrate,,,,,ABZSO,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144317,mbcd0030392,mbtp000002,mbrf0002351,,,,,substrate,,,,,MTX triglutamate,,,,,,,,,human,mbds0010,,2013-11-20 19:15:28
mbbd000144318,mbcd0030267,mbtp000002,mbrf0002351,,,,,substrate,,,,,quercetin-3-glucuronide,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144319,mbcd0000875,mbtp000002,mbrf0002351,,,,,substrate,,,,,TGZS,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144320,mbcd0030269,mbtp000002,mbrf0002351,,,,,substrate,,,,,harmol sulfate,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144321,mbcd0030042,mbtp000002,mbrf0002351,,,,,substrate,,,,,A771276,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144322,mbcd0030270,mbtp000002,mbrf0002351,,,,,non-substrate,,,,,Hematoporphyrin,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144323,mbcd0029387,mbtp000002,mbrf0002351,,,,,non-substrate,,,,,Bisdemethoxycurcumin,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144324,mbcd0028840,mbtp000002,mbrf0002351,,,,,non-substrate,,,,,DEHP,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144325,mbcd0000919,mbtp000002,mbrf0002351,,,,,non-substrate,,,,,Retinol,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144326,mbcd0013197,mbtp000002,mbrf0002351,,,,,non-substrate,,,,,Thiamine,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144327,mbcd0010622,mbtp000002,mbrf0002351,,,,,non-substrate,,,,,Pyridoxine,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144328,mbcd0027668,mbtp000002,mbrf0002351,,,,,non-substrate,,,,,Tocopherol,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144329,mbcd0030273,mbtp000002,mbrf0002351,,,,,non-substrate,,,,,Vitamin K1,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144330,mbcd0030274,mbtp000002,mbrf0002351,,,,,non-substrate,,,,,Moxidectin,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144331,mbcd0008195,mbtp000002,mbrf0002351,,,,,non-substrate,,,,,Fenbendazole,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144332,mbcd0030275,mbtp000002,mbrf0002351,,,,,non-substrate,,,,,Prodigiosin,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144333,mbcd0000182,mbtp000002,mbrf0002351,,,,,non-substrate,,,,,Sitosterol,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144334,mbcd0005225,mbtp000002,mbrf0002351,,,,,non-substrate,,,,,Pentoxifylline,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144335,mbcd0030276,mbtp000002,mbrf0002222,,=,,,substrate,25,40.6,nmol L-1,11.5,S38809,,,HEK293-ABCG2 - transfected cell line,HEK293,,,,,human,mbds0010,,2013-11-20 19:41:43
mbbd000144336,mbcd0030277,mbtp000002,mbrf0002222,,=,,,non-substrate,25,4.8,nmol L-1,1.2,S39625,,,HEK293-ABCG2 - transfected cell line,HEK293,,,,,human,mbds0010,,2013-11-20 19:41:44
mbbd000144337,mbcd0020601,mbtp000002,mbrf0002222,,=,,,substrate,25,34.2,nmol L-1,8.3,Camptothecin,,,HEK293-ABCG2 transfected cell line,HEK293,,,,weak substrate,human,mbds0010,,2014-02-25 07:46:11
mbbd000144338,mbcd0000779,mbtp000002,mbrf0002222,,=,,,substrate,25,244.8,nmol L-1,67.7,SN-38,,,HEK293-ABCG2 - transfected cell line,HEK293,,,,,human,mbds0010,,2013-11-20 19:41:44
mbbd000144339,mbcd0003187,mbtp000002,mbrf0002222,,=,,,substrate,25,308.8,nmol L-1,10.2,Topotecan,,,HEK293-ABCG2 - transfected cell line,HEK293,,,,,human,mbds0010,,2013-11-20 19:41:44
mbbd000144340,mbcd0030278,mbtp000002,mbrf0002351,,,,,non-substrate,,,,,Lobeline,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144341,mbcd0001381,mbtp000002,mbrf0002351,,,,,non-substrate,,,,,Ara-C,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144342,mbcd0030279,mbtp000002,mbrf0002351,,,,,non-substrate,,,,,FdUMP,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144343,mbcd0030280,mbtp000002,mbrf0002351,,,,,non-substrate,,,,,Dimethyl-benzoylphenylurea,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144344,mbcd0028598,mbtp000002,mbrf0002351,,,,,substrate,,,,,Plumbagin,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144345,mbcd0004738,mbtp000002,mbrf0002351,,,,,substrate,,,,,"7,8-benzoflavone",,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144346,mbcd0029343,mbtp000002,mbrf0002351,,,,,substrate,,,,,Methotrexate Diglutamate,,,,,,,,,human,mbds0010,,2013-11-12 06:21:10
mbbd000144347,mbcd0003001,mbtp000002,mbrf0002351,,,,,substrate,,,,,Testosterone,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144348,mbcd0030283,mbtp000002,mbrf0002351,,,,,substrate,,,,,ST1600,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144349,mbcd0029161,mbtp000002,mbrf0002351,,,,,non-substrate,,,,,ascorbic acid,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144350,mbcd0014953,mbtp000002,mbrf0002351,,,,,non-substrate,,,,,Albendazole,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144351,mbcd0031452,mbtp000002,mbrf0002351,,,,,non-substrate,,,,,BCECF,,,,,,,,,human,mbds0010,,2013-11-12 06:48:09
mbbd000144352,mbcd0003905,mbtp000002,mbrf0002351,,,,,non-substrate,,,,,Corticosterone,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144353,mbcd0001050,mbtp000002,mbrf0002351,,,,,non-substrate,,,,,Digoxin,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144354,mbcd0002959,mbtp000002,mbrf0002351,,,,,non-substrate,,,,,Dexamethasone,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144355,mbcd0030276,mbtp000002,mbrf0002351,,,,,non-substrate,,,,,S38809,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144356,mbcd0003234,mbtp000002,mbrf0002551,,=,,,inhibitor,17,1.5,microM,,MC70,,,MDCK-BCRP transfected cell line,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144357,mbcd0002563,mbtp000002,mbrf0002551,,=,,,inhibitor,17,2.97,microM,,MC18,,,MDCK-BCRP transfected cell line,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144358,mbcd0002824,mbtp000002,mbrf0002551,,=,,,inhibitor,17,5.37,microM,,PB28,,,MDCK-BCRP transfected cell line,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144359,mbcd0017980,mbtp000002,mbrf0002546,,~,,,substrate,138,0.2,nmol cm-2 hour-1,0.05,ciprofloxacin,,,BCRP-MDCK-II transfected cell line; Transepithelial [14C]ciprofloxacin fluxes across confluent monolayers of MDCKII in apical to basolateral direction,MDCKII,,10,microM,,human,mbds0010,,2013-11-24 23:12:02
mbbd000144360,mbcd0001221,mbtp000002,mbrf0001666,,=,,,substrate,82,217.0,,30,Nitrofurantoin,,,hBCRP-MDCK-II cell line; measurements of flux ratio of net nitrofurantoin transepithelial secretion; flux ratio calculated from Jb-a/Ja-b,MDCKII,,,,,human,mbds0010,,2014-03-04 00:29:06
mbbd000144361,mbcd0023111,mbtp000002,mbrf0001666,,~,,,inducer,98,4.5,AU,0.4,Rosiglitazone,,,qPCR analysis of BCRP mRNA expression in Caco-2 cells after 72-h pretreament,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144362,mbcd0023726,mbtp000002,mbrf0001666,,~,,,inducer,98,4.0,AU,0.4,TBHQ,,,qPCR analysis of BCRP mRNA expression in Caco-2 cells after 72-h pretreament,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144363,mbcd0002831,mbtp000002,mbrf0002378,,,,,substrate,,,,,Resveratrol,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144364,mbcd0002831,mbtp000002,mbrf0002378,,,,,inhibitor,,,,,Resveratrol,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144365,mbcd0030285,mbtp000002,mbrf0002378,,=,,,inhibitor,3,5.1,%,0.1,Compound 1,,,ABCG2-transfected HEK293 cell line; aInhibition of mitoxantrone efflux; percent inhibition was determined using GF120918 as a control (100% inhibition),,,5,microM,,human,mbds0010,,2013-11-23 22:11:38
mbbd000144366,mbcd0030286,mbtp000002,mbrf0002378,,=,,,inhibitor,3,9.9,microM,0.1,Compound 2,,,ABCG2-transfected HEK293 cell line; aInhibition of mitoxantrone efflux; percent inhibition was determined using GF120918 as a control (100% inhibition),,,5,microM,,human,mbds0010,,2013-11-23 22:11:40
mbbd000144367,mbcd0030287,mbtp000002,mbrf0002378,,=,,,inhibitor,3,6.6,microM,0.9,Compound 3,,,ABCG2-transfected HEK293 cell line; aInhibition of mitoxantrone efflux; percent inhibition was determined using GF120918 as a control (100% inhibition),,,5,microM,,human,mbds0010,,2013-11-23 22:11:47
mbbd000144368,mbcd0002108,mbtp000002,mbrf0002378,,=,,,inhibitor,3,36.2,%,4.6,Compound 4,,,ABCG2-transfected HEK293 cell line; aInhibition of mitoxantrone efflux; percent inhibition was determined using GF120918 as a control (100% inhibition),,,5,microM,,human,mbds0010,,2013-11-23 22:11:47
mbbd000144369,mbcd0030288,mbtp000002,mbrf0002378,,=,,,inhibitor,3,58.5,%,21.6,Compound 5,,,ABCG2-transfected HEK293 cell line; aInhibition of mitoxantrone efflux; percent inhibition was determined using GF120918 as a control (100% inhibition),,,5,microM,,human,mbds0010,,2013-11-23 22:11:47
mbbd000144370,mbcd0030289,mbtp000002,mbrf0002378,,=,,,inhibitor,3,32.5,%,12.2,Compound 6,,,ABCG2-transfected HEK293 cell line; aInhibition of mitoxantrone efflux; percent inhibition was determined using GF120918 as a control (100% inhibition),,,5,microM,,human,mbds0010,,2013-11-23 22:11:46
mbbd000144371,mbcd0030290,mbtp000002,mbrf0002378,,=,,,inhibitor,3,55.7,%,12.1,Compound 7,,,ABCG2-transfected HEK293 cell line; aInhibition of mitoxantrone efflux; percent inhibition was determined using GF120918 as a control (100% inhibition),,,5,microM,,human,mbds0010,,2013-11-20 18:11:06
mbbd000144372,mbcd0004748,mbtp000002,mbrf0002378,,=,,,inhibitor,3,67.4,%,8.6,Compound 8,,,ABCG2-transfected HEK293 cell line; aInhibition of mitoxantrone efflux; percent inhibition was determined using GF120918 as a control (100% inhibition),,,5,microM,,human,mbds0010,,2013-11-23 22:11:45
mbbd000144373,mbcd0004729,mbtp000002,mbrf0002378,,=,,,inhibitor,3,75.6,%,7.9,Compound 9,,,ABCG2-transfected HEK293 cell line; aInhibition of mitoxantrone efflux; percent inhibition was determined using GF120918 as a control (100% inhibition),HEK293,,5,microM,,human,mbds0010,,2013-11-05 01:59:13
mbbd000144374,mbcd0004748,mbtp000002,mbrf0002378,,=,,,inhibitor,25,0.47,microM,0.08,Compound 8,,,ABCG2-transfected HEK293 cell line; determined by flow cytometry,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144375,mbcd0004729,mbtp000002,mbrf0002378,,=,,,inhibitor,25,0.16,microM,0.04,Compound 9,,,ABCG2-transfected HEK293 cell line; determined by flow cytometry,HEK293,,,,,human,mbds0010,,2013-11-05 01:59:13
mbbd000144376,mbcd0004763,mbtp000002,mbrf0002378,,=,,,inhibitor,3,76.7,%,10.5,Compound 10,,,ABCG2-transfected HEK293 cell line; aInhibition of mitoxantrone efflux; percent inhibition was determined using GF120918 as a control (100% inhibition),,,5,microM,,human,mbds0010,,2013-11-23 22:11:38
mbbd000144377,mbcd0004763,mbtp000002,mbrf0002378,,=,,,inhibitor,25,0.29,microM,0.09,Compound 10,,,ABCG2-transfected HEK293 cell line; determined by flow cytometry,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144378,mbcd0030291,mbtp000002,mbrf0002378,,=,,,inhibitor,3,34.2,%,8.5,Compound 11,,,ABCG2-transfected HEK293 cell line; aInhibition of mitoxantrone efflux; percent inhibition was determined using GF120918 as a control (100% inhibition),,,5,microM,,human,mbds0010,,2013-11-23 22:11:38
mbbd000144379,mbcd0029456,mbtp000002,mbrf0001855,,=,,,substrate,17,0.45,microM,,Hesperetin 7-O-Glucuronide,,,Sf9 cell membranes overexpressing ABCG2; ATPase assay,Sf9,,,,,human,mbds0010,,2013-11-24 23:54:56
mbbd000144380,mbcd0029456,mbtp000002,mbrf0001855,,=,,,inhibitor,25,30.0,microM,6,Hesperetin 7-O-glucuronide,,,Sf9 cell membranes overexpressing ABCG2; Vesicular transport inhibition assay,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144381,mbcd0029457,mbtp000002,mbrf0001855,,=,,,inhibitor,25,42.0,microM,0.3,hesperetin 3'-O-glucuronide,,,Sf9 cell membranes overexpressing ABCG2; Vesicular transport inhibition assay,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144382,mbcd0020414,mbtp000002,mbrf0001934,,=,,,inhibitor,25,4.97,microM,0.31,Compound 5,,,MDCK BCRP transfected cell line; tested for BCRP inhibition by the Hoechst 33342 assay,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144383,mbcd0028557,mbtp000002,mbrf0001934,,=,,,inhibitor,25,12.05,microM,1.69,Compound 7,,,MDCK BCRP transfected cell line; tested for BCRP inhibition by the Hoechst 33342 assay,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144384,mbcd0027434,mbtp000002,mbrf0001934,,=,,,inhibitor,25,0.83,microM,0.13,Compound 8,,,MDCK BCRP transfected cell line; tested for BCRP inhibition by the Hoechst 33342 assay,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144385,mbcd0030293,mbtp000002,mbrf0001934,,=,,,inhibitor,25,1.94,microM,0.17,Compound 9,,,MDCK BCRP transfected cell line; tested for BCRP inhibition by the Hoechst 33342 assay,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144386,mbcd0030063,mbtp000002,mbrf0001934,,=,,,inhibitor,25,3.28,microM,0.5,Compound 10,,,MDCK BCRP transfected cell line; tested for BCRP inhibition by the Hoechst 33342 assay,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144387,mbcd0030065,mbtp000002,mbrf0001934,,=,,,inhibitor,25,6.37,microM,0.7,Compound 11,,,MDCK BCRP transfected cell line; tested for BCRP inhibition by the Hoechst 33342 assay,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144388,mbcd0030294,mbtp000002,mbrf0001934,,=,,,inhibitor,25,30.95,microM,1.34,Compound 12,,,MDCK BCRP transfected cell line; tested for BCRP inhibition by the Hoechst 33342 assay,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144389,mbcd0022499,mbtp000002,mbrf0001934,,=,,,inhibitor,25,2.2,microM,0.75,Compound 13,,,MDCK BCRP transfected cell line; tested for BCRP inhibition by the Hoechst 33342 assay,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144390,mbcd0030295,mbtp000002,mbrf0001934,,=,,,inhibitor,25,1.06,microM,0.17,Compound 14,,,MDCK BCRP transfected cell line; tested for BCRP inhibition by the Hoechst 33342 assay,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144391,mbcd0030296,mbtp000002,mbrf0001934,,=,,,inhibitor,25,1.47,microM,0.31,Compound 15,,,MDCK BCRP transfected cell line; tested for BCRP inhibition by the Hoechst 33342 assay,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144392,mbcd0030297,mbtp000002,mbrf0001934,,=,,,inhibitor,25,3.32,microM,0.57,Compound 16,,,MDCK BCRP transfected cell line; tested for BCRP inhibition by the Hoechst 33342 assay,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144393,mbcd0030298,mbtp000002,mbrf0001934,,=,,,inhibitor,25,10.72,microM,2.82,Compound 17,,,MDCK BCRP transfected cell line; tested for BCRP inhibition by the Hoechst 33342 assay,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144394,mbcd0030299,mbtp000002,mbrf0001934,,=,,,inhibitor,25,1.91,microM,0.78,Compound 19,,,MDCK BCRP transfected cell line; tested for BCRP inhibition by the Hoechst 33342 assay,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144395,mbcd0030300,mbtp000002,mbrf0001934,,=,,,inhibitor,25,1.03,microM,0.29,Compound 20,,,MDCK BCRP transfected cell line; tested for BCRP inhibition by the Hoechst 33342 assay,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144396,mbcd0030055,mbtp000002,mbrf0001934,,=,,,inhibitor,25,2.63,microM,0.29,Compound 21,,,MDCK BCRP transfected cell line; tested for BCRP inhibition by the Hoechst 33342 assay,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144397,mbcd0002508,mbtp000002,mbrf0001934,,=,,,inhibitor,25,1.13,microM,0.21,Compound 22,,,MDCK BCRP transfected cell line; tested for BCRP inhibition by the Hoechst 33342 assay,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144398,mbcd0030301,mbtp000002,mbrf0001934,,=,,,inhibitor,25,3.0,microM,0.5,Compound 24,,,MDCK BCRP transfected cell line; tested for BCRP inhibition by the Hoechst 33342 assay,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144399,mbcd0030302,mbtp000002,mbrf0001934,,=,,,inhibitor,25,0.53,microM,0.22,Compound 25,,,MDCK BCRP transfected cell line; tested for BCRP inhibition by the Hoechst 33342 assay,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144400,mbcd0030303,mbtp000002,mbrf0001934,,=,,,inhibitor,25,2.82,microM,0.26,Compound 26,,,MDCK BCRP transfected cell line; tested for BCRP inhibition by the Hoechst 33342 assay,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144401,mbcd0030304,mbtp000002,mbrf0001934,,=,,,inhibitor,25,1.16,microM,0.34,Compound 27,,,MDCK BCRP transfected cell line; tested for BCRP inhibition by the Hoechst 33342 assay,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144402,mbcd0030305,mbtp000002,mbrf0001934,,=,,,inhibitor,25,3.8,microM,0.13,Compound 28,,,MDCK BCRP transfected cell line; tested for BCRP inhibition by the Hoechst 33342 assay,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144403,mbcd0030306,mbtp000002,mbrf0001934,,=,,,inhibitor,25,7.8,microM,2.01,Compound 29,,,MDCK BCRP transfected cell line; tested for BCRP inhibition by the Hoechst 33342 assay,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144404,mbcd0030306,mbtp000002,mbrf0001934,,=,,,inhibitor,25,1.73,microM,0.13,Compound 30,,,MDCK BCRP transfected cell line; tested for BCRP inhibition by the Hoechst 33342 assay,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144405,mbcd0030308,mbtp000002,mbrf0001934,,=,,,inhibitor,25,9.23,microM,1,Compound 31,,,MDCK BCRP transfected cell line; tested for BCRP inhibition by the Hoechst 33342 assay,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144406,mbcd0030309,mbtp000002,mbrf0001934,,=,,,inhibitor,25,9.83,microM,0.72,Compound 32,,,MDCK BCRP transfected cell line; tested for BCRP inhibition by the Hoechst 33342 assay,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144407,mbcd0030310,mbtp000002,mbrf0001934,,=,,,inhibitor,25,1.95,microM,0.39,Compound 33,,,MDCK BCRP transfected cell line; tested for BCRP inhibition by the Hoechst 33342 assay,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144408,mbcd0030311,mbtp000002,mbrf0001934,,=,,,inhibitor,25,5.68,microM,0.5,Compound 34,,,MDCK BCRP transfected cell line; tested for BCRP inhibition by the Hoechst 33342 assay,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144409,mbcd0030312,mbtp000002,mbrf0001934,,=,,,inhibitor,25,22.39,microM,6.88,Compound 37,,,MDCK BCRP transfected cell line; tested for BCRP inhibition by the Hoechst 33342 assay,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144410,mbcd0030313,mbtp000002,mbrf0001934,,=,,,inhibitor,25,2.58,microM,0.94,Compound 38,,,MDCK BCRP transfected cell line; tested for BCRP inhibition by the Hoechst 33342 assay,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144411,mbcd0030314,mbtp000002,mbrf0001934,,=,,,inhibitor,25,2.89,microM,0.73,Compound 39,,,MDCK BCRP transfected cell line; tested for BCRP inhibition by the Hoechst 33342 assay,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144412,mbcd0030315,mbtp000002,mbrf0001934,,=,,,inhibitor,25,0.72,microM,0.14,Compound 40,,,MDCK BCRP transfected cell line; tested for BCRP inhibition by the Hoechst 33342 assay,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144413,mbcd0030316,mbtp000002,mbrf0001934,,=,,,inhibitor,25,1.93,microM,0.15,Compound 41,,,MDCK BCRP transfected cell line; tested for BCRP inhibition by the Hoechst 33342 assay,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144414,mbcd0030317,mbtp000002,mbrf0001934,,=,,,inhibitor,25,5.58,microM,0.6,Compound,,,MDCK BCRP transfected cell line; tested for BCRP inhibition by the Hoechst 33342 assay,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144415,mbcd0030318,mbtp000002,mbrf0001934,,=,,,inhibitor,25,5.58,microM,0.6,Compound 44,,,MDCK BCRP transfected cell line; tested for BCRP inhibition by the Hoechst 33342 assay,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144416,mbcd0002439,mbtp000002,mbrf0001934,,=,,,inhibitor,25,0.26,microM,0.02,Ko 143,,,MDCK BCRP transfected cell line; tested for BCRP inhibition by the Hoechst 33342 assay,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144417,mbcd0007286,mbtp000002,mbrf0002441,,=,,,substrate,17,327.2,microM,9.4,Chlorothiazide,,,MDCKII-BCRP cell line; ATPase assay,MDCKII,,,,,human,mbds0010,,2013-11-24 23:12:03
mbbd000144418,mbcd0007286,mbtp000002,mbrf0002441,,=,,,substrate,28,334.6,microM,325,Chlorothiazide,,,ABCG2 over-expressing Sf9 membranes; Vesicular transport assay,Sf9,,,,,human,mbds0010,,2013-11-24 23:54:56
mbbd000144419,mbcd0007286,mbtp000002,mbrf0002441,,=,,,inhibitor,25,212.3,microM,210.8,Chlorothiazide,,,MDCKII-BCRP cell line,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144420,mbcd0003162,mbtp000002,mbrf0001661,,=,,,inhibitor,3,62.5,%,2.4,Compound 2a,,,"HEK293-ABCG2 transfected cell line; Inhibition of Mitoxantrone Efflux; Percent inhibition was determined by flow cytometry, relative to 5 ?M GF120918 as a control producing 100% inhibition",,,5,microM,,human,mbds0010,,2013-11-23 22:11:37
mbbd000144421,mbcd0030320,mbtp000002,mbrf0001661,,=,,,inhibitor,3,9.8,%,2.5,Compound 2b,,,"HEK293-ABCG2 transfected cell line; Inhibition of Mitoxantrone Efflux; Percent inhibition was determined by flow cytometry, relative to 5 ?M GF120918 as a control producing 100% inhibition",,,5,microM,,human,mbds0010,,2013-11-23 22:11:47
mbbd000144422,mbcd0030321,mbtp000002,mbrf0001661,,=,,,inhibitor,3,26.7,%,4.6,Compound 5a,,,"HEK293-ABCG2 transfected cell line; Inhibition of Mitoxantrone Efflux; aPercent inhibition was determined by flow cytometry, relative to 5 ?M GF120918 as a control producing 100% inhibition",,,5,microM,,human,mbds0010,,2013-11-23 22:11:46
mbbd000144423,mbcd0030322,mbtp000002,mbrf0001661,,=,,,inhibitor,25,0.17,microM,,Compound 6a,,,HEK293-ABCG2 transfected cell line; Inhibition of Mitoxantrone Efflux,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144424,mbcd0030323,mbtp000002,mbrf0001661,,=,,,inhibitor,3,66.1,microM,12.4,Compound 6b,,,"HEK293-ABCG2 transfected cell line; Inhibition of Mitoxantrone Efflux; aPercent inhibition was determined by flow cytometry, relative to 5 ?M GF120918 as a control producing 100% inhibition",,,5,microM,,human,mbds0010,,2013-11-23 22:11:46
mbbd000144425,mbcd0030324,mbtp000002,mbrf0001661,,=,,,inhibitor,3,46.2,%,3.1,Compound 6c,,,"HEK293-ABCG2 transfected cell line; Inhibition of Mitoxantrone Efflux; aPercent inhibition was determined by flow cytometry, relative to 5 ?M GF120918 as a control producing 100% inhibition",,,5,microM,,human,mbds0010,,2013-11-23 22:11:46
mbbd000144426,mbcd0030325,mbtp000002,mbrf0001661,,=,,,inhibitor,3,48.3,microM,3.2,Compound 6d,,,"HEK293-ABCG2 transfected cell line; Inhibition of Mitoxantrone Efflux; aPercent inhibition was determined by flow cytometry, relative to 5 ?M GF120918 as a control producing 100% inhibition",,,5,microM,,human,mbds0010,,2013-11-23 22:11:45
mbbd000144427,mbcd0030326,mbtp000002,mbrf0001661,,=,,,inhibitor,25,0.47,microM,,Compound 6e,,,HEK293-ABCG2 transfected cell line; Inhibition of Mitoxantrone Efflux,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144428,mbcd0030327,mbtp000002,mbrf0001661,,=,,,inhibitor,25,0.18,microM,,Compound 6f,,,HEK293-ABCG2 transfected cell line; Inhibition of Mitoxantrone Efflux,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144429,mbcd0030328,mbtp000002,mbrf0001661,,=,,,inhibitor,25,0.11,microM,,Compound 6g,,,HEK293-ABCG2 transfected cell line; Inhibition of Mitoxantrone Efflux,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144430,mbcd0030329,mbtp000002,mbrf0001661,,=,,,inhibitor,25,0.2,microM,,Compound 6h,,,HEK293-ABCG2 transfected cell line; Inhibition of Mitoxantrone Efflux,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144431,mbcd0030330,mbtp000002,mbrf0001661,,=,,,inhibitor,25,0.16,microM,,Compound 6i,,,HEK293-ABCG2 transfected cell line; Inhibition of Mitoxantrone Efflux,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144432,mbcd0015116,mbtp000002,mbrf0001999,,,,,substrate,,,,,nifurtimox,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144433,mbcd0000167,mbtp000002,mbrf0002119,,,,,inhibitor,,,,,benidipine,,,Growth inhibition,HeLa,mbcd0002981,0.1; 1; 10,microM,,human,mbds0010,,2013-10-09 22:18:32
mbbd000144434,mbcd0003011,mbtp000002,mbrf0002119,,,,,inhibitor,,,,,felodipine,,,Growth inhibition,HeLa,mbcd0002981,0.1; 1; 10,microM,,human,mbds0010,,2013-10-09 22:18:32
mbbd000144435,mbcd0002576,mbtp000002,mbrf0002119,,,,,inhibitor,,,,,nicardipine,,,Growth inhibition,HeLa,mbcd0002981,0.1; 1; 10,microM,,human,mbds0010,,2013-10-09 22:18:32
mbbd000144436,mbcd0001058,mbtp000002,mbrf0002119,,,,,inhibitor,,,,,nisoldipine,,,Growth inhibition,HeLa,mbcd0002981,0.1; 1; 10,microM,,human,mbds0010,,2013-10-09 22:18:32
mbbd000144437,mbcd0003135,mbtp000002,mbrf0002119,,,,,inhibitor,,,,,nitrendipine,,,Growth inhibition,HeLa,mbcd0002981,0.1; 1; 10,microM,,human,mbds0010,,2013-10-09 22:18:32
mbbd000144438,mbcd0028580,mbtp000002,mbrf0002119,,,,,inhibitor,,,,,amlodipine,,,Growth inhibition,HeLa,mbcd0002981,0.1; 1; 10,microM,,human,mbds0010,,2013-10-09 22:18:33
mbbd000144439,mbcd0007511,mbtp000002,mbrf0002119,,,,,inhibitor,,,,,nifedipine,,,Growth inhibition,HeLa,mbcd0002981,0.1; 1; 10,microM,,human,mbds0010,,2013-10-09 22:18:33
mbbd000144440,mbcd0002338,mbtp000002,mbrf0002119,,,,,inhibitor,,,,,diltiazem,,,Growth inhibition,HeLa,mbcd0002981,0.1; 1; 10,microM,,human,mbds0010,,2013-10-09 22:18:33
mbbd000144441,mbcd0027062,mbtp000002,mbrf0002119,,,,,inhibitor,,,,,verapamil,,,Growth inhibition,HeLa,mbcd0002981,0.1; 1; 10,microM,,human,mbds0010,,2013-10-09 22:18:33
mbbd000144442,mbcd0030331,mbtp000002,mbrf0001810,,~,,,inhibitor,100,0.48,pmol (mg protein)-1,0.05,Purvalanol A,,,"ABCG2-transduced MDCKII subline; effect of inhibitor on accumulation of 10nM [3H]-glyburide, an established ABCG2 substrate, in MDCKII-ABCG2 cells",,,5,microM,,human,mbds0010,,2013-11-24 03:25:25
mbbd000144443,mbcd0030332,mbtp000002,mbrf0001810,,~,,,inhibitor,100,0.38,pmol (mg protein)-1,0.04,olomoucine II,,,"ABCG2-transduced MDCKII subline; effect of inhibitor on accumulation of 10nM [3H]-glyburide, an established ABCG2 substrate, in MDCKII-ABCG2 cells",,,5,microM,,human,mbds0010,,2013-11-24 22:14:59
mbbd000144444,mbcd0030333,mbtp000002,mbrf0001810,,~,,,inhibitor,100,0.3,pmol (mg protein)-1,0.01,roscovitine,,,"ABCG2-transduced MDCKII subline; effect of inhibitor on accumulation of 10nM [3H]-glyburide, an established ABCG2 substrate, in MDCKII-ABCG2 cells",,,5,microM,,human,mbds0010,,2013-11-24 22:15:06
mbbd000144445,mbcd0030334,mbtp000002,mbrf0001810,,~,,,inhibitor,100,0.28,pmol (mg protein)-1,0.05,bohemine,,,"ABCG2-transduced MDCKII subline; effect of inhibitor on accumulation of 10nM [3H]-glyburide, an established ABCG2 substrate, in MDCKII-ABCG2 cells",,,5,microM,,human,mbds0010,,2013-11-24 07:52:29
mbbd000144446,mbcd0002422,mbtp000002,mbrf0001810,,~,,,inhibitor,100,0.48,pmol (mg protein)-1,0.05,Fumitremorgin C,,,"ABCG2-transduced MDCKII subline; effect of inhibitor on accumulation of 10nM [3H]-glyburide, an established ABCG2 substrate, in MDCKII-ABCG2 cells",,,5,microM,,human,mbds0010,,2013-11-24 02:25:33
mbbd000144447,mbcd0030335,mbtp000002,mbrf0002413,,~,,,substrate,138,55.0,%,5,N-Desethyl Sunitinib,,,MDCKII-BCRP transfected cell line; Transepithelial transport from basolateral to apical compartment after 4 hours incubation time; measurements of amount of drug appearing in opposite compartment as a percentage of amount of initially applied drug,MDCKII,,5,microM,,human,mbds0010,,2013-11-24 23:12:03
mbbd000144448,mbcd0029825,mbtp000002,mbrf0002459,,,,,substrate,,,,,Mercaptopurine,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144449,mbcd0030337,mbtp000002,mbrf0002459,,,,,substrate,,,,,Thioguanine,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144450,mbcd0000960,mbtp000002,mbrf0002459,,,,,substrate,,,,,Cladribine,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144451,mbcd0029116,mbtp000002,mbrf0002459,,,,,substrate,,,,,Cladribine Monophosphate,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144452,mbcd0001190,mbtp000002,mbrf0002459,,,,,substrate,,,,,Clofarabine,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144453,mbcd0003110,mbtp000002,mbrf0002459,,,,,substrate,,,,,PMEA,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144454,mbcd0029345,mbtp000002,mbrf0001808,,~,,,substrate,138,5.0,microL (5 min)-1 (mg protein)-1,0.2,uric acid,,,hBCRP expressing membrane vesicles prepared from Sf9 cells,Sf9,,20,microM,,human,mbds0010,,2013-11-24 23:54:57
mbbd000144455,mbcd0003125,mbtp000002,mbrf0002013,,=,,,inhibitor,25,3.25,microM,0.51,gefitinib,,,MDCK II-BCRP cell line; Hoechst 33342 accumulation assay,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144456,mbcd0003099,mbtp000002,mbrf0002013,,=,,,inhibitor,25,2.46,microM,0.51,erlotinib,,,MDCK II-BCRP cell line; Hoechst 33342 accumulation assay,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144457,mbcd0015314,mbtp000002,mbrf0002013,,=,,,inhibitor,25,2.5,microM,0.42,PD 153035,,,MDCK II-BCRP cell line; Hoechst 33342 accumulation assay,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144458,mbcd0030339,mbtp000002,mbrf0002013,,=,,,inhibitor,25,0.36,microM,0.07,PD 158780,,,MDCK II-BCRP cell line; Hoechst 33342 accumulation assay,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144459,mbcd0011472,mbtp000002,mbrf0002013,,=,,,inhibitor,25,5.5,microM,0.38,AG 1428,,,MDCK II-BCRP cell line; Hoechst 33342 accumulation assay,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144460,mbcd0002828,mbtp000002,mbrf0002013,,=,,,inhibitor,25,9.24,microM,3.06,imatinib,,,MDCK II-BCRP cell line; Hoechst 33342 accumulation assay,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144461,mbcd0001690,mbtp000002,mbrf0002013,,=,,,inhibitor,25,0.67,microM,0.09,nilotinib,,,MDCK II-BCRP cell line; Hoechst 33342 accumulation assay,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144462,mbcd0030340,mbtp000002,mbrf0002197,,~,,,substrate,138,1000.0,pmol,5,(+)-Pantoprazole,,,ABCG2-MDCK II cell line; isomer trasnport in basolateral to apical direction,MDCKII,,10,microM,,human,mbds0010,,2013-11-24 23:12:03
mbbd000144463,mbcd0030341,mbtp000002,mbrf0002197,,~,,,substrate,138,9900.0,pmol,,(-)-Pantoprazole,,,ABCG2-MDCK II cell line; isomer trasnport in basolateral to apical direction,MDCKII,,10,microM,,human,mbds0010,,2013-12-09 05:58:31
mbbd000144464,mbcd0030340,mbtp000002,mbrf0002197,,=,,,substrate,82,5.8,,,(+)-Pantoprazole,PSobs B->A/PSobs A->B,,ABCG2-MDCKII cell line,MDCKII,,10,microM,,human,mbds0010,,2013-11-24 23:12:04
mbbd000144465,mbcd0030341,mbtp000002,mbrf0002197,,=,,,substrate,82,8.1,,,(-)-Pantoprazole,PSobs B->A/PSobs A->B,,ABCG2-MDCKII cell line,MDCKII,,10,microM,,human,mbds0010,,2013-11-24 23:12:04
mbbd000144466,mbcd0030340,mbtp000002,mbrf0002197,,=,,,substrate,28,5.32,microM,1.62,(+)-Pantoprazole,,,ABCG2-MDCK II cell line,MDCKII,,,,,human,mbds0010,,2013-12-09 05:57:09
mbbd000144467,mbcd0030341,mbtp000002,mbrf0002197,,=,,,substrate,28,0.59,microM,0.12,(-)-Pantoprazole,,,ABCG2-MDCK II cell line,MDCKII,,,,,human,mbds0010,,2013-12-09 05:58:31
mbbd000144468,mbcd0002494,mbtp000002,mbrf0002518,,,,,inhibitor,,,,,MK 571,,,estrone-3-sulfate and genistein used as substrates,Caco-2,mbcd0003075,50,microM,,human,mbds0010,,2013-10-09 22:18:31
mbbd000144469,mbcd0003075,mbtp000002,mbrf0002518,,=,,,substrate,14,39.7,*10^-6 cm s-1,1.2,Estrone-3-Sulfate,,,BCRP-Caco-2 cell line; permeability measurements from basolateral to apical compartment,Caco-2,,,,,human,mbds0010,,2013-11-24 23:12:41
mbbd000144470,mbcd0003116,mbtp000002,mbrf0002518,,=,,,substrate,14,75.2,*10^-6 cm s-1,2.9,Genistein,,,BCRP-Caco-2 cell line; permeability measurements from basolateral to apical compartment,Caco-2,,,,,human,mbds0010,,2013-11-24 23:12:42
mbbd000144471,mbcd0027129,mbtp000002,mbrf0001739,,~,,,inhibitor,3,0.16,pmol mg-1 minute-1,0.02,GW 583340,,,HEK293-ABCG2-482-R2 cell line membrane vesicles; measurements of methotrexate uptake,,,5,microM,,human,mbds0010,,2013-11-24 02:25:33
mbbd000144472,mbcd0007312,mbtp000002,mbrf0001739,,~,,,inhibitor,3,0.2,pmol mg-1 minute-1,0.01,GW 2974,,,HEK293-ABCG2-482-R2 cell line membrane vesicles; measurements of methotrexate uptake,,,5,microM,,human,mbds0010,,2013-11-24 02:25:33
mbbd000144473,mbcd0030342,mbtp000002,mbrf0001831,,=,,,substrate,25,7.5,nM,0.9,KP1089,,,MDA-MB-231/ABCG2(R482T) transfected cell line,MDA-MB-231,,,,,human,mbds0010,,2013-11-24 23:55:51
mbbd000144474,mbcd0016401,mbtp000002,mbrf0002398,,,,,inhibitor,,,,,LY 294002,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144475,mbcd0030343,mbtp000002,mbrf0002135,,=,,,inhibitor,3,18.3,%,15.6,Compound 5,,,HEK293/ABCG2 transfected cell line; percent inhibition on ABCG2-mediated mitoxantrone transport determined by flow cytometry; GF120918 (5 microM) was used as a control (100 ± 9.7%),,,10,microM,,human,mbds0010,,2013-11-23 22:11:44
mbbd000144476,mbcd0030344,mbtp000002,mbrf0002135,,=,,,inhibitor,3,9.4,%,13.3,Compound 6,,,HEK293/ABCG2 transfected cell line; percent inhibition on ABCG2-mediated mitoxantrone transport determined by flow cytometry; GF120918 (5 microM) was used as a control (100 ± 9.7%),,,10,microM,,human,mbds0010,,2013-11-23 22:11:44
mbbd000144477,mbcd0030345,mbtp000002,mbrf0002135,,=,,,inhibitor,3,18.9,%,18,Compound 7,,,HEK293/ABCG2 transfected cell line; percent inhibition on ABCG2-mediated mitoxantrone transport determined by flow cytometry; GF120918 (5 microM) was used as a control (100 ± 9.7%),,,10,microM,,human,mbds0010,,2013-11-23 22:11:45
mbbd000144478,mbcd0030346,mbtp000002,mbrf0002135,,=,,,inhibitor,3,40.4,%,19.6,Compound 8,,,HEK293/ABCG2 transfected cell line; percent inhibition on ABCG2-mediated mitoxantrone transport determined by flow cytometry; GF120918 (5 microM) was used as a control (100 ± 9.7%),,,10,microM,,human,mbds0010,,2013-11-23 22:11:45
mbbd000144479,mbcd0030347,mbtp000002,mbrf0002135,,=,,,inhibitor,3,55.1,%,11.7,Compound 9,,,HEK293/ABCG2 transfected cell line; percent inhibition on ABCG2-mediated mitoxantrone transport determined by flow cytometry; GF120918 (5 microM) was used as a control (100 ± 9.7%),,,10,microM,,human,mbds0010,,2013-11-23 22:11:45
mbbd000144480,mbcd0030348,mbtp000002,mbrf0002135,,=,,,inhibitor,3,45.4,%,13.3,Compound 11,,,HEK293/ABCG2 transfected cell line; percent inhibition on ABCG2-mediated mitoxantrone transport determined by flow cytometry; GF120918 (5 microM) was used as a control (100 ± 9.7%),,,10,microM,,human,mbds0010,,2013-11-23 22:11:44
mbbd000144481,mbcd0002210,mbtp000002,mbrf0002135,,=,,,inhibitor,3,55.3,%,13.4,Compound 12,,,HEK293/ABCG2 transfected cell line; percent inhibition on ABCG2-mediated mitoxantrone transport determined by flow cytometry; GF120918 (5 microM) was used as a control (100 ± 9.7%),,,10,microM,,human,mbds0010,,2013-11-23 22:11:38
mbbd000144482,mbcd0030349,mbtp000002,mbrf0002135,,=,,,inhibitor,3,71.8,%,11.4,Compound 13,,,HEK293/ABCG2 transfected cell line; percent inhibition on ABCG2-mediated mitoxantrone transport determined by flow cytometry; GF120918 (5 microM) was used as a control (100 ± 9.7%),,,10,microM,,human,mbds0010,,2013-11-23 22:11:39
mbbd000144483,mbcd0030350,mbtp000002,mbrf0002135,,=,,,inhibitor,3,54.3,%,17.4,Compound 14,,,HEK293/ABCG2 transfected cell line; percent inhibition on ABCG2-mediated mitoxantrone transport determined by flow cytometry; GF120918 (5 microM) was used as a control (100 ± 9.7%),,,10,microM,,human,mbds0010,,2013-11-23 22:11:39
mbbd000144484,mbcd0030351,mbtp000002,mbrf0002135,,=,,,inhibitor,3,55.0,%,11.2,Compound 16,,,HEK293/ABCG2 transfected cell line; percent inhibition on ABCG2-mediated mitoxantrone transport determined by flow cytometry; GF120918 (5 microM) was used as a control (100 ± 9.7%),,,10,microM,,human,mbds0010,,2013-11-23 22:11:39
mbbd000144485,mbcd0030352,mbtp000002,mbrf0002135,,=,,,inhibitor,3,63.2,%,9.2,Compound 18,,,HEK293/ABCG2 transfected cell line; percent inhibition on ABCG2-mediated mitoxantrone transport determined by flow cytometry; GF120918 (5 microM) was used as a control (100 ± 9.7%),,,10,microM,,human,mbds0010,,2013-11-23 22:11:39
mbbd000144486,mbcd0030353,mbtp000002,mbrf0002135,,=,,,inhibitor,3,59.7,%,1,Compound 19,,,HEK293/ABCG2 transfected cell line; percent inhibition on ABCG2-mediated mitoxantrone transport determined by flow cytometry; GF120918 (5 microM) was used as a control (100 ± 9.7%),,,10,microM,,human,mbds0010,,2013-11-23 22:11:40
mbbd000144487,mbcd0030295,mbtp000002,mbrf0002135,,=,,,inhibitor,3,76.5,%,6.7,Compound 20,,,HEK293/ABCG2 transfected cell line; percent inhibition on ABCG2-mediated mitoxantrone transport determined by flow cytometry; GF120918 (5 microM) was used as a control (100 ± 9.7%),,,10,microM,,human,mbds0010,,2013-11-23 22:11:40
mbbd000144488,mbcd0030354,mbtp000002,mbrf0002135,,=,,,inhibitor,3,68.4,%,12.4,Compound 21,,,HEK293/ABCG2 transfected cell line; percent inhibition on ABCG2-mediated mitoxantrone transport determined by flow cytometry; GF120918 (5 microM) was used as a control (100 ± 9.7%),,,10,microM,,human,mbds0010,,2013-11-23 22:11:41
mbbd000144489,mbcd0030355,mbtp000002,mbrf0002135,,=,,,inhibitor,3,48.5,microM,14,Compound 22,,,HEK293/ABCG2 transfected cell line; percent inhibition on ABCG2-mediated mitoxantrone transport determined by flow cytometry; GF120918 (5 microM) was used as a control (100 ± 9.7%),,,,,,human,mbds0010,,2013-11-23 22:11:48
mbbd000144490,mbcd0030356,mbtp000002,mbrf0002135,,=,,,inhibitor,3,41.6,%,23.1,Compound 23,,,HEK293/ABCG2 transfected cell line; percent inhibition on ABCG2-mediated mitoxantrone transport determined by flow cytometry; GF120918 (5 microM) was used as a control (100 ± 9.7%),,,10,microM,,human,mbds0010,,2013-11-23 22:11:41
mbbd000144491,mbcd0030357,mbtp000002,mbrf0002135,,=,,,inhibitor,3,101.2,%,14,Compound 24,,,HEK293/ABCG2 transfected cell line; percent inhibition on ABCG2-mediated mitoxantrone transport determined by flow cytometry; GF120918 (5 microM) was used as a control (100 ± 9.7%),,,10,microM,,human,mbds0010,,2013-11-23 22:11:41
mbbd000144492,mbcd0030358,mbtp000002,mbrf0002135,,=,,,inhibitor,3,79.3,%,13.8,Compound 25,,,HEK293/ABCG2 transfected cell line; percent inhibition on ABCG2-mediated mitoxantrone transport determined by flow cytometry; GF120918 (5 microM) was used as a control (100 ± 9.7%),,,10,microM,,human,mbds0010,,2013-11-23 22:11:41
mbbd000144493,mbcd0030359,mbtp000002,mbrf0002135,,=,,,inhibitor,3,54.7,microM,10.8,Compound 26,,,HEK293/ABCG2 transfected cell line; percent inhibition on ABCG2-mediated mitoxantrone transport determined by flow cytometry; GF120918 (5 microM) was used as a control (100 ± 9.7%),,,10,microM,,human,mbds0010,,2013-11-23 22:11:41
mbbd000144494,mbcd0030360,mbtp000002,mbrf0002135,,=,,,inhibitor,3,130.5,%,12.6,Compound 27,,,HEK293/ABCG2 transfected cell line; percent inhibition on ABCG2-mediated mitoxantrone transport determined by flow cytometry; GF120918 (5 microM) was used as a control (100 ± 9.7%),,,10,microM,,human,mbds0010,,2013-11-23 22:11:42
mbbd000144495,mbcd0030361,mbtp000002,mbrf0002135,,=,,,inhibitor,3,117.9,%,22.8,Compound 28,,,HEK293/ABCG2 transfected cell line; percent inhibition on ABCG2-mediated mitoxantrone transport determined by flow cytometry; GF120918 (5 microM) was used as a control (100 ± 9.7%),,,10,microM,,human,mbds0010,,2013-11-23 22:11:42
mbbd000144496,mbcd0025608,mbtp000002,mbrf0002135,,=,,,inhibitor,3,60.4,%,17.4,Compound 29,,,HEK293/ABCG2 transfected cell line; percent inhibition on ABCG2-mediated mitoxantrone transport determined by flow cytometry; GF120918 (5 microM) was used as a control (100 ± 9.7%),,,10,microM,,human,mbds0010,,2013-11-23 22:11:42
mbbd000144497,mbcd0030362,mbtp000002,mbrf0002135,,=,,,inhibitor,3,93.1,%,8.9,Compound 30,,,HEK293/ABCG2 transfected cell line; percent inhibition on ABCG2-mediated mitoxantrone transport determined by flow cytometry; GF120918 (5 microM) was used as a control (100 ± 9.7%),,,10,microM,,human,mbds0010,,2013-11-23 22:11:43
mbbd000144498,mbcd0030363,mbtp000002,mbrf0002135,,=,,,inhibitor,3,97.9,%,2.2,Compound 31,,,HEK293/ABCG2 transfected cell line; percent inhibition on ABCG2-mediated mitoxantrone transport determined by flow cytometry; GF120918 (5 microM) was used as a control (100 ± 9.7%),,,10,microM,,human,mbds0010,,2013-11-23 22:11:43
mbbd000144499,mbcd0030364,mbtp000002,mbrf0002135,,=,,,inhibitor,3,90.0,%,14.5,Compound 32,,,HEK293/ABCG2 transfected cell line; percent inhibition on ABCG2-mediated mitoxantrone transport determined by flow cytometry; GF120918 (5 microM) was used as a control (100 ± 9.7%),,,10,microM,,human,mbds0010,,2013-11-23 22:11:43
mbbd000144500,mbcd0030365,mbtp000002,mbrf0002135,,=,,,inhibitor,3,84.9,%,10.7,Compound 33,,,HEK293/ABCG2 transfected cell line; percent inhibition on ABCG2-mediated mitoxantrone transport determined by flow cytometry; GF120918 (5 microM) was used as a control (100 ± 9.7%),,,10,microM,,human,mbds0010,,2013-11-23 22:11:43
mbbd000144501,mbcd0030366,mbtp000002,mbrf0002135,,=,,,inhibitor,3,95.0,%,12.6,Compound 34,,,HEK293/ABCG2 transfected cell line; percent inhibition on ABCG2-mediated mitoxantrone transport determined by flow cytometry; GF120918 (5 microM) was used as a control (100 ± 9.7%),,,10,microM,,human,mbds0010,,2013-11-23 22:11:44
mbbd000144502,mbcd0016401,mbtp000002,mbrf0001977,,~,,,inhibitor,125,1.25,,0.1,LY 294002,,,hABCG2wt- expressing (Sf9) cell membranes; Data were normalized to the ABCG2-ATPase activities measured in the absence of inhibitor,,,10,microM,,human,mbds0010,,2013-11-24 02:54:45
mbbd000144503,mbcd0001324,mbtp000002,mbrf0001977,,~,,,inhibitor,125,0.2,,0.02,Rapamycin,,,hABCG2wt- expressing (Sf9) cell membranes; Data were normalized to the ABCG2-ATPase activities measured in the absence of inhibitor,,,10,microM,,human,mbds0010,,2013-11-24 03:25:27
mbbd000144504,mbcd0030367,mbtp000002,mbrf0002421,,~,,,inhibitor,96,25.0,%,5,triclabendazole,,,hABCG2-transfected inside-out mebrane vesicles,,,10,microM,,human,mbds0010,,2013-11-24 22:15:10
mbbd000144505,mbcd0030368,mbtp000002,mbrf0002421,,~,,,inhibitor,100,230.0,Units of fluorescence,20,triclabendazole sulfoxide,,,MDCK-II/BCRP cell line; accumulation of mitoxantrone (10microM),,,25,microM,,human,mbds0010,,2013-11-24 22:15:11
mbbd000144506,mbcd0030368,mbtp000002,mbrf0002421,,~,,,inhibitor,96,100.0,%,4,triclabendazole sulfoxide,,,hABCG2-transfected inside-out mebrane vesicles,,,10,microM,,human,mbds0010,,2013-11-24 22:15:11
mbbd000144507,mbcd0030369,mbtp000002,mbrf0002421,,~,,,inhibitor,96,180.0,%,5,triclabendazole sulfone,,,hABCG2-transfected inside-out mebrane vesicles,,,10,microM,,human,mbds0010,,2013-11-24 22:15:10
mbbd000144508,mbcd0030369,mbtp000002,mbrf0002421,,~,,,inhibitor,100,250.0,Units of fluorescence,10,triclabendazole sulfone,,,MDCK-II/BCRP cell line; accumulation of mitoxantrone (10microM),,,25,microM,,human,mbds0010,,2013-11-24 22:15:10
mbbd000144509,mbcd0026443,mbtp000002,mbrf0002375,,~,,,inhibitor,100,500.0,%,100,BITC,,,MCF-7/MX100 cell line; intracellular mitoxantrone accumulation,,,50,microM,,human,mbds0010,,2013-11-23 22:11:27
mbbd000144510,mbcd0003129,mbtp000002,mbrf0002375,,~,,,inhibitor,100,575.0,%,150,PEITC,,,MCF-7/MX100 cell line; intracellular accumulation of mitoxantrone was determined by flow cytometric analysis and expressed as percent of control,,,50,microM,,human,mbds0010,,2013-11-24 02:54:55
mbbd000144511,mbcd0028378,mbtp000002,mbrf0002375,,~,,,inhibitor,100,400.0,%,80,NITC,,,MCF-7/MX100 cell line; intracellular accumulation of mitoxantrone was determined by flow cytometric analysis and expressed as percent of control,,,50,microM,,human,mbds0010,,2013-11-24 02:54:49
mbbd000144512,mbcd0030370,mbtp000002,mbrf0002375,,~,,,inhibitor,100,350.0,%,100,HITC,,,MCF-7/MX100 cell line; intracellular accumulation of mitoxantrone was determined by flow cytometric analysis and expressed as percent of control,,,50,microM,,human,mbds0010,,2013-11-24 02:54:36
mbbd000144513,mbcd0030371,mbtp000002,mbrf0002375,,~,,,inhibitor,100,600.0,%,50,PBITC,,,MCF-7/MX100 cell line; intracellular accumulation of mitoxantrone was determined by flow cytometric analysis and expressed as percent of control,,,50,microM,,human,mbds0010,,2013-11-24 02:54:54
mbbd000144514,mbcd0030372,mbtp000002,mbrf0002375,,~,,,inhibitor,100,510.0,%,100,PPITC,,,MCF-7/MX100 cell line; intracellular accumulation of mitoxantrone was determined by flow cytometric analysis and expressed as percent of control,,,50,microM,,human,mbds0010,,2013-11-24 03:25:17
mbbd000144515,mbcd0000685,mbtp000002,mbrf0002375,,~,,,inhibitor,100,520.0,%,100,PHITC,,,MCF-7/MX100 cell line; intracellular accumulation of mitoxantrone was determined by flow cytometric analysis and expressed as percent of control,,,50,microM,,human,mbds0010,,2013-11-24 02:54:55
mbbd000144516,mbcd0030373,mbtp000002,mbrf0001703,,,,,substrate,,,,,phenolic MPA-glucuronide,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144517,mbcd0029769,mbtp000002,mbrf0002102,,,,,non-substrate,,,,,Cholyl-L-Lysyl-Fluorescein; CLF,,,Membrane vesicles of Ff21 insect cells,Sf21,,4,microM,,human,mbds0010,,2013-10-09 22:18:43
mbbd000144518,mbcd0030274,mbtp000002,mbrf0001982,,~,,,substrate,138,3.8,%,,moxidectin,,,"MDCKII-BCRP cell line; Transepithelial transport from basolateral to apical compartment; After 4 h, the radioactivity appearing in the opposite compartment was measured and plotted",MDCKII,,0.1,microM,,human,mbds0010,,2013-11-24 23:12:05
mbbd000144519,mbcd0030274,mbtp000002,mbrf0001982,,=,,,substrate,14,8.1,*10^-7 cm s-1,0.3,moxidectin,,,MDCKII-BCRP cell line; apparent permeability coefficient in basolateral to apical direction,MDCKII,,0.1,microM,,human,mbds0010,,2013-11-24 23:12:05
mbbd000144520,mbcd0003125,mbtp000002,mbrf0001694,,=,,,inhibitor,25,197.7,nM,13.1,Gefitinib,,,A431/ABCG2 cell line,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144521,mbcd0030146,mbtp000002,mbrf0001694,,=,,,inhibitor,25,979.2,nM,79.2,Vandetanib,,,A431/ABCG2 cell line,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144522,mbcd0030375,mbtp000002,mbrf0001694,,=,,,inhibitor,25,133.2,nM,21.9,Pelitinib,,,A431/ABCG2 cell line,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144523,mbcd0030376,mbtp000002,mbrf0001694,,=,,,inhibitor,25,21.8,nM,5.4,Neratinib,,,A431/ABCG2 cell line,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144524,mbcd0003125,mbtp000002,mbrf0001694,,~,,,inhibitor,96,150.0,nmol Pi min-1 (mg protein)-1,,Gefitinib,,,Sf9 membrane vesicles expressing ABCG2; basal ATPase activity,,,10,microM,,human,mbds0010,,2013-11-24 02:25:34
mbbd000144525,mbcd0030146,mbtp000002,mbrf0001694,,~,,,inhibitor,96,40.0,nmol Pi min-1 (mg protein)-1,2,Vandetanib,,,Sf9 membrane vesicles expressing ABCG2; basal ATPase activity,,,10,microM,,human,mbds0010,,2013-11-24 06:37:39
mbbd000144526,mbcd0030375,mbtp000002,mbrf0001694,,~,,,inhibitor,96,148.0,nmol Pi min-1 (mg protein)-1,,Pelitinib,,,Sf9 membrane vesicles expressing ABCG2; basal ATPase activity,,,10,microM,,human,mbds0010,,2013-12-09 06:26:02
mbbd000144527,mbcd0030376,mbtp000002,mbrf0001694,,~,,,inhibitor,96,10.0,nmol Pi min-1 (mg protein)-1,,neratinib,,,Sf9 membrane vesicles expressing ABCG2; basal ATPase activity,,,1,microM,,human,mbds0010,,2013-11-24 22:14:57
mbbd000144528,mbcd0030377,mbtp000002,mbrf0001730,,~,,,inhibitor,96,45.0,nmol min-1 (mg protein)-1,2,axitinib,,,ABCG2-transfected membrane vesicles,,,10,micromol L-1,,human,mbds0010,,2013-11-24 07:52:28
mbbd000144529,mbcd0026147,mbtp000002,mbrf0002509,,,,,substrate,,,,,Bisphenol A,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144530,mbcd0030378,mbtp000002,mbrf0002509,,,,,non-substrate,,,,,Bisphenol A Glucuronide,,,,,,,,,human,mbds0010,,2013-07-17 21:06:48
mbbd000144531,mbcd0001056,mbtp000002,mbrf0001839,,~,,,inhibitor,100,2.0,fold,0.2,sorafenib,,,HEK293/ABCG2 cell line; 30-minute incubation; intracellular mitoxantrone accumulation,,,2.5,micromol L-1,,human,mbds0010,,2013-11-21 02:28:15
mbbd000144532,mbcd0001056,mbtp000002,mbrf0001839,,=,,,inhibitor,25,1.31,micromol L-1,,sorafenib,,,HEK293/ABCG2 cell line,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144533,mbcd0023873,mbtp000002,mbrf0002322,,,,,inhibitor,,,,,Zafirlukast,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144534,mbcd0030379,mbtp000002,mbrf0002069,,=,,,inhibitor,25,0.55,microM,,Compound 3,,,ABCG2-transfected HEK293 cell line; Inhibition of mitoxantrone efflux,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144535,mbcd0030380,mbtp000002,mbrf0002069,,=,,,inhibitor,3,46.0,%,4,Compound 4,,,ABCG2-transfected HEK293 cell line; Inhibition of mitoxantrone efflux,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144536,mbcd0030381,mbtp000002,mbrf0002069,,=,,,inhibitor,25,0.6,microM,,Compound 5,,,ABCG2-transfected HEK293 cell line; Inhibition of mitoxantrone efflux,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144537,mbcd0030382,mbtp000002,mbrf0002069,,=,,,inhibitor,25,0.25,microM,,Compound 6,,,ABCG2-transfected HEK293 cell line; Inhibition of mitoxantrone efflux,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144538,mbcd0030383,mbtp000002,mbrf0002069,,=,,,inhibitor,25,0.3,microM,,Compound 7,,,ABCG2-transfected HEK293 cell line; Inhibition of mitoxantrone efflux,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144539,mbcd0013597,mbtp000002,mbrf0001811,,~,,,inhibitor,100,5.0,AU,,CCT129202,,,S1-M1-80 cell line; accumulation of doxorubicin relative to control value of 0.8 with no inhibitor present,,,0.5,microM,,human,mbds0010,,2013-11-23 22:11:30
mbbd000144540,mbcd0031255,mbtp000002,mbrf0002308,,,,,substrate,,,,,AZT 5'-monophosphate,,,,,,,,,human,mbds0010,,2013-10-28 19:33:29
mbbd000144541,mbcd0000071,mbtp000002,mbrf0002308,,,,,substrate,,,,,4-Methylumbelliferone sulfate,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144542,mbcd0030386,mbtp000002,mbrf0002308,,,,,substrate,,,,,E3040S,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144543,mbcd0000819,mbtp000002,mbrf0002308,,,,,substrate,,,,,TLC-S,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144544,mbcd0030387,mbtp000002,mbrf0002308,,,,,substrate,,,,,4-MUG,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144545,mbcd0030388,mbtp000002,mbrf0002308,,,,,substrate,,,,,E3040G,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144546,mbcd0000387,mbtp000002,mbrf0002308,,,,,substrate,,,,,E217betaG,,,,,,,,,human,mbds0010,,2013-11-05 07:35:52
mbbd000144547,mbcd0030390,mbtp000002,mbrf0002308,,,,,substrate,,,,,DNP-SG,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144548,mbcd0030204,mbtp000002,mbrf0002308,,,,,substrate,,,,,Phosphatidylserine,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144549,mbcd0030391,mbtp000002,mbrf0002308,,,,,inhibitor,,,,,Ko132,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144550,mbcd0000371,mbtp000002,mbrf0002308,,,,,inhibitor,,,,,EKI-785,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144551,mbcd0030282,mbtp000002,mbrf0002107,,=,,,non-substrate,100,7.5,pmol/10^7 cells,2.9,Methotrexate monoglutamate,,,HEK/BCRP-R482 and HEK/BCRP-G482 cell lines; measured after 24 hours,HEK,,,,,human,mbds0010,,2013-11-24 23:14:19
mbbd000144552,mbcd0029343,mbtp000002,mbrf0002107,,=,,,substrate,100,8.4,pmol/10^7 cells,1.3,Methotrexate diglutamate,,,HEK/BCRP-R482 and HEK/BCRP-G482 cell lines; measured after 24 hours,HEK,,,,,human,mbds0010,,2013-11-24 23:14:19
mbbd000144553,mbcd0030392,mbtp000002,mbrf0002107,,=,,,substrate,100,9.1,pmol/10^7 cells,3.3,Methotrexate triglutamate,,,HEK/BCRP-R482 and HEK/BCRP-G482 cell lines; measured after 24 hours,HEK,,,,,human,mbds0010,,2013-11-24 23:14:19
mbbd000144554,mbcd0030393,mbtp000002,mbrf0002107,,=,,,substrate,100,2.9,pmol/10^7 cells,2.6,Methotrexate tetraglutamate,,,HEK/BCRP-R482 and HEK/BCRP-G482 cell lines; measured after 24 hours,HEK,,,,,human,mbds0010,,2013-11-24 23:14:20
mbbd000144555,mbcd0031694,mbtp000002,mbrf0002107,,=,,,substrate,100,1.2,pmol/10^7 cells,1.1,Methotrexate pentaglutamate,,,HEK/BCRP-R482 and HEK/BCRP-G482 cell lines; measured after 24 hours,HEK,,,,,human,mbds0010,,2013-11-24 23:14:20
mbbd000144556,mbcd0013235,mbtp000002,mbrf0002319,,~,,,inducer,117,150.0,%,15,clofibrate,,,hCMEC/D3 cell line; mRNA expression relative to control; incubation time 24 hours,,,100,microM,,human,mbds0010,,2013-12-06 07:13:46
mbbd000144557,mbcd0008875,mbtp000002,mbrf0002319,,~,,,inducer,117,150.0,%,20,GW 7647,,,hCMEC/D3 cell line; mRNA expression relative to control; incubation time 24 hours,,,20,microM,,human,mbds0010,,2013-12-06 07:13:47
mbbd000144558,mbcd0001280,mbtp000002,mbrf0001887,,=,,,substrate,33,868.0,microL (10 min)-1 (mg protein)-1,104,sulphasalazine,,,membrane vesicles expressing hBCRP; in presence of ATP,membrane vesicles,,0.9,microM,,human,mbds0010,,2013-11-26 01:55:30
mbbd000144559,mbcd0000303,mbtp000002,mbrf0001887,,=,,,inhibitor,25,1.6,microM,0.93,Curcumin,,,membrane vesicles expressing hBCRP; incubation time 10 minutes in presence of ATP,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144560,mbcd0000303,mbtp000002,mbrf0001887,,=,,,inhibitor,29,0.7,microM,0.41,curcumin,,,membrane vesicles expressing hBCRP,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144561,mbcd0030394,mbtp000002,mbrf0001987,,,,,non-substrate,,,,,di-sulfonated meso-tetraphenylporphine,,,MA11 cells,MA11,,0.6,microg ml-1,,human,mbds0010,,2013-11-10 04:16:08
mbbd000144562,mbcd0030395,mbtp000002,mbrf0001987,,,,,non-substrate,,,,,di-sulfonated meso-tetraphenylchlorin,,,MA11 cells,MA11,,0.6,microg ml-1,,human,mbds0010,,2013-11-10 04:16:08
mbbd000144563,mbcd0030396,mbtp000002,mbrf0001987,,,,,non-substrate,,,,,ALPcS2a,,,MA11 cells,MA11,,5,microg ml-1,,human,mbds0010,,2013-11-10 04:16:09
mbbd000144565,mbcd0003930,mbtp000002,mbrf0002486,,=,,,inhibitor,130,39.3,,,Doxazosin,,,HeLa/SN100 cell line; Relative sensitivity: the ratio of IC50 values for mitoxantrone in the control divided by that in the groups treated with alpha-adrenoceptor antagonists,,,10,microM,,human,mbds0010,,2013-11-23 22:22:28
mbbd000144566,mbcd0003024,mbtp000002,mbrf0002486,,=,,,inhibitor,130,7.39,,,Prazosin,,,HeLa/SN100 cell line; Relative sensitivity: the ratio of IC50 values for mitoxantrone in the control divided by that in the groups treated with alpha-adrenoceptor antagonists,,,10,microM,,human,mbds0010,,2013-11-24 03:25:22
mbbd000144567,mbcd0030397,mbtp000002,mbrf0002498,,~,,,substrate,100,0.62,pmol (10^5 cells)-1,0.3,Genistein glucuronide,,,Engineered HeLa cells stably overexpressing UGT1A9; In presence of BCRP inhibitor 10microM Ko 143,HeLa,,10,microM,,human,mbds0010,,2013-11-24 23:55:12
mbbd000144568,mbcd0030406,mbtp000002,mbrf0002498,,~,,,substrate,100,1.3,pmol (10^5 cells)-1,0.1,Apigenin Glucuronide,,,Engineered HeLa cells stably overexpressing UGT1A9; In presence of BCRP inhibitor 10microM Ko 143,HeLa,,10,microM,,human,mbds0010,,2013-11-24 23:55:12
mbbd000144569,mbcd0026443,mbtp000002,mbrf0002144,,=,,,inhibitor,96,-17.89,nmol Pi min-1 (mg protein)-1,13.26,BITC,,,BCRP-overexpressing MCF-7/MX100 cell line; 20 minute incubation time,,,100,microM,,human,mbds0010,,2013-11-23 22:11:27
mbbd000144570,mbcd0003129,mbtp000002,mbrf0002144,,=,,,inhibitor,96,-13.37,nmol Pi min-1 (mg protein)-1,11.65,PEITC,,,BCRP-overexpressing MCF-7/MX100 cell line; 20 minute incubation time,,,100,microM,,human,mbds0010,,2013-11-24 02:54:54
mbbd000144571,mbcd0028378,mbtp000002,mbrf0002144,,=,,,inhibitor,96,-15.57,nmol Pi min-1 (mg protein)-1,11.97,NITC,,,BCRP-overexpressing MCF-7/MX100 cell line; 20 minute incubation time,,,100,microM,,human,mbds0010,,2013-11-24 02:54:49
mbbd000144572,mbcd0030371,mbtp000002,mbrf0002144,,=,,,inhibitor,96,-15.26,nmol Pi min-1 (mg protein)-1,12.72,PBITC,,,BCRP-overexpressing MCF-7/MX100 cell line; 20 minute incubation time,,,100,microM,,human,mbds0010,,2013-11-24 02:54:54
mbbd000144573,mbcd0030372,mbtp000002,mbrf0002144,,=,,,inhibitor,96,-7.92,nmol Pi min-1 (mg protein)-1,12.06,PPITC,,,BCRP-overexpressing MCF-7/MX100 cell line; 20 minute incubation time,,,100,microM,,human,mbds0010,,2013-11-24 03:25:17
mbbd000144574,mbcd0000685,mbtp000002,mbrf0002144,,=,,,inhibitor,96,6.72,nmol Pi min-1 (mg protein)-1,7.78,PHITC,,,BCRP-overexpressing MCF-7/MX100 cell line; 20 minute incubation time,,,100,microM,,human,mbds0010,,2013-11-24 02:54:55
mbbd000144575,mbcd0003129,mbtp000002,mbrf0002144,,~,,,substrate,100,350.0,pmol (mg protein)-1,20,PEITC,,,BCRP-expressing MCF-7/MX100 cell membrane vesicles; presence of ATP; incubation time 30 minutes,MCF7/MX100,,,,,human,mbds0010,,2013-11-24 23:10:01
mbbd000144576,mbcd0001675,mbtp000002,mbrf0001758,,~,,,non-substrate,138,20.0,%,,Aldosterone,,,MDCK II-ABCG2 transfected cell line; Drug transport given as a percentage of that added; transepithelial transport from apical to basolateral compartment; 4 hours incubation time,MDCKII,,0.1,micromol L-1,,human,mbds0010,,2013-11-24 23:12:05
mbbd000144577,mbcd0002488,mbtp000002,mbrf0001758,,~,,,non-substrate,138,21.0,%,,propranolol,,,MDCK II-ABCG2 transfected cell line; Drug transport given as a percentage of that added; transepithelial transport from apical to basolateral compartment; 4 hours incubation time,MDCKII,,0.1,micromol L-1,,human,mbds0010,,2013-11-24 23:12:06
mbbd000144578,mbcd0002822,mbtp000002,mbrf0001758,,~,,,non-substrate,138,32.0,%,,metoprolol,,,MDCK II-ABCG2 transfected cell line; Drug transport given as a percentage of that added; transepithelial transport from apical to basolateral compartment; 4 hours incubation time,MDCKII,,1,micromol L-1,,human,mbds0010,,2013-11-24 23:12:06
mbbd000144579,mbcd0001178,mbtp000002,mbrf0001758,,~,,,non-substrate,138,35.0,%,,bisoprolol,,,MDCK II-ABCG2 transfected cell line; Drug transport given as a percentage of that added; transepithelial transport from apical to basolateral compartment; 4 hours incubation time,MDCKII,,1,micromol L-1,,human,mbds0010,,2013-11-24 23:12:06
mbbd000144580,mbcd0001050,mbtp000002,mbrf0001758,,~,,,non-substrate,138,12.0,%,,Digoxin,,,MDCK II-ABCG2 transfected cell line; Drug transport given as a percentage of that added; transepithelial transport from apical to basolateral compartment; 4 hours incubation time,MDCKII,,0.01,micromol L-1,,human,mbds0010,,2013-11-24 23:12:06
mbbd000144581,mbcd0023111,mbtp000002,mbrf0001758,,~,,,substrate,138,52.0,%,,rosiglitazone,,,MDCK II-ABCG2 transfected cell line; Drug transport given as a percentage of that added; transepithelial transport from apical to basolateral compartment; 4 hours incubation time,MDCKII,,1,micromol L-1,,human,mbds0010,,2013-11-24 23:12:07
mbbd000144582,mbcd0023111,mbtp000002,mbrf0001758,,=,,,substrate,14,36.0,cm s-1,1.2,rosiglitazone,,,MDCK II -ABCG2 transfected cell line; transepithelial transport from basolateral to apical compartment,MDCKII,,1,micromol L-1,,human,mbds0010,,2013-11-24 23:12:07
mbbd000144583,mbcd0023111,mbtp000002,mbrf0001758,,=,,,inhibitor,25,25.0,micromol L-1,,rosiglitazone,,,HEK-293/ABCG2 transfected cell line,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144584,mbcd0002195,mbtp000002,mbrf0001758,,=,,,inhibitor,25,258.0,micromol L-1,,Propafenone,,,HEK-293/ABCG2 cell line,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144585,mbcd0030407,mbtp000002,mbrf0002336,,,,,substrate,,,,,ezetimibe glucuronide; EZ-gluc,,,Competition assay with Methotrexate; Membrane vesicles of Sf21 cells,Sf21,,4-400,microM,,human,mbds0010,,2013-10-09 22:18:43
mbbd000144586,mbcd0030407,mbtp000002,mbrf0002336,,=,,,inhibitor,25,51.8,microM,,ezetimibe glucuronide,,,ABCG2-transfected Sf21 membrane vesicles; inhibition of methotrexate transport; values are expressed as a percentage of maximal ATP-dependent transport,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144587,mbcd0030408,mbtp000002,mbrf0001914,,~,,,non-substrate,138,92.0,fmol min-1 mg-1,91,Tauroursodeoxycholate,,,ABCG2-transfected  Sf9 Membrane Vesicles; ATP dependant transport; 5 minutes incubation,Sf9,,100,microM,,human,mbds0010,,2013-11-24 23:15:30
mbbd000144588,mbcd0003075,mbtp000002,mbrf0001914,,~,,,substrate,138,80.0,pmol min-1 mg-1,20,estrone 3-sulfate,,,ABCG2- transfected Sf9 membrane vesicles; 5 minute incubation,Sf9,,60,nM,,human,mbds0010,,2013-11-24 23:54:57
mbbd000144589,mbcd0003007,mbtp000002,mbrf0002249,,~,,,non-substrate,138,42.0,%,2,Phenobarbital,,,MDCK II-ABCG2 transfected cell line; transport acros monolayers from basolateral t oapical compartment; te percentage in the opposite compartment was measured; 6 hours incubation time,MDCKII,,100,microM,,human,mbds0010,,2013-11-24 23:12:07
mbbd000144590,mbcd0002996,mbtp000002,mbrf0002249,,~,,,non-substrate,138,40.0,%,2,Phenytoin,,,MDCK II-ABCG2 transfected cell line; transport acros monolayers from basolateral to apical compartment; te percentage in the opposite compartment was measured; 6 hours incubation time,MDCKII,,100,microM,,human,mbds0010,,2013-11-24 23:12:07
mbbd000144591,mbcd0011455,mbtp000002,mbrf0002249,,~,,,non-substrate,138,20.0,%,2,Primidone,,,MDCK II-ABCG2 transfected cell line; transport acros monolayers from basolateral to apical compartment; te percentage in the opposite compartment was measured; 6 hours incubation time,MDCKII,,100,microM,,human,mbds0010,,2013-11-24 23:12:08
mbbd000144592,mbcd0002985,mbtp000002,mbrf0002249,,~,,,non-substrate,138,50.0,%,2,carbamazepine,,,MDCK II-ABCG2 transfected cell line; transport acros monolayers from basolateral to apical compartment; te percentage in the opposite compartment was measured; 6 hours incubation time,MDCKII,,100,microM,,human,mbds0010,,2013-11-24 23:12:08
mbbd000144593,mbcd0026528,mbtp000002,mbrf0002249,,~,,,non-substrate,138,55.0,%,2,ethosuximide,,,MDCK II-ABCG2 transfected cell line; transport acros monolayers from basolateral to apical compartment; te percentage in the opposite compartment was measured; 6 hours incubation time,MDCKII,,500,microM,,human,mbds0010,,2013-11-24 23:12:08
mbbd000144594,mbcd0013986,mbtp000002,mbrf0002249,,~,,,non-substrate,138,20.0,%,,lamotrigine,,,MDCK II-ABCG2 transfected cell line; transport acros monolayers from basolateral to apical compartment; te percentage in the opposite compartment was measured; 6 hours incubation time,MDCKII,,100,microM,,human,mbds0010,,2013-11-24 23:12:08
mbbd000144595,mbcd0001430,mbtp000002,mbrf0002249,,~,,,non-substrate,138,38.0,%,,clonazepam,,,MDCK II-ABCG2 transfected cell line; transport acros monolayers from basolateral to apical compartment; te percentage in the opposite compartment was measured; 6 hours incubation time,MDCKII,,25,microM,,human,mbds0010,,2013-11-24 23:12:09
mbbd000144596,mbcd0003008,mbtp000002,mbrf0002249,,~,,,non-substrate,138,55.0,%,4,Valproate,,,MDCK II-ABCG2 transfected cell line; transport acros monolayers from basolateral to apical compartment; te percentage in the opposite compartment was measured; 6 hours incubation time,MDCKII,,500,microM,,human,mbds0010,,2013-11-24 23:12:09
mbbd000144597,mbcd0001532,mbtp000002,mbrf0001948,,=,,,substrate,128,7.3,,,Paclitaxel,,,HEK-293/BCRP cell line;  RR factor is calculated as the ratio of IC50 of transporter-overexpressing cells over that of parent cells,HEK293,,,,,human,mbds0010,,2013-11-24 23:14:20
mbbd000144598,mbcd0027726,mbtp000002,mbrf0001948,,=,,,substrate,128,4.3,,,Docetaxel,,,HEK-293/BCRP cell line;  RR factor is calculated as the ratio of IC50 of transporter-overexpressing cells over that of parent cells,HEK293,,,,,human,mbds0010,,2013-11-24 23:14:20
mbbd000144599,mbcd0001151,mbtp000002,mbrf0001948,,=,,,substrate,128,2.9,,,Vinblastine,,,HEK-293/BCRP cell line;  RR factor is calculated as the ratio of IC50 of transporter-overexpressing cells over that of parent cells,HEK293,,,,weak substrate,human,mbds0010,,2014-02-25 08:26:13
mbbd000144600,mbcd0002981,mbtp000002,mbrf0001948,,=,,,substrate,128,11.9,,,Mitoxantrone,,,HEK-293/BCRP cell line;  RR factor is calculated as the ratio of IC50 of transporter-overexpressing cells over that of parent cells,HEK293,,,,,human,mbds0010,,2013-11-24 23:14:21
mbbd000144601,mbcd0001688,mbtp000002,mbrf0001948,,=,,,non-substrate,128,1.2,,,Ixabepilone,,,HEK-293/BCRP cell line;  RR factor is calculated as the ratio of IC50 of transporter-overexpressing cells over that of parent cells,HEK293,,,,,human,mbds0010,,2013-11-24 23:14:21
mbbd000144602,mbcd0030409,mbtp000002,mbrf0001948,,=,,,non-substrate,128,1.7,,,Epothilone B,,,HEK-293/BCRP cell line;  RR factor is calculated as the ratio of IC50 of transporter-overexpressing cells over that of parent cells,HEK293,,,,,human,mbds0010,,2013-11-24 23:14:21
mbbd000144603,mbcd0030410,mbtp000002,mbrf0001928,,~,,,inhibitor,96,170.0,%,10,ponatinib,,,ABCG2- expressing High-Five insect cells; measured as a percentage of basal activity,,,100,nM,,human,mbds0010,,2013-11-24 22:15:05
mbbd000144604,mbcd0030410,mbtp000002,mbrf0001928,,=,,,inhibitor,25,0.04,microM,,ponatinib,,,MCF-7  FLV1000/ABCG2 transfected cell line,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144605,mbcd0030331,mbtp000002,mbrf0001779,,~,,,inhibitor,3,20.0,%,10,purvalanol A,,,Sf9 cells; ABCG2-expressing plasma membrane vesicles; percentage inhibition of 20 microM hematoporphyrin transport,Sf9,mbcd0030270,10,microM,,human,mbds0010,,2013-11-19 06:00:32
mbbd000144606,mbcd0030411,mbtp000002,mbrf0001779,,~,,,inhibitor,3,8.0,%,10,WHI-P180,,,Sf9 cells; ABCG2-expressing plasma membrane vesicles; percentage inhibition of 20 microM hematoporphyrin transport,Sf9,mbcd0030270,30,microM,,human,mbds0010,,2013-11-19 06:00:32
mbbd000144607,mbcd0030333,mbtp000002,mbrf0001779,,~,,,inhibitor,3,40.0,%,5,roscovitine,,,Sf9 cells; ABCG2-expressing plasma membrane vesicles; percentage inhibition of 20 microM hematoporphyrin transport,Sf9,mbcd0030270,20,microM,,human,mbds0010,,2013-11-19 06:00:33
mbbd000144608,mbcd0030334,mbtp000002,mbrf0001779,,~,,,inhibitor,3,42.0,%,10,bohemine,,,Sf9 cells; ABCG2-expressing plasma membrane vesicles; percentage inhibition of 20 microM hematoporphyrin transport,Sf9,mbcd0030270,20,microM,,human,mbds0010,,2013-11-19 06:00:33
mbbd000144609,mbcd0015873,mbtp000002,mbrf0001779,,~,,,inhibitor,3,98.0,%,5,olomoucine,,,Sf9 cells; ABCG2-expressing plasma membrane vesicles; percentage inhibition of 20 microM hematoporphyrin transport,Sf9,mbcd0030270,20,microM,,human,mbds0010,,2013-11-19 06:00:33
mbbd000144610,mbcd0030412,mbtp000002,mbrf0001796,,~,,,substrate,138,25.0,%,2,Cholylglycylamido fluorescein,,,WIF-B9/R cell line with enhanced expression of ABCG2; measurements as a percentage of of the amount initially loaded into the cells,WIF-B9/R,,10,microM,,human,mbds0010,,2013-11-24 23:15:30
mbbd000144611,mbcd0001640,mbtp000002,mbrf0001796,,~,,,substrate,138,55.0,pmol (15 min)-1 (mg protein)-1,4,cholic acid,,,CHO-K1 cell line over-expressing ABCG2; measurement of CA net uptake as a percentage of initial CA present,CHO,,10,microM,,human,mbds0010,,2013-11-24 23:15:29
mbbd000144612,mbcd0000455,mbtp000002,mbrf0001796,,~,,,substrate,138,28.0,pmol (15 min)-1 (mg protein)-1,2,glycocholic acid,,,CHO-K1 cell line over-expressing ABCG2; measurement of CA net uptake as a percentage of initial GCA present,CHO,,10,microM,,human,mbds0010,,2013-11-24 23:15:29
mbbd000144613,mbcd0001664,mbtp000002,mbrf0001796,,~,,,substrate,138,10.0,pmol (15 min)-1 (mg protein)-1,1,taurocholic acid,,,CHO-K1 cell line over-expressing ABCG2; measurement of CA net uptake as a percentage of initial GCA present,CHO,,10,microM,,human,mbds0010,,2013-11-24 23:15:29
mbbd000144614,mbcd0030413,mbtp000002,mbrf0001796,,~,,,substrate,138,40.0,pmol (15 min)-1 (mg protein)-1,1,taurolithocholic acid-3-sulfate,,,CHO-K1 cell line over-expressing ABCG2; measurement of CA net uptake as a percentage of initial GCA present,CHO,,10,microM,,human,mbds0010,,2013-11-24 23:15:30
mbbd000144615,mbcd0003187,mbtp000002,mbrf0002064,,~,,,substrate,138,14.0,%,1,Topotecan,,,MDCK II -ABCG2 transfected cell line; transepithelial transport measured as a percentage in opposite compartment; translocation from basolateral to apical compartment; 4 hours incubation time,MDCKII,,1.6,microM,,human,mbds0010,,2013-11-24 23:12:09
mbbd000144616,mbcd0001056,mbtp000002,mbrf0002064,,~,,,substrate,138,31.0,%,1,sorafenib,,,MDCK II/ABCG2/ABCB1 transfected cell line in presence of ABCB1 inhibitor 5 ?M zosuquidar;transepithelial transport measured as a percentage in opposite compartment; translocation from basolateral to apical compartment; 4 hours incubation time,MDCKII,,0.3,microM,,human,mbds0010,,2013-11-24 23:12:09
mbbd000144617,mbcd0027319,mbtp000002,mbrf0002064,,~,,,substrate,138,38.0,%,2,Sunitinib,,,MDCK II/ABCG2/ABCB1 cell line in presence of ABCB1 inhibitor  5 ?M zosuquidar;transepithelial transport measured as a percentage in opposite compartment; translocation from basolateral to apical compartment; 4 hours incubation time,MDCKII,,0.2,microM,,human,mbds0010,,2013-11-24 23:12:10
mbbd000144618,mbcd0030210,mbtp000002,mbrf0002080,,~,,,substrate,138,35.0,fmol mg-1,0.5,daidzein-4'-sulfate,,,human ABCG2 cDNA-containing Sf9 inside-out membrane vesicles; incubation time 40seconds; In presence of ATP,Sf9,,250,microM,,human,mbds0010,,2013-11-24 23:54:58
mbbd000144619,mbcd0030408,mbtp000002,mbrf0002080,,~,,,substrate,138,120.0,fmol mg-1,,daidzein-7-sulfate,,,human ABCG2 cDNA-containing Sf9 inside-out membrane vesicles; incubation time 40seconds; In presence of ATP,Sf9,,222,microM,,human,mbds0010,,2013-11-24 23:54:58
mbbd000144620,mbcd0029980,mbtp000002,mbrf0002080,,~,,,substrate,138,300.0,fmol mg-1,,glycitein-sulfate,,,human ABCG2 cDNA-containing Sf9 inside-out membrane vesicles; incubation time 40seconds; In presence of ATP,Sf9,,273,pM,,human,mbds0010,,2013-11-24 23:54:59
mbbd000144621,mbcd0030409,mbtp000002,mbrf0002080,,~,,,substrate,138,17.0,fmol mg-1,0.5,equol-4'-sulfate,,,human ABCG2 cDNA-containing Sf9 inside-out membrane vesicles; incubation time 40seconds; In presence of ATP,Sf9,,200,pM,,human,mbds0010,,2013-11-24 23:54:59
mbbd000144622,mbcd0030410,mbtp000002,mbrf0002080,,~,,,substrate,138,68.0,fmol mg-1,2,equol-7-sulfate,,,human ABCG2 cDNA-containing Sf9 inside-out membrane vesicles; incubation time 40seconds; In presence of ATP,Sf9,,150,pM,,human,mbds0010,,2013-11-24 23:54:59
mbbd000144623,mbcd0030411,mbtp000002,mbrf0002080,,~,,,substrate,138,64.0,fmol mg-1,1,enterolactone-sulfate,,,human ABCG2 cDNA-containing Sf9 inside-out membrane vesicles; incubation time 40seconds; In presence of ATP,Sf9,,215,pM,,human,mbds0010,,2013-11-24 23:55:00
mbbd000144624,mbcd0030412,mbtp000002,mbrf0002080,,~,,,substrate,138,19.0,fmol mg-1,1,enterodiol-sulfate,,,human ABCG2 cDNA-containing Sf9 inside-out membrane vesicles; incubation time 40seconds; In presence of ATP,Sf9,,225,pM,,human,mbds0010,,2013-11-24 23:55:00
mbbd000144625,mbcd0030413,mbtp000002,mbrf0002080,,~,,,substrate,138,58.0,fmol mg-1,1,formononetin-sulfate,,,human ABCG2 cDNA-containing Sf9 inside-out membrane vesicles; incubation time 40seconds; In presence of ATP,Sf9,,91,pM,,human,mbds0010,,2013-11-24 23:55:00
mbbd000144626,mbcd0030414,mbtp000002,mbrf0002080,,~,,,substrate,138,125.0,fmol mg-1,,coumestrol-sulfate,,,human ABCG2 cDNA-containing Sf9 inside-out membrane vesicles; incubation time 40seconds; In presence of ATP,Sf9,,43,microM,,human,mbds0010,,2013-11-24 23:55:01
mbbd000144627,mbcd0030407,mbtp000002,mbrf0002080,,~,,,substrate,138,140.0,fmol mg-1,,genistein-sulfate (I),,,human ABCG2 cDNA-containing Sf9 inside-out membrane vesicles; incubation time 40seconds; In presence of ATP,Sf9,,213,pM,,human,mbds0010,,2013-11-24 23:55:02
mbbd000144628,mbcd0030406,mbtp000002,mbrf0002080,,~,,,substrate,138,260.0,fmol mg-1,10,Genistein Sulfate (II),,,human ABCG2 cDNA-containing Sf9 inside-out membrane vesicles; incubation time 40seconds; In presence of ATP,Sf9,,,,,human,mbds0010,,2013-11-24 23:55:02
mbbd000144629,mbcd0000875,mbtp000002,mbrf0001944,,~,,,substrate,138,280.0,microL (mg protein)-1,,Troglitazone Sulfate,,,MDCK-II/hABCG2 cell line; transcellular transport across monolayers from the apical to basolateral direction; incubation time 3 hours,MDCKII,,,,,human,mbds0010,,2013-11-24 23:12:10
mbbd000144631,mbcd0030415,mbtp000002,mbrf0002399,,~,,,non-substrate,135,2.0,,0.2,Amonafide L-malate,,,8226/MR20/BCRP transfected cell line; resistance ratio calculated from IC50 ratio of resistant/parental cells,8226/MR20,,,,,human,mbds0010,,2013-11-24 23:55:50
mbbd000144632,mbcd0030416,mbtp000002,mbrf0002399,,~,,,substrate,135,7.0,,0.5,N-Acetyl Amonafide,,,8226/MR20/BCRP transfected cell line; resistance ratio calculated from IC50 ratio of resistant/parental cells,8226/MR20,,,,,human,mbds0010,,2013-11-24 23:55:50
mbbd000144633,mbcd0001492,mbtp000002,mbrf0002399,,~,,,substrate,135,6.0,,1,idarubicin,,,8226/MR20/BCRP transfected cell line; resistance ratio calculated from IC50 ratio of resistant/parental cells,8226/MR20,,,,,human,mbds0010,,2013-11-24 23:55:50
mbbd000144634,mbcd0030417,mbtp000002,mbrf0001830,,=,,,substrate,127,5.0,fold,,NSC 725776,,,HEK-293-482R-5/ABCG2 cell line; relatvie resistance value from ratio of IC50s resistant cell line/parental line,HEK293,,,,,human,mbds0010,,2013-11-24 23:14:22
mbbd000144635,mbcd0030418,mbtp000002,mbrf0001830,,=,,,non-substrate,127,1.0,fold,,NSC 724998,,,HEK-293-482R-5/ABCG2 cell line; relatvie resistance value from ratio of IC50s resistant cell line/parental line,HEK293,,,,,human,mbds0010,,2013-11-24 23:14:22
mbbd000144636,mbcd0030419,mbtp000002,mbrf0001830,,=,,,substrate,127,4.0,fold,,NSC 706744,,,HEK-293-482R-5/ABCG2 cell line; relatvie resistance value from ratio of IC50s resistant cell line/parental line,HEK293,,,,,human,mbds0010,,2013-11-24 23:14:22
mbbd000144637,mbcd0000779,mbtp000002,mbrf0001830,,=,,,substrate,127,46.0,fold,,SN-38,,,HEK-293-482R-5/ABCG2 cell line; relatvie resistance value from ratio of IC50s resistant cell line/parental line,HEK293,,,,,human,mbds0010,,2013-11-24 23:14:23
mbbd000144638,mbcd0020601,mbtp000002,mbrf0001830,,=,,,substrate,127,2.0,fold,,camptothecin,,,HEK-293-482R-5/ABCG2 cell line; relatvie resistance value from ratio of IC50s resistant cell line/parental line,HEK293,,,,,human,mbds0010,,2013-11-12 20:35:04
mbbd000144639,mbcd0003187,mbtp000002,mbrf0001830,,=,,,substrate,127,9.0,fold,,Topotecan,,,HEK-293-482R-5/ABCG2 cell line; relatvie resistance value from ratio of IC50s resistant cell line/parental line,HEK293,,,,,human,mbds0010,,2013-11-24 23:14:23
mbbd000144640,mbcd0030280,mbtp000002,mbrf0001910,,=,,,non-substrate,127,3.0,,,BPU; dimethyl benzoylphenylurea,,,MCF-7/BCRP transfected cell line; IC50 ratio,MCF7,,,,,human,mbds0010,,2013-11-24 23:10:01
mbbd000144641,mbcd0030421,mbtp000002,mbrf0001910,,=,,,non-substrate,127,2.0,,,mmBPU; monomethyl benzoylphenylurea,,,MCF-7/BCRP transfected cell line; IC50 ratio,MCF7,,,,,human,mbds0010,,2013-11-24 23:10:01
mbbd000144642,mbcd0030422,mbtp000002,mbrf0001910,,=,,,non-substrate,127,3.0,,,aminoBPU; didesmethyl benzoylphenylurea,,,MCF-7/BCRP transfected cell line; IC50 ratio,MCF7,,,,,human,mbds0010,,2013-11-24 23:10:01
mbbd000144643,mbcd0002981,mbtp000002,mbrf0001910,,=,,,substrate,127,2437.0,,,Mitoxantrone,,,MCF-7/BCRP transfected cell line; IC50 ratio,MCF7,,,,,human,mbds0010,,2013-11-24 23:10:02
mbbd000144644,mbcd0001151,mbtp000002,mbrf0001824,,~,,,substrate,121,1.0,,,vinblastine,,,MCF7-MX cell line (mitoxantrone (MX)-resistant subclones); GI50 ratio calculated from ratio of GI50 in MCF7-MX and GI50 in MCF7,MCF7/MX,,,,,human,mbds0010,,2013-12-09 02:21:43
mbbd000144645,mbcd0030423,mbtp000002,mbrf0001824,,~,,,substrate,121,35.0,,10,SJG-136,,,MCF7-MX cell line (mitoxantrone (MX)-resistant subclones); GI50 ratio calculated from ratio of GI50 in MCF7-MX and GI50 in MCF7,MCF7/MX,,,,,human,mbds0010,,2013-12-09 02:21:43
mbbd000144646,mbcd0030424,mbtp000002,mbrf0001824,,~,,,substrate,121,18.0,,2,DSB-120,,,MCF7-MX cell line (mitoxantrone (MX)-resistant subclones); GI50 ratio calculated from ratio of GI50 in MCF7-MX and GI50 in MCF7,MCF7/MX,,,,,human,mbds0010,,2013-12-09 02:21:44
mbbd000144647,mbcd0030425,mbtp000002,mbrf0001824,,~,,,substrate,121,30.0,,5,DRG-16,,,MCF7-MX cell line (mitoxantrone (MX)-resistant subclones); GI50 ratio calculated from ratio of GI50 in MCF7-MX and GI50 in MCF7,MCF7/MX,,,,,human,mbds0010,,2013-12-09 02:21:44
mbbd000144648,mbcd0030426,mbtp000002,mbrf0001824,,~,,,substrate,121,30.0,,10,ELB-21,,,MCF7-MX cell line (mitoxantrone (MX)-resistant subclones); GI50 ratio calculated from ratio of GI50 in MCF7-MX and GI50 in MCF7,MCF7/MX,,,,,human,mbds0010,,2013-12-09 02:21:44
mbbd000144649,mbcd0029195,mbtp000002,mbrf0001895,,,,,substrate,,,,,Eltrombopag,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144650,mbcd0029345,mbtp000002,mbrf0001785,,=,,,substrate,28,8.24,mM,1.44,urate,,,HEK-293/ABCG2 transfected cell line,HEK293,,,,,human,mbds0010,,2013-11-24 23:14:23
mbbd000144651,mbcd0029345,mbtp000002,mbrf0001785,,=,,,substrate,22,6.96,nmol min-1 (mg protein)-1,0.89,urate,,,HEK-293/ABCG2 transfected cell line,HEK293,,,,,human,mbds0010,,2013-11-24 23:14:23
mbbd000144652,mbcd0030331,mbtp000002,mbrf0001779,,=,,,inhibitor,25,3.5,microM,,purvalanol A,,,ABCG2-expressing Sf9 inside-out membrane vesicles,Sf9,mbcd0030270,,,,human,mbds0010,,2013-11-19 06:00:34
mbbd000144653,mbcd0030438,mbtp000002,mbrf0001779,,=,,,inhibitor,25,10.0,microM,,WHI-P180,,,ABCG2-expressing Sf9 inside-out membrane vesicles,Sf9,mbcd0030270,,,,human,mbds0010,,2013-11-19 06:00:34
mbbd000144654,mbcd0030334,mbtp000002,mbrf0001779,,=,,,inhibitor,25,21.0,microM,,bohemine,,,ABCG2-expressing Sf9 inside-out membrane vesicles,Sf9,mbcd0030270,,,,human,mbds0010,,2013-11-19 06:00:34
mbbd000144655,mbcd0030333,mbtp000002,mbrf0001779,,=,,,inhibitor,25,21.0,microM,,roscovitine,,,ABCG2-expressing Sf9 inside-out membrane vesicles,Sf9,mbcd0030270,,,,human,mbds0010,,2013-11-19 06:00:34
mbbd000144656,mbcd0001381,mbtp000002,mbrf0001979,,,,,non-substrate,,,,,Ara-C,,,Cytotoxicity assays on acute lymphoblastic leukemia cells taken from children,acute lymphoblastic leukemia cells,,0.097-10,microg ml-1,,human,mbds0010,,2013-10-09 22:18:43
mbbd000144657,mbcd0003091,mbtp000002,mbrf0002340,,=,,,inhibitor,17,1.66,microM,0.55,Apigenin,,,MCF-7 MX100 cell line; EC50 value for increasing mitoxantrone accumulation inside cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144658,mbcd0003026,mbtp000002,mbrf0002340,,=,,,inhibitor,17,1.62,microM,1.02,Biochanin A,,,MCF-7 MX100 cell line; EC50 value for increasing mitoxantrone accumulation inside cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144659,mbcd0003045,mbtp000002,mbrf0002340,,=,,,inhibitor,17,0.39,microM,0.13,Chrysin,,,MCF-7 MX100 cell line; EC50 value for increasing mitoxantrone accumulation inside cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144660,mbcd0003116,mbtp000002,mbrf0002340,,=,,,inhibitor,17,14.9,microM,2.69,Genistein,,,MCF-7 MX100 cell line; EC50 value for increasing mitoxantrone accumulation inside cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144661,mbcd0004749,mbtp000002,mbrf0002340,,=,,,inhibitor,17,12.4,microM,2.21,Hesperetin,,,MCF-7 MX100 cell line; EC50 value for increasing mitoxantrone accumulation inside cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144662,mbcd0003215,mbtp000002,mbrf0002340,,=,,,inhibitor,17,6.04,microM,0.09,Kaempferol,,,MCF-7 MX100 cell line; EC50 value for increasing mitoxantrone accumulation inside cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144663,mbcd0003096,mbtp000002,mbrf0002340,,=,,,inhibitor,17,32.0,microM,3.22,Naringenin,,,MCF-7 MX100 cell line; EC50 value for increasing mitoxantrone accumulation inside cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144664,mbcd0022617,mbtp000002,mbrf0002340,,=,,,inhibitor,17,33.7,microM,2.78,Silymarin,,,MCF-7 MX100 cell line; EC50 value for increasing mitoxantrone accumulation inside cells,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144665,mbcd0003075,mbtp000002,mbrf0002028,,=,,,substrate,28,3.6,microM,0.3,estrone-3-sulfate,,,BCRP-overexpressing membrane vesicles,KM71,,0.1-10,microM,,human,mbds0010,,2013-11-04 22:08:34
mbbd000144666,mbcd0003075,mbtp000002,mbrf0002028,,=,,,substrate,22,55.2,pmol min-1 (mg protein)-1,1.6,estrone-3-sulfate,,,membrane vesicles from P. pastoris,KM71,,0.1-10,microM,,human,mbds0010,,2013-11-21 01:53:19
mbbd000144667,mbcd0000047,mbtp000002,mbrf0001726,,~,,,substrate,138,80.0,fmol min-1 (mg protein)-1,5,"2,4-dinitrophenyl-S-glutathione",,,BCRP-overexpressing inside-out Sf9 memebrane vesicles; ATP dependant membrane transport,Sf9,,60,nM,,human,mbds0010,,2013-11-24 23:55:02
mbbd000144668,mbcd0000387,mbtp000002,mbrf0001726,,~,,,substrate,138,550.0,fmol min-1 (mg protein)-1,10,estradiol 17-beta-d-glucuronide,,,BCRP-overexpressing inside-out Sf9 memebrane vesicles; ATP dependant membrane transport,Sf9,,,,,human,mbds0010,,2013-11-24 23:55:03
mbbd000144669,mbcd0030279,mbtp000002,mbrf0001746,,,,,non-substrate,,,,,FdUMP,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144670,mbcd0030428,mbtp000002,mbrf0002457,,,,,substrate,,,,,Bikaverin,,,Cytotoxicity assay comparing survival of BCRP1-expressing and control cells,HEK293,,0.1-500,microM,,human,mbds0010,,2013-10-09 22:18:38
mbbd000144671,mbcd0030429,mbtp000002,mbrf0002457,,,,,substrate,,,,,Sparoxomycin A1,,,Cytotoxicity assay comparing survival of BCRP1-expressing and control cells,HEK293,,0.1-500,microM,,human,mbds0010,,2013-10-09 22:18:38
mbbd000144672,mbcd0030179,mbtp000002,mbrf0002457,,,,,substrate,,,,,NSC 265473,,,Cytotoxicity assay comparing survival of BCRP1-expressing and control cells,HEK293,,0.1-500,microM,,human,mbds0010,,2013-10-09 22:18:38
mbbd000144673,mbcd0030430,mbtp000002,mbrf0002007,,,,,non-substrate,,,,,dLop; N-desmethyl-loperamide,,,H460 cells,H460,,1,nM,,human,mbds0010,,2013-11-10 04:16:02
mbbd000144674,mbcd0001472,mbtp000002,mbrf0002101,,~,,,non-substrate,138,12.0,pmol (mg protein)-1 min-1,2,cefadroxil,,,Sf21 insect cells; ABCG2-expressing membrane vesicle assay,Sf21,,10,microM,,human,mbds0010,,2013-11-25 04:54:11
mbbd000144675,mbcd0025844,mbtp000001,mbrf0002370,,=,,,substrate,17,10000.0,nM,2000,Doxorubicin,,,doxorubicin sensitive IPH-926 cell line,IPH-926,,,,,human,mbds0010,,2013-11-24 23:55:50
mbbd000144676,mbcd0030146,mbtp000001,mbrf0001981,,=,,,non-substrate,145,4.66,*10^6 cm s-1,0.26,Vandetanib,,,MDCK II/MRP1 transfected cell line; permeability values across MDCK cell monolayers from baslateral to apical compartment,MDCKII,,5,microM,,human,mbds0010,,2013-11-24 23:12:10
mbbd000144677,mbcd0002635,mbtp000001,mbrf0001704,,=,,,substrate,145,1.46,ng cm-2 min-1,0.06,Hydrocortisone,,,P-glycoprotein expressing CLEFF9 subclone of human Caco-2 cell line; pH 7.4; permeability thorough Caco-2 monolayers from basolateral to apical direction,Caco-2,,4,microM,,human,mbds0010,,2013-11-24 23:12:42
mbbd000144678,mbcd0002058,mbtp000001,mbrf0001704,,=,,,substrate,145,1.7,ng cm-2 min-1,0.02,Prednisone,,,P-glycoprotein expressing CLEFF9 subclone of human Caco-2 cell line; pH 7.4; permeability thorough Caco-2 monolayers from basolateral to apical direction,Caco-2,,4,microM,,human,mbds0010,,2013-11-24 23:12:42
mbbd000144679,mbcd0003096,mbtp000001,mbrf0001704,,=,,,substrate,145,1.47,ng cm-2 min-1,0.03,Prednisolone,,,P-glycoprotein expressing CLEFF9 subclone of human Caco-2 cell line; pH 7.4; permeability thorough Caco-2 monolayers from basolateral to apical direction,Caco-2,,4,microM,,human,mbds0010,,2013-11-24 23:12:43
mbbd000144680,mbcd0027669,mbtp000001,mbrf0001704,,=,,,substrate,145,2.99,ng cm-2 min-1,0.13,Methyl prednisolone,,,P-glycoprotein expressing CLEFF9 subclone of human Caco-2 cell line; pH 7.4; permeability thorough Caco-2 monolayers from basolateral to apical direction,Caco-2,,10,microM,,human,mbds0010,,2013-11-24 23:12:43
mbbd000144681,mbcd0002959,mbtp000001,mbrf0001704,,=,,,substrate,145,1.57,ng cm-1 min-1,0.05,Dexamethasone,,,P-glycoprotein expressing CLEFF9 subclone of human Caco-2 cell line; pH 7.4; permeability thorough Caco-2 monolayers from basolateral to apical direction,Caco-2,,4,microM,,human,mbds0010,,2013-11-24 23:12:43
mbbd000144682,mbcd0001675,mbtp000001,mbrf0001704,,=,,,substrate,145,1.67,ng cm-2 min-1,0.03,Aldosterone,,,P-glycoprotein expressing CLEFF9 subclone of human Caco-2 cell line; pH 7.4; permeability thorough Caco-2 monolayers from basolateral to apical direction,Caco-2,,4,microM,,human,mbds0010,,2013-11-24 23:12:43
mbbd000144683,mbcd0030431,mbtp000001,mbrf0001704,,=,,,non-substrate,145,0.14,ng cm-2 min-1,0.03,Fludrocortisone,,,P-glycoprotein expressing CLEFF9 subclone of human Caco-2 cell line; pH 7.4; permeability thorough Caco-2 monolayers from basolateral to apical direction,Caco-2,,4,microM,,human,mbds0010,,2013-11-24 23:12:44
mbbd000144684,mbcd0030432,mbtp000001,mbrf0001704,,=,,,substrate,145,2.6,ng cm-2 min-1,0,Beclomethasone dipropionate,,,P-glycoprotein expressing CLEFF9 subclone of human Caco-2 cell line; pH 7.4; permeability thorough Caco-2 monolayers from basolateral to apical direction,Caco-2,,10,microM,,human,mbds0010,,2013-11-24 23:12:44
mbbd000144685,mbcd0001052,mbtp000001,mbrf0001704,,=,,,substrate,145,44.2,ng cm-2 min-1,2.1,Beclomethasone,,,P-glycoprotein expressing CLEFF9 subclone of human Caco-2 cell line; pH 7.4; permeability thorough Caco-2 monolayers from basolateral to apical direction,Caco-2,,4,microM,,human,mbds0010,,2013-11-24 23:12:44
mbbd000144686,mbcd0001527,mbtp000001,mbrf0001704,,=,,,non-substrate,145,25.7,ng cm-1 min-1,0.8,Budesonide,,,P-glycoprotein expressing CLEFF9 subclone of human Caco-2 cell line; pH 7.4; permeability thorough Caco-2 monolayers from basolateral to apical direction,Caco-2,,2,microM,,human,mbds0010,,2013-11-24 23:12:44
mbbd000144687,mbcd0001164,mbtp000001,mbrf0001704,,=,,,substrate,145,1.4,ng cm-2 min-1,0.2,Fluticasone propionate,,,P-glycoprotein expressing CLEFF9 subclone of human Caco-2 cell line; pH 7.4; permeability thorough Caco-2 monolayers from basolateral to apical direction,Caco-2,,10,microM,,human,mbds0010,,2013-11-24 23:12:44
mbbd000144688,mbcd0001588,mbtp000001,mbrf0001704,,=,,,substrate,145,0.6,ng cm-2 min-1,0.6,Ciclesonide,,,P-glycoprotein expressing CLEFF9 subclone of human Caco-2 cell line; pH 7.4; permeability thorough Caco-2 monolayers from basolateral to apical direction,Caco-2,,100,microM,,human,mbds0010,,2013-11-24 23:12:45
mbbd000144689,mbcd0030433,mbtp000001,mbrf0001704,,=,,,substrate,145,2.8,ng cm-2 min-1,0.1,Desisobutyryl-ciclesonide,,,P-glycoprotein expressing CLEFF9 subclone of human Caco-2 cell line; pH 7.4; permeability thorough Caco-2 monolayers from basolateral to apical direction,Caco-2,,100,microM,,human,mbds0010,,2013-11-24 23:12:45
mbbd000144690,mbcd0029379,mbtp000001,mbrf0002516,,~,,,non-substrate,100,120.0,ng (mg protein)-1,5,melamine,,,MDCK-II/ABCB1 cell line,MDCKII,,1,mM,,human,mbds0010,,2013-11-24 23:12:11
mbbd000144691,mbcd0002996,mbtp000001,mbrf0002151,,,,,substrate,,,,,Phenytoin,,,MDCK II/P-gp cell line,MDCKII,,,,,human,mbds0010,,2013-11-24 23:12:11
mbbd000144692,mbcd0003007,mbtp000001,mbrf0002151,,,,,substrate,,,,,Phenobarbital,,,MDCK II/P-gp cell line,MDCKII,,,,,human,mbds0010,,2013-11-24 23:12:11
mbbd000144693,mbcd0013986,mbtp000001,mbrf0002151,,,,,substrate,,,,,Lamotrigine,,,LLC/P-gp cell line,LLC,,,,,human,mbds0010,,2013-11-24 23:10:09
mbbd000144694,mbcd0027734,mbtp000001,mbrf0002151,,,,,substrate,,,,,Oxcarbazepine,,,MDCK II/P-gp cell line,MDCKII,,,,,human,mbds0010,,2013-11-24 23:12:12
mbbd000144695,mbcd0026528,mbtp000001,mbrf0002151,,,,,non-substrate,,,,,Ethosuximide,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144696,mbcd0013982,mbtp000001,mbrf0002151,,,,,non-substrate,,,,,Vigabatrin,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144697,mbcd0020962,mbtp000001,mbrf0002151,,,,,non-substrate,,,,,Zonisamide,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144698,mbcd0003876,mbtp000001,mbrf0002523,,,,,substrate,,,,,Acebutolol,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144699,mbcd0030435,mbtp000001,mbrf0002523,,,,,substrate,,,,,Amisulpride,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144700,mbcd0002383,mbtp000001,mbrf0002523,,,,,substrate,,,,,Amprenavir,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144701,mbcd0001207,mbtp000001,mbrf0002523,,,,,substrate,,,,,Aprepitant,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144702,mbcd0002109,mbtp000001,mbrf0002523,,,,,substrate,,,,,Astemizole,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144703,mbcd0003056,mbtp000001,mbrf0002523,,,,,substrate,,,,,Atomoxetine,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144704,mbcd0026046,mbtp000001,mbrf0002523,,,,,substrate,,,,,Bromocriptine,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144705,mbcd0003901,mbtp000001,mbrf0002523,,,,,substrate,,,,,Cetirizine,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144706,mbcd0003088,mbtp000001,mbrf0002523,,,,,substrate,,,,,Chloroquine,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144707,mbcd0002340,mbtp000001,mbrf0002523,,,,,substrate,,,,,Chlorpromazine,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144708,mbcd0001111,mbtp000001,mbrf0002523,,,,,substrate,,,,,Cimetidine,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144709,mbcd0001517,mbtp000001,mbrf0002523,,,,,substrate,,,,,Clarithromycin,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144710,mbcd0003925,mbtp000001,mbrf0002523,,,,,substrate,,,,,Clomipramine,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144711,mbcd0003888,mbtp000001,mbrf0002523,,,,,substrate,,,,,Clozapine,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144712,mbcd0002667,mbtp000001,mbrf0002523,,,,,substrate,,,,,Colchicine,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144713,mbcd0000311,mbtp000001,mbrf0002523,,,,,substrate,,,,,Cyclosporin A,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144714,mbcd0001369,mbtp000001,mbrf0002523,,,,,substrate,,,,,Desloratadine,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144715,mbcd0002959,mbtp000001,mbrf0002523,,,,,substrate,,,,,Dexamethasone,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144716,mbcd0001050,mbtp000001,mbrf0002523,,,,,substrate,,,,,Digoxin,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144717,mbcd0003100,mbtp000001,mbrf0002523,,,,,substrate,,,,,Dipyridamole,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144718,mbcd0014045,mbtp000001,mbrf0002523,,,,,substrate,,,,,Domperidone,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144719,mbcd0028144,mbtp000001,mbrf0002523,,,,,substrate,,,,,Eletriptan,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144720,mbcd0003937,mbtp000001,mbrf0002523,,,,,substrate,,,,,Ergotamine,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144721,mbcd0000937,mbtp000001,mbrf0002523,,,,,substrate,,,,,Erythromycin,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144722,mbcd0002466,mbtp000001,mbrf0002523,,,,,substrate,,,,,Etoposide,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144723,mbcd0002323,mbtp000001,mbrf0002523,,,,,substrate,,,,,Indinavir,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144724,mbcd0001170,mbtp000001,mbrf0002523,,,,,substrate,,,,,Labetalol,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144725,mbcd0002539,mbtp000001,mbrf0002523,,,,,substrate,,,,,Loperamide,,,,,,,,,human,mbds0010,,2013-12-10 22:21:07
mbbd000144726,mbcd0027669,mbtp000001,mbrf0002523,,,,,substrate,,,,,Methylprednisolone,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144727,mbcd0026632,mbtp000001,mbrf0002523,,,,,substrate,,,,,Nelfinavir,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144728,mbcd0003928,mbtp000001,mbrf0002523,,,,,substrate,,,,,Neostigmine,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144729,mbcd0030085,mbtp000001,mbrf0002523,,,,,substrate,,,,,Paliperidone,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144730,mbcd0024931,mbtp000001,mbrf0002523,,,,,substrate,,,,,Paroxetine,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144731,mbcd0003024,mbtp000001,mbrf0002523,,,,,substrate,,,,,Prazosin,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144732,mbcd0027018,mbtp000001,mbrf0002523,,,,,substrate,,,,,Quinidine,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144733,mbcd0002666,mbtp000001,mbrf0002523,,,,,substrate,,,,,Ranitidine,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144734,mbcd0001941,mbtp000001,mbrf0002523,,,,,substrate,,,,,Reserpine,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144735,mbcd0001938,mbtp000001,mbrf0002523,,,,,substrate,,,,,Ritonavir,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144736,mbcd0001533,mbtp000001,mbrf0002523,,,,,substrate,,,,,Saquinavir,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144737,mbcd0022892,mbtp000001,mbrf0002523,,,,,substrate,,,,,Sertraline,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144738,mbcd0000804,mbtp000001,mbrf0002523,,,,,substrate,,,,,Talinolol,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144739,mbcd0002337,mbtp000001,mbrf0002523,,,,,substrate,,,,,Terfenadine,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144740,mbcd0003143,mbtp000001,mbrf0002523,,,,,substrate,,,,,Thioridazine,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144741,mbcd0003115,mbtp000001,mbrf0002523,,,,,substrate,,,,,Trimethoprim,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144742,mbcd0027062,mbtp000001,mbrf0002523,,,,,substrate,,,,,Verapamil,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144743,mbcd0002492,mbtp000001,mbrf0002523,,,,,substrate,,,,,Ziprasidone,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144744,mbcd0001003,mbtp000001,mbrf0002523,,,,,substrate,,,,,Zolmitriptan,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144745,mbcd0030436,mbtp000001,mbrf0002250,,=,,,non-substrate,14,2.37,*10^6 cm s-1,,Blonanserin,,,human MDR1 cDNA-transfected LLC-PK1 (LLC-MDR1) cell line; penetration across monolayers from apical to basolateral compartment,LLC-PK1,,2,nmol L-1,,human,mbds0010,,2013-11-24 23:10:10
mbbd000144746,mbcd0003893,mbtp000001,mbrf0002250,,=,,,substrate,14,15.6,*10^6 cm s-1,,Risperidone,,,human MDR1 cDNA-transfected LLC-PK1 (LLC-MDR1) cell line; penetration across monolayers from basolateral to apical compartment,LLC-PK1,,100,nmol L-1,,human,mbds0010,,2013-11-24 23:10:10
mbbd000144747,mbcd0030085,mbtp000001,mbrf0002250,,=,,,substrate,14,19.3,*10^6 cm s-1,,9-Hydroxyrisperidone,,,human MDR1 cDNA-transfected LLC-PK1 (LLC-MDR1) cell line; penetration across monolayers from basolateral to apical compartment,LLC-PK1,,70,nmol L-1,,human,mbds0010,,2013-11-24 23:10:10
mbbd000144748,mbcd0001050,mbtp000001,mbrf0002250,,=,,,substrate,14,8.2,*10^6 cm s-1,,Digoxin,,,human MDR1 cDNA-transfected LLC-PK1 (LLC-MDR1) cell line; penetration across monolayers from basolateral to apical compartment,LLC-PK1,,1000,nmol L-1,,human,mbds0010,,2013-11-24 23:10:10
mbbd000144749,mbcd0030438,mbtp000001,mbrf0002477,,=,,,substrate,25,194.82,microM,17.35,beta-Carotene,,,CEM/ADR5000 cell line,CEM/ADR5000,,,,,human,mbds0010,,2013-11-24 23:55:47
mbbd000144750,mbcd0030439,mbtp000001,mbrf0002477,,=,,,substrate,25,206.3,microM,10.14,Crocin,,,CEM/ADR5000 cell line,CEM/ADR5000,,,,,human,mbds0010,,2013-11-24 23:55:47
mbbd000144751,mbcd0026045,mbtp000001,mbrf0002477,,=,,,substrate,25,157.6,microM,8.33,Retinoic acid,,,CEM/ADR5000 cell line,CEM/ADR5000,,,,,human,mbds0010,,2013-11-24 23:55:48
mbbd000144752,mbcd0030440,mbtp000001,mbrf0002477,,=,,,substrate,25,136.59,microM,12.53,Canthaxanthin,,,CEM/ADR5000 cell line,CEM/ADR5000,,,,,human,mbds0010,,2013-11-24 23:55:48
mbbd000144753,mbcd0030441,mbtp000001,mbrf0002477,,=,,,substrate,25,125.94,microM,,Fucoxanthin,,,CEM/ADR5000 cell line,CEM/ADR5000,,,,,human,mbds0010,,2013-11-24 23:55:49
mbbd000144754,mbcd0025844,mbtp000001,mbrf0002477,,=,,,substrate,25,3.36,microM,0.34,Doxorubicin,,,Caco-2 cell line,Caco-2,,,,,human,mbds0010,,2013-11-24 23:12:45
mbbd000144755,mbcd0001151,mbtp000001,mbrf0002477,,=,,,substrate,25,18.03,microM,1.58,Vinblastine,,,Caco-2 cell line,Caco-2,,,,,human,mbds0010,,2013-11-24 23:12:45
mbbd000144756,mbcd0030442,mbtp000001,mbrf0002477,,=,,,substrate,25,58.06,microM,6.01,Amphotericin-B,,,Caco-2 cell line,Caco-2,,,,,human,mbds0010,,2013-11-24 23:12:46
mbbd000144757,mbcd0001532,mbtp000001,mbrf0002477,,=,,,substrate,25,9.0,microM,1,Paclitaxel,,,Caco-2 cell line,Caco-2,,,,,human,mbds0010,,2013-11-24 23:12:46
mbbd000144758,mbcd0003963,mbtp000001,mbrf0002477,,=,,,substrate,25,30.78,microM,3.12,5-Fluorouracil,,,Caco-2 cell line,Caco-2,,,,,human,mbds0010,,2013-11-24 23:12:46
mbbd000144759,mbcd0026456,mbtp000001,mbrf0002477,,=,,,substrate,25,106.71,microM,1.02,Cycloheximide,,,Caco-2 cell line,Caco-2,,,,,human,mbds0010,,2013-11-24 23:12:46
mbbd000144760,mbcd0002466,mbtp000001,mbrf0002477,,=,,,substrate,25,86.03,microM,7.99,Etoposide,,,Caco-2 cell line,Caco-2,,,,,human,mbds0010,,2013-11-24 23:12:47
mbbd000144761,mbcd0001117,mbtp000001,mbrf0002477,,=,,,substrate,25,51.17,microM,4.87,Cisplatin,,,Caco-2 cell line,Caco-2,,,,,human,mbds0010,,2013-11-24 23:12:48
mbbd000144762,mbcd0029831,mbtp000007,mbrf0002063,,=,,,inhibitor,25,20.7,microM,7.7,telaprevir,,,"HEK298 cells, overexpressing OCT1; inhibition of 0.025 microM MPP+ uptake",HEK293,,,,,human,mbds0010,,2014-02-21 02:22:05
mbbd000144763,mbcd0001172,mbtp000001,mbrf0002774,,=,,,substrate,29,0.05,microM,,Ivermectin,,,P-gp overexpressing membrane vesicles; Ki of ATPase activity; LLC-PK1 transfected with human P-gp,LLC-PK1,,,,,human,mbds0010,,2013-11-26 00:08:57
mbbd000144764,mbcd0030444,mbtp000001,mbrf0002774,,=,,,substrate,29,0.02,microM,,Eprinomectin,,,P-gp overexpressing membrane vesicles; Ki of ATPase activity; LLC-PK1 transfected with human P-gp,LLC-PK1,,,,,human,mbds0010,,2013-11-26 00:08:57
mbbd000144765,mbcd0030445,mbtp000001,mbrf0002774,,=,,,substrate,29,0.02,microM,,Abamectin,,,P-gp overexpressing membrane vesicles; Ki of ATPase activity; LLC-PK1 transfected with human P-gp,LLC-PK1,,,,,human,mbds0010,,2013-11-26 00:08:57
mbbd000144766,mbcd0030446,mbtp000001,mbrf0002774,,=,,,substrate,29,0.03,microM,,Doramectin,,,P-gp overexpressing membrane vesicles; Ki of ATPase activity; LLC-PK1 transfected with human P-gp,LLC-PK1,,,,,human,mbds0010,,2013-11-26 00:08:57
mbbd000144767,mbcd0030084,mbtp000001,mbrf0002774,,=,,,substrate,29,1.0,microM,,Selamectin,,,P-gp overexpressing membrane vesicles; Ki of ATPase activity; LLC-PK1 transfected with human P-gp,LLC-PK1,,,,,human,mbds0010,,2013-11-26 00:08:57
mbbd000144768,mbcd0030274,mbtp000001,mbrf0002774,,=,,,substrate,29,0.5,microM,,Moxidectin,,,P-gp overexpressing membrane vesicles; Ki of ATPase activity; LLC-PK1 transfected with human P-gp,LLC-PK1,,,,,human,mbds0010,,2013-11-26 00:08:57
mbbd000144769,mbcd0001305,mbtp000001,mbrf0002030,,~,,,non-substrate,138,98.0,%,2,mephobarbital,,,MDR1-transfected LLC cell line; data given as percentage of initial concentration in basolateral or apical compartment; incubation time 360minutes,LLC-PK1,,,,,human,mbds0010,,2013-11-24 23:10:11
mbbd000144770,mbcd0027062,mbtp000001,mbrf0002321,,=,,,substrate,114,9.5,*10^-7 M,,Verapamil,,,NIH-MDR1-G185 cells within inside-out membrane vesicles; K1 ia a measure of the concentration for half-maximal activity,NIH-3T3,,,,,human,mbds0010,,2013-12-09 08:23:32
mbbd000144771,mbcd0002338,mbtp000001,mbrf0002321,,=,,,substrate,114,8.04,*10^-6 M,,Diltiazem,,,NIH-MDR1-G185 cells within inside-out membrane vesicles; K1 ia a measure of the concentration for half-maximal activity,NIH-3T3,,,,,human,mbds0010,,2013-12-09 08:23:55
mbbd000144772,mbcd0005183,mbtp000001,mbrf0002321,,=,,,substrate,114,6.8,*10^-7 M,,Daunorubicin,,,NIH-MDR1-G185 cells within inside-out membrane vesicles; K1 ia a measure of the concentration for half-maximal activity,NIH-3T3,,,,,human,mbds0010,,2013-12-09 08:23:56
mbbd000144773,mbcd0026441,mbtp000001,mbrf0002321,,=,,,substrate,114,8.96,*10^-7 M,,Triton X-100,,,NIH-MDR1-G185 cells within inside-out membrane vesicles; K1 ia a measure of the concentration for half-maximal activity,NIH-3T3,,,,,human,mbds0010,,2013-12-09 08:23:56
mbbd000144774,mbcd0030447,mbtp000001,mbrf0002321,,=,,,substrate,114,9.24,*10^-7 M,,C12EO8,,,NIH-MDR1-G185 cells within inside-out membrane vesicles; K1 ia a measure of the concentration for half-maximal activity,NIH-3T3,,,,,human,mbds0010,,2013-12-09 08:23:57
mbbd000144775,mbcd0000879,mbtp000001,mbrf0002321,,=,,,substrate,114,1.12,*10^-8 M,,Tween 80,,,NIH-MDR1-G185 cells within inside-out membrane vesicles; K1 ia a measure of the concentration for half-maximal activity,NIH-3T3,,,,,human,mbds0010,,2013-12-09 08:23:57
mbbd000144776,mbcd0002488,mbtp000001,mbrf0001841,,~,,,non-substrate,138,-5.0,%,3,Propranolol,,,P-gp overexpressing L-MDR1 cell line; activation measured as ratio between acidification rates measured during and immediately before stimulation of L-MDR1 cells (?ECAR),LLC,,10,microM,,human,mbds0010,,2013-11-24 23:55:43
mbbd000144777,mbcd0003879,mbtp000001,mbrf0001841,,~,,,non-substrate,138,-2.0,%,1,caffeine,,,P-gp overexpressing L-MDR1 cell line; activation measured as ratio between acidification rates measured during and immediately before stimulation of L-MDR1 cells (?ECAR),LLC,,10,microM,,human,mbds0010,,2013-11-24 23:55:43
mbbd000144778,mbcd0027018,mbtp000001,mbrf0001841,,~,,,substrate,138,18.0,%,2,quinidine,,,P-gp overexpressing L-MDR1 cell line; activation measured as ratio between acidification rates measured during and immediately before stimulation of L-MDR1 cells (?ECAR),LLC,,10,microM,,human,mbds0010,,2013-11-24 23:55:43
mbbd000144779,mbcd0027062,mbtp000001,mbrf0001841,,~,,,substrate,138,25.0,%,2,verapamil,,,P-gp overexpressing L-MDR1 cell line; activation measured as ratio between acidification rates measured during and immediately before stimulation of L-MDR1 cells (?ECAR),LLC,,10,microM,,human,mbds0010,,2013-11-24 23:55:43
mbbd000144780,mbcd0002539,mbtp000001,mbrf0001841,,~,,,substrate,138,25.0,%,1,loperamide,,,P-gp overexpressing L-MDR1 cell line; activation measured as ratio between acidification rates measured during and immediately before stimulation of L-MDR1 cells (?ECAR),LLC,,10,microM,,human,mbds0010,,2013-11-24 23:55:44
mbbd000144781,mbcd0005183,mbtp000001,mbrf0001841,,~,,,substrate,138,7.0,%,2,daunorubicin,,,P-gp overexpressing L-MDR1 cell line; activation measured as ratio between acidification rates measured during and immediately before stimulation of L-MDR1 cells (?ECAR),LLC,,1,microM,,human,mbds0010,,2013-11-24 23:55:44
mbbd000144782,mbcd0001797,mbtp000001,mbrf0001841,,~,,,substrate,1,16.0,%,5,fexofenadine,concentration of fexofenadine had to be reduced to 1 microM to avoid cellular toxicity,,P-gp overexpressing L-MDR1 cell line; activation measured as ratio between acidification rates measured during and immediately before stimulation of L-MDR1 cells (DeltaECAR),LLC-PK1,,1,microM,,human,mbds0010,,2013-12-08 08:52:01
mbbd000144783,mbcd0005183,mbtp000001,mbrf0002256,,~,,,substrate,100,10.0,pmol (10^6 cells)-1,40,Daunorubicin,,,P-gp overexpressing K562/Dox cell line,K562/DOX,,1000,nM,,human,mbds0010,,2013-11-24 23:55:42
mbbd000144784,mbcd0003877,mbtp000001,mbrf0002134,,,,,substrate,,,,,CIT; Citalopram,,,human ABCB1 polymorphism studies; blood (plasma) and cerebrospinal fluid (CSF),human blood and cerebrospinal fluid,,,,,human,mbds0010,,2013-11-26 01:55:29
mbbd000144785,mbcd0001517,mbtp000001,mbrf0001962,,=,,,substrate,17,11.0,microM,,clarithromycin,,,MDR1-overexpressing Sf9 inside out membrane vesicles,Sf9,,,,,human,mbds0010,,2013-11-24 23:55:03
mbbd000144786,mbcd0001376,mbtp000001,mbrf0001962,,=,,,substrate,17,0.55,microM,,telithromycin,,,MDR1-overexpressing Sf9 inside out membrane vesicles,Sf9,,,,,human,mbds0010,,2013-11-24 23:55:03
mbbd000144787,mbcd0028157,mbtp000001,mbrf0001962,,=,,,substrate,17,120.0,microM,,azithromycin,,,MDR1-overexpressing Sf9 inside out membrane vesicles,Sf9,,,,,human,mbds0010,,2013-11-24 23:55:03
mbbd000144788,mbcd0000937,mbtp000001,mbrf0001962,,=,,,substrate,17,25.0,microM,,erythromycin,,,MDR1-overexpressing Sf9 inside out membrane vesicles,Sf9,,,,,human,mbds0010,,2013-11-24 23:55:04
mbbd000144789,mbcd0028769,mbtp000001,mbrf0001962,,=,,,substrate,17,2.5,microM,,roxithromycin,,,MDR1-overexpressing Sf9 inside out membrane vesicles,Sf9,,,,,human,mbds0010,,2013-11-24 23:55:05
mbbd000144795,mbcd0029094,mbtp000001,mbrf0001878,,~,,,substrate,96,500.0,%,50,guggulsterone,,,human P-gp overexpressing memebrane vesicles; activity measured as a percentage of basal activity; human P-gp gene containing baculovirus infected insect High Five cells,High Five insect cells,,200,microM,,human,mbds0010,,2013-12-13 18:38:41
mbbd000144796,mbcd0000182,mbtp000001,mbrf0001878,,=,,,non-substrate,81,0.995,,0.018,beta-sitosterol,,,KB-C2 cell line; intracellular fluorescent substrate (daunorubicin) accumulation ratio,KB-C2,,50,microM,,human,mbds0010,,2013-11-24 23:55:40
mbbd000144797,mbcd0030448,mbtp000001,mbrf0001878,,~,,,non-substrate,81,1.0,,,campesterol,,,effect on uptake rate of known substrates,KB-C2,,50,microM,,human,mbds0010,,2013-11-24 07:52:31
mbbd000144798,mbcd0030449,mbtp000001,mbrf0001878,,=,,,non-substrate,81,0.997,,0.049,stigmasterol,,,KB-C2 cell line; intracellular fluorescent substrate (daunorubicin) accumulation ratio,KB-C2,,50,microM,,human,mbds0010,,2013-11-24 23:55:41
mbbd000144799,mbcd0030450,mbtp000001,mbrf0001878,,=,,,non-substrate,81,1.014,,0.039,beta-sitostanol,,,KB-C2 cell line; intracellular fluorescent substrate (daunorubicin) accumulation ratio,KB-C2,,50,microM,,human,mbds0010,,2013-11-24 23:55:42
mbbd000144800,mbcd0030451,mbtp000001,mbrf0001878,,~,,,non-substrate,81,1.05,,,beta-cholestanol,,,KB-C2 cell line; intracellular fluorescent substrate (daunorubicin) accumulation ratio,KB-C2,,50,microM,,human,mbds0010,,2013-11-24 23:15:30
mbbd000144801,mbcd0030452,mbtp000001,mbrf0001878,,~,,,non-substrate,81,0.8,,,fucosterol,,,KB-C2 cell line; intracellular fluorescent substrate (daunorubicin) accumulation ratio,KB-C2,,50,microM,,human,mbds0010,,2013-11-24 23:55:42
mbbd000144803,mbcd0000723,mbtp000001,mbrf0002281,,~,,,substrate,133,17.0,,4,puromycin,,,MDCK II/P-gp overexpressing cell line;RF values were calculated by division of IC50 of ABC transporter overexpressing cells with IC50 of parental cells,MDCKII,,,,,human,mbds0010,,2013-11-24 23:12:12
mbbd000144804,mbcd0029874,mbtp000001,mbrf0002281,,~,,,non-substrate,133,0.8,,,hygromycin,,,MDCK II/P-gp overexpressing cell line;RF values were calculated by division of IC50 of ABC transporter overexpressing cells with IC50 of parental cells,MDCKII,,,,,human,mbds0010,,2013-11-24 23:12:12
mbbd000144805,mbcd0030455,mbtp000001,mbrf0002281,,~,,,substrate,133,22.0,,0.5,geneticin,,,MDCK II/P-gp overexpressing cell line;RF values were calculated by division of IC50 of ABC transporter overexpressing cells with IC50 of parental cells,MDCKII,,,,,human,mbds0010,,2013-11-24 23:12:12
mbbd000144806,mbcd0000311,mbtp000001,mbrf0002174,,=,,,substrate,17,6.5,*10^-11 M,,Cyclosporin A,,,P-gp-overexpressing inside-out Sf9 membrane vesicles,Sf9,,,,,human,mbds0010,,2013-11-24 23:55:05
mbbd000144807,mbcd0001808,mbtp000001,mbrf0002174,,=,,,non-substrate,25,1.3,*10^-8 M,,GF120918,,,L5178 MDR1 cell line; nhibition of Pgp-mediated R123 efflux,L5178,,5,microM,,human,mbds0010,,2013-11-24 23:55:40
mbbd000144808,mbcd0027726,mbtp000001,mbrf0001866,,,,,substrate,,,,,Docetaxel,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144809,mbcd0002828,mbtp000001,mbrf0001866,,,,,substrate,,,,,Imatinib,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144810,mbcd0002091,mbtp000001,mbrf0001866,,,,,substrate,,,,,Irinotecan,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144811,mbcd0000998,mbtp000001,mbrf0001866,,,,,substrate,,,,,Mitomycin C,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144812,mbcd0002981,mbtp000001,mbrf0001866,,,,,substrate,,,,,Mitoxantrone,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144813,mbcd0001080,mbtp000001,mbrf0001866,,,,,substrate,,,,,Teniposide,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144814,mbcd0003187,mbtp000001,mbrf0001866,,,,,substrate,,,,,Topotecan,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144815,mbcd0001135,mbtp000001,mbrf0001866,,,,,substrate,,,,,Vincristine,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144816,mbcd0000242,mbtp000001,mbrf0001866,,,,,substrate,,,,,Celiprolol,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144817,mbcd0027333,mbtp000001,mbrf0001866,,,,,substrate,,,,,Losartan,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144818,mbcd0002635,mbtp000001,mbrf0001866,,,,,substrate,,,,,Cortisol,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144819,mbcd0026093,mbtp000001,mbrf0001866,,,,,substrate,,,,,Atorvastatin,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144820,mbcd0027835,mbtp000001,mbrf0001866,,,,,substrate,,,,,Mefloquine,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144821,mbcd0001567,mbtp000001,mbrf0001866,,,,,substrate,,,,,Vecuronium,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144822,mbcd0001416,mbtp000001,mbrf0001866,,,,,substrate,,,,,Rifampin,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144823,mbcd0002989,mbtp000001,mbrf0001866,,,,,substrate,,,,,Sparfloxacin,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144824,mbcd0003016,mbtp000001,mbrf0001866,,,,,substrate,,,,,Tetracycline,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144825,mbcd0002191,mbtp000001,mbrf0001866,,,,,substrate,,,,,Itraconazole,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144826,mbcd0001324,mbtp000001,mbrf0001866,,,,,substrate,,,,,Sirolimus,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144827,mbcd0001316,mbtp000001,mbrf0001866,,,,,substrate,,,,,Tacrolimus,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144828,mbcd0000721,mbtp000001,mbrf0001866,,,,,substrate,,,,,Valspodar,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144829,mbcd0002723,mbtp000001,mbrf0001866,,,,,substrate,,,,,Morphine,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144830,mbcd0003920,mbtp000001,mbrf0001866,,,,,substrate,,,,,Ondansetron,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144831,mbcd0001636,mbtp000001,mbrf0002280,,,,,substrate,,,,,Platelet-activating factor,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144832,mbcd0030203,mbtp000001,mbrf0002280,,,,,substrate,,,,,sphingosine-1-phosphate,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144833,mbcd0030457,mbtp000001,mbrf0002190,,<,,,non-substrate,113,1.0,,,[Eu-DOTA]-,,,K562/ADR cell line; intracellular to extracellular Eu ratio at 90 min,K562/ADR,,100,microM,,human,mbds0010,,2013-11-24 23:55:39
mbbd000144834,mbcd0030458,mbtp000001,mbrf0002190,,=,,,non-substrate,113,11.0,,3,[Eu-DOTAM]3+,,,K562/ADR cell line; intracellular to extracellular Eu ratio at 90 min,K562/ADR,,10,microM,,human,mbds0010,,2013-11-24 23:55:39
mbbd000144835,mbcd0030459,mbtp000001,mbrf0002190,,~,,,non-substrate,113,2.0,,,[Eu-DTPA]2-,,,K562/ADR cell line; intracellular to extracellular Eu ratio at 90 min,K562/ADR,,10,microM,,human,mbds0010,,2013-11-24 23:55:39
mbbd000144836,mbcd0030460,mbtp000001,mbrf0002190,,<,,,non-substrate,113,1.0,,,Eu-DTPA-BMA,,,K562 cells,K562,,100,microM,,human,mbds0010,,2013-11-10 04:16:08
mbbd000144837,mbcd0030461,mbtp000001,mbrf0002190,,=,,,non-substrate,113,7.0,,2,Eu-DTPA-BBA,,,K562/ADR cell line; intracellular to extracellular Eu ratio at 90 min,K562/ADR,,10,microM,,human,mbds0010,,2013-12-09 07:12:57
mbbd000144838,mbcd0027062,mbtp000001,mbrf0002460,,=,,,non-substrate,85,0.65,,,Verapamil,,,"MDCKII/MDR1 cell line; permeability measurements from apical to basolateral compartments, bidirectional transepithelial flux",MDCKII,,10,microM,,human,mbds0010,,2013-11-04 06:29:10
mbbd000144839,mbcd0001299,mbtp000001,mbrf0002460,,=,,,non-substrate,85,0.7,,,Mifepristone,,,"MDCKII/MDR1 cell line; permeability measurements from apical to basolateral compartments, bidirectional transepithelial flux",MDCKII,,10,microM,,human,mbds0010,,2013-11-04 06:29:10
mbbd000144840,mbcd0002493,mbtp000001,mbrf0002460,,=,,,non-substrate,85,0.18,,,Clotrimazole,,,"MDCKII/MDR1 cell line; permeability measurements from apical to basolateral compartments, bidirectional transepithelial flux",MDCKII,,10,microM,,human,mbds0010,,2013-11-04 06:29:10
mbbd000144841,mbcd0030462,mbtp000001,mbrf0002460,,=,,,non-substrate,85,0.75,,,Mevastatin,,,"MDCKII/MDR1 cell line; permeability measurements from apical to basolateral compartments, bidirectional transepithelial flux",MDCKII,,10,microM,,human,mbds0010,,2013-11-04 06:29:11
mbbd000144842,mbcd0030463,mbtp000001,mbrf0002460,,=,,,non-substrate,85,0.81,,,Artemisinin,,,"MDCKII/MDR1 cell line; permeability measurements from apical to basolateral compartments, bidirectional transepithelial flux",MDCKII,,10,microM,,human,mbds0010,,2013-11-04 06:29:11
mbbd000144843,mbcd0027018,mbtp000001,mbrf0002460,,=,,,substrate,85,32.01,,,Quinidine,,,"MDCKII/MDR1 cell line; permeability measurements from apical to basolateral compartments, bidirectional transepithelial flux",MDCKII,,10,microM,,human,mbds0010,,2013-11-04 06:29:11
mbbd000144844,mbcd0002383,mbtp000001,mbrf0002460,,=,,,substrate,85,24.2,,,Amprenavir,,,"MDCKII/MDR1 cell line; permeability measurements from apical to basolateral compartments, bidirectional transepithelial flux",MDCKII,,10,microM,,human,mbds0010,,2013-11-04 06:29:12
mbbd000144845,mbcd0026093,mbtp000001,mbrf0002460,,=,,,substrate,85,8.92,,,Atorvastatin,,,"MDCKII/MDR1 cell line; permeability measurements from apical to basolateral compartments, bidirectional transepithelial flux",MDCKII,,10,microM,,human,mbds0010,,2013-11-04 06:29:12
mbbd000144846,mbcd0002091,mbtp000001,mbrf0002460,,=,,,substrate,85,7.11,,,Irinotecan,,,"MDCKII/MDR1 cell line; permeability measurements from apical to basolateral compartments, bidirectional transepithelial flux",MDCKII,,10,microM,,human,mbds0010,,2013-11-04 06:29:12
mbbd000144847,mbcd0000937,mbtp000001,mbrf0002460,,=,,,substrate,85,4.9,,,Erythromycin,,,"MDCKII/MDR1 cell line; permeability measurements from apical to basolateral compartments, bidirectional transepithelial flux",MDCKII,,10,microM,,human,mbds0010,,2013-11-04 06:29:12
mbbd000144848,mbcd0001111,mbtp000001,mbrf0002460,,=,,,substrate,85,2.52,,,Cimetidine,,,"MDCKII/MDR1 cell line; permeability measurements from apical to basolateral compartments, bidirectional transepithelial flux",MDCKII,,10,microM,weak substrate,human,mbds0010,,2013-11-04 06:29:13
mbbd000144849,mbcd0003187,mbtp000001,mbrf0002460,,=,,,substrate,85,1.81,,,Topotecan,,,"MDCKII/MDR1 cell line; permeability measurements from apical to basolateral compartments, bidirectional transepithelial flux",MDCKII,,10,microM,weak substrate,human,mbds0010,,2013-11-04 06:29:13
mbbd000144850,mbcd0002338,mbtp000001,mbrf0002460,,=,,,non-substrate,85,0.71,,,Diltiazem,,,"MDCKII/MDR1 cell line; permeability measurements from apical to basolateral compartments, bidirectional transepithelial flux",MDCKII,,10,microM,,human,mbds0010,,2013-11-04 06:29:13
mbbd000144851,mbcd0000977,mbtp000001,mbrf0002460,,=,,,non-substrate,85,0.85,,,Isradipine,,,"MDCKII/MDR1 cell line; permeability measurements from apical to basolateral compartments, bidirectional transepithelial flux",MDCKII,,10,microM,,human,mbds0010,,2013-11-04 06:29:13
mbbd000144852,mbcd0025591,mbtp000001,mbrf0002460,,=,,,non-substrate,85,0.48,,,Lovastatin,,,"MDCKII/MDR1 cell line; permeability measurements from apical to basolateral compartments, bidirectional transepithelial flux",MDCKII,,10,microM,,human,mbds0010,,2013-11-04 06:29:14
mbbd000144853,mbcd0029350,mbtp000001,mbrf0002174,,=,,,substrate,17,2.6,*10^-8 M,,Epirubicin,,,MDR1-overexpressing inside-out Sf9 membrane vesicles,Sf9,,,,,human,mbds0010,,2013-11-24 23:55:05
mbbd000144854,mbcd0029350,mbtp000001,mbrf0002174,,=,,,substrate,22,55.1,ng mg-1 min-1,6.7,Epirubicin,,,MDR1-overexpressing inside-out Sf9 membrane vesicles,Sf9,,,,,human,mbds0010,,2013-11-24 23:55:06
mbbd000144855,mbcd0000311,mbtp000001,mbrf0002174,,=,,,substrate,22,20.0,ng mg-1 min-1,0.6,cyclosporin a,,,P-gp-overexpressing inside-out Sf9 membrane vesicles,Sf9,,,,,human,mbds0010,,2013-11-24 23:55:06
mbbd000144856,mbcd0002883,mbtp000001,mbrf0002174,,=,,,substrate,17,7.9,*10^-11 M,,Compound 2c,,,P-gp-overexpressing inside-out Sf9 membrane vesicles,Sf9,,,,,human,mbds0010,,2013-11-24 23:55:06
mbbd000144857,mbcd0002883,mbtp000001,mbrf0002174,,=,,,substrate,22,12.7,ng mg-1 min-1,0.3,Compound 2c,,,P-gp-overexpressing inside-out Sf9 membrane vesicles,Sf9,,,,,human,mbds0010,,2013-11-24 23:55:07
mbbd000144858,mbcd0030464,mbtp000001,mbrf0002174,,=,,,substrate,17,8.7,*10^-8 M,,Compound 3c,,,P-gp-overexpressing inside-out Sf9 membrane vesicles,Sf9,,,,,human,mbds0010,,2013-11-24 23:55:07
mbbd000144859,mbcd0030464,mbtp000001,mbrf0002174,,=,,,substrate,22,12.5,ng mg-1 min-1,0.6,Compound 3c,,,P-gp-overexpressing inside-out Sf9 membrane vesicles,Sf9,,,,,human,mbds0010,,2013-11-24 23:55:07
mbbd000144860,mbcd0030465,mbtp000001,mbrf0002169,,=,,,substrate,144,41.0,*10^-6 cm s-1,19.9,HCV NS3 protease inhibitor 1,,,Pgp expressing Caco-2  cell line,Caco-2,,,,,human,mbds0010,,2013-11-24 23:12:49
mbbd000144861,mbcd0030466,mbtp000001,mbrf0002169,,=,,,substrate,144,53.9,*10^-6 cm s-1,14.8,HCV NS3 protease inhibitor 2,,,Pgp expressing Caco-2  cell line; membrane permeability measurements of transport from basolateral to apical compartment,Caco-2,,,,,human,mbds0010,,2013-11-24 23:12:49
mbbd000144862,mbcd0030467,mbtp000001,mbrf0002169,,=,,,substrate,144,101.4,*10^-6 cm s-1,14.2,HCV NS3 protease inhibitor 3,,,Pgp expressing Caco-2  cell line; membrane permeability measurements of transport from basolateral to apical compartment,Caco-2,,,,,human,mbds0010,,2013-11-24 23:12:49
mbbd000144863,mbcd0030468,mbtp000001,mbrf0002169,,=,,,substrate,144,125.9,*10^-6 cm s-1,0.9,HCV NS3 protease inhibitor 4,,,Pgp expressing Caco-2  cell line; membrane permeability measurements of transport from basolateral to apical compartment,Caco-2,,,,,human,mbds0010,,2013-11-24 23:12:49
mbbd000144864,mbcd0030469,mbtp000001,mbrf0002169,,=,,,substrate,144,43.5,*10^-6 cm s-1,4.7,HCV NS3 protease inhibitor 5,,,Pgp expressing Caco-2  cell line; membrane permeability measurements of transport from basolateral to apical compartment,Caco-2,,,,,human,mbds0010,,2013-11-24 23:12:50
mbbd000144865,mbcd0030470,mbtp000001,mbrf0002169,,=,,,substrate,144,4.3,*10^-6 cm s-1,0.2,HCV NS3 protease inhibitor 6,,,Pgp expressing Caco-2  cell line; membrane permeability measurements of transport from basolateral to apical compartment,Caco-2,,,,,human,mbds0010,,2013-11-24 23:12:50
mbbd000144866,mbcd0030471,mbtp000001,mbrf0002169,,=,,,substrate,144,82.1,*10^-6 cm s-1,1.2,HCV NS3 protease inhibitor 7,,,Pgp expressing Caco-2  cell line; membrane permeability measurements of transport from basolateral to apical compartment,Caco-2,,,,,human,mbds0010,,2013-11-24 23:12:50
mbbd000144867,mbcd0030472,mbtp000001,mbrf0002169,,=,,,substrate,144,19.4,*10^-6 cm s-1,0.6,HCV NS3 protease inhibitor 8,,,Pgp expressing Caco-2  cell line; membrane permeability measurements of transport from basolateral to apical compartment,Caco-2,,,,,human,mbds0010,,2013-11-24 23:12:50
mbbd000144868,mbcd0030473,mbtp000001,mbrf0002169,,=,,,substrate,144,121.9,*10^-6 cm s-1,9,HCV NS3 protease inhibitor 9,,,Pgp expressing Caco-2  cell line; membrane permeability measurements of transport from basolateral to apical compartment,Caco-2,,,,,human,mbds0010,,2013-11-24 23:12:51
mbbd000144869,mbcd0030474,mbtp000001,mbrf0002169,,=,,,substrate,144,0.2,*10^-6 cm s-1,,HCV NS3 protease inhibitor 10,,,Pgp expressing Caco-2  cell line; membrane permeability measurements of transport from basolateral to apical compartment,Caco-2,,,,,human,mbds0010,,2013-11-24 23:12:51
mbbd000144870,mbcd0030475,mbtp000001,mbrf0002169,,=,,,substrate,144,8.4,*10^-6 cm s-1,1.8,HCV NS3 protease inhibitor 11,,,Pgp expressing Caco-2  cell line; membrane permeability measurements of transport from basolateral to apical compartment,Caco-2,,,,,human,mbds0010,,2013-11-24 23:12:51
mbbd000144871,mbcd0014045,mbtp000001,mbrf0001737,,=,,,inhibitor,25,45.64,microM,0.17,Domperidone,,,Pgp overexpressing Caco-2 cell line; IC50 values for inhibition of Talinolol transport,,,,,,human,mbds0010,,2013-07-11 00:35:14
mbbd000144872,mbcd0030435,mbtp000001,mbrf0001737,,=,,,inhibitor,25,123.5,microM,1.4,Amisulpride,,,Pgp overexpressing Caco-2 cell line; IC50 values for inhibition of Talinolol transport,,,,,,human,mbds0010,,2013-07-11 00:35:14
mbbd000144873,mbcd0003888,mbtp000001,mbrf0001737,,=,,,inhibitor,25,92.78,microM,1.13,Clozapine,,,Pgp overexpressing Caco-2 cell line; IC50 values for inhibition of Talinolol transport,,,,,,human,mbds0010,,2013-07-11 00:35:14
mbbd000144874,mbcd0016232,mbtp000001,mbrf0001737,,=,,,inhibitor,25,125.9,microM,0.5,Desmethyl clozapine,,,Pgp overexpressing Caco-2 cell line; IC50 values for inhibition of Talinolol transport,,,,,,human,mbds0010,,2013-07-21 05:39:15
mbbd000144875,mbcd0003897,mbtp000001,mbrf0001737,,=,,,inhibitor,25,33.88,microM,1.5,Fluphenazine,,,Pgp overexpressing Caco-2 cell line; IC50 values for inhibition of Talinolol transport,,,,,,human,mbds0010,,2013-07-11 00:35:14
mbbd000144876,mbcd0001322,mbtp000001,mbrf0001737,,=,,,inhibitor,25,18.32,microM,0.04,Flupentixol,,,Pgp overexpressing Caco-2 cell line; IC50 values for inhibition of Talinolol transport,,,,,,human,mbds0010,,2013-07-11 00:35:15
mbbd000144877,mbcd0000923,mbtp000001,mbrf0001737,,=,,,inhibitor,25,146.7,microM,1.95,Fluvoxamine,,,Pgp overexpressing Caco-2 cell line; IC50 values for inhibition of Talinolol transport,,,,,,human,mbds0010,,2013-07-11 00:35:15
mbbd000144878,mbcd0030476,mbtp000001,mbrf0001737,,=,,,inhibitor,25,43.26,microM,0.76,Perazine,,,Pgp overexpressing Caco-2 cell line; IC50 values for inhibition of Talinolol transport,,,,,,human,mbds0010,,2013-07-11 00:35:15
mbbd000144879,mbcd0030477,mbtp000001,mbrf0001737,,=,,,inhibitor,25,166.1,microM,0.15,Desmethyl perazine,,,Pgp overexpressing Caco-2 cell line; IC50 values for inhibition of Talinolol transport,,,,,,human,mbds0010,,2013-07-11 00:35:15
mbbd000144880,mbcd0009152,mbtp000001,mbrf0001737,,=,,,inhibitor,25,15.45,microM,0.18,Perphenazine,,,Pgp overexpressing Caco-2 cell line; IC50 values for inhibition of Talinolol transport,,,,,,human,mbds0010,,2013-07-11 00:35:15
mbbd000144881,mbcd0001777,mbtp000001,mbrf0001737,,=,,,inhibitor,25,12.43,microM,0.03,Haloperidol,,,Pgp overexpressing Caco-2 cell line; IC50 values for inhibition of Talinolol transport,,,,,,human,mbds0010,,2013-07-11 00:35:15
mbbd000144882,mbcd0001583,mbtp000001,mbrf0001737,,=,,,inhibitor,25,23.04,microM,0.19,Levomepromazine,,,Pgp overexpressing Caco-2 cell line; IC50 values for inhibition of Talinolol transport,,,,,,human,mbds0010,,2013-07-11 00:35:15
mbbd000144883,mbcd0001018,mbtp000001,mbrf0001737,,>,,,inhibitor,25,250.0,microM,,Olanzapine,,,Pgp overexpressing Caco-2 cell line; IC50 values for inhibition of Talinolol transport,,,,,,human,mbds0010,,2013-07-11 00:35:16
mbbd000144884,mbcd0027670,mbtp000001,mbrf0001737,,=,,,inhibitor,25,0.8,microM,0.05,Quetiapine,,,Pgp overexpressing Caco-2 cell line; IC50 values for inhibition of Talinolol transport,,,,,,human,mbds0010,,2013-07-11 00:35:16
mbbd000144885,mbcd0027062,mbtp000001,mbrf0001737,,=,,,inhibitor,25,15.37,microM,0.07,Verapamil,,,Pgp overexpressing Caco-2 cell line; IC50 values for inhibition of Talinolol transport,,,,,,human,mbds0010,,2013-07-11 00:35:16
mbbd000144886,mbcd0003893,mbtp000001,mbrf0002397,,=,,,substrate,28,26.3,microM,5.5,risperidone,,,"human Pgp-overexpressing membranes; membrane fractions containing human P-gp purchased from Gentest, USA",membrane fractions,,,,,human,mbds0010,,2013-11-26 01:55:29
mbbd000144887,mbcd0003893,mbtp000001,mbrf0002397,,=,,,substrate,22,71.4,nmol phosphate released (mg protein)-1 min-1,3.2,risperidone,,,"human Pgp-overexpressing membranes; membrane fractions containing human P-gp purchased from Gentest, USA",membrane fractions,,,,,human,mbds0010,,2013-11-26 01:55:29
mbbd000144888,mbcd0030478,mbtp000001,mbrf0002397,,=,,,substrate,28,146.9,microM,29.7,9-OH-risperidone,,,"human Pgp-overexpressing membranes; membrane fractions containing human P-gp purchased from Gentest, USA",membrane fractions,,,,,human,mbds0010,,2013-11-26 01:55:29
mbbd000144889,mbcd0030478,mbtp000001,mbrf0002397,,=,,,substrate,22,67.0,nmol phosphate released (mg protein)-1 min-1,4.3,9-OH-risperidone,,,"human Pgp-overexpressing membranes; membrane fractions containing human P-gp purchased from Gentest, USA",membrane fractions,,,,,human,mbds0010,,2013-11-26 01:55:29
mbbd000144891,mbcd0002996,mbtp000001,mbrf0002463,,~,,,substrate,14,2.4,*10^-5 cells s-1,,phenytoin,,,MDCK II/MDR1 expresssing cell line,MDCKII,,,,,human,mbds0010,,2013-11-24 23:12:13
mbbd000144892,mbcd0003007,mbtp000001,mbrf0002463,,=,,,substrate,14,2.1,*10^-5 cells s-1,,phenobarbital,,,MDCK II/MDR1 expresssing cell line,MDCKII,,,,,human,mbds0010,,2013-11-24 23:12:13
mbbd000144893,mbcd0026528,mbtp000001,mbrf0002463,,=,,,non-substrate,14,1.6,*10^-5 cells s-1,,ethosuximide,,,MDCK II/MDR1 expresssing cell line,MDCKII,,,,,human,mbds0010,,2013-11-24 23:12:13
mbbd000144894,mbcd0003124,mbtp000001,mbrf0001900,,,,,substrate,,,,,abacavir,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144895,mbcd0002339,mbtp000001,mbrf0001900,,,,,non-substrate,,,,,nevirapine,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144896,mbcd0001868,mbtp000001,mbrf0001900,,,,,non-substrate,,,,,efavirenz,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144897,mbcd0002544,mbtp000001,mbrf0001900,,,,,substrate,,,,,delavirdine,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144898,mbcd0001107,mbtp000001,mbrf0001900,,,,,substrate,,,,,Zidovudine,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144899,mbcd0001938,mbtp000001,mbrf0001900,,,,,substrate,,,,,Ritonavir,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144900,mbcd0001533,mbtp000001,mbrf0001900,,,,,substrate,,,,,Saquinavir,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144901,mbcd0026632,mbtp000001,mbrf0001900,,,,,substrate,,,,,Nelfinavir,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144902,mbcd0002323,mbtp000001,mbrf0001900,,,,,substrate,,,,,Indinavir,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144903,mbcd0002383,mbtp000001,mbrf0001900,,,,,substrate,,,,,Amprenavir,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144904,mbcd0001797,mbtp000001,mbrf0002442,,=,,,substrate,23,0.01,%,0.001,Fexofenadine,"% of dose/2h; statistically significant difference from MDR1-knockdown Caco-2 cell monolayer (p < 0.01) for MDR1-overexpressing Caco-2 (for conventional Caco-2 cell line, permeated amount = 0.018+/-0.005 and also significant)",,MDR1-overexpressing and conventional Caco-2 cell lines; permeation from the apical side to the basal side of the Caco-2 cell monolayers; data expressed as a fraction of the dose permeated,Caco-2,,,,,human,mbds0010,,2013-12-08 07:22:53
mbbd000144905,mbcd0002539,mbtp000001,mbrf0002442,,~,,,substrate,23,0.18,%,,Loperamide,,,MDR1-overexpressing Caco-2 cell line; permeation from the apical side to the basal side of the Caco-2 cell monolayers; data expressed as a fraction of the dose permeated; incubation time 2 hours,Caco-2,,,,,human,mbds0010,,2013-11-24 23:12:52
mbbd000144906,mbcd0027018,mbtp000001,mbrf0002442,,~,,,substrate,23,1.6,%,0.5,Quinidine,,,MDR1-overexpressing Caco-2 cell line; permeation from the apical side to the basal side of the Caco-2 cell monolayers; data expressed as a fraction of the dose permeated; incubation time 2 hours,Caco-2,,,,,human,mbds0010,,2013-11-24 23:12:52
mbbd000144907,mbcd0000804,mbtp000001,mbrf0002442,,~,,,substrate,23,0.017,%,,Talinolol,,,MDR1-overexpressing Caco-2 cell line; permeation from the apical side to the basal side of the Caco-2 cell monolayers; data expressed as a fraction of the dose permeated; incubation time 2 hours,Caco-2,,,,,human,mbds0010,,2013-11-24 23:12:52
mbbd000144908,mbcd0030479,mbtp000001,mbrf0002586,,,,,substrate,,,,,ABT-737,,,Cytotoxicity assay comparing apoptosis levels between MRP1-expressing and control cells,MDCKII,,0-30,microM,,human,mbds0010,,2013-10-09 22:18:42
mbbd000144909,mbcd0030480,mbtp000001,mbrf0002586,,~,,,substrate,100,20.0,pmol (10^6 cells)-1,,ABT-263,,,MDCK II/MDR1 cell line; incubation time 30 minutes,MDCKII,,1,microM,,human,mbds0010,,2013-11-24 23:12:13
mbbd000144910,mbcd0029239,mbtp000001,mbrf0002257,,~,,,substrate,96,102.0,%,5,gatifloxacin,,,MDCK II/MDR1 cell line; activity measured as a percentage of control; 30 minute incubation time,MDCKII,,0.75,mM,,human,mbds0010,,2013-11-24 23:12:14
mbbd000144911,mbcd0030335,mbtp000001,mbrf0002413,,~,,,substrate,138,60.0,%,15,N-desethyl sunitinib,,,MDCK II-MDR1 trasnfected cell line; Transepithelial transport from basolateral to apical compartment after 4 hours incubation time; measurements of amount of drug appearing in opposite compartment as a percentage of amount of initially applied drug,MDCKII,,5,microM,,human,mbds0010,,2013-11-24 23:12:14
mbbd000144912,mbcd0003916,mbtp000001,mbrf0002548,,=,,,non-substrate,142,2.23,*10^-6 cm s-1,,Acyclovir,,,MDCK II-MDR1 transfected cell line; transport from apical to basolateral direction,MDCKII,,10 or 100,microM,,human,mbds0010,,2013-10-31 19:11:47
mbbd000144913,mbcd0002238,mbtp000001,mbrf0002548,,=,,,substrate,142,51.3,*10^-6 cm s-1,,Alprenolol,,,MDCK II-MDR1 transfected cell line; transport from apical to basolateral direction,MDCKII,,10 or 100,microM,,human,mbds0010,,2013-10-31 19:11:47
mbbd000144914,mbcd0003111,mbtp000001,mbrf0002548,,=,,,non-substrate,142,2.54,*10^-6 cm s-1,,Amiloride,,,MDCK II-MDR1 transfected cell line; transport from apical to basolateral direction,MDCKII,,10 or 100,microM,,human,mbds0010,,2013-10-31 19:11:47
mbbd000144915,mbcd0003069,mbtp000001,mbrf0002548,,=,,,non-substrate,142,84.7,*10^-6 cm s-1,,Antipyrine,,,MDCK II-MDR1 transfected cell line; transport from apical to basolateral direction,MDCKII,,10 or 100,microM,,human,mbds0010,,2013-10-31 19:11:47
mbbd000144916,mbcd0003875,mbtp000001,mbrf0002548,,=,,,non-substrate,142,1.31,*10^-6 cm s-1,,Atenolol,,,MDCK II-MDR1 transfected cell line; transport from apical to basolateral direction,MDCKII,,10 or 100,microM,,human,mbds0010,,2013-10-31 19:11:47
mbbd000144917,mbcd0003773,mbtp000001,mbrf0002548,,=,,,non-substrate,142,2.09,*10^-6 cm s-1,,Ceftriaxon,,,MDCK II-MDR1 transfected cell line; transport from apical to basolateral direction,MDCKII,,10 or 100,microM,,human,mbds0010,,2013-10-31 19:11:47
mbbd000144918,mbcd0001081,mbtp000001,mbrf0002548,,=,,,non-substrate,142,17.5,*10^-6 cm s-1,,Chloramphenicol,,,MDCK II-MDR1 transfected cell line; transport from apical to basolateral direction,MDCKII,,10 or 100,microM,,human,mbds0010,,2013-10-31 19:11:47
mbbd000144919,mbcd0003088,mbtp000001,mbrf0002548,,=,,,non-substrate,142,24.0,*10^-6 cm s-1,,Chloroquine,,,MDCK II-MDR1 transfected cell line; transport from apical to basolateral direction,MDCKII,,10 or 100,microM,,human,mbds0010,,2013-10-31 19:11:47
mbbd000144920,mbcd0001111,mbtp000001,mbrf0002548,,=,,,non-substrate,142,2.31,*10^-6 cm s-1,,Cimetidine,,,MDCK II-MDR1 transfected cell line; transport from apical to basolateral direction,MDCKII,,10 or 100,microM,,human,mbds0010,,2013-10-31 19:11:48
mbbd000144921,mbcd0000311,mbtp000001,mbrf0002548,,=,,,substrate,142,3.93,*10^-6 cm s-1,,Cyclosporine A,,,MDCK II-MDR1 transfected cell line; transport from apical to basolateral direction,MDCKII,,10 or 100,microM,,human,mbds0010,,2013-10-31 19:11:48
mbbd000144922,mbcd0002995,mbtp000001,mbrf0002548,,=,,,substrate,142,38.3,*10^-6 cm s-1,,Desipramine,,,MDCK II-MDR1 transfected cell line; transport from apical to basolateral direction,MDCKII,,10 or 100,microM,,human,mbds0010,,2013-10-31 19:11:48
mbbd000144923,mbcd0001050,mbtp000001,mbrf0002548,,=,,,substrate,142,3.2,*10^-6 cm s-1,,Digoxin,,,MDCK II-MDR1 transfected cell line; transport from apical to basolateral direction,MDCKII,,10 or 100,microM,,human,mbds0010,,2013-10-31 19:11:48
mbbd000144924,mbcd0025844,mbtp000001,mbrf0002548,,=,,,substrate,142,1.05,*10^-6 cm s-1,,Doxorubicin,,,MDCK II-MDR1 transfected cell line; transport from apical to basolateral direction,MDCKII,,10 or 100,microM,,human,mbds0010,,2013-10-31 19:11:48
mbbd000144925,mbcd0000937,mbtp000001,mbrf0002548,,=,,,substrate,142,1.7,*10^-6 cm s-1,,Erythromycin,,,Caco-2-MDR1 transfected cell line; transport from apical to basolateral direction,MDCKII,,10 or 100,microM,,human,mbds0010,,2013-10-31 19:11:48
mbbd000144926,mbcd0001445,mbtp000001,mbrf0002548,,=,,,substrate,142,30.7,*10^-6 cm s-1,,Fluvastatin,,,MDCK II-MDR1 transfected cell line; transport from apical to basolateral direction,MDCKII,,10 or 100,microM,,human,mbds0010,,2013-10-31 19:11:48
mbbd000144927,mbcd0003137,mbtp000001,mbrf0002548,,=,,,non-substrate,142,2.11,*10^-6 cm s-1,,Furosemide,,,MDCK II-MDR1 transfected cell line; transport from apical to basolateral direction,MDCKII,,10 or 100,microM,,human,mbds0010,,2013-10-31 19:11:48
mbbd000144928,mbcd0021164,mbtp000001,mbrf0002548,,=,,,substrate,142,113.0,*10^-6 cm s-1,,Guanabenz,,,MDCK II-MDR1 transfected cell line; transport from apical to basolateral direction,MDCKII,,10 or 100,microM,,human,mbds0010,,2013-10-31 19:11:48
mbbd000144929,mbcd0003898,mbtp000001,mbrf0002548,,=,,,substrate,142,154.0,*10^-6 cm s-1,,Imipramine,,,MDCK II-MDR1 transfected cell line; transport from apical to basolateral direction,MDCKII,,10 or 100,microM,,human,mbds0010,,2013-10-31 19:11:48
mbbd000144930,mbcd0003121,mbtp000001,mbrf0002548,,=,,,substrate,142,69.0,*10^-6 cm s-1,,Lansoprazole,,,MDCK II-MDR1 transfected cell line; transport from apical to basolateral direction,MDCKII,,10 or 100,microM,,human,mbds0010,,2013-10-31 19:11:48
mbbd000144931,mbcd0003904,mbtp000001,mbrf0002548,,,,,non-substrate,,,,,Levodopa,no data due to extensive metabolism of levodopa,,MDCK II-MDR1 transfected cell line; transport from apical to basolateral direction,MDCKII,,10 or 100,microM,,human,mbds0010,,2013-10-31 19:11:47
mbbd000144932,mbcd0003043,mbtp000001,mbrf0002548,,=,,,non-substrate,142,0.91,*10^-6 cm s-1,,Methotrexate,,,MDCK II-MDR1 transfected cell line; transport from apical to basolateral direction,MDCKII,,10 or 100,microM,,human,mbds0010,,2013-10-31 19:11:48
mbbd000144933,mbcd0002822,mbtp000001,mbrf0002548,,=,,,non-substrate,142,90.0,*10^-6 cm s-1,,Metoprolol,,,MDCK II-MDR1 transfected cell line; transport from apical to basolateral direction,MDCKII,,10 or 100,microM,,human,mbds0010,,2013-10-31 19:11:48
mbbd000144934,mbcd0001735,mbtp000001,mbrf0002548,,=,,,substrate,142,54.1,*10^-6 cm s-1,,Midazolam,,,MDCK II-MDR1 transfected cell line; transport from apical to basolateral direction,MDCKII,,10 or 100,microM,,human,mbds0010,,2013-10-31 19:11:48
mbbd000144935,mbcd0002981,mbtp000001,mbrf0002548,,=,,,substrate,142,3.06,*10^-6 cm s-1,,Mitoxantrone,compound did not interact with ABCB1-ATPase activity,,MDCK II-MDR1 transfected cell line; transport from apical to basolateral direction,MDCKII,,10 or 100,microM,,human,mbds0010,,2014-03-01 06:05:28
mbbd000144936,mbcd0001276,mbtp000001,mbrf0002548,,=,,,non-substrate,142,65.4,*10^-6 cm s-1,,Naproxen,,,MDCK II-MDR1 transfected cell line; transport from apical to basolateral direction,MDCKII,,10 or 100,microM,,human,mbds0010,,2013-10-31 19:11:48
mbbd000144937,mbcd0001021,mbtp000001,mbrf0002548,,=,,,substrate,142,59.0,*10^-6 cm s-1,,Omeprazole,,,MDCK II-MDR1 transfected cell line; transport from apical to basolateral direction,MDCKII,,10 or 100,microM,,human,mbds0010,,2013-10-31 19:11:48
mbbd000144938,mbcd0022900,mbtp000001,mbrf0002548,,=,,,substrate,142,49.5,*10^-6 cm s-1,,Pantoprazole,,,MDCK II-MDR1 transfected cell line; transport from apical to basolateral direction,MDCKII,,10 or 100,microM,,human,mbds0010,,2013-10-31 19:11:48
mbbd000144939,mbcd0003024,mbtp000001,mbrf0002548,,=,,,substrate,142,25.6,*10^-6 cm s-1,,Prazosin,,,MDCK II-MDR1 transfected cell line; transport from apical to basolateral direction,MDCKII,,10 or 100,microM,,human,mbds0010,,2013-10-31 19:11:48
mbbd000144940,mbcd0002488,mbtp000001,mbrf0002548,,=,,,substrate,142,82.3,*10^-6 cm s-1,,Propranolol,,,MDCK II-MDR1 transfected cell line; transport from apical to basolateral direction,MDCKII,,10 or 100,microM,,human,mbds0010,,2013-10-31 19:11:48
mbbd000144941,mbcd0027018,mbtp000001,mbrf0002548,,=,,,substrate,142,43.2,*10^-6 cm s-1,,Quinidine,,,MDCK II-MDR1 transfected cell line; transport from apical to basolateral direction,MDCKII,,10 or 100,microM,,human,mbds0010,,2013-10-31 19:11:48
mbbd000144942,mbcd0002666,mbtp000001,mbrf0002548,,=,,,non-substrate,142,1.42,*10^-6 cm s-1,,Ranitidine,,,MDCK II-MDR1 transfected cell line; transport from apical to basolateral direction,MDCKII,,10 or 100,microM,,human,mbds0010,,2013-10-31 19:11:48
mbbd000144943,mbcd0001938,mbtp000001,mbrf0002548,,=,,,substrate,142,32.0,*10^-6 cm s-1,,Ritonavir,,,MDCK II-MDR1 transfected cell line; transport from apical to basolateral direction,MDCKII,,10 or 100,microM,,human,mbds0010,,2013-10-31 19:11:48
mbbd000144944,mbcd0001280,mbtp000001,mbrf0002548,,=,,,non-substrate,142,1.79,*10^-6 cm s-1,,Sulfasalazine,,,MDCK II-MDR1 transfected cell line; transport from apical to basolateral direction,MDCKII,,10 or 100,microM,,human,mbds0010,,2013-10-31 19:11:48
mbbd000144945,mbcd0030482,mbtp000001,mbrf0002548,,=,,,non-substrate,142,0.89,*10^-6 cm s-1,,Sulpiride,,,MDCK II-MDR1 transfected cell line; transport from apical to basolateral direction,MDCKII,,10 or 100,microM,,human,mbds0010,,2013-10-31 19:11:48
mbbd000144946,mbcd0003880,mbtp000001,mbrf0002548,,=,,,non-substrate,142,2.59,*10^-6 cm s-1,,Terbutaline,,,MDCK II-MDR1 transfected cell line; transport from apical to basolateral direction,MDCKII,,10 or 100,microM,,human,mbds0010,,2013-10-31 19:11:48
mbbd000144947,mbcd0003001,mbtp000001,mbrf0002548,,=,,,substrate,142,199.0,*10^-6 cm s-1,,Testosterone,,,MDCK II-MDR1 transfected cell line; transport from apical to basolateral direction,MDCKII,,10 or 100,microM,,human,mbds0010,,2013-10-31 19:11:48
mbbd000144948,mbcd0030483,mbtp000001,mbrf0002548,,=,,,substrate,142,10.4,*10^-6 cm s-1,,Tolafentrine,,,MDCK II-MDR1 transfected cell line; transport from apical to basolateral direction,MDCKII,,10 or 100,microM,,human,mbds0010,,2013-10-31 19:11:48
mbbd000144949,mbcd0027062,mbtp000001,mbrf0002548,,=,,,substrate,142,55.2,*10^-6 cm s-1,,Verapamil,,,MDCK II-MDR1 transfected cell line; transport from apical to basolateral direction,MDCKII,,10 or 100,microM,,human,mbds0010,,2013-10-31 19:11:48
mbbd000144950,mbcd0030261,mbtp000001,mbrf0002730,,,,,substrate,,,,,BCECF-AM,,,NIH-3T3,NIH-3T3,,1,microM,,human,mbds0010,,2013-10-30 20:16:24
mbbd000144951,mbcd0000212,mbtp000001,mbrf0002730,,,,,substrate,,,,,calcein-AM,,,NIH-3T3,NIH-3T3,,2.5,microM,,human,mbds0010,,2013-10-30 20:16:24
mbbd000144953,mbcd0030333,mbtp000001,mbrf0002110,,=,,,substrate,17,4.2,microM,,Seliciclib,,,MDR1 overexpressing Sf9 membrane vesicles,Sf9,,,,,human,mbds0010,,2013-11-24 23:55:08
mbbd000144954,mbcd0030333,mbtp000001,mbrf0002110,,=,,,substrate,25,11.5,microM,,Seliciclib,,,K562-MDR cell line; Calcein AM assay,K562,,,,,human,mbds0010,,2013-11-24 23:55:38
mbbd000144955,mbcd0001135,mbtp000001,mbrf0002032,,=,,,substrate,25,72.1,nM,,vincristine,,,697-R cell line; MTT assay,697-R,,,,,human,mbds0010,,2013-11-24 23:55:38
mbbd000144956,mbcd0025666,mbtp000001,mbrf0002032,,=,,,substrate,25,8.6,nM,,romidepsin,,,697-R cell line; MTT assay,697-R,,,,,human,mbds0010,,2013-11-24 23:55:37
mbbd000144957,mbcd0026456,mbtp000001,mbrf0002032,,,,,non-substrate,,,,,cycloheximide,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144958,mbcd0030485,mbtp000001,mbrf0002032,,,,,substrate,,,,,silvestrol,,,697-R cells,697-R,,80,nM,,human,mbds0010,,2013-11-10 04:16:00
mbbd000144959,mbcd0030486,mbtp000001,mbrf0001780,,~,,,substrate,14,1.8,*10^-6 cm s-1,0.25e-6,Lenalidomide,,,MDCK II-Pgp cell line; transport across cell monlayers from the basolateral to apical comaprtment,MDCKII,,10,microM,,human,mbds0010,,2013-11-24 23:12:14
mbbd000144960,mbcd0030486,mbtp000001,mbrf0001780,,~,,,substrate,100,18.0,pmol (mg protein)-1,8,Lenalidomide,,,HL-60/VCR cell line; accumulation after 2 hours incubation,HL60/VCR,,,,,human,mbds0010,,2013-12-09 06:46:06
mbbd000144961,mbcd0001704,mbtp000001,mbrf0001780,,,,,substrate,,,,,CCI-779,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144962,mbcd0030487,mbtp000001,mbrf0001963,,~,,,substrate,138,6.0,%,1,(Z)-endoxifen,,,MDCK II/ABCB1 transfected cell line; translocation from basolateral to apical compartment after 8 hours incubation; measure of amount of drug in opposite compartment as a percentage of the initially applied drug,MDCKII,,5,microM,,human,mbds0010,,2013-11-24 23:12:14
mbbd000144963,mbcd0030487,mbtp000001,mbrf0001963,,=,,,substrate,100,0.93,ng microg protein-1,0.1,(Z)-endoxifen,,,MDCK II/ABCB1 transfected cell line; intracellulat accumulation at the end of the transwell assay,MDCKII,,5,microM,,human,mbds0010,,2013-11-24 23:12:15
mbbd000144964,mbcd0030488,mbtp000001,mbrf0001963,,=,,,substrate,100,0.89,ng microg protein-1,0.09,(E)-endoxifen,,,MDCK II/ABCB1 transfected cell line; intracellular accumulation at the end of the transwell assay,MDCKII,,5,microM,,human,mbds0010,,2013-11-24 23:12:15
mbbd000144965,mbcd0002985,mbtp000001,mbrf0002298,,~,,,non-substrate,138,98.0,%,,carbamazepine,,,MDCK II/MDR1 cell line; Data are given as the percentage of the initial drug concentration in basolateral compartment; incubation time 200minutes,MDCKII,,10,microg mL-1,,human,mbds0010,,2013-11-24 23:12:15
mbbd000144966,mbcd0030489,mbtp000001,mbrf0002298,,~,,,substrate,138,110.0,%,2,"carbamazepine-10,11-epoxide",,,MDCK II/MDR1 cell line; Data are given as the percentage of the initial drug concentration in apical compartment; incubation time 180minutes,MDCKII,,,,,human,mbds0010,,2013-11-24 23:12:15
mbbd000144967,mbcd0027734,mbtp000001,mbrf0002298,,~,,,substrate,138,120.0,%,,oxcarbazepine,,,MDCK II/MDR1 cell line; Data are given as the percentage of the initial drug concentration in apical compartment; incubation time 180minutes,MDCKII,,10,microg mL-1,,human,mbds0010,,2013-11-24 23:12:16
mbbd000144968,mbcd0030490,mbtp000001,mbrf0002298,,~,,,substrate,138,118.0,%,4,eslicarbazepine acetate,,,MDCK II/MDR1 cell line; Data are given as the percentage of the initial drug concentration in apical compartment; incubation time 180minutes,MDCKII,,10,microg mL-1,,human,mbds0010,,2013-11-24 23:12:16
mbbd000144969,mbcd0030491,mbtp000001,mbrf0002298,,~,,,substrate,138,109.0,%,1,S-licarbazepine,,,MDCK II/MDR1 cell line; Data are given as the percentage of the initial drug concentration in apical compartment; incubation time 180minutes,MDCKII,,10,microg mL-1,,human,mbds0010,,2013-11-24 23:12:16
mbbd000144971,mbcd0000069,mbtp000001,mbrf0001187,,,,,non-substrate,,,,,4-hydroxy-tamoxifen; 4OHT,,,Caco-2,Caco-2,,25,microM,,human,mbds0010,,2013-11-02 07:06:32
mbbd000144972,mbcd0030488,mbtp000001,mbrf0001922,,=,,,substrate,14,2.77,*10^-6 cm s-1,0.54,endoxifen,,,LMDR1 cell line,LLC,,,,,human,mbds0010,,2013-12-09 06:50:51
mbbd000144973,mbcd0030488,mbtp000001,mbrf0001922,,~,,,substrate,138,3.8,%,0.5,endoxifen,,,"LMDR1 cell line; translocation from basolateral to the apical compartment; Endoxifen levels were measured in the opposite compartment by LC-MS/MS, and percent transport was determined",LLC,,,,,human,mbds0010,,2013-12-09 06:50:51
mbbd000144974,mbcd0025844,mbtp000001,mbrf0002172,,>,,,substrate,25,1000.0,nM,,Doxorubicin,,,KB3.1/Vinbl cell line,KB3.1/Vinbl,,,,,human,mbds0010,,2013-11-24 23:55:36
mbbd000144975,mbcd0030493,mbtp000001,mbrf0002172,,=,,,substrate,25,314.0,nM,129.6,Genz-644282,,,KB3.1/Vinbl cell line,KB3.1/Vinbl,,,,,human,mbds0010,,2013-11-24 23:55:36
mbbd000144976,mbcd0001374,mbtp000001,mbrf0002569,,,,,substrate,,,,,ezetimibe,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000144977,mbcd0030494,mbtp000001,mbrf0002043,,~,,,substrate,100,40.0,pmol (mg protein)-1,3,ingenol-3-angelate,,,KB-V1 cell line; 15 minute incubation time,KB-V1,,500,nM,,human,mbds0010,,2013-11-24 23:55:35
mbbd000144978,mbcd0001496,mbtp000001,mbrf0001931,,,,,non-substrate,,,,,Naloxone,,,HeLa cells,HeLa,,0.01,microM,,human,mbds0010,,2013-11-10 04:16:07
mbbd000144979,mbcd0024448,mbtp000001,mbrf0001722,,=,,,substrate,14,77.13,nm s-1,1.83,methadone,,,Caco-2/Pgp overexpressing cell line; transocation from apical to basolateral compartment,Caco-2,,,,,human,mbds0010,,2013-11-24 23:12:52
mbbd000144980,mbcd0001345,mbtp000001,mbrf0001722,,=,,,non-substrate,14,446.95,nm s-1,36.92,Buprenorphine,,,Caco-2/Pgp overexpressing cell line; transocation from apical to basolateral compartment,Caco-2,,,,,human,mbds0010,,2013-11-24 23:12:53
mbbd000144981,mbcd0030495,mbtp000001,mbrf0001722,,=,,,non-substrate,14,249.36,nm s-1,13.36,Diprenorphine,,,Caco-2/Pgp overexpressing cell line; transocation from apical to basolateral compartment,Caco-2,,,,,human,mbds0010,,2013-11-24 23:12:53
mbbd000144982,mbcd0002634,mbtp000001,mbrf0001765,,~,,,substrate,138,20.0,%,5,darunavir,,,monolayers of Caco-2 cells; translocation from apical to basolateral compartment; measurements as a percentage of that applied; 6 hrs after incubation,Caco-2,,10,microM,,human,mbds0010,,2013-11-26 01:55:30
mbbd000144983,mbcd0001151,mbtp000001,mbrf0001541,,=,,,substrate,138,95.0,%,,Vinblastine,,,LLC-MDR1  cell line; transport from basolateral to apical compartment relative to Digoxin; data expressed per 60 minutes,LLC-PK1,,,,,human,mbds0010,,2013-11-17 20:11:29
mbbd000144984,mbcd0002996,mbtp000001,mbrf0001541,,=,,,substrate,145,258.0,AUC in apical chambre in % above initial conc. per 60 min,36.7,Phenytoin; PHT,,,LLC-PK1 cells,LLC-PK1,,5; 50,microM,,human,mbds0010,,2013-11-10 04:16:08
mbbd000144985,mbcd0003007,mbtp000001,mbrf0001541,,=,,,substrate,138,11.0,%,,Phenobarbital,,,LLC-MDR1  cell line; transport from basolateral to apical compartment relative to Digoxin; data expressed per 60 minutes,LLC-PK1,,,,,human,mbds0010,,2013-11-17 20:11:29
mbbd000144986,mbcd0013986,mbtp000001,mbrf0001541,,=,,,substrate,138,10.0,%,,Lamotrigine,,,LLC-MDR1  cell line; transport from basolateral to apical compartment relative to Digoxin; data expressed per 60 minutes,LLC-PK1,,,,,human,mbds0010,,2013-11-17 20:11:29
mbbd000144987,mbcd0001511,mbtp000001,mbrf0001541,,=,,,substrate,138,0.9,%,,Levetiracetam,,,LLC-MDR1  cell line; transport from basolateral to apical compartment relative to Digoxin; data expressed per 60 minutes,LLC-PK1,,,,,human,mbds0010,,2013-11-17 20:11:29
mbbd000144988,mbcd0002985,mbtp000001,mbrf0001541,,=,,,non-substrate,138,0.0,%,,Carbamazepine,,,MDCK II-ABCG2 transfected cell line; transport acros monolayers from basolateral to apical compartment; te percentage in the opposite compartment was measured; 6 hours incubation time,MDCKII,,,,,human,mbds0010,,2013-11-17 20:11:30
mbbd000144989,mbcd0027062,mbtp000001,mbrf0002120,,=,,,substrate,28,8.7,microM,,Verapamil,,,human Pgp-overexpressing membrane vesicles; ortho-Vanadate-Sensitive ATPase assay; human P-gp membranes from baculovirus-infected insect cells,insect cells,,,,,human,mbds0010,,2013-11-26 01:55:29
mbbd000144990,mbcd0022892,mbtp000001,mbrf0002120,,=,,,substrate,28,4.7,microM,,Sertralinc,,,human Pgp-overexpressing membrane vesicles; ortho-Vanadate-Sensitive ATPase assay; human P-gp membranes from baculovirus-infected insect cells,insect cells,,,,,human,mbds0010,,2013-11-26 01:55:29
mbbd000144991,mbcd0000334,mbtp000001,mbrf0002120,,=,,,substrate,28,6.5,microM,,Desmethylsertraline,,,human Pgp-overexpressing membrane vesicles; ortho-Vanadate-Sensitive ATPase assay; human P-gp membranes from baculovirus-infected insect cells,insect cells,,,,,human,mbds0010,,2013-11-26 01:55:29
mbbd000144992,mbcd0003003,mbtp000001,mbrf0002120,,=,,,substrate,28,2676.0,microM,,Bupropion,,,human Pgp-overexpressing membrane vesicles; ortho-Vanadate-Sensitive ATPase assay; human P-gp membranes from baculovirus-infected insect cells,insect cells,,,,,human,mbds0010,,2013-11-26 01:55:29
mbbd000144993,mbcd0030222,mbtp000001,mbrf0002120,,=,,,substrate,28,318.2,microM,,Hydroxybupropion,,,human Pgp-overexpressing membrane vesicles; ortho-Vanadate-Sensitive ATPase assay; human P-gp membranes from baculovirus-infected insect cells,insect cells,,,,,human,mbds0010,,2013-11-26 01:55:29
mbbd000144994,mbcd0030496,mbtp000001,mbrf0002120,,=,,,substrate,28,2066.0,microM,,threo-amino alcohol bupropion,,,human Pgp-overexpressing membrane vesicles; ortho-Vanadate-Sensitive ATPase assay; human P-gp membranes from baculovirus-infected insect cells,insect cells,,,,,human,mbds0010,,2013-11-26 01:55:29
mbbd000144995,mbcd0030496,mbtp000001,mbrf0002120,,=,,,substrate,22,19.5,ng (mg protein)-1 min-1,,threo-amino alcohol bupropion,,,human Pgp-overexpressing membrane vesicles; ortho-Vanadate-Sensitive ATPase assay; human P-gp membranes from baculovirus-infected insect cells,insect cells,,,,,human,mbds0010,,2013-11-26 01:55:29
mbbd000144996,mbcd0027062,mbtp000001,mbrf0002120,,=,,,substrate,22,14.8,ng (mg protein)-1 min-1,,Verapamil,,,human Pgp-overexpressing membrane vesicles; ortho-Vanadate-Sensitive ATPase assay; human P-gp membranes from baculovirus-infected insect cells,insect cells,,,,,human,mbds0010,,2013-11-26 01:55:29
mbbd000144997,mbcd0022892,mbtp000001,mbrf0002120,,=,,,substrate,22,7.7,ng (mg protein)-1 min-1,,Sertralinc,,,human Pgp-overexpressing membrane vesicles; ortho-Vanadate-Sensitive ATPase assay; human P-gp membranes from baculovirus-infected insect cells,insect cells,,,,,human,mbds0010,,2013-11-26 01:55:29
mbbd000144998,mbcd0000334,mbtp000001,mbrf0002120,,=,,,substrate,22,9.3,ng (mg protein)-1 min-1,,Desmethylsertraline,,,human Pgp-overexpressing membrane vesicles; ortho-Vanadate-Sensitive ATPase assay; human P-gp membranes from baculovirus-infected insect cells,insect cells,,,,,human,mbds0010,,2013-11-26 01:55:29
mbbd000144999,mbcd0001869,mbtp000001,mbrf0002079,,=,,,substrate,138,2.6,nmol (mg protein)-1 (60 min)-1,0.1,berberine,,,MDCK II-MDR1 cell line; transport across cell monolayers,MDCKII,,,,,human,mbds0010,,2013-12-06 08:02:22
mbbd000145000,mbcd0001869,mbtp000001,mbrf0002079,,=,,,substrate,100,5.8,nmol (mg protein)-1,0.3,berberine,,,MDCK II-MDR1 cell line; Intracellular berberine content was measured after 60 min,MDCKII,,25,microM,,human,mbds0010,,2013-11-24 23:12:17
mbbd000145001,mbcd0002667,mbtp000001,mbrf0002364,,~,,,substrate,14,1.2,*10^-5 cm s-1,,colchicine,,,Caco-2/Pgp overexpressing cell line,Caco-2,,0.1,microM,,human,mbds0010,,2013-11-24 23:12:53
mbbd000145002,mbcd0000600,mbtp000001,mbrf0002316,,=,,,inhibitor,25,67.7,microM,22.8,ALLN; N-acetyl-Leu-Leu-norleucinal,,,SW-1573/2R160 cell line,,,,,,human,mbds0010,,2013-07-11 00:23:26
mbbd000145003,mbcd0030497,mbtp000001,mbrf0002316,,>,,,non-inhibitor,25,25.0,microM,,4A6,4A6 is not soluble above 25 microM,,SW-1573/2R160 cell line,,,,,,human,mbds0010,,2013-07-11 00:23:27
mbbd000145004,mbcd0030498,mbtp000001,mbrf0001992,,~,,,substrate,100,75.0,%,5,vemurafenib,,,MDCK II/MDR1 cell line; measurements given as a percentage of wild-type control,MDCKII,,,,,human,mbds0010,,2013-11-24 23:12:17
mbbd000145005,mbcd0030498,mbtp000001,mbrf0001992,,~,,,substrate,14,17.0,*10^-6 cm sec-1,2,vemurafenib,,,MDCK II/MDR1 transfected cell line; transport from basolateral to apical compartment,MDCKII,,,,,human,mbds0010,,2013-11-24 23:12:17
mbbd000145006,mbcd0016560,mbtp000001,mbrf0002500,,~,,,substrate,100,38.0,%,2,guanfacine,,,LLC-PK1/MDR1 cell line; measurements given as a percentage of LLC-PK1 cell uptake,LLC-PK1,,50,microM,,human,mbds0010,,2013-11-24 23:10:11
mbbd000145007,mbcd0002634,mbtp000001,mbrf0001671,,~,,,substrate,138,60.0,%,,darunavir,,,MDCK II/MDR1 cell line; transport acros cell monolayers from basolateral to apical compartment,MDCKII,,,,,human,mbds0010,,2013-11-24 23:12:17
mbbd000145008,mbcd0000978,mbtp000001,mbrf0002138,,~,,,substrate,138,115.0,%,1,topiramate,,,LLC-MDR1 cell line; concentration equilibrium transport assay;  Data are given as the percentage of the initial drug concentration in the apical compartment,LLC,,,,,human,mbds0010,,2013-11-24 23:10:11
mbbd000145009,mbcd0001795,mbtp000001,mbrf0000069,25,=,7600.0,nM,non-inhibitor,25,7.6,micromol L-1,1.5,Etravirine,,,"MDCKII-MDR1 cell line, proliferation inhibition",MDCKII,,5,micromol L-1,,human,mbds0010,,2015-07-27 05:36:21
mbbd000145010,mbcd0002917,mbtp000001,mbrf0001787,,,,,substrate,,,,,Leukotriene C4,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000145011,mbcd0030500,mbtp000001,mbrf0001787,,,,,substrate,,,,,Prostaglandin A2,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000145012,mbcd0030501,mbtp000001,mbrf0001787,,,,,substrate,,,,,Prostaglandin J2,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000145013,mbcd0001688,mbtp000001,mbrf0001948,,=,,,substrate,25,1443.0,nM,,ixabepilone,,,MDCK II/MDR1 cell line,MDCKII,,,,,human,mbds0010,,2013-11-24 23:12:18
mbbd000145014,mbcd0001688,mbtp000001,mbrf0001948,,~,,,substrate,138,35.0,pmol,4,Ixabepilone,,,LLC-MDR1 cell line; transepithelial transport in basolateral to apical direction in cell monolayers,LLC,,1,microM,,human,mbds0010,,2013-12-09 06:25:07
mbbd000145015,mbcd0030502,mbtp000001,mbrf0001743,,,,,non-substrate,,,,,BPU; Benzoylphenylurea,,,Caco-2,Caco-2,,,,,human,mbds0010,,2013-11-24 23:12:53
mbbd000145017,mbcd0030503,mbtp000001,mbrf0002414,,,,,substrate,,,,,NSC 359449,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000145018,mbcd0030504,mbtp000001,mbrf0002414,,,,,substrate,,,,,NSC 618757,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000145019,mbcd0030505,mbtp000001,mbrf0002414,,,,,substrate,,,,,NSC 694268,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000145020,mbcd0022530,mbtp000001,mbrf0001736,,,,,substrate,,,,,Fluoxetine,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000145021,mbcd0022530,mbtp000001,mbrf0001736,,,,,inhibitor,,,,,Fluoxetine,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000145022,mbcd0030415,mbtp000001,mbrf0002399,,=,,,non-substrate,135,0.7,,,amonafide L-malate,,,HL60/VCR cell line,HL60/VCR,,,,,human,mbds0010,,2013-11-24 23:55:35
mbbd000145023,mbcd0030416,mbtp000001,mbrf0002399,,=,,,non-substrate,135,0.98,,,N-acetyl-amonafide,,,HL60/VCR cell line,HL60/VCR,,,,,human,mbds0010,,2013-11-24 23:55:35
mbbd000145024,mbcd0005183,mbtp000001,mbrf0002399,,=,,,substrate,135,25.0,,10,daunorubicin,,,HL60/VCR cell line,HL60/VCR,,,,,human,mbds0010,,2013-11-24 23:55:34
mbbd000145025,mbcd0025844,mbtp000001,mbrf0002399,,=,,,substrate,135,20.0,,5,doxorubicin,,,HL60/VCR cell line,HL60/VCR,,,,,human,mbds0010,,2013-11-24 23:55:34
mbbd000145026,mbcd0002981,mbtp000001,mbrf0002399,,=,,,substrate,135,20.0,,5,mitoxantrone,,,HL60/VCR cell line,HL60/VCR,,,,,human,mbds0010,,2013-11-24 23:55:34
mbbd000145027,mbcd0001492,mbtp000001,mbrf0002399,,=,,,substrate,135,3.0,,4,idarubicin,,,HL60/VCR cell line,HL60/VCR,,,,,human,mbds0010,,2013-11-24 23:55:34
mbbd000145028,mbcd0002466,mbtp000001,mbrf0002399,,=,,,substrate,135,9.0,,,etoposide,,,HL60/VCR cell line,HL60/VCR,,,,,human,mbds0010,,2013-11-24 23:55:33
mbbd000145029,mbcd0029380,mbtp000001,mbrf0001764,,=,,,substrate,14,2.8,*10^-6 cm s-1,0.42,Deoxynivalenol,,,Caco-2/MDR1 transfected cell line; transepithelical transport measured from basolateral to apical compartment,Caco-2,,30,microM,,human,mbds0010,,2013-11-24 23:12:54
mbbd000145030,mbcd0030238,mbtp000001,mbrf0002089,,~,,,substrate,14,13.0,*10^-6 cm s-1,2,Danofloxacin-Mesylate,,,Caco-2/MDR1 overexpressing cell line; transport measurements for secretion,Caco-2,,10,micromol L-1,,human,mbds0010,,2013-11-24 23:12:54
mbbd000145031,mbcd0030507,mbtp000001,mbrf0002066,,=,,,substrate,25,4.8,microg mL-1,,TP-110,,,K-562/DOX cell line,K562/DOX,,,,,human,mbds0010,,2013-11-24 23:55:32
mbbd000145032,mbcd0030508,mbtp000001,mbrf0002066,,=,,,substrate,25,5.1,microg mL-1,,MG-1312,,,K-562/DOX cell line,K562/DOX,,,,,human,mbds0010,,2013-11-24 23:55:31
mbbd000145033,mbcd0000930,mbtp000001,mbrf0002066,,=,,,substrate,25,0.037,microg mL-1,,Bortezomib,,,K-562/DOX cell line,K562/DOX,,,,,human,mbds0010,,2013-11-24 23:55:31
mbbd000145034,mbcd0030509,mbtp000001,mbrf0002066,,=,,,substrate,25,0.4,microg mL-1,,lactacystin,,,K-562/DOX cell line,K562,,,,,human,mbds0010,,2013-10-16 22:45:02
mbbd000145035,mbcd0025844,mbtp000001,mbrf0002066,,=,,,substrate,25,2.8,microg mL-1,,Doxorubicin,,,K-562/DOX cell line,K562/DOX,,,,,human,mbds0010,,2013-11-24 23:55:31
mbbd000145036,mbcd0001050,mbtp000001,mbrf0002574,,=,,,substrate,82,8.32,,0.53,Digoxin,,,LLC-GA5-COL150 cell line; transepithelial transport from basolateral to apical compartment; transport measurements taken as a percentage of that applied after 3 hours,LLC-GA5-COL150,,,,,human,mbds0010,,2013-12-08 02:13:25
mbbd000145037,mbcd0001151,mbtp000001,mbrf0002574,,=,,,substrate,82,28.4,,4.2,Vinblastine,,,LLC-GA5-COL150 cell line; transepithelial transport from basolateral to apical compartment; transport measurements taken as a percentage of that applied after 3 hours,LLC-GA5-COL150,,,,,human,mbds0010,,2013-12-08 02:13:25
mbbd000145038,mbcd0001777,mbtp000001,mbrf0002574,,=,,,non-substrate,82,0.957,,0.044,Haloperidol,,,LLC-GA5-COL150 cell line; transepithelial transport from basolateral to apical compartment; transport measurements taken as a percentage of that applied after 3 hours,LLC-GA5-COL150,,,,,human,mbds0010,,2013-12-08 02:13:25
mbbd000145039,mbcd0030510,mbtp000001,mbrf0001744,,,,,substrate,,,,,Enniatin B1; EBB-B1,,,Caco-2 cell line and MDCK II cells over-expressing Pgp,Caco-2,,,,,human,mbds0010,,2013-12-10 22:19:00
mbbd000145040,mbcd0001690,mbtp000001,mbrf0002409,,,,,non-substrate,,,,,nilotinib; AMN107,,,Mononuclear cells isolated from the blood of CML patients,CEM/VBL100,,0-2,microM,,human,mbds0010,,2021-06-05 20:20:20
mbbd000145041,mbcd0027129,mbtp000001,mbrf0001739,,,,,inhibitor,,,,,GW583340,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000145042,mbcd0007312,mbtp000001,mbrf0001739,,,,,inhibitor,,,,,GW2974,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000145043,mbcd0011472,mbtp000001,mbrf0002395,,~,,,substrate,96,28.0,nmol Pi (mg protein)-1 min-1,1,AG1478,,,ABCB1-overexpressing membrane vesicles of High Five insect cells; Vi-sensitive ATPase activity of ABCB1,High Five insect cells,,5,microM,weak substrate,human,mbds0010,,2013-12-09 07:14:18
mbbd000145044,mbcd0030237,mbtp000001,mbrf0001892,,~,,,inhibitor,96,16.0,nmol min-1 (mg protein)-1,0.5,apatinib,,,ABCB1-overexpressing recombinant human P-gp membranes,,,100,micromol L-1,,human,mbds0010,,2013-11-24 07:52:24
mbbd000145045,mbcd0001080,mbtp000001,mbrf0001838,,,,,substrate,,,,,Teniposide,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000145046,mbcd0001372,mbtp000001,mbrf0001838,,,,,substrate,,,,,Actinomycin D,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000145047,mbcd0000373,mbtp000001,mbrf0001838,,,,,substrate,,,,,Emetine,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000145048,mbcd0030511,mbtp000001,mbrf0001838,,,,,substrate,,,,,Leupeptin,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000145049,mbcd0000463,mbtp000001,mbrf0001838,,,,,substrate,,,,,Gramicidin D,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000145050,mbcd0030512,mbtp000001,mbrf0001838,,,,,substrate,,,,,Nonactin,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000145051,mbcd0000746,mbtp000001,mbrf0001838,,,,,substrate,,,,,Rhodamine 123,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000145052,mbcd0002338,mbtp000001,mbrf0001838,,,,,inhibitor,,,,,Diltiazem,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000145053,mbcd0002576,mbtp000001,mbrf0001838,,,,,inhibitor,,,,,Nicardipine,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000145054,mbcd0000311,mbtp000001,mbrf0001838,,,,,inhibitor,,,,,Cyclosporin A,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000145055,mbcd0026585,mbtp000001,mbrf0001838,,,,,inhibitor,,,,,Valinomycin,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000145056,mbcd0001316,mbtp000001,mbrf0001838,,,,,inhibitor,,,,,Tacrolimus,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000145057,mbcd0002885,mbtp000001,mbrf0001838,,,,,inhibitor,,,,,Trifluoperazine,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000145058,mbcd0002340,mbtp000001,mbrf0001838,,,,,inhibitor,,,,,Chlorpromazine,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000145059,mbcd0001892,mbtp000001,mbrf0001838,,,,,inhibitor,,,,,Progesterone,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000145060,mbcd0002889,mbtp000001,mbrf0001838,,,,,inhibitor,,,,,Tamoxifen,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000145061,mbcd0002635,mbtp000001,mbrf0001838,,,,,inhibitor,,,,,Cortisol,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000145062,mbcd0000937,mbtp000001,mbrf0001838,,,,,inhibitor,,,,,Erythromycin,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000145063,mbcd0003773,mbtp000001,mbrf0001838,,,,,inhibitor,,,,,Ceftriaxone,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000145064,mbcd0003100,mbtp000001,mbrf0001838,,,,,inhibitor,,,,,Dipyridamole,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000145065,mbcd0002192,mbtp000001,mbrf0001838,,,,,inhibitor,,,,,Amiodarone,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000145066,mbcd0027018,mbtp000001,mbrf0001838,,,,,inhibitor,,,,,Quinidine,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000145067,mbcd0002488,mbtp000001,mbrf0001838,,,,,inhibitor,,,,,Propranolol,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000145068,mbcd0003088,mbtp000001,mbrf0001838,,,,,inhibitor,,,,,Chloroquine,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000145069,mbcd0002337,mbtp000001,mbrf0001838,,,,,inhibitor,,,,,Terfenadine,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000145070,mbcd0001941,mbtp000001,mbrf0001838,,,,,inhibitor,,,,,Reserpine,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000145071,mbcd0024448,mbtp000001,mbrf0002743,,,,,substrate,,,,,methadone,,,LLC-PK1,LLC-PK1,,200; 600; 5000,ng ml-1,,human,mbds0010,,2013-10-31 20:22:14
mbbd000145072,mbcd0005183,mbtp000001,mbrf0001727,,~,,,substrate,33,210.0,counts,,daunorubicin,,,K562/Dox cell line; measurements undertaken using a flow cytometry assay,K562/DOX,,2,microM,,human,mbds0010,,2013-11-24 23:55:31
mbbd000145073,mbcd0030513,mbtp000001,mbrf0001727,,~,,,non-substrate,33,400.0,counts,,3'-azidodaunorubicin,,,K562/Dox cell line; measurements undertaken using a flow cytometry assay; evidence of lack of P-gp binding; compound 2 microM,K562/DOX,,,,,human,mbds0010,,2013-11-24 23:55:30
mbbd000145074,mbcd0030514,mbtp000001,mbrf0001727,,~,,,non-substrate,33,240.0,counts,,A1,,,K562/Dox cell line; measurements undertaken using a flow cytometry assay; evidence of lack of P-gp binding,K562/DOX,,2,microM,,human,mbds0010,,2013-11-24 23:55:30
mbbd000145075,mbcd0030515,mbtp000001,mbrf0001727,,~,,,non-substrate,33,240.0,counts,,A2,,,K562/Dox cell line; measurements undertaken using a flow cytometry assay; evidence of lack of P-gp binding,K562/DOX,,2,microM,,human,mbds0010,,2013-11-24 23:55:30
mbbd000145076,mbcd0030516,mbtp000001,mbrf0001727,,~,,,non-substrate,33,230.0,counts,,A3,,,K562/Dox cell line; measurements undertaken using a flow cytometry assay; evidence of lack of P-gp binding,K562/DOX,,2,microM,,human,mbds0010,,2013-11-24 23:55:28
mbbd000145077,mbcd0030517,mbtp000001,mbrf0001727,,~,,,non-substrate,138,230.0,counts,,A4,,,K562/Dox cell line; measurements undertaken using a flow cytometry assay; evidence of lack of P-gp binding,K562/DOX,,2,microM,,human,mbds0010,,2013-11-24 23:55:28
mbbd000145078,mbcd0022754,mbtp000001,mbrf0001766,,=,,,substrate,14,0.133,*10^-6 cm s-1,0.066,clopidogrel,,,Caco-2/Pgp overexpressing cell line; Papp value of absorption,Caco-2,,,,,human,mbds0010,,2013-11-24 23:55:28
mbbd000145079,mbcd0022754,mbtp000001,mbrf0001766,,~,,,substrate,100,0.9,pmol (mg protein)-1 (5 min)-1,,clopidogrel,,,Caco-2/Pgp overexpressing cell line,Caco-2,,1,micromol L-1,,human,mbds0010,,2013-11-24 23:55:28
mbbd000145080,mbcd0018125,mbtp000001,mbrf0002317,,,,,non-substrate,,,,,hydroxyurea,,,,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000145081,mbcd0030518,mbtp000001,mbrf0001687,,=,,,substrate,104,26.1,,,CP-615003,,,MDCK II/MDR1 cell line; bi-directional transport measurements given as Papp(B-A)/Papp(A-B),MDCKII,,,,,human,mbds0010,,2013-11-12 23:08:11
mbbd000145082,mbcd0030519,mbtp000001,mbrf0001687,,=,,,substrate,104,1.4,,,CP-900725,,,MDCK II/MDR1 cell line; bi-directional transport measurements given as Papp(B-A)/Papp(A-B),MDCKII,,,,,human,mbds0010,,2013-11-12 23:08:11
mbbd000145083,mbcd0027018,mbtp000001,mbrf0001687,,=,,,substrate,104,12.2,,,Quinidine,,,MDCK II/MDR1 cell line; bi-directional transport measurements given as Papp(B-A)/Papp(A-B),MDCKII,,,,,human,mbds0010,,2013-11-12 23:08:11
mbbd000145084,mbcd0003024,mbtp000001,mbrf0001687,,=,,,substrate,104,2.4,,,Prazosin,,,MDCK II/MDR1 cell line; bi-directional transport measurements given as Papp(B-A)/Papp(A-B),MDCKII,,,,,human,mbds0010,,2013-11-12 23:08:11
mbbd000145085,mbcd0001072,mbtp000001,mbrf0001687,,=,,,substrate,104,1.2,,,Triprolidine,,,MDCK II/MDR1 cell line; bi-directional transport measurements given as Papp(B-A)/Papp(A-B),MDCKII,,,,,human,mbds0010,,2013-11-12 23:08:11
mbbd000145086,mbcd0000721,mbtp000001,mbrf0001820,,=,,,inhibitor,17,0.5,microM,,PSC833,,,LLC-PK1/MDR1 cell line,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000145087,mbcd0003893,mbtp000001,mbrf0001820,,=,,,inhibitor,17,6.6,microM,,Risperidone,,,LLC-PK1/MDR1 cell line,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000145088,mbcd0030478,mbtp000001,mbrf0001820,,=,,,inhibitor,17,12.5,microM,,9-OH-risperidone,,,LLC-PK1/MDR1 cell line,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000145089,mbcd0001018,mbtp000001,mbrf0001820,,=,,,inhibitor,17,3.9,microM,,Olanzapine,,,LLC-PK1/MDR1 cell line,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000145090,mbcd0003888,mbtp000001,mbrf0001820,,=,,,inhibitor,17,30.0,microM,,Clozapine,,,LLC-PK1/MDR1 cell line,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000145091,mbcd0027670,mbtp000001,mbrf0001820,,=,,,inhibitor,17,9.8,microM,,Quetiapine,,,LLC-PK1/MDR1 cell line,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000145092,mbcd0002340,mbtp000001,mbrf0001820,,=,,,inhibitor,17,5.8,microM,,Chlorpromazine,,,LLC-PK1/MDR1 cell line,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000145093,mbcd0001777,mbtp000001,mbrf0001820,,=,,,inhibitor,17,9.1,microM,,Haloperidol,,,LLC-PK1/MDR1 cell line,,,,,,human,mbds0010,,2012-10-26 18:21:13
mbbd000145094,mbcd0022555,mbtp000001,mbrf0002057,,~,,,inhibitor,100,13.0,nmol (mg protein)-1,0.5,Sesamin,,,KB-C2/MDR1  overexpressing cell line; Daunorubicin intracellular accumulation,,,50,microM,,human,mbds0010,,2013-11-24 03:25:32
mbbd000145095,mbcd0030520,mbtp000001,mbrf0002057,,~,,,inhibitor,100,20.0,nmol (mg protein)-1,2,ginkgolic acid I,,,KB-C2/MDR1  overexpressing cell line; Daunorubicin intracellular accumulation,,,50,microM,,human,mbds0010,,2013-11-24 07:52:50
mbbd000145096,mbcd0030521,mbtp000001,mbrf0002057,,~,,,inhibitor,100,24.0,nmol (mg protein)-1,4,ginkgolic acid II,,,KB-C2/MDR1  overexpressing cell line; Daunorubicin intracellular accumulation,,,50,microM,,human,mbds0010,,2013-11-24 07:52:51
mbbd000145097,mbcd0030522,mbtp000001,mbrf0002057,,~,,,inhibitor,100,9.0,nmol (mg protein)-1,0.5,matairesinol,,,KB-C2/MDR1  overexpressing cell line; Daunorubicin intracellular accumulation,,,50,microM,,human,mbds0010,,2013-11-24 08:05:39
mbbd000145098,mbcd0025634,mbtp000001,mbrf0002057,,~,,,inhibitor,100,21.0,nmol (mg protein)-1,1,glycyrrhetinic acid,,,KB-C2/MDR1  overexpressing cell line; Daunorubicin intracellular accumulation,,,50,microM,,human,mbds0010,,2013-11-24 07:52:52
mbbd000145099,mbcd0030523,mbtp000001,mbrf0002057,,~,,,inhibitor,100,27.0,nmol (mg protein)-1,2,glabridin,,,KB-C2/MDR1  overexpressing cell line; Daunorubicin intracellular accumulation,,,50,microM,,human,mbds0010,,2013-11-24 07:52:51
mbbd000145100,mbcd0030524,mbtp000001,mbrf0002057,,~,,,inhibitor,100,11.0,nmol (mg protein)-1,1,phyllodulcin,,,KB-C2/MDR1  overexpressing cell line; Daunorubicin intracellular accumulation,,,50,microM,,human,mbds0010,,2013-11-24 22:15:05
mbbd000145101,mbcd0001938,mbtp000024,mbrf0000074,,,,,inhibitor,,,,,Ritonavir,,,,,,,,,human,mbds0001,v14,2013-12-11 05:34:05
mbbd000145102,mbcd0000615,mbtp000024,mbrf0000074,,,,,inhibitor,,,,,Naringin,,,,,,,,,human,mbds0001,v14,2013-12-11 05:34:05
mbbd000145103,mbcd0001533,mbtp000024,mbrf0000074,,,,,inhibitor,,,,,Saquinavir,,,,,,,,,human,mbds0001,v14,2013-12-11 05:34:05
mbbd000145104,mbcd0001470,mbtp000024,mbrf0000074,,,,,substrate,,,,,Levofloxacin,,,,,,,,,human,mbds0001,v14,2013-12-11 05:34:05
mbbd000145105,mbcd0002241,mbtp000024,mbrf0000074,,,,,inhibitor,,,,,Lopinavir,,,,,,,,,human,mbds0001,v14,2013-12-11 05:34:05
mbbd000145106,mbcd0003043,mbtp000024,mbrf0000074,,,,,substrate,,,,,Methotrexate,,,,,,,,,human,mbds0001,v14,2013-12-11 05:34:05
mbbd000145107,mbcd0003075,mbtp000024,mbrf0000074,,,,,substrate,,,,,Estrone-3-sulfate,,,,,,,,,human,mbds0001,v14,2013-12-11 05:34:05
mbbd000145108,mbcd0001442,mbtp000024,mbrf0000074,,,,,substrate,,,,,Ouabain,,,,,,,,,human,mbds0001,v14,2013-12-11 05:34:05
mbbd000145109,mbcd0003035,mbtp000024,mbrf0000074,,,,,substrate,,,,,Bromosulfophthalein,,,,,,,,,human,mbds0001,v14,2013-12-11 05:34:05
mbbd000145110,mbcd0003070,mbtp000024,mbrf0000074,,,,,substrate,,,,,dehydroepiandrosterone sulfate,,,,,,,,,human,mbds0001,v14,2013-12-11 05:34:05
mbbd000145112,mbcd0001416,mbtp000024,mbrf0000074,,,,,inhibitor,,,,,Rifampin,,,,,,,,,human,mbds0001,v14,2013-12-11 05:34:05
mbbd000145113,mbcd0004000,mbtp000019,mbrf0000124,,,,,non-inhibitor,,,,,1,low reliability,,Data not shown: Inhibition of hGLUT1,,,,,,human,mbds0001,v14,2012-10-30 22:11:00
mbbd000145114,mbcd0003996,mbtp000019,mbrf0000124,,,,,non-inhibitor,,,,,3,low reliability,,Data not shown: Inhibition of hGLUT1,,,,,,human,mbds0001,v14,2012-10-30 22:11:00
mbbd000145115,mbcd0004023,mbtp000019,mbrf0000124,,,,,non-inhibitor,,,,,4,low reliability,,Data not shown: Inhibition of hGLUT1,,,,,,human,mbds0001,v14,2012-10-30 22:11:00
mbbd000145116,mbcd0003984,mbtp000019,mbrf0000124,,,,,non-inhibitor,,,,,5,low reliability,,Data not shown: Inhibition of hGLUT1,,,,,,human,mbds0001,v14,2012-10-30 22:11:00
mbbd000145117,mbcd0003974,mbtp000019,mbrf0000124,,,,,non-inhibitor,,,,,6,low reliability,,Data not shown: Inhibition of hGLUT1,,,,,,human,mbds0001,v14,2012-10-30 22:11:00
mbbd000145118,mbcd0004021,mbtp000019,mbrf0000124,,,,,non-inhibitor,,,,,7,low reliability,,Data not shown: Inhibition of hGLUT1,,,,,,human,mbds0001,v14,2012-10-30 22:11:00
mbbd000145119,mbcd0004003,mbtp000019,mbrf0000124,,,,,non-inhibitor,,,,,8,low reliability,,Data not shown: Inhibition of hGLUT1,,,,,,human,mbds0001,v14,2012-10-30 22:11:00
mbbd000145120,mbcd0003994,mbtp000019,mbrf0000124,,,,,non-inhibitor,,,,,9,low reliability,,Data not shown: Inhibition of hGLUT1,,,,,,human,mbds0001,v14,2012-10-30 22:11:00
mbbd000145121,mbcd0004025,mbtp000019,mbrf0000124,,,,,non-inhibitor,,,,,10,low reliability,,Data not shown: Inhibition of hGLUT1,,,,,,human,mbds0001,v14,2012-10-30 22:11:00
mbbd000145122,mbcd0004019,mbtp000019,mbrf0000124,,,,,non-inhibitor,,,,,12,low reliability,,Data not shown: Inhibition of hGLUT1,,,,,,human,mbds0001,v14,2012-10-30 22:11:00
mbbd000145123,mbcd0004013,mbtp000019,mbrf0000124,,,,,non-inhibitor,,,,,13,low reliability,,Data not shown: Inhibition of hGLUT1,,,,,,human,mbds0001,v14,2012-10-30 22:11:00
mbbd000145124,mbcd0004016,mbtp000019,mbrf0000124,,,,,non-inhibitor,,,,,14,low reliability,,Data not shown: Inhibition of hGLUT1,,,,,,human,mbds0001,v14,2012-10-30 22:11:00
mbbd000145125,mbcd0003983,mbtp000019,mbrf0000124,,,,,non-inhibitor,,,,,15,low reliability,,Data not shown: Inhibition of hGLUT1,,,,,,human,mbds0001,v14,2012-10-30 22:11:00
mbbd000145126,mbcd0004010,mbtp000019,mbrf0000124,,,,,non-inhibitor,,,,,16,low reliability,,Data not shown: Inhibition of hGLUT1,,,,,,human,mbds0001,v14,2012-10-30 22:11:00
mbbd000145127,mbcd0004004,mbtp000019,mbrf0000124,,,,,non-inhibitor,,,,,17,low reliability,,Data not shown: Inhibition of hGLUT1,,,,,,human,mbds0001,v14,2012-10-30 22:11:00
mbbd000145128,mbcd0004011,mbtp000019,mbrf0000124,,,,,non-inhibitor,,,,,21,low reliability,,Data not shown: Inhibition of hGLUT1,,,,,,human,mbds0001,v14,2012-10-30 22:11:00
mbbd000145129,mbcd0004018,mbtp000019,mbrf0000124,,,,,non-inhibitor,,,,,22,low reliability,,Data not shown: Inhibition of hGLUT1,,,,,,human,mbds0001,v14,2012-10-30 22:11:00
mbbd000145130,mbcd0004006,mbtp000019,mbrf0000124,,,,,non-inhibitor,,,,,23,low reliability,,Data not shown: Inhibition of hGLUT1,,,,,,human,mbds0001,v14,2012-10-30 22:11:00
mbbd000145131,mbcd0003976,mbtp000019,mbrf0000124,,,,,non-inhibitor,,,,,26,low reliability,,Data not shown: Inhibition of hGLUT1,,,,,,human,mbds0001,v14,2012-10-30 22:11:00
mbbd000145132,mbcd0004015,mbtp000019,mbrf0000124,,,,,non-inhibitor,,,,,27,low reliability,,Data not shown: Inhibition of hGLUT1,,,,,,human,mbds0001,v14,2012-10-30 22:11:00
mbbd000145133,mbcd0003999,mbtp000019,mbrf0000124,,,,,non-inhibitor,,,,,28,low reliability,,Data not shown: Inhibition of hGLUT1,,,,,,human,mbds0001,v14,2012-10-30 22:11:00
mbbd000145134,mbcd0004014,mbtp000019,mbrf0000124,,,,,non-inhibitor,,,,,29,low reliability,,Data not shown: Inhibition of hGLUT1,,,,,,human,mbds0001,v14,2012-10-30 22:11:00
mbbd000145135,mbcd0004022,mbtp000019,mbrf0000124,,,,,non-inhibitor,,,,,32,low reliability,,Data not shown: Inhibition of hGLUT1,,,,,,human,mbds0001,v14,2012-10-30 22:11:00
mbbd000145136,mbcd0003991,mbtp000019,mbrf0000124,,,,,non-inhibitor,,,,,33,low reliability,,Data not shown: Inhibition of hGLUT1,,,,,,human,mbds0001,v14,2012-10-30 22:11:00
mbbd000145137,mbcd0004008,mbtp000019,mbrf0000124,,,,,non-inhibitor,,,,,34,low reliability,,Data not shown: Inhibition of hGLUT1,,,,,,human,mbds0001,v14,2012-10-30 22:11:00
mbbd000145138,mbcd0004007,mbtp000019,mbrf0000124,,,,,non-inhibitor,,,,,37,low reliability,,Data not shown: Inhibition of hGLUT1,,,,,,human,mbds0001,v14,2012-10-30 22:11:00
mbbd000145139,mbcd0004024,mbtp000019,mbrf0000124,,,,,non-inhibitor,,,,,40,low reliability,,Data not shown: Inhibition of hGLUT1,,,,,,human,mbds0001,v14,2012-10-30 22:11:00
mbbd000145140,mbcd0004001,mbtp000019,mbrf0000123,,,,,non-inhibitor,,,,,2,,,Inhibition of [3H]glucose uptake at mammalian GLUT1 expressed in Xenopus laevis oocytes,,,,,,human,mbds0001,v14,2012-10-30 22:11:00
mbbd000145141,mbcd0003998,mbtp000019,mbrf0000123,29,>,500000.0,nM,inhibitor,29,0.5,mM,,3,,,Inhibition of [3H]glucose uptake at mammalian GLUT1 expressed in Xenopus laevis oocytes,,,,,,human,mbds0001,v14,2013-11-27 23:09:00
mbbd000145142,mbcd0003978,mbtp000019,mbrf0000123,,,,,non-inhibitor,,,,,4,,,Inhibition of [3H]glucose uptake at mammalian GLUT1 expressed in Xenopus laevis oocytes,,,,,,human,mbds0001,v14,2012-10-30 22:11:00
mbbd000145143,mbcd0003982,mbtp000019,mbrf0000123,,,,,non-inhibitor,,,,,5,,,Inhibition of [3H]glucose uptake at mammalian GLUT1 expressed in Xenopus laevis oocytes,,,,,,human,mbds0001,v14,2012-10-30 22:11:00
mbbd000145144,mbcd0004005,mbtp000019,mbrf0000123,,,,,non-inhibitor,,,,,6,,,Inhibition of [3H]glucose uptake at mammalian GLUT1 expressed in Xenopus laevis oocytes,,,,,,human,mbds0001,v14,2012-10-30 22:11:00
mbbd000145145,mbcd0004000,mbtp000019,mbrf0000123,29,=,98000.0,nM,inhibitor,29,0.098,mM,,7,"Two independent values determined, 0.098 mM and 0.200 mM, in two experiments",,Inhibition of [3H]glucose uptake at mammalian GLUT1 expressed in Xenopus laevis oocytes,,,,,,human,mbds0001,v14,2013-11-27 23:09:00
mbbd000145146,mbcd0004000,mbtp000019,mbrf0000123,29,=,200000.0,nM,inhibitor,29,0.2,mM,,7,"Two independent values determined, 0.098 mM and 0.200 mM, in two experiments",,Inhibition of [3H]glucose uptake at mammalian GLUT1 expressed in Xenopus laevis oocytes,,,,,,human,mbds0001,v14,2013-11-27 23:09:00
mbbd000145147,mbcd0003988,mbtp000019,mbrf0000123,,,,,non-inhibitor,,,,,8,,,Inhibition of [3H]glucose uptake at mammalian GLUT1 expressed in Xenopus laevis oocytes,,,,,,human,mbds0001,v14,2012-10-30 22:11:00
mbbd000145148,mbcd0003995,mbtp000019,mbrf0000123,29,=,400000.0,nM,inhibitor,29,0.4,mM,,9,,,Inhibition of [3H]glucose uptake at mammalian GLUT1 expressed in Xenopus laevis oocytes,,,,,,human,mbds0001,v14,2013-11-27 23:09:00
mbbd000145149,mbcd0003977,mbtp000019,mbrf0000122,41,=,100.0,nM,binder,,,,30,14,,,Inhibition of [125I]-7-IHPP-Fsk binding to glucose transporter of human erythrocyte membrane,,,,,,human,mbds0001,v14,2012-10-30 22:11:00
mbbd000145150,mbcd0004002,mbtp000019,mbrf0000122,41,=,240.0,nM,binder,,,,40,7,,,Inhibition of [125I]-7-IHPP-Fsk binding to glucose transporter of human erythrocyte membrane,,,,,,human,mbds0001,v14,2012-10-30 22:11:00
mbbd000145151,mbcd0003985,mbtp000019,mbrf0000122,41,=,300.0,nM,binder,,,,100,22,,,Inhibition of [125I]-7-IHPP-Fsk binding to glucose transporter of human erythrocyte membrane,,,,,,human,mbds0001,v14,2012-10-30 22:11:00
mbbd000145152,mbcd0004009,mbtp000019,mbrf0000122,41,=,400.0,nM,binder,,,,100,13,,,Inhibition of [125I]-7-IHPP-Fsk binding to glucose transporter of human erythrocyte membrane,,,,,,human,mbds0001,v14,2012-10-30 22:11:00
mbbd000145153,mbcd0003981,mbtp000019,mbrf0000122,41,=,500.0,nM,binder,,,,200,20,,,Inhibition of [125I]-7-IHPP-Fsk binding to glucose transporter of human erythrocyte membrane,,,,,,human,mbds0001,v14,2012-10-30 22:11:00
mbbd000145154,mbcd0003979,mbtp000019,mbrf0000122,41,=,800.0,nM,binder,,,,100,12,,,Inhibition of [125I]-7-IHPP-Fsk binding to glucose transporter of human erythrocyte membrane,,,,,,human,mbds0001,v14,2012-10-30 22:11:00
mbbd000145155,mbcd0003992,mbtp000019,mbrf0000122,41,=,1100.0,nM,binder,,,,200,11,,,Inhibition of [125I]-7-IHPP-Fsk binding to glucose transporter of human erythrocyte membrane,,,,,,human,mbds0001,v14,2012-10-30 22:11:00
mbbd000145156,mbcd0004026,mbtp000019,mbrf0000122,41,=,1300.0,nM,binder,,,,600,19,,,Inhibition of [125I]-7-IHPP-Fsk binding to glucose transporter of human erythrocyte membrane,,,,,,human,mbds0001,v14,2012-10-30 22:11:00
mbbd000145157,mbcd0004020,mbtp000019,mbrf0000122,41,=,2800.0,nM,binder,,,,700,18,,,Inhibition of [125I]-7-IHPP-Fsk binding to glucose transporter of human erythrocyte membrane,,,,,,human,mbds0001,v14,2012-10-30 22:11:00
mbbd000145158,mbcd0003975,mbtp000019,mbrf0000122,41,=,5000.0,nM,binder,,,,2000,forskolin,,,Inhibition of [125I]-7-IHPP-Fsk binding to glucose transporter of human erythrocyte membrane,,,,,,human,mbds0001,v14,2012-10-30 22:11:00
mbbd000145159,mbcd0003993,mbtp000019,mbrf0000122,41,=,17000.0,nM,binder,,,,3000,21,,,Inhibition of [125I]-7-IHPP-Fsk binding to glucose transporter of human erythrocyte membrane,,,,,,human,mbds0001,v14,2012-10-30 22:11:00
mbbd000145160,mbcd0003986,mbtp000019,mbrf0000122,41,=,28000.0,nM,binder,,,,5000,2,,,Inhibition of [125I]-7-IHPP-Fsk binding to glucose transporter of human erythrocyte membrane,,,,,,human,mbds0001,v14,2012-10-30 22:11:00
mbbd000145161,mbcd0003989,mbtp000019,mbrf0000122,41,>,100000.0,nM,binder,,,,,16,,,Inhibition of [125I]-7-IHPP-Fsk binding to glucose transporter of human erythrocyte membrane,,,,,,human,mbds0001,v14,2012-10-30 22:11:00
mbbd000145162,mbcd0004017,mbtp000019,mbrf0000122,41,>,100000.0,nM,binder,,,,,17,,,Inhibition of [125I]-7-IHPP-Fsk binding to glucose transporter of human erythrocyte membrane,,,,,,human,mbds0001,v14,2012-10-30 22:11:00
mbbd000145163,mbcd0003997,mbtp000019,mbrf0000122,41,>,100000.0,nM,binder,,,,,3,,,Inhibition of [125I]-7-IHPP-Fsk binding to glucose transporter of human erythrocyte membrane,,,,,,human,mbds0001,v14,2012-10-30 22:11:00
mbbd000145164,mbcd0003980,mbtp000019,mbrf0000122,41,>,100000.0,nM,binder,,,,,10,,,Inhibition of [125I]-7-IHPP-Fsk binding to glucose transporter of human erythrocyte membrane,,,,,,human,mbds0001,v14,2012-10-30 22:11:00
mbbd000145165,mbcd0003990,mbtp000019,mbrf0000122,41,>,100000.0,nM,binder,,,,,15,,,Inhibition of [125I]-7-IHPP-Fsk binding to glucose transporter of human erythrocyte membrane,,,,,,human,mbds0001,v14,2012-10-30 22:11:00
mbbd000145166,mbcd0001416,mbtp000025,mbrf0000074,,,,,inhibitor,,,,,rifampicin,,,,,,,,,human,mbds0001,v14,2013-12-11 05:34:05
mbbd000145167,mbcd0003074,mbtp000025,mbrf0000074,,,,,substrate,,,,,glyburide,,,,,,,,,human,mbds0001,v14,2013-12-11 05:34:05
mbbd000145168,mbcd0000311,mbtp000025,mbrf0000074,,,,,inhibitor,,,,,cyclosporine,,,,,,,,,human,mbds0001,v14,2013-12-11 05:34:05
mbbd000145169,mbcd0001664,mbtp000025,mbrf0000074,,,,,substrate,,,,,taurocholate,,,,,,,,,human,mbds0001,v14,2013-12-11 05:34:05
mbbd000145171,mbcd0003035,mbtp000025,mbrf0000074,,,,,substrate,,,,,bromosulphophthalein,,,,,,,,,human,mbds0001,v14,2013-12-11 05:34:05
mbbd000145172,mbcd0003075,mbtp000025,mbrf0000074,,,,,substrate,,,,,oestrone-3-sulphate,,,,,,,,,human,mbds0001,v14,2013-12-11 05:34:05
mbbd000145174,mbcd0001735,mbtp000025,mbrf0000156,89,=,0.7,,non-substrate,89,0.7,,,midazolam,negative control,,drug uptake by human hepatic OATP2B1 transporter expressed in HEK293 cells at 10 microM compound relative to wild type HEK293 cells,HEK293,,10,microM,,human,mbds0001,v14,2013-11-28 01:14:02
mbbd000145175,mbcd0001735,mbtp000025,mbrf0000156,89,=,0.8,,non-substrate,89,0.8,,,midazolam,negative control,,drug uptake by human hepatic OATP2B1 transporter expressed in HEK293 cells at 1 microM compound relative to wild type HEK293 cells,HEK293,,1,microM,,human,mbds0001,v14,2013-11-28 01:14:03
mbbd000145176,mbcd0004704,mbtp000025,mbrf0000156,89,=,1.4,,non-substrate,89,1.4,,,2,,,drug uptake by human hepatic OATP2B1 transporter expressed in HEK293 cells at 10 microM compound relative to wild type HEK293 cells,HEK293,,10,microM,,human,mbds0001,v14,2013-11-28 01:14:03
mbbd000145177,mbcd0004704,mbtp000025,mbrf0000156,89,=,2.1,,non-substrate,89,2.1,,,2,,,drug uptake by human hepatic OATP2B1 transporter expressed in HEK293 cells at 1 microM compound relative to wild type HEK293 cells,HEK293,,1,microM,,human,mbds0001,v14,2013-11-28 01:14:03
mbbd000145178,mbcd0004700,mbtp000025,mbrf0000156,89,=,6.8,,substrate,89,6.8,,,26,,,drug uptake by human hepatic OATP2B1 transporter expressed in HEK293 cells at 10 microM compound relative to wild type HEK293 cells,HEK293,,10,microM,,human,mbds0001,v14,2013-11-28 01:14:04
mbbd000145179,mbcd0004700,mbtp000025,mbrf0000156,89,=,7.1,,substrate,89,7.1,,,26,,,drug uptake by human hepatic OATP2B1 transporter expressed in HEK293 cells at 1 microM compound relative to wild type HEK293 cells,HEK293,,1,microM,,human,mbds0001,v14,2013-11-28 01:14:04
mbbd000145180,mbcd0001448,mbtp000025,mbrf0000156,89,=,5.5,,substrate,89,5.5,,,rosuvastatin,positive control,,drug uptake by human hepatic OATP2B1 transporter expressed in HEK293 cells at 1 microM compound relative to wild type HEK293 cells,HEK293,,1,microM,,human,mbds0001,v14,2013-11-28 01:14:04
mbbd000145181,mbcd0001448,mbtp000025,mbrf0000156,89,=,6.6,,substrate,89,6.6,,,rosuvastatin,positive control,,drug uptake by human hepatic OATP2B1 transporter expressed in HEK293 cells at 10 microM compound relative to wild type HEK293 cells,HEK293,,10,microM,,human,mbds0001,v14,2013-11-28 01:14:04
mbbd000145185,mbcd0000327,mbtp000006,mbrf0001369,,,,,non-substrate,,,,,Deoxyglucose,,,Xenopus laevis oocyte,Xenopus laevis oocytes,,,,,human,mbds0010,,2013-11-24 23:14:58
mbbd000145186,mbcd0000462,mbtp000024,mbrf0001401,,<,,,non-inhibitor,3,53.0,%,,GL,,,Xenopus laevis oocyte,,,,,,human,mbds0010,,2013-12-10 22:19:00
mbbd000145187,mbcd0002041,mbtp000024,mbrf0002357,,=,,,inhibitor,72,50.0,%,,"[D-Pen2,D-Pen5]-enkephalin; DPDPE",,,"Xenopus laevis oocyte; inhibition of Deltorphin II uptake (Deltorphin II: 50 microM, DPDPE: 500 microM)",,,,,,human,mbds0003,v2007,2013-12-09 19:58:14
mbbd000145188,mbcd0002041,mbtp000024,mbrf0002357,,=,,,substrate,28,202.0,microM,,"[D-Pen2,D-Pen5]-enkephalin; DPDPE",,,Xenopus laevis oocyte,Xenopus laevis oocytes,,,,,human,mbds0003,v2007,2013-11-24 23:14:58
mbbd000145189,mbcd0000163,mbtp000024,mbrf0001373,,=,,,substrate,28,23.8,microM,8.1,Bamet-R2,,,Xenopus laevis oocyte,Xenopus laevis oocytes,,,,,human,mbds0003,v2007,2013-11-24 23:14:58
mbbd000145190,mbcd0000164,mbtp000024,mbrf0001373,,=,,,substrate,28,14.1,microM,2.4,Bamet-UD2,,,Xenopus laevis oocyte,Xenopus laevis oocytes,,,,,human,mbds0003,v2007,2013-11-24 23:14:59
mbbd000145191,mbcd0004702,mbtp000024,mbrf0001399,,=,,,inhibitor,28,100.0,microM,,Bilirubin,,,Xenopus laevis oocyte; inhibition of E217betaG uptake (E217betaG: 10 microM),,,,,,human,mbds0003,v2007,2013-12-09 20:52:31
mbbd000145192,mbcd0000199,mbtp000024,mbrf0001393,,=,,,substrate,89,3.7,,,BQ-123,,,Xenopus laevis oocyte,Xenopus laevis oocytes,,0.5,microM,,human,mbds0003,v2007,2013-11-04 02:02:22
mbbd000145193,mbcd0003035,mbtp000024,mbrf0002038,,=,,,substrate,28,20.0,microM,,Bromosulfophthalein,,,Xenopus laevis oocyte,Xenopus laevis oocytes,,,,,human,mbds0003,v2007,2013-11-24 23:14:59
mbbd000145194,mbcd0000254,mbtp000024,mbrf0002038,,=,,,inhibitor,72,34.0,%,,Chenodeoxycholate,,,"Xenopus laevis oocyte; inhibition of BSP uptake (BSP: 10 microM, CDCA: 200 microM)",,,,,,human,mbds0003,v2007,2013-12-09 20:52:28
mbbd000145195,mbcd0000254,mbtp000024,mbrf0002038,,=,,,inhibitor,72,15.0,%,,Chenodeoxycholate,,,"Xenopus laevis oocyte; inhibition of Taurocholate uptake (Taurochorate: 10 microM, CDCA: 200 microM)",,,,,,human,mbds0003,v2007,2013-12-09 20:52:30
mbbd000145196,mbcd0001640,mbtp000024,mbrf0002038,,=,,,inhibitor,72,53.0,%,,Cholate,,,"Xenopus laevis oocyte; inhibition of Taurocholate uptake (Taurochorate: 10 microM, CA: 200 microM)",,,,,,human,mbds0003,v2007,2013-12-09 20:52:28
mbbd000145197,mbcd0001640,mbtp000024,mbrf0002038,,=,,,substrate,28,93.0,microM,,Cholate,,,"Xenopus laevis oocyte; inhibition of BSP uptake (BSP: 10 microM, CA: 100 microM)",Xenopus laevis oocytes,,,,,human,mbds0003,v2007,2013-12-09 20:52:28
mbbd000145198,mbcd0001640,mbtp000024,mbrf0002038,,=,,,inhibitor,72,14.0,%,,Cholate,,,Xenopus laevis oocyte,,,,,,human,mbds0003,v2007,2012-10-30 22:11:00
mbbd000145199,mbcd0029230,mbtp000024,mbrf0002357,,=,,,inhibitor,72,50.0,%,,DAMGO,,,"Xenopus laevis oocyte; inhibition of Deltorphin II uptake (Deltorphin II: 50 microM, DAMGO: 200 microM)",,,,,,human,mbds0003,v2007,2013-12-09 20:52:28
mbbd000145200,mbcd0000324,mbtp000024,mbrf0002357,,=,,,substrate,28,330.0,microM,,Deltorphin II,,,Xenopus laevis oocyte,Xenopus laevis oocytes,,,,,human,mbds0003,v2007,2013-11-24 23:14:59
mbbd000145201,mbcd0002959,mbtp000024,mbrf0002148,,=,,,inhibitor,72,97.3,%,,Dexamethasone,,,"Xenopus laevis oocyte; inhibition of DHEAS uptake (DHEAS: 5 microM, Dexamethasone: 100 microM)",,,,,,human,mbds0003,v2007,2013-12-09 20:58:31
mbbd000145202,mbcd0003070,mbtp000024,mbrf0002148,,=,,,substrate,28,6.6,microM,1.3,DHEAS,,,Xenopus laevis oocyte,Xenopus laevis oocytes,,,,,human,mbds0003,v2007,2013-11-24 23:15:00
mbbd000145203,mbcd0000387,mbtp000024,mbrf0001393,,=,,,substrate,89,1.6,,,E217betaG,,,Xenopus laevis oocyte,Xenopus laevis oocytes,,10,microM,,human,mbds0003,v2007,2013-11-04 02:02:22
mbbd000145204,mbcd0000387,mbtp000024,mbrf0001399,,=,,,inhibitor,28,100.0,microM,,E217betaG,,,Xenopus laevis oocyte; Inhibiton of UCB uptake (UCB: 10 microM),,,,,,human,mbds0003,v2007,2013-12-09 20:52:37
mbbd000145205,mbcd0003498,mbtp000024,mbrf0002581,,,,,non-substrate,,,,,Enalapril,organic anion transporting polypeptide cloned from human liver,,OATP-expressing HeLa cells; uptake,HeLa,,,,,human,mbds0003,v2007,2013-11-29 07:46:34
mbbd000145206,mbcd0000937,mbtp000024,mbrf0001167,,=,,,inhibitor,72,66.0,%,8,Erythromycin,,,"Xenopus laevis oocyte; inhibition of Fexofenadine uptake (Fexofenadine: 2 microM, Erythromycin: 100 microM)",,,,,,human,mbds0003,v2007,2013-12-09 20:58:30
mbbd000145207,mbcd0000389,mbtp000024,mbrf0002148,,=,,,inhibitor,72,92.9,%,,Estradiol-3-sulfate,,,"Xenopus laevis oocyte; inhibition of DHEAS uptake (DHEAS: 5 microM, Estradiol-3-sulfate: 100 microM)",,,,,,human,mbds0003,v2007,2013-12-09 20:52:37
mbbd000145208,mbcd0003075,mbtp000024,mbrf0002357,,=,,,inhibitor,72,10.0,%,,Estrone-3-sulfate,,,"Xenopus laevis oocyte; inhibition of Deltorphin II uptake (Deltorphin II: 50 microM, E1S: 150 microM)",,,,,,human,mbds0003,v2007,2013-12-09 20:08:10
mbbd000145209,mbcd0003075,mbtp000024,mbrf0002302,,=,,,substrate,28,59.0,microM,12,Estrone-3-sulfate,,,Xenopus laevis oocyte,Xenopus laevis oocytes,,,,,human,mbds0003,v2007,2013-11-24 23:15:00
mbbd000145210,mbcd0003075,mbtp000024,mbrf0002148,,=,,,inhibitor,72,82.3,%,,Estrone-3-sulfate,,,"Xenopus laevis oocyte; inhibition of DHEAS uptake (DHEAS: 5 microM, E1S: 100 microM)",,,,,,human,mbds0003,v2007,2013-12-09 19:58:50
mbbd000145211,mbcd0001797,mbtp000024,mbrf0001167,,=,,,substrate,28,6.4,microM,2.2,Fexofenadine,,,OATP-A-expressing HeLa cell,HeLa,,2,microM,,human,mbds0003,v2007,2013-12-08 08:52:02
mbbd000145212,mbcd0000462,mbtp000024,mbrf0001401,,=,,,non-inhibitor,28,100.0,microM,,GL,,,"Xenopus laevis oocyte; inhibition of E1S uptake (E1S: 0.05 microM, GL: 100 microM)",,,,,,human,mbds0003,v2007,2013-12-09 19:58:50
mbbd000145213,mbcd0000455,mbtp000024,mbrf0001393,,=,,,substrate,89,4.3,,,Glycocholate,,,Xenopus laevis oocyte,Xenopus laevis oocytes,,10,microM,,human,mbds0003,v2007,2013-11-04 02:02:22
mbbd000145214,mbcd0000455,mbtp000024,mbrf0002038,,=,,,inhibitor,72,24.0,%,,Glycocholate,,,"Xenopus laevis oocyte; inhibition of Taurocholate uptake (Taurochorate: 10 microM, GC: 200 microM)",,,,,,human,mbds0003,v2007,2013-12-09 19:58:50
mbbd000145215,mbcd0000455,mbtp000024,mbrf0002038,,=,,,inhibitor,72,81.0,%,,Glycocholate,,,"Xenopus laevis oocyte; inhibition of BSP uptake (BSP: 10 microM, GC: 100 microM)",,,,,,human,mbds0003,v2007,2013-12-09 19:58:49
mbbd000145216,mbcd0002323,mbtp000024,mbrf0001167,,=,,,inhibitor,72,70.0,%,5.2,Indinavir,,,"Xenopus laevis oocyte; inhibition of Fexofenadine uptake (Fexofenadine: 2 microM, Indinavir: 100 microM)",,,,,,human,mbds0003,v2007,2013-12-09 19:58:50
mbbd000145217,mbcd0000487,mbtp000024,mbrf0002038,,=,,,inhibitor,72,28.0,%,,Indocyanine green,,,"Xenopus laevis oocyte; inhibition of Taurocholate uptake (Taurochorate: 10 microM, ICG: 100 microM)",,,,,,human,mbds0003,v2007,2013-12-09 19:58:50
mbbd000145218,mbcd0000487,mbtp000024,mbrf0002038,,=,,,inhibitor,72,60.0,%,,Indocyanine green,,,"Xenopus laevis oocyte; inhibition of BSP uptake (BSP: 10 microM, ICG: 100 microM)",,,,,,human,mbds0003,v2007,2013-12-09 19:58:47
mbbd000145219,mbcd0029232,mbtp000024,mbrf0001371,,,,,inhibitor,,,,,k-Strophantoside,,,Xenopus laevis oocyte; Inhibition of rocuronium uptake,,,,,,human,mbds0003,v2007,2012-10-30 22:11:00
mbbd000145220,mbcd0017104,mbtp000024,mbrf0001167,,=,,,inhibitor,72,107.0,%,1.2,Ketoconazole,,,"Xenopus laevis oocyte; inhibition of Fexofenadine uptake (Fexofenadine: 2 microM, Ketoconazole: 100 microM)",,,,,,human,mbds0003,v2007,2013-12-09 20:52:54
mbbd000145221,mbcd0000523,mbtp000024,mbrf0002357,,=,,,inhibitor,72,40.0,%,,Leu-enkephalin,,,"Xenopus laevis oocyte; inhibition of Deltorphin II uptake (Deltorphin II: 50 microM, Leu-enkephalin: 200 microM)",,,,,,human,mbds0003,v2007,2013-12-09 20:52:54
mbbd000145222,mbcd0025591,mbtp000024,mbrf0001167,,=,,,inhibitor,72,95.0,%,11,Lovastatin,,,"Xenopus laevis oocyte; inhibition of Fexofenadine uptake (Fexofenadine: 2 microM, Lovastatin: 100 microM)",,,,,,human,mbds0003,v2007,2013-12-09 20:52:55
mbbd000145223,mbcd0000575,mbtp000024,mbrf0001410,,=,,,substrate,28,20.0,microM,8,Microcystin-LR,,,Xenopus laevis oocyte,Xenopus laevis oocytes,,,,,human,mbds0003,v2007,2013-11-24 23:15:01
mbbd000145224,mbcd0000604,mbtp000024,mbrf0001807,,=,,,substrate,28,25.6,microM,,N-methyl-quinidine,,,Xenopus laevis oocyte,Xenopus laevis oocytes,,,,,human,mbds0003,v2007,2013-11-24 23:15:02
mbbd000145225,mbcd0000604,mbtp000024,mbrf0001371,,,,,inhibitor,,,,,N-methyl-quinidine; NMQD,,,Xenopus laevis oocyte; Inhibition of rocuronium uptake,,,,,,human,mbds0003,v2007,2012-10-30 22:11:00
mbbd000145226,mbcd0000605,mbtp000024,mbrf0001807,,=,,,substrate,28,5.1,microM,,N-methyl-quinine,,,Xenopus laevis oocyte,Xenopus laevis oocytes,,,,,human,mbds0003,v2007,2013-11-24 23:15:02
mbbd000145227,mbcd0001496,mbtp000024,mbrf0002357,,=,,,inhibitor,72,20.0,%,,Naloxone,,,"Xenopus laevis oocyte; inhibition of Deltorphin II uptake (Deltorphin II: 50 microM, Naloxone: 1500 microM)",,,,,,human,mbds0003,v2007,2013-12-09 20:52:54
mbbd000145228,mbcd0010908,mbtp000024,mbrf0002357,,=,,,inhibitor,72,10.0,%,,Naltrindole,,,"Xenopus laevis oocyte; inhibition of Deltorphin II uptake (Deltorphin II: 50 microM, Naltrindole: 1500 microM)",,,,,,human,mbds0003,v2007,2013-12-09 20:52:55
mbbd000145229,mbcd0026632,mbtp000024,mbrf0001167,,=,,,inhibitor,72,81.0,%,14,Nelfinavir,,,"Xenopus laevis oocyte; inhibition of Fexofenadine uptake (Fexofenadine: 2 microM, Nelfinavir: 100 microM)",,,,,,human,mbds0003,v2007,2013-12-09 20:52:55
mbbd000145230,mbcd0001442,mbtp000024,mbrf0001393,,=,,,substrate,89,1.5,,,Ouabain,,,Xenopus laevis oocyte,Xenopus laevis oocytes,,200,microM,,human,mbds0003,v2007,2013-11-04 02:02:23
mbbd000145231,mbcd0001442,mbtp000024,mbrf0002302,,=,,,substrate,28,5.5,mM,4,Ouabain,,,Xenopus laevis oocyte,Xenopus laevis oocytes,,,,,human,mbds0003,v2007,2013-11-24 23:15:03
mbbd000145232,mbcd0001343,mbtp000024,mbrf0001393,,=,,,substrate,89,4.3,,,PGE2,,,Xenopus laevis oocyte,Xenopus laevis oocytes,,20,microM,,human,mbds0003,v2007,2013-11-04 02:02:23
mbbd000145233,mbcd0000693,mbtp000024,mbrf0002087,,=,,,substrate,28,3.4,microM,0.3,Pitavastatin,,,Xenopus laevis oocyte,Xenopus laevis oocytes,,,,,human,mbds0003,v2007,2013-11-24 23:15:03
mbbd000145234,mbcd0003126,mbtp000024,mbrf0001403,,,,,non-substrate,,,,,Pravastatin,,,OATP-A-expressing 293c18 cell,HEK293c18,,,,,human,mbds0003,v2007,2013-12-09 06:40:44
mbbd000145235,mbcd0000721,mbtp000024,mbrf0001167,,=,,,inhibitor,72,85.0,%,5.4,PSC-883,,,"Xenopus laevis oocyte; inhibition of Fexofenadine uptake (Fexofenadine: 2 microM, PSC-833: 100 microM)",,,,,,human,mbds0003,v2007,2013-12-09 20:00:18
mbbd000145236,mbcd0027018,mbtp000024,mbrf0001167,,=,,,inhibitor,72,91.0,%,9.6,Quinidine,,,"Xenopus laevis oocyte; inhibition of Fexofenadine uptake (Fexofenadine: 2 microM, Quinidine: 100 microM)",,,,,,human,mbds0003,v2007,2013-12-09 20:00:18
mbbd000145237,mbcd0027018,mbtp000024,mbrf0001371,,,,,inhibitor,,,,,Quinidine; QD,,,Xenopus laevis oocyte; Inhibition of rocuronium uptake,,,,,,human,mbds0003,v2007,2012-10-30 22:11:00
mbbd000145238,mbcd0001416,mbtp000024,mbrf0001396,,=,,,inhibitor,29,51.0,microM,1.2,Rifampin,,,Xenopus laevis oocyte; Inhibition of BSP uptake,Xenopus laevis oocytes,mbcd0003035,,,,human,mbds0003,v2007,2013-11-04 02:41:38
mbbd000145239,mbcd0001416,mbtp000024,mbrf0001396,,,,,non-substrate,,,,,Rifampin,,,Xenopus laevis oocyte,Xenopus laevis oocytes,,,,,human,mbds0003,v2007,2013-11-04 02:41:38
mbbd000145240,mbcd0000749,mbtp000024,mbrf0001396,,=,,,inhibitor,29,11.0,microM,0.8,Rifamycin SV,,,Xenopus laevis oocyte; Inhibition of BSP uptake,Xenopus laevis oocytes,mbcd0003035,,,,human,mbds0003,v2007,2013-11-04 02:41:39
mbbd000145241,mbcd0001938,mbtp000024,mbrf0001167,,=,,,inhibitor,72,94.0,%,2.9,Ritonavir,,,"Xenopus laevis oocyte; inhibition of Fexofenadine uptake (Fexofenadine: 2 microM, Ritonavir: 100 microM)",,,,,,human,mbds0003,v2007,2013-12-09 20:54:05
mbbd000145242,mbcd0001239,mbtp000024,mbrf0001807,,,,,substrate,,,,,Rocuronium,,,Xenopus laevis oocyte,Xenopus laevis oocytes,,,,,human,mbds0003,v2007,2013-11-24 23:15:03
mbbd000145243,mbcd0029231,mbtp000024,mbrf0001391,,,,,substrate,,,,,rT3,,,Xenopus laevis oocyte,Xenopus laevis oocytes,,,,,human,mbds0003,v2007,2013-11-24 23:15:04
mbbd000145244,mbcd0001533,mbtp000024,mbrf0001167,,=,,,inhibitor,72,105.0,%,5.6,Saquinavir,,,"Xenopus laevis oocyte; inhibition of Fexofenadine uptake (Fexofenadine: 2 microM, Saquinavir: 100 microM)",,,,,,human,mbds0003,v2007,2013-12-09 20:54:05
mbbd000145245,mbcd0000984,mbtp000024,mbrf0001391,,=,,,substrate,28,6.5,microM,,T3,,,Xenopus laevis oocyte,Xenopus laevis oocytes,,,,,human,mbds0003,v2007,2013-11-24 23:15:04
mbbd000145246,mbcd0003957,mbtp000024,mbrf0001391,,=,,,substrate,28,8.0,microM,,T4,,,Xenopus laevis oocyte,Xenopus laevis oocytes,,,,,human,mbds0003,v2007,2013-11-24 23:15:04
mbbd000145247,mbcd0000815,mbtp000024,mbrf0002038,,=,,,inhibitor,72,28.0,microM,,Taurochenodeoxycholate,,,"Xenopus laevis oocyte; inhibition of Taurocholate uptake (Taurochorate: 10 microM, TCDC: 100 microM)",,,,,,human,mbds0003,v2007,2013-12-09 20:08:32
mbbd000145248,mbcd0000815,mbtp000024,mbrf0002038,,=,,,inhibitor,72,17.0,microM,,Taurochenodeoxycholate,,,"Xenopus laevis oocyte; inhibition of BSP uptake (BSP: 10 microM, TCDC: 100 microM)",,,,,,human,mbds0003,v2007,2013-12-09 20:08:33
mbbd000145249,mbcd0000815,mbtp000024,mbrf0002302,,=,,,inhibitor,72,91.0,%,,Taurochenodeoxycholate,,,"Xenopus laevis oocyte; inhibition of E1S uptake (E1S: 0.2 microM, TCDC: 100 microM)",,,,,,human,mbds0003,v2007,2013-12-09 20:54:06
mbbd000145250,mbcd0000815,mbtp000024,mbrf0002302,,=,,,inhibitor,72,100.0,%,,Taurochenodeoxycholate,,,"Xenopus laevis oocytei; nhibition of Ouabain uptake (Ouabain: 100 microM, TCDC: 100 microM)",,,,,,human,mbds0003,v2007,2013-12-09 20:02:33
mbbd000145251,mbcd0001664,mbtp000024,mbrf0001371,,,,,inhibitor,,,,,Taurocholate,,,Xenopus laevis oocyte; Inhibition of rocuronium uptake,,,,,,human,mbds0003,v2007,2012-10-30 22:11:00
mbbd000145252,mbcd0001664,mbtp000024,mbrf0002038,,=,,,inhibitor,72,48.0,%,,Taurocholate,,,"Xenopus laevis oocyte; inhibition of BSP uptake (BSP: 10 microM, TCA: 100 microM)",,,,,,human,mbds0003,v2007,2013-12-09 20:02:35
mbbd000145253,mbcd0001664,mbtp000024,mbrf0002038,,=,,,substrate,28,60.0,microM,,Taurocholate,,,Xenopus laevis oocyte,Xenopus laevis oocytes,,,,,human,mbds0003,v2007,2013-11-24 23:15:04
mbbd000145254,mbcd0001664,mbtp000024,mbrf0002038,,=,,,substrate,28,64.0,microM,,Taurocholate,,,HepG2 cell,HepG2,,,,,human,mbds0003,v2007,2013-11-24 23:55:24
mbbd000145255,mbcd0029348,mbtp000024,mbrf0002038,,=,,,inhibitor,72,9.0,%,,Tauroursodeoxycholate,,,"Xenopus laevis oocyte; inhibition of Taurocholate uptake (Taurochorate: 10 microM, TUDC: 100 microM)",,,,,,human,mbds0003,v2007,2013-12-09 20:02:36
mbbd000145256,mbcd0029348,mbtp000024,mbrf0002038,,=,,,inhibitor,72,9.0,%,,Tauroursodeoxycholate,,,"Xenopus laevis oocyte; inhibition of BSP uptake (BSP: 10 microM, TUDC: 100 microM)",,,,,,human,mbds0003,v2007,2013-12-09 20:02:36
mbbd000145257,mbcd0029348,mbtp000024,mbrf0002038,,=,,,substrate,28,19.0,microM,,Tauroursodeoxycholate,,,Xenopus laevis oocyte,Xenopus laevis oocytes,,,,,human,mbds0003,v2007,2013-11-24 23:15:05
mbbd000145258,mbcd0029348,mbtp000024,mbrf0002148,,=,,,inhibitor,72,85.7,%,,Tauroursodeoxycholate,,,"Xenopus laevis oocyte; inhibition of DHEAS uptake (DHEAS: 5 microM, TUDC: 100 microM)",,,,,,human,mbds0003,v2007,2013-12-09 20:02:38
mbbd000145259,mbcd0029348,mbtp000024,mbrf0002148,,=,,,inhibitor,72,75.2,%,,Tauroursodeoxycholate,,,"Xenopus laevis oocyte; inhibition of DHEAS uptake (DHEAS: 5 microM, TCDC: 100 microM)",,,,,,human,mbds0003,v2007,2013-12-09 20:02:36
mbbd000145260,mbcd0000887,mbtp000024,mbrf0001390,,,,,non-substrate,,,,,Unoprostone isopropyl ester,,,Xenopus laevis oocyte,Xenopus laevis oocytes,,,,,human,mbds0003,v2007,2013-11-24 23:15:05
mbbd000145261,mbcd0029123,mbtp000024,mbrf0001390,,=,,,substrate,28,93.0,microM,,Unoprostone M1,,,Xenopus laevis oocyte,Xenopus laevis oocytes,,,,,human,mbds0003,v2007,2013-11-24 23:15:05
mbbd000145262,mbcd0001612,mbtp000024,mbrf0002038,,=,,,inhibitor,72,14.0,%,,Ursodeoxycholate,,,"Xenopus laevis oocyte; inhibition of Taurocholate uptake (Taurochorate: 10 microM, UDCA: 200 microM)",,,,,,human,mbds0003,v2007,2013-12-09 20:54:39
mbbd000145263,mbcd0001612,mbtp000024,mbrf0002038,,=,,,inhibitor,72,57.0,%,,Ursodeoxycholate,,,"Xenopus laevis oocyte; inhibition of BSP uptake (BSP: 10 microM, UDCA: 100 microM)",,,,,,human,mbds0003,v2007,2013-12-09 20:54:39
mbbd000145264,mbcd0027062,mbtp000024,mbrf0001167,,=,,,inhibitor,72,100.0,%,3.8,Verapamil,,,"Xenopus laevis oocyte; inhibition of Fexofenadine uptake (Fexofenadine: 2 microM, Verapamil: 100 microM)",,,,,,human,mbds0003,v2007,2013-12-09 20:54:40
mbbd000145267,mbcd0003075,mbtp000025,mbrf0001393,,~,,,substrate,28,6.3,microM,,Estrone-3-sulfate,,,Xenopus laevis oocyte (transfected); 10 microM compound,Xenopus laevis oocytes,,,,,human,mbds0003,v2007,2013-11-04 02:02:23
mbbd000145268,mbcd0000201,mbtp000025,mbrf0001393,,=,,,substrate,28,0.7,microM,0.2,BSP,,,Xenopus laevis oocyte (transfected); 10 microM compound,Xenopus laevis oocytes,,,,,human,mbds0003,v2007,2013-11-04 02:02:23
mbbd000145269,mbcd0000749,mbtp000025,mbrf0001396,,=,,,inhibitor,29,3.0,microM,0.1,Rifamycin SV,,,Xenopus laevis oocytes (transfected); inhibition of BSP (350 nM) uptake,Xenopus laevis oocytes,mbcd0003035,,,,human,mbds0003,v2007,2013-11-04 02:41:39
mbbd000145270,mbcd0001416,mbtp000025,mbrf0001396,,,,,non-substrate,,,,,Rifampin,,,Xenopus laevis oocytes (transfected); data not shown in paper,Xenopus laevis oocytes,,,,,human,mbds0003,v2007,2013-11-04 02:41:39
mbbd000145271,mbcd0003126,mbtp000025,mbrf0002051,,,,,substrate,,,,,Pravastatin,,,HEK293 (transfected); uptake pH dependant; Pravastatin (14.7 microM),HEK293,,,,,human,mbds0003,v2007,2013-11-24 23:14:26
mbbd000145272,mbcd0029119,mbtp000025,mbrf0002051,,=,,,inhibitor,72,42.7,%,3.5,Phthalic acid,,,HEK293 (transfected); relative uptake; substrate estrone-3-sulfate (4.76 nM); inhibitor (10 microM),,,,,,human,mbds0003,v2007,2012-10-30 22:11:00
mbbd000145273,mbcd0029120,mbtp000025,mbrf0002051,,=,,,inhibitor,72,83.9,%,1.9,Oxalic acid,,,HEK293 (transfected); relative uptake; substrate estrone-3-sulfate (4.76 nM); inhibitor (10 microM),,,,,,human,mbds0003,v2007,2012-10-30 22:11:00
mbbd000145274,mbcd0014275,mbtp000025,mbrf0002051,,=,,,inhibitor,72,59.7,%,2.9,Nicotinic Acid,,,HEK293 (transfected); relative uptake; substrate estrone-3-sulfate (4.76 nM); inhibitor (10 microM),,,,,,human,mbds0003,v2007,2012-10-30 22:11:00
mbbd000145275,mbcd0000516,mbtp000025,mbrf0002051,,=,,,inhibitor,72,85.6,%,2.9,Lactic acid,,,HEK293 (transfected); relative uptake; substrate estrone-3-sulfate (4.76 nM); inhibitor (10 microM),,,,,,human,mbds0003,v2007,2012-10-30 22:11:00
mbbd000145276,mbcd0003075,mbtp000025,mbrf0002051,,,,,substrate,,,,,Estrone-3-sulfate,,,HEK293 (transfected); uptake pH dependant;  Estrone-3-sulfate (4.82 nM),HEK293,,,,,human,mbds0003,v2007,2013-11-24 23:14:26
mbbd000145277,mbcd0027883,mbtp000025,mbrf0002051,,=,,,inhibitor,72,8.4,%,1.3,DIDS,,,HEK293 (transfected); relative uptake; substrate estrone-3-sulfate (4.76 nM); inhibitor (1 microM),,,,,,human,mbds0003,v2007,2012-10-30 22:11:00
mbbd000145278,mbcd0029121,mbtp000025,mbrf0002051,,=,,,inhibitor,72,97.7,%,2.2,Citric acid,,,HEK293 (transfected); relative uptake; substrate estrone-3-sulfate (4.76 nM); inhibitor (10 microM),,,,,,human,mbds0003,v2007,2012-10-30 22:11:00
mbbd000145279,mbcd0029122,mbtp000025,mbrf0002051,,=,,,inhibitor,72,56.1,%,3.5,Benzoic acid,,,HEK293 (transfected); relative uptake; substrate estrone-3-sulfate (4.76 nM); inhibitor (10 microM),,,,,,human,mbds0003,v2007,2012-10-30 22:11:00
mbbd000145280,mbcd0001648,mbtp000025,mbrf0002051,,=,,,inhibitor,72,86.1,%,3.1,Acetic acid,,,HEK293 (transfected); relative uptake; substrate estrone-3-sulfate (4.76 nM); inhibitor (10 microM),,,,,,human,mbds0003,v2007,2012-10-30 22:11:00
mbbd000145281,mbcd0000462,mbtp000025,mbrf0001401,,<,,,non-inhibitor,3,53.0,%,,Glycyrrhizi; GL,,,Xenopus laevis oocyte (transfected); GL 100 microM; E1S 0.5 microM; inhibition of E1S uptake,,,,,,human,mbds0003,v2007,2013-12-10 22:19:00
mbbd000145282,mbcd0001664,mbtp000025,mbrf0001340,,=,,,substrate,28,71.8,microM,12.2,taurocholic acid,,,HEK293 (transfected); pH 5.0; substrate 0.2 nM - 100 microM,HEK293,,0.0002-100,microM,,human,mbds0003,v2007,2013-11-24 23:14:26
mbbd000145283,mbcd0001664,mbtp000025,mbrf0001340,,=,,,non-substrate,33,3.28,microL / mg protein,1.28,taurocholic acid,,,HEK293 (transfected); pH 7.4; substrate 0.15 microM; 2 min; OATP-B specific uptake,HEK293,,0.15,microM,,human,mbds0003,v2007,2013-11-24 23:14:27
mbbd000145284,mbcd0003126,mbtp000025,mbrf0001340,,=,,,substrate,33,20.3,microL / mg protein,1.86,Pravastatin,,,HEK293 (transfected); pH 5.0; substrate 14.7 microM; 10 min; OATP-B specific uptake,HEK293,,14.7,microM,,human,mbds0003,v2007,2013-11-24 23:14:27
mbbd000145285,mbcd0003126,mbtp000025,mbrf0001340,,=,,,substrate,28,2.25,mM,0.94,Pravastatin,,,HEK293 (transfected); pH 5.0; substrate 29.4 nM - 10 microM; 10 min,HEK293,,0.0294-10,microM,,human,mbds0003,v2007,2013-11-24 23:14:27
mbbd000145286,mbcd0003126,mbtp000025,mbrf0001340,,=,,,non-substrate,33,0.44,microL / mg protein,0.46,Pravastatin,,,HEK293 (transfected); pH 7.4; substrate 14.7 microM; 10 min; OATP-B specific uptake,HEK293,,14.7,microM,,human,mbds0003,v2007,2013-11-24 23:14:28
mbbd000145287,mbcd0000516,mbtp000025,mbrf0001340,,=,,,non-substrate,33,1.17,microL / mg protein,1.66,Lactic acid,,,HEK293 (transfected); pH 5.0; substrate 1.91 microM; 10 min; OATP-B specific uptake,HEK293,,,,,human,mbds0003,v2007,2013-11-24 23:14:28
mbbd000145288,mbcd0000516,mbtp000025,mbrf0001340,,=,,,non-substrate,33,0.84,microL / mg protein,0.93,Lactic acid,,,HEK293 (transfected); pH 7.4; substrate 1.91 microM; 10 min; OATP-B specific uptake,HEK293,,,,,human,mbds0003,v2007,2013-11-24 23:14:28
mbbd000145289,mbcd0001797,mbtp000025,mbrf0001340,,=,,,substrate,33,23.7,microL (mg protein)-1 (30 min)-1,2.66,Fexofenadine,,,HEK293 (transfected); pH 5.0; substrate 10 microM; 30 min; OATP-B specific uptake,HEK293,,10,microM,,human,mbds0003,v2007,2013-12-08 08:52:02
mbbd000145290,mbcd0001797,mbtp000025,mbrf0001340,,=,,,substrate,33,6.82,microL (mg protein)-1 (30 min)-1,1,Fexofenadine,,,HEK293 (transfected); pH 7.4; substrate 10 microM; 30 min; OATP-B specific uptake,HEK293,,10,microM,,human,mbds0003,v2007,2013-12-08 08:52:02
mbbd000145291,mbcd0003075,mbtp000025,mbrf0001340,,=,,,substrate,28,13.1,microM,3.2,Estrone-3-sulfate,,,HEK293 (transfected); pH 5.0; substrate 9.2 nM - 20 microM,HEK293,,,,,human,mbds0003,v2007,2013-11-24 23:14:29
mbbd000145292,mbcd0003075,mbtp000025,mbrf0001340,,=,,,substrate,28,8.09,microM,1.67,Estrone-3-sulfate,,,HEK293 (transfected); pH 7.4; substrate 9.2 nM - 20 microM,HEK293,,,,,human,mbds0003,v2007,2013-11-24 23:14:29
mbbd000145293,mbcd0003075,mbtp000025,mbrf0001340,,=,,,substrate,33,310.0,microL / mg protein,3.67,Estrone-3-sulfate,,,HEK293 (transfected); pH 5.0; substrate 5.43 nM; 5 min; OATP-B specific uptake,HEK293,,,,,human,mbds0003,v2007,2013-11-24 23:14:30
mbbd000145294,mbcd0003075,mbtp000025,mbrf0001340,,=,,,substrate,33,96.0,microL / mg protein,6.78,Estrone-3-sulfate,,,HEK293 (transfected); pH 7.4; substrate 5.43 nM; 5 min; OATP-B specific uptake,HEK293,,,,,human,mbds0003,v2007,2013-11-24 23:14:30
mbbd000145295,mbcd0000387,mbtp000025,mbrf0001340,,=,,,non-substrate,33,5.31,microL / mg protein,1.93,E217betaG,,,HEK293 (transfected); pH 5.0; substrate 5.72 nM; 10 min; OATP-B specific uptake,HEK293,,,,,human,mbds0003,v2007,2013-11-24 23:14:30
mbbd000145296,mbcd0000387,mbtp000025,mbrf0001340,,=,,,non-substrate,33,-0.68,microL / mg protein,1.81,E217betaG,,,HEK293 (transfected); pH 7.4; substrate 5.72 nM; 10 min; OATP-B specific uptake,HEK293,,,,,human,mbds0003,v2007,2013-11-24 23:14:31
mbbd000145297,mbcd0003070,mbtp000025,mbrf0001340,,=,,,substrate,33,213.0,microL / mg protein,2.63,DHEAS,,,HEK293 (transfected); pH 5.0; substrate 2.98 nM; 5 min; OATP-B specific uptake,HEK293,,,,,human,mbds0003,v2007,2013-11-24 23:14:30
mbbd000145298,mbcd0003070,mbtp000025,mbrf0001340,,=,,,substrate,33,76.4,microL / mg protein,5.19,DHEAS,,,HEK293 (transfected); pH 7.4; substrate 2.98 nM; 5 min; OATP-B specific uptake,HEK293,,,,,human,mbds0003,v2007,2013-11-24 23:14:31
mbbd000145299,mbcd0001648,mbtp000025,mbrf0001340,,=,,,non-substrate,33,4.5,microL / mg protein,5.63,Acetic acid,,,HEK293 (transfected); pH 5.0; substrate 4.94 microM; 10 min; OATP-B specific uptake,HEK293,,,,,human,mbds0003,v2007,2013-11-24 23:14:31
mbbd000145300,mbcd0001648,mbtp000025,mbrf0001340,,=,,,non-substrate,33,2.81,microL / mg protein,1,Acetic acid,,,HEK293 (transfected); pH 7.4; substrate 4.94 microM; 10 min; OATP-B specific uptake,HEK293,,,,,human,mbds0003,v2007,2013-11-24 23:14:31
mbbd000145301,mbcd0000325,mbtp000025,mbrf0001407,,,,,non-substrate,,,,,Demethylphalloin,,,Xenopus laevis oocyte (transfected),Xenopus laevis oocytes,,,,,human,mbds0003,v2007,2013-11-24 23:15:05
mbbd000145302,mbcd0000779,mbtp000025,mbrf0001408,,,,,non-substrate,,,,,SN-38,,,Xenopus laevis oocyte (transfected); uptake; 60 min,Xenopus laevis oocytes,,,,,human,mbds0003,v2007,2014-02-26 20:16:02
mbbd000145303,mbcd0003243,mbtp000025,mbrf0001648,,=,,,non-inhibitor,72,58.0,%,,Nobiletin,,,HEK293 (transfected); pH 7.4; Substrate glibenclamide 10 nM; inhibitor 10 microM,,,,,,human,mbds0003,v2007,2012-10-30 22:11:00
mbbd000145304,mbcd0001893,mbtp000025,mbrf0001648,,=,,,inhibitor,72,25.0,%,,Tangeretin,,,HEK293 (transfected); pH 7.4; Substrate glibenclamide 10 nM; inhibitor 10 microM,,,,,,human,mbds0003,v2007,2012-10-30 22:11:00
mbbd000145305,mbcd0027402,mbtp000025,mbrf0001648,,=,,,inhibitor,72,35.0,%,,Dihydroxybergamottin,,,HEK293 (transfected); pH 7.4; Substrate glibenclamide 10 nM; inhibitor 10 microM,,,,,,human,mbds0003,v2007,2012-10-30 22:11:00
mbbd000145306,mbcd0022804,mbtp000025,mbrf0001648,,=,,,non-inhibitor,72,89.0,%,,Bergamottin,,,HEK293 (transfected); pH 7.4; Substrate glibenclamide 10 nM; inhibitor 10 microM,,,,,,human,mbds0003,v2007,2012-10-30 22:11:00
mbbd000145307,mbcd0003120,mbtp000025,mbrf0001648,,=,,,non-inhibitor,72,112.0,%,,Quercetin,,,HEK293 (transfected); pH 7.4; Substrate glibenclamide 10 nM; inhibitor 10 microM,,,,,,human,mbds0003,v2007,2012-10-30 22:11:00
mbbd000145308,mbcd0003076,mbtp000025,mbrf0001648,,=,,,non-inhibitor,72,45.0,%,,Naringenin,,,HEK293 (transfected); pH 7.4; Substrate glibenclamide 10 nM; inhibitor 10 microM,,,,,,human,mbds0003,v2007,2012-10-30 22:11:00
mbbd000145309,mbcd0000615,mbtp000025,mbrf0001648,,=,,,non-inhibitor,72,70.0,%,,Naringin,,,HEK293 (transfected); pH 7.4; Substrate glibenclamide 10 nM; inhibitor 10 microM,,,,,,human,mbds0003,v2007,2012-10-30 22:11:00
mbbd000145310,mbcd0017644,mbtp000025,mbrf0001648,,=,,,non-substrate,33,0.25,microL / mg protein / 10 min,,Tolbutamide,,,HEK293 (transfected); OATP-B mediated uptake; pH 7.4; substrate concentration 8.82 microM,HEK293,,,,,human,mbds0003,v2007,2013-11-24 23:14:32
mbbd000145311,mbcd0003013,mbtp000025,mbrf0001648,,=,,,non-substrate,33,-0.2,microL / mg protein / 10 min,,Ibuprofen,,,HEK293 (transfected); OATP-B mediated uptake; pH 7.4; substrate concentration 11.3 microM,HEK293,,,,,human,mbds0003,v2007,2013-11-24 23:14:32
mbbd000145312,mbcd0001353,mbtp000025,mbrf0001648,,=,,,non-substrate,33,1.7,microL / mg protein / 10 min,,Salicylic acid,,,HEK293 (transfected); OATP-B mediated uptake; pH 7.4; substrate concentration 1.43 microM,HEK293,,,,,human,mbds0003,v2007,2013-11-24 23:14:32
mbbd000145313,mbcd0001664,mbtp000025,mbrf0001648,,=,,,non-substrate,33,0.4,microL / mg protein / 10 min,,Taurocholic Acid,,,HEK293 (transfected); OATP-B mediated uptake; pH 7.4; substrate concentration 41.9 nM,HEK293,,,,,human,mbds0003,v2007,2013-11-24 23:14:33
mbbd000145314,mbcd0003070,mbtp000025,mbrf0001648,,=,,,substrate,33,6.8,microL / mg protein / 10 min,,dehydroepiandrosterone sulfate,,,HEK293 (transfected); OATP-B mediated uptake; pH 7.4; substrate concentration 17.4 nM,HEK293,,,,,human,mbds0003,v2007,2013-11-24 23:14:33
mbbd000145315,mbcd0003074,mbtp000025,mbrf0001648,,=,,,substrate,28,6.26,microM,3.15,Glibenclamide,,,HEK293 (transfected); pH 7.4;,HEK293,,,,,human,mbds0003,v2007,2013-11-24 23:14:33
mbbd000145316,mbcd0003243,mbtp000025,mbrf0001648,,=,,,inhibitor,72,40.0,%,,Nobiletin,,,HEK293 (transfected); pH 7.4; Substrate estrone-3-sulfate 10 nM; inhibitor 10 microM,,,,,,human,mbds0003,v2007,2012-10-30 22:11:00
mbbd000145317,mbcd0001893,mbtp000025,mbrf0001648,,=,,,inhibitor,72,89.0,%,,Tangeretin,,,HEK293 (transfected); pH 7.4; Substrate estrone-3-sulfate 10 nM; inhibitor 10 microM,,,,,,human,mbds0003,v2007,2012-10-30 22:11:00
mbbd000145318,mbcd0027402,mbtp000025,mbrf0001648,,=,,,inhibitor,72,58.0,%,,"6',7'-Dihydroxybergamottin",,,HEK293 (transfected); pH 7.4; Substrate estrone-3-sulfate 10 nM; inhibitor 10 microM,,,,,,human,mbds0003,v2007,2012-10-30 22:11:00
mbbd000145319,mbcd0022804,mbtp000025,mbrf0001648,,=,,,inhibitor,72,40.0,%,,Bergamottin,,,HEK293 (transfected); pH 7.4; Substrate estrone-3-sulfate 10 nM; inhibitor 10 microM,,,,,,human,mbds0003,v2007,2012-10-30 22:11:00
mbbd000145320,mbcd0003120,mbtp000025,mbrf0001648,,=,,,inhibitor,72,80.0,%,,Quercetin,,,HEK293 (transfected); pH 7.4; Substrate estrone-3-sulfate 10 nM; inhibitor 10 microM,,,,,,human,mbds0003,v2007,2012-10-30 22:11:00
mbbd000145321,mbcd0003076,mbtp000025,mbrf0001648,,=,,,inhibitor,72,72.0,%,,Naringenin,,,HEK293 (transfected); pH 7.4; Substrate estrone-3-sulfate 10 nM; inhibitor 10 microM,,,,,,human,mbds0003,v2007,2012-10-30 22:11:00
mbbd000145322,mbcd0000615,mbtp000025,mbrf0001648,,=,,,inhibitor,72,61.0,%,,Naringin,,,HEK293 (transfected); pH 7.4; Substrate estrone-3-sulfate 10 nM; inhibitor 10 microM,,,,,,human,mbds0003,v2007,2012-10-30 22:11:00
mbbd000145323,mbcd0003075,mbtp000025,mbrf0001648,,=,,,substrate,28,7.14,microM,2.25,Estrone-3-sulfate,,,HEK293 (transfected); pH 7.4; 10 nM - 1 mM,HEK293,,,,,human,mbds0003,v2007,2013-11-24 23:14:33
mbbd000145324,mbcd0029123,mbtp000025,mbrf0001390,,=,,,substrate,28,91.0,microM,,unoprostone carboxylate,,,HEK293 (transfected); 0 - 200 microM; uptake,HEK293,,,,,human,mbds0003,v2007,2013-11-24 23:14:35
mbbd000145325,mbcd0000887,mbtp000025,mbrf0001390,,,,,non-substrate,,,,,unoprostone isopropyl ester,,,HEK293 (transfected); 4 microM; uptake,HEK293,,,,,human,mbds0003,v2007,2013-11-24 23:14:36
mbbd000145326,mbcd0000575,mbtp000025,mbrf0001410,,~,,,non-substrate,33,60.0,fmol oocyte-1 (30 min)-1,5,microcystin-LR,,,Xenopus laevis oocyte (transfected); uptake,Xenopus laevis oocytes,,,,,human,mbds0003,v2007,2013-11-24 23:15:06
mbbd000145327,mbcd0003074,mbtp000001,mbrf0001293,,,,,non-substrate,,,,,glyburide,,,PGP over-expressing A2780/Adr cell line,A2780/ADR,,,,,human,mbds0010,,2013-11-24 23:55:27
mbbd000145328,mbcd0000124,mbtp000001,mbrf0001337,,,,,non-substrate,,,,,Albendazole Sulfoxide; ABZSO,,,MDR1-expressing MDCKII cells; transepithelial transport,MDCKII,,,,,human,mbds0010,,2013-11-24 23:12:18
mbbd000145329,mbcd0026840,mbtp000005,mbrf0001337,,,,,non-substrate,,,,,Oxfendazole; OXF,,,MRP2-expressing MDCKII cells; transepithelial transport,MDCKII,,,,,human,mbds0010,,2013-11-24 23:12:18
mbbd000145330,mbcd0014953,mbtp000001,mbrf0001337,,,,,non-substrate,,,,,albendazole; ABZ,,,MDR1-expressing MDCKII cells; transepithelial transport,MDCKII,,,,,human,mbds0010,,2013-11-24 23:12:19
mbbd000145331,mbcd0008195,mbtp000005,mbrf0001337,,,,,non-substrate,,,,,fenbendazole; FBZ,,,MRP2-expressing MDCKII cells; transepithelial transport,MDCKII,,,,,human,mbds0010,,2013-11-24 23:12:19
mbbd000145332,mbcd0000164,mbtp000007,mbrf0001373,,=,,,substrate,67,162.0,nL oocyte-1 (10 min)-1,,Bamet-UD2,,,Xenopus laevis oocytes; uptake; compound 0-100 microM,Xenopus laevis oocytes,,,,,human,mbds0010,,2013-11-24 23:15:06
mbbd000145333,mbcd0000163,mbtp000007,mbrf0001373,,=,,,substrate,67,48.0,nL oocyte-1 (10 min)-1,,Bamet-R2,,,Xenopus laevis oocytes; uptake; compound 0-100 microM,Xenopus laevis oocytes,,,,,human,mbds0010,,2013-11-24 23:15:06
mbbd000145334,mbcd0000164,mbtp000012,mbrf0001373,,=,,,substrate,67,567.0,nL oocyte-1 (10 min)-1,,Bamet-UD2,,,Xenopus laevis oocytes; uptake; compound 0-100 microM,Xenopus laevis oocytes,,,,,human,mbds0010,,2013-11-24 23:15:07
mbbd000145335,mbcd0000163,mbtp000012,mbrf0001373,,=,,,substrate,67,450.0,nL oocyte-1 (10 min)-1,,Bamet-R2,,,Xenopus laevis oocytes; uptake; compound 0-100 microM,Xenopus laevis oocytes,,,,,human,mbds0010,,2013-11-24 23:15:07
mbbd000145336,mbcd0000164,mbtp000024,mbrf0001373,,=,,,substrate,67,262.0,nL oocyte-1 (10 min)-1,,Bamet-UD2,,,Xenopus laevis oocytes; uptake; compound 0-100 microM,Xenopus laevis oocytes,,,,,human,mbds0010,,2013-11-24 23:15:07
mbbd000145337,mbcd0000163,mbtp000024,mbrf0001373,,=,,,substrate,67,147.0,nL oocyte-1 (10 min)-1,,Bamet-R2,,,Xenopus laevis oocytes; uptake; compound 0-100 microM,Xenopus laevis oocytes,,,,,human,mbds0010,,2013-11-24 23:15:07
mbbd000145338,mbcd0001343,mbtp000011,mbrf0001389,,=,,,inhibitor,33,0.0,%,,PGE2,,,Xenopus laevis oocyte; inhibition of PGE2 uptake (PGE2: 15 nM); compound 150 nM,,,,,,human,mbds0010,,2012-11-05 18:19:05
mbbd000145339,mbcd0003043,mbtp000008,mbrf0001299,,=,,,substrate,22,2.93,nM mg-1 min-1,0.32,Methotrexate,,,membrane vesicle from MRP3-expressing HEK293 cell; uptake,HEK293,,,,,human,mbds0010,,2013-12-09 20:02:40
mbbd000145340,mbcd0030526,mbtp000003,mbrf0001385,,>,,,non-inhibitor,29,100.0,mM,,Fructose-6-phosphate,,,PGT-expressing HeLa cell; inhibition of PGE2 uptake,,,,,,human,mbds0010,,2013-12-09 20:52:38
mbbd000145341,mbcd0030527,mbtp000003,mbrf0001385,,>,,,non-inhibitor,29,100.0,mM,,3-Phosphoglycerate,,,PGT-expressing HeLa cell; inhibition of PGE2 uptake,,,,,,human,mbds0010,,2013-12-09 20:52:37
mbbd000145342,mbcd0030528,mbtp000003,mbrf0001385,,>,,,non-inhibitor,29,100.0,mM,,2-Phosphoglycerate,,,PGT-expressing HeLa cell; inhibition of PGE2 uptake,,,,,,human,mbds0010,,2013-12-09 20:52:37
mbbd000145343,mbcd0001299,mbtp000008,mbrf0001501,,,,,inducer,,,,,RU486,,,HuH7 cells; compound 25 microM,HuH7,,,,,human,mbds0010,,2013-11-04 00:36:43
mbbd000145344,mbcd0027721,mbtp000008,mbrf0001501,,,,,non-inducer,,,,,LCA,,,HuH7 cells; compound 50 microM,HuH7,,,,,human,mbds0010,,2013-11-04 00:36:43
mbbd000145345,mbcd0000702,mbtp000008,mbrf0001501,,,,,inducer,,,,,PCN,,,HuH7 cells; compound 25 microM,HuH7,,,,,human,mbds0010,,2013-11-04 00:36:43
mbbd000145346,mbcd0027062,mbtp000012,mbrf0001551,,=,,,non-inhibitor,82,3.2,,,verapamil,,,MDCKII-OATP1B1 monolayers; uptake of 0.2 microM BNP1350; compound 10 microM,MDCKII,,10,microM,,human,mbds0010,,2013-10-31 00:25:08
mbbd000145347,mbcd0027062,mbtp000012,mbrf0001551,,=,,,inhibitor,82,1.6,,,verapamil,,,MDCKII-OATP1B1 monolayers; uptake of 1 microM gimatecan; compound 10 microM,MDCKII,mbcd0029844,10,microM,,human,mbds0010,,2013-10-31 00:25:08
mbbd000145348,mbcd0001416,mbtp000012,mbrf0001551,,=,,,inhibitor,82,1.1,,,rifampicin,,,MDCKII-OATP1B1 monolayers; uptake of 1 microM E2G or gimatecan and 0.2 microM BNP1350; compound 10 microM,MDCKII,mbcd0000387,10,microM,,human,mbds0010,,2013-11-11 03:52:51
mbbd000145349,mbcd0001056,mbtp000005,mbrf0001581,,,,,non-substrate,,,,,sorafenib,,,MDCKII cells; compound 1 microM,MDCKII,,1,microM,,human,mbds0010,,2013-11-04 00:59:25
mbbd000145350,mbcd0027319,mbtp000005,mbrf0001581,,,,,non-substrate,,,,,sunitinib,,,MDCKII cells; compound 1 microM,MDCKII,,1,microM,,human,mbds0010,,2013-11-04 00:59:25
mbbd000145351,mbcd0027319,mbtp000002,mbrf0001581,,,,,non-substrate,,,,,sunitinib,,,Saos-2 cells; compound 1 microM,Saos-2,,1,microM,,human,mbds0010,,2013-11-04 00:59:26
mbbd000145352,mbcd0001056,mbtp000024,mbrf0001581,,,,,non-substrate,,,,,sorafenib,,,Xenopus laevis oocytes; compound 0.35-1.5 microM,Xenopus laevis oocytes,,0.35-1.5,microM,,human,mbds0010,,2013-11-04 00:59:19
mbbd000145353,mbcd0027319,mbtp000024,mbrf0001581,,,,,non-substrate,,,,,sunitinib,,,Xenopus laevis oocytes; compound 0.15-0.45 microM,Xenopus laevis oocytes,,0.15-0.45,microM,,human,mbds0010,,2013-11-04 00:59:20
mbbd000145354,mbcd0001056,mbtp000007,mbrf0001581,,,,,non-substrate,,,,,sorafenib,,,Xenopus laevis oocytes; compound 0.35-1.5 microM,Xenopus laevis oocytes,,0.35-1.5,microM,,human,mbds0010,,2013-11-04 00:59:22
mbbd000145355,mbcd0027319,mbtp000007,mbrf0001581,,,,,non-substrate,,,,,sunitinib,,,Xenopus laevis oocytes; compound 0.15-0.45 microM,Xenopus laevis oocytes,,0.15-0.45,microM,,human,mbds0010,,2013-11-04 00:59:22
mbbd000145356,mbcd0001056,mbtp000012,mbrf0001581,,,,,non-substrate,,,,,sorafenib,,,Xenopus laevis oocytes; compound 0.35-1.5 microM,Xenopus laevis oocytes,,0.35-1.5,microM,,human,mbds0010,,2013-11-04 00:59:22
mbbd000145357,mbcd0027319,mbtp000012,mbrf0001581,,,,,non-substrate,,,,,sunitinib,,,Xenopus laevis oocytes; compound 0.15-0.45 microM,Xenopus laevis oocytes,,0.15-0.45,microM,,human,mbds0010,,2013-11-04 00:59:22
mbbd000145358,mbcd0001056,mbtp000013,mbrf0001581,,,,,non-substrate,,,,,sorafenib,,,Xenopus laevis oocytes; compound 0.35-1.5 microM,Xenopus laevis oocytes,,0.35-1.5,microM,,human,mbds0010,,2013-11-04 00:59:23
mbbd000145359,mbcd0027319,mbtp000013,mbrf0001581,,,,,non-substrate,,,,,sunitinib,,,Xenopus laevis oocytes; compound 0.15-0.45 microM,Xenopus laevis oocytes,,0.15-0.45,microM,,human,mbds0010,,2013-11-04 00:59:24
mbbd000145360,mbcd0001056,mbtp000001,mbrf0001581,,,,,substrate,,,,,sorafenib,,,LLC-PK1 cells expressing ABCB1; compound 1 microM,LLC-PK1,,1,microM,,human,mbds0010,,2013-11-04 00:59:26
mbbd000145361,mbcd0001056,mbtp000001,mbrf0001581,,,,,non-substrate,,,,,sorafenib,,,LLC-PK1 cells expressing ABCB1; compound 10 microM,LLC-PK1,,10,microM,,human,mbds0010,,2013-11-04 00:59:26
mbbd000145362,mbcd0027319,mbtp000001,mbrf0001581,,,,,substrate,,,,,sunitinib,,,"LLC-PK1 cells expressing ABCB1; compound 1 microM (and 10 microM, but substantially reduced transport)",LLC-PK1,,1,microM,,human,mbds0010,,2013-11-04 00:59:26
mbbd000145363,mbcd0001056,mbtp000001,mbrf0001581,,,,,inhibitor,,,,,sorafenib,,,calcein-AM efflux by cells overexpressing ABCB1; compound 16.6 microM,,mbcd0000212,16.6,microM,,human,mbds0010,,2013-11-04 00:59:27
mbbd000145364,mbcd0027319,mbtp000001,mbrf0001581,,,,,inhibitor,,,,,sunitinib,,,calcein-AM efflux by cells overexpressing ABCB1; compound 6.7 microM,,mbcd0000212,6.7,microM,,human,mbds0010,,2013-11-04 00:59:27
mbbd000145365,mbcd0001056,mbtp000002,mbrf0001581,,,,,inhibitor,,,,,sorafenib,,,Hoechst 33342 efflux by cells overexpressing ABCG2; compound 3.1 microM,,mbcd0000474,3.1,microM,,human,mbds0010,,2013-11-04 00:59:27
mbbd000145366,mbcd0027319,mbtp000002,mbrf0001581,,,,,inhibitor,,,,,sunitinib,,,Hoechst 33342 efflux by cells overexpressing ABCG2; compound 3.0 microM,,mbcd0000474,3.0,microM,,human,mbds0010,,2013-11-04 00:59:27
mbbd000145367,mbcd0030530,mbtp000001,mbrf0001586,,,,,substrate,,,,,(R)-Met,,,MDR1-MDCKII transfected cells; compound 5 microM,MDCKII,,5,microM,,human,mbds0010,,2013-11-17 19:23:35
mbbd000145368,mbcd0030529,mbtp000001,mbrf0001586,,,,,substrate,,,,,(S)-Met,,,MDR1-MDCKII transfected cells; compound 5 microM,MDCKII,,5,microM,,human,mbds0010,,2013-11-17 19:23:37
mbbd000145369,mbcd0030531,mbtp000001,mbrf0001586,,,,,substrate,,,,,norBup,,,MDR1-MDCKII transfected cells; compound 10 microM,MDCKII,,10,microM,,human,mbds0010,,2013-11-17 19:23:37
mbbd000145370,mbcd0001345,mbtp000002,mbrf0001586,,,,,non-substrate,,,,,Bup,,,BCRP-MDCKII transfected cells; compound 5 microM,MDCKII,,5,microM,,human,mbds0010,,2013-11-17 19:23:39
mbbd000145371,mbcd0030531,mbtp000002,mbrf0001586,,,,,non-substrate,,,,,norBup,,,BCRP-MDCKII transfected cells; compound 10 microM,MDCKII,,10,microM,,human,mbds0010,,2013-11-17 19:23:39
mbbd000145372,mbcd0001345,mbtp000002,mbrf0001586,,,,,inhibitor,,,,,Bup,,,"BCRP-HEK293 cells, efflux of MXR or Ph-a; compound 100 microM",HEK293,mbcd0029883,100,microM,,human,mbds0010,,2013-11-17 19:23:40
mbbd000145373,mbcd0030531,mbtp000002,mbrf0001586,,,,,inhibitor,,,,,norBup,,,"BCRP-HEK293 cells, efflux of MXR or Ph-a; compound 100 microM",HEK293,mbcd0029883,100,microM,,human,mbds0010,,2013-11-17 19:23:40
mbbd000145374,mbcd0001345,mbtp000002,mbrf0001586,,,,,non-inhibitor,,,,,Bup,,,"BCRP-HEK293 cells, efflux of methadone; compound 100 microM",HEK293,mbcd0024448,100,microM,,human,mbds0010,,2013-11-17 19:23:40
mbbd000145375,mbcd0027062,mbtp000002,mbrf0001600,,,,,non-inhibitor,,,,,verapamil,,,MDCKII-BCRP cells; transport of 1 microM PhA,,,,,,human,mbds0010,,2012-11-15 20:05:25
mbbd000145376,mbcd0027018,mbtp000002,mbrf0001600,,,,,non-inhibitor,,,,,qunidine,,,MDCKII-BCRP cells; transport of 1 microM PhA,,,,,,human,mbds0010,,2012-11-15 20:05:25
mbbd000145377,mbcd0027729,mbtp000002,mbrf0001600,,,,,inhibitor,,,,,candesartan-cx,significant inhibition; IC50 not established due to cytotoxicity of the compound,,MDCKII-BCRP cells; transport of 1 microM PhA; compound 5 microM,,,,,,human,mbds0010,,2012-11-15 20:05:25
mbbd000145378,mbcd0028570,mbtp000002,mbrf0001600,,,,,non-inhibitor,,,,,irbesartan,,,MDCKII-BCRP cells; transport of 1 microM PhA,,,,,,human,mbds0010,,2012-11-15 20:05:25
mbbd000145379,mbcd0003962,mbtp000002,mbrf0001600,,,,,non-inhibitor,,,,,candesartan,,,MDCKII-BCRP cells; transport of 1 microM PhA,,,,,,human,mbds0010,,2012-11-15 20:05:25
mbbd000145380,mbcd0001323,mbtp000002,mbrf0001600,,,,,non-inhibitor,,,,,eprosartan,,,MDCKII-BCRP cells; transport of 1 microM PhA,,,,,,human,mbds0010,,2012-11-15 20:05:25
mbbd000145381,mbcd0027333,mbtp000002,mbrf0001600,,,,,non-inhibitor,,,,,losartan,,,MDCKII-BCRP cells; transport of 1 microM PhA,,,,,,human,mbds0010,,2012-11-15 20:05:25
mbbd000145382,mbcd0003005,mbtp000002,mbrf0001600,,,,,non-inhibitor,,,,,olmesartan,,,MDCKII-BCRP cells; transport of 1 microM PhA,,,,,,human,mbds0010,,2012-11-15 20:05:25
mbbd000145383,mbcd0027486,mbtp000002,mbrf0001600,,,,,non-inhibitor,,,,,olmesartan-mx,,,MDCKII-BCRP cells; transport of 1 microM PhA,,,,,,human,mbds0010,,2012-11-15 20:05:25
mbbd000145384,mbcd0003005,mbtp000005,mbrf0001600,,,,,inducer,,,,,olmesartan,,,MRP2 mRNA expression in LS180 cells; compound 10 microM,,,,,,human,mbds0010,,2012-11-15 20:05:25
mbbd000145385,mbcd0027486,mbtp000005,mbrf0001600,,,,,non-inducer,,,,,olmesartan-mx,,,LS180 cells; 10 microM compound,,,,,,human,mbds0010,,2012-11-15 20:05:25
mbbd000145386,mbcd0028570,mbtp000005,mbrf0001600,,,,,non-inducer,,,,,irbesartan,,,LS180 cells; 10 microM compound,,,,,,human,mbds0010,,2012-11-15 20:05:25
mbbd000145387,mbcd0003962,mbtp000005,mbrf0001600,,,,,non-inducer,,,,,candesartan,,,LS180 cells; 10 microM compound,,,,,,human,mbds0010,,2012-11-15 20:05:25
mbbd000145388,mbcd0027729,mbtp000005,mbrf0001600,,,,,non-inducer,,,,,candesartan-cx,,,LS180 cells; 10 microM compound,,,,,,human,mbds0010,,2012-11-15 20:05:25
mbbd000145389,mbcd0027333,mbtp000005,mbrf0001600,,,,,non-inducer,,,,,losartan,,,LS180 cells; 10 microM compound,,,,,,human,mbds0010,,2012-11-15 20:05:25
mbbd000145390,mbcd0004705,mbtp000005,mbrf0001600,,~,,,non-inducer,117,1.1,fold,0.05,telmisartan,,,LS180 cells; mRNA expression; RT-PCR; 1 week treatment,LS180,,10,microM,,human,mbds0010,,2013-12-13 22:01:27
mbbd000145391,mbcd0004705,mbtp000002,mbrf0001600,,,,,non-inducer,,,,,telmisartan,,,HuH-7 cells; mRNA expression; exposure: 4 days,HuH7,,10,microM,,human,mbds0010,,2013-12-13 20:42:52
mbbd000145392,mbcd0027729,mbtp000002,mbrf0001600,,,,,non-inducer,,,,,candesartan-cx,,,HuH-7 cells,,,,,,human,mbds0010,,2012-11-15 20:05:25
mbbd000145394,mbcd0027729,mbtp000001,mbrf0001600,,,,,non-inducer,,,,,candesartan-cx,,,LS180 cells,,,,,,human,mbds0010,,2012-11-15 20:05:25
mbbd000145395,mbcd0028570,mbtp000001,mbrf0001600,,,,,non-inducer,,,,,irbesartan,,,LS180 cells,,,,,,human,mbds0010,,2012-11-15 20:05:25
mbbd000145396,mbcd0003962,mbtp000001,mbrf0001600,,,,,non-inducer,,,,,candesartan,,,LS180 cells,,,,,,human,mbds0010,,2012-11-15 20:05:25
mbbd000145397,mbcd0001323,mbtp000001,mbrf0001600,,,,,non-inducer,,,,,eprosartan,,,LS180 cells,,,,,,human,mbds0010,,2012-11-15 20:05:25
mbbd000145398,mbcd0027333,mbtp000001,mbrf0001600,,,,,non-inducer,,,,,losartan,,,LS180 cells,,,,,,human,mbds0010,,2012-11-15 20:05:25
mbbd000145399,mbcd0003005,mbtp000001,mbrf0001600,,,,,non-inducer,,,,,olmesartan,,,LS180 cells,,,,,,human,mbds0010,,2012-11-15 20:05:25
mbbd000145400,mbcd0027486,mbtp000001,mbrf0001600,,,,,non-inducer,,,,,olmesartan-mx,,,LS180 cells,,,,,,human,mbds0010,,2012-11-15 20:05:25
mbbd000145401,mbcd0013478,mbtp000005,mbrf0001275,,,,,non-inducer,,,,,TCDD,,,HepG2 hepatoma cells; MRP2 mRNA and protein,HepG2,,,,,human,mbds0010,,2013-11-17 07:11:37
mbbd000145402,mbcd0002889,mbtp000005,mbrf0001275,,,,,non-inducer,,,,,tamoxifen,,,HepG2 hepatoma cells; MRP2 mRNA and protein,HepG2,,,,,human,mbds0010,,2013-11-17 07:11:37
mbbd000145403,mbcd0025844,mbtp000005,mbrf0001275,,,,,non-inducer,,,,,doxorubicine,,,HepG2 hepatoma cells; MRP2 mRNA and protein,HepG2,,,,,human,mbds0010,,2013-11-17 07:11:37
mbbd000145404,mbcd0001117,mbtp000008,mbrf0001275,,=,,,inducer,97,1.5,fold,,cisplatin,protein levels,,HepG2 hepatoma cells; MRP2 mRNA; compound 10 microM,HepG2,,,,,human,mbds0003,v2007,2013-12-08 01:54:56
mbbd000145405,mbcd0001416,mbtp000008,mbrf0001275,,=,,,inducer,97,1.5,fold,,rifampicin,protein levels,,HepG2 hepatoma cells; MRP2 mRNA; compound 20 microM,HepG2,,,,,human,mbds0010,,2013-12-08 01:54:56
mbbd000145406,mbcd0002959,mbtp000008,mbrf0001275,,,,,non-inducer,,,,,dexamethasone,,,HepG2 hepatoma cells; MRP2 expression,HepG2,,,,,human,mbds0010,,2013-11-17 07:19:23
mbbd000145407,mbcd0002889,mbtp000008,mbrf0001275,,,,,non-inducer,,,,,tamoxifen,,,HepG2 hepatoma cells; MRP2 expression,HepG2,,,,,human,mbds0010,,2013-11-17 07:19:23
mbbd000145408,mbcd0001664,mbtp000010,mbrf0001341,,=,,,inhibitor,116,24.8,microM,10.0,taurocholate,,,ASBT-expressing COS cells; inhibition of taurocholate uptake,,,,,,human,mbds0010,,2012-11-21 21:10:37
mbbd000145409,mbcd0029348,mbtp000010,mbrf0001341,,=,,,inhibitor,116,28.0,microM,6.1,tauroursodeoxycholate,,,ASBT-expressing COS cells; inhibition of taurocholate uptake,,,,,,human,mbds0010,,2012-11-21 21:10:37
mbbd000145410,mbcd0001547,mbtp000002,mbrf0001603,,,,,non-inhibitor,,,,,dasatinib,,,ABCG2-expressing HEK293 cells; efflux of 1 microM pheophorbide a,HEK293,mbcd0029883,,,,human,mbds0010,,2013-11-17 20:21:56
mbbd000145411,mbcd0002828,mbtp000002,mbrf0001603,,,,,inhibitor,,,,,imatinib,,,ABCG2-expressing HEK293 cells; efflux of 1 microM pheophorbide a (compound 10 microM) or 200 nM BODIPY-prazosin (compound 1 microM),HEK293,mbcd0029883,1,microM,,human,mbds0010,,2013-11-17 20:21:56
mbbd000145412,mbcd0001690,mbtp000002,mbrf0001603,,,,,inhibitor,,,,,nilotinib,,,ABCG2-expressing HEK293 cells; efflux of 1 microM pheophorbide a (compound 1 microM) or 200 nM BODIPY-prazosin (compound 1 microM),HEK293,mbcd0029883,1,microM,,human,mbds0010,,2013-11-17 20:21:56
mbbd000145413,mbcd0001690,mbtp000001,mbrf0001583,,~,,,non-substrate,146,95.0,%,20,nilotinib,,,K562/ABCB1 cells; compound 25 nM,K562,,,,,human,mbds0010,,2013-11-24 23:55:27
mbbd000145414,mbcd0001690,mbtp000002,mbrf0001583,,~,,,substrate,146,20.0,%,10,nilotinib,,,K562/ABCG2 cells; compound 25 nM,K562,,,,,human,mbds0010,,2013-11-24 23:55:27
mbbd000145415,mbcd0001547,mbtp000001,mbrf0001583,,~,,,substrate,146,45.0,%,10,dasatinib,,,K562/ABCB1 cells; compound 5 nM,K562,,,,,human,mbds0010,,2013-11-24 23:55:27
mbbd000145416,mbcd0001547,mbtp000002,mbrf0001583,,~,,,substrate,146,15.0,%,20,dasatinib,,,K562/ABCG2 cells; compound 5 nM,K562,,,,,human,mbds0010,,2013-11-24 23:55:26
mbbd000145417,mbcd0030532,mbtp000001,mbrf0001583,,~,,,non-substrate,146,90.0,%,20,bosutinib,,,K562/ABCB1 cells; compound 20 nM,K562,,,,,human,mbds0010,,2013-11-24 23:55:25
mbbd000145418,mbcd0030532,mbtp000002,mbrf0001583,,~,,,non-substrate,146,80.0,%,10,bosutinib,,,K562/ABCG2 cells; compound 20 nM,K562,,,,,human,mbds0010,,2013-11-24 23:55:25
mbbd000145419,mbcd0001690,mbtp000001,mbrf0001583,,~,,,inhibitor,25,100.0,nM,,nilotinib,,,K562/ABCB1 cells; efflux of calcein-AM,,,,,,human,mbds0010,,2012-11-22 18:48:17
mbbd000145420,mbcd0001690,mbtp000002,mbrf0001583,,~,,,inhibitor,25,50.0,nM,,nilotinib,,,K562/ABCG2 cells; efflux of Hoechst 33342,,,,,,human,mbds0010,,2012-11-22 18:48:17
mbbd000145421,mbcd0001547,mbtp000001,mbrf0001583,,,,,inhibitor,,,,,dasatinib,,,K562/ABCB1 cells; efflux of calcein-AM; compound >1-2 microM,,,,,,human,mbds0010,,2012-11-22 18:48:17
mbbd000145422,mbcd0001547,mbtp000002,mbrf0001583,,,,,inhibitor,,,,,dasatinib,,,K562/ABCG2 cells; efflux of Hoechst 33342; compound >2-20 microM,,,,,,human,mbds0010,,2012-11-22 18:48:17
mbbd000145423,mbcd0030532,mbtp000001,mbrf0001583,,,,,inhibitor,,,,,bosutinib,,,K562/ABCB1 cells; efflux of calcein-AM; compound >1-2 microM,,,,,,human,mbds0010,,2012-11-22 18:48:17
mbbd000145424,mbcd0030532,mbtp000002,mbrf0001583,,,,,inhibitor,,,,,bosutinib,,,K562/ABCG2 cells; efflux of Hoechst 33342; compound >2-20 microM,,,,,,human,mbds0010,,2012-11-22 18:48:17
mbbd000145425,mbcd0003005,mbtp000012,mbrf0002214,,,,,substrate,,,,,olmesartan,,,OATP1B1-expressing HEK293 cells,HEK293,,,,,human,mbds0010,,2013-11-24 23:14:36
mbbd000145426,mbcd0003005,mbtp000013,mbrf0002214,,,,,substrate,,,,,olmesartan,,,OATP1B3-expressing HEK293 cells,HEK293,,,,,human,mbds0010,,2013-11-24 23:14:37
mbbd000145427,mbcd0027486,mbtp000001,mbrf0002214,,,,,substrate,,,,,olmesartan medoxomil,,,MDCKII monolayers; transcellular transport assay using OATP1B1/MDR1 double transfected cells,MDCKII,,,,,human,mbds0010,,2013-11-26 01:55:30
mbbd000145428,mbcd0027486,mbtp000005,mbrf0002214,,,,,substrate,,,,,olmesartan medoxomil,,,MDCKII monolayers; transcellular transport assay using OATP1B1/MRP2 double transfected cells,MDCKII,,,,,human,mbds0010,,2013-11-26 01:55:30
mbbd000145429,mbcd0027486,mbtp000002,mbrf0002214,,,,,substrate,,,,,olmesartan medoxomil,,,MDCKII monolayers; transcellular transport assay using OATP1B1/BCRP double transfected cells,MDCKII,,,,,human,mbds0010,,2013-11-26 01:55:30
mbbd000145430,mbcd0003005,mbtp000001,mbrf0002214,,,,,non-substrate,,,,,olmesartan,,,MDCKII cells coexpressing OATP1B1/MDR1,MDCKII,,,,,human,mbds0010,,2013-11-24 23:12:19
mbbd000145431,mbcd0003005,mbtp000002,mbrf0002214,,,,,non-substrate,,,,,olmesartan,,,ABCG2-expressing MDCKII cells,MDCKII,,,,,human,mbds0010,,2013-11-24 23:12:19
mbbd000145447,mbcd0003022,mbtp000007,mbrf0001377,,=,,,substrate,22,1.7,nmol min-1 (mg protein)-1,0.1,MPP+,,,OCT1-expressing 293 cell; uptake,HEK293,,,,,human,mbds0010,,2013-12-09 20:04:33
mbbd000145448,mbcd0030903,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-01-17 22:11:01
mbbd000145450,mbcd0015425,mbtp000001,mbrf0002598,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145452,mbcd0030899,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-10-28 19:47:27
mbbd000145453,mbcd0030900,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-01-17 22:11:01
mbbd000145454,mbcd0030901,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-01-17 22:11:01
mbbd000145455,mbcd0010791,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-01-17 22:11:01
mbbd000145456,mbcd0030907,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-01-17 22:11:01
mbbd000145458,mbcd0030857,mbtp000001,mbrf0002598,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145459,mbcd0030858,mbtp000001,mbrf0002598,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145460,mbcd0030855,mbtp000001,mbrf0002598,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145461,mbcd0030856,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-01-17 22:11:01
mbbd000145462,mbcd0030853,mbtp000001,mbrf0002598,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145463,mbcd0030854,mbtp000001,mbrf0002598,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145464,mbcd0030851,mbtp000001,mbrf0002598,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145465,mbcd0030852,mbtp000001,mbrf0002598,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145466,mbcd0030849,mbtp000001,mbrf0002598,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145467,mbcd0030850,mbtp000001,mbrf0002598,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145468,mbcd0028403,mbtp000001,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-01-17 22:11:01
mbbd000145469,mbcd0002191,mbtp000001,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-01-17 22:11:01
mbbd000145470,mbcd0002917,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145471,mbcd0030749,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145472,mbcd0001078,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145473,mbcd0030751,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145474,mbcd0030829,mbtp000001,mbrf0002598,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145475,mbcd0030830,mbtp000001,mbrf0002598,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145476,mbcd0030831,mbtp000001,mbrf0002598,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145477,mbcd0030832,mbtp000001,mbrf0002598,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145478,mbcd0030833,mbtp000001,mbrf0002598,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145479,mbcd0030834,mbtp000001,mbrf0002598,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145481,mbcd0030836,mbtp000001,mbrf0002598,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145482,mbcd0030837,mbtp000001,mbrf0002598,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145483,mbcd0030838,mbtp000001,mbrf0002598,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145485,mbcd0031086,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-01-17 22:11:01
mbbd000145501,mbcd0030667,mbtp000001,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-01-17 22:11:01
mbbd000145502,mbcd0030668,mbtp000001,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-01-17 22:11:01
mbbd000145503,mbcd0030661,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145504,mbcd0030662,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145505,mbcd0030659,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145506,mbcd0030660,mbtp000001,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-01-17 22:11:01
mbbd000145507,mbcd0030665,mbtp000001,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-01-17 22:11:01
mbbd000145508,mbcd0030666,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145509,mbcd0030663,mbtp000001,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-01-17 22:11:01
mbbd000145510,mbcd0030664,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145511,mbcd0030598,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145512,mbcd0030597,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145513,mbcd0030592,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145514,mbcd0030591,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145515,mbcd0030590,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145516,mbcd0030589,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145517,mbcd0030596,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145518,mbcd0030595,mbtp000001,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-01-17 22:11:01
mbbd000145519,mbcd0030594,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145520,mbcd0030593,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145536,mbcd0030889,mbtp000001,mbrf0002598,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145538,mbcd0030565,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145539,mbcd0030658,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145540,mbcd0030657,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145541,mbcd0030650,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145542,mbcd0030649,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145543,mbcd0030652,mbtp000001,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-01-17 22:11:01
mbbd000145544,mbcd0030651,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145545,mbcd0030654,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145546,mbcd0030653,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145547,mbcd0030656,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145548,mbcd0030655,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145549,mbcd0030797,mbtp000001,mbrf0002598,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145550,mbcd0030798,mbtp000001,mbrf0002598,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145551,mbcd0030793,mbtp000001,mbrf0002598,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145552,mbcd0030794,mbtp000001,mbrf0002598,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145553,mbcd0030795,mbtp000001,mbrf0002598,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145554,mbcd0030796,mbtp000001,mbrf0002598,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145555,mbcd0030789,mbtp000001,mbrf0002598,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145556,mbcd0030790,mbtp000001,mbrf0002598,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145557,mbcd0030791,mbtp000001,mbrf0002598,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145558,mbcd0030792,mbtp000001,mbrf0002598,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145559,mbcd0030560,mbtp000001,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-01-17 22:11:01
mbbd000145560,mbcd0030705,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145561,mbcd0030706,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145562,mbcd0030703,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145563,mbcd0030704,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145564,mbcd0030701,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145565,mbcd0030702,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145566,mbcd0030699,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145567,mbcd0030700,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145568,mbcd0030707,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145569,mbcd0030708,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145570,mbcd0030692,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145571,mbcd0030691,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145572,mbcd0030690,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145573,mbcd0030689,mbtp000001,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-01-17 22:11:01
mbbd000145574,mbcd0030696,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145575,mbcd0030695,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145576,mbcd0030694,mbtp000001,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-01-17 22:11:01
mbbd000145577,mbcd0030693,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145579,mbcd0030698,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145580,mbcd0030697,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145585,mbcd0030583,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145586,mbcd0030584,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145587,mbcd0030585,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145588,mbcd0030586,mbtp000001,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-01-17 22:11:01
mbbd000145589,mbcd0030579,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145590,mbcd0030580,mbtp000001,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-01-17 22:11:01
mbbd000145591,mbcd0030581,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145593,mbcd0030587,mbtp000001,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-01-17 22:11:01
mbbd000145594,mbcd0030588,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145598,mbcd0030962,mbtp000001,mbrf0002598,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145603,mbcd0010857,mbtp000001,mbrf0002598,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145609,mbcd0030934,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-01-17 22:11:01
mbbd000145614,mbcd0030647,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145615,mbcd0030648,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145618,mbcd0030954,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-01-17 22:11:01
mbbd000145619,mbcd0002507,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-01-17 22:11:01
mbbd000145620,mbcd0030641,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145621,mbcd0030642,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145622,mbcd0030639,mbtp000001,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-01-17 22:11:01
mbbd000145623,mbcd0030640,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145624,mbcd0030645,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145625,mbcd0030646,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145626,mbcd0030643,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145627,mbcd0030644,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145628,mbcd0030566,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145629,mbcd0030804,mbtp000001,mbrf0002598,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145630,mbcd0030803,mbtp000001,mbrf0002598,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145631,mbcd0030806,mbtp000001,mbrf0002598,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145632,mbcd0030805,mbtp000001,mbrf0002598,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145633,mbcd0016189,mbtp000001,mbrf0002598,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145635,mbcd0030179,mbtp000001,mbrf0002598,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145636,mbcd0030801,mbtp000001,mbrf0002598,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145637,mbcd0030807,mbtp000001,mbrf0002598,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145651,mbcd0001633,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-01-17 22:11:01
mbbd000145659,mbcd0030737,mbtp000001,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-01-17 22:11:01
mbbd000145661,mbcd0030735,mbtp000001,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-01-17 22:11:01
mbbd000145662,mbcd0003889,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145663,mbcd0030732,mbtp000001,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-01-17 22:11:01
mbbd000145665,mbcd0030729,mbtp000001,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-01-17 22:11:01
mbbd000145666,mbcd0030812,mbtp000001,mbrf0002598,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145669,mbcd0003906,mbtp000001,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-01-17 22:11:01
mbbd000145670,mbcd0030740,mbtp000001,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-01-17 22:11:01
mbbd000145671,mbcd0026589,mbtp000001,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-01-17 22:11:01
mbbd000145672,mbcd0007577,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145673,mbcd0003011,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145674,mbcd0030748,mbtp000001,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-01-17 22:11:01
mbbd000145675,mbcd0030570,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145676,mbcd0030569,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145677,mbcd0030572,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145678,mbcd0030571,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145679,mbcd0030574,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145680,mbcd0030573,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145681,mbcd0030576,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145682,mbcd0030575,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145683,mbcd0030578,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145684,mbcd0030577,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145685,mbcd0030621,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145686,mbcd0030881,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-01-17 22:11:01
mbbd000145687,mbcd0030882,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-01-17 22:11:01
mbbd000145688,mbcd0030879,mbtp000001,mbrf0002598,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145689,mbcd0030880,mbtp000001,mbrf0002598,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145691,mbcd0030883,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-01-17 22:11:01
mbbd000145692,mbcd0030884,mbtp000001,mbrf0002598,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145693,mbcd0030887,mbtp000001,mbrf0002598,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145695,mbcd0030759,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145696,mbcd0030762,mbtp000001,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-01-17 22:11:01
mbbd000145697,mbcd0030761,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145698,mbcd0030764,mbtp000001,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-01-17 22:11:01
mbbd000145699,mbcd0030763,mbtp000001,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-01-17 22:11:01
mbbd000145700,mbcd0030766,mbtp000001,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-01-17 22:11:01
mbbd000145702,mbcd0030636,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145703,mbcd0030635,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145704,mbcd0030634,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145705,mbcd0030633,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145706,mbcd0030632,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145707,mbcd0030638,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145708,mbcd0030637,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145709,mbcd0030561,mbtp000001,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-01-17 22:11:01
mbbd000145710,mbcd0030567,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145711,mbcd0030627,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145713,mbcd0030680,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145714,mbcd0030681,mbtp000001,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-01-17 22:11:01
mbbd000145715,mbcd0030682,mbtp000001,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-01-17 22:11:01
mbbd000145716,mbcd0030683,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145717,mbcd0030684,mbtp000001,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-01-17 22:11:01
mbbd000145718,mbcd0031192,mbtp000001,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-10-01 22:00:59
mbbd000145719,mbcd0030686,mbtp000001,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-01-17 22:11:01
mbbd000145720,mbcd0030687,mbtp000001,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-01-17 22:11:01
mbbd000145721,mbcd0030688,mbtp000001,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-01-17 22:11:01
mbbd000145728,mbcd0028108,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-01-17 22:11:01
mbbd000145732,mbcd0001425,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-01-17 22:11:01
mbbd000145734,mbcd0030878,mbtp000001,mbrf0002598,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145736,mbcd0030872,mbtp000001,mbrf0002598,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145737,mbcd0030871,mbtp000001,mbrf0002598,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145738,mbcd0030870,mbtp000001,mbrf0002598,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145739,mbcd0030869,mbtp000001,mbrf0002598,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145740,mbcd0030876,mbtp000001,mbrf0002598,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145741,mbcd0030875,mbtp000001,mbrf0002598,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145742,mbcd0030874,mbtp000001,mbrf0002598,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145743,mbcd0030873,mbtp000001,mbrf0002598,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145745,mbcd0030562,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145751,mbcd0030924,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-01-17 22:11:01
mbbd000145756,mbcd0030941,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-01-17 22:11:01
mbbd000145757,mbcd0030942,mbtp000001,mbrf0002598,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145758,mbcd0030943,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-01-17 22:11:01
mbbd000145761,mbcd0029421,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-01-17 22:11:01
mbbd000145762,mbcd0026854,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-01-17 22:11:01
mbbd000145763,mbcd0030948,mbtp000001,mbrf0002598,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145764,mbcd0030619,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145765,mbcd0030620,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145766,mbcd0030817,mbtp000001,mbrf0002598,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145767,mbcd0030818,mbtp000001,mbrf0002598,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145768,mbcd0030623,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145769,mbcd0030624,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145770,mbcd0030625,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145771,mbcd0030626,mbtp000001,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-01-17 22:11:01
mbbd000145772,mbcd0030811,mbtp000001,mbrf0002598,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145773,mbcd0030628,mbtp000001,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-01-17 22:11:01
mbbd000145774,mbcd0030809,mbtp000001,mbrf0002598,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145775,mbcd0030810,mbtp000001,mbrf0002598,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145776,mbcd0030815,mbtp000001,mbrf0002598,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145777,mbcd0030816,mbtp000001,mbrf0002598,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145778,mbcd0030813,mbtp000001,mbrf0002598,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145780,mbcd0031067,mbtp000001,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-01-17 22:11:01
mbbd000145785,mbcd0014828,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-01-17 22:11:01
mbbd000145793,mbcd0031026,mbtp000001,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-01-17 22:11:01
mbbd000145794,mbcd0031025,mbtp000001,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-01-17 22:11:01
mbbd000145796,mbcd0031019,mbtp000001,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-01-17 22:11:01
mbbd000145798,mbcd0030727,mbtp000001,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-01-17 22:11:01
mbbd000145799,mbcd0030728,mbtp000001,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-01-17 22:11:01
mbbd000145800,mbcd0030723,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145801,mbcd0030724,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145802,mbcd0030725,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145804,mbcd0030719,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145805,mbcd0030720,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145806,mbcd0000843,mbtp000001,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-01-17 22:11:01
mbbd000145807,mbcd0030568,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145808,mbcd0016927,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-01-17 22:11:01
mbbd000145809,mbcd0000337,mbtp000001,mbrf0002598,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145818,mbcd0030775,mbtp000001,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-01-17 22:11:01
mbbd000145819,mbcd0030776,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145821,mbcd0029983,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145822,mbcd0013872,mbtp000001,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-01-17 22:11:01
mbbd000145823,mbcd0030777,mbtp000001,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-01-17 22:11:01
mbbd000145824,mbcd0030778,mbtp000001,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-01-17 22:11:01
mbbd000145825,mbcd0030848,mbtp000001,mbrf0002598,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145826,mbcd0030847,mbtp000001,mbrf0002598,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145827,mbcd0030563,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145828,mbcd0030840,mbtp000001,mbrf0002598,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145829,mbcd0030839,mbtp000001,mbrf0002598,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145830,mbcd0030842,mbtp000001,mbrf0002598,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145831,mbcd0030841,mbtp000001,mbrf0002598,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145832,mbcd0030844,mbtp000001,mbrf0002598,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145833,mbcd0030843,mbtp000001,mbrf0002598,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145834,mbcd0030846,mbtp000001,mbrf0002598,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145835,mbcd0030845,mbtp000001,mbrf0002598,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145836,mbcd0030822,mbtp000001,mbrf0002598,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145837,mbcd0030821,mbtp000001,mbrf0002598,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145838,mbcd0030820,mbtp000001,mbrf0002598,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145839,mbcd0030819,mbtp000001,mbrf0002598,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145840,mbcd0030826,mbtp000001,mbrf0002598,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145841,mbcd0030825,mbtp000001,mbrf0002598,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145842,mbcd0030824,mbtp000001,mbrf0002598,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145843,mbcd0030823,mbtp000001,mbrf0002598,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145845,mbcd0030827,mbtp000001,mbrf0002598,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145846,mbcd0030618,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145847,mbcd0030617,mbtp000001,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-01-17 22:11:01
mbbd000145848,mbcd0030614,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145849,mbcd0030613,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145850,mbcd0030616,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145851,mbcd0030615,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145852,mbcd0030610,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145853,mbcd0030609,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145854,mbcd0030612,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145855,mbcd0030611,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145858,mbcd0030622,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145860,mbcd0031091,mbtp000001,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-01-17 22:11:01
mbbd000145861,mbcd0031090,mbtp000001,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-01-17 22:11:01
mbbd000145863,mbcd0030674,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145864,mbcd0030673,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145865,mbcd0030676,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145866,mbcd0030675,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145867,mbcd0030670,mbtp000001,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-01-17 22:11:01
mbbd000145868,mbcd0030669,mbtp000001,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-01-17 22:11:01
mbbd000145869,mbcd0030672,mbtp000001,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-01-17 22:11:01
mbbd000145870,mbcd0030671,mbtp000001,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-01-17 22:11:01
mbbd000145871,mbcd0030678,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145872,mbcd0030677,mbtp000001,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-01-17 22:11:01
mbbd000145883,mbcd0030867,mbtp000001,mbrf0002598,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145884,mbcd0030868,mbtp000001,mbrf0002598,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145885,mbcd0030859,mbtp000001,mbrf0002598,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145886,mbcd0030860,mbtp000001,mbrf0002598,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145887,mbcd0030861,mbtp000001,mbrf0002598,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145888,mbcd0030862,mbtp000001,mbrf0002598,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145889,mbcd0030863,mbtp000001,mbrf0002598,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145890,mbcd0030864,mbtp000001,mbrf0002598,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145891,mbcd0030865,mbtp000001,mbrf0002598,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145892,mbcd0030866,mbtp000001,mbrf0002598,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145893,mbcd0030788,mbtp000001,mbrf0002598,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145894,mbcd0030787,mbtp000001,mbrf0002598,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145895,mbcd0030786,mbtp000001,mbrf0002598,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145896,mbcd0030785,mbtp000001,mbrf0002598,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145898,mbcd0030782,mbtp000001,mbrf0002598,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145899,mbcd0002041,mbtp000001,mbrf0002598,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145900,mbcd0030016,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-07-19 05:17:42
mbbd000145901,mbcd0001107,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145903,mbcd0029866,mbtp000001,mbrf0002598,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145904,mbcd0030710,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145905,mbcd0030709,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145906,mbcd0030712,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145907,mbcd0030711,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145908,mbcd0030714,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145909,mbcd0030713,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145910,mbcd0030716,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145911,mbcd0030715,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145912,mbcd0030718,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145913,mbcd0030717,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145916,mbcd0030607,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145917,mbcd0030608,mbtp000001,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-01-17 22:11:01
mbbd000145918,mbcd0030605,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145919,mbcd0030606,mbtp000001,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-01-17 22:11:01
mbbd000145920,mbcd0030603,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145921,mbcd0030604,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145922,mbcd0030601,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145923,mbcd0028490,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145924,mbcd0030599,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145925,mbcd0030600,mbtp000001,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-01-17 22:11:01
mbbd000145926,mbcd0030564,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145934,mbcd0031041,mbtp000001,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-01-17 22:11:01
mbbd000145940,mbcd0026046,mbtp000001,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-01-17 22:11:01
mbbd000145947,mbcd0019953,mbtp000001,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-01-17 22:11:01
mbbd000145948,mbcd0014287,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145949,mbcd0001824,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145956,mbcd0018374,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-01-17 22:11:01
mbbd000145957,mbcd0003622,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145959,mbcd0020821,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145962,mbcd0028474,mbtp000001,mbrf0002598,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145963,mbcd0003876,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-01-17 22:11:01
mbbd000145964,mbcd0026829,mbtp000001,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-01-17 22:11:01
mbbd000145965,mbcd0010193,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145966,mbcd0028088,mbtp000001,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-01-17 22:11:01
mbbd000145967,mbcd0001792,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-01-17 22:11:01
mbbd000145968,mbcd0002176,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145969,mbcd0022906,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145970,mbcd0024931,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145971,mbcd0001170,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-01-17 22:11:01
mbbd000145972,mbcd0006268,mbtp000001,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-01-17 22:11:01
mbbd000145974,mbcd0010470,mbtp000001,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-01-17 22:11:01
mbbd000145975,mbcd0002375,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145976,mbcd0006172,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145977,mbcd0025286,mbtp000001,mbrf0002598,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145978,mbcd0024605,mbtp000001,mbrf0002598,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145979,mbcd0016306,mbtp000001,mbrf0002598,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145980,mbcd0021513,mbtp000001,mbrf0002598,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2014-01-14 22:12:24
mbbd000145982,mbcd0001317,mben000013,mbrf0002600,,=,,,substrate,147,3.8,min-1,0.2,Benzphetamine,,,"0.75-1.5 ml of 100mM potassium phosphate buffer, pH 7.4",,,,,,human,mbds0010,,2012-08-31 21:11:01
mbbd000145983,mbcd0001671,mben000013,mbrf0002600,,=,,,substrate,147,0.05,min-1,,Arachidonic acid,metabolises at small rate,,"1.0 ml of 100mM potassium phosphate buffer, pH 7.4",,,,,,human,mbds0010,,2012-08-31 21:11:01
mbbd000145984,mbcd0001317,mben000013,mbrf0002600,,=,,,substrate,28,380.0,microM,40,Benzphetamine,,,"0.75-1.5 ml of 100mM potassium phosphate buffer, pH 7.4",,,,,,human,mbds0010,,2012-08-31 21:11:01
mbbd000145985,mbcd0029292,mben000013,mbrf0002600,,,,,substrate,,,,,"Chrysene-1,2-diol",only graphical data available (Fig 5),,S. typhimurium NM2009 umu system,,,,,,human,mbds0010,,2012-08-31 21:11:01
mbbd000145986,mbcd0031164,mben000013,mbrf0002600,,,,,substrate,,,,,"(-)-Benzo[a]pyrene-7,8-diol",only graphical data available (Fig 5),,S. typhimurium NM2009 umu system,,,,,,human,mbds0010,,2012-08-31 21:11:01
mbbd000145987,mbcd0029338,mben000013,mbrf0002600,,,,,substrate,,,,,"(+)-Benzo[a]pyrene-7,8-diol",only graphical data available (Fig 5),,S. typhimurium NM2009 umu system,,,,,,human,mbds0010,,2012-08-31 21:11:01
mbbd000145988,mbcd0029294,mben000013,mbrf0002600,,,,,substrate,,,,,"5-Methylchrysene-1,2-diol",only graphical data available (Fig 5),,S. typhimurium NM2009 umu system,,,,,,human,mbds0010,,2012-08-31 21:11:01
mbbd000145989,mbcd0029316,mben000013,mbrf0002600,,,,,substrate,,,,,"(+/-)-Benzo[a]pyrene-7,8-diol",only graphical data available (Fig 5),,S. typhimurium NM2009 umu system,,,,,,human,mbds0010,,2012-08-31 21:11:01
mbbd000145990,mbcd0029295,mben000013,mbrf0002600,,,,,substrate,,,,,Sterigmatocystin,only graphical data available (Fig 5),,S. typhimurium NM2009 umu system,,,,,,human,mbds0010,,2012-08-31 21:11:01
mbbd000145991,mbcd0029932,mben000013,mbrf0002600,,,,,substrate,,,,,Aflatoxin B1,only graphical data available (Fig 5),,S. typhimurium NM2009 umu system,,,,,,human,mbds0010,,2012-08-31 21:11:01
mbbd000145992,mbcd0029297,mben000013,mbrf0002600,,,,,substrate,,,,,3-MeO-AAB,only graphical data available (Fig 5),,S. typhimurium NM2009 umu system,,,,,weak substrate,human,mbds0010,,2013-11-24 22:15:01
mbbd000145993,mbcd0029298,mben000013,mbrf0002600,,,,,substrate,,,,,2-Aminofluorene,only graphical data available (Fig 5),,S. typhimurium NM2009 umu system,,,,,weak substrate,human,mbds0010,,2013-11-24 22:15:02
mbbd000145994,mbcd0027262,mben000013,mbrf0002600,,,,,substrate,,,,,2-Aminoanthracene,only graphical data available (Fig 5),,S. typhimurium NM2009 umu system,,,,,weak substrate,human,mbds0010,,2013-11-24 22:15:03
mbbd000145995,mbcd0029299,mben000013,mbrf0002601,,=,,,substrate,147,2.0,min-1,0.27,indole,,,"Membrane fractions prepared from DH5a/pCD2W1hR expressing D2W1 and human CPR, and yeast microsomes containing CYP2A6 and yeast NADPH-P450 reductase were used for metabolism of indole. The reaction mixture contains D2W1(60-120 nM) or CYP2A6 [13] and 0.5-5 mM indole in a final volume of 0.50 ml of 100 mM Tris-HCl buffer (pH 7.4). The reaction was initiated by the addition of 1 mM NADPH, and the reaction mixture was incubated at 37 C for 0-60 min",,,,,,human,mbds0010,,2013-12-09 20:57:48
mbbd000145996,mbcd0029299,mben000013,mbrf0002601,,=,,,substrate,28,4.53,microM,0.3,indole,,,"Membrane fractions prepared from DH5a/pCD2W1hR expressing D2W1 and human CPR, and yeast microsomes containing CYP2A6 and yeast NADPH-P450 reductase were used for metabolism of indole. The reaction mixture contains D2W1(60-120 nM) or CYP2A6 [13] and 0.5-5 mM indole in a final volume of 0.50 ml of 100 mM Tris-HCl buffer (pH 7.4). The reaction was initiated by the addition of 1 mM NADPH, and the reaction mixture was incubated at 37 C for 0-60 min",,,,,,human,mbds0010,,2013-12-09 20:52:32
mbbd000145997,mbcd0003000,mben000013,mbrf0002601,,,,,substrate,,,,,Chlorzoxazone,only mentioned in discussion; show monooxygenase activity,,,,,,,,human,mbds0010,,2012-08-31 21:11:01
mbbd000145998,mbcd0029300,mben000013,mbrf0002601,,,,,substrate,,,,,3-methylindole,only mentioned in discussion; show monooxygenase activity,,,,,,,,human,mbds0010,,2012-08-31 21:11:01
mbbd000145999,mbcd0029301,mben000013,mbrf0002603,,,,,substrate,,,,,5-bromoindoline,only graphical value available; derivatives form,,"CYP2W1 stably expressing HEK 293 and mock cells were incubated with 150 microM 5-bromoindoline for 2h. The cells were harvested, washed with phosphate- buffered saline, and centrifuged at 2000 rpm for 10 min. Cell pellet was frozen to -70 degC for 2 h and thawed thereafter with the addition of 100 microl of water. Suspension was mixed with 100% ice-cold acetonitrile, vortexed, and centrifuged at 13,300 rpm for 20 min. Supernatant was collected and analyzed by HPLC",,,,,,human,mbds0010,,2013-12-09 20:52:33
mbbd000146000,mbcd0029302,mben000013,mbrf0002603,,,,,substrate,,,,,2-methyl-5-nitroindoline,only graphical value available; derivatives form,,"CYP2W1 stably expressing HEK 293 and mock cells were incubated with 100 microM 2-methyl-5-nitroindoline for 24h. The cells were harvested, washed with phosphate- buffered saline, and centrifuged at 2000 rpm for 10 min. Cell pellet was frozen to -70 degC for 2 h and thawed thereafter with the addition of 100 microl of water. Suspension was mixed with 100% ice-cold acetonitrile, vortexed, and centrifuged at 13,300 rpm for 20 min. Supernatant was collected and analyzed by HPLC",,,,,,human,mbds0010,,2013-12-09 20:54:38
mbbd000146001,mbcd0006222,mben000013,mbrf0002603,,,,,substrate,,,,,pargyline,no data; unpublished observations,,,,,,,,human,mbds0010,,2012-08-31 21:11:01
mbbd000146002,mbcd0010771,mben000013,mbrf0002603,,,,,substrate,,,,,aminopyrine,no data; unpublished observations,,,,,,,,human,mbds0010,,2012-08-31 21:11:01
mbbd000146003,mbcd0029303,mben000013,mbrf0002600,,<,,,non-substrate,148,0.02,nmol min-1,,"N,N-Dimethylnitrosamine",,,Catalysed using E. coli membranes in which the P450 was coexpressed with human NADPH-P450 reductase,,,1,mM,,human,mbds0010,,2013-12-09 20:54:38
mbbd000146004,mbcd0022339,mben000013,mbrf0002600,,<,,,non-substrate,148,0.05,nmol min-1,,Naphthalene,,,Catalysed using E. coli membranes in which the P450 was coexpressed with human NADPH-P450 reductase,,,300,microM,,human,mbds0010,,2013-12-09 20:54:37
mbbd000146005,mbcd0003001,mben000013,mbrf0002600,,<,,,non-substrate,148,0.08,nmol min-1,,Testosterone,,,Catalysed using E. coli membranes in which the P450 was coexpressed with human NADPH-P450 reductase,,,100,microM,,human,mbds0010,,2013-12-09 20:54:36
mbbd000146006,mbcd0000169,mben000013,mbrf0002600,,<,,,non-substrate,148,0.05,nmol min-1,,Benzo[a]pyrene,,,Catalysed using E. coli membranes in which the P450 was coexpressed with human NADPH-P450 reductase,,,100,microM,,human,mbds0010,,2013-12-09 20:54:38
mbbd000146007,mbcd0011835,mben000013,mbrf0002600,,<,,,non-substrate,148,0.03,nmol min-1,,Oleic acid,,,Catalysed using E. coli membranes in which the P450 was coexpressed with human NADPH-P450 reductase,,,9,microM,,human,mbds0010,,2013-12-09 20:54:37
mbbd000146008,mbcd0026045,mben000013,mbrf0002600,,<,,,non-substrate,148,0.003,nmol min-1,,All-trans-retinoic acid,,,Catalysed using E. coli membranes in which the P450 was coexpressed with human NADPH-P450 reductase,,,10,microM,,human,mbds0010,,2013-12-09 20:54:36
mbbd000146009,mbcd0029304,mben000013,mbrf0002600,,,,,non-substrate,,,,,"Dibenzo[a,l]pyrene",only graphical data available (Fig 5),,S. typhimurium NM2009 umu system,,,,,weak substrate,human,mbds0010,,2013-11-24 22:14:59
mbbd000146010,mbcd0028165,mben000013,mbrf0002600,,,,,non-substrate,,,,,"7,12-DMBA",only graphical data available (Fig 5),,S. typhimurium NM2009 umu system,,,,,weak substrate,human,mbds0010,,2013-11-24 22:14:59
mbbd000146011,mbcd0029305,mben000013,mbrf0002600,,,,,non-substrate,,,,,"Benz[a]anthracene-3,4-diol",only graphical data available (Fig 5),,S. typhimurium NM2009 umu system,,,,,weak substrate,human,mbds0010,,2013-11-24 22:14:59
mbbd000146012,mbcd0029307,mben000013,mbrf0002600,,,,,non-substrate,,,,,"5,6-Dimethylchrysene-1,2-diol",only graphical data available (Fig 5),,S. typhimurium NM2009 umu system,,,,,weak substrate,human,mbds0010,,2013-11-24 22:15:00
mbbd000146013,mbcd0029306,mben000013,mbrf0002600,,,,,non-substrate,,,,,"7,12-DMBA-3,4-diol",only graphical data available (Fig 5),,S. typhimurium NM2009 umu system,,,,,weak substrate,human,mbds0010,,2013-11-24 22:15:00
mbbd000146014,mbcd0029308,mben000013,mbrf0002600,,,,,substrate,,,,,"Dibenzo[a,l]pyrene-11,12-diol",only graphical data available (Fig 5),,S. typhimurium NM2009 umu system,,,,,weak substrate,human,mbds0010,,2013-11-24 22:15:00
mbbd000146015,mbcd0029309,mben000013,mbrf0002600,,,,,non-substrate,,,,,Trp-P-1,only graphical data available (Fig 5),,S. typhimurium NM2009 umu system,,,,,weak substrate,human,mbds0010,,2013-11-24 22:15:00
mbbd000146016,mbcd0029310,mben000013,mbrf0002600,,,,,non-substrate,,,,,MeIQ,only graphical data available (Fig 5),,S. typhimurium NM2009 umu system,,,,,weak substrate,human,mbds0010,,2013-11-24 22:15:01
mbbd000146017,mbcd0029311,mben000013,mbrf0002600,,,,,non-substrate,,,,,Benz[a]anthracene,only graphical data available (Fig 5),,S. typhimurium NM2009 umu system,,,,,,human,mbds0010,,2012-08-31 21:11:01
mbbd000146018,mbcd0029312,mben000013,mbrf0002600,,,,,non-substrate,,,,,5-Methylchrysene,only graphical data available (Fig 5),,S. typhimurium NM2009 umu system,,,,,,human,mbds0010,,2012-08-31 21:11:01
mbbd000146019,mbcd0029313,mben000013,mbrf0002600,,,,,non-substrate,,,,,"B[b]FA-9,10-diol",only graphical data available (Fig 5),,S. typhimurium NM2009 umu system,,,,,,human,mbds0010,,2012-08-31 21:11:01
mbbd000146020,mbcd0029314,mben000013,mbrf0002604,,=,,,substrate,28,30.0,microM,,AQ4N,,,1.5-ml Eppendorf tubes at 37 degC in an anaerobic chamber,,,,,,human,mbds0010,,2012-08-31 21:11:01
mbbd000146021,mbcd0029314,mben000013,mbrf0002604,,=,,,substrate,22,12.0,min-1,,AQ4N,,,1.5-ml Eppendorf tubes at 37 degC in an anaerobic chamber,,,,,,human,mbds0010,,2012-08-31 21:11:01
mbbd000146022,mbcd0029314,mben000011,mbrf0002604,,=,,,substrate,28,27.0,microM,,AQ4N,,,1.5-ml Eppendorf tubes at 37 degC in an anaerobic chamber,,,,,,human,mbds0010,,2012-08-31 21:11:01
mbbd000146023,mbcd0029314,mben000011,mbrf0002604,,=,,,substrate,22,12.0,min-1,,AQ4N,,,1.5-ml Eppendorf tubes at 37 degC in an anaerobic chamber,,,,,,human,mbds0010,,2012-08-31 21:11:01
mbbd000146024,mbcd0001317,mben000011,mbrf0002600,,<,,,non-substrate,148,0.02,nmol min-1,,d-Benzphetamine,,,Catalysed using E. coli membranes in which the P450 was coexpressed with human NADPH-P450 reductase,,,1,mM,,human,mbds0010,,2013-12-09 20:55:08
mbbd000146025,mbcd0029303,mben000011,mbrf0002600,,<,,,non-substrate,148,0.02,nmol min-1,,"N,N-Dimethylnitrosamine",,,Catalysed using E. coli membranes in which the P450 was coexpressed with human NADPH-P450 reductase,,,1,mM,,human,mbds0010,,2013-12-09 20:55:08
mbbd000146026,mbcd0022339,mben000011,mbrf0002600,,<,,,non-substrate,148,0.05,nmol min-1,,Naphthalene,,,Catalysed using E. coli membranes in which the P450 was coexpressed with human NADPH-P450 reductase,,,300,microM,,human,mbds0010,,2013-12-09 20:55:08
mbbd000146027,mbcd0003001,mben000011,mbrf0002600,,<,,,non-substrate,148,0.08,nmol min-1,,Testosterone,,,Catalysed using E. coli membranes in which the P450 was coexpressed with human NADPH-P450 reductase,,,100,microM,,human,mbds0010,,2013-12-09 20:55:07
mbbd000146028,mbcd0000169,mben000011,mbrf0002600,,<,,,non-substrate,148,0.3,nmol min-1,,Benzo[a]pyrene,,,Catalysed using E. coli membranes in which the P450 was coexpressed with human NADPH-P450 reductase,,,100,microM,,human,mbds0010,,2013-12-09 20:55:04
mbbd000146029,mbcd0026045,mben000011,mbrf0002600,,<,,,non-substrate,148,0.003,nmol min-1,,All-trans-retinoic acid,,,Catalysed using E. coli membranes in which the P450 was coexpressed with human NADPH-P450 reductase,,,10,microM,,human,mbds0010,,2013-12-09 20:55:02
mbbd000146030,mbcd0011835,mben000011,mbrf0002600,,<,,,non-substrate,148,0.003,nmol min-1,,Oleic acid,,,Catalysed using E. coli membranes in which the P450 was coexpressed with human NADPH-P450 reductase,,,9,microM,,human,mbds0010,,2013-12-09 20:07:51
mbbd000146031,mbcd0001671,mben000011,mbrf0002600,,<,,,non-substrate,148,0.01,nmol min-1,,Arachidonic acid,,,Catalysed using E. coli membranes in which the P450 was coexpressed with human NADPH-P450 reductase,,,50,microM,,human,mbds0010,,2013-12-09 20:07:53
mbbd000146032,mbcd0029311,mben000011,mbrf0002600,,,,,non-substrate,,,,,Benz[a]anthracene,only graphical data available (Fig 5),,S. typhimurium NM2009 umu system,,,,,,human,mbds0010,,2012-08-31 21:11:01
mbbd000146033,mbcd0029304,mben000011,mbrf0002600,,,,,non-substrate,,,,,"Dibenzo[a,l]pyrene",only graphical data available (Fig 5),,S. typhimurium NM2009 umu system,,,,,,human,mbds0010,,2012-08-31 21:11:01
mbbd000146034,mbcd0029312,mben000011,mbrf0002600,,,,,non-substrate,,,,,5-Methylchrysene,only graphical data available (Fig 5),,S. typhimurium NM2009 umu system,,,,,,human,mbds0010,,2012-08-31 21:11:01
mbbd000146035,mbcd0028165,mben000011,mbrf0002600,,,,,non-substrate,,,,,"7,12-DMBA",only graphical data available (Fig 5),,S. typhimurium NM2009 umu system,,,,,,human,mbds0010,,2012-08-31 21:11:01
mbbd000146036,mbcd0029305,mben000011,mbrf0002600,,,,,non-substrate,,,,,"Benz[a]anthracene-3,4-diol",only graphical data available (Fig 5),,S. typhimurium NM2009 umu system,,,,,,human,mbds0010,,2012-08-31 21:11:01
mbbd000146037,mbcd0029313,mben000011,mbrf0002600,,,,,non-substrate,,,,,"B[b]FA-9,10-diol",only graphical data available (Fig 5),,S. typhimurium NM2009 umu system,,,,,,human,mbds0010,,2012-08-31 21:11:01
mbbd000146038,mbcd0029307,mben000011,mbrf0002600,,,,,non-substrate,,,,,"5,6-Dimethylchrysene-1,2-diol",only graphical data available (Fig 5),,S. typhimurium NM2009 umu system,,,,,,human,mbds0010,,2012-08-31 21:11:01
mbbd000146039,mbcd0029292,mben000011,mbrf0002600,,,,,non-substrate,,,,,"Chrysene-1,2-diol",only graphical data available (Fig 5),,S. typhimurium NM2009 umu system,,,,,,human,mbds0010,,2012-08-31 21:11:01
mbbd000146040,mbcd0029306,mben000011,mbrf0002600,,,,,non-substrate,,,,,"7,12-DMBA-3,4-diol",only graphical data available (Fig 5),,S. typhimurium NM2009 umu system,,,,,,human,mbds0010,,2012-08-31 21:11:01
mbbd000146041,mbcd0031164,mben000011,mbrf0002600,,,,,non-substrate,,,,,"(-)-benzo[a]pyrene-7,8-diol",only graphical data available (Fig 5),,S. typhimurium NM2009 umu system,,,,,,human,mbds0010,,2012-08-31 21:11:01
mbbd000146042,mbcd0029338,mben000011,mbrf0002600,,,,,non-substrate,,,,,"(+)-benzo[a]pyrene-7,8-diol",only graphical data available (Fig 5),,S. typhimurium NM2009 umu system,,,,,,human,mbds0010,,2012-08-31 21:11:01
mbbd000146043,mbcd0029316,mben000011,mbrf0002600,,,,,non-substrate,,,,,"(+/-)-benzo[a]pyrene-7,8-diol",only graphical data available (Fig 5),,S. typhimurium NM2009 umu system,,,,,,human,mbds0010,,2012-08-31 21:11:01
mbbd000146044,mbcd0029308,mben000011,mbrf0002600,,,,,non-substrate,,,,,"Dibenzo[a,l]pyrene-11,12-diol",only graphical data available (Fig 5),,S. typhimurium NM2009 umu system,,,,,,human,mbds0010,,2012-08-31 21:11:01
mbbd000146045,mbcd0029294,mben000011,mbrf0002600,,,,,non-substrate,,,,,"5-Methylchrysene-1,2-diol",only graphical data available (Fig 5),,S. typhimurium NM2009 umu system,,,,,,human,mbds0010,,2012-08-31 21:11:01
mbbd000146046,mbcd0029295,mben000011,mbrf0002600,,,,,non-substrate,,,,,Sterigmatocystin,only graphical data available (Fig 5),,S. typhimurium NM2009 umu system,,,,,,human,mbds0010,,2012-08-31 21:11:01
mbbd000146047,mbcd0029932,mben000011,mbrf0002600,,,,,non-substrate,,,,,Aflatoxin B1,only graphical data available (Fig 5),,S. typhimurium NM2009 umu system,,,,,,human,mbds0010,,2012-08-31 21:11:01
mbbd000146048,mbcd0029297,mben000011,mbrf0002600,,,,,non-substrate,,,,,3-MeO-AAB,only graphical data available (Fig 5),,S. typhimurium NM2009 umu system,,,,,,human,mbds0010,,2012-08-31 21:11:01
mbbd000146049,mbcd0029298,mben000011,mbrf0002600,,,,,non-substrate,,,,,2-Aminofluorene,only graphical data available (Fig 5),,S. typhimurium NM2009 umu system,,,,,,human,mbds0010,,2012-08-31 21:11:01
mbbd000146050,mbcd0027262,mben000011,mbrf0002600,,,,,substrate,,,,,2-Aminoanthracene,only graphical data available (Fig 5),,S. typhimurium NM2009 umu system,,,,,,human,mbds0010,,2012-08-31 21:11:01
mbbd000146051,mbcd0029309,mben000011,mbrf0002600,,,,,non-substrate,,,,,Trp-P-1,only graphical data available (Fig 5),,S. typhimurium NM2009 umu system,,,,,,human,mbds0010,,2012-08-31 21:11:01
mbbd000146052,mbcd0029310,mben000011,mbrf0002600,,,,,non-substrate,,,,,MeIQ,only graphical data available (Fig 5),,S. typhimurium NM2009 umu system,,,,,,human,mbds0010,,2012-08-31 21:11:01
mbbd000146053,mbcd0026045,mben000011,mbrf0002626,,,,,substrate,,,,,all-trans retinoic acid,Metabolism occurs as shown by Fig.5,,Measured by high-performance liquid chromatography analysis,,,,,,human,mbds0010,,2012-08-31 21:11:01
mbbd000146054,mbcd0013478,mben000011,mbrf0002605,,,,,inducer,,,,,dioxin,,,human lung epithelial cell line,,,,,,human,mbds0010,,2012-08-31 21:11:01
mbbd000146055,mbcd0029315,mben000011,mbrf0002606,,,,,non-substrate,,,,,NNK,cell viability unchanged,,"Modified MTS [3-(4,5-dimethylthiazol- 2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfopheny)-2H-tetrazolium] assay using the Cell Titer 96 AQueous nonradioactive cell proliferation assay kit",,,,,,human,mbds0010,,2012-08-31 21:11:01
mbbd000146056,mbcd0000169,mben000011,mbrf0002606,,,,,non-substrate,,,,,BaP,cell viability unchanged,,"Modified MTS [3-(4,5-dimethylthiazol- 2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfopheny)-2H-tetrazolium] assay using the Cell Titer 96 AQueous nonradioactive cell proliferation assay kit",,,,,,human,mbds0010,,2012-08-31 21:11:01
mbbd000146057,mbcd0000928,mben000011,mbrf0002606,,,,,non-substrate,,,,,Nicotine,Substrate not detectable; CYP2A6 and CYP2A13 used as control,,Incubation of either 10 microM or 100 microM of nicotine with CYP2S1,,,,,,human,mbds0010,,2012-08-31 21:11:01
mbbd000146058,mbcd0000043,mben000011,mbrf0002606,,,,,non-substrate,,,,,PhIP,Substrate not detectable; CYP1A2 used as control,,Incubation of 200 microM PhIP with CYP2S1,,,,,,human,mbds0010,,2012-08-31 21:11:01
mbbd000146059,mbcd0022339,mben000011,mbrf0002607,,,,,substrate,,,,,Naphthalene,Metabolism occurs as shown in Fig.2,,Microsomes from yeast transfected with CYP2S1 or empty vector were incubated with naphthalene for 1 h at 37C,,,,,,human,mbds0010,,2012-08-31 21:11:01
mbbd000146060,mbcd0029292,mben000011,mbrf0002606,,,,,substrate,,,,,Aflatoxin B1,Metabolites detected; unpublished results,,,,,,,,human,mbds0010,,2012-08-31 21:11:01
mbbd000146061,mbcd0028096,mben000011,mbrf0002608,,,,,non-substrate,,,,,ABP,No ABP N-hydroxylase activity detected,,,,,,,,human,mbds0010,,2012-08-31 21:11:01
mbbd000146063,mbcd0000919,mben000011,mbrf0002610,,,,,substrate,,,,,vitamin A,Stated in the paper,,,,,,,,human,mbds0010,,2012-08-31 21:11:01
mbbd000146064,mbcd0029316,mben000011,mbrf0002611,,,,,substrate,,,,,"BaP-7,8-diol",The substrate is tested with different fatty acid hydroperoxides,,,,,,,,human,mbds0010,,2012-08-31 21:11:01
mbbd000146065,mbcd0031165,mben000011,mbrf0002611,,=,,,inhibitor,3,100.0,%,,BHA,"CYP2S1 activity is inhibited by the antioxidant, butylated hydroxyanisole (see Fig.2)",,,,,,,,human,mbds0010,,2012-08-31 21:11:01
mbbd000146066,mbcd0029316,mben000011,mbrf0002611,,=,,,substrate,28,2.7,microM,0.8,"BaP-7,8-diol",supported by 5-HpETE,,,,,,,,human,mbds0010,,2012-08-31 21:11:01
mbbd000146067,mbcd0029316,mben000011,mbrf0002611,,=,,,substrate,22,2.7337,nM min-1,,"BaP-7,8-diol",supported by 5-HpETE,,,,,,,,human,mbds0010,,2012-08-31 21:11:01
mbbd000146068,mbcd0029316,mben000011,mbrf0002611,,=,,,substrate,28,2.8,microM,0.7,"BaP-7,8-diol",supported by 12-HpETE,,,,,,,,human,mbds0010,,2012-08-31 21:11:01
mbbd000146069,mbcd0029316,mben000011,mbrf0002611,,=,,,substrate,22,368.0,nM min-1,,"BaP-7,8-diol",supported by 12-HpETE,,,,,,,,human,mbds0010,,2012-08-31 21:11:01
mbbd000146070,mbcd0029316,mben000011,mbrf0002611,,=,,,substrate,28,11.6,microM,3,"BaP-7,8-diol",supported by 15-HpETE,,,,,,,,human,mbds0010,,2012-08-31 21:11:01
mbbd000146071,mbcd0029316,mben000011,mbrf0002611,,=,,,substrate,22,69.0,nM min-1,,"BaP-7,8-diol",supported by 15-HpETE,,,,,,,,human,mbds0010,,2012-08-31 21:11:01
mbbd000146072,mbcd0029316,mben000011,mbrf0002611,,=,,,substrate,28,3.4,microM,0.8,"BaP-7,8-diol",supported by 13-HpODE,,,,,,,,human,mbds0010,,2012-08-31 21:11:01
mbbd000146073,mbcd0029316,mben000011,mbrf0002611,,=,,,substrate,22,463.0,microM,,"BaP-7,8-diol",supported by 13-HpODE,,,,,,,,human,mbds0010,,2012-08-31 21:11:01
mbbd000146074,mbcd0000169,mben000011,mbrf0002612,,=,,,substrate,28,94.0,microM,22,Benzo[a]pyrene,"1,6-Dione as product",,"150-microL reactions contained 100 mM KPi, pH 7.5, purified synthetically encoded CYP2S1, 1mM of CHP, and various concentration of substrates. The reactions were carried out at 37 degC for 5 min before being stopped with 150 microL of acetonitrile (2% acetic acid)",,,,,,human,mbds0010,,2013-12-09 20:10:13
mbbd000146075,mbcd0000169,mben000011,mbrf0002612,,=,,,substrate,147,0.83,nmol product / nmol CYP2S1 / min,,Benzo[a]pyrene,"1,6-Dione as product",,"150-microL reactions contained 100 mM KPi, pH 7.5, purified synthetically encoded CYP2S1, 1mM of CHP, and various concentration of substrates. The reactions were carried out at 37 degC for 5 min before being stopped with 150 microL of acetonitrile (2% acetic acid)",,,,,,human,mbds0010,,2013-12-09 20:10:14
mbbd000146076,mbcd0000169,mben000011,mbrf0002612,,=,,,substrate,28,48.6,microM,8,Benzo[a]pyrene,"3,6-Dione as product",,"150-microL reactions contained 100 mM KPi, pH 7.5, purified synthetically encoded CYP2S1, 1mM of CHP, and various concentration of substrates. The reactions were carried out at 37 degC for 5 min before being stopped with 150 microL of acetonitrile (2% acetic acid)",,,,,,human,mbds0010,,2013-12-09 20:10:15
mbbd000146077,mbcd0000169,mben000011,mbrf0002612,,=,,,substrate,147,1.85,nmol product / nmol CYP2S1 / min,,Benzo[a]pyrene,"3,6-Dione as product",,"150-microL reactions contained 100 mM KPi, pH 7.5, purified synthetically encoded CYP2S1, 1mM of CHP, and various concentration of substrates. The reactions were carried out at 37 degC for 5 min before being stopped with 150 microL of acetonitrile (2% acetic acid)",,,,,,human,mbds0010,,2013-12-09 20:10:16
mbbd000146078,mbcd0000169,mben000011,mbrf0002612,,=,,,substrate,28,72.7,microM,14,Benzo[a]pyrene,"6,12-Dione as product",,"150-microL reactions contained 100 mM KPi, pH 7.5, purified synthetically encoded CYP2S1, 1mM of CHP, and various concentration of substrates. The reactions were carried out at 37 degC for 5 min before being stopped with 150 microL of acetonitrile (2% acetic acid)",,,,,,human,mbds0010,,2013-12-09 20:10:12
mbbd000146079,mbcd0000169,mben000011,mbrf0002612,,=,,,substrate,147,3.25,nmol product / nmol CYP2S1 / min,,Benzo[a]pyrene,"6,12-Dione as product",,"150-microL reactions contained 100 mM KPi, pH 7.5, purified synthetically encoded CYP2S1, 1mM of CHP, and various concentration of substrates. The reactions were carried out at 37 degC for 5 min before being stopped with 150 microL of acetonitrile (2% acetic acid)",,,,,,human,mbds0010,,2013-12-09 20:10:12
mbbd000146080,mbcd0028165,mben000011,mbrf0002612,,=,,,substrate,28,219.0,microM,4,"7,12-Dimethylbenz[a]anthracene",7-OH-DMBA as product,,"150-microL reactions contained 100 mM KPi, pH 7.5, purified synthetically encoded CYP2S1, 1mM of CHP, and various concentration of substrates. The reactions were carried out at 37 degC for 5 min before being stopped with 150 microL of acetonitrile (2% acetic acid)",,,,,,human,mbds0010,,2013-12-09 20:58:18
mbbd000146081,mbcd0028165,mben000011,mbrf0002612,,=,,,substrate,147,15.7,nmol product / nmol CYP2S1 / min,,"7,12-Dimethylbenz[a]anthracene",7-OH-DMBA as product,,"150-microL reactions contained 100 mM KPi, pH 7.5, purified synthetically encoded CYP2S1, 1mM of CHP, and various concentration of substrates. The reactions were carried out at 37 degC for 5 min before being stopped with 150 microL of acetonitrile (2% acetic acid)",,,,,,human,mbds0010,,2013-12-09 20:58:18
mbbd000146082,mbcd0028165,mben000011,mbrf0002612,,=,,,substrate,28,34.0,microM,9,"7,12-Dimethylbenz[a]anthracene",12-OH-DMBA as product,,"150-microL reactions contained 100 mM KPi, pH 7.5, purified synthetically encoded CYP2S1, 1mM of CHP, and various concentration of substrates. The reactions were carried out at 37 degC for 5 min before being stopped with 150 microL of acetonitrile (2% acetic acid)",,,,,,human,mbds0010,,2013-12-09 20:58:18
mbbd000146083,mbcd0028165,mben000011,mbrf0002612,,=,,,substrate,147,26.0,nmol product / nmol CYP2S1 / min,,"7,12-Dimethylbenz[a]anthracene",12-OH-DMBA as product,,"150-microL reactions contained 100 mM KPi, pH 7.5, purified synthetically encoded CYP2S1, 1mM of CHP, and various concentration of substrates. The reactions were carried out at 37 degC for 5 min before being stopped with 150 microL of acetonitrile (2% acetic acid)",,,,,,human,mbds0010,,2013-12-09 20:58:18
mbbd000146084,mbcd0029321,mben000011,mbrf0002612,,=,,,substrate,28,22.6,microM,6,"9,10-Dihydro-benzo[a]pyrene","9,10H2-BaP-7,8-dihydrodiol as product",,"150-microL reactions contained 100 mM KPi, pH 7.5, purified synthetically encoded CYP2S1, 1mM of CHP, and various concentration of substrates. The reactions were carried out at 37 degC for 5 min before being stopped with 150 microL of acetonitrile (2% acetic acid)",,,,,,human,mbds0010,,2013-12-09 20:58:17
mbbd000146085,mbcd0029321,mben000011,mbrf0002612,,=,,,substrate,147,1.6,nmol product / nmol CYP2S1 / min,,"9,10-Dihydro-benzo[a]pyrene","9,10H2-BaP-7,8-dihydrodiol as product",,"150-microL reactions contained 100 mM KPi, pH 7.5, purified synthetically encoded CYP2S1, 1mM of CHP, and various concentration of substrates. The reactions were carried out at 37 degC for 5 min before being stopped with 150 microL of acetonitrile (2% acetic acid)",,,,,,human,mbds0010,,2013-12-09 20:58:17
mbbd000146086,mbcd0029316,mben000011,mbrf0002612,,=,,,substrate,28,12.43,microM,2,"Benzo[a]pyrene-trans-7,8-dihydrodiol","r7,t8,t9,c10-tertol as product",,"150-microL reactions contained 100 mM KPi, pH 7.5, purified synthetically encoded CYP2S1, 1mM of CHP, and various concentration of substrates. The reactions were carried out at 37 degC for 5 min before being stopped with 150 microL of acetonitrile (2% acetic acid)",,,,,,human,mbds0010,,2013-12-09 20:58:18
mbbd000146087,mbcd0029316,mben000011,mbrf0002612,,=,,,substrate,147,2.3,nmol product / nmol CYP2S1 / min,,"Benzo[a]pyrene-trans-7,8-dihydrodiol","r7,t8,t9,c10-tertol as product",,"150-microL reactions contained 100 mM KPi, pH 7.5, purified synthetically encoded CYP2S1, 1mM of CHP, and various concentration of substrates. The reactions were carried out at 37 degC for 5 min before being stopped with 150 microL of acetonitrile (2% acetic acid)",,,,,,human,mbds0010,,2013-12-09 20:58:17
mbbd000146088,mbcd0029932,mben000011,mbrf0002612,,=,,,substrate,28,266.0,microM,40,Aflatoxin B1,,,"150-microL reactions contained 100 mM KPi, pH 7.5, purified synthetically encoded CYP2S1, 1mM of CHP, and various concentration of substrates. The reactions were carried out at 37 degC for 5 min before being stopped with 150 microL of acetonitrile (2% acetic acid)",,,,,,human,mbds0010,,2013-12-09 20:58:19
mbbd000146089,mbcd0026045,mben000011,mbrf0002612,,=,,,substrate,28,20.9,microM,0.9,all-trans-Retinoic acid,4-OH-retinoic acid as product,,"150-microL reactions contained 100 mM KPi, pH 7.5, purified synthetically encoded CYP2S1, 1mM of CHP, and various concentration of substrates. The reactions were carried out at 37 degC for 5 min before being stopped with 150 microL of acetonitrile (2% acetic acid)",,,,,,human,mbds0010,,2013-12-09 20:58:19
mbbd000146090,mbcd0003001,mben000011,mbrf0002612,,,,,non-substrate,,,,,Testosterone,No activity,,"150-microL reactions contained 100 mM KPi, pH 7.5, purified synthetically encoded CYP2S1, 1mM of CHP, and various concentration of substrates. The reactions were carried out at 37 degC for 5 min before being stopped with 150 microL of acetonitrile (2% acetic acid)",,,,,,human,mbds0010,,2013-12-09 20:13:21
mbbd000146091,mbcd0029184,mben000011,mbrf0002612,,,,,non-substrate,,,,,Coumarin,No activity,,"150-microL reactions contained 100 mM KPi, pH 7.5, purified synthetically encoded CYP2S1, 1mM of CHP, and various concentration of substrates. The reactions were carried out at 37 degC for 5 min before being stopped with 150 microL of acetonitrile (2% acetic acid)",,,,,,human,mbds0010,,2013-12-09 20:13:23
mbbd000146092,mbcd0029323,mben000011,mbrf0002613,,=,,,substrate,28,0.27,microM,0.07,PGG2,See Fig.5,,"100-microL reaction mixture containing 100 mM potassium phosphate buffer (Kpi), pH 7.5, and 0.25 microM CYP2S1 was incubated with 133 microM PGG2. Incubations containing heat-treated CYP2S1 (20 min at 85C). The reactions with PGG2 were incubated at 37 degC for 15 min",,,10,microM,,human,mbds0010,,2013-12-09 20:13:19
mbbd000146093,mbcd0029323,mben000011,mbrf0002613,,=,,,substrate,147,8.0,min-1,,PGG2,See Fig.5,,"100-microL reaction mixture containing 100 mM potassium phosphate buffer (Kpi), pH 7.5, and 0.25 microM CYP2S1 was incubated with 133 microM PGG2. Incubations containing heat-treated CYP2S1 (20 min at 85C). The reactions with PGG2 were incubated at 37 degC for 15 min",,,,,,human,mbds0010,,2013-12-09 20:03:47
mbbd000146094,mbcd0029326,mben000011,mbrf0002613,,=,,,substrate,28,11.7,microM,3.8,PGH2,See Fig.5,,"100-microL reaction mixture containing 100 mM potassium phosphate buffer (Kpi), pH 7.5, and 0.25 microM CYP2S1 was incubated with 50 microM PGH2. Incubations containing heat-treated CYP2S1 (20 min at 85C). The reactions with PGG2 were incubated at 37 degC for 5 min",,,,,,human,mbds0010,,2013-12-09 20:13:18
mbbd000146095,mbcd0029326,mben000011,mbrf0002613,,=,,,substrate,147,1.59,min-1,0.04,PGH2,See Fig.5,,"100-microL reaction mixture containing 100 mM potassium phosphate buffer (Kpi), pH 7.5, and 0.25 microM CYP2S1 was incubated with 50 microM PGH2. Incubations containing heat-treated CYP2S1 (20 min at 85C). The reactions with PGG2 were incubated at 37 degC for 5 min",,,,,,human,mbds0010,,2013-12-09 20:13:19
mbbd000146096,mbcd0029324,mben000011,mbrf0002613,,,,,substrate,,,,,15-oxo-PGG2,See Fig.5,,Onward metabolism of PGG2,,,,,,human,mbds0010,,2012-08-31 21:11:01
mbbd000146097,mbcd0031464,mben000011,mbrf0002613,,,,,substrate,,,,,12-HpHT,See Fig.5,,Onward metabolism of PGG2,,,,,,human,mbds0010,,2012-08-31 21:11:01
mbbd000146098,mbcd0029317,mben000011,mbrf0002613,,=,,,substrate,147,16.7,min-1,0.3,5-HpETE,See Table 2,,50 microM and five progressive 1:3 dilutions of each substrate were incubated in 50-microL reaction mixtures containing 100 nM CYP2S1. The reactions were terminated after 120 s at room temperature by the addition of 50 microL of ice-cold acetonitrile containing 2% acetic acid,,,,,,human,mbds0010,,2013-12-09 20:13:23
mbbd000146099,mbcd0029319,mben000011,mbrf0002613,,=,,,substrate,147,16.9,min-1,0.8,15-HpETE,See Table 2,,50 microM and five progressive 1:3 dilutions of each substrate were incubated in 50-microL reaction mixtures containing 100 nM CYP2S1. The reactions were terminated after 120 s at room temperature by the addition of 50 microL of ice-cold acetonitrile containing 2% acetic acid,,,,,,human,mbds0010,,2013-12-09 20:13:23
mbbd000146100,mbcd0029318,mben000011,mbrf0002613,,=,,,substrate,147,11.5,min-1,0.9,12-HpETE,See Table 2,,50 microM and five progressive 1:3 dilutions of each substrate were incubated in 50-microL reaction mixtures containing 100 nM CYP2S1. The reactions were terminated after 120 s at room temperature by the addition of 50 microL of ice-cold acetonitrile containing 2% acetic acid,,,,,,human,mbds0010,,2013-12-09 21:01:10
mbbd000146101,mbcd0029320,mben000011,mbrf0002613,,=,,,substrate,147,20.2,min-1,0.9,13-HpODE,See Table 2,,50 microM and five progressive 1:3 dilutions of each substrate were incubated in 50-microL reaction mixtures containing 100 nM CYP2S1. The reactions were terminated after 120 s at room temperature by the addition of 50 microL of ice-cold acetonitrile containing 2% acetic acid,,,,,,human,mbds0010,,2013-12-09 21:01:10
mbbd000146102,mbcd0029317,mben000011,mbrf0002613,,=,,,substrate,28,18.0,microM,3.5,5-HpETE,See Table 3,,50 microM and five progressive 1:3 dilutions of each substrate were incubated in 50-microL reaction mixtures containing 100 nM CYP2S1. The reactions were terminated after 120 s at room temperature by the addition of 50 microL of ice-cold acetonitrile containing 2% acetic acid,,,,,,human,mbds0010,,2013-12-09 21:01:10
mbbd000146103,mbcd0029317,mben000011,mbrf0002613,,=,,,substrate,45,0.93,microM-1 min-1,,5-HpETE,See Table 3,,50 microM and five progressive 1:3 dilutions of each substrate were incubated in 50-microL reaction mixtures containing 100 nM CYP2S1. The reactions were terminated after 120 s at room temperature by the addition of 50 microL of ice-cold acetonitrile containing 2% acetic acid,,,,,,human,mbds0010,,2013-12-09 21:01:12
mbbd000146104,mbcd0029318,mben000011,mbrf0002613,,=,,,substrate,28,38.8,microM,5.5,12-HpETE,See Table 3,,50 microM and five progressive 1:3 dilutions of each substrate were incubated in 50-microL reaction mixtures containing 100 nM CYP2S1. The reactions were terminated after 120 s at room temperature by the addition of 50 microL of ice-cold acetonitrile containing 2% acetic acid,,,,,,human,mbds0010,,2013-12-09 21:01:09
mbbd000146105,mbcd0029318,mben000011,mbrf0002613,,=,,,substrate,45,0.296,microM-1 min-1,,12-HpETE,See Table 3,,50 microM and five progressive 1:3 dilutions of each substrate were incubated in 50-microL reaction mixtures containing 100 nM CYP2S1. The reactions were terminated after 120 s at room temperature by the addition of 50 microL of ice-cold acetonitrile containing 2% acetic acid,,,,,,human,mbds0010,,2013-12-09 21:01:09
mbbd000146106,mbcd0029319,mben000011,mbrf0002613,,=,,,substrate,28,42.0,microM,4.2,15-HpETE,See Table 3,,50 microM and five progressive 1:3 dilutions of each substrate were incubated in 50-microL reaction mixtures containing 100 nM CYP2S1. The reactions were terminated after 120 s at room temperature by the addition of 50 microL of ice-cold acetonitrile containing 2% acetic acid,,,,,,human,mbds0010,,2013-12-09 21:01:09
mbbd000146107,mbcd0029319,mben000011,mbrf0002613,,=,,,substrate,45,0.401,microM-1 min-1,,15-HpETE,See Table 3,,50 microM and five progressive 1:3 dilutions of each substrate were incubated in 50-microL reaction mixtures containing 100 nM CYP2S1. The reactions were terminated after 120 s at room temperature by the addition of 50 microL of ice-cold acetonitrile containing 2% acetic acid,,,,,,human,mbds0010,,2013-12-09 21:01:09
mbbd000146108,mbcd0029320,mben000011,mbrf0002613,,=,,,substrate,28,14.1,microM,1.5,13-HpODE,See Table 3,,50 microM and five progressive 1:3 dilutions of each substrate were incubated in 50-microL reaction mixtures containing 100 nM CYP2S1. The reactions were terminated after 120 s at room temperature by the addition of 50 microL of ice-cold acetonitrile containing 2% acetic acid,,,,,,human,mbds0010,,2013-12-09 21:01:14
mbbd000146109,mbcd0029320,mben000011,mbrf0002613,,=,,,substrate,45,1.43,microM-1 min-1,,13-HpODE,See Table 3,,50 microM and five progressive 1:3 dilutions of each substrate were incubated in 50-microL reaction mixtures containing 100 nM CYP2S1. The reactions were terminated after 120 s at room temperature by the addition of 50 microL of ice-cold acetonitrile containing 2% acetic acid,,,,,,human,mbds0010,,2013-12-09 21:01:14
mbbd000146110,mbcd0029314,mben000011,mbrf0002614,,=,,,substrate,148,18.2,min-1,,AQ4N,See P.945,,"Anerobic incubations were carried out under a nitrogen atmosphere inside of a glovebox; Enzyme reaction mixtures typically contained 0.1 microM P450 2S1, 0.2 microM NADPH-P450 reductase, 160 microM L-alpha-1,2-dilauoryl-sn-glycero-3-phosphocholine, 1 mM desferoxamine, 100 mM potassium phosphate buffer (pH 7.4), and 200 microM AQ4N (Nishida et al., 2010). After preincubation for 5 min, the reactions were started by the addition of an NADPH-generating system (Guengerich and Bartleson, 2007), and aliquots were terminated by the addition of three volumes of CH3OH (with 5 microM mitoxantrone as an internal standard) at 0, 1, 2, 3, 4, 5, and 6 min",,,,,,human,mbds0010,,2013-12-09 20:15:47
mbbd000146111,mbcd0029327,mben000011,mbrf0002615,,,,,inducer,,,,,5F-203,Graphical data only; see P.1986-1987; more data on P.1988,,MTT cell viability assay,,,,,,human,mbds0010,,2012-08-31 21:11:01
mbbd000146113,mbcd0029328,mben000011,mbrf0002615,,,,,inducer,,,,,GW-610,Graphical data only; see P.1986-1987; more data on P.1988,,MTT cell viability assay,,,,,,human,mbds0010,,2012-08-31 21:11:01
mbbd000146115,mbcd0001052,mben000011,mbrf0002616,,,,,repressor,,,,,beclomethasone,Treated the cells with 100 nM of corticosteroid,,,,,,,,human,mbds0010,,2012-08-31 21:11:01
mbbd000146116,mbcd0000926,mben000011,mbrf0002616,,,,,repressor,,,,,flunisolide,Treated the cells with 100 nM of corticosteroid,,,,,,,,human,mbds0010,,2012-08-31 21:11:01
mbbd000146117,mbcd0002635,mben000011,mbrf0002616,,,,,repressor,,,,,hydrocortisone,Treated the cells with 100 nM of corticosteroid,,,,,,,,human,mbds0010,,2012-08-31 21:11:01
mbbd000146118,mbcd0003096,mben000011,mbrf0002616,,,,,repressor,,,,,prednisolone,Treated the cells with 1 microM of corticosteroid,,,,,,,,human,mbds0010,,2012-08-31 21:11:01
mbbd000146119,mbcd0029329,mben000011,mbrf0002616,,,,,repressor,,,,,triamcinolone acetonide,Treated the cells with 100 nM of corticosteroid,,,,,,,,human,mbds0010,,2012-08-31 21:11:01
mbbd000146120,mbcd0002959,mben000011,mbrf0002616,,,,,repressor,,,,,DEX,dependent on the glucocorticoid receptor; does not decrease half-life; mediated by histone deacetylation,,,,,,,,human,mbds0010,,2012-08-31 21:11:01
mbbd000146121,mbcd0029330,mben000011,mbrf0002617,,,,,repressor,,,,,lycopene,Down-regulation of CYP2S1 observed,,,,,,,,human,mbds0010,,2012-08-31 21:11:01
mbbd000146122,mbcd0003001,mben000012,mbrf0002618,,=,,,substrate,148,12.91,nmol/flask/h,2.88,Testosterone,,,Testosterone was added at final concentration of 100 mM 1h before cells were harvested and the amount of 6beta-hydroxytestosterone in the media was evaluated using high performance liquid chromatography,,,,,,human,mbds0010,,2013-12-09 21:00:47
mbbd000146123,mbcd0025602,mben000012,mbrf0002619,,=,,,substrate,1,22.0,pmol/min/mg microsomal protein,,7-ethoxycoumarin,,,"Recombinant vaccinia viruses containing individual human P450 cDNAs were constructed and then used to infect human Hep G2 hepatoma cells at a multiplicity of infection of 10. Cells were harvested 24 h after infection, and then washed twice with 50 mM NaP, buffer, pH 7.4,0.14 M NaCl. Cells were stored at -8OC until disrupted by sonication followed by microsome preparation by differential centrifugation",,,,,,human,mbds0010,,2013-12-09 21:00:47
mbbd000146124,mbcd0029331,mben000012,mbrf0002619,,=,,,substrate,1,8.0,pmol/min/mg microsomal protein,,7-benzyloxyresorufin,,,"Recombinant vaccinia viruses containing individual human P450 cDNAs were constructed and then used to infect human Hep G2 hepatoma cells at a multiplicity of infection of 10. Cells were harvested 24 h after infection, and then washed twice with 50 mM NaP, buffer, pH 7.4,0.14 M NaCl. Cells were stored at -8OC until disrupted by sonication followed by microsome preparation by differential centrifugation",,,,,,human,mbds0010,,2013-12-09 21:00:47
mbbd000146125,mbcd0029184,mben000012,mbrf0002619,,<,,,non-substrate,1,3.0,pmol/min/mg microsomal protein,,Coumarin,,,"Recombinant vaccinia viruses containing individual human P450 cDNAs were constructed and then used to infect human Hep G2 hepatoma cells at a multiplicity of infection of 10. Cells were harvested 24 h after infection, and then washed twice with 50 mM NaP, buffer, pH 7.4,0.14 M NaCl. Cells were stored at -8OC until disrupted by sonication followed by microsome preparation by differential centrifugation",,,,,,human,mbds0010,,2013-12-09 21:00:47
mbbd000146126,mbcd0003001,mben000012,mbrf0002619,,=,,,substrate,1,190.0,pmol/min/mg,,Testosterone,,,"TLC method is used. Hep G2 microsomes were incubated with 10nmol of [C14]-labeled testosterone (58-60 mCi/mmol) in 0.1M Hepes buffer, pH 7.4, containing 1 mM NADPH for 20min at 37C. Reaction mixtures were extracted with ethyl acetate and chromatographed on TLC plates, and were exposed to X-ray film overnight and individual metabolites quantitated by liquid scintillation counting",,,,,,human,mbds0010,,2013-12-09 20:55:05
mbbd000146127,mbcd0003889,mben000012,mbrf0002619,,=,,,substrate,1,205.0,pmol/min/mg,,Androstenedione,,,"TLC method is used. Hep G2 microsomes were incubated with 10nmol of [C14]-labeled androstenedione (58-60 mCi/mmol) in 0.1M Hepes buffer, pH 7.4, containing 1 mM NADPH for 20min at 37C. Reaction mixtures were extracted with ethyl acetate and chromatographed on TLC plates, and were exposed to X-ray film overnight and individual metabolites quantitated by liquid scintillation counting",,,,,,human,mbds0010,,2013-12-09 19:56:17
mbbd000146128,mbcd0001892,mben000012,mbrf0002619,,=,,,substrate,1,195.0,pmol/min/mg,,Progesterone,,,"TLC method is used. Hep G2 microsomes were incubated with 10nmol of [C14]-labeled progesterone (58-60 mCi/mmol) in 0.1M Hepes buffer, pH 7.4, containing 1 mM NADPH for 20min at 37C. Reaction mixtures were extracted with ethyl acetate and chromatographed on TLC plates, and were exposed to X-ray film overnight and individual metabolites quantitated by liquid scintillation counting",,,,,,human,mbds0010,,2013-12-09 20:55:02
mbbd000146129,mbcd0003001,mben000012,mbrf0002619,,<=,,,substrate,1,10.0,pmol/min/mg,,Testosterone,,,"TLC method is used. Hep G2 microsomes were incubated with 10nmol of [C14]-labeled testosterone (58-60 mCi/mmol) in 0.1M Hepes buffer, pH 7.4, containing 1 mM NADPH for 20min at 37C. Reaction mixtures were extracted with ethyl acetate and chromatographed on TLC plates, and were exposed to X-ray film overnight and individual metabolites quantitated by liquid scintillation counting",,,,,,human,mbds0010,,2013-12-09 20:55:02
mbbd000146130,mbcd0003889,mben000012,mbrf0002619,,=,,,substrate,1,21.0,pmol/min/mg,,Androstenedione,,,"TLC method is used. Hep G2 microsomes were incubated with 10nmol of [C14]-labeled androstenedione (58-60 mCi/mmol) in 0.1M Hepes buffer, pH 7.4, containing 1 mM NADPH for 20min at 37C. Reaction mixtures were extracted with ethyl acetate and chromatographed on TLC plates, and were exposed to X-ray film overnight and individual metabolites quantitated by liquid scintillation counting",,,,,,human,mbds0010,,2013-12-09 20:51:24
mbbd000146131,mbcd0003001,mben000012,mbrf0002619,,=,,,substrate,28,152.0,microM,,Testosterone,6beta-hydroxylation,,"Hep G2 cells were lysed with a probe sonicator, and centrifuged at 450000g for 10min. The pellet was resuspended in 50mM KPi, pH7.4. Incubation mixtures (1ml, 50mM KPi, pH7.4) contained about 20 pmol P450. Substrate was introduced in 5 microl methanol and reactions were initiated by addition of 0.83 mg NADPH, and were terminated after 10min by addition of 2.5 ml dichloromethane. 11alpha-hydroxyprogesterone was added as internal standard and 1 micromol progesterone was added to prevent nonspecific binding",,,,,,human,mbds0010,,2013-12-09 20:51:24
mbbd000146132,mbcd0003001,mben000012,mbrf0002619,,=,,,substrate,22,24.0,nmol hydroxysteroid/nmol P450/min,,Testosterone,6beta-hydroxylation,,"Hep G2 cells were lysed with a probe sonicator, and centrifuged at 450000g for 10min. The pellet was resuspended in 50mM KPi, pH7.4. Incubation mixtures (1ml, 50mM KPi, pH7.4) contained about 20 pmol P450. Substrate was introduced in 5 microl methanol and reactions were initiated by addition of 0.83 mg NADPH, and were terminated after 10min by addition of 2.5 ml dichloromethane. 11alpha-hydroxyprogesterone was added as internal standard and 1 micromol progesterone was added to prevent nonspecific binding",,,,,,human,mbds0010,,2013-12-09 20:08:09
mbbd000146133,mbcd0029300,mben000012,mbrf0002620,,,,,substrate,,,,,3MI,only graphical data available,,,,,,,weak substrate,human,mbds0010,,2013-11-24 22:15:04
mbbd000146134,mbcd0029332,mben000012,mbrf0002621,,=,,,substrate,148,13.3,nmol per dish per 2h,1,Styrene,,,"Hep G2 cells, cultured in dishes containing DMEM and 10% fetal calf serum, were infected with vaccinia virus encoding one of P450 isozymes, and styrene was directly added to the dishes",,,,,,human,mbds0010,,2013-12-09 20:51:24
mbbd000146135,mbcd0029332,mben000012,mbrf0002621,,=,,,substrate,148,0.025,nmol (mg protein)-1 min-1,,Styrene,,,"Hep G2 cells expressing P450 isozyme were destroyed by sonication, and the microsomal fraction was used as a source of enzyme",,,,,,human,mbds0010,,2013-12-09 20:51:24
mbbd000146136,mbcd0029334,mben000012,mbrf0002622,,<,,,non-substrate,1,30.0,pmol/mg of membrane protein/min,,12-OH LA,human CYP4B1 (Ser),,,,,,,,human,mbds0010,,2012-08-31 21:11:01
mbbd000146137,mbcd0029333,mben000012,mbrf0002622,,<,,,non-substrate,1,30.0,pmol/mg of membrane protein/min,,11-OH LA,human CYP4B1 (Ser),,,,,,,,human,mbds0010,,2012-08-31 21:11:01
mbbd000146138,mbcd0029334,mben000012,mbrf0002622,,=,,,substrate,1,904.0,pmol/mg of membrane protein/min,20,12-OH LA,human CYP4B1 (Pro),,,,,,,,human,mbds0010,,2012-08-31 21:11:01
mbbd000146139,mbcd0029333,mben000012,mbrf0002622,,=,,,substrate,1,260.0,pmol/mg of membrane protein/min,8,11-OH LA,human CYP4B1 (Pro),,,,,,,,human,mbds0010,,2012-08-31 21:11:01
mbbd000146140,mbcd0025568,mben000012,mbrf0002622,,=,,,substrate,1,20.4,nmol/nmol/min,,dodecanoic acid,,,"Purified human CYP4B1(Pro) (100 pmol) was reconstituted with P450 reductase (200 pmol), dilaurylphosphatidylcholine (20 mg), and cytochrome b5 (100 pmol), and the rates of formation of the omega-hydroxy metabolites of substrates were measured by GC/FID",,,,,,human,mbds0010,,2013-12-09 19:54:49
mbbd000146141,mbcd0029335,mben000012,mbrf0002622,,=,,,substrate,1,11.6,nmol/nmol/min,,decanoic acid,,,"Purified human CYP4B1(Pro) (100 pmol) was reconstituted with P450 reductase (200 pmol), dilaurylphosphatidylcholine (20 mg), and cytochrome b5 (100 pmol), and the rates of formation of the omega-hydroxy metabolites of substrates were measured by GC/FID",,,,,,human,mbds0010,,2013-12-09 19:54:50
mbbd000146142,mbcd0029336,mben000012,mbrf0002622,,=,,,substrate,1,6.5,nmol/nmol/min,,nonanoic acid,,,"Purified human CYP4B1(Pro) (100 pmol) was reconstituted with P450 reductase (200 pmol), dilaurylphosphatidylcholine (20 mg), and cytochrome b5 (100 pmol), and the rates of formation of the omega-hydroxy metabolites of substrates were measured by GC/FID",,,,,,human,mbds0010,,2013-12-09 19:54:52
mbbd000146143,mbcd0029337,mben000012,mbrf0002622,,<,,,substrate,1,2.5,nmol/nmol/min,,octanoic acid,,,"Purified human CYP4B1(Pro) (100 pmol) was reconstituted with P450 reductase (200 pmol), dilaurylphosphatidylcholine (20 mg), and cytochrome b5 (100 pmol), and the rates of formation of the omega-hydroxy metabolites of substrates were measured by GC/FID",,,,,,human,mbds0010,,2013-12-09 19:54:53
mbbd000146144,mbcd0003001,mben000012,mbrf0002622,,,,,substrate,,,,,Testosterone,only graphical data available,,"human CYP4B1(Pro) membranes (100 pmol, 0.42 mg) were first combined with cytochrome P450 reductase (200 pmol), and then cytochrome b5 (100 pmol) was added. Reaction mixtures were subsequently diluted to 0.9 mL with 0.1 M potassium phosphate buffer, pH 7.4, containing 0.5 mmol of testosterone and preincubated for a final 5 min at 37 degC prior to initiation of the reaction with 10 mM NADPH (0.1 mL). Reactions were terminated after 20 min by the addition of 5 mL of dichloromethane, and the formation of 6?-hydroxytestosterone was determined by HPLC",,,,,,human,mbds0010,,2013-12-09 19:54:53
mbbd000146145,mbcd0025568,mben000012,mbrf0002623,,,,,substrate,,,,,Lauric Acid,Only graphical data available; Lauric acid omega-hydroxylation of transgenic mice was higher than that of control mice by 25%,,transgenic mouse expressing human CYP4B1 in the liver,,,,,,human,mbds0010,,2013-11-24 02:54:54
mbbd000146146,mbcd0003001,mben000012,mbrf0002623,,,,,non-substrate,,,,,Testosterone,The testosterone hydroxylation activity of transgenic mice was not different from that of control mice (data not shown).,,,,,,,,human,mbds0010,,2012-08-31 21:11:01
mbbd000146149,mbcd0026806,mben000003,mbrf0000934,,,,,non-substrate,,,,,BILR 355,,,Activity of human recombinant CYP2D6,,,,,,human,mbds0010,,2013-05-16 21:02:06
mbbd000146150,mbcd0026806,mben000005,mbrf0000934,,,,,non-substrate,,,,,BILR 355,,,Activity of human recombinant CYP1A2,,,,,,human,mbds0010,,2013-05-16 21:02:06
mbbd000146151,mbcd0026806,mben000004,mbrf0000934,,,,,non-substrate,,,,,BILR 355,,,Activity of human recombinant CYP2C9,,,,,,human,mbds0010,,2013-05-16 21:02:06
mbbd000146152,mbcd0026806,mben000006,mbrf0000934,,,,,non-substrate,,,,,BILR 355,,,Activity of human recombinant CYP2C19,,,,,,human,mbds0010,,2013-05-16 21:02:06
mbbd000146153,mbcd0011356,mben000001,mbrf0000479,,=,,,substrate,22,1600.0,pmol nabumetone (nmol protein)-1 min-1,780-2400,2; nabumetone hydroxyimine,,A,Conversion of 2 (100 microM) to nabumetone by CYP3A4 (5 pmol),,,,,,human,mbds0001,v12,2013-11-20 20:06:19
mbbd000146154,mbcd0011356,mben000005,mbrf0000479,,=,,,substrate,67,3.7,microM-1 min-1,,2; nabumetone hydroxyimine,,A,Conversion of 2 (100 microM) to nabumetone by CYP1A2 (5 pmol),,,,,,human,mbds0001,v12,2013-11-20 20:06:19
mbbd000146155,mbcd0011356,mben000006,mbrf0000479,,=,,,substrate,67,6.3,microM-1 min-1,,2; nabumetone hydroxyimine,,A,Conversion of 2 (100 microM) to nabumetone by CYP2C19 (5 pmol),,,,,,human,mbds0001,v12,2013-11-20 20:06:19
mbbd000146156,mbcd0011356,mben000003,mbrf0000479,,=,,,substrate,67,9.7,microM-1 min-1,,2; nabumetone hydroxyimine,,A,Conversion of 2 (100 microM) to nabumetone by CYP2D6 (5 pmol),,,,,,human,mbds0001,v12,2013-11-20 20:06:19
mbbd000146157,mbcd0011356,mben000002,mbrf0000479,,=,,,substrate,67,11.0,microM-1 min-1,,2; nabumetone hydroxyimine,,A,Conversion of 2 (100 microM) to nabumetone by CYP2E1 (5 pmol),,,,,,human,mbds0001,v12,2013-11-20 20:06:19
mbbd000146158,mbcd0011356,mben000001,mbrf0000479,,=,,,substrate,67,8.0,microM-1 min-1,,2; nabumetone hydroxyimine,,A,Conversion of 2 (100 microM) to nabumetone by CYP3A4 (5 pmol),,,,,,human,mbds0001,v12,2013-11-20 20:06:19
mbbd000146159,mbcd0031246,mbtp000010,mbrf0002628,,,,,non-substrate,,,,,1,,,stably transfected ASBT-MDCK cells,MDCK,,,,,human,mbds0010,,2013-05-30 18:22:36
mbbd000146160,mbcd0031247,mbtp000010,mbrf0002628,,,,,non-substrate,,,,,5,,,stably transfected ASBT-MDCK cells,MDCK,,,,,human,mbds0010,,2013-05-30 18:22:36
mbbd000146161,mbcd0031248,mbtp000010,mbrf0002628,,,,,non-substrate,,,,,6,,,stably transfected ASBT-MDCK cells,MDCK,,,,,human,mbds0010,,2013-05-30 18:22:36
mbbd000146162,mbcd0031249,mbtp000010,mbrf0002628,,,,,non-substrate,,,,,9,,,stably transfected ASBT-MDCK cells,MDCK,,,,,human,mbds0010,,2013-05-30 18:22:36
mbbd000146163,mbcd0031250,mbtp000010,mbrf0002628,,=,,,substrate,28,8.49,microM,1.34,10,,,stably transfected ASBT-MDCK cells,MDCK,,,,,human,mbds0010,,2013-05-30 18:22:36
mbbd000146164,mbcd0031251,mbtp000010,mbrf0002628,,=,,,substrate,28,34.0,microM,7.64,12,,,stably transfected ASBT-MDCK cells,MDCK,,,,,human,mbds0010,,2013-05-30 18:22:36
mbbd000146165,mbcd0031250,mbtp000010,mbrf0002628,,=,,,substrate,22,0.000242,nmol s-1 cm-2,,10,,,stably transfected ASBT-MDCK cells,MDCK,,,,,human,mbds0010,,2013-05-30 18:22:36
mbbd000146166,mbcd0031251,mbtp000010,mbrf0002628,,=,,,substrate,22,9.1e-05,nmol s-1 cm-2,,12,,,stably transfected ASBT-MDCK cells,MDCK,,,,,human,mbds0010,,2013-05-30 18:22:36
mbbd000146167,mbcd0031252,mbtp000010,mbrf0002628,,,,,non-substrate,,,,,14,,,stably transfected ASBT-MDCK cells,MDCK,,,,,human,mbds0010,,2013-05-30 18:22:36
mbbd000146168,mbcd0031253,mbtp000010,mbrf0002628,,,,,non-substrate,,,,,8,,,stably transfected ASBT-MDCK cells,MDCK,,,,,human,mbds0010,,2013-05-30 18:22:36
mbbd000146178,mbcd0031236,mbtp000010,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146179,mbcd0031235,mbtp000010,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146180,mbcd0031234,mbtp000010,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146181,mbcd0031233,mbtp000010,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146182,mbcd0031232,mbtp000010,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146183,mbcd0031231,mbtp000010,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146184,mbcd0031230,mbtp000010,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146185,mbcd0031229,mbtp000010,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146186,mbcd0031228,mbtp000010,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146187,mbcd0031227,mbtp000010,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146188,mbcd0031226,mbtp000010,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146189,mbcd0031225,mbtp000010,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146190,mbcd0031224,mbtp000010,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146191,mbcd0031223,mbtp000010,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146192,mbcd0031222,mbtp000010,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146193,mbcd0031221,mbtp000010,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146194,mbcd0031220,mbtp000010,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146195,mbcd0031219,mbtp000010,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146196,mbcd0031218,mbtp000010,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146197,mbcd0031217,mbtp000010,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146198,mbcd0031216,mbtp000010,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146199,mbcd0031215,mbtp000010,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146200,mbcd0031212,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146201,mbcd0031211,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146202,mbcd0031210,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146203,mbcd0031209,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146204,mbcd0031208,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146205,mbcd0031207,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146208,mbcd0031205,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146209,mbcd0031204,mbtp000001,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146213,mbcd0031199,mbtp000005,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146216,mbcd0031195,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146223,mbcd0031188,mbtp000001,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146224,mbcd0031186,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146228,mbcd0031179,mbtp000001,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146229,mbcd0031177,mbtp000002,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146231,mbcd0031175,mbtp000009,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146232,mbcd0031174,mbtp000010,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146233,mbcd0031173,mbtp000010,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146234,mbcd0031172,mbtp000010,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146235,mbcd0031171,mbtp000010,mbrf0002330,,=,,,non-substrate,23,0.216,*10^6 cm s-1,0.012,28,,,hASBT-MDCK cells; uptake,MDCK,,0-5000,microM,,human,mbds0010,,2013-11-20 21:27:57
mbbd000146236,mbcd0031170,mbtp000010,mbrf0002330,,=,,,non-substrate,23,0.104,*10^6 cm s-1,0.005,29,,,hASBT-MDCK cells; uptake,MDCK,,0-5000,microM,,human,mbds0010,,2013-11-20 21:27:57
mbbd000146237,mbcd0031169,mbtp000001,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146241,mbcd0031140,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146242,mbcd0031132,mbtp000007,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146243,mbcd0031130,mbtp000005,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146244,mbcd0031130,mbtp000008,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146245,mbcd0031129,mbtp000005,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146246,mbcd0031129,mbtp000008,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146247,mbcd0031128,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146249,mbcd0031107,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146250,mbcd0031106,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146251,mbcd0031105,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146252,mbcd0031103,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146253,mbcd0031102,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146254,mbcd0031102,mbtp000007,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146255,mbcd0031101,mbtp000005,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146256,mbcd0031101,mbtp000025,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146257,mbcd0031100,mbtp000001,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146258,mbcd0031099,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146260,mbcd0030543,mbtp000009,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146262,mbcd0030404,mbtp000005,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146263,mbcd0030270,mbtp000002,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146265,mbcd0030261,mbtp000001,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146266,mbcd0030261,mbtp000005,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146268,mbcd0030172,mbtp000002,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146269,mbcd0030172,mbtp000001,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146270,mbcd0030083,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146271,mbcd0030066,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146272,mbcd0030066,mbtp000005,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146273,mbcd0029986,mbtp000002,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146274,mbcd0029983,mbtp000002,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146277,mbcd0029982,mbtp000002,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146278,mbcd0029976,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146279,mbcd0029950,mbtp000002,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146280,mbcd0029946,mbtp000002,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146281,mbcd0029944,mbtp000002,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146282,mbcd0029943,mbtp000002,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146283,mbcd0029940,mbtp000002,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146284,mbcd0029939,mbtp000002,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146285,mbcd0029938,mbtp000002,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146286,mbcd0029929,mbtp000001,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146287,mbcd0029918,mbtp000001,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146288,mbcd0029891,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146289,mbcd0029889,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146291,mbcd0029849,mbtp000005,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146292,mbcd0029754,mbtp000005,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146293,mbcd0029754,mbtp000008,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146294,mbcd0029730,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146295,mbcd0029455,mbtp000002,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146297,mbcd0029425,mbtp000025,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146298,mbcd0029406,mbtp000002,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146299,mbcd0029387,mbtp000001,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146300,mbcd0029386,mbtp000001,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146301,mbcd0029351,mbtp000002,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146302,mbcd0029351,mbtp000001,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146303,mbcd0029347,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146304,mbcd0029347,mbtp000008,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146305,mbcd0029347,mbtp000025,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146306,mbcd0029329,mbtp000002,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146310,mbcd0029230,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146314,mbcd0029142,mbtp000001,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146315,mbcd0029142,mbtp000025,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146316,mbcd0029125,mbtp000005,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146318,mbcd0029079,mbtp000005,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146319,mbcd0029064,mbtp000009,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146327,mbcd0028570,mbtp000005,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146328,mbcd0028512,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146329,mbcd0028309,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146331,mbcd0028095,mbtp000001,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146333,mbcd0027925,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146337,mbcd0027251,mbtp000001,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146339,mbcd0027248,mbtp000005,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146341,mbcd0026905,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146342,mbcd0026840,mbtp000001,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146347,mbcd0026093,mbtp000005,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146348,mbcd0026055,mbtp000002,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146349,mbcd0026044,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146355,mbcd0023817,mbtp000005,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146359,mbcd0022552,mbtp000002,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146360,mbcd0022281,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146364,mbcd0021323,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146368,mbcd0020601,mbtp000002,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146370,mbcd0020523,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146377,mbcd0017426,mbtp000001,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146378,mbcd0017319,mbtp000001,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146381,mbcd0016500,mbtp000007,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146384,mbcd0015981,mbtp000001,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146387,mbcd0015401,mbtp000005,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146388,mbcd0003016,mbtp000005,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-07-19 01:39:59
mbbd000146391,mbcd0014785,mbtp000007,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146395,mbcd0013197,mbtp000009,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146396,mbcd0012958,mbtp000001,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146397,mbcd0012636,mbtp000001,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146398,mbcd0011365,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146399,mbcd0010603,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146400,mbcd0010498,mbtp000001,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146403,mbcd0009560,mbtp000009,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146405,mbcd0008195,mbtp000001,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146410,mbcd0007741,mbtp000007,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146414,mbcd0006583,mbtp000005,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146418,mbcd0003945,mbtp000007,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146423,mbcd0003926,mbtp000007,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146426,mbcd0003904,mbtp000002,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146427,mbcd0003904,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146428,mbcd0003904,mbtp000009,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146429,mbcd0003890,mbtp000009,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146430,mbcd0003877,mbtp000001,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146431,mbcd0003789,mbtp000009,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146432,mbcd0003775,mbtp000009,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146433,mbcd0003774,mbtp000009,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146434,mbcd0003773,mbtp000009,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146435,mbcd0003772,mbtp000009,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146436,mbcd0003769,mbtp000009,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146437,mbcd0003756,mbtp000009,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146438,mbcd0003718,mbtp000009,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146439,mbcd0003714,mbtp000009,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146440,mbcd0003692,mbtp000009,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146441,mbcd0003686,mbtp000009,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146443,mbcd0003680,mbtp000009,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146444,mbcd0003660,mbtp000009,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146445,mbcd0003629,mbtp000009,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146446,mbcd0003623,mbtp000009,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146447,mbcd0003604,mbtp000009,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146448,mbcd0003597,mbtp000009,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146449,mbcd0003593,mbtp000009,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146450,mbcd0003592,mbtp000009,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146451,mbcd0003591,mbtp000009,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146453,mbcd0003557,mbtp000009,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146454,mbcd0003550,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146456,mbcd0003525,mbtp000009,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146458,mbcd0003513,mbtp000009,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146460,mbcd0003472,mbtp000010,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146461,mbcd0003404,mbtp000010,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146462,mbcd0003394,mbtp000010,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146463,mbcd0003260,mbtp000002,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146464,mbcd0003168,mbtp000001,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146465,mbcd0003155,mbtp000001,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146467,mbcd0003142,mbtp000001,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146468,mbcd0003142,mbtp000005,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146469,mbcd0003141,mbtp000005,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146471,mbcd0003140,mbtp000005,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146472,mbcd0003131,mbtp000005,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146473,mbcd0003130,mbtp000005,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146474,mbcd0003129,mbtp000001,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146475,mbcd0003129,mbtp000005,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146476,mbcd0003128,mbtp000002,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146477,mbcd0003128,mbtp000005,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146478,mbcd0003124,mbtp000005,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146479,mbcd0003124,mbtp000008,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146480,mbcd0003122,mbtp000005,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146481,mbcd0003115,mbtp000005,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146482,mbcd0003110,mbtp000002,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146483,mbcd0003106,mbtp000005,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146484,mbcd0003097,mbtp000005,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146485,mbcd0003096,mbtp000005,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146486,mbcd0003095,mbtp000005,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146487,mbcd0003091,mbtp000001,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146488,mbcd0003090,mbtp000005,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146489,mbcd0003088,mbtp000005,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146490,mbcd0003087,mbtp000005,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146491,mbcd0003086,mbtp000002,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146492,mbcd0003086,mbtp000001,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146493,mbcd0003083,mbtp000005,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146495,mbcd0003073,mbtp000001,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146496,mbcd0003071,mbtp000005,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146497,mbcd0003062,mbtp000005,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146498,mbcd0003056,mbtp000005,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146501,mbcd0003046,mbtp000005,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146502,mbcd0003045,mbtp000001,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146503,mbcd0003037,mbtp000005,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146504,mbcd0003036,mbtp000002,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146505,mbcd0003030,mbtp000005,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146506,mbcd0003029,mbtp000002,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146507,mbcd0003028,mbtp000002,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146508,mbcd0003028,mbtp000005,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146511,mbcd0003021,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146512,mbcd0003019,mbtp000002,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146513,mbcd0003017,mbtp000002,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146514,mbcd0003017,mbtp000005,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146515,mbcd0003013,mbtp000005,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146516,mbcd0003012,mbtp000005,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146517,mbcd0003003,mbtp000005,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146518,mbcd0003002,mbtp000005,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146520,mbcd0002999,mbtp000002,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146521,mbcd0002997,mbtp000005,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146522,mbcd0002991,mbtp000005,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146523,mbcd0002988,mbtp000001,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146524,mbcd0002983,mbtp000005,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146525,mbcd0002982,mbtp000005,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146526,mbcd0002982,mbtp000008,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146528,mbcd0002921,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146529,mbcd0002903,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146530,mbcd0002885,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146531,mbcd0002882,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146532,mbcd0002868,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146533,mbcd0002857,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146535,mbcd0002820,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146538,mbcd0002765,mbtp000005,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146539,mbcd0002734,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146540,mbcd0002667,mbtp000005,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146541,mbcd0002595,mbtp000005,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146542,mbcd0002585,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146543,mbcd0002575,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146544,mbcd0002563,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146545,mbcd0002436,mbtp000005,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146546,mbcd0002422,mbtp000005,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146547,mbcd0002403,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146548,mbcd0002393,mbtp000002,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146549,mbcd0002393,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146550,mbcd0002391,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146551,mbcd0002371,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146552,mbcd0002360,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146553,mbcd0002339,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146554,mbcd0002305,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146555,mbcd0002302,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146556,mbcd0002294,mbtp000008,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146557,mbcd0002268,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146558,mbcd0002246,mbtp000001,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146559,mbcd0002195,mbtp000001,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146560,mbcd0002145,mbtp000005,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146561,mbcd0002142,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146562,mbcd0002137,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146563,mbcd0002130,mbtp000005,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146564,mbcd0002123,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146565,mbcd0002104,mbtp000005,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146566,mbcd0002088,mbtp000001,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146567,mbcd0001950,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146568,mbcd0001918,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146570,mbcd0001892,mbtp000025,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146571,mbcd0001868,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146572,mbcd0001846,mbtp000005,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146573,mbcd0001797,mbtp000005,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146574,mbcd0001789,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146575,mbcd0001786,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146576,mbcd0001783,mbtp000001,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146577,mbcd0001777,mbtp000005,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146580,mbcd0001731,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146581,mbcd0001691,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146582,mbcd0001681,mbtp000007,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146583,mbcd0001677,mbtp000005,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146584,mbcd0001664,mbtp000002,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146585,mbcd0001644,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146590,mbcd0001591,mbtp000009,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146592,mbcd0001533,mbtp000007,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146593,mbcd0001508,mbtp000007,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146594,mbcd0001492,mbtp000002,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146595,mbcd0001465,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146596,mbcd0001459,mbtp000001,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146597,mbcd0001448,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146599,mbcd0001441,mbtp000025,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146602,mbcd0001381,mbtp000007,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146603,mbcd0001378,mbtp000001,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146605,mbcd0001355,mbtp000002,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146606,mbcd0001353,mbtp000005,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146607,mbcd0001343,mbtp000008,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146608,mbcd0001267,mbtp000008,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146610,mbcd0001265,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146613,mbcd0001221,mbtp000005,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146614,mbcd0001194,mbtp000002,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146615,mbcd0001173,mbtp000005,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146616,mbcd0001164,mbtp000002,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146617,mbcd0001151,mbtp000002,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146618,mbcd0001145,mbtp000001,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146620,mbcd0001120,mbtp000001,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146624,mbcd0001107,mbtp000005,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146625,mbcd0001107,mbtp000007,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146628,mbcd0001050,mbtp000005,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146629,mbcd0001021,mbtp000005,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146630,mbcd0000960,mbtp000007,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146631,mbcd0000928,mbtp000005,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146634,mbcd0000910,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146635,mbcd0000910,mbtp000009,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146636,mbcd0000882,mbtp000009,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146638,mbcd0000848,mbtp000025,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146639,mbcd0000843,mbtp000002,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146641,mbcd0000841,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146643,mbcd0000819,mbtp000002,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146646,mbcd0000772,mbtp000005,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146647,mbcd0000759,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146648,mbcd0000719,mbtp000005,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146649,mbcd0000719,mbtp000008,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146650,mbcd0000719,mbtp000025,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146651,mbcd0000713,mbtp000005,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146652,mbcd0000593,mbtp000001,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146653,mbcd0000542,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146654,mbcd0000542,mbtp000005,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146656,mbcd0000522,mbtp000001,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146657,mbcd0000512,mbtp000009,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146658,mbcd0000462,mbtp000005,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146661,mbcd0000441,mbtp000008,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146662,mbcd0000369,mbtp000002,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146663,mbcd0000303,mbtp000001,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146664,mbcd0000289,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146665,mbcd0000245,mbtp000009,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146666,mbcd0000235,mbtp000001,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146667,mbcd0000231,mbtp000009,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146668,mbcd0000212,mbtp000002,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146669,mbcd0000212,mbtp000005,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146670,mbcd0000199,mbtp000005,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146671,mbcd0000193,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146672,mbcd0000154,mbtp000002,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146673,mbcd0000124,mbtp000005,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146674,mbcd0000122,mbtp000009,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146676,mbcd0000080,mbtp000001,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146677,mbcd0000080,mbtp000008,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146678,mbcd0000076,mbtp000001,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146679,mbcd0000072,mbtp000001,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146680,mbcd0000034,mbtp000001,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146681,mbcd0000002,mbtp000025,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-05-31 18:28:43
mbbd000146687,mbcd0000442,mbtp000022,mbrf0002662,,,,,substrate,,,,,bimane-GS,,,MRP4-expressing HepG2 cell; efflux,HepG2,,,,,human,mbds0003,v2007,2013-12-09 20:07:50
mbbd000146688,mbcd0031255,mbtp000022,mbrf0002645,,,,,substrate,,,,,AZTMP,,,CEM-r1; efflux,CEM-r1,,,,,human,mbds0003,v2007,2013-12-09 19:52:41
mbbd000146689,mbcd0003110,mbtp000022,mbrf0002645,,,,,substrate,,,,,PMEA,,,CEM-r1; efflux,CEM-r1,,,,,human,mbds0003,v2007,2013-12-09 20:54:05
mbbd000146690,mbcd0029825,mbtp000022,mbrf0002652,,,,,substrate,,,,,6-MP,,,MRP4-expressing NIH3T3 cell; efflux,NIH-3T3,,,,,human,mbds0003,v2007,2013-12-09 20:15:48
mbbd000146691,mbcd0003078,mbtp000022,mbrf0002654,,,,,substrate,,,,,GSH,,,MRP4-expressing HepG4 cell; efflux,HepG2,,,,,human,mbds0003,v2007,2013-12-09 20:15:49
mbbd000146692,mbcd0031256,mbtp000022,mbrf0002654,,,,,substrate,,,,,cAMP,,,MRP4-expressing HepG4 cell; efflux,HepG2,,,,,human,mbds0003,v2007,2013-12-09 20:15:51
mbbd000146693,mbcd0003070,mbtp000022,mbrf0001723,,=,,,substrate,28,1.9,microM,0.2,DHEAS,,,membrane vesicle from MRP4-expressing Sf9 cell; uptake,Sf9,,0-10,microM,,human,mbds0010,,2013-12-09 20:10:10
mbbd000146694,mbcd0003043,mbtp000022,mbrf0002655,28,=,1300.0,microM,substrate,28,1.3,mM,0.2,MTX,,,membrane vesicle from MRP4-expressing Sf9 cell; uptake,Sf9,,0.1,microM,,human,mbds0003,v2007,2013-12-09 20:09:01
mbbd000146695,mbcd0003959,mbtp000022,mbrf0001847,28,=,170.0,microM,substrate,28,0.17,mM,0.02,FA,,,membrane vesicle from MRP4-expressing Sf9 cell; uptake,Sf9,,0-1.0,mM,,human,mbds0003,v2007,2013-12-09 20:15:40
mbbd000146696,mbcd0000387,mbtp000022,mbrf0002652,,=,,,substrate,28,30.3,microM,6.2,E217betaG,,,membrane vesicle from MRP4-expressing Sf9 cell; uptake,Sf9,,1,microM,,human,mbds0003,v2007,2013-12-09 20:09:32
mbbd000146697,mbcd0031256,mbtp000022,mbrf0002652,,=,,,substrate,28,44.5,microM,5.8,cAMP,,,membrane vesicle from MRP4-expressing Sf9 cell; uptake,Sf9,,1; 30; 100; 300,microM,,human,mbds0003,v2007,2013-12-09 20:09:36
mbbd000146698,mbcd0001197,mbtp000022,mbrf0001847,28,=,640.0,microM,substrate,28,0.64,mM,0.23,Leucovorin,,,membrane vesicle from MRP4-expressing Sf9 cell; uptake,Sf9,,0-3.0,mM,,human,mbds0003,v2007,2013-12-09 20:13:07
mbbd000146699,mbcd0029143,mbtp000022,mbrf0002652,,=,,,substrate,28,9.69,microM,2.30,cGMP,,,membrane vesicle from MRP4-expressing Sf9 cell; uptake,Sf9,,1; 30; 100; 300,microM,,human,mbds0003,v2007,2013-12-09 20:13:08
mbbd000146700,mbcd0001267,mbtp000022,mbrf0001305,,=,,,substrate,16,2.1,microM,,PGE1,,,membrane vesicle from MRP4-expressing Sf9 cell; uptake,Sf9,,0-16,microM,,human,mbds0003,v2007,2013-12-09 20:55:20
mbbd000146701,mbcd0001343,mbtp000022,mbrf0001305,,=,,,substrate,16,3.4,microM,,PGE2,,,membrane vesicle from MRP4-expressing Sf9 cell; uptake,Sf9,,0-16,microM,,human,mbds0003,v2007,2013-12-09 19:57:29
mbbd000146702,mbcd0031257,mbtp000030,mbrf0002659,,,,,substrate,,,,,chlorpropham,,,MRP1-expressing NIH3T3 cell; drug resistance,NIH-3T3,,,,,human,mbds0003,v2007,2013-12-09 20:55:19
mbbd000146703,mbcd0031258,mbtp000030,mbrf0002663,,,,,substrate,,,,,NBD-PC,,,MRP1-asolectin proteoliposome; translocation from outer to inner leaflet,BHK-21,,,,,human,mbds0003,v2007,2013-12-09 20:55:19
mbbd000146704,mbcd0031259,mbtp000030,mbrf0002664,,,,,substrate,,,,,zoledronic acid,,,hMRP1-expressing HEK293; inhibition of apoptosis,HEK293,,,,,human,mbds0003,v2007,2013-12-09 20:55:22
mbbd000146705,mbcd0031260,mbtp000030,mbrf0002632,,,,,substrate,,,,,6alpha-glucuronosylhyodeoxycholate,,,membrane vesicle from MRP1-expressing HeLa cell; uptake,HeLa,,,,,human,mbds0003,v2007,2013-12-09 20:55:23
mbbd000146706,mbcd0031261,mbtp000030,mbrf0002632,,,,,substrate,,,,,LTD4,,,membrane vesicle from MRP1-expressing HeLa cell; uptake,HeLa,,,,,human,mbds0003,v2007,2013-12-09 20:55:20
mbbd000146707,mbcd0031262,mbtp000030,mbrf0002632,,,,,substrate,,,,,LTE4NAc,,,membrane vesicle from MRP1-expressing HeLa cell; uptake,HeLa,,,,,human,mbds0003,v2007,2013-12-09 20:55:21
mbbd000146708,mbcd0031263,mbtp000030,mbrf0002661,,,,,substrate,,,,,Rh 123,,,MRP1-expressing GLC4/ADR cell; intracellular accumulation,GLC4,,,,,human,mbds0003,v2007,2013-12-09 20:55:23
mbbd000146709,mbcd0031264,mbtp000030,mbrf0002640,,,,,substrate,,,,,99mTc-MIBI,,,GLC4/ADR cell; cell accumulation,GLC4,,,,,human,mbds0003,v2007,2013-12-09 20:55:24
mbbd000146710,mbcd0031265,mbtp000030,mbrf0002656,,,,,substrate,,,,,Bodipy-FL-Verapamil,,,"PANC-1 cell; efflux, inhibited by MK571",PANC-1,,,,,human,mbds0003,v2007,2014-01-27 21:28:32
mbbd000146711,mbcd0031266,mbtp000030,mbrf0002639,,,,,substrate,,,,,bisglutathionyl chlorambucil,,,membrane vesicle from MRP1-expressing HeLa cell; uptake,HeLa,,,,,human,mbds0003,v2007,2013-12-09 20:05:59
mbbd000146712,mbcd0031267,mbtp000030,mbrf0002639,,,,,substrate,,,,,monohydroxy monoglutathionyl chlorambucil,,,membrane vesicle from MRP1-expressing HeLa cell; uptake,HeLa,,,,,human,mbds0003,v2007,2013-12-09 20:06:03
mbbd000146713,mbcd0031268,mbtp000030,mbrf0002647,,=,,,substrate,28,1.6,microM,0.21,GS-4HNE,,,membrane vesicle from MRP1-expressing High Five insect cell; uptake,High Five (BTI-TN5B1-4),,0-20,microM,,human,mbds0003,v2007,2014-03-04 00:45:10
mbbd000146714,mbcd0031269,mbtp000030,mbrf0002635,28,=,0.189,microM,substrate,28,189.0,nM,,AFB1-GSH,,,membrane vesicle from MRP1-expressing HeLa cell; uptake,HeLa,,250,nM,,human,mbds0003,v2007,2013-12-09 20:06:05
mbbd000146715,mbcd0031270,mbtp000030,mbrf0002638,,=,,,substrate,28,0.8,microM,,PGA2-GS,Km between 0.8 and 1 microM,,membrane vesicle from MRP1-expressing DTY 168 yeast cell; uptake,DTY168,,1-10,microM,,human,mbds0003,v2007,2013-12-09 20:06:04
mbbd000146716,mbcd0031271,mbtp000030,mbrf0002665,,=,,,substrate,28,0.75,microM,,LNO2-SG,"refers to four different compounds; glutathione conjugates of (9, 10, 12, or 13)-nitro-9-cis,12-cis-octadecadienoic acid",,MRP1-expressing membrane vesicles; vesicle uptake,MCF7,,0-8.5,microM,,human,mbds0003,v2007,2013-12-09 20:06:06
mbbd000146717,mbcd0031272,mbtp000030,mbrf0002650,,=,,,substrate,28,1.14,microM,,MLP-SG,,,membrane vesicle from MCF/VP cell; uptake,MCF7,,0-1,mM,,human,mbds0003,v2007,2013-12-09 20:06:06
mbbd000146718,mbcd0029142,mbtp000030,mbrf0001272,,,,,substrate,,,,,EGCG,,,MRP1-expressing MDCKII cells; uptake,MDCKII,,,,,human,mbds0003,v2007,2013-10-29 19:55:35
mbbd000146719,mbcd0000047,mbtp000030,mbrf0002636,,=,,,substrate,28,1.2,microM,0.2,GS-DNP,,,membrane vesicle from GLC4/ADR cell; uptake,GLC4/ADR,,20-5000,nM,,human,mbds0003,v2007,2013-12-09 20:06:07
mbbd000146720,mbcd0000047,mbtp000030,mbrf0002632,,=,,,substrate,28,3.6,microM,0.7,DNP-SG,,,membrane vesicle from MRP1-expressing HeLa cell; uptake,HeLa,,200,nM,,human,mbds0003,v2007,2013-12-09 20:57:45
mbbd000146721,mbcd0000072,mbtp000030,mbrf0001272,,,,,substrate,,,,,MeEGCG,,,MRP1-expressing MDCKII cells; uptake,MDCKII,,,,,human,mbds0003,v2007,2013-10-29 19:55:35
mbbd000146722,mbcd0000076,mbtp000030,mbrf0001272,,,,,substrate,,,,,DiMeEGCG,,,MRP1-expressing MDCKII cells; uptake,MDCKII,,,,,human,mbds0010,,2013-10-17 21:45:42
mbbd000146723,mbcd0000187,mbtp000030,mbrf0001278,,,,,substrate,,,,,monoglucuronosylbilirubin,,,membrane vesicle from MRP1-expressing HeLa cell; uptake,HeLa,,,,,human,mbds0003,v2007,2013-12-09 20:57:45
mbbd000146724,mbcd0000387,mbtp000030,mbrf0002660,,,,,substrate,,,,,E217betaG,,,membrane vesicle from MRP1-expressing HEK293 cell; uptake,HEK293,,,,,human,mbds0003,v2007,2013-12-09 20:57:45
mbbd000146725,mbcd0000387,mbtp000030,mbrf0002632,,=,,,substrate,28,1.5,microM,0.3,17beta-Glucuronosyl estradiol,,,membrane vesicle from MRP1-expressing HeLa cell; uptake,HeLa,,200,nM,,human,mbds0003,v2007,2013-12-09 20:57:45
mbbd000146726,mbcd0000387,mbtp000030,mbrf0002631,,=,,,substrate,28,2.5,microM,,E217betaG,,,membrane vesicle from MRP1-expressing HeLa cell; uptake,HeLa,,0-20,microM,,human,mbds0003,v2007,2013-12-09 20:57:46
mbbd000146727,mbcd0000387,mbtp000030,mbrf0002637,,=,,,substrate,28,2.9,microM,,E217betaG,,,membrane vesicle from MRP1-expressing HEK 293 cell; uptake,HEK293,,0.2-200,microM,,human,mbds0003,v2007,2013-12-09 20:57:46
mbbd000146728,mbcd0000387,mbtp000030,mbrf0002646,,=,,,substrate,28,1.5,microM,0.3,17beta-glucuronosyl estradiol,,,membrane vesicle from MRP1-expressing HEK 293 cell; uptake,HEK293,,1.5,microM,,human,mbds0003,v2007,2013-12-09 20:57:44
mbbd000146729,mbcd0000398,mbtp000030,mbrf0002632,,,,,substrate,,,,,glucuronosyl etoposide,,,membrane vesicle from MRP1-expressing HeLa cell; uptake,HeLa,,,,,human,mbds0003,v2007,2013-12-09 20:57:45
mbbd000146730,mbcd0000440,mbtp000030,mbrf0001303,,=,,,substrate,28,1.4,microM,,15-d-PGJ2-SG,,,MRP1-expressing MCF7 cell; uptake,MCF7,,0.1-50,microM,,human,mbds0003,v2007,2013-12-09 20:08:26
mbbd000146731,mbcd0000528,mbtp000030,mbrf0002632,,,,,substrate,,,,,LTE4,,,membrane vesicle from MRP1-expressing HeLa cell; uptake,HeLa,,,,,human,mbds0003,v2007,2013-12-09 20:08:26
mbbd000146732,mbcd0000603,mbtp000030,mbrf0001289,,=,,,substrate,77,200.0,microM,,NEM-GS,,,membrane vesicle from MRP1-expressing Sf9 cell; uptake,Sf9,,0-10,mM,,human,mbds0003,v2007,2013-12-09 20:08:26
mbbd000146733,mbcd0000603,mbtp000030,mbrf0002642,,=,,,substrate,28,155.0,microM,40,NEM-GS,,,membrane vesicle from MRP1-expressing Sf9 cell; uptake,Sf9,,5; 50,microM,,human,mbds0003,v2007,2013-12-09 20:08:26
mbbd000146734,mbcd0000627,mbtp000030,mbrf0001259,,=,,,substrate,28,39.0,microM,,NNAL-O-glucuronide,,,membrane vesicle from MRP1-expressing T5 HeLa cell; uptake in the presence of GSH,HeLa,,0.25-25,microM,,human,mbds0003,v2007,2013-12-09 20:08:26
mbbd000146735,mbcd0000779,mbtp000030,mbrf0002643,,,,,substrate,,,,,SN-38,,,KB-3-1 and MRP1-expressing KB-3-1 cell; intracellular accumulation,KB,,,,,human,mbds0003,v2007,2013-12-09 20:08:26
mbbd000146736,mbcd0001038,mbtp000030,mbrf0002648,,,,,substrate,,,,,grepafloxacin,,,HL60 and HL60/ADM cell; decrease in intracellular accumulation,HL60,,,,,human,mbds0003,v2007,2013-12-09 20:08:25
mbbd000146737,mbcd0001135,mbtp000030,mbrf0002660,,,,,substrate,,,,,vincristine,,,MRP1-expressing HEK293 cell; drug resistance,HEK293,,,,,human,mbds0003,v2007,2013-12-09 20:08:24
mbbd000146738,mbcd0001135,mbtp000030,mbrf0002657,,,,,substrate,,,,,vincristine,,,MRP1-expressing PEAK[STABEL] cell; drug resistance,PEAK[STABLE],,,,,human,mbds0003,v2007,2013-12-09 20:08:23
mbbd000146739,mbcd0001135,mbtp000030,mbrf0001160,,,,,substrate,,,,,vincristine,,,membrane vesicle from GLC4/ADR cell; uptake,GLC4,,,,,human,mbds0003,v2007,2013-12-09 20:08:21
mbbd000146740,mbcd0001135,mbtp000030,mbrf0002634,,,,,substrate,,,,,VCR,,,KB-3-1 and C-A120 cell; intracellular accumulation,KB,,,,,human,mbds0003,v2007,2013-12-09 20:54:20
mbbd000146741,mbcd0001151,mbtp000030,mbrf0001272,,,,,substrate,,,,,vinblastine,,,MRP1-expressing MDCKII cells; uptake,MDCKII,,,,,human,mbds0003,v2007,2013-10-29 19:55:35
mbbd000146742,mbcd0001151,mbtp000030,mbrf0001264,,,,,substrate,,,,,vinblastine,,,MRP1-expressing LLC-PK1 cell; transepithelial transport (basal to apical),LLC-PK1,,,,,human,mbds0003,v2007,2013-12-09 20:54:20
mbbd000146743,mbcd0001216,mbtp000030,mbrf0002651,,,,,substrate,,,,,fluorescein,,,MRP1-expressing MDCKII cell; intracellular accumulation,MDCKII,,,,,human,mbds0003,v2007,2013-12-09 20:54:20
mbbd000146744,mbcd0001372,mbtp000030,mbrf0002629,,,,,substrate,,,,,actinomycin D,,,MRP1-expressing NIH/3T3 cell; drug sensitivity,NIH-3T3,,,,,human,mbds0003,v2007,2013-12-09 20:54:19
mbbd000146745,mbcd0001533,mbtp000030,mbrf0001268,,,,,substrate,,,,,saquinavir,,,MRP1-expressing MDCKII cell; transepithelial transport (basal to apical),MDCKII,,,,,human,mbds0003,v2007,2013-12-09 20:54:20
mbbd000146746,mbcd0002091,mbtp000030,mbrf0002643,,,,,substrate,,,,,CPT-11,,,KB-3-1 and MRP1-expressing KB-3-1 cell; intracellular accumulation,KB,,,,,human,mbds0003,v2007,2013-12-09 20:54:19
mbbd000146747,mbcd0002466,mbtp000030,mbrf0002660,,,,,substrate,,,,,VP-16,,,MRP1-expressing HEK293 cell; drug resistance,HEK293,,,,,human,mbds0003,v2007,2013-12-09 20:54:19
mbbd000146748,mbcd0002466,mbtp000030,mbrf0002657,,,,,substrate,,,,,etoposide,,,MRP1-expressing PEAK[STABEL] cell; drug resistance,PEAK[STABLE],,,,,human,mbds0003,v2007,2013-12-09 20:54:19
mbbd000146749,mbcd0002466,mbtp000030,mbrf0002637,,,,,substrate,,,,,VP-16,,,MRP1-expressing HEK293 cell; efflux,HEK293,,,,,human,mbds0003,v2007,2013-12-09 20:54:19
mbbd000146750,mbcd0002466,mbtp000030,mbrf0001042,,,,,non-substrate,,,,,etoposide,,,MRP1-expressing MDCKII cell; transepithelial transport (basal to apical),MDCKII,,,,,human,mbds0003,v2007,2013-12-09 20:03:16
mbbd000146751,mbcd0002667,mbtp000030,mbrf0002637,,,,,substrate,,,,,colchicine,,,MRP1-expressing HEK293 cell; drug resistance,HEK293,,,,,human,mbds0003,v2007,2013-12-09 20:03:16
mbbd000146752,mbcd0002917,mbtp000030,mbrf0002657,,,,,substrate,,,,,LTC4,,,membrane vesicle from MRP1-expressing PEAK[STABEL] cell; uptake,PEAK[STABLE],,,,,human,mbds0003,v2007,2013-12-09 20:08:19
mbbd000146753,mbcd0002917,mbtp000030,mbrf0002660,,,,,substrate,,,,,LTC4,,,membrane vesicle from MRP1-expressing HEK293 cell; drug resistance,HEK293,,,,,human,mbds0003,v2007,2013-12-09 20:03:17
mbbd000146754,mbcd0002917,mbtp000030,mbrf0002658,,,,,substrate,,,,,LTC4,,,membrane vesicle from MRP1-expressing LLC-PK1 cell; uptake,LLC-PK1,,,,,human,mbds0003,v2007,2013-12-09 20:08:16
mbbd000146755,mbcd0002917,mbtp000030,mbrf0002632,,=,,,substrate,28,0.097,microM,0.02,LTC4,,,membrane vesicle from MRP1-expressing HeLa cell; uptake,HeLa,,50,nM,,human,mbds0003,v2007,2013-12-09 20:03:15
mbbd000146756,mbcd0002917,mbtp000030,mbrf0002637,28,=,0.098,microM,substrate,28,98.0,nM,,LTC4,,,membrane vesicle from MRP1-expressing HEK 293 cell; uptake,HEK293,,0.01-2,microM,,human,mbds0003,v2007,2013-12-09 20:03:16
mbbd000146757,mbcd0002917,mbtp000030,mbrf0002641,28,=,0.125,microM,substrate,28,125.0,nM,25,LTC4,,,membrane vesicle from SR3A cell; uptake,SR3A,,50-750,nM,,human,mbds0003,v2007,2013-12-09 20:03:16
mbbd000146758,mbcd0002917,mbtp000030,mbrf0002642,28,=,0.135,microM,substrate,28,135.0,nM,35,LTC4,,,membrane vesicle from MRP1-expressing Sf9 cell; uptake,Sf9,,3; 50,nM,,human,mbds0003,v2007,2013-12-09 20:03:15
mbbd000146759,mbcd0002917,mbtp000030,mbrf0002646,,=,,,substrate,28,0.1,microM,0.02,LTC4,,,membrane vesicle from MRP1-expressing HEK 293 cell; uptake,HEK293,,100,nM,,human,mbds0003,v2007,2013-12-09 20:03:14
mbbd000146760,mbcd0002981,mbtp000030,mbrf0001524,,,,,substrate,,,,,MX,,,MCF7/MRP1-10 cells; ATP- and GSH-dependent transport,MCF7,,,,,human,mbds0003,v2007,2013-12-09 20:54:54
mbbd000146761,mbcd0002981,mbtp000030,mbrf0002653,,,,,substrate,,,,,MX,,,MCF7/VP and MCF cell; efflux,MCF7,,,,,human,mbds0003,v2007,2013-12-09 20:54:54
mbbd000146762,mbcd0002981,mbtp000030,mbrf0001524,,,,,substrate,,,,,MX,,,etoposide-selected MCF7 cells; transport,MCF7,,,,,human,mbds0003,v2007,2013-12-09 20:54:54
mbbd000146763,mbcd0002990,mbtp000030,mbrf0002636,,=,,,substrate,28,43.0,microM,3,GSSG,,,membrane vesicle from GLC4/ADR cell; uptake,GLC4/ADR,,10; 20; 500,nM,,human,mbds0003,v2007,2013-12-09 20:54:54
mbbd000146764,mbcd0002990,mbtp000030,mbrf0002632,,=,,,substrate,28,93.0,microM,26,GSSG,,,membrane vesicle from MRP1-expressing HeLa cell; uptake,HeLa,,0.2; 100,microM,,human,mbds0003,v2007,2013-12-09 20:54:53
mbbd000146765,mbcd0003043,mbtp000030,mbrf0001303,,=,,,substrate,28,930.0,microM,,Methotrexate,,,MRP1-expressing MCF7 cell; uptake,MCF7,,,,,human,mbds0003,v2007,2013-12-09 20:54:54
mbbd000146766,mbcd0003043,mbtp000030,mbrf0001299,28,=,2150.0,microM,substrate,28,2.15,mM,0.79,MTX,,,membrane vesicle from MRP1-expressing NIH3T3 cell; uptake,NIH-3T3,,1.0,microM,,human,mbds0003,v2007,2013-12-09 20:54:54
mbbd000146767,mbcd0003070,mbtp000030,mbrf0001723,,=,,,substrate,28,5.0,microM,1,DHEAS,,,membrane vesicle from MRP1-expressing Sf9 cell; uptake,Sf9,,0-20,microM,,human,mbds0010,,2013-12-09 20:54:54
mbbd000146768,mbcd0003075,mbtp000030,mbrf0002649,,=,,,substrate,28,0.73,microM,0.17,Estrone 3-sulfate,,,"membrane vesicle from MRP1-expressing HeLa cell; uptake, in the presence of GSH (GSH: 1mM)",HeLa,,300; 2000,nM,,human,mbds0003,v2007,2013-12-09 20:54:54
mbbd000146769,mbcd0003078,mbtp000030,mbrf0001255,,,,,substrate,,,,,GSH,,,MRP1-expressing MDCKII cell; efflux,MDCKII,,,,,human,mbds0003,v2007,2013-12-09 20:54:55
mbbd000146770,mbcd0003146,mbtp000030,mbrf0001253,,=,,,substrate,28,372.0,microM,,PAH,,,membrane vesicle from MRP1-expressing HeLa cell; uptake,HeLa,,0.1; 10,microM,,human,mbds0003,v2007,2013-12-09 20:04:48
mbbd000146771,mbcd0003155,mbtp000030,mbrf0002646,,=,,,substrate,28,12.0,microM,,Fluo-3,,,membrane vesicle from MRP1-expressing HeLa cell; uptake,HeLa,,1-10,microM,,human,mbds0003,v2007,2013-12-09 20:04:47
mbbd000146772,mbcd0004701,mbtp000030,mbrf0001278,,,,,substrate,,,,,bisglucuronosylbilirubin,,,membrane vesicle from MRP1-expressing HeLa cell; uptake,HeLa,,,,,human,mbds0003,v2007,2013-12-09 20:04:47
mbbd000146773,mbcd0005183,mbtp000030,mbrf0002666,,,,,substrate,,,,,daunorubicin,,,membrane hMRP1-expressing tobacco; growth inhibition,tobacco,,,,,human,mbds0003,v2007,2013-12-09 20:04:47
mbbd000146774,mbcd0005183,mbtp000030,mbrf0002657,,,,,substrate,,,,,daunorubicin,,,MRP1-expressing PEAK[STABEL] cell; drug resistance,PEAK[STABLE],,,,,human,mbds0003,v2007,2013-12-09 20:04:50
mbbd000146775,mbcd0005183,mbtp000030,mbrf0002660,,,,,substrate,,,,,daunorubicin,,,MRP1-expressing HEK293 cell; drug resistance,HEK293,,,,,human,mbds0003,v2007,2013-12-09 20:04:49
mbbd000146776,mbcd0005183,mbtp000030,mbrf0002630,,=,,,substrate,28,1.4,microM,0.4,DNR,,,GLC4/ADR cell; efflux,GLC4/ADR,,0.5-10,microM,,human,mbds0003,v2007,2013-12-09 20:04:48
mbbd000146777,mbcd0025844,mbtp000030,mbrf0002659,,,,,substrate,,,,,doxorubicin,,,MRP1-expressing NIH3T3 cell; drug resistance,NIH-3T3,,,,,human,mbds0003,v2007,2013-12-09 20:04:48
mbbd000146778,mbcd0025844,mbtp000030,mbrf0002657,,,,,substrate,,,,,doxorubicin,,,MRP1-expressing PEAK[STABEL] cell; drug resistance,PEAK[STABLE],,,,,human,mbds0003,v2007,2013-12-09 20:04:46
mbbd000146779,mbcd0025844,mbtp000030,mbrf0002660,,,,,substrate,,,,,doxorubicin,,,MRP1-expressing HEK293 cell; drug resistance,HEK293,,,,,human,mbds0003,v2007,2013-12-09 20:04:46
mbbd000146780,mbcd0025844,mbtp000030,mbrf0002637,,,,,substrate,,,,,doxorubicin,,,MRP1-expressing HEK293 cell; efflux,HEK293,,,,,human,mbds0003,v2007,2013-12-09 21:00:40
mbbd000146781,mbcd0029350,mbtp000030,mbrf0002657,,,,,substrate,,,,,epirubicin,,,MRP1-expressing PEAK[STABEL] cell; drug resistance,PEAK[STABLE],,,,,human,mbds0003,v2007,2013-12-09 20:52:57
mbbd000146782,mbcd0029350,mbtp000030,mbrf0002660,,,,,substrate,,,,,epirubicin,,,MRP1-expressing HEK293 cell; drug resistance,HEK293,,,,,human,mbds0003,v2007,2013-12-09 21:00:38
mbbd000146783,mbcd0029350,mbtp000030,mbrf0002637,,,,,substrate,,,,,epirubicin,,,MRP1-expressing HEK293 cell; efflux,HEK293,,,,,human,mbds0003,v2007,2013-12-09 20:14:46
mbbd000146784,mbcd0029351,mbtp000030,mbrf0001143,,=,,,substrate,28,268.0,microM,160,CAL,,,GLC4/ADR cell; efflux,GLC4/ADR,,,,,human,mbds0003,v2007,2013-12-09 20:52:57
mbbd000146785,mbcd0029352,mbtp000030,mbrf0002633,,=,,,substrate,28,28.0,microM,4,EA-SG,,,membrane vesicle from S1(MRP) cell; uptake,SW-1573/S1,,0-300,microM,,human,mbds0003,v2007,2013-12-09 20:52:57
mbbd000146786,mbcd0029361,mbtp000030,mbrf0002650,,=,,,substrate,28,0.37,microM,,CHB-SG,,,membrane vesicle from MCF/VP cell; uptake,MCF7,,0.05; 0.1; 0.2,microM,,human,mbds0003,v2007,2013-12-09 20:01:09
mbbd000146787,mbcd0029372,mbtp000030,mbrf0002644,,,,,substrate,,,,,CDF,,,GLC4/sb30 cells; efflux,GLC4/sb30,,,,,human,mbds0003,v2007,2013-12-10 22:19:00
mbbd000146788,mbcd0030762,mbtp000030,mbrf0002659,,,,,substrate,,,,,methoxychlor,,,MRP1-expressing NIH3T3 cell; drug resistance,NIH-3T3,,,,,human,mbds0003,v2007,2013-12-09 20:06:13
mbbd000146789,mbcd0000212,mbtp000030,mbrf0001143,,=,,,substrate,28,0.05,microM,0.01,CAL-AM,,,GLC4/ADR cell; efflux,GLC4/ADR,,0.05-2,microM,,human,mbds0003,v2007,2013-12-09 20:52:55
mbbd000146790,mbcd0031180,mbtp000030,mbrf0002661,,,,,substrate,,,,,Rh II,,,MRP1-expressing GLC4/ADR cell; intracellular accumulation,GLC4,,,,,human,mbds0003,v2007,2013-12-09 20:51:14
mbbd000146791,mbcd0031181,mbtp000030,mbrf0002661,,,,,substrate,,,,,Rh I,,,MRP1-expressing GLC4/ADR cell; intracellular accumulation,GLC4,,,,,human,mbds0003,v2007,2013-12-09 20:51:14
mbbd000146792,mbcd0000841,mbtp000030,mbrf0002661,,,,,substrate,,,,,TMR; tetramethylrosamine,,,MRP1-expressing GLC4/ADR cell; intracellular accumulation,GLC4/ADR,,,,,human,mbds0003,v2007,2013-12-09 20:54:35
mbbd000146793,mbcd0031202,mbtp000030,mbrf0002659,,,,,substrate,,,,,fenitrothion,,,MRP1-expressing NIH3T3 cell; drug resistance,NIH-3T3,,,,,human,mbds0003,v2007,2013-12-09 20:51:15
mbbd000146794,mbcd0031461,mbtp000001,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146795,mbcd0031461,mbtp000005,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146797,mbcd0031276,mbtp000005,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146798,mbcd0031459,mbtp000005,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146799,mbcd0031458,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146800,mbcd0031457,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146801,mbcd0031456,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146802,mbcd0031455,mbtp000002,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146806,mbcd0031452,mbtp000001,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146807,mbcd0031452,mbtp000030,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146808,mbcd0031452,mbtp000005,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146809,mbcd0031451,mbtp000001,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146810,mbcd0031451,mbtp000030,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146811,mbcd0031451,mbtp000005,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146812,mbcd0031450,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146813,mbcd0031449,mbtp000030,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146814,mbcd0031448,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146817,mbcd0031446,mbtp000030,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146818,mbcd0031446,mbtp000005,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146819,mbcd0031446,mbtp000008,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146820,mbcd0031445,mbtp000030,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146821,mbcd0031445,mbtp000005,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146822,mbcd0031445,mbtp000008,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146823,mbcd0031444,mbtp000030,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146824,mbcd0031444,mbtp000005,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146825,mbcd0031444,mbtp000008,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146826,mbcd0031443,mbtp000030,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146827,mbcd0031443,mbtp000005,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146828,mbcd0031443,mbtp000008,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146829,mbcd0031442,mbtp000001,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146830,mbcd0031441,mbtp000030,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146831,mbcd0031441,mbtp000005,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146832,mbcd0031441,mbtp000008,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146833,mbcd0031440,mbtp000002,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146836,mbcd0031438,mbtp000001,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146837,mbcd0031437,mbtp000001,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146838,mbcd0031436,mbtp000001,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146840,mbcd0031434,mbtp000005,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146845,mbcd0031431,mbtp000005,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146850,mbcd0031427,mbtp000009,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146851,mbcd0031426,mbtp000030,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146852,mbcd0031425,mbtp000002,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146853,mbcd0031424,mbtp000001,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146854,mbcd0031424,mbtp000030,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146855,mbcd0031424,mbtp000005,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146856,mbcd0031423,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146857,mbcd0031422,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146858,mbcd0031421,mbtp000001,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146863,mbcd0031417,mbtp000001,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146865,mbcd0031415,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146866,mbcd0031414,mbtp000001,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146867,mbcd0031413,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146868,mbcd0031412,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146869,mbcd0031411,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146870,mbcd0031410,mbtp000002,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146871,mbcd0031410,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146872,mbcd0031410,mbtp000030,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146873,mbcd0031409,mbtp000002,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146874,mbcd0031409,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146875,mbcd0031409,mbtp000030,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146877,mbcd0020727,mbtp000030,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-07-22 18:39:46
mbbd000146878,mbcd0031214,mbtp000030,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146879,mbcd0031213,mbtp000030,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146881,mbcd0031405,mbtp000001,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146883,mbcd0031403,mbtp000001,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146884,mbcd0031402,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146885,mbcd0031401,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146886,mbcd0031400,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146887,mbcd0031399,mbtp000001,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146888,mbcd0031398,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146889,mbcd0031397,mbtp000022,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146890,mbcd0031396,mbtp000030,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146891,mbcd0031396,mbtp000005,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146892,mbcd0031395,mbtp000007,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146893,mbcd0031394,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146894,mbcd0031275,mbtp000009,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146895,mbcd0031393,mbtp000022,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146897,mbcd0031392,mbtp000001,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146898,mbcd0031391,mbtp000001,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146905,mbcd0031387,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146906,mbcd0031386,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146907,mbcd0031385,mbtp000001,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146908,mbcd0031384,mbtp000022,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146909,mbcd0031383,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146910,mbcd0031383,mbtp000030,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146911,mbcd0031383,mbtp000005,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146912,mbcd0031382,mbtp000030,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146913,mbcd0031381,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146914,mbcd0031380,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146915,mbcd0031379,mbtp000010,mbrf0002330,,=,,,non-substrate,23,0.204,*10^6 cm s-1,0.023,31,,,hASBT-MDCK cells; uptake,MDCK,,0-5000,microM,,human,mbds0010,,2013-11-20 21:27:57
mbbd000146916,mbcd0031378,mbtp000010,mbrf0002330,,=,,,non-substrate,23,0.336,*10^6 cm s-1,0.017,32,,,hASBT-MDCK cells; uptake,MDCK,,0-5000,microM,,human,mbds0010,,2013-11-20 21:27:57
mbbd000146917,mbcd0031377,mbtp000010,mbrf0002330,,=,,,non-substrate,23,4.71,*10^6 cm s-1,0.09,30,,,hASBT-MDCK cells; uptake,MDCK,,0-5000,microM,,human,mbds0010,,2013-11-20 21:27:57
mbbd000146918,mbcd0031376,mbtp000010,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146919,mbcd0031375,mbtp000010,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146920,mbcd0031374,mbtp000010,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146921,mbcd0031373,mbtp000010,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146922,mbcd0031372,mbtp000010,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146923,mbcd0031371,mbtp000010,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146924,mbcd0031370,mbtp000010,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146925,mbcd0031369,mbtp000010,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146926,mbcd0031368,mbtp000010,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146927,mbcd0031367,mbtp000010,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146928,mbcd0031366,mbtp000010,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146929,mbcd0031365,mbtp000010,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146930,mbcd0031364,mbtp000010,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146931,mbcd0031363,mbtp000010,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146932,mbcd0031362,mbtp000010,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146933,mbcd0031361,mbtp000010,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146934,mbcd0031360,mbtp000010,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146935,mbcd0031359,mbtp000010,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146936,mbcd0031358,mbtp000010,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146937,mbcd0031357,mbtp000010,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146938,mbcd0031356,mbtp000010,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146939,mbcd0031355,mbtp000010,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146940,mbcd0031354,mbtp000005,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146941,mbcd0029346,mbtp000030,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-10-28 19:27:33
mbbd000146943,mbcd0031351,mbtp000002,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146944,mbcd0031350,mbtp000001,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146945,mbcd0031349,mbtp000005,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146947,mbcd0031347,mbtp000008,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146949,mbcd0031274,mbtp000009,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146950,mbcd0001172,mbtp000030,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146951,mbcd0001563,mbtp000001,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146953,mbcd0010468,mbtp000030,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-07-22 18:20:16
mbbd000146955,mbcd0031261,mbtp000005,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146956,mbcd0031345,mbtp000005,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146957,mbcd0031344,mbtp000009,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146958,mbcd0031343,mbtp000009,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146959,mbcd0030393,mbtp000002,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-11-12 06:28:48
mbbd000146960,mbcd0031342,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146961,mbcd0029118,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146964,mbcd0031339,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146968,mbcd0031262,mbtp000005,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146969,mbcd0031337,mbtp000007,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146970,mbcd0031336,mbtp000001,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146975,mbcd0031333,mbtp000002,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146977,mbcd0031331,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-10-01 22:23:43
mbbd000146988,mbcd0031320,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146989,mbcd0031320,mbtp000005,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146990,mbcd0029883,mbtp000002,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146991,mbcd0031319,mbtp000022,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146993,mbcd0031317,mbtp000022,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146994,mbcd0031316,mbtp000022,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146995,mbcd0031315,mbtp000030,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146996,mbcd0031315,mbtp000005,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146997,mbcd0031315,mbtp000008,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146998,mbcd0031315,mbtp000022,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000146999,mbcd0031314,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147000,mbcd0031313,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147001,mbcd0031312,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147002,mbcd0031311,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147003,mbcd0031310,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147004,mbcd0031309,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147005,mbcd0031308,mbtp000030,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147006,mbcd0031263,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147007,mbcd0031307,mbtp000005,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147008,mbcd0031306,mbtp000005,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147009,mbcd0031305,mbtp000007,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147010,mbcd0031304,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147014,mbcd0031302,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147016,mbcd0031300,mbtp000002,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147017,mbcd0031299,mbtp000002,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147018,mbcd0031298,mbtp000002,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147019,mbcd0031297,mbtp000002,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147020,mbcd0031296,mbtp000002,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147021,mbcd0031295,mbtp000002,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147022,mbcd0031294,mbtp000002,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147023,mbcd0031293,mbtp000002,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147024,mbcd0031292,mbtp000002,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147025,mbcd0031291,mbtp000002,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147026,mbcd0031290,mbtp000002,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147027,mbcd0031289,mbtp000002,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147028,mbcd0031288,mbtp000002,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147029,mbcd0031287,mbtp000002,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147030,mbcd0031286,mbtp000002,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147031,mbcd0031285,mbtp000002,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147032,mbcd0031284,mbtp000002,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147033,mbcd0031283,mbtp000002,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147034,mbcd0031282,mbtp000001,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147035,mbcd0031273,mbtp000009,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147036,mbcd0031281,mbtp000009,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147038,mbcd0003046,mbtp000030,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147039,mbcd0030092,mbtp000030,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147040,mbcd0030096,mbtp000030,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147041,mbcd0030099,mbtp000030,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147042,mbcd0030101,mbtp000030,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147043,mbcd0030103,mbtp000030,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147044,mbcd0030109,mbtp000030,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147045,mbcd0030111,mbtp000030,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147046,mbcd0030114,mbtp000030,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147047,mbcd0030116,mbtp000030,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147048,mbcd0030100,mbtp000030,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147049,mbcd0030106,mbtp000030,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147050,mbcd0030093,mbtp000030,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147051,mbcd0031129,mbtp000030,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147052,mbcd0000080,mbtp000030,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147053,mbcd0003122,mbtp000030,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147054,mbcd0031130,mbtp000030,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147055,mbcd0000100,mbtp000030,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147056,mbcd0029455,mbtp000030,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147057,mbcd0003110,mbtp000030,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147058,mbcd0029932,mbtp000030,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-10-28 18:41:19
mbbd000147059,mbcd0027677,mbtp000030,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147060,mbcd0000133,mbtp000030,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147061,mbcd0030261,mbtp000030,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147062,mbcd0000172,mbtp000030,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147063,mbcd0031237,mbtp000030,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147064,mbcd0026443,mbtp000030,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147065,mbcd0000182,mbtp000030,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147068,mbcd0001075,mbtp000030,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147069,mbcd0003072,mbtp000030,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147070,mbcd0002645,mbtp000030,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147071,mbcd0002643,mbtp000030,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147072,mbcd0002471,mbtp000030,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147073,mbcd0002644,mbtp000030,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147074,mbcd0002805,mbtp000030,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147075,mbcd0002962,mbtp000030,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147076,mbcd0002019,mbtp000030,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147077,mbcd0002890,mbtp000030,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147078,mbcd0002291,mbtp000030,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147079,mbcd0001837,mbtp000030,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147080,mbcd0002295,mbtp000030,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147081,mbcd0002612,mbtp000030,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147082,mbcd0001839,mbtp000030,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147083,mbcd0002775,mbtp000030,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147084,mbcd0017980,mbtp000030,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147085,mbcd0003877,mbtp000030,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147086,mbcd0000303,mbtp000030,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147087,mbcd0013632,mbtp000030,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147088,mbcd0031204,mbtp000030,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147089,mbcd0031006,mbtp000030,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147090,mbcd0027726,mbtp000030,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147091,mbcd0029142,mbtp000030,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147092,mbcd0012636,mbtp000030,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147093,mbcd0029347,mbtp000030,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147095,mbcd0023723,mbtp000030,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147096,mbcd0003106,mbtp000030,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147097,mbcd0029371,mbtp000030,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147098,mbcd0029377,mbtp000030,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147099,mbcd0000441,mbtp000030,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147100,mbcd0003074,mbtp000030,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147101,mbcd0004749,mbtp000030,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-10-28 22:40:22
mbbd000147102,mbcd0003013,mbtp000030,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147103,mbcd0001492,mbtp000030,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147104,mbcd0002323,mbtp000030,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147105,mbcd0026436,mbtp000030,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147106,mbcd0002991,mbtp000030,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147107,mbcd0028095,mbtp000030,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147108,mbcd0003071,mbtp000030,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147109,mbcd0003076,mbtp000030,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147110,mbcd0000615,mbtp000030,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147112,mbcd0001532,mbtp000030,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147113,mbcd0000659,mbtp000030,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147114,mbcd0002824,mbtp000030,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147115,mbcd0000679,mbtp000030,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147116,mbcd0000680,mbtp000030,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147117,mbcd0003129,mbtp000030,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147118,mbcd0003506,mbtp000030,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147119,mbcd0000713,mbtp000030,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147120,mbcd0030500,mbtp000030,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147121,mbcd0001267,mbtp000030,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147122,mbcd0001343,mbtp000030,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147123,mbcd0000719,mbtp000030,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147124,mbcd0003120,mbtp000030,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147125,mbcd0002831,mbtp000030,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-10-28 21:32:30
mbbd000147126,mbcd0002393,mbtp000030,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147127,mbcd0001129,mbtp000030,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147128,mbcd0027483,mbtp000030,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147129,mbcd0022552,mbtp000030,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147130,mbcd0000843,mbtp000030,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147131,mbcd0003187,mbtp000030,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147132,mbcd0031178,mbtp000030,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147133,mbcd0027062,mbtp000030,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147134,mbcd0026115,mbtp000022,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147135,mbcd0030337,mbtp000022,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147136,mbcd0029455,mbtp000022,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147137,mbcd0003124,mbtp000022,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147138,mbcd0020601,mbtp000022,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147140,mbcd0001640,mbtp000022,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147141,mbcd0029406,mbtp000022,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147143,mbcd0000960,mbtp000022,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147145,mbcd0003906,mbtp000022,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147146,mbcd0001381,mbtp000022,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147147,mbcd0013632,mbtp000022,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147150,mbcd0029347,mbtp000022,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147151,mbcd0002466,mbtp000022,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-07-19 02:23:53
mbbd000147153,mbcd0003963,mbtp000022,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147154,mbcd0003890,mbtp000022,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147156,mbcd0001078,mbtp000022,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147157,mbcd0001635,mbtp000022,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147158,mbcd0000455,mbtp000022,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147159,mbcd0000456,mbtp000022,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147160,mbcd0004749,mbtp000022,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-10-28 22:40:22
mbbd000147161,mbcd0002091,mbtp000022,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147167,mbcd0003076,mbtp000022,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147168,mbcd0031193,mbtp000022,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147169,mbcd0003005,mbtp000022,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147175,mbcd0000713,mbtp000022,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147176,mbcd0000719,mbtp000022,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147177,mbcd0003120,mbtp000022,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147179,mbcd0002831,mbtp000022,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-10-28 21:32:30
mbbd000147180,mbcd0001129,mbtp000022,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147181,mbcd0001353,mbtp000022,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147183,mbcd0027483,mbtp000022,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147184,mbcd0000779,mbtp000022,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147185,mbcd0031241,mbtp000022,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147187,mbcd0000815,mbtp000022,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147188,mbcd0001664,mbtp000022,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147189,mbcd0003028,mbtp000022,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147190,mbcd0000848,mbtp000022,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147191,mbcd0003187,mbtp000022,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147195,mbcd0001151,mbtp000022,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147196,mbcd0001135,mbtp000022,mbrf0002627,,,,,non-substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147197,mbcd0001107,mbtp000022,mbrf0002627,,,,,substrate,,,,,,,,,,,,,,human,mbds0011,,2013-06-16 00:28:43
mbbd000147198,mbcd0001797,mbtp000013,mbrf0002299,,=,,,substrate,22,56.7,pmol min-1 (mg protein)-1,3.2,FEX,,,HEK293 cells,HEK293,,10,microM,,human,mbds0010,,2013-12-08 06:41:18
mbbd000147199,mbcd0001797,mbtp000012,mbrf0002299,,=,,,non-substrate,140,0.0622,microL min-1 (mg protein)-1,0.0586,FEX,"OATP1B1-mediated uptake of FEX was only slightly observed, although not statistically significant",,HEK293 (transfected); FEX 10 microM; uptake; 10 mins,HEK293,,10,microM,,human,mbds0010,,2013-12-08 06:41:17
mbbd000147200,mbcd0029964,mbtp000002,mbrf0001657,,=,,,non-substrate,135,1.0,fold,,AG 377,,,ABCG2-overexpressing MCF-7/MR cell line; growth inhibition after 72 hours exposure to the drug; IC50 ratio,MCF7/MR,,,,,human,mbds0010,,2013-11-24 23:10:02
mbbd000147201,mbcd0029284,mbtp000009,mbrf0002411,,,,,non-inhibitor,,,,,L-Lys,,,no inihibition on Gly-Sar uptake in Caco-2 cells,Caco-2,,,,,human,mbds0010,,2013-07-12 01:01:34
mbbd000147202,mbcd0030502,mbtp000002,mbrf0001743,,,,,substrate,,,,,BPU; Benzoylphenylurea,,,MCF-7/BCRP-R482T,MCF7,,,,,human,mbds0010,,2013-11-24 23:10:02
mbbd000147203,mbcd0029384,mbtp000008,mbrf0002427,,,,,substrate,,,,,beta-zearalenol; beta-ZOL,,,MDCKII,MDCKII,,10,microM,,human,mbds0010,,2013-07-17 00:25:32
mbbd000147204,mbcd0000387,mbtp000005,mbrf0001495,,=,,,non-inhibitor,33,100.0,%,3,E217betaG,,,sf9 membrane vesicles,Sf9,mbcd0000047,5,microM,,human,mbds0010,,2013-10-11 19:32:51
mbbd000147205,mbcd0003137,mbtp000005,mbrf0001495,,=,,,non-inhibitor,33,111.0,%,3,Furosemide,,,sf9 membrane vesicles,Sf9,mbcd0000047,500,microM,,human,mbds0010,,2013-10-11 19:32:51
mbbd000147206,mbcd0017104,mbtp000001,mbrf0001171,,=,,,inhibitor,143,4.0,,,KET,,,Caco-2 cells; inhibition of Saquinavir transepithelial transport (basal to apical),Caco-2,mbcd0001533,500,microM,,human,mbds0010,,2013-11-11 03:52:51
mbbd000147207,mbcd0027402,mbtp000001,mbrf0001171,,=,,,inhibitor,143,7.1,,,DHB,,,Caco-2 cells; inhibition of Saquinavir transepithelial transport (basal to apical),Caco-2,mbcd0001533,200,microM,,human,mbds0010,,2013-11-11 03:52:51
mbbd000147208,mbcd0027062,mbtp000005,mbrf0001204,,=,,,non-inhibitor,89,83.6,%,5.7,VER,,,LLC-PK1,LLC-PK1,mbcd0001151,100,microM,,human,mbds0010,,2012-10-26 18:21:13
mbbd000147209,mbcd0000311,mbtp000005,mbrf0001204,,=,,,inhibitor,89,150.0,%,5.1,Cys A,,,LLC-PK1,LLC-PK1,mbcd0001151,20,microM,,human,mbds0010,,2012-10-26 18:21:13
mbbd000147210,mbcd0002494,mbtp000005,mbrf0001204,,=,,,inhibitor,89,153.0,%,5.7,MK571,,,LLC-PK1,LLC-PK1,mbcd0001151,50,microM,,human,mbds0010,,2012-10-26 18:21:13
mbbd000147211,mbcd0002988,mbtp000005,mbrf0001204,,=,,,inhibitor,89,143.0,%,8.2,Sulfinpyrazone,,,LLC-PK1,LLC-PK1,mbcd0001151,5,mM,,human,mbds0010,,2012-10-26 18:21:13
mbbd000147212,mbcd0003154,mbtp000005,mbrf0001204,,=,,,inhibitor,89,135.0,%,1.8,Probenecid,,,LLC-PK1,LLC-PK1,mbcd0001151,5,mM,,human,mbds0010,,2012-10-26 18:21:13
mbbd000147213,mbcd0027402,mbtp000005,mbrf0001204,,=,,,non-inhibitor,89,89.0,%,5.3,DHBG,,,LLC-PK1,LLC-PK1,mbcd0001151,20,microM,,human,mbds0010,,2012-10-26 18:21:13
mbbd000147214,mbcd0022804,mbtp000005,mbrf0001204,,=,,,inhibitor,89,116.0,%,4.3,BG,,,LLC-PK1,LLC-PK1,mbcd0001151,20,microM,,human,mbds0010,,2012-10-26 18:21:13
mbbd000147215,mbcd0027062,mbtp000005,mbrf0001204,,=,,,inhibitor,89,122.0,%,2.7,VER,,,LLC-PK1,LLC-PK1,mbcd0001533,100,microM,,human,mbds0010,,2012-10-26 18:21:13
mbbd000147216,mbcd0000311,mbtp000005,mbrf0001204,,=,,,inhibitor,89,217.0,%,5.0,Cys A,,,LLC-PK1,LLC-PK1,mbcd0001533,20,microM,,human,mbds0010,,2012-10-26 18:21:13
mbbd000147217,mbcd0002494,mbtp000005,mbrf0001204,,=,,,inhibitor,89,143.0,%,4.8,MK571,,,LLC-PK1,LLC-PK1,mbcd0001533,50,microM,,human,mbds0010,,2012-10-26 18:21:13
mbbd000147218,mbcd0002988,mbtp000005,mbrf0001204,,=,,,inhibitor,89,153.0,%,3.1,Sulfinpyrazone,,,LLC-PK1,LLC-PK1,mbcd0001533,5,mM,,human,mbds0010,,2012-10-26 18:21:13
mbbd000147219,mbcd0003154,mbtp000005,mbrf0001204,,=,,,inhibitor,89,137.0,%,3.1,Probenecid,,,LLC-PK1,LLC-PK1,mbcd0001533,5,mM,,human,mbds0010,,2012-10-26 18:21:13
mbbd000147220,mbcd0027402,mbtp000005,mbrf0001204,,=,,,non-inhibitor,89,113.0,%,3.1,DHBG,,,LLC-PK1,LLC-PK1,mbcd0001533,20,microM,,human,mbds0010,,2012-10-26 18:21:13
mbbd000147221,mbcd0022804,mbtp000005,mbrf0001204,,=,,,non-inhibitor,89,108.0,%,11,BG,,,LLC-PK1,LLC-PK1,mbcd0001533,20,microM,,human,mbds0010,,2012-10-26 18:21:13
mbbd000147222,mbcd0001893,mbtp000005,mbrf0001204,,=,,,inhibitor,89,147.0,%,2.8,TAN,,,LLC-PK1,LLC-PK1,mbcd0001533,20,microM,,human,mbds0010,,2012-10-26 18:21:13
mbbd000147223,mbcd0029344,mbtp000005,mbrf0001204,,=,,,inhibitor,89,131.0,%,6.4,HMF,,,LLC-PK1,LLC-PK1,mbcd0001533,20,microM,,human,mbds0010,,2012-10-26 18:21:13
mbbd000147224,mbcd0003243,mbtp000005,mbrf0001204,,=,,,inhibitor,89,162.0,%,9.1,NBL,,,LLC-PK1,LLC-PK1,mbcd0001533,20,microM,,human,mbds0010,,2012-10-26 18:21:13
mbbd000147225,mbcd0027402,mbtp000001,mbrf0001204,,=,,,inhibitor,89,338.0,%,24,DHBG,,,LLC-GA5-COL150 cells; increase in saquinavir intracellular accumulation,LLC-GA5-COL150,mbcd0001533,20,microM,,human,mbds0010,,2012-04-04 22:10:06
mbbd000147226,mbcd0029344,mbtp000001,mbrf0001204,,=,,,inhibitor,89,128.0,%,2.8,HMF,,,LLC-GA5-COL150 cells; increase in saquinavir intracellular accumulation,LLC-GA5-COL150,mbcd0001533,20,microM,,human,mbds0010,,2012-04-04 22:10:06
mbbd000147227,mbcd0027402,mbtp000001,mbrf0001204,,=,,,inhibitor,89,114.0,%,3.1,DHBG,,,LLC-GA5-COL150 cells; increase in Vinblastine intracellular accumulation,LLC-GA5-COL150,mbcd0001151,20,microM,,human,mbds0010,,2012-04-04 22:10:06
mbbd000147228,mbcd0029344,mbtp000001,mbrf0001204,,=,,,inhibitor,89,157.0,%,2.7,HMF,,,LLC-GA5-COL150 cells; increase in Vinblastine intracellular accumulation,LLC-GA5-COL150,mbcd0001151,20,microM,,human,mbds0010,,2012-04-04 22:10:06
mbbd000147229,mbcd0001808,mbtp000005,mbrf0001272,,,,,non-inhibitor,,,,,GF; GF120918,,,MRP2-expressing MDCKII cells; inhibition of EGCG,MDCKII,mbcd0029142,1,microM,,human,mbds0010,,2013-10-17 22:36:05
mbbd000147230,mbcd0003025,mbtp000005,mbrf0001272,,,,,non-inhibitor,,,,,IND; indomethacin,,,MRP2-expressing MDCKII cells; inhibition of EGCG,MDCKII,mbcd0029142,10,microM,,human,mbds0010,,2013-10-17 22:36:08
mbbd000147231,mbcd0001808,mbtp000030,mbrf0001272,,,,,non-inhibitor,,,,,GF; GF120918,,,MRP1-expressing MDCKII cells; inhibition of EGCG,MDCKII,mbcd0029142,1,microM,,human,mbds0010,,2013-10-17 22:36:06
mbbd000147232,mbcd0003025,mbtp000030,mbrf0001272,,,,,inhibitor,,,,,IND; indomethacin,,,MRP1-expressing MDCKII cells; inhibition of EGCG,MDCKII,mbcd0029142,10,microM,,human,mbds0010,,2013-10-17 22:36:07
mbbd000147233,mbcd0003154,mbtp000030,mbrf0001272,,,,,inhibitor,,,,,PRB; Probenecid,,,MRP1-expressing MDCKII cells; inhibition of EGCG,MDCKII,mbcd0029142,1,mM,,human,mbds0010,,2013-10-17 22:35:54
mbbd000147234,mbcd0001151,mbtp000030,mbrf0001272,,,,,non-inhibitor,,,,,VIN; vinblastine,,,MRP1-expressing MDCKII cells; inhibition of EGCG,MDCKII,mbcd0029142,50,microM,,human,mbds0010,,2013-10-17 22:35:57
mbbd000147235,mbcd0002494,mbtp000030,mbrf0001272,,,,,non-inhibitor,,,,,MK; MK-571,,,MRP1-expressing MDCKII cells; inhibition of EGCG,MDCKII,mbcd0029142,50,microM,,human,mbds0010,,2013-10-17 22:35:59
mbbd000147236,mbcd0000311,mbtp000030,mbrf0001272,,,,,non-inhibitor,,,,,CsA; cyclosporin A,,,MRP1-expressing MDCKII cells; inhibition of EGCG,MDCKII,mbcd0029142,10,microM,,human,mbds0010,,2013-10-17 22:36:00
mbbd000147237,mbcd0001151,mbtp000001,mbrf0001272,,,,,non-inhibitor,,,,,VIN; vinblastine,,,Pgp-expressing MDCKII cells; inhibition of EGCG,MDCKII,mbcd0029142,50,microM,,human,mbds0010,,2013-10-17 22:41:39
mbbd000147238,mbcd0000311,mbtp000001,mbrf0001272,,,,,non-inhibitor,,,,,CsA; cyclosporin A,,,Pgp-expressing MDCKII cells; inhibition of EGCG,MDCKII,mbcd0029142,10,microM,,human,mbds0010,,2013-10-17 22:41:40
mbbd000147239,mbcd0001808,mbtp000001,mbrf0001272,,,,,non-inhibitor,,,,,GF; GF120918,,,Pgp-expressing MDCKII cells; inhibition of EGCG,MDCKII,mbcd0029142,1,microM,,human,mbds0010,,2013-10-17 22:41:41
mbbd000147240,mbcd0003154,mbtp000001,mbrf0001272,,,,,non-inhibitor,,,,,PRB; Probenecid,,,Pgp-expressing MDCKII cells; inhibition of EGCG,MDCKII,mbcd0029142,1,mM,,human,mbds0010,,2014-01-17 20:49:27
mbbd000147241,mbcd0000311,mbtp000001,mbrf0001185,,,,,inhibitor,,,,,cyclosporin A,,,K562/S cells; cell accumulation of doxorubicin,K562/S,mbcd0025844,1,microM,,human,mbds0010,,2013-10-18 17:57:32
mbbd000147242,mbcd0000937,mbtp000001,mbrf0001185,,,,,inhibitor,,,,,Erythromycin,,,K562/S cells; cell accumulation of doxorubicin,K562/S,mbcd0025844,1,mM,,human,mbds0010,,2013-10-18 17:57:35
mbbd000147243,mbcd0028157,mbtp000001,mbrf0001185,,,,,inhibitor,,,,,Azithromycin,,,K562/S cells; cell accumulation of doxorubicin,K562/S,mbcd0025844,0.3,mM,,human,mbds0010,,2013-10-18 17:58:37
mbbd000147244,mbcd0029350,mbtp000030,mbrf0001814,,~,,,repressor,117,40.0,%,5,Epi; epirubicin,,,Gene expression was calculated as a ratio of the band intensity of the studied gene to that in the internal standard (GAPDH),Caco-2,,10,microg mL-1,,human,mbds0010,,2013-10-18 19:02:23
mbbd000147245,mbcd0000455,mbtp000030,mbrf0001814,,~,,,repressor,117,30.0,%,2,GC; glycocholic acid,,,Gene expression was calculated as a ratio of the band intensity of the studied gene to that in the internal standard (GAPDH),Caco-2,,10,microg mL-1,,human,mbds0010,,2013-10-18 19:02:25
mbbd000147246,mbcd0029350,mbtp000001,mbrf0001814,,~,,,repressor,117,90.0,%,2,Epi; epirubicin,,,Gene expression was calculated as a ratio of the band intensity of the studied gene to that in the internal standard (GAPDH),Caco-2,,10,microg mL-1,,human,mbds0010,,2013-10-18 19:02:26
mbbd000147247,mbcd0000455,mbtp000001,mbrf0001814,,~,,,repressor,117,40.0,%,1,GC; glycocholic acid,,,Gene expression was calculated as a ratio of the band intensity of the studied gene to that in the internal standard (GAPDH),Caco-2,,10,microg mL-1,,human,mbds0010,,2013-10-18 19:02:28
mbbd000147248,mbcd0001664,mbtp000012,mbrf0001273,,~,,,inhibitor,102,15.0,%,5,cholyl taurine,,,OATP-C-expressing HEK 293 cells; inhibition of demethylphalloin uptake (demethylphalloin: 1 microM),HEK293,mbcd0000325,20,microM,,human,mbds0010,,2013-12-06 08:06:57
mbbd000147249,mbcd0000325,mbtp000012,mbrf0001273,,,,,substrate,,,,,demethylphalloin,,,OATP-C-expressing HEK 293 cell; uptake,HEK293,,1,microM,,human,mbds0010,,2013-12-09 20:15:45
mbbd000147250,mbcd0000325,mbtp000013,mbrf0001273,,,,,substrate,,,,,demethylphalloin,,,OATP8-expressing HEK 293 cell; uptake,HEK293,,1,microM,weak substrate,human,mbds0010,,2014-02-26 22:25:53
mbbd000147251,mbcd0000675,mbtp000013,mbrf0001273,,,,,non-substrate,,,,,phalloidin,,,OATP8-expressing HEK 293 cell; uptake,HEK293,,1,microM,,human,mbds0010,,2013-12-09 20:05:36
mbbd000147252,mbcd0001668,mbtp000001,mbrf0001006,,=,,,substrate,28,58.5,microM,21.9,cholesterol,,,NIH-3T3-G185 cell line (expressing hMDR1); ATP hydrolysis assay,NIH-3T3-G185,,,,,human,mbds0010,,2013-12-09 08:30:08
mbbd000147253,mbcd0001668,mbtp000001,mbrf0001006,,=,,,substrate,22,35.0,nmol min-1 mg-1,1.4,cholesterol,,,NIH-3T3-G185 cell line (expressing hMDR1); ATP hydrolysis assay,NIH-3T3-G185,,,,,human,mbds0010,,2013-12-09 08:30:09
mbbd000147254,mbcd0001668,mbtp000001,mbrf0001006,,,,,non-inhibitor,,,,,cholesterol,,,NIH-3T3-G185 cell line (expressing hMDR1); inhibition of Rhodamine 123 efflux,NIH-3T3-G185,mbcd0000746,~115,microM,,human,mbds0010,,2013-12-09 08:30:10
mbbd000147255,mbcd0029353,mbtp000005,mbrf0002254,,=,,,non-inhibitor,1,125.0,%,14,Nicotine-N-glucuronide,,,HEK293T membrane vesicles,HEK293T,mbcd0000387,100,microM,,human,mbds0010,,2013-10-29 23:14:03
mbbd000147256,mbcd0029354,mbtp000005,mbrf0002254,,=,,,non-inhibitor,1,97.0,%,18,Cotinine-N-glucuronide,,,HEK293T membrane vesicles,HEK293T,mbcd0003043,100,microM,,human,mbds0010,,2013-10-29 23:14:03
mbbd000147257,mbcd0029353,mbtp000005,mbrf0002254,,=,,,non-inhibitor,1,106.0,%,8,Nicotine-N-glucuronide,,,HEK293T membrane vesicles,HEK293T,mbcd0000387,100,microM,,human,mbds0010,,2013-10-29 23:14:03
mbbd000147258,mbcd0029354,mbtp000005,mbrf0002254,,=,,,non-inhibitor,1,109.0,%,8,Cotinine-N-glucuronide,,,HEK293T membrane vesicles,HEK293T,mbcd0003043,100,microM,,human,mbds0010,,2013-10-29 23:14:03
mbbd000147259,mbcd0000086,mbtp000001,mbrf0001190,,~,,,inhibitor,100,120.0,%,2,PMF,,,AML-2/D100 cells; rhodamine 123 intracellular accumulation,AML-2/D100,mbcd0000746,10,microM,,human,mbds0010,,2013-10-29 23:23:46
mbbd000147260,mbcd0000086,mbtp000001,mbrf0001190,,~,,,inhibitor,100,140.0,%,3,PMF,,,AML-2/D100 cells; rhodamine 123 intracellular accumulation,AML-2/D100,mbcd0000746,20,microM,,human,mbds0010,,2013-10-29 23:23:46
mbbd000147261,mbcd0000086,mbtp000001,mbrf0001190,,~,,,inhibitor,100,170.0,%,8,PMF,,,AML-2/D100 cells; rhodamine 123 intracellular accumulation,AML-2/D100,mbcd0000746,40,microM,,human,mbds0010,,2013-10-29 23:23:46
mbbd000147262,mbcd0003025,mbtp000001,mbrf0001029,,>,,,non-inhibitor,25,500.0,microM,,indomethacin,,,NIH-3T3-G185 cells; inhibition of LDS-751 efflux,NIH-3T3-G185,mbcd0030453,,,,human,mbds0010,,2013-10-29 23:43:21
mbbd000147263,mbcd0003025,mbtp000001,mbrf0001029,,>,,,non-inhibitor,25,500.0,microM,,indomethacin,,,NIH-3T3-G185 cells; inhibition of Rhodamine 123 efflux,NIH-3T3-G185,mbcd0000746,,,,human,mbds0010,,2013-10-29 23:43:21
mbbd000147264,mbcd0003141,mbtp000005,mbrf0002493,,>,,,non-inhibitor,25,100.0,microM,,Disopyramide,,,sf9 membrane vesicles; CDCF substrate; no activity,sf9,mbcd0029372,,,,human,mbds0010,,2013-10-30 00:00:35
mbbd000147265,mbcd0003141,mbtp000005,mbrf0002493,,>,,,non-inhibitor,25,100.0,microM,,Disopyramide,,,sf9 membrane vesicles; E217betaG substrate; no activity,sf9,mbcd0000387,,,,human,mbds0010,,2013-10-30 00:00:35
mbbd000147266,mbcd0003872,mbtp000005,mbrf0002493,,,,,non-inhibitor,,,,,Paracetamol,,,sf9 membrane vesicles; CDCF substrate; no activity,sf9,mbcd0029372,,,,human,mbds0010,,2013-10-30 00:00:35
mbbd000147267,mbcd0003872,mbtp000005,mbrf0002493,,,,,non-inhibitor,,,,,Paracetamol,,,sf9 membrane vesicles; E217betaG substrate; no activity,sf9,mbcd0000387,,,,human,mbds0010,,2013-10-30 00:00:35
mbbd000147268,mbcd0002422,mbtp000002,mbrf0001325,,,,,inhibitor,,,,,Fumitremorgin C,Growth inhibition,,BCRP-expressing PA317 cells; drug resistance,PA317,mbcd0000779,,,,human,mbds0010,,2013-10-30 00:08:12
mbbd000147269,mbcd0003211,mbtp000002,mbrf0001325,,,,,inhibitor,,,,,Estrone,Growth inhibition,,BCRP-expressing PA317 cells; drug resistance,PA317,mbcd0000779,,,,human,mbds0010,,2013-10-30 00:08:12
mbbd000147270,mbcd0003211,mbtp000002,mbrf0001325,,,,,inhibitor,,,,,Estrone,Growth inhibition,,BCRP-expressing PA317 cells; drug resistance,PA317,mbcd0025844,,,,human,mbds0010,,2013-10-30 00:08:12
mbbd000147271,mbcd0029500,mbtp000009,mbrf0002115,,=,,,substrate,28,1.34,mM,0.30,Ser(Reb)-Gly,,,Xenopus laevis oocytes and HeLa cells,Xenopus laevis oocytes,,250,microM,,human,mbds0010,,2013-11-11 03:52:51
mbbd000147272,mbcd0029501,mbtp000009,mbrf0002115,,,,,substrate,,,,,Gly-Ser(Reb),,,Xenopus laevis oocytes and HeLa cells,HeLa,,250,microM,,human,mbds0010,,2013-10-30 23:42:34
mbbd000147273,mbcd0029502,mbtp000009,mbrf0002115,,,,,non-substrate,,,,,Lys(Reb)-Gly,,,Xenopus laevis oocytes,Xenopus laevis oocytes,,250,microM,,human,mbds0010,,2013-10-30 23:42:34
mbbd000147274,mbcd0029503,mbtp000009,mbrf0002115,,,,,non-substrate,,,,,Gly-Lys(Reb),,,Xenopus laevis oocytes,Xenopus laevis oocytes,,250,microM,,human,mbds0010,,2013-10-30 23:42:35
mbbd000147275,mbcd0029500,mbtp000009,mbrf0002115,,=,,,substrate,22,0.76,nmol min-1 (mg protein)-1,0.1,Ser(Reb)-Gly,,,HeLa cells,HeLa,,250,microM,,human,mbds0010,,2013-10-30 23:42:35
mbbd000147276,mbcd0029500,mbtp000009,mbrf0002115,,~,,,substrate,33,4.25,microL (mg protein)-1,,Ser(Reb)-Gly,,,HeLa cells; uptake after 10 min,HeLa,,250,microM,,human,mbds0010,,2013-10-30 23:42:35
mbbd000147277,mbcd0002091,mbtp000012,mbrf0001551,,~,,,non-inhibitor,100,105.0,%,5,irinotecan; CPT-11,,,Cellular accumulation of 1 microM E2G in MDCKII-OATP1B1 cells,MDCKII,mbcd0000387,10,microM,,human,mbds0010,,2013-12-09 20:58:33
mbbd000147278,mbcd0003035,mbtp000012,mbrf0002056,,=,,,substrate,28,0.69,microM,0.16,BSP,,,HEK293,HEK293,,,,,human,mbds0010,,2013-11-03 21:46:33
mbbd000147279,mbcd0003035,mbtp000013,mbrf0002056,,=,,,substrate,28,2.86,microM,1.56,BSP,,,HEK293,HEK293,,,,,human,mbds0010,,2013-11-03 21:46:33
mbbd000147280,mbcd0029170,mbtp000012,mbrf0002056,,=,,,inhibitor,25,0.6,mM,,Gd-EOB-DTPA,,,HEK293,HEK293,mbcd0003035,,,,human,mbds0010,,2013-11-03 21:46:34
mbbd000147281,mbcd0029170,mbtp000013,mbrf0002056,,=,,,inhibitor,25,0.4,mM,,Gd-EOB-DTPA,,,HEK293,HEK293,mbcd0003035,,,,human,mbds0010,,2013-11-03 21:46:34
mbbd000147282,mbcd0029170,mbtp000012,mbrf0002056,,=,,,substrate,22,10.5,pmol mg-1 min-1,,Gd-EOB-DTPA,,,HEK293,HEK293,,,,,human,mbds0010,,2013-11-03 21:46:34
mbbd000147283,mbcd0029170,mbtp000013,mbrf0002056,,=,,,substrate,22,22.7,pmol mg-1 min-1,,Gd-EOB-DTPA,,,HEK293,HEK293,,,,,human,mbds0010,,2013-11-03 21:46:35
mbbd000147284,mbcd0029271,mbtp000001,mbrf0002279,,,,,non-substrate,,,,,butyrate; BT,,,IEC-6 and Caco-2 cell lines,IEC-6,,,,,human,mbds0010,,2013-11-10 03:37:25
mbbd000147285,mbcd0029271,mbtp000002,mbrf0002279,,,,,non-substrate,,,,,butyrate; BT,,,well differentiated (21 day old) Caco-2 cells,Caco-2,,,,,human,mbds0010,,2013-11-10 03:37:27
mbbd000147286,mbcd0000201,mbtp000012,mbrf0001393,,=,,,substrate,89,5.0,,,BSP,,,Xenopus laevis oocyte (transfected); 10 microM compound,Xenopus laevis oocytes,,10,microM,,human,mbds0010,,2013-11-20 20:45:32
mbbd000147287,mbcd0001664,mbtp000012,mbrf0001393,,=,,,substrate,89,4.7,,,Taurocholate,,,Xenopus laevis oocyte (transfected); 10 microM compound,Xenopus laevis oocytes,,10,microM,,human,mbds0010,,2013-11-20 20:45:32
mbbd000147288,mbcd0003075,mbtp000012,mbrf0001393,,=,,,substrate,89,4.5,,,Estrone-3-sulfate,,,Xenopus laevis oocyte (transfected); 10 microM compound,Xenopus laevis oocytes,,10,microM,,human,mbds0010,,2013-11-20 20:45:32
mbbd000147289,mbcd0000387,mbtp000012,mbrf0001393,,=,,,substrate,89,6.2,,,E217betaG,,,Xenopus laevis oocyte (transfected); 10 microM compound,Xenopus laevis oocytes,,10,microM,,human,mbds0010,,2013-11-20 20:45:33
mbbd000147290,mbcd0003070,mbtp000012,mbrf0001393,,=,,,substrate,89,7.3,,,DHEAS,,,Xenopus laevis oocyte (transfected); 10 microM compound,Xenopus laevis oocytes,,10,microM,,human,mbds0010,,2013-11-20 20:45:33
mbbd000147291,mbcd0001442,mbtp000012,mbrf0001393,,=,,,non-substrate,89,1.0,,,Ouabain,,,Xenopus laevis oocyte (transfected); 10 microM compound,Xenopus laevis oocytes,,200,microM,,human,mbds0010,,2013-11-20 20:45:33
mbbd000147292,mbcd0001050,mbtp000012,mbrf0001393,,=,,,non-substrate,89,0.7,,,Digoxin,,,Xenopus laevis oocyte (transfected); 10 microM compound,Xenopus laevis oocytes,,0.5,microM,,human,mbds0010,,2013-11-20 20:45:33
mbbd000147293,mbcd0000605,mbtp000012,mbrf0001393,,=,,,non-substrate,89,1.1,,,N-Methyl quinine,,,Xenopus laevis oocyte (transfected); 10 microM compound,Xenopus laevis oocytes,,10,microM,,human,mbds0010,,2013-11-20 20:45:34
mbbd000147294,mbcd0002917,mbtp000012,mbrf0001393,,=,,,substrate,89,2.7,,,LTC4,,,Xenopus laevis oocyte (transfected); 10 microM compound,Xenopus laevis oocytes,,5,microM,,human,mbds0010,,2013-11-20 20:45:34
mbbd000147295,mbcd0001343,mbtp000012,mbrf0001393,,=,,,substrate,89,4.7,,,PGE2,,,Xenopus laevis oocyte (transfected); 10 microM compound,Xenopus laevis oocytes,,20,microM,,human,mbds0010,,2013-11-20 20:45:34
mbbd000147296,mbcd0000984,mbtp000012,mbrf0001393,,=,,,substrate,89,2.2,,,T3,,,Xenopus laevis oocyte (transfected); 10 microM compound,Xenopus laevis oocytes,,10,microM,,human,mbds0010,,2013-11-20 20:45:34
mbbd000147297,mbcd0003957,mbtp000012,mbrf0001393,,=,,,substrate,89,2.0,,,T4,,,Xenopus laevis oocyte (transfected); 10 microM compound,Xenopus laevis oocytes,,10,microM,,human,mbds0010,,2013-11-20 20:45:34
mbbd000147298,mbcd0000324,mbtp000012,mbrf0001393,,=,,,non-substrate,89,1.3,,,Deltorphin II,,,Xenopus laevis oocyte (transfected); 10 microM compound,Xenopus laevis oocytes,,50,microM,,human,mbds0010,,2013-11-20 20:45:35
mbbd000147299,mbcd0003070,mbtp000013,mbrf0001393,,=,,,substrate,89,7.1,,,DHEAS,,,Xenopus laevis oocyte (transfected); 10 microM compound,Xenopus laevis oocytes,,10,microM,,human,mbds0010,,2013-11-20 20:45:35
mbbd000147300,mbcd0000201,mbtp000013,mbrf0001393,,=,,,substrate,89,8.9,,,BSP,,,Xenopus laevis oocyte (transfected); 10 microM compound,Xenopus laevis oocytes,,10,microM,,human,mbds0010,,2013-11-20 20:45:35
mbbd000147301,mbcd0000387,mbtp000013,mbrf0001393,,=,,,substrate,89,2.5,,,E217betaG,,,Xenopus laevis oocyte (transfected); 10 microM compound,Xenopus laevis oocytes,,10,microM,,human,mbds0010,,2013-11-20 20:45:35
mbbd000147302,mbcd0001343,mbtp000013,mbrf0001393,,=,,,non-substrate,89,1.0,,,PGE2,,,Xenopus laevis oocyte (transfected); 10 microM compound,Xenopus laevis oocytes,,20,microM,,human,mbds0010,,2013-11-20 20:45:36
mbbd000147303,mbcd0000201,mbtp000024,mbrf0001393,,=,,,substrate,89,9.5,,,BSP,,,Xenopus laevis oocyte (transfected); 10 microM compound,Xenopus laevis oocytes,,10,microM,,human,mbds0010,,2013-11-20 20:45:36
mbbd000147304,mbcd0001664,mbtp000024,mbrf0001393,,=,,,substrate,89,3.0,,,Taurocholate,,,Xenopus laevis oocyte (transfected); 10 microM compound,Xenopus laevis oocytes,,10,microM,,human,mbds0010,,2013-11-20 20:45:36
mbbd000147305,mbcd0003075,mbtp000024,mbrf0001393,,=,,,substrate,89,6.3,,,Estrone-3-sulfate,,,Xenopus laevis oocyte (transfected); 10 microM compound,Xenopus laevis oocytes,,10,microM,,human,mbds0010,,2013-11-20 20:45:36
mbbd000147306,mbcd0003070,mbtp000024,mbrf0001393,,=,,,substrate,89,10.0,,,DHEAS,,,Xenopus laevis oocyte (transfected); 10 microM compound,Xenopus laevis oocytes,,10,microM,,human,mbds0010,,2013-11-20 20:45:37
mbbd000147307,mbcd0001050,mbtp000024,mbrf0001393,,=,,,non-substrate,89,0.7,,,Digoxin,,,Xenopus laevis oocyte (transfected); 10 microM compound,Xenopus laevis oocytes,,0.5,microM,,human,mbds0010,,2013-11-20 20:45:37
mbbd000147308,mbcd0000324,mbtp000024,mbrf0001393,,=,,,substrate,89,2.8,,,Deltorphin II,,,Xenopus laevis oocyte (transfected); 10 microM compound,Xenopus laevis oocytes,,50,microM,,human,mbds0010,,2013-11-20 20:45:37
mbbd000147309,mbcd0001299,mbtp000001,mbrf0002460,,=,,,inducer,117,3.87,,0.97,Quinidine,,,T84 intestinal cell line; real-time PCR (TaqMan) following 72 h xenobiotic pre-treatment ,T84,,10,microM,,human,mbds0010,,2013-11-04 21:37:53
mbbd000147310,mbcd0003187,mbtp000005,mbrf0002460,,=,,,repressor,117,0.14,,0.02,Topotecan,,,T84 intestinal cell line; real-time PCR (TaqMan) following 72 h xenobiotic pre-treatment ,T84,,10,microM,,human,mbds0010,,2013-11-04 21:37:56
mbbd000147311,mbcd0003187,mbtp000001,mbrf0002460,,=,,,inducer,117,2.29,,0.18,Topotecan,,,T84 intestinal cell line; real-time PCR (TaqMan) following 72 h xenobiotic pre-treatment ,T84,,10,microM,,human,mbds0010,,2013-11-04 21:37:54
mbbd000147312,mbcd0026093,mbtp000005,mbrf0002460,,=,,,repressor,117,0.42,,0.13,Atorvastatin,,,T84 intestinal cell line; real-time PCR (TaqMan) following 72 h xenobiotic pre-treatment ,T84,,10,microM,,human,mbds0010,,2013-11-04 21:37:56
mbbd000147313,mbcd0026093,mbtp000001,mbrf0002460,,~,,,inducer,117,4.0,,1,Atorvastatin,,,T84 intestinal cell line; real-time PCR (TaqMan) following 72 h xenobiotic pre-treatment ,T84,,10,microM,,human,mbds0010,,2013-11-04 06:29:15
mbbd000147314,mbcd0000937,mbtp000005,mbrf0002460,,~,,,non-inducer,117,1.25,,0.5,Erythromycin,,,T84 intestinal cell line; real-time PCR (TaqMan) following 72 h xenobiotic pre-treatment ,T84,,10,microM,,human,mbds0010,,2013-11-04 06:29:15
mbbd000147315,mbcd0000937,mbtp000001,mbrf0002460,,=,,,non-inducer,117,0.42,,0.11,Erythromycin,,,T84 intestinal cell line; real-time PCR (TaqMan) following 72 h xenobiotic pre-treatment ,T84,,10,microM,,human,mbds0010,,2013-11-04 21:37:54
mbbd000147316,mbcd0002383,mbtp000005,mbrf0002460,,~,,,non-inducer,117,1.0,,0.4,Amprenavir,,,T84 intestinal cell line; real-time PCR (TaqMan) following 72 h xenobiotic pre-treatment ,T84,,10,microM,,human,mbds0010,,2013-11-04 06:29:16
mbbd000147317,mbcd0002383,mbtp000001,mbrf0002460,,=,,,non-inducer,117,5.05,,2.13,Amprenavir,not statisitcally significant increase in MDR1 gene expression,,T84 intestinal cell line; real-time PCR (TaqMan) following 72 h xenobiotic pre-treatment ,T84,,10,microM,,human,mbds0010,,2013-11-04 21:37:54
mbbd000147318,mbcd0002091,mbtp000005,mbrf0002460,,=,,,repressor,117,0.52,,0.06,Irinotecan,,,T84 intestinal cell line; real-time PCR (TaqMan) following 72 h xenobiotic pre-treatment ,T84,,10,microM,,human,mbds0010,,2013-11-04 21:37:56
mbbd000147319,mbcd0002091,mbtp000001,mbrf0002460,,=,,,non-inducer,117,1.09,,0.21,Irinotecan,,,T84 intestinal cell line; real-time PCR (TaqMan) following 72 h xenobiotic pre-treatment ,T84,,10,microM,,human,mbds0010,,2013-11-04 21:37:54
mbbd000147320,mbcd0001632,mbtp000005,mbrf0002460,,,,,non-inducer,,,,,Hyperforin,,,T84 intestinal cell line; real-time PCR (TaqMan) following 72 h xenobiotic pre-treatment ,T84,,10,microM,,human,mbds0010,,2013-11-04 21:14:53
mbbd000147321,mbcd0001632,mbtp000001,mbrf0002460,,=,,,inducer,117,3.0,fold increase,,Hyperforin,3-fold increase in MDR1 transcript levels,,T84 intestinal cell line; real-time PCR (TaqMan) following 72 h xenobiotic pre-treatment ,T84,,10,microM,,human,mbds0010,,2013-11-21 02:28:15
mbbd000147322,mbcd0030463,mbtp000001,mbrf0002460,,=,,,non-inducer,117,1.24,,0.39,Artemisinin,,,T84 intestinal cell line; real-time PCR (TaqMan) following 72 h xenobiotic pre-treatment ,T84,,10,microM,,human,mbds0010,,2013-11-04 21:37:55
mbbd000147323,mbcd0001299,mbtp000001,mbrf0002460,,,,,non-inducer,,,,,Mifepristone,,,T84 intestinal cell line; real-time PCR (TaqMan) following 72 h xenobiotic pre-treatment ,T84,,10,microM,,human,mbds0010,,2013-11-04 21:37:55
mbbd000147324,mbcd0001111,mbtp000001,mbrf0002460,,,,,non-inducer,,,,,Cimetidine,,,T84 intestinal cell line; real-time PCR (TaqMan) following 72 h xenobiotic pre-treatment ,T84,,10,microM,,human,mbds0010,,2013-11-04 21:37:55
mbbd000147325,mbcd0027062,mbtp000001,mbrf0002460,,,,,non-inducer,,,,,Verapamil,,,T84 intestinal cell line; real-time PCR (TaqMan) following 72 h xenobiotic pre-treatment ,T84,,10,microM,,human,mbds0010,,2013-11-04 21:37:55
mbbd000147326,mbcd0030462,mbtp000001,mbrf0002460,,=,,,inducer,117,2.45,,0.56,Mevastatin,,,T84 intestinal cell line; real-time PCR (TaqMan) following 72 h xenobiotic pre-treatment ,T84,,10,microM,,human,mbds0010,,2013-11-04 21:37:56
mbbd000147327,mbcd0001111,mbtp000005,mbrf0002460,,=,,,inducer,117,2.98,,0.76,Cimetidine,,,T84 intestinal cell line; real-time PCR (TaqMan) following 72 h xenobiotic pre-treatment ,T84,,10,microM,,human,mbds0010,,2013-11-04 21:37:57
mbbd000147328,mbcd0003618,mbtp000009,mbrf0002731,,=,,,substrate,28,2.9,mM,,cephalexin; CPX,,,Caco-2; pH 6,Caco-2,,0.1-25,mM,,human,mbds0010,,2013-11-04 21:47:28
mbbd000147329,mbcd0003494,mbtp000009,mbrf0001884,,=,,,substrate,28,1.2,mM,0.1,Gly-Sar,,,Caco-2; uptake,Caco-2,,0-5,mM,,human,mbds0010,,2013-11-04 22:03:18
mbbd000147330,mbcd0003075,mbtp000012,mbrf0001395,,=,,,substrate,22,549.0,pmol (mg protein)-1 (30 min)-1,119,estrone 3 sulfate,,,"OATP-C-expressing HEK293 cells; uptake; low affinity, high capacity component of a biphasic concentration dependence (compound concentrations are approximate)",HEK293,,0.1-10,microM,,human,mbds0010,,2013-11-04 22:28:31
mbbd000147331,mbcd0003075,mbtp000012,mbrf0001395,,=,,,substrate,22,14.8,pmol (mg protein)-1 (30 min)-1,0.065,estrone 3 sulfate,,,"OATP-C-expressing HEK293 cells; uptake; high affinity, low capacity component of a biphasic concentration dependence (compound concentrations are approximate)",HEK293,,10-100,nM,,human,mbds0010,,2013-11-04 22:28:31
mbbd000147332,mbcd0031470,mbtp000001,mbrf0001073,,,,,substrate,,,,,C6-NBD-PS,,,MDR1-expressing EPG85-257 cells,EPG85-257,,,,,human,mbds0010,,2013-11-05 07:28:14
mbbd000147334,mbcd0031470,mbtp000002,mbrf0001073,,,,,substrate,,,,,C6-NBD-PS,,,BCRP-expressing EPG85-257 cells,EPG85-257,,,,,human,mbds0010,,2013-11-05 07:28:15
mbbd000147336,mbcd0001343,mbtp000022,mbrf0001305,,=,,,substrate,22,6.4,pmol (mg protein)-1 min-1,,PGE2,,,membrane vesicle from MRP4-expressing Sf9 cells,Sf9,,,,,human,mbds0010,,2013-11-05 07:28:15
mbbd000147337,mbcd0001267,mbtp000022,mbrf0001305,,=,,,substrate,22,6.9,pmol (mg protein)-1 min-1,,PGE1,,,membrane vesicle from MRP4-expressing Sf9 cells,Sf9,,,,,human,mbds0010,,2013-11-05 07:28:15
mbbd000147338,mbcd0000723,mbtp000007,mbrf0002748,,=,,,non-substrate,8,1.0,,,328; Puromycin,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 01:26:34
mbbd000147339,mbcd0001107,mbtp000007,mbrf0002748,,=,,,non-substrate,8,0.9,,,322; Zidovudine,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:34
mbbd000147340,mbcd0001111,mbtp000007,mbrf0002748,,=,,,substrate,8,4.0,,,118; Cimetidine,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:35
mbbd000147341,mbcd0001153,mbtp000007,mbrf0002748,,=,,,substrate,8,1.7,,,37; Atropine,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:35
mbbd000147342,mbcd0001204,mbtp000007,mbrf0002748,,=,,,substrate,8,14.6,,,25; Sumatriptan,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:35
mbbd000147343,mbcd0001251,mbtp000007,mbrf0002748,,=,,,non-substrate,8,1.1,,,47; Scopolamine,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:35
mbbd000147344,mbcd0001389,mbtp000007,mbrf0002748,,=,,,substrate,8,6.5,,,14; Albuterol,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:35
mbbd000147345,mbcd0001539,mbtp000007,mbrf0002748,,=,,,non-substrate,8,0.3,,,329; Chlorprothixene,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:35
mbbd000147346,mbcd0001777,mbtp000007,mbrf0002748,,=,,,non-substrate,8,1.2,,,9; Haloperidol,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:35
mbbd000147347,mbcd0002192,mbtp000007,mbrf0002748,,=,,,non-substrate,8,1.2,,,17; Amiodarone,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:35
mbbd000147348,mbcd0002195,mbtp000007,mbrf0002748,,=,,,non-substrate,8,1.1,,,119; Propafenone,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:35
mbbd000147349,mbcd0002338,mbtp000007,mbrf0002748,,=,,,non-substrate,8,1.3,,,19; Diltiazem,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:35
mbbd000147350,mbcd0002488,mbtp000007,mbrf0002748,,=,,,non-substrate,8,1.1,,,2; Propanolol,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:35
mbbd000147351,mbcd0002539,mbtp000007,mbrf0002748,,=,,,non-substrate,8,1.1,,,20; Loperamide,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:35
mbbd000147352,mbcd0002666,mbtp000007,mbrf0002748,,=,,,substrate,8,18.1,,,24; Ranitidine,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:35
mbbd000147353,mbcd0002820,mbtp000007,mbrf0002748,,=,,,non-substrate,8,1.1,,,28; Mibefradil,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:35
mbbd000147354,mbcd0002828,mbtp000007,mbrf0002748,,=,,,non-substrate,8,1.1,,,11; Imatinib,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:35
mbbd000147355,mbcd0002995,mbtp000007,mbrf0002748,,=,,,non-substrate,8,0.8,,,315; Desipramine,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:35
mbbd000147356,mbcd0002997,mbtp000007,mbrf0002748,,=,,,non-substrate,8,1.3,,,27; Terazosin,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:35
mbbd000147357,mbcd0003003,mbtp000007,mbrf0002748,,=,,,non-substrate,8,0.9,,,323; Bupropion,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:35
mbbd000147358,mbcd0003024,mbtp000007,mbrf0002748,,=,,,non-substrate,8,0.9,,,321; Prazosin,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:35
mbbd000147359,mbcd0003105,mbtp000007,mbrf0002748,,>,,,substrate,8,39.3,,,158; Phenformin,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:35
mbbd000147360,mbcd0003111,mbtp000007,mbrf0002748,,=,,,substrate,8,75.7,,,6; Amiloride,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:35
mbbd000147361,mbcd0003115,mbtp000007,mbrf0002748,,=,,,substrate,8,1.9,,,1; Trimethoprim,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:35
mbbd000147362,mbcd0003125,mbtp000007,mbrf0002748,,=,,,non-substrate,8,1.2,,,3; Iressa,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:35
mbbd000147363,mbcd0003138,mbtp000007,mbrf0002748,,=,,,substrate,8,3.1,,,45; Nizatidine,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:35
mbbd000147364,mbcd0003141,mbtp000007,mbrf0002748,,=,,,substrate,8,1.7,,,13; Disopyramide,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:35
mbbd000147365,mbcd0003871,mbtp000007,mbrf0002748,,=,,,non-substrate,8,0.5,,,320; Apomorphine,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:35
mbbd000147366,mbcd0003875,mbtp000007,mbrf0002748,,=,,,substrate,8,8.1,,,109; Atenolol racemate,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:35
mbbd000147367,mbcd0003880,mbtp000007,mbrf0002748,,=,,,substrate,8,7.3,,,115; Terbutaline,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:35
mbbd000147368,mbcd0003886,mbtp000007,mbrf0002748,,>,,,substrate,8,1.7,,,157; Metformin,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:35
mbbd000147369,mbcd0003888,mbtp000007,mbrf0002748,,=,,,non-substrate,8,1.0,,,5; Clozapine,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:35
mbbd000147370,mbcd0003894,mbtp000007,mbrf0002748,,=,,,substrate,8,1.8,,,12; Metoclopramide,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:35
mbbd000147371,mbcd0003897,mbtp000007,mbrf0002748,,=,,,non-substrate,8,0.9,,,316; Fluphenazine,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:35
mbbd000147372,mbcd0003898,mbtp000007,mbrf0002748,,=,,,non-substrate,8,1.1,,,15; Imipramine,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:35
mbbd000147373,mbcd0003910,mbtp000007,mbrf0002748,,=,,,non-substrate,8,0.8,,,313; Prochlorperazine,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:35
mbbd000147374,mbcd0003914,mbtp000007,mbrf0002748,,=,,,non-substrate,8,1.1,,,317; Memantine,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:35
mbbd000147375,mbcd0003915,mbtp000007,mbrf0002748,,=,,,non-substrate,8,0.9,,,314; Promethazine,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:35
mbbd000147376,mbcd0003925,mbtp000007,mbrf0002748,,=,,,non-substrate,8,0.8,,,318; Clomipramine,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:35
mbbd000147377,mbcd0003929,mbtp000007,mbrf0002748,,=,,,non-substrate,8,1.1,,,111; Oxyprenolol,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:35
mbbd000147378,mbcd0003941,mbtp000007,mbrf0002748,,=,,,substrate,8,2.5,,,21; Procainamide,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:35
mbbd000147379,mbcd0003947,mbtp000007,mbrf0002748,,=,,,non-substrate,8,1.2,,,110; Clonidine,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:35
mbbd000147380,mbcd0003951,mbtp000007,mbrf0002748,,=,,,substrate,8,76.2,,,7; Mepenzolate,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:35
mbbd000147381,mbcd0005282,mbtp000007,mbrf0002748,,=,,,non-substrate,8,1.1,,,16; Sulfaphenazole,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:35
mbbd000147382,mbcd0009152,mbtp000007,mbrf0002748,,=,,,substrate,8,1.8,,,113; Perphenazine,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:35
mbbd000147383,mbcd0014496,mbtp000007,mbrf0002748,,=,,,non-substrate,8,1.1,,,126; Selegiline,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:35
mbbd000147384,mbcd0016517,mbtp000007,mbrf0002748,,=,,,substrate,8,4.7,,,36; Atenolol (chiral S),,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:35
mbbd000147385,mbcd0019953,mbtp000007,mbrf0002748,,=,,,substrate,8,1.5,,,112; Triamterene,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:35
mbbd000147386,mbcd0026636,mbtp000007,mbrf0002748,,=,,,substrate,8,17.5,,,18; Fenoterol,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:35
mbbd000147387,mbcd0026922,mbtp000007,mbrf0002748,,=,,,non-substrate,8,0.8,,,319; Bupivacain,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:35
mbbd000147388,mbcd0027018,mbtp000007,mbrf0002748,,=,,,non-substrate,8,1.2,,,23; Quinidine,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:35
mbbd000147389,mbcd0027062,mbtp000007,mbrf0002748,,=,,,non-substrate,8,1.2,,,10; Verapamil,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:35
mbbd000147390,mbcd0027314,mbtp000007,mbrf0002748,,=,,,non-substrate,8,1.1,,,114; Ketamine,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:35
mbbd000147391,mbcd0027318,mbtp000007,mbrf0002748,,=,,,non-substrate,8,1.2,,,125; Pindolol,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:35
mbbd000147392,mbcd0028157,mbtp000007,mbrf0002748,,=,,,non-substrate,8,1.1,,,8; Azithromycin,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:35
mbbd000147393,mbcd0029177,mbtp000007,mbrf0002748,,=,,,substrate,8,1.6,,,84; Varenicline,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:35
mbbd000147394,mbcd0029732,mbtp000007,mbrf0002748,,=,,,substrate,8,4.6,,,40; Atenolol (chiral R),,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:35
mbbd000147395,mbcd0031109,mbtp000007,mbrf0002748,,=,,,substrate,8,41.9,,,124; Ipratropium,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:35
mbbd000147396,mbcd0031539,mbtp000007,mbrf0002748,,=,,,non-substrate,8,1.0,,,127; Anisomycin,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:35
mbbd000147397,mbcd0031540,mbtp000007,mbrf0002748,,=,,,non-substrate,8,0.8,,,330; Anisomycin (chiral),,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:35
mbbd000147398,mbcd0014022,mbtp000007,mbrf0002748,,=,,,non-substrate,8,1.0,,,120; Buflomedil,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:35
mbbd000147399,mbcd0031541,mbtp000007,mbrf0002748,,=,,,non-substrate,8,0.8,,,335; Capromorelin,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:35
mbbd000147400,mbcd0031542,mbtp000007,mbrf0002748,,=,,,non-substrate,8,0.8,,,327; Ibutamoren,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:35
mbbd000147401,mbcd0031543,mbtp000007,mbrf0002748,,=,,,non-substrate,8,0.8,,,326; Lappaconitine,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:35
mbbd000147402,mbcd0012785,mbtp000007,mbrf0002748,,=,,,non-substrate,8,0.9,,,324; Methoctramine,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2014-02-27 03:11:42
mbbd000147403,mbcd0012286,mbtp000007,mbrf0002748,,=,,,non-substrate,8,1.0,,,325; Phenamil,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:35
mbbd000147404,mbcd0031556,mbtp000007,mbrf0002748,,=,,,non-substrate,8,0.7,,,342; Project A,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:35
mbbd000147405,mbcd0031557,mbtp000007,mbrf0002748,,=,,,non-substrate,8,1.1,,,104; Project A,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:35
mbbd000147406,mbcd0031558,mbtp000007,mbrf0002748,,=,,,non-substrate,8,1.1,,,122; Project A,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:35
mbbd000147407,mbcd0031559,mbtp000007,mbrf0002748,,=,,,non-substrate,8,1.1,,,144; Project A,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:35
mbbd000147408,mbcd0031560,mbtp000007,mbrf0002748,,=,,,non-substrate,8,1.1,,,155; Project A,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:36
mbbd000147409,mbcd0031561,mbtp000007,mbrf0002748,,=,,,non-substrate,8,1.2,,,100; Project A,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:36
mbbd000147410,mbcd0031562,mbtp000007,mbrf0002748,,=,,,non-substrate,8,1.2,,,116; Project A,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:36
mbbd000147411,mbcd0031563,mbtp000007,mbrf0002748,,=,,,non-substrate,8,1.0,,,31; Project A,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:36
mbbd000147412,mbcd0031564,mbtp000007,mbrf0002748,,=,,,non-substrate,8,1.0,,,67; Project A,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:36
mbbd000147413,mbcd0031565,mbtp000007,mbrf0002748,,=,,,non-substrate,8,1.0,,,99; Project A,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:36
mbbd000147414,mbcd0031566,mbtp000007,mbrf0002748,,=,,,non-substrate,8,1.0,,,123; Project A,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:36
mbbd000147415,mbcd0031567,mbtp000007,mbrf0002748,,=,,,non-substrate,8,1.0,,,340; Project A,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:36
mbbd000147416,mbcd0031568,mbtp000007,mbrf0002748,,=,,,non-substrate,8,1.1,,,52; Project A,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:36
mbbd000147417,mbcd0031569,mbtp000007,mbrf0002748,,=,,,non-substrate,8,1.1,,,89; Project A,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:36
mbbd000147418,mbcd0031570,mbtp000007,mbrf0002748,,=,,,non-substrate,8,1.1,,,92; Project A,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:36
mbbd000147419,mbcd0031571,mbtp000007,mbrf0002748,,=,,,non-substrate,8,1.1,,,33; Project AA,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:36
mbbd000147420,mbcd0031572,mbtp000007,mbrf0002748,,=,,,non-substrate,8,1.0,,,352; Project BB,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:36
mbbd000147421,mbcd0031573,mbtp000007,mbrf0002748,,=,,,non-substrate,8,1.2,,,351; Project BB,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:36
mbbd000147422,mbcd0031574,mbtp000007,mbrf0002748,,=,,,non-substrate,8,0.7,,,337; Project T,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:36
mbbd000147423,mbcd0031575,mbtp000007,mbrf0002748,,=,,,non-substrate,8,0.9,,,349; Project T,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:36
mbbd000147424,mbcd0031576,mbtp000007,mbrf0002748,,=,,,non-substrate,8,1.0,,,103; Project T,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:36
mbbd000147425,mbcd0031577,mbtp000007,mbrf0002748,,=,,,non-substrate,8,1.2,,,39; Project T,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:36
mbbd000147426,mbcd0031578,mbtp000007,mbrf0002748,,=,,,non-substrate,8,1.2,,,79; Project T,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:36
mbbd000147427,mbcd0031579,mbtp000007,mbrf0002748,,=,,,non-substrate,8,1.3,,,56; Project T,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:36
mbbd000147428,mbcd0031580,mbtp000007,mbrf0002748,,=,,,non-substrate,8,1.3,,,77; Project T,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:36
mbbd000147429,mbcd0031581,mbtp000007,mbrf0002748,,=,,,non-substrate,8,0.8,,,344; Project W,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:36
mbbd000147430,mbcd0031582,mbtp000007,mbrf0002748,,=,,,non-substrate,8,0.8,,,350; Project W,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:36
mbbd000147431,mbcd0031583,mbtp000007,mbrf0002748,,=,,,non-substrate,8,0.9,,,343; Project W,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:36
mbbd000147432,mbcd0031584,mbtp000007,mbrf0002748,,=,,,non-substrate,8,1.0,,,97; Project W,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:36
mbbd000147433,mbcd0031585,mbtp000007,mbrf0002748,,=,,,non-substrate,8,1.0,,,108; Project W,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:36
mbbd000147434,mbcd0031586,mbtp000007,mbrf0002748,,=,,,non-substrate,8,1.2,,,341; Project W,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:36
mbbd000147435,mbcd0031587,mbtp000007,mbrf0002748,,=,,,non-substrate,8,1.2,,,345; Project W,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:36
mbbd000147436,mbcd0031588,mbtp000007,mbrf0002748,,=,,,non-substrate,8,1.0,,,336; Project X,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:36
mbbd000147437,mbcd0031589,mbtp000007,mbrf0002748,,=,,,non-substrate,8,1.0,,,347; Project X,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:36
mbbd000147438,mbcd0031590,mbtp000007,mbrf0002748,,=,,,non-substrate,8,1.1,,,62; Project X,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:36
mbbd000147439,mbcd0031591,mbtp000007,mbrf0002748,,=,,,non-substrate,8,1.1,,,80; Project X,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:36
mbbd000147440,mbcd0031592,mbtp000007,mbrf0002748,,=,,,non-substrate,8,1.1,,,81; Project X,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:36
mbbd000147441,mbcd0031593,mbtp000007,mbrf0002748,,=,,,non-substrate,8,1.1,,,102; Project X,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:36
mbbd000147442,mbcd0031594,mbtp000007,mbrf0002748,,=,,,non-substrate,8,1.2,,,63; Project X,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:36
mbbd000147443,mbcd0031595,mbtp000007,mbrf0002748,,=,,,non-substrate,8,0.9,,,339; Project Y,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:36
mbbd000147444,mbcd0031596,mbtp000007,mbrf0002748,,=,,,non-substrate,8,1.0,,,44; Project Z,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:36
mbbd000147445,mbcd0026853,mbtp000007,mbrf0002748,,=,,,non-substrate,8,1.0,,,121; Salmeterol,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:36
mbbd000147446,mbcd0010743,mbtp000007,mbrf0002748,,=,,,non-substrate,8,1.0,,,48; Vesamicol,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:36
mbbd000147447,mbcd0031544,mbtp000007,mbrf0002748,,=,,,substrate,8,1.8,,,22; Benzamil,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:36
mbbd000147448,mbcd0031545,mbtp000007,mbrf0002748,,=,,,substrate,8,1.7,,,29; Camostat,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:36
mbbd000147449,mbcd0031546,mbtp000007,mbrf0002748,,=,,,substrate,8,56.5,,,26; Clidinium,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:36
mbbd000147450,mbcd0001380,mbtp000007,mbrf0002748,,=,,,substrate,8,3.0,,,30; Formoterol,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-15 23:03:58
mbbd000147451,mbcd0031547,mbtp000007,mbrf0002748,,=,,,substrate,8,59.1,,,41; Glycopyrrolate,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:36
mbbd000147452,mbcd0031548,mbtp000007,mbrf0002748,,=,,,substrate,8,1.4,,,42; Indacaterol,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:36
mbbd000147453,mbcd0031549,mbtp000007,mbrf0002748,,=,,,substrate,8,25.2,,,4; Oxyphenonium,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:36
mbbd000147454,mbcd0017593,mbtp000007,mbrf0002748,,=,,,substrate,8,10.7,,,49; Procaterol,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:36
mbbd000147455,mbcd0031597,mbtp000007,mbrf0002748,,=,,,substrate,8,1.4,,,68; Project A,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:36
mbbd000147456,mbcd0031598,mbtp000007,mbrf0002748,,=,,,substrate,8,1.4,,,72; Project A,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:36
mbbd000147457,mbcd0031599,mbtp000007,mbrf0002748,,=,,,substrate,8,1.4,,,86; Project A,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:36
mbbd000147458,mbcd0031600,mbtp000007,mbrf0002748,,=,,,substrate,8,1.4,,,88; Project A,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:36
mbbd000147459,mbcd0031601,mbtp000007,mbrf0002748,,=,,,substrate,8,1.4,,,140; Project A,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:36
mbbd000147460,mbcd0031602,mbtp000007,mbrf0002748,,=,,,substrate,8,1.9,,,71; Project A,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:36
mbbd000147461,mbcd0031603,mbtp000007,mbrf0002748,,=,,,substrate,8,1.9,,,106; Project A,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:36
mbbd000147462,mbcd0031604,mbtp000007,mbrf0002748,,=,,,substrate,8,1.9,,,143; Project A,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:36
mbbd000147463,mbcd0031605,mbtp000007,mbrf0002748,,=,,,substrate,8,2.0,,,101; Project A,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:36
mbbd000147464,mbcd0031606,mbtp000007,mbrf0002748,,=,,,substrate,8,2.5,,,107; Project A,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:36
mbbd000147465,mbcd0031607,mbtp000007,mbrf0002748,,=,,,substrate,8,2.7,,,135; Project A,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:36
mbbd000147466,mbcd0031608,mbtp000007,mbrf0002748,,=,,,substrate,8,2.9,,,59; Project A,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:36
mbbd000147467,mbcd0031609,mbtp000007,mbrf0002748,,=,,,substrate,8,3.0,,,90; Project A,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:36
mbbd000147468,mbcd0031610,mbtp000007,mbrf0002748,,=,,,substrate,8,3.0,,,94; Project A,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:36
mbbd000147469,mbcd0031611,mbtp000007,mbrf0002748,,=,,,substrate,8,3.1,,,58; Project A,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:36
mbbd000147470,mbcd0031612,mbtp000007,mbrf0002748,,=,,,substrate,8,3.4,,,147; Project A,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:36
mbbd000147471,mbcd0031613,mbtp000007,mbrf0002748,,=,,,substrate,8,3.4,,,153; Project A,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:36
mbbd000147472,mbcd0031614,mbtp000007,mbrf0002748,,=,,,substrate,8,3.5,,,69; Project A,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:36
mbbd000147473,mbcd0031615,mbtp000007,mbrf0002748,,=,,,substrate,8,3.6,,,138; Project A,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:36
mbbd000147474,mbcd0031616,mbtp000007,mbrf0002748,,=,,,substrate,8,3.7,,,78; Project A,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:36
mbbd000147475,mbcd0031617,mbtp000007,mbrf0002748,,=,,,substrate,8,4.5,,,32; Project A,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:36
mbbd000147476,mbcd0031618,mbtp000007,mbrf0002748,,=,,,substrate,8,4.5,,,142; Project A,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:36
mbbd000147477,mbcd0031619,mbtp000007,mbrf0002748,,=,,,substrate,8,4.6,,,148; Project A,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:36
mbbd000147478,mbcd0031620,mbtp000007,mbrf0002748,,=,,,substrate,8,5.1,,,132; Project A,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:36
mbbd000147479,mbcd0031621,mbtp000007,mbrf0002748,,=,,,substrate,8,5.2,,,95; Project A,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:36
mbbd000147480,mbcd0031622,mbtp000007,mbrf0002748,,=,,,substrate,8,5.3,,,60; Project A,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:36
mbbd000147481,mbcd0031623,mbtp000007,mbrf0002748,,=,,,substrate,8,5.3,,,133; Project A,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:36
mbbd000147482,mbcd0031624,mbtp000007,mbrf0002748,,=,,,substrate,8,6.5,,,57; Project A,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:37
mbbd000147483,mbcd0031625,mbtp000007,mbrf0002748,,=,,,substrate,8,6.5,,,137; Project A,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:37
mbbd000147484,mbcd0031626,mbtp000007,mbrf0002748,,=,,,substrate,8,6.6,,,93; Project A,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:37
mbbd000147485,mbcd0031627,mbtp000007,mbrf0002748,,=,,,substrate,8,6.6,,,98; Project A,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:37
mbbd000147486,mbcd0031628,mbtp000007,mbrf0002748,,=,,,substrate,8,6.7,,,87; Project A,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:37
mbbd000147487,mbcd0031629,mbtp000007,mbrf0002748,,=,,,substrate,8,6.8,,,131; Project A,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:37
mbbd000147488,mbcd0031630,mbtp000007,mbrf0002748,,=,,,substrate,8,7.1,,,156; Project A,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:37
mbbd000147489,mbcd0031631,mbtp000007,mbrf0002748,,=,,,substrate,8,7.2,,,139; Project A,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:37
mbbd000147490,mbcd0031632,mbtp000007,mbrf0002748,,=,,,substrate,8,7.8,,,141; Project A,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:37
mbbd000147491,mbcd0031633,mbtp000007,mbrf0002748,,=,,,substrate,8,8.0,,,154; Project A,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:37
mbbd000147492,mbcd0031634,mbtp000007,mbrf0002748,,=,,,substrate,8,8.4,,,130; Project A,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:37
mbbd000147493,mbcd0031635,mbtp000007,mbrf0002748,,=,,,substrate,8,8.6,,,152; Project A,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:37
mbbd000147494,mbcd0031636,mbtp000007,mbrf0002748,,=,,,substrate,8,9.1,,,96; Project A,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:37
mbbd000147495,mbcd0031637,mbtp000007,mbrf0002748,,=,,,substrate,8,10.0,,,151; Project A,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:37
mbbd000147496,mbcd0031638,mbtp000007,mbrf0002748,,=,,,substrate,8,10.7,,,75; Project A,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:37
mbbd000147497,mbcd0031639,mbtp000007,mbrf0002748,,=,,,substrate,8,11.3,,,73; Project A,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:37
mbbd000147498,mbcd0031640,mbtp000007,mbrf0002748,,=,,,substrate,8,11.3,,,117; Project A,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:37
mbbd000147499,mbcd0031641,mbtp000007,mbrf0002748,,=,,,substrate,8,11.3,,,146; Project A,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:37
mbbd000147500,mbcd0031642,mbtp000007,mbrf0002748,,=,,,substrate,8,11.4,,,51; Project A,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:37
mbbd000147501,mbcd0031643,mbtp000007,mbrf0002748,,=,,,substrate,8,12.5,,,145; Project A,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:37
mbbd000147502,mbcd0031644,mbtp000007,mbrf0002748,,=,,,substrate,8,12.7,,,70; Project A,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:37
mbbd000147503,mbcd0031645,mbtp000007,mbrf0002748,,=,,,substrate,8,13.4,,,85; Project A,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:37
mbbd000147504,mbcd0031646,mbtp000007,mbrf0002748,,=,,,substrate,8,13.9,,,53; Project A,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:37
mbbd000147505,mbcd0031647,mbtp000007,mbrf0002748,,=,,,substrate,8,13.9,,,76; Project A,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:37
mbbd000147506,mbcd0031648,mbtp000007,mbrf0002748,,=,,,substrate,8,14.6,,,61; Project A,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:37
mbbd000147507,mbcd0031649,mbtp000007,mbrf0002748,,=,,,substrate,8,15.5,,,128; Project A,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:37
mbbd000147508,mbcd0031650,mbtp000007,mbrf0002748,,=,,,substrate,8,16.1,,,136; Project A,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:37
mbbd000147509,mbcd0031651,mbtp000007,mbrf0002748,,=,,,substrate,8,16.7,,,91; Project A,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:37
mbbd000147510,mbcd0031652,mbtp000007,mbrf0002748,,=,,,substrate,8,17.0,,,129; Project A,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:37
mbbd000147511,mbcd0031653,mbtp000007,mbrf0002748,,=,,,substrate,8,20.6,,,105; Project A,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:37
mbbd000147512,mbcd0031654,mbtp000007,mbrf0002748,,=,,,substrate,8,21.5,,,65; Project A,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:37
mbbd000147513,mbcd0031655,mbtp000007,mbrf0002748,,=,,,substrate,8,23.4,,,83; Project A,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:37
mbbd000147514,mbcd0031656,mbtp000007,mbrf0002748,,=,,,substrate,8,23.5,,,66; Project A,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:37
mbbd000147515,mbcd0031657,mbtp000007,mbrf0002748,,=,,,substrate,8,25.9,,,43; Project A,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:37
mbbd000147516,mbcd0031658,mbtp000007,mbrf0002748,,=,,,substrate,8,33.7,,,149; Project A,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:37
mbbd000147517,mbcd0031659,mbtp000007,mbrf0002748,,=,,,substrate,8,37.0,,,150; Project A,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:37
mbbd000147518,mbcd0031660,mbtp000007,mbrf0002748,,=,,,substrate,8,38.6,,,50; Project A,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:37
mbbd000147519,mbcd0031661,mbtp000007,mbrf0002748,,=,,,substrate,8,52.7,,,64; Project A,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:37
mbbd000147520,mbcd0031662,mbtp000007,mbrf0002748,,=,,,substrate,8,68.0,,,54; Project A,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:37
mbbd000147521,mbcd0031663,mbtp000007,mbrf0002748,,=,,,substrate,8,69.1,,,55; Project A,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:37
mbbd000147522,mbcd0031664,mbtp000007,mbrf0002748,,=,,,substrate,8,73.1,,,134; Project A,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:37
mbbd000147523,mbcd0031665,mbtp000007,mbrf0002748,,=,,,substrate,8,1.6,,,346; Project W,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:37
mbbd000147524,mbcd0031550,mbtp000007,mbrf0002748,,=,,,substrate,8,65.5,,,46; Tiotropium,,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:37
mbbd000147525,mbcd0015977,mbtp000007,mbrf0002748,,=,,,substrate,8,38.5,,,34; Xamoterol (chiral R),,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:37
mbbd000147526,mbcd0031551,mbtp000007,mbrf0002748,,=,,,substrate,8,46.8,,,35; Xamoterol (chiral S),,,HEK293 cells transfected with hOCT1; ratio total/passive uptake,HEK293,,,,,human,mbds0010,,2013-11-07 18:58:37
mbbd000147527,mbcd0031666,mbtp000010,mbrf0001341,,,,,non-substrate,,,,,CDC-3-SO4; chenodeoxycholate-3-sulfate,,,ASBT-transfected COS-1 cells,COS,,,,,human,mbds0010,,2012-09-09 19:21:12
mbbd000147529,mbcd0004706,mbtp000012,mbrf0001415,,~,,,non-substrate,102,70.0,%,,CCK-8,,,Xenopus laevis oocytes; uptake,Xenopus laevis oocytes,,0.5-100,microM,,human,mbds0010,,2013-12-06 08:06:57
mbbd000147530,mbcd0004706,mbtp000013,mbrf0001415,,=,,,substrate,22,55.1,fmol oocyte-1 min-1,4,CCK-8,,,Xenopus laevis oocytes; uptake,Xenopus laevis oocytes,,0.5-100,microM,,human,mbds0010,,2013-11-23 21:09:54
mbbd000147531,mbcd0003916,mbtp000010,mbrf0002749,,=,,,non-substrate,33,202.0,pmol min-1 (mg of protein)-1,9,acyclovir,,,Transiently hASBT-transfected COS-7 (hASBT-COS) cells,COS,,15,microM,,human,mbds0010,,2013-11-11 03:52:51
mbbd000147532,mbcd0031688,mbtp000010,mbrf0002749,,=,,,substrate,33,12.9,pmol min-1 (mg of protein)-1,0.3,acyclovir valylchenodeoxycholate,acyclovir prodrug,,Transiently hASBT-transfected COS-7 (hASBT-COS) cells,COS,,15,microM,,human,mbds0010,,2013-11-11 03:52:51
mbbd000147533,mbcd0003026,mbtp000012,mbrf0002750,,=,,,inhibitor,29,10.2,microM,1.89,biochanin A,,,HeLa; DHEAS uptake in presence of biochanin A,HeLa,mbcd0003070,up to 50,microM,,human,mbds0010,,2012-09-09 19:21:12
mbbd000147534,mbcd0001532,mbtp000012,mbrf0002751,,~,,,non-substrate,102,80.0,%,7,paclitaxel,,,Xenopus laevis oocytes; uptake study using radiolabelled paclitaxel,Xenopus laevis oocytes,,20,nM,,human,mbds0010,,2013-12-06 08:06:58
mbbd000147535,mbcd0027726,mbtp000012,mbrf0002751,,~,,,non-substrate,102,125.0,%,15,docetaxel,,,Xenopus laevis oocytes; uptake study using radiolabelled docetaxel,Xenopus laevis oocytes,,20,nM,,human,mbds0010,,2013-12-06 08:06:58
mbbd000147536,mbcd0004705,mbtp000012,mbrf0002389,,,,,non-substrate,,,,,telmisartan,,,Uptake study; HEK293; 10 min,HEK293,,0.1,microM,,human,mbds0010,,2013-12-13 22:00:41
mbbd000147537,mbcd0003078,mbtp000013,mbrf0002752,,~,,,non-substrate,138,2.0,%,,GSH,,,Efflux in oocytes for 1 hour at 25 deg C; increase in transport 2% of control,Xenopus laevis oocytes,,20,mM,,human,mbds0010,,2012-09-09 19:21:12
mbbd000147538,mbcd0003078,mbtp000012,mbrf0002752,,,,,non-substrate,,,,,GSH,,,Efflux in oocytes for 1 hour at 25 deg C,Xenopus laevis oocytes,,20,mM,,human,mbds0010,,2012-09-09 19:21:12
mbbd000147539,mbcd0001050,mbtp000002,mbrf0002224,,=,,,non-inhibitor,81,2.0,fold increase,,Digoxin,,,accumulation expressed as ratio mitoxantrone with inhibitor/mitoxantrone only; ratios normalized to that obtained with Ko143 (100% inhibition),Saos-2,mbcd0002981,50,microM,,human,mbds0010,,2013-11-17 23:10:22
mbbd000147540,mbcd0001092,mbtp000002,mbrf0002224,,=,,,non-inhibitor,81,2.0,fold increase,,Quinine,,,accumulation expressed as ratio mitoxantrone with inhibitor/mitoxantrone only; ratios normalized to that obtained with Ko143 (100% inhibition),Saos-2,mbcd0002981,50,microM,,human,mbds0010,,2013-11-17 23:10:22
mbbd000147541,mbcd0001111,mbtp000002,mbrf0002224,,=,,,non-inhibitor,81,1.1,fold increase,,Cimetidine,,,accumulation expressed as ratio mitoxantrone with inhibitor/mitoxantrone only; ratios normalized to that obtained with Ko143 (100% inhibition),Saos-2,mbcd0002981,50,microM,,human,mbds0010,,2013-11-17 23:10:23
mbbd000147542,mbcd0001280,mbtp000002,mbrf0002224,,=,,,non-inhibitor,81,0.4,fold increase,,Sulfasalazine,,,accumulation expressed as ratio mitoxantrone with inhibitor/mitoxantrone only; ratios normalized to that obtained with Ko143 (100% inhibition),Saos-2,mbcd0002981,50,microM,,human,mbds0010,,2013-11-17 23:10:23
mbbd000147543,mbcd0003043,mbtp000002,mbrf0002224,,=,,,non-inhibitor,81,1.5,fold increase,,Methotrexate,,,accumulation expressed as ratio mitoxantrone with inhibitor/mitoxantrone only; ratios normalized to that obtained with Ko143 (100% inhibition),Saos-2,mbcd0002981,50,microM,,human,mbds0010,,2013-11-17 23:10:22
mbbd000147544,mbcd0003043,mbtp000002,mbrf0002224,,=,,,non-inhibitor,81,2.2,fold increase,,Methotrexate,significant cell toxicity at methotrexate concentrations above 500 microM,,accumulation expressed as ratio mitoxantrone with inhibitor/mitoxantrone only; ratios normalized to that obtained with Ko143 (100% inhibition),Saos-2,mbcd0002981,500,microM,,human,mbds0010,,2013-11-17 23:10:22
mbbd000147545,mbcd0003094,mbtp000002,mbrf0002224,,=,,,non-inhibitor,81,2.6,fold increase,,Spironolactone,,,accumulation expressed as ratio mitoxantrone with inhibitor/mitoxantrone only; ratios normalized to that obtained with Ko143 (100% inhibition),Saos-2,mbcd0002981,50,microM,,human,mbds0010,,2013-11-17 23:10:23
mbbd000147546,mbcd0020385,mbtp000002,mbrf0002224,,=,,,non-inhibitor,81,2.3,fold increase,,Maprotiline,,,accumulation expressed as ratio mitoxantrone with inhibitor/mitoxantrone only; ratios normalized to that obtained with Ko143 (100% inhibition),Saos-2,mbcd0002981,50,microM,,human,mbds0010,,2013-11-17 23:10:23
mbbd000147547,mbcd0030025,mbtp000012,mbrf0001772,,,,,non-substrate,,,,,CP-671305,,,Uptake for 5 min at 37 deg C; HEK293,HEK293,,0.5-64,microM,,human,mbds0010,,2012-09-09 19:21:12
mbbd000147548,mbcd0030025,mbtp000013,mbrf0001772,,,,,non-substrate,,,,,CP-671305,,,Uptake for 5 min at 37 deg C; HEK293,HEK293,,0.5-64,microM,,human,mbds0010,,2012-09-09 19:21:12
mbbd000147549,mbcd0003684,mbtp000009,mbrf0002753,,,,,substrate,,,,,10,,,Transport is inhibited by known PEPT1 substrate Gly-Sar,Caco-2,,4,mM,,human,mbds0010,,2012-09-09 19:21:12
mbbd000147550,mbcd0003762,mbtp000009,mbrf0002753,,,,,substrate,,,,,11,,,Transport is inhibited by known PEPT1 substrate Gly-Sar,Caco-2,,4,mM,,human,mbds0010,,2012-09-09 19:21:12
mbbd000147551,mbcd0003187,mbtp000012,mbrf0001551,,,,,non-substrate,,,,,TPT,,,MCDKII; transcellular transport studies using cells grown on microporous polycarbonate membrane filters,MDCKII,,5; 10; 100,microM,,human,mbds0010,,2013-12-09 07:09:38
mbbd000147552,mbcd0030260,mbtp000012,mbrf0001551,,,,,non-substrate,,,,,lurtotecan,,,MCDKII; transcellular transport studies using cells grown on microporous polycarbonate membrane filters,MDCKII,,1-100,microM,,human,mbds0010,,2013-12-09 07:09:38
mbbd000147553,mbcd0008235,mbtp000012,mbrf0002215,,~,,,non-substrate,102,99.0,%,,MPA,,,Uptake assay; HEK293,HEK293,,20,microM,,human,mbds0010,,2013-12-06 08:06:58
mbbd000147554,mbcd0029428,mbtp000013,mbrf0002567,,~,,,non-substrate,150,85.0,%,,GA,,,DCA transport in pBCEC,pBCEC,,1,mM,,human,mbds0010,,2012-09-09 19:21:12
mbbd000147555,mbcd0029429,mbtp000013,mbrf0002567,,~,,,non-substrate,150,108.0,%,,3-OH-GA,,,DCA transport in pBCEC,pBCEC,,1,mM,,human,mbds0010,,2012-09-09 19:21:12
mbbd000147556,mbcd0029430,mbtp000013,mbrf0002567,,~,,,non-substrate,150,95.0,%,,MMA,,,DCA transport in pBCEC,pBCEC,,1,mM,,human,mbds0010,,2012-09-09 19:21:12
mbbd000147557,mbcd0031512,mbtp000007,mbrf0002754,,,,,non-substrate,,,,,Pramipexole,,,hOCT1-MDCK monolayers,MDCK,,0-200,microM,,human,mbds0010,,2012-09-09 19:21:12
mbbd000147558,mbcd0000311,mbtp000012,mbrf0002755,,=,,,inhibitor,25,0.021,microM,0.004,CsA,,,Uptake of atorvastatin in presence of cyclosporin A; preincubation experiment,HEK293,mbcd0026093,up to 3,microM,,human,mbds0010,,2012-09-09 19:21:12
mbbd000147559,mbcd0000311,mbtp000012,mbrf0002755,,=,,,inhibitor,25,0.47,microM,0.34,CsA,,,Uptake of atorvastatin in presence of cyclosporin A; coincubation experiment,HEK293,mbcd0026093,up to 3,microM,,human,mbds0010,,2012-09-09 19:21:12
mbbd000147560,mbcd0001353,mbtp000012,mbrf0002756,,,,,non-substrate,,,,,salicylic acid,,,HEK-OATP1B1; uptake of labelled NSAIDs,HEK293,,,,,human,mbds0010,,2012-09-09 19:21:12
mbbd000147561,mbcd0001353,mbtp000013,mbrf0002756,,,,,non-substrate,,,,,salicylic acid,,,HEK-OATP1B3; uptake of labelled NSAIDs,HEK293,,,,,human,mbds0010,,2012-09-09 19:21:12
mbbd000147562,mbcd0001557,mbtp000012,mbrf0002756,,~,,,inhibitor,102,38.0,%,4,lumiracoxib,,,inhibition of BSP uptake in HEK293 and/or MDCKII cells,HEK293; MCDKII,mbcd0003035,50,microM,,human,mbds0010,,2013-12-06 08:06:59
mbbd000147563,mbcd0001557,mbtp000012,mbrf0002756,,=,,,stimulator,138,4.2,fold increase,,lumiracoxib,,,inhibition of pravastatin uptake in HEK293 and/or MDCKII cells,HEK293; MCDKII,mbcd0003126,10,microM,,human,mbds0010,,2013-11-27 07:26:52
mbbd000147564,mbcd0002998,mbtp000012,mbrf0002756,,,,,non-substrate,,,,,naproxen,,,HEK-OATP1B1; uptake of labelled NSAIDs,HEK293,,,,,human,mbds0010,,2012-09-09 19:21:12
mbbd000147565,mbcd0002998,mbtp000013,mbrf0002756,,,,,non-substrate,,,,,naproxen,,,HEK-OATP1B3; uptake of labelled NSAIDs,HEK293,,,,,human,mbds0010,,2012-09-09 19:21:12
mbbd000147566,mbcd0003013,mbtp000012,mbrf0002756,,,,,non-substrate,,,,,ibuprofen,,,HEK-OATP1B1; uptake of labelled NSAIDs,HEK293,,,,,human,mbds0010,,2012-09-09 19:21:12
mbbd000147567,mbcd0003013,mbtp000013,mbrf0002756,,,,,non-substrate,,,,,ibuprofen,,,HEK-OATP1B3; uptake of labelled NSAIDs,HEK293,,,,,human,mbds0010,,2012-09-09 19:21:12
mbbd000147568,mbcd0003113,mbtp000012,mbrf0002756,,~,,,non-substrate,33,95.0,%,1,diclofenac,,,HEK-OATP1B1; % of uptake into HEK-Co cells; uptake of labelled NSAIDs,HEK293,,1; 10; 100,microM,,human,mbds0010,,2012-09-09 19:21:12
mbbd000147569,mbcd0003113,mbtp000013,mbrf0002756,,~,,,substrate,33,117.0,%,15,diclofenac,,,HEK-OATP1B3; % of uptake into HEK-Co cells; uptake of labelled NSAIDs,HEK293,,1; 10; 100,microM,,human,mbds0010,,2012-09-09 19:21:12
mbbd000147570,mbcd0001324,mbtp000012,mbrf0002757,,~,,,non-substrate,102,110.0,%,,sirolimus,,,SLCO1B1-transfected HEK293T/17 cells; uptake,HEK293T/17,,1,microM,,human,mbds0010,,2013-12-06 08:06:59
mbbd000147571,mbcd0001324,mbtp000013,mbrf0002757,,~,,,non-substrate,102,90.0,%,5,sirolimus,,,SLCO1B3-transfected HEK293T/17 cells; uptake,HEK293T/17,,1,microM,,human,mbds0010,,2013-12-06 08:06:59
mbbd000147572,mbcd0001616,mbtp000012,mbrf0002757,,~,,,non-substrate,102,103.0,%,3,everolimus,,,SLCO1B1-transfected HEK293T/17 cells; uptake,HEK293T/17,,1,microM,,human,mbds0010,,2013-12-06 08:06:59
mbbd000147573,mbcd0001616,mbtp000013,mbrf0002757,,~,,,non-substrate,102,110.0,%,8,everolimus,,,SLCO1B3-transfected HEK293T/17 cells; uptake,HEK293T/17,,1,microM,,human,mbds0010,,2013-12-06 08:07:00
mbbd000147574,mbcd0000387,mbtp000012,mbrf0002758,,=,,,substrate,28,12.85,microM,2.4,E17betaG,,,Flp-In-293 cells transfected with pOG44 vector and OATP1B1-pcDNA5/FRT expression vector,HEK Flp-In-293,,1-200,microM,,human,mbds0010,,2013-11-20 20:22:06
mbbd000147575,mbcd0000387,mbtp000012,mbrf0002758,,=,,,substrate,22,1.37,pmol /min /mg protein,0.12,E17betaG,,,Flp-In-293 cells transfected with pOG44 vector and OATP1B1-pcDNA5/FRT expression vector,HEK Flp-In-293,,1-200,microM,,human,mbds0010,,2013-11-20 20:22:06
mbbd000147576,mbcd0026093,mbtp000012,mbrf0002758,,=,,,substrate,28,0.77,microM,0.24,Atorvastatin,,,Flp-In-293 cells transfected with pOG44 vector and OATP1B1-pcDNA5/FRT expression vector,HEK Flp-In-293,,0.2-50,microM,,human,mbds0010,,2013-11-20 20:22:06
mbbd000147577,mbcd0026093,mbtp000012,mbrf0002758,,=,,,substrate,22,6.61,pmol /min /microg protein,1.24,Atorvastatin,,,Flp-In-293 cells transfected with pOG44 vector and OATP1B1-pcDNA5/FRT expression vector,HEK Flp-In-293,,0.2-50,microM,,human,mbds0010,,2013-11-20 20:22:06
mbbd000147578,mbcd0001517,mbtp000012,mbrf0002759,,=,,,non-substrate,28,4.2,microM,0.7,CLR,,,HEK-OATP1B1 cells; uptake,HEK293,,0.01,mM,,human,mbds0010,,2012-09-09 19:21:12
mbbd000147579,mbcd0001517,mbtp000013,mbrf0002759,,=,,,non-substrate,28,1.0,microM,0.4,CLR,,,HEK-OATP1B3 cells; uptake,HEK293,,0.01,mM,,human,mbds0010,,2012-09-09 19:21:12
mbbd000147580,mbcd0001517,mbtp000012,mbrf0002759,,=,,,non-substrate,22,52.9,pmol mg-1 min-1,3.6,CLR,,,HEK-OATP1B1 cells; uptake,HEK293,,0.01,mM,,human,mbds0010,,2012-09-09 19:21:12
mbbd000147581,mbcd0001517,mbtp000013,mbrf0002759,,=,,,non-substrate,22,11.3,pmol mg-1 min-1,1,CLR,,,HEK-OATP1B3 cells; uptake,HEK293,,0.01,mM,,human,mbds0010,,2012-09-09 19:21:12
mbbd000147582,mbcd0031667,mbtp000001,mbrf0002760,,,,,non-substrate,,,,,7-HC,Uptake was below detection limits,,Membrane vesicles; Uptake,HEK293,,400,microM,,human,mbds0010,,2012-09-09 19:21:12
mbbd000147583,mbcd0031667,mbtp000002,mbrf0002760,,,,,non-substrate,,,,,7-HC,Uptake was below detection limits,,Membrane vesicles; Uptake,HEK293,,400,microM,,human,mbds0010,,2012-09-09 19:21:12
mbbd000147584,mbcd0031667,mbtp000005,mbrf0002760,,,,,non-substrate,,,,,7-HC,Uptake was below detection limits,,Membrane vesicles; Uptake,HEK293,,400,microM,,human,mbds0010,,2012-09-09 19:21:12
mbbd000147585,mbcd0031667,mbtp000008,mbrf0002760,,,,,non-substrate,,,,,7-HC,Uptake was below detection limits,,Membrane vesicles; Uptake,HEK293,,400,microM,,human,mbds0010,,2012-09-09 19:21:12
mbbd000147586,mbcd0031667,mbtp000022,mbrf0002760,,,,,non-substrate,,,,,7-HC,Uptake was below detection limits,,Membrane vesicles; Uptake,HEK293,,400,microM,,human,mbds0010,,2012-09-09 19:21:12
mbbd000147587,mbcd0031667,mbtp000030,mbrf0002760,,,,,non-substrate,,,,,7-HC,Uptake was below detection limits,,Membrane vesicles; Uptake,HEK293,,400,microM,,human,mbds0010,,2012-09-09 19:21:12
mbbd000147588,mbcd0031668,mbtp000008,mbrf0002760,,=,,,substrate,28,187.0,microM,22,7-HC-G,,,Membrane vesicles; Uptake,HEK293,,0-800,microM,,human,mbds0010,,2012-09-09 19:21:12
mbbd000147589,mbcd0031668,mbtp000022,mbrf0002760,,=,,,substrate,28,63.0,microM,11,7-HC-G,,,Membrane vesicles; Uptake,HEK293,,0-800,microM,,human,mbds0010,,2012-09-09 19:21:12
mbbd000147590,mbcd0031668,mbtp000008,mbrf0002760,,=,,,substrate,22,460.0,pmol mg-1 min-1,20,7-HC-G,,,Membrane vesicles; Uptake,HEK293,,0-800,microM,,human,mbds0010,,2012-09-09 19:21:12
mbbd000147591,mbcd0031668,mbtp000022,mbrf0002760,,=,,,substrate,22,920.0,pmol mg-1 min-1,50,7-HC-G,,,Membrane vesicles; Uptake,HEK293,,0-800,microM,,human,mbds0010,,2012-09-09 19:21:12
mbbd000147592,mbcd0031668,mbtp000001,mbrf0002760,,,,,non-substrate,,,,,7-HC-G,,,Membrane vesicles; Uptake,HEK293,,400,microM,,human,mbds0010,,2012-09-09 19:21:12
mbbd000147593,mbcd0031668,mbtp000002,mbrf0002760,,,,,non-substrate,,,,,7-HC-G,,,Membrane vesicles; Uptake,HEK293,,400,microM,,human,mbds0010,,2012-09-09 19:21:12
mbbd000147594,mbcd0031668,mbtp000005,mbrf0002760,,,,,non-substrate,,,,,7-HC-G,,,Membrane vesicles; Uptake,HEK293,,400,microM,,human,mbds0010,,2012-09-09 19:21:12
mbbd000147595,mbcd0031668,mbtp000030,mbrf0002760,,,,,non-substrate,,,,,7-HC-G,,,Membrane vesicles; Uptake,HEK293,,400,microM,,human,mbds0010,,2012-09-09 19:21:12
mbbd000147596,mbcd0003075,mbtp000010,mbrf0002761,,,,,non-substrate,,,,,3H-estrone-3-sulfate,,,COS-7 cells transfected with hASBT,COS,,25,microM,,human,mbds0010,,2012-09-09 19:21:12
mbbd000147597,mbcd0012405,mbtp000001,mbrf0002762,,,,,substrate,,,,,RAL,,,Transport reduced by known MDR1 inhibitor verapamil,Caco-2,,30,microM,,human,mbds0010,,2012-09-09 19:21:12
mbbd000147598,mbcd0012405,mbtp000002,mbrf0002762,,,,,non-substrate,,,,,RAL,,,Transport not reduced by known MRP inhibitor FumC,Caco-2,,30,microM,,human,mbds0010,,2012-09-09 19:21:12
mbbd000147599,mbcd0012405,mbtp000005,mbrf0002762,,,,,non-substrate,,,,,RAL,,,Transport not reduced by known MRP inhibitor MK571,Caco-2,,30,microM,,human,mbds0010,,2012-09-09 19:21:12
mbbd000147600,mbcd0012405,mbtp000008,mbrf0002762,,,,,non-substrate,,,,,RAL,,,Transport not reduced by known MRP inhibitor MK571,Caco-2,,30,microM,,human,mbds0010,,2012-09-09 19:21:12
mbbd000147601,mbcd0012405,mbtp000030,mbrf0002762,,,,,non-substrate,,,,,RAL,,,Transport not reduced by known MRP inhibitor MK571,Caco-2,,30,microM,,human,mbds0010,,2012-09-09 19:21:12
mbbd000147602,mbcd0031669,mbtp000001,mbrf0002762,,,,,non-substrate,,,,,M1; raloxifene-6-beta-glucuronide,,,No activation of ATPase activity; Membrane vesicles from PREDEASY ATPase Kit,Membrane vesicles from PREDEASY ATPase Kit,,0.32-41.4,microM,,human,mbds0010,,2012-09-09 19:21:12
mbbd000147603,mbcd0031669,mbtp000002,mbrf0002762,,,,,non-substrate,,,,,M1; raloxifene-6-beta-glucuronide,,,No activation of ATPase activity; Membrane vesicles from PREDEASY ATPase Kit,Membrane vesicles from PREDEASY ATPase Kit,,0.32-41.4,microM,,human,mbds0010,,2012-09-09 19:21:12
mbbd000147604,mbcd0031669,mbtp000005,mbrf0002762,,,,,non-substrate,,,,,M1; raloxifene-6-beta-glucuronide,,,No activation of ATPase activity; Membrane vesicles from PREDEASY ATPase Kit,Membrane vesicles from PREDEASY ATPase Kit,,0.32-41.4,microM,,human,mbds0010,,2012-09-09 19:21:12
mbbd000147605,mbcd0031669,mbtp000008,mbrf0002762,,,,,substrate,,,,,M1; raloxifene-6-beta-glucuronide,,,Activation of ATPase activity; Membrane vesicles from PREDEASY ATPase Kit,Membrane vesicles from PREDEASY ATPase Kit,,0.32-41.4,microM,,human,mbds0010,,2012-09-09 19:21:12
mbbd000147606,mbcd0031669,mbtp000030,mbrf0002762,,,,,non-substrate,,,,,M1; raloxifene-6-beta-glucuronide,,,No activation of ATPase activity; Membrane vesicles from PREDEASY ATPase Kit,Membrane vesicles from PREDEASY ATPase Kit,,0.32-41.4,microM,,human,mbds0010,,2012-09-09 19:21:12
mbbd000147607,mbcd0031670,mbtp000001,mbrf0002762,,,,,non-substrate,,,,,M2; raloxifene-4'-beta-glucuronide,,,No activation of ATPase activity; Membrane vesicles from PREDEASY ATPase Kit,Membrane vesicles from PREDEASY ATPase Kit,,0.25-31.4,microM,,human,mbds0010,,2013-11-13 19:42:04
mbbd000147608,mbcd0031670,mbtp000002,mbrf0002762,,,,,non-substrate,,,,,M2; raloxifene-4'-beta-glucuronide,,,No activation of ATPase activity; Membrane vesicles from PREDEASY ATPase Kit,Membrane vesicles from PREDEASY ATPase Kit,,0.25-31.4,microM,,human,mbds0010,,2013-11-13 19:42:04
mbbd000147609,mbcd0031670,mbtp000005,mbrf0002762,,,,,non-substrate,,,,,M2; raloxifene-4'-beta-glucuronide,,,No activation of ATPase activity; Membrane vesicles from PREDEASY ATPase Kit,Membrane vesicles from PREDEASY ATPase Kit,,0.25-31.4,microM,,human,mbds0010,,2013-11-13 19:42:04
mbbd000147610,mbcd0031670,mbtp000008,mbrf0002762,,,,,substrate,,,,,M2; raloxifene-4'-beta-glucuronide,,,Activation of ATPase activity; Membrane vesicles from PREDEASY ATPase Kit,Membrane vesicles from PREDEASY ATPase Kit,,0.25-31.4,microM,,human,mbds0010,,2013-11-13 19:42:04
mbbd000147611,mbcd0031670,mbtp000030,mbrf0002762,,,,,non-substrate,,,,,M2; raloxifene-4'-beta-glucuronide,,,No activation of ATPase activity; Membrane vesicles from PREDEASY ATPase Kit,Membrane vesicles from PREDEASY ATPase Kit,,0.25-31.4,microM,,human,mbds0010,,2013-11-13 19:42:04
mbbd000147612,mbcd0031671,mbtp000001,mbrf0002762,,,,,substrate,,,,,"M3; raloxifene-6,4'-diglucuronide",,,Activation of ATPase activity; Membrane vesicles from PREDEASY ATPase Kit,Membrane vesicles from PREDEASY ATPase Kit,,0.06-8,microM,,human,mbds0010,,2013-11-13 19:43:06
mbbd000147613,mbcd0031671,mbtp000002,mbrf0002762,,,,,non-substrate,,,,,"M3; raloxifene-6,4'-diglucuronide",,,No activation of ATPase activity; Membrane vesicles from PREDEASY ATPase Kit,Membrane vesicles from PREDEASY ATPase Kit,,0.06-8,microM,,human,mbds0010,,2013-11-13 19:43:06
mbbd000147614,mbcd0031671,mbtp000005,mbrf0002762,,,,,non-substrate,,,,,"M3; raloxifene-6,4'-diglucuronide",,,No activation of ATPase activity; Membrane vesicles from PREDEASY ATPase Kit,Membrane vesicles from PREDEASY ATPase Kit,,0.06-8,microM,,human,mbds0010,,2013-11-13 19:43:06
mbbd000147615,mbcd0031671,mbtp000008,mbrf0002762,,,,,non-substrate,,,,,"M3; raloxifene-6,4'-diglucuronide",,,No activation of ATPase activity; Membrane vesicles from PREDEASY ATPase Kit,Membrane vesicles from PREDEASY ATPase Kit,,0.06-8,microM,,human,mbds0010,,2013-11-13 19:43:06
mbbd000147616,mbcd0031671,mbtp000030,mbrf0002762,,,,,substrate,,,,,"M3; raloxifene-6,4'-diglucuronide",,,Activation of ATPase activity; Membrane vesicles from PREDEASY ATPase Kit,Membrane vesicles from PREDEASY ATPase Kit,,0.06-8,microM,,human,mbds0010,,2013-11-13 19:43:06
mbbd000147617,mbcd0031672,mbtp000025,mbrf0002763,,=,,,substrate,28,43.0,microM,23.7,S-6-G,,,HEK293,HEK293,,0-100,microM,,human,mbds0010,,2012-09-09 19:21:12
mbbd000147618,mbcd0031672,mbtp000002,mbrf0002763,,=,,,substrate,150,6250.0,%,,S-6-G,,,Membrane vesicles; control was the absence of ATP,Sf9,,15,microM,,human,mbds0010,,2012-09-09 19:21:12
mbbd000147619,mbcd0031672,mbtp000002,mbrf0002763,,=,,,substrate,150,5750.0,%,,S-6-G,,,Membrane vesicles; control was the absence of ATP,Sf9,,20,microM,,human,mbds0010,,2012-09-09 19:21:12
mbbd000147620,mbcd0031672,mbtp000005,mbrf0002763,,=,,,substrate,150,432.0,%,,S-6-G,,,Membrane vesicles; control was the absence of ATP,Sf9,,40,microM,,human,mbds0010,,2012-09-09 19:21:12
mbbd000147621,mbcd0031672,mbtp000005,mbrf0002763,,=,,,substrate,150,307.0,%,,S-6-G,,,Membrane vesicles; control was the absence of ATP,Sf9,,60,microM,,human,mbds0010,,2012-09-09 19:21:12
mbbd000147622,mbcd0031672,mbtp000008,mbrf0002763,,=,,,substrate,150,285.0,%,,S-6-G,,,Membrane vesicles; control was the absence of ATP,Sf9,,25,microM,,human,mbds0010,,2012-09-09 19:21:12
mbbd000147623,mbcd0031672,mbtp000008,mbrf0002763,,=,,,substrate,150,217.0,%,,S-6-G,,,Membrane vesicles; control was the absence of ATP,Sf9,,35,microM,,human,mbds0010,,2012-09-09 19:21:12
mbbd000147624,mbcd0031672,mbtp000030,mbrf0002763,,~,,,non-substrate,150,66.0,%,,S-6-G,,,Membrane vesicles; Control is the absence of ATP,Sf9,,150,microM,,human,mbds0010,,2012-09-09 19:21:12
mbbd000147625,mbcd0031672,mbtp000025,mbrf0002763,,=,,,substrate,22,113.0,pmol mg-1 min-1,49,S-6-G,,,HEK293,HEK293,,0-100,microM,,human,mbds0010,,2012-09-09 19:21:12
mbbd000147626,mbcd0031673,mbtp000025,mbrf0002763,,=,,,substrate,28,1.77,microM,0.54,S-7-G,,,HEK293,HEK293,,0-100,microM,,human,mbds0010,,2012-09-09 19:21:12
mbbd000147627,mbcd0031673,mbtp000002,mbrf0002763,,=,,,substrate,150,6510.0,%,,S-7-G,,,Membrane vesicles; control was the absence of ATP,Sf9,,5,microM,,human,mbds0010,,2012-09-09 19:21:12
mbbd000147628,mbcd0031673,mbtp000002,mbrf0002763,,=,,,substrate,150,6350.0,%,,S-7-G,,,Membrane vesicles; control was the absence of ATP,Sf9,,15,microM,,human,mbds0010,,2012-09-09 19:21:12
mbbd000147629,mbcd0031673,mbtp000005,mbrf0002763,,=,,,substrate,150,375.0,%,,S-7-G,,,Membrane vesicles; control was the absence of ATP,Sf9,,40,microM,,human,mbds0010,,2012-09-09 19:21:12
mbbd000147630,mbcd0031673,mbtp000005,mbrf0002763,,=,,,substrate,150,380.0,%,,S-7-G,,,Membrane vesicles; control was the absence of ATP,Sf9,,60,microM,,human,mbds0010,,2012-09-09 19:21:12
mbbd000147631,mbcd0031673,mbtp000008,mbrf0002763,,=,,,substrate,150,190.0,%,,S-7-G,,,Membrane vesicles; control was the absence of ATP,Sf9,,125,microM,,human,mbds0010,,2012-09-09 19:21:12
mbbd000147632,mbcd0031673,mbtp000008,mbrf0002763,,=,,,substrate,150,161.0,%,,S-7-G,,,Membrane vesicles; control was the absence of ATP,Sf9,,175,microM,,human,mbds0010,,2012-09-09 19:21:12
mbbd000147633,mbcd0031673,mbtp000030,mbrf0002763,,~,,,non-substrate,150,110.0,%,,S-7-G,,,Membrane vesicles; Control is the absence of ATP,Sf9,,200,microM,,human,mbds0010,,2012-09-09 19:21:12
mbbd000147634,mbcd0031673,mbtp000025,mbrf0002763,,=,,,substrate,22,19.7,pmol mg-1 min-1,1.3,S-7-G,,,HEK293,HEK293,,0-100,microM,,human,mbds0010,,2012-09-09 19:21:12
mbbd000147635,mbcd0031467,mbtp000012,mbrf0002764,,~,,,non-substrate,102,137.0,%,,BOC,,,MCDKII; uptake of labelled BOC,MDCKII,,1,microM,,human,mbds0010,,2013-12-09 07:09:38
mbbd000147636,mbcd0031467,mbtp000013,mbrf0002764,,~,,,non-substrate,102,103.0,%,,BOC,,,MCDKII; uptake of labelled BOC,MDCKII,,1,microM,,human,mbds0010,,2013-12-09 07:09:38
mbbd000147637,mbcd0031468,mbtp000012,mbrf0002765,,~,,,non-substrate,102,90.0,%,,dioscin,,,MDCKII; transepithelial transport,MDCKII,,2.5,microM,,human,mbds0010,,2013-12-09 07:09:38
mbbd000147638,mbcd0003948,mbtp000012,mbrf0002766,,~,,,non-substrate,102,80.0,%,,fentanyl,,,HEK293; uptake,HEK293,,10,mM,,human,mbds0010,,2013-12-06 08:07:00
mbbd000147639,mbcd0029351,mbtp000030,mbrf0002767,,=,,,substrate,104,1.4,,0.1,Calcein,,,"basolateral efflux of fluorescent calcein in immature Caco-2 cells in medium containing 1 microM cadmium, relative to control",Caco-2,,1.3,microM,,human,mbds0010,,2013-11-20 21:08:05
mbbd000147640,mbcd0029351,mbtp000030,mbrf0002767,,=,,,substrate,104,1.05,,0.15,Calcein,,,"apical efflux of fluorescent calcein in immature Caco-2 cells in medium containing 1 microM cadmium, relative to control",Caco-2,,1.3,microM,,human,mbds0010,,2013-11-20 21:08:05
mbbd000147641,mbcd0003535,mbtp000009,mbrf0002768,,=,,,non-substrate,89,1.0,,,H-Phe-Phe-NH2 analogue 1,,,uptake expressed as ratio CHO-PEPT1/CHO-K1; the ratio PEPT1/K1 for [14C]GlySar (PEPT1 substrate used as positive control) was equal to or larger than 5 under the applied conditions,CHO,,100,microM,,human,mbds0010,,2012-09-09 19:21:12
mbbd000147642,mbcd0031675,mbtp000009,mbrf0002768,,=,,,non-substrate,89,0.7,,,H-Phe-Phe-NH2 analogue 10,,,uptake expressed as ratio CHO-PEPT1/CHO-K1; the ratio PEPT1/K1 for [14C]GlySar (PEPT1 substrate used as positive control) was equal to or larger than 5 under the applied conditions,CHO,,100,microM,,human,mbds0010,,2012-09-09 19:21:12
mbbd000147643,mbcd0031676,mbtp000009,mbrf0002768,,=,,,non-substrate,89,0.6,,,H-Phe-Phe-NH2 analogue 11,,,uptake expressed as ratio CHO-PEPT1/CHO-K1; the ratio PEPT1/K1 for [14C]GlySar (PEPT1 substrate used as positive control) was equal to or larger than 5 under the applied conditions,CHO,,100,microM,,human,mbds0010,,2012-09-09 19:21:12
mbbd000147644,mbcd0031677,mbtp000009,mbrf0002768,,=,,,non-substrate,89,0.7,,,H-Phe-Phe-NH2 analogue 12,,,uptake expressed as ratio CHO-PEPT1/CHO-K1; the ratio PEPT1/K1 for [14C]GlySar (PEPT1 substrate used as positive control) was equal to or larger than 5 under the applied conditions,CHO,,100,microM,,human,mbds0010,,2012-09-09 19:21:12
mbbd000147645,mbcd0031674,mbtp000009,mbrf0002768,,=,,,non-substrate,89,0.9,,,H-Phe-Phe-NH2 analogue 2,,,uptake expressed as ratio CHO-PEPT1/CHO-K1; the ratio PEPT1/K1 for [14C]GlySar (PEPT1 substrate used as positive control) was equal to or larger than 5 under the applied conditions,CHO,,100,microM,,human,mbds0010,,2012-09-09 19:21:12
mbbd000147646,mbcd0031678,mbtp000009,mbrf0002768,,=,,,non-substrate,89,0.7,,,H-Phe-Phe-NH2 analogue 3,,,uptake expressed as ratio CHO-PEPT1/CHO-K1; the ratio PEPT1/K1 for [14C]GlySar (PEPT1 substrate used as positive control) was equal to or larger than 5 under the applied conditions,CHO,,100,microM,,human,mbds0010,,2012-09-09 19:21:12
mbbd000147647,mbcd0031679,mbtp000009,mbrf0002768,,=,,,non-substrate,89,0.8,,,H-Phe-Phe-NH2 analogue 4,,,uptake expressed as ratio CHO-PEPT1/CHO-K1; the ratio PEPT1/K1 for [14C]GlySar (PEPT1 substrate used as positive control) was equal to or larger than 5 under the applied conditions,CHO,,100,microM,,human,mbds0010,,2012-09-09 19:21:12
mbbd000147648,mbcd0031680,mbtp000009,mbrf0002768,,=,,,non-substrate,89,1.0,,,H-Phe-Phe-NH2 analogue 5,,,uptake expressed as ratio CHO-PEPT1/CHO-K1; the ratio PEPT1/K1 for [14C]GlySar (PEPT1 substrate used as positive control) was equal to or larger than 5 under the applied conditions,CHO,,100,microM,,human,mbds0010,,2012-09-09 19:21:12
mbbd000147649,mbcd0031681,mbtp000009,mbrf0002768,,=,,,non-substrate,89,0.7,,,H-Phe-Phe-NH2 analogue 6,,,uptake expressed as ratio CHO-PEPT1/CHO-K1; the ratio PEPT1/K1 for [14C]GlySar (PEPT1 substrate used as positive control) was equal to or larger than 5 under the applied conditions,CHO,,100,microM,,human,mbds0010,,2012-09-09 19:21:12
mbbd000147650,mbcd0031682,mbtp000009,mbrf0002768,,=,,,non-substrate,89,1.4,,,H-Phe-Phe-NH2 analogue 7a,,,uptake expressed as ratio CHO-PEPT1/CHO-K1; the ratio PEPT1/K1 for [14C]GlySar (PEPT1 substrate used as positive control) was equal to or larger than 5 under the applied conditions,CHO,,100,microM,,human,mbds0010,,2012-09-09 19:21:12
mbbd000147651,mbcd0031683,mbtp000009,mbrf0002768,,=,,,non-substrate,89,1.4,,,H-Phe-Phe-NH2 analogue 7b,,,uptake expressed as ratio CHO-PEPT1/CHO-K1; the ratio PEPT1/K1 for [14C]GlySar (PEPT1 substrate used as positive control) was equal to or larger than 5 under the applied conditions,CHO,,100,microM,,human,mbds0010,,2012-09-09 19:21:12
mbbd000147652,mbcd0031684,mbtp000009,mbrf0002768,,=,,,non-substrate,89,1.3,,,H-Phe-Phe-NH2 analogue 8b,,,uptake expressed as ratio CHO-PEPT1/CHO-K1; the ratio PEPT1/K1 for [14C]GlySar (PEPT1 substrate used as positive control) was equal to or larger than 5 under the applied conditions,CHO,,100,microM,,human,mbds0010,,2012-09-09 19:21:12
mbbd000147653,mbcd0031686,mbtp000009,mbrf0002768,,=,,,non-substrate,89,0.9,,,H-Phe-Phe-NH2 analogue 9a,,,uptake expressed as ratio CHO-PEPT1/CHO-K1; the ratio PEPT1/K1 for [14C]GlySar (PEPT1 substrate used as positive control) was equal to or larger than 5 under the applied conditions,CHO,,100,microM,,human,mbds0010,,2012-09-09 19:21:12
mbbd000147654,mbcd0031687,mbtp000009,mbrf0002768,,=,,,non-substrate,89,1.1,,,H-Phe-Phe-NH2 analogue 9b,,,uptake expressed as ratio CHO-PEPT1/CHO-K1; the ratio PEPT1/K1 for [14C]GlySar (PEPT1 substrate used as positive control) was equal to or larger than 5 under the applied conditions,CHO,,100,microM,,human,mbds0010,,2012-09-09 19:21:12
mbbd000147655,mbcd0031685,mbtp000009,mbrf0002768,,=,,,non-substrate,89,1.2,,,H-Phe-Phe-NH2 analogues 8a/8b (8a:8b=2:1),,,uptake expressed as ratio CHO-PEPT1/CHO-K1; the ratio PEPT1/K1 for [14C]GlySar (PEPT1 substrate used as positive control) was equal to or larger than 5 under the applied conditions,CHO,,100,microM,,human,mbds0010,,2012-09-09 19:21:12
mbbd000147656,mbcd0000069,mbtp000012,mbrf0002770,,~,,,non-substrate,150,95.0,%,,4-hydroxytamoxifen,,,HEK293; uptake,HEK293,,,,,human,mbds0010,,2012-09-09 19:21:12
mbbd000147657,mbcd0000069,mbtp000013,mbrf0002770,,~,,,non-substrate,150,70.0,%,,4-hydroxytamoxifen,,,HEK293; uptake,HEK293,,,,,human,mbds0010,,2012-09-09 19:21:12
mbbd000147658,mbcd0000602,mbtp000012,mbrf0002770,,~,,,non-substrate,150,90.0,%,,N-desmethyl-4-hydroxytamoxifen,,,HEK293; uptake,HEK293,,,,,human,mbds0010,,2012-09-09 19:21:12
mbbd000147659,mbcd0000602,mbtp000013,mbrf0002770,,~,,,non-substrate,150,75.0,%,,N-desmethyl-4-hydroxytamoxifen,,,HEK293; uptake,HEK293,,,,,human,mbds0010,,2012-09-09 19:21:12
mbbd000147660,mbcd0001557,mbtp000012,mbrf0002770,,,,,non-substrate,,,,,lumiracoxib,,,HEK293; uptake,HEK293,,,,,human,mbds0010,,2012-09-09 19:21:12
mbbd000147661,mbcd0001557,mbtp000013,mbrf0002770,,,,,non-substrate,,,,,lumiracoxib,,,HEK293; uptake,HEK293,,,,,human,mbds0010,,2012-09-09 19:21:12
mbbd000147662,mbcd0003113,mbtp000013,mbrf0002770,,~,,,non-substrate,150,100.0,%,,Diclo; diclofenac,,,HEK293; uptake,HEK293,,0.1; 0.5,microM,,human,mbds0010,,2014-02-27 20:06:46
mbbd000147663,mbcd0003083,mbtp000012,mbrf0002576,,~,,,non-substrate,150,105.0,%,,amantadin,,,MCDKII; uptake,MDCKII,,0.7,microM,,human,mbds0010,,2012-09-09 19:21:12
mbbd000147664,mbcd0001735,mbtp000012,mbrf0002769,,,,,non-substrate,,,,,MDZ,,,LC/MS/MS analysis of the respective plasma samples; influence of genetic polymorphisms of SLCO1B1 on MDZ pharmacokinetics,human plasma,,,,,human,mbds0010,,2012-09-09 19:21:12
mbbd000147665,mbcd0003026,mbtp000001,mbrf0002582,,,,,non-substrate,,,,,biochanin A,,,P-gp overexpressing MCF7/ADR cells; 5 microM GF120918 was used as a P-gp inhibitor,MCF7/ADR,,,,,human,mbds0010,,2013-12-09 06:52:08
mbbd000147666,mbcd0003116,mbtp000005,mbrf0002582,,,,,non-substrate,,,,,genistein,,,MDCK/MRP2 cells,MDCK,,,,,human,mbds0010,,2013-11-10 02:15:06
mbbd000147667,mbcd0003135,mbtp000002,mbrf0001946,,~,,,inhibitor,81,550.0,%,100,Nitrendipine,,,BCRP-tranfected HEK/482R cells; BCRP-mediated MX efflux,HEK293,mbcd0002981,10,microM,,human,mbds0010,,2013-11-17 22:13:09
mbbd000147668,mbcd0003100,mbtp000002,mbrf0001946,,,,,substrate,,,,,Dipyridamole,,,hBCRP expressed in MDCK cells (MDCK/482R),MDCK,,,,,human,mbds0010,,2013-11-17 22:13:09
mbbd000147669,mbcd0027925,mbtp000002,mbrf0001946,,~,,,non-inhibitor,81,200.0,%,50,bepridil,,,BCRP-tranfected HEK/482R cells; BCRP-mediated MX efflux,HEK293,mbcd0002981,50,microM,,human,mbds0010,,2013-11-17 22:13:10
mbbd000147670,mbcd0002338,mbtp000002,mbrf0001946,,~,,,non-inhibitor,81,100.0,%,10,diltiazem,,,BCRP-tranfected HEK/482R cells; BCRP-mediated MX efflux,HEK293,mbcd0002981,50,microM,,human,mbds0010,,2013-11-17 22:13:10
mbbd000147671,mbcd0027062,mbtp000002,mbrf0001946,,~,,,non-inhibitor,81,90.0,%,10,verapamil,,,BCRP-tranfected HEK/482R cells; BCRP-mediated MX efflux,HEK293,mbcd0002981,10,microM,,human,mbds0010,,2013-11-17 22:13:10
mbbd000147672,mbcd0003718,mbtp000009,mbrf0001357,,,,,inducer,,,,,Gly-Gln,,,Caco-2 cells; upregulation of mRNA and protein ,Caco-2,,,,,human,mbds0003,v2007,2013-11-18 19:44:22
mbbd000147673,mbcd0003087,mbtp000009,mbrf0001359,,=,,,substrate,22,15.7,nmol h-1 cm-2,1.3,L-Val-ACV,,,"Caco-2 cells; transepithelial transport (apical to basal), L-form",Caco-2,,0.01; 1,mM,,human,mbds0010,,2013-11-19 20:16:10
mbbd000147674,mbcd0001445,mbtp000012,mbrf0002304,,=,,,substrate,28,2.4,microM,0.9,fluvastatin,,,ABCC2-OATP1B1 double transfected MDCKII cells,MDCKII,,,,,human,mbds0010,,2013-11-21 05:02:38
mbbd000147675,mbcd0001445,mbtp000025,mbrf0002304,,=,,,substrate,28,0.7,microM,0.3,fluvastatin,,,ABCC2-OATP2B1 double transfected MDCKII cells,MDCKII,,,,,human,mbds0010,,2013-11-21 05:02:38
mbbd000147676,mbcd0003075,mbtp000005,mbrf0002304,,,,,substrate,,,,,estrone-3-sulfate,,,MDCKII cells,MDCKII,,,,,human,mbds0010,,2013-11-21 05:02:39
mbbd000147677,mbcd0003075,mbtp000012,mbrf0002304,,,,,substrate,,,,,estrone-3-sulfate,,,MDCKII cells,MDCKII,,,,,human,mbds0010,,2013-11-21 05:02:40
mbbd000147678,mbcd0003075,mbtp000013,mbrf0002304,,,,,substrate,,,,,estrone-3-sulfate,,,MDCKII cells,MDCKII,,,,,human,mbds0010,,2013-11-21 05:02:40
mbbd000147679,mbcd0003075,mbtp000025,mbrf0002304,,,,,substrate,,,,,estrone-3-sulfate,,,MDCKII cells,MDCKII,,,,,human,mbds0010,,2013-11-21 05:02:41
mbbd000147680,mbcd0004706,mbtp000013,mbrf0002304,,=,,,substrate,28,11.1,microM,,CCK-8,,,MDCKII cells,MDCKII,,,,,human,mbds0010,,2013-11-23 21:09:54
mbbd000147681,mbcd0004706,mbtp000005,mbrf0002304,,=,,,substrate,28,8.1,microM,,CCK-8,,,MDCKII cells,MDCKII,,,,,human,mbds0010,,2013-11-23 21:09:54
mbbd000147682,mbcd0004706,mbtp000012,mbrf0002304,,,,,non-substrate,,,,,CCK-8,,,MDCKII cells,MDCKII,,,,,human,mbds0010,,2013-11-23 21:09:54
mbbd000147683,mbcd0004706,mbtp000025,mbrf0002304,,,,,non-substrate,,,,,CCK-8,,,MDCKII cells,MDCKII,,,,,human,mbds0010,,2013-11-23 21:09:55
mbbd000147684,mbcd0003035,mbtp000012,mbrf0002304,,,,,substrate,,,,,BSP,,,MDCKII cells,MDCKII,,,,,human,mbds0010,,2013-11-21 05:02:38
mbbd000147685,mbcd0003035,mbtp000025,mbrf0002304,,,,,substrate,,,,,BSP,,,MDCKII cells,MDCKII,,,,,human,mbds0010,,2013-11-21 05:02:39
mbbd000147686,mbcd0003035,mbtp000013,mbrf0002304,,,,,substrate,,,,,BSP,,,MDCKII cells,MDCKII,,,,,human,mbds0010,,2013-11-21 05:02:40
mbbd000147687,mbcd0003035,mbtp000005,mbrf0002304,,,,,substrate,,,,,BSP,,,MDCKII cells,MDCKII,,,,,human,mbds0010,,2013-11-21 05:02:41
mbbd000147688,mbcd0027726,mbtp000013,mbrf0001701,,,,,non-substrate,,,,,docetaxel,,,HEK293-OATP1B3 transfected cells,HEK293,,5,microM,,human,mbds0010,,2013-11-21 06:15:20
mbbd000147689,mbcd0001372,mbtp000013,mbrf0001701,,,,,non-substrate,,,,,actinomycin D,,,HEK293-OATP1B3 transfected cells,HEK293,,5,microM,,human,mbds0010,,2013-11-21 06:15:20
mbbd000147690,mbcd0002981,mbtp000013,mbrf0001701,,,,,non-substrate,,,,,mitoxantrone,,,HEK293-OATP1B3 transfected cells,HEK293,,5,microM,,human,mbds0010,,2013-11-21 06:15:20
mbbd000147691,mbcd0001532,mbtp000013,mbrf0001701,,,,,non-substrate,,,,,paclitaxel,,,HEK293-OATP1B3 transfected cells,HEK293,,5,microM,,human,mbds0010,,2013-11-21 06:15:20
mbbd000147692,mbcd0001472,mbtp000030,mbrf0002101,,~,,,substrate,138,39.0,pmol (mg protein)-1 min-1,2,cefadroxil,,,Sf21 insect cells; ABCC1-expressing membrane vesicle assay,Sf21,,10,microM,,human,mbds0010,,2013-11-26 00:08:57
mbbd000147693,mbcd0001472,mbtp000005,mbrf0002101,,~,,,substrate,138,20.0,pmol (mg protein)-1 min-1,2,cefadroxil,,,Sf21 insect cells; ABCC2-expressing membrane vesicle assay,Sf21,,10,microM,,human,mbds0010,,2013-11-26 00:08:57
mbbd000147694,mbcd0001472,mbtp000008,mbrf0002101,,~,,,substrate,138,15.0,pmol (mg protein)-1 min-1,0.5,cefadroxil,,,Sf21 insect cells; ABCC3-expressing membrane vesicle assay,Sf21,,10,microM,,human,mbds0010,,2013-11-26 00:08:57
mbbd000147695,mbcd0001472,mbtp000022,mbrf0002101,,~,,,substrate,138,39.0,pmol (mg protein)-1 min-1,3,cefadroxil,,,Sf21 insect cells; ABCC4-expressing membrane vesicle assay,Sf21,,10,microM,,human,mbds0010,,2013-11-26 00:08:57
mbbd000147696,mbcd0029416,mbtp000030,mbrf0002132,,=,,,substrate,28,23.8,microM,2.6,2-chloro-N-(2-methyl-6-ethylphenyl)acetamide-SG,,,sf9 membrane vesicles,Sf9,,,,,human,mbds0010,,2013-11-25 04:42:26
mbbd000147697,mbcd0029416,mbtp000030,mbrf0002132,,=,,,substrate,22,171.0,pmol (mg protein)-1 min-1,6.7,2-chloro-N-(2-methyl-6-ethylphenyl)acetamide-SG,,,sf9 membrane vesicles,Sf9,,,,,human,mbds0010,,2013-11-25 04:42:27
mbbd000147698,mbcd0029417,mbtp000030,mbrf0002132,,,,,non-substrate,,,,,2-chloro-N-(2-methyl-6-ethylphenyl)acetamide-Cys,,,sf9 membrane vesicles,Sf9,,,,,human,mbds0010,,2013-11-25 04:42:27
mbbd000147699,mbcd0029414,mbtp000030,mbrf0002132,,,,,non-substrate,,,,,acetochlor-GSH,,,sf9 membrane vesicles,Sf9,,,,,human,mbds0010,,2013-11-25 04:42:27
mbbd000147700,mbcd0029415,mbtp000030,mbrf0002132,,,,,non-substrate,,,,,Acetochlor-Cys,,,sf9 membrane vesicles,Sf9,,,,,human,mbds0010,,2013-11-25 04:42:27
mbbd000147701,mbcd0003037,mbtp000007,mbrf0002410,,,,,substrate,,,,,N-1-methylnicotinamide,Table 1,,,,,,,,human,mbds0010,,2013-11-25 23:28:17
mbbd000147702,mbcd0003923,mbtp000007,mbrf0002410,,,,,substrate,,,,,tetraethylammonium,Table 1,,,,,,,,human,mbds0010,,2013-11-25 23:28:17
mbbd000147703,mbcd0002091,mbtp000012,mbrf0001920,,,,,non-substrate,,,,,CPT-11,,,MDCKII cells,MDCKII,,5,microM,,human,mbds0010,,2013-11-27 01:18:37
mbbd000147704,mbcd0000779,mbtp000012,mbrf0001920,,,,,substrate,,,,,SN-38,,,MDCKII cells,MDCKII,,5,microM,,human,mbds0010,,2013-11-27 01:18:37
mbbd000147705,mbcd0003187,mbtp000012,mbrf0001920,,,,,non-substrate,,,,,TPT; topotecan,,,MDCKII cells,MDCKII,,5,microM,,human,mbds0010,,2013-11-27 01:18:37
mbbd000147706,mbcd0030260,mbtp000012,mbrf0001920,,,,,non-substrate,,,,,lurtotecan,,,MDCKII cells,MDCKII,,5,microM,,human,mbds0010,,2013-11-27 01:18:37
mbbd000147707,mbcd0029844,mbtp000012,mbrf0001920,,=,,,substrate,82,2.6,,,gimatecan,ratio BA/AB after 4 h,,MDCKII cells,MDCKII,,1,microM,,human,mbds0010,,2013-12-09 05:54:21
mbbd000147708,mbcd0029850,mbtp000012,mbrf0001920,,=,,,substrate,82,3.4,,,BNP1350,ratio BA/AB after 4 h,,MDCKII cells,MDCKII,,0.2,microM,,human,mbds0010,,2013-12-09 05:54:21
mbbd000147709,mbcd0000387,mbtp000012,mbrf0001920,,=,,,substrate,82,2.4,,,E2G,ratio BA/AB after 4 h,,MDCKII cells,MDCKII,,1,microM,,human,mbds0010,,2013-12-09 05:54:22
mbbd000147710,mbcd0000387,mbtp000012,mbrf0001590,,=,,,substrate,28,6.3,microM,1.2,oestradiol 17beta-glucuronide,,,HEK293-OATP1B1 cells,HEK293,,up to 50,microM,,human,mbds0010,,2013-12-03 22:42:48
mbbd000147711,mbcd0000387,mbtp000012,mbrf0001590,,=,,,substrate,22,460.0,pmol min-1 mg-1,96,oestradiol 17beta-glucuronide,,,HEK293-OATP1B1 cells,HEK293,,up to 50,microM,,human,mbds0010,,2013-12-03 22:42:48
mbbd000147712,mbcd0003075,mbtp000012,mbrf0001590,,~,,,substrate,89,43.0,,,oestrone 3-sulfate,,,HEK293-OATP1B1 cells; uptake after 4 min,HEK293,,1,microM,,human,mbds0010,,2013-12-03 22:42:48
mbbd000147713,mbcd0003126,mbtp000012,mbrf0001590,,~,,,substrate,89,12.2,,,pravastatin,,,HEK293-OATP1B1 cells; uptake after 4 min,HEK293,,1,microM,,human,mbds0010,,2013-12-03 22:42:48
mbbd000147714,mbcd0002488,mbtp000012,mbrf0001590,,~,,,non-substrate,89,1.1,,,propranolol,,,HEK293-OATP1B1 cells; uptake after 4 and 10 min,HEK293,,1; 10; 100,microM,,human,mbds0010,,2013-12-03 22:42:48
mbbd000147715,mbcd0000387,mbtp000012,mbrf0001590,,~,,,substrate,89,10.5,,,oestradiol 17beta-glucuronide,,,HEK293-OATP1B1 cells; uptake after 4 min,HEK293,,1,microM,,human,mbds0010,,2013-12-03 22:42:48
mbbd000147716,mbcd0000749,mbtp000012,mbrf0001590,,=,,,inhibitor,25,0.23,microM,0.07,rifamycin SV,,,HEK293-OATP1B1 cells; uptake of oestradiol and 17beta-glucuronide; concentration-dependent inhibition; avg IC50,HEK293,mbcd0000387,,,,human,mbds0010,,2013-12-03 22:51:40
mbbd000147717,mbcd0002488,mbtp000012,mbrf0001590,,,,,non-inhibitor,,,,,propranolol,,,HEK293-OATP1B1 cells; uptake of oestradiol and 17beta-glucuronide,HEK293,mbcd0000387,up to 100,microM,,human,mbds0010,,2013-12-03 22:51:40
mbbd000147718,mbcd0001797,mbtp000012,mbrf0002299,,=,,,inhibitor,29,148.0,microM,61,FEX,,,HEK293 cells inhibition of 0.1 microM E2-17betaG uptake,HEK293,mbcd0030389,,,,human,mbds0010,,2013-12-08 06:41:18
mbbd000147719,mbcd0001797,mbtp000012,mbrf0002299,,=,,,inhibitor,29,257.0,microM,84,FEX,,,HEK293 cells inhibition of 0.1 microM E1S uptake,HEK293,mbcd0003075,,,,human,mbds0010,,2013-12-08 06:41:18
mbbd000147720,mbcd0001797,mbtp000013,mbrf0002299,,=,,,inhibitor,29,83.3,microM,15.3,FEX,,,HEK293 cells inhibition of 0.1 microM CCK-8 uptake,HEK293,mbcd0004706,,,weak inhibitor,human,mbds0010,,2013-12-08 06:41:19
mbbd000147721,mbcd0001797,mbtp000022,mbrf0002744,,~,,,non-substrate,89,1.4,,,FEX,,,Membrane vesicles from hMRP4-expressing HEK293 cells; uptake after 10 min,HEK293,,10,microM,,human,mbds0010,,2013-12-08 06:41:19
mbbd000147722,mbcd0001797,mbtp000002,mbrf0002744,,,,,non-substrate,,,,,FEX,,,hBCRP-expressing MDCKII cell monolayers,MDCKII,,5,microM,,human,mbds0010,,2013-12-08 06:41:20
mbbd000147723,mbcd0001797,mbtp000024,mbrf0001167,,=,,,substrate,22,58.0,pmol (mg protein)-1 min-1,4,Fexofenadine,,,OATP-A-expressing HeLa cell,HeLa,,2,microM,,human,mbds0010,,2013-12-08 08:54:29
mbbd000147724,mbcd0001797,mbtp000024,mbrf0002777,,,,,substrate,,,,,fexofenadine,,,recombinant vaccinia-transfected HeLa cells; uptake after 30 min,HeLa,,0.5,microM,,human,mbds0010,,2013-12-09 01:09:30
mbbd000147725,mbcd0001797,mbtp000025,mbrf0002777,,,,,non-substrate,,,,,fexofenadine,,,recombinant vaccinia-transfected HeLa cells; uptake after 30 min,HeLa,,0.5,microM,,human,mbds0010,,2013-12-09 01:09:30
mbbd000147726,mbcd0001797,mbtp000012,mbrf0002777,,,,,non-substrate,,,,,fexofenadine,,,recombinant vaccinia-transfected HeLa cells; uptake after 30 min,HeLa,,0.5,microM,,human,mbds0010,,2013-12-09 01:09:30
mbbd000147727,mbcd0001797,mbtp000013,mbrf0002777,,,,,non-substrate,,,,,fexofenadine,,,recombinant vaccinia-transfected HeLa cells; uptake after 30 min,HeLa,,0.5,microM,,human,mbds0010,,2013-12-09 01:09:31
mbbd000147728,mbcd0001797,mbtp000010,mbrf0002777,,,,,non-substrate,,,,,fexofenadine,,,recombinant vaccinia-transfected HeLa cells; uptake after 30 min,HeLa,,0.5,microM,,human,mbds0010,,2013-12-09 01:09:31
mbbd000147729,mbcd0001797,mbtp000007,mbrf0002777,,,,,substrate,,,,,fexofenadine,,,recombinant vaccinia-transfected HeLa cells; uptake after 30 min,HeLa,,0.5,microM,,human,mbds0010,,2013-12-09 01:09:31
mbbd000147730,mbcd0001533,mbtp000001,mbrf0001875,,=,,,substrate,25,40.8,microM,3.6,saquinavir,growth inhibition; control MDCKII cells had IC50 value of 24.0 +/- 3.2 microM,,MDCKII cells,MDCKII,,,,,human,mbds0010,,2013-12-09 02:51:34
mbbd000147731,mbcd0002634,mbtp000001,mbrf0001875,,=,,,substrate,25,675.7,microM,145.0,darunavir,growth inhibition; control MDCKII cells had IC50 value of 404.3 +/- 84.8 microM,,MDCKII cells,MDCKII,,,,,human,mbds0010,,2013-12-09 02:51:35
mbbd000147732,mbcd0001533,mbtp000030,mbrf0001875,,=,,,substrate,25,30.7,microM,2.8,saquinavir,growth inhibition; control MDCKII cells had IC50 value of 24.0 +/- 3.2 microM,,MDCKII cells,MDCKII,,,,,human,mbds0010,,2013-12-09 02:51:35
mbbd000147733,mbcd0002634,mbtp000030,mbrf0001875,,=,,,non-substrate,25,284.5,microM,19.5,darunavir,growth inhibition; control MDCKII cells had IC50 value of 404.3 +/- 84.8 microM,,MDCKII cells,MDCKII,,,,,human,mbds0010,,2013-12-09 02:51:35
mbbd000147734,mbcd0001533,mbtp000005,mbrf0001875,,=,,,non-substrate,25,24.6,microM,2.6,saquinavir,growth inhibition; control MDCKII cells had IC50 value of 24.0 +/- 3.2 microM,,MDCKII cells,MDCKII,,,,,human,mbds0010,,2013-12-09 02:51:35
mbbd000147735,mbcd0002634,mbtp000005,mbrf0001875,,=,,,non-substrate,25,378.1,microM,48.6,darunavir,growth inhibition; control MDCKII cells had IC50 value of 404.3 +/- 84.8 microM,,MDCKII cells,MDCKII,,,,,human,mbds0010,,2013-12-09 02:51:36
mbbd000147736,mbcd0001533,mbtp000002,mbrf0001875,,=,,,non-substrate,25,23.4,microM,1.5,saquinavir,growth inhibition; control MDCKII cells had IC50 value of 24.0 +/- 3.2 microM,,MDCKII cells,MDCKII,,,,,human,mbds0010,,2013-12-09 02:51:36
mbbd000147737,mbcd0002634,mbtp000002,mbrf0001875,,=,,,non-substrate,25,323.7,microM,21.3,darunavir,growth inhibition; control MDCKII cells had IC50 value of 404.3 +/- 84.8 microM,,MDCKII cells,MDCKII,,,,,human,mbds0010,,2013-12-09 02:51:36
mbbd000147738,mbcd0004705,mbtp000013,mbrf0002389,,=,,,substrate,22,6.7,pmol min-1 (mg protein)-1,0.91,telmisartan,,,HEK293 (transfected); drug uptake,HEK293,,,,,human,mbds0010,,2013-12-13 21:59:53
mbbd000147739,mbcd0004705,mbtp000013,mbrf0002389,,=,,,substrate,33,2.6,microL/5 min/mg protein,0.4,telmisartan,,,HEK293 (transfected); drug uptake,HEK293,,,,,human,mbds0010,,2013-12-13 22:00:33
mbbd000147740,mbcd0004705,mbtp000006,mbrf0002778,,,,,non-substrate,,,,,telmisartan,,,Caco-2 cells; L-lactate (a substrate of MCT1) had no effect on telmisartan uptake,Caco-2,,,,,human,mbds0010,,2013-12-13 22:02:03
mbbd000147741,mbcd0002466,mbtp000012,mbrf0002112,,=,,,substrate,28,42.2,microM,11.6,etoposide,,,HEK-OATP1B1; 5 min,HEK293,,0-100,microM,,human,mbds0010,,2014-02-25 06:03:23
mbbd000147742,mbcd0002466,mbtp000012,mbrf0002112,,=,,,substrate,33,1.9,fold increase,,etoposide,,,HEK293 (transfected); 1 microM substrate; 5 min,HEK293,,1,microM,,human,mbds0010,,2014-02-25 06:03:24
mbbd000147743,mbcd0002466,mbtp000012,mbrf0002112,,=,,,substrate,33,1.6,fold increase,,etoposide,,,HEK293 (transfected); 10 microM substrate; 5 min,HEK293,,10,microM,,human,mbds0010,,2014-02-25 06:03:24
mbbd000147744,mbcd0002466,mbtp000013,mbrf0002112,,=,,,substrate,33,1.3,fold increase,,etoposide,modest uptake!,,HEK293 (transfected); 1 microM substrate; 5 min,HEK293,,1,microM,weak substrate,human,mbds0010,,2014-02-25 06:03:24
mbbd000147745,mbcd0002466,mbtp000013,mbrf0002112,,,,,non-substrate,,,,,etoposide,,,HEK293 (transfected); 10 microM substrate; 5 min,HEK293,,10,microM,,human,mbds0010,,2014-02-25 06:03:24
mbbd000147746,mbcd0002466,mbtp000001,mbrf0001027,,,,,substrate,,,,,etoposide,,,MDR1-expressing MDCKII cell; transepithelial transport (basal to apical),MDCKII,,,,,human,mbds0010,,2014-02-26 08:40:50
mbbd000147747,mbcd0001735,mbtp000001,mbrf0001027,,,,,non-substrate,,,,,midazolam,,,MDR1-expressing MDCKII cell; transepithelial transport (basal to apical),MDCKII,,,,,human,mbds0010,,2014-02-26 08:40:50
mbbd000147748,mbcd0005183,mbtp000001,mbrf0001027,,,,,substrate,,,,,daunorubicin,,,MDR1-expressing MDCKII cell; transepithelial transport (basal to apical),MDCKII,,,,,human,mbds0010,,2014-02-26 08:40:50
mbbd000147749,mbcd0007511,mbtp000001,mbrf0001027,,,,,non-substrate,,,,,nifedipine,,,MDR1-expressing MDCKII cell; transepithelial transport (basal to apical),MDCKII,,,,,human,mbds0010,,2014-02-26 08:40:50
mbbd000147750,mbcd0001135,mbtp000001,mbrf0001027,,,,,substrate,,,,,vincristine,,,MDR1-expressing MDCKII cell; transepithelial transport (basal to apical),MDCKII,,,,,human,mbds0010,,2014-02-26 08:40:50
mbbd000147751,mbcd0027062,mbtp000001,mbrf0001027,,,,,non-substrate,,,,,verapamil,"found to be an ATPase activator, but found not to be effluxed in MDCKII-MDR1 cells",,MDR1-expressing Sf9 cell; ATP hydrolysis,Sf9,,,,,human,mbds0010,,2014-03-01 04:42:09
mbbd000147752,mbcd0001808,mbtp000001,mbrf0001027,,,,,non-substrate,,,,,GF120918,found not to be an ATPase activator and not to be effluxed in MDCKII-MDR1 cells,,MDR1-expressing Sf9 cell; ATP hydrolysis,Sf9,,,,,human,mbds0010,,2014-03-01 05:01:09
mbbd000147753,mbcd0000474,mbtp000001,mbrf0001027,,,,,substrate,,,,,Hoechst 33342,"found not to be an ATPase activator, but found to be effluxed in MDCKII-MDR1 cells",,MDR1-expressing Sf9 cell; ATP hydrolysis,Sf9,,,,,human,mbds0010,,2014-03-01 04:41:52
mbbd000147754,mbcd0002340,mbtp000001,mbrf0001027,,,,,non-substrate,,,,,chlorpromazine,"found to be an ATPase activator, but found not to be effluxed in MDCKII-MDR1 cells",,MDR1-expressing Sf9 cell; ATP hydrolysis,Sf9,,,,,human,mbds0010,,2014-03-01 04:41:52
mbbd000147755,mbcd0000311,mbtp000001,mbrf0001027,,,,,substrate,,,,,cyclosporin A,,,MDR1-expressing MDCKII cell; transepithelial transport (basal to apical),MDCKII,,,,,human,mbds0010,,2014-02-26 08:40:50
mbbd000147756,mbcd0029195,mbtp000012,mbrf0001658,,,,,non-substrate,,,,,eltrombopag,,,,,,,,,human,mbds0010,,2014-02-26 19:59:44
mbbd000147757,mbcd0029195,mbtp000001,mbrf0001658,,,,,non-substrate,,,,,eltrombopag,,,,,,,,,human,mbds0010,,2014-02-26 19:59:44
mbbd000147758,mbcd0001324,mbtp000024,mbrf0002757,,,,,non-substrate,,,,,sirolimus,,,SLCO1A2-transfected HEK293T/17 cells; uptake,HEK293T/17,,,,,human,mbds0010,,2014-02-26 20:26:31
mbbd000147759,mbcd0001616,mbtp000024,mbrf0002757,,,,,non-substrate,,,,,everolimus,,,SLCO1A2-transfected HEK293T/17 cells; uptake,HEK293T/17,,,,,human,mbds0010,,2014-02-26 20:26:32
mbbd000147760,mbcd0002041,mbtp000012,mbrf0001394,,,,,substrate,,,,,DPDPE,,,Xenopus laevis oocyte; uptake,Xenopus laevis oocytes,,10,microM,,human,mbds0010,,2014-02-26 21:08:39
mbbd000147761,mbcd0003959,mbtp000012,mbrf0001394,,,,,non-substrate,,,,,folate,,,Xenopus laevis oocyte; uptake,Xenopus laevis oocytes,,1,microM,,human,mbds0010,,2014-02-26 21:08:39
mbbd000147762,mbcd0003959,mbtp000013,mbrf0001394,,,,,non-substrate,,,,,folate,,,Xenopus laevis oocyte; uptake,Xenopus laevis oocytes,,1,microM,,human,mbds0010,,2014-02-26 21:08:39
mbbd000147763,mbcd0003070,mbtp000012,mbrf0001394,,,,,substrate,,,,,DHEAS,,,Xenopus laevis oocyte; uptake,Xenopus laevis oocytes,,10,microM,,human,mbds0010,,2014-02-26 21:08:39
mbbd000147764,mbcd0003070,mbtp000013,mbrf0001394,,,,,substrate,,,,,DHEAS,,,Xenopus laevis oocyte; uptake,Xenopus laevis oocytes,,10,microM,,human,mbds0010,,2014-02-26 21:08:39
mbbd000147765,mbcd0000984,mbtp000012,mbrf0001394,,,,,substrate,,,,,T3,,,Xenopus laevis oocyte; uptake,Xenopus laevis oocytes,,1,microM,,human,mbds0010,,2014-02-26 21:08:39
mbbd000147766,mbcd0001664,mbtp000012,mbrf0001394,,,,,substrate,,,,,TCA; taurocholate,,,Xenopus laevis oocyte; uptake,Xenopus laevis oocytes,,1,microM,,human,mbds0010,,2014-02-26 21:08:39
mbbd000147767,mbcd0003134,mbtp000013,mbrf0002576,,=,,,substrate,33,1.7,pmol/min/mg protein,0.1,Penicillin G,,,MDCKII (transfected); drug uptake; 1.3 microM Penicillin G; 10 min,MDCKII,,1.3,microM,,human,mbds0010,,2014-02-26 23:38:30
mbbd000147768,mbcd0003075,mbtp000025,mbrf0002349,,,,,substrate,,,,,E3S,,,OATP2B1-transfected MDCKII cells; 15 min,MDCKII,,20,nM,,human,mbds0010,,2014-02-27 00:05:37
mbbd000147769,mbcd0003070,mbtp000025,mbrf0002349,,,,,substrate,,,,,DHEAS,,,OATP2B1-transfected MDCKII cells; 15 min,MDCKII,,17,nM,,human,mbds0010,,2014-02-27 00:05:37
mbbd000147770,mbcd0003001,mbtp000025,mbrf0002349,,,,,non-substrate,,,,,testosterone,,,OATP2B1-transfected MDCKII cells; 15 min,MDCKII,,20,nM,,human,mbds0010,,2014-02-27 00:05:38
mbbd000147771,mbcd0001892,mbtp000025,mbrf0002349,,,,,non-substrate,,,,,progesterone,,,OATP2B1-transfected MDCKII cells; 15 min,MDCKII,,20,nM,,human,mbds0010,,2014-02-27 00:05:38
mbbd000147772,mbcd0000713,mbtp000025,mbrf0001969,,,,,non-substrate,,,,,PGA1,,,CHO (transfected),CHO,,,,,human,mbds0010,,2014-02-27 00:18:28
mbbd000147773,mbcd0003113,mbtp000012,mbrf0002770,,,,,non-substrate,,,,,Diclo; diclofenac,,,HEK293; uptake,HEK293,,0.1; 0.5; 1; 10; 100,microM,,human,mbds0010,,2014-02-27 20:06:46
mbbd000147774,mbcd0003113,mbtp000013,mbrf0002770,,~,,,substrate,150,120.0,%,,Diclo; diclofenac,,,HEK293; uptake,HEK293,,1; 10; 100,microM,,human,mbds0010,,2014-02-27 20:06:46
mbbd000147775,mbcd0003013,mbtp000012,mbrf0002770,,,,,non-substrate,,,,,Ibu; ibuprofen,,,HEK293; uptake,HEK293,,0.1; 0.5; 1; 10; 100,microM,,human,mbds0010,,2014-02-27 20:06:46
mbbd000147776,mbcd0003013,mbtp000013,mbrf0002770,,,,,non-substrate,,,,,Ibu; ibuprofen,,,HEK293; uptake,HEK293,,0.1; 0.5; 1; 10; 100,microM,,human,mbds0010,,2014-02-27 20:06:46
mbbd000147777,mbcd0002998,mbtp000012,mbrf0002770,,,,,non-substrate,,,,,Napro; naproxen,,,HEK293; uptake,HEK293,,0.1; 0.5; 1; 10; 100,microM,,human,mbds0010,,2014-02-27 20:06:46
mbbd000147778,mbcd0002998,mbtp000013,mbrf0002770,,,,,non-substrate,,,,,Napro; naproxen,,,HEK293; uptake,HEK293,,0.1; 0.5; 1; 10; 100,microM,,human,mbds0010,,2014-02-27 20:06:46
mbbd000147779,mbcd0001353,mbtp000012,mbrf0002770,,,,,non-substrate,,,,,SA; salicylic acid,,,HEK293; uptake,HEK293,,0.1; 0.5; 1; 10; 100,microM,,human,mbds0010,,2014-02-27 20:06:46
mbbd000147780,mbcd0001353,mbtp000013,mbrf0002770,,,,,non-substrate,,,,,SA; salicylic acid,,,HEK293; uptake,HEK293,,0.1; 0.5; 1; 10; 100,microM,,human,mbds0010,,2014-02-27 20:06:46
mbbd000147781,mbcd0001795,mben000001,mbrf0000069,,=,,,inducer,111,3.0,fold increase,,etravirine,strong inducer,,Induction of CYP3A4 activity; mRNA level,,,1,micromol L-1,,human,mbds0010,,2015-07-27 05:36:21
mbbd000147782,mbcd0001795,mben000015,mbrf0000069,,,,,inducer,,,,,etravirine,weak inducer,,Induction of CYP3A5 activity,,,1,micromol L-1,,human,mbds0010,,2015-07-27 05:36:21
mbbd000147783,mbcd0001795,mbtp000025,mbrf0000069,,,,,inducer,,,,,etravirine,,,Induction of SLCO2B1 activity,,,1,micromol L-1,,human,mbds0010,,2015-07-27 05:36:21
mbbd000147784,mbcd0001795,mbtp000030,mbrf0000069,,,,,non-inducer,,,,,etravirine,,,Induction of MRP1 activity,,,1,micromol L-1,,human,mbds0010,,2015-07-27 05:36:21
mbbd000147785,mbcd0001795,mbtp000005,mbrf0000069,,,,,non-inducer,,,,,etravirine,,,Induction of MRP2 activity,,,1,micromol L-1,,human,mbds0010,,2015-07-27 05:36:21
mbbd000147786,mbcd0001795,mbtp000022,mbrf0000069,,,,,non-inducer,,,,,etravirine,,,Induction of MRP4 activity,,,1,micromol L-1,,human,mbds0010,,2015-07-27 05:36:21
mbbd000147787,mbcd0001795,mbtp000013,mbrf0000069,,,,,non-inducer,,,,,etravirine,,,Induction of SLCO1B3 activity,,,1,micromol L-1,,human,mbds0010,,2015-07-27 05:36:21
mbbd000147788,mbcd0001795,mbtp000022,mbrf0000069,,,,,non-inducer,,,,,etravirine,,,Induction of MRP5 activity,,,1,micromol L-1,,human,mbds0010,,2015-07-27 05:36:21
mbbd000147789,mbcd0001795,mbtp000030,mbrf0000069,25,=,8500.0,nM,non-inhibitor,25,8.5,micromol L-1,0.5,etravirine,,,"MDCKII-MRP1 cell line, proliferation inhibition",MDCKII,,,,,human,mbds0010,,2015-07-27 05:36:21
mbbd000147790,mbcd0001795,mbtp000005,mbrf0000069,25,=,7800.0,nM,non-inhibitor,25,7.8,micromol L-1,1.1,etravirine,,,"MDCKII-MRP2 cell line, proliferation inhibition",MDCKII,,,,,human,mbds0010,,2015-07-27 05:36:21
mbbd000147791,mbcd0001795,mbtp000030,mbrf0000069,,,,,non-substrate,,,,,etravirine,,,growth inhibition assay in MDCKII cells overexpressing human MRP1,MDCKII,,,,,human,mbds0010,,2015-07-27 05:36:21
mbbd000147792,mbcd0001795,mbtp000005,mbrf0000069,,,,,non-substrate,,,,,etravirine,,,growth inhibition assay in MDCKII cells overexpressing human MRP2,MDCKII,,,,,human,mbds0010,,2015-07-27 05:36:21
mbbd000147793,mbcd0001795,mbtp000002,mbrf0000069,,,,,non-substrate,,,,,etravirine,,,growth inhibition assay in MDCKII cells overexpressing human BCRP,MDCKII,,,,,human,mbds0010,,2015-07-27 05:36:21
mbbd000147794,mbcd0001795,mbtp000001,mbrf0000069,,,,,non-substrate,,,,,etravirine,,,growth inhibition assay in MDCKII cells overexpressing human MDR1,MDCKII,,,,,human,mbds0010,,2015-07-27 05:36:21
mbbd000147795,mbcd0001795,mbtp000008,mbrf0000069,,,,,non-substrate,,,,,etravirine,,,growth inhibition assay in MDCKII cells overexpressing human MRP3,MDCKII,,,,,human,mbds0010,,2015-07-27 05:36:21
mbbd000147796,mbcd0003658,mbtp000009,mbrf0000105,,=,,,substrate,21,3.6,pmol s-1 cm-2,,BipR-OH,weak substrate,,Activity of human PEPT1 expressed in Xenopus laevis oocytes assessed as induction of transport-associated flux rate current at 1 mM at -60 mV membrane potential by two-electrode voltage clamp method,Xenopus laevis oocytes,,1.0,mM,,human,mbds0010,,2015-08-03 01:57:36
mbbd000147797,mbcd0003821,mbtp000009,mbrf0000105,,,,,non-substrate,,,,,RBipR-NH2,,,hPEPT1 expressed by Xenopus laevis oocytes,Xenopus laevis oocytes,,1.0,mM,,human,mbds0010,,2015-08-03 01:57:36
mbbd000147798,mbcd0003811,mbtp000009,mbrf0000105,,,,,non-substrate,,,,,RWR-NHBn,,,hPEPT1 expressed by Xenopus laevis oocytes,Xenopus laevis oocytes,,1.0,mM,,human,mbds0010,,2015-08-03 01:57:36
mbbd000147799,mbcd0003648,mbtp000009,mbrf0000105,,,,,non-substrate,,,,,TbtR-NH2,,,hPEPT1 expressed by Xenopus laevis oocytes,Xenopus laevis oocytes,,1.0,mM,,human,mbds0010,,2015-08-03 01:57:36
mbbd000147800,mbcd0029620,mbtp000009,mbrf0000105,,,,,non-substrate,,,,,BipR-OMe,,,hPEPT1 expressed by Xenopus laevis oocytes,Xenopus laevis oocytes,,1.0,mM,,human,mbds0010,,2015-08-03 01:57:36
mbbd000147801,mbcd0029622,mbtp000009,mbrf0000105,,,,,non-substrate,,,,,RWR-NH2,,,hPEPT1 expressed by Xenopus laevis oocytes,Xenopus laevis oocytes,,1.0,mM,,human,mbds0010,,2015-08-03 01:57:36
